drug_id,drug_name,drug_synonyms_value,drug_synonyms_type,therapy_areas,drug_primary_action_value,drug_primary_action_id,drug_secondary_action_value,drug_secondary_action_id,drug_primary_indication_value,drug_primary_indication_id,drug_secondary_indication_value,drug_secondary_indication_id,drug_primary_company_value,drug_primary_company_id,drug_secondary_company_value,drug_secondary_company_id,drug_company_originator_value,drug_company_originator_id,drug_brand_names,drug_generic_names,molecular_mechanism_value,molecular_mechanism_id,cellular_mechanism_value,cellular_mechanism_id
100013,"asparaginase, Medac","asparaginase, Medac|Spectrila",Trade Name,Cancer,Asparaginase stimulator,517,Apoptosis stimulator|Anticancer,1589|1545,Acute lymphoblastic leukemia,1728,,,Medac GmbH,17967,,,Medac GmbH,17967,,,,,,
100057,MRx-518,"live biotherapeutic preparation (MicroRx, cancer), 4d pharma|MRx-518|live biotherapeutic preparation (oral, cancer), 4d pharma|MRx-0518",Research Code|Research Code,Cancer,,,Microbiome modulator|Immunostimulant|Anticancer,173474|393|1545,Pancreas tumor|Prostate tumor|Stage IV melanoma|Metastatic bladder cancer|Metastatic non small cell lung cancer|Urethral cancer|Metastatic renal cell carcinoma|Breast tumor|Head and neck tumor|Uterus tumor|Lung tumor|Ovary tumor,249|276|3257|3466|3665|3678|4250|49|623|740|755|799,Cancer,651,4D pharma plc,1093689,,,4D pharma plc,1093689,,,,,,
100070,naporafenib,"LXH-254|pan-RAF inhibitor (oral/tablet, advanced solid tumors/NSCLC/melanoma/ovarian cancer/colorectal), Novartis Pharmaceuticals|naporafenib",Research Code|PINN,Cancer,Raf 1 protein kinase inhibitor|Raf B protein kinase inhibitor,4550|4548,Anticancer protein kinase inhibitor,62255,Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic ovary cancer,3257|3658|3665|3713|3866,Non-small-cell lung cancer|Solid tumor,1262|725,Novartis Pharmaceuticals Corp,24818,,,Novartis Pharmaceuticals Corp,24818,,,,,,
100109,"tirapazamine (hepatocellular carcinoma), Teclison/Cheery Pharma","tirapazamine|tirapazamine (hepatocellular carcinoma), Teclison/Cheery Pharma",USAN|INN,Cancer,,,Bioreducible cytotoxin|Anticancer,1585|1545,Neuroendocrine tumor|Hepatocellular carcinoma|Liver tumor|Metastatic gastrointestinal cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer,1128|1767|202|3460|3658|3665,,,Teclison Ltd|Cheery Pharma,1116794|1104733,,,Teclison Ltd,1116794,,,,,,
100129,"topotecan hydrochloride (oral, small-cell lung cancer), Novartis","Hycamtin|topotecan hydrochloride|topotecan|topotecan (oral, small-cell lung cancer), GlaxoSmithKline|topotecan (oral, small-cell lung cancer), Novartis|topotecan hydrochloride (oral, small-cell lung cancer), Novartis",Trade Name|USAN|BAN|INN,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,Small-cell lung cancer,1261,Non-small-cell lung cancer,1262,Novartis AG,23137,GlaxoSmithKline plc,28355,GlaxoSmithKline plc,28355,,,,,,
100157,loncastuximab tesirine,ADCT-402|loncastuximab tesirine|Lonca-T|Lonca|loncastuximab tesirine-lpyl|Zynlonta,Research Code|INN|Trade Name,Cancer,B-lymphocyte antigen CD19 inhibitor,5082,Anticancer monoclonal antibody,55685,B-cell acute lymphoblastic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|High grade B-cell lymphoma|Hematological neoplasm|B-cell lymphoma|Non-Hodgkin lymphoma|Burkitts lymphoma,1729|1743|1744|1745|1746|1749|1751|2054|316|319|791,,,ADC Therapeutics Sarl|Overland ADCT BioPharma (CY) Limited,1068935|1232531,,,ADC Therapeutics Sarl,1068935,,,,,,
100159,PLX-51107,"BRD4 inhibitors (hematological cancer), Plexxikon|PLX-51107",Research Code,Cancer|Immune,Bromodomain containing protein 4 inhibitor,34570,Anticancer,1545,Graft versus host disease,616,Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm|Solid tumor,1272|1731|2054|725,Plexxikon Inc,29155,,,Plexxikon Inc,29155,,,,,,
100161,bomedemstat bis-tosylate,"lysine-specific histone demethylase-1 inhibitors (myeloproliferative disorder), Imago Biosciences|LSD1 inhibitors (myeloproliferative disorder), Imago Biosciences|IMG-98|IMG-7289|bomedemstat|bomedemstat bis-tosylate",Research Code|Research Code|INN,Cancer|Hematologic,Lysine specific histone demethylase 1 inhibitor,14681,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Thrombocythemia|Polycythemia vera|Myelofibrosis|Myeloproliferative disorder,1272|1731|2317|2319|2436|273,,,Imago Biosciences,1101559,,,Imago Biosciences,1101559,,,,,,
100198,S-64315,"Mcl-1 inhibitors (cancer), Servier/Novartis|S-63845|S-64315|MIK-665",Research Code|Research Code|Research Code,Cancer,Mcl-1 differentiation protein inhibitor,11381,Synergist|Apoptosis stimulator|Anticancer,7293|1589|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Multiple myeloma|Non-Hodgkin lymphoma,1272|1731|1749|1828|319,Cancer,651,Servier|Novartis AG,19863|23137,,,Servier,19863,,,,,,
100207,RNA CART123,"RNA CART123|anti-CD123 CAR T-cell therapy (AML), University of Pennsylvania/Novartis|MIH-911",Research Code|Research Code,Cancer,CDw123 modulator,5427,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,Acute myelogenous leukemia,1731,,,Novartis AG,23137,University of Pennsylvania,20658,University of Pennsylvania,20658,,,,,,
100225,"quavonlimab + pembrolizumab (fixed-dose combination, advanced solid tumors), Merck","AK-107|MK-1308|CTLA-4 checkpoint inhibitor (solid tumor), Merck Sharp & Dohme|CTLA-4 checkpoint inhibitor (advanced solid tumor), Merck & Co/Akeso Biopharma|humanized anti-CTLA-4 monoclonal antibody (advanced solid tumor), Merck & Co/Akeso Biopharma|quavonlimab|quavonlimab + pembrolizumab (fixed-dose combination, advanced solid tumors), Merck|MK-1308A",Research Code|Research Code|INN|Research Code,Cancer,Cytotoxic T-lymphocyte protein-4 inhibitor|Programmed cell death protein 1 inhibitor,5482|67136,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,Small-cell lung cancer|Hepatocellular carcinoma|Stage III melanoma|Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic renal cell carcinoma,1261|1767|3256|3257|3658|3665|3713|4250,Cancer,651,Merck & Co Inc,18077,Akeso Biopharma Inc,1075032,Akeso Biopharma Inc,1075032,,,Angiotensin-I Converting Enzyme (ACE) Inhibitors,381,,
100231,HX-008,"AK-103|PD-1 checkpoint inhibitor (recombinant humanized antibody, cancer), Akeso Biopharma|PD-1 checkpoint inhibitor (cancer), HanX Biopharmaceuticals|HX-008|PD-1 checkpoint inhibitor (recombinant humanized antibody, cancer), Akeso Biopharma/Taizhou Hanzhong/Hangzhou Hansi",Research Code|Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Hepatocellular carcinoma|Bladder cancer|Stage IV melanoma|Soft tissue sarcoma|Metastatic liver cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic head and neck cancer|Advanced solid tumor,1767|2380|3257|3378|3462|3657|3665|3666|3673|3713,Cancer,651,HanX Biopharmaceuticals Inc|Akeso Biopharma Inc|Taizhou Hanzhong Biomed Co Ltd,1158103|1075032|1160384,,,Akeso Biopharma Inc,1075032,,,,,,
100233,AK-104,"AK-104|PD-1 checkpoint inhibitor (bispecific humanized antibody, cancer), Akeso Biopharma|humanized PD-1/CTLA-4 bispecific antibody (advanced solid tumors, gastric or gastroesophageal junction adenocarcinoma), Akeso Biopharma|cadonilimab",Research Code,Cancer,Cytotoxic T-lymphocyte protein-4 inhibitor|Programmed cell death protein 1 inhibitor,5482|67136,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Peripheral T-cell lymphoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Melanoma|Squamous cell carcinoma|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor|Uterine cervix tumor|Breast tumor,1753|1767|1768|1771|205|307|3665|3666|3667|3713|427|49,Cancer,651,Akeso Biopharma Inc,1075032,,,Akeso Biopharma Inc,1075032,,,Angiotensin-I Converting Enzyme (ACE) Inhibitors,381,,
100235,penpulimab,"AK-105|PD-1 checkpoint inhibitor (cancer), Akeso Biopharma|PD-1 checkpoint inhibtor (cancer), Akeso Biopharma/Chi Tai Tianqing Pharmaceutical|penpulimab|annike",Research Code|PINN|Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Esophagus tumor|Neuroendocrine tumor|Non-small-cell lung cancer|Gastrointestinal tumor|Hodgkins disease|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Squamous cell carcinoma|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Cancer|Urinary tract tumor,1011|1128|1262|131|161|1767|1768|307|3666|3667|3673|3713|651|738,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd|Akeso Biopharma Inc,1025425|1075032,,,Akeso Biopharma Inc,1075032,,,,,,
100274,OXS-3550,"anti-CD16/anti-CD33/IL-15 trispecific NK-cell engager (TriKE, cancer), University of Minnesota/New York Medical College/GT Biopharma|OXS-3550|anti-CD16/anti-CD33 antibody + modified IL-15 crosslinker (cancer, TriKE), Oxis International|OXS-3350|1633 TriKE|161533 TriKE|GTB-3550|CD16-IL-15-CD33 trispecific killer cell engager (AML/MDS/mastocytosis/mast cell leukemia), University of Minnesota|161533|CD16-IL-15-CD33 Trike|TriKE 161533|anti-CD16/anti-CD33/IL-15 trispecific immune-cell engager (TriKE, cancer), University of Minnesota/New York Medical College/GT Biopharma|GTB-3550 Trike",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Musculoskeletal,CD33 modulator|IL-15 receptor agonist|Immunoglobulin gamma Fc receptor III agonist,5119|3085|5072,Immunostimulant|Leukocyte stimulator|Anticancer antibody|Natural killer cell stimulator,393|7747|55684|7757,Myelodysplastic syndrome|Acute myelogenous leukemia|Mastocytosis,1272|1731|2795,Cancer,651,GT Biopharma Inc,18728,University of Minnesota|New York Medical College,20626|23270,University of Minnesota,20626,,,,,,
100286,18F-ODS-2004436,IMAkinib|18F-ODS-2004436|Fluorine-18-ODS-2004436|ODS-2004436-[18F],Research Code|Research Code|Research Code,Cancer,,,Radiodiagnostic|Neoplasm diagnostic agent|Imaging agent,5720|7220|4155,Non-small-cell lung cancer,1262,Cancer,651,Oncodesign Biotechnology SA|Laboratoires Cyclopharma,1049167|1045160,,,Oncodesign Biotechnology SA,1049167,,,,,,
100322,ASP-1235,AGS-62P1|ASP-1235,Research Code|Research Code,Cancer,Flt3 tyrosine kinase modulator,3805,Microtubule inhibitor|Anticancer monoclonal antibody,2575|55685,,,Acute myelogenous leukemia,1731,,,Astellas Pharma Inc,1013295,Astellas Pharma Inc,1013295,,,,,,
100346,TAB-004,"BTLA checkpoint inhibitor (solid tumors), Shanghai Junshi Biosciences|JS-004|TAB-004/JS-004, Shanghai Junshi Biosciences|TAB-004, Shanghai Junshi Biosciences|recombinant humanized anti-BTLA monoclonal antibody (melanoma/lung cancer/lymphoma), Shanghai Junshi Biosciences|icatolimab|TAB-004",Research Code|Research Code|Research Code|PINN|Research Code,Cancer,B and T lymphocyte attenuator inhibitor,37611,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Lymphoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Solid tumor,203|3257|3466|3668|3673|3713|4250|725,,,Shanghai Junshi Biosciences Co Ltd,1104388,,,Shanghai Junshi Biosciences Co Ltd,1104388,,Tenilapine,5-HT2C Receptor Ligands|Dopamine D1 Receptor (DRD1) Ligands|Muscarinic M4 Receptor Ligands|Muscarinic M2 Receptor Ligands|Muscarinic M1 Receptor Ligands|5-HT7 Receptor Ligands|5-HT6 Receptor Ligands|5-HT2A Receptor Ligands,1778|1532|2066|2064|2063|1967|1428|1966,Signal Transduction Modulators,1402
100355,PLB-1003,"PLB-1003|ALK Inhibitor (oral capsule, non-small cell lung cancer), Beijing Purunao Biotech",Research Code,Cancer,Anaplastic lymphoma kinase receptor inhibitor,3736,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer,1262,,,Beijing Purunao Biotech Co Ltd,1094627,,,Beijing Purunao Biotech Co Ltd,1094627,,,,,,
100408,"[18F]F-AraG (cancer), CellSight/Standford University/University of California San Francisco","[18F]F-AraG|[18F]F-AraG (cancer), CellSight/Standford University/University of California San Francisco|fluorine-18(18F)-radiolabeled-D-arabinofuranosylguanine (cancer), CellSight/University of California San Francisco/Stanford University|VisAcT|[18F]F-AraG (GvHD), CellSight/Standford University/University of California San Francisco|fluorine-18-F-AraG|F-AraG-[18F]",Research Code|Research Code,Cancer|Immune|Infection,,,Immune diagnostic agent|PET contrast agent|Imaging agent|Neoplasm diagnostic agent|Radiodiagnostic,7215|5555|4155|7220|5720,Coronavirus disease 19 infection|HIV infection|Bladder cancer|Squamous cell carcinoma|Metastatic non small cell lung cancer|Graft versus host disease|Head and neck tumor|Cancer,10406|158|2380|307|3665|616|623|651,,,"Stanford University|CellSight Technology, Inc.|University of California San Francisco",20679|1104255|24773,,,"CellSight Technology, Inc.",1104255,,,,,,
100409,ECT-100,"ECT-100|UM-171-expanded allogeneic umbilical cord-derived CD34+ hematopoietic stem cell therapy (hematologic malignancies), ExCellThera|UM-171|ECT-001|ECT-001-CB",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Hematologic|Immune,,,Hematopoietic stimulator|Anticancer,610|1545,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Multiple myeloma|Leukemia|Hematological neoplasm|Sickle cell anemia|Non-Hodgkin lymphoma|Hematopoietic stem cell transplantation|Graft versus host disease,1272|1728|1731|1828|199|2054|303|319|3888|616,,,ExCellThera,1110204,,,ExCellThera,1110204,,,,,,
100434,SGM-101,SGM-101,Research Code,Cancer,CD66e antagonist,5275,Neoplasm diagnostic agent|Imaging agent|Anticancer|Anticancer monoclonal antibody|Gastrointestinal diagnostic agent,7220|4155|1545|55685|7213,Rectal tumor|Metastatic colorectal cancer|Metastatic lung cancer|Cancer|Colorectal tumor,1055|3658|3668|651|989,,,Institut de Recherche en Cancerologie de Montpellier|SurgiMab,1043085|1117982,,,Institut de Recherche en Cancerologie de Montpellier,1043085,,,Mineralocorticoid Receptor (MR) Antagonists,2526,Signal Transduction Modulators,1402
100436,"anti-BCMA CAR T-cell therapy (multiple myeloma), National Cancer Institute","anti-BCMA CAR T-cell therapy (multiple myeloma), National Cancer Institute",,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Multiple myeloma,1828,,,National Cancer Institute (NCI),20519,,,National Cancer Institute (NCI),20519,,,,,,
100441,IMA-101,"IMA-101|autologous adoptive T-cell therapy (ACTolog, cancer), Immatics",Research Code,Cancer,,,Anticancer,1545,Cancer|Solid tumor,651|725,,,Immatics NV,1005804,,,Immatics NV,1005804,,,,,,
100445,IMA-202,"IMA-202|TCR T-cell therapy (solid tumor/NSCLC/hepatocellular carcinoma), Immatics",Research Code,Cancer,HLA antigen modulator,19106,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Hepatocellular carcinoma|Metastatic non small cell lung cancer|Advanced solid tumor,1767|3665|3713,,,Immatics NV,1005804,,,Immatics NV,1005804,,,,,,
100523,INCB-59872,"INCB-59872|INCB-059872|LSD1 inhibitor (oral tablet, small cell lung cancer/ Ewing sarcoma/ neuroendocrine tumors/ acute myeloid leukemia/ myelodysplastic syndrome/ myelofibrosis/ sickle cell anemia), Incyte Corp|LSD1 inhibitor (oral tablet, small cell lung cancer/ Ewing sarcoma/ neuroendocrine tumors/ acute myeloid leukemia/ myelodysplastic syndrome/ myelofibrosis), Incyte Corp",Research Code|Research Code,Cancer|Hematologic,Lysine specific histone demethylase 1 inhibitor,14681,Anticancer,1545,,,Neuroendocrine tumor|Small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm|Myelofibrosis|Ewing sarcoma|Sickle cell anemia|Solid tumor,1128|1261|1272|1731|2054|2436|2975|303|725,,,Incyte Corp,17216,Incyte Corp,17216,,,,,,
100525,INCAGN-1876,"INCAGN-1876|INCAGN-01876|anti-GITR antibody (solid tumors), Incyte Corp|ragifilimab",Research Code|Research Code|INN,Cancer,Activation-inducible TNF receptor agonist,8259,Anticancer|Anticancer antibody,1545|55684,Hematological neoplasm|Glioblastoma|Metastatic head and neck cancer|Advanced solid tumor,2054|2454|3673|3713,,,Agenus Inc|Incyte Corp,23221|17216,,,Incyte Corp,17216,,,,,,
100585,SLATE-001,"tumor-specific neo-antigen therapy (cancer), Gritstone Oncology|SLATE-001|GRT-C903|GRT-R904|personalized shared neoantigen-based prime-boost cancer vaccine (im, advanced solid tumor), Gritstone Oncology|GRT-C903/GRT-R904|SLATE",Research Code|Research Code|Research Code,Cancer,,,Immunomodulator|Therapeutic vaccine|Anticancer,1596|12379|1545,Pancreatic ductal adenocarcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Cancer,1507|3658|3665|3669|3713|651,,,Gritstone Oncology,1115276,,,Gritstone Oncology,1115276,,,,,,
10060,KRN-7000,"KRN-7000|AGL-506|AGL-514|AGL-517|AGL-525|AGL-529|AGL-533|AGL-535|AGL-553|AGL-582|AGL-583|agelasphin derivatives, Kirin|alpha-galactosylceramide, Kirin",Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Research Code|Analogue|Research Code,Cancer|Infection,,,Immunostimulant|Natural killer T-lymphocyte stimulator|Antiviral|Anticancer,393|173716|991|1545,,,Hepatitis B virus infection|Hepatitis C virus infection|Cancer,152|153|651,,,Kirin Brewery Co Ltd,17661,Kirin Brewery Co Ltd,17661,,,,,,
100612,troriluzole hydrochloride,"trigriluzole|riluzole prodrug (spinocerebellar ataxia), Biohaven Pharmaceutical|riluzole prodrug (spinocerebellar ataxia/anxiety disorder/mood disorder/depression), Biohaven Pharmaceutical|FC-4157|BHV-4157|riluzole prodrug (spinocerebellar ataxia/anxiety disorder/mood disorder/depression/Alzheimer disease), Biohaven Pharmaceutical|troriluzole|troriluzole hydrochloride",Research Code|Research Code|USAN|PINN|USAN,Cancer|Neurology/Psychiatric,,,Antidepressant|Anticancer|Anxiolytic|Glutamate modulator|Neuroprotectant,2941|1545|2942|869|1615,Alzheimers disease|Hodgkins disease|Renal cell carcinoma|Lymphoma|Spinocerebellar ataxia|Friedreich ataxia|Squamous cell carcinoma|Stage III melanoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Essential tremor|Metastatic renal cell carcinoma|Obsessive compulsive disorder|Ataxia,14|161|1766|203|2407|2974|307|3256|3257|3466|3665|3673|3713|4085|4250|468|813,Generalized anxiety disorder|Mood disorder|Solid tumor,1937|533|725,Biohaven Pharmaceutical Holding Co Ltd|BioShin Ltd,1095923|1176447,,,Biohaven Pharmaceutical Holding Co Ltd,1095923,,,Growth Hormone Release Inhibitors,582,Signal Transduction Modulators,1402
100661,ISB-1342,"GBR-1342|CD38/CD3 bispecific monoclonal antibody (cancer/multiple myeloma), Glenmark Pharmaceuticals|anti-CD3/anti-CD38 bispecific Tcell engager (bsAb/BEAT, cancer), Glenmark|CD38/CD3 bispecific monoclonal antibody (cancer/multiple myeloma), Ichnos Sciences|anti-CD3/anti-CD38 bispecific Tcell engager (bsAb/BEAT, cancer), Ichnos Sciences|ISB-1342",Research Code|Research Code,Cancer,CD3 modulator|ADP ribosyl cyclase-1 modulator,5023|5134,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Multiple myeloma|Cancer,1828|651,,,Ichnos Sciences,1197193,Glenmark Pharmaceuticals SA,1078429,Glenmark Pharmaceuticals SA,1078429,,,,,,
100695,"alflutinib mesylate (oral/tablet, cancer), Allist Pharmaceuticals/ArriVent Biopharma","small molecule therapeutic (oral/tablet, cancer), Allist Pharmaceuticals|aifutini mesylate|aifutinib mesylate|AST-2818|alflutinib|alflutinib mesylate (oral/tablet, cancer), Allist Pharmaceuticals|fumeitini mesylate|furmonertinib|alflutinib mesylate (oral/tablet, cancer), Allist Pharmaceuticals/ArriVent Biopharma",Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Metastatic non small cell lung cancer|Solid tumor,1262|3665|725,,,ArriVent Biopharma Inc.|Allist Pharmaceuticals Inc,1258805|1033850,,,Allist Pharmaceuticals Inc,1033850,,,,,,
100744,PF-06671008,"anti-CD3/anti-cadherin 3 bispecific T-cell engager (DART, cancer), MacroGenics/Pfizer|P-cadherin LP-DART|PF-06671008|anti-CD3/anti-p-cadherin bispecific T-cell engager (DART, cancer), MacroGenics/Pfizer",Research Code,Cancer,CD3 modulator|Cadherin-3 modulator,5023|6148,Anticancer|T-lymphocyte stimulator|Anticancer antibody|Immunostimulant,1545|7761|55684|393,,,Advanced solid tumor|Cancer,3713|651,,,Pfizer Inc|MacroGenics Inc,18767|29060,MacroGenics Inc,29060,,,,,,
100751,PNK-007,"PNK-007|placental natural killer (PNK) cell therapy (AML/MM/GBM), Celularity",Research Code,Cancer,,,Anticancer|Natural killer cell stimulator,1545|7757,Acute myelogenous leukemia|Multiple myeloma|Glioblastoma,1731|1828|2454,,,Celularity Inc,1152669,Celgene Cellular Therapeutics,1003012,Celgene Cellular Therapeutics,1003012,,,,,,
100780,"engineered trastuzumab + pyrrolobenzodiazepine dimer cytotoxin (iv infusion, solid tumors), ADC Therapeutics","ADCT-502|antibody drug conjugate (solid tumors), ADC Therapeutics|engineered trastuzumab + pyrrolobenzodiazepine dimer cytotoxin (iv infusion, solid tumors), ADC Therapeutics",Research Code,Cancer,Erbb2 tyrosine kinase receptor inhibitor,3756,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,,,Advanced solid tumor|Cancer,3713|651,,,ADC Therapeutics Sarl,1068935,ADC Therapeutics Sarl,1068935,,,,,,
100784,ET-190,"ET-190|CD19-ARTEMIS T-cells (cancer), Eureka Therapeutics|ET190L1-ARTEMIS T cells (hematological cancer), Eureka therapeutics|ET190L1-ARTEMIS|anti-CD19 CAR T-cell therapy (cancer), Eureka Therapeutics",Research Code|Trade Name,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Burkitts lymphoma,1734|1744|1745|1749|316|319|791,Hematological neoplasm,2054,Eureka Therapeutics Inc,1053219,,,Eureka Therapeutics Inc,1053219,,,,,,
10084,tegafur + gimeracil + oteracil potassium,"Cefesone|S-1, Sanofi|TS-1, Sanofi|BMS-247616|tegafur + gimeracil + oxonate potassium|tegafur + gimeracil + oteracil potassium|Teysuno|TS-ONE|TS-1 combination capsule T20|TS-1 combination capsule T25|T-20, Taiho|T-25",Trade Name|Research Code|Research Code|Research Code|Trade Name|Trade Name,Cancer,Orotate phosphoribosyltransferase inhibitor|Dihydropyrimidine dehydrogenase inhibitor,6661|782,Anticancer antimetabolite|Anticancer,1569|1545,Non-small-cell lung cancer|Stomach tumor|Biliary cancer|Adenocarcinoma|Pancreas tumor|Metastatic colorectal cancer|Metastatic stomach cancer|Breast tumor|Head and neck tumor|Cancer|Lung tumor|Colorectal tumor,1262|127|1516|2399|249|3658|3666|49|623|651|755|989,Hepatocellular carcinoma|Prostate tumor|Squamous cell carcinoma|Metastatic esophageal cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Uterine cervix tumor,1767|276|307|3667|3713|4250|427,Taiho Pharmaceutical Co Ltd|Jeil Pharmaceutical Co Ltd|TTY Biopharm Co Ltd|Nordic Group|Taiho Oncology Inc,18720|17331|29954|1045267|1092741,Sanofi SA|Bristol-Myers Squibb Co,1009547|15065,Taiho Pharmaceutical Co Ltd,18720,,,,,,
100902,GB-5005,"anti-CD19 CAR T-cell therapy (leukemia, lupus), Shanghai GeneChem|GB-5005",Research Code|Research Code,Cancer|Immune,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,393|1545|7761|4790,B-cell acute lymphoblastic leukemia|Leukemia|B-cell lymphoma|Non-Hodgkin lymphoma,1729|199|316|319,Systemic lupus erythematosus,318,Shanghai GeneChem Co Ltd,1079360,,,Shanghai GeneChem Co Ltd,1079360,,,Progesterone Receptor Antagonists,561,Signal Transduction Modulators,1402
100983,"tapotoclax (intravenous, cancer), Amgen","AMG-176|MCL-1 inhibitor (intravenous, cancer), Amgen|tapotoclax|tapotoclax (intravenous, cancer), Amgen",Research Code|INN,Cancer,Mcl-1 differentiation protein inhibitor,11381,Anticancer,1545,Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Multiple myeloma|Non-Hodgkin lymphoma,1731|1749|1828|319,Non-small-cell lung cancer,1262,Amgen Inc,14109,,,Amgen Inc,14109,,,CCK Receptor Agonists,113,Signal Transduction Modulators,1402
101034,"paclitaxel (micelle, NSCLC), Shanghai Yizhong Biotechnology/Shanghai Kaibao Pharmaceutical","paclitaxel (micelle, NSCLC), Shanghai Yizhong Biotechnology/Shanghai Kaibao Pharmaceutical",,Cancer,,,Anticancer|Microtubule stabilizer,1545|2576,Non-small-cell lung cancer,1262,Cancer,651,Shanghai Yizhong Biotechnology Co Ltd,31372,,,Shanghai Yizhong Biotechnology Co Ltd,31372,,,,,,
101064,BI-765063,"Effi-DEM|OSE-172|SIRPa checkpoint inhibitor (cancer), OSE Immunotherapeutics|BI-765063",Research Code|Research Code,Cancer,Tyrosine phosphatase substrate 1 inhibitor,53055,Immunostimulant|Macrophage stimulator|Anticancer monoclonal antibody,393|7751|55685,Advanced solid tumor|Cancer,3713|651,,,OSE Immunotherapeutics|Boehringer Ingelheim International GmbH,1059851|14881,Effimune SA,1055517,Effimune SA,1055517,,,,,,
101079,azercabtagene zapreleucel,"allogeneic CAR T-cell therapy (ARCUS, cancer), Baxalta/ Precision BioSciences|allogeneic CAR T-cell therapy (ARCUS, cancer), Shire/Precision BioSciences|anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia), Precision BioSciences/Shire|PBCAR-0191|azercabtagene zapreleucel",Research Code|PINN,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,B-cell acute lymphoblastic leukemia|Mantle cell lymphoma|Non-Hodgkin lymphoma,1729|1744|319,Cancer,651,Precision BioSciences Inc,1032090,Baxalta Inc|Servier|Shire plc,1109518|19863|24652,Precision BioSciences Inc,1032090,,,,,,
101102,retifanlimab,"MGA-012|PD-1 checkpoint inhibitor (cancer), MacroGenics|INCMGA-00012|INCMGA-0012|retifanlimab",Research Code|Research Code|Research Code|USAN|INN,Cancer,Programmed cell death protein 1 inhibitor,67136,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Mesothelioma|Vascular neoplasm|Endometrioid carcinoma|Transitional cell carcinoma|Penis tumor|Sarcoma|Hematological neoplasm|Anal tumor|Bladder cancer|Fibrosarcoma|Leiomyosarcoma|Liposarcoma|Glioblastoma|Myxosarcoma|Squamous cell carcinoma|Merkel cell carcinoma|Stage III melanoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Solid tumor,1240|1539|1705|1771|1791|194|2054|2193|2380|2445|2446|2447|2454|2819|307|3235|3256|3257|3378|3466|3657|3665|3666|3669|3673|3713|4250|725,,,Zai Lab Limited|Incyte Corp,1101935|17216,MacroGenics Inc,29060,MacroGenics Inc,29060,,,Histamine H2 Receptor Antagonists,197,Signal Transduction Modulators,1402
101143,glumetinib,"small molecule therapeutic (oral/tablet, solid tumor), Shanghai Haihe Pharmaceutical/Shanghai Institute of Materia Medica/Shanghai Green Valley Pharmaceutical|gumeitini|HH-SCC-244|SCC-244|glumetinib",Research Code|Research Code,Cancer,Hepatocyte growth factor receptor antagonist,675,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer|Advanced solid tumor|Solid tumor,3665|3713|725,,,Shanghai Institute of Materia Medica of the Chinese Academy of Sciences|Shanghai Green Valley Pharmaceutical Co Ltd|HaiHe Pharmaceuticals Co Ltd,25314|1074069|1074074,,,Shanghai Institute of Materia Medica of the Chinese Academy of Sciences,25314,,,,,,
101162,"thiotepa (hematopoietic stem cell transplantation/solid tumors), Adienne","triethylenethiophosphoramide|52-24-4|thiotepa|thiotepa (hematopoietic stem cell transplantation/solid tumors), Adienne|Tepadina",USAN|BANN|INN|Trade Name,Cancer|Immune,,,Anticancer,1545,Hematopoietic stem cell transplantation|Solid tumor,3888|725,,,Accord Healthcare Inc|ADIENNE Pharma & Biotech SA,1052220|1037960,,,ADIENNE Pharma & Biotech SA,1037960,,,,,,
101174,valemetostat,"enhancer of zeste homolog 1/2 dual inhibitor (acute myeloid leukemia), Daiichi Sankyo|DS-3201b|OR-S1|(R)-OR-S2|DS-3201|valemetostat|DS-3201a|valemetostat tosylate",Research Code|Research Code|Research Code|Research Code|INN|Research Code|Research Code,Cancer,Enhancer of zeste homolog 2 inhibitor|Enhancer of zeste homolog 1 inhibitor,43815|43812,Anticancer,1545,Small-cell lung cancer|Hodgkins disease|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Mantle cell lymphoma|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Anaplastic large cell lymphoma|Adult T-cell lymphoma|Angioimmunoblastic T-cell lymphoma|Intestinal T-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1261|161|1728|1731|1744|1745|1747|1749|1750|1753|1754|1755|1757|1758|1760|316|319,Hematological neoplasm,2054,Daiichi Sankyo Co Ltd,1017506,,,Daiichi Sankyo Co Ltd,1017506,,,Xanthine Oxidase Inhibitors,514,,
101314,upifitamab rilsodotin,"XMT-1536|auristatin/NaPi2b-targeting-antibody drug conjugate (cancer), Mersana Therapeutics|auristatin-MERS-67 drug conjugate (cancer), Mersana Therapeutics|auristatin-XMT-1535 drug conjugate (cancer), Mersana Therapeutics|auristatin-upifitamab drug conjugate (cancer), Mersana Therapeutics|upifitamab rilsodotin|UpRi, Mersana Therapeutics Inc",Research Code,Cancer,Sodium phosphate cotransporter 2B modulator,32669,Microtubule inhibitor|Anticancer antibody,2575|55684,Thyroid tumor|Renal cell carcinoma|Fallopian tube cancer|Peritoneal tumor|Metastatic non small cell lung cancer|Metastatic ovary cancer|Salivary gland cancer|Cancer|Ovary tumor,1134|1766|2243|3083|3665|3866|4299|651|799,,,Mersana Therapeutics Inc|Recepta biopharma,1002523|1035632,,,Mersana Therapeutics Inc,1002523,,,,,,
101322,MV-NIS,"oncolytic measles virus therapy expressing NIS (bladder cancer, medulloblastoma, recurrent ATRT), Vyriad|MV-NIS|Measles-NIS",Research Code|Research Code,Cancer,,,Immunostimulant|Anticancer,393|1545,Bladder cancer|Medulloblastoma,2380|2533,Mesothelioma|Gastrointestinal tumor|Multiple myeloma|Hematological neoplasm|Glioblastoma|Metastatic non small cell lung cancer|Head and neck tumor|Ovary tumor,1240|131|1828|2054|2454|3665|623|799,Vyriad Inc,1121040,,,Vyriad Inc,1121040,,,,,,
101385,"prolgolimab (iv, advanced solid tumor/renal cell carcinoma/stage III melanoma/stage IV melanoma/metastatic non-small cell lung cancer/lung tumor), Biocad","anti PD-1 mAb (cancer), Biocad|BCD-100, Biocad|anti PD-1 monoclonal antibody (cancer), Biocad|PD-1 checkpoint inhibitor (solid tumor), Biocad|prolgolimab|prolgolimab (iv, advanced solid tumor/renal cell carcinoma/stage III melanoma/stage IV melanoma/metastatic non-small cell lung cancer/lung tumor), Biocad|Forteca|prolgolimab (iv, advanced solid tumor/renal cell carcinoma/stage III melanoma/stage IV melanoma/metastatic non-small cell lung cancer/lung tumor/squamous carcinoma/cervical cancer), Biocad",Research Code|INN|Trade Name,Cancer,Programmed cell death protein 1 inhibitor,67136,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Renal cell carcinoma|Squamous cell carcinoma|Stage III melanoma|Stage IV melanoma|Metastatic non small cell lung cancer|Advanced solid tumor|Uterine cervix tumor|Lung tumor,1766|307|3256|3257|3665|3713|427|755,,,SPH-BIOCAD (HK) Limited|Biocad Ltd,1250828|1035286,,,Biocad Ltd,1035286,,,Leukotriene Synthesis Inhibitors|Leukotriene Receptor Antagonists|Mediator Release Inhibitors,356|237|802,Signal Transduction Modulators,1402
101423,INCB-057643,"INCB-057643|BET inhibitors (advanced tumor), Incyte Corp|INCB-57643",Research Code|Research Code,Cancer|Hematologic,Bromodomain containing protein inhibitor,34558,Synergist|Anticancer,7293|1545,Metastasis|Lymphoma|Hematological neoplasm|Myelofibrosis|Ewing sarcoma|Hormone refractory prostate cancer|Advanced solid tumor,1069|203|2054|2436|2975|3246|3713,,,Incyte Corp,17216,,,Incyte Corp,17216,,,,,,
101425,rineterkib,LTT-462|rineterkib,Research Code|PINN,Cancer,Extracellular signal related kinase inhibitor|Extracellular signal related kinase-1 inhibitor|Extracellular signal related kinase-2 inhibitor,173760|4364|4366,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Melanoma|Stage IV melanoma|Metastatic colorectal cancer|Advanced solid tumor|Ovary tumor,1262|205|3257|3658|3713|799,,,Novartis AG,23137,,,Novartis AG,23137,,,Dopamine Receptor Agonists,129,Signal Transduction Modulators,1402
101427,simurosertib hydrate,TAK-931|simurosertib hydrate|simurosertib,Research Code|PINN,Cancer,CDC7 protein kinase inhibitor,4758,Anticancer protein kinase inhibitor,62255,Carcinosarcoma|Metastatic pancreas cancer|Advanced solid tumor|Uterus tumor|Ovary tumor,2614|3669|3713|740|799,Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Cancer|Colorectal tumor,3658|3665|3667|651|989,Takeda Oncology,21991,,,Takeda Oncology,21991,,,,,,
101434,JNJ-63709178,"JNJ-63709178|CNTO-9958|anti-CD3/anti-CD123 bispecific T-cell engager (DuoBody, acute myeloid leukemia), Janssen|JNJ-9178",Research Code|Research Code|Research Code,Cancer,CDw123 modulator|CD3 modulator,5427|5023,Anticancer antibody|Immunostimulant|T-lymphocyte stimulator,55684|393|7761,Acute myelogenous leukemia,1731,,,Janssen Research & Development LLC,1067538,,,Janssen Research & Development LLC,1067538,,,,,,
10144,rasburicase,urate oxidase|Elitek|SR-29142|Fasturtec|rasburicase|urate oxydase|Rasuritek,Trade Name|Research Code|Trade Name|USAN|BANN|INN|Trade Name,Endocrine/Metabolic|Inflammatory,Uricase stimulator,11816,Uric acid modulator,1808,Hyperuricemia,180,Gout,136,Sanofi SA,1009547,Sanofi-Synthelabo|Sanofi (pre-1999),26494|26495,Sanofi-Synthelabo,26494,,,,,,
101498,olutasidenib,"FT-2102|mutated isocitrate dehydrogenase 1 inhibitor (oral, AML/MDS), FORMA Therapeutics|mIDH1 inhibitor (AML/MDS), FORMA Therapeutics|olutasidenib",Research Code|USAN|PINN,Cancer,Isocitrate dehydrogenase inhibitor|Mitochondrial isocitrate dehydrogenase inhibitor,6333|67505,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Cholangiocarcinoma|Chondrosarcoma|Glioblastoma|Advanced solid tumor|Hepatobiliary system tumor,1272|1731|1765|2444|2454|3713|629,,,FORMA Therapeutics Inc,1043304,,,FORMA Therapeutics Inc,1043304,,Pyrrolomycin F1,,,,
101613,SHR-1316,"SHR-1316|HTI-1088|anti-PD-L1 humanized IgG4 monoclonal antibody (cancer), Jiangsu Hengrui Medicine|PD-L1 checkpoint inhibitor (cancer), Jiangsu Hengrui Medicine/Atridia|HTI-1316|adebrelimab",Research Code|Research Code|Research Code|INN,Cancer,Programmed cell death ligand 1 inhibitor,14007,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Small-cell lung cancer|Hematological neoplasm|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Advanced solid tumor|Cancer,1261|2054|3665|3667|3713|651,,,Jiangsu Hengrui Medicine Co Ltd|Atridia Pty Ltd,1006925|1111516,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,,,,
101614,BAY-1436032,"BAY-1436032|mIDH-1 inhibitor (cancer), Bayer",Research Code,Cancer,Isocitrate dehydrogenase inhibitor,6333,Anticancer,1545,,,Acute myelogenous leukemia|Advanced solid tumor|Cancer,1731|3713|651,,,Bayer AG,14455,Bayer AG,14455,,,,,,
101634,"anti-CD20 CAR T-cell therapy (diffuse large B cell lymphoma), Southwest Hospital Chongqing","anti-CD20 CAR T-cell therapy (diffuse large B cell lymphoma), Southwest Hospital Chongqing",,Cancer,B-lymphocyte antigen CD20 modulator,5083,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,Diffuse large B-cell lymphoma,1749,,,Southwest Hospital Chongqing,1056033,,,Southwest Hospital Chongqing,1056033,,,,,,
101638,BMS-986178,"anti-OX40 antibodies (cancer), Bristol-Myers Squibb|BMS-986178|OX40 costimulator (cancer), Bristol-Myers Squibb",Research Code,Cancer,OX-40 receptor agonist,5443,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Metastatic breast cancer|Advanced solid tumor,3657|3713,Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|B-cell lymphoma,1743|1744|1745|1746|316,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
101683,SGN-CD352A,"SGN-CD352A|CD352-targeted antibody-drug conjugate (cancer), Seattle Genetics|SGN-352A",Research Code|Research Code,Cancer,SLAM family member 6 modulator,45390,Anticancer monoclonal antibody,55685,,,Cancer,651,,,Seagen Inc,25554,Seagen Inc,25554,,,,,,
101717,CDX-1140,"CD40 agonist antibodies (cancer), Celldex Therapeutics|CDX-1140|CD40 costimulator (cancer), Celldex Therapeutics|human IgG2 CD40 agonist mAb (cancer/melanoma/uveal melanoma/brain tumor), Celldex Therapeutics|human IgG2 CD40 agonist mAb (cancer/melanoma/uveal melanoma/brain tumor/pancreatic ductal adenocarcinoma), Celldex Therapeutics",Research Code,Cancer,CD40 ligand receptor agonist,5141,B-lymphocyte stimulator|Dendritic cell stimulator|Macrophage stimulator|Immunostimulant|Anticancer monoclonal antibody|Anticancer,7741|173472|7751|393|55685|1545,Pancreatic ductal adenocarcinoma|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Cholangiocarcinoma|Fallopian tube cancer|Bladder cancer|Squamous cell carcinoma|Peritoneal tumor|B-cell lymphoma|Non-Hodgkin lymphoma|Stage I melanoma|Stage II melanoma|Stage III melanoma|Stage IV melanoma|Metastatic liver cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Uveal melanoma|Metastatic ovary cancer|Metastatic renal cell carcinoma|Cancer|Brain tumor,1507|1744|1749|1765|2243|2380|307|3083|316|319|3254|3255|3256|3257|3462|3657|3658|3665|3666|3667|3669|3673|3713|3788|3866|4250|651|760,,,Celldex Therapeutics Inc,25726,,,Celldex Therapeutics Inc,25726,,,,,,
101721,SPH-1188-11,"SPH-1188|SPH-1188-11|small molecule therapeutic (oral/tablet, NSCLC), Shanghai Pharmaceuticals Holding|I-010",Research Code|Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer,1262,,,Shanghai Pharmaceuticals Holding Co Ltd,1060612,,,Shanghai Pharmaceuticals Holding Co Ltd,1060612,,STA-Protease,,,,
101738,AFM-24,"AFM-24|EGFR/CD16A antibodies (solid tumors), Affimed GmbH|anti-CD16A/anti-EGFR bispecific immune-cell engager (TandAb, cancer), Affimed|anti-CD16A/anti-EGFR bispecific NK-cell engager (TandAb, cancer), Affimed|ICE (Affimed’s innate cell engager)",Research Code|Trade Name,Cancer,Immunoglobulin gamma Fc receptor IIIA agonist|Epidermal growth factor receptor modulator,27981|3605,Natural killer cell stimulator|Anticancer antibody|Leukocyte stimulator|Immunostimulant,7757|55684|7747|393,Glioblastoma|Metastatic bladder cancer|Metastatic renal cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Uterine cervix tumor|Ovary tumor,2454|3466|3467|3657|3658|3666|3667|3668|3669|3673|3713|427|799,Cancer,651,Affimed NV,30783,,,Affimed NV,30783,,,,,,
101768,ADP-A2M4,"MAGE-A4 SPEAR TCR therapy (cancer), Adaptimmune Therapeutics|autologous genetically modified MAGE-A4 C1032 T cells (cancer), Adaptimmune|anti-MAGE-A4/HLA-A*02 TCR T cell therapy (SPEAR, cancer), Adaptimmune Therapeutics|ADP-A2M4",Research Code,Cancer,Melanoma associated antigen 4 modulator|HLA class I antigen A-2 alpha modulator,21961|19115,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Melanoma|Bladder cancer|Liposarcoma|Soft tissue sarcoma|Metastatic head and neck cancer|Head and neck tumor|Ovary tumor,1011|1262|127|205|2380|2447|3378|3673|623|799,Cancer,651,Adaptimmune Therapeutics plc,1047486,,,Adaptimmune Therapeutics plc,1047486,,,,,,
101821,sirpiglenastat,"JHU-083|JHU-083, John Hopkins University|5c, Dracen Pharmaceuticals|DON prodrug (iv, glioblastoma), Dracen Pharmaceuticals|glutamine antagonist (iv/prodrug, glioblastoma), Dracen Pharmaceuticals|DRP-104|DON prodrug (cancer), Dracen Pharmaceuticals|sirpiglenastat",Research Code|Research Code|USAN,Cancer|Immune|Inflammatory|Neurology/Psychiatric,Glutaminase inhibitor,85018,Anti-inflammatory|Anticancer|Synergist,2953|1545|7293,HIV associated dementia|Inflammatory disease|Squamous cell carcinoma|Larynx tumor|Autoimmune disease|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer|Lung tumor|Mouth tumor|Pharynx tumor,1275|188|307|3198|36|3665|3713|651|755|793|794,,,Dracen Pharmaceuticals Inc,1159967,Johns Hopkins University,20596,Johns Hopkins University,20596,,,,,,
101844,ZSP-1602,ZSYM-004|ZSP-1602,Research Code|Research Code,Cancer,Smoothened receptor antagonist,11036,Anticancer,1545,Esophagus tumor|Neuroendocrine tumor|Small-cell lung cancer|Stomach tumor|Basal cell carcinoma|Glioblastoma|Medulloblastoma|Cancer,1011|1128|1261|127|1764|2454|2533|651,,,Guangdong Zhongsheng Pharmaceutical Co Ltd|WuXi AppTec Co Ltd,1063219|1014227,,,Guangdong Zhongsheng Pharmaceutical Co Ltd,1063219,,,,,,
101870,BA-3011,"CAB-Axl-ADC|anti-Axl conditionally active biologic antibody-drug conjugate (cancer), BioAtla/Himalaya|BA-3011|anti-AXL antibody-monomethyl auristatin E (MMAE) conjugate (cancer), BioAtla/Himalaya",Research Code|Research Code,Cancer,Axl tyrosine kinase receptor inhibitor,3742,Microtubule inhibitor|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor|Immunotoxin,2575|55685|62255|539,Hormone refractory prostate cancer|Soft tissue sarcoma|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Ovary tumor,3246|3378|3665|3669|3713|799,Pancreas tumor|Cancer,249|651,BioAtla llc|Himalaya Therapeutics SEZC,1054676|1241379,Sinobioway Group Co Ltd,1087964,BioAtla llc,1054676,,,,,,
101872,zimberelimab,"GLS-010|anti-PD-1 fully human mAb (cancer), Harbin Gloria Pharmaceuticals/WuXi PharmaTech|WBP-3055|PD-1 checkpoint inhibitor (OmniRat, cancer), Harbin Gloria Pharmaceuticals/WuXi Pharma Tech/Arcus Biosciences|AB-122|Zimberelimab|zimberelimab|GS-0122",Research Code|Research Code|Research Code|PINN|Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Esophagus tumor|Non-small-cell lung cancer|Hodgkins disease|Endometrioid carcinoma|Diffuse large B-cell lymphoma|Renal cell carcinoma|Multiple myeloma|Melanoma|Bladder cancer|Glioblastoma|Squamous cell carcinoma|Non-Hodgkin lymphoma|Larynx tumor|Merkel cell carcinoma|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Advanced solid tumor|Uterine cervix tumor|Breast tumor|Head and neck tumor|Cancer|Lung tumor|Mouth tumor|Pharynx tumor|Ovary tumor|Colorectal tumor,1011|1262|161|1705|1749|1766|1828|205|2380|2454|307|319|3198|3235|3246|3257|3658|3665|3666|3667|3669|3713|427|49|623|651|755|793|794|799|989,,,Harbin Gloria Pharmaceuticals Co Ltd|Taiho Pharmaceutical Co Ltd|Gilead Sciences Inc|WuXi Biologics (Cayman) Inc|Arcus Biosciences Inc,1065561|18720|16450|1122083|1129346,,,Harbin Gloria Pharmaceuticals Co Ltd,1065561,,,Calcium Channel Blockers,361,,
101878,IO-101,IO-101,Research Code,Cancer,"T-cell surface glycoprotein CD8 modulator|Indoleamine-pyrrole-2,3-dioxygenase modulator",5038|6365,Anticancer|Therapeutic vaccine,1545|12379,Stage IV melanoma|Metastatic non small cell lung cancer,3257|3665,,,IO Biotech ApS,1121281,,,IO Biotech ApS,1121281,,,,,,
101880,AZD-5153,"AZD-5153|bivalent BRD4 bromodomain inhibitor (cancer), AstraZeneca",Research Code,Cancer,Bromodomain containing protein 4 inhibitor,34570,Anticancer protein kinase inhibitor,62255,Myelodysplastic syndrome|Acute myelogenous leukemia|Lymphoma|Non-Hodgkin lymphoma|Solid tumor|Ovary tumor,1272|1731|203|319|725|799,Cancer,651,AstraZeneca plc,14190,,,AstraZeneca plc,14190,,,Angiotensin-I Converting Enzyme (ACE) Inhibitors,381,,
101883,IO-102,"IO-102|IDO-derived peptide vaccine (cancer), IO Biotech|Treg modulator (cancer), IO Biotech",Research Code,Cancer,"Indoleamine-pyrrole-2,3-dioxygenase modulator",6365,Therapeutic vaccine|Anticancer|Regulatory T lymphocyte inhibitor|T-lymphocyte stimulator|Protein subunit vaccine,12379|1545|174668|7761|12372,Melanoma|Squamous cell carcinoma|Metastatic non small cell lung cancer|Head and neck tumor,205|307|3665|623,,,IO Biotech ApS,1121281,,,IO Biotech ApS,1121281,,,,,,
101884,IO-103,"IO-103|PD-L1-derived peptide vaccine (cancer), IO Biotech|Treg modulator 2 (cancer) IO Biotech",Research Code,Cancer,Programmed cell death protein 1 modulator,67134,Anticancer|Immunostimulant|Regulatory T lymphocyte inhibitor|Therapeutic vaccine|Protein subunit vaccine,1545|393|174668|12379|12372,Chronic lymphocytic leukemia|Follicle center lymphoma|Basal cell carcinoma|Multiple myeloma,1734|1745|1764|1828,Cancer,651,IO Biotech ApS,1121281,,,IO Biotech ApS,1121281,,,beta-Adrenoceptor Antagonists,44,Signal Transduction Modulators,1402
101906,BTX-A51,"casein kinase-I alpha inhibitor (myelodysplastic syndrome/AML), Hebrew University/ Yissum|casein kinase-I alpha inhibitor (myelodysplastic syndrome/AML), BioTheryX|A-51|A-86 (BioTheryx)|BTX-A51",Research Code|Research Code,Cancer,Cyclin-dependent kinase-7 inhibitor|Cyclin-dependent kinase-9 inhibitor|Casein kinase-I alpha inhibitor,4304|8110|4292,Anticancer protein kinase inhibitor,62255,Myelodysplastic syndrome|Acute myelogenous leukemia|Non-Hodgkin lymphoma|Advanced solid tumor,1272|1731|319|3713,,,BioTheryX Inc,1058331,"Hebrew University of Jerusalem,|Yissum Research Development Co",20586|20978,"Hebrew University of Jerusalem,",20586,,,Estrogen Receptor (ER) alpha Antagonists,1286,Signal Transduction Modulators,1402
101953,ICTCAR-003,"anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia/acute lymphocytic leukemia), Innovative Cellular Therapeutics|CD19CART|ICT-19G1|ICTCAR-003",Research Code|Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|T-lymphocyte stimulator|Anticancer,393|7761|1545,Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|B-cell lymphoma,1728|1729|316,,,Innovative Cellular Therapeutics Co Ltd,1094076,,,Innovative Cellular Therapeutics Co Ltd,1094076,,,,,,
101966,VOR-33,"CAR T-cell therapy (cancer), Vor Biopharma|antigen-modified haematopoietic stem cells (B-celll malignacies), Vor Biophamra|VOR-33|anti-CD33 CAR T-cell therapy (cancer/hematological malignancy/AML), Vor BioPharma",Research Code,Cancer,CD33 modulator,5119,Immunostimulant|Anticancer|T-lymphocyte stimulator,393|1545|7761,Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm,1272|1731|2054,Cancer,651,Vor BioPharma,1123556,Columbia University,20559,Columbia University,20559,,,,,,
10209,aprinocarsen,"CGP-64128A|ISIS-3521|aprinocarsen|ISI-641|ISI-641A|Affinitac|Affinitak|LY-900003|aprinocarsen sodium|antisense oligonucleotide (PKC alpha), Lilly|antisense oligonucleotide (PKC alpha), Isis/Novartis",Research Code|Research Code|INN|Research Code|Research Code|Trade Name|Trade Name|Research Code|USAN,Cancer,Protein kinase C alpha inhibitor,3932,Anticancer protein kinase inhibitor|Antisense oligonucleotide inhibitor|Anticancer,62255|7294|1545,,,Non-small-cell lung cancer|Prostate tumor|Non-Hodgkin lymphoma|Cancer|Solid tumor,1262|276|319|651|725,,,Ionis Pharmaceuticals Inc|Eli Lilly & Co|Novartis AG,17269|17810|23137,Ionis Pharmaceuticals Inc,17269,,,,,,
102138,CIK-CAR.CD19,"CIK-CAR.CD19|anti-CD19 CAR cytokine induced killer cell therapy (ALL/NHL), Formula Pharmaceuticals|anti-CD19 CAR CIK-cell therapy (ALL/NHL), Formula Pharmaceuticals|CARCIK-CD19",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Non-Hodgkin lymphoma,1728|1734|319,,,CoImmune Inc (formerly Argos Therapeutics Inc),28019,Formula Pharmaceuticals Inc,1059000,Formula Pharmaceuticals Inc,1059000,,,,,,
102191,"disulfiram + copper gluconate (oral/chelate, glioblastoma/breast cancer/prostate cancer/metastatic pancreatic cancer), Cantex","CX-02 (disulfiram-copper), Cantex|disulfiram + copper gluconate (oral/chelate, glioblastoma), Cantex|disulfiram + copper gluconate (oral/chelate, glioblastoma/breast cancer/prostate cancer), Cantex|Dicopp|disulfiram + copper gluconate (oral/chelate, glioblastoma/breast cancer/prostate cancer/metastatic pancreatic cancer), Cantex",Research Code|Trade Name,Cancer|Infection,Proteasome inhibitor,4917,Antiviral|Anticancer,991|1545,Coronavirus disease 19 infection|Multiple myeloma|Glioblastoma|Metastatic prostate cancer|Metastatic pancreas cancer,10406|1828|2454|3664|3669,Breast tumor|Cancer,49|651,Washington University School of Medicine in St Louis|Cantex Pharmaceuticals Inc,1160134|29951,University of Utah,20690,University of Utah,20690,,,Calcium Channel Blockers,361,,
102208,MK-4280,"MK-4280|LAG-3 checkpoint inhibitor (solid tumor), Merck Sharp & Dohme|mavezelimab|MK-4280A|favezelimab",Research Code|PINN|Research Code,Cancer,CD223 antagonist,8413,Anticancer antibody|T-lymphocyte stimulator|Immunostimulant,55684|7761|393,Small-cell lung cancer|Hodgkins disease|Hematological neoplasm|B-cell lymphoma|Non-Hodgkin lymphoma|Metastatic non small cell lung cancer|Metastatic renal cell carcinoma|Solid tumor,1261|161|2054|316|319|3665|4250|725,,,Merck Sharp & Dohme Corp,1059823,,,Merck Sharp & Dohme Corp,1059823,,,,,,
102219,lodapolimab,"LY-3300054|PD-L1 mAb (cancer), Eli Lilly|PD-L1 checkpoint inhibitor (solid tumor), Eli Lilly|PD-L1 antibody + LY combo (cancer), Eli Lilly|anti-PD-L1 antibody (solid tumors), Eli Lilly|lodapolimab",Research Code|USAN|INN,Cancer,Programmed cell death ligand 1 inhibitor,14007,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Stage IV melanoma|Metastatic pancreas cancer|Advanced solid tumor|Breast tumor,3257|3669|3713|49,Solid tumor,725,Eli Lilly & Co,17810,,,Eli Lilly & Co,17810,,,,,,
102232,ONC-392,"ONC-392|CTLA-4 checkpoint inhibitor (cancer), OncoImmune|anti-CTLA4 humanized monoclonal antibody (cancer), OncoImmune",Research Code,Cancer,Cytotoxic T-lymphocyte protein-4 inhibitor,5482,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,Small-cell lung cancer|Hepatocellular carcinoma|Sarcoma|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma|Cancer,1261|1767|194|3257|3657|3658|3664|3665|3666|3673|3713|3866|4250|651,,,Pfizer Inc|OncoImmune Inc,18767|1049281,,,OncoImmune Inc,1049281,,,,,,
102234,PGV-001,"PGV-001|Personalized Genome Vaccine 001|personalized peptide vaccine (solid tumors), Mount Sinai Medical Center|mutation-derived tumor antigen based personalized vaccine (glioblastoma), Mount Sinai School of Medicine|MTA-based personalized vaccine (glioblastoma), Mount Sinai School of Medicine",Research Code,Cancer,TLR-3 agonist,7809,Natural killer cell stimulator|Therapeutic vaccine|Anticancer|T-lymphocyte stimulator|TNF release modulator|IL release stimulator,7757|12379|1545|7761|3510|4994,Bladder cancer|Glioblastoma|Solid tumor,2380|2454|725,,,Mount Sinai Medical Center,24815,,,Mount Sinai Medical Center,24815,,,,,,
102242,LY-3410738,"mutant IDH1 inhibitor (cancer), Eli Lilly|inhibitor selective for mutant IDH1 (IDH1-mutant tumors), Eli Lilly|LY-3410738",Research Code,Cancer,Mitochondrial isocitrate dehydrogenase inhibitor,67505,Anticancer,1545,Glioma|Myelodysplastic syndrome|Acute myelogenous leukemia|Cholangiocarcinoma|Hematological neoplasm|Chondrosarcoma|Advanced solid tumor|Cancer|Chronic myelomonocytic leukemia,1108|1272|1731|1765|2054|2444|3713|651|6833,,,Eli Lilly & Co,17810,,,Eli Lilly & Co,17810,Astat,Tazobactam sodium,beta-Lactamase (Bacterial) Inhibitors,501,,
102248,"anti-CD19 CAR T-cell therapy (B-cell malignancies), Sheba Medical Center","anti-CD19 CAR T-cell therapy (B-cell malignancies), Sheba Medical Center|CAR T-cell therapy (B-cell lymphoma), Sheba Medical Center",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Acute lymphoblastic leukemia|Acute myelogenous leukemia|B-cell lymphoma,1728|1731|316,,,Sheba Medical Center,DOL1000637,,,Sheba Medical Center,DOL1000637,,,,,,
10231,"resiquimod (topical gel, cutaneous T cell lymphoma) Galderma/University of Pennsylvania","S-28463|resiquimod (topical), 3M/Celldex|imiquimod analog, 3M/Lilly|resiquimod|R-848|resiquimod (topical gel, cutaneous T cell lymphoma) Galderma/University of Pennsylvania|CD-11301",Research Code|INN|Research Code|Research Code,Cancer|Dermatologic|Immune|Infection,IL2 gene stimulator|TLR-7 agonist|TLR-8 agonist,1653|7821|7824,Adjuvant|Interferon modulator|Anticancer|Immunostimulant,524|1379|1545|393,Cutaneous T-cell lymphoma,1754,Keratosis|Eczema|Herpes simplex virus infection|Basal cell carcinoma|Vaccination,1057|109|157|1764|384,Pennsylvania State University,25251,Eli Lilly & Co|Galderma Spirig|3M Pharmaceuticals|Celldex Therapeutics Inc,17810|20233|21568|25726,3M Pharmaceuticals,21568,,,,,,
102320,"anti-CD19 CAR T-cell therapy (cancer), iCarTAB BioMed","anti-CD19 CAR T-cell therapy (cancer), iCarTAB BioMed|anti-CD19 scFv CAR T-cell therapy (acute lymphoblastic leukemia), Xuzhou Medical University",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer,393|4790|7761|1545,B-cell lymphoma|Cancer,316|651,,,iCarTAB BioMed Inc|Xuzhou Medical University,1124570|1083396,,,iCarTAB BioMed Inc,1124570,,,,,,
102325,CID-103,"CD38 checkpoint inhibitor (cancer), Tusk Therapeutics|fully human anti‐CD38 antibodies (cancer), Tusk Therapeutics|TSK-011010|CD38 checkpoint inhibitor (cancer), Black Belt Therapeutics|CD38 checkpoint inhibitor (multiple myeloma/solid tumors), Black Belt Therapeutics|CD38 checkpoint inhibitor (cancer), CASI Pharmaceuticals|CID-103",Research Code|Research Code,Cancer,ADP ribosyl cyclase-1 modulator,5134,Immunostimulant|Anticancer antibody|T-lymphocyte stimulator,393|55684|7761,Multiple myeloma|Hematological neoplasm|Solid tumor,1828|2054|725,,,CASI Pharmaceuticals Inc,21794,Tusk Therapeutics Ltd|Black Belt Therapeutics Ltd,1124670|1172390,Tusk Therapeutics Ltd,1124670,,,,,,
102390,68Ga-NeoBOMB1,68Ga-NeoBOMB1|67Ga-NeoBOMB1|68Ga-NeoB,,Cancer,Bombesin BB2 receptor antagonist,3206,Radiodiagnostic|Endocrine diagnostic agent|Anticancer|Gastrointestinal diagnostic agent|PET contrast agent|Neoplasm diagnostic agent,5720|7212|1545|7213|5555|7220,Small-cell lung cancer|Non-small-cell lung cancer|Prostate tumor|Gastrointestinal stromal tumor|Advanced solid tumor|Breast tumor|Colorectal tumor,1261|1262|276|3205|3713|49|989,Cancer,651,Advanced Accelerator Applications SA,1017958,"Erasmus University Medical Center Rotterdam|National Centre For Scientific Research ""Demokritos""",1018611|31095,Erasmus University Medical Center Rotterdam,1018611,,,,,,
102416,IMGN-632,"IMGN-632|anti-CD123 antibody-drug conjugate (intravenous, acute lymphoblastic leukemia/acute myelogenous leukemia/hematological neoplasm), ImmunoGen/Jazz Pharmaceuticals|DGN549/G4723A conjugate (intravenous, acute lymphoblastic leukemia/acute myelogenous leukemia/hematological neoplasm), ImmunoGen/Jazz Pharmaceuticals",Research Code,Cancer,CDw123 modulator,5427,Anticancer alkylating agent|Anticancer monoclonal antibody|DNA modulator|Immunotoxin,50|55685|803|539,Acute lymphoblastic leukemia|Acute myelogenous leukemia|Hematological neoplasm,1728|1731|2054,,,ImmunoGen Inc,17202,,,ImmunoGen Inc,17202,,,,,,
102424,ABBV-927,"ABBV-927|CD40 costimulator (solid tumors), AbbVie|anti-CD40 monoclonal antibody (solid tumors), AbbVie|giloralimab",Research Code|INN,Cancer,CD40 ligand receptor agonist,5141,Dendritic cell stimulator|Anticancer monoclonal antibody|B-lymphocyte stimulator|Immunostimulant|Macrophage stimulator,173472|55685|7741|393|7751,Squamous cell carcinoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor,307|3657|3665|3669|3673|3713,Solid tumor,725,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
102425,budigalimab,"ABBV-181|anticancer mAbs (iv, ovarian cancer/solid tumor), AbbVie Inc|budigalimab|anticancer monoclonal antibody (iv, ovarian cancer/solid tumor/SCLC), AbbVie|PD-1 checkpoint inhibitor (cancer), AbbVie|budigalimab (cancer), AbbVie|budigalimab (HIV-1 infection), AbbVie",Research Code|INN,Cancer|Infection,Programmed cell death protein 1 inhibitor,67136,Antiviral|T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody|Anticancer,991|7761|393|55685|1545,Small-cell lung cancer|HIV-1 infection|Hematological neoplasm|Squamous cell carcinoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Solid tumor|Ovary tumor,1261|159|2054|307|3657|3665|3669|3673|3713|725|799,,,AbbVie Inc,1072507,Stemcentrx Inc,1063564,AbbVie Inc,1072507,,,,,,
102427,ABBV-368,"ABBV-368|OX40 costimulator (solid tumor), AbbVie|revdofilimab",Research Code|PINN,Cancer,OX-40 receptor agonist,5443,Immunostimulant|Anticancer monoclonal antibody|Anticancer|T-lymphocyte stimulator,393|55685|1545|7761,Squamous cell carcinoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Solid tumor,307|3657|3665|3673|3713|725,,,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
102436,Flysyn,"Flysyn|chimeric Fc-optimized anti-FLT3 IgG1 antibody (acute myeloid leukemia), Synimmune",,Cancer,Flt3 tyrosine kinase inhibitor,3806,Anticancer antibody|Anticancer protein kinase inhibitor,55684|62255,Acute myelogenous leukemia,1731,,,Synimmune GmbH,1063372,,,Synimmune GmbH,1063372,,,,,,
102457,XS-15,"XS-15|adjuvant, tumor peptide vaccine (cancer), EMC microcollections/University Tubingen|adjuvant, tumor peptide vaccine (glioblastoma), University Tubingen",Research Code,Cancer,,,Adjuvant|Anticancer,524|1545,Astrocytoma|Glioblastoma,2453|2454,Cancer,651,Eberhard Karls Universität Tübingen,23358,EMC Microcollections GmbH,1005390,EMC Microcollections GmbH,1005390,,,Thromboxane A2 Receptor (TBXA2R; TP) Antagonists,298,Signal Transduction Modulators,1402
102461,tiragolumab,"anti-TIGIT antibody (cancer), Roche|tiragolumab|TIGIT checkpoint inhibitor (OmniAb, solid tumor), Genentech|MTIG-7192A|RG-6058|RO-7092284",INN|Research Code|Research Code|Research Code,Cancer,T cell immunoreceptor Ig ITIM protein inhibitor,64787,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,Rectal tumor|Small-cell lung cancer|Hepatocellular carcinoma|Multiple myeloma|Adenocarcinoma|Pancreas tumor|Squamous cell carcinoma|B-cell lymphoma|Non-Hodgkin lymphoma|Larynx tumor|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Uterine cervix tumor|Mouth tumor|Pharynx tumor,1055|1261|1767|1828|2399|249|307|316|319|3198|3657|3665|3666|3667|3673|3713|427|793|794,Cancer,651,Roche Holding AG|Chugai Pharmaceutical Co Ltd|Genentech Inc,19446|15414|19453,,,Genentech Inc,19453,,,,,,
102486,SEL-403,"LMB-100|SEL-403|LMB-100 + SVP-Rapamycin (mesothelioma), Selecta Biosciences",Research Code|Research Code,Cancer,mTOR inhibitor|Mesothelin modulator,10240|11484,Anticancer antibody|Immunomodulator,55684|1596,Mesothelioma|Non-small-cell lung cancer|Pancreas tumor|Solid tumor,1240|1262|249|725,,,National Cancer Institute (NCI)|Selecta Biosciences Inc,20519|1045799,National Institutes of Health Clinical Center,1069368,National Institutes of Health Clinical Center,1069368,,,Lysosomal alpha-Glucosidase (GAA) Inhibitors,391,,
102507,ABBV-428,"ABBV-428|dual CD40 costimulator/anti-mesothelin (solid tumors), AbbVie|anti-CD40/anti-mesothelin bispecific antibody (solid tumors), AbbVie",Research Code,Cancer,Mesothelin modulator|CD40 ligand receptor agonist,11484|5141,B-lymphocyte stimulator|Dendritic cell stimulator|Immunostimulant|Anticancer antibody|Macrophage stimulator,7741|173472|393|55684|7751,Advanced solid tumor,3713,Solid tumor,725,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
10252,insulin glargine,"Hoe-901|insulin glargine|Lantus|recombinant insulin analog, Aventis|Lantus SoloStar|Optisulin|U100|Lantus ClikSTAR|Lantus AllSTAR|Gla-100",Research Code|USAN|BANN|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Research Code,Endocrine/Metabolic,Insulin receptor agonist|Insulin ligand,400|23014,Human insulin long acting product|Hypoglycemic agent,38215|399,Insulin dependent diabetes|Non-insulin dependent diabetes|Diabetes mellitus,836|837|97,,,Aventis Pharma AG|Sanofi SA,25218|1009547,Hoechst AG,16807,Aventis Pharma AG,25218,,,,,,
102520,CART-33,"CART-33|anti-CD33 CAR T-cell therapy (leukemia), Chinese PLA General Hospital",,Cancer,CD33 modulator,5119,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,,,Acute myelogenous leukemia,1731,,,Chinese PLA General Hospital Medical School Of Chinese PLA,1021685,Chinese PLA General Hospital Medical School Of Chinese PLA,1021685,,,,,,
102549,ATLCAR.CD30,"ATLCAR.CD30|anti-CD30 CAR T-cell therapy (lymphoma), UNC Lineberger|ATLCAR.CD30 T-cell therapy (Hodgkin's lymphoma/non-hodgkin lymphoma/peripheral T-cell lymphoma), UNC Lineberger",Research Code,Cancer,CD30 modulator,5110,Anticancer|Genetically engineered autologous cell therapy|Immunostimulant|T-lymphocyte stimulator,1545|4790|393|7761,Hodgkins disease|Peripheral T-cell lymphoma|Lymphoma|Non-Hodgkin lymphoma,161|1753|203|319,,,UNC Lineberger Comprehensive Cancer Center,1041077,,,UNC Lineberger Comprehensive Cancer Center,1041077,,,,,,
102552,CART-138,"CART-138|anti-CD138 CAR T-cell therapy (multiple myeloma), Chinese PLA General Hospital",Research Code,Cancer,Syndecan-1 modulator,5452,Immunostimulant|T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy,393|7761|1545|4790,,,Multiple myeloma,1828,,,Chinese PLA General Hospital Medical School Of Chinese PLA,1021685,Chinese PLA General Hospital Medical School Of Chinese PLA,1021685,,,,,,
102553,CD7-CAR-T,"CAR-pNK|anti-CD7 CAR pNK-cell therapy (leukemia/lymphoma), PersonGen Biomedicine|anti-CD7 CAR NK-cell therapy (leukemia/lymphoma), PersonGen Biomedicine|CD7-CAR-T|PA3-17|anti-CD7 CAR-gamma-delta T-cell therapy (intravenous, leukemia/lymphoma), PersonGen Biomedicine",Research Code|Research Code|Research Code,Cancer,T-cell antigen CD7 modulator,5035,Immunostimulant|Natural killer cell stimulator|Genetically engineered autologous cell therapy|Anticancer,393|7757|4790|1545,Acute leukemia|T-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Precursor T-lymphoblastic lymphoma-leukemia|Peripheral T-cell lymphoma|Leukemia|Lymphoma,1727|1730|1731|1752|1753|199|203,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,,,,
102613,1928z-41BBL,"1928z-41BBL|anti-CD19 CAR T-cell therapy (cancer), Memorial Sloan-Kettering/Juno",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer|Immunostimulant,4790|7761|1545|393,Chronic lymphocytic leukemia,1734,Cancer,651,Memorial Sloan-Kettering Cancer Center,22122,,,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
102630,tidutamab,"XmAb-18087|anti-CD3/anti-SSTR2 bispecific T-cell engager (neuroendocrine tumor/GIST), Xencor|tidutamab",Research Code|USAN|INN,Cancer,Somatostatin 2 receptor modulator|CD3 modulator,2561|5023,Anticancer|Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,1545|393|55685|7761,Neuroendocrine tumor|Small-cell lung cancer|Gastrointestinal stromal tumor|Merkel cell carcinoma,1128|1261|3205|3235,,,Xencor Inc,27617,,,Xencor Inc,27617,,Eudistomicin C,,,,
102631,XmAb-20717,"XmAb-20717|PD-1 x CTLA-4 bispecific antibodies (cancer), Xencor|dual CTLA-4 checkpoint inhibitor/PD-1 checkpoint inhibitor (FcRn-mediated half-life extension/Xtend, cancer), Xencor|XENP-20053|vudalimab",Research Code|Research Code|PINN,Cancer,Programmed cell death protein 1 inhibitor|IgG receptor FcRn large subunit p51 modulator|Cytotoxic T-lymphocyte protein-4 inhibitor,67136|72028|5482,Anticancer monoclonal antibody|Immunostimulant|Anticancer|T-lymphocyte stimulator,55685|393|1545|7761,Endometrioid carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Squamous cell carcinoma|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma,1705|1767|1771|307|3246|3257|3657|3658|3665|3666|3673|3713|4250,Cancer,651,Xencor Inc,27617,,,Xencor Inc,27617,,,Angiotensin-I Converting Enzyme (ACE) Inhibitors,381,,
10271,palbociclib,"PD-0332991|cell cycle regulators, Pfizer|cell cycle regulators, Onyx/Pfizer|cell cycle regulators, Onyx/Parke-Davis|PD-0205606|PD-332991|PF-332991|PD-991|palbociclib|palbociclib isethionate|Ibrance|PD-0332991-00|PF-0332991|Aiboxin",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|USAN|Trade Name|Research Code|Research Code|Trade Name,Cancer,Retinoblastoma associated protein modulator|Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase-6 inhibitor,19467|4314|4318,Apoptosis stimulator|Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Synergist|Cell cycle inhibitor|Anticancer,1589|62255|61|7293|767|1545,Pancreatic ductal adenocarcinoma|Male breast neoplasm|Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Mantle cell lymphoma|Fallopian tube cancer|Rhabdomyosarcoma|Medulloblastoma|Neuroblastoma|Ewing sarcoma|Peritoneal tumor|Hormone refractory prostate cancer|Metastatic liver cancer|Metastatic brain cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic ovary cancer,1507|1656|1728|1729|1731|1744|2243|2448|2533|2726|2975|3083|3246|3462|3471|3657|3665|3866,Multiple myeloma|Liposarcoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic prostate cancer|Metastatic head and neck cancer|Urethral cancer|Breast tumor|Cancer|Solid tumor,1828|2447|3257|3466|3664|3673|3678|49|651|725,Pfizer Inc,18767,Onyx Pharmaceuticals Inc|Parke-Davis & Co,18683|20805,Onyx Pharmaceuticals Inc,18683,,,,,,
102733,"idronoxil (suppository, late-stage prostate cancer/soft tissue sarcoma/cancers/COVID-19-associated diseases), Noxopharm","idronoxil|idronoxil innovative dosage form (cancer), Noxopharm|NOX-66|Veyonda|idronoxil (suppository, cancer), Noxopharm|STING agonist (suppository, cancer), Noxopharm|idronoxil (suppository, late-stage prostate cancer/soft tissue sarcoma/cancers/COVID-19-associated diseases), Noxopharm",USAN|INN|Research Code|Trade Name,Cancer|Cardiovascular|Infection|Respiratory,Topoisomerase inhibitor|CASP8-FADD-like regulator inhibitor|Sphingosine kinase inhibitor|Ecto NOX disulfide thiol exchanger 2 inhibitor|X-linked inhibitor of apoptosis protein inhibitor|Sphingosine-1-phosphate receptor-1 antagonist|Stimulator of interferon genes protein stimulator,143|14467|6789|75726|13605|8520|89933,Apoptosis stimulator|Immunostimulant|Anticancer|Dendritic cell stimulator|Anticancer chemosensitizer|T-lymphocyte stimulator,1589|393|1545|173472|1586|7761,Coronavirus disease 19 infection|Multiple organ failure|Hormone refractory prostate cancer|Soft tissue sarcoma|Metastatic breast cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Cancer|Solid tumor|Respiratory distress syndrome|Septic shock,10406|3094|3246|3378|3657|3664|3665|651|725|8|816,,,Noxopharm Ltd,1126344,,,Noxopharm Ltd,1126344,,,,,,
102736,UCPVax,UCPVax|Universal Cancer Peptide vaccine,,Cancer,Uncoupling protein-2 modulator,9724,Therapeutic vaccine|Adjuvant|Anticancer,12379|524|1545,Anal tumor|Adenocarcinoma|Glioblastoma|Squamous cell carcinoma|Large cell lung carcinoma|Metastatic non small cell lung cancer|Uterine cervix tumor,2193|2399|2454|307|3407|3665|427,,,Invectys,1088324,,,Invectys,1088324,,,beta-Adrenoceptor Antagonists,44,Signal Transduction Modulators,1402
102798,"anti-CD33 CAR T-cell therapy (acute myeloid leukemia), Ziopharm Oncology/Precigen","autologous T cell therapy (acute myeloid leukemia), ZIOPHARM Oncology Inc|anti-CD33 CAR T-cell therapy (acute myeloid leukemia), Ziopharm Oncology/Intrexon|INXN-3004|INXN-3004 Viral CAR-T|anti-CD33 CAR T-cell therapy (acute myeloid leukemia), Ziopharm Oncology/Precigen",Research Code,Cancer,CD33 modulator,5119,Immunostimulant|T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy,393|7761|1545|4790,Acute myelogenous leukemia,1731,,,ZIOPHARM Oncology Inc|Precigen Inc,1009856|1021778,,,ZIOPHARM Oncology Inc,1009856,,,,,,
102807,M-7583,M-7583,Research Code,Cancer,Btk tyrosine kinase inhibitor,3592,Anticancer protein kinase inhibitor,62255,,,Hematological neoplasm,2054,,,EMD Serono Inc,1035512,EMD Serono Inc,1035512,,Kolaviron,LDL Antioxidants,700,Antioxidants|Free Radical Scavengers,778|913
102917,EU-101,"EU-101|4-1BB costimulator (cancer), Eutilex/Zhejiang Huahai Pharmaceutical|NOV-1801",Research Code|Research Code,Cancer,CDw137 agonist,5450,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Neoplasm|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,230|3658|3665|3713|651,,,Eutilex Co Ltd|Zhejiang Huahai Pharmaceutical Group Co Ltd,1126644|1030330,,,Eutilex Co Ltd,1126644,,Transcainide,,,,
102932,"4-1BB CTL adoptive T cell therapy (cancer/T-cell lymphoma), Eutilex","4-1BB CTL adoptive T cell therapy (cancer), Eutilex|EBV latent membrane protein-2a specific eutil autologous blood-derived T cell therapy (lymphoma), Eutilex|4-1BB CTL adoptive T cell therapy (cancer/T-cell lymphoma), Eutilex|EBViNT Cell therapy (cancer/T-cell lymphoma), Eutilex",,Cancer,,,Genetically engineered autologous cell therapy|Anticancer,4790|1545,T-cell lymphoma|Cancer,311|651,,,Eutilex Co Ltd,1126644,,,Eutilex Co Ltd,1126644,,,,,,
102972,KY-1044,"KY-1044|ICOS costimulator (Kymouse, cancer), Wellcome Trust Sanger Institute/Kymab",Research Code,Cancer,Inducible T-cell co-stimulator stimulator,15391,T-lymphocyte inhibitor|T-lymphocyte stimulator|Anticancer monoclonal antibody|Anticancer|Synergist|Immunostimulant,7760|7761|55685|1545|7293|393,Metastasis|Hepatocellular carcinoma|Squamous cell carcinoma|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Metastatic renal cell carcinoma|Uterine cervix tumor,1069|1767|307|3257|3657|3665|3666|3667|3669|3673|4250|427,Cancer,651,Kymab Ltd,1065894,Wellcome Trust Sanger Institute,24961,Wellcome Trust Sanger Institute,24961,,,,,,
103015,CC-90009,"CC-90009|cereblon E3 ligase modulator (intravenous, acute myeloid leukemi), Celgene/AbbVie|cereblon E3 ligase modulator (iv, acute myeloid leukemi), AbbVie/Bristol-Myers Squibb",Research Code,Cancer,Ubiquitin ligase modulator|Protein cereblon modulator,2963|77059,Anticancer,1545,Acute myelogenous leukemia,1731,,,Bristol-Myers Squibb Co|AbbVie Inc,15065|1072507,Celgene Corp,15331,Celgene Corp,15331,,,,,,
103016,"autologous dendritic cell vaccine (acute myeloid leukemia/glioma/glioblastoma), Antwerp University Hospital","dendritic cell vaccine (acute myeloid leukemia), Antwerp University Hospital|dendritic cell vaccine (acute myeloid leukemia/glioma), Antwerp University Hospital|autologous dendritic cell vaccine (acute myeloid leukemia/glioma/glioblastoma), Antwerp University Hospital",,Cancer,Wilms tumor protein modulator,30009,Dendritic cell vaccine|Anticancer|RNA vaccine|Therapeutic vaccine|Genetically engineered autologous cell vaccine,102926|1545|12377|12379|4791,Glioma|Acute myelogenous leukemia|Glioblastoma,1108|1731|2454,,,Antwerp University Hospital,1056894,,,Antwerp University Hospital,1056894,,,,,,
103041,SPARC-147709,SPARC-147709,Research Code,Cancer,,,Anticancer,1545,,,Multiple myeloma,1828,,,Sun Pharmaceutical Advanced Research Co Ltd,1035705,Sun Pharmaceutical Advanced Research Co Ltd,1035705,,,,,,
103049,dendritic cell survivin vaccine,dendritic cell survivin vaccine|DC:AdmS,Research Code,Cancer,,,Dendritic cell vaccine|Anticancer|Therapeutic vaccine,102926|1545|12379,Multiple myeloma,1828,,,H Lee Moffitt Cancer Center and Research Institute,29603,,,H Lee Moffitt Cancer Center and Research Institute,29603,,,,,,
103054,orvacabtagene autoleucel,"ET-140|anti-BCMA CAR T-cell therapy (lentiviral vector, multiple myeloma), MSKCC/Eureka/Juno Therapeutics|JCARH-125|125-BBz|BCMA-125|JCAR-125|orvacabtagene autoleucel|Orva-cel",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN,Cancer,APRIL receptor modulator,8255,Immunostimulant|Anticancer|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,393|1545|4790|7761,,,Multiple myeloma,1828,,,Eureka Therapeutics Inc|Juno Therapeutics Inc|Bristol-Myers Squibb Co|Celgene Corp|Memorial Sloan-Kettering Cancer Center,1053219|1090676|15065|15331|22122,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
103057,BM-4,BM-4|BM-41,Research Code|Research Code,Immune|Ocular,,,Immunomodulator|Allergen|Anti-inflammatory,1596|1570|2953,Allergic rhinitis|Allergic conjunctivitis,1107|2438,,,Academic Medical Center University of Amsterdam|Biomay AG|University of Salzburg|University of Turku,26011|1022510|1041640|DOL1000739,,,Biomay AG,1022510,,,,,,
103058,aumolertinib,HS-10296|omatinib mesylate|almonertinib|AMEILE|aumolertinib|EQ-143,Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer,3665,Lung tumor,755,EQRx|Jiangsu Hansoh Pharmaceutical Group Co Ltd,1203707|1017684,,,Jiangsu Hansoh Pharmaceutical Group Co Ltd,1017684,,,,,,
103080,LY-3214996,"ERK 1/2 inhibitor (cancer), Loxo Oncology|LY-3214996|ERK inhibitor (cancer), Elli Lilly",Research Code,Cancer,Extracellular signal related kinase-1 inhibitor|Extracellular signal related kinase-2 inhibitor,4364|4366,Anticancer protein kinase inhibitor|Anticancer|Synergist,62255|1545|7293,Metastasis|Glioma|Acute myelogenous leukemia|Adenocarcinoma|Glioblastoma|Metastatic non small cell lung cancer|Metastatic pancreas cancer,1069|1108|1731|2399|2454|3665|3669,Cancer,651,Loxo Oncology at Lilly,1086092,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
10309,abiraterone,CB-7630|abiraterone|piraterone|CB-7598|abiraterone acetate|Zytiga|JNJ-212082|JNJ-589485,Research Code|BANN|INN|Research Code|USAN|Trade Name|Research Code|Research Code,Cancer|Endocrine/Metabolic,Cytochrome P450 17 inhibitor,7472,Androgen synthesis inhibitor|Anticancer,937|1545,Hormone refractory prostate cancer|Hormone dependent prostate cancer|Metastatic breast cancer|Breast tumor,3246|3247|3657|49,Congenital adrenal hyperplasia|Prostate tumor,1654|276,Janssen Pharmaceutical KK|Johnson & Johnson|Janssen Research & Development LLC|Janssen-Cilag Ltd|Janssen Inc,17408|17332|1067538|17392|17403,Cougar Biotechnology Inc|Boehringer Ingelheim International GmbH|BTG plc|Cancer Research Campaign Technology Ltd|Janssen Biotech Inc,1007756|14881|15266|24077|26997,Cancer Research Campaign Technology Ltd,24077,,,,,,
103106,olafertinib,CK-101|olafertinib|RX-518,Research Code|INN|Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Adenocarcinoma|Advanced solid tumor,1262|2399|3713,Cancer,651,Suzhou Neupharma Co Ltd|Checkpoint Therapeutics Inc,1063709|1106471,Neupharma Inc,1078973,Suzhou Neupharma Co Ltd,1063709,,,,,,
10315,beta-alethine,"beta-alethine|vitalethine|Betathines|cysteamine derivatives, Dovetail|Betathine|Beta LT",INN|Trade Name|Trade Name|Trade Name,Cancer,,,Anticancer|Immunostimulant|Unspecified drug target,1545|393|59620,,,Multiple myeloma|Non-Hodgkin lymphoma|Cancer,1828|319|651,,,CureImmune Corp|FindCure Org Inc|Dovetail Technologies Inc|University of New Mexico|LifeTime Pharmaceuticals Inc,1153753|1153754|15747|20639|26470,University of New Mexico,20639,,,,,,
103151,"trivalent influenza vaccine (influenza), National Cancer Institute","trivalent influenza vaccine (influenza), National Cancer Institute",,Infection,,,Unspecified drug target|Antiviral,59620|991,Influenza virus infection,191,,,National Cancer Institute (NCI),20519,,,National Cancer Institute (NCI),20519,,,,,,
103218,HEC-73543,"kelifutinib besylate|benhuangsuan kelifutini|HEC-73543|FLT3 inhibitor (acute myeloid leukemia), Sunshine Lake Pharma",Research Code,Cancer,Flt3 tyrosine kinase inhibitor,3806,Apoptosis stimulator|Anticancer protein kinase inhibitor,1589|62255,Acute myelogenous leukemia,1731,,,Guangdong HEC Pharmaceutical Co Ltd,1053610,,,Guangdong HEC Pharmaceutical Co Ltd,1053610,,,,,,
103221,PCAR-019,"PCAR-019|anti-CD19 CAR T-cell therapy (leukemia/lymphoma), PersonGen Biomedicine|BSJAK-001|anti-CD19 CAR T-cell therapy (leukemia/lymphoma), PersonGen Anke Cell Technology",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant,1545|7761|4790|393,B-cell acute lymphoblastic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Leukemia|Lymphoma|Non-Hodgkin lymphoma,1729|1744|1745|1749|199|203|319,,,PersonGen Anke Cell Technology Co Ltd|Anhui Anke Biotechnology (Group) Co Ltd,1201203|1027048,,,PersonGen Anke Cell Technology Co Ltd,1201203,,,,,,
103222,"anti-ROR1 CAR T-cell therapy (cancer), Fred Hutchinson Cancer Research Center/NCI","anti-ROR1 CAR T-cell therapy (cancer), Fred Hutchinson Cancer Research Center/NCI",,Cancer,Ntrkr1 tyrosine kinase receptor modulator,3821,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,Cancer,651,,,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),16218|20519,,,National Cancer Institute (NCI),20519,,,,,,
103242,CC-90011,"CC-90011|LSD1 inhibitor (solid tumors/SCLC/NSCLC/lymphoma), Bristol-Myers Squib",Research Code,Cancer,Lysine specific histone demethylase 1 inhibitor,14681,Anticancer,1545,Small-cell lung cancer|Non-small-cell lung cancer|Acute myelogenous leukemia|Adenocarcinoma|Prostate tumor|Squamous cell carcinoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Advanced solid tumor|Solid tumor,1261|1262|1731|2399|276|307|319|3246|3713|725,,,Bristol-Myers Squibb Co,15065,Quanticel Pharmaceuticals Inc|Celgene Corp,1064636|15331,Quanticel Pharmaceuticals Inc,1064636,,,,,,
103286,TAEST-16001,"anticancer immunotherapy (solid tumors), Guangzhou Xiangxue Pharmaceutical|TAEST-16001|anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy (NSCLC/sarcoma), Guangzhou Xiangxue Pharmaceutical",Research Code,Cancer,HLA class I antigen A-2 alpha modulator|Cancer testis antigen NY-ESO-1 modulator,19115|50096,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,Osteosarcoma|Soft tissue sarcoma|Metastatic non small cell lung cancer|Solid tumor,1772|3378|3665|725,Sarcoma,194,Guangzhou Xiangxue Pharmaceutical Co Ltd|Axis Therapeutics Ltd,1063220|1167338,,,Guangzhou Xiangxue Pharmaceutical Co Ltd,1063220,,,,,,
103329,"etrumadenant (cancer), Arcus Biosciences","A2aR/A2bR checkpoint inhibitor (cancer), Arcus Biosciences|adenosine (A2a/A2b) dual receptor antagonist (cancer), Arcus Biosciences|A2bR/A2aR checkpoint inhibitor (cancer), Arcus Biosciences|AB-928|etrumadenant (cancer), Arcus Biosciences",Research Code,Cancer,Adenosine A2a receptor antagonist|Adenosine A2b receptor antagonist,596|598,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,Esophagus tumor|Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Endometrioid carcinoma|Renal cell carcinoma|Melanoma|Bladder cancer|Squamous cell carcinoma|Larynx tumor|Merkel cell carcinoma|Hormone refractory prostate cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Breast tumor|Head and neck tumor|Cancer|Lung tumor|Mouth tumor|Pharynx tumor|Colorectal tumor,1011|1262|1507|1705|1766|205|2380|307|3198|3235|3246|3658|3665|49|623|651|755|793|794|989,,,Taiho Pharmaceutical Co Ltd|Arcus Biosciences Inc,18720|1129346,,,Arcus Biosciences Inc,1129346,,,,,,
103335,AMG-420,"BI-836909|AMG-420|anti-CD3/anti-BCMA bispecific T-cell engager (BiTE, multiple myeloma), Micromet/Amgen/Boehringer Ingelheim|pacanalotamab",PINN,Cancer,CD3 modulator|APRIL receptor modulator,5023|8255,Anticancer antibody|Immunostimulant|T-lymphocyte stimulator,55684|393|7761,,,Multiple myeloma,1828,,,Micromet Inc|Amgen Inc|Boehringer Ingelheim International GmbH,1020809|14109|14881,Micromet Inc,1020809,,,,,,
103388,"ublituximab + umbralisib (leukemia/lymphoma), TG Therapeutics","1303, TG Therapeutics|TG-1202 + ublituximab, TG Therapeutics|TG-1303|TG-1101 + TGR-1202, TG Therapeutics|ublituximab + umbralisib (leukemia/lymphoma), TG Therapeutics|TG-1101 + umbralisib, TG Therapeutics|CD16A activator/anti-CD20 immune-cell engager + PI3K delta inhibitor (leukemia/lymphoma), TG Therapeutics|CD16A activator/anti-CD20 NK-cell engager + PI3K delta inhibitor (leukemia/lymphoma), TG Therapeutics",Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor|Immunoglobulin gamma Fc receptor IIIA agonist|Casein kinase-I epsilon inhibitor|B-lymphocyte antigen CD20 modulator,11183|27981|4296|5083,Cell cycle inhibitor|Leukocyte stimulator|Anticancer monoclonal antibody|Natural killer cell stimulator|Apoptosis stimulator|Anticancer protein kinase inhibitor|Immunostimulant,767|7747|55685|7757|1589|62255|393,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1734|1744|1745|1746|1749|319,,,TG Therapeutics Inc,31093,,,TG Therapeutics Inc,31093,,,,,,
103535,LY-3295668 erbumine,"AUR-A selective inhibitor (Rb-deficient tumors), Eli Lilly|aurora A inhibitor (Rb-deficient tumors), Eli Lilly|solid tumor therapeutic, AurKa Pharma Inc/ Eli Lilly|LY-3295668|LY-3295668 erbumine|aur A kin inh (cancer), Eli Lilly|AK-01|aur A kinase inhibitor (cancer), Eli Lilly",Research Code|Research Code,Cancer,Aurora protein kinase 2 inhibitor,4420,Anticancer protein kinase inhibitor,62255,Small-cell lung cancer|Neuroblastoma|Solid tumor,1261|2726|725,Metastatic breast cancer|Breast tumor|Cancer,3657|49|651,Eli Lilly & Co|AurKa Pharma Inc,17810|1130009,,,Eli Lilly & Co,17810,,,,,,
103541,HDP-101,"HDP-101|HDP-101-ATAC|amanitin-BCMA antibody drug conjugate (multiple myeloma), Heidelberg Pharma|amanitin-B cell maturation antigen antibody drug conjugate (multiple myeloma), Heidelberg Pharma|BCMA-ATAC|HD-101",Research Code|Research Code|Research Code,Cancer,RNA polymerase II inhibitor|APRIL receptor modulator,6827|8255,Immunotoxin|Anticancer antibody,539|55684,Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Multiple myeloma,1734|1749|1828,,,Heidelberg Pharma Holding GmbH,30880,Max Delbruck Centrum Fur Molekulare Medizin,17961,Max Delbruck Centrum Fur Molekulare Medizin,17961,,,,,,
103544,"OTS-167 (intravenous), OncoTherapy","OTSSP-167|OTS-167 (intravenous), OncoTherapy",Research Code,Cancer,Tyrosine protein kinase MELK inhibitor,4192,Anticancer protein kinase inhibitor|Apoptosis stimulator,62255|1589,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia,1272|1728|1731|1735,Solid tumor,725,OncoTherapy Science Inc,1004292,,,OncoTherapy Science Inc,1004292,,,,,,
103577,cetrelimab,"JNJ-63723283|PD-1 checkpoint inhibitor (cancer), Janssen|JNJ-3283|JNJ-283|cetrelimab",Research Code|Research Code|Research Code|USAN|INN,Cancer,Programmed cell death protein 1 inhibitor,67136,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Esophagus tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Transitional cell carcinoma|Multiple myeloma|Melanoma|Bladder cancer|Hormone refractory prostate cancer|Metastatic bladder cancer|Renal tumor,1011|1261|1262|127|1771|1828|205|2380|3246|3466|999,Metastasis,1069,Janssen Research & Development LLC,1067538,,,Janssen Research & Development LLC,1067538,,,,,,
103619,FOR-46,"anti-CD46 antibody-drug conjugate (metastatic castration-resistant prostate cancer), Fortis Therapeutics|FOR-46|anti-CD46 antibody-drug conjugate (metastatic castration-resistant prostate cancer and multiple myeloma), Fortis Therapeutics",Research Code,Cancer,Membrane cofactor protein modulator,5180,Anticancer antibody,55684,Multiple myeloma|Hormone refractory prostate cancer,1828|3246,,,Fortis Therapeutics Inc,1130518,University of California San Francisco,24773,University of California San Francisco,24773,,,,,,
103623,ONO-4686,"BMS-986207|ONO-4686|TIGIT checkpoint inhibitor (solid tumor), Bristol-Myers Squibb/Ono|TIGIT checkpoint inhibitor (solid tumor/multiple myeloma), Bristol-Myers Squibb/Ono",Research Code|Research Code,Cancer,T cell immunoreceptor Ig ITIM protein inhibitor,64787,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Endometrioid carcinoma|Multiple myeloma|Fallopian tube cancer|Peritoneal tumor|Advanced solid tumor|Metastatic ovary cancer,1705|1828|2243|3083|3713|3866,,,Bristol-Myers Squibb Co|Ono Pharmaceutical Co Ltd,15065|18681,,,Bristol-Myers Squibb Co,15065,,,,,,
103654,ezabenlimab,"BI-754091|anti-PD-1 checkpoint inhibitors (solid tumors/multiple myeloma), Boehringer Ingelheim|PD-1 checkpoint inhibitor (cancer), Boehringer Ingelheim|ezabenlimab",Research Code|INN,Cancer,Programmed cell death protein 1 inhibitor,67136,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody|Anticancer,7761|393|55685|1545,Non-small-cell lung cancer|Stomach tumor|Gastrointestinal tumor|Endometrioid carcinoma|Follicle center lymphoma|Hepatocellular carcinoma|Multiple myeloma|Melanoma|Anal tumor|Liposarcoma|Pancreas tumor|Squamous cell carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor|Head and neck tumor,1262|127|131|1705|1745|1767|1828|205|2193|2447|249|307|3658|3665|3666|3667|3713|623,Solid tumor,725,Boehringer Ingelheim International GmbH,14881,,,Boehringer Ingelheim International GmbH,14881,,Plumieride,,,,
103655,BI-754111,"BI-754111|LAG-3 checkpoint inhibitor (cancer), Boehringer Ingelheim|miptenalimab",Research Code|PINN,Cancer,CD223 antagonist,8413,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,Non-small-cell lung cancer|Follicle center lymphoma|Hepatocellular carcinoma|Melanoma|Liposarcoma|Squamous cell carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor|Head and neck tumor,1262|1745|1767|205|2447|307|3658|3665|3666|3667|3713|623,,,Boehringer Ingelheim International GmbH,14881,,,Boehringer Ingelheim International GmbH,14881,,,,,,
103763,sugemalimab,"recombinant anti-PD-L1 mAb, CStone Pharmaceuticals|WBP-3155|CS-1001|PD-L1 checkpoint inhibitor (cancer), CStone Pharmaceuticals|PD-L1 targeting human IgG mAb (solid tumor/Hodgkin lymphoma), CStone Pharmaceuticals|sugemalimab",Research Code|Research Code|PINN,Cancer,Programmed cell death ligand 1 inhibitor,14007,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Esophagus tumor|Small-cell lung cancer|Stomach tumor|Hodgkins disease|Endometrioid carcinoma|Hepatocellular carcinoma|T-cell lymphoma|Metastatic liver cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Solid tumor,1011|1261|127|161|1705|1767|311|3462|3665|3673|3713|725,Non-small-cell lung cancer|Cancer,1262|651,Pfizer Inc|EQRx,18767|1203707,CStone Pharmaceuticals,1126254,CStone Pharmaceuticals,1126254,,,,,,
103787,cintirorgon,LYC-55716|cintirorgon,Research Code|USAN|INN,Cancer,Retinoid Z receptor gamma agonist,11939,Immunostimulant|Anticancer,393|1545,Metastatic non small cell lung cancer|Advanced solid tumor,3665|3713,,,Lycera Corp,1040082,,,Lycera Corp,1040082,,,,,,
103799,NGM-707,"NGM-707|dual ILT2/ILT4 checkpoint inhibitor (advanced solid tumors), NGM Biopharmaceuticals/Merck|dual LILRB1/LILRB2 checkpoint inhibitor (advanced solid tumors), NGM Biopharmaceuticals/Merck",Research Code,Cancer,Leukocyte Ig-like receptor-4 antagonist|Leukocyte Ig-like receptor-2 antagonist,9615|9609,Anticancer antibody|Immunostimulant|Macrophage stimulator,55684|393|7751,Mesothelioma|Pancreatic ductal adenocarcinoma|Cholangiocarcinoma|Glioblastoma|Squamous cell carcinoma|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor,1240|1507|1765|2454|307|3257|3657|3658|3665|3666|3667|3713|3866|4250|427,Cancer,651,NGM Biopharmaceuticals Inc|Merck & Co Inc,1052345|18077,,,NGM Biopharmaceuticals Inc,1052345,,,,,,
103803,patritumab deruxtecan,"U3-1402|HER3-ADC (cancer), Daiichi Sankyo|HER3-ADC (cancer), Daiichi Sankyo/Institut Gustave Roussy|patritumab deruxtecan|HER3-DXd",Research Code|INN,Cancer,Topoisomerase I inhibitor|Erbb3 tyrosine kinase receptor inhibitor,141|3758,Anticancer|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,1545|55685|62255,Non-small-cell lung cancer|Adenocarcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer,1262|2399|3657|3658|3665,Lung tumor,755,Daiichi Sankyo Co Ltd|Institut Gustave Roussy,1017506|21081,,,Daiichi Sankyo Co Ltd,1017506,,,,,,
103844,lisaftoclax,"APG-2575|Bcl-2 inhibitor (oral, B-cell malignancies), Ascentage Pharma|lisaftoclax",Research Code|INN,Cancer,Bcl-2 protein inhibitor,16111,Apoptosis stimulator|Anticancer|Synergist,1589|1545|7293,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Prolymphocytic leukemia|Lymphoplasmacytic lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma|Hematological neoplasm|Non-Hodgkin lymphoma|Metastatic breast cancer|Advanced solid tumor|Solid tumor,1731|1734|1738|1743|1745|1749|1828|2054|319|3657|3713|725,B-cell lymphoma,316,Ascentage Pharma Group Corporation Ltd,1052437,,,Ascentage Pharma Group Corporation Ltd,1052437,,,,,,
103852,ND-021,"multispecific antibody fragment-based therapeutics (cancer), Numab|ND-021|trispecific PD-L1 checkpoint inhibitor/4-1BB costimulator/anti-HSA scDb-scFv (cancer), Numab|PD-L1/HSA/Costim tri-specific scDb-scFv|PD-L1xCostim scDb-scFv|triple anti-PD-L1/anti-4-1BB/anti-HSA scDb-scFv (scMATCH3, cancer), Numab/CStone|NM21-1480|NM21-1186|CS-2006",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Programmed cell death ligand 1 inhibitor|Albumin modulator|CDw137 agonist,14007|815|5450,T-lymphocyte stimulator|Immunostimulant|Anticancer|Anticancer antibody,7761|393|1545|55684,Transitional cell carcinoma|Squamous cell carcinoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Cancer|Solid tumor,1771|307|3257|3466|3665|3666|3713|4250|651|725,,,CStone Pharmaceuticals|Numab Therapeutics AG,1126254|1162593,Numab Innovation AG,1064725,Numab Innovation AG,1064725,,,,,,
103853,AUTO-1,"CD19CAT-41BBZ CAR T-cells|anti-CD19 scFv-CAR (B-cell leukemia), Autolus/University College London|anti-CD19 CAR T-cell therapy (B-cell leukemia), Autolus/University College London|anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia/Burkitts lymphoma), University College London/Autolus|AUTO-1",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Genetically engineered autologous cell therapy|Immunostimulant|Anticancer|T-lymphocyte stimulator,4790|393|1545|7761,Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Non-Hodgkin lymphoma|Burkitts lymphoma,1728|1729|319|791,B-cell lymphoma,316,Autolus Therapeutics Ltd,1105192,UCL Business PLC|University College London,1070053|23505,University College London,23505,,,,,,
103856,KITE-585,"KITE-585|anti-BCMA CAR T-cell therapy (multiple myeloma), Kite Pharma",Research Code,Cancer,APRIL receptor modulator,8255,Anticancer|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant,1545|4790|7761|393,,,Multiple myeloma,1828,,,Kite Pharma Inc,1056870,Kite Pharma Inc,1056870,,,,,,
103857,pirtobrutinib,"RXC-005|REDX-08608|LOXO-305|BTK inhibitor (oral, CLL/NHL), Loxo Oncology/Eli Lilly/RedX Pharma|LY-3527727|pirtobrutinib",Research Code|Research Code|Research Code|Research Code,Cancer,Btk tyrosine kinase inhibitor,3592,Anticancer protein kinase inhibitor,62255,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Marginal zone B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1734|1743|1744|1746|316|319,,,Loxo Oncology at Lilly,1086092,Redx Pharma Plc,1060461,Redx Pharma Plc,1060461,,,,,,
10388,cetuximab,"C225|cetuximab|Erbitux|IMC-C 22|IMC-C225|EMR-62202|EMD-271786|MAb225, ImClone|NSC-714692|LY-2939777|BMS-564717",Research Code|INN|Trade Name|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Neurology/Psychiatric,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor|Synergist|Analgesic|Anticancer|Anticancer monoclonal antibody,62255|7293|2946|1545|55685,Anal tumor|Thymoma|Metastatic colorectal cancer|Metastatic head and neck cancer|Head and neck tumor,2193|2939|3658|3673|623,Glioma|Mesothelioma|Stomach tumor|Neuropathic pain|Biliary cancer|Endometrioid carcinoma|Hepatocellular carcinoma|Sarcoma|Bladder cancer|Hormone refractory prostate cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Breast tumor|Ovary tumor|Colorectal tumor,1108|1240|127|1295|1516|1705|1767|194|2380|3246|3665|3666|3669|4250|427|49|799|989,Merck KGaA|Imclone LLC|Merck Serono SA,18101|17193|19862,Inven2|Bristol-Myers Squibb Co,1062214|15065,Imclone LLC,17193,,,,,,
103885,CCS-1477,"histone acetyltransferase inhibitors (castrate resistant prostate cancer, lung cancer), CellCentric Ltd|HAT inhibitors (castrate resistant prostate cancer, lung cancer), CellCentric Ltd|p300/CBP inhibitors (oral, castrate resistant prostate cancer/lung cancer/bladder cancer), CellCentric|CCS-1477|p300/CBP inhibitors (oral capsule, castrate resistant prostate cancer/lung cancer/bladder cancer), CellCentric|p300/CBP inhibitor (oral, CRPC/lung cancer/bladder cancer/hemotoogical neoplasms), CellCentric",Research Code,Cancer,AR gene inhibitor|Histone acetyltransferase p300 inhibitor|CREB binding protein inhibitor|Ubiquitin inhibitor,17163|37716|67694|58716,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Hematological neoplasm|Bladder cancer|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Advanced solid tumor|Lung tumor,1272|1731|1828|2054|2380|319|3246|3713|755,,,CellCentric Ltd,1016073,,,CellCentric Ltd,1016073,,,Angiotensin-I Converting Enzyme (ACE) Inhibitors,381,,
103897,LY-3200882,"TGF-beta-R1 Effort II (solid tumors), Eli Lilly|LY-3200882|TGFbeta RI Kinase inhibitor|TGF beta receptor I inhibitor II (solid tumors/colorectal cancer), Eli Lilly",Research Code,Cancer,Alk-5 protein kinase inhibitor,4588,Anticancer protein kinase inhibitor,62255,,,Metastasis|Metastatic colorectal cancer|Solid tumor,1069|3658|725,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
103949,"candesartan cilexetil + amlodipine besylate (essential hypertension), Shin Poong Pharmaceutical","candesartan cilexetil + amlodipine besylate|candesartan cilexetil + amlodipine besylate (essential hypertension), Shin Poong Pharmaceutical|Candeamlo",Trade Name,Cardiovascular,Angiotensin II receptor antagonist|Calcium channel inhibitor,64|93,Antihypertensive,2657,Essential hypertension,3366,,,Shin Poong Pharmaceutical Co Ltd,19896,,,Shin Poong Pharmaceutical Co Ltd,19896,,,,,,
103956,SGN-CD48A,"SGN-CD48A|CD48-targeting ADC (PEGylated MMAE, multiple myeloma), Seattle Genetics",Research Code,Cancer,CD48 antigen modulator,5186,Immunotoxin|Microtubule inhibitor|Anticancer monoclonal antibody,539|2575|55685,,,Multiple myeloma,1828,,,Seagen Inc,25554,Seagen Inc,25554,,Luzopeptin E2,,,,
103989,RO-7297089,"AFM-26|anti-CD16A/anti-BCMA bispecific immune-cell engager (multiple myeloma), Affimed|anti-CD16A/anti-BCMA bispecific NK-cell engager (multiple myeloma), Affimed/Genentech/Roche|RO-7297089|RG-6296",Research Code|Research Code|Research Code,Cancer,Immunoglobulin gamma Fc receptor IIIA agonist|APRIL receptor modulator,27981|8255,Anticancer antibody|Natural killer cell stimulator|Immunostimulant|Leukocyte stimulator,55684|7757|393|7747,,,Multiple myeloma,1828,,,Genentech Inc|Affimed NV,19453|30783,Affimed NV,30783,,,,,,
104048,SRF-231,"SRF-231|anti-CD47 human monoclonal antibody (cancer), Surface Oncology/Novartis|CD47 checkpoint inhibitor (cancer), Surface Oncology|urabrelimab",Research Code|PINN,Cancer,CD47 antagonist,5185,Anticancer antibody|Immunostimulant|Macrophage stimulator,55684|393|7751,,,Multiple myeloma|Hematological neoplasm|Advanced solid tumor|Cancer,1828|2054|3713|651,,,Surface Oncology|Novartis AG,1104698|23137,Surface Oncology,1104698,,,,,,
104093,MCM-998,"CART-BCMA|MCM-998|anti-BCMA CAR T-cell therapy (multiple myeloma), University of Pennsylvania/Novartis|MTV-273",Research Code|Research Code|Research Code,Cancer,APRIL receptor modulator,8255,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,Multiple myeloma,1828,,,University of Pennsylvania|Novartis AG,20658|23137,,,University of Pennsylvania,20658,,,,,,
10411,insulin aspart,insulin aspart|B28-Asp-insulin|INA-X14|insulin-x14|NovoLog|NovoRapid|NNX-14|BIAsp30|NovoMix30|Biphasic insulin aspart 30|NN-X14Mix50|NN-X14Mix70|NovoMix 50 and 70|NovoLog Mix 70/30|NovoLog Mix|NovoRapid Mix|NovoRapid FlexPen|NovoRapid 30 Mix|NN-X14Mix30|NovoMix 30 FlexPen|NN2000-Mix30|NovoRapid FlexTouch|NovoMix Penfill|NovoMix FlexPen|NovoLog FlexTouch|NovoTwist|NovoFine,USAN|INN|Research Code|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Endocrine/Metabolic,Insulin ligand|Insulin receptor agonist,23014|400,Human insulin fast acting product|Hypoglycemic agent,38211|399,Insulin dependent diabetes|Non-insulin dependent diabetes,836|837,,,Novo Nordisk A/S,18614,,,Novo Nordisk A/S,18614,,,,,,
104185,vibostolimab,"MK-7684|TIGIT checkpoint inhibitor (solid tumor), Merck Sharp & Dohme|vibostolimab",Research Code|USAN|INN,Cancer,T cell immunoreceptor Ig ITIM protein inhibitor,64787,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Stage III melanoma|Stage IV melanoma|Metastatic non small cell lung cancer|Advanced solid tumor,3256|3257|3665|3713,,,Merck Sharp & Dohme Corp,1059823,,,Merck Sharp & Dohme Corp,1059823,,,,,,
104199,TQ-B3525,TQ-B3525,Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor|PTEN modulator|Phosphoinositide-3 kinase alpha inhibitor,11183|9300|11177,Anticancer protein kinase inhibitor,62255,Stomach tumor|Endometrioid carcinoma|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Osteosarcoma|Lymphoma|Advanced solid tumor|Uterine cervix tumor|Breast tumor|Colon tumor|Ovary tumor,127|1705|1734|1744|1745|1749|1753|1772|203|3713|427|49|767|799,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,,,,,,
104206,AK-112,"AK-112|dual PD-1 checkpoint inhibitor/anti-VEGF (cancer), Akeso Biopharma|PD-1 checkpoint inhibitor + anti-VEGF (cancer), Akeso Biopharma",Research Code,Cancer|Genitourinary/Sexual Function,VEGF receptor modulator|Programmed cell death protein 1 inhibitor,3676|67136,Immunostimulant|Anticancer protein kinase inhibitor|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|62255|7761|55685,Mesothelioma|Small-cell lung cancer|Stomach tumor|Liver tumor|Metastatic non small cell lung cancer|Advanced solid tumor|Gynecological disorder|Ovary tumor|Colorectal tumor,1240|1261|127|202|3665|3713|438|799|989,Cancer,651,Akeso Biopharma Inc,1075032,,,Akeso Biopharma Inc,1075032,,,,,,
104312,TAS-0728,"TPC-107|mutant HER2 inhibitor (cancer), Taiho Pharmaceuticals|TAS-0728",Research Code|Research Code,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Erbb3 tyrosine kinase receptor inhibitor,3756|3758,Anticancer protein kinase inhibitor|Apoptosis stimulator,62255|1589,Biliary cancer|Endometrioid carcinoma|Transitional cell carcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Advanced solid tumor|Cancer,1516|1705|1771|3657|3658|3665|3666|3713|651,,,Taiho Pharmaceutical Co Ltd,18720,,,Taiho Pharmaceutical Co Ltd,18720,,,,,,
104349,"T-007, TNK Therapeutics/Celularity","anti-CD38 CAR T-cell therapy (multiple myeloma), TNK Therapeutics/Celularity|T-007, TNK Therapeutics/Celularity|CAR2 anti-CD38 A2 CAR-T cells (intravenous, multiple myeloma), TNK Therapeutics/Cellularity",Research Code,Cancer,ADP ribosyl cyclase-1 modulator,5134,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,Multiple myeloma,1828,,,Celularity Inc|TNK Therapeutics Inc,1152669|1109265,,,TNK Therapeutics Inc,1109265,,,,,,
104352,TAS-6417,"mutant-selective EGFR inhibitor (cancer), Taiho Pharmaceutical|TAS-6417|mutant-selective EGFR inhibitor (oral, cancer), Taiho Pharmaceutical/ Cullinan Pearl|CLN-081|TPC-064",Research Code|Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Metastatic non small cell lung cancer|Cancer,1262|3665|651,,,Zai Lab Limited|Taiho Pharmaceutical Co Ltd|Cullinan Pearl,1101935|18720|1191823,,,Taiho Pharmaceutical Co Ltd,18720,,,,,,
104387,AZD-4785,AZD-4785|IONIS-KRAS-2.5|IONIS-KRAS-2.5Rx|IONIS-651987,Research Code|Research Code,Cancer,KRAS gene inhibitor,22393,Antisense oligonucleotide inhibitor|Anticancer,7294|1545,,,Advanced solid tumor|Cancer,3713|651,,,AstraZeneca plc|Ionis Pharmaceuticals Inc,14190|17269,Ionis Pharmaceuticals Inc,17269,,,,,,
104436,COM-902,"anti-CGEN-15137 antibody (cancer), Compugen|anti-TIGIT antibody (cancer), Compugen|COM-902|TIGIT checkpoint inhibitor (cancer), Compugen",Research Code,Cancer,T cell immunoreceptor Ig ITIM protein inhibitor,64787,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Metastasis|Breast tumor|Cancer|Lung tumor|Colon tumor|Ovary tumor,1069|49|651|755|767|799,,,Compugen USA Inc|Compugen Ltd,1068977|27293,,,Compugen Ltd,27293,,,,,,
104482,ADXS-503,"ADXS-HOT program (non-small-cell lung cancer), Advaxis|ADXS-503|HOT-Lung",Research Code,Cancer,,,Therapeutic vaccine|Anticancer|Live attenuated bacterial vaccine,12379|1545|12363,Bladder cancer|Prostate tumor|Metastatic non small cell lung cancer,2380|276|3665,,,Advaxis Inc,1002696,,,Advaxis Inc,1002696,,,,,,
104491,datopotamab deruxtecan,"TROP2 ADC (cancer), Daiichi Sankyo|DS-1062|DS-1062a|humanized anti-TROP2 Mab (ADC technology, metastatic NSCLC/metastatic TNBC), Daiichi Sankyo|TROP2 ADC (cancer), Daiichi Sankyo/Institut Gustave Roussy|datopotamab deruxtecan|Dato-DXd",Research Code|Research Code|INN,Cancer,Topoisomerase I inhibitor|Trop-2 calcium signal transducer modulator,141|17893,Anticancer antibody,55684,Metastatic breast cancer|Metastatic non small cell lung cancer|Cancer,3657|3665|651,Solid tumor,725,Daiichi Sankyo Co Ltd|AstraZeneca plc,1017506|14190,,,Daiichi Sankyo Co Ltd,1017506,,,,,,
104507,MGD-019,"PD-1/CTLA4 bispecific antibodies (cancer), MacroGenics|tetravalent PD-1 x CTLA-4 bispecific DARTi protein (cancer), MacroGenics|trivalent PD-1 x CTLA-4 TRIDENTi protein (cancer), MacroGenics|dual CTLA-4 checkpoint inhibitor/PD-1 checkpoint inhibitor (cancer), MacroGenics|MGD-019",Research Code,Cancer,Cytotoxic T-lymphocyte protein-4 inhibitor|Programmed cell death protein 1 inhibitor,5482|67136,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Melanoma|Fallopian tube cancer|Thymoma|Squamous cell carcinoma|Hormone refractory prostate cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,205|2243|2939|307|3246|3658|3665|3713|651,,,Zai Lab Limited|MacroGenics Inc,1101935|29060,,,MacroGenics Inc,29060,,,,,,
104557,cevostamab,"anti-FcRH5/anti-CD3 bispecific antibody (multiple myeloma), Genentech|anti-CD3/anti-FcRH5 bispecific T-cell engager (TDB, multiple myeloma), Genentech|BFCR-4350A|RO-7187797|RG-6160|FcRH5-TDB|cevostamab",Research Code|Research Code|Research Code|INN,Cancer,CD3 modulator|Fc receptor like protein 5 modulator,5023|52183,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Multiple myeloma,1828,,,Genentech Inc,19453,,,Genentech Inc,19453,,,,,,
104563,elranatamab,"anti-CD3/anti-BCMA bispecific T-cell engager (multiple myeloma), Pfizer|PF-06863135|B-cell maturation antigen (BCMA) CD3 bi-specific (relapsed/refractory multiple myeloma), Pfizer|BMCA + CD3 therapeutic (triple MM/double MM), Pfizer|elranatamab",Research Code,Cancer,CD3 modulator|APRIL receptor modulator,5023|8255,Anticancer antibody|T-lymphocyte stimulator|Immunostimulant,55684|7761|393,Multiple myeloma,1828,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
104571,NZV-930,"anti-CD73 human monoclonal antibody (cancer), Surface Oncology/Novartis|CD73 checkpoint inhibitor (cancer), Surface Oncology|SRF-373|NZV-930",Research Code|Research Code,Cancer,CD73 antagonist,5300,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody|Leukocyte stimulator|Anticancer antibody,7761|393|55685|7747|55684,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic colorectal cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma,1262|1507|3246|3657|3658|3713|3866|4250,Cancer,651,Novartis AG,23137,Surface Oncology,1104698,Surface Oncology,1104698,,,,,,
104579,FATE-NK100,"FATE-NK100|allogeneic adoptive NK cells (acute myelogenous leukemia/solid tumors), Fate Therapeutics",Research Code,Cancer,,,Natural killer cell stimulator|Immunostimulant|Anticancer,7757|393|1545,,,Acute myelogenous leukemia|Fallopian tube cancer|Peritoneal tumor|Advanced solid tumor|Cancer|Ovary tumor,1731|2243|3083|3713|651|799,,,Fate Therapeutics Inc,1036293,Fate Therapeutics Inc,1036293,,,,,,
104583,HBM-4003,"HCAbs (solid tumor), Harbour BioMed|HBM-4003-2|CTLA-4 checkpoint inhibitor (solid tumor), Harbour Biomed|HBM-4003",Research Code|Research Code,Cancer,Cytotoxic T-lymphocyte protein-4 inhibitor,5482,Immunostimulant|Anticancer antibody|T-lymphocyte stimulator,393|55684|7761,Stage IV melanoma|Metastatic non small cell lung cancer|Advanced solid tumor|Solid tumor,3257|3665|3713|725,Cancer,651,Harbour BioMed,1141056,,,Harbour BioMed,1141056,,,,,,
104593,teclistamab,"JNJ-957|JNJ-64007957|BCMA x CD3 DuoBody bispecific antibody (hematological neoplasm), Janssen Biotech/ Genmab|Ab-957|JNJ-7957|anti-CD3/anti-BCMA bispecific T-cell engager (DuoBody, hematological neoplasm), Janssen|anti-CD3/anti-BCMA bispecific T-cell engager (DuoBody, multiple myeloma), Janssen|teclistamab|AB-957",Research Code|Research Code|Research Code|Research Code|INN|Research Code,Cancer,CD3 modulator|APRIL receptor modulator,5023|8255,Anticancer antibody|T-lymphocyte stimulator|Immunostimulant,55684|7761|393,Multiple myeloma|Hematological neoplasm,1828|2054,,,Janssen Research & Development LLC,1067538,,,Janssen Research & Development LLC,1067538,,,,,,
104614,RMC-5552,"mTORC1 inhibitors (cancer), REVOLUTION Medicines|RMC-5552|RM-006|RM-001, Revolution Medicines|RMC-6272",Research Code|Research Code|Research Code|Research Code,Cancer,mTOR complex 1 inhibitor,76090,Anticancer protein kinase inhibitor,62255,Advanced solid tumor|Cancer,3713|651,,,REVOLUTION Medicines Inc,1105504,,,REVOLUTION Medicines Inc,1105504,,,,,,
104631,linperlisib,YY-20394|linperlisib|linpulisi,Research Code|PINN,Cancer,Phosphoinositide-3 kinase delta inhibitor,11183,Anticancer protein kinase inhibitor,62255,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|T-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Advanced solid tumor,1734|1743|1744|1745|1746|1749|1753|311|316|319|3713,Lymphoma|Cancer|Solid tumor,203|651|725,Shanghai Yingli Pharmaceutical Co Ltd|Jiangsu Hengrui Medicine Co Ltd,1107569|1006925,,,Shanghai Yingli Pharmaceutical Co Ltd,1107569,,,,,,
104686,WX-0593,"WX-0593|ALK receptor tyrosine kinase inhibitor (non-small-cell lung cancer), Qilu Pharmaceutical|yiluaoke",Research Code|Trade Name,Cancer,Anaplastic lymphoma kinase receptor inhibitor,3736,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer|Advanced solid tumor,3665|3713,,,Qilu Pharmaceutical Co Ltd,1006577,,,Qilu Pharmaceutical Co Ltd,1006577,,,Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors,1494,,
104732,ADV/HSV-tk,"ADV/HSV-tk|thymidine kinase-expressing adenovirus suicide gene therapy (intratumoral, breast/non-small cell lung/prostate cancer), Houston Methodist|oncolytic adenovirus therapy expressing HSV-tk (cancer), Houston Methodist|HSV-tk gene therapy (intratumoral, breast/non-small cell lung/prostate cancer/glioblastoma/anaplastic astrocytoma), Houston Methodist",Research Code,Cancer,Thymidine kinase stimulator,6751,Immunostimulant|Anticancer,393|1545,Glioblastoma|Anaplastic astrocytoma|Prostate tumor|Metastatic breast cancer|Metastatic non small cell lung cancer,2454|2567|276|3657|3665,,,The Methodist Hospital System,1041623,Houston Methodist Hospital,1088270,The Methodist Hospital System,1041623,,,,,,
104798,"TCR alpha/beta- and CD19-cell-depleted haploidentical stem cell therapy (CliniMACS Plus), Miltenyi Biotec/Heinrich-Heine-University/University Medical Center Ulm/University of Heidelberg/Children's University Hospital Tubingen","TCR alpha/beta- and CD19-cell-depleted haploidentical stem cell therapy (CliniMACS Plus), Miltenyi Biotec/Heinrich-Heine-University/University Medical Center Ulm/University of Heidelberg/Children's University Hospital Tubingen|TCRabCD19PBSC",,Cancer|Other/Miscellaneous,,,Anticancer,1545,Hematological neoplasm|Genetic disorder|Solid tumor,2054|609|725,,,Miltenyi Biotec GmbH|Heinrich Heine Universitat Dusseldorf|Universitat Ulm|University Children's Hospital Tuebingen|University of Heidelberg,28791|24988|25172|1084964|28348,,,Miltenyi Biotec GmbH,28791,,,,,,
104824,inavolisib,"GDC-0077|RG-6114|RO-7113755|alpha selective PI3K inhibitors (cancer), Genentech|inavolisib",Research Code|Research Code|Research Code|USAN|INN,Cancer,Phosphoinositide-3 kinase alpha inhibitor,11177,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Adenocarcinoma|Metastatic breast cancer|Breast tumor|Solid tumor,2399|3657|49|725,,,Roche Holding AG,19446,,,Roche Holding AG,19446,,,,,,
104834,XY-0206,"XY-0206|FLT-3 inhibitor (oral tablet, acute myelogenous leukemia/lung cancer), Yiling Pharmaceutical Group",Research Code,Cancer,Flt3 tyrosine kinase inhibitor,3806,Anticancer protein kinase inhibitor,62255,Acute myelogenous leukemia|Solid tumor|Lung tumor,1731|725|755,,,Yiling Pharmaceutical Group,1056617,,,Yiling Pharmaceutical Group,1056617,Apristor,Onapristone,Progesterone Receptor Antagonists,561,Signal Transduction Modulators,1402
104872,adagrasib,"G12C KRAS inhibitors (cancer), Mirati Therapeutics|MRTX-849|mutation-specific KRAS G12C inhibitor (oral, NSCLC/CRC), Array BioPharma/Mirati Therapeutics|KRAS G12C inhibitor (oral, lung cancer/colorectal cancer), Mirati Therapeutics/Array BioPharma|adagrasib",Research Code,Cancer,K-Ras GTPase inhibitor,28039,Anticancer,1545,Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,3658|3665|3713|651,,,Zai Lab Limited|Mirati Therapeutics Inc,1101935|1085701,Array BioPharma Inc,25902,Mirati Therapeutics Inc,1085701,,,,,,
104875,DV-281,"DV-281|SD-101 (inhaled, lung cancer), Dynavax|VR-347",Research Code|Research Code,Cancer,TLR-9 agonist,7827,Anticancer|Immunostimulant,1545|393,Metastatic non small cell lung cancer,3665,Lung tumor,755,Dynavax Technologies Corp,24774,,,Dynavax Technologies Corp,24774,,,,,,
104905,edralbrutinib,SHR-1459|TG-1701|EBI-1459|edralbrutinib,Research Code|Research Code|Research Code|PINN,Cancer|Immune|Neurology/Psychiatric,Btk tyrosine kinase inhibitor,3592,Anti-inflammatory|Immunomodulator|Anticancer protein kinase inhibitor,2953|1596|62255,Chronic lymphocytic leukemia|Hematological neoplasm|Neuromyelitis optica|Rheumatoid arthritis|B-cell lymphoma|Non-Hodgkin lymphoma|Autoimmune disease,1734|2054|2316|291|316|319|36,,,Jiangsu Hengrui Medicine Co Ltd|TG Therapeutics Inc,1006925|31093,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,Vasopressin (AVP) Receptor Antagonists,329,Signal Transduction Modulators,1402
104911,SY-5609,"CDK7 inhibitor (oral, cancer), Syros Pharmaceuticals|SY-5609|SY-5102|CDK7 inhibitor (oral, breast cancer), Syros Pharmaceuticals",Research Code|Research Code,Cancer,Cyclin-dependent kinase-7 inhibitor,4304,Anticancer protein kinase inhibitor|Apoptosis stimulator,62255|1589,Metastatic breast cancer|Metastatic colorectal cancer|Metastatic lung cancer|Advanced solid tumor|Metastatic ovary cancer,3657|3658|3668|3713|3866,Breast tumor|Cancer|Solid tumor|Lung tumor|Ovary tumor|Colorectal tumor,49|651|725|755|799|989,Syros Pharmaceuticals,1081616,,,Syros Pharmaceuticals,1081616,,,,,,
104921,ALX-148,"ALX-148|CD47 inhibitor (cancer), Alexo Therapeutics|CD47-SIRPalpha interaction inhibitors (cancer), Alexo Therapeutics|CD47 checkpoint inhibitor (cancer/acute myelogenous leukemia/), Alexo Therapeutics|CD47-SIRPalpha interaction inhibitors (Myelodysplastic Syndrome/acute myelogenous leukemia), ALX Oncology",Research Code,Cancer,CD47 antagonist,5185,Anticancer|Macrophage stimulator|Immunostimulant,1545|7751|393,Stomach tumor|Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm|Squamous cell carcinoma|Non-Hodgkin lymphoma|Advanced solid tumor|Head and neck tumor,127|1272|1731|2054|307|319|3713|623,Cancer,651,ALX Oncology,1119479,,,ALX Oncology,1119479,,,,,,
104978,TBI-1501,"TBI-1501|anti-CD19 CAR T-cell therapy (ALL, NHL), Takara Bio|anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma, acute lymphocytic leukemia), Takara/Jichi Medical University",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,B-cell acute lymphoblastic leukemia,1729,Non-Hodgkin lymphoma,319,Takara Bio Inc|Otsuka Pharmaceutical Co Ltd,30649|18717,,,Takara Bio Inc,30649,,,,,,
104983,"dual anti-CD19/anti-CD20 CAR T-cell therapy (cancer), Medical College of Wisconsin","CAR T-cell therapy (cancer), Medical College of Wisconsin|dual anti-CD19/anti-CD20 CAR T-cell therapy (cancer), Medical College of Wisconsin|41BB/CD3-zeta CAR-20.19T-cell|LV20.19 bispecific CAR T-cells",,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte antigen CD20 modulator,5080|5083,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Non-Hodgkin lymphoma|Cancer,1729|1734|1744|319|651,,,Medical College of Wisconsin,21040,,,Medical College of Wisconsin,21040,,,,,,
105074,YBL-006,YBL-006,Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Stage III melanoma|Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Central nervous system tumor,3256|3257|3658|3665|3673|3713|759,Cancer|Solid tumor,651|725,Y-Biologics Inc,1073900,,,Y-Biologics Inc,1073900,,,,,,
105079,"anti-CD19 CAR-T cell therapy (CaspaCIDe, cancer), Bellicum Pharmaceuticals/Ospedale Pediatrico Bambino Gesu","anti-CD19 CAR-T cell therapy (CaspaCIDe, cancer), Bellicum Pharmaceuticals/Ospedale Pediatrico Bambino Gesu|CD19 CAR-T (CaspaCIDe, cancer), Bellicum Pharmaceuticals/Ospedale Pediatrico Bambino Gesu|ATLCAR.CD19|iC9-CAR19 cells",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Anticancer|T-lymphocyte stimulator,393|1545|7761,Acute lymphoblastic leukemia|B-cell lymphoma|Non-Hodgkin lymphoma,1728|316|319,Cancer,651,Bellicum Pharmaceuticals Inc|Ospedale Pediatrico Bambino Gesù (IRCCS),1023406|1037327,,,Bellicum Pharmaceuticals Inc,1023406,,,,,,
105098,"WT1 peptide vaccine (myeloid leukemia), University of Chicago","WT1 peptide vaccine (myeloid leukemia), University of Chicago|WT1(126-134)|human Wilms tumor protein (126-134)",,Cancer,Wilms tumor protein modulator,30009,Protein subunit vaccine|Therapeutic vaccine|Anticancer,12372|12379|1545,,,Myeloid leukemia,223,,,University of Chicago,26013,University of Chicago,26013,,,,,,
105129,SL-1904B,"anti-CD19 CAR T-cell therapy (B-cell maligancy), Hebei Senlang Biotechnology Inc|Senl_001|SENL-B19|SL-1904B",Research Code|Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Hematological neoplasm|B-cell lymphoma|Non-Hodgkin lymphoma,1728|1729|2054|316|319,,,Hebei Senlang Biotechnology Inc,1139326,,,Hebei Senlang Biotechnology Inc,1139326,,,,,,
105189,TH-1579,"MTH1 protein inhibitor (oral solution, cancer), Thomas Helleday Foundation|TH-1579|karonudib",Research Code,Cancer,"DNA repair protein inhibitor|7,8 dihydro 8 oxoguanine triphosphatase inhibitor",18829|58260,Anticancer,1545,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Leukemia|B-cell lymphoma|Cancer|Solid tumor,1272|1728|1731|199|316|651|725,,,Helleday Laboratory,1096903,,,Helleday Laboratory,1096903,,,Neprilysin (Enkephalinase; Neutral Endopeptidase; NEP) Inhibitors,461,,
105204,TTI-622,"TTI-622|SIRPalpha Fc (multiple myeloma, lymphoma), Trillium Therapeutics|dual CD47 checkpoint inhibitor/modest FcgR activator (cancer/lymphoma/myeloma), Trillium Therapeutics|dual CD47 checkpoint inhibitor/modest FcgR activator (Hodgkins lymphoma/multiple myleoma), Trillium Therapeutics",Research Code,Cancer,Immunoglobulin gamma Fc receptor agonist|CD47 antagonist,16018|5185,Anticancer|Leukocyte stimulator|Immunostimulant|Macrophage stimulator,1545|7747|393|7751,Hodgkins disease|Acute myelogenous leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Multiple myeloma|Lymphoma,161|1731|1744|1745|1749|1753|1828|203,Cancer,651,Trillium Therapeutics Inc,1010234,,,Trillium Therapeutics Inc,1010234,,,,,,
105207,BPI-D0316,D-0316|BPI-D0316|befotertinib|beifutini,Research Code|Research Code|PINN,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer,3665,,,Betta Pharmaceuticals Co Ltd,1051889,InventisBio Inc,1119771,InventisBio Inc,1119771,,,,,,
105259,ONO-7475,ONO-7475,Research Code,Cancer,Mer tyrosine kinase receptor inhibitor|Axl tyrosine kinase receptor inhibitor,3744|3742,Synergist|Anticancer protein kinase inhibitor,7293|62255,Acute leukemia|Acute myelogenous leukemia|Advanced solid tumor,1727|1731|3713,,,Ono Pharmaceutical Co Ltd,18681,,,Ono Pharmaceutical Co Ltd,18681,,,,,,
105268,"para-toluenesulfonamide (intratumoral, cancer), PTS International","PTS|para-toluenesulfonamide|p-toluene sulfonamide|para-toluenesulfonamide (intratumoral, cancer), PTS International|PTS-02|PTS-100|para-toluenesulfonamide (intratumoral, adenoid cystic carcinoma/hepatocellular carcinom/non small cell lung cancer), PTS International|PTS-302|PTS-500",Research Code|Research Code|Research Code|Research Code,Cancer|Respiratory,,,Anticancer,1545,Non-small-cell lung cancer|Hepatocellular carcinoma|Adenoid tumor|Metastatic liver cancer|Pleural disease,1262|1767|3153|3462|704,Cancer,651,PTS International Inc|Gongwin Biopharm Holdings Co Ltd,30136|1149047,,,PTS International Inc,30136,,,,,,
105274,TCB-002,"OmnImmune|allogeneic gamma delta T-cell therapy (cancer, viral infection, bacterial infection), TC BioPharm|allogeneic gamma delta T-cell therapy (cancer, viral infection, acute myelogenous leukemia/viral pneumonia/viral infection/bacterial infection/cancer), TC BioPharm|TCB-002",Trade Name|Research Code,Cancer|Infection,,,Anticancer|T-lymphocyte stimulator|Antibacterial|Immunostimulant|Antiviral,1545|7761|1594|393|991,Acute myelogenous leukemia|Viral pneumonia|Viral infection|Bacterial infection|Cancer,1731|1818|344|40|651,,,TC BioPharm Ltd,1093918,,,TC BioPharm Ltd,1093918,,,,,,
105317,4SCAR19,"anti-CD19 CAR T-cell therapy (B-cell lymphoma), Shenzhen Genoimmune|4SCAR19",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,B-cell acute lymphoblastic leukemia|B-cell lymphoma,1729|316,,,Shenzhen Geno-Immune Medical Institute,1130728,,,Shenzhen Geno-Immune Medical Institute,1130728,,,,,,
105356,Haplo HCT,"Haplo HCT|haploidentical related hematopoietic stem cell transplant ( hematological neoplasm), University of Minnesota",,Cancer,,,Anticancer,1545,Hematological neoplasm,2054,,,University of Minnesota,20626,,,University of Minnesota,20626,,,,,,
105375,TAK-007,"iC9/CAR.19/IL15-transduced CB-NK cells (B-cell lymphoma), Bellicum /MD Anderson Cancer Center|CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (cancer), Bellicum/ MD Anderson Cancer Center|CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (B-cell/diffuse large B-cell/follicular/mantle cell lymphoma), Bellicum/ MD Anderson Cancer Center|CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (B-cell/diffuse large B-cell/follicular/mantle cell lymphoma), MD Anderson Cancer Center|CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (B-cell/diffuse large B-cell/follicular/mantle cell lymphoma), Takeda|anti-CD19 CAR NK-cell therapy (B-cell lymphoma), Takeda/MD Anderson Cancer Center|allogeneic anti-CD19 CAR NK-cell therapy (membrane-bound IL-15, B-cell lymphoma), Takeda/MD Anderson Cancer Center|TAK-007|CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (B-cell acute lymphocytic leukemia/chronic lymphocytic leukemia/non-Hodgkin lymphoma/diffuse large B-cell/follicular/mantle cell lymphoma), MD Anderson Cancer Center",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Natural killer cell stimulator|Anticancer|Immunostimulant,7757|1545|393,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1731|1734|1749|316|319,Mantle cell lymphoma|Follicle center lymphoma,1744|1745,Takeda Pharmaceutical Co Ltd,20300,Bellicum Pharmaceuticals Inc|MD Anderson Cancer Center,1023406|23382,Bellicum Pharmaceuticals Inc,1023406,,,,,,
105385,"Lactobacillus plantarum strain 299 (graft versus host disease), National Cancer Institute","Lactobacillus plantarum strain 299 (graft versus host disease), National Cancer Institute|DSM-6595",Research Code,Immune,,,Microbiome modulator|Unspecified drug target|Immunomodulator,173474|59620|1596,Graft versus host disease,616,,,National Cancer Institute (NCI),20519,,,National Cancer Institute (NCI),20519,,,,,,
105387,"lactobacillus plantarum strain 299v (GvHD), National Cancer Institute","DSM-9843|lactobacillus plantarum strain 299v (GvHD), National Cancer Institute|Lp-299v",Research Code,Immune,,,Immunomodulator|Unspecified drug target|Microbiome modulator,1596|59620|173474,Graft versus host disease,616,,,National Cancer Institute (NCI),20519,,,National Cancer Institute (NCI),20519,,,,,,
105445,"nelfinavir (multiple myeloma), Swiss Group for Clinical Cancer Research","nelfinavir|nelfinavir (multiple myeloma), Swiss Group for Clinical Cancer Research",INN,Cancer,HIV protease inhibitor,204,Anticancer chemosensitizer,1586,Multiple myeloma,1828,Hematological neoplasm,2054,Swiss Group for Clinical Cancer Research,1041703,,,Swiss Group for Clinical Cancer Research,1041703,,,,,,
105532,"bevacizumab biosimilar, Zhejiang Teruisi Pharmaceutical","bevacizumab|bevacizumab biosimilar, Zhejiang Teruisi Pharmaceutical|TRS-003",INN|Research Code,Cancer,VEGF ligand inhibitor,12521,Anticancer monoclonal antibody|Angiogenesis inhibitor,55685|61,Metastatic non small cell lung cancer|Cancer|Ovary tumor|Colorectal tumor,3665|651|799|989,,,Zhejiang Teruisi Pharmaceutical Inc,1069890,,,Zhejiang Teruisi Pharmaceutical Inc,1069890,,,,,,
105603,"anti-CD19 CAR T-cell therapy (B-cell lymphoma/B- cell leukemia), Uppsala University","anti-CD19 CAR T-cell therapy (B-cell lymphoma/B- cell leukemia), Uppsala University|3G CD19-CAR T cell therapy (B-cell lymphoma/B-cell leukemia), Uppsala University|autologous 3rd generation CD19-targeting CAR T cells (B-cell lymphoma/B-cell leukemia), Uppsala Univeristy",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,B-cell acute lymphoblastic leukemia|B-cell lymphoma,1729|316,,,Uppsala University,22324,,,Uppsala University,22324,,,,,,
105617,K-NK002,"natural killer cell therapy (cancer), CytoSen|CSTD002-NK|adoptive haploidentical natural killer cell therapy (acute myelogenous leukemia/myelodysplastic syndrome), CytoSen|CSDT002-NK|adoptive haploidentical natural killer cell therapy (acute myelogenous leukemia/myelodysplastic syndrome), Kiadis|natural killer cell therapy (cancer), Kiadis|K-NK002",Research Code|Research Code|Research Code,Cancer,,,Anticancer|Natural killer cell stimulator|Immunomodulator,1545|7757|1596,Myelodysplastic syndrome|Acute myelogenous leukemia|Cancer,1272|1731|651,,,Kiadis Pharma BV,29823,CytoSen Therapeutics Inc,1144944,CytoSen Therapeutics Inc,1144944,,,,,,
105648,NGM-120,"NGM-120|GFRAL antagonist monoclonal antibody (cachexia), NGM Biopharmaceuticals",Research Code,Cancer|Other/Miscellaneous,GDNF family receptor alpha like antagonist,112988,Therapeutic antibody|Anticancer monoclonal antibody,172641|55685,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Melanoma|Bladder cancer|Pancreas tumor|Appetite loss|Squamous cell carcinoma|Hormone refractory prostate cancer|Metastatic pancreas cancer|Cachexia|Head and neck tumor|Solid tumor|Ovary tumor|Colorectal tumor,1011|1262|127|205|2380|249|3038|307|3246|3669|425|623|725|799|989,,,NGM Biopharmaceuticals Inc,1052345,,,NGM Biopharmaceuticals Inc,1052345,,,,,,
105651,MB-102,"anti-CD123 CAR T-cell therapy (acute myeloid leukemia), Mustang Bio|MB-102|anti-CD123 CAR T-cell therapy (acute myleloid leukemia), Fortress Biotech|anti-CD123 CAR T-cell therapy (acute myeloid leukemia), City of Hope",Research Code,Cancer,CDw123 modulator,5427,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Mustang Bio Inc|City of Hope,1107137|20558,,,Fortress Biotech Inc,1032809,,,,,,
105655,"autologous dendritic cells vaccine (WT1-electroporated, myelodysplastic syndromes/acute myeloid leukemia), Universidade Estadual de Campinas","autologous dendritic cells vaccine (WT1-electroporated, myelodysplastic syndromes/acute myeloid leukemia), Universidade Estadual de Campinas|WT1-electroporated autologous dendritic cell vaccine (MDS/AML), Universidade Estadual de Campinas",,Cancer,Wilms tumor protein modulator,30009,Therapeutic vaccine|Anticancer|Dendritic cell vaccine|Genetically engineered autologous cell vaccine,12379|1545|102926|4791,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Universidade Estadual de Campina,24983,,,Universidade Estadual de Campina,24983,,,beta-Lactamase (Bacterial) Inhibitors,501,,
105695,INB-100,"expanded/activated gamma delta T-cell therapy (cancer), Incysus Therapeutics/University of Alabama at Birmingham|EAGD T-cell infusion|ICS-100|EAGD T-cell therapy (cancer), Incysus Therapeutics/University of Alabama at Birmingham|INB-100|expanded/activated gamma delta T-cell therapy (cancer), IN8bio Inc/University of Alabama at Birmingham|EAGD T-cell therapy (cancer), IN8bio Inc/University of Alabama at Birmingham",Research Code|Research Code,Cancer,,,Immunomodulator|T-lymphocyte stimulator|Anticancer,1596|7761|1545,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia|Lymphoma|Cancer,1272|1728|1731|1735|203|651,,,Incysus Therapeutics Inc|University of Alabama at Birmingham,1145554|20524,,,University of Alabama at Birmingham,20524,,,,,,
105708,XmAb-22841,"CTLA-4/LAG-3 bispecific mAbs (cancer), Xencor|cytotoxic T-lymphocyte protein 4/lymphocyte activation gene-3 bispecific mAbs (cancer), Xencor|dual CTLA-4 checkpoint inhibitor/LAG-3 checkpoint inhibitor (FcRn-mediated half-life extension/Xtend, cancer), Xencor|XmAb-22841|pavunalimab",Research Code|PINN,Cancer,Cytotoxic T-lymphocyte protein-4 inhibitor|IgG receptor FcRn large subunit p51 modulator|CD223 antagonist,5482|72028|8413,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Esophagus tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Melanoma|Pancreas tumor|Squamous cell carcinoma|Metastatic breast cancer|Advanced solid tumor|Uterine cervix tumor|Head and neck tumor|Cancer|Colorectal tumor,1011|1261|1262|127|1705|1766|1767|1768|1771|205|249|307|3657|3713|427|623|651|989,,,Xencor Inc,27617,,,Xencor Inc,27617,,,,,,
105715,XmAb-23104,"dual PD-1 checkpoint inhibitor/ICOS costimulator (FcRn-mediated half-life extension/Xtend, cancer), Xencor|PD1/ICOS bispecific mAbs (cancer), Xencor|XmAb-23104",Research Code,Cancer,Inducible T-cell co-stimulator stimulator|Programmed cell death protein 1 inhibitor|IgG receptor FcRn large subunit p51 modulator,15391|67136|72028,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Melanoma|Bladder cancer|Pancreas tumor|Squamous cell carcinoma|Advanced solid tumor|Uterine cervix tumor|Breast tumor|Colorectal tumor,1261|1262|127|1705|1766|1767|1768|205|2380|249|307|3713|427|49|989,Cancer,651,Xencor Inc,27617,,,Xencor Inc,27617,,,,,,
105729,"domvanalimab (cancer), Arcus Biosciences","AB-154|anti-TIGIT antibody (cancer), Arcus Biosciences|TIGIT checkpoint inhibitor (cancer), Arcus Biosciences|domvanalimab (cancer), Arcus Biosciences",Research Code,Cancer,T cell immunoreceptor Ig ITIM protein inhibitor,64787,Anticancer monoclonal antibody|Immunostimulant|Anticancer antibody|T-lymphocyte stimulator,55685|393|55684|7761,Esophagus tumor|Non-small-cell lung cancer|Gastrointestinal tumor|Endometrioid carcinoma|Renal cell carcinoma|Melanoma|Bladder cancer|Glioblastoma|Squamous cell carcinoma|Merkel cell carcinoma|Metastatic non small cell lung cancer|Advanced solid tumor|Breast tumor|Lung tumor|Ovary tumor|Colorectal tumor,1011|1262|131|1705|1766|205|2380|2454|307|3235|3665|3713|49|755|799|989,Cancer,651,Arcus Biosciences Inc,1129346,Abmuno Therapeutics Llc,1153506,Abmuno Therapeutics Llc,1153506,,,,,,
105730,LAM-003,"LAM-003|immunomodulator (oral, cancer/acute myeloid leukemia), Lam Therapeutics|HSP90 inhibitor (oral, acute myeloid leukemia), Al Therapeutics",Research Code,Cancer,Hsp 90 inhibitor,8012,Anticancer|Immunomodulator|Synergist,1545|1596|7293,Acute myelogenous leukemia|Cancer,1731|651,,,AI Therapeutics,1084743,,,AI Therapeutics,1084743,,,Chymotrypsin Inhibitors,816,,
105746,icapamespib,"PU-AD|PU-AD dihydrochloride|epichaperome inhibitor (oral, Alzheimer's disease), Samus Therapeutics|icapamespib",Research Code|INN,Cancer|Neurology/Psychiatric,Hsp 90 inhibitor,8012,Neuroprotectant|Anticancer,1615|1545,Glioma|Alzheimers disease|Motor neurone disease|Astrocytoma|Glioblastoma|Gliosarcoma,1108|14|212|2453|2454|2727,,,Samus Therapeutics Inc,1106247,Memorial Sloan-Kettering Cancer Center,22122,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
105758,APVO-436,"APVO-436|anti-CD3/anti-CD123 bispecific T-cell engager (ADAPTIR, hematological malignancies), Aptevo",Research Code,Cancer,CD3 modulator|CDw123 modulator,5023|5427,Anticancer|T-lymphocyte stimulator|Anticancer antibody|Immunostimulant,1545|7761|55684|393,Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm,1272|1731|2054,,,Aptevo Therapeutics Inc,1122543,,,Aptevo Therapeutics Inc,1122543,,,,,,
105767,elimusertib,"ATR inhibitor (cancer), Bayer|BAY-1895344|elimusertib",Research Code|Research Code,Cancer|Immune,Serine threonine protein kinase ATR inhibitor,24838,Anticancer|Anticancer protein kinase inhibitor|Synergist,1545|62255|7293,Neuroendocrine tumor|Small-cell lung cancer|Transitional cell carcinoma|Fallopian tube cancer|Bladder cancer|Adenocarcinoma|Pancreas tumor|Squamous cell carcinoma|Peritoneal tumor|Non-Hodgkin lymphoma|Larynx tumor|Metastatic gastrointestinal cancer|Metastatic colorectal cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Lymphadenopathy|Mouth tumor|Pharynx tumor|Ovary tumor,1128|1261|1771|2243|2380|2399|249|307|3083|319|3198|3460|3658|3666|3667|3669|3673|3713|3866|784|793|794|799,Cancer,651,Bayer AG|National Cancer Institute (NCI),14455|20519,,,Bayer AG,14455,,,,,,
105771,MEDI-5083,"MEDI-5083|CD40 ligand-antibody fragment fusion protein (advanced solid tumor), MedImmune|CD40 costimulator (advanced solid tumor), MedImmune",Research Code,Cancer,CD40 ligand receptor antagonist,5142,Immunostimulant|B-lymphocyte stimulator|Anticancer antibody|Dendritic cell stimulator|Macrophage stimulator,393|7741|55684|173472|7751,Advanced solid tumor,3713,,,MedImmune LLC,18008,,,MedImmune LLC,18008,,,,,,
105773,LY-3143921 hydrate,"LY-3143921|CDC7 inhibitors (advanced solid tumors), Cancer Research|LY-3143921 hydrate",Research Code|Research Code,Cancer,CDC7 protein kinase inhibitor,4758,Anticancer protein kinase inhibitor,62255,Advanced solid tumor,3713,,,Cancer Research UK,29469,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
105776,ACTR-087 + SEA-BCMA,"ACTR-087|SEA-BCMA|anti-BCMA mAb + CD16V-BB-zeta T cells (multiple myeloma), Seattle Genetics/Unum Therapeutics|ACTR-087 + SEA-BCMA|anti-BCMA mAb + CD16 anti-Fc CAR T-cell therapy (multiple myeloma), Seattle Genetics/Unum Therapeutics|anti-BCMA mAb + chimeric CD16V-41BB-CD3zeta receptor T cells (multiple myeloma), Seattle Genetics/Unum Therapeutics",Research Code|Research Code,Cancer,APRIL receptor antagonist,8257,Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer monoclonal antibody,1545|7761|4790|393|55685,,,Multiple myeloma,1828,,,Cogent Biosciences Inc|Seagen Inc,1101952|25554,Seagen Inc,25554,,3'-Deoxyneplanocin A,,,,
105789,TNO-155,"SHP-099|allosteric inhibitors of oncoprotein cytoplasmic protein Src homology 2 (SHP2) phosphatase (cancer), Novartis|allosteric inhibitors of SHP2 phosphatase (cancer), Novartis|TNO-155|SHP2 inhibitor (advanced solid tumor), Novartis|SHP-504|SHP-836|SHP-394",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Protein tyrosine phosphatase-2C inhibitor,10327,Anticancer protein kinase inhibitor,62255,Gastrointestinal stromal tumor|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Cancer,3205|3658|3665|3667|3673|3713|651,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
105813,DZD-4205,"AZD-4205|JAK1 kinase inhibitor (cancer), AstraZeneca|AZ-3|JAK1 kinase inhibitor (inflammatory bowel disease), Dizal (Jiangsu) Pharmaceutical|DZD-4205|NC-0322",Research Code|Research Code|Research Code|Research Code,Cancer|Dermatologic|Gastrointestinal|Hematologic|Ocular,Jak1 tyrosine kinase inhibitor,3562,Anticancer protein kinase inhibitor|Anti-inflammatory,62255|2953,Atopic dermatitis|Non-small-cell lung cancer|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Multiple myeloma|Inflammatory bowel disease|Myeloproliferative disorder|Xerophthalmia|Ulcerative colitis|Metastatic non small cell lung cancer|Cancer|Crohns disease,1102|1262|1753|1754|1828|189|273|3016|337|3665|651|84,,,AstraZeneca plc|Dizal Pharm Co Ltd,14190|1157162,,,AstraZeneca plc,14190,,,Adenosine A3 Receptor Ligands,1970,Signal Transduction Modulators,1402
105819,EMB-01,"FIT-013a|EMB-01|cMET/EGFR bispecific antibody (cancer), Epimab Biotherapeutics",Research Code|Research Code,Cancer,Hepatocyte growth factor receptor antagonist|Epidermal growth factor receptor antagonist,675|740,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Cancer,651,,,WuXi Biologics (Cayman) Inc|Epimab Biotherapeutics Inc,1122083|1139169,,,Epimab Biotherapeutics Inc,1139169,,,,,,
105856,epcoritamab,"anti-CD3/anti-CD20 bispecific T-cell engager (DuoBody, cancer), Genmab|bispecific CD3xCD20 targeting antibody program (DuoBody, cancer), Genmab|GEN-3013|Duobody-CD3xCD20|epcoritamab",Research Code|Research Code|INN,Cancer,CD3 modulator|B-lymphocyte antigen CD20 modulator,5023|5083,Anticancer|Immunostimulant|T-lymphocyte stimulator|Anticancer antibody,1545|393|7761|55684,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Cancer,1734|1744|1745|1747|1749|1750|316|319|651,,,Genmab A/S|AbbVie Inc,26469|1072507,,,Genmab A/S,26469,,,,,,
105860,BI-891065,"BI-891065|BI-5|SMAC mimetics (cancer), Boehringer Ingelheim",Research Code|Research Code,Cancer,Inhibitor of apoptosis protein 1 inhibitor|SMAC protein stimulator,13602|14457,Anticancer|Synergist,1545|7293,Advanced solid tumor|Cancer,3713|651,,,Boehringer Ingelheim GmbH,22546,,,Boehringer Ingelheim GmbH,22546,,,,,,
105865,OMO-103,"Omomyc cell-penetrating peptide (cancer), Peptomyc SL|Anti-Myc (cancer), Peptomyc SL/Syros Pharmaceuticals/University of Sherbrooke/Universitat Autonoma de Barcelona|Omomyc-AF660|Omomyc cell-penetrating peptide (intravenous, cancer), Peptomyc SL|Anti-Myc (intravenous, cancer), Peptomyc SL/Syros Pharmaceuticals/University of Sherbrooke/Universitat Autonoma de Barcelona|OMO-103",Research Code,Cancer,Myc proto-oncogene protein inhibitor,14615,Anticancer|Immunostimulant,1545|393,Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,3657|3658|3665|3713|651,,,Universite de Sherbrooke|Peptomyc SL|Syros Pharmaceuticals|Universitat Autonoma de Barcelona,23853|1146259|1081616|25611,,,Peptomyc SL,1146259,,,,,,
105917,BS-HH-002.SA,BS-HH-002.SA|BS-HH-002,Research Code|Research Code,Cancer,Jak2 tyrosine kinase inhibitor|STAT-5 inhibitor|STAT-3 inhibitor,3564|7973|7967,Anticancer protein kinase inhibitor,62255,Stomach tumor|Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm|Pancreas tumor|Cancer|Solid tumor|Lung tumor|Colon tumor,127|1272|1731|2054|249|651|725|755|767,,,Shanghai Bensheng Pharma Co Ltd,1068370,,,Shanghai Bensheng Pharma Co Ltd,1068370,,,,,,
105930,"dendritic cell/AML cell fusion vaccine (acute myelogenous leukemia), Dana Farber/Bristol-Myers Squibb","dendritic cell/AML cell fusion vaccine (acute myelogenous leukemia), Dana Farber/Celgene|dendritic cell/AML cell fusion vaccine (acute myelogenous leukemia), Dana Farber/Bristol-Myers Squibb",,Cancer,,,Dendritic cell vaccine|Anticancer|Therapeutic vaccine,102926|1545|12379,Acute myelogenous leukemia,1731,,,Dana-Farber Cancer Institute Inc|Bristol-Myers Squibb Co,15615|15065,Celgene Corp,15331,Dana-Farber Cancer Institute Inc,15615,,,,,,
105933,FLX-475,"FLX CCR4 antagonists (cancer), FLX Bio|FLX-475|FLX CCR4 antagonists (cancer), RAPT Therapeutics|Treg modulator (cancer), RAPT Therapeutics",Research Code,Cancer,CCR4 chemokine antagonist,3104,Regulatory T lymphocyte inhibitor|Anticancer|Immunostimulant,174668|1545|393,Stomach tumor|Hodgkins disease|Nasopharyngeal carcinoma|Lymphoma|Squamous cell carcinoma|Non-Hodgkin lymphoma|Stage III melanoma|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Uterine cervix tumor,127|161|1768|203|307|319|3256|3257|3657|3665|3666|3667|3673|3713|427,Cancer,651,Hanmi Pharmaceutical Co Ltd|RAPT Therapeutics Inc,16611|1110021,,,RAPT Therapeutics Inc,1110021,,,,,,
105998,HM-43239,HM-43239,Research Code,Cancer,Syk tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor,3602|3806,Anticancer protein kinase inhibitor,62255,Acute myelogenous leukemia,1731,,,Hanmi Pharmaceutical Co Ltd,16611,,,Hanmi Pharmaceutical Co Ltd,16611,,,,,,
106011,MEDI-7247,MEDI-7247|anti-ASCT2 mAb-tesirine|anti-ASCT2 mAb-SG-3249,Research Code,Cancer,Neutral amino acid transporter B0 inhibitor,13392,Anticancer monoclonal antibody,55685,,,Small-cell lung cancer|Pancreatic ductal adenocarcinoma|Hematological neoplasm|Squamous cell carcinoma|Hormone refractory prostate cancer|Colorectal tumor,1261|1507|2054|307|3246|989,,,MedImmune LLC,18008,MedImmune LLC,18008,,,,,,
106046,"talabostat (cancer), BioXcel","talabostat|talabostat (cancer), BioXcel|BXCL-701|DPP4/DPP8/DPP9/FAP inhibitor (oral, cancer), BioXcel",USAN|INN|Research Code,Cancer,Dipeptidyl peptidase VIII inhibitor|Seprase inhibitor|Dipeptidyl peptidase IV inhibitor|Dipeptidyl peptidase IX inhibitor,21597|10910|5537|21600,Immunostimulant|Anticancer,393|1545,Acute myelogenous leukemia|Melanoma|Pancreas tumor|Prostate tumor|Soft tissue sarcoma|Metastatic pancreas cancer|Solid tumor,1731|205|249|276|3378|3669|725,,,BioXcel Therapeutics Inc,1102582,,,BioXcel Therapeutics Inc,1102582,,,,,,
10606,eltrombopag,"SB-394725|SB-497115|hematopoietic growth factor mimetics, Ligand/SB|thrombopoietin peptide mimetics, GlaxoSmithKline/Ligand|hematopoietic growth factor mimetics, Ligand/GlaxoSmithKline|eltrombopag olamine|SB-497117GR|eltrombopag|497115|Promacta|SB-497115-GR|Revolade|ETB-115",Research Code|Research Code|USAN|Research Code|INN|Trade Name|Research Code|Trade Name|Research Code,Gastrointestinal|Hematologic|Toxicity/Intoxication,Thrombopoietin receptor agonist,3610,Hematopoietic stimulator,610,Aplastic anemia|Immune thrombocytopenic purpura|Thrombocytopenia|Radiation sickness,1006|2259|324|367,Anemia|Liver cirrhosis,17|70,Novartis AG,23137,Ligand Pharmaceuticals Inc|SmithKline Beecham plc|GlaxoSmithKline plc,17808|19962|28355,Ligand Pharmaceuticals Inc,17808,,,,,,
106077,RP-4010,"RP-4010|calcium release-activated calcium channel inhibitor (non-Hodgkin lymphoma), Rhizen|CRAC inhibitor (non-Hodgkin lymphoma), Rhizen",Research Code,Cancer,Ca2+ release activated Ca2+ channel inhibitor|Ca2+ release activated Ca2+ channel 1 inhibitor,15584|15587,Immunomodulator|Anticancer|Synergist,1596|1545|7293,Gastrointestinal tumor|Hematological neoplasm|Non-Hodgkin lymphoma|Solid tumor,131|2054|319|725,,,Incozen Therapeutics Pvt Ltd|Rhizen Pharmaceuticals SA,1050981|1052344,,,Rhizen Pharmaceuticals SA,1052344,,,,,,
106078,GC-4711,"GC-4711|superoxide dismutase mimetic (iv, NSCLC), Galera",Research Code,Cancer,Superoxide dismutase stimulator,479,Anticancer|Antioxidant agent,1545|74,Non-small-cell lung cancer|Pancreas tumor,1262|249,,,Galera Therapeutics Inc,1054887,,,Galera Therapeutics Inc,1054887,,,,,,
106105,IGM-8444,"multimeric anti-death receptor 5 antibody (cancer), IGM Biosciences|Death Receptor 5, IGM Biosciences|multimeric anti-DR5 antibody (cancer), IGM Biosciences|multimeric IgM antibodies targeting DR5 (cancer), IGM Biosciences|IGM-8444",Research Code,Cancer,TRAIL-2 receptor agonist,8232,Synergist|Anticancer antibody,7293|55684,Non-small-cell lung cancer|Stomach tumor|Sarcoma|Non-Hodgkin lymphoma|Metastatic prostate cancer|Metastatic ovary cancer|Solid tumor|Colorectal tumor,1262|127|194|319|3664|3866|725|989,Hematological neoplasm|Cancer,2054|651,IGM Biosciences Inc,1014332,,,IGM Biosciences Inc,1014332,,,,,,
106309,BA-3021,"RoR-2 conditionally active biologic antibody-drug conjugate (triple-negative breast cancer), BioAtla/Himalaya|CAB-Ror2-ADC|ROR-2 conditionally active biologic antibody based drug conjugate (cancer), BioAtla/Himalaya|BA-3021",Research Code,Cancer,Ntrkr2 tyrosine kinase receptor inhibitor,3824,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Stage IV melanoma|Soft tissue sarcoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Head and neck tumor|Cancer|Ovary tumor,3257|3378|3657|3665|3713|623|651|799,,,BioAtla llc|Himalaya Therapeutics SEZC,1054676|1241379,Sinobioway Group Co Ltd,1087964,BioAtla llc,1054676,,,,,,
106338,TY-9591,"pyrimidine derivative (lung cancer), Guangzhou Boji Medical & Biotechnological/Changzhou Runnor Biological Technology|RUNNOR-9591|pyrimidine derivate (lung cancer), Tetranov Biopharm|TY-9591",Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Solid tumor|Lung tumor,1262|725|755,,,Tetranov Biopharm Inc,1077209,Guangzhou Boji Medical & Biotechnological Co Ltd|Changzhou Runnor Biological Technology Co Ltd,1070576|1119755,Guangzhou Boji Medical & Biotechnological Co Ltd,1070576,,,,,,
106366,BinD-19,"BinD-19|anti-CD19 CAR T-cell therapy, Shenzhen BinDeBio",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,B-cell acute lymphoblastic leukemia|B-cell lymphoma,1729|316,,,Shenzhen BinDeBio Ltd.,1148302,,,Shenzhen BinDeBio Ltd.,1148302,,,,,,
106371,"CVD908delta-ssb-based SVN and MYCN vaccines (cancer), University of Maryland School of Medicine/Baylor College of Medicine","CVD908delta-ssb-based SVN and MYCN vaccines (cancer), University of Maryland School of Medicine/Baylor College of Medicine|cancer vaccine (attenuated Salmonella strain), University of Maryland School of Medicine/Baylor College of Medicine|CVD908ssb-TXSVN",,Cancer,Survivin protein modulator|MYCN gene modulator,13606|56764,Anticancer|Recombinant bacterial vector vaccine,1545|12369,Cancer,651,,,Baylor College of Medicine|University of Maryland School of Medicine,20534|1070952,,,University of Maryland School of Medicine,1070952,,,,,,
106389,IM-19,"IM19 CAR-T|anti-CD19 CAR T-cell therapy (leukemia), Beijing Immunochina Medical Science & Technology|IM-19|anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma/B-cell acute lymphoblastic leukemia), Simcere Pharmaceutical Group/Beijing Immunochina Medical Science & Technology",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy,393|7761|1545|4790,B-cell acute lymphoblastic leukemia|Mantle cell lymphoma|Non-Hodgkin lymphoma,1729|1744|319,Leukemia,199,Simcere Pharmaceutical Group|Beijing Immunochina Medical Science & Technology Co Ltd,1023261|1140907,,,Beijing Immunochina Medical Science & Technology Co Ltd,1140907,,,,,,
106390,ciltacabtagene autoleucel,"LCAR-B38M|anti-BCMA CAR T-cell therapy (multiple myeloma), Nanjing Legend Biotech|JNJ-4528|JNJ-68284528|anti-BCMA CAR T-cell therapy (multiple myeloma), Janssen|ciltacabtagene autoleucel|cilta-cel",Research Code|Research Code|Research Code|INN,Cancer,APRIL receptor modulator,8255,Immunostimulant|Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,393|1545|7761|4790,Multiple myeloma,1828,,,Janssen Biotech Inc|Nanjing Legend Biotech Co Ltd,26997|1143778,,,Nanjing Legend Biotech Co Ltd,1143778,,,,,,
106420,CT-041,"CAR-CLD18 T-cell therapy (gastric cancer/pancreatic cancer), CARsgen|Claudin18.2-targeted chimeric antigen receptor redirected autologous T-cell therapy (gastric cancerrcinoma/pancreatic cancer), CARsgen|CAR-CLD18 T-cells|anti-Claudin18.2 CAR T-cell therapy (gastric cancer/pancreatic cancer), CARsgen|CLDN18.2-CAR-T cells|CT-041",Research Code|Research Code|Research Code,Cancer,Claudin 18 modulator,13891,Anticancer|Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,1545|393|4790|7761,Esophagus tumor|Stomach tumor|Adenocarcinoma|Metastatic stomach cancer|Metastatic pancreas cancer|Advanced solid tumor,1011|127|2399|3666|3669|3713,,,Carsgen Therapeutics Ltd,1103310,,,Carsgen Therapeutics Ltd,1103310,,,,,,
106461,AZD-1390,"AZD-1390|ATM kinase inhibitor (cancer/glioblastoma/metastatic brain cancer), AstraZeneca",Research Code,Cancer,ATM serine protein kinase inhibitor,15151,Anticancer protein kinase inhibitor,62255,Glioblastoma|Metastatic brain cancer,2454|3471,Cancer,651,AstraZeneca plc,14190,,,AstraZeneca plc,14190,,,,,,
106494,SI-B-001,SI-B-001,Research Code,Cancer,,,Anticancer monoclonal antibody|Unspecified drug target,55685|59620,Esophagus tumor|Non-small-cell lung cancer|Breast tumor|Head and neck tumor|Lung tumor|Colorectal tumor,1011|1262|49|623|755|989,,,Sichuan Biokin Pharmaceutical Co Ltd,1069227,,,Sichuan Biokin Pharmaceutical Co Ltd,1069227,,,,,,
106499,SI-B-003,SI-B-003,Research Code,Cancer,,,Immunomodulator|Unspecified drug target|Anticancer monoclonal antibody,1596|59620|55685,Non-small-cell lung cancer|Transitional cell carcinoma|Melanoma|Glioblastoma|Metastatic breast cancer|Metastatic stomach cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Solid tumor|Lung tumor|Colorectal tumor,1262|1771|205|2454|3657|3666|4250|427|725|755|989,Renal tumor,999,Sichuan Biokin Pharmaceutical Co Ltd,1069227,,,Sichuan Biokin Pharmaceutical Co Ltd,1069227,,beta-Hederin,Nitric Oxide (NO) Production Inhibitors,1130,,
106518,CT-0508,"CARMA-0508|CAR macrophage therapy (CARMA, solid tumor), Carisma Therapeutics|anti-HER2 CAR macrophage therapy (advanced solid tumor), Carisma Therapeutics|CT-0508",Research Code|Research Code,Cancer,Erbb2 tyrosine kinase receptor modulator,3755,Anticancer|Macrophage stimulator|Immunostimulant,1545|7751|393,Metastatic breast cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor,3657|3666|3667|3713,,,Carisma Therapeutics,1149316,,,Carisma Therapeutics,1149316,,,,,,
106533,"autologous AdHER2 dendritic cell vaccine (advanced metastatic tumors), National Cancer Institute/National Institutes of Health Clinical Center/University of Cincinnati","autologous AdHER2 dendritic cell vaccine (advanced metastatic tumors), National Cancer Institute/National Institutes of Health Clinical Center/University of Cincinnati",,Cancer,,,Therapeutic vaccine|Dendritic cell vaccine|Anticancer,12379|102926|1545,Metastasis,1069,,,University of Cincinnati|National Cancer Institute (NCI)|National Institutes of Health Clinical Center,20555|20519|1069368,,,National Cancer Institute (NCI),20519,,,,,,
106539,gavocabtagene autoleucel,"TC-210|anti-mesothelin TRuC T-cell therapy (solid tumor), TCR2 Therapeutics|mesothelin-TRuC-T cell therapy|anti-mesothelin TCR T-cell therapy (TRuC, solid tumor), TCR2 Therapeutics|TC-210 + PD1 Switch|MSLN-e-TRuC|Gavo-cel|gavocabtagene autoleucel|gavocabtagene autoleucel (solid tumor), TCR2 Therapeutics",Research Code|Research Code|Research Code|PINN,Cancer,Mesothelin modulator,11484,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,Mesothelioma|Cholangiocarcinoma|Metastatic non small cell lung cancer|Metastatic ovary cancer,1240|1765|3665|3866,Non-small-cell lung cancer|Solid tumor,1262|725,TCR2 Therapeutics Inc,1139759,,,TCR2 Therapeutics Inc,1139759,,Venritidine hydrochloride,Histamine H2 Receptor Antagonists,197,Signal Transduction Modulators,1402
106542,TC-110,"anti-CD19 TCR T-cell therapy (TRuC, hematological cancer), TCR2 Therapeutics|CD19-TRuC-T cells (hematological cancer), TCR2 Therapeutics|FMC-63-TCR fusion protein T-cell therapy (TRuC, hematological cancer), TCR2 Therapeutics|TC-110",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer|Immunostimulant,4790|7761|1545|393,Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|Non-Hodgkin lymphoma,1728|1729|1744|1745|1749|1750|319,Hematological neoplasm,2054,TCR2 Therapeutics Inc,1139759,,,TCR2 Therapeutics Inc,1139759,,,,,,
106574,orelabrutinib,"ICP-022|ICP-022 (autoimmune diseases), Innocare Pharma|Bruton tyrosine kinase inhibitors (cancer/immune disease), Beijing Innocare Pharma Tech|Btk inhibitors (cancer/immune disease), Beijing Innocare Pharma Tech|ICP-022 (chronic lymphocytic leukemia), Innocare Pharma|ICP-022 (mantle cell lymphoma), Innocare Pharma|orelabrutinib|Bruton tyrosine kinase inhibitors (oral, marginal zone lymphoma), Beijing Innocare Pharma Tech|yinuokai",Research Code|Research Code|Trade Name,Cancer|Immune,Btk tyrosine kinase inhibitor,3592,Anticancer protein kinase inhibitor|Anti-inflammatory,62255|2953,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Multiple sclerosis|Rheumatoid arthritis|B-cell lymphoma|Systemic lupus erythematosus|Non-Hodgkin lymphoma|Autoimmune disease,1734|1743|1744|1745|1746|1749|213|291|316|318|319|36,Lymphoma,203,Beijing Innocare Pharma Tech Co Ltd|Biogen Inc,1151691|1005244,,,Beijing Innocare Pharma Tech Co Ltd,1151691,,,,,,
106615,MHC-001,"PD1 knockout engineered T cell autologous therapy (lung cancer), MedGenCell|MHC-001|PD1 knockout engineered T cell autologous therapy (lung cancer), Aomiao Biotechnology/MedGenCell/Sichuan University",Research Code,Cancer,PDCD1 gene inhibitor,67142,Genetically engineered autologous cell therapy|Anticancer,4790|1545,Metastatic non small cell lung cancer,3665,,,"Sichuan University|MedGenCell, Co Ltd",1003379|1125280,,,Sichuan University,1003379,,,,,,
106633,ETBX-061,"ETBX-061|MUC1-based Ad5-vector vaccine (cancer), Etubics|Ad5 [E1-, E2b-]-MUC1|Ad5 [E1-, E2b-]-mucin1",Research Code,Cancer,Mucin 1 modulator,32076,Recombinant viral vector vaccine|Anticancer|Therapeutic vaccine,12370|1545|12379,Metastasis|Hormone refractory prostate cancer,1069|3246,Cancer,651,Etubics Corp,1034204,,,Etubics Corp,1034204,,,,,,
106636,alphaCD19-TCRz-41BB + alphaCD22-TCRz-41BB,"anti-CD19 CAR T-cell therapy + anti-CD22 CAR T-cell therapy (B-lineage leukemia/lymphoma), Xuzhou Medical University/Shanghai Hrain Biotechnology|alphaCD19-TCRz-41BB + alphaCD22-TCRz-41BB|alphaCD19-TCRz-41BB|alphaCD22-TCRz-41BB|aCD19-TCRz-41BB|aCD22-TCRz-41BB|aCD19-TCRz-41BB + aCD22-TCRz-41BB",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte cell adhesion molecule modulator,5080|5089,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Lymphoma leukemia,1737,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,,,,
106659,CKD-702,CKD-702|KDDF-201709-11,Research Code,Cancer,Hepatocyte growth factor receptor antagonist|Epidermal growth factor receptor antagonist,675|740,Anticancer|Anticancer antibody|Anticancer protein kinase inhibitor,1545|55684|62255,Stomach tumor|Metastatic non small cell lung cancer|Cancer|Colorectal tumor,127|3665|651|989,,,Chong Kun Dang Pharmaceutical Corp,15410,,,Chong Kun Dang Pharmaceutical Corp,15410,,,,,,
106666,SAR-439459,"SAR-439459|anti-TGF beta monoclonal antibody (intravenous, solid tumor), Sanofi",Research Code,Cancer,TGF beta receptor antagonist,377,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Multiple myeloma|Solid tumor,1828|725,,,Sanofi SA,1009547,,,Sanofi SA,1009547,,,,,,
106733,NANT Non-small Cell Lung Cancer Vaccine,"NANT Non-small Cell Lung Cancer Vaccine|capecitabine + cisplatin + cyclophosphamide + fluorouracil + fulvestrant + leucovorin + nab-paclitaxel + omega-3-acid ethyl esters + oxaliplatin + bevacizumab + avelumab + nivolumab + aNK cells + ALT-803 + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + GI-4000 + GI-6207 + GI-6301 (NSCLC), NantCell/NantKwest|metronomic chemotherapy + anti-VEGF mAb + anti-PD-L1 mAb + anti-PD1 antibody + activated NK cells + IL-15 super agonist complex + Ad5 anti-CEA vaccine + Ad5 anti-EGFR2 vaccine + Ad5 anti-brachyury vaccine + Ad5 anti-MUC1 vaccine + recombinant S cerevisiae Ras protein vaccine + recombinant S cerevisiae anti-carcinoembryonic antigen vaccine + recombinant S cerevisiae anti-brachyury antigen vaccine (NSCLC), NantCell/NantKwest|low-dose chemotherapy + anti-VEGF mAb + PD-L1 checkpoint inhibitor + PD-1 checkpoint inhibitor + NK-92 cells + IL-15/IL-15R super agonist complex + Ad5 [E1-, E2b-]-CEA + Ad5 [E1-, E2b-]-HER2/neu + Ad5 [E1-, E2b-]-Brachyury + Ad5 [E1-, E2b-]-MUC1 + yeast anti-Ras vaccine + yeast anti-CEA vaccine + yeast anti-brachyury vaccine (NSCLC), NantCell/NantKwest",,Cancer,Mucin 1 modulator|IL-15 receptor agonist|IL-15 receptor modulator|Estrogen receptor antagonist|Programmed cell death ligand 1 inhibitor|VEGF ligand inhibitor|Ras GTPase modulator|Thymidylate synthase inhibitor|Programmed cell death protein 1 inhibitor|Erbb2 tyrosine kinase receptor modulator|CD66 modulator|Brachyury protein modulator,32076|3085|3083|286|14007|12521|10449|372|67136|3755|5262|62319,Recombinant viral vector vaccine|Natural killer cell stimulator|Anticancer chemosensitizer|T-lymphocyte stimulator|Anticancer monoclonal antibody|Folic acid analog|Anticancer|Anticancer hormone antagonist|Therapeutic vaccine|Microtubule stabilizer|Recombinant fungal vector vaccine|Angiogenesis inhibitor|Anticancer alkylating agent|DNA synthesis inhibitor,12370|7757|1586|7761|55685|686|1545|62254|12379|2576|33963|61|50|140,,,Non-small-cell lung cancer,1262,,,NantKwest Inc|NantCell Inc,1015036|1104834,NantCell Inc,1104834,,,,,,
106748,SH-1028,Oritinib mesylate|SH-1028,Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Advanced solid tumor,1262|3713,,,Nanjing Sanhome Pharmaceutical Co Ltd,1023952,,,Nanjing Sanhome Pharmaceutical Co Ltd,1023952,,,,,,
10675,soblidotin,auristatin PE|soblidotin|ZT-1027|TZT-1027|dolastatin derivative|YHI-501,INN|Research Code|Research Code,Cancer|Infection,,,Apoptosis stimulator|Fungicide|Microtubule modulator|Angiogenesis inhibitor|Anticancer,1589|1748|563|61|1545,,,Fungal infection|Cancer|Lung tumor,124|651|755,,,ASKA Pharmaceutical Co Ltd|Daiichi Seiyaku Co Ltd|Teikoku Hormone Manufacturing Co Ltd|Yakult Honsha Co Ltd,1019817|15593|20333|20961,Teikoku Hormone Manufacturing Co Ltd,20333,,,,,,
106850,stenoparib,"E-7449|PARP1/2 and Tankyrase 1/2 inhibitor (advanced solid tumors/COVID-19), 2X Oncology|PARP inhibitor (cancer), Eisai|PARP1/2 and Tankyrase 1/2 inhibitor (oral, advanced solid tumors/coronavirus disease 19 infection), Oncology Venture US|2X-121|MGI-25036|stenoparib|stenoparib, Allarity Therapeutics",Research Code|Research Code|Research Code,Cancer|Infection,Tankyrase-1 inhibitor|Tankyrase-2 inhibitor|Poly ADP ribose polymerase 1 inhibitor|Poly ADP ribose polymerase 2 inhibitor,11150|11153|38283|38286,Anticancer|Antiviral,1545|991,Coronavirus disease 19 infection|Endometrioid carcinoma|Pancreas tumor|Prostate tumor|Metastatic breast cancer|Advanced solid tumor|Metastatic ovary cancer|Breast tumor|Ovary tumor,10406|1705|249|276|3657|3713|3866|49|799,B-cell lymphoma|Stage IV melanoma,316|3257,Oncology Venture US Inc,1129699,Eisai Co Ltd,15872,Eisai Co Ltd,15872,,Lifibrol,,,,
106943,ASK-120067,"ASK-120067|EGFR tyrosine kinase inhibitor (NSCLC), Jiangsu/Shangai Institute/Guangzhou Institutes|CCB-120067",Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer,3665,Non-small-cell lung cancer,1262,Jiangsu Aosaikang Pharmaceutical Co Ltd|Shanghai Institute of Materia Medica of the Chinese Academy of Sciences|Guangzhou Institutes of Biomedicine and Health,1040018|25314|1053800,,,Jiangsu Aosaikang Pharmaceutical Co Ltd,1040018,,Fenpyramin|Milverine,,,,
107004,TQB-3456,TQB-3456,Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer,1545,Non-small-cell lung cancer,1262,,,Centaurus BioPharma Co Ltd|CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1069948|1025425,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,,,,,,
107015,AMG-673,"AMG-673|anti-CD3/anti-CD33 bispecific T-cell engager (HLE-BiTE, acute myeloid leukemia), Amgen|emerfetamab",Research Code|PINN,Cancer,CD3 modulator|CD33 modulator,5023|5119,Immunostimulant|Anticancer antibody|T-lymphocyte stimulator,393|55684|7761,Acute myelogenous leukemia,1731,,,Amgen Inc,14109,,,Amgen Inc,14109,,,,,,
107017,TAK-573,"TAK-573|TEV-48573|CD38-Attenukine|CD38-attenukine (intravenous, infusion, advanced solid tumors/NSCLC/CRPC/multiple myeloma), Takeda/Teva|modakafusp alfa",Research Code|Research Code|PINN,Cancer,ADP ribosyl cyclase-1 modulator|Interferon alpha 2 ligand modulator,5134|920,Immunomodulator|Anticancer|Anticancer monoclonal antibody,1596|1545|55685,Multiple myeloma|Hormone refractory prostate cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Solid tumor,1828|3246|3665|3713|725,,,Takeda Oncology|Teva Pharmaceutical Industries Ltd,21991|20348,,,Takeda Oncology,21991,,,,,,
107063,GT-103,"GT-103|complement Factor H inhibiting immunoglobulin G-3 antibodies (iv, cancer), Grid",Research Code,Cancer,Complement Factor H inhibitor|Immunoglobulin G3 modulator,26227|5759,Anticancer antibody,55684,Metastatic non small cell lung cancer|Solid tumor,3665|725,,,Grid Therapeutics LLC,1152723,Duke University,20567,Duke University,20567,,,,,,
107085,FN-1501,FN-1501,Research Code,Cancer,Flt3 tyrosine kinase inhibitor,3806,Anticancer protein kinase inhibitor,62255,Acute myelogenous leukemia|Advanced solid tumor,1731|3713,,,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Shanghai Fosun Medical Technology Development Co Ltd|China Pharmaceutical University,1074127|21231,China Pharmaceutical University,21231,,,,,,
107091,BOS-172738,"DS-5010|RET inhibitor (cancer), Daiichi Sankyo/Boston Pharmaceuticals|BOS-172738",Research Code|Research Code,Cancer,Ret tyrosine kinase receptor inhibitor,3818,Anticancer protein kinase inhibitor,62255,Medullary thyroid cancer|Metastatic non small cell lung cancer|Advanced solid tumor,3240|3665|3713,Cancer,651,Boston Pharmaceuticals,1116437,Daiichi Sankyo Co Ltd,1017506,Daiichi Sankyo Co Ltd,1017506,,,Growth Hormone Release Inhibitors,582,Signal Transduction Modulators,1402
107100,MRG-003,MRG-003,Research Code,Cancer,Epidermal growth factor receptor modulator,3605,Anticancer monoclonal antibody,55685,Non-small-cell lung cancer|Biliary cancer|Nasopharyngeal carcinoma|Metastatic colorectal cancer|Advanced solid tumor|Head and neck tumor,1262|1516|1768|3658|3713|623,Colorectal tumor,989,Shanghai Miracogen Biotechnology Co Ltd,1153010,,,Shanghai Miracogen Biotechnology Co Ltd,1153010,,,,,,
107214,"AP-002, Altum Pharmaceuticals","LX-001|AP-002, Altum Pharmaceuticals",Research Code,Cancer|Endocrine/Metabolic|Musculoskeletal,Osteoclast differentiation factor antagonist,4128,Osteoclast inhibitor|Apoptosis stimulator|Anticancer,12596|1589|1545,Non-small-cell lung cancer|Hypercalcemia|Prostate tumor|Bone disease|Breast tumor,1262|173|276|45|49,,,Altum Pharmaceuticals Inc,1153730,Lexi Pharma Inc,1153469,Lexi Pharma Inc,1153469,,,,,,
107232,vusolimogene oderparepvec,"RP-1 (oncolytic virus), Replimune|HSV-engineered oncolytic immunotherapy (Immulytic, cancer), Replimune|oncolytic HSV therapy expressing GALV-GP-R + GM-CSF (Immulytic, cancer), Replimune|vusolimogene oderparepvec",,Cancer,GM-CSF receptor agonist,410,Immunostimulant|Anticancer|T-lymphocyte stimulator,393|1545|7761,Basal cell carcinoma|Skin cancer|Squamous cell carcinoma|Merkel cell carcinoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Uveal melanoma|Ocular melanoma,1764|2170|307|3235|3257|3378|3466|3657|3665|3713|3788|3789,,,Replimune Group Inc,1114214,,,Replimune Group Inc,1114214,,,,,,
107239,PHI-101,"PHI-101|Flt3 tyrosine kinase inhibitor (oral, cancer), Pharos",Research Code,Cancer,Flt3 tyrosine kinase inhibitor,3806,Anticancer protein kinase inhibitor,62255,Acute myelogenous leukemia|Fallopian tube cancer|Peritoneal tumor|Metastatic ovary cancer|Breast tumor,1731|2243|3083|3866|49,Myelodysplastic syndrome,1272,Pharos I&BT Co Ltd,1153680,Daegu-Gyeongbuk Medical Innovation Foundation|Korea Institute of Science and Technology,1121416|21211,Daegu-Gyeongbuk Medical Innovation Foundation,1121416,,,,,,
107252,BDC-1001,"HER2 Boltbody|dendritic cell-activating anti-HER2 antibody (breast cancer). Bolt Biotherapeutics|anti-HER2 TLR7/8 ISAC (cancer), Bolt Biotherapeutics|immune-stimulating antibody conjugates (cancer), Bolt Biotherapeutics|BDC-1001",Research Code,Cancer,TLR-7 agonist|Erbb2 tyrosine kinase receptor modulator|TLR-8 agonist,7821|3755|7824,Dendritic cell stimulator|Immunostimulant|Anticancer monoclonal antibody,173472|393|55685,Metastatic breast cancer|Metastatic stomach cancer|Advanced solid tumor,3657|3666|3713,Breast tumor|Cancer,49|651,Bolt Biotherapeutics Inc,1153707,,,Bolt Biotherapeutics Inc,1153707,,,,,,
107274,"fadraciclib  (intravenous, advanced cancer), Cyclacel","CYC-065|CYC-065 (intravenous, advanced cancer), Cyclacel|dual CDK 2/9 inhibitor (advanced cancer), Cyclacel|fadraciclib|fadraciclib  (intravenous, advanced cancer), Cyclacel",Research Code|INN,Cancer,Cyclin-dependent kinase-5 inhibitor|Cyclin-dependent kinase-2 inhibitor|Cyclin-dependent kinase-9 inhibitor|KMT2A gene inhibitor|Cyclin E inhibitor,4316|4310|8110|87157|9497,Anticancer protein kinase inhibitor|Apoptosis stimulator|Anticancer,62255|1589|1545,Metastasis|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Solid tumor,1069|1272|1731|1734|725,,,Cyclacel Pharmaceuticals Inc,24341,,,Cyclacel Pharmaceuticals Inc,24341,,,,,,
107290,DS-1205c,"DS-1205b|AXL tyrosine kinase inhibitor (NSCLC), Daiichi Sankyo|DS-1205c|DS-1205|AB-329",Research Code|Research Code|Research Code|Research Code,Cancer,Axl tyrosine kinase receptor inhibitor,3742,Anticancer protein kinase inhibitor,62255,Hematological neoplasm|Metastatic non small cell lung cancer|Solid tumor,2054|3665|725,,,AnHeart Therapeutics Inc,1177488,Daiichi Sankyo Co Ltd,1017506,Daiichi Sankyo Co Ltd,1017506,,,,,,
107371,AUTO-3,"AUTO-3|dual anti-CD19/anti-CD22 CAR T-cell therapy (acute lymphocytic leukaemia/diffuse large B-cell lymphoma), Autolus",Research Code,Cancer,B-lymphocyte cell adhesion molecule modulator|B-lymphocyte antigen CD19 modulator,5089|5080,Anticancer|Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,1545|393|4790|7761,Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1728|1729|1749|319,,,Autolus Therapeutics Ltd,1105192,,,Autolus Therapeutics Ltd,1105192,,,,,,
107419,MORAb-202,MORAb-202,Research Code,Cancer,Folate receptor alpha antagonist,12800,Anticancer monoclonal antibody|Microtubule inhibitor,55685|2575,Endometrioid carcinoma|Fallopian tube cancer|Peritoneal tumor|Metastatic breast cancer|Metastatic non small cell lung cancer|Breast tumor|Ovary tumor,1705|2243|3083|3657|3665|49|799,Cancer,651,Eisai Co Ltd,15872,Morphotek Inc,29741,Morphotek Inc,29741,,,,,,
107457,mRNA-5671,"mRNA-5671|V-941|KRAS vaccine (cancer), ModeRNA Therapeutics/Merck",Research Code|Research Code,Cancer,KRAS gene modulator,22391,Therapeutic vaccine|Anticancer|RNA vaccine,12379|1545|12377,Non-small-cell lung cancer|Pancreas tumor|Colorectal tumor,1262|249|989,,,ModeRNA Therapeutics|Merck & Co Inc,1060964|18077,,,ModeRNA Therapeutics,1060964,Factrel (as hydrochloride)|Kryptocur|Lutrelef (as acetate)|Lutrepulse (as acetate),Gonadoliberin|Gonadorelin|Luteinizing hormone releasing factor,Gonadotropin-Releasing Hormone Receptor (GNRHR) Ligands,1633,Signal Transduction Modulators,1402
107463,autogene cevumeran,"RG-6180|mRNA-based personalized cancer vaccine (IVAC MUTANOME, iv, solid tumors), Genentech/BioNTech|RO-7198457|individualized Neoantigen-Specific Therapy, Roche/BioNTech|iNeST, Roche/BioNTech|BNT-122|autogene cevumeran",Research Code|Research Code|Research Code|INN,Cancer,,,Anticancer|RNA vaccine|Therapeutic vaccine,1545|12377|12379,Non-small-cell lung cancer|Pancreas tumor|Stage IV melanoma|Advanced solid tumor|Colorectal tumor,1262|249|3257|3713|989,,,BioNTech RNA Pharmaceuticals GmbH|Genentech Inc,1071590|19453,,,Genentech Inc,19453,,,,,,
107480,SHC-014748M,SHC-014748M|SH-748,Research Code|Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor,11183,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Chronic lymphocytic leukemia|Follicle center lymphoma|Marginal zone B-cell lymphoma|Peripheral T-cell lymphoma|Non-Hodgkin lymphoma,1734|1745|1746|1753|319,Hematological neoplasm,2054,Nanjing Sanhome Pharmaceutical Co Ltd,1023952,,,Nanjing Sanhome Pharmaceutical Co Ltd,1023952,,,,,,
107495,SC-43,"SC-43|SHP-1 agonist (cancers/liver fibrosis), SupremeCure Pharma/Taipei Veterans General Hospital/National Yang-Ming University",Research Code,Cancer|Gastrointestinal,Hematopoietic cell phosphatase stimulator,7652,Anticancer,1545,Biliary cancer|Metastatic non small cell lung cancer,1516|3665,Cholangiocarcinoma|Hepatocellular carcinoma|Liver fibrosis|Breast tumor|Solid tumor|Colorectal tumor,1765|1767|2318|49|725|989,RaND Biosciences,1234575,National Yang Ming University|National Taiwan University Hospital|SupremeCure Pharma|Taipei Veterans General Hospital,1002709|1038961|1154445|30729,SupremeCure Pharma,1154445,,,,,,
10751,apolizumab,"apolizumab|hu 1D10|Remitogen|Hu1D10, PDL|SMART anti-B cell lymphoma|SMART 1D10 MAb, Protein Design Labs",USAN|INN|Trade Name,Cancer,,,Unspecified drug target|Anticancer monoclonal antibody,59620|55685,,,B-cell lymphoma|Solid tumor,316|725,,,PDL BioPharma Inc,19162,PDL BioPharma Inc,19162,,,,,,
107537,AZD-0466,"AZD-0466|dual Bcl-2/Bcl-xL inhibitor (solid tumor/hematological neoplasm), AstraZeneca",Research Code,Cancer,Bcl-2 protein inhibitor|Bcl-xL Bcl-2 associated death promotor inhibitor,16111|14541,Anticancer|Apoptosis stimulator,1545|1589,Small-cell lung cancer|Myelodysplastic syndrome|Acute lymphoblastic leukemia|T-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Multiple myeloma|Lymphoma|Hematological neoplasm|Non-Hodgkin lymphoma|Solid tumor,1261|1272|1728|1730|1731|1734|1744|1828|203|2054|319|725,,,AstraZeneca plc,14190,,,AstraZeneca plc,14190,,,,,,
107557,NTX-301,"methyl transferase inhibitors (cancer), Bionetix/Southern Research|NTX-301|DNMT1 inhibitor (oral, acute myeloid leukemia/myelodysplastic syndromes/chronic myelomonocytic leukemia), Bionetix/Southern Research Institute",Research Code,Cancer,DNA cytosine-5 methyltransferase 1 inhibitor,25901,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelomonocytic leukemia,1272|1731|6833,Cancer,651,Bionetix Inc|Southern Research Institute,1153648|20226,,,Southern Research Institute,20226,,,,,,
10756,ASP-0113,"bivalent plasmid DNA vaccine (CMV infection), Vical/PMC|bivalent immunotherapeutic vaccine (CMV), Vical|bivalent CMV DNA vaccine, Vical|VCL-CB01|TransVax CMV vaccine, Vical|Transvax|bivalent plasmid DNA vaccine (cytomegalovirus infection), Vical|bivalent plasmid DNA vaccine (CMV infection), Vical/Aventis Pasteur|ASP-0113",Research Code|Trade Name|Research Code,Cancer|Infection,CMV 65kDa lower matrix phosphoprotein modulator|Human cytomegalovirus glycoprotein B modulator,52420|30504,Antiviral|Therapeutic vaccine|Prophylactic vaccine|DNA vaccine|Anticancer,991|12379|12378|1879|1545,,,Glioblastoma|Cytomegalovirus infection,2454|89,,,Astellas Pharma Inc|Brickell Biotech Inc|Sanofi Pasteur,1013295|20743|22127,Brickell Biotech Inc,20743,,,,,,
107568,BBP-398,"SHP-2 inhibitors (cancer), Navire Pharmaceuticals/MD Anderson Cancer Center|PTPN11 gene modulator (cancer), Navire Pharmaceuticals/MD Anderson Cancer Center|BBP-398|IACS-13909|SHP-2 inhibitors (cancer/advanced solid tumor/metatsatic non small cell lung cancer), Navire Pharmaceuticals/MD Anderson Cancer Center",Research Code|Research Code,Cancer,Protein tyrosine phosphatase-2C inhibitor|MAP kinase inhibitor|Tyrosine kinase receptor inhibitor|PTPN11 gene modulator|SHP2 interacting transmembrane protein inhibitor,10327|2511|3520|53822|79870,Anticancer protein kinase inhibitor|Immunomodulator,62255|1596,Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,3665|3713|651,Non-small-cell lung cancer,1262,MD Anderson Cancer Center|Navire Pharmaceuticals|University of Texas System|LianBio Co Ltd,23382|1154708|21864|1219797,,,MD Anderson Cancer Center,23382,,,,,,
107594,"dual anti-CD19/anti-CD22 CAR‐T cell therapy (B-cell malignancies), Stanford University","dual anti-CD19/anti-CD22 CAR‐T cell therapy (B-cell malignancies), Stanford University",,Cancer,B-lymphocyte cell adhesion molecule modulator|B-lymphocyte antigen CD19 modulator,5089|5080,Genetically engineered autologous cell therapy|Immunostimulant|Anticancer|T-lymphocyte stimulator,4790|393|1545|7761,B-cell lymphoma,316,,,Stanford University,20679,,,Stanford University,20679,,,,,,
107606,"bevacizumab biosimilar, Sinocelltech","bevacizumab|bevacizumab biosimilar, Sinocelltech|SCT-510",INN|Research Code,Cancer,VEGF ligand inhibitor,12521,Angiogenesis inhibitor|Anticancer monoclonal antibody,61|55685,Non-small-cell lung cancer|Hepatocellular carcinoma,1262|1767,Cancer,651,Sinocelltech Ltd,1079269,,,Sinocelltech Ltd,1079269,,,,,,
107613,AVM-0703,"AugmenStem|PlenaStem|stem cell sequestration inhibitor, AVM Biotechnology|AVM-0703|stem cell engraftment enhancer (osteoarthritis, cancer, biliary atresia, Parkinson's disease, liver failure, diabetes mellitus), AVM Biotechnology|Supra-Pharmacologic Dexamethasone sodium phosphate (intravenous, DLBCL/follicular lymphoma/high-grade B-cell lymphoma/Burkitt lymphoma/Chronic lymphocytic leukemia/T-cell lymphoma/ Acute lymphoblastic leukemia/mantle cell lymphoma), AVM Biotechnology|AVM-0703 (respiratory distress syndrome/COVID-19), AVM Biotechnology/Medpace",Trade Name|Trade Name|Research Code,Cancer|Endocrine/Metabolic|Gastrointestinal|Immune|Infection|Inflammatory|Neurology/Psychiatric|Respiratory,,,Stem cell modulator|Anti-inflammatory|Anticancer|Antiviral,53558|2953|1545|991,Coronavirus disease 19 infection|Liver failure|Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|T-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|High grade B-cell lymphoma|Multiple myeloma|Influenza virus infection|Biliary atresia|Osteoarthritis|Parkinsons disease|Stem cell transplantation|B-cell lymphoma|Non-Hodgkin lymphoma|Cancer|Burkitts lymphoma|Respiratory distress syndrome|Diabetes mellitus,10406|1529|1728|1729|1730|1734|1744|1745|1749|1751|1828|191|2412|245|255|2990|316|319|651|791|8|97,,,Medpace Inc|AVM Biotechnology LLC,1041552|1054857,,,AVM Biotechnology LLC,1054857,,,,,,
107644,CC-93269,"EM-901|CC-93269|anti-CD3/anti-BCMA T-cell bispecific antibody (multiple myeloma), Celgene|anti-CD3/anti-BCMA bispecific T-cell engager (TCB, multiple myeloma), EngMab|alnuctamab",Research Code|Research Code|PINN,Cancer,APRIL receptor modulator|CD3 modulator,8255|5023,Immunostimulant|Anticancer antibody|T-lymphocyte stimulator,393|55684|7761,Multiple myeloma,1828,,,Engmab Sarl,1099313,,,Engmab Sarl,1099313,Altemia|Retriacyl,Doconexent|Docosahexaenoic acid,PPARalpha Agonists|Free Fatty Acid Receptor 4 (FFAR4; GPR120) Agonists,893|3631,Signal Transduction Modulators|Pyroptosis Inducers,1402|9968
107645,CC-92480,"CC-92480|cereblon modulator (multiple myeloma), Celgene|cereblon E3  ligase modulator (oral, multiple myeloma), Bristol-Myers Squibb",Research Code,Cancer,Protein cereblon modulator,77059,Anticancer|Apoptosis stimulator,1545|1589,Multiple myeloma,1828,,,Bristol-Myers Squibb Co,15065,Celgene Corp,15331,Celgene Corp,15331,,,,,,
107650,BYC-001,"anti-CD19 CAR-T cell therapy (hematological malignancy), Shanghai Bioray Laboratory|U-CART|BYC-001|anti-CD19 allogeneic CAR-T cell therapy (acute lymphoblastic leukemia/non-Hodgkin's lymphoma), Shanghai Bioray Laboratory",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,B-cell acute lymphoblastic leukemia|Non-Hodgkin lymphoma,1729|319,,,Shanghai Bioray Laboratory Inc,1151487,,,Shanghai Bioray Laboratory Inc,1151487,,,,,,
107655,OMT-110,OMT-110|OMT-111,Research Code|Research Code,Cancer,,,Anticancer,1545,Adenocarcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer,2399|3657|3658|3665|3669,,,Metimedi Pharmaceuticals Co Ltd,1156470,OncoMetPlus Pharmaceuticals Co,1155196,OncoMetPlus Pharmaceuticals Co,1155196,,,,,,
107658,GPC3-T2-CAR-T,"anti-GPC3 CAR T-cell therapy (hepatocellular carcinoma), Second Affiliated Hospital of Guangzhou Medical University|GPC3-T2-CAR-T",Research Code,Cancer,Glypican-3 modulator,9953,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Hepatocellular carcinoma,1767,,,"The Second Affiliated Hospital of Guangzhou Medical University, China",1149636,,,"The Second Affiliated Hospital of Guangzhou Medical University, China",1149636,,,,,,
107659,PLX-2853,"PLX-2853|bromodomain containing protein inhibitor (oral tablet, advanced malignancies), Plexxikon|BRD4 inhibitor (oral tablet, advanced malignancies), Plexxikon|BRD4 inhibitor (oral tablet, advanced malignancies/hematological malignancies), Plexxikon",Research Code,Cancer|Genitourinary/Sexual Function|Immune,Bromodomain containing protein 4 inhibitor,34570,Anticancer,1545,Small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Fallopian tube cancer|Peritoneal tumor|Vulvar intraepithelial neoplasia|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Vaginal cancer|Ovarian clear cell carcinoma|Advanced solid tumor|Uveal melanoma|Metastatic ovary cancer|Uterine cervix tumor|Graft versus host disease|Uterus tumor,1261|1272|1731|1745|1749|2243|3083|3105|319|3246|3291|3525|3713|3788|3866|427|616|740,,,Plexxikon Inc,29155,,,Plexxikon Inc,29155,,,,,,
107662,"anti-CD19 CAR T-cell therapy (leukemia/lymphoma/multiple myeloma ), Shanghai Unicar-Therapy","anti-CD19 CAR T-cell therapy (leukemia/lymphoma/multiple myeloma ), Shanghai Unicar-Therapy|CD19-CART, Shanghai Unicar-Therapy|anti-CD19 CAR T-cell therapy (knocked down IL-6 secretion, ALL/CLL/lymphoma/multiple myeloma/NHL), Shanghai Unicar-Therapy Bio-medicine Technology",,Cancer,B-lymphocyte antigen CD19 modulator,5080,IL-6 release inhibitor|Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator|Immunostimulant,4935|4790|1545|7761|393,Acute leukemia|Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Multiple myeloma|Lymphoma|Non-Hodgkin lymphoma,1727|1728|1734|1828|203|319,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd,1144294,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd,1144294,,,,,,
107690,anti-MUC1 CAR-pNK,"anti-MUC1 CAR-pNK|anti-MUC1 CAR NK-cell therapy (solid tumor), PersonGen Biomedicine/Anke Biotechnology",,Cancer,Mucin 1 modulator,32076,Immunostimulant|Anticancer|Genetically engineered autologous cell therapy|Natural killer cell stimulator,393|1545|4790|7757,Solid tumor,725,,,PersonGen Biomedicine (Suzhou) Co Ltd|Anhui Anke Biotechnology (Group) Co Ltd,1115492|1027048,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,,,,
107702,"anti-CD33 allogenic NK92 NK-cell therapy (acute myeloid leukemia), PersonGen Biomedicine","anti-CD33 CAR NK-cell therapy (acute myeloid leukemia), PersonGen Biomedicine|anti-CD33 allogenic NK92 NK-cell therapy (acute myeloid leukemia), PersonGen Biomedicine",,Cancer,CD33 modulator,5119,Anticancer|Immunostimulant|Natural killer cell stimulator,1545|393|7757,Acute myelogenous leukemia,1731,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,,,,
107706,PCAR-119,"PCAR-119|anti-CD19 CAR-NK cell therapy, PersonGen BioTherapeutics",Research Code,Cancer,B-lymphocyte antigen CD19 inhibitor,5082,Anticancer|Immunostimulant|Natural killer cell stimulator,1545|393|7757,Leukemia|Lymphoma,199|203,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,,,,
107722,"CT-053, Carsgen Therapeutics","anti-BCMA CAR T-cell therapy, Carsgen Therapeutics|CT-053, Carsgen Therapeutics|anti-BCMA CAR T-cell therapy (intravenous infusion, multiple myeloma), Carsgen Therapeutics",Research Code,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Anticancer|Immunostimulant|Genetically engineered autologous cell therapy,7761|1545|393|4790,Multiple myeloma,1828,,,Carsgen Therapeutics Ltd,1103310,,,Carsgen Therapeutics Ltd,1103310,,,,,,
107761,GRANITE-001,"RNA-based personalized neoantigen immunotherapies (lipid nanoparticle, cancer), Gritstone Oncology|GRANITE-001|GRT-C901|GRT-R902|GRT-C901/GRT-R902|GRANITE",Trade Name|Research Code|Research Code,Cancer,,,Anticancer|Therapeutic vaccine,1545|12379,Esophagus tumor|Stomach tumor|Adenocarcinoma|Metastatic bladder cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Colorectal tumor,1011|127|2399|3466|3665|3713|989,Bladder cancer,2380,Gritstone Oncology,1115276,,,Gritstone Oncology,1115276,Adehl|Ocufors,Boforsin|Coleonol|Colforsin|Forskolin,Adenylate Cyclase Activators,525,,
107780,Sym-021,"PD-1 checkpoint inhibitor (cancer), Symphogen/Shire|Sym-021|PD-1 checkpoint inhibitor (cancer), Symphogen/Baxalta",Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Metastasis|Mesothelioma|Small-cell lung cancer|Pancreatic ductal adenocarcinoma|Endometrioid carcinoma|Cholangiocarcinoma|Lymphoma|Bladder cancer|Squamous cell carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Urethral cancer|Advanced solid tumor|Cancer,1069|1240|1261|1507|1705|1765|203|2380|307|3658|3665|3666|3667|3673|3678|3713|651,,,Symphogen A/S|Takeda Pharmaceutical Co Ltd,28600|20300,Baxalta Inc|Shire plc,1109518|24652,Symphogen A/S,28600,,,,,,
107781,AMG-701,"AMG-701|anti-CD3/anti-BCMA bispecific T-cell engager (HLE-BiTE, multiple myeloma), Amgen|anti-BCMA HLE BiTE|pavurutamab",Research Code|Research Code|INN,Cancer,APRIL receptor modulator|CD3 modulator,8255|5023,T-lymphocyte stimulator|Anticancer antibody|Immunostimulant,7761|55684|393,Multiple myeloma,1828,,,BeiGene Co Ltd|Amgen Inc,1063251|14109,,,Amgen Inc,14109,,,Calcium Channel Blockers,361,,
107783,RG-6109,"DCLL-9718S|anti-CLL-1 antibody-drug conjugate (acute myeloid leukemia), Genentech|RG-6109",Research Code|Research Code,Cancer,C-type lectin domain protein 12A modulator,82256,Immunotoxin|Anticancer antibody|Anticancer,539|55684|1545,,,Acute myelogenous leukemia,1731,,,Genentech Inc,19453,Genentech Inc,19453,,,,,,
107784,64Cu-DOTA-daratumumab,"64Cu-DOTA-daratumumab|64Cu-DOTA-daratumumab (multiple myeloma), City of Hope Medical Center|radiolabeled CD38 inhibitor (multiple myeloma), City of Hope Medical Center|radiolabeled IgG1 kappa mAb (multiple myeloma), City of Hope Medical Center|64Cu-DOTA-Dara",,Cancer,ADP ribosyl cyclase-1 inhibitor,5136,Neoplasm diagnostic agent|Immune diagnostic agent|Radiodiagnostic|PET contrast agent,7220|7215|5720|5555,Multiple myeloma,1828,,,City of Hope Medical Center,1051922,,,City of Hope Medical Center,1051922,,,Leukotriene Receptor Antagonists|Mediator Release Inhibitors,237|802,Signal Transduction Modulators,1402
107814,SNDX-5613 sesquifumarate,"menin-MLL inhibitors (oral, acute leukemia), Syndax Pharmaceuticals|menin-MLL inhibitors (oral, acute leukemia), Allergan|VTP-50469|SNDX-5613|SNDX-5613 sesquifumarate",Research Code|Research Code|Research Code,Cancer,Menin inhibitor|Myeloid lymphoid leukemia protein inhibitor,37755|44220,Anticancer,1545,Acute leukemia|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Ewing sarcoma,1727|1728|1731|2975,,,Syndax Pharmaceuticals Inc,1031631,Allergan plc,1088700,Vitae Pharmaceuticals Inc,29775,,,,,,
107837,AL-034,"JNJ-4964|TLR agonist (hepatitis B), Chia Tai Tianqing/Janssen|AL-034|TQ-A3334, Chia Tai Tianqing Pharmaceutical Group|TQ-A3334|JNJ-64794964",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Infection,TLR-7 agonist,7821,Immunostimulant|Anticancer|Antiviral,393|1545|991,Non-small-cell lung cancer|Hepatitis B virus infection,1262|152,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd|Alios BioPharma Inc|Janssen Pharmaceutica NV,1025425|1034134|17421,,,Alios BioPharma Inc,1034134,,,,,,
107865,serclutamab talirine,"ABBV-321|EGFR-targeting antibody-drug conjugate (iv, advanced solid tumors), AbbVie|serclutamab talirine",Research Code|USAN|PINN,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor|DNA intercalator,55685|62255|750,Sarcoma|Glioblastoma|Squamous cell carcinoma|Metastatic bladder cancer|Metastatic renal cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Uterine cervix tumor|Breast tumor,194|2454|307|3466|3467|3658|3665|3667|3673|3713|427|49,,,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
10788,BL-22,"BL-22|NSC-691237|RFB4(dsFv)-PE38|PE38-conjugated anti-CD22 immunotoxin, NCI/Cambridge Antibody Technology/AstraZeneca|GCR-3888|CAT-3888",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Elongation factor 2 inhibitor|B-lymphocyte cell adhesion molecule inhibitor,53707|5091,Immunotoxin|Protein synthesis inhibitor|Anticancer,539|339|1545,,,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Hairy cell leukemia|Pancreas tumor|B-cell lymphoma|Non-Hodgkin lymphoma|Ovary tumor,1728|1734|1736|249|316|319|799,,,Genencor International Inc|Enzon Pharmaceuticals Inc|MedImmune LLC|National Cancer Institute (NCI)|Cambridge Antibody Technology Group plc,15856|16045|18008|20519|24236,National Cancer Institute (NCI),20519,,,,,,
107930,"NK/NKT cell therapy (non-small-cell lung cancer), Houchao Biotechnology","NK/NKT cell therapy (non-small-cell lung cancer), Houchao Biotechnology",,Cancer,,,Anticancer|Immunostimulant|Natural killer cell stimulator|Natural killer T-lymphocyte stimulator,1545|393|7757|173716,Non-small-cell lung cancer,1262,,,"Shanghai Houchao Biotechnology Co., Ltd",1149925,,,"Shanghai Houchao Biotechnology Co., Ltd",1149925,,,,,,
107956,"CAR T-cell therapy (acute myeloid leukemia), Shenzhen Geno-Immune Medical Institute","CAR T-cell therapy (acute myeloid leukemia), Shenzhen Geno-Immune Medical Institute|anti-Muc1 CAR T-cell therapy (acute myeloid leukemia), Shenzhen Geno-Immune Medical Institute|anti-CD33 CAR T-cell therapy (acute myeloid leukemia), Shenzhen Geno-Immune Medical Institute|anti-CD38 CAR T-cell therapy (acute myeloid leukemia), Shenzhen Geno-Immune Medical Institute|anti-CD56 CAR T-cell therapy (acute myeloid leukemia), Shenzhen Geno-Immune Medical Institute|anti-CD117 CAR T-cell therapy (acute myeloid leukemia), Shenzhen Geno-Immune Medical Institute|anti-CD123 CAR T-cell therapy (acute myeloid leukemia), Shenzhen Geno-Immune Medical Institute",,Cancer,Mucin 1 modulator|Kit tyrosine kinase modulator|CD33 modulator|ADP ribosyl cyclase-1 modulator|Neural cell adhesion molecule 1 modulator|CDw123 modulator,32076|3807|5119|5134|5228|5427,T-lymphocyte stimulator|Anticancer|Immunostimulant|Genetically engineered autologous cell therapy,7761|1545|393|4790,Acute myelogenous leukemia,1731,,,Shenzhen Geno-Immune Medical Institute,1130728,,,Shenzhen Geno-Immune Medical Institute,1130728,,,,,,
107986,"CART-19, Pregene (Shenzhen) Biotechnology/Henan Cancer Hospital","anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), Pregene (Shenzhen) Biotechnology/Henan Cancer Hospital|CART-19, Pregene (Shenzhen) Biotechnology/Henan Cancer Hospital",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,B-cell acute lymphoblastic leukemia,1729,,,Pregene (Shenzhen) Biotechnology Co Ltd|Henan Province Hospital,1155884|1058888,,,Pregene (Shenzhen) Biotechnology Co Ltd,1155884,,,,,,
107991,PZ-01,"anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia, B-cell lymphoma), Pinze Lifetechnology/Chinese Academy of Sciences/Navy General Hospital|PZ-01",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Genetically engineered autologous cell therapy|Immunostimulant|T-lymphocyte stimulator,1545|4790|393|7761,B-cell acute lymphoblastic leukemia|B-cell lymphoma,1729|316,,,Navy General Hospital|Pinze Lifetechnology Co Ltd|Chinese Academy of Sciences,1075063|1153896|23863,,,Pinze Lifetechnology Co Ltd,1153896,,,,,,
108029,"anti-CD19 CAR T-cells (PD-1 knockout, lymphoma/leukemia), Third Military Medical University","anti-CD19 CAR T-cells (PD-1 knockout, lymphoma/leukemia), Third Military Medical University",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,393|1545|7761|4790,B-cell acute lymphoblastic leukemia|B-cell lymphoma,1729|316,,,Third Military Medical University of the Chinese PLA,1006996,,,Third Military Medical University of the Chinese PLA,1006996,,,,,,
108039,AMG-757,"delta-like ligand-3 bispecific T-cell engager antibody construct (small-cell lung cancer), Amgen|DLL3-BiTE|HLE DLL3-BiTE|anti-CD3/anti-DLL3 bispecific T-cell engager (HLE-BiTE, solid tumor), Amgen|AMG-757|tarlatamab",Research Code|Research Code|Research Code|PINN,Cancer,Delta-like protein ligand 3 modulator|CD3 modulator,18188|5023,Anticancer|Anticancer antibody|Immunostimulant|T-lymphocyte stimulator,1545|55684|393|7761,Neuroendocrine tumor|Small-cell lung cancer|Metastatic prostate cancer,1128|1261|3664,Solid tumor,725,Amgen Inc,14109,,,Amgen Inc,14109,,,,,,
108102,TTX-030,"anti-CD39 monoclonal antibodies, Tizona Therapeutics|CD39 checkpoint inhibitor (cancer), Tizona Therapeutics|TTX-030|CD39 checkpoint inhibitor (cancer/solid tumor/lymphoma), Tizona Therapeutics|CD39 checkpoint inhibitor (cancer/solid tumor/lymphoma), Trishula Therapeutics|anti-CD39 monoclonal antibodies, Trishula Therapeutics",Research Code,Cancer,CD39 antagonist,5139,T-lymphocyte stimulator|Anticancer monoclonal antibody|Leukocyte stimulator|Immunostimulant,7761|55685|7747|393,Lymphoma|Advanced solid tumor|Solid tumor,203|3713|725,Cancer,651,Trishula Therapeutics Inc,1221067,Tizona Therapeutics Inc,1114602,Tizona Therapeutics Inc,1114602,,,,,,
108233,CTX-110,"CRISPR/Cas9 gene-corrected stem autologous cells (cancer), CRISPR Therapeutics|CTX-101, CRISPR Therapeutics|anti-CD19 CAR T-cell therapy (cancer), CRISPR Therapeutics|CTX-110",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,Acute lymphoblastic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1728|1745|1749|316|319,Cancer,651,CRISPR Therapeutics AG,1095307,,,CRISPR Therapeutics AG,1095307,,,,,,
108235,"allogeneic EBV-specific anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia), Memorial Sloan-Kettering Cancer Center","allogeneic EBV-specific anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia), Memorial Sloan-Kettering Cancer Center|allogeneic anti-CD19 EBV-CTL therapy (acute lymphoblastic leukemia), Memorial Sloan-Kettering Cancer Center|anti-CD19 EBV-CTL therapy (acute lymphoblastic leukemia), MSKCC",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,Acute lymphoblastic leukemia,1728,,,Memorial Sloan-Kettering Cancer Center,22122,,,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
108243,"immune killer cells (non-small-cell lung cancer/hepatocellular carcinoma), Ivy Life Sciences","immune killer cells (non-small-cell lung cancer), Newmed Life Sciences|IKC|aiyouxiao|yikeai|immune killer cells (non-small-cell lung cancer/hepatocellular carcinoma), Ivy Life Sciences",Trade Name,Cancer,,,Anticancer|T-lymphocyte stimulator|Immunostimulant|Natural killer cell stimulator|Natural killer T-lymphocyte stimulator,1545|7761|393|7757|173716,Hepatocellular carcinoma|Metastatic non small cell lung cancer,1767|3665,,,Ivy Life Sciences Co Ltd,1064381,,,Ivy Life Sciences Co Ltd,1064381,,,,,,
108252,CTX-120,"anti-BCMA CAR T-cell therapy (multiple myeloma), CRISPR Therapeutics|CTX-120",Research Code,Cancer,APRIL receptor modulator,8255,Immunostimulant|T-lymphocyte stimulator|Anticancer,393|7761|1545,Multiple myeloma,1828,Cancer,651,CRISPR Therapeutics AG,1095307,,,CRISPR Therapeutics AG,1095307,,,,,,
108295,P-BCMA-ALLO1,"P-BCMA-ALLO1|anti-BCMA CAR T-cell therapy (allogeneic, multiple myeloma), Poseida",Research Code,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,Multiple myeloma,1828,,,Poseida Therapeutics Inc,1109809,,,Poseida Therapeutics Inc,1109809,,,,,,
10834,CC-1088,"CDC-801|CC-801|CC-1088|CC-5048|lead SelCID (1), Celgene",Research Code|Research Code|Research Code|Research Code,Cancer|Gastrointestinal|Inflammatory,PDE 4 inhibitor,304,Immunosuppressant|Anti-inflammatory|TNF alpha synthesis inhibitor|Cytokine release inhibitor|Anticancer,396|2953|382|1072|1545,,,Myelodysplastic syndrome|Inflammatory disease|Crohns disease,1272|188|84,,,Celgene Corp,15331,Celgene Corp,15331,,,,,,
108374,"anti-CD22 CAR T-cell therapy, No 307 Hospital","anti-CD22 CAR T-cell therapy, No 307 Hospital",,Cancer,B-lymphocyte cell adhesion molecule modulator,5089,Anticancer|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant,1545|4790|7761|393,B-cell acute lymphoblastic leukemia,1729,,,No 307 Hospital of the Chinese People’s Liberation Army,1061547,,,No 307 Hospital of the Chinese People’s Liberation Army,1061547,Geref,Sermorelin,,,,
108382,"CAR T-cell therapy (multiple myeloma), Shenzhen Geno-Immune Medical Institute","CAR T-cell therapy (multiple myeloma), Shenzhen Geno-Immune Medical Institute|anti-BCMA CAR T-cell therapy (multiple myeloma), Shenzhen Geno-Immune Medical Institute|anti-CD56 CAR T-cell therapy (multiple myeloma), Shenzhen Geno-Immune Medical Institute|anti-CD38 CAR T-cell therapy (multiple myeloma), Shenzhen Geno-Immune Medical Institute|anti-CD138 CAR T-cell therapy (multiple myeloma), Shenzhen Geno-Immune Medical Institute",,Cancer,ADP ribosyl cyclase-1 modulator|APRIL receptor modulator|Syndecan-1 modulator|Neural cell adhesion molecule 1 modulator,5134|8255|5452|5228,Anticancer|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant,1545|4790|7761|393,Multiple myeloma,1828,,,Shenzhen Geno-Immune Medical Institute,1130728,,,Shenzhen Geno-Immune Medical Institute,1130728,,,,,,
108389,AZD-8701,"Foxp3-targeting antisense oligonucleotides (cancer), Ionis/AstraZeneca|AZD-8701|ION-AZ7|FOXP3 inhibitor (cancer), Astrazenca/Ionis|antisense oligonucleotide targeting forkhead Box P3 (cancer), Astrazenca|ION-736|Treg modulator (cancer), AstraZenca/Ionis",Research Code|Research Code|Research Code,Cancer,FOXP3 gene inhibitor,16751,Immunostimulant|Anticancer|Antisense oligonucleotide inhibitor|Regulatory T lymphocyte inhibitor|Unspecified non-viral vector based gene therapy,393|1545|7294|174668|4793,Small-cell lung cancer|Squamous cell carcinoma|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Uterine cervix tumor|Cancer,1261|307|3257|3657|3665|3666|3673|3713|4250|427|651,,,AstraZeneca plc|Ionis Pharmaceuticals Inc,14190|17269,,,Ionis Pharmaceuticals Inc,17269,,,,,,
108405,MaaT-001.3,MaaT-001.3|MaaT-011,Research Code|Research Code,Gastrointestinal,,,Microbiome modulator|Unspecified drug target,173474|59620,Intestine disease,599,,,MaaT Pharma SA,1109165,,,MaaT Pharma SA,1109165,,,,,,
108411,PRG-1801,"anti-BCMA CAR T-cell therapy (multiple myeloma), Pregene (Shenzhen) Biotechnology/ Henan Province Hospital|BCMA CAR-T cells|PRG-1801",Research Code,Cancer,APRIL receptor modulator,8255,Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator|Immunostimulant,4790|1545|7761|393,Multiple myeloma,1828,,,Biocast Co Ltd|Dr Reddy's Laboratories Ltd|Simcere Pharmaceutical Group,1203424|29387|1023261,Pregene (Shenzhen) Biotechnology Co Ltd,1155884,Pregene (Shenzhen) Biotechnology Co Ltd,1155884,,,,,,
10844,maribavir,1263W94|maribavir|GW-1263|VP-41263|benzimidavir|Camvia|BW-1263W94|GW-257406X|SHP-620|TAK-620,Research Code|USAN|BANN|INN|Research Code|Research Code|Trade Name|Research Code|Research Code|Research Code|Research Code,Infection,Serine threonine protein kinase UL97 inhibitor,85000,CMV replication inhibitor|Antiviral|DNA synthesis inhibitor,2833|991|140,Cytomegalovirus infection,89,,,Takeda Pharmaceutical Co Ltd,20300,Glaxo Group Ltd|Shire ViroPharma|GlaxoSmithKline plc,16453|19046|28355,Glaxo Group Ltd,16453,,,,,,
108482,APG-2449,APG-2449,,Cancer,Anaplastic lymphoma kinase receptor inhibitor|Ros1 tyrosine kinase receptor inhibitor|Focal adhesion kinase inhibitor,3736|3826|3540,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Esophagus tumor|Mesothelioma|Non-small-cell lung cancer|Advanced solid tumor|Ovary tumor,1011|1240|1262|3713|799,Colorectal tumor,989,Ascentage Pharma Group Corporation Ltd,1052437,,,Ascentage Pharma Group Corporation Ltd,1052437,,,Antimetabolites,1043,,
108506,CLL-442,"CLL-442|mTOR/PI3K inhibitor (topical cream, Bowen's disease), Novartis",Research Code,Cancer,mTOR inhibitor|Phosphoinositide 3-kinase inhibitor,10240|1575,Anticancer protein kinase inhibitor,62255,Bowen disease,3720,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
10854,omacetaxine mepesuccinate,homoharringtonine|omacetaxine mepesuccinate|NSC-141633,USAN|INN|Research Code,Cancer,,,Cell cycle inhibitor|Unspecified drug target|Anticancer,767|59620|1545,Chronic myelocytic leukemia,1735,,,Chinese Academy of Medical Sciences,21189,Sang-A Pharmaceutical Co Ltd,22145,Chinese Academy of Medical Sciences,21189,,,,,,
108604,"sodium selenite (oral, prostate cancer), Stanford University School of Medicine","sodium selenite (oral, prostate cancer), Stanford University School of Medicine|sk-03014|sodium selenite|selenious acid disodium salt",Research Code,Cancer,AR gene inhibitor,17163,Radiosensitizer|Anticancer hormone antagonist,1542|62254,Prostate tumor|Hormone refractory prostate cancer,276|3246,,,Stanford University School of Medicine,1129709,,,Stanford University School of Medicine,1129709,,,,,,
108607,BT-001,"CTLA-4 checkpoint inhibitor (oncolytic vaccinia virus delivery, Invir.IOTM/n-CoDeR/FIRST, solid tumor), Transgene/BioInvent|VV-α-CTLA-4|BT-001|Treg (oncolytic vaccinia virus delivery, Invir.IOTM/n-CoDER/FIRST, solid tumor), Transgene/BioInvent",Research Code|Research Code,Cancer,Cytotoxic T-lymphocyte protein-4 inhibitor,5482,T-lymphocyte stimulator|Anticancer monoclonal antibody|Regulatory T lymphocyte inhibitor|Anticancer|Immunostimulant,7761|55685|174668|1545|393,Non-Hodgkin lymphoma|Merkel cell carcinoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Solid tumor,319|3235|3257|3378|3657|3665|3713|725,,,BioInvent International AB|Transgene SA,18592|23924,,,Transgene SA,23924,,,,,,
108615,NM-01,"anti-PD-L1 nanobody, Suzhou Nanomab Technology|NM-01|99mTc-NM-01|99mTc-labeled anti-PD-L1 single-domain antibody (diagnostic agent, cancer/non-small cell lung cancer), Suzhou Nanomab Technology",Research Code|Research Code,Cancer,Programmed cell death ligand 1 modulator,14005,Neoplasm diagnostic agent|Imaging agent|Radiopharmaceutical|Radioimmunodiagnostic,7220|4155|1617|4405,Non-small-cell lung cancer|Cancer,1262|651,,,Lantheus Holdings Inc|Suzhou Nanomab Technology Ltd,1004416|1154142,,,Suzhou Nanomab Technology Ltd,1154142,,,,,,
108659,JJO-686,"anti-CD22 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), University of Pennsylvania/Novartis|anti-CD22 scFv TCRz:41BB CAR T-cell therapy|CART22-65s cells|JJO-686",Research Code,Cancer,B-lymphocyte cell adhesion molecule modulator,5089,Immunostimulant|Anticancer|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,393|1545|4790|7761,B-cell acute lymphoblastic leukemia,1729,,,University of Pennsylvania|Novartis AG,20658|23137,,,University of Pennsylvania,20658,,,,,,
108671,TNB-383B,"TNB-383B|anti-CD3 + anti-BCMA bispecific antibody (TeneoSeek, multiple myeloma), TeneoBio|anti-CD3/anti-BCMA bispecific T-cell engager (TeneoSeek, multiple myeloma), TeneoBio|anti-BCMAxCD3 (TeneoSeek, multiple myeloma), TenBio",Research Code,Cancer,CD3 modulator|APRIL receptor modulator,5023|8255,Immunostimulant|Anticancer antibody|T-lymphocyte stimulator,393|55684|7761,Multiple myeloma,1828,,,Teneobio Inc,1072877,,,Teneobio Inc,1072877,,,,,,
108673,"anti-BCMA CAR T-cell therapy (UniDabs, multiple myeloma), Kite","anti-BCMA CAR T-cell therapy (UniDabs, multiple myeloma), TeneoBio|FHVH33-CD8BBZ|anti-BCMA CAR T-cell therapy (UniDabs, multiple myeloma), Kite",,Cancer,APRIL receptor modulator,8255,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,Multiple myeloma,1828,,,Kite Pharma Inc,1056870,Teneobio Inc,1072877,Teneobio Inc,1072877,,,Leukotriene Receptor Antagonists|Lipoxygenase Inhibitors,237|447,Signal Transduction Modulators,1402
108675,SM-08502,"SM-08502|wnt-pathway inhibitor (oral tablet, advanced solid tumor), Samumed|CDC-like kinase inhibitor (pancreatic cancer), Samumed|Clk inhibitor (pancreatic cancer), Samumed|CLK2 inhibitor (oral, advanced solid tumors), Samumed|CLK3 inhibitor (oral, advanced solid tumors), Samumed|CDC-like kinase inhibitor (pancreatic cancer/gastrointestinal tumor/advanced solid tumors), Samumed|cirtuvivint",Research Code,Cancer,Clk protein kinase inhibitor|CLK2 protein kinase inhibitor|CLK3 protein kinase inhibitor,4344|4348|4350,Anticancer protein kinase inhibitor,62255,Gastrointestinal tumor|Pancreas tumor|Hormone refractory prostate cancer|Advanced solid tumor,131|249|3246|3713,,,Samumed LLC,1040378,,,Samumed LLC,1040378,,,,,,
108687,MGTA-145,"MGTA-M100|GRObetaT (stem cell mobilization), Magenta Therapeutics|MGTA-145",Research Code|Research Code,Cancer|Hematologic|Immune,CXCR2 chemokine agonist,3130,Stem cell stimulator|Anticancer,53559|1545,Multiple myeloma|Sickle cell anemia|Bone marrow transplantation,1828|303|46,,,Magenta Therapeutics Inc,1140317,,,Magenta Therapeutics Inc,1140317,,,,,,
108694,LY-3381916,"LY-3381916|indoleamine 2,3-dioxygenase 1 inhibitor (oral, solid tumor), Eli Lilly & Co|IDO-1 checkpoint inhibitor (solid tumor), Eli Lilly|IDO1 inhibitor (cancer), Eli Lilly|IDO checkpoint inhibitor (solid tumor), Eli Lilly",Research Code,Cancer,Indoleamine pyrrole 2 3-dioxygenase 1 inhibitor,64856,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,,,Solid tumor,725,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
108705,HPN-217,"HPN-217|anti-CD3/anti-BCMA/anti-albumin trispecific T-cell engager (TriTAC, multiple myeloma), Harpoon Therapeutics",Research Code,Cancer,APRIL receptor modulator|CD3 modulator|Albumin modulator,8255|5023|815,Anticancer antibody|Immunostimulant|T-lymphocyte stimulator,55684|393|7761,Multiple myeloma|Cancer,1828|651,,,Harpoon Therapeutics Inc,1138978,,,Harpoon Therapeutics Inc,1138978,,,,,,
108768,MEDI-2228,"MEDI-2228|pyrrolobenzodiazepine-linked antibody drug conjugate (BCMA, multiple myeloma), MedImmune/Dana-Farber Cancer Institute",Research Code,Cancer,APRIL receptor modulator,8255,Anticancer antibody|Anticancer alkylating agent|Immunotoxin,55684|50|539,,,Multiple myeloma,1828,,,MedImmune LLC,18008,MedImmune LLC,18008,,,,,,
108773,Descartes-08,"Descartes-08|CD8+ anti-BCMA CAR T-cell therapy (multiple myeloma), Cartesian Therapeutics/Harvard Medical School",Research Code,Cancer|Immune,APRIL receptor modulator,8255,Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator|Immunostimulant,4790|1545|7761|393,Multiple myeloma|Myasthenia gravis,1828|848,,,Harvard Medical School|Cartesian Therapeutics,24839|1158040,,,Cartesian Therapeutics,1158040,,,,,,
108777,MatchCART,"anti-CD19 CAR T-cell therapy (leukemia/lymphoma), Hrain Biotechnology|MatchCART|anti-CD19-TCRz-CD137 CAR-T cells|anti-CD19-TCRz-CD28 CAR-T cells",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Leukemia|B-cell lymphoma,199|316,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,,,,
108782,BR-101801,"BR-101801|dual target inhibitor of DNA-PK and P13K delta (DLBCL), Boryung Pharmaceutical",Research Code,Cancer,Phosphoinositide 3-kinase inhibitor|DNA dependent protein kinase inhibitor,1575|25889,Synergist|Anticancer protein kinase inhibitor,7293|62255,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Hematological neoplasm|B-cell lymphoma,1734|1743|1744|1745|1746|1749|1753|2054|316,,,Boryung Pharm Co Ltd,14987,,,Boryung Pharm Co Ltd,14987,,,,,,
108834,D-CIK,D-CIK|DC-CIK,,Cancer,,,T-lymphocyte stimulator|Natural killer cell stimulator|Dendritic cell vaccine|Anticancer,7761|7757|102926|1545,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Hepatocellular carcinoma,1011|1262|127|1767,,,Shenzhen Hornetcorn Bio-technology Company,1099442,,,Shenzhen Hornetcorn Bio-technology Company,1099442,,,,,,
108841,FT-596,"NKCAR-iPSC-NK cells|hnCD16-expressing anti-CD19 CAR NK-cell therapy (cancer), Fate Therapeutics/University of California San Diego|FT-596|CAR19 + hnCD16 + IL-15RF",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Natural killer cell stimulator|Immunostimulant|Anticancer,7757|393|1545,Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1734|1749|316|319,Cancer,651,Fate Therapeutics Inc,1036293,University of California San Diego,25451,Fate Therapeutics Inc,1036293,,,,,,
108854,MCARH-171,"anti-BCMA CAR T-cell therapy (retroviral vector, multiple myeloma), MSKCC/Juno Therapeutics|anti-BCMA scFv(171)/CD8a hinge/4-1BB/CD3zeta CAR T-cells (retroviral vector, multiple myeloma), MSKCC/Juno Therapeutics|MCARH-171|171-BBz|130-BBz|137-BBz|183-BBz|BCMA-171|BCMA-130|BCMA-137|BCMA-183|EGFRt/hBCMA-41BBz|EGFRt/BCMA-41BBz",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,APRIL receptor modulator,8255,Immunostimulant|Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator,393|4790|1545|7761,Multiple myeloma,1828,,,Bristol-Myers Squibb Co|Memorial Sloan-Kettering Cancer Center,15065|22122,Juno Therapeutics Inc|Celgene Corp,1090676|15331,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
108885,SHR-2554,EBI-2554|SHR-2554,Research Code|Research Code,Cancer,Enhancer of zeste homolog 2 inhibitor,43815,Anticancer,1545,Lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Advanced solid tumor,203|316|319|3246|3713,Cancer,651,Jiangsu Hengrui Medicine Co Ltd|Eternity Bioscience Inc,1006925|1072530,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,,,,
108894,"anti-BCMA CAR T-cell therapy (multiple myeloma), Hrain Biotechnology","anti-BCMA CAR T-cell therapy (multiple myeloma), Hrain Biotechnology",,Cancer,APRIL receptor modulator,8255,Anticancer|Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,1545|393|4790|7761,Multiple myeloma,1828,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,,,,
108897,CD123CAR-41BB-CD3zeta-EGFRt,"anti-CD123 CAR T-cell therapy (acute myeloid leukemia), Hrain Biotechnology|CD123CAR-41BB-CD3zeta-EGFRt|HRAIN-004",Research Code|Research Code,Cancer,CDw123 modulator,5427,Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant,1545|7761|4790|393,Acute myelogenous leukemia,1731,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,,,,
108905,HRAIN-001,"anti-CD19 CAR T-cell therapy (B-cell leukemia/lymphoma), Hrain Biotechnology|anti-CD19-TCRz-CD28 CAR|HRAIN-001",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Genetically engineered autologous cell therapy|Immunostimulant|Anticancer|T-lymphocyte stimulator,4790|393|1545|7761,Lymphoid leukemia|B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Follicle center lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1255|1729|1734|1745|316|319,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,,,,
108906,HG-146,HG-146,Research Code,Cancer,Histone deacetylase-2 inhibitor|Histone deacetylase-1 inhibitor,7844|7841,Anticancer,1545,Multiple myeloma|Lymphoma|Advanced solid tumor,1828|203|3713,,,HitGen Ltd,1097673,,,HitGen Ltd,1097673,,,,,,
108970,dilanubicel,"NLA-101|allogeneic umbilical cord blood cells expanded ex vivo with Notch ligand Delta1, Nohla Therapeutics|dilanubicel",Research Code|USAN,Hematologic|Immune|Toxicity/Intoxication,,,Stem cell stimulator|Immunomodulator|Immunostimulant|Hematopoietic stimulator,53559|1596|393|610,Neutropenia|Radiation sickness|Hematopoietic stem cell transplantation|Graft versus host disease,1991|367|3888|616,,,Nohla Therapeutics Inc,1117012,,,Nohla Therapeutics Inc,1117012,,,,,,
109014,ASP-1948,"PTZ-329|antibody targeting immuno-regulatory pathway (cancer), Potenza/Astellas|ASP-1948",Research Code|Research Code,Cancer,Neuropilin 1 inhibitor,21882,Anticancer antibody|Immunomodulator,55684|1596,Non-small-cell lung cancer|Melanoma|Squamous cell carcinoma|Hormone refractory prostate cancer|Advanced solid tumor|Breast tumor|Ovary tumor,1262|205|307|3246|3713|49|799,Cancer,651,Potenza Therapeutics,1102074,Astellas Pharma Inc,1013295,Potenza Therapeutics,1102074,,,,,,
109015,ASP-1951,"PTZ-522|antibody targeting immuno-regulatory pathway (cancer), Potenza/Astellas|GITR costimulator (cancer), Potenza/Astellas|ASP-1951",Research Code|Research Code,Cancer,Activation-inducible TNF receptor agonist,8259,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,Squamous cell carcinoma|Metastatic colorectal cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Uterine cervix tumor|Cancer,307|3658|3664|3665|3713|427|651,,,Potenza Therapeutics,1102074,Astellas Pharma Inc,1013295,Potenza Therapeutics,1102074,,,,,,
109021,GEM-333,"GEM-333|anti-CD3/CD33 bispecific mAb (AML), GEMoaB/Celgene|anti-CD3/anti-CD33 bispecific T-cell engager (AML), Celgene",Research Code,Cancer,CD3 antagonist|CD33 antagonist,5025|5121,Anticancer monoclonal antibody,55685,Acute myelogenous leukemia,1731,,,GEMoaB Monoclonals GmbH,1120339,Celgene Corp,15331,GEMoaB Monoclonals GmbH,1120339,,,,,,
109070,FCARH-143,"FCARH-143|anti-BCMA CAR T-cell therapy (lentiviral vector, multiple myeloma), Juno Therapeutics",Research Code,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy|Immunostimulant,7761|1545|4790|393,Multiple myeloma,1828,,,Bristol-Myers Squibb Co,15065,Juno Therapeutics Inc|Celgene Corp,1090676|15331,Juno Therapeutics Inc,1090676,,Cefuroxime pivoxetil,,,,
109078,JAB-3068,"JAB-3068|SHP2 inhibitor (cancer), Jacobio Pharmaceuticals",Research Code,Cancer,Protein tyrosine phosphatase-2C inhibitor,10327,Anticancer,1545,Esophagus tumor|Squamous cell carcinoma|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor,1011|307|3665|3673|3713,,,Jacobio Pharmaceuticals Co Ltd|AbbVie Inc,1157883|1072507,,,Jacobio Pharmaceuticals Co Ltd,1157883,,,,,,
109084,EDP-1503,"monoclonal microbial (cancer), Evelo Biosciences|microbiome based immunotherapy (cancer), Evelo Biosciences/University of Chicago|monoclonal microbial developed from bifidobacteria (cancer), Evelo Biosciences/University of Chicago|EDP-1503",Research Code,Cancer,,,Immunostimulant|Anticancer|Microbiome modulator,393|1545|173474,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Renal cell carcinoma|Bladder cancer|Stage IV melanoma|Metastatic colorectal cancer|Breast tumor,1011|1262|127|1766|2380|3257|3658|49,Advanced solid tumor|Cancer|Colorectal tumor,3713|651|989,Evelo Biosciences Inc,1115767,University of Chicago,26013,University of Chicago,26013,,,,,,
109085,"anti-CD19 CAR T-cell therapy (B cell malignancies), Lentigen Technology","anti-CD19 CAR T-cell therapy (B cell malignancies), Lentigen Technology",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Anticancer|T-lymphocyte stimulator,393|1545|7761,B-cell lymphoma,316,,,Lentigen Technology Inc,1018047,,,Lentigen Technology Inc,1018047,,,,,,
109087,bb-21217,"bb-2121 matured ex vivo with bb-007|BCMA-targeting CAR T-cells (bb-007, hematological malignancies), bluebird bio|anti B-cell maturation antigen-targeting chimeric antigen receptor T-cells (bb-007, hematological malignancies), bluebird bio|anti-BCMA CAR T-cell therapy (bb-007, hematological malignancies), bluebird bio/Celgene|bb-21217",Research Code,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,Multiple myeloma,1828,Hematological neoplasm,2054,bluebird bio Inc|Bristol-Myers Squibb Co,16284|15065,Celgene Corp,15331,bluebird bio Inc,16284,,,,,,
109202,REGN-5458,"BCMAxCD3 bispecific antibody (cancer), Regeneron|anti-CD3/anti-BCMA bispecific T-cell engager (cancer), Regeneron|REGN-5458|anti-CD3/anti-BCMA bispecific T-cell engager (cancer), Regeneron/Sanofi",,Cancer,CD3 modulator|APRIL receptor modulator,5023|8255,Anticancer antibody|T-lymphocyte stimulator|Immunostimulant,55684|7761|393,Multiple myeloma,1828,,,Regeneron Pharmaceuticals Inc,19214,,,Regeneron Pharmaceuticals Inc,19214,,Stacofylline,,,,
109255,talquetamab,"JNJ-7564|JNJ-64407564|DuoBody CD3xGPRC5D bispecific antibody (multiple myeloma), Genmab/Janssen|anti-CD3/anti-GPRC5D bispecific mAb (relapsed or refractory multiple myeloma), Genmab/Janssen|CD3xGPRC5D bispecific mAb (relapsed or refractory multiple myeloma), Genmab/Janssen|anti-CD3/anti-GPRC5D bispecific T-cell engager (DuoBody, multiple myeloma), Janssen/Genmab|talquetamab",Research Code|Research Code|INN,Cancer,G protein coupled receptor C 5D modulator|CD3 modulator,127815|5023,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Multiple myeloma,1828,,,Janssen Pharmaceuticals Inc,25863,,,Janssen Pharmaceuticals Inc,25863,,,,,,
109257,BAY-2402234,"BAY-2402234|DHODH inhibitor (hematological neoplasm), Bayer",Research Code,Cancer,Dihydroorotate dehydrogenase inhibitor,1716,Anticancer,1545,,,Myelodysplastic syndrome|Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Chronic myelomonocytic leukemia|Colorectal tumor,1272|1731|1749|6833|989,,,Broad Institute Inc|Bayer AG,1031693|14455,Broad Institute Inc,1031693,,,Angiotensin-I Converting Enzyme (ACE) Inhibitors,381,,
109259,ABBV-744,"ABBV-744|BRD4 bromodomain inhibitor (metastatic castration resistant prostate cancer), AbbVie|BRD4 bromodomain inhibitor (oral, metastatic castration resistant prostate cancer/myelofibrosis) AbbVie Inc",Research Code,Cancer|Hematologic,Bromodomain containing protein 4 inhibitor,34570,Anticancer,1545,Acute myelogenous leukemia|Multiple myeloma|Polycythemia vera|Myelofibrosis|Thrombocytopenia|Hormone refractory prostate cancer,1731|1828|2319|2436|324|3246,Cancer,651,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
109285,"dual anti-CD19/anti-CD22 CAR T-cell therapy (leukemia), Hebei Senlang","dual anti-CD19/anti-CD22 CAR T-cell therapy (leukemia), Hebei Senlang",,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte cell adhesion molecule modulator,5080|5089,Anticancer|Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,1545|393|4790|7761,Acute lymphoblastic leukemia|Leukemia|Non-Hodgkin lymphoma,1728|199|319,,,Hebei Senlang Biotechnology Inc,1139326,,,Hebei Senlang Biotechnology Inc,1139326,,,,,,
109296,spCART-269,"anti-BCMA CAR T-cell therapy (multiple myeloma), Shanghai Unicar-Therapy Bio-medicine Technology|spCART-269|PD-1 knock-down anti-CD269 CAR T-cell therapy (lymphoma), Shanghai Unicar-Therapy Bio-medicine Technology",Research Code,Cancer,APRIL receptor modulator,8255,Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer,393|7761|4790|1545,Multiple myeloma,1828,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd,1144294,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd,1144294,,,,,,
109338,SHR-1701,"SHR-1701|anti-PD-L1/anti-TGF-beta receptor type 2 therapy (advanced solid tumors, metastatic castration-resistant prostate cancer), Jiangsu Hengrui Medicine|dual PD-L1 checkpoint inhibitor/TGFbRII inhibitor (advanced solid tumors, metastatic castration-resistant prostate cancer), Jiangsu Hengrui Medicine|anti-PD-L1 mAb + TGF-beta receptor II bi-functional fusion protein (advanced solid tumros/mCRPC), Jiangsu Hengrui Medicine|anti-PD-L1/anti-TGF-beta receptor II monoclonal antibody (pancreas cancer/advanced cancer), Dong-A ST/Jiangsu Hengrui Medicine",Research Code,Cancer,Programmed cell death ligand 1 inhibitor|TGF-beta type II receptor antagonist,14007|4598,T-lymphocyte stimulator|Immunostimulant|Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,7761|393|62255|55685,Esophagus tumor|Small-cell lung cancer|Stomach tumor|Renal cell carcinoma|Nasopharyngeal carcinoma|B-cell lymphoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor,1011|1261|127|1766|1768|316|3658|3665|3666|3667|3669|3673|3713,,,Jiangsu Hengrui Medicine Co Ltd|Dong-A ST Co Ltd,1006925|15742,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,,,,
109355,"anti-CD19 CAR T-cell therapy/IL-15 (cancer), Precigen/ZIOPHARM/Eden BioCell","third-generation anti-CD19 CAR T-cell therapy with mbIL15 (cancer), Precigen/ZIOPHARM|third-generation non-viral adoptive CAR T-cell therapy with mbIL15 (cancer), Precigen/ ZIOPHARM|third-generation non-viral adoptive CAR T-cell therapy with mbIL15 (cancer), MD Anderson Cancer Center|anti-CD19 CAR T-cell therapy co-expressing membrane-bound IL-15 (cancer), Precigen/ ZIOPHARM|anti-CD19 CAR T-cell therapy/IL-15 (cancer), Precigen/ ZIOPHARM|anti-CD19 CAR T-cell therapy/IL-15 (cancer), Precigen/ZIOPHARM/Eden BioCell|CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells|anti-CD19 CAR T-cell therapy (mbIL15 and HER1t safety switch, B-cell lymphoid malignancies), NCI/MD Anderson Cancer Center|RPM CD19-mbIL15-CAR-T cells",,Cancer,IL-15 receptor agonist|B-lymphocyte antigen CD19 modulator,3085|5080,T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy|Immunostimulant,7761|1545|4790|393,B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Cancer,1729|1734|1744|1745|1749|1750|316|319|651,,,MD Anderson Cancer Center|Precigen Inc|ZIOPHARM Oncology Inc|Eden BioCell Ltd,23382|1021778|1009856|1177852,National Cancer Institute (NCI),20519,MD Anderson Cancer Center,23382,,,,,,
109356,PD1-Vaxx,"mimotope immuno-oncologic B-cell peptide vaccine (cancer), Medical University of Vienna/Imugene|PD-1-mimotope vaccine (cancer), Medical University of Vienna/Imugene|PD1-Vaxx|PD-1 checkpoint inhibitor-inducing vaccine (cancer), Medical University of Vienna/Imugene|IMU-201, Imugene|APi-2568",Research Code|Research Code|Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Therapeutic vaccine|T-lymphocyte stimulator|Protein subunit vaccine|Anticancer|Immunostimulant,12379|7761|12372|1545|393,Non-small-cell lung cancer|Squamous cell carcinoma|Large cell lung carcinoma|Metastatic non small cell lung cancer|Cancer|Colon tumor,1262|307|3407|3665|651|767,,,Imugene Ltd|Medical University of Vienna,1037404|1015721,,,Medical University of Vienna,1015721,,,,,,
109374,anti-BCMA CAR T-cell therapy (multiple myeloma) soochow Hospital/Youkadi,"anti-BCMA CAR T-cell therapy (multiple myeloma), Shanghai Unicar-Therapy Bio-medicine Technology/First Affiliated Hospital of Suzhou University|anti-BCMA CAR T-cell therapy (multiple myeloma) soochow Hospital/Youkadi",,Cancer,APRIL receptor modulator,8255,Genetically engineered autologous cell therapy|Immunostimulant|Anticancer|T-lymphocyte stimulator,4790|393|1545|7761,Multiple myeloma,1828,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd|First Affiliated Hospital of Suzhou University,1144294|1076412,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd,1144294,,,,,,
10943,Angiostatin,"Angiostatin|K1-4|angiostatin protein|rhuAngiostatin, EntreMed|rhuAngiostatin, Alchemgen/CMCC|angiogenesis inhibitor, Entremed/BMS|angiogenesis inhibitor, Alchemgen/CMCC|recombinant human angiostatin, EntreMed|recombinant human angiostatin, Alchemgen/CMCC",Trade Name,Cancer|Neurology/Psychiatric|Ocular,,,Unspecified drug target|Angiogenesis inhibitor|Anticancer,59620|61|1545,,,Spinal cord injury|Non-small-cell lung cancer|Diabetic retinopathy|Cancer,1258|1262|576|651,,,Alchemgen Therapeutics Inc|Bristol-Myers Squibb Co|Childrens Medical Center Corp|CASI Pharmaceuticals Inc,1006726|15065|21051|21794,CASI Pharmaceuticals Inc,21794,,,,,,
109497,"anti-CD19 CAR T-cell therapy (B-cell malignancy), Wuhan Sian Medical Technology","anti-CD19 CAR T-cell therapy (B-cell malignancy), Wuhan Sian Medical Technology",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Acute lymphoblastic leukemia|B-cell lymphoma,1728|316,,,"Wuhan Sian Medical Technology Co, Ltd",1139510,,,"Wuhan Sian Medical Technology Co, Ltd",1139510,,,,,,
109500,"anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia), Beijing Sanwater Biological Technology","anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia), Beijing Sanwater Biological Technology|CART-19 (acute lymphoblastic leukemia), Beijing Sanwater Biological Technology|CTL-019 (acute lymphoblastic leukemia), Beijing Sanwater Biological Technology",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,,,B-cell acute lymphoblastic leukemia,1729,,,Beijing Sanwater Biological Technology Co,1125908,Beijing Sanwater Biological Technology Co,1125908,,,5-HT2A Receptor Antagonists|alpha1-Adrenoceptor Antagonists,210|36,Signal Transduction Modulators,1402
109505,pCAR-19B,"anti-CD19 CAR-T cell therapy (cancer), Chongqing Precision Biotech|pCAR-19B",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,393|1545|7761|4790,Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Leukemia|B-cell lymphoma,1728|1729|1744|1745|1749|199|316,,,Chongqing Precision Biotech Co Ltd,1161028,,,Chongqing Precision Biotech Co Ltd,1161028,,,,,,
109507,alkotinib,"small molecule therapeutic (oral/capsule, cancer), Suzhou Zelgen Biopharmaceuticals|aokatini|ZG-0418|alkotinib|ocatinib",Research Code,Cancer,Anaplastic lymphoma kinase receptor inhibitor|Ros1 tyrosine kinase receptor inhibitor,3736|3826,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer,1262,,,Suzhou Zelgen Biopharmaceuticals Co Ltd,1065043,,,Suzhou Zelgen Biopharmaceuticals Co Ltd,1065043,,,,,,
109528,ZN-e4,"KP-673|ZN-e4|EGFR inhibitor (oral, non-small-cell lung cancer), Zentalis/SciClone Pharmaceuticals",Research Code|Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer,1545,Metastatic non small cell lung cancer,3665,,,Zentalis Pharmaceuticals|SciClone Pharmaceutical (Holdings) Ltd,1201287|1155766,,,Zentalis Pharmaceuticals,1201287,,,,,,
109571,KUR-502,"CMD-502|allogeneic CAR NKT-cell therapy (hematological cancers), Cell Medica/Baylor College of Medicine|allogeneic CAR T-cell therapy (hematological cancers), Cell Medica/Baylor College of Medicine|ANCHOR cells, Baylor College of Medicine/Cell Medica|anti-CD19 CAR NK-cell therapy (B-cell lymphoma), Baylor College of Medicine/Cell Medica|CD19.CAR-aNKT cells|anti-CD19 CAR NK-cell therapy (hematological malignancies), Baylor College of Medicine/Kuur Therapeutics|ANCHOR cells, Baylor College of Medicine/Kuur Therapeutics|KUR-502",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Natural killer T-lymphocyte stimulator|Anticancer|Immunostimulant,173716|1545|393,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Hematological neoplasm|B-cell lymphoma|Non-Hodgkin lymphoma,1728|1734|1749|2054|316|319,,,Kuur Therapeutics|Baylor College of Medicine,1041182|20534,,,Baylor College of Medicine,20534,,,,,,
109580,fosciclopirox disodium heptahydrate,"ciclopirox prodrug (bladder cancer/urothelial cancer), CicloMed|CPX-POM|gamma-secretase complex inhibitor (bladder cancer), Ciclomed|fosciclopirox|fosciclopirox disodium heptahydrate",Research Code|INN,Cancer,Gamma-secretase inhibitor,7578,Anticancer,1545,Transitional cell carcinoma|Bladder cancer|Metastatic bladder cancer|Advanced solid tumor,1771|2380|3466|3713,,,CicloMed LLC,1156931,The University of Kansas Cancer Center,1067054,The University of Kansas Cancer Center,1067054,,,,,,
109628,MSCTRAIL,"MSCTRAIL|TRAIL-expressing allogeneic mesenchymal stromal cell therapy (iv infusion, lung adenocarcinoma), University College London",,Cancer,TNF related apoptosis inducing ligand modulator,13588,Apoptosis stimulator|Anticancer,1589|1545,Mesothelioma|Metastatic non small cell lung cancer,1240|3665,,,University College London,23505,,,University College London,23505,,,,,,
109665,EVX-01,EVX-01|EVAX-01-CAF09b|NPV-ds001-CAF09b|NPV-ds001|NeoPepVac,Research Code|Research Code|Research Code|Research Code,Cancer,,,Anticancer|Therapeutic vaccine|Protein subunit vaccine,1545|12379|12372,Bladder cancer|Stage IV melanoma|Metastatic renal cancer|Metastatic non small cell lung cancer,2380|3257|3467|3665,Cancer,651,Evaxion Biotech ApS,1073911,,,Evaxion Biotech ApS,1073911,,,,,,
109671,JY-025,"JY-025|recombinant anti-VEGFR2 fully human monoclonal antibody (cancer), Beijing Dongfang Baitai Biotechnology",Research Code,Cancer,VEGF-2 receptor antagonist,3848,Anticancer monoclonal antibody|Angiogenesis inhibitor|Anticancer protein kinase inhibitor,55685|61|62255,Metastatic non small cell lung cancer|Advanced solid tumor,3665|3713,,,Beijing Dongfang Baitai Biotechnology Co Ltd,1109140,,,Beijing Dongfang Baitai Biotechnology Co Ltd,1109140,,,,,,
109676,ICAR-19,"anti-CD19 CAR T-cell therapy (B-cell leukemia/B-cell lymphoma), Immune Cell Therapy|ICAR-19",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer,393|4790|7761|1545,Leukemia|B-cell lymphoma,199|316,,,Immune Cell Therapy Inc,1071882,,,Immune Cell Therapy Inc,1071882,,,,,,
109718,NEO-PV-01,"NEO-PV-01|cancer vaccine, Neon Therapeutics|personal neoantigen vaccine (melanoma/NSCLC/bladder cancer), Neon Therapeutics|personal neoantigen vaccine (melanoma/NSCLC/bladder cancer), BioNTech US",,Cancer,,,Anticancer|Therapeutic vaccine,1545|12379,Glioblastoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic non small cell lung cancer,2454|3257|3466|3665,Cancer,651,Broad Institute Inc|BioNTech US Inc,1031693|1114527,,,Broad Institute Inc,1031693,,,,,,
109719,"anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia), Fujian Medical University","anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia), Fujian Medical University|anti-CD19-scFv-4-1BB-CD3zeta CAR-T-cells (diffuse large B-cell lymphoma), Fujian Medical University",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,B-cell acute lymphoblastic leukemia|Diffuse large B-cell lymphoma,1729|1749,B-cell lymphoma,316,Fujian Medical University,1054278,,,Fujian Medical University,1054278,,,,,,
109742,ZW-49,"ZW-49|cytotoxic payload-linked bispecific anti-HER2 ADC (ZymeLink/Azymetric, HER2-expressing cancers/breast cancer), Zymeworks|zanidatamab zovodotin",Research Code|PINN,Cancer,Erbb2 tyrosine kinase receptor inhibitor,3756,Anticancer antibody,55684,Metastatic breast cancer,3657,,,Zymeworks Inc|BeiGene Co Ltd,1038924|1063251,,,Zymeworks Inc,1038924,,,,,,
109746,SCT-I10A,"PD-1 checkpoint inhibitor (cancer), Sinocelltech|SCT-I10A",Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Hepatocellular carcinoma|Lymphoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Advanced solid tumor|Head and neck tumor,1767|203|3658|3665|3667|3713|623,Cancer,651,Sinocelltech Ltd,1079269,,,Sinocelltech Ltd,1079269,,,,,,
109778,PF-06939999,"PRMT5 inhibitors (cancer), Pfizer|PF-06855800|PF-06939999",Research Code|Research Code,Cancer,Protein arginine N-methyltransferase 5 inhibitor,14756,Anticancer,1545,Endometrioid carcinoma|Squamous cell carcinoma|Metastatic bladder cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Uterine cervix tumor,1705|307|3466|3665|3667|3673|3713|427,Cancer,651,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
109839,huMesoCART,"autologous huCART-meso T-cell therapy (cancer), University of Pennsylvania/Novartis|huMesoCART|SS-1|MSLN-5|MSLN-11|MSLN-12|MSLN-14|MSLN-16|MSLN-18|MSLN-21|MSLN-23|anti-mesothelin CAR T-cell therapy (mesothelin expressing cancer), University of Pennsylvania/Novartis",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Mesothelin modulator,11484,Anticancer|Genetically engineered autologous cell therapy|Immunostimulant|T-lymphocyte stimulator,1545|4790|393|7761,Mesothelioma|Non-small-cell lung cancer|Fallopian tube cancer|Pancreas tumor|Peritoneal tumor|Cancer|Ovary tumor,1240|1262|2243|249|3083|651|799,,,Novartis AG|University of Pennsylvania,23137|20658,,,University of Pennsylvania,20658,,,,,,
109918,TPST-1120,"TPST-1120|PPAR alpha antagonist (cancer), Tempest Therapeutics|NXT-629|PPAR alpha antagonist (cancer), Inception Sciences",Research Code|Research Code,Cancer,PPAR alpha antagonist,3034,Synergist|Anticancer|Apoptosis stimulator,7293|1545|1589,Esophagus tumor|Non-small-cell lung cancer|Cholangiocarcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Sarcoma|Pancreas tumor|Squamous cell carcinoma|Hormone refractory prostate cancer|Breast tumor|Head and neck tumor|Colorectal tumor,1011|1262|1765|1766|1767|1771|194|249|307|3246|49|623|989,Cancer,651,Tempest Therapeutics Inc,1162307,Inception Therapeutics Inc,1069359,Inception Therapeutics Inc,1069359,,,,,,
109921,TPST-1495,"E-prostanoid receptor antagonists (cancer), Tempest Therapeutics|E-prostanoid receptor antagonists (cancer), Inception Sciences|EP2 receptor antagonists (cancer), Tempest Therapeutics|TPST-1495|dual EP2/EP4 antagonists (cancer), Tempest Therapeutics",,Cancer,EP2 prostanoid receptor antagonist|EP4 prostanoid receptor antagonist,3475|3478,Anticancer|Immunostimulant,1545|393,Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Bladder cancer|Adenocarcinoma|Squamous cell carcinoma|Breast tumor|Head and neck tumor|Cancer|Lung tumor|Colorectal tumor,1262|127|1705|2380|2399|307|49|623|651|755|989,,,Tempest Therapeutics Inc,1162307,Inception Therapeutics Inc,1069359,Inception Therapeutics Inc,1069359,,,,,,
109943,MAX-40279,"MAX-40279|MAX-4|dual FLT3/FGFR inhibitor (oral/capsule, acute myelogenous leukemia), Maxinovel Pharmaceuticals|MAX-40279-01",Research Code|Research Code|Research Code,Cancer,FGF receptor antagonist|Flt3 tyrosine kinase inhibitor,168|3806,Anticancer protein kinase inhibitor,62255,Myelodysplastic syndrome|Acute myelogenous leukemia|Advanced solid tumor,1272|1731|3713,,,Maxinovel Pharmaceuticals Inc,1138294,,,Maxinovel Pharmaceuticals Inc,1138294,,,,,,
109983,BT-5528,"BT-5528|bicycle toxin conjugate targeting EphA2 (cancer), Bicycle",Research Code,Cancer,Epha2 tyrosine kinase receptor inhibitor,3766,Anticancer protein kinase inhibitor,62255,Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer,3466|3657|3665|3666|3669|3713|3866,,,Bicycle Therapeutics Ltd,1050067,,,Bicycle Therapeutics Ltd,1050067,,,,,,
109989,NC-318,"NC-318|anti-siglec-15 monoclonal antibody (advanced solid tumors), NextCure|siglec-15 checkpoint inhibitor (advanced solid tumors), NextCure",Research Code,Cancer,Sialic acid-binding Ig-like lectin 15 inhibitor,73543,Immunostimulant|Macrophage stimulator|Dendritic cell stimulator|Anticancer monoclonal antibody,393|7751|173472|55685,Non-small-cell lung cancer|Squamous cell carcinoma|Metastatic non small cell lung cancer|Advanced solid tumor|Breast tumor|Head and neck tumor|Cancer|Ovary tumor,1262|307|3665|3713|49|623|651|799,Solid tumor,725,NextCure Inc,1118074,,,NextCure Inc,1118074,,,,,,
110070,E-CEL UVEC,"AB-110|allogeneic umbilical cord blood-derived CD34-positive hematopoietic stem cells + endothelial cells expressing E4ORF1 (E-CEL, hematological malignancies), Angiocrine Bioscience|E-CEL UVEC|AB-205, Angiocrine Bioscience|allogeneic umbilical cord blood-derived CD34-positive hematopoietic stem cells + endothelial cells expressing E4ORF1 (E-CEL, hematological malignancies/anal fistula), Angiocrine Bioscience",Research Code,Cancer|Cardiovascular|Gastrointestinal|Hematologic|Neurology/Psychiatric,,,Anti-inflammatory|Anticancer,2953|1545,Mucositis|Myelodysplastic syndrome|Acute leukemia|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Vascular injury|Sickle cell anemia|Anal fistula|Spina bifida,1263|1272|1727|1728|1731|2421|303|3056|306,Hodgkins disease|Hematological neoplasm|Non-Hodgkin lymphoma,161|2054|319,Angiocrine Bioscience,1109253,,,Angiocrine Bioscience,1109253,,,,,,
110120,REGN-4659,"REGN-4659|anti-CTLA-4 mAbs (cancer), Regeneron Pharmaceuticals/Sanofi|CTLA-4 checkpoint inhibitor (cancer), Regeneron Pharmaceuticals/Sanofi|CTLA-4 checkpoint inhibitor (metastatic non-small-cell lung cancer), Regeneron Pharmaceuticals/Sanofi",Research Code,Cancer,Cytotoxic T-lymphocyte protein-4 inhibitor,5482,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Metastatic non small cell lung cancer,3665,Cancer,651,Regeneron Pharmaceuticals Inc,19214,Sanofi SA,1009547,Regeneron Pharmaceuticals Inc,19214,,,,,,
110121,WSD-0922-FU,"WSD-0922|EGFR inhibitor (NSCLC/glioblastoma), Wayshine Biopharma|EGFR inhibitor (NSCLC/glioblastoma/head and neck tumor), Wayshine Biopharma|EGFR inhibitor (NSCLC/glioblastoma/head and neck tumor/anaplastic astrocytoma), Wayshine Biopharma|WSD-0922-FU",Research Code|Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Glioblastoma|Anaplastic astrocytoma,1262|2454|2567,Head and neck tumor,623,Wayshine Biopharma,1163463,,,Wayshine Biopharma,1163463,,,,,,
110188,AMG-553,"anti-Flt3 CAR-T cell therapy (acute myeloid leukemia), Amgen/Kite Pharma|AMG-553",Research Code,Cancer,Flt3 tyrosine kinase modulator,3805,Genetically engineered autologous cell therapy|Anticancer|Immunostimulant|T-lymphocyte stimulator,4790|1545|393|7761,Acute myelogenous leukemia,1731,,,Amgen Inc|Kite Pharma Inc,14109|1056870,,,Amgen Inc,14109,,,,,,
110220,tinurilimab,"BAY-1834942|CD66c antagonist (cancer), Bayer/Cologne/German Cancer Research Center|BAY-942|CEACAM6 fb antibody (cancer), Bayer|tinurilimab",Research Code|Research Code|INN,Cancer,CD66c antagonist,5273,Anticancer monoclonal antibody|Immunostimulant,55685|393,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Cholangiocarcinoma|Bladder cancer|Pancreas tumor|Uterine cervix tumor|Breast tumor|Head and neck tumor|Colorectal tumor,1011|1262|127|1765|2380|249|427|49|623|989,Advanced solid tumor,3713,Deutsches Krebsforschungszentrum DKFZ|Bayer AG,23844|14455,,,Bayer AG,14455,,,,,,
110263,BI-907828,"BI-907828|MDM2 inhibitor (solid tumor), Boehringer Ingelheim",Research Code,Cancer,E3 ubiquitin protein ligase MDM2 inhibitor,51304,Anticancer|Synergist,1545|7293,Non-small-cell lung cancer|Hepatocellular carcinoma|Melanoma|Liposarcoma|Advanced solid tumor|Cancer,1262|1767|205|2447|3713|651,,,Boehringer Ingelheim International GmbH,14881,,,Boehringer Ingelheim International GmbH,14881,,,,,,
11027,posaconazole,"Sch-56592|posaconazole|Sch-56588|Sch-56984|Sch-207962|antifungal, Schering-Plough|triazole (oral), Schering-Plough|Noxafil|Posaconazole SP|Posanol|Spriafil|MK-5592 (oral suspension), Merck & Co|SCH 056592",Research Code|USAN|BANN|INN|Analogue|Research Code|Analogue|Research Code|Research Code|Metabolite|Trade Name|Trade Name|Trade Name|Trade Name|Research Code,Infection|Other/Miscellaneous,Lanosterol-14 demethylase inhibitor,777,Systemic dermatological antifungal product|Fungicide|Ergosterol synthesis inhibitor,15178|1748|161,Fungal infection|Candida infection|Blastomyces infection|Coccidioides infection|Fusarium infection|Mucor infection|Chromoblastomycosis|Aspergillus infection|Prophylaxis,124|1308|1322|1323|1337|1380|2628|29|706,Onychomycosis|Trypanosoma cruzi infection,1775|335,Merck & Co Inc|Merck Sharp & Dohme Ltd,18077|18090,MSD Belgium|Schering-Plough Corp,1004432|19711,Schering-Plough Corp,19711,,,,,,
11031,ravuconazole,BMS-207147|ER-30346|ravuconazole,Research Code|Research Code|INN,Infection,,,Fungicide|Ergosterol synthesis inhibitor,1748|161,,,Fungal infection,124,,,Bristol-Myers Squibb Co|Eisai Co Ltd,15065|15872,Eisai Co Ltd,15872,,,,,,
110322,NBF-006,"NBF-006|glutathione S-transferase-P inhibitors (cancer), Nitto BioPharma",Research Code,Cancer,Glutathione S-transferase P inhibitor,14022,Anticancer|siRNA agent,1545|26035,Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer,3658|3665|3669,Non-small-cell lung cancer,1262,Nitto BioPharma Inc,1118863,,,Nitto BioPharma Inc,1118863,,,,,,
110328,THOR-707,"Synthorin cytokine (cancer), Synthorx|Synthorin IL-2|synthetic IL-2 (cancer), Synthorx|THOR-707|SYTX80-013-A|IL-2 IO synthorin|pegylated IL-2 (lyophilized, intravenous, cancer/solid tumor), Synthorx|SAR-444245",Research Code|Research Code|Research Code|Research Code,Cancer|Respiratory,IL-2 receptor agonist,221,Immunostimulant|Anticancer|T-lymphocyte stimulator,393|1545|7761,Mesothelioma|Squamous cell carcinoma|Stage IV melanoma|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer|Pleural disease|Solid tumor,1240|307|3257|3665|3713|651|704|725,,,Synthorx Inc,1095799,,,Synthorx Inc,1095799,MENK,Menkophian|Met5-enkephalin|Metenkephalin|Methionine enkephalin|Opioid growth factor,mu-Opioid Receptor Agonists|delta-Opioid Receptor Agonists,271|272,Signal Transduction Modulators,1402
11036,linezolid,PNU-100766|linezolid|U-100766|MDL 100766|PNU-766-INF-0026|PNU-10766|PNU-10766SS|Zyvox|Zyvoxa|Gabriox|Zyvoxid,USAN|BANN|Research Code|Research Code|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Dermatologic|Infection|Musculoskeletal,MAO inhibitor,256,Antibacterial|Ribosome binding agent|Bacterial protein synthesis inhibitor|Systemic dermatological antibacterial product,1594|463|1538|15187,Sepsis|Enterococcus faecium infection|MRSA infection|Gram positive bacterium infection|Streptococcus pyogenes infection|Streptococcus agalactiae infection|Bacterial pneumonia|Staphylococcus aureus infection|Streptococcus pneumoniae infection|Bacterial skin infection|Multidrug resistant infection|Diabetic foot ulcer,114|117|1267|138|1475|1476|1815|308|313|485|758|790,Osteomyelitis|Bacterial infection,1135|40,Pfizer Inc,18767,Pharmacia & Upjohn Inc|Pharmacia Corp,22006|27638,Pharmacia Corp,27638,,,,,,
110394,INBRX-105,"anti-4-1BB/PD-L1 bispecific antibody (cancer), INHIBRx/Elpiscience Biopharma|INBRX-105|ES-101|dual PD-L1 checkpoint inhibitor/4-1BB costimulator (bispecific antibody, cancer), INHIBRx/Elpiscience Biopharma|anti-4-1BB/PD-L1 tetravalent bispecific antibody (cancer), INHIBRx/Elpiscience Biopharma|dual 4-1BB costimulator + PD-L1 checkpoint inhibitor bispecific antibody (advanced solid tumors), INHIBRx/Elpiscience Biopharma",Research Code|Research Code,Cancer,CDw137 agonist|Programmed cell death ligand 1 inhibitor,5450|14007,Anticancer|Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,1545|393|55685|7761,Esophagus tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Hodgkins disease|Renal cell carcinoma|Transitional cell carcinoma|Melanoma|Non-Hodgkin lymphoma|Metastatic non small cell lung cancer|Advanced solid tumor|Head and neck tumor|Cancer,1011|1261|1262|127|161|1766|1771|205|319|3665|3713|623|651,,,Elpiscience Biopharmaceuticals Inc|Inhibrx Inc,1156548|1063813,,,Inhibrx Inc,1063813,,,,,,
110487,FT-819,"FT-819|TCR-less anti-CD19 TRAC-CAR-TiPSC (cancer), Fate Therapeutics/Memorial Sloan Kettering Cancer Center|anti-CD19 CAR T-cell therapy (cancer), Fate Therapeutics/Memorial Sloan Kettering Cancer Center",Research Code,Cancer|Hematologic,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,Hematological disease|Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|B-cell lymphoma|Non-Hodgkin lymphoma|Cancer,142|1728|1734|316|319|651,,,Fate Therapeutics Inc,1036293,Memorial Sloan-Kettering Cancer Center,22122,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
110511,"paclitaxel (polymeric micelle), Zhejiang Hisun Pharmaceutical/Zhejiang University","paclitaxel|paclitaxel (polymeric micelle), Zhejiang Hisun Pharmaceutical/Zhejiang University",USAN|BANN|INN,Cancer,,,Microtubule stabilizer|Anticancer,2576|1545,Non-small-cell lung cancer|Stomach tumor|Advanced solid tumor|Breast tumor,1262|127|3713|49,,,Zhejiang Hisun Pharmaceutical Co Ltd,1019688,,,Zhejiang Hisun Pharmaceutical Co Ltd,1019688,,(+)-Pancratistatin|+-Pancratistatin|Pancratistatin,Pyruvate Phosphate Dikinase (PPDK) (Entamoeba histolytica) Inhibitors,8020,Autophagy Inducers|Apoptosis Inducers,3626|1062
110547,MDG-1011,"anti-PRAME/HLA-A*0201 TCR T-cell therapy (hematological cancers), MediGene|MDG-1011|MDG-1014",Research Code|Research Code,Cancer,Tumor expressed melanoma antigen modulator|HLA class I antigen A-2 alpha modulator,18578|19115,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Solid tumor,1272|1731|1828|725,,,MediGene AG,24224,,,MediGene AG,24224,,,,,,
110598,CDX-527,"dual PD-L1 checkpoint inhibitor/CD27 costimulator (bispecific antibody, cancer), Celldex Therapeutics|anti-CD27/anti-PD-L1 bispecific antibodies|anti-CD27/anti-PD-L1 BsAbs|CDX-527",Research Code,Cancer,Programmed cell death ligand 1 inhibitor|CD27 agonist,14007|5102,Anticancer antibody|T-lymphocyte stimulator|Immunostimulant,55684|7761|393,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Cholangiocarcinoma|Renal cell carcinoma|Transitional cell carcinoma|Liver tumor|Fallopian tube cancer|Bladder cancer|Peritoneal tumor|Advanced solid tumor|Breast tumor|Head and neck tumor|Cancer|Ovary tumor|Colorectal tumor,1011|1262|127|1765|1766|1771|202|2243|2380|3083|3713|49|623|651|799|989,,,Celldex Therapeutics Inc,25726,,,Celldex Therapeutics Inc,25726,,,,,,
11064,zastumotide,"249553|SB-249553|melanoma vaccine, SmithKline Beecham|melanoma/lung cancer vaccine, GlaxoSmithKline|pharmaccine (MAGE-3 + SBAS-2), GlaxoSmithKline|MAGE-3 vaccine, GlaxoSmithKline|MAGE-3 antigen specific cancer immunotherapeutic, GlaxoSmithKline|MAGE-3 ASCI, GlaxoSmithKline|GSK-1572932A|recMAGE-A3|GSK-2132231A|GSK-249553|MAGE-3/Vaximmune vaccine, GSK|astuprotimut-r, GlaxoSmithKline|GSK-1203486A|zastumotide|MAGE-A3 ASCI|astuprotimut-R|Zumagev",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|INN|USAN|Trade Name,Cancer,Melanoma associated antigen 3 modulator,21958,Therapeutic vaccine|Protein subunit vaccine|Anticancer,12379|12372|1545,Stage IV melanoma,3257,Non-small-cell lung cancer|Melanoma|Bladder cancer|Stage III melanoma,1262|205|2380|3256,GlaxoSmithKline plc,28355,SmithKline Beecham plc,19962,SmithKline Beecham plc,19962,,,,,,
110673,SL-279252,"SL-279252|PD-1 x OX40L (Agonist Redirected Checkpoint, cancer), Shattuck Labs/Takeda|dual PD-L1 checkpoint inhibitor/OX40 costimulator (ARC, cancer), Shattuck Labs/Takeda|TAK-252|PD1-Fc-OX40L (cancer), Shattuck Labs",Research Code|Research Code,Cancer,Programmed cell death ligand 1 inhibitor|OX-40 receptor agonist,14007|5443,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,Esophagus tumor|Stomach tumor|Hodgkins disease|Renal cell carcinoma|Transitional cell carcinoma|Melanoma|Skin cancer|Anal tumor|Squamous cell carcinoma|B-cell lymphoma|Metastatic non small cell lung cancer|Advanced solid tumor|Uterine cervix tumor|Head and neck tumor,1011|127|161|1766|1771|205|2170|2193|307|316|3665|3713|427|623,Cancer,651,Shattuck Labs Inc,1141703,Takeda Pharmaceutical Co Ltd,20300,Shattuck Labs Inc,1141703,,,,,,
110695,BION-202,"BION-202|BND-22|LILRB checkpoint inhibitor (cancer), Biond Biologics|ILT2 checkpoint inhibitor (cancer), Biond Biologics|SAR-444881",Research Code|Research Code|Research Code,Cancer,Leukocyte Ig-like receptor antagonist,33875,Immunostimulant|Anticancer|Anticancer monoclonal antibody|Macrophage stimulator,393|1545|55685|7751,Cholangiocarcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Skin cancer|Adenocarcinoma|Squamous cell carcinoma|Gallbladder tumor|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Uterine cervix tumor,1765|1767|1771|2170|2399|307|3146|3657|3665|3666|3667|3673|3713|4250|427,Cancer|Solid tumor,651|725,Biond Biologics Ltd,1124684,,,Biond Biologics Ltd,1124684,,,,,,
110736,FT-500,"iPSC-derived NK cell therapy (cancer), Fate Therapeutics/University of Minnesota|FT-500",Research Code,Cancer,,,Natural killer cell stimulator|Immunostimulant|Anticancer,7757|393|1545,Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Renal cell carcinoma|Hepatocellular carcinoma|Lymphoma|Melanoma|Pancreas tumor|Squamous cell carcinoma|Merkel cell carcinoma|Advanced solid tumor|Uterine cervix tumor|Breast tumor|Head and neck tumor|Uterus tumor|Colorectal tumor,1261|1262|127|1766|1767|203|205|249|307|3235|3713|427|49|623|740|989,,,Fate Therapeutics Inc,1036293,University of Minnesota,20626,University of Minnesota,20626,,,,,,
110743,KN-046,"recombinant humanized anti-PD-L1/anti-CTLA-4 mAb-Fc fusion protein, Suzhou Alphamab|KN-046|humanized PD-L1/CTLA-4 bispecific antibody (advanced solid tumor), Suzhou Alphamab|dual CTLA-4 checkpoint inhibitor/PD-L1 checkpoint inhibitor (solid tumor), Alphamab",Research Code,Cancer,Cytotoxic T-lymphocyte protein-4 inhibitor|Programmed cell death ligand 1 inhibitor,5482|14007,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Esophagus tumor|Hepatocellular carcinoma|Pancreas tumor|Thymus neoplasm|Squamous cell carcinoma|T-cell lymphoma|Metastatic gastrointestinal cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor,1011|1767|249|2938|307|311|3460|3657|3665|3713,Metastatic esophageal cancer|Cancer,3667|651,Suzhou Alphamab Co Ltd,1085850,,,Suzhou Alphamab Co Ltd,1085850,,,,,,
110744,yinnuokati-19,"yinnuokati-19|anti-CD19 CAR T-cell therapy (B cell malignancy), Shenzhen Institute for Innovation and Translational Medicine",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|T-lymphocyte stimulator|Immunostimulant,1545|7761|393,Hematological neoplasm,2054,,,Shenzhen Innovation Immunotechnology Co Ltd,1109969,,,Shenzhen Innovation Immunotechnology Co Ltd,1109969,,,,,,
110765,VMD-928,"TrkA antagonist (pancreatic cancer), VM Oncology|TrkA antagonist (oral, pancreatic cancer/advanced solid tumor/lymphoma), VM Oncology|VMD-928",,Cancer,TrkA receptor antagonist,3840,Anticancer protein kinase inhibitor,62255,Lymphoma|Pancreas tumor|Thymoma|Advanced solid tumor,203|249|2939|3713,,,VM Oncology LLC,1112561,,,VM Oncology LLC,1112561,,,,,,
110832,AMG-427,"AMG-427|anti-CD3/anti-FLT3 bispecific T-cell engager (HLE-BiTE, acute myeloid leukemia), Amgen",Research Code,Cancer,Flt3 tyrosine kinase modulator|CD3 modulator,3805|5023,Immunostimulant|T-lymphocyte stimulator|Anticancer antibody,393|7761|55684,Acute myelogenous leukemia,1731,,,Amgen Inc,14109,,,Amgen Inc,14109,,,,,,
110841,YE-NEO-001,"YE-NEO-001|neoepitope yeast vaccine (cancer), NantWorks|neoepitope-based personalized yeast vaccine (cancer), NantWorks|YE-NEO-011",Research Code|Research Code,Cancer,,,Anticancer|T-lymphocyte stimulator|Therapeutic vaccine,1545|7761|12379,Non-small-cell lung cancer|Liver tumor|Melanoma|Pancreas tumor|Squamous cell carcinoma|Breast tumor|Head and neck tumor|Cancer|Colorectal tumor,1262|202|205|249|307|49|623|651|989,,,NantWorks LLC,1103920,,,NantWorks LLC,1103920,,,,,,
110860,MB-CART19.1,"MB-CART19.1|anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), Shanghai Children's Medical Center|anti-CD19 CAR T-cell therapy (B-cell ALL), Shanghai Children's Medical Center",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|B-cell lymphoma,1729|1734|316,,,Shanghai Children's Medical Center,1074043,,,Shanghai Children's Medical Center,1074043,,,,,,
110893,68Ga-pentixafor,68Ga-pentixafor,,Cancer,CXCR4 chemokine modulator,3135,Immune diagnostic agent|Radiodiagnostic|PET contrast agent|Imaging agent|Neoplasm diagnostic agent,7215|5720|5555|4155|7220,Multiple myeloma|Lymphoma,1828|203,,,Peking Union Medical College Hospital,1039932,,,Peking Union Medical College Hospital,1039932,,,,,,
110898,"NK cell therapy (small cell lung cancer), First Hospital of Jilin University","NK cell therapy (small cell lung cancer), First Hospital of Jilin University",,Cancer,,,Natural killer cell stimulator|Immunostimulant|Anticancer,7757|393|1545,Small-cell lung cancer,1261,,,First Hospital of Jilin University,1074117,,,First Hospital of Jilin University,1074117,,,,,,
110904,"dual anti-CD19/anti-CD22 CAR T-cell therapy (B-cell lymphoma/B-cell acute lymphoblastic leukemia), Shanghai Unicar-Therapy Bio-medicine Technology","dual anti-CD19/anti-CD22 CAR T-cell therapy (B-cell lymphoma/B-cell acute lymphoblastic leukemia), Shanghai Unicar-Therapy Bio-medicine Technology|anti-CD19/CD22 CAR T-cell therapy (B-cell lymphoma/B-cell acute lymphoblastic leukemia), Unicar-Therapy",,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte cell adhesion molecule modulator,5080|5089,Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer,393|7761|4790|1545,B-cell acute lymphoblastic leukemia|B-cell lymphoma|Non-Hodgkin lymphoma,1729|316|319,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd,1144294,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd,1144294,,,,,,
110926,"anti-PD-L1 CAR T-cell therapy (NSCLC), Sun Yat-sen/Guangzhou Yi Yan","anti-PD-L1 CAR T-cell therapy (NSCLC), Sun Yat-sen/Guangzhou Yi Yan",,Cancer,Programmed cell death ligand 1 modulator,14005,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,Metastatic non small cell lung cancer,3665,,,Guangzhou Yiyang Biological Technology Co|Sun Yat-Sen University,1156266|1004360,,,Sun Yat-Sen University,1004360,,Cefonicid monosodium,,,,
11093,ATIR-101,"TH-9402|TH-9401|Theralux|PDT, Theratechnologies|antileukemics (photoactive), Theratechnologies|ATIR|Add-Back of T Cell for Immune Reconstitution|alloreactive T cell-depletion therapy (GvHD), Kiadis/ Hospira|Theralux extracorporeal photochemotherapy|allodepleted T-cell immunotherapeutics (GvHD), Kiadis Pharma|ATIR-101",Research Code|Research Code|Trade Name|Research Code,Immune,,,Photosensitizer|Immunomodulator|Anticancer,799|1596|1545,Graft versus host disease,616,Autoimmune disease,36,Hospira Inc,1010293,Theratechnologies Inc|Celmed BioSciences Inc|Kiadis Pharma BV,22170|28897|29823,Theratechnologies Inc,22170,,,,,,
110958,BI-3011441,"LNP-3794|mitogen-activated protein kinase inhibitor (oral, advanced solid tumor with RAS/BRAF mutation), Lupin|BI-3011441",Research Code|Research Code,Cancer,MEK protein kinase inhibitor,4760,Anticancer protein kinase inhibitor,62255,Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,3658|3665|3713,,,Boehringer Ingelheim International GmbH,14881,Lupin Ltd,21932,Lupin Ltd,21932,,,,,,
110964,BCD-135,"BCD-135|anti PD-L1 mAb (advanced solid tumor), Biocad|anti PD-L1 monoclonal antibody (advanced solid tumor), Biocad|PD-L1 checkpoint inhibitor (advanced solid tumor), Biocad|manelimab",Research Code|INN,Cancer,Programmed cell death ligand 1 inhibitor,14007,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Non-small-cell lung cancer|Renal cell carcinoma|Melanoma|Bladder cancer|Advanced solid tumor,1262|1766|205|2380|3713,,,Biocad Ltd,1035286,,,Biocad Ltd,1035286,,,,,,
110984,murizatoclax,"AMG-397|protein-protein interaction inhibitor (multiple myeloma/non-Hodgkin's lymphoma/acute myeloid leukemia), Amgen|PPI inhibitor (hematological malignancies), Amgen|murizatoclax|AM-2721",Research Code|PINN|Research Code,Cancer,Mcl-1 differentiation protein inhibitor,11381,Anticancer,1545,Acute myelogenous leukemia|Multiple myeloma|Non-Hodgkin lymphoma,1731|1828|319,,,Amgen Inc,14109,,,Amgen Inc,14109,,,,,,
110991,"anti-ROR1 CAR T-cell therapy (cancer), MD Anderson Cancer Center/Bellicum Pharmaceuticals","ROR1-specific CAR T-cells|ROR1RCD28|ROR1RCD137|anti-ROR1 CAR T-cell therapy (cancer), MD Anderson Cancer Center/Bellicum Pharmaceuticals",Research Code|Research Code,Cancer,Ntrkr1 tyrosine kinase receptor modulator,3821,Immunostimulant|Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator,393|4790|1545|7761,,,Chronic lymphocytic leukemia|Cancer,1734|651,,,Bellicum Pharmaceuticals Inc|MD Anderson Cancer Center,1023406|23382,MD Anderson Cancer Center,23382,,,,,,
111059,"anti-HA-1/HLA-A*0201 TCR T-cell therapy (leukemia), Fred Hutchinson Cancer Research Center","anti-HA-1/HLA-A*0201 TCR T-cell therapy (leukemia), Fred Hutchinson Cancer Research Center",,Cancer,HLA class I antigen A-2 alpha modulator|Minor histocompatibility protein HA-1 modulator,19115|70021,Immunostimulant|T-lymphocyte stimulator|Anticancer,393|7761|1545,Acute leukemia|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia,1727|1728|1731|1735,,,HighPass Bio Inc,1196431,Fred Hutchinson Cancer Research Center,16218,Fred Hutchinson Cancer Research Center,16218,,,,,,
111063,NYESO-1 TCR-T -Triple Knockout TCR,"NYCE T cells|anti-NY-ESO-1/HLA-A*0201 TCR T cell therapy (endogenous TCR and PD-1 deleted, multiple myeloma/melanoma/synovial sarcoma/liposarcoma), University of Pennsylvania/Tmunity|NYESO-1 TCR-T -Triple Knockout TCR",Research Code|Research Code,Cancer,HLA class I antigen A-2 alpha modulator|Cancer testis antigen NY-ESO-1 modulator,19115|50096,Anticancer|Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,1545|393|4790|7761,Multiple myeloma|Melanoma|Liposarcoma|Soft tissue sarcoma,1828|205|2447|3378,,,University of Pennsylvania|Tmunity Therapeutics Inc,20658|1118342,,,University of Pennsylvania,20658,,,,,,
11114,uridine triphosphate,"INS-316|ProLucin|UTP, Inspire|uridine triphosphate|UTP|INS-316 Diagnostic",Research Code|Trade Name,Cancer|Other/Miscellaneous|Respiratory,Purinoceptor modulator,887,Neoplasm diagnostic agent|Gastrointestinal diagnostic agent|Diagnostic agent|Cardiovascular diagnostic agent,7220|7213|4154|7210,,,Kartagener syndrome|Lung disease|Bronchitis|Respiratory disease|Lung tumor|Cystic fibrosis,2122|283|50|711|755|88,,,Kirin Brewery Co Ltd|University of North Carolina|Inspire Pharmaceuticals Inc,17661|20634|22360,University of North Carolina,20634,,,,,,
111157,SH-1573,SH-1573,Research Code,Cancer,,,Unspecified drug target|Anticancer,59620|1545,Acute myelogenous leukemia,1731,,,Nanjing Sanhome Pharmaceutical Co Ltd,1023952,,,Nanjing Sanhome Pharmaceutical Co Ltd,1023952,,,,,,
111158,"HLX-10 + bevacizumab biosimilar (advanced solid tumor), Shanghai Henlius Biotech/Kalbe Genexine Biologics","HLX-04|HLX-10 + HLX-04 (advanced solid tumor), Shanghai Henlius Biotech|PD-1 checkpoint inhibitor + bevacizumab biosimilar (advanced solid tumor), Shanghai Henlius Biotech|HLX-10 + HLX-04|HLX-10 + bevacizumab biosimilar (advanced solid tumor), Shanghai Henlius Biotech|HLX-10 + bevacizumab biosimilar (advanced solid tumor), Shanghai Henlius Biotech/Kalbe Genexine Biologics",Research Code,Cancer,VEGF ligand inhibitor|Programmed cell death protein 1 inhibitor,12521|67136,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator|Angiogenesis inhibitor,55685|393|7761|61,Hepatocellular carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,1767|3658|3665|3713,,,Kalbe Genexine Biologics|Shanghai Henlius Biotech Co Ltd,1194985|1073079,,,Shanghai Henlius Biotech Co Ltd,1073079,,,,,,
111265,ARI-0002,"ARI-0002|anti-BCMA CAR T-cell therapy (multiple myeloma), IDIBAPS/MD Anderson Cancer Center|CAR-BCMA|anti-BCMA-4-1BB-CD3zeta CAR (multiple myeloma), IDIBAPS/MD Anderson Cancer Center|ARI-0002h",Research Code|Research Code,Cancer,T-cell CD3 glycoprotein zeta chain stimulator|APRIL receptor modulator|CDw137 agonist,16030|8255|5450,Immunostimulant|T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy,393|7761|1545|4790,Multiple myeloma|Non-Hodgkin lymphoma,1828|319,,,MD Anderson Cancer Center|Institut d'Investigacions Biomediques August Pi I Sunyer,23382|1017771,,,Institut d'Investigacions Biomediques August Pi I Sunyer,1017771,,,,,,
111349,MK-4830,"MK-4830|anti-ILT4-specific mAb (advanced solid tumors), Merck/Agenus",Research Code,Cancer,Leukocyte Ig-like receptor-2 antagonist,9609,Anticancer monoclonal antibody,55685,Mesothelioma|Small-cell lung cancer|Squamous cell carcinoma|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Metastatic renal cell carcinoma,1240|1261|307|3665|3669|3673|4250,Advanced solid tumor,3713,Agenus Inc|Merck Sharp & Dohme Corp,23221|1059823,,,Agenus Inc,23221,,,,,,
111389,LP-002,"LP-002|anti-PD-L1 recombinant humanized monoclonal antibody (advanced solid tumor), Taizhou Houdeaoke Technology|PD-L1 chekcpoint inhibitor (advanced solid tumor), Taizhou Houdeaoke Technology",Research Code,Cancer,Programmed cell death ligand 1 inhibitor,14007,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Small-cell lung cancer|Gastrointestinal tumor|Squamous cell carcinoma|Stage IV melanoma|Metastatic stomach cancer|Advanced solid tumor,1261|131|307|3257|3666|3713,,,Taizhou Houdeaoke Technology Co Ltd,1167233,,,Taizhou Houdeaoke Technology Co Ltd,1167233,,,,,,
11141,basiliximab,"basiliximab|CHI-621|SDZ-CHI-621|Simulect|anti-CD25 monoclonal antibody (immunosuppressant), Novartis|BSX-003",INN|Research Code|Research Code|Trade Name|Research Code,Gastrointestinal|Immune|Ocular,IL-2 receptor alpha subunit inhibitor,5100,Anti-inflammatory|Immunosuppressant,2953|396,Transplant rejection,515,Ulcerative colitis|Uveitis,337|341,Novartis AG,23137,Cerimon Pharmaceuticals Inc|Beth Israel Deaconess Medical Center|Seragen Inc,1017512|24877|25767,Beth Israel Deaconess Medical Center,24877,,,,,,
111424,letaplimab,"IBI-188|CD47 checkpoint inhibitor (intravenous, advanced malignancies/cancer), Innovent Biologics|CD47 checkpoint inhibitor (intravenous, advanced solid tumor/lymphomas/cancer), Innovent Biologics|Letaplimab|letaplimab",Research Code|PINN,Cancer,CD47 antagonist,5185,Macrophage stimulator|Immunostimulant|Anticancer monoclonal antibody,7751|393|55685,Myelodysplastic syndrome|Acute myelogenous leukemia|Lymphoma|Hematological neoplasm|Non-Hodgkin lymphoma|Advanced solid tumor|Ovary tumor,1272|1731|203|2054|319|3713|799,Cancer|Solid tumor,651|725,Innovent Biologics Inc,1070750,,,Innovent Biologics Inc,1070750,,,,,,
111475,"anti-BCMA CAR T-cell therapy (multiple myeloma), Allife Medical Science and Technology","anti-BCMA CAR T-cell therapy (multiple myeloma), Allife Medical Science and Technology",,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,Multiple myeloma,1828,,,Allife Medical Science and Technology Co Ltd,1166273,,,Allife Medical Science and Technology Co Ltd,1166273,,,,,,
11149,SN-29222,"NSC-646394|SN-23862|SN-24927|SN-23816|SN-25341|SN-27686|SN-27858|SN-29546|SN-29222|PR-104|hypoxia-activated anticancer prodrugs, Proacta|bioreductive cytotoxins (cancer), University of Auckland|hypoxia-activated anticancer prodrugs, University of Auckland|PR-104H|PR-104A|PR-104M",Research Code|Research Code|Prodrug|Analogue|Research Code|Research Code|Research Code|Research Code|Research Code|Metabolite|Prodrug|Research Code|Research Code|Research Code|Prodrug|Research Code|Metabolite|Research Code|Metabolite|Prodrug|Research Code,Cancer,,,Bioreducible cytotoxin|Anticancer alkylating agent,1585|50,T-cell acute lymphoblastic leukemia,1730,Small-cell lung cancer|Non-small-cell lung cancer|Acute myelogenous leukemia|Hepatocellular carcinoma|Cancer|Solid tumor,1261|1262|1731|1767|651|725,Children's Cancer Institute Australia for Medical Research,1010097,University of Auckland|Proacta Inc,20647|29494,University of Auckland,20647,,,,,,
11152,banoxantrone,"AQ4N|AQ4|AQ4M|banoxantrone|AQ4N, AstraZeneca/Novacea|AZD-1689",Research Code|Research Code|Metabolite|Metabolite|INN|Research Code,Cancer,Topoisomerase II inhibitor,142,Bioreducible cytotoxin|DNA intercalator|Anticancer,1585|750|1545,,,Esophagus tumor|Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Non-Hodgkin lymphoma|Cancer|Solid tumor|Brain tumor,1011|1728|1734|319|651|725|760,,,Transcept Pharmaceuticals Inc|BTG plc|De Montfort University|KuDOS Pharmaceuticals Ltd,1004325|15266|22501|27874,De Montfort University,22501,,,,,,
11155,Gardasil,"HPV vaccine, CSL/Merck & Co|HPV vaccine (quadrivalent), Merck & Co|human papilloma virus vaccine, CSL/Merck & Co|HPV vaccine (quadrivalent), Aventis Pasteur MSD/CSL|Gardasil|HPV vaccine (quadrivalent), Sanofi Pasteur MSD/CSL|human papillomavirus vaccine, CSL/Merck & Co|Silgard|V-501, Uniquest",Trade Name|Research Code,Cancer|Genitourinary/Sexual Function|Infection,,,Prophylactic vaccine|Protein subunit vaccine,12378|12372,Condyloma|Cervical dysplasia|Anal dysplasia|Anal tumor|Vulvar intraepithelial neoplasia|Vaginal cancer|Vaginal intraepithelial neoplasia|Papillomavirus infection|Uterine cervix tumor,1232|1235|1517|2193|3105|3291|3292|396|427,,,MSD Japan|Korea Kolmar Holdings Co Ltd|Seqirus|Merck & Co Inc,24019|17678|1113858|18077,CSL Ltd|GC Pharma|UniQuest Pty Ltd|Sanofi Pasteur MSD|SK Chemicals Co Ltd,15563|16583|20666|23408|26914,UniQuest Pty Ltd,20666,,,,,,
111567,"relatlimab + nivolumab (solid tumors), Bristol-Myers Squibb","BMS-986213|relatlimab + nivolumab (solid tumors), Bristol-Myers Squibb|LAG-3 checkpoint inhibitor + PD-1 checkpoint inhibitor (solid tumor), Bristol-Myers Squibb|PD-1 checkpoint inhibitor + LAG-3 checkpoint inhibitor (solid tumor), Bristol-Myers Squibb|relatlimab + nivolumab",Research Code,Cancer,CD223 antagonist|Programmed cell death protein 1 inhibitor,8413|67136,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,Stomach tumor|Stage IV melanoma|Soft tissue sarcoma|Advanced solid tumor,127|3257|3378|3713,,,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
111613,LY-007,"anti-CD20 CAR T-cell therapy (B-cell lymphoma/acute lymphocytic leukemia/chronic lymphocytic leukemia), Shanghai Longyao Biotechnology|CD20 CAR T-cells (B-cell lymphoma/ALL/CLL), Shanghai Longyao Biotechnology|LY-007",Research Code,Cancer,B-lymphocyte antigen CD20 modulator,5083,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1728|1734|1745|1749|316|319,,,"Shanghai Longyao Biotechnology Inc., Ltd.",1150655,,,"Shanghai Longyao Biotechnology Inc., Ltd.",1150655,,,,,,
111615,RMC-4630,"RMC-4630|SHP2 inhibitor (non-small-cell lung cancer), REVOLUTION Medicines/Sanofi|SAR-442720",Research Code|Research Code,Cancer,Protein tyrosine phosphatase-2C inhibitor,10327,Anticancer,1545,Non-small-cell lung cancer|Pancreas tumor|Advanced solid tumor|Colorectal tumor,1262|249|3713|989,,,REVOLUTION Medicines Inc|Sanofi SA,1105504|1009547,,,REVOLUTION Medicines Inc,1105504,,,,,,
111750,SAR-440234,"SAR-440234|anti-CD3/anti-CD123 bispecific T-cell engager (leukemia), Sanofi",Research Code,Cancer,CDw123 modulator|CD3 modulator,5427|5023,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,,,Myelodysplastic syndrome|B-cell acute lymphoblastic leukemia|Acute myelogenous leukemia,1272|1729|1731,,,Sanofi SA,1009547,Sanofi SA,1009547,,,,,,
111786,mirzotamab clezutoclax,"ABBV-155|antineoplastic agent (iv, advanced solid tumour), AbbVie|Bcl-xL inhibitor antibody-drug conjugate (cancer), AbbVie|Bcl-xL inhibitor ADC (cancer), AbbVie|B7-H3 antibody-Bcl-xl inhibitor conjugate (cancer), AbbVie|mirzotamab clezutoclax|P01-18-P10-18|huAb13v1|huAb13.1a|B7-H3 antibody-clezutoclax conjugate (cancer), AbbVie",Research Code|INN,Cancer,Bcl-xL Bcl-2 associated death promotor inhibitor|CD276 antigen modulator,14541|48835,Anticancer antibody,55684,Small-cell lung cancer|Non-small-cell lung cancer|Hematological neoplasm|Advanced solid tumor|Breast tumor,1261|1262|2054|3713|49,,,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
111789,sotorasib,"AMG-510|KRAS inhibitor (G12C-mutated solid tumors), Amgen|sotorasib|Lumakras",Research Code|PINN|Trade Name,Cancer,K-Ras GTPase inhibitor,28039,Synergist|Anticancer,7293|1545,Gastrointestinal tumor|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,131|3658|3665|3713,,,Amgen Inc|BeiGene Co Ltd,14109|1063251,,,Amgen Inc,14109,,,,,,
111798,ponsegromab,"PF-06946860|growth factor blocker (sc, cachexia), Pfizer|growth factor blocker (sc, cachexia/metastatic non-small cell lung cancer), Pfizer|anti-GDF15 mAb (cachexia), Pfizer|ponsegromab",Research Code|USAN|PINN,Other/Miscellaneous,GDF-15 ligand inhibitor,7946,Appetite stimulator|Therapeutic antibody,1839|172641,Appetite loss|Cachexia,3038|425,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
111836,LB-1909,"LCAR-L10D|dual anti-CD19/anti-CD22 CAR T-cell therapy (r/r B-cell lymphoma), Nanjing Legend Biotech|LB-1909",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte cell adhesion molecule modulator,5080|5089,Immunostimulant|Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator,393|4790|1545|7761,B-cell acute lymphoblastic leukemia|Diffuse large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1729|1749|316|319,,,Nanjing Legend Biotech Co Ltd,1143778,,,Nanjing Legend Biotech Co Ltd,1143778,,,,,,
111889,SG-001,"PD-1 checkpoint inhibitor (cancer), Hangzhou Sumgen Biotechnology|SG-001|PD-1 checkpoint inhibitor (advanced solid tumors), CSPC Zhongqi Pharmaceutical/Hangzhou Sumgen Biotechnology|SYSA-1802",Research Code|Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Metastasis|Mesothelioma|Lymphoma|Metastatic non small cell lung cancer|Advanced solid tumor|Uterine cervix tumor|Ovary tumor,1069|1240|203|3665|3713|427|799,Cancer,651,CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd,1047791,Hangzhou Sumgen Biotechnology Co Ltd,1150089,Hangzhou Sumgen Biotechnology Co Ltd,1150089,,,,,,
111894,JNJ-64264681,"JNJ-64264681|BTK inhibitor (oral solution, immune disorder/cancer), Janssen|BTK inhibitor (oral capsule, non-Hodgkin lymphoma/chronic lymphocytic leukemia), Janssen",Research Code,Cancer|Immune,Btk tyrosine kinase inhibitor,3592,Immunomodulator|Synergist|Anticancer protein kinase inhibitor,1596|7293|62255,Chronic lymphocytic leukemia|Immune disorder|B-cell lymphoma|Non-Hodgkin lymphoma|Cancer,1734|185|316|319|651,,,Janssen Research & Development LLC,1067538,,,Janssen Research & Development LLC,1067538,,,Calcium Channel Blockers,361,,
111933,RS-0139,RS-0139,Research Code,Cancer,,,Anticancer,1545,Non-small-cell lung cancer|Prostate tumor|Breast tumor,1262|276|49,,,RS Research,1128655,,,RS Research,1128655,,,,,,
111964,"anti-CD19 CAR T-cell therapy (B-cell ALL), First Hospital of Jilin University","anti-CD19 CAR T-cell therapy (B-cell ALL), First Hospital of Jilin University|anti-CD19 scFv CAR T-cell therapy (iv, B-cell ALL), First Hospital of Jilin University|second generation CAR-T cell therapy (iv, B-cell ALL), First Hospital of Jilin University",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer,393|4790|7761|1545,B-cell acute lymphoblastic leukemia,1729,,,First Hospital of Jilin University,1074117,,,First Hospital of Jilin University,1074117,,,,,,
111965,XLCART-001,"XLCART-001|anti-CD19 CAR T-cell therapy (r/r B-cell lymphoma), Nanjing Medical University",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|T-lymphocyte stimulator|Immunostimulant,1545|7761|393,B-cell lymphoma,316,,,Nanjing Medical University,1025431,,,Nanjing Medical University,1025431,,,,,,
112161,ABBV-011,"ABBV-011|antineoplastic agent (iv, SCLC), AbbVie|antibody-drug conjugate (SCLC), AbbVie|SC-011|SEZ6 ADC, AbbVie|anti-SEZ6 antibody-calicheamicin conjugate, AbbVie",Research Code|Research Code,Cancer,Seizure protein 6 homolog modulator,77664,Apoptosis stimulator|Anticancer monoclonal antibody,1589|55685,Small-cell lung cancer,1261,,,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
112258,subasumstat,"TAK-981|antineoplastic agent (iv, relapsed/refractory lymphoma), Takeda|subasumstat",Research Code|PINN,Cancer,Small ubiquitin related modifier inhibitor,63555,Synergist|Anticancer,7293|1545,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma|Lymphoma|Non-Hodgkin lymphoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Uterine cervix tumor|Head and neck tumor|Burkitts lymphoma,1734|1744|1745|1746|1749|1828|203|319|3658|3665|3713|427|623|791,,,Takeda Oncology,21991,,,Takeda Oncology,21991,,,,,,
112335,SEA-BCMA,"SEA-BCMA|SGN-BCMA|anti-BCMA (IV, multiple myeloma), Seattle genetics",Research Code|Research Code,Cancer,APRIL receptor antagonist,8257,Anticancer monoclonal antibody,55685,Multiple myeloma,1828,,,Seagen Inc,25554,,,Seagen Inc,25554,,Dihydromycoplanecin A,,,,
112408,PMB-101,"anti-BAFF-R CAR T-cell therapy (B-cell malignancies), City of Hope/PeproMene|BAFF-R CAR T-cell therapy (B-cell malignancies), PeproMene|BAFF-R targeted CAR T-cell therapy (B-cell malignancies), City of Hope/PeproMene|anti-TNFRSF13C CAR T-cell therapy (B-cell malignancies), City of Hope/PeproMene|PMB-101",Research Code,Cancer,Tumor necrosis factor 13C receptor antagonist,53124,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,B-cell acute lymphoblastic leukemia|B-cell lymphoma,1729|316,,,PeproMene Bio Inc,1170958,City of Hope,20558,City of Hope,20558,,,Mediator Release Inhibitors,802,,
112450,KPG-818,"KPG-818|Cullin-RING E3 ubiquitin ligase complex modulator (SLE/DLBCL/MCL/FCL/MM/hematological malignancies), Kangpu biopharmaceuticals|Cullin-RING E3 ubiquitin ligase complex modulator (COVID-19), Kangpu biopharmaceuticals",Research Code,Cancer|Immune|Infection,Ubiquitin ligase modulator,2963,Antiviral|Anticancer,991|1545,Coronavirus disease 19 infection|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Adult T-cell lymphoma|Multiple myeloma|Lymphoma|Hematological neoplasm|Systemic lupus erythematosus,10406|1734|1744|1745|1749|1757|1828|203|2054|318,,,Kangpu Biopharmaceuticals Ltd,1123435,,,Kangpu Biopharmaceuticals Ltd,1123435,,,,,,
112464,OPC-415,"MMG49 CAR T-cell therapy (multiple myeloma), Osaka University/Otsuka Pharmaceutical|MMG49 CAR T-cell therapy|anti-integrin beta-7 CAR T-cell therapy (multiple myeloma), Osaka University/Otsuka Pharmaceutical|OPC-415",Research Code,Cancer,Integrin beta-7 modulator,6135,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,Multiple myeloma,1828,,,Otsuka Pharmaceutical Co Ltd,18717,Osaka University,20653,Osaka University,20653,,,,,,
112505,GSK-3368715,"GSK-3368715|protein arginine N-methyltransferase 1 inhibitor (oral capsule, diffuse large B-cell lymphoma/solid tumors), GlaxoSmithKline|protein arginine N-methyltransferase 1 inhibitor (oral capsule, diffuse large B-cell lymphoma/solid tumors), Epizyme|GSK'715",Research Code|Research Code,Cancer,Protein arginine N-methyltransferase 1 inhibitor,14747,Anticancer,1545,Diffuse large B-cell lymphoma|Metastatic bladder cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer,1749|3466|3665|3669,Advanced solid tumor|Cancer,3713|651,GlaxoSmithKline plc,28355,Epizyme Inc,1048714,Epizyme Inc,1048714,,,,,,
112529,ATLCAR.CD138,"anti-CD138 CAR T-cell therapy (multiple myeloma), UNC Lineberger Comprehensive Cancer Center|ATLCAR.CD138",Research Code,Cancer,Syndecan-1 modulator,5452,Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant,1545|7761|4790|393,Multiple myeloma,1828,,,UNC Lineberger Comprehensive Cancer Center,1041077,,,UNC Lineberger Comprehensive Cancer Center,1041077,,,,,,
112543,LCAR-B4822M,"LCAR-B4822M|anti-BCMA CAR T-cell therapy (r/r multiple myeloma), Nanjing Legend Biotech|LCAR-B4822M-02",Research Code|Research Code,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy|Anticancer,7761|393|4790|1545,Multiple myeloma,1828,,,Nanjing Legend Biotech Co Ltd,1143778,,,Nanjing Legend Biotech Co Ltd,1143778,,,,,,
112546,"anti-CD123 CAR T-cell therapy (acute leukemia), Nanjing Legend Biotech","anti-CD123 CAR T-cell therapy (acute leukemia), Nanjing Legend Biotech",,Cancer,CDw123 modulator,5427,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,,,Acute leukemia,1727,,,Nanjing Legend Biotech Co Ltd,1143778,Nanjing Legend Biotech Co Ltd,1143778,,,,,,
112564,PF-06936308,"PF-06936308|vaccine-based immunotherapy regimen-2 (VBIR-2, NSCLC/TNBC), Pfizer|PF-06936308 + tremelimumab + other (undisclosed) therapeutics (NSCLC, TNBC), Pfizer|CTLA-4 checkpoint inhibitor + PD-1 checkpoint inhibitor + undisclosed components  (NSCLC/TNBC), Pfizer|PF-06801591 + tremelimumab + undisclosed components  (NSCLC/TNBC), Pfizer",Research Code,Cancer,Cytotoxic T-lymphocyte protein-4 inhibitor|Programmed cell death protein 1 inhibitor,5482|67136,Therapeutic vaccine|Anticancer|Anticancer monoclonal antibody|T-lymphocyte stimulator,12379|1545|55685|7761,,,Metastatic breast cancer|Metastatic non small cell lung cancer,3657|3665,,,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
112587,"anti-CD19 CAR T-cell therapy (B-cell lymphoblastic leukemia), Tianjin Mycure Medical Technology","anti-CD19 CAR T-cell therapy (B-cell lymphoblastic leukemia), Tianjin Mycure Medical Technology",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Anticancer|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,393|1545|4790|7761,B-cell acute lymphoblastic leukemia,1729,,,"Tianjin Mycure Medical Technology Co., Ltd",1171629,,,"Tianjin Mycure Medical Technology Co., Ltd",1171629,,,,,,
112604,GSK-3145095,"GSK-3145095|RIPK1 inhibitor (oral/tablet/capsule, pancreatic ductal adenocarcinoma/advanced solid tumors), GlaxoSmithKline|GSK-095|GSK'095",Research Code|Research Code|Research Code,Cancer,RIP-1 kinase inhibitor,11689,Anticancer protein kinase inhibitor,62255,,,Pancreatic ductal adenocarcinoma|Advanced solid tumor,1507|3713,,,GlaxoSmithKline plc,28355,GlaxoSmithKline plc,28355,,,,,,
11277,semaxanib,"semaxanib|SU-5416|FLK-1 RTK antagonists, SUGEN/Taiho|angiogenesis inhibitors, SUGEN/Taiho|aryl hydrocarbon receptor activator/VEGF-2 tyrosine kinase inhibitor, SUGEN/Taiho|TSU-16",INN|Research Code|Research Code,Cancer|Cardiovascular,VEGF-2 receptor antagonist|MAP kinase inhibitor|Aryl hydrocarbon receptor agonist,3848|2511|11774,Anticancer protein kinase inhibitor|Angiogenesis inhibitor,62255|61,,,Multiple myeloma|Melanoma|Myeloid leukemia|Angiogenesis disorder|Cancer|Solid tumor|Lung tumor|Kaposis sarcoma|Colorectal tumor,1828|205|223|422|651|725|755|936|989,,,SUGEN Inc|Taiho Pharmaceutical Co Ltd,15997|18720,SUGEN Inc,15997,,,,,,
112780,SHR-1702,"SHR-1702|TIM-3 checkpoint inhibitor (advanced solid tumors/hematological malignancies), Jiangsu Hengrui Medicine|anti-TIM-3 monoclonal antibody (advanced solid tumors/hematological malignancies), Jiangsu Hengrui Medicine",Research Code,Cancer,Hepatitis A virus cellular receptor 2 antagonist,34783,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm|Advanced solid tumor,1272|1731|2054|3713,Cancer,651,Jiangsu Hengrui Medicine Co Ltd,1006925,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,,,,
11287,palifermin,"palifermin|FGF-7, Amgen|rHuKGF, Amgen|human keratinocyte growth factor (recombinant), Amgen|Kepivance|rhKGF, Amgen",USAN|INN|Trade Name,Dermatologic|Endocrine/Metabolic|Gastrointestinal|Immune,FGF-7 ligand,3632,Anti-inflammatory,2953,Mucositis|Immune disorder,1263|185,Dysphagia|Toxic epidermal necrolysis|Stevens Johnson syndrome|Graft versus host disease|Diabetes mellitus,2085|2963|3053|616|97,Swedish Orphan Biovitrum AB|MegaPharm Ltd|BL&H Co Ltd,28921|26786|1037227,Amgen Inc,14109,Amgen Inc,14109,,,,,,
11290,colesevelam,GT31-104|CholestaGel|colesevelam|colesevelam hydrochloride|GT31-104HB|Welchol|Welchol DM|Lodalis,Research Code|Trade Name|INN|USAN|Research Code|Trade Name|Trade Name|Trade Name,Endocrine/Metabolic|Gastrointestinal,,,Bile acid sequestrant|Antihypercholesterolemic agent,466|71,Hypercholesterolemia|Non-insulin dependent diabetes,174|837,Non-alcoholic steatohepatitis,2637,Sanofi Genzyme|Bausch Health Companies Inc|Daiichi Sankyo Co Ltd,16299|17058|1017506,GelTex Pharmaceuticals Inc|Ono Pharmaceutical Co Ltd|Sankyo Pharma Inc,16279|18681|27147,GelTex Pharmaceuticals Inc,16279,,,,,,
112909,BI-1808,"T reg immuno-modulatory program (cancer), BioInvent/University of Southampton|regulatory T cells modulatory program (cancer), BioInvent/University of Southampton|BI-1808|anti-TNFRS antibody (n-CoDeR/F.I.R.S.T., solid tumor), Bioinvent|anti-TNFR2 antibody (solid tumor), Bioinvent|anti-TNFR2 antibody (n-CoDeR/F.I.R.S.T., solid tumor), Bioinvent|FIRST alphaTreg|Treg modulator (n-CoDeR/F.I.R.S.T., solid tumor), BioInvent",Research Code,Cancer,Type II TNF receptor modulator,8222,Immunostimulant|Anticancer antibody|Regulatory T lymphocyte inhibitor,393|55684|174668,Mycosis fungoides|Non-small-cell lung cancer|Cutaneous T-cell lymphoma|Sezary syndrome|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic ovary cancer|Ovary tumor,1115|1262|1754|1756|3665|3713|3866|799,Cancer,651,BioInvent International AB,18592,University Of Southampton,20678,BioInvent International AB,18592,,,,,,
112966,"bispecific anti-CD19/anti-BCMA CAR T-cell therapy (multiple myeloma), Shanghai Hrain Biotechnology","bispecific anti-CD19/anti-BCMA CAR T-cell therapy (multiple myeloma), Shanghai Hrain Biotechnology|dual anti-CD19/anti-BCMA CAR T-cell therapy (multiple myeloma), Shanghai Hrain Biotechnology|HRAIN-002",Research Code,Cancer,B-lymphocyte antigen CD19 modulator|APRIL receptor modulator,5080|8255,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,Multiple myeloma,1828,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,Shanghai Hrain Biotechnology Co Ltd,1158030,,,,,,
113029,MB-104,"CS1-CAR T-cell therapy (multiple myeloma), City of Hope Medical Center/NCI|anti-CS1 CAR T-cell therapy (multiple myeloma), City of Hope Medical Center/NCI|MB-104|anti-CS1 CAR T-cell therapy (multiple myeloma), City of Hope Medical Center/NCI/Mustang Bio",Research Code,Cancer,SLAM family member 7 modulator,45393,Immunostimulant|Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,393|1545|7761|4790,Multiple myeloma,1828,,,National Cancer Institute (NCI)|Mustang Bio Inc|City of Hope Medical Center,20519|1107137|1051922,,,City of Hope Medical Center,1051922,,,,,,
113044,RG-7769,"RO-7121661|dual PD-1 checkpoint inhibitor/TIM-3 checkpoint inhibitor (NSCLC/melanoma/solid tumor), Roche|anti-PD-1/TIM-3 bispecific antibody (intravenous, advanced solid tumor), Roche|dual PD-1/TIM-3 checkpoint inhibitor (intravenous, NSCLC/stage IV melanoma/advanced solid tumor), Roche|RG-7769|anti-PD-1/TIM-3 bispecific antibody (intravenous, advanced solid tumor/esophageal squamous cell carcinoma), Hoffmann-La Roche|anti-PD-1/TIM-3 bispecific antibody (intravenous, NSCLC/stage IV melanoma/advanced solid tumor/esophageal squamous cell carcinoma), Roche",Research Code|Research Code,Cancer,Hepatitis A virus cellular receptor 2 antagonist|Programmed cell death protein 1 inhibitor,34783|67136,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Non-small-cell lung cancer|Squamous cell carcinoma|Stage IV melanoma|Metastatic esophageal cancer|Advanced solid tumor,1262|307|3257|3667|3713,,,Hoffmann-La Roche AG,19449,,,Hoffmann-La Roche AG,19449,,,,,,
113047,"anti-MUC1 CAR T-cell therapy + PD-1 knockout T cell therapy (esophageal cancer/NSCLC), Guangzhou Anjie Biomedical Technology/University of Technology Sydney","anti-MUC1 CAR T-cell therapy + PD-1 knockout T cell therapy (esophageal cancer/NSCLC), Guangzhou Anjie Biomedical Technology/University of Technology Sydney|anti-MUC1 CAR T-cell + PD-1 knockout T cell therapies (cancer), GABT",,Cancer,Mucin 1 modulator,32076,Immunostimulant|Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,393|1545|7761|4790,Metastatic non small cell lung cancer|Metastatic esophageal cancer,3665|3667,,,University of Technology Sydney|Guangzhou Anjie Biomedical Technology Co LTD,29463|1164911,,,Guangzhou Anjie Biomedical Technology Co LTD,1164911,,,,,,
113104,IM-21,"anti-BCMA CAR T-cell therapy (multiple myeloma), Peking Union Medical College Hospital/Beijing Immunochina Medical Science & Technology|IM21 CART|IM-21|anti-BCMA CAR T-cell therapy (multiple myeloma), Beijing Immunochina Medical Science & Technology",Research Code|Research Code,Cancer,APRIL receptor modulator,8255,Immunostimulant|Anticancer|T-lymphocyte stimulator,393|1545|7761,Multiple myeloma,1828,,,Beijing Immunochina Medical Science & Technology Co Ltd,1140907,,,Beijing Immunochina Medical Science & Technology Co Ltd,1140907,,,,,,
113107,C-CAR088,"anti-BCMA CAR T-cell therapy (multiple myeloma), Cellular Biomedicine|C-CAR088",Research Code,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Multiple myeloma,1828,,,Cellular Biomedicine Group Inc,1080369,,,Cellular Biomedicine Group Inc,1080369,,,,,,
113265,NKX-101,"allogeneic anti-NKG2D-ligand CAR NK-cell therapy (IL-15 technology, cancer), Nkarta Therapeutics|allogeneic CAR NK cell therapy (NK cell expansion technology, cancer), Nkarta|NKX-101|allogeneic CAR NK cell therapy (NK cell expansion technology, hepatocellular carcinoma (HCC)/ intrahepatic cholangiocarcinoma (ICC)/metastatic colorectal cancer (mCRC)), Nkarta",Research Code,Cancer,NKG2D ligand modulator,26384,Immunostimulant|Natural killer cell stimulator|Anticancer,393|7757|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Cholangiocarcinoma|Hepatocellular carcinoma|Metastatic colorectal cancer|Solid tumor,1272|1731|1765|1767|3658|725,Cancer,651,Nkarta Therapeutics Inc,1161398,,,Nkarta Therapeutics Inc,1161398,,Carboxyamidotriazole,Calcium Channel Blockers,361,Signal Transduction Modulators|Antimitotic Drugs|Angiogenesis Inhibitors,1402|1401|885
113291,IOV-2001,"peripheral blood lymphocytes (chronic lymphocytic leukemia), Iovance/OSUCCC|IOV-2001|Autologous PBL",Research Code,Cancer,,,Unspecified drug target|Anticancer|Immunostimulant,59620|1545|393,Chronic lymphocytic leukemia,1734,,,Ohio State University Comprehensive Cancer Center|Iovance Biotherapeutics Inc,1042263|1057053,,,Ohio State University Comprehensive Cancer Center,1042263,,,,,,
113309,"topotecan (liposomal formulation, cancer), Fujifilm","topotecan|FF-10850|liposomal topotecan (iv, cancer), Fujifilm|topotecan (liposomal formulation, cancer), Fujifilm",BAN|INN|Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,Neuroendocrine tumor|Small-cell lung cancer|Sarcoma|Advanced solid tumor|Metastatic ovary cancer|Uterine cervix tumor|Cancer,1128|1261|194|3713|3866|427|651,,,Fujifilm Corp,1031240,,,Fujifilm Corp,1031240,,,,,,
113331,MDG-1021,"anti-HA-1/HLA-A*0201 TCR T-cell therapy (hematological cancer/solid tumor), Leiden University Medical Center (LUMC)/Medigene|HA-1 TCR transduced virus-specific T-cells|MDG-1021",PINN,Cancer|Hematologic,Minor histocompatibility protein HA-1 modulator|HLA class I antigen A-2 alpha modulator,70021|19115,Immunostimulant|Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator,393|4790|1545|7761,Lymphoid leukemia|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia|Multiple myeloma|Hematological neoplasm|Myelofibrosis|Myeloproliferative disorder|T-cell lymphoma|B-cell lymphoma|Solid tumor,1255|1272|1731|1735|1828|2054|2436|273|311|316|725,,,MediGene AG,24224,Leiden University Medical Center,27406,Leiden University Medical Center,27406,,,,,,
113332,JTX-8064,"JTX-8064|macrophage targeting program, Jounce Therapeutics|anti-leukocyte immunoglobulin like receptor B2 antibody (cancer), Jounce Therapeutics|anti-LILRB2 antibody (cancer), Jounce Therapeutics|LILRB2 antagonist (cancer), Jounce Therapeutics|LILRB2 checkpoint inhibitor (cancer), Jounce Therapeutics/Celgene|anti-LILRB2 antibody (iv/infusion, advanced solid tumors), Jounce Therapeutics",Research Code,Cancer,Leukocyte Ig-like receptor-2 antagonist,9609,Anticancer monoclonal antibody|Macrophage stimulator|Immunostimulant,55685|7751|393,Advanced solid tumor|Cancer,3713|651,Solid tumor,725,Jounce Therapeutics Inc,1079075,Celgene Corp,15331,Jounce Therapeutics Inc,1079075,,,,,,
113450,TAS-1553,"TAS-1553|ribonucleotide reductase inhibitors (cancer), Taiho Pharmaceutical|RNR inhibitors (cancer), Taiho Pharmaceutical",Research Code,Cancer|Hematologic,Ribonucleotide reductase inhibitor,346,Anticancer|Synergist,1545|7293,Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm|Myeloproliferative disorder|Solid tumor,1272|1731|2054|273|725,,,Taiho Pharmaceutical Co Ltd,18720,,,Taiho Pharmaceutical Co Ltd,18720,,,,,,
113487,"anti-MUC1 CAR T-cell therapy (esophageal cancer/NSCLC), Guangzhou Anjie Biomedical Technology/University of Technology Sydney","anti-MUC1 CAR T-cell therapy (esophageal cancer/NSCLC), Guangzhou Anjie Biomedical Technology/University of Technology Sydney|anti-MUC1 CAR T-cell therapy (cancer), GABT|CAR T-cell therapy, Guangzhou Anjie/University of Technology Sydney",,Cancer,Mucin 1 modulator,32076,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,Metastatic non small cell lung cancer|Metastatic esophageal cancer,3665|3667,,,Guangzhou Anjie Biomedical Technology Co LTD|University of Technology Sydney,1164911|29463,,,Guangzhou Anjie Biomedical Technology Co LTD,1164911,,,,,,
113489,"PD-1 knockout T cell therapy (esophageal cancer/NSCLC), Guangzhou Anjie Biomedical Technology/University of Technology Sydney","PD-1 knockout T cell therapy (esophageal cancer/NSCLC), Guangzhou Anjie Biomedical Technology/University of Technology Sydney|PD-1 knockout T cell therapy (cancer), GABT|T cell therapy, Guangzhou Anjie Biomedical/University of Technology Sydney|PD-1 knockout T cell therapy (cancer),GABT/Univ Technol Sydney|PD-1 knockout Engineered T cells (cancer),GABT/Univ Technol Sydney",,Cancer,,,Genetically engineered autologous cell therapy|Anticancer,4790|1545,Metastatic non small cell lung cancer|Metastatic esophageal cancer,3665|3667,,,University of Technology Sydney|Guangzhou Anjie Biomedical Technology Co LTD,29463|1164911,,,Guangzhou Anjie Biomedical Technology Co LTD,1164911,,,,,,
113605,"Bcl-2 inhibitor (intravenous,  acute myeloid leukemia/Non-Hodgkin's lymphoma/multiple myeloma), Institut de Recherches Internationales Servier","Bcl-2 inhibitor (intravenous,  acute myeloid leukemia/Non-Hodgkin's lymphoma/multiple myeloma), Institut de Recherches Internationales Servier|VOB-560|S-65487",Research Code|Research Code,Cancer,Bcl-2 protein inhibitor,16111,Anticancer,1545,Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Multiple myeloma|Non-Hodgkin lymphoma|Cancer,1731|1749|1828|319|651,,,Institut de Recherches Internationales Servier (France)|Novartis AG,1072647|23137,,,Institut de Recherches Internationales Servier (France),1072647,,,,,,
113645,"anti-GPRC5D CAR T-cell therapy (multiple myeloma), Eureka Therapeutics/Memorial Sloan Kettering Cancer Center","anti-GPRC5D CAR T-cell therapy (multiple myeloma), Eureka Therapeutics/Memorial Sloan Kettering Cancer Center|anti-G-protein coupled receptor family C group 5 member D CAR T-cell therapy (multiple myeloma), Eureka Therapeutics/MSKCC|MCARH-109",Research Code,Cancer,G protein coupled receptor C 5D modulator,127815,Immunostimulant|Anticancer|T-lymphocyte stimulator,393|1545|7761,Multiple myeloma,1828,,,Eureka Therapeutics Inc|Memorial Sloan-Kettering Cancer Center,1053219|22122,,,Eureka Therapeutics Inc,1053219,,,,,,
113671,AMG-160,"AMG-160|anti-CD3/anti-PSMA bispecific T-cell engager (HLE-BiTE, prostate cancer), Amgen|acapatamab",Research Code|PINN,Cancer,CD3 modulator|Glutamate carboxypeptidase II modulator,5023|9267,T-lymphocyte stimulator|Anticancer antibody|Immunostimulant,7761|55684|393,Hormone refractory prostate cancer|Metastatic non small cell lung cancer,3246|3665,,,Amgen Inc|BeiGene Co Ltd,14109|1063251,,,Amgen Inc,14109,,Dulofibrate,,,,
113725,INCB-086550,"INCB-086550|INCB-86550|PD-L1 checkpoint inhibitor (advanced solid tumor), Incyte",Research Code|Research Code,Cancer,Programmed cell death ligand 1 inhibitor,14007,Anticancer|T-lymphocyte stimulator|Immunostimulant,1545|7761|393,Non-small-cell lung cancer|Renal cell carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Melanoma|Advanced solid tumor|Cancer,1262|1766|1767|1771|205|3713|651,,,Incyte Corp,17216,,,Incyte Corp,17216,,,,,,
113766,GEN-1046,"dual PD-L1 checkpoint inhibitor/4-1BB costimulator (DuoBody, cancer), Genmab/BioNTech|bispecific PD-L1 x 4-1BB targeting antibody (DuoBody, cancer), Genmab/BioNTech|GEN-1046|DuoBody-PD-L1x4-1BB|BNT-311",Research Code|Research Code|Research Code,Cancer,Programmed cell death ligand 1 inhibitor|CDw137 agonist,14007|5450,T-lymphocyte stimulator|Anticancer|Immunostimulant|Anticancer antibody,7761|1545|393|55684,Endometrioid carcinoma|Transitional cell carcinoma|Squamous cell carcinoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Uterine cervix tumor,1705|1771|307|3657|3665|3673|3713|427,Cancer,651,BioNTech SE|Genmab Holding BV,1047330|1098487,,,Genmab Holding BV,1098487,,,Dopamine D2 Receptor (DRD2) Agonists,131,Signal Transduction Modulators,1402
113807,JEZ-567,"anti-CD123 CAR T cell therapy (acute myeloid leukemia), Novartis/University of Pennsylvania|CART123 cells|autologous anti-CD123 CAR T-cells expressing tandem TCR zeta and 4-1BB costimulatory domains (acute myeloid leukemia), Novartis/University of Pennsylvania|JEZ-567",Research Code,Cancer,CDw123 modulator,5427,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,Acute myelogenous leukemia,1731,,,Novartis AG|University of Pennsylvania,23137|20658,,,University of Pennsylvania,20658,,,,,,
11392,"ciclosporin (CycloTech), SangStat","cyclosporine A|ciclosporin|Sang-35|cyclosporine|Sang-A|Sang-2000|Sang-35 (CycloTech), SangStat|ciclosporin (CycloTech), SangStat|cyclosporine (CycloTech), SangStat|cyclosporin A (CycloTech), SangStat|cyclosporin A|Gengraf|SangCya",BANN|INN|USAN|Trade Name|Trade Name|Trade Name|Trade Name,Immune,Calcineurin inhibitor,4010,Immunosuppressant,396,Transplant rejection,515,,,SangStat Medical Corp|Abbott Laboratories,19651|13601,,,SangStat Medical Corp,19651,,,,,,
11396,ISCAR,ISCAR,,Infection,,,Immunostimulant|Unspecified drug target,393|59620,,,HIV infection,158,,,Biotech Australia,16820,Biotech Australia,16820,,,,,,
114005,Tn MUC-1 CAR-T,"Tn MUC-1 CAR-T|anti-Tn MUC-1 CAR T-cell therapy (advanced solid tumor/multiple myeloma), Tmunity|anti-Tn MUC-1 CAR T-cell therapy (advanced solid tumor/multiple myeloma), University of Pennsylvania",Research Code,Cancer,Mucin 1 modulator,32076,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Multiple myeloma|Fallopian tube cancer|Breast tumor|Ovary tumor,1262|1507|1828|2243|49|799,Cancer,651,Tmunity Therapeutics Inc,1118342,University of Pennsylvania,20658,University of Pennsylvania,20658,,,,,,
114069,PRGN-3006,"PRGN-3006|PRGN-3006 UltraCAR-T|CAR T-cell therapy co-expressing membrane-bound IL-15 (acute myelogenous leukemia/myelodysplastic syndrome), Precigen|non-viral adoptive CAR T-cell therapy with mbIL15 (acute myeloid leukemia/higher risk myelodysplastic syndrome), Precigen|CAR T-cell therapy/IL-15 (non-viral Sleeping Beauty/UltraCAR-T, acute myeloid leukemia/higher risk myelodysplastic syndrome), Precigen",Research Code,Cancer,IL-15 receptor agonist,3085,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Precigen Inc,1021778,Precigen Inc (pre-merger),1144880,Precigen Inc (pre-merger),1144880,,,,,,
114144,MCLA-129,"anti-EGFR/ cMET bispecific antibody (Biclonics/ GlymaxX, solid tumor), Merus/ Betta|MCLA-129",Research Code,Cancer,Hepatocyte growth factor receptor antagonist|Epidermal growth factor receptor antagonist,675|740,Anticancer protein kinase inhibitor|Anticancer antibody,62255|55684,Stomach tumor|Metastatic non small cell lung cancer|Advanced solid tumor|Head and neck tumor|Solid tumor,127|3665|3713|623|725,,,Betta Pharmaceuticals Co Ltd|Merus BV,1051889|1008818,,,Merus BV,1008818,,,,,,
114210,TAK-169,"TAK-169|CD38-targeted second-generation Engineered Toxin Bodies (multiple myeloma), Molecular Templates/Takeda|CD38 ETB",Research Code|Research Code,Cancer,ADP ribosyl cyclase-1 modulator,5134,Immunotoxin|Anticancer,539|1545,Multiple myeloma,1828,,,Molecular Templates Inc,30181,Takeda Pharmaceutical Co Ltd,20300,Molecular Templates Inc,30181,,,,,,
114224,RTX-240,"RTX-240|RTX-212|dual 4-1BB costimulator + IL-15TP red blood cell therapy (solid tumor/AML), Rubius Therapeutics|RCT therapy (solid tumor/AML), Rubius Therapeutics|dual 4-1BBL + IL-15TP expressing red blood cell therapy (solid tumor/AML), Rubius Therapeutics|mRBC-240|RCT therapy (solid tumor/AML/melanoma/colorectal cancer), Rubius Therapeutics",Research Code|Research Code|Research Code,Cancer,IL-15 receptor agonist|CDw137 agonist,3085|5450,Natural killer cell stimulator|Anticancer|Immunostimulant|T-lymphocyte stimulator,7757|1545|393|7761,Acute myelogenous leukemia|Solid tumor,1731|725,,,RUBIUS THERAPEUTICS,1108468,,,RUBIUS THERAPEUTICS,1108468,,,,,,
114237,MT- 401,"LAAP T-cell therapy (ALL/MDS/AML), Marker Therapeutics/ Baylor College of Medicine)|MT- 401|zelenoleucel",Research Code|USAN,Cancer,Survivin protein modulator|Tumor expressed melanoma antigen modulator|Wilms tumor protein modulator,13606|18578|30009,Genetically engineered autologous cell therapy|Immunostimulant|Anticancer|T-lymphocyte stimulator,4790|393|1545|7761,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia,1272|1728|1731,,,Marker Therapeutics Inc|Baylor College of Medicine,27762|20534,,,Marker Therapeutics Inc,27762,,,,,,
114416,UCAR-011,"anti-CD19 CAR T-cell therapy (B-cell lymphoma/DLBCL/B-cell ALL), UWELL Biopharma|UCAR-011|UWC-19|welgenaleucel",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,393|1545|7761|4790,B-cell acute lymphoblastic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|High grade B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Burkitts lymphoma,1729|1744|1745|1749|1750|1751|316|319|791,,,UWELL Biopharma,1179514,,,UWELL Biopharma,1179514,,,,,,
114467,AGuIX,"AGuIX|polysiloxane gadolinium (Gd) chelates based nanoparticles (intravenous/theranostic, cancer), NH TherAguix|AGuIX-NP",,Cancer,,,Gastrointestinal diagnostic agent|Anticancer|Endocrine diagnostic agent|Radiosensitizer|CNS diagnostic agent|MRI imaging agent|Neoplasm diagnostic agent,7213|1545|7212|1542|7211|4158|7220,Rectal tumor|Metastasis|Non-small-cell lung cancer|Gastrointestinal tumor|Pancreatic ductal adenocarcinoma|Melanoma|Glioblastoma|Pancreas tumor|Uterine cervix tumor|Breast tumor|Head and neck tumor|Lung tumor|Brain tumor|Colorectal tumor,1055|1069|1262|131|1507|205|2454|249|427|49|623|755|760|989,,,NH TherAguix SAS,1126317,,,NH TherAguix SAS,1126317,,,,,,
114504,lemzoparlimab,"TJC-4|CD47 checkpoint inhibitor (cancer), I-Mab Biopharma|TJ-011133|lemzoparlimab",Research Code|Research Code,Cancer,CD47 antagonist,5185,Macrophage stimulator|Immunostimulant|Anticancer monoclonal antibody|Anticancer,7751|393|55685|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Lymphoma|Non-Hodgkin lymphoma|Advanced solid tumor,1272|1731|1828|203|319|3713,Hematological neoplasm|Solid tumor,2054|725,I-Mab Biopharma|AbbVie Inc,1141058|1072507,,,I-Mab Biopharma,1141058,,,,,,
114567,UniCAR02-T-CD123 cell therapy,"TM-123 4-1BBL|TM-123 + UniCAR-T|4-1BB costimulator + peptide-expressing anti-CD123 targeting molecule + anti-peptide CAR T-cell therapy (acute leukemia), GEMoaB Monoclonals/Cellex|TM-123|UniCAR02-T-CD123 cell therapy|UniCAR-T-CD123",Research Code|Research Code,Cancer,CDw123 modulator|CDw137 agonist,5427|5450,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,Acute leukemia|B-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Hematological neoplasm,1727|1729|1731|2054,,,GEMoaB Monoclonals GmbH|Cellex GmbH,1120339|1106993,,,GEMoaB Monoclonals GmbH,1120339,,,,,,
11460,imatinib,"CGP-57148|CGP-57148B|Gleevec|Glivec|imatinib|STI-571|imatinib mesilate|imatinib mesylate|STI-571A|CGS-57148|Abl tyrosine protein kinase inhibitors, Novartis|QTI-571|QTI-517|NSC-716051|Ruvise",Research Code|Research Code|Trade Name|Trade Name|BANN|INN|Research Code|USAN|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name,Cancer|Cardiovascular|Hematologic|Immune|Musculoskeletal|Respiratory,Bcr protein inhibitor|Abl tyrosine kinase inhibitor|PDGF receptor antagonist|Signal transduction protein inhibitor|Kit tyrosine kinase inhibitor,13571|3524|948|7025|3808,Anticancer|Fibrosuppressant|Anticancer protein kinase inhibitor|Apoptosis stimulator|Anti-inflammatory,1545|664|62255|1589|2953,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Chronic myelocytic leukemia|Hypereosinophilic syndrome|Myeloid leukemia|Dermatofibrosarcoma|Myeloproliferative disorder|Gastrointestinal stromal tumor|Pulmonary artery hypertension|Systemic mastocytosis,1272|1728|1735|2036|223|2547|273|3205|3510|3728,Scleroderma|Glioma|Thyroid tumor|Acute myelogenous leukemia|Sarcoma|Melanoma|Prostate tumor|Meningioma|Rheumatoid arthritis|Asthma|Hormone refractory prostate cancer|Aggressive fibromatosis|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Chordoma|Idiopathic pulmonary fibrosis|Metastatic renal cell carcinoma|Bone marrow transplantation|Graft versus host disease|Cancer|Solid tumor|Lung tumor|Intestine tumor|Ovary tumor,1105|1108|1134|1731|194|205|276|2802|291|31|3246|3504|3665|3673|3736|3771|4250|46|616|651|725|755|765|799,Novartis AG,23137,Ciba-Geigy AG,24437,Novartis AG,23137,,,,,,
114604,GC-007F,"GC-007F|anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), Gracell Biotechnology|CD19-F-CAR-T|FasT CAR-19|GC-019F",Research Code|Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer,393|4790|7761|1545,B-cell acute lymphoblastic leukemia|Non-Hodgkin lymphoma,1729|319,,,Gracell Biotechnology Ltd,1180179,,,Gracell Biotechnology Ltd,1180179,,,,,,
114617,MT-6402,"MT-6035|anti-PD-L1/Shiga-like toxin 1 (SLT-1A) MHC class I-antigen-seeding engineered toxin body (melanoma), Molecular Templates|MT-6020-AST (cancer), Molecular Templates|MT-6402",Research Code,Cancer,Programmed cell death ligand 1 modulator,14005,Anticancer antibody|Immunostimulant|Immunotoxin,55684|393|539,Melanoma|Squamous cell carcinoma|Larynx tumor|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Cancer|Mouth tumor|Pharynx tumor,205|307|3198|3665|3673|3713|651|793|794,,,Molecular Templates Inc,30181,,,Molecular Templates Inc,30181,,,,,,
114628,Iomab-ACT,"Iomab-ACT|Iodine (131I) apamistamab (lower dose/single infusionchemo-free, hematological malignancies), Actinium pharmaceuticals|iodine-131-radiolabeled anti-CD45 antibody (lower dose/single infusionchemo-free, hematological malignancies), Actinium pharmaceuticals",,Cancer,CD45 antagonist,5171,Immunomodulator|Radioimmunotherapeutic|Anticancer monoclonal antibody|Hematopoietic inhibitor,1596|1552|55685|1677,B-cell acute lymphoblastic leukemia|Diffuse large B-cell lymphoma|Hematological neoplasm,1729|1749|2054,,,Actinium Pharmaceuticals Inc,24594,,,Actinium Pharmaceuticals Inc,24594,,,,,,
114687,MK-2140,"VLS-101|anticancer therapeutic (hematological malignancies), VelosBio|anti-ROR1 antibody-drug conjugate (Richter's syndrome), VelosBio|anti-ROR1 antibody-drug conjugate (iv, solid tumor/non small cell lung cancer/triple negatve breast cancer) VelosBio|MK-2140",Research Code|Research Code,Cancer,Ntrkr1 tyrosine kinase receptor inhibitor,3822,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor,1734|1744|1745|1747|1749|3657|3665|3713,Solid tumor,725,Merck & Co Inc,18077,VelosBio Inc,1172385,VelosBio Inc,1172385,,,,,,
114728,GEN-011,"GEN-011|adoptive T-cell therapy (cancer), Genocea Biosciences",Research Code,Cancer,,,T-lymphocyte stimulator|Anticancer,7761|1545,Small-cell lung cancer|Non-small-cell lung cancer|Renal cell carcinoma|Transitional cell carcinoma|Melanoma|Anal tumor|Bladder cancer|Squamous cell carcinoma|Urethral cancer|Ureter cancer|Head and neck tumor|Cancer|Solid tumor,1261|1262|1766|1771|205|2193|2380|307|3678|4265|623|651|725,,,Genocea Biosciences Inc,1033185,,,Genocea Biosciences Inc,1033185,,,,,,
11474,siltuximab,"cCLB8|MAb (IL-6), Centocor|monoclonal antibody (IL-6), Centocor|siltuximab|CNTO-328|Sylvant|monoclonal antibody (IL-6), Centocor Janssen/EUSA|anti-IL-6 monoclonal antibody (Castlemans disease/multiple myeloma/COVID-19), Janssen Biotech/EUSA",Research Code|USAN|INN|Research Code|Trade Name,Cancer|Immune|Infection|Other/Miscellaneous|Respiratory,Heat shock protein inhibitor|IL-6 receptor antagonist,7994|471,Anti-inflammatory|Anticancer monoclonal antibody|Antiviral,2953|55685|991,Coronavirus disease 19 infection|Castlemans disease|Multiple myeloma|Lung disease|Pneumonia|Respiratory distress syndrome,10406|1294|1828|283|360|8,Myelodysplastic syndrome|Renal cell carcinoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Cachexia|Ovary tumor,1272|1766|319|3246|425|799,EUSA Pharma|BeiGene Co Ltd,1107183|1063251,Johnson & Johnson|Janssen Biotech Inc,17332|26997,Janssen Biotech Inc,26997,,,,,,
114849,"anti-CD19 CAR T-cell therapy (silenced IL-6 expression, cancer), Shanghai Unicar-Therapy Bio-medicine Technology","anti-CD19 CAR T-cell therapy (silenced IL-6 expression, cancer), Shanghai Unicar-Therapy Bio-medicine Technology|anti-CD19 CAR T-cell therapy (silenced IL-6 expression, cancer/AML), Shanghai Unicar-Therapy Bio-medicine Technology|ssCART-19",Research Code,Cancer,IL-6 receptor antagonist|B-lymphocyte antigen CD19 modulator,471|5080,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,Acute lymphoblastic leukemia|Acute myelogenous leukemia|Leukemia|Cancer,1728|1731|199|651,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd,1144294,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd,1144294,,,,,,
114885,SG-301,"SG-301|humanized anti-CD38 mAb (multiple myeloma), Hangzhou Sumgen Biotechnology",Research Code,Cancer,ADP ribosyl cyclase-1 inhibitor,5136,Anticancer monoclonal antibody,55685,Multiple myeloma|Hematological neoplasm,1828|2054,,,Hangzhou Sumgen Biotechnology Co Ltd,1150089,,,Hangzhou Sumgen Biotechnology Co Ltd,1150089,,,,,,
11497,L-778123,L-778123|L-739750,Research Code|Analogue|Research Code,Cancer,Protein farnesyltransferase inhibitor|Ras GTPase inhibitor,1875|10451,Anticancer,1545,,,Cancer|Solid tumor,651|725,,,Merck & Co Inc,18077,Merck & Co Inc,18077,,,,,,
114999,TPX-0022,"TPX-0022|MET/CSF1R/SRC inhibitor (advanced solid tumor), Turning Point Therapeutics|TPX-02226",Research Code|Research Code,Cancer,Hepatocyte growth factor receptor antagonist|Src tyrosine kinase inhibitor|CSF-1 antagonist,675|3576|3154,Anticancer protein kinase inhibitor,62255,Stomach tumor|Metastatic non small cell lung cancer|Advanced solid tumor,127|3665|3713,,,Turning Point Therapeutics Inc|Zai Lab Limited,1112197|1101935,,,Turning Point Therapeutics Inc,1112197,,,,,,
115000,TPX-0046,"TPX-0046|RET/SRC inhibitor (advanced solid tumor), Turning Point Therapeutics",Research Code,Cancer,Ret tyrosine kinase receptor inhibitor|Src tyrosine kinase inhibitor,3818|3576,Anticancer protein kinase inhibitor,62255,Thyroid tumor|Metastatic non small cell lung cancer|Advanced solid tumor,1134|3665|3713,,,Turning Point Therapeutics Inc,1112197,,,Turning Point Therapeutics Inc,1112197,,,,,,
115024,AMG-404,"AMG-404|anti-PD-1 mAb (solid tumor), Amgen|PD-1 checkpoint inhibitor (advanced solid tumor), Amgen|PD-1 checkpoint inhibitor (iv, advanced solid tumor/B-cell acute lymphoblastic leukemia/glioblastoma), Amgen|anti-PD-1 mAb (iv, advanced solid tumor/B-cell acute lymphoblastic leukemia/glioblastoma), Amgen",Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Glioma|Mesothelioma|Small-cell lung cancer|B-cell acute lymphoblastic leukemia|Adenocarcinoma|Glioblastoma|Squamous cell carcinoma|Hormone refractory prostate cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer,1108|1240|1261|1729|2399|2454|307|3246|3665|3669|3713|3866,,,Amgen Inc,14109,,,Amgen Inc,14109,,Lodazecar,,,,
115025,SBT-6050,"SBT-6050|TLR8 agonist conjugated mAb (systemic, HER2-expressing tumors), Silverback",Research Code,Cancer,TLR-8 agonist|Erbb2 tyrosine kinase receptor modulator,7824|3755,Anticancer monoclonal antibody,55685,Non-small-cell lung cancer|Stomach tumor|Advanced solid tumor|Breast tumor,1262|127|3713|49,Cancer,651,Silverback Therapeutics,1140381,,,Silverback Therapeutics,1140381,,Irindalone,5-HT2A Receptor Antagonists,210,Signal Transduction Modulators,1402
115033,"atezolizumab (sc Enhanze), Roche","atezolizumab|RG-7446|atezolizumab (sc Enhanze), Roche|atezolizumab (sc, rHuPH20 formulation, cancer), Roche|Tecentriq SC|PD-L1 checkpoint inhibitor (sc Enhanze, cancer), Genentech/Roche/Chugai|atezolizumab + hyaluronidase (cancer, sc Enhanze), Roche/Halozyme",USAN|INN|Research Code|Trade Name,Cancer,Programmed cell death ligand 1 inhibitor,14007,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Small-cell lung cancer|Non-small-cell lung cancer|Hepatocellular carcinoma|Metastatic non small cell lung cancer,1261|1262|1767|3665,,,Roche Holding AG,19446,,,Roche Holding AG,19446,,Eptaloprost|Eptaprost,Prostacyclin Mimetics,297,,
115062,IM-23,"IM-23|anti-CD123 CAR T-cell therapy (acute myeloid leukemia), Beijing Immunochina Medical",Research Code,Cancer,CDw123 modulator,5427,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,Acute myelogenous leukemia,1731,,,Beijing Immunochina Medical Science & Technology Co Ltd,1140907,,,Beijing Immunochina Medical Science & Technology Co Ltd,1140907,,,,,,
115073,SNK-01,"SNK-01|autologous NK cell adoptive immunotherapy (SuperNK, cancer), NKMax America|natural killer cell stimulator (SuperNK, cancer), NKMax America|autologous NK cell adoptive immunotherapy (SuperNK, iv, cancer/psoriasis), NKMax America|natural killer cell stimulator (SuperNK, iv, cancer/psoriasis), NKMax America|autologous NK cell adoptive immunotherapy (SuperNK, iv, cancer/psoriasis/mild cognitive impairment/AD), NKMax America|autologous NK cell adoptive immunotherapy (SuperNK, iv, cancer/psoriasis/mild cognitive impairment/AD), NKGen Biotech",Research Code,Cancer|Dermatologic|Neurology/Psychiatric,,,Anticancer|Natural killer cell stimulator|Anti-inflammatory|Systemic antipsoriatic product|Immunostimulant,1545|7757|2953|15184|393,Alzheimers disease|Sarcoma|Psoriasis|Mild cognitive impairment|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer|Solid tumor|Colorectal tumor,14|194|281|3122|3657|3665|3713|651|725|989,,,NKGen Biotech Inc,1182154,,,NKGen Biotech Inc,1182154,Carcinil|Enanton|Enantone|Lucrin|Lupron|Onectyl|Ovarest (oral formulation)|Prostap,Leuprolide acetate|Leuprorelin acetate,Gonadotropin-Releasing Hormone Receptor (GNRHR) Agonists,590,Signal Transduction Modulators,1402
11519,mitoxantrone,mitoxantrone hydrochloride|Novantrone|mitoxantrone|mitozantrone|Ralenova|Elsep|CL-232315,USAN|Trade Name|BANN|INN|Trade Name|Trade Name|Research Code,Cancer|Immune,Topoisomerase II modulator,1513,DNA intercalator|Anticancer,750|1545,Acute myelogenous leukemia|Liver tumor|Multiple sclerosis|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Breast tumor|Cancer,1731|202|213|319|3246|49|651,Ovary tumor,799,OSI Pharmaceuticals Inc|Pfizer Inc|Merck Serono SA|Mylan NV|Immunex Corp,18676|18767|19862|18439|14131,Amgen Inc|Meda AB,14109|18954,Immunex Corp,14131,,,,,,
115208,XZP-5809-TT1,"XZP-5809-TT1|XZP-5809|epithelial growth factor receptor tyrosine kinase inhibitor (lung cancer), Sihuan pharmaceutical holdings group ltd.",Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3754|740,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer|Metastatic lung cancer|Solid tumor,3665|3668|725,Non-small-cell lung cancer,1262,Xuanzhu Pharma Co Ltd,1099478,,,Xuanzhu Pharma Co Ltd,1099478,,,,,,
115210,MB-CART2019.1,"MB-CART2019.1|dual anti-CD19/anti-CD20 CAR T-cell therapy (non-Hodgkin's lymphoma/chronic lymphocytic leukemia/small lymphocytic lymphoma), Miltenyi Biotec|CD20/CD19 bispecific CAR T-cell therapy (NHL/CLL/SLL), Miltenyi Biotec",Research Code,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte antigen CD20 modulator,5080|5083,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,Chronic lymphocytic leukemia|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|High grade B-cell lymphoma|Lymphoma|Non-Hodgkin lymphoma,1734|1745|1747|1749|1750|1751|203|319,,,Miltenyi Biotec GmbH,28791,,,Miltenyi Biotec GmbH,28791,,,,,,
115246,HPN-328,"HPN-328|triple anti-CD3/anti-DLL3/anti-HSA T-cell engager (small cell lung cancer), Harpoon Therapeutics|anti-CD3/anti-DLL3/anti-albumin trispecific T-cell engager (TriTAC, small-cell lung cancer), Harpoon Therapeutics|triple anti-CD3/anti-DLL3/anti-HSA T-cell engager (iv, advanced cancers/small cell lung cancer), Harpoon Therapeutics|anti-CD3/anti-DLL3/anti-albumin trispecific T-cell engager (iv, TriTAC, advanced cancers/small-cell lung cancer), Harpoon Therapeutics",Research Code,Cancer,Albumin modulator|Delta-like protein ligand 3 modulator|CD3 modulator,815|18188|5023,Anticancer antibody|T-lymphocyte stimulator|Immunostimulant,55684|7761|393,Metastasis|Small-cell lung cancer,1069|1261,,,Harpoon Therapeutics Inc,1138978,,,Harpoon Therapeutics Inc,1138978,,Fluorotamoxifen-[18F]|[18F]Fluorotamoxifen,,,,
115306,CYAD-211,"anti-BCMA CAR T-cell therapy (multiple myeloma), Celyad Oncology|CYAD-211|anti-BCMA CAR T-cell therapy (TCR knock-out shRNA SMARTvector platform, multiple myeloma), Celyad Oncology",Research Code,Cancer,APRIL receptor modulator,8255,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,Multiple myeloma,1828,,,Celyad Oncology,1034997,,,Celyad Oncology,1034997,,,,,,
115317,CYAD-02,"CYAD-02|next generation NKG2D CAR-T cell therapy, Celyad Oncology|autologous NKG2D T-cell therapy (cancer), Celyad Oncology|anti-MICA/MICB CAR T-cell therapy (NKG2D CAR, cancer), Celyad Oncology",Research Code,Cancer,MHC class I polypeptide sequence B modulator|MHC class I polypeptide sequence A modulator,78999|78993,Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer,393|4790|7761|1545,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,Cancer,651,Celyad Oncology,1034997,,,Celyad Oncology,1034997,,,,,,
115368,"anti-SLAMF7 CAR T-cell therapy (virus-free transfer system, multiple myeloma), University of Wurzburg","anti-SLAMF7 CAR T-cell therapy (virus-free transfer system, multiple myeloma), University of Wurzburg|huLuc63-based anti-SLAMF7 CAR T-cell therapy (virus-free transfer system, multiple myeloma), University of Wurzburg|anti-CS1 CAR T-cell therapy (virus-free transfer system, multiple myeloma), University of Wurzburg",,Cancer,SLAM family member 7 modulator,45393,Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator|Immunostimulant,4790|1545|7761|393,Multiple myeloma,1828,,,University of Wurzburg,24121,,,University of Wurzburg,24121,,,,,,
115383,DKY-709,"DKY-709|IKZF2 degrader (advanced solid tumor), Novartis",Research Code,Cancer,Zinc finger binding protein Helios inhibitor,53671,Anticancer|Immunomodulator,1545|1596,Non-small-cell lung cancer|Nasopharyngeal carcinoma|Melanoma|Advanced solid tumor|Breast tumor|Colorectal tumor,1262|1768|205|3713|49|989,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
115384,PRT-543,"PRT-543|protein arginine N-methyltransferase 5 inhibitor (oral, solid tumor/hematological malignancies/advanced diffuse large B-cell lymphoma/advanced mantle cell lymphoma/myelodysplastic syndrome/myelofibrosis), Prelude Therapeutics|PRMT5 inhibitor (oral, solid tumor/hematological malignancies/advanced diffuse large B-cell lymphoma/advanced mantle cell lymphoma/myelodysplastic syndrome/myelofibrosis), Prelude Therapeutics",Research Code,Cancer|Hematologic|Neurology/Psychiatric,Protein arginine N-methyltransferase 5 inhibitor,14756,Synergist|Anticancer,7293|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Hematological neoplasm|Myelofibrosis|Spina bifida|Adenoid tumor|Advanced solid tumor|Uveal melanoma|Breast tumor|Chronic myelomonocytic leukemia|Ovary tumor,1272|1731|1744|1749|2054|2436|306|3153|3713|3788|49|6833|799,,,Prelude Therapeutics Inc,1158197,,,Prelude Therapeutics Inc,1158197,,,,,,
11547,memantine hydrochloride,memantine hydrochloride|memantine|Namenda|Axura|Memary|Namenda IR|Ebixa|Akatinol|Ebix|D-145|SUN-Y7017,USAN|BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Research Code,Musculoskeletal|Neurology/Psychiatric|Ocular,NMDA receptor antagonist,281,Neuroprotectant|Nootropic agent|Analgesic|Antidepressant|Antiparkinsonian,1615|284|2946|2941|2947,Alzheimers disease|Fibromyalgia|Dementia,14|2527|90,Diabetic neuropathy|HIV associated dementia|Neuropathic pain|Glaucoma|Binge eating disorder|Pervasive child developmental disorder|Asperger syndrome|Pain|Ocular hypertension|Parkinsons disease|Schizophrenia|Lewy body dementia|Bipolar I disorder|Cognitive disorder|Autism|Major depressive disorder,101|1275|1295|134|1909|1947|1948|20|240|255|299|3064|3114|353|423|4898,Merz & Co GmbH|H Lundbeck A/S|Daewoong Pharmaceutical Co Ltd|AbbVie Inc|Daiichi Sankyo Co Ltd,18187|17900|15587|1072507|1017506,Allergan plc|Allergan Inc|Forest Laboratories Inc|Neurobiological Technologies Inc|Asubio Pharma Co Ltd,1088700|14042|16198|18499|30572,Merz & Co GmbH,18187,,,,,,
115471,taniraleucel,"CYNK-001|PNK-007 (cryopreserved formulation, hematologic cancers/solid tumors), Celularity|allogeneic NK cell therapy (COVID-19), Celularity/Sorrento Therapeutics|human placental hematopoietic stem cell derived natural killer cells (cryopreserved formulation, hematologic cancers/solid tumors), Celularity|allogeneic NK cell therapy (COVID-19/ARDS), Celularity/Lung Biotech|taniraleucel",Research Code|Research Code|PINN,Cancer|Infection|Respiratory,,,Immunostimulant|Anticancer|Respiratory system agent|Natural killer cell stimulator,393|1545|1470|7757,Coronavirus disease 19 infection|Acute myelogenous leukemia|Multiple myeloma|Glioblastoma|Solid tumor|Respiratory distress syndrome,10406|1731|1828|2454|725|8,Hematological neoplasm,2054,Sorrento Therapeutics Inc|Lung Biotechnology Inc|Celularity Inc,1048574|1023357|1152669,,,Celularity Inc,1152669,,,,,,
115475,BT-8009,"BT-8009|bicycle toxin conjugate targeting Nectin-4 (iv, solid tumors), BicycleRD|second-generation bicycle toxin conjugate targeting Nectin-4 (iv, solid tumors), Bicycle Therapeutics",Research Code,Cancer,Poliovirus receptor-related protein 4 inhibitor,64793,Anticancer,1545,Transitional cell carcinoma|Bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer|Solid tumor,1771|2380|3657|3665|3666|3667|3669|3713|3866|725,,,Bicycle Therapeutics Ltd,1050067,,,Bicycle Therapeutics Ltd,1050067,,,,,,
115566,JNJ-67856633,"JNJ-67856633|MALT1 inhibitor (oral, B-cell non-Hodgkin lymphoma/chronic lymphocytic leukemia), Janssen Research & Development|JNJ-6633",Research Code|Research Code,Cancer,MALT protein 1 inhibitor,56088,Synergist|Anticancer,7293|1545,Chronic lymphocytic leukemia|B-cell lymphoma|Non-Hodgkin lymphoma,1734|316|319,,,Janssen Research & Development LLC,1067538,,,Janssen Research & Development LLC,1067538,,,,,,
115593,SGN-CD228A,"SGN-CD228A|anti-CD228A antibody-drug conjugate (solid tumors), Seattle Genetics|hL49-MMAE antibody-drug conjugate (solid tumors), Seattle Genetics|anti-melanotransferrin antibody drug conjugate (solid tumors), Seattle Genetics|ADC targeted to CD228 (cancer), Seattle Genetics",,Cancer,Melanotransferrin inhibitor,82733,Anticancer monoclonal antibody,55685,Mesothelioma|Pancreatic ductal adenocarcinoma|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Solid tumor,1240|1507|3257|3657|3658|3665|725,,,Seagen Inc,25554,,,Seagen Inc,25554,,,,,,
115642,FCN-338,"FCN-338|Bcl-2 inhibitor (B-cell lymphoma), Fochon Pharmaceuticals|Bcl-2 inhibitor (oral tablet, hematological cancer), Eli Lilly/Chongqing Fochon Pharmaceuticals|LOXO-338",Research Code|Research Code,Cancer,Bcl-2 protein inhibitor,16111,Synergist|Apoptosis stimulator|Anticancer,7293|1589|1545,Chronic lymphocytic leukemia|Hematological neoplasm|B-cell lymphoma,1734|2054|316,,,Eli Lilly & Co|Chongqing Fochon Pharmaceuticals Co Ltd,17810|1063683,,,Chongqing Fochon Pharmaceuticals Co Ltd,1063683,,,,,,
115645,ADP-A2M4CD8,ADP-A2M4CD8|second-generation ADP-A2M4,Research Code,Cancer,Melanoma associated antigen 4 modulator|HLA class I antigen A-2 alpha modulator,21961|19115,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Transitional cell carcinoma|Melanoma|Liposarcoma|Soft tissue sarcoma|Metastatic stomach cancer|Metastatic esophageal cancer|Head and neck tumor|Solid tumor|Ovary tumor,1011|1262|127|1771|205|2447|3378|3666|3667|623|725|799,,,Adaptimmune Therapeutics plc,1047486,,,Adaptimmune Therapeutics plc,1047486,,,,,,
115734,M-3258,"M-3258|LMP7 inhibitor (oral, multiple myeloma), Merck KGaA|inhibitor of LMP7 subunit of the immunoproteasome (multiple myeloma), Merck KGaA",Research Code,Cancer,Proteasome beta-8 subunit inhibitor,11459,Anticancer,1545,Multiple myeloma,1828,,,Merck KGaA,18101,,,Merck KGaA,18101,,,,,,
115735,MVR-T3011,"T-1012G|T-2850|T-2010|T-3855|T-3011|Oncolytic herpes simplex virus (cancer), Immvira Co Ltd|Oncolytic herpes simplex virus gene therapy (cancer), Immvira Co Ltd|MVR-T3011|oHSVT-3011|PD-1 checkpoint inhibitor + IL-12 (oncolytic herpes simplex virus delivery, intratumoral, advanced solid tumor), Shanghai Pharmaceuticals/Immvira|oHSV-1 expressing anti-PD-1 antibody and IL-12 (intratumoral, advanced solid tumor), Shanghai Pharmaceuticals Holding/Immvira|B-015",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Programmed cell death protein 1 inhibitor|IL-12 receptor agonist,67136|1583,T-lymphocyte stimulator|Anticancer|Immunostimulant|Anticancer antibody,7761|1545|393|55684,Metastasis|Liver tumor|Skin cancer|Stage IV melanoma|Soft tissue sarcoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic lung cancer|Metastatic head and neck cancer|Advanced solid tumor,1069|202|2170|3257|3378|3657|3665|3667|3668|3673|3713,,,Immvira Co Ltd|Shanghai Pharmaceuticals Holding Co Ltd,1155722|1060612,,,Immvira Co Ltd,1155722,,,,,,
115752,NeoTCR-P1,"NeoTCR-P1|NeoTCR-P1 T-cells (solid tumors), PACT Pharma|TCR T-cell therapy (solid tumors), PACT Pharma|neoantigen/neoepitope-specific adoptive cell therapy (solid tumor), PACT Pharma|NeoTCR-T cells",,Cancer,HLA antigen modulator,19106,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Solid tumor,725,Cancer,651,PACT Pharma,1145616,,,PACT Pharma,1145616,,,,,,
115805,BI-764532,"anti-CD3/anti-DLL3 bispecific T-cell engager (HLE-BiTE, small-cell lung cancer), Boehringer Ingelheim|anti-CD3/anti-DLL3 bispecific T-cell engager (small-cell lung cancer), Boehringer Ingelheim|delta-like Ligand 3/CD3 IgG-like T cell engager (small-cell lung cancer), Boehringer Ingelheim|anti-CD3/anti-DLL3 BiTE (small-cell lung cancer), Boehringer Ingelheim|anti-CD3/anti-DLL3 BiTE (half-life extended, small-cell lung cancer), Boehringer Ingelheim|BI-764532",Research Code,Cancer,Delta-like protein ligand 3 modulator|CD3 modulator,18188|5023,T-lymphocyte stimulator|Anticancer antibody|Immunostimulant,7761|55684|393,Neuroendocrine tumor|Small-cell lung cancer,1128|1261,,,Boehringer Ingelheim Corp,22586,,,Boehringer Ingelheim Corp,22586,,,,,,
115853,JNJ-67571244,"JNJ-67571244|anti-CD3/anti-CD33 bispecific T-cell engager (acute myeloid leukemia/myelodysplastic syndrome), Janssen/Genmab|CD3xCD33 DuoBody (acute myeloid leukemia/myelodysplastic syndrome), Janssen/Genmab|JNJ-1244",Research Code|Research Code,Cancer,CD3 modulator|CD33 modulator,5023|5119,Immunostimulant|T-lymphocyte stimulator|Anticancer antibody,393|7761|55684,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Janssen Research & Development LLC,1067538,,,Janssen Research & Development LLC,1067538,,Thymocartin,,,,
115885,SYHA-1807,"SYHA-1807|lysine specific demethylase 1 inhibitor (cancer), CSPC Zhongqi Pharmaceutical Technology|LSD1 inhibitor (cancer), CSPC Zhongqi Pharmaceutical Technology",Research Code,Cancer,Lysine specific demethylase inhibitor,64002,Anticancer,1545,Small-cell lung cancer,1261,,,CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd,1047791,,,CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd,1047791,,,Dopamine D2 Receptor (DRD2) Agonists,131,Signal Transduction Modulators,1402
11589,imetelstat,"GRN-163L|GRN-163|GRN-163 (modified)|telomerase inhibitors, Geron|telomerase modulators, Geron|telomere modulators, Geron/Pharmacia/Kyowa Hakko|telomerase inhibitors, Geron/Pharmacia/Kyowa Hakko|GRN-719|imetelstat|imetelstat sodium|NSC-754228|IND-110934|JNJ-63935937",Research Code|Research Code|Research Code|USAN|INN|USAN|Research Code|Research Code|Research Code,Cancer|Hematologic|Ocular,Telomerase inhibitor,1614,Anticancer|Synergist|Angiogenesis inhibitor|Antisense oligonucleotide inhibitor|Apoptosis stimulator,1545|7293|61|7294|1589,Myelodysplastic syndrome|Acute myelogenous leukemia|Myelofibrosis,1272|1731|2436,Non-small-cell lung cancer|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Multiple myeloma|Hematological neoplasm|Thrombocythemia|Polycythemia vera|Ocular disease|Metastatic breast cancer|Cancer|Solid tumor,1262|1734|1735|1828|2054|2317|2319|239|3657|651|725,Geron Corp,16315,Kyowa Hakko Kogyo Co Ltd|Pharmacia & Upjohn Ltd|Janssen Biotech Inc,17724|23928|26997,Geron Corp,16315,,,,,,
115928,DZD-9008,"DZD-9008|EGFR tyrosine kinase inhibitor (cancer), Dizal|DZ-0586",Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer|Cancer|Solid tumor,3665|651|725,Non-Hodgkin lymphoma,319,Dizal Pharm Co Ltd,1157162,,,Dizal Pharm Co Ltd,1157162,,,,,,
115940,MK-0482,"MK-0482|anticancer mAb (iv, advanced solid tumors), Merck Sharp & Dohme",Research Code,Cancer,,,Anticancer monoclonal antibody,55685,Advanced solid tumor,3713,,,Merck Sharp & Dohme Corp,1059823,,,Merck Sharp & Dohme Corp,1059823,,,,,,
116028,GEM3PSCA,"GEM3PSCA|PSCA targeted bispecific antibody engaging T-cells (cancer), GEMoab|anti-CD3/anti-PSCA bispecific T-cell engager (PSCA-positive cancer), GEMoaB",Research Code,Cancer,Prostate stem cell antigen modulator|CD3 modulator,14592|5023,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Non-small-cell lung cancer|Pancreas tumor|Hormone refractory prostate cancer|Metastatic prostate cancer|Breast tumor|Genitourinary tract tumor,1262|249|3246|3664|49|613,,,GEMoaB Monoclonals GmbH|Bristol-Myers Squibb Co,1120339|15065,Celgene Corp,15331,GEMoaB Monoclonals GmbH,1120339,,,,,,
11603,gefitinib,gefitinib|Iressa|ZD-1839|Iressat,USAN|INN|Trade Name|Research Code|Trade Name,Cancer|Respiratory,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Non-small-cell lung cancer|Metastatic non small cell lung cancer|Ovary tumor,1262|3665|799,Esophagus tumor|Glioma|Chronic obstructive pulmonary disease|Mesothelioma|Sarcoma|Liver tumor|Skin cancer|Hormone refractory prostate cancer|Metastatic bladder cancer|Metastatic renal cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Uterine cervix tumor|Carcinoma|Solid tumor|Brain tumor|Nasopharynx tumor,1011|1108|1185|1240|194|202|2170|3246|3466|3467|3657|3658|3666|3669|3673|427|54|725|760|795,AstraZeneca plc,14190,,,AstraZeneca plc,14190,,,,,,
116125,NEXI-002,"NEXI-002|adoptive T-cell therapy (AIM ACT, multiple myeloma), NexImmune|anti-WT1/HLA-A0201 + anti-CD138/HLA-A0201 + anti-NY-ESO-1/HLA-A0201 + anti-CS1/HLA-A0201 adoptive T-cell therapy (AIM ACT, multiple myeloma), NexImmune|artificial antigen-presenting cell-based adoptive cell therapy (AIM, multiple myeloma), NexImmune|aAPC-based adoptive cell therapy (AIM, multiple myeloma), NexImmune",Research Code,Cancer,SLAM family member 7 modulator|Wilms tumor protein modulator|HLA class I antigen A-2 alpha modulator|Cancer testis antigen NY-ESO-1 modulator|Syndecan-1 modulator,45393|30009|19115|50096|5452,Anticancer|T-lymphocyte stimulator|Immunostimulant,1545|7761|393,Multiple myeloma,1828,,,NexImmune Inc,1067250,,,NexImmune Inc,1067250,,,,,,
116163,CC-99282,CC-99282,Research Code,Cancer,Protein cereblon modulator,77059,Anticancer,1545,Chronic lymphocytic leukemia|Lymphoma|Non-Hodgkin lymphoma,1734|203|319,,,Bristol-Myers Squibb Co,15065,Celgene Corp,15331,Celgene Corp,15331,,,,,,
11619,CRL-1005,"CRL-1005|Optivax|CRL-1005 (adjuvant), Vaxcel|CRL-1005 (TranzFect technology), CytRx|CRL-1005 (TranzFect technology), SynthRx",Research Code|Trade Name,Immune,,,Adjuvant,524,,,Vaccination,384,,,SynthRx Inc|CytRx Corp|Vaxcel Inc,1004439|15585|22158,Vaxcel Inc,22158,,,,,,
116266,"anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), Universiti Kebangsaan Malaysia","anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), Universiti Kebangsaan Malaysia|CD19 CAR-T Cells, Universiti Kebangsaan Malaysia",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer,393|7761|4790|1545,B-cell acute lymphoblastic leukemia,1729,,,Universiti Kebangsaan Malaysia,1018520,,,Universiti Kebangsaan Malaysia,1018520,,,,,,
11629,fluvoxamine,fluvoxamine|Depromel|DU-23000|fluvoxamine maleate|Luvox|SME-3110|Floxyfral|Fevarin|immediate-release fluvoxamine|Fluvox|Faverin|Dumirox|Favoxil|Dumyrox|Uvox|Lubox,BAN|INN|Trade Name|Research Code|USAN|Trade Name|Research Code|Trade Name|USAN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Neurology/Psychiatric,,,Antidepressant|5-HT uptake inhibitor,2941|3,Social phobia|Obsessive compulsive disorder|Depression,3150|468|93,Anxiety disorder|Bulimia nervosa,25|51,Solvay SA|Abbott Laboratories|AbbVie Inc|Meiji Seika Pharma Co Ltd,20199|13601|1072507|18049,Jazz Pharmaceuticals plc|Astellas Pharma Inc|Fujisawa Pharmaceutical Co Ltd,1007377|1013295|16227,Solvay SA,20199,,,,,,
116368,"anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma/acute lymphoblastic leukemia), University of Alberta","autologous CD19-directed chimeric antigen receptor T-cells (non-Hodgkin lymphoma/acute lymphoblastic leukemia), University of Alberta|autologous CD19-directed CAR T-cells (NHL/ALL), University of Alberta|anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma/acute lymphoblastic leukemia), University of Alberta|anti-CD19 CAR T-cell therapy (NHL/ALL), University of Alberta",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,Acute lymphoblastic leukemia|Non-Hodgkin lymphoma,1728|319,,,University of Alberta,20525,,,University of Alberta,20525,,,,,,
116391,IO-120 + IO-103,"IO-120 + IO-103|dual PD-L1-derived peptide vaccine/PD-L2-derived peptide vaccine (T-win/Montanide ISA51 adjuvant, chronic lymphocytic leukemia/follicular lymphoma), IO Biotech",Research Code,Cancer,Programmed cell death protein 2 modulator|Programmed cell death protein 1 modulator,67137|67134,Therapeutic vaccine|T-lymphocyte stimulator|Protein subunit vaccine|Anticancer,12379|7761|12372|1545,Chronic lymphocytic leukemia|Follicle center lymphoma,1734|1745,,,IO Biotech ApS,1121281,,,IO Biotech ApS,1121281,,,,,,
116458,XB-002,"ICON-2|anti-tissue factor monoclonal antibody-drug conjugate (ZymeLink ADC, solid tumors), Iconic Therapeutics|XB-002|anti-tissue factor monoclonal antibody-drug conjugate (ZymeLink ADC, solid tumors), Exelixis",Research Code|Research Code,Cancer,Tissue factor inhibitor,8039,Immunotoxin|Anticancer monoclonal antibody,539|55685,Transitional cell carcinoma|Fallopian tube cancer|Bladder cancer|Adenocarcinoma|Squamous cell carcinoma|Peritoneal tumor|Larynx tumor|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Urethral cancer|Advanced solid tumor|Metastatic ovary cancer|Ureter cancer|Uterine cervix tumor|Solid tumor|Mouth tumor|Pharynx tumor,1771|2243|2380|2399|307|3083|3198|3665|3669|3673|3678|3713|3866|4265|427|725|793|794,,,Exelis Inc,1069994,Iconic Therapeutics Inc,1014665,Iconic Therapeutics Inc,1014665,,,,,,
116485,GC-022,"GC-022|dual anti-CD19/anti-CD22 CAR T-cell therapy (B-cell acute lymphoblastic leukemia/Non-Hodgkin Lymphoma), Gracell Biotechnology|anti-CD19 + anti-CD22 CAR T-cell therapy (B-cell acute lymphoblastic leukemia/Non-Hodgkin Lymphoma), Gracell Biotechnology|GC-022F|Dual CAR-19-22",Research Code|Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte cell adhesion molecule modulator,5080|5089,Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator|Immunostimulant,4790|1545|7761|393,B-cell acute lymphoblastic leukemia|Non-Hodgkin lymphoma,1729|319,,,Gracell Biotechnology Ltd,1180179,,,Gracell Biotechnology Ltd,1180179,,,,,,
116488,GC-012,"GC-012|dual anti-BCMA/undisclosed target CAR T-cell therapy (multiple myeloma), Gracell Biotechnology|anti-BCMA + anti-undisclosed target CAR T-cell therapy (multiple myeloma), Gracell Biotechnology|GC-012F|anti-BCMA + anti-CD19 CAR T-cell therapy (multiple myeloma), Gracell Biotechnology|dual anti-BCMA/CD19 CAR T-cell therapy (multiple myeloma), Gracell Biotechnology|Dual CAR-BCMA-19",Research Code|Research Code|Research Code,Cancer,APRIL receptor modulator|B-lymphocyte antigen CD19 modulator,8255|5080,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,Multiple myeloma,1828,,,Gracell Biotechnology Ltd,1180179,,,Gracell Biotechnology Ltd,1180179,,,Aromatase Inhibitors,393,,
116527,ARS-3248,"ARS-3248|K-Ras G12C inhibitor (oral, advanced solid tumors), Wellspring Biosciences/Janssen Biotech|K-Ras G12C inhibitor (oral, advanced solid tumors), Araxes Pharma/Janssen Biotech|JNJ-74699157",Research Code|Research Code,Cancer,K-Ras GTPase inhibitor,28039,Anticancer,1545,Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,3658|3665|3713,,,Wellspring Biosciences LLC|Janssen Biotech Inc,1078509|26997,,,Wellspring Biosciences LLC,1078509,,,,,,
116568,Hu-8F4,"Hu-8F4|h8F4|anti-PR1/HLA-A2 monoclonal antibody (iv, acute myeloid leukemia), MD Anderson Cancer Center",Research Code|Research Code,Cancer,HLA class II antigen modulator,19334,Anticancer monoclonal antibody,55685,Acute myelogenous leukemia,1731,,,MD Anderson Cancer Center,23382,,,MD Anderson Cancer Center,23382,,,,,,
116606,MIDRIXNEO,"MIDRIXNEO|autologous dendritic cell vaccine (cancer), University of Ghent|autologous dendritic cell vaccine (iv, NSCLC), University of Ghent",Research Code,Cancer,,,Dendritic cell vaccine|Therapeutic vaccine|Anticancer|Genetically engineered autologous cell vaccine,102926|12379|1545|4791,Non-small-cell lung cancer,1262,Cancer,651,Universitaet Gent,24987,,,Universitaet Gent,24987,,,,,,
116615,"peptide subunit vaccine (acute lymphoblastic leukemia), University Children’s Hospital Tuebingen","peptide subunit vaccine (acute lymphoblastic leukemia), University Children’s Hospital Tuebingen",,Cancer,,,Protein subunit vaccine|Anticancer|Therapeutic vaccine,12372|1545|12379,Acute lymphoblastic leukemia,1728,,,University Children's Hospital Tuebingen,1084964,,,University Children's Hospital Tuebingen,1084964,,,,,,
116616,"anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia/Non-Hodgkin's lymphoma), University Hospital Heidelberg","anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia/Non-Hodgkin's lymphoma), University Hospital Heidelberg",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer,393|4790|7761|1545,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma,1728|1734|1744|1745|1749,,,University Hospital Heidelberg,1079364,,,University Hospital Heidelberg,1079364,,,,,,
116625,SGN-CD47M,"SGN-CD47M|CD47 checkpoint inhibitor (solid tumors), Seattle Genetics",Research Code,Cancer,CD47 antagonist,5185,Anticancer|Macrophage stimulator|Immunostimulant,1545|7751|393,Non-small-cell lung cancer|Stomach tumor|Pancreas exocrine tumor|Melanoma|Squamous cell carcinoma|Soft tissue sarcoma|Breast tumor|Head and neck tumor|Ovary tumor|Colorectal tumor,1262|127|1506|205|307|3378|49|623|799|989,,,Seagen Inc,25554,,,Seagen Inc,25554,,,,,,
116628,INA-03,INA-03,Research Code,Cancer,,,Anticancer monoclonal antibody|Unspecified drug target,55685|59620,Acute leukemia|B-cell acute lymphoblastic leukemia|T-cell acute lymphoblastic leukemia|Acute myelogenous leukemia,1727|1729|1730|1731,,,Inatherys,1069362,,,Inatherys,1069362,,,,,,
116733,YTB-323,"YTB-323|anti-CD19 CAR T-cell therapy (chronic lymphocytic leukemia/small lymphocytic lymphoma/diffuse large B-cell lymphoma), Novartis",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma,1734|1749,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
117006,Sym-024,"Sym-024|CD73 checkpoint inhibitor (Fc-attenuated, cancer), Symphogen|anti-CD73 mAb (Fc-attenuated, cancer), Symphogen",Research Code,Cancer,CD73 antagonist,5300,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody|Leukocyte stimulator,393|7761|55685|7747,Mesothelioma|Pancreatic ductal adenocarcinoma|Cholangiocarcinoma|Squamous cell carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Cancer,1240|1507|1765|307|3658|3665|3666|3667|3673|3713|651,,,Symphogen A/S,28600,,,Symphogen A/S,28600,,,,,,
117045,DCC-3116,"DCC-3116|ULK kinase inhibitor (cancer), Deciphera|autophagy inhibitors (cancer), Deciphera Pharmaceuticals|mutant RAS cancer therapy, Deciphera Pharmaceuticals",Research Code,Cancer,Ulk-1 protein kinase inhibitor,4622,Anticancer protein kinase inhibitor,62255,Pancreatic ductal adenocarcinoma|Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,1507|3257|3658|3665|3713|651,,,Deciphera Pharmaceuticals LLC,1009096,,,Deciphera Pharmaceuticals LLC,1009096,,,Thromboxane A2 Receptor (TBXA2R; TP) Antagonists|Thromboxane Synthase Inhibitors,298|503,Signal Transduction Modulators,1402
117052,INBRX-106,"ES-102|anti-OX40 antibody (cancer), Elpiscience Biopharmaceuticals|INBRX-106|OX40 costimulator (cancer), Inhibrx/Elpiscience Biopharmaceuticals|Hexavalent OX-40 agonist antibody, Inhibrx|hexavalent OX40 costimulator (cancer), Elpiscience Biopharmaceuticals/Inhibrx",Research Code|Research Code,Cancer,OX-40 receptor agonist,5443,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Non-small-cell lung cancer|Stomach tumor|Gastrointestinal tumor|Renal cell carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Melanoma|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Advanced solid tumor|Uterine cervix tumor|Head and neck tumor|Solid tumor,1262|127|131|1766|1768|1771|205|3665|3667|3713|427|623|725,Cancer,651,Inhibrx Inc|Elpiscience Biopharmaceuticals Inc,1063813|1156548,,,Inhibrx Inc,1063813,,,,,,
117067,HexaBody-CD38,HexaBody-CD38|GEN-3014,Research Code,Cancer,ADP ribosyl cyclase-1 inhibitor,5136,Anticancer monoclonal antibody|Anticancer,55685|1545,Acute myelogenous leukemia|Acute promyelocytic leukemia|Plasmacytoma|Diffuse large B-cell lymphoma|Multiple myeloma,1731|1732|1748|1749|1828,,,Genmab A/S,26469,,,Genmab A/S,26469,,,,,,
117109,HMPL-306,"HMPL-306|dual-inhibitor of Isocitrate dehydrogenase 1/2 enzymes, Hutchison Medipharma Enterprises|IDH 1/2 enzyme inhibitor, Hutchison Medipharma Enterprises",Research Code,Cancer,IDH1 gene inhibitor|IDH2 gene inhibitor,67514|67517,Anticancer,1545,Glioma|Myelodysplastic syndrome|Acute myelogenous leukemia|Cholangiocarcinoma|Hematological neoplasm|Chondrosarcoma|Advanced solid tumor|Cancer|Chronic myelomonocytic leukemia|Solid tumor,1108|1272|1731|1765|2054|2444|3713|651|6833|725,,,Hutchison Medipharma Enterprises Ltd,1011918,,,Hutchison Medipharma Enterprises Ltd,1011918,,,,,,
117448,Descartes-011,"Descartes-11|CD8-positive anti-BCMA CAR T-cell therapy (multiple myeloma/RNA Armory platform), Cartesian Therapeutics|Descartes-011",Research Code|Research Code,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,Multiple myeloma,1828,,,Cartesian Therapeutics,1158040,,,Cartesian Therapeutics,1158040,,,,,,
117477,IBI-323,"IBI-323|anti PD-L1/LAG-3 bispecific monoclonal antibody (cancer), Innovent Biologics|dual PD-L1 checkpoint inhibitor/LAG-3 checkpoint inhibitor (cancer), Innovent Biologics",Research Code,Cancer,CD223 antagonist|Programmed cell death ligand 1 inhibitor,8413|14007,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Advanced solid tumor,3713,Cancer,651,Innovent Biologics Inc,1070750,,,Innovent Biologics Inc,1070750,,,,,,
117479,IBI-939,"IBI-939|anti-TIGIT monoclonal antibody (advanced solid cancer), Innovent Biologics|TIGIT checkpoint inhibitor (iv, advanced malignancies), Innovent Biologics",Research Code,Cancer,T cell immunoreceptor Ig ITIM protein inhibitor,64787,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Small-cell lung cancer|Hematological neoplasm|Metastatic non small cell lung cancer|Advanced solid tumor,1261|2054|3665|3713,,,Innovent Biologics Inc,1070750,,,Innovent Biologics Inc,1070750,,,,,,
117545,ATL-001,"ATL-001|autologous clonal neoantigen reactive T cell therapy (iv/infusion, stage IV melanoma), Achilles Therapeutics|cNeTs therapy, Achilles Therapeutics|autologous clonal neoantigen reactive T cell therapy (iv/infusion, stage IV melanoma/NSCLC), Achilles Therapeutics",Research Code,Cancer,,,T-lymphocyte stimulator|Anticancer|Immunomodulator,7761|1545|1596,Stage IV melanoma|Metastatic non small cell lung cancer,3257|3665,,,Achilles Therapeutics Ltd,1131006,,,Achilles Therapeutics Ltd,1131006,,,,,,
117585,PD-L1 t-haNK,"PD-L1 t-haNK|PD-L1 t-haNK cell therapy (advanced solid tumors), NantKwest|next generation PD-L1 t-haNK therapy (advanced solid tumors), NantKwest|second bi-specific NK cell therapy (advanced solid tumors), NantKwest|CD16/IL-2-expressing anti-PD-L1 CAR NK-cell therapy (t-haNK, metastatic solid tumors/NSCLC), NantKwest|PD-L1 t-haNK cell therapy (metastatic solid tumors, non small cell lung cancer), NantKwest",,Cancer,Programmed cell death ligand 1 modulator,14005,Immunostimulant|Natural killer cell stimulator|Anticancer,393|7757|1545,Non-small-cell lung cancer|Metastatic breast cancer|Metastatic pancreas cancer|Advanced solid tumor,1262|3657|3669|3713,,,NantKwest Inc,1015036,,,NantKwest Inc,1015036,,,,,,
117637,SAR-442085,"SAR-442085|anti-CD38 Fc engineered mAb (multiple myeloma), Sanofi",Research Code,Cancer,ADP ribosyl cyclase-1 modulator,5134,Anticancer monoclonal antibody,55685,Multiple myeloma,1828,,,Sanofi SA,1009547,,,Sanofi SA,1009547,,,Leukotriene Receptor Antagonists|Lipoxygenase Inhibitors,237|447,Signal Transduction Modulators,1402
117786,"dual anti-CD19/anti-CD20 CAR T-cells (chronic lymphocytic leukemia/B-cell lymphomas), NCI","CD19/CD20 CAR-T cells|bispecific anti-CD19/anti-CD20 CAR T-cell therapy (B-cell lymphomas/CLL/MCL/FL/DLBCL/NHL/PMBCL), National Cancer Institute|dual anti-CD19/anti-CD20 CAR T-cells (chronic lymphocytic leukemia/B-cell lymphomas), NCI",,Cancer,B-lymphocyte antigen CD20 modulator|B-lymphocyte antigen CD19 modulator,5083|5080,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Hodgkins disease|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,161|1734|1744|1745|1749|1750|316|319,,,National Cancer Institute (NCI),20519,,,National Cancer Institute (NCI),20519,,,,,,
117894,ELI-002,"ELI-002|amphiphile vaccine (pancreatic/colorectal/non-small cell lung cancers), Elicio Therapeutics|KRAS gene mutation targeted vaccine (pancreatic/colorectal/non-small cell lung cancer), Elicio Therapeutics|VED-002|AMP KRAS vaccine|ELI-002 lymph node immunotherapy",Research Code|Research Code,Cancer,K-Ras GTPase stimulator,28038,Therapeutic vaccine|Immunomodulator|Anticancer,12379|1596|1545,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Endometrioid carcinoma|Cholangiocarcinoma|Pancreas tumor|Solid tumor|Ovary tumor|Colorectal tumor,1262|1507|1705|1765|249|725|799|989,,,Elicio Therapeutics,1183532,,,Elicio Therapeutics,1183532,,,,,,
117960,"fosmanogepix (oral, fungal infections), Amplyx/Pfizer","E-1210|glycosylphosphatidylinositol biosynthesis inhibitor (fungal infection), Eisai|nicotinamide derivatives (glycosylphosphatidylinositol biosynthesis inhibitor), Eisai Co Ltd|APX-001, Amplyx|APX-001A|fosmanogepix|fosmanogepix (oral, fungal infections), Amplyx/Pfizer",Research Code|Research Code|USAN|INN,Infection,GPI anchored wall transfer protein 1 inhibitor,89147,Fungicide,1748,Fungal infection|Candida infection|Blastomyces infection|Coccidioides infection|Fusarium infection|Scedosporium infection|Mucorales infection|Mucor infection|Rhizopus infection|Aspergillus infection|Cryptococcus infection,124|1308|1322|1323|1337|1347|1376|1380|1382|29|85,,,Amplyx Pharmaceuticals Inc,1032319,Eisai Co Ltd,15872,Eisai Co Ltd,15872,,Cyclosporine G|Geclosporin,,,,
118029,PBCAR-20A,"PBCAR-20A|allogeneic CAR T-cell therapy (ARCUS, Non-Hodgkin lymphoma/chronic lymphocytic leukemia/small lymphocytic leukemia), Precision BioSciences/Servier|anti-CD20 CAR T-cell therapy (ARCUS, Non-Hodgkin lymphoma/chronic lymphocytic leukemia/small lymphocytic leukemia), Precision BioSciences/Servier",Research Code,Cancer,B-lymphocyte antigen CD20 modulator,5083,Anticancer|T-lymphocyte stimulator|Immunostimulant,1545|7761|393,Chronic lymphocytic leukemia|Mantle cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Cancer,1734|1744|316|319|651,,,Precision BioSciences Inc,1032090,Servier,19863,Precision BioSciences Inc,1032090,,,,,,
11805,"Equine antithymocyte immunoglobulin, Pfizer","lymphocyte immune globulin, anti-thymocyte globulin (equine), Pharmacia & Upjohn|Atgam|Equine antithymocyte immunoglobulin, Pfizer|PF-06462700|anti-thymocyte equine immunoglobulin C-15 (aplastic anemia), Pfizer",Trade Name|Research Code,Hematologic|Immune,,,Therapeutic antibody|Immunosuppressant|T-lymphocyte inhibitor,172641|396|7760,Aplastic anemia|Transplant rejection,1006|515,,,Pharmacia & Upjohn Inc|Pfizer Inc,22006|18767,,,Pharmacia & Upjohn Inc,22006,,,,,,
118109,"anti-CD7 CAR T-cell therapy (CD7-positive hematological malignancies), Shenzhen Geno-Immune Medical Institute","multiple CAR T-cell therapy (hematological malignancies), Shenzhen Geno-Immune Medical Institute|anti-CD7 CAR T-cell therapy (CD7-positive hematological malignancies), Shenzhen Geno-Immune Medical Institute",,Cancer,T-cell antigen CD7 modulator,5035,T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy|Immunostimulant,7761|1545|4790|393,T-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Lymphoma|T-cell lymphoma,1730|1731|203|311,,,Shenzhen Geno-Immune Medical Institute,1130728,,,Shenzhen Geno-Immune Medical Institute,1130728,,,,,,
118113,GI-101,"GI-101|dual PD-L1/CTLA-4  checkpoint inhibitor + CD28 costimulator + IL2 fusion protein (cancer), GI Innovation|SIM-323",Research Code|Research Code,Cancer,IL-2 receptor agonist|Programmed cell death ligand 1 inhibitor|T cell surface glycoprotein CD28 stimulator|Cytotoxic T-lymphocyte protein-4 inhibitor,221|14007|5105|5482,Natural killer cell stimulator|Apoptosis inhibitor|T-lymphocyte stimulator|Immunostimulant|Anticancer antibody,7757|1590|7761|393|55684,Advanced solid tumor|Cancer|Solid tumor,3713|651|725,,,GI Innovation Inc|Simcere Pharmaceutical Group,1190832|1023261,,,GI Innovation Inc,1190832,,,,,,
118125,JAB-3312,"JAB-3312|KRAS-MAPK pathway small molecule blocker (capsule formulation), Jacobio Pharmaceuticals|SHP2 inhibitor (oral, solid tumors), Jacobio Pharmaceuticals",Research Code,Cancer,Protein tyrosine phosphatase-2C inhibitor,10327,Anticancer protein kinase inhibitor,62255,Esophagus tumor|Pancreas tumor|Squamous cell carcinoma|Metastatic non small cell lung cancer|Advanced solid tumor|Breast tumor|Head and neck tumor|Solid tumor|Colorectal tumor,1011|249|307|3665|3713|49|623|725|989,,,Jacobio Pharmaceuticals Co Ltd|AbbVie Inc,1157883|1072507,,,Jacobio Pharmaceuticals Co Ltd,1157883,,,,,,
118249,VRC-EBOADC086-00-VP,"VRC-EBOADC086-00-VP|cAd3-EBO S|adenoviral vector vaccine (im, Ebola virus infection), NIAID/MHRP",,Infection,,,Protein subunit vaccine|Recombinant viral vector vaccine|Prophylactic vaccine,12372|12370|12378,Ebola virus infection,1049,,,US Military HIV Research Program|National Institute of Allergy and Infectious Diseases|Sabin Vaccine Institute,1073709|20520|30792,,,National Institute of Allergy and Infectious Diseases,20520,,,,,,
118267,CB-5339,"CB-5339|valosin-containing protein (VCP)/p97 enzyme inhibitor (oral, acute myeloid leukemia/solid tumor), Cleave Therapeutics|CB-5339 Tosylate|valosin-containing protein (VCP)/p97 enzyme inhibitor (oral, acute myeloid leukemia/solid tumor/non-Hodgkin lymphoma/myelodysplastic syndrome), Cleave Therapeutics|valosin-containing protein (VCP)/p97 enzyme inhibitor (oral, acute myeloid leukemia/advanced solid tumor/non-Hodgkin lymphoma/myelodysplastic syndrome/lymphoma), Cleave Therapeutics",Research Code,Cancer,AAA ATPase inhibitor|Transitional endoplasmic ATPase inhibitor,36013|26608,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Lymphoma|Non-Hodgkin lymphoma|Advanced solid tumor,1272|1731|203|319|3713,Solid tumor,725,CASI Pharmaceuticals Inc|Cleave Therapeutics Inc,21794|1065450,,,Cleave Therapeutics Inc,1065450,,,,,,
118268,KL-A264,"KL-A264|TROP-2-targeted antibody-drug conjugate (solid tumor), Sichuan Kelun-Biotech Biopharmaceutical|SKB-264|A-264",Research Code|Research Code|Research Code,Cancer,Trop-2 calcium signal transducer modulator|Topoisomerase inhibitor,17893|143,Anticancer monoclonal antibody,55685,Stomach tumor|Bladder cancer|Advanced solid tumor|Breast tumor|Ovary tumor,127|2380|3713|49|799,,,Sichuan Kelun Pharmaceutical Co Ltd,1039722,,,Sichuan Kelun Pharmaceutical Co Ltd,1039722,,,,,,
118275,ociperlimab,"BGB-A1217|TIGIT checkpoint inhibitor (advanced solid tumors), BeiGene|anti-TIGIT monoclonal antibody (advanced solid tumors), BeiGene|ociperlimab",Research Code|PINN,Cancer,T cell immunoreceptor Ig ITIM protein inhibitor,64787,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Esophagus tumor|Small-cell lung cancer|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Squamous cell carcinoma|Metastatic non small cell lung cancer|Advanced solid tumor|Uterine cervix tumor,1011|1261|1767|1768|307|3665|3713|427,,,BeiGene Co Ltd,1063251,,,BeiGene Co Ltd,1063251,,,,,,
118377,ASP-7517,"ASP-7517|artificial adjuvant vector cells loaded with WT1 (cancer), Astellas",Research Code,Cancer,Wilms tumor protein modulator,30009,Anticancer|Immunostimulant,1545|393,Myelodysplastic syndrome|Acute myelogenous leukemia|Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic ovary cancer,1272|1731|3257|3658|3665|3713|3866,Cancer,651,Astellas Pharma Inc,1013295,,,Astellas Pharma Inc,1013295,,,,,,
118428,CM-313,CM-313,Research Code,Cancer,,,Anticancer monoclonal antibody|Unspecified drug target,55685|59620,Multiple myeloma|Lymphoma|Hematological neoplasm,1828|203|2054,Cancer,651,KeyMed Biosciences Co Ltd,1186427,,,KeyMed Biosciences Co Ltd,1186427,,,,,,
118479,CTA-101,"CTA-101|anti-CD19/anti-CD22 CAR T-cell therapy (UCAR, B-cell acute lymphoblastic leukemia/diffuse large B-cell lymphoma), Nanjing Bioheng Biotech|CTA-101 UCART|CTA-301|CTA-30X",Research Code|Research Code|Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte cell adhesion molecule modulator,5080|5089,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,B-cell acute lymphoblastic leukemia|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1729|1749|319,,,Nanjing Bioheng Biotech Co Ltd,1164786,,,Nanjing Bioheng Biotech Co Ltd,1164786,,,,,,
118574,HH-2710,"HH-2710|ERK1/2 inhibitor ( oral capsule, advanced tumors), HaiHe Biopharma/Shanghai Institute of Materia Medica of the Chinese Academy of Sciences",Research Code,Cancer|Cardiovascular,Extracellular signal related kinase inhibitor,173760,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Metastasis|Gsell Erdheim syndrome|Melanoma|Metastatic non small cell lung cancer,1069|1859|205|3665,,,Shanghai Institute of Materia Medica of the Chinese Academy of Sciences|HaiHe Biopharma,25314|1181217,,,HaiHe Biopharma,1181217,,,,,,
118577,PY-314,"PY-314|TREM2 modulator ((Myeloid Tuning, cancer), Pionyr Immunotherapeutics|Macrophage modulator (Myeloid Tuning, cancer), Pionyr Immunotherapeutics|PI-103 inhibitor (Myeloid Tuning, cancer), Pionyr Immunotherapeutics|anti PI-103 monoclonal antibody (Myeloid Tuning, cancer), Pionyr Immunotherapeutics|anti PI-103 monoclonal antibody (Myeloid Tuning, advanced solid tumor), Pionyr Immunotherapeutics",Research Code,Cancer,Phosphoinositide 3-kinase inhibitor|TREM receptor 2 modulator,1575|54428,Macrophage modulator|Immunostimulant|Anticancer monoclonal antibody|Anticancer,5662|393|55685|1545,Endometrioid carcinoma|Vaginal tumor|Metastatic renal cancer|Metastatic breast cancer|Metastatic stomach cancer|Metastatic lung cancer|Metastatic colon cancer|Metastatic ovary cancer|Uterine cervix tumor,1705|3293|3467|3657|3666|3668|3672|3866|427,Solid tumor,725,Pionyr Immunotherapeutics Inc,1121635,,,Pionyr Immunotherapeutics Inc,1121635,,,,,,
118627,"HLA-A2402-restricted URLC10, CDCA1 and KIF20A epitope peptide vaccine (non-small cell lung cancer), University of Tokyo","HLA-A2402-restricted URLC10, CDCA1 and KIF20A epitope peptide vaccine (non-small cell lung cancer), University of Tokyo|URLC10 + CDCA1 + KIF20A-derived HLA-A2402-restricted epitope peptide multiple vaccine (NSCLC), University of Tokyo",,Cancer,HLA class I antigen A-24 alpha modulator|Kinesin like protein 20A modulator,19127|64114,Therapeutic vaccine|Protein subunit vaccine|Anticancer,12379|12372|1545,Non-small-cell lung cancer,1262,,,University of Tokyo,20686,,,University of Tokyo,20686,,,,,,
118679,BAY-2416964,"BAY-2416964|AhR inhibitor (advanced solid tumor), Bayer",Research Code,Cancer,Aryl hydrocarbon receptor antagonist,11775,Immunomodulator|Anticancer,1596|1545,Non-small-cell lung cancer|Squamous cell carcinoma|Advanced solid tumor|Colorectal tumor,1262|307|3713|989,,,Bayer AG,14455,,,Bayer AG,14455,,,,,,
118688,"allogeneic CD56-positive CD3-negative natural killer cells (myeloid malignancies), MD Anderson Cancer Center/National Cancer Institute","allogeneic CD56-positive CD3-negative natural killer cells (myeloid malignancies), MD Anderson Cancer Center/National Cancer Institute",,Cancer,,,Anticancer|Natural killer cell stimulator|Immunostimulant,1545|7757|393,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia|Chronic myelomonocytic leukemia,1272|1731|1735|6833,,,National Cancer Institute (NCI)|MD Anderson Cancer Center,20519|23382,,,MD Anderson Cancer Center,23382,,,,,,
118724,211[At]-OKT10-B10,"211[At]-OKT10-B10|211-At labelled anti-CD38 monoclonal antibody (multiple myeloma), Fred Hutchinson Cancer Research Center|Astatine 211-labeled Anti-CD38 Monoclonal Antibody OKT10-B10|Astatine At 211 Anti-CD38 MoAb OKT10-B10|Astatine-211-OKT10-B10|At211-OKT10-B10",,Cancer,,,Radioimmunotherapeutic|Anticancer monoclonal antibody,1552|55685,Multiple myeloma,1828,,,Fred Hutchinson Cancer Research Center,16218,,,Fred Hutchinson Cancer Research Center,16218,,,,,,
118737,REGN-5093,REGN-5093,Research Code,Cancer,,,Unspecified drug target|Anticancer,59620|1545,Metastatic non small cell lung cancer,3665,,,Regeneron Pharmaceuticals Inc,19214,,,Regeneron Pharmaceuticals Inc,19214,,,,,,
11879,triptolide,PG-27|PG-490|triptolide,Research Code|Research Code,Immune,,,Immunosuppressant|Cytokine synthesis inhibitor|T-lymphocyte inhibitor,396|940|7760,,,Autoimmune disease,36,,,Pharmagenesis Inc|PhytoHealth Corp,19060|30020,Pharmagenesis Inc,19060,,,,,,
11880,PG-2,PG-2|PHN-011|PHN-012|PHN-013|PHN-014|PHN-015|XueBao,Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name,Cancer|Hematologic|Neurology/Psychiatric|Other/Miscellaneous,,,Unspecified drug target|Anticancer|Hematopoietic stimulator,59620|1545|610,Thrombocytopenic purpura|Ischemic stroke|Cachexia|Stroke|Fatigue,1133|3676|425|65|829,Metastasis|Thrombocytopenia|Leukopenia,1069|324|680,Pharmagenesis Inc|PhytoHealth Corp,19060|30020,,,Pharmagenesis Inc,19060,,,,,,
118841,VRC-MARADC087-00-VP,"cAd3-Marburg|VRC-MARADC087-00-VP|ChAd3-MARV|ChAd3-Marburg|recombinant adenovirus type-3 vector vaccine (intramuscular, Marburg virus infection), National Institute of Allergy and Infectious Diseases/GlaxoSmithKline/Sabin Vaccine Institute",Research Code,Infection,,,Recombinant viral vector vaccine|Protein subunit vaccine|Prophylactic vaccine,12370|12372|12378,Marburg virus infection,1048,,,National Institute of Allergy and Infectious Diseases|Sabin Vaccine Institute,20520|30792,ReiThera Srl|GlaxoSmithKline plc,1035490|28355,National Institute of Allergy and Infectious Diseases,20520,,,,,,
118853,MIDRIX4-LUNG,"MIDRIX4-LUNG|tetravalent autologous dendritic cell vaccine (iv, NSCLC), University of Ghent",,Cancer,,,Therapeutic vaccine|Anticancer|Genetically engineered autologous cell vaccine|Dendritic cell vaccine,12379|1545|4791|102926,Non-small-cell lung cancer,1262,,,Universitaet Gent,24987,,,Universitaet Gent,24987,,,,,,
118858,DSP-107,"dual CD47 checkpoint inhibitor/4-1BB costimulator (intravenous infusion, metastatic non small cell lung cancer/squamous cell carcinoma/advanced solid tumor), KAHR|SIRPalpha-4-1BBL|DSP-107",Research Code,Cancer,CD47 antagonist|CDw137 agonist,5185|5450,Macrophage stimulator|Anticancer|Natural killer cell stimulator|T-lymphocyte stimulator|Immunostimulant,7751|1545|7757|7761|393,Diffuse large B-cell lymphoma|Squamous cell carcinoma|Metastatic non small cell lung cancer|Advanced solid tumor,1749|307|3665|3713,Cancer,651,KAHR Medical Ltd,1039221,,,KAHR Medical Ltd,1039221,,,,,,
11886,"histamine dihydrochloride (subcutaneous, cancer), Immune Pharmaceuticals","histamine dihydrochloride|Maxamine|EpiLeukin|histamine dihydrochloride (subcutaneous), Maxim|histamine|histamine dihydrochloride (subcutaneous), Meda|Ceplene|histamine dihydrochloride (subcutaneous, cancer), Meda/EpiCept|histamine dihydrochloride (subcutaneous, cancer), Immune Pharmaceuticals",Trade Name|Trade Name,Cancer|Gastrointestinal|Infection,Histamine H2 receptor agonist|NADPH oxidase 2 inhibitor,200|32334,Antiviral|T-lymphocyte stimulator|Natural killer cell stimulator|Anticancer|Natural killer T-lymphocyte stimulator|Immunostimulant,991|7761|7757|1545|173716|393,Acute myelogenous leukemia|Chronic myelocytic leukemia,1731|1735,Herpesvirus infection|Myelodysplastic syndrome|Hepatitis C virus infection|Herpes simplex virus infection|Renal cell carcinoma|Liver disease|Melanoma|Prostate tumor|Metastatic renal cell carcinoma|Cancer,1124|1272|153|157|1766|201|205|276|4250|651,Immune Pharmaceuticals Inc|Pint Pharma|MegaPharm Ltd,1053945|1110054|26786,Meda AB|Estero-Anstalt|Maxim Pharmaceuticals Inc|EpiCept Corp,18954|21493|23065|27183,Estero-Anstalt,21493,,,,,,
118869,REGN-5459,"REGN-5459|BCMAxCD3 bispecific antibody (intravenous, multiple myeloma), Regeneron|anti-CD3/anti-BCMA bispecific T-cell engager (multiple myeloma), Regeneron",Research Code,Cancer,CD3 modulator|APRIL receptor modulator,5023|8255,Immunostimulant|T-lymphocyte stimulator|Anticancer antibody,393|7761|55684,Multiple myeloma,1828,,,Regeneron Pharmaceuticals Inc,19214,,,Regeneron Pharmaceuticals Inc,19214,,,,,,
118887,ACE-1702,"ACE-1702|oNK program (recurrent ovarian/endometrial/breast cancers), Acepodia|Antibody mediated effector T-cell therapies (cancer), Acepodia|JWACE-002",Research Code|Research Code,Cancer,Erbb2 tyrosine kinase receptor inhibitor,3756,Anticancer protein kinase inhibitor|Immunostimulant|Natural killer T-lymphocyte stimulator|Anticancer monoclonal antibody,62255|393|173716|55685,Endometrioid carcinoma|Metastatic breast cancer|Metastatic stomach cancer|Advanced solid tumor|Breast tumor|Solid tumor|Ovary tumor,1705|3657|3666|3713|49|725|799,,,JW Therapeutics (Shanghai) Co Ltd|Acepodia Inc,1122031|1115895,,,Acepodia Inc,1115895,,,,,,
118964,"anti-CD22 CAR T-cell therapy (B-cell lymphoma), Stanford University","anti-CD22 CAR T-cell therapy (B-cell lymphoma), Stanford University|anti-CD22 CAR T-cell therapy (B-cell lymphoma/pediatric acute lymphoblastic leukemia/non-hodgkin lymphoma/DLBCL), Stanford University",,Cancer,B-lymphocyte cell adhesion molecule modulator,5089,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,B-cell acute lymphoblastic leukemia|Diffuse large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1729|1749|316|319,,,Stanford University,20679,,,Stanford University,20679,,Thiarubrine A,,,,
119012,BCMA-UCART,"BCMA-UCART|anti-BCMA CAR T-cell therapy (allogeneic, UCAR technology, multiple myeloma), Shanghai Bioray Laboratory",Research Code,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,Multiple myeloma,1828,,,Shanghai Bioray Laboratory Inc,1151487,,,Shanghai Bioray Laboratory Inc,1151487,,,,,,
119079,TTX-080,"TTX-080|immune checkpoint inhibitor (cancer), Tizona Therapeutics|anti-HLA-G antibody (cancer), Tizona Therapeutics",Research Code,Cancer,HLA class I antigen alpha G inhibitor,19330,Anticancer|T-lymphocyte stimulator|Immunostimulant|Anticancer antibody,1545|7761|393|55684,Metastasis|Advanced solid tumor|Cancer,1069|3713|651,,,Tizona Therapeutics Inc,1114602,,,Tizona Therapeutics Inc,1114602,,,,,,
119095,ICG-132,"dual anti-CD19/anti-CD20 CAR T-cell therapy (B-cell malignancies), iCell Gene Therapeutics|ICG-132|CD20-CD19 cCAR",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte antigen CD20 modulator,5080|5083,Anticancer|Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,1545|393|4790|7761,B-cell lymphoma,316,,,iCell Gene Therapeutics,1124295,,,iCell Gene Therapeutics,1124295,,,,,,
119107,BDTX-189,"BDTX-189|ErbB1 and ErbB2 tyrosine kinase modulators (oral, cancer), Black Diamond",Research Code,Cancer,Epidermal growth factor receptor antagonist|Erbb2 tyrosine kinase receptor inhibitor,740|3756,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Advanced solid tumor,3713,Cancer,651,Black Diamond Therapeutics Inc,1103522,,,Black Diamond Therapeutics Inc,1103522,,,,,,
119110,"CC-1, German Cancer Research Center/University Hospital Tubingen","PSMAxCD3 bispecific antibody (hormone refractory prostate cancer), German Cancer Research Center/University Hospital Tubingen|CC-1, German Cancer Research Center/University Hospital Tubingen|anti-CD3/anti-PSMA bispecific T-cell engager (hormone refractory prostate cancer), German Cancer Research Center/University Hospital Tubingen",Research Code,Cancer,CD3 modulator|Glutamate carboxypeptidase II modulator,5023|9267,T-lymphocyte stimulator|Immunostimulant|Anticancer antibody,7761|393|55684,Squamous cell carcinoma|Hormone refractory prostate cancer|Metastatic non small cell lung cancer,307|3246|3665,,,University Hospital Tubingen|Deutsches Krebsforschungszentrum DKFZ,1039869|23844,,,Deutsches Krebsforschungszentrum DKFZ,23844,,,,,,
119195,BI-1701963,BI-1701963,Research Code,Cancer,Son of sevenless homolog 1 inhibitor|K-Ras GTPase modulator,44636|28037,Anticancer,1545,Adenocarcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,2399|3658|3665|3713,,,Boehringer Ingelheim International GmbH,14881,FORMA Therapeutics Inc,1043304,FORMA Therapeutics Inc,1043304,,,,,,
11920,indisulam,"indisulam|E-7070|ER-35744|sulfonamide indisulam analogs, Eisai",USAN|INN|Research Code|Research Code,Cancer,Carbonic anhydrase modulator,1266,Anticancer|Apoptosis stimulator|Cell cycle inhibitor,1545|1589|767,,,Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Melanoma|Hematological neoplasm|Metastatic renal cell carcinoma|Breast tumor|Cancer|Solid tumor|Lung tumor|Colon tumor,1261|1262|127|205|2054|4250|49|651|725|755|767,,,Eisai Co Ltd,15872,Eisai Co Ltd,15872,,,,,,
119318,WVT-078,"WVT-078|anti-CD3/anti-BCMA T-cell engager (intravenous, multiple myeloma), Novartis|CD3/BCMA bispecific T-cell engager antibody (intravenous, multiple myeloma), Novartis",Research Code,Cancer,CD3 modulator|APRIL receptor modulator,5023|8255,T-lymphocyte stimulator|Immunostimulant|Anticancer antibody,7761|393|55684,Multiple myeloma,1828,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
119329,TQB-3602,"TQB-3602|proteasome inhibitor (oral capsule, relapsed/refractory multiple myeloma), Chia Tai Tianqing Pharmaceutical Group",Research Code,Cancer,Proteasome inhibitor,4917,Anticancer,1545,Multiple myeloma,1828,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,,,,,,
119449,"anti-mutated neoantigen TCR T-cell therapy (sleeping beauty transposon/transposase, cancer), Ziopharm/National Cancer Institute","anti-mutated neoantigen TCR T-cell therapy (sleeping beauty transposon/transposase, cancer), Ziopharm/National Cancer Institute",,Cancer,HLA antigen modulator,19106,Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer,393|4790|7761|1545,Cholangiocarcinoma|Glioblastoma|Metastatic gastrointestinal cancer|Metastatic genitourinary cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer,1765|2454|3460|3464|3657|3658|3665|3669|3713|3866,,,National Cancer Institute (NCI)|Precigen Inc (pre-merger)|ZIOPHARM Oncology Inc,20519|1144880|1009856,Precigen Inc,1021778,National Cancer Institute (NCI),20519,,,,,,
119539,personalized neoantigen peptide-based vaccine,"personalized neoantigen peptide-based vaccine|neoantigen peptide-based vaccine (NSCLC), Tianjin HengJia Biotechnology Development Co Ltd/The University of Texas MD Anderson Cancer Center/Nankai University|HJ-N-001",Research Code,Cancer,,,Anticancer|Protein subunit vaccine|Genetically engineered autologous cell vaccine|Immunostimulant|Therapeutic vaccine,1545|12372|4791|393|12379,Non-small-cell lung cancer,1262,,,MD Anderson Cancer Center|Nankai University|Tianjin HengJia Biotechnology Development Co Ltd,23382|1021149|1197786,,,Tianjin HengJia Biotechnology Development Co Ltd,1197786,,,,,,
11961,erlotinib,"CP-358774|erlotinib|OSI-744|OSI-420|Ro-50-8231|CP-358774-01|angiogenesis therapy, OSI/Genentech/Roche|NSC-718781|erlotinib hydrochloride|OSI-774|R-1415|Tarceva|RG-1415",Research Code|INN|Research Code|Research Code|Metabolite|Research Code|Research Code|Research Code|USAN|Research Code|Research Code|Trade Name|Research Code,Cancer|Dermatologic,Epidermal growth factor receptor antagonist|EGFR family tyrosine kinase receptor inhibitor,740|3754,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Acute myelogenous leukemia|Pancreas tumor|Metastatic colorectal cancer|Breast tumor|Head and neck tumor|Solid tumor,1262|1731|249|3658|49|623|725,Esophagus tumor|Glioma|Myelodysplastic syndrome|Renal cell carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Glioblastoma|Ependymoma|Psoriasis|Squamous cell carcinoma|Metastatic breast cancer|Hepatobiliary system tumor|Cancer|Ovary tumor|Colorectal tumor,1011|1108|1272|1766|1767|1768|2454|2455|281|307|3657|629|651|799|989,Astellas Pharma Inc|Roche Holding AG|OSI Pharmaceuticals Inc|Baheal Pharmaceutical group|Chugai Pharmaceutical Co Ltd|Genentech Inc,1013295|19446|18676|1165685|15414|19453,Pfizer Inc|Nippon Roche KK,18767|19447,OSI Pharmaceuticals Inc,18676,,,,,,
119626,LP-108,"LP-108|small molecule therapeutic (oral, myelodysplastic syndromes/chronic myelomonocytic leukemia/acute myeloid leukemia), Newave Pharmaceutical|Bcl-2 protein inhibitorr (cancer), Guangzhou Lupeng Pharmaceutical/Newave Pharmaceutical|small molecule therapeutic (oral, myelodysplastic syndromes/chronic myelomonocytic leukemia/acute myeloid leukemia/ALL/leukemia), Newave Pharmaceutical",Research Code,Cancer,Bcl-2 protein inhibitor,16111,Anticancer protein kinase inhibitor,62255,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Leukemia|B-cell lymphoma|Chronic myelomonocytic leukemia,1272|1728|1731|199|316|6833,Cancer,651,Newave Pharmaceutical LLC|Guangzhou Lupeng Pharmaceutical Co Ltd,1127022|1200314,,,Newave Pharmaceutical LLC,1127022,,,,,,
119666,RG-6139,"RO-7247669|anti PD-1/LAG-3 bispecific antibody (advanced solid tumor), Roche|dual PD-1 checkpoint inhibitor/LAG-3 checkpoint inhibitor (advanced solid tumor), Roche|RG-6139|anti-PD1 x LAG3 (solid tumors), Roche|anti PD-1/LAG-3 bispecific antibody (advanced solid tumor/esophageal squamous cell carcinoma), Roche",Research Code|Research Code,Cancer,CD223 antagonist|Programmed cell death protein 1 inhibitor,8413|67136,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Squamous cell carcinoma|Metastatic esophageal cancer|Advanced solid tumor,307|3667|3713,,,Roche Holding AG,19446,,,Roche Holding AG,19446,,,,,,
119748,NEXI-001,"NEXI-001|adoptive T-cell therapy (AIM ACT, acute myeloid leukemia/myelodysplastic syndrome), NexImmune|anti-WT1/HLA-A0201 + anti-Prame/HLA-A0201 + anti-Cyclin A1/HLA-A0201 adoptive T-cell therapy (AIM ACT, acute myeloid leukemia/myelodysplastic syndrome), NexImmune|artificial antigen-presenting cell-based adoptive cell therapy (AIM, acute myeloid leukemia/myelodysplasic syndrome), NexImmune|aAPC-based adoptive cell therapy (AIM, acute myeloid leukemia/myelodysplasic syndrome), NexImmune",Research Code,Cancer,Cyclin A1 modulator|Wilms tumor protein modulator|HLA class I antigen A-2 alpha modulator|Tumor expressed melanoma antigen modulator,9445|30009|19115|18578,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,NexImmune Inc,1067250,,,NexImmune Inc,1067250,,,,,,
11978,picoplatin,AMD-473|Nexplatin|picoplatin|NX-473|ZD-0473|JM-473,Research Code|USAN|BANN|INN|Research Code|Research Code|Research Code,Cancer,,,Anticancer alkylating agent|DNA synthesis inhibitor|Anticancer,50|140|1545,Squamous cell carcinoma|Colorectal tumor,307|989,Small-cell lung cancer|Hormone refractory prostate cancer|Solid tumor|Lung tumor|Ovary tumor,1261|3246|725|755|799,Accelerated Pharma Inc,1138566,AstraZeneca plc|Zeneca Group plc|Johnson Matthey plc|Poniard Pharmaceuticals Inc|AnorMED Inc|Cancer Research Campaign Technology Ltd,14190|16955|17609|18472|23816|24077,Johnson Matthey plc,17609,,,,,,
119815,TAK-676,"TAK-676|STING agonist (cancer), Takeda Oncology",Research Code,Cancer,Stimulator of interferon genes protein stimulator,89933,Immunostimulant|Anticancer|T-lymphocyte stimulator|Dendritic cell stimulator,393|1545|7761|173472,Advanced solid tumor|Head and neck tumor|Cancer,3713|623|651,,,Takeda Oncology,21991,,,Takeda Oncology,21991,,,,,,
119869,LY-3475070,"LY-3475070|CD73 checkpoint inhibitor (oral, advanced solid tumor), Eli Lilly|CD73 inhibitor (cancer), Eli Lilly",Research Code,Cancer,CD73 antagonist,5300,Immunostimulant|T-lymphocyte stimulator|Anticancer,393|7761|1545,Stage IV melanoma|Metastatic renal cancer|Metastatic breast cancer|Metastatic prostate cancer|Metastatic lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer,3257|3467|3657|3664|3668|3669|3713|3866,,,Eli Lilly & Co,17810,,,Eli Lilly & Co,17810,,,,,,
119870,CPL-304-110,"CPL-304-110|PG-19|fibroblast growth factor receptor inhibitor (advanced solid malignancies), Celon Pharma|fibroblast growth factor receptor inhibitor (gastric cancer/bladder cancer/squamous non-small cell lung cancer/cholangiocarcinoma/sarcoma/endometrial/ovarian cancer), Celon Pharma",Research Code,Cancer,FGF receptor antagonist,168,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Cholangiocarcinoma|Sarcoma|Bladder cancer|Squamous cell carcinoma|Metastatic bladder cancer|Metastatic stomach cancer|Advanced solid tumor|Lung tumor|Ovary tumor,1262|127|1705|1765|194|2380|307|3466|3666|3713|755|799,,,Celon Pharma SP,1018191,,,Celon Pharma SP,1018191,,,,,,
119871,TPX-0131,"ALK inhibitors (non-small cell lung cancer), Turning Point Therapeutics|TPX-0131",Research Code,Cancer,Anaplastic lymphoma kinase receptor inhibitor,3736,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer,1262,,,Turning Point Therapeutics Inc,1112197,,,Turning Point Therapeutics Inc,1112197,,,,,,
119930,PF-06940434,PF-06940434,Research Code,Cancer,Integrin alpha-V/beta-8 antagonist,6077,Anticancer,1545,Biliary cancer|Endometrioid carcinoma|Transitional cell carcinoma|Squamous cell carcinoma|Stage IV melanoma|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Metastatic ovary cancer|Metastatic renal cell carcinoma,1516|1705|1771|307|3257|3666|3667|3668|3669|3673|3866|4250,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
120005,BGB-11417,"BGB-11417|Bcl-2 inhibitor (oral film-coated tablets, B-cell lymphomas), BeiGene",Research Code,Cancer,Bcl-2 protein inhibitor,16111,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1272|1731|1734|1745|1747|1749|316|319,,,BeiGene Co Ltd,1063251,,,BeiGene Co Ltd,1063251,,,beta-Adrenoceptor Antagonists|alpha-Adrenoceptor Antagonists,44|35,Signal Transduction Modulators,1402
120013,ICG-134,"CD19 CARvac T cells|anti-CD19 CAR T-cell therapy + tumor vaccine (CARvac, B-cell lymphoma/B cell leukemia), iCell Gene Therapeutics/iCAR Bio|ICG-134",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|T-lymphocyte stimulator|Therapeutic vaccine|Immunostimulant,1545|7761|12379|393,Leukemia|B-cell lymphoma,199|316,,,iCar Bio Therapeutics Ltd|iCell Gene Therapeutics,1195729|1124295,,,iCell Gene Therapeutics,1124295,,,,,,
120016,KP-1237,"CD38-ARM|KP-1237|CD38 targeting antibody recruiting molecule (short acting, relapsed/refractory multiple myeloma), Kleo Pharmaceuticals/PeptiDream",Research Code|Research Code,Cancer,ADP ribosyl cyclase-1 modulator,5134,Natural killer cell stimulator|Immunostimulant|Macrophage stimulator|Therapeutic antibody|Anticancer,7757|393|7751|172641|1545,Multiple myeloma,1828,,,Kleo Pharmaceuticals Inc|PeptiDream Inc,1129154|1061958,,,Kleo Pharmaceuticals Inc,1129154,,,,,,
120018,CART-ddBCMA,"CART-ddBCMA|anti-BCMA CAR T-cell therapy (multiple myeloma), Arcellx|BCMA-targeted CAR T-cell therapy (iv, relapsed/refractory multiple myeloma), Arcellx",Research Code,Cancer,APRIL receptor modulator,8255,Anticancer|Genetically engineered autologous cell therapy|Immunostimulant|T-lymphocyte stimulator,1545|4790|393|7761,Multiple myeloma,1828,,,Arcellx Inc,1131314,,,Arcellx Inc,1131314,,,Calcium Channel Blockers,361,,
120028,BCMA-CS1 cCAR,"BCMA-CS1 cCAR|dual anti-BCMA/anti-CS1 CAR T-cell therapy (multiple myeloma), iCell Gene Therapeutics/iCAR Bio Therapeutics",,Cancer,SLAM family member 7 modulator|APRIL receptor modulator,45393|8255,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,Multiple myeloma,1828,,,iCar Bio Therapeutics Ltd|iCell Gene Therapeutics,1195729|1124295,,,iCell Gene Therapeutics,1124295,,,,,,
120032,K-NK003,"K-NK003|natural killer cell therapy (acute myeloid leukemia), Kiadis Pharma|membrane-bound interleukin-21-expanded haploidentical natural killer cells (acute myeloid leukemia/myelodysplastic syndrome), Kiadis Pharma|mbIL21-expanded haploidentical NK cells (acute myeloid leukemia/myelodysplastic syndrome), Kiadis Pharma",Research Code,Cancer,IL-21 agonist,4845,Natural killer cell stimulator|Anticancer|Immunostimulant,7757|1545|393,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Kiadis Pharma BV,29823,,,Kiadis Pharma BV,29823,,,,,,
120068,ZN-c3,"ZN-c3|Wee-1 protein kinase inhibitor (advanced solid tumors, oral), K-Group Beta/Zentalis Pharmaceuticals",Research Code,Cancer,Wee-1 protein kinase inhibitor,4640,Anticancer protein kinase inhibitor,62255,Small-cell lung cancer|Non-small-cell lung cancer|Transitional cell carcinoma|Osteosarcoma|Melanoma|Fallopian tube cancer|Peritoneal tumor|Breast tumor|Solid tumor|Uterus tumor|Ovary tumor,1261|1262|1771|1772|205|2243|3083|49|725|740|799,,,Zentera Therapeutics|K-Group Beta|Zentalis Pharmaceuticals,1213285|1199185|1201287,,,Zentalis Pharmaceuticals,1201287,,,,,,
120104,GC-007G,"GC-007G|allogeneic anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), Gracell Biotechnology|donor-derived anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), Gracell Biotechnology|donor CAR-19|anti-CD19 allo-CAR-T cells",Research Code|Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,B-cell acute lymphoblastic leukemia,1729,,,Gracell Biotechnology Ltd,1180179,,,Gracell Biotechnology Ltd,1180179,,,,,,
120106,LAVA-051,"LAVA-051|anti-TCR/anti-CD1d bispecific T-cell engager (hematological malignancies), Lava Therapeutics/Leiden University Medical Center|CD1d-Vd2 bispecific VHH|CD1d-Vd2 bsVHH|CD1d-VHH + Vd2-VHH|anti-TCR/anti-CD1d bispecific gamma-delta T-cell engager (hematological malignancies), Lava Therapeutics/Leiden University Medical Center",Research Code,Cancer,T-cell surface glycoprotein CD1d modulator|T cell receptor modulator,5014|74842,T-lymphocyte stimulator|Anticancer antibody|Immunostimulant|Natural killer T-lymphocyte stimulator,7761|55684|393|173716,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Multiple myeloma|Hematological neoplasm,1731|1734|1828|2054,,,Lava Therapeutics BV,1153990,Vrije Universiteit van Amsterdam,23905,Vrije Universiteit van Amsterdam,23905,,,,,,
120109,BCMA-CD19 cCAR,"BCMA-CD19 cCAR|dual anti-BCMA/anti-CD19 CAR T-cell therapy (intravenous, multiple myeloma/plasmacytoid lymphoma), iCell Gene Therapeutics/iCAR Bio Therapeutics",,Cancer,APRIL receptor modulator|B-lymphocyte antigen CD19 modulator,8255|5080,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer|Immunostimulant,4790|7761|1545|393,Lymphoplasmacytic lymphoma|Multiple myeloma,1743|1828,,,iCell Gene Therapeutics|iCar Bio Therapeutics Ltd,1124295|1195729,,,iCell Gene Therapeutics,1124295,,,Angiotensin-I Converting Enzyme (ACE) Inhibitors,381,,
120133,LY-3499446,"LY-3499446|KRAS G12C inhibitor (cancer), Eli Lilly",Research Code,Cancer,K-Ras GTPase inhibitor,28039,Anticancer,1545,,,Non-small-cell lung cancer|Solid tumor|Colorectal tumor,1262|725|989,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
120275,GEN-1044,"DuoBody-CD3x5T4|anti-CD3/anti-5T4 bispecific T-cell engager (Fc-silenced DuoBody, cancer), Genmab|GEN-1044",Research Code|Research Code,Cancer,Trophoblast glycoprotein modulator|CD3 modulator,14327|5023,Anticancer antibody|T-lymphocyte stimulator|Immunostimulant,55684|7761|393,Squamous cell carcinoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Uterus tumor,307|3466|3657|3664|3665|3667|3673|740,Cancer,651,AbbVie Inc|Genmab A/S,1072507|26469,,,Genmab A/S,26469,,,,,,
120278,PBCAR-269A,"PBCAR-269A|allogeneic CAR T-cell therapy (ARCUS, multiple myeloma), Precision BioSciences|anti-BCMA CAR T-cell therapy (ARCUS, multiple myeloma), Precision BioSciences",Research Code,Cancer,APRIL receptor modulator,8255,Immunostimulant|T-lymphocyte stimulator|Anticancer,393|7761|1545,Multiple myeloma,1828,,,Precision BioSciences Inc,1032090,,,Precision BioSciences Inc,1032090,,,,,,
120283,MANA-312,"MANA-312|tumor associated antigen specific T-cells (Hodgkin lymphoma), Mana Therapeutics|TAA-targeted T-cell therapy (PRAME, Survivin, WT1), Mana Therapeutics",Research Code,Cancer,Survivin protein modulator|Tumor expressed melanoma antigen modulator|Wilms tumor protein modulator,13606|18578|30009,Anticancer|T-lymphocyte stimulator|Immunostimulant,1545|7761|393,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Mana Therapeutics,1198166,,,Mana Therapeutics,1198166,,,,,,
120304,RAPA-201,"RAPA-201|RAPA-201 cells|autologous rapamycin-resistant Th1/Tc1 cells (multiple myeloma), Rapa Therapeutics/Medical College of Wisconsin|RAPA-201 autologous T cells (multiple myeloma), Rapa Therapeutics/Medical College of Wisconsin",Research Code,Cancer,,,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,Multiple myeloma,1828,,,Rapa Therapeutics|Medical College of Wisconsin,1178562|21040,,,Rapa Therapeutics,1178562,,,,,,
120388,TAK-186,"MVC-101|anti-CD3/anti-EGFR bispecific T-cell engager (COBRA, solid tumors), Maverick Therapeutics|TAK-186",Research Code|Research Code,Cancer,CD3 modulator|Epidermal growth factor receptor modulator,5023|3605,Immunostimulant|Anticancer antibody|T-lymphocyte stimulator,393|55684|7761,Squamous cell carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor,307|3658|3665|3673|3713,Solid tumor,725,Maverick Therapeutics Inc,1142064,,,Maverick Therapeutics Inc,1142064,,,,,,
120504,ET-019003,"ET-019003|ET019003-T Cells|dual anti-CD19 CAR T-cell therapy/anti-CD19 CSR T-cell therapy (ARTEMIS AbTCR, lymphoma/leukemia), Eureka Therapeutics|dual anti-CD19 CAR T-cell therapy/anti-CD19 chimeric signaling receptor ET190L1-CSR T-cell therapy (ARTEMIS antibody-TCR, lymphoma/leukemia), Eureka Therapeutics",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy|Immunostimulant,7761|1545|4790|393,Acute lymphoblastic leukemia|Leukemia|Lymphoma|Non-Hodgkin lymphoma,1728|199|203|319,,,Eureka Therapeutics Inc,1053219,,,Eureka Therapeutics Inc,1053219,,,,,,
120529,"anti-BCMA CAR T-cell therapy (multiple myeloma), PersonGen Biomedicine","anti-BCMA CAR T-cell therapy (multiple myeloma), PersonGen Biomedicine|BCMA-CART cells, PersonGen Biomedicine",Research Code,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,Multiple myeloma,1828,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,,,,
120612,ABM-1310,"ABM-1310|B-Raf inhibitor (oral capsule, advanced solid tumor), ABM Therapeutics Inc",Research Code,Cancer,Raf B protein kinase inhibitor,4548,Anticancer protein kinase inhibitor,62255,Thyroid tumor|Cholangiocarcinoma|Glioblastoma|Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic ovary cancer,1134|1765|2454|3257|3658|3665|3713|3866,,,ABM Therapeutics Inc,1183606,,,ABM Therapeutics Inc,1183606,,,,,,
120625,VOB-560,"VOB-560|Bcl-2 inhibitor (cancer), Novartis|S-65487",Research Code|Research Code,Cancer,Bcl-2 protein inhibitor,16111,Anticancer,1545,Acute myelogenous leukemia|Multiple myeloma|Non-Hodgkin lymphoma|Cancer,1731|1828|319|651,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
120630,"exatecan (intracellular/alphalex, solid tumors), Cybrexa","exatecan|CBX-12|alphalex-exatecan|exatecan (intracellular/alphalex, solid tumors), Cybrexa",INN|Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,Advanced solid tumor,3713,,,Cybrexa Therapeutics,1173226,,,Cybrexa Therapeutics,1173226,,,,,,
120632,GNR-084,"GNR-084|anti-CD3/anti-CD19 bispecific T-cell engager (IONTAS, B-cell acute lymphoblastic leukemia), IBC Generium",,Cancer,CD3 modulator|B-lymphocyte antigen CD19 modulator,5023|5080,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,B-cell acute lymphoblastic leukemia,1729,,,International Biotechnology Center Generium LLC,1065293,,,International Biotechnology Center Generium LLC,1065293,,,Leukotriene Receptor Antagonists|Lipoxygenase Inhibitors|Thromboxane Synthase Inhibitors,237|447|503,Signal Transduction Modulators,1402
120774,NX-2127,"NRX-0492|BTK degraders (PROTAC, chronic lymphocytic leukemia), Nurix Therapeutics/NIH|BTK targeting PROTACS (chronic lymphocytic leukemia), Nurix Therapeutics/National Institutes of Health|NX-2127|BTK degraders (PROTAC, oral, B-cell lymphoma/CLL), Nurix Therapeutics/NIH",Research Code,Cancer,Btk tyrosine kinase inhibitor|Zinc finger binding protein Aiolos inhibitor,3592|53674,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1734|1743|1744|1745|1747|1749|316|319,,,Nurix Therapeutics Inc|National Institutes of Health,1096437|20518,,,National Institutes of Health,20518,,,,,,
120783,FT-538,"FT-538|iPSC-derived hnCD16/CD38null NK cells (multiple myeloma), Fate Therapeutics/University of Minnesota|IL-15RF and hnCD16-expressing iPSC-derived NK cell therapy with CD38 knock out (cancer), Fate Therapeutics/University of Minnesota",,Cancer,,,Immunostimulant|Anticancer|Natural killer cell stimulator,393|1545|7757,Acute myelogenous leukemia|Multiple myeloma|Solid tumor,1731|1828|725,,,Fate Therapeutics Inc,1036293,University of Minnesota,20626,University of Minnesota,20626,,,,,,
120849,VTP-600,VTP-600,Research Code,Cancer,T-cell surface glycoprotein CD8 stimulator,5039,Therapeutic vaccine|Recombinant viral vector vaccine|Anticancer,12379|12370|1545,Esophagus tumor|Non-small-cell lung cancer|Squamous cell carcinoma,1011|1262|307,,,Ludwig Institute for Cancer Research (US)|Vaccitech Oncology Limited,22000|1202416,,,Vaccitech Oncology Limited,1202416,,,,,,
120851,BBT-176,"BBT-176|epidermal growth factor receptor-tyrosine kinase inhibitor (NSCLC), Korea Research Institute of Chemical Technology/Bridge Biotherapeutics|epidermal growth factor receptor-tyrosine kinase inhibitor (oral, NSCLC), Bridge Biotherapeutics",Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer,1545,Non-small-cell lung cancer,1262,,,Bridge Biotherapeutics Inc,1153465,Korea Research Institute of Chemical Technology,17684,Korea Research Institute of Chemical Technology,17684,,,,,,
120907,"anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia/Non-hodgkins lymphoma), Acibadem University","anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia/Non-hodgkins lymphoma), Acibadem University",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,Acute lymphoblastic leukemia|Non-Hodgkin lymphoma,1728|319,Cancer,651,Acibadem University,1060817,,,Acibadem University,1060817,,Senazodan hydrochloride,Calcium Sensitizers|Phosphodiesterase PDE3 Inhibitors,1058|469,Signal Transduction Modulators,1402
121041,SAR-442257,"CD3/CD38/CD28 trispecific T-cell engager/costimulator (multiple myeloma), Sanofi|dual anti-CD3/anti-CD38 T-cell engager/CD28 costimulator (multiple myeloma), Sanofi|SAR-442257",Research Code,Cancer,CD3 modulator|T cell surface glycoprotein CD28 stimulator|ADP ribosyl cyclase-1 modulator,5023|5105|5134,Anticancer antibody|T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,55684|7761|55685|393,Mycosis fungoides|Lymphoma leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Cutaneous T-cell lymphoma|Sezary syndrome|Multiple myeloma|Non-Hodgkin lymphoma,1115|1737|1743|1744|1745|1746|1749|1754|1756|1828|319,,,Sanofi SA,1009547,,,Sanofi SA,1009547,,,,,,
121043,BCMA-CART,"BCMA-CART|anti-BCMA CAR T-cell therapy (multiple myeloma), Shanghai Bioray Laboratory",Research Code,Cancer,APRIL receptor modulator,8255,Immunostimulant|T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy,393|7761|1545|4790,Multiple myeloma,1828,,,Shanghai Bioray Laboratory Inc,1151487,,,Shanghai Bioray Laboratory Inc,1151487,,,,,,
12105,IRX-4204,"AGN-191701|AGN-194204|AGN-4202|ALRT-326|LGD-4204|LGD-4326|ALRT-4204|AGN-190205|AGN-191659|AGN-192326|AGN-192327|AGN-192509|AGN-192599|AGN-192870|AGN-194277|AGN-195393|RXR ligands, ALRT|RXR ligands, Allergan|RXR agonists, Allergan/Pfizer|RXR agonists, Allergan/Parke-Davis|retinoid X receptor agonists, ALRT|retinoid X receptor agonists, Allergan|VTP-4204|VTP-194204|RXR agonists (cancer/ diabetes), Vitae Pharmaceuticals|NRX-4204|rexinoid receptor agonist (cancer), NuRx|NRX-194202|NRX-194204|AGN-4204|IRX-4204|AGN-191183",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Endocrine/Metabolic|Immune|Neurology/Psychiatric,Synuclein alpha inhibitor|Tau aggregation inhibitor|Beta amyloid antagonist|Retinoid X receptor agonist,11111|2425|7343|4059,Anti-inflammatory|Neuroprotectant|Apoptosis stimulator|Hypoglycemic agent|Anticancer|Antiparkinsonian,2953|1615|1589|399|1545|2947,Non-small-cell lung cancer|Alzheimers disease|Multiple sclerosis|Pancreas tumor|Parkinsons disease|Prostate tumor|Autoimmune encephalomyelitis|Breast tumor|Graft versus host disease,1262|14|213|249|255|276|3858|49|616,Neoplasm|Traumatic brain injury|Cancer|Metabolic disorder|Diabetes mellitus,230|3733|651|655|97,Io Therapeutics Inc,1061417,NuRx Pharmaceuticals Inc|Allergan Inc|Allergan Ligand Retinoid Therapeutics Inc|Pfizer Inc|Parke-Davis & Co|Vitae Pharmaceuticals Inc,1032578|14042|16824|18767|20805|29775,Allergan Ligand Retinoid Therapeutics Inc,16824,,,,,,
121144,"anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia/lymphoma), Loyola University of Chicago","CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia/B-cell lymphoma), Loyola University of Chicago|anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia/lymphoma), Loyola University of Chicago|CD19-CD34 CAR transduced T cell therapy (B-cell acute lymphoblastic leukemia/lymphoma), Loyala University",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy|Anticancer,7761|393|4790|1545,B-cell acute lymphoblastic leukemia|B-cell lymphoma,1729|316,,,Loyola University of Chicago,20610,,,Loyola University of Chicago,20610,,,,,,
121147,GC-027,"GC-027|allogeneic CAR T-cell therapy (TruUCAR technology, T cell malignancies), Gracell Biotechnology|anti-CD7 CAR-T-cell therapy (TruUCAR, CD7+ relapsed and/or refractory T/NK cell hematologic malignancies), Gracell Biotechnology",Research Code,Cancer,T-cell antigen CD7 modulator,5035,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,T-cell acute lymphoblastic leukemia|Precursor T-lymphoblastic lymphoma-leukemia|Leukemia|T-cell lymphoma|Lymphoblastic leukemia,1730|1752|199|311|3436,,,Gracell Biotechnology Ltd,1180179,,,Gracell Biotechnology Ltd,1180179,,,,,,
12117,"methylphenidate hydrochloride (oral controlled-release, OROS), ALZA","methylphenidate|Concerta|methylphenidate hydrochloride|methylphenidate, ALZA/Crescendo|methylphenidate (once-daily oral, OROS), ALZA|methylphenidate (oral controlled-release, OROS), ALZA|JNS-001|OROS-MPH|methylphenidate HCI|Concerta XL|methylphenidate hydrochloride (oral controlled-release, OROS), ALZA",USAN|BANN|INN|Trade Name|USAN|Research Code|Trade Name|Trade Name,Neurology/Psychiatric|Other/Miscellaneous,Alpha 2 adrenoceptor agonist,33,Dopamine uptake modulator|CNS modulator|Psychomodulator,1306|2939|2940,Attention deficit hyperactivity disorder,34,Fatigue,829,Janssen-Cilag Ltd|Janssen Pharmaceutical KK|Johnson & Johnson|McNeil-PPC Inc|Xian-Janssen Pharmaceutical Ltd|ALZA Corp|moksha8 Pharmaceuticals Inc,17392|17408|17332|17560|17608|14095|1050182,Crescendo Pharmaceuticals Corp,25201,Crescendo Pharmaceuticals Corp,25201,,,,,,
121213,XMT-1592,"XMT-1592|auristatin/NaPi2b-targeting antibody drug conjugate (Dolasynthen platform, cancer), Mersana Therapeutics",Research Code,Cancer,Sodium phosphate cotransporter 2B inhibitor,32671,Microtubule inhibitor|Anticancer antibody,2575|55684,Non-small-cell lung cancer|Adenocarcinoma|Cancer|Ovary tumor,1262|2399|651|799,,,Mersana Therapeutics Inc|Recepta biopharma,1002523|1035632,,,Mersana Therapeutics Inc,1002523,,,,,,
121278,ATLCAR.k.28 cells,"ATLCAR.k.28 cells|CAR.k.28 cells|kappa Chimeric Antigen Receptor and CD28 Endodomain expressing T cells|anti-kappa CAR T-cell therapy (non-Hodgkin lymphoma), UNC Lineberger Comprehensive Cancer Center|ATLCAR.k.28 T-cell therapy (indolent non-Hodgkin lymphoma/follicular lymphoma/marginal zone lymphoma/mantle cell lymphoma), UNC Lineberger",,Cancer,Immunoglobulin kappa modulator,63442,Anticancer|Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,1545|393|4790|7761,Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Splenic marginal zone lymphoma|Non-Hodgkin lymphoma,1744|1745|1746|1747|319,,,UNC Lineberger Comprehensive Cancer Center,1041077,,,UNC Lineberger Comprehensive Cancer Center,1041077,,,,,,
121331,SEA-CD70,SEA-CD70,Research Code,Cancer,CD70 antigen modulator,5289,Anticancer monoclonal antibody,55685,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Seagen Inc|BeiGene Co Ltd,25554|1063251,,,Seagen Inc,25554,,,,,,
121344,GEN-001,"GEN-001|microbiome-based therapeutic (oral enteric capsule/lyophilized, cancer), Genome & Co",Research Code,Cancer,,,Macrophage stimulator|Dendritic cell stimulator|T-lymphocyte stimulator|Anticancer|Immunostimulant,7751|173472|7761|1545|393,Non-small-cell lung cancer|Gastrointestinal tumor|Squamous cell carcinoma|Advanced solid tumor|Head and neck tumor|Uterus tumor,1262|131|307|3713|623|740,Cancer|Lung tumor,651|755,Genome & Co,1182701,,,Genome & Co,1182701,,,,,,
12135,celecoxib,Celebrex|celecoxib|SC-58635|YM-177|Celebra|Onsenal|YM-74177|celecoxib FAP|Celecox,Trade Name|USAN|INN|Research Code|Research Code|Trade Name|Trade Name|Research Code|Trade Name,Cancer|Dermatologic|Gastrointestinal|Genitourinary/Sexual Function|Immune|Inflammatory|Musculoskeletal|Neurology/Psychiatric|Other/Miscellaneous,Cyclooxygenase 2 inhibitor,1001,Non-steroidal anti-inflammatory|Analgesic|Anticancer,2955|2946|1545,Dysmenorrhea|Familial adenomatous polyposis|Pain|Osteoarthritis|Periarthritis|Tenosynovitis|Rheumatoid arthritis|Back pain|Ankylosing spondylitis,105|1277|20|245|2471|2489|291|3221|398,Esophagus tumor|Keratosis|Non-small-cell lung cancer|Gout|Alzheimers disease|Inflammatory disease|Pancreas tumor|Prostate tumor|Non-Hodgkin lymphoma|Bladder tumor|Cachexia|Metastatic renal cell carcinoma|Uterine cervix tumor|Breast tumor|Skin tumor|Lung tumor|Colon tumor|Colorectal tumor,1011|1057|1262|136|14|188|249|276|319|42|425|4250|427|49|722|755|767|989,Viatris Inc|Astellas Pharma Inc,1136574|1013295,GD Searle & Co|Pfizer Inc|Yamanouchi Pharmaceutical Co Ltd,18362|18767|20967,GD Searle & Co,18362,,,,,,
121449,JBH-492,"JBH-492|anti-CCR7 antibody-drug conjugate (chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma), Novartis",Research Code,Cancer,CCR7 chemokine antagonist,3113,Anticancer antibody,55684,Chronic lymphocytic leukemia|Hematological neoplasm|Non-Hodgkin lymphoma,1734|2054|319,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
121466,elasomeran,"mRNA vaccine (COVID-19), ModeRNA/NIAID Vaccine Research Center|mRNA vaccine (COVID-19), ModeRNA|SARS-CoV-2 mRNA vaccine (COVID-19), ModeRNA|COVID-19 Vaccine Moderna Intramuscular Injection|elasomeran|TAK-919|Moderna COVID-19 Vaccine|mRNA-1273|Spikevax",Trade Name|PINN|Research Code|Research Code|Trade Name,Infection,COVID19 Spike glycoprotein modulator,174434,Prophylactic vaccine|RNA vaccine,12378|12377,Coronavirus disease 19 infection,10406,,,Medison Pharma Ltd|Takeda Pharmaceutical Co Ltd|GC Pharma|ModeRNA Therapeutics,29943|20300|16583|1060964,,,ModeRNA Therapeutics,1060964,,,,,,
12150,"vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals","vincristine|vincristine sulfate|VSLI, Inex|vincristine-TCS, Inex|vincristine sulfate (liposomal injection, Optisome), Inex|transmembrane carrier system (vincristine), Inex|vincristine sulfate liposomes for injection, Inex|vincristine sulfate (liposomal injection), Hana|transmembrane carrier system (vincristine), Hana|vincristine sulfate liposomes for injection, Hana|VSLI, Hana|vincristine-TCS, Hana|vincristine sulfate (liposomal injection), Talon|Marqibo|Onco-TCS|vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals|vincristine sulfate (liposomal injection), Spectrum / CASI Pharmaceuticals",INN|USAN|Trade Name|Trade Name,Cancer,Tubulin modulator,814,Cell cycle inhibitor|Microtubule inhibitor|Anticancer,767|2575|1545,Acute lymphoblastic leukemia|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1728|1749|319,Small-cell lung cancer|Hodgkins disease|Mantle cell lymphoma|Leukemia|Melanoma|Pancreas tumor|Burkitts lymphoma|Colorectal tumor,1261|161|1744|199|205|249|791|989,Servier Canada Inc|CASI Pharmaceuticals Inc|Acrotech Biopharma LLC,22730|21794|1179286,Talon Therapeutics Inc|Arbutus Biopharma Corp|Elan Corp plc|Enzon Pharmaceuticals Inc|Inex Pharmaceuticals Corp|Spectrum Pharmaceuticals Inc,1010798|1032153|15873|16045|16173|24232,Inex Pharmaceuticals Corp,16173,,,,,,
12153,exisulind,Aptosyn|FGN-1|Prevatac|sulindac sulfone|CP-246|exisulind,Trade Name|Research Code|Trade Name|Research Code|INN,Cancer|Gastrointestinal,Cyclic GMP phosphodiesterase inhibitor,429,Apoptosis modulator|Anticancer,1588|1545,,,Barretts esophagus|Familial adenomatous polyposis|Prostate tumor|Bladder tumor|Uterine cervix tumor|Breast tumor|Lung tumor,1273|1277|276|42|427|49|755,,,Bristol-Myers Squibb Co|OSI Pharmaceuticals Inc|Cell Pathways Inc,15065|18676|23024,Cell Pathways Inc,23024,,,,,,
121595,UCD19 CAR T Cells,"anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma), University of Colorado|UCD19 CAR T Cells|CD19CAR-CD3Zeta-4-1BB-expressing allogeneic T-lymphocyte cells (iv/infusion. B-cell malignancies), University of Colorado",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Genetically engineered autologous cell therapy|Immunostimulant|Anticancer|T-lymphocyte stimulator,4790|393|1545|7761,B-cell acute lymphoblastic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma|Burkitts lymphoma,1729|1744|1745|1749|319|791,,,University of Colorado,1164766,,,University of Colorado,1164766,,,Angiotensin-I Converting Enzyme (ACE) Inhibitors,381,,
12165,"belotecan (injectable), Chong Kun Dang","CKD 602|CRD-602|Camtobell Inj|CKD-602 (injectable), Chong Kun Dang|camptothecin analogs, Chong Kun Dang|belotecan|belotecan (injectable), Chong Kun Dang|belotecan hydrochloride",Research Code|Trade Name|INN|USAN,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,Small-cell lung cancer|Ovary tumor,1261|799,Cancer,651,Chong Kun Dang Pharmaceutical Corp,15410,,,Chong Kun Dang Pharmaceutical Corp,15410,,,,,,
121708,IO-112,"IO-112|arginase-I modulator (Solid tumor), IO Biotech ApS|arginase derived peptide vaccine (arginase-positive solid tumor), IO Biotech",Research Code,Cancer,Arginase-I modulator,7086,T-lymphocyte stimulator|Therapeutic vaccine|Immunomodulator|Protein subunit vaccine|Anticancer,7761|12379|1596|12372|1545,Solid tumor,725,,,IO Biotech ApS,1121281,,,IO Biotech ApS,1121281,,,,,,
121733,SEA-TGT,"SGN-TGT|SEA-TGT|nonfucosylated human IgG antibody (SEA, solid tumor/lymphoma), Seattle Genetics",Research Code|Research Code,Cancer,T cell immunoreceptor Ig ITIM protein inhibitor,64787,Anticancer monoclonal antibody,55685,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Hodgkins disease|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Melanoma|Bladder cancer|Breast tumor|Head and neck tumor|Ovary tumor,1011|1262|127|161|1749|1753|205|2380|49|623|799,Metastatic non small cell lung cancer|Metastatic stomach cancer,3665|3666,Seagen Inc,25554,,,Seagen Inc,25554,,,,,,
121735,"cedazuridine + azacitidine (fixed-dose combination/oral/tablet formulation, myeloid diseases), Astex Pharmaceuticals","ASTX-030|cedazuridine + azacitidine (fixed-dose combination/oral/tablet formulation, myeloid diseases), Astex Pharmaceuticals|cedazuridine + azacitidine",Research Code,Cancer,DNA methyltransferase inhibitor|Cytidine deaminase inhibitor,6512|7117,Anticancer antimetabolite|Anticancer,1569|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia|Myeloid leukemia,1272|1731|1735|223,,,Astex Pharmaceuticals Inc,21885,,,Astex Pharmaceuticals Inc,21885,,,Phospholipase C Inhibitors|Lipoxygenase Inhibitors,474|447,Signal Transduction Modulators,1402
121760,YT-19/20,"dual anti-CD19/anti-CD20 CAR-T cell therapy (B-cell lymphoma/leukemia), China Immunotech|YT-19/20",Research Code,Cancer,B-lymphocyte antigen CD20 modulator|B-lymphocyte antigen CD19 modulator,5083|5080,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,B-cell acute lymphoblastic leukemia|Diffuse large B-cell lymphoma|Leukemia|B-cell lymphoma|Non-Hodgkin lymphoma,1729|1749|199|316|319,,,China Immunotech Co Ltd,1186841,,,China Immunotech Co Ltd,1186841,,,,,,
121765,OC-001,"OC-001|tumor necrosis factor inhibitor (intravenous, advanced cancers), Ocellaris Pharma|TNF inhibitor (intravenous, advanced cancers), Ocellaris Pharma",Research Code,Cancer,TNF antagonist,511,Anticancer,1545,Metastasis|Hepatocellular carcinoma|Sarcoma|Skin cancer|Squamous cell carcinoma|Merkel cell carcinoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor,1069|1767|194|2170|307|3235|3466|3657|3665|3666|3673|3713|3866|4250|427,,,Ocellaris Pharma Inc,1205490,,,Ocellaris Pharma Inc,1205490,,,,,,
121832,AZD-1222,"ChAdOx1 nCoV-19|SARS-CoV-2 vaccine (COVID-19), The Jenner Institute at the University of Oxford|recombinant viral vector ChAdOx vaccine (COVID-19, intramuscular), Jenner Institute|recombinant viral vector ChAdOx vaccine (2019-nCoV infection), Jenner Institute|SARS-CoV-2 spike glycoprotein vaccine (adenoviral vector vaccine, COVID-19), Jenner Institute/UCB/AstraZeneca|ChAdOX1 SARS2|AZD-1222|AZN-1222|SII-ChAdOx1 nCoV-19|SII-Covishield|Vaxzevria|C19VAZ|ChAdOx1-S (recombinant)|COVID-19 Vaccine, AstraZeneca",Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code,Infection,COVID19 Spike glycoprotein modulator,174434,Recombinant viral vector vaccine|Prophylactic vaccine,12370|12378,Coronavirus disease 19 infection,10406,,,AstraZeneca plc|The Jenner Institute|Shenzhen Kangtai Biological Products Co Ltd,14190|1007663|1071345,UCB SA|Oxford BioMedica plc,20452|23434,The Jenner Institute,1007663,,,,,,
121865,INCB-00928,"INCB-00928|ALK2 inhibitors (fibrodysplasia ossificans progressiva/myelofibrosis), Incyte|activin receptor-like kinase-2 inhibitors (fibrodysplasia ossificans progressiva/myelofibrosis), Incyte|INCB-000928",Research Code|Research Code,Cancer|Hematologic|Musculoskeletal,Alk-2 protein kinase inhibitor,4582,Anticancer,1545,Myelodysplastic syndrome|Anemia|Multiple myeloma|Thrombocythemia|Polycythemia vera|Myelofibrosis|Fibrodysplasia ossificans progressiva,1272|17|1828|2317|2319|2436|3219,,,Incyte Corp,17216,,,Incyte Corp,17216,,,,,,
121887,"CD123 CAR-T cells (AML), Chongqing Precision Biotech","CD123 CAR-T cells (AML), Chongqing Precision Biotech|anti-CD123 CAR T-cell therapy (acute myeloid leukemia), Chongqing Precision Biotech",,Cancer,CDw123 modulator,5427,T-lymphocyte stimulator|Anticancer|Immunostimulant|Genetically engineered autologous cell therapy,7761|1545|393|4790,Acute myelogenous leukemia,1731,,,Chongqing Precision Biotech Co Ltd,1161028,,,Chongqing Precision Biotech Co Ltd,1161028,,,,,,
121889,C-4-29,"anti-BCMA CAR T-cell therapy (multiple myeloma), Chongqing Precision Biotech|C-4-29",Research Code,Cancer,APRIL receptor modulator,8255,T-lymphocyte stimulator|Anticancer|Immunostimulant|Genetically engineered autologous cell therapy,7761|1545|393|4790,Acute myelogenous leukemia|Multiple myeloma,1731|1828,,,Chongqing Precision Biotech Co Ltd,1161028,,,Chongqing Precision Biotech Co Ltd,1161028,,,,,,
121948,ABBV-184,"ABBV-184|anti-CD3/anti-survivin bispecific T-cell engager (cancer/AML/NSCLC), AbbVie",Research Code,Cancer,CD3 modulator|Survivin protein modulator,5023|13606,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,Non-small-cell lung cancer|Acute myelogenous leukemia|Cancer,1262|1731|651,,,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
121980,CLBR-001,"CLBR-001|anti-CD19 CAR T-cell therapy (SWI019 safety switch, relapsed/refractory B cell chronic lymphocytic leukemia/non-Hodgkin lymphoma), Calibr/AbbVie",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Genetically engineered autologous cell therapy|Anticancer|Immunostimulant|T-lymphocyte stimulator,4790|1545|393|7761,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1734|1744|1745|1747|1749|1750|316|319,,,California Institute for Biomedical Research|AbbVie Inc,1068758|1072507,,,California Institute for Biomedical Research,1068758,,,,,,
12202,phenylbutyrate,phenylbutyrate,,Cancer,,,Anticancer|Unspecified drug target,1545|59620,,,Solid tumor,725,,,University of Virginia,20695,University of Virginia,20695,,,,,,
12205,capecitabine,capecitabine|Ro-09-1978|R-340|Xeloda|RG-340,USAN|BANN|INN|Research Code|Research Code|Trade Name|Research Code,Cancer,Thymidylate synthase inhibitor,372,Anticancer antimetabolite|Anticancer,1569|1545,Rectal tumor|Neuroendocrine tumor|Stomach tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic stomach cancer|Metastatic rectal cancer|Breast tumor|Colon tumor,1055|1128|127|3657|3658|3666|3671|49|767,Glioma|Nasopharyngeal carcinoma|Liver tumor|Pancreas tumor|Head and neck tumor|Cancer|Solid tumor|Colorectal tumor,1108|1768|202|249|623|651|725|989,F Hoffmann-La Roche AG|Hoffmann-La Roche Inc|Chugai Pharmaceutical Co Ltd|Baheal Pharmaceutical group|Roche Holding AG,26178|19461|15414|1165685|19446,Nippon Roche KK,19447,Hoffmann-La Roche Inc,19461,,,,,,
12210,UFT,"tegafur + uracil|UFT|tegafur|uracil|Orzel|Futraful|BMS-200604-01|UFT + leucovorin|tegafur + uracil, Taiho/Bristol-Myers Squibb|UFUR",Trade Name|USAN|BANN|INN|Trade Name|Trade Name|Research Code|Trade Name,Cancer,,,Unspecified drug target|Anticancer,59620|1545,Metastatic colorectal cancer|Solid tumor|Colorectal tumor,3658|725|989,,,Merck Serono SA|Taiho Pharmaceutical Co Ltd|Jeil Pharmaceutical Co Ltd|Merck KGaA,19862|18720|17331|18101,Bristol-Myers Squibb Co|Wyeth KK,15065|22673,Taiho Pharmaceutical Co Ltd,18720,,,,,,
122125,TAS-1440,"TAS-1440|LSD1 inhibitor (oral capsule, AML), Taiho Pharmaceutical/ Astex Pharmaceuticals",Research Code,Cancer,Lysine specific histone demethylase 1 inhibitor,14681,Anticancer,1545,Acute myelogenous leukemia,1731,,,Taiho Pharmaceutical Co Ltd|Astex Pharmaceuticals Inc,18720|21885,,,Astex Pharmaceuticals Inc,21885,,,Histamine H2 Receptor Antagonists,197,Signal Transduction Modulators,1402
122169,"anti-CD19/anti-CD22 CAR T-cell therapy (B cell Leukemia/Lymphoma), Chongqing Precision Biotech","dual-target bispecific CAR T-cell therapy (cancer), Chongqing Precision Biotech|anti-CD19/anti-CD22 CAR T-cell therapy (B cell Leukemia/Lymphoma), Chongqing Precision Biotech",,Cancer,B-lymphocyte cell adhesion molecule modulator|B-lymphocyte antigen CD19 modulator,5089|5080,Genetically engineered autologous cell therapy|Immunostimulant|Anticancer|T-lymphocyte stimulator,4790|393|1545|7761,Leukemia|B-cell lymphoma,199|316,Cancer,651,Chongqing Precision Biotech Co Ltd,1161028,,,Chongqing Precision Biotech Co Ltd,1161028,,,Thromboxane A2 Receptor (TBXA2R; TP) Antagonists|Thromboxane Synthase Inhibitors,298|503,Signal Transduction Modulators,1402
122172,"CYC-140, Cyclacel Pharmaceuticals","CYC-140, Cyclacel Pharmaceuticals|PLK1 inhibitors (iv, cancers), Cyclacel|Polo-like kinase 1 inhibitors (iv, leukemias), Cyclacel",Research Code,Cancer,Polo-like kinase 1 inhibitor,4536,Anticancer protein kinase inhibitor|Anticancer|Cell cycle inhibitor,62255|1545|767,Esophagus tumor|Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Leukemia|Hematological neoplasm|Solid tumor,1011|1272|1728|1731|1734|1735|199|2054|725,,,Cyclacel Pharmaceuticals Inc,24341,,,Cyclacel Pharmaceuticals Inc,24341,,,,,,
122208,BDB-1,"BDB-001|anti-C5aR monoclonal antibody (intravenous infusion/IFX-1, hidradenitis suppurativa/COVID-19), Beijing Defengrei Biotechnology|BDB-1|anti-human complement factor C5a monoclonal antibody (intravenous infusion/IFX-1, hidradenitis suppurativa/coronavirus disease 19 infection), Beijing Defengrei Biotechnology|anti-C5aR monoclonal antibody (intravenous infusion/IFX-1, hidradenitis suppurativa/COVID-19/advanced solid tumors), Beijing Defengrei Biotechnology",Research Code|Research Code,Cancer|Cardiovascular|Dermatologic|Infection,Complement C5a factor inhibitor,86590,Anti-inflammatory|Anticancer|Antiviral,2953|1545|991,Coronavirus disease 19 infection|Non-small-cell lung cancer|Vasculitis|Melanoma|Bladder cancer|Pancreas tumor|Hidradenitis suppurativa|Metastatic breast cancer|Advanced solid tumor,10406|1262|1532|205|2380|249|3542|3657|3713,,,Beijing Defengrei Biotechnology Co Ltd,1159963,,,Beijing Defengrei Biotechnology Co Ltd,1159963,,,beta-Adrenoceptor Antagonists|alpha-Adrenoceptor Antagonists,44|35,Signal Transduction Modulators,1402
12229,efaproxiral,efaproxiral|RSR-13|efaproxiral sodium|RSR-4|Efaproxyn|Revaproxyn,USAN|INN|Research Code|USAN|Analogue|Research Code|Trade Name|Trade Name,Cancer|Cardiovascular|Neurology/Psychiatric,Hemoglobin modulator,474,Radiosensitizer|Anticancer chemosensitizer,1542|1586,,,Metastasis|Non-small-cell lung cancer|Myocardial infarction|Angina|Movement disorder|Uterine cervix tumor|Stroke|Cancer|Brain tumor,1069|1262|224|23|368|427|65|651|760,,,MediBIC|Allos Therapeutics Inc|King's College London,1012583|23253|23507,King's College London,23507,,,,,,
122305,UniCAR-T-PSMA,"UniCAR-T-PSMA|TM-pPSMA peptide adaptor + UniCAR-T cells (metastatic castrate-resistant prostate cancer/solid tumor), GEMoaB Monoclonals|UC02-T-pPSMA|peptide-expressing anti-PSMA targeting molecule + anti-peptide CAR T-cell therapy (metastatic castrate-resistant prostate cancer/solid tumor), GEMoaB Monoclonals|UniCAR02-T-pPSMA",Research Code|Research Code|Research Code,Cancer,Glutamate carboxypeptidase II modulator,9267,Genetically engineered autologous cell therapy|Anticancer|Immunostimulant|T-lymphocyte stimulator,4790|1545|393|7761,Non-small-cell lung cancer|Renal cell carcinoma|Transitional cell carcinoma|Prostate tumor|Hormone refractory prostate cancer|Breast tumor|Solid tumor|Colorectal tumor,1262|1766|1771|276|3246|49|725|989,,,GEMoaB Monoclonals GmbH,1120339,,,GEMoaB Monoclonals GmbH,1120339,,,,,,
12243,penclomedine,CRC-88-04|NSC-338720|penclomedine|penclomidine,Research Code|Research Code,Cancer,,,Anticancer alkylating agent,50,,,Cancer,651,,,National Cancer Institute (NCI),20519,National Cancer Institute (NCI),20519,,,,,,
122446,EMB-06,"EMB-06|undisclosed target bispecific T-cell engager (FIT-Ig, cancer), EpimAb Biotherapeutics|anti-CD3/anti-BCMA bispecific T-cell engager (multiple myeloma), Epimab Biotherapeutics",Research Code,Cancer,CD3 modulator|APRIL receptor modulator,5023|8255,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,Multiple myeloma|Cancer,1828|651,,,Epimab Biotherapeutics Inc,1139169,,,Epimab Biotherapeutics Inc,1139169,,,,,,
122461,agenT-797,"allogeneic iNKT cell-based immunotherapy (multiple myeloma/chronic lymphocytic leukemia/small lymphocytic lymphoma/non-hodgkin's lymphoma/follicular lymphoma/marginal zone lymphoma/diffuse large B-cell lymphoma/solid tumor), Agenus|agenT-797|allogeneic iNKT cell-based immunotherapy (MM/CLL/small lymphocytic lymphoma/NHL/follicular lymphoma/marginal zone lymphoma/DLBCL/solid tumors/COVID-19/inflammation), Agenus",Research Code,Cancer|Infection|Inflammatory|Respiratory,,,Natural killer T-lymphocyte stimulator|Anti-inflammatory|Anticancer|Antiviral,173716|2953|1545|991,Coronavirus disease 19 infection|Chronic lymphocytic leukemia|Lymphoma leukemia|Follicle center lymphoma|Marginal zone B-cell lymphoma|Multiple myeloma|Inflammatory disease|Non-Hodgkin lymphoma|Solid tumor|Respiratory distress syndrome,10406|1734|1737|1745|1746|1828|188|319|725|8,Cancer,651,Agenus Inc,23221,,,Agenus Inc,23221,,,,,,
122625,DTRM-555,"DTRM-555|DTRMWXHS-12 + everolimus + pomalidomide (chronic lymphocytic leukemia/non-Hodgkin's lymphoma/B-cell lymphoma), DTRM Biopharma|DTRMWXHS-12 + everolimus + pomalidomide",Research Code,Cancer,mTOR inhibitor|Btk tyrosine kinase inhibitor|Protein cereblon modulator,10240|3592|77059,Angiogenesis inhibitor|Immunomodulator|TNF alpha synthesis inhibitor|Anticancer protein kinase inhibitor,61|1596|382|62255,Chronic lymphocytic leukemia|B-cell lymphoma|Non-Hodgkin lymphoma,1734|316|319,,,DTRM Biopharma Co Ltd,1071880,,,DTRM Biopharma Co Ltd,1071880,,,,,,
122759,"allogeneic interferon gamma-primed human bone marrow-derived mesenchymal stem cell therapy (intravenous, GVHD), Emory University","allogeneic interferon gamma-primed human bone marrow-derived mesenchymal stem cell therapy (intravenous, GVHD), Emory University",,Immune,,,Immunomodulator|Unspecified drug target,1596|59620,Graft versus host disease,616,,,Emory University,20573,,,Emory University,20573,,Saframycin Yd-1,,,,
122788,GNR-051,"GNR-051|PD-1 checkpoint inhibitor (solid tumors), Generium|IgG2 anti-PD-1 monoclonal antibody (solid tumor), Generium",Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,Stage IV melanoma|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Solid tumor,3257|3665|3713|4250|725,,,International Biotechnology Center Generium LLC,1065293,,,International Biotechnology Center Generium LLC,1065293,,,,,,
123080,Covax-19,"SARS-CoV-2 spike protein subunit vaccine (COVID-19), Vaxine/Genecure/MedyTox|Covax-19|SARS-CoV-2 subunit vaccine (COVID-19), Genecure/Vaxine/MedyTox|SpikoGen",Research Code|Trade Name,Infection,Coronavirus spike glycoprotein inhibitor,174424,Therapeutic vaccine|Antiviral|Protein subunit vaccine|Adjuvant,12379|991|12372|524,Coronavirus disease 19 infection,10406,,,Genecure LLC|University of Georgia|Medy-Tox Inc|Vaxine Pty Ltd,27346|20579|1036114|1016757,,,Vaxine Pty Ltd,1016757,,,,,,
123204,BMS-986315,"BMS-986315|NKG2A checkpoint inhibitor (advanced solid tumor), Bristol Myers Squibb",Research Code,Cancer,NKG2 A B activating NK receptor antagonist,77513,Natural killer cell stimulator|Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,7757|393|55685|7761,Squamous cell carcinoma|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma,307|3665|3673|3713|4250,,,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
123347,tozinameran,"BNT-162 program|uridine containing mRNA vaccine (COVID-19, lipid nanoparticle, intramuscular), BioNTech/Pfizer|P2-mutated full spike protein modRNA prime/boost vaccine (COVID-19), BioNTech/Pfizer|BNT-162b2|PF-07302048 program|lead PF-07302048 vaccine (COVID-19), Pfizer/BioNTech|lead BNT-162 vaccine (COVID-19), Pfizer/BioNTech|Comirnaty|tozinameran",Research Code|Research Code|Research Code|Trade Name|PINN,Infection,COVID19 Spike glycoprotein modulator,174434,Prophylactic vaccine|RNA vaccine,12378|12377,Coronavirus disease 19 infection,10406,,,Shanghai Fosun Pharmaceutical (Group) Co Ltd|Pfizer Inc|BioNTech SE,1015871|18767|1047330,,,BioNTech SE,1047330,,,,,,
12347,gadopentetate dimeglumine,"gadolinium-DTPA-dimeglumine|gadopentetate dimeglumine|Magnevist|SH-L-451A|SH-L-545|Gd-DTPA, Schering AG|Magnevist MRA|Magnevist Syringe|BAY-86-4882",USAN|Trade Name|Research Code|Analogue|Research Code|Trade Name|Trade Name|Research Code,Cancer|Cardiovascular,,,Cardiovascular diagnostic agent|MRI imaging agent|Neoplasm diagnostic agent,7210|4158|7220,Cancer|Coronary artery disease,651|80,,,Abbott Laboratories|Schering AG|Bayer AG|Bayer Schering Pharma AG,13601|1052089|14455|19687,,,Schering AG,1052089,,,,,,
123587,ZN-d5,"ZN-d5|B-cell lymphoma 2 inhibitor (oral, hematologic malignancies), Zentalis Pharmaceuticals",Research Code,Cancer,Bcl-2 protein inhibitor,16111,Anticancer,1545,Acute myelogenous leukemia|Hematological neoplasm|B-cell lymphoma|Non-Hodgkin lymphoma|Breast tumor,1731|2054|316|319|49,,,Zentera Therapeutics|Zentalis Pharmaceuticals,1213285|1201287,,,Zentalis Pharmaceuticals,1201287,,,,,,
123604,BLU-945,"BLU-945|triple mutant EGFR kinase (EGFR+ T790M/C797S) inhibitor (non-small cell lung cancer), Blueprint Medicines",Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Adenocarcinoma|Metastatic non small cell lung cancer|Lung tumor|Respiratory tract tumor,1262|2399|3665|755|756,,,Blueprint Medicines Corp,1067683,,,Blueprint Medicines Corp,1067683,,,,,,
123699,SHR-A1811,"SHR-A1811|anti-HER2 mAb-cytotoxin conjugate (iv, advanced solid tumor), Jiangsu Hengrui Medicine",Research Code,Cancer,Erbb2 tyrosine kinase receptor modulator,3755,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Advanced solid tumor,3658|3665|3666|3713,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,,,,
123796,IO-202,"IO-202|anti-LILRB4 antibody (AML/CMML), Immune-Onc Therapeutics|anti-LILRB4 antibody (AML/CMML/solid tumors), Immune-Onc Therapeutics/University of Texas Southwestern Medical Center",Research Code,Cancer,Leukocyte Ig-like receptor-4 antagonist,9615,Anticancer antibody,55684,Acute myelogenous leukemia|Hematological neoplasm|Chronic myelomonocytic leukemia|Solid tumor,1731|2054|6833|725,,,University of Texas Southwestern Medical Center|Immune-Onc Therapeutics Inc,25760|1129266,,,Immune-Onc Therapeutics Inc,1129266,,,,,,
123844,ThisCART19,"anti-CD19 CAR T-cell therapy (B cell malignancies/acute or chronic lymphocytic leukemia/lymphoma), Suzhou Fundamenta Therapeutics|ThisCART19",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|T-lymphocyte stimulator|Anticancer,393|7761|1545,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|B-cell lymphoma,1728|1734|316,,,Suzhou Fundamenta Therapeutics Ltd,1212539,,,Suzhou Fundamenta Therapeutics Ltd,1212539,,,,,,
123998,CC-98633,"CC-98633|anti-BCMA CAR T-cell therapy (NEX-T, multiple myeloma), Juno Therapeutics|anti-BCMA NEX-T CAR T-cell therapy (multiple myeloma), Juno Therapeutics|anti-BCMA NEX-T CAR T-cell therapy (multiple myeloma), Bristol-Myers Squibb Co",Research Code,Cancer,APRIL receptor modulator,8255,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,Multiple myeloma,1828,,,Bristol-Myers Squibb Co,15065,Juno Therapeutics Inc,1090676,Juno Therapeutics Inc,1090676,,,,,,
12406,vedolizumab,"MLN-02|integrin antagonists, Millennium/Genentech|anti alpha-4/beta-7 integrin antibody, LeukoSite|anti alpha-4/beta-7 integrin antibody, Millennium/Genentech|vedolizumab|MLN-0002|LDP-02|Entyvio|Kintelles|Kynteles",Research Code|USAN|INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name,Gastrointestinal|Immune|Infection,MAdCAM inhibitor|Integrin alpha-4/beta-7 antagonist,2617|2950,Anti-inflammatory|Therapeutic antibody|Immunosuppressant|Antiviral|Gastrointestinal system agent|Anticancer monoclonal antibody|Antibacterial,2953|172641|396|991|1332|55685|1594,HIV infection|Pouchitis|Ulcerative colitis|Graft versus host disease|Crohns disease,158|2468|337|616|84,Inflammatory bowel disease|Primary sclerosing cholangitis,189|2477,Takeda Pharmaceutical Co Ltd,20300,Genentech Inc|Takeda Oncology|LeukoSite Inc,19453|21991|27414,LeukoSite Inc,27414,,,,,,
124190,PHE-885,"PHE-885|anti-BCMA CAR T-cell therapy (multiple myeloma), Novartis",Research Code,Cancer,APRIL receptor modulator,8255,Immunostimulant|T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy,393|7761|1545|4790,Multiple myeloma,1828,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
12420,rosuvastatin,rosuvastatin calcium|S-4522|rosuvastatin|ZD-4522|Crestor|keding|Crestor OD|AZD-4522,USAN|Research Code|INN|Research Code|Trade Name|Trade Name|Research Code,Cardiovascular|Endocrine/Metabolic|Genitourinary/Sexual Function|Neurology/Psychiatric,HMG CoA reductase inhibitor,205,Antihypercholesterolemic agent|Antihypertriglyceridemic agent|Antihyperlipidemic agent|Cardioprotectant|Antiarteriosclerotic,71|7018|72|2659|2667,Hypercholesterolemia|Hyperlipidemia|Myocardial infarction|Familial hypercholesterolemia|Atherosclerosis|Stroke,174|175|224|3204|33|65,Congestive heart failure|Aortic stenosis|Proteinuria|Renal disease,1559|2383|277|286,Daewoong Pharmaceutical Co Ltd|Grunenthal GmbH|AstraZeneca plc|Shionogi & Co Ltd|Almirall Prodesfarma SA,15587|16587|14190|19898|14061,Zeneca Group plc,16955,Shionogi & Co Ltd,19898,,,,,,
124507,"dual anti-CD19/anti-CD20 CAR T-cell therapy (non-Hodgkin's lymphoma), Chinese PLA General Hospital","dual anti-CD19/anti-CD20 CAR T-cell therapy (non-Hodgkin's lymphoma), Chinese PLA General Hospital|tandem CD19/CD20 CAR-engineered T-cells (non-Hodgkin's lymphoma), Chinese PLA General Hospital|CD19/CD20 bispecific CAR T-cells (non-Hodgkin's lymphoma), Chinese PLA General Hospital",,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte antigen CD20 modulator,5080|5083,Immunostimulant|T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy,393|7761|1545|4790,Non-Hodgkin lymphoma,319,,,Chinese PLA General Hospital Medical School Of Chinese PLA,1021685,,,Chinese PLA General Hospital Medical School Of Chinese PLA,1021685,Mexidol (succinate)|Mexifin (succinate),Emoxypine|Epygid,,,,
124524,TL-895,"TL-895|bruton tyrosine kinase inhibitor (oral, COVID-19/viral pneumonia), Telios Pharma|bruton tyrosine kinase inhibitor (myelofibrosis), Telios Pharma",Research Code,Cancer|Hematologic|Infection,Btk tyrosine kinase inhibitor,3592,Antiviral|Anticancer protein kinase inhibitor|Anticancer,991|62255|1545,Coronavirus disease 19 infection|Macroglobulinemia|Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Viral pneumonia|Myelofibrosis,10406|1264|1734|1743|1744|1745|1746|1749|1818|2436,,,Telios Pharmaceuticals Inc,22148,,,Telios Pharmaceuticals Inc,22148,,,Renin Inhibitors,484,,
124561,CXCR5 modified EGFR chimeric antigen receptor autologous T cells therapy,"CXCR5 modified EGFR chimeric antigen receptor autologous T cells therapy|anti-EGFR CAR T-cell therapy (advanced non-small cell lung cancer), Sun Yat-sen University/Guangzhou Bio-gene Technology",,Cancer,Epidermal growth factor receptor modulator,3605,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,Metastatic non small cell lung cancer,3665,,,Sun Yat-Sen University|Guangzhou Bio-gene Technology Co Ltd,1004360|1168835,,,Guangzhou Bio-gene Technology Co Ltd,1168835,,,Vasopressin (AVP) Receptor Antagonists,329,Signal Transduction Modulators,1402
124586,DF-6002,"DF-6002|monovalent human IL-12/Fc fusion protein (subcutaneous, advanced solid tumors), Dragonfly Therapeutics|BMS-986415",Research Code|Research Code,Cancer,,,Anticancer|Immunomodulator|IL-12 modulator,1545|1596|1581,Small-cell lung cancer|Stomach tumor|Hodgkins disease|Endometrioid carcinoma|Primary mediastinal large B-cell lymphoma|Cutaneous T-cell lymphoma|Hepatocellular carcinoma|Transitional cell carcinoma|Squamous cell carcinoma|Merkel cell carcinoma|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Urethral cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Ureter cancer|Uterine cervix tumor,1261|127|161|1705|1750|1754|1767|1771|307|3235|3257|3657|3665|3667|3673|3678|3713|4250|4265|427,,,Dragonfly Therapeutics Inc,1126911,,,Dragonfly Therapeutics Inc,1126911,,,,,,
124664,JSI-1187,JSI-1187,Research Code,Cancer,Extracellular signal related kinase-1 inhibitor|Extracellular signal related kinase-2 inhibitor,4364|4366,Anticancer protein kinase inhibitor,62255,Advanced solid tumor,3713,,,Js Innopharm (Shanghai) Ltd,1128772,,,Js Innopharm (Shanghai) Ltd,1128772,,,,,,
124690,BCA-101,"BCA-101|Bifunctional monoclonal antibody (iv, EGFR-driven advanced solid tumors) Bicara Therapeutics|EGFR/TGFbeta fusion monoclonal antibody (advanced solid tumors), Bicara Therapeutics",Research Code,Cancer,Epidermal growth factor receptor agonist|TGF beta receptor agonist,662|376,Anticancer monoclonal antibody,55685,Hepatocellular carcinoma|Anal tumor|Glioblastoma|Squamous cell carcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Chordoma|Anaplastic thyroid cancer|Uveal melanoma|Ovary tumor,1767|2193|2454|307|3657|3658|3668|3669|3673|3713|3736|3769|3788|799,,,Bicara Therapeutics Inc,1215145,,,Bicara Therapeutics Inc,1215145,,,,,,
124712,"transcription factor protein degraders (hematological malignancies), C4 Therapeutics","transcription factor protein degraders (hematological malignancies), C4 Therapeutics|CFT-7455",Research Code,Cancer,DNA binding protein Ikaros modulator|Zinc finger binding protein Aiolos modulator|Transcription factor modulator,53666|53672|2650,Anticancer,1545,Mantle cell lymphoma|Peripheral T-cell lymphoma|Multiple myeloma|Hematological neoplasm|Non-Hodgkin lymphoma,1744|1753|1828|2054|319,,,C4 Therapeutics Inc,1118122,,,C4 Therapeutics Inc,1118122,,,,,,
124751,HLX-70,"fully human anti-spike protein monoclonal antibody (COVID-19), Shanghai Henlius/Shanghai ZJ Bio-Tech/Sanyou Biopharmaceuticals|SARS-CoV-2 anti-spike glycoprotein fully human monoclonal antibody (COVID-19), Shanghai Henlius Biotech/Shanghai ZJ Bio-Tech/Sanyou Biopharmaceuticals (Shanghai)|HLX-70",Research Code,Infection,COVID19 Spike glycoprotein modulator,174434,Therapeutic antibody|Antiviral,172641|991,Coronavirus disease 19 infection,10406,,,Shanghai ZJ Bio-Tech|Shanghai Henlius Biotech Co Ltd|Sanyou Biopharmaceuticals (Shanghai) Co Ltd,1212034|1073079|1212031,,,Shanghai ZJ Bio-Tech,1212034,,,,,,
124796,MILs,"MILs|marrow infiltrating lymphocyte therapy (NSCLC), WindMIL Therapeutics|marrow infiltrating lymphocyte therapy (NSCLC/SCLC), WindMIL Therapeutics",Trade Name,Cancer,,,Anticancer|T-lymphocyte stimulator|Immunostimulant,1545|7761|393,Small-cell lung cancer|Non-small-cell lung cancer,1261|1262,,,WindMIL Therapeutics,1155853,,,WindMIL Therapeutics,1155853,,,,,,
124925,BGB-10188,"BGB-10188|PI3Kdelta inhibitor (cancer), BeiGene",Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor,11183,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Hematological neoplasm|Stage IV melanoma|Advanced solid tumor|Solid tumor,1262|1734|1744|1745|1747|1749|2054|3257|3713|725,,,BeiGene Co Ltd,1063251,,,BeiGene Co Ltd,1063251,,,,,,
124926,ARI-0001,"ARI-0001|anti-CD19 CAR T-cell therapy (ALL, NHL and CLL), Institut d'Investigacions Biomediques August Pi i Sunyer|anti-CD19-4-1BB-CD3zeta CAR-T cells (ALL, NHL and CLL), IDIBAPS",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Non-Hodgkin lymphoma,1728|1734|319,,,Immuneel Therapeutics Pvt Ltd|Institut d'Investigacions Biomediques August Pi I Sunyer,1238956|1017771,Hospital Clinic of Barcelona,1039423,Institut d'Investigacions Biomediques August Pi I Sunyer,1017771,,,,,,
124969,GLR-2007,"GLR-2007|GLR2007-237FA|CDK4 inhibitor (glioblastoma/non small cell lung caner/advanced solid tumors/brain tumor/breast cancer), Gan and Lee Pharmaceuticals|cyclin-dependent kinase 4 inhibitor (glioblastoma/non small cell lung caner/advanced solid tumors/brain tumor/breast cancer), Gan and Lee Pharmaceuticals|CDK6 inhibitor (glioblastoma/non small cell lung caner/advanced solid tumors/brain tumor/breast cancer), Gan and Lee Pharmaceuticals|cyclin-dependent kinase 6 inhibitor (glioblastoma/non small cell lung caner/advanced solid tumors/brain tumor/breast cancer), Gan and Lee Pharmaceuticals|GLR-007",Research Code|Research Code|Research Code,Cancer,Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase-6 inhibitor,4314|4318,Anticancer protein kinase inhibitor,62255,Glioma|Glioblastoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Brain tumor,1108|2454|3657|3665|3713|760,,,Gan & Lee Pharmaceuticals,1071507,,,Gan & Lee Pharmaceuticals,1071507,,Corilagin,Penicillin-Binding Protein 2a (PBP2a) (Methicillin-Resistant Staphylococcus aureus (MRSA)) Ligands|Serine Protease NS3/Non-Structural Protein 4A (NS3/NS4A) (HCV) Inhibitors,5551|3148,Cell Wall Biosynthesis Inhibitors|Antioxidants|Free Radical Scavengers|Apoptosis Inducers,2788|778|913|1062
124980,ST-067,"ST-067|decoy-resistant IL-18 (cancer), Simcha Therapeutics",Research Code,Cancer,IL-18 agonist,4812,Immunostimulant|Anticancer,393|1545,Small-cell lung cancer|Endometrioid carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Squamous cell carcinoma|Merkel cell carcinoma|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Cancer,1261|1705|1767|1771|307|3235|3257|3657|3665|3666|3667|3673|3713|3866|4250|427|651,,,Simcha Therapeutics,1193569,,,Simcha Therapeutics,1193569,,,,,,
125052,REGN-7075,"REGN-7075|dual CD28 costimulator/anti-EGFR antibody (non-small cell lung cancer/head and neck squamous cell carcinoma/cutaneous squamous cell carcinoma/colorectal cancer), Regeneron|EGFRxCD28|anti-EGFR/anti-CD28 bispecific antibody (non-small cell lung cancer/head and neck squamous cell carcinoma/cutaneous squamous cell carcinoma/colorectal cancer), Regeneron",Research Code,Cancer,Epidermal growth factor receptor modulator|T cell surface glycoprotein CD28 stimulator,3605|5105,Anticancer antibody|T-lymphocyte stimulator|Immunostimulant,55684|7761|393,Non-small-cell lung cancer|Squamous cell carcinoma|Advanced solid tumor|Breast tumor|Colorectal tumor,1262|307|3713|49|989,,,Regeneron Pharmaceuticals Inc,19214,,,Regeneron Pharmaceuticals Inc,19214,,,,,,
125065,"BCMA CAR-T, Hebei Senlang Biotechnology","BCMA CAR-T, Hebei Senlang Biotechnology|anti-BCMA CAR T-cell therapy (multiple myeloma), Hebei Senlang Biotechnology",Research Code,Cancer,APRIL receptor modulator,8255,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer|Immunostimulant,4790|7761|1545|393,Multiple myeloma,1828,,,Hebei Senlang Biotechnology Inc,1139326,,,Hebei Senlang Biotechnology Inc,1139326,,,,,,
125134,GDC-6036,GDC-6036|RG-6330,Research Code|Research Code,Cancer,K-Ras GTPase inhibitor,28039,Anticancer,1545,Non-small-cell lung cancer|Advanced solid tumor|Colorectal tumor,1262|3713|989,,,Genentech Inc,19453,,,Genentech Inc,19453,,,,,,
125259,BMS-986340,"BMS-986340|nonfucosylated anti-CCR8 mAb (cancer), Bristol-Myers Squibb|Treg modulator (cancer), Bristol-Myers Squibb",,Cancer,CCR8 chemokine modulator,3114,Anticancer monoclonal antibody|Regulatory T lymphocyte inhibitor|Immunostimulant,55685|174668|393,Squamous cell carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Uterine cervix tumor|Cancer,307|3658|3665|3666|3667|3673|3713|427|651,,,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
12544,caspofungin,caspofungin acetate|MK-0991|MK-991|Cansidas|caspofungin|Cancidas|L-743872,USAN|Research Code|Research Code|Trade Name|BANN|INN|Trade Name|Research Code,Gastrointestinal|Infection,"1,3 beta glucan synthase inhibitor",61991,Fungicide,1748,Fungal infection|Candida infection|Aspergillus infection|Abdominal abscess|Peritonitis,124|1308|29|3082|452,,,Merck & Co Inc,18077,,,Merck & Co Inc,18077,,,,,,
12551,vadimezan,"5,6-dimethylxanthenone-4-acetic acid|NSC-640488|R-1564|AS-1404|DMXAA|ASA-404|NSC-649488|5,6-MeXAA|vadimezan|[14C]ASA-404",Research Code|Research Code|Research Code|Research Code|Research Code|INN|Research Code,Cancer,Nuclear factor kappa B modulator,2652,Vascular damaging agent|Apoptosis stimulator|Anticancer,2969|1589|1545,,,Small-cell lung cancer|Non-small-cell lung cancer|Bladder cancer|Prostate tumor|Breast tumor|Solid tumor|Ovary tumor,1261|1262|2380|276|49|725|799,,,Antisoma plc|Roche Holding AG|University of Auckland|Novartis AG,14239|19446|20647|23137,University of Auckland,20647,,,,,,
125553,TAK-940,"CD19-targeted 19(T2)28z1XX CAR T-cell therapy (B-cell cancer), Memorial Sloan-Kettering Cancer Center/Takeda|anti-CD19 CAR T-cell therapy (B-cell cancer), Memorial Sloan-Kettering Cancer Center/Takeda|TAK-940",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,Chronic lymphocytic leukemia|Follicle center lymphoma|Marginal zone B-cell lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Central nervous system tumor|Burkitts lymphoma,1734|1745|1746|1747|1749|1750|316|319|759|791,,,Takeda Pharmaceutical Co Ltd|Memorial Sloan-Kettering Cancer Center,20300|22122,,,Memorial Sloan-Kettering Cancer Center,22122,Piraldina|Zinamide,Pyrazinamide,Fatty Acid Synthase (FAS) Inhibitors,1242,,
125850,SCTA-01,"SCTA-01|neutralizing monoclonal antibody (COVID-19), Sinocelltech|anti-SARS-CoV-2 spike protien mAb (COVID-19), Sinocelltech|anti-SARS-CoV-2 spike protien mAb (iv, COVID-19), Sinocelltech",Research Code,Infection,COVID19 Spike glycoprotein inhibitor,174436,Therapeutic antibody|Antiviral,172641|991,Coronavirus disease 19 infection,10406,,,Sinocelltech Ltd,1079269,,,Sinocelltech Ltd,1079269,,,,,,
125875,TRGFT-201,"TRGFT-201|TregGraft|allogeneic T-cell depleted stem cell therapy + conventional T cells + regulatory T cells (iv, ALL/AML/MS/AL), Orca Biosystems|allogeneic donor-blood-derived CD34-positive hematopoietic stem cell and progenitor cell therapy + highly purified CD34-negative CD25-positive CD4-positive CD127-negative regulatory T cells/conventional T cells (iv, hematologic malignancies), Orca Biosystems|Orca-T",Research Code|Trade Name|Trade Name,Cancer,,,Immunosuppressant|Anticancer|Regulatory T lymphocyte stimulator|Hematopoietic stimulator,396|1545|174667|610,Myelodysplastic syndrome|Acute leukemia|Acute lymphoblastic leukemia|Acute myelogenous leukemia,1272|1727|1728|1731,Hematological neoplasm,2054,Orca Biosystems Inc,1162211,,,Orca Biosystems Inc,1162211,,,Histamine H2 Receptor Antagonists,197,Signal Transduction Modulators,1402
125949,SPYK-04,SPYK-04,Research Code,Cancer,,,Anticancer|Unspecified drug target,1545|59620,Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic ovary cancer,3665|3713|3866,,,Chugai Pharmaceutical Co Ltd,15414,,,Chugai Pharmaceutical Co Ltd,15414,,,,,,
126235,MB-CAR-T19-22,"anti-CD19/anti-CD22 CAR T-cell therapy (B-lineage acute lymphoblastic leukemia), Federal Research Institute of Pediatric Hematology, Oncology and Immunology|bispecific CD19/CD22 CAR-T cell therapy (B-lineage acute lymphoblastic leukemia), Federal Research Institute of Pediatric Hematology, Oncology and Immunology|MB-CAR-T19-22|dual anti-CD19/anti-CD22 CAR T-cell therapy (B-lineage acute lymphoblastic leukemia), Federal Research Institute of Pediatric Hematology, Oncology and Immunology",Research Code,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte cell adhesion molecule modulator,5080|5089,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,B-cell acute lymphoblastic leukemia,1729,,,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",1162301,,,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",1162301,,,,,,
126250,ETH-155008,"ETH-155008|CDK4/CDK6/PIM/FLT3 inhibitor (cancer/NHL/AML), Shengke Therapeutics",Research Code,Cancer,Flt3 tyrosine kinase inhibitor|Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase-6 inhibitor|PIM protein kinase inhibitor,3806|4314|4318|4522,Anticancer protein kinase inhibitor,62255,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Non-Hodgkin lymphoma|Cancer,1731|1734|319|651,,,Shengke Pharmaceuticals (Jiangsu) Ltd,1180972,,,Shengke Pharmaceuticals (Jiangsu) Ltd,1180972,,,,,,
126265,brexucabtagene autoleucel,"eACT (cancer), Kite Pharma|anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma), Kite Pharma|Tecartus|brexucabtagene autoleucel|KTE-X19|Brexu-cel",Trade Name|USAN|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma,1728|1734|1744,Non-Hodgkin lymphoma,319,Kite Pharma Inc,1056870,Cabaret Biotech Ltd,1096601,Cabaret Biotech Ltd,1096601,,,,,,
126302,YT-19/22,"YT-19/22|dual anti-CD19/anti-CD22 STAR-T cells (B-cell acute lymphoblastic leukemia), China Immunotech|dual anti-CD19/anti-CD22 CAR T-cell therapy (STAR-T Technology, B-ALL), China Immunotech",Research Code,Cancer,B-lymphocyte antigen CD19 modulator|B-lymphocyte cell adhesion molecule modulator,5080|5089,Anticancer|T-lymphocyte stimulator|Immunostimulant,1545|7761|393,B-cell acute lymphoblastic leukemia,1729,,,China Immunotech Co Ltd,1186841,,,China Immunotech Co Ltd,1186841,,,,,,
126433,JWCAR-129,"JWCAR-129|anti-BCMA CAR-T cell therapy (multiple myeloma), JW Therapeutics (Shanghai)/Juno Therapeutics|anti-BCMA CAR-T cell therapy (multiple myeloma), JW Therapeutics (Shanghai)/Celgene",Research Code,Cancer,APRIL receptor modulator,8255,Genetically engineered autologous cell therapy|Immunostimulant|T-lymphocyte stimulator|Anticancer,4790|393|7761|1545,Multiple myeloma,1828,,,Bristol-Myers Squibb Co|JW Therapeutics (Shanghai) Co Ltd,15065|1122031,Juno Therapeutics Inc|Celgene Corp,1090676|15331,Juno Therapeutics Inc,1090676,,,,,,
126457,PRT-1419,"PRT-1419|myeloid leukemia cell differentiation protein 1 inhibitor (hematological neoplasm), Prelude Therapeutics",Research Code,Cancer,Mcl-1 differentiation protein inhibitor,11381,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Hematological neoplasm|Non-Hodgkin lymphoma,1272|1731|1828|2054|319,,,Prelude Therapeutics Inc,1158197,,,Prelude Therapeutics Inc,1158197,,,,,,
12646,panitumumab,"ABX-EGF|panitumumab|rHuMAb-EGFr, Amgen/ Abgenix|anti-EGFr antibody, Abgenix/Amgen|anti-EGFr antibody, Abgenix/Immunex|Vectibix",Research Code|USAN|BANN|INN|Trade Name,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Rectal tumor|Pancreatic ductal adenocarcinoma|Metastatic colorectal cancer|Inflammatory breast cancer,1055|1507|3658|3948,Esophagus tumor|Biliary tumor|Renal cell carcinoma|Anal tumor|Pancreas tumor|Gallbladder tumor|Hormone refractory prostate cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Solid tumor|Ovary tumor,1011|1515|1766|2193|249|3146|3246|3665|3666|3667|3673|725|799,Amgen Inc|Amgen-Beta Pharmaceuticals Co Ltd|Dr Reddy's Laboratories Ltd|Takeda Pharmaceutical Co Ltd,14109|1083224|29387|20300,Hypera Pharma SA|Immunex Corp|Abgenix Inc|GlaxoSmithKline plc,1058614|14131|23748|28355,Abgenix Inc,23748,,,,,,
126526,RC-1012,"RC-1012|DNT-UHN-1|WYZE-DNT|double negative T-cell therapy (acute myeloid leukemia/solid tumor/hematological cancer), Wyze Biotech/University of Toronto",Research Code|Research Code|Research Code,Cancer,,,Immunostimulant|T-lymphocyte stimulator|Anticancer,393|7761|1545,Acute myelogenous leukemia|Metastatic non small cell lung cancer,1731|3665,,,University of Toronto|Wyze Biotech Co Ltd,20688|1220994,,,University of Toronto,20688,,,,,,
126549,GSK-3901961,"GSK-3901961|anti-NY-ESO-1/LAGE-1a/HLA-A*02:01/HLA-A*02:05/HLA-A*02:06 TCR T-cell therapy (synovial sarcoma/NSCLC/advanced tumor), GlaxoSmithKline|CD8alpha-expressing anti-NY-ESO-1/LAGE-1a/HLA-A*02:01/HLA-A*02:05/HLA-A*02:06 TCR T-cell therapy (synovial sarcoma/NSCLC/advanced tumor), GlaxoSmithKline|adoptive T-cell therapy (synovial sarcoma/non small cell lung cancer/advanced tumor), GlaxoSmithKline",Research Code,Cancer,Cancer testis antigen NY-ESO-1 modulator|HLA class I antigen A-2 alpha modulator,50096|19115,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer|Immunostimulant,7761|4790|1545|393,Sarcoma|Metastatic non small cell lung cancer|Advanced solid tumor,194|3665|3713,,,GlaxoSmithKline plc,28355,,,GlaxoSmithKline plc,28355,,,,,,
126550,GSK-3845097,"GSK-3845097|anti-NY-ESO-1/LAGE-1a/HLA-A*02:01/HLA-A*02:05/HLA-A*02:06 TCR T-cell therapy (synovial sarcoma/advanced tumor), GlaxoSmithKline|adoptive T-cell therapy (synovial sarcoma/advanced tumor), GlaxoSmithKline",Research Code,Cancer,Cancer testis antigen NY-ESO-1 modulator|HLA class I antigen A-2 alpha modulator,50096|19115,T-lymphocyte stimulator|Anticancer|Immunostimulant|Genetically engineered autologous cell therapy,7761|1545|393|4790,Sarcoma|Advanced solid tumor,194|3713,,,GlaxoSmithKline plc,28355,,,GlaxoSmithKline plc,28355,,,,,,
126610,KIN-2787,"BRAF inhibitors (melanoma/NSCLC), Kinnate Biopharma|KIN00-2787|KIN-2787",Research Code|Research Code,Cancer,Raf B protein kinase inhibitor,4548,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Non-small-cell lung cancer|Melanoma|Stage IV melanoma|Metastatic non small cell lung cancer|Advanced solid tumor|Solid tumor,1262|205|3257|3665|3713|725,,,Kinnate Biopharma Inc|undisclosed,1166126|1051267,,,Kinnate Biopharma Inc,1166126,,,,,,
126633,SMART-101,"allogeneic T-cell therapy, Smart Immune|CD7-positive/CD34-negative/CD5-negative ProTcell (injectable, SCID/AML/ALL/SCID/AML/ALL/infections), Smart Immune|allogenic human T-lymphoid progenitor cells (ex-vivo thymus platform, injectable, SCID/AML/ALL/infections), Smart Immune|ProTcell, Smart Immune|SMART-101",Research Code,Cancer|Immune|Infection,,,Unspecified drug target|Immunostimulant|Anticancer|T-lymphocyte stimulator,59620|393|1545|7761,Acute lymphoblastic leukemia|Acute myelogenous leukemia|Severe combined immunodeficiency syndrome|Hematopoietic stem cell transplantation|Infectious disease,1728|1731|3623|3888|746,,,Smart Immune SAS,1221351,,,Smart Immune SAS,1221351,,,,,,
126644,FL-101,"FL-101|IL-1 beta inhibitors (inflammation driven lung cancer), Flame Biosciences|IL-1 beta inhibitors (non-small cell lung cancer), Flame Biosciences",Research Code,Cancer|Inflammatory,Interleukin-1 beta ligand inhibitor,12479,Anti-inflammatory|Anticancer,2953|1545,Inflammatory disease|Metastatic non small cell lung cancer|Lung tumor,188|3665|755,,,Flame Biosciences  Inc,1221301,,,Flame Biosciences  Inc,1221301,,,Thromboxane A2 Receptor (TBXA2R; TP) Antagonists|Thromboxane Synthase Inhibitors,298|503,Signal Transduction Modulators,1402
126751,INCB-106385,"INCB-106385|A2a/A2b adenosine receptor antagonist (cancer), Incyte|A2aR checkpoint inhibitor/A2bR checkpoint inhibitor (cancer), Incyte",Research Code,Cancer,Adenosine A2a receptor antagonist|Adenosine A2b receptor antagonist,596|598,Immunostimulant|T-lymphocyte stimulator|Anticancer,393|7761|1545,Squamous cell carcinoma|Hormone refractory prostate cancer|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Solid tumor,307|3246|3466|3657|3665|3673|3713|3866|725,,,Incyte Corp,17216,,,Incyte Corp,17216,,,,,,
126844,JAB-8263,"JAB-8263|BET inhibitor (oral tablet, solid tumors/myelofibrosis/acute myeloid leukemia), Jacobio Pharmaceuticals|BET inhibitor (oral tablet, solid tumors/myelofibrosis/acute myeloid leukemia/Hematological neoplasm), Jacobio Pharmaceuticals",Research Code,Cancer|Hematologic,Bromodomain containing protein inhibitor,34558,Anticancer,1545,Small-cell lung cancer|Acute myelogenous leukemia|Multiple myeloma|Hematological neoplasm|Myelofibrosis|Hormone refractory prostate cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Advanced solid tumor|Metastatic ovary cancer|Solid tumor,1261|1731|1828|2054|2436|3246|3665|3667|3713|3866|725,,,Jacobio Pharmaceuticals Co Ltd,1157883,,,Jacobio Pharmaceuticals Co Ltd,1157883,,,,,,
126908,JNJ-75348780,"JNJ-75348780|anti-CD3/anti-CD22 bispecific T-cell engager (B-cell non-Hodgkin lymphoma/chronic lymphocytic leukemia), Janssen",Research Code,Cancer,CD3 modulator|B-lymphocyte cell adhesion molecule modulator,5023|5089,T-lymphocyte stimulator|Immunostimulant|Anticancer antibody,7761|393|55684,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1734|1743|1744|1745|1746|1749|319,,,Janssen Research & Development LLC,1067538,,,Janssen Research & Development LLC,1067538,,,,,,
126964,ESG-401,"ESG-401|humanized mAb anti-TROP-2 program (cancer), Shanghai Escugen Biotechnology",Research Code,Cancer,Trop-2 calcium signal transducer inhibitor,17895,Anticancer monoclonal antibody,55685,Unidentified indication|Small-cell lung cancer|Endometrioid carcinoma|Hepatocellular carcinoma|Metastatic urinary tract cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor,1005|1261|1705|1767|3465|3657|3658|3664|3665|3666|3667|3669|3673|3866|4250|427,,,Shanghai Escugen Biotechnology Co Ltd,1222085,,,Shanghai Escugen Biotechnology Co Ltd,1222085,,,,,,
126969,PF-07284890,"PF-07284890|ARRY-461|B-Raf inhibitor (oral, brain penetrant, advanced solid tumor), Pfizer|BRAF BP (melanoma), Pfizer|brain-penetrant V600X BRAF inhibitor (melanoma and other BRAF-driven cancers), Pfizer",Research Code|Research Code,Cancer,Raf B protein kinase inhibitor,4548,Anticancer protein kinase inhibitor,62255,Stage IV melanoma|Metastatic non small cell lung cancer|Advanced solid tumor|Brain tumor,3257|3665|3713|760,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
127010,"anti-CD19 CAR T-cell therapy (B-cell non-Hodgkin lymphoma), University of California, San Francisco/University of California, Davis","anti-CD19 CAR T-cell therapy (B-cell non-Hodgkin lymphoma), University of California, San Francisco/University of California, Davis",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|Lymphoma|Non-Hodgkin lymphoma|Burkitts lymphoma,1743|1744|1745|1749|1750|203|319|791,,,University of California San Francisco|University of California Davis,24773|29856,,,University of California San Francisco,24773,,,,,,
127045,PF-07248144,"PF-07248144|KAT6 inhibitor (cancer), Pfizer",Research Code,Cancer,Histone acetyltransferase MYST inhibitor,90663,Anticancer,1545,Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Breast tumor,3246|3657|3665|3713|49,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
127046,PF-07284892,"PF-07284892|SHP2 inhibitor (cancer), Pfizer",Research Code,Cancer,Protein tyrosine phosphatase-2C inhibitor,10327,Anticancer,1545,Cancer,651,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
127048,PF-07104091,"PF-07104091|CDK2 selective next-generation CDK inhibitor (breast cancer, ovarian cancer, NSCLC, SCLC), Pfizer",Research Code,Cancer,Cyclin-dependent kinase-2 inhibitor,4310,Cell cycle inhibitor|Anticancer protein kinase inhibitor|Synergist,767|62255|7293,Small-cell lung cancer|Fallopian tube cancer|Peritoneal tumor|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic ovary cancer|Breast tumor,1261|2243|3083|3657|3665|3866|49,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
127049,PF-07220060,PF-07220060,Research Code,Cancer,Cyclin-dependent kinase-4 inhibitor,4314,Anticancer protein kinase inhibitor|Cell cycle inhibitor,62255|767,Liposarcoma|Prostate tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Breast tumor|Lung tumor|Colorectal tumor,2447|276|3657|3658|3664|3665|49|755|989,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
127055,CoVac-1,"CoVac-1|SARS-CoV-2 multipeptide vaccine (subcutaneous, COVID-19), University Hospital Tuebingen|personalizied multi-peptide vaccine (chronic lymphocytic leukemia), University Hospital Tuebingen",Research Code,Cancer|Immune|Infection,CD4 agonist|T-cell surface glycoprotein CD8 stimulator,5027|5039,Protein subunit vaccine|Prophylactic vaccine|Anticancer,12372|12378|1545,Coronavirus disease 19 infection|Chronic lymphocytic leukemia|Immune deficiency,10406|1734|504,,,University Hospital Tubingen,1039869,,,University Hospital Tubingen,1039869,ABLC (former Brand Name)|Abelcet,Amphotericin B lipid complex|Liposomal amphotericin B|Liposome-encapsulated amphotericin B,Ergosterol Ligands,10369,Cell Membrane Disrupting Agents,2787
127168,RO-7425781,RO-7425781|RG-6234,Research Code|Research Code,Cancer,,,Unspecified drug target|Anticancer,59620|1545,Multiple myeloma,1828,,,Roche Holding AG,19446,,,Roche Holding AG,19446,,,,,,
127244,"XYF19 CAR-T cell therapy, Yufan/Abound Bio","XYF19 CAR-T cell therapy, Yufan/Abound Bio|anti-CD19 autologous CAR T-cell therapy (relapsed or refractory CD19+ leukemia/lymphoma), Yufan Biotechnologies|anti-CD19 CAR T-cell therapy (relapsed or refractory CD19+ leukemia/lymphoma), Yufan/Abound Bio|XYF19 CAR-T cells|anti-CD19 CAR T-cell therapy (CRISPR/Cas9 HPK1 knock-out, relapsed/refractory CD19-positive leukemia/lymphoma), Yufan/Abound Bio",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,Acute leukemia|Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Hairy cell leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Lymphoma|B-cell lymphoma|Burkitts lymphoma,1727|1728|1729|1734|1736|1743|1744|1745|1746|1747|1749|203|316|791,,,Xi'An Yufan Biotechnologies Co Ltd|Abound Bio,1186100|1217092,,,Xi'An Yufan Biotechnologies Co Ltd,1186100,,,,,,
12737,"dexamethasone (sustained release ophthalmic), Allergan/Sanwa","dexamethasone|Posurdex|dexamethasone (ophthalmic), Oculex|intraocular DDS (uveitis), Oculex|dexamethasone (sustained release ophthalmic), Allergan/Sanwa|SK-0503|Ozurdex|AoDiShi",BANN|INN|Trade Name|Research Code|Trade Name,Ocular,,,Ophthalmological agent|Corticosteroid agonist|Steroidal anti-inflammatory,15128|3189|2954,Retinal venous occlusion|Diabetic macular edema|Macular edema|Uveitis,2656|2659|3352|341,Age related macular degeneration|Ocular inflammation,1226|686,AbbVie Inc,1072507,Samil Allergan|Allergan plc|Allergan Inc|Oculex Pharmaceuticals Inc|Sanwa Kagaku Kenkyusho Co Ltd,1086108|1088700|14042|21374|22960,Oculex Pharmaceuticals Inc,21374,,,,,,
127415,ASP-0739,"undisclosed tumor antigen loaded aAVCs (cancer), Astellas|ASP-0739|NY-ESO-1 cancer testis antigen loaded aAVCs (cancer), Astellas",Research Code,Cancer,Cancer testis antigen NY-ESO-1 modulator,50096,Immunostimulant|Anticancer,393|1545,Esophagus tumor|Non-small-cell lung cancer|Sarcoma|Melanoma|Adenocarcinoma|Liposarcoma|Squamous cell carcinoma|Advanced solid tumor,1011|1262|194|205|2399|2447|307|3713,Cancer,651,Astellas Pharma Inc,1013295,,,Astellas Pharma Inc,1013295,,,,,,
127591,RG-6007,"RO-7283420|RG-6007|HLA-A2-WT1 x CD3 (acute myeloid leukemia), Roche|anti-CD3/anti-WT1/anti-HLA-A2 bispecific T-cell engager (AML), Roche",Research Code,Cancer,CD3 modulator|Wilms tumor protein modulator|HLA class I antigen A-2 alpha modulator,5023|30009|19115,T-lymphocyte stimulator|Anticancer antibody|Immunostimulant,7761|55684|393,Acute myelogenous leukemia,1731,,,Hoffmann-La Roche Inc,19461,,,Hoffmann-La Roche Inc,19461,,,,,,
127656,EP-0042,EP-0042,Research Code,Cancer,Flt3 tyrosine kinase inhibitor|Aurora protein kinase inhibitor,3806|4412,Anticancer protein kinase inhibitor,62255,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelomonocytic leukemia,1272|1731|6833,,,The Insitute of Cancer Research|Ellipses Pharma Ltd,1125142|1137885,,,The Insitute of Cancer Research,1125142,,,,,,
127685,GNC-039,GNC-039,Research Code,Cancer,,,Anticancer antibody|Unspecified drug target,55684|59620,Glioma|Advanced solid tumor,1108|3713,,,Sichuan Biokin Pharmaceutical Co Ltd,1069227,,,Sichuan Biokin Pharmaceutical Co Ltd,1069227,,Arpromidine,,,,
127686,D-1553,"D-1553|KRAS G12C inhibitor (advanced solid tumor), InventisBio",Research Code,Cancer,K-Ras GTPase inhibitor,28039,Anticancer,1545,Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,3658|3665|3713,,,InventisBio Inc,1119771,,,InventisBio Inc,1119771,,,Renin Inhibitors,484,,
127854,OPD-5,"OPD-5|peptide conjugated alkylator (peptide-drug conjugate (PDC) platform, multiple myeloma), Oncopeptides",Research Code,Cancer,Aminopeptidase modulator,1768,Anticancer alkylating agent,50,Multiple myeloma|Cancer,1828|651,,,Oncopeptides AB,29334,,,Oncopeptides AB,29334,,,,,,
127860,FHD-286,"FHD-286|allosteric ATPase inhibitor of BRG1 and BRM (oral, acute myeloid leukemia/uveal melanoma), Foghorn Therapeutics",Research Code,Cancer,Transcription activator SNF2L2 inhibitor|Transcription activator BRG1 inhibitor,72813|66992,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm|Uveal melanoma,1272|1731|2054|3788,,,Foghorn Therapeutics Inc,1154647,,,Foghorn Therapeutics Inc,1154647,,(-)-(S)-Bromofosfamide|--S-Bromofosfamide,DNA Alkylating Drugs,1895,,
127888,GFH-009,"GFH-009|CDK9 inhibitor (intravenous, solid tumor/hematological cancer), GenFleet Therapeutics",Research Code,Cancer,Cyclin-dependent kinase-9 inhibitor,8110,Anticancer protein kinase inhibitor,62255,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Lymphoma|Hematological neoplasm|Solid tumor,1731|1734|203|2054|725,,,GenFleet Therapeutics,1167362,,,GenFleet Therapeutics,1167362,,,,,,
12799,CLR-131,"NM-324|125I-NM-404|125I-NM-412|Iodine-125-NM-404|small molecule phospholipid ether analogs (cancer), University of Michigan|radiolabeled phospholipid ether (cancer), Cellectar|131I-CLR-1404|125I-CLR-1404|131I-NM-404|NM-404-[131I]|CLR-1404-[131I]|Iodine-131-NM-404|Iodine-131-CLR-1404|NM-404-[125I]|Iodine-125-CLR-1404|CLR-1404-[125I]|Iodine-125-NM-412|NM-412-[125I]|CLR-131|I-131-CLR1404|CLR-127",Research Code|Research Code|Analogue|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Analogue|Research Code|Analogue|Research Code|Research Code|Research Code|Research Code,Cancer,,,Anticancer|Radiotherapeutic,1545|5721,Glioma|Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Osteosarcoma|Multiple myeloma|Lymphoma|Rhabdomyosarcoma|Neuroblastoma|Ewing sarcoma|Soft tissue sarcoma|Head and neck tumor|Solid tumor|Uterus tumor,1108|1734|1743|1744|1747|1749|1772|1828|203|2448|2726|2975|3378|623|725|740,,,Cellectar Biosciences Inc,27692,Cellectar LLC|University of Michigan,1016193|20623,University of Michigan,20623,,,,,,
128044,"anti-CD7 CAR T-cell therapy (CD7-positive hematological malignancies), Zhejiang University/Yake Biotechnology Ltd","anti-CD7 CAR T-cell therapy (CD7-positive hematological malignancies), Zhejiang University/Yake Biotechnology Ltd|anti-CD7 CAR T-cell therapy (CD7-positive hematological malignancies), Zhejiang University|anti-CD7 CAR T-cell therapy (CD7-positive hematological malignancies), Yake Biotechnology|anti-CD7 CAR T-cell therapy (CD7-positive T-cell acute lymphoblastic leukemia/non-hodgkin lymphoma/acute myelogenous leukemia), Yake Biotechnology/Zhejiang University",,Cancer,T-cell antigen CD7 modulator,5035,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,T-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|T-cell lymphoma|Non-Hodgkin lymphoma,1730|1731|311|319,Leukemia,199,Shanghai YaKe Biotechnology Ltd|Zhejiang University,1163468|1014561,,,Zhejiang University,1014561,,,Thromboxane Synthase Inhibitors,503,,
12806,dexamethasone cipecilate,ST-126|TO-199|ST-126P|dexamethasone cipecilate|Erizas|NS-126|NS-126C|NS-126Z,Research Code|Research Code|Research Code|INN|Trade Name|Research Code|Research Code|Research Code,Immune|Respiratory,Glucocorticoid receptor agonist,3191,Respiratory system agent|Steroidal anti-inflammatory,1470|2954,Allergic rhinitis,1107,Asthma,31,YooYoung Pharmaceuticals Co Ltd|Nippon Shinyaku Co Ltd,1040351|18552,Hisamitsu Pharmaceutical Co Inc|SS Pharmaceutical - ethical drug division|Torii Pharmaceutical Co Ltd,16802|20235|26065,SS Pharmaceutical - ethical drug division,20235,,,,,,
128249,JNJ-74856665,"JNJ-74856665|dihydroorotate dehydrogenase inhibitor (oral, acute myeloid leukemia/myelodysplastic syndrome), Janssen Research & Development LLC",Research Code,Cancer,Dihydroorotate dehydrogenase inhibitor,1716,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Janssen Research & Development LLC,1067538,,,Janssen Research & Development LLC,1067538,,,,,,
128365,NewishT,"NewishT|autologous T central memory cells therapy (solid cancer), Newish Technology",Research Code,Cancer,,,Anticancer|T-lymphocyte modulator,1545|5692,Cholangiocarcinoma|Hepatocellular carcinoma|Metastatic non small cell lung cancer|Solid tumor,1765|1767|3665|725,,,Newish Technology (Beijing) Co,1160600,,,Newish Technology (Beijing) Co,1160600,,,,,,
12838,bimatoprost,"AGN-192024|bimatoprost|Lumigan|AGN-024|glaucoma therapy, Allergan|Lumigan X|Lumigan RC|Lumigan UD",Research Code|USAN|INN|Trade Name|Research Code|Trade Name|Trade Name|Trade Name,Ocular,Prostanoid receptor agonist,317,Topical antiglaucoma agent|Antihypertensive,15137|2657,Glaucoma|Ocular hypertension,134|240,,,Senju Pharmaceutical Co Ltd|AbbVie Inc,19854|1072507,Allergan plc|Allergan Inc,1088700|14042,Allergan Inc,14042,,,,,,
128808,CBG-002,"anti-BCMA CAR T-cell therapy (multiple myeloma), Carbiogene Therapeutics|CBG-002",Research Code,Cancer,APRIL receptor modulator,8255,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,Multiple myeloma,1828,,,Carbiogene Therapeutics Co. Ltd,1226756,,,Carbiogene Therapeutics Co. Ltd,1226756,,,,,,
12887,"lintuzumab/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome), Targa Therapeutics","HuM195/rGel (leukemia), Targa Therapeutics|HuM195/rGel, MD Anderson|conjugated anti-CD33 antibodies (cancer), MD Anderson|anti-CD33 immunotoxin (leukemia), Memorial Sloan-Kettering|HuM195-gelonin immunotoxin, Memorial Sloan-Kettering/MD Anderson|HuM195-gelonin immunotoxin (leukemia), Targa Therapeutics|HuM195/rGel (intravenous infusion, acute myelogenous leukemia/chronic myelogenous leukemia/meylodisplastic syndrome), Targa Therapeutics|HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome), Targa Therapeutics|lintuzumab/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome), Targa Therapeutics",,Cancer,CD33 antagonist,5121,Anticancer monoclonal antibody|Immunotoxin,55685|539,,,Leukemia,199,,,Targa Therapeutics Corp|Memorial Sloan-Kettering Cancer Center|MD Anderson Cancer Center,1022016|22122|23382,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
128907,PF-07209960,PF-07209960|PD-1 targeting IL-15 fusion protein (advanced/metastatic solid tumors) Pfizer|PD-1 targeted IL-15 mutein (advanced/metastatic solid tumors) Pfizer|PD-1 targeted IL-15 mutein (advanced/metastatic solid tumor/NSCLC/squamous cell carcinoma of the head and neck/renal cell/urothelial/ovarian carcinoma) Pfizer|PD-1 targeting IL-15 fusion protein (advanced/metastatic solid tumor/NSCLC/squamous cell carcinoma of the head and neck/renal cell/urothelial/ovarian carcinoma) Pfizer,Research Code,Cancer,IL-15 receptor agonist|Programmed cell death protein 1 modulator,3085|67134,Immunomodulator|Anticancer antibody,1596|55684,Transitional cell carcinoma|Squamous cell carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Ovary tumor,1771|307|3658|3665|3713|4250|799,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
128969,SH-3809,SH-3809,Research Code,Cancer,,,Unspecified drug target|Anticancer,59620|1545,Advanced solid tumor,3713,,,Nanjing Sanhome Pharmaceutical Co Ltd,1023952,,,Nanjing Sanhome Pharmaceutical Co Ltd,1023952,,,Thromboxane A2 Receptor (TBXA2R; TP) Antagonists|Thromboxane Synthase Inhibitors,298|503,Signal Transduction Modulators,1402
128984,FH-MagIC TCR-T cell therapy,"MAGE-A1-specific TCR T-cell therapy|FH-MagIC TCR-T cell therapy|anti-MAGE-A1/HLA-A*0201 TCR T-cell therapy (metastatic breast cancer/metastatic non small cell lung cancer/urothelial carcinoma/advanced solid tumor), Fred Hutchinson Cancer Research Center/SignalOneBio|autologous T-cell therapy (intravenous, metastatic breast cancer/metastatic non small cell lung cancer/urothelial carcinoma/advanced solid tumor), Fred Hutchinson Cancer Research Center/SignalOneBio",,Cancer,Melanoma associated antigen 1 modulator|HLA class I antigen A-2 alpha modulator,21952|19115,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,Transitional cell carcinoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor,1771|3657|3665|3713,,,SignalOneBio Inc.,1228395,,,SignalOneBio Inc.,1228395,,,,,,
12901,broxuridine,"5-BDU|broxuridine|BudR|NSC-38297|Broxine|NEOMARK-BU|BUdR, NeoPharm",INN|Research Code|Trade Name|Trade Name,,,,Anticancer|Diagnostic agent|Radiosensitizer|CNS diagnostic agent|Cell cycle inhibitor|Neoplasm diagnostic agent|Endocrine diagnostic agent,1545|4154|1542|7211|767|7220|7212,,,Glioma|Breast tumor|Brain tumor,1108|49|760,,,BioChem Therapeutic Inc|National Cancer Institute (NCI)|NeoPharm Inc,14692|20519|23940,National Cancer Institute (NCI),20519,,,,,,
129281,NVG-111,"NVG-111|anti-CD3/anti-ROR1 bispecific T-cell engager (hematological cancer), NovalGen",Research Code,Cancer,CD3 modulator|Ntrkr1 tyrosine kinase receptor modulator,5023|3821,Immunostimulant|T-lymphocyte stimulator|Anticancer antibody,393|7761|55684,Chronic lymphocytic leukemia|Mantle cell lymphoma|Non-Hodgkin lymphoma,1734|1744|319,,,NovalGen Ltd,1223598,,,NovalGen Ltd,1223598,,,,,,
129347,LNK-01002,"LNK-01002|Ras protein inhibitor (oral/capsule/PROTAC), malignant myeloid hematological tumor), Lynk Pharmaceuticals/Kobe University/RIKEN|LNK-1000318",Research Code|Research Code,Cancer|Hematologic,Ras GTPase inhibitor,10451,Anticancer,1545,Acute myelogenous leukemia|Hematological neoplasm|Thrombocythemia|Polycythemia vera|Myelofibrosis|Cancer,1731|2054|2317|2319|2436|651,,,Lynk Pharmaceuticals Co Ltd,1212081,RIKEN|Kobe University,19442|25421,Kobe University,25421,,,,,,
129367,"dual anti-CS-1/anti-BCMA CAR T-cell therapy (multiple myeloma), Wuhan Sian Medical Technology","dual anti-BCMA/anti-CS-1 CAR T-cell therapy (multiple myeloma), Wuhan Sian Medical Technology|dual anti-CS-1/anti-BCMA CAR T-cell therapy (multiple myeloma), Wuhan Sian Medical Technology",,Cancer,SLAM family member 7 modulator|APRIL receptor modulator,45393|8255,T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy|Anticancer,7761|393|4790|1545,Multiple myeloma,1828,,,"Wuhan Sian Medical Technology Co, Ltd",1139510,,,"Wuhan Sian Medical Technology Co, Ltd",1139510,,,,,,
129406,SGN-STNV,"SGN-STNV|anti-SialylTn-vedotin conjugate (solid tumors), Seagen Inc",Research Code,Cancer,,,Sialyl Thomsen nouveau antigen inhibitor|Anticancer antibody,172922|55684,Endometrioid carcinoma|Adenocarcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer|Appendix adenoma|Uterine cervix tumor,1705|2399|3657|3658|3665|3666|3667|3669|3713|3866|3987|427,,,Seagen Inc,25554,,,Seagen Inc,25554,,,Calcium Channel Blockers,361,,
129484,68Ga-NOTA-hGZP,"68Ga-NOTA-hGZP|68Ga-NOTA-GZP, Massachusetts General Hospital|Gallium-68-NOTA-hGZP|Granzyme B PET imaging agent (metastatic melanoma/non small cell lung cancer), Cytosite Biopharma|68Ga-NOTA-hGZP, Massachusetts General Hospital/University of Alabama at Birmingham",,Cancer,,,Imaging agent|PET contrast agent|Neoplasm diagnostic agent|Diagnostic agent|Anticancer|Radiodiagnostic,4155|5555|7220|4154|1545|5720,Stage IV melanoma|Metastatic non small cell lung cancer,3257|3665,,,Cytosite Biopharma Inc,1193330,University of Alabama at Birmingham|Massachusetts General Hospital,20524|21569,Massachusetts General Hospital,21569,,,,,,
129568,"anti-CD38 CAR T-cell therapy (acute myeloid leukemia), Shanghai Unicar-Therapy Bio-Medicine Technology/Soochow University/East China Normal University","anti-CD38 CAR T-cell therapy (acute myeloid leukemia), Shanghai Unicar-Therapy Bio-Medicine Technology/Soochow University/East China Normal University",,Cancer,ADP ribosyl cyclase-1 modulator,5134,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,Acute myelogenous leukemia,1731,,,Shanghai Unicar-Therapy Bio-medicine Technology Co Ltd|Soochow University|East China Normal University,1144294|1031298|1045499,,,Soochow University,1031298,Canef|Cranoc|Fractal|Lescol|Lescol XL|Lochol|Locol|Xilep XL,Fluindostatin sodium|Fluvastatin sodium,3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Inhibitors,437,Apoptosis Inducers,1062
12963,"Triapine (intravenous, cancer), Ology Bioservices","3-AP|3-AMP|Triapine|ortho-3AP|3-AP, Vion|5-fluoro-ortho-phosphate-3AP, Vion|Triapine (intravenous, cancer), Vion|OCX-191|Triapine (myeloproliferative disorder), Vion|Triapine (intravenous, cancer), Nanotherapeutics|NTO-1151|Triapine (intravenous, cancer), Ology Bioservices|Triapine (intravenous, cancer), National Resilience Inc",Research Code|Trade Name|Research Code|Research Code,Cancer|Hematologic|Infection,Ribonucleotide reductase M2 subunit inhibitor,23195,Iron chelator|Antiviral|HIV replication inhibitor|Apoptosis stimulator|Anticancer|Angiogenesis inhibitor,2557|991|747|1589|1545|61,Vaginal cancer|Uterine cervix tumor,3291|427,Myelodysplastic syndrome|Hepatitis B virus infection|Herpes simplex virus infection|HIV infection|Leukemia|Myeloproliferative disorder|Solid tumor,1272|152|157|158|199|273|725,National Resilience Inc,1227544,Ology Bioservices Inc|Beijing Pason Pharmaceuticals Inc|Vion Pharmaceuticals Inc,1003870|1004411|23318,Vion Pharmaceuticals Inc,23318,,,,,,
129685,CC-95266,CC-95266,Research Code,Cancer,,,Anticancer|Unspecified drug target,1545|59620,Multiple myeloma,1828,,,Juno Therapeutics Inc,1090676,,,Juno Therapeutics Inc,1090676,,,,,,
129688,LM-061,"LM-061|kinase inhibitor (oral, advanced tumor/hematologic malignancy), LaNova",Research Code,Cancer,Protein kinase inhibitor,336,Anticancer protein kinase inhibitor,62255,Metastasis|Hematological neoplasm|Advanced solid tumor|Cancer,1069|2054|3713|651,,,LaNova Medicines Ltd,1228941,,,LaNova Medicines Ltd,1228941,,,,,,
129694,GDT-002,"TEG-002|autologous T cells transduced with a specific gamma delta T-cell receptor (infusion, multiple myeloma), Gadeta|TCR gamma delta T-cell therapy (multiple myeloma), Gadeta|autologous T-cells expressing gamma delta T-cell receptor (breast tumor), Gadeta|TCR T-cell therapy (multiple myeloma), Gadeta|GDT-002",Research Code|Research Code,Cancer,HLA antigen modulator,19106,Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator|Immunostimulant,4790|1545|7761|393,Multiple myeloma,1828,Breast tumor,49,Gadeta BV,1121405,,,Gadeta BV,1121405,,,,,,
12973,sunitinib,"SU-11248|SU-12662|SU-11248J|PDGF TK antagonist (cancer), SUGEN|Sutent|sunitinib malate|SU-011248|SU-010398|PHA-290940AD|sunitinib|Sutene|SU-012662",Research Code|Metabolite|Research Code|Trade Name|USAN|Research Code|Research Code|Research Code|INN|Trade Name|Metabolite,Cancer|Cardiovascular,Flt3 tyrosine kinase inhibitor|PDGF receptor beta antagonist|PDGF receptor alpha antagonist|VEGF-3 receptor antagonist|VEGF-2 receptor antagonist|VEGF-1 receptor antagonist|RET tyrosine kinase receptor family inhibitor|Kit tyrosine kinase inhibitor|CSF-1 antagonist,3806|48492|48489|3850|3848|3846|3816|3808|3154,Angiogenesis inhibitor|Anticancer protein kinase inhibitor,61|62255,Neuroendocrine tumor|Thyroid tumor|Pancreatic endocrine tumor|Adrenal cortical carcinoma|Endometrioid carcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Osteosarcoma|Hemangiopericytoma|Hemangiosarcoma|Angiosarcoma|Chondrosarcoma|Glioblastoma|Pheochromocytoma|Paraganglioma|Thymus neoplasm|Gastrointestinal stromal tumor|Soft tissue sarcoma|Ovarian clear cell carcinoma|Uveal melanoma|Blastoma|Metastatic renal cell carcinoma|Ovary tumor,1128|1134|1510|1648|1705|1766|1767|1772|2103|2104|2443|2444|2454|262|2876|2938|3205|3378|3525|3788|3997|4250|799,Testis tumor|Glioma|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Hippel Lindau syndrome|Acute myelogenous leukemia|Cholangiocarcinoma|Transitional cell carcinoma|Pulmonary hypertension|Anaplastic astrocytoma|Gallbladder tumor|Hormone refractory prostate cancer|Stage IV melanoma|Neurofibromatosis type I|Metastatic stomach cancer|Uterine cervix tumor|Breast tumor|Genitourinary tract tumor|Cancer|Central nervous system tumor|Colorectal tumor,1054|1108|1240|1261|1262|1612|1731|1765|1771|1867|2567|3146|3246|3257|3521|3666|427|49|613|651|759|989,Pfizer Inc,18767,SUGEN Inc|Pharmacia Corp,15997|27638,SUGEN Inc,15997,,,,,,
12978,moxifloxacin,Avalox|Avelox|moxifloxacin|BAY-12-8039|moxifloxacin hydrochloride|Avilox|Izilox|Actira|Octegra,Trade Name|Trade Name|BANN|INN|Research Code|USAN|Trade Name|Trade Name|Trade Name|Trade Name,Genitourinary/Sexual Function|Infection|Inflammatory|Respiratory,DNA gyrase inhibitor|Topoisomerase IV inhibitor,431|9320,Antibacterial|Bacterial nucleic acid synthesis inhibitor|Systemic dermatological antibacterial product,1594|3984|15187,Haemophilus infection|Enterobacter infection|Escherichia coli infection|Bacteroides infection|Bacteroides fragilis infection|Yersinia pestis infection|Clostridiaceae infection|Haemophilus influenzae infection|Moraxella catarrhalis infection|Streptococcus pyogenes infection|Enterococcus faecalis infection|Bacterial respiratory tract infection|Acute bronchitis|Bacterial pneumonia|Chlamydia pneumoniae infection|Klebsiella pneumoniae infection|Mycobacterium tuberculosis infection|Mycoplasma infection|Salpingitis|Acute sinusitis|Staphylococcus aureus infection|Abdominal abscess|Streptococcus infection|Streptococcus pneumoniae infection|Pelvic inflammatory disease|Bacterial infection|Clostridium infection|Proteus mirabilis infection|Bacterial skin infection|Multidrug resistant infection,1075|116|120|1393|1394|1397|1410|145|1455|1475|1482|1484|1487|1815|1819|195|221|222|2227|2999|308|3082|312|313|3140|40|428|456|485|758,Gram positive bacterium infection|Bronchitis,138|50,Bayer Korea Ltd|TB Alliance|Bayer Yakuhin Ltd|Merck & Co Inc|Bayer AG|Chong Kun Dang Pharmaceutical Corp|FUJIFILM Pharma Co Ltd,14519|29411|14557|18077|14455|15410|1061684,Schering-Plough Corp|Shionogi & Co Ltd,19711|19898,Bayer AG,14455,,,,,,
129885,JDQ-443,"JDQ-443|KRAS G12C inhibitor (advanced solid tumors), Novartis Pharmaceuticals",Research Code,Cancer,K-Ras GTPase inhibitor,28039,Anticancer,1545,Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic lung cancer|Advanced solid tumor,3658|3665|3668|3713,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
129964,ZX-101A,"ZX-101A|PI3K-delta/gamma dual inhibitor (oral, hematologic malignancies/solid tumor), Hangzhou Zenshine Pharmaceuticals|ZX-101",Research Code|Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor|Phosphoinositide-3 kinase gamma inhibitor,11183|11186,Anticancer protein kinase inhibitor,62255,Chronic lymphocytic leukemia|Hematological neoplasm|Non-Hodgkin lymphoma|Solid tumor,1734|2054|319|725,,,Hangzhou Zenshine Pharmaceuticals Co Ltd,1219705,,,Hangzhou Zenshine Pharmaceuticals Co Ltd,1219705,,,,,,
129984,TBX-2400,TBX-2400,Research Code,Cancer|Hematologic|Immune,,,Unspecified drug target|Immunomodulator|Anticancer,59620|1596|1545,Acute myelogenous leukemia|Myelofibrosis|Myeloproliferative disorder|Bone marrow transplantation,1731|2436|273|46,,,Taiga Biotechnologies Inc,1047275,,,Taiga Biotechnologies Inc,1047275,,,,,,
129996,TAA-6,"TAA-6|anti-CD276 CAR T-cell therapy (acute myeloid leukemia/advanced solid tumors), PersonGen Biomedicine (Suzhou)|anti-B7-H3 CAR T-cell therapy (acute myeloid leukemia/advanced solid tumors), PersonGen Biomedicine (Suzhou)|TAA6-CAR-T",Research Code|Research Code,Cancer,CD276 antigen modulator,48835,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer,7761|4790|393|1545,Acute myelogenous leukemia|Neuroblastoma|Metastatic colorectal cancer|Metastatic pancreas cancer|Advanced solid tumor,1731|2726|3658|3669|3713,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,PersonGen Biomedicine (Suzhou) Co Ltd,1115492,,,,,,
130065,HSK-29116,"HSK-26784|PROTAC-BTK degrader (B lymphocyte derived malignancy), HAISCO pharmaceutical|HSK-29116|Btk-targeted PROTAC protein degrader program (oral powder, B-cell malignancies), Haisco Pharmaceutical Group",Research Code|Research Code,Cancer,Btk tyrosine kinase inhibitor|Ubiquitin associated protein stimulator,3592|60388,Anticancer protein kinase inhibitor,62255,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|B-cell lymphoma,1734|1743|1744|1745|1746|1749|316,,,Haisco Pharmaceutical Group Co Ltd,1063506,,,Haisco Pharmaceutical Group Co Ltd,1063506,,,,,,
13016,famotidine,Famodine|Pepcid|famotidine|Quamatel|Gaster OD|YM-1170|Pepcid Complete,Trade Name|INN|Research Code|Trade Name|Trade Name|Research Code|Trade Name,Cancer|Gastrointestinal,Histamine H2 receptor antagonist,201,Histamine H2 antagonist antiulcerant product|Anticancer,38199|1545,Gastroesophageal reflux|Zollinger-Ellison syndrome|Peptic ulcer|Stomach ulcer,1243|1512|258|805,,,LTL Pharma Co Ltd|Astellas Pharma Inc|Merck & Co Inc|Salix Pharmaceuticals Ltd|Dong-A ST Co Ltd|Johnson & Johnson,1145602|1013295|18077|24643|15742|17332,Marathon Pharmaceuticals LLC|Yamanouchi Pharmaceutical Co Ltd,1060734|20967,Yamanouchi Pharmaceutical Co Ltd,20967,,,,,,
130167,ABBV-637,"ABBV-637|apoptosis stimulator (iv, NSCLC), AbbVie",Research Code,Cancer,,,Anticancer|Apoptosis stimulator,1545|1589,Non-small-cell lung cancer|Advanced solid tumor|Solid tumor,1262|3713|725,,,AbbVie Inc,1072507,,,AbbVie Inc,1072507,Magnevist,Gadopentetate dimeglumine,Chelating Agents,1041,,
130171,HBI-0101 CART,"HBI-0101 CART|HBI-0101-CART-BCMA|anti-BCMA CAR T-cell therapy (multiple myeloma), Hadassah Medical Organization",Research Code,Cancer,APRIL receptor modulator,8255,Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant,1545|7761|4790|393,Multiple myeloma,1828,,,Hadassah Medical Organization,16594,,,Hadassah Medical Organization,16594,,Venustatriol,,,,
13022,epirubicin,epirubicin|epirubicin hydrochloride|Farmorubicin|Pharmorubicin|IMI-28|Ellence|4'-epi-doxorubicin HCl|4'-epiadriamycin,INN|USAN|Trade Name|Trade Name|Research Code|Trade Name,Cancer,Topoisomerase II inhibitor|DNA helicase inhibitor,142|82444,Anticancer|DNA intercalator,1545|750,Breast tumor|Cancer,49|651,Metastatic breast cancer|Metastatic non small cell lung cancer|Carcinoma,3657|3665|54,Pfizer Inc|Kyowa Hakko Kirin Co Ltd|Pharmacia Corp,18767|1042596|27638,Kyowa Hakko Kogyo Co Ltd|Pharmacia & Upjohn Inc,17724|22006,Pharmacia & Upjohn Inc,22006,,,,,,
130246,AB-308,"AB-308|anti-TIGIT antibody (FcR-competent, hematological malignancies/solid tumor), Arcus Biosciences",Research Code,Cancer,T cell immunoreceptor Ig ITIM protein inhibitor,64787,Anticancer antibody,55684,Diffuse large B-cell lymphoma|Multiple myeloma|Hematological neoplasm|Non-Hodgkin lymphoma|Stage IV melanoma|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor|Uterine cervix tumor,1749|1828|2054|319|3257|3665|3666|3667|3713|427,Solid tumor,725,Arcus Biosciences Inc,1129346,,,Arcus Biosciences Inc,1129346,,,,,,
130440,"vibostolimab + pembrolizumab (advanced solid tumor/NSCLC/CRPC), Merck Sharp & Dohme","pembrolizumab|vibostolimab|MK-7684A|vibostolimab + pembrolizumab coformulation|TIGIT checkpoint inhibitor + PD-1 checkpoint inhibitor (advanced solid tumor/NSCLC/CRPC), Merck Sharp & Dohme|(MK-7684 + MK-3475) (advanced solid tumor/NSCLC/CRPC), Merck Sharp & Dohme|vibostolimab + pembrolizumab (advanced solid tumor/NSCLC/CRPC), Merck Sharp & Dohme",USAN|INN|USAN|INN|Research Code,Cancer,T cell immunoreceptor Ig ITIM protein inhibitor|Programmed cell death protein 1 inhibitor,64787|67136,Immunostimulant|Anticancer monoclonal antibody|Apoptosis stimulator|T-lymphocyte stimulator,393|55685|1589|7761,Hormone refractory prostate cancer|Metastatic non small cell lung cancer|Advanced solid tumor,3246|3665|3713,,,Merck Sharp & Dohme Corp,1059823,,,Merck Sharp & Dohme Corp,1059823,,,,,,
130520,ABBV-CLS-484,"ABBV-CLS-484|PTPN2 inhibitor (oral, solid tumor), AbbVie/Calico Life Sciences|PTPN2 inhibitor (oral, advanced solid tumor), AbbVie/Calico Life Sciences",Research Code,Cancer,T cell protein tyrosine phosphatase inhibitor,50062,Anticancer,1545,Adenocarcinoma|Squamous cell carcinoma|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Solid tumor,2399|307|3665|3666|3667|3673|3713|4250|725,,,Calico Life Sciences LLC|AbbVie Inc,1100041|1072507,,,AbbVie Inc,1072507,,,,,,
13063,5-methoxypsoralen,5-MOP|5-methoxypsoralen,,Dermatologic,,,Unspecified drug target|Systemic antipsoriatic product,59620|15184,,,Psoriasis|Vitiligo,281|346,,,Actavis Inc|Oclassen Pharmaceuticals Inc,21717|24616,Oclassen Pharmaceuticals Inc,24616,,,,,,
130630,DS-1594,"DS-1594b|DS-1594|menin inhibitor (oral, myelodysplastic syndrome/acute lymphoblastic leukemia/acute myelogenous leukemia/chronic myelomonocytic leukemia), Daiichi Sankyo",Research Code|Research Code,Cancer,Menin inhibitor,37755,Anticancer,1545,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelomonocytic leukemia,1272|1728|1731|6833,,,Daiichi Sankyo Co Ltd,1017506,,,Daiichi Sankyo Co Ltd,1017506,,,Calcium Channel Blockers,361,,
130648,"thioridazine + cytarabine (oral, acute myeloid leukemia), McMaster University","thioridazine + cytarabine|thioridazine + cytarabine (oral, acute myeloid leukemia), McMaster University",,Cancer,Dopamine D2 receptor antagonist|Monocyte differentiation antigen CD14 modulator,150|5065,Anticancer,1545,Acute myelogenous leukemia,1731,,,McMaster University,21238,,,McMaster University,21238,,,Lipoxygenase Inhibitors,447,,
130693,BI-765049,BI-765049,Research Code,Cancer,,,Anticancer,1545,Non-small-cell lung cancer|Gastrointestinal tumor|Hepatocellular carcinoma|Pancreas tumor|Metastatic colorectal cancer|Head and neck tumor|Solid tumor,1262|131|1767|249|3658|623|725,,,Boehringer Ingelheim International GmbH,14881,,,Boehringer Ingelheim International GmbH,14881,,,,,,
13071,dimesna,BNP-7787|dimesna|Coenzyme M|NSC-716976|Tavocept|LP-300,Research Code|INN|Research Code|Trade Name|Research Code,Cancer|Gastrointestinal|Toxicity/Intoxication,Anaplastic lymphoma kinase receptor modulator,3735,Neuroprotectant|Anti-emetic|Chemoprotectant|Anticancer|Protectant,1615|2970|1276|1545|959,Non-small-cell lung cancer,1262,Chemotherapy-induced emesis|Cancer|Toxicity,352|651|735,Lantern Pharma Inc,1106466,ASKA Pharmaceutical Co Ltd|BioNumerik Pharmaceuticals Inc|ASTA Medica AG|Grelan Pharmaceutical Co Ltd|KI Pharmaceuticals LLC|Baxter Oncology GmbH,1019817|14778|15623|16584|28197|29750,BioNumerik Pharmaceuticals Inc,14778,,,,,,
130765,CT-125A,"CT-125A|anti-CD5 CAR T-cell therapy (chronic lymphocytic leukemia/mantle cell lymphoma/diffuse large B-cell lymphoma/follicular lymphoma/peripheral T-cell lymphomas/ B cell lymphoma/T cell lymphoma/anaplastic large cell lymphoma/T-cell large granular lymphocyte leukemia), Huazhong University of Science and Technology/Shanghai IASO Biotechnology|anti-CD5 CAR T-cell therapy (CRISPR, CD5-positive relapsed/refractory hematopoietic malignancies), Huazhong University of Science and Technology/Shanghai IASO Biotechnology|RD-125",Research Code|Research Code,Cancer,T-cell surface glycoprotein CD5 modulator,5029,Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator|Immunostimulant,4790|1545|7761|393,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Anaplastic large cell lymphoma|Adult T-cell lymphoma|Angioimmunoblastic T-cell lymphoma|T-cell large granular lymphocyte leukemia|Hematological neoplasm|T-cell lymphoma|B-cell lymphoma,1734|1744|1745|1749|1753|1755|1757|1758|1762|2054|311|316,,,Shanghai IASO Biotechnology Co Ltd|Huazhong University of Science and Technology,1236432|CM27909,,,Huazhong University of Science and Technology,CM27909,,,,,,
130766,LP-118,"LP-118|dual Bcl-2/Bcl-xL inhibitor (oral tablet, cancer), Newave Pharmaceutical",Research Code,Cancer|Hematologic,Bcl-xL Bcl-2 associated death promotor inhibitor|Bcl-2 protein inhibitor,14541|16111,Anticancer,1545,Myelodysplastic syndrome|Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Prolymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Anaplastic large cell lymphoma|Adult T-cell lymphoma|Angioimmunoblastic T-cell lymphoma|Multiple myeloma|Myelofibrosis|Myeloproliferative disorder|Non-Hodgkin lymphoma|Cancer,1272|1728|1729|1731|1734|1738|1743|1744|1745|1747|1749|1753|1755|1757|1758|1828|2436|273|319|651,,,Newave Pharmaceutical LLC,1127022,,,Newave Pharmaceutical LLC,1127022,,,,,,
13105,AE-941,AE-941|Neovastat|Neoretna|Arthrovas|Psovascar,Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Cancer|Dermatologic|Inflammatory|Ocular,Metalloprotease-9 inhibitor|Metalloprotease-2 inhibitor|VEGF receptor antagonist|Tissue plasminogen activator modulator|Metalloprotease-12 inhibitor,2462|2461|1722|9138|9278,Apoptosis stimulator|Plasminogen activator stimulator|Anticancer|Angiogenesis inhibitor|Anticancer protein kinase inhibitor|Systemic antipsoriatic product,1589|311|1545|61|62255|15184,,,Age related macular degeneration|Non-small-cell lung cancer|Renal cell carcinoma|Multiple myeloma|Prostate tumor|Arthritis|Psoriasis|Acne|Breast tumor|Lung tumor,1226|1262|1766|1828|276|28|281|3|49|755,,,Alcon Inc|AEterna Zentaris Inc,18478|22711,AEterna Zentaris Inc,22711,,,,,,
131098,NC-762,"NC-762|B7-H4 checkpoint inhibitor (solid tumor/melanoma), NextCure|B7-H4 checkpoint inhibitor (advanced solid tumors), NextCure",Research Code,Cancer,Immune costimulatory protein B7H4 inhibitor|Immunoglobulin G1 modulator|Immunoglobulin kappa modulator,31925|5755|63442,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic ovary cancer|Solid tumor,205|3657|3665|3713|3866|725,,,NextCure Inc,1118074,,,NextCure Inc,1118074,,,,,,
131145,CC-96191,CC-96191,Research Code,Cancer,,,Anticancer|Unspecified drug target,1545|59620,Acute myelogenous leukemia,1731,,,Celgene Corp,15331,,,Celgene Corp,15331,,,,,,
131287,AT-19,"AT-19|anti-CD19 CAR T-cell therapy (TCR and HLA KO, hematological malignancies/B-cell acute lymphoblastic leukemia/B-cell chronic lymphoblastic leukemia/B-cell lymphoma), Chengdu USino Technology Biology",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Hematological neoplasm|B-cell lymphoma,1729|1734|2054|316,,,Chengdu USino Technology Biology Co Ltd,1238337,,,Chengdu USino Technology Biology Co Ltd,1238337,,,,,,
131310,GB-261,"GB-261|anti-CD3/anti-CD20 bispecific T-cell engager (non-Hodgkin lymphoma), Genor Biopharma|bispecific CD3xCD20 targeting antibody (non-Hodgkin lymphoma), Genor Biopharma",Research Code,Cancer,B-lymphocyte antigen CD20 modulator|CD3 modulator,5083|5023,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,Chronic lymphocytic leukemia|Non-Hodgkin lymphoma,1734|319,,,Genor Biopharma Co Ltd,1056962,,,Genor Biopharma Co Ltd,1056962,,,,,,
131364,"anti-ILT3 CAR T-cell therapy (acute myeloid leukemia), Carbiogene Therapeutics","anti-ILT3 CAR T-cell therapy (acute myeloid leukemia), Carbiogene Therapeutics|anti-LILRB4 CAR T-cell therapy (acute myeloid leukemia), Carbiogene Therapeutics",,Cancer,Leukocyte Ig-like receptor-4 modulator,9613,Immunostimulant|Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator,393|4790|1545|7761,Acute myelogenous leukemia,1731,,,Carbiogene Therapeutics Co. Ltd,1226756,,,Carbiogene Therapeutics Co. Ltd,1226756,,,,,,
13142,"busulfan (solubilized intravenous formulation, Partaject), SuperGen","busulfan|busulfan (Spartaject)|busulfan, RTP Pharma/SuperGen|busulfan (solubilised), SkyePharma|busulfan (solubilized intravenous formulation, Partaject), SuperGen",BANN|INN,Cancer|Immune|Neurology/Psychiatric,,,Anticancer alkylating agent,50,,,Neoplastic meningitis|Bone marrow transplantation|Cancer,1814|46|651,,,Sparta Pharmaceuticals Inc|Swedish Orphan AB|Astex Pharmaceuticals Inc|SkyePharma plc|Orphan Europe SARL,15961|20277|21885|23151|24064,Sparta Pharmaceuticals Inc,15961,,,,,,
131436,ABBV-623,ABBV-623,Research Code,Cancer,,,Anticancer|Unspecified drug target,1545|59620,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma,1734|1743|1744|1745|1747|1749,,,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
131437,ABBV-992,ABBV-992,Research Code,Cancer,,,Unspecified drug target|Anticancer,59620|1545,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma,1734|1743|1744|1745|1747|1749,,,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
131453,"PRT-1419 (iv, solid tumors/small-cell lung cancer/sarcoma/stage iv melanoma/metastatic breast cancer/metastatic non small cell lung cancer/advanced solid tumor), Prelude Therapeutics","PRT-1419 (iv, solid tumors/small-cell lung cancer/sarcoma/stage iv melanoma/metastatic breast cancer/metastatic non small cell lung cancer/advanced solid tumor), Prelude Therapeutics|myeloid leukemia cell differentiation protein 1 inhibitor (iv, solid tumors/small-cell lung cancer/sarcoma/stage iv melanoma/metastatic breast cancer/metastatic non small cell lung cancer/advanced solid tumor), Prelude Therapeutics",,Cancer,Mcl-1 differentiation protein inhibitor,11381,Anticancer,1545,Small-cell lung cancer|Sarcoma|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Solid tumor,1261|194|3257|3657|3665|3713|725,,,Prelude Therapeutics Inc,1158197,,,Prelude Therapeutics Inc,1158197,,,,,,
131500,JNJ-75276617,"JNJ-75276617|histone lysine methyltransferase 2A-menin interaction inhibitor (oral, acute leukemiaa/acute myeloid leukemia/acute lymphoblastic leukemia), Janssen Research & Development|KMT2A- Menin interaction inhibitor (acute leukemiaa/acute myeloid leukemia/acute lymphoblastic leukemia), Janssen Research & Development",Research Code,Cancer,Histone lysine methyltransferase 2A inhibitor|Menin inhibitor,87154|37755,Anticancer,1545,Acute leukemia|Acute lymphoblastic leukemia|Acute myelogenous leukemia,1727|1728|1731,,,Janssen Research & Development LLC,1067538,,,Janssen Research & Development LLC,1067538,,,,,,
131768,CCI-001,"CCI-001|tubulin beta 3 inhibitor (iv infusion, advanced solid tumors), PharmaMatrix/University of Alberta|colchicine derivative (iv infusion, advanced solid tumors), PharmaMatrix/University of Alberta",Research Code,Cancer,Tubulin beta 3 inhibitor,55317,Anticancer,1545,Biliary cancer|Endometrioid carcinoma|Transitional cell carcinoma|Adenocarcinoma|Metastatic lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer|Bladder tumor|Uterine cervix tumor,1516|1705|1771|2399|3668|3669|3713|3866|42|427,,,PharmaMatrix Holdings Ltd|University of Alberta,1239790|20525,,,PharmaMatrix Holdings Ltd,1239790,,,,,,
131945,HC-5404,"HC-5404|HC-5404-FU|hemi fumarate salt of HC-5404|PERK inhibitor (oral capsule, advanced solid tumor/renal cell carcinoma/gastric cancer/metastatic breast cancer/small-cell lung cancer), HiberCell|protein kinase R–like endoplasmic reticulum kinase inhibitor (oral capsule, advanced solid tumor/renal cell carcinoma/gastric cancer/metastatic breast cancer/small-cell lung cancer), HiberCell",Research Code|Research Code,Cancer,Eukaryotic initiation 2 alpha kinase 3 inhibitor,51124,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Small-cell lung cancer|Metastatic breast cancer|Metastatic stomach cancer|Advanced solid tumor|Metastatic renal cell carcinoma,1261|3657|3666|3713|4250,,,HiberCell Inc,1180565,Mount Sinai Medical Center,24815,Mount Sinai Medical Center,24815,,,,,,
132193,LY-3537982,"LY-3537982|KRAS G12C inhibitor (NSCLC), Loxo Oncology at Lilly|KRAS G12C inhibitor (oral, NSCLC/colorectal/endometrial/ovarian/pancreatic neoplasms), Loxo Oncology at Lilly",Research Code,Cancer,K-Ras GTPase inhibitor,28039,Anticancer,1545,Non-small-cell lung cancer|Endometrioid carcinoma|Pancreas tumor|Advanced solid tumor|Ovary tumor|Colorectal tumor,1262|1705|249|3713|799|989,,,Loxo Oncology at Lilly,1086092,,,Loxo Oncology at Lilly,1086092,,,,,,
132242,TQB-2928,"TQB-2928|CD47 checkpoint inhibitor/SIRPa checkpoint inhibitor (solid tumors/hematologic malignancies), Chia Tai Tianqing Pharmaceutical Group|CD47-SIRPalpha interaction inhibitors (solid tumors/hematologic malignancies), Chia Tai Tianqing Pharmaceutical Group",Research Code,Cancer,CD47 antagonist|Tyrosine phosphatase substrate 1 inhibitor,5185|53055,Macrophage stimulator|Immunostimulant|Anticancer,7751|393|1545,Hematological neoplasm|Advanced solid tumor,2054|3713,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,,,,,,
13239,decitabine,"5-aza-2'-deoxycytidine|5-azadeoxycytidine|DAC|decitabine|NSC-127716|5-CdR|AZA-DC|5-aza-CdR|5-aza-2-deoxycytidine|JNJ-30979754|Dacogen|IND-50733|E-7373|decitabine (intravenous, myelodysplastic syndromes/acute myeloid leukemia), Eisai|Dakogen",INN|Research Code|Research Code|Trade Name|Research Code|Research Code|Trade Name,Cancer|Genitourinary/Sexual Function|Hematologic,Cytosine DNA methyltransferase inhibitor,6515,Anticancer|Anticancer antimetabolite,1545|1569,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Penis tumor|Anal tumor|Vulva disease|Vaginal tumor|Uterine cervix tumor|Head and neck tumor|Chronic myelomonocytic leukemia|Uterus tumor|Mouth tumor|Pharynx tumor,1272|1728|1731|1791|2193|2232|3293|427|623|6833|740|793|794,Chronic myelocytic leukemia|Leukemia|Melanoma|Prostate tumor|Sickle cell anemia|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic renal cell carcinoma|Breast tumor|Solid tumor|Colon tumor|Ovary tumor,1735|199|205|276|303|3246|3257|3658|3665|4250|49|725|767|799,Johnson & Johnson|Otsuka Pharmaceutical Co Ltd|Janssen-Cilag Ltd,17332|18717|17392,Eisai Co Ltd|MGI Pharma Inc|Astex Pharmaceuticals Inc|Pharmachemie BV,15872|18203|21885|26234,Pharmachemie BV,26234,,,,,,
13253,"morphine (oral SR, Multipor), Tanabe","morphine sulfate anyhdrous|(-)-morphine|Pguard|TA-2620|DCV morphine OD|morphine (once-daily sustained release), Tanabe|morphine (oral SR, Multipor), Tanabe|morphine (diffuse controlled vesicle technology), Amarin|Statex SR|morphine|morphine sulfate",Trade Name|Research Code|Trade Name|Trade Name|BANN|USAN,Neurology/Psychiatric,Opioid receptor mu agonist,293,Analgesic,2946,Pain,20,,,Tanabe Seiyaku Co Ltd,20315,Amarin Development AB|undisclosed|Cangene Corp|Boehringer Ingelheim GmbH|Paladin Labs Inc,1003215|1051267|14129|22546|27477,Amarin Development AB,1003215,,,,,,
13279,IMO-2055,"IMOxine|HYB-2055|IMO program, Hybridon|immunomodulatory oligonucleotides (cancer), Merck Serono|oligonucleotides (immune disorders), Hybridon|oligonucleotide (asthma), Hybridon/Institut Pasteur|oligonucleotide (allergy), Hybridon/Institut Pasteur|oligonucleotide (anti IL-5), Institut Pasteur/Hybridon|oligonucleotide (inflammation), Hybridon/Institut Pasteur|synthetic immunomodulatory oligonucleotides (IMO), Hybridon|IMO-2055|IMO program, Idera|immunomodulatory oligonucleotides, Idera|oligonucleotides (immune disorders), Idera|oligonucleotide (asthma), Idera/Institut Pasteur|oligonucleotide (allergy), Idera/Institut Pasteur|oligonucleotide (anti IL-5), Insitut Pasteur/Idera|oligonucleotide (inflammation), Idera/Institut Pasteur|synthetic immunomodulatory oligonucleotides (IMO), Idera|EMD-1201081",Trade Name|Research Code|Research Code|Research Code,Cancer|Immune|Infection,TLR-9 agonist,7827,Anticancer|Immunomodulator|Antimicrobial,1545|1596|1593,,,Non-small-cell lung cancer|Renal cell carcinoma|Immune disorder|Metastatic renal cell carcinoma|Head and neck tumor|Cancer|Solid tumor|Infectious disease|Colorectal tumor,1262|1766|185|4250|623|651|725|746|989,,,Idera Pharmaceuticals Inc|Merck Serono SA,17006|19862,Idera Pharmaceuticals Inc,17006,,,,,,
132824,"anti-CD3/anti-SLAMF7 bispecific T-cell engager-armed autologous T cells (multiple myeloma), University of Virginia","anti-CD3/anti-HER2 bispecific antibody-armed activated T-cell therapy (multiple myeloma), University of Virginia|anti-CD3/anti-SLAMF7 bispecific antibody-armed T-cell therapy (multiple myeloma), University of Virginia|anti-CD3/anti-SLAMF7 bispecific T-cell engager-armed autologous T cells (multiple myeloma), University of Virginia",,Cancer,SLAM family member 7 modulator|CD3 modulator,45393|5023,Immunostimulant|Anticancer antibody|T-lymphocyte stimulator,393|55684|7761,Multiple myeloma,1828,,,University of Virginia,20695,,,University of Virginia,20695,,,,,,
13338,ursodeoxycholic acid,"Urso|ursodeoxycholic acid|ursodiol|Urso DS|Delursan|Urso 250|Urso 500|UDCA, Axcan|ursodeoxycholic acid, Axcan|Urso Forte|ursodiol disulfate|ursodiol disulphate|ursodesoxycholic acid|Urusa",Trade Name|BANN|INN|USAN|Trade Name|Trade Name|Trade Name,Cancer|Endocrine/Metabolic|Gastrointestinal,,,Bile acid transport inhibitor|Bile acid modulator|Anticancer,743|863|1545,Gallbladder disease|Hepatitis|Primary biliary cholangitis|Liver disease|Cholelithiasis,125|154|1995|201|2625,Precancer|Hypercholesterolemia|Primary sclerosing cholangitis|Non-alcoholic steatohepatitis|Colon tumor,1060|174|2477|2637|767,Aptalis Pharma Inc|Mitsubishi Tanabe Pharma Corp|Daewoong Pharmaceutical Co Ltd,22872|1035060|15587,Mitsubishi-Tokyo Pharmaceuticals Inc|Mitsubishi Pharma Corp|Dr Falk Pharma GmbH|Schwarz Pharma Inc|Jouveinal SA|Aventis Pharma SA,18229|20983|22542|23738|24791|27779,Mitsubishi-Tokyo Pharmaceuticals Inc,18229,,,,,,
13340,everolimus,Certican|everolimus|RAD-001|SDZ-RAD|RAD001C|Afinitor|Zortress|Apinito|Votubia|RAD-001A|Afinitor Disperz,Trade Name|USAN|INN|Research Code|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name,Cancer|Gastrointestinal|Genitourinary/Sexual Function|Immune|Infection|Neurology/Psychiatric|Ocular|Other/Miscellaneous|Respiratory,mTOR complex 1 inhibitor|mTOR inhibitor,76090|10240,Anticonvulsant agent|Immunosuppressant|Angiogenesis inhibitor|Anticancer protein kinase inhibitor|Antiviral|Anticancer,70|396|61|62255|991|1545,Esophagus tumor|Glioma|Neuroendocrine tumor|Thyroid tumor|Non-small-cell lung cancer|Pancreatic endocrine tumor|Hodgkins disease|Hippel Lindau syndrome|Endometrioid carcinoma|Acute lymphoblastic leukemia|Lymphoplasmacytic lymphoma|Renal cell carcinoma|Bladder cancer|Astrocytoma|Pheochromocytoma|Angiomyolipoma|Paraganglioma|Heart transplant rejection|Liver transplant rejection|Kidney transplant rejection|Multiple hamartoma sydrome|Medullary thyroid cancer|Partial seizure|Metastatic breast cancer|Metastatic renal cell carcinoma|Breast tumor|Transplant rejection|Head and neck tumor|Colorectal tumor,1011|1108|1128|1134|1262|1510|161|1612|1705|1728|1743|1766|2380|2453|262|2789|2876|2987|2988|2989|3070|3240|3439|3657|4250|49|515|623|989,Herpesvirus type 8 infection|Epilepsy|Age related macular degeneration|Mesothelioma|Small-cell lung cancer|Stomach tumor|Sturge-Weber syndrome|Acute myelogenous leukemia|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Cutaneous T-cell lymphoma|Hepatocellular carcinoma|Multiple myeloma|Inflammatory bowel disease|Sarcoma|Lymphoma|Melanoma|Hematological neoplasm|Fallopian tube cancer|Autosomal dominant polycystic kidney disease|Pancreas tumor|Meningioma|Rheumatoid arthritis|Peritoneal tumor|Tuberous sclerosis|Lung transplant rejection|Non-Hodgkin lymphoma|Gastrointestinal stromal tumor|Hormone refractory prostate cancer|Uveitis|Neurofibromatosis type I|Advanced solid tumor|Uveal melanoma|Renal insufficiency|Uterine cervix tumor|Genetic disorder|Pulmonary fibrosis|Solid tumor|Ovary tumor,1123|119|1226|1240|1261|127|1614|1731|1744|1749|1754|1767|1828|189|194|203|205|2054|2243|2300|249|2802|291|3083|3129|3141|319|3205|3246|341|3521|3713|3788|3907|427|609|708|725|799,Novartis AG,23137,,,Novartis AG,23137,,,,,,
134127,TAS-0953,"HM-06|TAS-0953|RET inhibitor (advanced solid tumor/metastatic NSCLC), Taiho Pharmaceutical/Helsinn Healthcare",Research Code|Research Code,Cancer,Ret tyrosine kinase receptor inhibitor,3818,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer|Advanced solid tumor,3665|3713,,,Helsinn Healthcare SA|Taiho Pharmaceutical Co Ltd,27361|18720,,,Taiho Pharmaceutical Co Ltd,18720,,,,,,
134419,AZD-7789,"anti-PD-1/anti-TIM-3 bispecific antibody (cancer), AstraZeneca|PD1-TIM3 bsAb (cancer), AstraZeneca|AZD-7789|dual PD-1 checkpoint inhibitor/TIM-3 checkpoint inhibitor (cancer), AstraZeneca",Research Code,Cancer,Hepatitis A virus cellular receptor 2 antagonist|Programmed cell death protein 1 inhibitor,34783|67136,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,3665|3713|651,,,AstraZeneca plc,14190,,,AstraZeneca plc,14190,,,K(ATP) Channel Activators|Prostaglandin E2 Receptor EP3 Subtype (PTGER3; EP3) Agonists,366|292,Signal Transduction Modulators,1402
13486,entecavir,entecavir|Baraclude,USAN|INN|Trade Name,Infection,Reverse transcriptase inhibitor|DNA polymerase inhibitor,345|138,Antiviral|Hepatitis B virus replication inhibitor|Viral replication inhibitor,991|32411|1532,Hepatitis B virus infection,152,Herpes simplex virus infection,157,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
134919,VCAR-33,"VCAR-33|anti-CD33 CAR T-cell therapy (acute myeloid leukemia),  Vor Biopharma|CD33CART|CD33CART (VCAR33 construct), Vor Biopharma",Research Code,Cancer,CD33 modulator,5119,T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy|Anticancer,7761|393|4790|1545,Acute myelogenous leukemia,1731,,,Vor BioPharma,1123556,National Institutes of Health,20518,National Institutes of Health,20518,,,,,,
13539,"captopril SODAS, Elan","capoten|captopril|captopril, Elan|captopril SODAS, Elan",USAN|BANN|INN,Cardiovascular,ACE inhibitor,18,Antihypertensive,2657,,,Hypertension,178,,,Elan Corp plc,15873,Elan Corp plc,15873,,,,,,
13562,"cositecan (intravenous), BioNumerik","BNP-1100|BNP-1350|DB-172|Karenitecin|BNP-1051|BNP-1111|BNP-1200|BNP-1205|BNP-1220|BNP-1225|BNP-1330|lipophilic camptothecins|camptothecins, BioNumerik|camptothecin derivatives, BioNumerik|BNP-1350 (intravenous), BioNumerik|cositecan|cositecan (intravenous), BioNumerik|MCC-12824",Analogue|Research Code|Research Code|Research Code|Trade Name|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|USAN|INN|Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,Non-small-cell lung cancer|Melanoma|Solid tumor|Brain tumor|Ovary tumor,1262|205|725|760|799,,,BioNumerik Pharmaceuticals Inc,14778,ASKA Pharmaceutical Co Ltd,1019817,BioNumerik Pharmaceuticals Inc,14778,,,,,,
13693,"rubitecan (oral), SuperGen","9-nitrocamptothecin|RFS-2000|rubitecan|9NC|Camptogen|Orathecin|rubitecan (oral), SuperGen",Research Code|USAN|INN|Trade Name|Trade Name,Cancer|Infection,Topoisomerase I inhibitor,141,Anticancer|Antiviral,1545|991,,,Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|HIV infection|Chronic myelocytic leukemia|Pancreas tumor|Chordoma|Cancer|Chronic myelomonocytic leukemia|Solid tumor|Ovary tumor|Colorectal tumor,1261|1262|127|158|1735|249|3736|651|6833|725|799|989,,,Abbott Laboratories|Stehlin Foundation For Cancer Research|Astex Pharmaceuticals Inc,13601|21409|21885,Stehlin Foundation For Cancer Research,21409,,,,,,
13759,A-dmDT390-bisFv(UCHT1),"FN18-CRM9|UCHT1-CRM9|A-dmDT390-sFv|scFv(UCHT1)-PE38|DT-389-scFv(UCHT1)|anti-CD3 immunotoxins, Novartis/NIH|anti-CD3 scFv immunotoxins, NIH/Novartis|anti-CD3 scFv immunotoxins, Novartis/NIH|Resimmune|A-dmDT390-bisFv(UCHT1)|anti-CD3 bivalent antibody-diphtheria toxin conjugate (T-cell lymphoma/leukemia), Angimmune/AOP Orphan|LAX-699|anti-CD3 bivalent antibody-diphtheria toxin conjugate (T-cell lymphoma/leukemia/melanoma), Angimmune/AOP Orphan",Prodrug|Trade Name|Research Code,Cancer|Immune,CD3 antagonist,5025,Immunotoxin|Anticancer monoclonal antibody|Immunosuppressant,539|55685|396,Mycosis fungoides|T-cell acute lymphoblastic leukemia|Cutaneous T-cell lymphoma|Melanoma|Hematological neoplasm|T-cell lymphoma|Autoimmune disease,1115|1730|1754|205|2054|311|36,Transplant rejection,515,AOP Orphan Pharmaceuticals AG|Angimmune LLC,1008173|1071544,National Institutes of Health|Novartis AG,20518|23137,National Institutes of Health,20518,,,,,,
13916,vitespen,"HSPPC-96-C|HSPPC-96-GH|gp96 vaccine, Antigenics|vitespen|HSPPC-96|Oncophage|Prophage G-100|Prophage G-200|NP-150|Prophage R-100|Prophage R-200|Prophage M-100|Prophage M-200|Prophage NP-150",Research Code|Research Code|USAN|Research Code|Trade Name|Research Code,Cancer|Endocrine/Metabolic|Immune|Infection,Endoplasmin modulator,14246,Immunomodulator|Anticancer|Therapeutic vaccine|Antiviral,1596|1545|12379|991,Glioma|Renal cell carcinoma|Glioblastoma,1108|1766|2454,Stomach tumor|Herpes simplex virus infection|Sarcoma|Melanoma|Multiple sclerosis|Pancreas tumor|Gliosarcoma|Non-Hodgkin lymphoma|Metastatic renal cell carcinoma|Cancer|Lung tumor|Insulin dependent diabetes|Colorectal tumor,127|157|194|205|213|249|2727|319|4250|651|755|836|989,NewVac LLC|Agenus Inc,1066959|23221,Mount Sinai School of Medicine|Medison Pharma Ltd,20631|29943,Mount Sinai School of Medicine,20631,,,,,,
13928,enoxaparin sodium,Klexane|RPY-005|XRP-4563|enoxaparin sodium|Lovenox|PK-10169|Clexane|RP-54563,Trade Name|Research Code|Research Code|USAN|BANN|INN|Trade Name|Research Code|Trade Name|Research Code,Cardiovascular|Hematologic,Low molecular weight heparin,1741,Coagulation inhibitor,659,Myocardial infarction|Thromboembolism,224|325,,,Sanofi SA,1009547,Kaken Pharmaceutical Co Ltd|Rhone-Poulenc Rorer Inc,17633|19365,Rhone-Poulenc Rorer Inc,19365,,,,,,
14100,veltuzumab,"cA20 antibody, Immunomedics|hA20 antibody, Immunomedics|hCD20 antibody, Immunomedics|anti-NHL antibody, Immunomedics|veltuzumab|IMMU-106",USAN|INN|Research Code,Cancer|Dermatologic|Hematologic|Immune,B-lymphocyte antigen CD20 inhibitor,5085,Anti-inflammatory|Anticancer monoclonal antibody,2953|55685,,,Pemphigus|Chronic lymphocytic leukemia|Immune thrombocytopenic purpura|Rheumatoid arthritis|Systemic lupus erythematosus|Non-Hodgkin lymphoma|Autoimmune disease,1114|1734|2259|291|318|319|36,,,Takeda Pharmaceuticals International GmbH|Immunomedics Inc,1002503|17204,Immunomedics Inc,17204,,,,,,
14128,endostatin,endostatin|AdEndo|NSC-704805|rhEndostatin|Endostatin protein,Analogue|Research Code,Cancer|Inflammatory,,,Anticancer|Unspecified drug target|Angiogenesis inhibitor,1545|59620|61,,,Neuroendocrine tumor|Melanoma|Arthritis|Cancer,1128|205|28|651,,,Alchemgen Therapeutics Inc|Childrens Medical Center Corp|CASI Pharmaceuticals Inc|Boston Children's Hospital,1006726|21051|21794|24334,Boston Children's Hospital,24334,,,,,,
14142,tariquidar,tariquidar|XR-9576|XR-9351 series,USAN|INN|Research Code|Research Code,Cancer,P-Glycoprotein inhibitor,7494,Anticancer multidrug resistance inhibitor|Anticancer,759|1545,,,Non-small-cell lung cancer|Breast tumor|Cancer|Solid tumor|Lung tumor|Ovary tumor,1262|49|651|725|755|799,,,Novelion Therapeutics Inc|Xenova Group plc,19180|24133,Xenova Group plc,24133,,,,,,
14148,L-alanosine,L-alanosine|SDX-102|alanosine,USAN|INN|Research Code,Cancer,,,Purine nucleotide metabolism modulator|Anticancer antimetabolite,5541|1569,,,Glioma|Mesothelioma|Non-small-cell lung cancer|Acute lymphoblastic leukemia|Osteosarcoma|Sarcoma|Pancreas tumor|Cancer|Lung tumor|Brain tumor,1108|1240|1262|1728|1772|194|249|651|755|760,,,Triangle Pharmaceuticals Inc|University of California San Diego|Salmedix Inc,22659|25451|29254,University of California San Diego,25451,,,,,,
14163,adalimumab,"adalimumab|D2E7|Humira|anti-TNF-alpha antibody, Knoll/CAT|MAb (anti-TNF-alpha), humanized, Knoll/CAT|Humira Pen|Trudexa|ABT-D2E7|LU 200134|Raheara|undisclosed biosimilar (rheumatoid arthritis), Tanvex BioPharma",USAN|INN|Research Code|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Trade Name,Cardiovascular|Dermatologic|Gastrointestinal|Immune|Infection|Inflammatory|Musculoskeletal|Neurology/Psychiatric|Ocular|Respiratory,TNF alpha ligand inhibitor|TNF binding agent,381|721,Analgesic|Cardioprotectant|Therapeutic antibody|Systemic antipsoriatic product|Antiviral|Anti-inflammatory,2946|2659|172641|15184|991|2953,Coronavirus disease 19 infection|Psoriatic arthritis|Osteoarthritis|Pouchitis|Arthritis|Psoriasis|Rheumatoid arthritis|Spondylarthritis|Juvenile rheumatoid arthritis|Ulcerative colitis|Uveitis|Lower back pain|Pyoderma gangrenosum|Hidradenitis suppurativa|Ankylosing spondylitis|Behcets disease|Crohns disease,10406|1781|245|2468|28|281|291|2921|3003|337|341|3437|3517|3542|398|768|84,Sarcoidosis|Temporal arteritis|Asthma|Heart disease,1036|1850|31|626,AbbVie Inc|Eisai Co Ltd,1072507|15872,Abbott Laboratories|Cambridge Antibody Technology Group plc|Knoll GmbH|Knoll Japan KK,13601|24236|25360|25384,Cambridge Antibody Technology Group plc,24236,,,,,,
14169,emepepimut-S,"encapsulated MUC-1 peptide vaccine (cancer), Biomira|encapsulated MUC-1 peptide vaccine (cancer), Oncothyreon|tecemotide|L-BLP-25|BLP-25 liposome vaccine|EMD 531444|Stimuvax|emepepimut-S|ONO-7165|BLP-25|BP-24",USAN|INN|Research Code|Research Code|Research Code|Trade Name|USAN|Research Code|Research Code|Research Code,Cancer,Mucin 1 inhibitor,32078,Anticancer|Protein subunit vaccine|Therapeutic vaccine,1545|12372|12379,,,Rectal tumor|Non-small-cell lung cancer|Multiple myeloma|Prostate tumor|Breast tumor|Cancer|Ovary tumor,1055|1262|1828|276|49|651|799,,,EMD Serono Inc|Cascadian Therapeutics Inc|Merck KGaA|Ono Pharmaceutical Co Ltd|Merck Serono SA,1035512|14774|18101|18681|19862,Cascadian Therapeutics Inc,14774,,,,,,
14216,siplizumab,"MEDI-507|siplizumab|AlloMune component II, Biotransplant|TCD-601",Research Code|USAN|INN|Research Code,Cancer|Dermatologic|Immune,,,Systemic antipsoriatic product|Anti-inflammatory|Lymphocyte function antigen-3 receptor antagonist|Anticancer monoclonal antibody|Immunomodulator,15184|2953|5019|55685|1596,Kidney transplantation|Organ transplantation,2984|3004,Psoriatic arthritis|Leukemia|Lymphoma|Psoriasis|Autoimmune disease|Transplant rejection|Graft versus host disease,1781|199|203|281|36|515|616,ITB-MED AB,1158077,BioTransplant Inc|MedImmune LLC|Universite Catholique de Louvain,14847|18008|21279,Universite Catholique de Louvain,21279,,,,,,
14311,"GCS-100 (iv, end stage renal disease/renal transplantation/cancer), La Jolla Pharmaceutical","GBC-590|GCS-100 (iv)|GCS-100LE|NCCG, IGG|NCCG, SafeScience|GCS-100 (intravenous, cancer), GlycoGenesys|GCS-100 (intravenous, cancer), Prospect Therapeutics|GCS-100 (iv, end stage renal disease/renal transplantation/cancer), La Jolla Pharmaceutical|GCS-100 (intravenous, cancer), Solana Therapeutics|GCS-100",Research Code|Research Code,Cancer|Gastrointestinal|Genitourinary/Sexual Function|Immune,Cell adhesion molecule inhibitor|Galectin-3 inhibitor,650|9979,Metastasis inhibitor|Anticancer|Angiogenesis modulator|Apoptosis stimulator|Synergist,695|1545|961|1589|7293,,,Chronic lymphocytic leukemia|Multiple myeloma|Liver disease|Melanoma|Pancreas tumor|Prostate tumor|Kidney transplant rejection|End stage renal disease|Cancer|Colorectal tumor,1734|1828|201|205|249|276|2989|3251|651|989,,,Prospect Therapeutics Inc|Solana Therapeutics Inc|Elan Corp plc|La Jolla Pharmaceutical Co|GlycoGenesys Inc,1034100|1067663|15873|17748|22525,GlycoGenesys Inc,22525,,,,,,
14344,"2-methoxyestradiol, CASI Pharmaceuticals","2-methoxyestradiol|NSC 659853|Panzem|NSC-650853|2-methoxyestradiol, EntreMed|2-ME2|Panzem Capsules|2-methoxyestradiol, CASI Pharmaceuticals",Trade Name|Research Code|Trade Name,Cancer|Immune|Musculoskeletal,Hypoxia inducible factor-1 inhibitor|VEGF receptor antagonist,9677|1722,Angiogenesis inhibitor|Anti-inflammatory|Anticancer protein kinase inhibitor|Anticancer|Apoptosis stimulator|Microtubule modulator,61|2953|62255|1545|1589|563,Multiple sclerosis,213,Multiple myeloma|Osteoporosis|Prostate tumor|Rheumatoid arthritis|Breast tumor|Solid tumor|Ovary tumor,1828|246|276|291|49|725|799,CASI Pharmaceuticals Inc,21794,Harvard University,20584,Harvard University,20584,,,,,,
14395,GI-4000,"GI-4014|GI-4015|GI-4016|CERES-Vax vaccine delivery system (cancer)|vaccine delivery system (cancer), GlobeImmune|GI-4000 series (anticancer vaccine), GlobeImmune|GI-4000 series (anticancer vaccine, Tarmogen), GlobeImmune|GI-4000 series (Ras), GlobeImmune|GI-4000|GI-4000 series (anticancer vaccine), NantCell|GI-4000 series (Ras), NantCell",Research Code|Research Code|Research Code|Research Code,Cancer,Ras GTPase modulator,10449,Recombinant fungal vector vaccine|Therapeutic vaccine|Anticancer,33963|12379|1545,Non-small-cell lung cancer|Pancreas tumor|Colorectal tumor,1262|249|989,Cancer,651,NantCell Inc,1104834,GlobeImmune Inc,28802,GlobeImmune Inc,28802,,,,,,
14493,tenofovir disoproxil fumarate,"tenofovir DF|tenofovir disoproxil fumarate|Viread|bis(POC)PMPA|oral PMPA prodrug|tenofovir (oral prodrug), Gilead|GSK-548470|TDF|Tenozet",USAN|Trade Name|Research Code|Trade Name|Trade Name,Infection,HIV-1 reverse transcriptase inhibitor|DNA polymerase inhibitor,1016|138,Antiviral|Hepatitis B virus replication inhibitor,991|32411,Hepatitis B virus infection|HIV infection|HIV-1 infection,152|158|159,Viral infection,344,Viatris Inc|GlaxoSmithKline plc|Yuhan Corp|Gilead Sciences Inc,1136574|28355|20984|16450,Japan Tobacco Inc|Mylan NV|Rega Institute for Medical Research|Torii Pharmaceutical Co Ltd,17327|18439|24727|26065,Rega Institute for Medical Research,24727,,,,,,
14630,OVI-123,"Cordycepin|Cordycepin (ALL), OXiGENE|Cordycepin (acute lymphoid leukemia), OXiGENE|Cordycepin (acute lymphoid leukemia ), OncoVista/AAIPharma|OVI-123",Research Code,Cancer,,,Anticancer|Apoptosis stimulator,1545|1589,,,Acute lymphoblastic leukemia|Leukemia,1728|199,,,OncoVista Innovative Therapies Inc|Mateon Therapeutics Inc|AAIPharma Inc,1017768|21303|21865,Mateon Therapeutics Inc,21303,,,,,,
14643,nelarabine,"506U|nelarabine|ara-G prodrug, Glaxo Wellcome|ara-G prodrug, GlaxoSmithKline|guanine arabinoside prodrug, Glaxo Wellcome|guanine arabinoside prodrug, GlaxoSmithKline|Arranon|506U78|GW-506U78|Atriance|NSC-686673|Arranon G",Research Code|USAN|INN|Trade Name|Research Code|Research Code|Trade Name|Research Code|Trade Name,Cancer,,,DNA synthesis inhibitor|Anticancer antimetabolite,140|1569,T-cell acute lymphoblastic leukemia,1730,Chronic lymphocytic leukemia|Non-Hodgkin lymphoma,1734|319,Novartis AG,23137,Glaxo Group Ltd|GlaxoSmithKline plc,16453|28355,Glaxo Group Ltd,16453,,,,,,
14658,"bupivacaine (extended release/DepoFoam, postoperative pain), Pacira BioSciences/Nuance Biotech","bupivacaine|bupivacaine (DepoFoam), SkyePharma/Maruho|bupivacaine (controlled release, DepoFoam), Pacira|DUR-843|SKY-0402|bupivacaine (liposomal, postoperative pain), SkyePharma|bupivacaine (liposomal, postoperative pain), Pacira Pharmaceuticals|bupivacaine (DepoFoam), Pacira Pharmaceuticals|Exparel|DepoBupivacaine|bupivacaine hydrochloride|bupivacaine (extended release/DepoFoam, postoperative pain), Pacira Pharmaceuticals/Maruho|bupivacaine (extended release/DepoFoam, postoperative pain), SkyePharma/Maruho|bupivacaine (extended release/DepoFoam, postoperative pain), Pacira Pharmaceuticals/Nuance Biotech|bupivacaine (extended release/DepoFoam, postoperative pain), Pacira BioSciences/Nuance Biotech",USAN|INN|Research Code|Research Code|Trade Name|Trade Name|USAN,Neurology/Psychiatric,Sodium channel inhibitor,498,Local anesthetic|Analgesic,1669|2946,Pain|Topical anesthesia,20|328,,,Eurofarma|Nuance Biotech Inc|Pacira BioSciences Inc,1042566|1118419|26338,Maruho Co Ltd|SkyePharma plc,17950|23151,Pacira BioSciences Inc,26338,,,,,,
14703,rebimastat,BMS-275291|rebimastat|D-2163,Research Code|USAN|INN|Research Code,Cancer,Matrix metalloprotease inhibitor,253,Angiogenesis inhibitor|Anticancer,61|1545,,,Non-small-cell lung cancer|Prostate tumor|Cancer|Kaposis sarcoma,1262|276|651|936,,,Bristol-Myers Squibb Co|UCB Celltech|Chiroscience R&D Ltd,15065|15336|15978,UCB Celltech,15336,,,,,,
14861,ISCOMATRIX,"ISCOM|ISCOM, CSL|ISCOMATRIX|ISCOPREP703|vaccine adjuvants, CSL",Trade Name|Trade Name|Trade Name,Immune,,,Adjuvant|Immunostimulant,524|393,,,Vaccination,384,,,CSL Ltd,15563,CSL Ltd,15563,,,,,,
14923,lorvotuzumab mertansine,"huN901-DM1|BB-10901|CD56-targeted MAb-DM1 conjugate, ImmunoGen|IMGN-901|lorvotuzumab mertansine|NCAM1-targeted MAb-DM1 conjugate, ImmunoGen|lorvotuzumab-DM1",Research Code|Research Code|USAN|INN,Cancer,Tubulin binding agent|Neural cell adhesion molecule 1 modulator,499|5228,Anticancer monoclonal antibody|Microtubule inhibitor|Immunotoxin,55685|2575|539,Leukemia,199,Small-cell lung cancer|Acute myelogenous leukemia|Multiple myeloma|Merkel cell carcinoma|Solid tumor,1261|1731|1828|3235|725,ImmunoGen Inc,17202,Vernalis plc,15262,ImmunoGen Inc,17202,,,,,,
14985,BBR-3464,"BBR-3464|trinuclear platinum complex, Roche/Novuspharma|trinuclear platinum complex, Boehringer Mannheim|trinuclear platinum complex, Roche/Cell Therapeutics|triplatin tetranitrate",Research Code|BANN|INN,Cancer,,,Unspecified drug target|Anticancer|Apoptosis stimulator,59620|1545|1589,,,Stomach tumor|Pancreas tumor|Cancer|Solid tumor|Lung tumor|Ovary tumor,127|249|651|725|755|799,,,Roche Holding AG|Boehringer Mannheim Italia SpA|Novuspharma SpA,19446|25479|27036,Roche Holding AG,19446,,,,,,
15062,epratuzumab,"epratuzumab|hLL2, Immunomedics|hCD22 antibody, Immunomedics|lymphoma antibody, Immunomedics|humanized LL2 antibody, Immunomedics|hLL2, UCB|hCD22 antibody (iv, NHL/ALL/SLE), UCB/Immunomedics|lymphoma antibody, UCB|humanized LL2 antibody, UCB|IMMU-103|LymphoCide|AMG-412|CDP-3194|epratuzumab (humanized anti-CD22)",USAN|INN|Research Code|Trade Name|Research Code|Research Code|Research Code,Cancer|Hematologic|Immune,B-lymphocyte cell adhesion molecule inhibitor,5091,Anticancer monoclonal antibody|Anti-inflammatory|Apoptosis stimulator|Immunosuppressant,55685|2953|1589|396,,,Sjoegrens syndrome|Macroglobulinemia|Acute lymphoblastic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Systemic lupus erythematosus|Non-Hodgkin lymphoma|Autoimmune disease,1148|1264|1728|1745|1749|318|319|36,,,Amgen Inc|Immunomedics Inc|UCB SA|UCB Japan Co Ltd,14109|17204|20452|23570,Immunomedics Inc,17204,,,,,,
15130,vinflunine,vinflunine|L-0070|F-13667|F-13840|vinflunine ditartrate|F-12158|Javlor|BMS-710485,INN|Research Code|Analogue|Analogue|USAN|Research Code|Trade Name|Research Code,Cancer,Tubulin modulator,814,Cell cycle inhibitor|Microtubule modulator|Anticancer|Apoptosis stimulator,767|563|1545|1589,Non-small-cell lung cancer|Transitional cell carcinoma|Metastatic breast cancer|Metastatic head and neck cancer|Bladder tumor|Breast tumor,1262|1771|3657|3673|42|49,Mesothelioma|Cancer|Ovary tumor,1240|651|799,Biotoscana International|Pierre Fabre Group,1063950|19087,Bristol-Myers Squibb Co,15065,Pierre Fabre Group,19087,,,,,,
15183,sertraline,sertraline hydrochloride|CP-51974|sertraline|CP-519741|sertraline HCl|Serad|Tatig|Aremis|Gladem|Zoloft|Lustral|Serlain|Besitran|J Zoloft,USAN|Research Code|INN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Genitourinary/Sexual Function|Neurology/Psychiatric,,,Anxiolytic|5-HT uptake inhibitor|Antidepressant,2942|3|2941,Panic disorder|Post traumatic stress disorder|Social phobia|Obsessive compulsive disorder|Premenstrual syndrome|Major depressive disorder|Depression,1279|1935|3150|468|480|4898|93,,,Dong Wha Pharmaceutical Co Ltd|Viatris Inc,15745|1136574,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
15214,"fosbretabulin (iv, cancer), Mateon Therapeutics Inc","combretastatin A4 disodium phosphate|combretastatin A4 prodrug|CA4P, OXiGENE/Arizona State|combretastatin A4 phosphate|combretastatin A4 prodrug (cancer/diabetes), OXiGENE|combretastatin, Arizona State University/OXiGENE|combretastatin A-4 prodrug, OXiGENE/Arizona State University|Zybrestat (iv formulation)|fosbretabulin (iv formulation)|fosbretabulin disodium|fosbretabulin disodium (cancer/diabetes), OXiGENE|CA4DP|CA4P|fosbretabulin|fosbretabulin (iv, cancer), OXiGENE|fosbretabulin tromethamine|Zybrestat|fosbretabulin (iv, cancer), Mateon Therapeutics Inc|fosbretabulin (iv, melanoma), Mateon Therapeutics",USAN|INN|USAN|Trade Name,Cancer|Dermatologic|Endocrine/Metabolic|Inflammatory|Ocular,PPAR modulator|Vascular cell adhesion protein 1 antagonist|Tubulin receptor antagonist,2476|5400|541,Anti-inflammatory|Vascular damaging agent|Anticancer|Angiogenesis inhibitor|Hypoglycemic agent|Systemic antipsoriatic product,2953|2969|1545|61|399|15184,Stage II melanoma|Stage IV melanoma,3255|3257,Glioma|Neuroendocrine tumor|Thyroid tumor|Age related macular degeneration|Non-small-cell lung cancer|Gastrointestinal tumor|Ocular disease|Glioblastoma|Prostate tumor|Arthritis|Psoriasis|Retinopathy|Uterine cervix tumor|Head and neck tumor|Solid tumor|Lung tumor|Ovary tumor|Diabetes mellitus|Colorectal tumor,1108|1128|1134|1226|1262|131|239|2454|276|28|281|288|427|623|725|755|799|97|989,Mateon Therapeutics Inc,21303,Bristol-Myers Squibb Co|Arizona State University,15065|20526,Arizona State University,20526,,,,,,
15367,visilizumab,"HuM291|Nuvion|visilizumab|visiluzumab|SMART anti-CD3 MAb, PDL|anti-CD3 MAb (humanized), PDL|SMART anti-CD3 MAb, Protein Design Labs",Research Code|Trade Name|INN,Dermatologic|Gastrointestinal|Immune,CD3 modulator,5023,Anti-inflammatory|Systemic antipsoriatic product|Gastrointestinal system agent,2953|15184|1332,,,Psoriasis|Ulcerative colitis|Transplant rejection|Graft versus host disease|Crohns disease,281|337|515|616|84,,,PDL BioPharma Inc,19162,PDL BioPharma Inc,19162,,,,,,
15472,rofecoxib,MK-0966|MK-966|rofecoxib|Vioxx|L-001069957,Research Code|Research Code|INN|Trade Name|Research Code,Cancer|Genitourinary/Sexual Function|Immune|Inflammatory|Neurology/Psychiatric,Cyclooxygenase 2 inhibitor,1001,Anticancer|Non-steroidal anti-inflammatory|Analgesic,1545|2955|2946,,,Dysmenorrhea|Alzheimers disease|Inflammatory disease|Pain|Migraine|Osteoarthritis|Rheumatoid arthritis|Prostatitis|Colon tumor,105|14|188|20|210|245|291|473|767,,,Merck & Co Inc|MSD Japan,18077|24019,Merck & Co Inc,18077,,,,,,
15541,ixabepilone,"BMS-247550|ixabepilone|BMS-747550|epothilone, BMS/GBF|anticancer agents, BMS/GBF|NSC-710428|Ixempra",Research Code|USAN|INN|Research Code|Research Code|Trade Name,Cancer,Tubulin modulator,814,Cell cycle inhibitor|Anticancer|Microtubule inhibitor,767|1545|2575,Fallopian tube cancer|Peritoneal tumor|Metastatic breast cancer|Breast tumor|Ovary tumor,2243|3083|3657|49|799,Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Melanoma|Pancreas tumor|Prostate tumor|Non-Hodgkin lymphoma|Cancer|Solid tumor,1262|127|1705|205|249|276|319|651|725,Allarity Therapeutics A/S|R-Pharm,1025145|1059001,Bristol-Myers Squibb Co|Helmholtz Zentrum fur Infektionsforschung GmbH,15065|16277,Helmholtz Zentrum fur Infektionsforschung GmbH,16277,,,,,,
15593,eculizumab,"5G1.1|eculizumab|C5 complement inhibitor (2), Alexion|Soliris|h5G1.1|h5G1.1scFv",Research Code|USAN|INN|Trade Name|Research Code,Cardiovascular|Dermatologic|Genitourinary/Sexual Function|Hematologic|Immune|Infection|Inflammatory|Neurology/Psychiatric|Ocular,Complement C5 factor inhibitor,81927,Therapeutic antibody|Immunomodulator|Antiviral,172641|1596|991,Coronavirus disease 19 infection|Paroxysmal nocturnal hemoglobinuria|Guillain Barre syndrome|Neuromyelitis optica|Liver transplantation|Kidney transplantation|Kidney transplant rejection|Brain hemorrhage|Systemic lupus erythematosus|Thrombotic microangiopathy|Atypical hemolytic uremic syndrome|Myasthenia gravis,10406|1297|141|2316|2983|2984|2989|315|318|3699|4084|848,Pemphigus|Glomerulonephritis|Antiphospholipid syndrome|Nephritis|Dermatomyositis|Cold agglutinin disease|Psoriasis|Rheumatoid arthritis|Dry age related macular degeneration|Neuropathy,1114|135|2065|231|2475|2644|281|291|3355|678,Handok Inc|Alexion Pharmaceuticals Inc,19986|13979,,,Alexion Pharmaceuticals Inc,13979,,,,,,
15676,"imexon (injectable), AmpliMed","AMP-404|imexon analogs, AmpliMed|imexon|Amplimexon|imexon (injectable), AmpliMed|AMP-019",Analogue|Research Code|USAN|INN|Trade Name|Research Code,Cancer|Immune,Hypoxia inducible factor-1 alpha inhibitor|Ribonucleotide reductase inhibitor,9680|346,DNA synthesis inhibitor|Anticancer|Glutathione modulator|Cell cycle inhibitor,140|1545|825|767,,,Multiple myeloma|Immune disorder|Lymphoma|Melanoma|Pancreas tumor|Non-Hodgkin lymphoma|Cancer,1828|185|203|205|249|319|651,,,Handok Inc|AmpliMed Corp,19986|25748,AmpliMed Corp,25748,,,,,,
15730,"aminopterin (oral), Syntrix Biosystems","Aminopterin|aminopterin, University of Texas/ILEX|aminopterin, University of Medicine & Dentistry of New Jersey|NSC-739|aminopterin (oral), Syntrix Biosystems|aminotrexate, Syntrix Biosystems|LD-aminopterin",Research Code,Cancer|Dermatologic|Immune,,,Unspecified drug target|Anticancer|Anti-inflammatory|Systemic antipsoriatic product,59620|1545|2953|15184,Psoriasis,281,Atopic dermatitis|Endometrioid carcinoma|Acute lymphoblastic leukemia|Rheumatoid arthritis|Cancer,1102|1705|1728|291|651,Syntrix Biosystems Inc,1023036,University of Medicine and Dentistry of New Jersey|University of Texas System|ILEX Oncology Inc,20638|21864|23744,University of Texas System,21864,,,,,,
15820,S-3304,"BPHA|S-3304|BPHA, Shionogi|MMP inhibitors, Shionogi|matrix metalloproteinase inhibitor, Shionogi",Research Code|Analogue,Cancer,Matrix metalloprotease inhibitor,253,Anticancer|Metastasis inhibitor,1545|695,,,Cancer|Solid tumor,651|725,,,Shionogi & Co Ltd,19898,Shionogi & Co Ltd,19898,,,,,,
15860,nimotuzumab,DiaCIM|TheraCIM|RadioTheraCIM|TheraCIM-h-R3|Theraloc|nimotuzumab|BioMab|DE-766|Vecthix|BIOMAb-EGFR|KI-0501|OSAG-101|CIMAher|Taixinsheng,Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|INN|Trade Name|Research Code|Trade Name|Trade Name|Research Code|Research Code|Trade Name,Cancer,Epidermal growth factor receptor modulator|Epidermal growth factor receptor antagonist|Erbb2 tyrosine kinase receptor modulator,3605|740|3755,Anticancer|Synergist|Therapeutic vaccine|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,1545|7293|12379|55685|62255,Esophagus tumor|Glioma|Nasopharyngeal carcinoma|Pancreas tumor|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Uterine cervix tumor|Breast tumor|Head and neck tumor|Cancer|Lung tumor|Colorectal tumor,1011|1108|1768|249|3665|3666|3667|427|49|623|651|755|989,Non-small-cell lung cancer|Stomach tumor|Astrocytoma|Glioblastoma|Prostate tumor|Solid tumor|Brain tumor,1262|127|2453|2454|276|725|760,The Center of Molecular Immunology|InnoMab Pte Ltd|Eurofarma|Biocon Biopharmaceuticals Pvt Ltd|PiSA Farmaceutica|InnoKeys PTE Ltd|Biotech Pharmaceutical Co Ltd|El Kendi|Innogene Kalbiotech Pte Ltd|Ferozsons Laboratories Ltd|Laboratorio Elea,29496|1075944|1042566|1018304|1049784|1075942|1050244|1073529|1011255|1051917|30635,Sun Yat-Sen University|Oncoscience AG|Daiichi Sankyo Co Ltd|YM BioSciences Inc|Kuhnil Pharmaceutical Co Ltd,1004360|1005242|1017506|24845|27398,The Center of Molecular Immunology,29496,,,,,,
15954,bortezomib,bortezomib|LDP-341|MG-341|MLN-341|NSC-681239|PS-341|Velcade|JNJ-26866138|PDP-341,USAN|BANN|INN|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code|Research Code,Cancer|Endocrine/Metabolic|Hematologic|Immune|Neurology/Psychiatric,Proteasome inhibitor|26S proteasome complex inhibitor,4917|76469,Apoptosis stimulator|Anticancer,1589|1545,Non-small-cell lung cancer|Macroglobulinemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Multiple myeloma,1262|1264|1743|1744|1828,Amyloidosis|Myelodysplastic syndrome|Hodgkins disease|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Kidney transplant rejection|Squamous cell carcinoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Stage IV melanoma|Breast tumor|Carcinoma|Graft versus host disease|Head and neck tumor|Stroke|Solid tumor|Ovary tumor|Colorectal tumor,1143|1272|161|1728|1731|1734|1745|1749|1753|2989|307|319|3246|3257|49|54|616|623|65|725|799|989,Johnson & Johnson|Takeda Oncology|Janssen-Cilag Ltd,17332|21991|17392,Janssen Korea Ltd|LeukoSite Inc,17407|27414,LeukoSite Inc,27414,,,,,,
15979,OSE-2101,"EP-2101|MAGE-3, IDM|cancer vaccine, IDM|anti-MAGE-3 vaccine, IDM|IDM-2101|OSE-2101|Tedopi",Research Code|Research Code|Research Code|Trade Name,Cancer,Erbb2 tyrosine kinase receptor modulator|Melanoma associated antigen 3 modulator|Melanoma associated antigen 2 modulator|p53 tumor suppressor protein modulator|CD66e modulator,3755|21958|21955|17119|5281,Therapeutic vaccine|T-lymphocyte stimulator|Protein subunit vaccine|Anticancer,12379|7761|12372|1545,Non-small-cell lung cancer|Metastatic pancreas cancer|Ovary tumor,1262|3669|799,Breast tumor|Cancer|Lung tumor|Colon tumor|Colorectal tumor,49|651|755|767|989,Chong Kun Dang Pharmaceutical Corp|OSE Immunotherapeutics,15410|1059851,IDM Pharma Inc|Biotech Synergy|Epimmune Inc|GD Searle & Co,1015687|1061705|15573|18362,Epimmune Inc,15573,,,,,,
15985,muparfostat sodium,"PI-88|phosphomannopentaose sulfate|sulfated mannopentaose phosphate|heparanase inhibitor (cancer), Progen/Australian National University|sulfated oligosaccharides (cancer), Progen/Australian National University|muparfostat sodium|muparfostat",Research Code|USAN|USAN,Cancer|Cardiovascular|Hematologic|Inflammatory,FGF receptor antagonist|VEGF receptor antagonist|Heparanase inhibitor|FGF-1 ligand inhibitor|FGF-2 ligand inhibitor,168|1722|2606|3615|3618,Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Coagulation inhibitor,62255|61|659,Hepatocellular carcinoma,1767,Thrombosis|Non-small-cell lung cancer|Multiple myeloma|Inflammatory disease|Prostate tumor|Stage IV melanoma|Restenosis|Cancer,1076|1262|1828|188|276|3257|330|651,Medigen Biotechnology Corp|TBG Diagnostics Ltd,27795|24251,Global TransBiotech Inc,1048340,TBG Diagnostics Ltd,24251,,,,,,
16021,fosaprepitant,L-758298|c-9280|MK-0517|MK-517|fosaprepitant|fosaprepitant dimeglumine|Emend for Injection|Ivemend|ONO-7847|Proemend for Injection|Emend IV|Proemend,Research Code|Research Code|Research Code|Research Code|INN|USAN|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name,Gastrointestinal|Neurology/Psychiatric|Toxicity/Intoxication,NK1 receptor antagonist,266,Anti-emetic,2970,Emesis|Nausea|Chemotherapy induced nausea and vomiting,110|226|3847,Pain,20,Ono Pharmaceutical Co Ltd|Merck Sharp & Dohme Ltd|Merck & Co Inc,18681|18090|18077,,,Merck & Co Inc,18077,,,,,,
16063,olaparib,"NU-1025|NU-1085|KU-0687|MRU-687|MRU-868|TBI-361|PARP inhibitors (cancer), AstraZeneca|NU-1070|KU-0058684|KU-0058948|KU-0051529|KU-59436|KU-0059436|PARP inhibitors (cancer), KuDOS|AZD-2281|olaparib|KU-58948|KU-56186|KU-59449|Lynparza|MK-7339|Lipzol",Analogue|Research Code|Analogue|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code|Research Code|Trade Name|Research Code|Trade Name,Cancer,Poly ADP ribose polymerase 3 inhibitor|Poly ADP ribose polymerase 2 inhibitor|Poly ADP ribose polymerase 1 inhibitor|PARP inhibitor,38289|38286|38283|2507,Anticancer,1545,Esophagus tumor|Small-cell lung cancer|Stomach tumor|Biliary cancer|Endometrioid carcinoma|Transitional cell carcinoma|Osteosarcoma|Sarcoma|Fallopian tube cancer|Leiomyosarcoma|Liposarcoma|Glioblastoma|Squamous cell carcinoma|Peritoneal tumor|Hormone refractory prostate cancer|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Germ cell and embryonic cancer|Metastatic ovary cancer|Uterine cervix tumor|Breast tumor|Head and neck tumor|Solid tumor|Lung tumor|Ovary tumor|Colorectal tumor,1011|1261|127|1516|1705|1771|1772|194|2243|2446|2447|2454|307|3083|3246|3466|3657|3665|3669|3713|3737|3866|427|49|623|725|755|799|989,Non-small-cell lung cancer|Pancreas tumor|Metastatic stomach cancer|Cancer,1262|249|3666|651,AstraZeneca plc|Merck & Co Inc,14190|18077,The University of Newcastle Upon Tyne|Cancer Research Campaign Technology Ltd|Agouron Pharmaceuticals Inc|KuDOS Pharmaceuticals Ltd,21243|24077|26488|27874,The University of Newcastle Upon Tyne,21243,,,,,,
16096,quaratusugene ozeplasmid,"INGN-401|p53 bystander effector, Introgen|FUS1-DOTAP:cholesterol|Fus-1 tumor suppressor gene therapy (nanoparticles, cancer), MD Anderson|DOTAP:chol-TUSC2|CNVN-202|Oncoprex|DOTAP:chol-FUS1|TUSC2 gene therapy (intravenous nanoparticles, NSCLC), Genprex|FUS1 gene therapy (iv nanoparticle formulation, NSCLC), Genprex|GEN-001, Genprex|GPX-001|quaratusugene ozeplasmid|Reqorsa",Research Code|Research Code|Research Code|Trade Name|Research Code|USAN|Trade Name,Cancer,TUSC2 gene stimulator,47320,Anti-inflammatory|Apoptosis stimulator|Plasmid based gene therapy|Anticancer,2953|1589|4788|1545,Thyroid tumor|Metastatic non small cell lung cancer,1134|3665,Non-small-cell lung cancer|Cancer,1262|651,Genprex Inc,1063954,Introgen Therapeutics Inc|National Cancer Institute (NCI)|MD Anderson Cancer Center|University of Texas Southwestern Medical Center,17255|20519|23382|25760,MD Anderson Cancer Center,23382,,,,,,
16161,"boanmycin hydrochloride (intramuscular, intravenous, head and neck tumor), Tianjin Taihe Pharmaceutical","boanmycin|boanmycin hydrochloride (intramuscular, intravenous, head and neck tumor), Tianjin Taihe Pharmaceutical|boanmycin hydrochloride|boanmycin HCl|Ye Li Ning",Trade Name,Cancer,,,Anticancer|Unspecified drug target,1545|59620,Squamous cell carcinoma|Head and neck tumor|Lung tumor,307|623|755,Cancer,651,Tianjin Taihe Pharmaceutical Co Ltd,1029464,Chinese Academy of Medical Sciences,21189,Chinese Academy of Medical Sciences,21189,,,,,,
16353,LungVax,"L-Vax|vaccine (myeloid leukemia), Avax|AC vaccine (lung cancer), AVAX/University of Pennsylvania|LungVax",Trade Name|Trade Name,Cancer,,,Therapeutic vaccine|Anticancer,12379|1545,,,Non-small-cell lung cancer|Acute myelogenous leukemia,1262|1731,,,AVAX Technologies Inc,24659,AVAX Technologies Inc,24659,,,,,,
16376,tanespimycin,"NSC-330507|NSC-704057|geldanamycin analog, Kosan|Hsp90 inhibitors, NCI/Institute of Cancer Research/Kosan|17-AAG analogs (injectable, cancer), Kosan/ National Cancer Institute/ UK Institute of Cancer Research|Hsp90 inhibitors, Cancer Research UK/Institute of Cancer Research/NCI|17-AAG|17-(Allylamino)-17-demethoxygeldanamycin|17-(Allylamino)geldanamycin|17-(allylamino)demethoxygeldanamycin|tanespimycin|17-allylaminogeldanamycin (injectable, cancer), Kosan/ National Cancer Institute/ UK Institute of Cancer Research|KOS-953",Research Code|Metabolite|Research Code|Research Code|Analogue|Metabolite|Metabolite|Metabolite|Metabolite|USAN|INN|Metabolite|Research Code|Metabolite,Cancer,Hsp 90 inhibitor|MET tyrosine kinase receptor family inhibitor,8012|3796,Anticancer|Apoptosis stimulator|Anticancer protein kinase inhibitor,1545|1589|62255,,,Thyroid tumor|Hodgkins disease|Chronic myelocytic leukemia|Multiple myeloma|Melanoma|Non-Hodgkin lymphoma|Breast tumor|Cancer,1134|161|1735|1828|205|319|49|651,,,Bristol-Myers Squibb Co|National Cancer Institute (NCI)|University of Maryland|Institute of Cancer Research UK|Kosan Biosciences Inc,15065|20519|20611|21072|24027,University of Maryland,20611,,,,,,
16383,sapacitabine,"CS-682|CNDAC prodrug (cancer), Cyclacel|CNDAU|CYC-682|sapacitabine|CNDAC",Research Code|Metabolite|Research Code|USAN|INN|Metabolite,Cancer,DNA polymerase inhibitor,138,Cell cycle inhibitor|Anticancer,767|1545,Non-small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|B-cell lymphoma|Metastatic breast cancer|Solid tumor|Ovary tumor,1262|1272|1731|1734|316|3657|725|799,Cutaneous T-cell lymphoma|Cancer,1754|651,Cyclacel Pharmaceuticals Inc,24341,Sankyo Co Ltd,19658,Sankyo Co Ltd,19658,,,,,,
16545,delamanid,"2-nitroimidazole derivatives (tuberculosis), Otsuka|OPC-67683|nitro-dihydroimidazo-oxazole derivatives (tuberculosis), Otsuka|delamanid|Deltyba",Research Code|USAN|INN|Trade Name,Cancer|Infection|Inflammatory|Ocular,Mycolic acid synthase inhibitor,6542,Anti-inflammatory|Angiogenesis inhibitor|Antibacterial|Anticancer,2953|61|1594|1545,Mycobacterium tuberculosis infection,221,Inflammatory disease|Retinopathy|Carcinoma,188|288|54,Mylan NV|Otsuka Pharmaceutical Co Ltd|R-Pharm,18439|18717|1059001,,,Otsuka Pharmaceutical Co Ltd,18717,,,,,,
16631,"ortataxel (intravenous, cancer), Spectrum","BAY-59-8862|IDN-5109|SB-T-101131|ortataxel|IDN-5111|SB-T-101144|SB-T-101141|BAY-55-8862|ortataxel (iv), Bayer|taxane analog (intravenous, anticancer), Bayer|ortataxel (intravenous, cancer), Spectrum",Research Code|Research Code|Research Code|INN|Analogue|Research Code|Research Code|Research Code|Research Code,Cancer,,,Anticancer|Microtubule inhibitor,1545|2575,Solid tumor,725,Non-small-cell lung cancer|Metastatic renal cell carcinoma|Breast tumor|Cancer,1262|4250|49|651,Spectrum Pharmaceuticals Inc,24232,Bayer AG|Indena SpA|State University of New York at Stony Brook,14455|17217|26884,State University of New York at Stony Brook,26884,,,,,,
16748,aprepitant,aprepitant|L-754030|MK-0869|MK-869|Emend|ONO-7436,USAN|INN|Research Code|Research Code|Research Code|Trade Name|Research Code,Gastrointestinal|Genitourinary/Sexual Function|Neurology/Psychiatric|Toxicity/Intoxication,NK1 receptor antagonist,266,Anti-emetic|Antidepressant,2970|2941,Emesis|Chemotherapy-induced emesis|Chemotherapy induced nausea and vomiting,110|352|3847,Pain|Overactive bladder|Depression,20|2376|93,Ono Pharmaceutical Co Ltd|Merck & Co Inc,18681|18077,,,Merck & Co Inc,18077,,,,,,
16758,plerixafor,AMD-3100|JM-3100|SID-791|SDZ-SID-791|Mozobil|plerixafor|GZ316455|plerixafor octahydrochloride,Research Code|Research Code|Research Code|Research Code|Trade Name|USAN|BANN|INN|Research Code,Cancer|Cardiovascular|Dermatologic|Hematologic|Immune|Infection,CXCR4 chemokine antagonist|Neuroplastin inhibitor,3137|89499,Antiviral|Anticancer,991|1545,Multiple myeloma|Sickle cell anemia|Non-Hodgkin lymphoma|Metastatic pancreas cancer|Bone marrow transplantation,1828|303|319|3669|46,Glioma|Myelodysplastic syndrome|HIV infection|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Neutropenia|Myocardial infarction|Rheumatoid arthritis|Cancer|Diabetic foot ulcer,1108|1272|158|1731|1734|1735|1991|224|291|651|790,Sanofi SA|Sanofi Genzyme,1009547|16299,AnorMED Inc,23816,AnorMED Inc,23816,,,,,,
16778,zibotentan,ZD-4054|zibotentan|AZD-4054|AZ-11922817,Research Code|USAN|INN|Research Code|Research Code,Cancer|Cardiovascular|Genitourinary/Sexual Function|Immune|Neurology/Psychiatric,Endothelin ET-A receptor antagonist,770,Anticancer|Neuroprotectant|Angiogenesis inhibitor|Immunomodulator,1545|1615|61|1596,Scleroderma|Alzheimers disease|Intermittent claudication|End stage renal disease,1105|14|1865|3251,Non-small-cell lung cancer|Hormone refractory prostate cancer|Cardiac failure|Solid tumor,1262|3246|55|725,University of Virginia|AstraZeneca plc|University College London|University of Bristol,20695|14190|23505|20544,Zeneca Group plc,16955,Zeneca Group plc,16955,,,,,,
16915,calcium levofolinate,calcium levofolinate|Isovorin|levoleucovorin calcium|levofolinic acid|LFA|L-Folinic acid|(S)-Leucovorin|Fusilev|Khapzory|levoleucovorin,BANN|INN|Trade Name|USAN|Trade Name|Trade Name,Cancer|Hematologic|Toxicity/Intoxication,,,Anticancer antimetabolite|Folic acid analog,1569|686,Metastatic colorectal cancer|Metastatic pancreas cancer|Small intestine cancer|Toxicity|Colorectal tumor|Renal tumor,3658|3669|4166|735|989|999,Anemia|Metastatic stomach cancer,17|3666,Sanofi SA|Pfizer Inc|Acrotech Biopharma LLC,1009547|18767|1179286,Targent Inc|Wyeth|American Cyanamid Co|Lederle Laboratories|Merck & Cie Schaffhausen|Takeda Pharmaceutical Co Ltd|Spectrum Pharmaceuticals Inc,1006011|14112|14113|14118|16055|20300|24232,Merck & Cie Schaffhausen,16055,,,,,,
17015,pentostatin,"pentostatin|CI-825|PD-81565|NSC-218321|pentostatin, GvH disease|pentostatin, rheumatoid arthritis|Nipent",USAN|BAN|INN|Research Code|Research Code|Research Code|Trade Name,Cancer|Immune,Adenosine deaminase inhibitor,24,Anticancer|Immunomodulator,1545|1596,Hairy cell leukemia,1736,Chronic lymphocytic leukemia|Hematological neoplasm|Rheumatoid arthritis|Graft versus host disease,1734|2054|291|616,Hospira Inc|Mayne Pharma Pty Ltd,1010293|31290,Pfizer Inc|Astex Pharmaceuticals Inc,18767|21885,Pfizer Inc,18767,,,,,,
17091,agatolimod,"CpG-8916|CpG-8954|CpG DNA, Coley|TLR9 agonists, Coley|CpG DNA, CpG ImmunoPharmaceuticals|PF-3512676|PF-676|agatolimod sodium|ProMune|CpG-7909|agatolimod|Vaximmune",Analogue|Research Code|Research Code|Research Code|Research Code|USAN|Trade Name|Research Code|USAN|INN|Trade Name,Cancer|Immune|Infection,TLR-9 agonist,7827,Immunostimulant|Anticancer|Adjuvant,393|1545|524,,,Non-small-cell lung cancer|Chronic lymphocytic leukemia|Follicle center lymphoma|Marginal zone B-cell lymphoma|Cutaneous T-cell lymphoma|Basal cell carcinoma|Renal cell carcinoma|Melanoma|Non-Hodgkin lymphoma|Autoimmune disease|Vaccination|Breast tumor|Cancer|Infectious disease,1262|1734|1745|1746|1754|1764|1766|205|319|36|384|49|651|746,,,Merck & Co Inc|Pfizer Inc|Novartis AG|SmithKline Beecham Corp|Coley Pharmaceutical Group Inc|GlaxoSmithKline plc,18077|18767|23137|24155|27288|28355,Coley Pharmaceutical Group Inc,27288,,,,,,
17113,tipifarnib,"tipifarnib|R-115777|Zarnestra|ras farnesyl inibitor, Janssen|NSC-702818",USAN|INN|Research Code|Trade Name|Research Code,Cancer|Hematologic|Infection,Ras GTPase inhibitor|Protein farnesyltransferase inhibitor,10451|1875,Anticancer|Antiviral|Anti-inflammatory,1545|991|2953,Non-small-cell lung cancer|Myelodysplastic syndrome|Chronic myelocytic leukemia|Follicle center lymphoma|Peripheral T-cell lymphoma|Angioimmunoblastic T-cell lymphoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Rhabdomyosarcoma|Squamous cell carcinoma|Larynx tumor|Metastatic head and neck cancer|Advanced solid tumor|Solid tumor|Mouth tumor|Pharynx tumor,1262|1272|1735|1745|1753|1758|1768|1771|2448|307|3198|3673|3713|725|793|794,Acute myelogenous leukemia|Glioblastoma|Pancreas tumor|Myeloproliferative disorder|Prostate tumor|Hepatitis D virus infection|Breast tumor|Cancer|Lung tumor|Colorectal tumor,1731|2454|249|273|276|362|49|651|755|989,Kura Oncology Inc|Johnson & Johnson Pharmaceutical Research & Development LLC,1106202|29481,Eiger BioPharmaceuticals Inc|Johnson & Johnson|Janssen Pharmaceutica BV,1045741|17332|17413,Janssen Pharmaceutica BV,17413,,,,,,
17413,"noscapine (cancer), Cougar","noscapine|noscapine (cancer), Cougar|noscapine (cancer), Emory University|CB-3304",BANN|INN|Research Code,Cancer,Tubulin binding agent,499,Anticancer|Apoptosis stimulator|Microtubule inhibitor,1545|1589|2575,,,Multiple myeloma|Non-Hodgkin lymphoma|Cancer,1828|319|651,,,Cougar Biotechnology Inc|Emory University,1007756|20573,Emory University,20573,,,,,,
17472,lonafarnib,"lonafarnib|Sch-66336|FPT inhibitor (lead, progeria), Schering-Plough|ras farnesyl protein transferase inhibitor (lead), Schering-Plough|Sch-704742|SCH-066336|MK-6336|Zokinvy",USAN|PINN|Research Code|Research Code|Research Code|Research Code|Trade Name,Cancer|Other/Miscellaneous,Ras GTPase inhibitor|Protein farnesyltransferase inhibitor,10451|1875,Antiviral|Anticancer|Anti-inflammatory,991|1545|2953,Hutchinson Gilford progeria syndrome|Genetic disorder,3200|609,Non-small-cell lung cancer|Myelodysplastic syndrome|Leukemia|Pancreas tumor|Breast tumor|Cancer|Chronic myelomonocytic leukemia|Urinary tract tumor,1262|1272|199|249|49|651|6833|738,Eiger BioPharmaceuticals Inc,1045741,The Progeria Research Foundation Inc|Merck & Co Inc|Schering-Plough Corp|Schering-Plough Research Institute,1007957|18077|19711|24009,Schering-Plough Research Institute,24009,,,,,,
17495,dulanermin,"PRO-1762|TRAIL protein, Immunex|TRAIL/Apo2L (Cancer), Genentech/Amgen|Apo2L/TRAIL (cancer), Amgen/Genentech|TRAIL/Apo2L, Genentech/Immunex|AMG-951|Apo2L/TRAIL (cell death signaling), Amgen/Genentech|APO2L/tumor necrosis factor-related apoptosis inducing ligand (cancer), Amgen/Genentech|rhApo2L/TRAIL (cancer), Amgen/Genentech|rhApo2L/TRAIL|dulanermin|RG-3639",Research Code|Research Code|USAN|INN|Research Code,Cancer,TRAIL-2 receptor agonist|TRAIL-1 receptor agonist,8232|8229,Anticancer|Apoptosis stimulator,1545|1589,,,Non-small-cell lung cancer|Non-Hodgkin lymphoma|Cancer|Colorectal tumor,1262|319|651|989,,,Amgen Inc|Immunex Corp|Genentech Inc,14109|14131|19453,Immunex Corp,14131,,,,,,
17518,escitalopram,"S-citalopram|escitalopram|MLD-55|Lexapro|Sipralex|Sipralexa|citalopram enantiomer, Actavis/Lundbeck|Cipralex|LU-26-054|escitalopram oxalate|Entact|Esertia|Seroplex|Cipralex Meltz|citalopram enantiomer, Forest/Lundbeck",INN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|USAN|Trade Name|Trade Name|Trade Name|Trade Name,Genitourinary/Sexual Function|Neurology/Psychiatric,,,5-HT uptake inhibitor|Anxiolytic|Antidepressant,3|2942|2941,Panic disorder|Generalized anxiety disorder|Social phobia|Obsessive compulsive disorder|Major depressive disorder|Depression,1279|1937|3150|468|4898|93,Binge eating disorder|Anxiety disorder|Premenstrual syndrome,1909|25|480,Xian-Janssen Pharmaceutical Ltd|Mitsubishi Tanabe Pharma Corp|Mochida Pharmaceutical Co Ltd|H Lundbeck A/S|Abbott Laboratories|Almirall Prodesfarma SA|AbbVie Inc,17608|1035060|18278|17900|13601|14061|1072507,Allergan plc|Forest Laboratories Inc|Recordati SpA,1088700|16198|24154,H Lundbeck A/S,17900,,,,,,
17554,LMB-9,LMB-9|NSC-691236|B3ds(Fv)-PE38,Research Code|Research Code,Cancer,,,Unspecified drug target|Anticancer|Immunotoxin,59620|1545|539,,,Stomach tumor|Pancreas tumor|Cancer|Colon tumor,127|249|651|767,,,IVAX Corp|National Cancer Institute (NCI),17284|20519,National Cancer Institute (NCI),20519,,,,,,
17558,fluoxetine hydrochloride,fluoxetine|Prozac|fluoxetine hydrochloride|Prozac Weekly|Sarafem|LY-110140,INN|Trade Name|USAN|Trade Name|Trade Name|Research Code,Genitourinary/Sexual Function|Neurology/Psychiatric,,,Antidepressant|Anxiolytic|5-HT uptake inhibitor,2941|2942|3,Panic disorder|Obsessive compulsive disorder|Premenstrual syndrome|Major depressive disorder|Bulimia nervosa|Depression,1279|468|480|4898|51|93,,,Eli Lilly & Co|AbbVie Inc,17810|1072507,Allergan plc|Chugai Lilly Clinical Research Co Ltd|Endo Pharmaceuticals Solutions Inc|Warner Chilcott plc,1088700|14165|17247|27724,Eli Lilly & Co,17810,,,,,,
17592,"arsenic trioxide, Mount Sinai","arsenic trioxide|As2O3|arsenic trioxide, Mount Sinai",USAN|Research Code,Cancer,,,Unspecified drug target|Anticancer,59620|1545,,,Acute promyelocytic leukemia|Cancer,1732|651,,,Mount Sinai School of Medicine,20631,Mount Sinai School of Medicine,20631,,,,,,
17600,cilengitide,cilengitide|EMD-121974|EMD-85189|NSC-707544|EspoiR-003,USAN|INN|Research Code|Research Code|Research Code|Research Code,Cancer|Genitourinary/Sexual Function,Integrin alpha-V/beta-3 antagonist|Integrin alpha-V/beta-5 antagonist,2458|2459,Anti-inflammatory|Angiogenesis inhibitor|Anticancer,2953|61|1545,,,Non-small-cell lung cancer|Melanoma|Glioblastoma|Pancreas tumor|Focal segmental glomerulosclerosis|Hormone refractory prostate cancer|Breast tumor|Head and neck tumor|Solid tumor|Kaposis sarcoma|Colorectal tumor,1262|205|2454|249|3084|3246|49|623|725|936|989,,,EspeRare Foundation|Merck KGaA|Merck Serono SA,1081667|18101|19862,Merck KGaA,18101,,,,,,
17606,carotuximab,"SN6f|SN6j|P3-2G8|Y4-2F1|K4-2C10|endoglin MAbs, TRACON|anti-CD105 antibody (cancer), TRACON Pharmaceuticals|endoglin-targeting monoclonal antibody (cancer), TRACON Pharmaceuticals|SN6a|SN6k|64Cu-NOTA-TRC-105-800CW|64Cu-TRC-105|64Cu-NOTA-GO-TRC-105|66Ga-NOTA-GO-TRC-105|66Ga-NOTA-TRC-105|66Ga-TRC-105|carotuximab|TRC-105|177Lu-DTPA-TRC-105",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|PINN|Research Code|Research Code,Cancer|Cardiovascular,Endoglin inhibitor,5397,Angiogenesis inhibitor|Anticancer monoclonal antibody|Anticancer|Cardiovascular diagnostic agent|Imaging agent|Gastrointestinal diagnostic agent|Endocrine diagnostic agent|Neoplasm diagnostic agent|Apoptosis stimulator,61|55685|1545|7210|4155|7213|7212|7220|1589,,,Non-small-cell lung cancer|B-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Sarcoma|Liver tumor|Bladder cancer|Angiosarcoma|Glioblastoma|Hormone refractory prostate cancer|Soft tissue sarcoma|Choriocarcinoma|Angiogenesis disorder|Metastatic renal cell carcinoma|Breast tumor|Cancer|Solid tumor|Ovary tumor,1262|1729|1731|194|202|2380|2443|2454|3246|3378|3738|422|4250|49|651|725|799,,,Ambrx Inc|TRACON Pharmaceuticals Inc|Roswell Park Comprehensive Cancer Center,1003709|1020043|21099,Roswell Park Comprehensive Cancer Center,21099,,,,,,
17625,"vorinostat (oral), Merck & Co","SAHA|Suberoylanilide hydroxamic acid|SAHA (oral), Merck|suberanilohydroxamic acid (oral), Aton Pharma|suberoylanilide hydroxamic acid (oral), Aton Pharma|vorinostat (oral), Aton Pharma|vorinostat|MK-0683|vorinostat (oral), Merck & Co|suberoylanilide hydroxamic acid (oral), Merck|L-001079038|MSK-390|Zolinza|NSC-701852",USAN|INN|Research Code|Research Code|Research Code|Trade Name|Research Code,Cancer|Infection,Histone deacetylase inhibitor|Histone deacetylase-1 inhibitor|Histone deacetylase-6 inhibitor|Histone deacetylase-3 inhibitor|Histone deacetylase-2 inhibitor,2574|7841|7856|7847|7844,Antiviral|Anticancer,991|1545,HIV infection|Diffuse large B-cell lymphoma|Cutaneous T-cell lymphoma|Sarcoma|Leukemia|Lymphoma|Glioblastoma|B-cell lymphoma|Non-Hodgkin lymphoma|Metastatic non small cell lung cancer|Solid tumor|Colorectal tumor|Renal tumor,158|1749|1754|194|199|203|2454|316|319|3665|725|989|999,Metastasis|Glioma|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Follicle center lymphoma|Marginal zone B-cell lymphoma|Multiple myeloma|Melanoma|Fallopian tube cancer|Prostate tumor|Peritoneal tumor|Soft tissue sarcoma|Metastatic renal cell carcinoma|Breast tumor|Head and neck tumor|Cancer|Urinary tract tumor|Ovary tumor,1069|1108|1240|1261|1262|1272|1731|1734|1745|1746|1828|205|2243|276|3083|3378|4250|49|623|651|738|799,Taiho Pharmaceutical Co Ltd|Merck & Co Inc,18720|18077,Columbia University|Memorial Sloan-Kettering Cancer Center|MSD Japan|Aton Pharma Inc,20559|22122|24019|29378,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
17682,ombrabulin,"AC-7739|AC-7700|AVE-8062A|RPR-258063|combretastatin A4 analog, Ajinomoto/sanofi-aventis|AVE-8062|ombrabulin",Research Code|Research Code|Prodrug|Research Code|Research Code|Metabolite|Analogue|Research Code|Research Code|INN,Cancer,,,Microtubule inhibitor|Cell cycle inhibitor|Vascular damaging agent|Anticancer|Apoptosis stimulator,2575|767|2969|1545|1589,,,Non-small-cell lung cancer|Sarcoma|Soft tissue sarcoma|Metastatic non small cell lung cancer|Advanced solid tumor|Solid tumor|Ovary tumor,1262|194|3378|3665|3713|725|799,,,Sanofi SA|Ajinomoto Co Inc|Aventis Pharma SA,1009547|13794|27779,Ajinomoto Co Inc,13794,,,,,,
17752,rabusertib,"Atr gene inhibitors, ICOS/Oregon Health|cell cycle regulator, ICOS/Oregon Health|cell cycle checkpoint/DNA repair antagonists, ICOS/Oregon Health|cell cycle checkpoint/DNA repair antagonists, Eli Lilly/Oregon Health|IC-83|LY-2603618|lead Chk-1 inhibitor (cancer), Eli Lilly|rabusertib",Research Code|Research Code|USAN|INN,Cancer,Checkpoint kinase 1 inhibitor,4438,Synergist|Anticancer protein kinase inhibitor|Apoptosis stimulator|Cell cycle inhibitor,7293|62255|1589|767,,,Non-small-cell lung cancer|Pancreas tumor|Cancer,1262|249|651,,,ICOS Corp|Eli Lilly & Co|Array BioPharma Inc,17082|17810|25902,ICOS Corp,17082,,,,,,
17767,LMB-2,"LMB-2|LMB-2a|AntiTac(Fv)-PE38|immunotoxin (cancer), National Cancer Institute|alpha Tac-Fv-M18-PE24",,Cancer|Immune,IL-2 receptor alpha subunit modulator|Elongation factor 2 inhibitor,5098|53707,Protein synthesis inhibitor|Anticancer monoclonal antibody|Immunotoxin,339|55685|539,Hairy cell leukemia|Adult T-cell lymphoma,1736|1757,Chronic lymphocytic leukemia|Prolymphocytic leukemia|Lymphoma|Melanoma|Non-Hodgkin lymphoma|Graft versus host disease|Cancer,1734|1738|203|205|319|616|651,National Cancer Institute (NCI),20519,National Institutes of Health,20518,National Cancer Institute (NCI),20519,,,,,,
17772,canertinib,canertinib dihydrochloride|CI-1033|PD-183805|canertinib|SN-26606|PD-0183805,USAN|Research Code|Analogue|Research Code|INN|Research Code|Analogue|Research Code,Cancer,Erbb3 tyrosine kinase receptor inhibitor|Erbb2 tyrosine kinase receptor inhibitor|Erbb4 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3758|3756|3760|740,Anticancer protein kinase inhibitor|Apoptosis stimulator|Anticancer|Angiogenesis inhibitor,62255|1589|1545|61,,,Cancer,651,,,Pfizer Inc|University of Auckland|Parke-Davis & Co,18767|20647|20805,University of Auckland,20647,,,,,,
17814,pregabalin,pregabalin|CI-1008|PGB|PD-144723|S-isobutylGABA|Lyrica|Lyrica Capsules|Lyrica OD Tablets,INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name,Musculoskeletal|Neurology/Psychiatric,GABA A receptor alpha-2 subunit stimulator|GABA A receptor delta subunit stimulator|GABA receptor agonist|CACNA2D calcium channel subunit modulator,17217|17247|173|50960,Analgesic|Anticonvulsant agent,2946|70,Epilepsy|Neuropathic pain|Generalized anxiety disorder|Fibromyalgia|Postherpetic neuralgia,119|1295|1937|2527|3300,Restless legs syndrome|Pain|Complex regional pain syndrome|Tonic clonic epilepsy|Antisocial personality disorder,1774|20|2618|2992|724,Viatris Inc,1136574,Pfizer Inc|Warner-Lambert Co|Parke-Davis & Co,18767|20787|20805,Warner-Lambert Co,20787,,,,,,
17817,laromustine,"VNP-40101M|SHP, Vion|VN-40101M|alkylating agents, Vion|sulfonyl hydrazine prodrugs, Vion|Cloretazine|laromustine|VNP-4090-CE|90CE|Onrigin|NTO-1152",Research Code|Research Code|Trade Name|USAN|INN|Research Code|Research Code|Trade Name|Research Code,Cancer,AGT gene inhibitor,21636,Anticancer alkylating agent,50,Acute myelogenous leukemia,1731,Glioma|Small-cell lung cancer|Myelodysplastic syndrome|Chronic lymphocytic leukemia|Leukemia|Hematological neoplasm|Solid tumor|Brain tumor,1108|1261|1272|1734|199|2054|725|760,Vion Pharmaceuticals Inc,23318,Ology Bioservices Inc,1003870,Vion Pharmaceuticals Inc,23318,,,,,,
17878,"paclitaxel (DHA-linked, cancer), Luitpold","paclitaxel|paclitaxel (DHA-linked), Protarga|paclitaxel-DHA conjugate, Protarga|Taxoprexin|paclitaxel (DHA-linked, cancer), Luitpold|paclitaxel (docosahexaenoic acid-linked, cancer), Luitpold",USAN|BANN|INN|Trade Name,Cancer,Tubulin binding agent,499,Microtubule stabilizer|Anticancer,2576|1545,,,Cancer,651,,,Protarga Inc|American Regent Inc,18503|24732,Protarga Inc,18503,,,,,,
17964,"lurtotecan (liposomal), OSI","GI 147211C|lurtotecan dihydrochloride|NX-211|lurtotecan (liposomal), OSI|GG211 (liposomal), NeXstar/Glaxo Wellcome|GG211 (liposomal), NeXstar/GlaxoSmithKline|lurtotecan (liposomal), NeXstar/Glaxo Wellcome|lurtotecan (liposomal), NeXstar/GlaxoSmithKline|OSI-211",Research Code|Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,,,Small-cell lung cancer|Cancer|Ovary tumor,1261|651|799,,,NeXstar Pharmaceuticals Inc|Glaxo Group Ltd|OSI Pharmaceuticals Inc|GlaxoSmithKline plc,15906|16453|18676|28355,Glaxo Group Ltd,16453,,,,,,
17990,pralatrexate,"10-propargyl-10-deazaaminopterin|DHFR inhibitor (anticancer), Allos|DHFR inhibitor (anticancer), Memorial Sloan-Kettering|pralatrexate|PDX, Allos|Folotyn|Difolta",USAN|INN|Trade Name|Trade Name,Cancer,DHFR inhibitor|Folate transporter 1 modulator|Folate receptor antagonist,135|43954|665,Anticancer|Apoptosis stimulator,1545|1589,Peripheral T-cell lymphoma,1753,Esophagus tumor|Mesothelioma|Non-small-cell lung cancer|Stomach tumor|Follicle center lymphoma|Diffuse large B-cell lymphoma|Cutaneous T-cell lymphoma|Multiple myeloma|Fallopian tube cancer|Peritoneal tumor|B-cell lymphoma|Non-Hodgkin lymphoma|Metastatic bladder cancer|Breast tumor|Head and neck tumor|Cancer|Solid tumor|Ovary tumor,1011|1240|1262|127|1745|1749|1754|1828|2243|3083|316|319|3466|49|623|651|725|799,Servier Canada Inc|Mundipharma International Corp Ltd|Baxter Oncology GmbH|Acrotech Biopharma LLC,22730|1045514|29750|1179286,Southern Research Institute|SRI International|Memorial Sloan-Kettering Cancer Center|Allos Therapeutics Inc|Spectrum Pharmaceuticals Inc,20226|20234|22122|23253|24232,SRI International,20234,,,,,,
18004,90Y-edotreotide,OctreoTher|Onalta|90Y-SMT-487|90Y-SDZ-SMT-487|yttrium-90-edotreotide|90Y-edotreotide|edotreotide-[90Y]|90Y-DOTATOC|90Y-DOTA-[3-Tyr]octreotide,Trade Name|Trade Name|Research Code|Research Code,Cancer,Somatostatin receptor agonist,1120,Radiopharmaceutical|Anticancer hormone|Growth hormone release inhibitor,1617|62253|3272,,,Neuroendocrine tumor|Carcinoid tumor|Cancer,1128|2538|651,,,Biomedica Life Sciences SA|Progenics Pharmaceuticals Inc|Novartis Pharma AG|Molecular Insight Pharmaceuticals Inc,1006049|19156|25599|27965,Novartis Pharma AG,25599,,,,,,
18017,DTGM,"DTGM|DT388-GM-CSF|truncated diphtheria toxin-GM-CSF, Univ South Carolina",Research Code,Cancer,GM-CSF receptor agonist,410,Anticancer,1545,,,Acute myelogenous leukemia,1731,,,Medical University of South Carolina,20675,Medical University of South Carolina,20675,,,,,,
18031,troxacitabine,L-OddC|troxacitabine|Troxatyl|SPD-758|BCH-4556,INN|Trade Name|Research Code|Research Code,Cancer,,,Anticancer|DNA synthesis inhibitor,1545|140,,,Non-small-cell lung cancer|Acute myelogenous leukemia|Chronic myelocytic leukemia|Melanoma|Pancreas tumor|Prostate tumor|Breast tumor|Solid tumor|Ovary tumor|Colorectal tumor|Renal tumor,1262|1731|1735|205|249|276|49|725|799|989|999,,,Shire BioChem Inc|Shire plc|SGX Pharmaceuticals Inc,14691|24652|27653,Shire plc,24652,,,,,,
18129,"skeletal targeted radiotherapy, NeoRx","STR, NeoRx|STAR, NeoRx|166-Ho-DOTMP, NeoRx|holmium-166 DOTMP, NeoRx|skeletal targeted radiotherapy, NeoRx",,Cancer,,,Unspecified drug target|Radiopharmaceutical|Anticancer,59620|1617|1545,,,Multiple myeloma|Bone metastases|Ewing sarcoma|Breast tumor,1828|1829|2975|49,,,Poniard Pharmaceuticals Inc,18472,Poniard Pharmaceuticals Inc,18472,,,,,,
18194,batabulin,T-138067|T-138068|batabulin|T-67,Research Code|Analogue|Research Code|USAN|PINN|Research Code,Cancer,Tubulin binding agent|Tubulin modulator,499|814,Anticancer,1545,,,Glioma|Non-small-cell lung cancer|Hepatocellular carcinoma|Breast tumor|Cancer|Colorectal tumor,1108|1262|1767|49|651|989,,,Amgen Inc|Tularik Inc,14109|20449,Tularik Inc,20449,,,,,,
18325,"elacytarabine (intravenous, cancer), Clavis","P-4055|ara-C analogs, Norsk Hydro|Elacyt|elacytarabine|CP-4055|elacytarabine (intravenous, cancer), Clavis|ELACYT (intravenous, cancer), Clavis|CP-4055 (intravenous, cancer), Clavis",Research Code|Trade Name|USAN|INN|Research Code,Cancer,DNA polymerase inhibitor|RNA polymerase inhibitor,138|347,DNA synthesis inhibitor|Anticancer antimetabolite,140|1569,,,Non-small-cell lung cancer|Acute myelogenous leukemia|Leukemia|Melanoma|Cancer|Ovary tumor|Colorectal tumor,1262|1731|199|205|651|799|989,,,Norsk Hydro AS|Aqualis ASA,18584|30630,Norsk Hydro AS,18584,,,,,,
18694,barasertib,"AZD-1152|aurora kinase inhibitors, AstraZeneca|AZD-1152-hydroxyQPA|AZD-1152-hQPA|barasertib",Research Code|Metabolite|Metabolite|INN,Cancer,Aurora protein kinase 1 inhibitor|Aurora protein kinase 2 inhibitor,4418|4420,Anticancer protein kinase inhibitor,62255,Diffuse large B-cell lymphoma,1749,Acute myelogenous leukemia|Cancer|Solid tumor,1731|651|725,Oxford University Hospitals NHS Trust,1066819,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
19081,lestaurtinib,CEP-701|SPM-924|lestaurtinib|KT-5555|NSC-617807,Research Code|Research Code|USAN|INN|Research Code|Research Code,Cancer|Dermatologic|Hematologic,Jak2 tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|TrkA receptor antagonist,3564|3806|3840,Anticancer protein kinase inhibitor|Systemic antipsoriatic product|Anticancer,62255|15184|1545,,,Acute myelogenous leukemia|Multiple myeloma|Myeloid leukemia|Polycythemia vera|Myelofibrosis|Pancreas tumor|Myeloproliferative disorder|Prostate tumor|Psoriasis|Thrombocytosis|Solid tumor,1731|1828|223|2319|2436|249|273|276|281|467|725,,,Cephalon Inc|Kyowa Hakko Kogyo Co Ltd|UCB Pharma GmbH|TAP Pharmaceutical Products Inc,15358|17724|19821|23077,Cephalon Inc,15358,,,,,,
19181,pelitrexol,AG-2037|pelitrexol,Research Code|USAN|INN,Cancer,GAR transformylase inhibitor,181,Anticancer,1545,,,Cancer,651,,,Agouron Pharmaceuticals Inc,26488,Agouron Pharmaceuticals Inc,26488,,,,,,
19300,deferasirox,"deferasirox|ICL-670|ICL-670A|iron chelator, Novartis|Exjade|Exjade FCT|Jadenu|Jadenu Sprinkle|Osveral|CGP-72670",INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code,Cancer|Endocrine/Metabolic|Hematologic|Infection,Ferritin inhibitor,47096,Fungicide|Antiviral|Anticancer|Iron chelator|Blood system agent,1748|991|1545|2557|1546,Iron overload|Myelodysplastic syndrome|Hemochromatosis|Sickle cell anemia|Thalassemia,1252|1272|1994|303|322,Fungal infection|Mucor infection|HIV-1 infection,124|1380|159,Novartis AG,23137,,,Novartis AG,23137,,,,,,
19462,micafungin,FK-463|micafungin|Funguard|Mycamine|micafungin sodium,Research Code|INN|Trade Name|Trade Name|USAN,Gastrointestinal|Infection,"1,3 beta glucan synthase inhibitor",61991,Fungal cell wall synthesis inhibitor,2956,Candida infection|Fungal respiratory tract infection|Aspergillus infection|Abscess|Peritonitis|Gastrointestinal infection,1308|1486|29|3081|452|577,Fungal infection,124,Astellas Pharma Inc,1013295,Fujisawa Pharmaceutical Co Ltd|Fujisawa Healthcare Inc,16227|25526,Fujisawa Healthcare Inc,25526,,,,,,
19520,KOS-862,"desoxyepothilone B|epothilone D|NSC-703147|dEpoB analog, Koson/Roche|R-1492|KOS-862|epothilone B analog, Kosan/Roche|epothilone D, Kosan|desoxyepothilone B analog, Kosan/Roche|epothilone D, Kosan/Roche",Research Code|Research Code,Cancer,,,Microtubule stabilizer|Anticancer,2576|1545,,,Non-small-cell lung cancer|Prostate tumor|Breast tumor|Cancer|Solid tumor|Colorectal tumor,1262|276|49|651|725|989,,,Roche Holding AG|Memorial Sloan-Kettering Cancer Center|Kosan Biosciences Inc,19446|22122|24027,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
20136,carbendazim,carbendazim|carbendazol|carbendazime|carbendazole,,Infection,,,Fungicide|Unspecified drug target,1748|59620,,,Fungal infection,124,,,Indiana University,20593,Indiana University,20593,,,,,,
20294,ALVAC-CEA/B7.1,"TBC-CEA|ALVAC-CEA|avipox-CEA|ALVAC-hB7.1|ALVAC-CEA/B7.1|recombinant pox virus vaccine (colorectal cancer), Therion/Aventis Pasteur|recombinant pox virus vaccine (colorectal cancer), Therion/sanofi-aventis|CEA/CD80 costimulator expressing recombinant canarypox virus-based vaccine (colorectal cancer), Therion/sanofi-aventis",,Cancer,CD66e modulator|CD80 modulator,5281|5325,Recombinant viral vector vaccine|Therapeutic vaccine|T-lymphocyte stimulator|Anticancer,12370|12379|7761|1545,,,Melanoma|Lung tumor|Colorectal tumor,205|755|989,,,Sanofi SA|Therion Biologics Corp|Sanofi Pasteur,1009547|20371|22127,Therion Biologics Corp,20371,,,,,,
20524,paclitaxel poliglumex,"paclitaxel|PG-TXL|Xyotax|CHC-12103|drug delivery system, paclitaxel, Cell Therapeutics|paclitaxel poliglumex|CT-2103|polyglutamate paclitaxel|PG-paclitaxel|Opaxio|PPX|drug delivery system, paclitaxel, CTI BioPharma Corp",USAN|BANN|INN|Trade Name|Research Code|USAN|INN|Research Code|Trade Name,Cancer,Tubulin binding agent,499,Anticancer|Microtubule stabilizer,1545|2576,,,Esophagus tumor|Glioma|Non-small-cell lung cancer|Stomach tumor|Hormone refractory prostate cancer|Breast tumor|Head and neck tumor|Cancer|Solid tumor|Brain tumor|Ovary tumor|Colorectal tumor,1011|1108|1262|127|3246|49|623|651|725|760|799|989,,,Fem CadeT Taxol LLC|CTI BioPharma Corp|Chugai Pharmaceutical Co Ltd|Novartis AG|MD Anderson Cancer Center,1104293|15337|15414|23137|23382,MD Anderson Cancer Center,23382,,,,,,
20601,MDNA-55,"IL4-PE|NBI-3001|IL4(38-37)-PE38KDEL|IL-4 fusion toxin, NIH/Neurocrine|Interleukin-4 (circularly permuted) + endotoxin, NCI/Neurocrine|PRX-321|IL-4 fusion toxin (cancer), Sophiris|INxin|MDNA-55|IL-4 targeting fusion protein (intratumoral, bladder cancer/glioblastoma/prostrate tumor), Medicenna BioPharma",Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code,Cancer,IL-4 receptor modulator,3054,Anticancer|Cell cycle inhibitor|Apoptosis stimulator|Immunotoxin,1545|767|1589|539,Glioblastoma|Ovary tumor,2454|799,Non-small-cell lung cancer|Melanoma|Hematological neoplasm|Bladder cancer|Astrocytoma|Prostate tumor|Metastatic brain cancer|Metastatic renal cell carcinoma|Breast tumor|Cancer|Colon tumor|Renal tumor,1262|205|2054|2380|2453|276|3471|4250|49|651|767|999,Medicenna Therapeutics Pte Ltd,1090434,Sophiris Bio Inc|Neurocrine Biosciences Inc|National Institutes of Health,1010880|18501|20518,National Institutes of Health,20518,,,,,,
20635,L523S,"L523S|L523S-NSCLC|vaccine (lung cancer), Corixa/Japan Tobacco/Zambon|vaccine (lung cancer), Corixa/Zambon",,Cancer,,,DNA vaccine|Anticancer,1879|1545,,,Non-small-cell lung cancer,1262,,,Corixa Corp|Japan Tobacco Inc|Zambon Co SpA|GlaxoSmithKline plc,15542|17327|20999|28355,Corixa Corp,15542,,,,,,
20637,seliciclib,"Roscovitine|CYC-200|CYC-201|CYC-204|NSC-701554|CYC-200 series|CDK inhibitors, Cyclacel|(R)-roscovitine, Cyclacel|CYC-202|(R)-roscovitine|seliciclib",Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Research Code|Analogue|Research Code|INN,Cancer|Endocrine/Metabolic|Genitourinary/Sexual Function|Immune|Infection|Inflammatory|Respiratory,MCL1 gene inhibitor|Cyclin-dependent kinase-7 inhibitor|Cyclin-dependent kinase-9 inhibitor|Cyclin-dependent kinase-2 inhibitor,31382|4304|8110|4310,Anticancer protein kinase inhibitor|Anti-inflammatory|Apoptosis stimulator|Antiviral|Antibacterial|Anticancer|Cell cycle inhibitor,62255|2953|1589|991|1594|1545|767,Coronavirus disease 19 infection|Non-small-cell lung cancer|Nasopharyngeal carcinoma|Rheumatoid arthritis|Solid tumor|Cushings disease|Cystic fibrosis,10406|1262|1768|291|725|87|88,Lymphoid leukemia|Glomerulonephritis|HIV infection|Mantle cell lymphoma|Multiple myeloma|Inflammatory disease|Hematological neoplasm|Breast tumor|Cancer,1255|135|158|1744|1828|188|2054|49|651,The University of Newcastle Upon Tyne|University of Glasgow|ManRos Therapeutics|Cyclacel Pharmaceuticals Inc|The University of Birmingham|Cedars-Sinai Medical Center,21243|20580|1045573|24341|20537|15328,,,Cyclacel Pharmaceuticals Inc,24341,,,,,,
20700,orantinib,SU-6668|TSU-68|SU-006668|orantinib,Research Code|Research Code|Research Code|PINN,Cancer,FGF receptor antagonist|PDGF receptor antagonist|VEGF-2 receptor antagonist,168|948|3848,Synergist|Angiogenesis inhibitor|Anticancer protein kinase inhibitor,7293|61|62255,,,Non-small-cell lung cancer|Stomach tumor|Renal cell carcinoma|Hepatocellular carcinoma|Breast tumor|Cancer|Solid tumor|Colorectal tumor,1262|127|1766|1767|49|651|725|989,,,SUGEN Inc|Taiho Pharmaceutical Co Ltd,15997|18720,SUGEN Inc,15997,,,,,,
20714,OSI-632,CP-547632|CP-564959|OSI-632,Research Code|Analogue|Research Code|Research Code,Cancer,VEGF receptor antagonist,1722,Angiogenesis inhibitor|Anticancer protein kinase inhibitor|Anticancer,61|62255|1545,,,Non-small-cell lung cancer|Cancer|Ovary tumor,1262|651|799,,,OSI Pharmaceuticals Inc|Pfizer Inc,18676|18767,OSI Pharmaceuticals Inc,18676,,,,,,
21058,Xcellerated T cells,"Xcellerated T cells|activated T-cell therapy (Xcellerate), Xcyte/University of Chicago",Trade Name,Cancer|Infection,,,Antiviral|Immunostimulant|Anticancer,991|393|1545,,,Hepatitis C virus infection|HIV infection|Chronic lymphocytic leukemia|Multiple myeloma|Prostate tumor|Non-Hodgkin lymphoma|Cancer|Renal tumor,153|158|1734|1828|276|319|651|999,,,Cyclacel Pharmaceuticals Inc|University of Chicago,24341|26013,Cyclacel Pharmaceuticals Inc,24341,,,,,,
21065,tucotuzumab celmoleukin,"EMD-273066|hKS1/4-IL-2|huKS1/4-IL-2|IL-2 fusion protein, Scripps/Lexigen|fusion protein-directed IL-2 therapy, Scripps/Lexigen|tucotuzumab celmoleukin|KS-IL-2|huKS-IL-2",Research Code|USAN|INN,Cancer,EpCAM inhibitor|IL-2 receptor agonist,14555|221,Anticancer|Anticancer monoclonal antibody,1545|55685,,,Small-cell lung cancer|Non-small-cell lung cancer|Prostate tumor|Breast tumor|Cancer|Brain tumor|Ovary tumor|Colorectal tumor|Renal tumor,1261|1262|276|49|651|760|799|989|999,,,Merck Serono SA|EMD Lexigen Research Center Corp,19862|21956,EMD Lexigen Research Center Corp,21956,,,,,,
21097,CEL-031,"CP-461|cGMP PDE inhibitor, CellPath|OSI 461|CEL-031",Research Code|Research Code|Research Code,Cancer|Gastrointestinal,Protein kinase G inhibitor|Cyclic GMP phosphodiesterase inhibitor,3958|429,Angiogenesis inhibitor|Anticancer protein kinase inhibitor|Apoptosis stimulator,61|62255|1589,,,Chronic lymphocytic leukemia|Inflammatory bowel disease|Melanoma|Bladder cancer|Pancreas tumor|Prostate tumor|Cancer|Crohns disease|Renal tumor,1734|189|205|2380|249|276|651|84|999,,,Celek Pharmaceuticals LLC|OSI Pharmaceuticals Inc|Cell Pathways Inc,1063579|18676|23024,Cell Pathways Inc,23024,,,,,,
21138,certolizumab pegol,CDP-870|Cimzia|certolizumab pegol|Perstymab,Research Code|Trade Name|INN|Trade Name,Cardiovascular|Dermatologic|Gastrointestinal|Immune|Musculoskeletal,TNF antagonist|TNF alpha ligand inhibitor|TNF binding agent,511|381|721,Anti-inflammatory|Systemic antipsoriatic product|Therapeutic antibody,2953|15184|172641,Psoriatic arthritis|Psoriasis|Rheumatoid arthritis|Spondylarthritis|Juvenile rheumatoid arthritis|Ulcerative colitis|Ankylosing spondylitis|Crohns disease,1781|281|291|2921|3003|337|398|84,Cardiac failure,55,Orient Europharma|UCB SA|NewBridge Pharmaceuticals Ltd|Laboratorios Farmaceuticos Rovi SA|Astellas Pharma Inc|Otsuka Pharmaceutical Co Ltd,DOL1000087|20452|1043434|21332|1013295|18717,Dermira Inc|AstraZeneca plc|UCB Celltech|Pfizer Inc|Pharmacia Corp,1065735|14190|15336|18767|27638,UCB Celltech,15336,,,,,,
21259,LOR-2040,"GTI-2040|R2 ribonucleotide reductase mRNA antisense oligo, Lorus|LOR-2040",Research Code|Research Code,Cancer,Ribonucleotide reductase inhibitor,346,Antisense oligonucleotide inhibitor|Anticancer,7294|1545,,,Rectal tumor|Metastasis|Non-small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Renal cell carcinoma|Hormone refractory prostate cancer|Bladder tumor|Breast tumor|Cancer,1055|1069|1262|1272|1731|1766|3246|42|49|651,,,Aptose Biosciences Inc|National Cancer Institute (NCI),17215|20519,Aptose Biosciences Inc,17215,,,,,,
21294,"inecalcitol (oral, cancer/psoriasis), Hybrigenics","TX-522|TX-527|vitamin D analogs, KULeuven|vitamin D analogs, Catholic University of Leuven|inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics|inecalcitol (oral, hyperthyroidism), Hybrigenics|inecalcitol|inecalcitol (oral, cancer/psoriasis), Hybrigenics",Research Code|Analogue|Research Code|Analogue|Analogue|INN,Cancer|Dermatologic|Endocrine/Metabolic,Parathyroid hormone ligand inhibitor|Vitamin D3 receptor agonist,13410|756,Hypoglycemic agent|Vitamin D analog|Anticancer|Systemic antipsoriatic product|Synergist,399|2593|1545|15184|7293,,,Secondary hyperparathyroidism|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Psoriasis|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Cancer|Insulin dependent diabetes,1665|1731|1734|1735|281|3246|3247|651|836,,,Hybrigenics SA|Katholieke Universiteit Leuven|Theramex,14161|23009|27576,Katholieke Universiteit Leuven,23009,,,,,,
21374,pegfilgrastim,"Neulasta|pegfilgrastim|SD-01|R-1471|r-metHuG-CSF-SD/01|PEGylated filgrastim|PEG-GCSF, Amgen/Roche|Neupogen (sustained release)|Neupopeg|KRN-125|Neulastim|Peglasta|Filgrastim SD-01|G-Lasta|Ristempa|Neulasta Onpro",Trade Name|USAN|BANN|INN|Research Code|Research Code|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Hematologic|Immune|Toxicity/Intoxication,GCSF receptor agonist,3151,Hematopoietic stimulator|Anticancer,610|1545,Neutropenia|Radiation sickness|Febrile neutropenia|Hematopoietic stem cell transplantation,1991|367|3795|3888,,,Kyowa Hakko Kirin Co Ltd|Amgen Inc,1042596|14109,Kirin Pharma Co Ltd|Kirin Brewery Co Ltd|Roche Holding AG,1034843|17661|19446,Amgen Inc,14109,,,,,,
21494,"DC-Ad-CCL-21 intratumoral therapy, UCLA/Department of Veterans Affairs","gene therapy (CCL-21), UCLA/Department of Veterans Affairs|DC-AdIL-7 intratumoral therapy|dendritic cell therapy (CCL-21), UCLA/Department of Veterans Affairs|DC-Ad-CCL-21 intratumoral therapy, UCLA/Department of Veterans Affairs|gene therapy (interleukin-7), UCLA/Department of Veterans Affairs|dendritic cell therapy (IL-7), UCLA/Department of Veterans Affairs|AdCCL21-DC|CCL21-DC",Research Code|Research Code|Research Code,Cancer,Chemokine CC21 ligand modulator,51071,Therapeutic vaccine|Adenovirus based gene therapy|Genetically engineered autologous cell therapy|Anticancer|Dendritic cell vaccine,12379|4780|4790|1545|102926,Non-small-cell lung cancer,1262,Lung tumor,755,US Department of Veterans Affairs|University of California Los Angeles,26104|25623,,,University of California Los Angeles,25623,,,,,,
21534,navitoclax,"A-317267|A-371191|A-385358|A-438744|Bax modulators (anticancer), Idun/Abbott|Bcl-2/Bcl-xL inhibitors (anticancer), Abbott/Idun|cancer therapeutics (Bcl-2/Bcl-xL inhibitors), Abbott/Idun|Bax modulators (anticancer, oral), Abbott|Bcl-2/Bcl-xL inhibitors (anticancer), Abbott|cancer therapeutics (Bcl-2/Bcl-xL inhibitors), Abbott|ABT-263|navitoclax|RG-7433|navitoclax dihydrochloride|A-855071.0",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code|USAN|Research Code,Cancer|Hematologic|Immune|Respiratory,Bcl-xL Bcl-2 associated death promotor inhibitor|Bcl-2 protein inhibitor,14541|16111,Apoptosis stimulator|Anticancer,1589|1545,Myelofibrosis|Idiopathic pulmonary fibrosis|Breast tumor,2436|3771|49,Small-cell lung cancer|Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Lymphoma|Hematological neoplasm|Lupus nephritis|Cancer|Solid tumor,1261|1728|1734|1749|203|2054|2404|651|725,AbbVie Inc,1072507,Abbott Laboratories|Genentech Inc|Idun Pharmaceuticals Inc,13601|19453|24182,Abbott Laboratories,13601,,,,,,
21820,roflumilast,roflumilast|roflumist|Daxas|APTA-2217|B9302-107|BYK-20869|BY-217|Daliresp|Libertek|Xevex|Dalveza,USAN|INN|Trade Name|Research Code|Research Code|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Endocrine/Metabolic|Neurology/Psychiatric|Respiratory,PDE 4 inhibitor,304,Antipsychotic|Bronchodilator|Anti-inflammatory,2943|646|2953,Chronic obstructive pulmonary disease|Alzheimers disease,1185|14,Schizophrenia|Asthma|Pulmonary fibrosis|Non-insulin dependent diabetes,299|31|708|837,Daewoong Pharmaceutical Co Ltd|AstraZeneca plc|Almirall Prodesfarma SA,15587|14190|14061,Mitsubishi Tanabe Pharma Corp|Allergan plc|Takeda GmbH|Forest Laboratories Inc|Merck & Co Inc|Pfizer Inc|Handok Inc|Tanabe Seiyaku Co Ltd|Pharmacia Corp,1035060|1088700|14069|16198|18077|18767|19986|20315|27638,Takeda GmbH,14069,,,,,,
21919,paricalcitol,"paricalcitol|Zemplar|paricalcitol (iv), Abbott|ABT-358",USAN|INN|Trade Name|Research Code,Cardiovascular|Endocrine/Metabolic|Genitourinary/Sexual Function,,,Vitamin D analog|Parathyroid hormone modulator,2593|1060,Secondary hyperparathyroidism,1665,Cardiac hypertrophy|Proteinuria,1889|277,AbbVie Inc,1072507,Abbott Laboratories|University of Wisconsin-Madison,13601|DOL1000742,University of Wisconsin-Madison,DOL1000742,,,,,,
22204,"dapsone (solvent/microparticle delivery, acne), Allergan","dapsone|Atrisone|topical dapsone (SMP), Atrix|dapsone (solvent/microparticle delivery system, SMP), Atrix|Aczone|topical dapsone (SMP), QLT USA|dapsone (solvent/microparticle delivery system, SMP), QLT USA|dapsone (acne), Allergan|dapsone (solvent/microparticle delivery, acne), Allergan|ACZONE X",BANN|INN|Trade Name|Trade Name|Trade Name,Dermatologic,,,Antibacterial|Systemic antipruritic product|Unspecified drug target|Anti-inflammatory|Topical dermatological antibacterial product,1594|15181|59620|2953|15186,Acne vulgaris,3040,Atopic dermatitis|Rosacea|Pruritus|Skin rash,1102|2164|279|3020,Almirall Prodesfarma SA|AbbVie Inc|Bausch Health Companies Inc,14061|1072507|17058,Astellas Pharma Inc|Allergan plc|Allergan Inc|TOLMAR Therapeutics Inc|Novelion Therapeutics Inc|Fujisawa Healthcare Inc,1013295|1088700|14042|14333|19180|25526,TOLMAR Therapeutics Inc,14333,,,,,,
22354,baltaleucel-T,"Epstein-Barr virus specific T cells, St Jude/Baylor|immunotherapy (EBV-associated lymphoma), St Jude/Baylor|Epstein-Barr virus cytotoxic T lymphocytes, Baylor College/ Cell Medica|EBV CTLs (EBV-associated lymphoma, nasopharyngeal carcinoma), Baylor College/ Cell Medica|GRALE T-cells (EBV-associated lymphoma), Baylor College/Cell Medica|CMD-003|Cytorex EBV|baltaleucel-T|baltaleucel|EBV CTLs (EBV-associated lymphoma, nasopharyngeal carcinoma), Baylor College/Kuur Therapeutics",Research Code|Trade Name|USAN|INN,Cancer|Immune|Infection,Epstein-Barr nuclear antigen 1 modulator|Latent membrane protein 1 modulator|Latent membrane protein 2 modulator|Secreted protein BARF1 modulator,18197|50363|57799|79191,Anticancer|T-lymphocyte stimulator|Antiviral|Immunostimulant,1545|7761|991|393,Lymphoproliferative disease|Hodgkins disease|Lymphoma|Non-Hodgkin lymphoma|Epstein Barr virus infection,1037|161|203|319|3299,Diffuse large B-cell lymphoma|Nasopharyngeal carcinoma|T-cell lymphoma|Post transplant lymphoproliferative disease,1749|1768|311|3530,Baylor College of Medicine|Kuur Therapeutics,20534|1041182,St Jude Children's Research Hospital,21814,St Jude Children's Research Hospital,21814,,,,,,
22774,PD-184352,PD-184352|PD-170611|PD-318088|CI-1040,Research Code|Analogue|Research Code|Research Code|Research Code,Cancer|Immune,MEK-1 protein kinase inhibitor,4762,Immunosuppressant|Anticancer|Anticancer protein kinase inhibitor,396|1545|62255,,,Non-small-cell lung cancer|Pancreas tumor|Breast tumor|Transplant rejection|Cancer|Colon tumor,1262|249|49|515|651|767,,,Pfizer Inc|Parke-Davis & Co,18767|20805,Pfizer Inc,18767,,,,,,
22883,vosaroxin,"AT-3639|naphthyridines (anticancer), Sunesis|naphthyridines (anticancer), Dainippon|AG-7352|SPC-595|SNS-595|voreloxin|vosaroxin|Qinprezo|DB-106",Research Code|Research Code|Research Code|Research Code|USAN|INN|Trade Name|Research Code,Cancer,Topoisomerase II inhibitor,142,Anticancer|Cell cycle inhibitor|DNA intercalator|Apoptosis stimulator,1545|767|750|1589,Acute myelogenous leukemia,1731,Small-cell lung cancer|Non-small-cell lung cancer|Myelodysplastic syndrome|Leukemia|Metastatic non small cell lung cancer|Cancer|Solid tumor|Ovary tumor,1261|1262|1272|199|3665|651|725|799,Denovo Biopharma LLC,1076271,Dainippon Pharmaceutical Co Ltd|Viracta Therapeutics Inc,15606|27713,Dainippon Pharmaceutical Co Ltd,15606,,,,,,
22964,brostallicin,brostallicin|PNU-166196|SMi-BX1|PNU-248427|PNU-248482|PNU-230858|PNU-166196A,INN|Research Code|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Research Code,Cancer,,,DNA modulator|Anticancer alkylating agent|Apoptosis stimulator,803|50|1589,,,Sarcoma|Breast tumor|Head and neck tumor|Cancer|Solid tumor|Colon tumor|Ovary tumor,194|49|623|651|725|767|799,,,Nerviano Medical Sciences Srl|Systems Medicine Inc|Pfizer Inc|Pharmacia & Upjohn Inc|Pharmacia Corp,1013717|1033744|18767|22006|27638,Pharmacia & Upjohn SpA,18917,,,,,,
22965,temsirolimus,CCI-779|temsirolimus|Torisel|NSC-683864,Research Code|USAN|PINN|Trade Name|Research Code,Cancer|Immune,FK506 binding protein-12 modulator|mTOR inhibitor,15887|10240,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Thyroid tumor|Adrenal cortical carcinoma|Endometrioid carcinoma|Acute lymphoblastic leukemia|Mantle cell lymphoma|Hepatocellular carcinoma|Hemangiopericytoma|Hemangiosarcoma|Angiosarcoma|Pheochromocytoma|Paraganglioma|Thymus neoplasm|Non-Hodgkin lymphoma|Lymphoblastic leukemia|Ovarian clear cell carcinoma|Blastoma|Metastatic renal cell carcinoma|Head and neck tumor|Central nervous system tumor,1134|1648|1705|1728|1744|1767|2103|2104|2443|262|2876|2938|319|3436|3525|3997|4250|623|759,Glioma|Myelodysplastic syndrome|Hodgkins disease|Multiple myeloma|Sarcoma|Leukemia|Melanoma|Multiple sclerosis|Bladder cancer|Rhabdomyosarcoma|Prostate tumor|Rheumatoid arthritis|Breast tumor|Cancer|Solid tumor,1108|1272|161|1828|194|199|205|213|2380|2448|276|291|49|651|725,Pfizer Inc|Wyeth|Wyeth Research,18767|14112|25247,,,Wyeth Research,25247,,,,,,
22979,A-6,"A-6|CD44 binding peptide (cancer), Angstrom|Angstrom-6",Research Code,Cancer|Ocular,Hyaluronic acid receptor antagonist,2618,Anticancer|Angiogenesis inhibitor|Apoptosis stimulator|Metastasis inhibitor,1545|61|1589|695,,,Age related macular degeneration|Chronic lymphocytic leukemia|Lymphoma|Fallopian tube cancer|Peritoneal tumor|Diabetic retinopathy|Cancer|Ovary tumor,1226|1734|203|2243|3083|576|651|799,,,Splash Pharmaceuticals Inc,25616,Splash Pharmaceuticals Inc,25616,,,,,,
23300,sibrotuzumab,"sibrotuzumab|BIBH-1|F19 antibody (humanized), Ludwig/Boehringer Ingelheim|anti-FAP antibody (humanized), Ludwig/Boehringer Ingelheim",INN|Research Code,Cancer,Seprase inhibitor,10910,Anticancer monoclonal antibody,55685,,,Non-small-cell lung cancer|Cancer|Colorectal tumor,1262|651|989,,,Boehringer Ingelheim International GmbH|Ludwig Institute for Cancer Research,14881|21091,Ludwig Institute for Cancer Research,21091,,,,,,
23381,insulin glulisine,"insulin glulisine|1964|HMR-1153|HMR-1423|Glulisine|insulin analogs, Aventis|Apidra|HMR-1964|Shorant|Apidra SoloStar|Apidra ClikStar",USAN|INN|Research Code|Analogue|Research Code|Analogue|Research Code|Trade Name|Research Code|Trade Name|Trade Name|Trade Name,Endocrine/Metabolic,Insulin ligand|Insulin receptor agonist,23014|400,Human insulin fast acting product|Hypoglycemic agent,38211|399,Diabetes mellitus,97,Insulin dependent diabetes|Non-insulin dependent diabetes,836|837,Sanofi SA|Aventis Pharma AG,1009547|25218,,,Hoechst Marion Roussel Inc,25224,,,,,,
23383,Rhenium-188-P-2045,"Rhenium-188-P-2045|rhenium-188-labeled peptide (lung cancer), Antisoma|rhenium-188-labeled peptide (lung cancer), Bryan Oncor/ Antisoma|Re-P2045|188Re-P-2045|Neotide|P-2045-[188Re]|Tozaride|BAY-86-5284",Research Code|Research Code|Research Code|Trade Name|Research Code|Research Code,Cancer,Somatostatin 2 receptor modulator,2561,Radiotherapeutic|Anticancer,5721|1545,Pancreas tumor|Lung tumor,249|755,Cancer,651,Wuxi Fortune Pharmaceutical Co Ltd|Andarix Pharmaceuticals Inc,1030454|1049065,Antisoma plc|Bayer Schering Pharma AG|Diatide Inc,14239|19687|27169,Diatide Inc,27169,,,,,,
23481,"SS (dsFv) PE38 immunotoxin, NCI","SS1P, Enzon/NCI|SS1-PE38|SS1(dsFv)-PE38|SS (dsFv) PE38 immunotoxin, NCI|CAT-5001",Research Code|Research Code,Cancer,Mesothelin modulator,11484,Anticancer monoclonal antibody|Protein synthesis inhibitor|Immunotoxin,55685|339|539,Mesothelioma|Pancreas tumor|Solid tumor|Ovary tumor,1240|249|725|799,Head and neck tumor,623,National Cancer Institute (NCI)|National Institutes of Health,20519|20518,Enzon Pharmaceuticals Inc|MedImmune LLC|NeoPharm Inc|Cambridge Antibody Technology Group plc,16045|18008|23940|24236,National Cancer Institute (NCI),20519,,,,,,
23553,"tasidotin HCl (intravenous), Genzyme","LU-223651|BSF-223651|ILX-651|syn-D|synthadotin|tasidotin HCl|tasidotin hydrochloride|tasidotin HCl (intravenous), Genzyme|tasidotin",Research Code|Research Code|Research Code|USAN|INN,Cancer,,,Anticancer|Microtubule stabilizer,1545|2576,,,Non-small-cell lung cancer|Melanoma|Prostate tumor|Solid tumor,1262|205|276|725,,,BASF Bioresearch Corp|Sanofi Genzyme|ILEX Oncology Inc,14359|16299|23744,BASF Bioresearch Corp,14359,,,,,,
23624,clofarabine,clofarabine|Evoltra|Clofarex|Clolar|JC-0707,USAN|BANN|INN|Trade Name|Trade Name|Trade Name|Research Code,Cancer|Dermatologic|Hematologic,DNA polymerase inhibitor|Ribonucleotide reductase inhibitor,138|346,Anticancer antimetabolite|DNA synthesis inhibitor,1569|140,Acute lymphoblastic leukemia|Non-Hodgkin lymphoma|Histiocytosis,1728|319|4682,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Multiple myeloma|Psoriasis|B-cell lymphoma|Solid tumor,1272|1731|1734|1749|1828|281|316|725,Sanofi SA|Sanofi Genzyme|Hospira Inc,1009547|16299|1010293,Southern Research Institute|ILEX Oncology Inc|Bioenvision Inc|Mayne Pharma Pty Ltd,20226|23744|26493|31290,Southern Research Institute,20226,,,,,,
23625,peginterferon alfa-2a,"Pegasys|peginterferon alfa-2a|R-442|R-420|Ro-25-8310|PEG-IFN-alfa-2a, Chugai|PEG-IFN-alpha-2a, Roche|peginterferon alfa-2a, Roche|peginterferon alfa-2a, Chugai|pegylated IFN alpha-2a, Roche|pegylated IFN alpha-2a, Chugai|interferon (pegylated, alpha-2a), Roche|polyethylene glycol interferon alfa-2a, Roche|RG-442|Pegasys ProClick|Pegferon|Ro 25-8310/000|pegylated IFN alpha-2a, Roche/Ascletis BioScience",Trade Name|BANN|INN|Research Code|Research Code|Research Code|Research Code|Trade Name|Trade Name|Research Code,Cancer|Hematologic|Infection,Interferon alpha 2 ligand,214,Antiviral|Anticancer,991|1545,Hepatitis B virus infection|Hepatitis C virus infection|HIV-1 infection|Myeloproliferative disorder|Hepatitis D virus infection,152|153|159|273|362,HIV infection|Melanoma|Myeloid leukemia|Metastatic renal cell carcinoma|Solid tumor,158|205|223|4250|725,Ascletis Biopharmaceutical (Hangzhou) Co Ltd|Chugai Pharmaceutical Co Ltd|Roche Holding AG,1177646|15414|19446,Maxim Pharmaceuticals Inc,23065,Hoffmann-La Roche Inc,19461,,,,,,
23820,remestemcel-L,"JR-031|Allogen|MSC therapy (GvHD), Osiris|mesenchymal stem cell therapy (GvHD), Osiris|MSC therapy (graft verses host disease), Osiris|mesenchymal stem cell therapy (graft verses host disease), Osiris|MSC therapy (bone marrow transplant peripheral blood support), Osiris|mesenchymal stem cell therapy (bone marrow transplant peripheral blood support), Osiris|Prochymal|human mesenchyma stem cell therapy (graft vesus host disease), JCR Pharmaceuticals|MSC therapy (GvHD), JCR/ Mochida|remestemcel-L|JR-0301|OTI-010|MSC-100-IV|Temcell HS|JR-031EB|Ryoncil",Research Code|Trade Name|Trade Name|USAN|INN|Research Code|Research Code|Research Code|Trade Name|Research Code|Trade Name,Dermatologic|Endocrine/Metabolic|Gastrointestinal|Immune|Infection|Musculoskeletal|Neurology/Psychiatric|Respiratory|Toxicity/Intoxication,,,Immunosuppressant|Anti-inflammatory|Antiviral|Anticancer|Cytokine modulator,396|2953|991|1545|925,Coronavirus disease 19 infection|Brain hypoxia-ischemia|Back pain|Graft versus host disease|Respiratory distress syndrome|Crohns disease,10406|1635|3221|616|8|84,Epidermolysis bullosa|Chronic obstructive pulmonary disease|Lung disease|Radiation sickness|Insulin dependent diabetes,1112|1185|283|367|836,JCR Pharmaceuticals Co Ltd|Mesoblast Ltd,17330|1024520,Sanofi Genzyme|Mochida Pharmaceutical Co Ltd|Osiris Therapeutics Inc,16299|18278|22888,Osiris Therapeutics Inc,22888,,,,,,
23870,diflomotecan,"BN-80915|diflomotecan|R-1536|BN-80362|BN-80942|anticancer homocamptothecins, Beafour-Ipsen|topoisomerase inhibitors, Beaufour-Ipsen (Biomeasure/Institut Henri Beaufour)|BN-90915",Research Code|INN|Research Code|Analogue|Research Code|Research Code|Metabolite|Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,,,Small-cell lung cancer|Cancer,1261|651,,,Ipsen|Roche Holding AG,17259|19446,Ipsen,17259,,,,,,
23886,urelumab,"BMS-469492|BMS-554271|4-1BB MAb, BMS|4-1BB costimulator (UlitMAb, cancer), Bristol-Myers Squibb/Ono|anti-CD137 monoclonal antibody, BMS|urelumab|BMS-663513|CD137 MAb|BMS-66513|ONO-4481",Research Code|Research Code|USAN|INN|Research Code|Research Code|Research Code,Cancer,CDw137 agonist,5450,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,B-cell lymphoma|Advanced solid tumor,316|3713,Non-small-cell lung cancer|Chronic lymphocytic leukemia|Multiple myeloma|Glioblastoma|Stage IV melanoma|Metastatic colorectal cancer|Metastatic head and neck cancer|Cancer,1262|1734|1828|2454|3257|3658|3673|651,Bristol-Myers Squibb Co,15065,Ono Pharmaceutical Co Ltd,18681,Bristol-Myers Squibb Co,15065,,,,,,
24003,"pelareorep (cancer), Oncolytics","cancer therapy (reovirus), Oncolytics|NSC-729968|IND-13370|pelareorep|pelareorep (cancer), Oncolytics|Reosyn|Reolysin|AN-1004|oncolytic retrovirus therapy (cancer), Oncolytics|P-BB0209",Research Code|Research Code|USAN|Trade Name|Trade Name|Research Code|Research Code,Cancer,,,T-lymphocyte stimulator|T-lymphocyte infiltration stimulator|Anticancer|Immunostimulant,7761|5698|1545|393,Non-small-cell lung cancer|Multiple myeloma|Anal tumor|Fallopian tube cancer|Bladder cancer|Adenocarcinoma|Glioblastoma|Pancreas tumor|Peritoneal tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Cancer|Brain tumor|Ovary tumor|Colorectal tumor,1262|1828|2193|2243|2380|2399|2454|249|3083|3657|3658|3665|3669|651|760|799|989,Sarcoma|Prostate tumor|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic head and neck cancer|Breast tumor|Head and neck tumor|Solid tumor,194|276|3246|3257|3673|49|623|725,Oncolytics Biotech Inc|Adlai Nortye Pharmaceutical Co Ltd,26917|1111343,,,Oncolytics Biotech Inc,26917,,,,,,
24087,entinostat,"MS-275|histone deacetylase inhibitors, Schering AG|histone deacetylase inhibitors, Mitsui Pharmaceuticals|histone deacetylase inhibitors, Bayer Schering|histone deacetylase inhibitors (oral), Syndax Pharmaceuticals|SNDX-275|entinostat|MS-27-275|KHK-2375|EDP 103|EOC-103|Treg modulator (cancer), Sydax Pharmaceuticals",Research Code|Research Code|USAN|INN|Research Code|Research Code|Research Code|Research Code,Cancer,Histone deacetylase inhibitor,2574,Immunostimulant|Regulatory T lymphocyte inhibitor|Synergist|Anticancer|Apoptosis stimulator,393|174668|7293|1545|1589,Non-small-cell lung cancer|Hodgkins disease|Stage IV melanoma|Metastatic breast cancer|Metastatic pancreas cancer|Uveal melanoma|Metastatic renal cell carcinoma|Breast tumor,1262|161|3257|3657|3669|3788|4250|49,Myelodysplastic syndrome|Acute myelogenous leukemia|Melanoma|Metastatic non small cell lung cancer|Cancer|Lung tumor|Colon tumor|Ovary tumor|Colorectal tumor,1272|1731|205|3665|651|755|767|799|989,Eddingpharm Inc|Syndax Pharmaceuticals Inc|NovaMedica|Kyowa Hakko Kirin Co Ltd,1056888|1031631|1075052|1042596,Bayer Schering Pharma AG|Mitsui Pharmaceuticals Inc,19687|26779,Mitsui Pharmaceuticals Inc,26779,,,,,,
24142,mesna,"uromitexan|mesna|Mexan|Mesnex|S-7878|Mitexan|mesna, Shionogi|2-mercaptoethane sulfonate",Trade Name|INN|Trade Name|Trade Name|Research Code|Trade Name,Genitourinary/Sexual Function,,,Unspecified drug target|Protectant,59620|959,Urinary dysfunction,483,,,Baxter Oncology GmbH|Shionogi & Co Ltd,29750|19898,ASTA Medica AG,15623,ASTA Medica AG,15623,,,,,,
24243,APC-8020,"APC-80200|Mylovenge|dendritic cell therapy (myeloma/amyloidosis/lymphoma), Dendreon|APC-8020",Research Code|Trade Name|Research Code,Cancer|Endocrine/Metabolic|Infection,,,Dendritic cell vaccine|Therapeutic vaccine|Antiviral|Anticancer,102926|12379|991|1545,,,Amyloidosis|HIV infection|Multiple myeloma|Lymphoma|Cancer,1143|158|1828|203|651,,,Dendreon Corp|Kirin Brewery Co Ltd,13709|17661,Dendreon Corp,13709,,,,,,
24343,dabigatran etexilate mesylate,BIBR-1048|BIBR-953|dabigatran etexilate|BIBR-953ZW|Rendix|dabigatran etexilate mesylate|Pradax|Prazaxa|Pradaxar|Pradaxa,Research Code|Prodrug|Research Code|USAN|INN|Prodrug|Research Code|Trade Name|USAN|Trade Name|Trade Name|Research Code|Trade Name,Cardiovascular|Hematologic|Neurology/Psychiatric,Factor IIa antagonist|Protease-activated receptor-1 antagonist,111|11192,Antiarrhythmic agent,449,Lung embolism|Alzheimers disease|Phlebothrombosis|Mild cognitive impairment|Thromboembolism|Deep vein thrombosis|Stroke,1078|14|1845|3122|325|574|65,Embolism|Heart valve disease,1077|1562,Boehringer Ingelheim International GmbH|Boryung Pharm Co Ltd,14881|14987,Yuhan Corp,20984,Boehringer Ingelheim International GmbH,14881,,,,,,
24470,givinostat,ITF-2357|givinostat,Research Code|INN,Cancer|Cardiovascular|Gastrointestinal|Hematologic|Immune|Inflammatory|Musculoskeletal|Neurology/Psychiatric,Histone deacetylase inhibitor,2574,Analgesic|Anticancer|Muscle system agent|Anti-inflammatory|Apoptosis stimulator,2946|1545|1408|2953|1589,Duchenne dystrophy|Polycythemia vera|Becker muscular dystrophy|Diastolic heart failure,2020|2319|3289|3296,Hodgkins disease|Acute myelogenous leukemia|Multiple myeloma|Inflammatory disease|Pain|Myeloproliferative disorder|Juvenile rheumatoid arthritis|Crohns disease,161|1731|1828|188|20|273|3003|84,Italfarmaco SpA,17278,,,Italfarmaco SpA,17278,,,,,,
24604,talmapimod,"SCIO-469|p38 MAP kinase inhibitors (inflammation), Scios|talmapimod",Research Code|USAN|INN,Cancer|Immune|Neurology/Psychiatric,p38 MAP kinase inhibitor,2419,Anticancer protein kinase inhibitor|Analgesic|TNF alpha synthesis inhibitor|Anti-inflammatory,62255|2946|382|2953,,,Multiple myeloma|Pain|Rheumatoid arthritis,1828|20|291,,,Scios Inc,19831,Scios Inc,19831,,,,,,
2495,amifostine,amifostine|Ethiofos|Ethyol|Gammaphos|NSC-296961|WR-2721|WR-2721C|YM-08310,USAN|BAN|INN|Trade Name|Research Code|Research Code|Research Code|Research Code,Cancer|Gastrointestinal|Hematologic|Other/Miscellaneous|Toxicity/Intoxication,,,Free radical scavenger|Anticancer|Radioprotectant,170|1545|1465,Xerostomia|Neutropenia|Toxicity,1063|1991|735,Mucositis|Myelodysplastic syndrome,1263|1272,Clinigen Group plc|ADVANZ PHARMA Corp|Merck & Co Inc,1062207|1083136|18077,Pinnacle Biologics Inc|ALZA Corp|Eli Lilly & Co|MedImmune LLC|Schering-Plough Corp|Scherico Ltd|SmithKline Beecham plc|Medimmune Oncology Inc|Cumberland Pharmaceuticals Inc,1037721|14095|17810|18008|19711|19773|19962|27597|30826,Medimmune Oncology Inc,27597,,,,,,
2500,amlodipine,amlodipine|amlodipine besylate|K-48340|UK-4834026|Norvasc|Istin|Amlodin|Amlor|Astudal|Norvas|Amlogin|Amlodine|amlodipine besilate,BAN|INN|USAN|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Cardiovascular,Calcium channel inhibitor L-type,2588,Antihypertensive|Vasodilator,2657|388,Variant angina pectoris|Hypertension|Angina|Coronary artery disease,1583|178|23|80,,,Almirall Prodesfarma SA|Sumitomo Pharmaceuticals Co Ltd|Viatris Inc,14061|14911|1136574,Pfizer Inc|Pfizer Ltd,18767|18862,Pfizer Ltd,18862,,,,,,
2503,"amphotericin B (liposomal iv, visceral leishmaniasis), Drugs for Neglected Diseases initiative","AmBisome|amphotericin B|SM-26000|SMP-26000|liposomal formulation (amphotericin B), NeXstar|amphotericin B (liposomal iv, visceral leishmaniasis), Drugs for Neglected Diseases initiative",Trade Name|INN|Research Code|Research Code,Infection,,,Ergosterol modulator|Antiparasitic|Antimicrobial permeability enhancer|Fungicide,839|2638|955|1748,Leishmania donovani infection|Fungal infection|Candida infection|Histoplasma infection|Blastomyces infection|Coccidioides infection|Cladophialophora infection|Exophiala infection|Mucor infection|Rhizomucor infection|Rhizopus infection|Absidia infection|Fungal respiratory tract infection|Fungal meningitis|Cryptococcus neoformans meningitis|Aspergillus infection|Cryptococcus infection,1137|124|1308|1320|1322|1323|1332|1333|1380|1381|1382|1383|1486|1805|1813|29|85,,,Viatris Inc|Biotoscana International|Sumitomo Dainippon Pharma Co Ltd|Gilead Sciences Inc|Astellas Pharma Inc,1136574|1063950|1017117|16450|1013295,Sumitomo Pharmaceuticals Co Ltd|NeXstar Pharmaceuticals Inc|Fujisawa Pharmaceutical Co Ltd|Fujisawa USA Inc|Mylan NV,14911|15906|16227|16236|18439,NeXstar Pharmaceuticals Inc,15906,,,,,,
25182,valganciclovir,valganciclovir|Valcyt|Cymeval|Valcyte|TA-9070|Valixa|Darilin|RG-127|RoValcyte,INN|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Research Code|Trade Name,Gastrointestinal|Infection|Other/Miscellaneous,DNA polymerase inhibitor,138,CMV replication inhibitor|Antiviral,2833|991,CMV retinitis|Cytomegalovirus infection,1293|89,Chronic fatigue syndrome|Ulcerative colitis,1058|337,Tanabe Seiyaku Co Ltd|Recordati SpA|Roche Holding AG|Mitsubishi Tanabe Pharma Corp,20315|24154|19446|1035060,,,Roche Holding AG,19446,,,,,,
25210,"doxorubicin (inhaled), Zivena","doxorubicin|Resmycin|inhaled doxorubicin, BPT|doxorubicin (inhalant formulation), BattellePharma|doxorubicin (inhaled), Zivena",USAN|BAN|INN|Trade Name,Cancer,DNA polymerase inhibitor|Topoisomerase II inhibitor,138|142,Anticancer|DNA intercalator,1545|750,,,Cancer|Solid tumor|Lung tumor,651|725|755,,,Zivena Inc|Ventaira Pharmaceuticals Inc,1003626|16015,Ventaira Pharmaceuticals Inc,16015,,,,,,
25306,naptumomab estafenatox,"TTS-CD3|5T4FabV13-SEA(D227A)|CD-3, Active Biotech|TTS (cancer), Active Biotech|tumor targeted superantigen, Active Biotech|anticancer antigen, Active Biotech/Pharmacia & Upjohn|tumor targeted superantigen, Active Biotech/Pharmacia & Upjohn|ABR-217620|Anyara|naptumomab estafenatox|tumor targeted superantigen, NeoTX|naptumumab",Research Code|Research Code|Trade Name|INN,Cancer,Trophoblast glycoprotein modulator|Staphylococcus enterotoxin A stimulator,14327|23597,Immunostimulant|Immunotoxin|Synergist|Anticancer monoclonal antibody,393|539|7293|55685,Mesothelioma|Non-small-cell lung cancer|Endometrioid carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Melanoma|Pancreas tumor|Prostate tumor|Squamous cell carcinoma|Metastatic bladder cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Breast tumor|Head and neck tumor|Solid tumor|Ovary tumor|Renal tumor,1240|1262|1705|1767|1771|205|249|276|307|3466|3658|3665|3666|3667|4250|427|49|623|725|799|999,Renal cell carcinoma|Cancer,1766|651,Active Biotech AB|NeoTX Therapeutics Ltd,26312|1138261,Pharmacia & Upjohn Inc|Pharmacia Corp,22006|27638,Active Biotech AB,26312,,,,,,
2539,"antineoplaston A-10, Burzynski Institute","antineoplaston A-10|NSC-648539|antineoplaston A-10, Burzynski Institute|atengenal",Research Code,Cancer,,,DNA synthesis inhibitor|DNA intercalator|Anticancer,140|750|1545,Glioma,1108,Multiple myeloma|Anaplastic astrocytoma|Breast tumor|Cancer|Solid tumor|Brain tumor|Colon tumor,1828|2567|49|651|725|760|767,Burzynski Research Institute Inc,15282,,,Burzynski Research Institute Inc,15282,,,,,,
2540,"antineoplaston AS2-1, Burzynski Institute","antineoplaston AS2-1|NSC-620621|antineoplaston AS2-1, Burzynski Institute|astugenal",Research Code,Cancer|Infection,,,Viral replication inhibitor|Anticancer|DNA synthesis inhibitor,1532|1545|140,Glioma,1108,HIV infection|Multiple myeloma|Anaplastic astrocytoma|Cancer|Brain tumor|Colon tumor,158|1828|2567|651|760|767,Burzynski Research Institute Inc,15282,,,Burzynski Research Institute Inc,15282,,,,,,
2546,"daclizumab (intravenous, transplant rejection), PDL/Roche","Ro-34-7375|anti-Tac antibody, PDL|SMART anti-Tac MAb, PDL|anti-Tac antibody, Roche|SMART anti-Tac MAb, Protein Design Labs|anti-Tac antibody, PDL/Roche/Biogen Idec|dacliximab|daclizumab|Zenepax|Ro-247375|Zenapax|daclizumab (intravenous, transplant rejection), PDL/Roche",Research Code|USAN|BANN|INN|Trade Name|Research Code|Trade Name,Cancer|Dermatologic|Endocrine/Metabolic|Gastrointestinal|Immune|Ocular|Respiratory,IL-2 receptor antagonist|IL-2 receptor alpha subunit inhibitor,488|5100,Immunosuppressant|Anticancer monoclonal antibody|Lymphocyte inhibitor|Systemic antipsoriatic product,396|55685|7748|15184,,,Inflammatory bowel disease|Leukemia|Multiple sclerosis|Psoriasis|Rheumatoid arthritis|Asthma|Systemic lupus erythematosus|Ulcerative colitis|Uveitis|Autoimmune disease|Transplant rejection|Graft versus host disease|Insulin dependent diabetes,189|199|213|281|291|31|318|337|341|36|515|616|836,,,PDL BioPharma Inc|Roche Holding AG|Hoffmann-La Roche Inc|F Hoffmann-La Roche AG,19162|19446|19461|26178,PDL BioPharma Inc,19162,,,,,,
25591,obatoclax,"GX-011|GX-022|GX-015-000|GX-01 series, Gemin X|GX-015 series, Gemin X|Bcl-2 inhibitors (cancer), Gemin X|GX-15-070|GX-015-034|GX-15-000|GX-15-034|Bcl-2 pan-inhibitors (cancer), Gemin X|GX-15-003|GX-015-003|obatoclax|GX-015-070|obatoclax mesylate|GX-15-070MS|NSC-729280|CEP-41601",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|INN|Research Code|USAN|Research Code|Research Code|Research Code,Cancer|Hematologic,Mcl-1 differentiation protein inhibitor|Bcl-2 protein inhibitor,11381|16111,Anticancer|Apoptosis stimulator,1545|1589,,,Small-cell lung cancer|Non-small-cell lung cancer|Myelodysplastic syndrome|Hodgkins disease|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Multiple myeloma|Myeloid leukemia|Myelofibrosis|Non-Hodgkin lymphoma|Cancer|Solid tumor,1261|1262|1272|161|1731|1734|1744|1745|1828|223|2436|319|651|725,,,Cephalon Inc|Gemin X Pharmaceuticals Inc,15358|26990,Gemin X Pharmaceuticals Inc,26990,,,,,,
2573,pegaspargase,"Oncaspar|Leucogen|NSC-109229|PEG-asparaginase|PEG-L-asparaginase|asparaginase, Enzon Inc|Escherichia coli L-asparaginase|E. coli L-asparaginase|pegaspargase|PEG-74-L-asparginase|pegaspargase, Servier|SHP-674|S-95014",Trade Name|Trade Name|Research Code|USAN|INN|Research Code|Research Code,Cancer,Asparaginase stimulator,517,Anticancer,1545,Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia,1728|1729,Lymphoma|Advanced solid tumor,203|3713,Servier|HB Human BioScience SAS,19863|1154393,Baxalta Inc|Tzamal Pharma|Enzon Pharmaceuticals Inc|Medac GmbH|Rhone-Poulenc SA|Sigma-Tau Ind Farm Riunite SpA|Shire plc|Aventis Pharmaceuticals Inc,1109518|1136521|16045|17967|19234|21159|24652|27251,Enzon Pharmaceuticals Inc,16045,,,,,,
25731,"paclitaxel (iv emulsion, TOCOSOL), Sorrento Therapeutics","paclitaxel|S-8184|QW-8184|TOCOSOL Paclitaxel|paclitaxel, emulsion formulation|paclitaxel (iv emulsion, TOCOSOL), Sonus|paclitaxel (iv emulsion, TOCOSOL), Schering|paclitaxel (iv emulsion, TOCOSOL), Bayer Schering|paclitaxel (iv emulsion, TOCOSOL), Eagle Pharmaceuticals|IG-004|paclitaxel (iv emulsion, TOCOSOL), Sorrento Therapeutics",USAN|BANN|INN|Research Code|Research Code|Trade Name|Research Code,Cancer,Tubulin binding agent,499,Anticancer|Microtubule stabilizer,1545|2576,,,Non-small-cell lung cancer|Bladder tumor|Breast tumor|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,1262|42|49|651|725|799|989,,,Eagle Pharmaceuticals Inc|Sorrento Therapeutics Inc|Bayer Schering Pharma AG|Achieve Life Sciences Inc,1041920|1048574|19687|20225,Achieve Life Sciences Inc,20225,,,,,,
25735,CimaVax EGF,"cancer vaccine, York Medical|cancer vaccine, YM BioSciences|EGF vaccine (cancer), CIMAB/CancerVax/Biocon|SAI-EGF|EGF vaccine (cancer), CIMAB/ Micromet/Biocon/Bioven|rEGF-rP64K/Montanide ISA 51 vaccine (NSCLC), Bioven|recombinant human EGF-rP64K/Montanide ISA 51 vaccine (NSCLC), Bioven|CimaVax EGF|EGF vaccine (lung cancer), Cuba Center of Molecular Immunology|EGF vaccine (lung cancer), Centro de Immunologica Molecular|EGF vaccine (lung cancer), Biotech Pharmaceutical|BV-NSCLC-001|BVN-NSCLC-002|BVN-NSCLC-003|EGF-PTI",Research Code|Trade Name|Research Code|Research Code|Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Therapeutic vaccine|Anticancer protein kinase inhibitor,12379|62255,Non-small-cell lung cancer|Metastatic non small cell lung cancer|Cancer|Lung tumor,1262|3665|651|755,,,Bioven Holdings Sdn Bhd|Beijing Jingyitaixiang Technology Development Co Ltd|Innovative Immunotherapy Alliance SA|Biotech Pharmaceutical Co Ltd|The Center of Molecular Immunology,1034205|1066848|1172391|1050244|29496,Biocon Biopharmaceuticals Pvt Ltd|Micromet Inc|YM BioSciences Inc,1018304|1020809|24845,The Center of Molecular Immunology,29496,,,,,,
25750,ADH-1,"cadherin antagonist, Adherex|peptide N-cadherin antagonist (cancer, intravenous/peptide), Adherex|ADH-1|Exherin|peptide N-cadherin antagonist (cancer), Shire Pharmaceuticals|peptide N-cadherin antagonist (cancer), BioChem Pharma|peptide N-cadherin antagonist (cancer), AstraZeneca",Research Code|Trade Name,Cancer,Cadherin-2 antagonist,6147,Anticancer|Vascular damaging agent,1545|2969,,,Melanoma|Cancer,205|651,,,AstraZeneca plc|Shire BioChem Inc|McGill University|Shire plc|Fennec Pharmaceuticals Inc,14190|14691|20617|24652|26408,McGill University,20617,,,,,,
2577,atovaquone,566C80|atovaquone|Mepron|Acuvel|BW-566C|Metrone|BW-A566C|BW-566C-80|Samtirel Oral Suspension 15%|Wellvone,Research Code|USAN|BAN|INN|Trade Name|Trade Name|Research Code|Trade Name|Research Code|Research Code|Trade Name|Trade Name,Infection,,,Electron transport inhibitor|Antiparasitic,518|2638,Pneumocystis carinii infection,271,Babesia infection|Toxoplasma infection,3165|329,GlaxoSmithKline plc|Laboratorios Wellcome de Portugal Lda|Glaxo Group Ltd,28355|20922|16453,,,Glaxo Group Ltd,16453,,,,,,
2587,azithromycin,azithromycin|Azitrocin|CP-62993|Sumamed|Trozocina|XZ-405|XZ-450|Zithromac|Zithromax|Zitromax|rezid|CP-57577|CP-57578|CP-58822|Trulimax|Azitromicina Unizitro|Azyter,USAN|BAN|INN|Research Code|Trade Name|Trade Name|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Research Code|Trade Name|Trade Name|Trade Name,Dermatologic|Genitourinary/Sexual Function|Infection|Inflammatory|Ocular|Other/Miscellaneous|Respiratory,,,Systemic dermatological antibacterial product|Antiviral|Bacterial protein synthesis inhibitor|Antibacterial|Macrolide antibiotic,15187|991|1538|1594|1540,Female genital tract infection|Chronic obstructive pulmonary disease|Legionella pneumophila infection|Haemophilus influenzae infection|Moraxella catarrhalis infection|Streptococcus pyogenes infection|Streptococcus agalactiae infection|Bacterial respiratory tract infection|Bacterial pneumonia|Chlamydia pneumoniae infection|Mycobacterium infection|Mycoplasma infection|Neisseria gonorrhoeae infection|Tonsillitis|Urethritis|Acute sinusitis|Haemophilus ducreyi infection|Genital tract infection|Staphylococcus aureus infection|Abscess|Streptococcus pneumoniae infection|Pelvic inflammatory disease|Genital ulcer|Otitis media|Bacterial infection|Pharyngitis|Bacterial skin infection|Bronchitis|Chlamydia trachomatis infection|Prophylaxis,1027|1185|1447|145|1455|1475|1476|1484|1815|1819|218|222|227|2345|2951|2999|3019|3078|308|3081|313|3140|3842|394|40|453|485|50|68|706,Cryptosporidium infection|Helicobacter pylori infection|Ocular disease|Plasmodium falciparum infection|Bronchiolitis|Acne|Toxoplasma infection|Vibrio cholerae infection|Cystic fibrosis,1126|149|239|267|2976|3|329|343|88,Pfizer Inc|Pfizer Pharmaceuticals Korea Ltd|Alfasigma SpA|PLIVA dd,18767|18802|1153354|19117,Sigma-Tau Ind Farm Riunite SpA,21159,PLIVA dd,19117,,,,,,
25880,"enteric-coated mycophenolate sodium, Novartis","mycophenolic acid|ERL-080|mycophenolate sodium|enteric-coated MPA, Novartis|enteric-coated mycophenolate sodium, Novartis|Myfortic",USAN|BAN|INN|Research Code|USAN|Trade Name,Genitourinary/Sexual Function|Immune|Ocular,Inosine monophosphate dehydrogenase inhibitor,629,Anti-inflammatory|Immunosuppressant,2953|396,Lupus nephritis|Kidney transplant rejection,2404|2989,Nephrotic syndrome|Uveitis,2315|341,Novartis AG,23137,,,Novartis AG,23137,,,,,,
2606,oblimersen,"augmerosen|G-3139|oblimersen|Genasense|anticode (bcl-2), Genta/La Jolla|antisense oligonucleotides (bcl-2), Genta|oblimersen sodium",Research Code|INN|Trade Name|USAN,Cancer|Hematologic,BCL2 gene inhibitor,7709,Antisense oligonucleotide inhibitor|Anticancer chemosensitizer,7294|1586,,,Small-cell lung cancer|Non-small-cell lung cancer|Macroglobulinemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Mantle cell lymphoma|Nasopharyngeal carcinoma|Multiple myeloma|Leukemia|Melanoma|Myeloid leukemia|B-cell lymphoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Breast tumor|Solid tumor|Colon tumor|Colorectal tumor,1261|1262|1264|1731|1734|1735|1744|1768|1828|199|205|223|316|319|3246|49|725|767|989,,,Sanofi SA|Chugai Pharmaceutical Co Ltd|Genta Inc|Aventis SA,1009547|15414|16292|27254,Genta Inc,16292,,,,,,
26070,"IFN beta gene therapy (anticancer), Biogen Idec","BG-00001|IDEC-201|Ad-hIFNbeta|tgAd-IFNbeta-1a|IFN beta gene therapy (anticancer), Biogen Idec|anticancer gene therapy vector (IFN-beta), Biogen Idec|interferon beta gene therapy (anticancer), Biogen Idec",Research Code|Research Code,Cancer,IFNB gene stimulator,21686,Adenovirus based gene therapy|Anticancer,4780|1545,,,Glioma|Cancer,1108|651,,,Biogen Inc|Biogen Inc (FL)|IDEC Pharmaceuticals Corp,1005244|14729|17085,Biogen Inc (FL),14729,,,,,,
26072,131I-TM-601,"TM-602|TM-603|TM-803|131I-TM-601|iodine-131-TM-601|glioma therapy, Transmolecular|solid tumor imaging, TransMolecular|toxin-based anticancers, Transmolecular",Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Research Code|Research Code|Research Code,Cancer,Chloride channel modulator,1104,Anticancer|Neoplasm diagnostic agent|Radiotherapeutic|Angiogenesis inhibitor|Imaging agent,1545|7220|5721|61|4155,,,Glioma|Melanoma|Solid tumor,1108|205|725,,,TransMolecular Inc|Morphotek Inc,27184|29741,TransMolecular Inc,27184,,,,,,
2617,mitumomab,"mitumomab|BEC-2|LuVax|MelVax|EMD-60205|melanoma vaccine, ImClone/Merck KGaA|antimelanoma antibody, ImClone/Merck KGaA|antimetastatic agents, ImClone/Merck KGaA|GD3 ganglioside (vaccine 1), Memorial Sloan-Kettering|IMC-BEC2",INN|Research Code|Trade Name|Trade Name|Research Code|Research Code,Cancer,,,Anticancer monoclonal antibody|Unspecified drug target,55685|59620,,,Small-cell lung cancer|Melanoma,1261|205,,,Imclone LLC|Merck KGaA|Memorial Sloan-Kettering Cancer Center,17193|18101|22122,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
2642,"ibandronic acid (injectable), Roche","ibandronate|ibandronic acid|Ro-200-5450|R-484 (injectable)|Boniva (injectable)|Bonviva (injectable)|Bondronat (injectable)|bisphosphonate, Boehringer Mannheim|ibandronic acid (injectable), Roche|ibandronate sodium|BM-210955NaH2O|Bondenza|RG-484 (injectable)|ibandronate sodium monohydrate|Boniva|Bonviva|Bondronat|CT-064|BM-210955",BANN|INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name|USAN|Research Code|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Research Code|Research Code,Cancer|Endocrine/Metabolic|Musculoskeletal,,,Metastasis inhibitor|Bone resorption inhibitor|Anticancer|Osteoclast inhibitor,695|89|1545|12596,Hypercalcemia|Bone metastases|Osteoporosis|Postmenopausal osteoporosis,173|1829|246|2549,,,Chugai Pharmaceutical Co Ltd|Taisho Pharmaceutical Co Ltd|Roche Holding AG|Atnahs Pharma UK Limited|moksha8 Pharmaceuticals Inc,15414|20289|19446|1123655|1050182,Takeda Pharmaceuticals International GmbH|Rhone-Poulenc SA|Nippon Roche KK|Boehringer Mannheim GmbH|Aventis Pharma AG|GlaxoSmithKline plc,1002503|19234|19447|24098|25218|28355,Roche Holding AG,19446,,,,,,
26495,vandetanib,ZD-6474|Zactima|vandetanib|AZD-6474|Zictifa|Caprelsa,Research Code|Trade Name|USAN|BANN|INN|Research Code|Trade Name|Trade Name,Cancer,EPH family tyrosine kinase inhibitor|EGFR family tyrosine kinase receptor inhibitor|Src tyrosine kinase inhibitor|VEGF receptor antagonist|RET tyrosine kinase receptor family inhibitor|Protein tyrosine kinase 6 inhibitor|Epidermal growth factor receptor antagonist|VEGF-2 receptor antagonist|Tek tyrosine kinase receptor inhibitor,3762|3754|3576|1722|3816|84304|740|3848|3834,Anticancer protein kinase inhibitor|Angiogenesis inhibitor,62255|61,Thyroid tumor|Medullary thyroid cancer|Papillary thyroid tumor|Metastatic breast cancer,1134|3240|3351|3657,Glioma|Small-cell lung cancer|Non-small-cell lung cancer|Biliary cancer|Hepatocellular carcinoma|Transitional cell carcinoma|Multiple myeloma|Glioblastoma|Pancreas tumor|Hormone refractory prostate cancer|Stage IV melanoma|Breast tumor|Head and neck tumor|Cancer|Solid tumor|Central nervous system tumor|Brain tumor|Ovary tumor|Colorectal tumor,1108|1261|1262|1516|1767|1771|1828|2454|249|3246|3257|49|623|651|725|759|760|799|989,Sanofi Genzyme,16299,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
26552,"arsenic trioxide, CTI BioPharma","arsenic trioxide|Trisenox|ATO, Cell Therapeutics|arsenic trioxide, PolaRx|arsenic trioxide, Cell Therapeutics|NSC-706363|arsenic trioxide, CTI BioPharma|Phenasen",USAN|Trade Name|Research Code|Trade Name,Cancer|Hematologic,,,Apoptosis stimulator|Anticancer|Unspecified drug target,1589|1545|59620,Glioma|Acute myelogenous leukemia|Acute promyelocytic leukemia,1108|1731|1732,Lymphoid leukemia|Myelodysplastic syndrome|Hodgkins disease|Chronic myelocytic leukemia|Renal cell carcinoma|Multiple myeloma|Lymphoma|Myeloproliferative disorder|Prostate tumor|Non-Hodgkin lymphoma|Bladder tumor|Uterine cervix tumor|Chronic myelomonocytic leukemia,1255|1272|161|1735|1766|1828|203|273|276|319|42|427|6833,Lundbeck Canada Inc|Phebra Pty Ltd|Zodiac Produtos Farmaceticos SA|Cephalon Inc|Teva Sante SAS|BL&H Co Ltd|Nippon Shinyaku Co Ltd|Teva Pharmaceuticals Ltd (UK)|Teva Pharma BV (Netherlands)|CTI BioPharma Corp,23826|1047394|1007261|15358|1006988|1037227|18552|24090|24088|15337,Jeil-Kirin Pharmaceutical Inc|PolaRx Biopharmaceuticals Inc,1044697|27496,PolaRx Biopharmaceuticals Inc,27496,,,,,,
2670,brequinar,brequinar|brequinar sodium|DuP-785|NSC-368390|CS-2,INN|USAN|Research Code|Research Code|Research Code,Cancer|Dermatologic|Immune|Infection,Dihydroorotate dehydrogenase inhibitor|Dehydrogenase inhibitor,1716|550,Immunosuppressant|Antiviral|Anticancer|Systemic antipsoriatic product,396|991|1545|15184,Coronavirus disease 19 infection|Ebola virus infection|Acute myelogenous leukemia|Breast tumor|Zika virus infection,10406|1049|1731|49|6927,Immune disorder|Psoriasis|Transplant rejection|Carcinoma|Cancer,185|281|515|54|651,"Clear Creek Bio, Inc",1176665,Bristol-Myers Squibb Co|Bristol-Myers Squibb Pharma Co,15065|26864,Bristol-Myers Squibb Pharma Co,26864,,,,,,
2714,inotuzumab ozogamicin,"calicheamicin-gamma-1|CMC-544|L-E33288|LL-33288|Cal-7411C7|Hu3S193-CM, Wyeth|LL-E33288-gamma1-I|LL-E33288-gamma1-Br|calicheamicin-beta1|calicheamicin-alpha2|calicheamicin-beta1-Br|calicheamicin-gamma1-I|calicheamicin-gamma1-Br|anti-CD22 MAb-caliceamicin, Wyeth/Celltech|non-Hodgkins lymphoma therapy, Wyeth/Celltech|antibody-calicheamicin conjugates, Celltech/Wyeth|antibody-calicheamicin conjugates, Celltech/Wyeth-Ayerst|inotuzumab ozogamicin|anti-CD22 MAb-caliceamicin, Wyeth/UCB|non-Hodgkins lymphoma therapy, Wyeth/UCB|antibody-calicheamicin conjugates, Celltech/UCB|Hu3S193-CM, Pfizer|anti-CD22 MAb-caliceamicin, Pfizer/Celltech|non-Hodgkins lymphoma therapy, Pfizer/Celltech|antibody-calicheamicin conjugates, Celltech/Pfizer|PF-5208773|Besponsa",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code|Trade Name,Cancer,B-lymphocyte cell adhesion molecule modulator,5089,Anticancer monoclonal antibody|Immunotoxin|Apoptosis stimulator,55685|539|1589,Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Chronic myelocytic leukemia,1728|1729|1735,Follicle center lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1745|1749|319,Pfizer Inc,18767,UCB Celltech|Wyeth Research,15336|25247,Wyeth Research,25247,,,,,,
2716,alemtuzumab,"alemtuzumab|LDP-03|CAMPATH-1|ZK-217699|anti-CD52 mAb, Millennium/ILEX/Schering|DE-04188|BAY-86-5045|CAMPATH|CAMPATH-1H|MabCampath|MabCampath-1H|Lemtrada|GZ-402673",INN|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Research Code,Cancer|Immune,CD52 antagonist,5218,Apoptosis stimulator|Therapeutic antibody|Anticancer monoclonal antibody|Anti-inflammatory,1589|172641|55685|2953,Chronic lymphocytic leukemia|Multiple sclerosis|Bone marrow transplantation,1734|213|46,Mycosis fungoides|Peripheral T-cell lymphoma|Sezary syndrome|Rheumatoid arthritis|Non-Hodgkin lymphoma|Transplant rejection|Graft versus host disease,1115|1753|1756|291|319|515|616,Sanofi Genzyme|Sanofi SA,16299|1009547,Schering AG|Bayer AG|Berlex Laboratories Inc|University of Cambridge|Burroughs Wellcome International Ltd|Takeda Oncology|ILEX Oncology Inc|BTG USA Inc|LeukoSite Inc,1052089|14455|19693|20550|20898|21991|23744|25956|27414,University of Cambridge,20550,,,,,,
27336,DCVax-Direct,"DCVax|CaPVax|DCVax-Renal|DCVax-Direct|GM-CSF/G250 + DCVax|dendritic cell-based immunotherapy, Northwest Biotherapeutics",Trade Name|Trade Name,Cancer,,,Genetically engineered autologous cell vaccine|Anticancer|Therapeutic vaccine|Dendritic cell vaccine,4791|1545|12379|102926,Glioma|Liver tumor|Melanoma|Pancreas tumor|Metastatic breast cancer|Metastatic non small cell lung cancer|Solid tumor|Colorectal tumor,1108|202|205|249|3657|3665|725|989,Colon tumor|Renal tumor,767|999,Northwest Biotherapeutics Inc,24930,,,Northwest Biotherapeutics Inc,24930,,,,,,
2736,cefepime,Axepim|Axepime|cefipime|cefepime|BMY-28142|Cepimax|Maxcef|Maxipime|cefepime hydrochloride,Trade Name|Trade Name|USAN|INN|Research Code|Trade Name|Trade Name|Trade Name|USAN,Gastrointestinal|Genitourinary/Sexual Function|Infection|Inflammatory,Penicillin binding protein inhibitor,66340,Bacterial cell wall synthesis inhibitor|Antibacterial|Beta lactam antibiotic|Cephalosporin|Systemic dermatological antibacterial product,104|1594|1535|1537|15187,Sinusitis|Sepsis|Enterobacter infection|Escherichia coli infection|Bacteroides fragilis infection|Streptococcus pyogenes infection|Bacterial urinary tract infection|Bacterial pneumonia|Klebsiella pneumoniae infection|Cholecystitis|Cholangitis|Tonsillitis|Pseudomonas aeruginosa infection|Pyelonephritis|Staphylococcus aureus infection|Abscess|Abdominal abscess|Streptococcus infection|Streptococcus pneumoniae infection|Uterus infection|Lung abscess|Otitis media|Bacterial infection|Cystitis|Proteus mirabilis infection|Prostatitis|Bacterial skin infection,1061|114|116|120|1394|1475|1798|1815|195|2019|2216|2345|280|284|308|3081|3082|312|313|3653|3886|394|40|403|456|473|485,,,Bristol-Myers Squibb Co|Hospira Inc,15065|1010293,Elan Corp plc|Meiji Seika Pharma Co Ltd,15873|18049,Bristol-Myers Squibb Co,15065,,,,,,
2752,cetirizine,cetirizine|Zyrtec|cetirizine hydrochloride|P-071|Zetir|Virlix|Zirtek|Zyrtek|Benadryl|Reactine|Alerlisin|UCB-P 071|formistin|salvalerg|Zirtek Plus Decongestant|Zyrlex,BAN|INN|Trade Name|USAN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name,Dermatologic|Immune,Histamine H1 receptor antagonist,199,Anti-inflammatory|Topical antipruritic product,2953|15180,Allergic rhinitis|Allergy|Pruritus|Urticaria,1107|12|279|340,,,GlaxoSmithKline plc|Daiichi Seiyaku Co Ltd|Daiichi Sankyo Co Ltd|Dr Reddy's Laboratories Ltd|moksha8 Pharmaceuticals Inc|UCB SA|Pfizer Inc,28355|15593|1017506|29387|1050182|20452|18767,Sanofi SA|Sumitomo Pharmaceuticals Co Ltd|Hoechst AG|UCB Pharma SA,1009547|14911|16807|22752,UCB Pharma SA,22752,,,,,,
27532,ciforadenant,"VER-6623|Parkinsons therapeutics, Vernalis|adenosine A2a antagonists (Parkinsons disease), Vernalis|Parkinsons therapeutics, Vernalis/Biogen Idec|adenosine A2a antagonists (Parkinsons disease), Vernalis/Biogen Idec|VER-4187|checkpoint inhibitor A (oral, cancer), Corvus Pharmaceuticals|CPI-444|V-81444|A2aR checkpoint inhibitor (cancer), Vernalis/Corvus|ciforadenant|A2aR checkpoint inhibitor (cancer/infectious disease/autoimmune diseases), Corvus/Angel",Research Code|Research Code|Research Code|Research Code|USAN|INN,Cancer|Neurology/Psychiatric,Adenosine A2a receptor antagonist,596,Anxiolytic|Antidepressant|Anticancer|Immunostimulant|Antiparkinsonian|Synergist|T-lymphocyte stimulator,2942|2941|1545|393|2947|7293|7761,Non-small-cell lung cancer|Endometrioid carcinoma|Renal cell carcinoma|Sarcoma|Melanoma|Bladder cancer|Squamous cell carcinoma|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer|Uterine cervix tumor|Cancer,1262|1705|1766|194|205|2380|307|3246|3657|3658|3669|3713|3866|427|651,Anxiety disorder|Parkinsons disease|Central nervous system disease|Depression,25|255|60|93,Corvus Pharmaceuticals Inc|Angel Pharmaceuticals,1112757|1232824,Vernalis plc|Vernalis Group plc,15262|27600,Vernalis Group plc,27600,,,,,,
27572,lenalidomide,CC-5013|CDC-501|Revimid|ENMD-0997|CDC-5013|IMiD-1|lenalidomide|Revlimid|IMiD-3|NSC-703813|IND-70116,Research Code|Research Code|Trade Name|Research Code|Research Code|Research Code|USAN|INN|Trade Name|Research Code|Research Code|Research Code,Cancer|Cardiovascular|Endocrine/Metabolic|Gastrointestinal|Hematologic|Immune|Inflammatory|Neurology/Psychiatric,Protein cereblon modulator,77059,Anticancer|Angiogenesis inhibitor|TNF alpha synthesis inhibitor|Immunomodulator,1545|61|382|1596,Myelodysplastic syndrome|Hodgkins disease|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Adult T-cell lymphoma|Multiple myeloma|Immune disorder|Bladder cancer|Peripheral neuropathy|T-cell lymphoma|Non-Hodgkin lymphoma|POEMS syndrome|Metastatic non small cell lung cancer|Plasma cell dyscrasia|Histiocytosis,1272|161|1743|1744|1745|1746|1749|1753|1754|1757|1828|185|2380|259|311|319|3243|3665|4339|4682,Amyloidosis|B-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Renal cell carcinoma|Inflammatory disease|Melanoma|Glioblastoma|Pancreas tumor|Complex regional pain syndrome|Peritoneal tumor|Hormone refractory prostate cancer|Metastatic head and neck cancer|Cardiac failure|Cancer|Ovary tumor|Crohns disease|Kaposis sarcoma|Colorectal tumor,1143|1729|1731|1734|1766|188|205|2454|249|2618|3083|3246|3673|55|651|799|84|936|989,Celgene Corp|Bristol-Myers Squibb Co|BeiGene Co Ltd,15331|15065|1063251,CASI Pharmaceuticals Inc,21794,Celgene Corp,15331,,,,,,
2764,midostaurin,benzoylstaurosporine|CGP-41251|midostaurin|STI-412|PKC-412A|PKC-412|Rydapt,Research Code|USAN|INN|Research Code|Research Code|Research Code|Trade Name,Cancer|Musculoskeletal|Ocular,Protein kinase C inhibitor|Flt3 tyrosine kinase inhibitor|Kit tyrosine kinase inhibitor,334|3806|3808,Anticancer protein kinase inhibitor|Angiogenesis inhibitor,62255|61,Acute myelogenous leukemia|Systemic mastocytosis,1731|3728,Myelodysplastic syndrome|Gastrointestinal tumor|Chronic lymphocytic leukemia|Melanoma|Diabetic macular edema|Non-Hodgkin lymphoma|Breast tumor|Solid tumor|Colorectal tumor,1272|131|1734|205|2659|319|49|725|989,Novartis AG,23137,,,Novartis AG,23137,,,,,,
2765,zoledronic acid,ZOL-446|CGP-42446A|zoledronate disodium|zoledronate trisodium|zoledronic acid|Zometa|CGP-42446|zoledronate|Aclasta|Reclast|AK-156,Research Code|Research Code|USAN|USAN|USAN|INN|Trade Name|Research Code|Trade Name|Trade Name|Research Code,Cancer|Endocrine/Metabolic|Immune|Musculoskeletal|Neurology/Psychiatric,,,Osteoclast inhibitor|Anticancer|Bone resorption inhibitor|Metastasis inhibitor,12596|1545|89|695,Mesothelioma|Hypercalcemia|Multiple myeloma|Bone metastases|Osteoporosis|Male osteoporosis|Postmenopausal osteoporosis|Pagets bone disease|Bone resorption,1240|173|1828|1829|246|2548|2549|2855|3443,Bone tumor|Metastasis|Osteogenesis imperfecta|Complex regional pain syndrome|Rheumatoid arthritis|Lower back pain|Metastatic breast cancer|Knee injury|Bone disease|Breast tumor,1012|1069|2498|2618|291|3437|3657|3754|45|49,SciClone Pharmaceutical (Holdings) Ltd|Asahi Kasei Pharma Corp|Novartis AG,1155766|14303|23137,Ciba-Geigy AG,24437,Novartis AG,23137,,,,,,
27696,pomalidomide,Actimid|CC-4047|Actimid (current lead)|IMiD-1|S-3APG|ENMD-0995|pomalidomide|Pomalyst|Imnovid,Trade Name|Research Code|Research Code|Research Code|USAN|INN|Trade Name|Trade Name,Cancer|Cardiovascular|Endocrine/Metabolic|Hematologic|Immune|Inflammatory,Protein cereblon modulator,77059,Anticancer|Angiogenesis inhibitor|Antiviral|TNF alpha synthesis inhibitor|Immunomodulator,1545|61|991|382|1596,Multiple myeloma|Hereditary hemorrhagic telangiectasia|Glioblastoma|AL amyloidosis|Brain tumor|Kaposis sarcoma,1828|1879|2454|3492|760|936,Scleroderma|Small-cell lung cancer|Inflammatory disease|Myelofibrosis|Pancreas tumor|Arthritis|Sickle cell anemia|Hormone refractory prostate cancer|Soft tissue sarcoma|Graft versus host disease|Cancer,1105|1261|188|2436|249|28|303|3246|3378|616|651,Bristol-Myers Squibb Co,15065,Celgene Corp|CASI Pharmaceuticals Inc,15331|21794,CASI Pharmaceuticals Inc,21794,,,,,,
27698,iberdomide,"CC-3052|IMiD-2|CC-4059|CC-5022|CC-5031|CC-5098|CC-10062|CC-10095|CC-12025|IMiDs, Celgene|Immunomodulatory drugs, Celgene|CC-10015|IMiD-5|CC-220|iberdomide|iberdomide hydrochloride|TNF alpha synthesis inhibitor (oral, SLE/MM/lymphomas), Bristol-Myers Squibb",Analogue|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|USAN,Cancer|Immune|Inflammatory,Zinc finger binding protein Aiolos inhibitor|Protein cereblon modulator|DNA binding protein Ikaros inhibitor,53674|77059|53668,TNF alpha synthesis inhibitor|Immunomodulator|Synergist|Anti-inflammatory|Cell cycle inhibitor|Anticancer|Angiogenesis inhibitor,382|1596|7293|2953|767|1545|61,Sjoegrens syndrome|Hodgkins disease|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Peripheral T-cell lymphoma|Multiple myeloma|Lymphoma|B-cell lymphoma|Systemic lupus erythematosus|Non-Hodgkin lymphoma|Cancer,1148|161|1744|1745|1746|1753|1828|203|316|318|319|651,Sarcoidosis|Scleroderma|Inflammatory disease,1036|1105|188,Bristol-Myers Squibb Co,15065,Celgene Corp,15331,Celgene Corp,15331,,,,,,
2773,valsartan,CGP-48933|Diovan|valsartan|Miten|Tareg|VAL-489|Provas|Tareg FCT|Diovan OD,Research Code|Trade Name|USAN|BANN|INN|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name,Cardiovascular|Endocrine/Metabolic,Angiotensin II receptor antagonist|Angiotensin I receptor antagonist,64|741,Antihypertensive,2657,Hypertension|Cardiac failure,178|55,Metabolic syndrome X,3294,Novartis AG|UCB SA,23137|20452,Ciba-Geigy AG,24437,Ciba-Geigy AG,24437,,,,,,
2784,letrozole,Femora|FEM-345|retrozol|tetrozole|Femara|CGS 20267|letrozole,Trade Name|Research Code|Trade Name|Research Code|INN,Cancer,Aromatase inhibitor,76,Anticancer,1545,Endometrioid carcinoma|Peritoneal tumor|Metastatic breast cancer|Breast tumor|Ovary tumor,1705|3083|3657|49|799,Fallopian tube cancer,2243,Novartis AG|Chugai Pharmaceutical Co Ltd,23137|15414,Ciba-Geigy Corp,24452,Novartis AG,23137,,,,,,
28035,cabazitaxel,"106258|116258|TXD-258|taxoid (cancer), sanofi-aventis|XRP-6258|cabazitaxel|RPR-116258A|Jevtana",Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code|Trade Name,Cancer,,,Anticancer|Microtubule inhibitor|Cell cycle inhibitor,1545|2575|767,Transitional cell carcinoma|Liposarcoma|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic prostate cancer,1771|2447|3246|3657|3664,Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Penis tumor|Metastatic non small cell lung cancer|Metastatic stomach cancer|Breast tumor|Solid tumor|Brain tumor|Ovary tumor,1261|1262|127|1791|3665|3666|49|725|760|799,Sanofi SA,1009547,Aventis Pharma AG,25218,Aventis Pharma AG,25218,,,,,,
2807,atorvastatin,atorvastatin|Zarator|atorvastatin calcium|CI 981|Sortis|Lipitor|YM-548|Lipramar|Prevencor|Cardyl|Citalor,INN|Trade Name|USAN|Research Code|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Endocrine/Metabolic|Neurology/Psychiatric,HMG CoA reductase inhibitor,205,Antiarteriosclerotic|Antihypercholesterolemic agent|Antihyperlipidemic agent,2667|71|72,Hypercholesterolemia|Hyperlipidemia|Familial hypercholesterolemia|Stroke,174|175|3204|65,Alzheimers disease,14,Almirall Prodesfarma SA|Viatris Inc|Astellas Pharma Inc,14061|1136574|1013295,Pfizer Inc|Parke-Davis & Co|Yamanouchi Pharmaceutical Co Ltd,18767|20805|20967,Parke-Davis & Co,20805,,,,,,
2810,tacedinaline,acetyldinaline|CI-994|Goe-5549|PD-123654|tacedinaline|PD-130636|N-acetyldinaline,Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer,Histone deacetylase inhibitor,2574,Angiogenesis inhibitor|Anticancer,61|1545,,,Non-small-cell lung cancer|Renal cell carcinoma|Leukemia|Melanoma|Pancreas tumor|Metastatic renal cell carcinoma|Breast tumor|Cancer|Solid tumor|Colon tumor,1262|1766|199|205|249|4250|49|651|725|767,,,Pfizer Inc|Parke-Davis & Co,18767|20805,Pfizer Inc,18767,,,,,,
28135,Heplisav,"HBV-ISS|HBV vaccine (ISS-1018), Dynavax|ISS-based therapies (HBV), Dynavax|ISS-1018 (HBV), Dynavax|ISS-1018-based vaccine (HBV), Dynavax|Heplisav|V-270|Heplisav-B|HBsAg-1018",Research Code|Trade Name|Research Code|Trade Name|Research Code,Immune|Infection,TLR-9 agonist,7827,Adjuvant|Prophylactic vaccine|Protein subunit vaccine,524|12378|12372,Hepatitis B virus infection,152,Vaccination,384,Dynavax Technologies Corp,24774,Merck & Co Inc|Triangle Pharmaceuticals Inc,18077|22659,Dynavax Technologies Corp,24774,,,,,,
28176,sagopilone,"epothilone analogs, Schering AG|epothilone analogs, Bayer Schering|sagopilone|SH-Y-03757|ZK-219477|ZK-EPO|ZK-epothilone|SH-Y03757A|DE-03757|BAY-86-5302|EPO-477",USAN|INN|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,,,Microtubule stabilizer|Anticancer,2576|1545,,,Small-cell lung cancer|Non-small-cell lung cancer|Melanoma|Glioblastoma|Hormone refractory prostate cancer|Breast tumor|Cancer|Solid tumor|Ovary tumor,1261|1262|205|2454|3246|49|651|725|799,,,Bayer Schering Pharma AG,19687,Bayer Schering Pharma AG,19687,,,,,,
28211,apricoxib,"CS-706|TG-01 (inflammation), Tragara|TG-01 (oral, cancer), Tragara|R-109339|apricoxib|TG-01|Capoxigem|TP-1001|TP-2001|Kymena",Research Code|Research Code|USAN|INN|Research Code|Trade Name|Research Code|Research Code|Trade Name,Cancer|Inflammatory|Neurology/Psychiatric,Cyclooxygenase 2 inhibitor,1001,Analgesic|Anti-inflammatory|Anticancer,2946|2953|1545,,,Non-small-cell lung cancer|Inflammatory disease|Pain|Pancreas tumor|Breast tumor|Cancer|Colorectal tumor,1262|188|20|249|49|651|989,,,Daiichi Sankyo Co Ltd|Adastra Pharmaceuticals Inc|Sankyo Co Ltd,1017506|1031241|19658,Sankyo Co Ltd,19658,,,,,,
2822,citalopram hydrobromide,citalopram|LU-10171|nitalapram|ZD-211|citalopram hydrobromide|Pharmacor Citalo 20|Celexa|Cipram|Lupram|Sepram|Elopram|Cipramil|Seropram|Celapram|Talam|Ciazil|Citalobell|Celica,BAN|INN|Research Code|Research Code|USAN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Gastrointestinal|Neurology/Psychiatric,,,Anxiolytic|Antidepressant|5-HT uptake inhibitor,2942|2941|3,Panic disorder|Obsessive compulsive disorder|Depression,1279|468|93,Irritable bowel syndrome,192,Xian-Janssen Pharmaceutical Ltd|Almirall Prodesfarma SA|Recordati SpA|H Lundbeck A/S|Allergan plc,17608|14061|24154|17900|1088700,Bayer AG|Forest Laboratories Inc,14455|16198,H Lundbeck A/S,17900,,,,,,
28230,"tetrathiomolybdate, Adeona Pharmaceuticals","tetrathiomolybdate|TM, University of Michigan|Oral TTM|Coprexa|TTM|tetrathiomolybdate, Adeona Pharmaceuticals|tetrathiomolybdate, Pipex Pharmaceuticals|tiomolibdate diammonium|tiomolibdic acid",Trade Name|Trade Name|USAN|INN,Cancer|Dermatologic|Gastrointestinal|Immune|Neurology/Psychiatric|Ocular|Respiratory|Toxicity/Intoxication,VEGF receptor antagonist|Unspecified cytokine receptor antagonist,1722|9662,Anticancer|Nootropic agent|Anticancer protein kinase inhibitor|Systemic antipsoriatic product|Fibrosuppressant|Angiogenesis inhibitor|Chelating agent|Neuroprotectant,1545|284|62255|15184|664|61|105|1615,Breast tumor,49,Cardiotoxicity drug-induced|Scleroderma|Age related macular degeneration|Mesothelioma|Alzheimers disease|Huntingtons chorea|Primary biliary cholangitis|Wilson disease|Psoriasis|Idiopathic pulmonary fibrosis|Metal intoxication|Head and neck tumor|Cancer|Colorectal tumor,1090|1105|1226|1240|14|170|1995|2219|281|3771|386|623|651|989,University of Michigan,20623,Synthetic Biologics Inc,1017428,University of Michigan,20623,,,,,,
28271,SG-2000,SJG-136|NCI-694501|SP-2001|BN-2629|NSC-694501|NSC-D694501|SG-2000,Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,,,Anticancer|DNA intercalator,1545|750,,,Lymphoma|Cancer|Ovary tumor,203|651|799,,,ADC Products (UK) Limited|Ipsen|Spirogen Ltd,1117047|17259|28599,Spirogen Ltd,28599,,,,,,
28275,pyroxamide,pyroxamide|NSC-696085,Research Code,Cancer,Histone deacetylase inhibitor,2574,Anticancer,1545,,,Cancer,651,,,National Cancer Institute (NCI)|Aton Pharma Inc,20519|29378,National Cancer Institute (NCI),20519,,,,,,
2829,clarithromycin,A-56268|antibiotic A-56268|antibiotic TE-31|Biaxin|clarithromycin|Klacid|Klaricid|Macladin|TE-031|Biclar|Kofron|Velcam|Zaclar|Clarith|Cyllind|acladin|Claricid|Klacid SR|Klaricid XL|Klacid LA,Research Code|Research Code|Research Code|Trade Name|USAN|BAN|INN|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Gastrointestinal|Genitourinary/Sexual Function|Immune|Infection|Inflammatory|Other/Miscellaneous|Respiratory,,,Macrolide antibiotic|Ribosome binding agent|Systemic dermatological antibacterial product|Antibacterial|Bacterial protein synthesis inhibitor,1540|463|15187|1594|1538,Sinusitis|Haemophilus influenzae infection|Moraxella catarrhalis infection|Streptococcus pyogenes infection|Bacterial respiratory tract infection|Acute bronchitis|Chronic bronchitis|Helicobacter pylori infection|Bacterial pneumonia|Chlamydia pneumoniae infection|Legionella infection|Enterocolitis|Mycobacterium infection|Mycoplasma infection|Laryngitis|Tonsillitis|Pericoronitis|Periodontitis|Urethritis|Acute sinusitis|Staphylococcus aureus infection|Abscess|Staphylococcus infection|Streptococcus infection|Streptococcus pneumoniae infection|Haemophilus parainfluenzae infection|Peptostreptococcus infection|Cervicitis|Lymphadenitis|Lymphangitis|Otitis media|Bacterial infection|Campylobacter infection|Pharyngitis|Bordetella pertussis infection|Bacterial skin infection|Prophylaxis|Chlamydia infection,1061|145|1455|1475|1484|1487|1488|149|1815|1819|196|2088|218|222|2339|2345|2359|2360|2951|2999|308|3081|309|312|313|3261|3305|3820|3844|3845|394|40|426|453|47|485|706|778,,,Taisho Pharmaceutical Co Ltd|Abbott Laboratories|AbbVie Inc,20289|13601|1072507,Boehringer Ingelheim International GmbH|Dainippon Pharmaceutical Co Ltd|Takeda Pharmaceutical Co Ltd,14881|15606|20300,Taisho Pharmaceutical Co Ltd,20289,,,,,,
2834,clodronic acid,"clodronic acid|KCO-692|Clastoban|clodronate tetrahydrate|clodronate disodium, Leiras|Bonefos|clodronate sodium|Clasteon|clodronate disodium|BAY-94-8393",USAN|BAN|INN|Research Code|Trade Name|Trade Name|Trade Name|USAN|Research Code,Musculoskeletal,,,Anticancer|Unspecified drug target|Bone resorption inhibitor,1545|59620|89,Osteolysis,3445,,,NewBridge Pharmaceuticals Ltd|Abiogen Pharma SpA|Sunovion Pharmaceuticals Canada Inc|Bayer AG,1043434|25553|29723|14455,Schering AG|Kissei Pharmaceutical Co Ltd|Anthra Pharmaceuticals Inc|Bayer Schering Pharma AG|Leiras Oy,1052089|17665|17935|19687|24032,Leiras Oy,24032,,,,,,
28379,Glutoxim,BAM-002|Glutoxim|NOV-002|Glutoxim + cisplatin,Research Code|Trade Name|Research Code,Cancer|Dermatologic|Gastrointestinal|Toxicity/Intoxication,,,Immunomodulator|Anticancer|Hematopoietic stimulator|Radioprotectant|Chemoprotectant|Glutathione modulator|Systemic antipsoriatic product,1596|1545|610|1465|1276|825|15184,Radiation sickness|Breast tumor|Cancer|Lung tumor|Ovary tumor,367|49|651|755|799,Non-small-cell lung cancer|Hepatitis|Psoriasis,1262|154|281,Pharma Vam|Cellectar Biosciences Inc,1015614|27692,Lee's Pharmaceutical Holdings Limited|Mundipharma International Corp Ltd|Phytera Inc,1023179|1045514|23066,Pharma Vam,1015614,,,,,,
28384,patupilone,"EPO-906|epothilone B|patupilone|EPO-906A|epothilone B, Novartis",Research Code|INN|Research Code,Cancer,,,Anticancer|Angiogenesis inhibitor|Microtubule stabilizer,1545|61|2576,Colorectal tumor,989,Non-small-cell lung cancer|Stomach tumor|Fallopian tube cancer|Peritoneal tumor|Hormone refractory prostate cancer|Metastatic liver cancer|Cancer|Solid tumor|Ovary tumor|Renal tumor,1262|127|2243|3083|3246|3462|651|725|799|999,Novartis AG,23137,Novartis Pharma AG,25599,Novartis Pharma AG,25599,,,,,,
28453,degarelix,degarelix|FE-200486|degarelix ART|ASP-3550|degarelix acetate|Firmagon|Gonax,USAN|INN|Research Code|Research Code|USAN|Trade Name|Trade Name,Cancer|Genitourinary/Sexual Function,GNRH receptor antagonist,455,Anticancer hormone antagonist|Anticancer,62254|1545,Hormone refractory prostate cancer|Hormone dependent prostate cancer|Metastatic prostate cancer,3246|3247|3664,Female infertility|Prostate hyperplasia,1080|1241,Ferring Pharmaceuticals SA|Astellas Pharma Inc,29708|1013295,,,Ferring Pharmaceuticals SA,29708,,,,,,
28475,"177Lu-rosopatamab tetraxetan, Telix Pharma","J591|huJ591|MLN-591|MLN-591RL|MLN-5591RL|anti-PSMA, Millennium|anti-PSMA, Millennium/BZL Biologics|177Lu-MLN-591|lutetium-177-MLN-591|177Lu-J591|lutetium-177-J591|90Y-MLN-591|yttrium-90-MLN-591|90Y-J591|yttrium-90-J591|111In-J591|anti-PSMA, ATLAB|ATL-101, ATLAB|TLX-591|TX-591|177Lu-DOTA-rosopatamab|Lutetium-177-DOTA-rosopatamab|DOTA-rosopatamab-[177Lu]|177Lu-J-591|Lutetium-177-J-591|Lutetium-177-MLN-591|177Lu-DOTA-rosopatamab, Telix Pharma|J-591|J-591-[177Lu]|MLN-591-[177Lu]|177Lu-rosopatamab tetraxetan|rosopatamab tetraxetan-[177Lu]|Lutetium-177-rosopatamab tetraxetan|177Lu-rosopatamab tetraxetan, Telix Pharma|177Lu-DOTA-TLX591-CHO",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Glutamate carboxypeptidase II inhibitor,9269,Radioimmunotherapeutic|Anticancer monoclonal antibody,1552|55685,Hormone refractory prostate cancer,3246,,,Telix Pharmaceuticals Ltd|China Grand Pharmaceutical and Healthcare Holdings Limited,1142357|1134150,ATLAB Pharma SAS|Takeda Oncology|Cornell University|BZL Biologics Inc,1065868|21991|24136|27772,Cornell University,24136,,,,,,
28532,pertuzumab,"pertuzumab|rhuHAb 2C4|2C4|anti-2C4, Genentech|Herceptin-like antibody, Genentech|Perjeta|Omnitarg|rhuMAb 2C4|RO-4368451|RG-1273|R-1273",USAN|INN|Research Code|Trade Name|Trade Name|Research Code|Research Code|Research Code,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3756|740,Apoptosis stimulator|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor|Cell cycle inhibitor|Synergist,1589|55685|62255|767|7293,Esophagus tumor|Metastatic breast cancer|Metastatic stomach cancer|Breast tumor|Solid tumor,1011|3657|3666|49|725,Neuroendocrine tumor|Cholangiocarcinoma|Pancreas tumor|Gallbladder tumor|Hormone refractory prostate cancer|Metastatic non small cell lung cancer|Cancer|Ovary tumor,1128|1765|249|3146|3246|3665|651|799,Chugai Pharmaceutical Co Ltd|Roche Holding AG|Genentech Inc,15414|19446|19453,,,Genentech Inc,19453,,,,,,
2871,irinotecan,Campto|Camptothecin 11|Camptothecin 11 hydrochloride|irinotecan hydrochloride|Topotecin|irinotecan hydrochloride hydrate|irinotecan|DQ-2805|NSC-616348|camptothecin II|camptothecin II hydrochloride|Camptosar,Trade Name|USAN|Trade Name|INN|Research Code|Research Code|Trade Name,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,Stomach tumor|Squamous cell carcinoma|Non-Hodgkin lymphoma|Metastatic colorectal cancer|Metastatic pancreas cancer|Breast tumor|Solid tumor|Uterus tumor|Lung tumor|Brain tumor|Ovary tumor|Colorectal tumor,127|307|319|3658|3669|49|725|740|755|760|799|989,Small-cell lung cancer|Non-small-cell lung cancer|Glioblastoma|Pancreas tumor|Uterine cervix tumor|Head and neck tumor|Cancer,1261|1262|2454|249|427|623|651,Pfizer Inc|Daiichi Sankyo Co Ltd|Yakult Honsha Co Ltd,18767|1017506|20961,Daiichi Seiyaku Co Ltd|Upjohn Inc|Rhone-Poulenc SA|Rhone-Poulenc Rorer Inc|Pharmacia & Upjohn Inc|European Organisation for Research and Treatment of Cancer (EORTC)|Aventis SA|Pharmacia Corp,15593|19025|19234|19365|22006|23119|27254|27638,Yakult Honsha Co Ltd,20961,,,,,,
28773,eribulin mesylate,"ER-076349|anticancer agent, Eisai/NCI|halichondrin B analogs, Eisai|NSC-707390|ER-086526|NSC-707389|E-7389|B-1939|eribulin|eribulin mesylate|B-1793|Halaven|BOLD|ER-094039|eribulin mesilate|Teceris",Analogue|Research Code|Analogue|Research Code|Research Code|Research Code|Research Code|Research Code|INN|USAN|Analogue|Research Code|Trade Name|Trade Name|Analogue|Research Code|Trade Name,Cancer,,,Synergist|Anticancer|Cell cycle inhibitor|Microtubule inhibitor,7293|1545|767|2575,Angiosarcoma|Leiomyosarcoma|Liposarcoma|Rhabdomyosarcoma|Fibrous tissue neoplasm|Ewing sarcoma|Soft tissue sarcoma|Metastatic breast cancer|Solid tumor|Ovary tumor,2443|2446|2447|2448|2716|2975|3378|3657|725|799,Non-small-cell lung cancer|Sarcoma|Hormone refractory prostate cancer|Metastatic bladder cancer|Metastatic pancreas cancer|Breast tumor|Female genital tract tumor|Head and neck tumor|Cancer|Urinary tract tumor,1262|194|3246|3466|3669|49|606|623|651|738,Ewopharma AG|NewBridge Pharmaceuticals Ltd|Eisai Co Ltd|Biotoscana International,17764|1043434|15872|1063950,,,Eisai Co Ltd,15872,,,,,,
2888,abatacept,"abatacept|BMS-1888667|BMS-188667|CTLA4-Ig, BMS|Orencia|ONO-4164|ONO-4164SC|BMS-188667SC|Orenica|ONO-4164IV|BMS-188667IV",USAN|PINN|Research Code|Research Code|Trade Name|Research Code|Research Code|Research Code|Trade Name|Research Code|Research Code,Cardiovascular|Dermatologic|Gastrointestinal|Genitourinary/Sexual Function|Immune|Inflammatory|Musculoskeletal|Neurology/Psychiatric|Ocular|Respiratory,T cell surface glycoprotein CD28 inhibitor|Cytotoxic T-lymphocyte protein-4 stimulator,5106|5481,Anti-inflammatory|Systemic antipsoriatic product,2953|15184,Scleroderma|Sjoegrens syndrome|Psoriatic arthritis|Immune disorder|Temporal arteritis|Wegener granulomatosis|Lupus nephritis|Interstitial lung disease|Dermatomyositis|Polymyositis|Alopecia areata|Rheumatoid arthritis|Juvenile rheumatoid arthritis|Focal segmental glomerulosclerosis|Asthma|Uveitis|Minimal change disease|Vitiligo|Ankylosing spondylitis|Graft versus host disease|Behcets disease|Myasthenia gravis,1105|1148|1781|185|1850|1888|2404|2466|2475|2476|2564|291|3003|3084|31|341|3410|346|398|616|768|848,Vasculitis|Multiple sclerosis|Polychondritis|Psoriasis|Systemic lupus erythematosus|Ulcerative colitis|Urticaria|Transplant rejection|Crohns disease,1532|213|2473|281|318|337|340|515|84,Simcere Pharmaceutical Group|Ono Pharmaceutical Co Ltd|Bristol-Myers Squibb Co,1023261|18681|15065,Novartis AG,23137,Bristol-Myers Squibb Co,15065,,,,,,
28972,selumetinib sulfate,"ARRY-142886|MEK inhibitors (cancer), Array Biopharma|kinase inhibitors (cancer), Array Biopharma|neurodegenerative disease therapeutics, Array BioPharma|ARRY-886|AZD-6244|selumetinib|selumetinib sulfate|NSC-748727|IND-77782|MK-5618|Koselugo|AZD-6244 hydrogen sulfate|AZD-6244 hyd-sulfate|selumetinib hyd-sulfate",Research Code|Research Code|Research Code|USAN|INN|USAN|Research Code|Research Code|Research Code|Trade Name|Research Code|Research Code,Cancer|Neurology/Psychiatric,MEK-2 protein kinase inhibitor|MEK-1 protein kinase inhibitor,4764|4762,Anticancer protein kinase inhibitor|Anticancer|Synergist|Cell cycle inhibitor,62255|1545|7293|767,Acute lymphoblastic leukemia|Neurofibromatosis type I|Neurofibromatosis type II|Metastatic non small cell lung cancer|Advanced solid tumor,1728|3521|3522|3665|3713,Thyroid tumor|Non-small-cell lung cancer|Biliary cancer|Acute myelogenous leukemia|Hepatocellular carcinoma|Melanoma|Neurodegenerative disease|Pancreas tumor|Uveal melanoma|Cancer|Solid tumor|Kaposis sarcoma|Colorectal tumor,1134|1262|1516|1731|1767|205|233|249|3788|651|725|936|989,Recombinetics|Merck & Co Inc|AstraZeneca plc,1052042|18077|14190,Array BioPharma Inc,25902,Array BioPharma Inc,25902,,,,,,
29016,"paclitaxel (albumin-bound nanoparticle, intravenous), Celgene","paclitaxel|ABI-007|paclitaxel (albumin-bound nanoparticle, intravenous), American Bioscience|paclitaxel (albumin-bound nanoparticle, intravenous), American Pharmaceutical Partners|paclitaxel (albumin-bound nanoparticle, intravenous), Abraxis/Taiho|Abraxane|paclitaxel (albumin-bound nanoparticle, intravenous), Celgene|Capxol|nab-paclitaxel|Abraxus",USAN|BANN|INN|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Cardiovascular,,,Anticancer|Microtubule stabilizer,1545|2576,Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Transitional cell carcinoma|Pancreas tumor|Squamous cell carcinoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Solid tumor,1261|1262|127|1771|249|307|3257|3378|3657|3665|3669|3673|725,Esophagus tumor|Pancreatic cystadenocarcinoma|Biliary cancer|Melanoma|Bladder cancer|Peritoneal tumor|Hormone refractory prostate cancer|Metastatic colorectal cancer|Uveal melanoma|Vein graft failure|Uterine cervix tumor|Breast tumor|Head and neck tumor|Large intestine tumor|Ovary tumor|Colorectal tumor,1011|1508|1516|205|2380|3083|3246|3658|3788|3903|427|49|623|766|799|989,Taiho Pharmaceutical Co Ltd|Specialised Therapeutics Australia Pty Ltd|Celgene Corp|Bristol-Myers Squibb Co|BeiGene Co Ltd|Biotoscana International|Abraxis BioScience Inc|GC Pharma,18720|1044298|15331|15065|1063251|1063950|1020514|16583,American BioScience Inc|Biocon Ltd,20775|28769,American BioScience Inc,20775,,,,,,
29050,L9NC,9-Nitro-20(S)-camptothecin|L9NC|aerosolized liposomal 9 nitro-20 (S) camptothecin,,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,,,Lung tumor,755,,,MD Anderson Cancer Center,23382,MD Anderson Cancer Center,23382,,,,,,
2944,pamidronate disodium,"APD|Aredia|CGP-23339A|disodium pamidronate|pamidronate disodium|Pamidronic Acid Disodium Salt|pamidronic acid|Aminomax|Aredia R|CGP-23339|PD, Henkel|amidronate|APD, Henkel|pamidronate",Trade Name|Research Code|USAN|BAN|INN|Trade Name|Trade Name|Research Code,Cancer|Endocrine/Metabolic|Musculoskeletal,,,Anticancer|Bone resorption inhibitor|Calcium metabolism inhibitor,1545|89|484,Bone tumor|Hypercalcemia|Osteoporosis|Osteogenesis imperfecta|Pagets bone disease|Bone disease|Breast tumor,1012|173|246|2498|2855|45|49,Bone injury,1091,Novartis AG|Chiron Corp|Novartis Pharma KK|Searle CIBA-GEIGY Korea Ltd|Ciba-Geigy AG|Ciba-Geigy Corp|Novartis Pharma AG|Novartis Pharmaceuticals Corp,23137|15385|16018|18381|24437|24452|25599|24818,Henkel KGaA,16658,Henkel KGaA,16658,,,,,,
29446,"piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho","Tazocin|YP-14|Zosyn|Penmode|Tazosyn|piperacillin sodium + tazobactam sodium (injectable), Wyeth/Toyama/Taiho|YP-18|Zosin|piperacillin + tazobactam|piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho|piperacillin sodium + tazobactam sodium|Zocyn|piperacillin + tazobactam (injectable), Pfizer/Toyama/Taiho|Tazocilline",Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name,Cardiovascular|Dermatologic|Gastrointestinal|Genitourinary/Sexual Function|Hematologic|Infection,Beta lactamase inhibitor,86,Bacterial cell wall synthesis inhibitor|Systemic dermatological antibacterial product|Penicillin|Anti-inflammatory,104|15187|1536|2953,Sepsis|Escherichia coli infection|Bacteroides infection|Bacteroides fragilis infection|Haemophilus influenzae infection|Acinetobacter infection|Bacterial urinary tract infection|Bacterial pneumonia|Klebsiella pneumoniae infection|Cholecystitis|Cholangitis|Cellulitis|Appendicitis|Pseudomonas aeruginosa infection|Pyelonephritis|Staphylococcus aureus infection|Abscess|Abdominal abscess|Pelvic inflammatory disease|Febrile neutropenia|Bacterial infection|Cystitis|Peritonitis|Bacterial skin infection|Lower respiratory tract infection|Diabetic foot ulcer,114|120|1393|1394|145|1453|1798|1815|195|2019|2216|2525|26|280|284|308|3081|3082|3140|3795|40|403|452|485|511|790,Endocarditis,434,Pfizer Inc|Taiho Pharmaceutical Co Ltd|Taisho Pharma Co Ltd,18767|18720|1020932,Wyeth|Wyeth Pharmaceuticals|Toyama Chemical Co Ltd,14112|14199|20424,Taiho Pharmaceutical Co Ltd,18720,,,,,,
2953,docetaxel,docetaxel|RP-56976|Taxotere|XRP-6976|doxetaxel|NSC-628503|Docetaxel Winthrop,USAN|INN|Research Code|Trade Name|Research Code|Trade Name|Research Code|Trade Name,Cancer,,,Microtubule stabilizer|Cell cycle inhibitor|Anticancer protein kinase inhibitor,2576|767|62255,Esophagus tumor|Endometrioid carcinoma|Prostate tumor|Squamous cell carcinoma|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Breast tumor|Head and neck tumor|Cancer|Ovary tumor,1011|1705|276|307|3246|3247|3657|3665|3666|49|623|651|799,Non-small-cell lung cancer|Stomach tumor|Nasopharyngeal carcinoma|Melanoma|Uterine cervix tumor,1262|127|1768|205|427,Sanofi SA,1009547,Chugai Pharmaceutical Co Ltd|Rhone-Poulenc Rorer Inc|National Institutes of Health|Aventis SA,15414|19365|20518|27254,Rhone-Poulenc Rorer Inc,19365,,,,,,
2959,DaunoXome,"daunorubicin|daunorubicin hydrochloride|liposomal formulation (daunorubicin), NeXstar|DaunoXome",BANN|INN|USAN|Trade Name,Cancer,,,Anticancer|DNA intercalator,1545|750,Acute myelogenous leukemia|Kaposis sarcoma,1731|936,Multiple myeloma|Leukemia|Liver tumor|Lymphoma|Bladder tumor|Uterine cervix tumor|Breast tumor|Cancer|Lung tumor|Brain tumor|Colon tumor,1828|199|202|203|42|427|49|651|755|760|767,Sayre Therapeutics Private Ltd|Galen Ltd|HB Human BioScience SAS,1125796|16269|1154393,NeXstar Pharmaceuticals Inc|Gilead Sciences Inc|Swedish Orphan AB,15906|16450|20277,NeXstar Pharmaceuticals Inc,15906,,,,,,
29592,lucanthone,lucanthone hydrochloride|lucanthone,USAN|BANN|INN,Cancer,Endonuclease inhibitor|Topoisomerase II inhibitor,1310|142,Radiochemosensitizer|Anticancer,572|1545,Glioblastoma|Brain tumor,2454|760,Cancer,651,Spectrum Pharmaceuticals Inc,24232,Astex Pharmaceuticals Inc|Albert Einstein College of Medicine,21885|24282,Albert Einstein College of Medicine,24282,,,,,,
29671,AZA-DR,"azathioprine|AZA-DR|azathioprine delayed release, Santarus",USAN|INN,Gastrointestinal,,,,,,,Crohns disease,84,,,Santarus Inc,15957,Santarus Inc,15957,,,,,,
29751,gallium maltolate,"gallium maltolate|GaM|gallium maltolate (oral, glioblastoma multiforme), IQ-AI Ltd",,Cancer|Endocrine/Metabolic|Immune|Infection|Musculoskeletal,,,Antiviral|Antibacterial|Apoptosis stimulator|Anticancer,991|1594|1589|1545,Glioblastoma,2454,HIV infection|Hyperparathyroidism|Multiple myeloma|Lymphoma|Prostate tumor|Pagets bone disease|Rheumatoid arthritis|Bacterial infection|Bladder tumor|Cancer,158|176|1828|203|276|2855|291|40|42|651,IQ-AI Ltd,1225608,Titan Pharmaceuticals Inc,20377,Geomed Inc,29217,,,,,,
29831,sorafenib,"BAY-43-9006|raf kinase inhibitor, Bayer/Onyx|sorafenib|sorafenib analogs, Bayer|sorafenib tosylate|Nexavar|BAY-54-9085",Research Code|USAN|INN|USAN|Trade Name|Research Code,Cancer|Cardiovascular,Raf 1 protein kinase inhibitor|PDGF receptor beta antagonist|PDGF receptor antagonist|Raf B protein kinase inhibitor|Raf protein kinase inhibitor|VEGF-3 receptor antagonist|RET tyrosine kinase receptor family inhibitor|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist|Kit tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|VEGF receptor antagonist,4550|48492|948|4548|4542|3850|3816|3846|3848|3808|3806|1722,Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Anticancer,62255|61|1545,Glioma|Thyroid tumor|Renal cell carcinoma|Hepatocellular carcinoma|Bone metastases|Medullary thyroid cancer|Aggressive fibromatosis|Anaplastic thyroid cancer|Metastatic renal cell carcinoma,1108|1134|1766|1767|1829|3240|3504|3769|4250,Esophagus tumor|Rectal tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Myelodysplastic syndrome|Biliary cancer|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Nasopharyngeal carcinoma|Pulmonary hypertension|Astrocytoma|Pancreas tumor|Peritoneal tumor|Gallbladder tumor|Stage IV melanoma|Soft tissue sarcoma|Breast tumor|Head and neck tumor|Cancer|Ovary tumor|Colorectal tumor,1011|1055|1261|1262|127|1272|1516|1731|1734|1735|1768|1867|2453|249|3083|3146|3257|3378|49|623|651|799|989,Bayer AG|Amgen Inc,14455|14109,Onyx Pharmaceuticals Inc,18683,Bayer AG,14455,,,,,,
29835,ferumoxytol,AMI-7228|Code 7228|ferumoxytol|ultrasmall superparamagnetic iron oxide|USPIO|Feraheme|Rienso,Research Code|Research Code|USAN|Trade Name|Trade Name,Cancer|Cardiovascular|Hematologic,,,Iron metabolism modulator|Anticancer,834|1545,Iron deficiency anemia,3191,Cardiovascular disease|Cancer,57|651,Covis Pharma Sarl,1067053,3SBio Inc|AMAG Pharmaceuticals Inc|Takeda Pharmaceutical Co Ltd,1016672|13726|20300,AMAG Pharmaceuticals Inc,13726,,,,,,
2992,donepezil hydrochloride,"donepezil hydrochloride|Aricept|E-2020|donepezil|MF-5844|donepexil hydrochloride|E-2020 (tablet formulation), Eisai|donepezil (tablet formulation), Eisai|E-2020 (RDT), Eisai|donepezil (RDT), Eisai|E-2020 (Rapid Disintegration Tablet), Eisai|donepezil (Rapid Disintegration Tablet), Eisai|E-2020 (liquid formulation), Eisai|donepezil (liquid formulation), Eisai|Aricept Evess|donepezil (oral sustained release formulation), Eisai|donepezil (oral jelly formulation), Eisai|Aricept SR|Aricep|donepezil hydrochloride (dry syrup, Alzheimers disease), Eisai|donepezil hydrochloride (fine granules, Alzheimers disease), Eisai|donepexil|Eranz",USAN|Trade Name|Research Code|BAN|INN|Research Code|USAN|Trade Name|Trade Name|Trade Name,Neurology/Psychiatric|Other/Miscellaneous,Acetylcholinesterase inhibitor,19,Neuroprotectant|Nootropic agent,1615|284,Alzheimers disease|Vascular dementia|Lewy body dementia,14|1634|3064,Migraine|Delirium|Cognitive disorder|Fatigue|Dementia,210|3063|353|829|90,Chong Kun Dang Pharmaceutical Corp|Wyeth-Ayerst International Inc|Pfizer Inc|Eisai Co Ltd,15410|14198|18767|15872,Daewoong Pharmaceutical Co Ltd,15587,Eisai Co Ltd,15872,,,,,,
29992,"aflibercept (intravenous, cancer), Regeneron/Sanofi","VEGF Trap, Regeneron/Aventis|VEGF antagonist (cancer), Regeneron/Aventis|VEGF Trap, Regeneron/sanofi-aventis|VEGF antagonist (cancer), Regeneron/sanofi-aventis|systemic VEGF Trap (cancer), Regeneron/sanofi-aventis|aflibercept|aflibercept (intravenous, cancer), Regeneron/sanofi-aventis|AVE-0005|VEGF trap|Zaltrap|aflibercept (intravenous, cancer), Regeneron/Sanofi|ziv-aflibercept|Aflitiv|Lidaveg",USAN|INN|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Dermatologic|Gastrointestinal|Ocular,VEGF-A ligand inhibitor|Placenta growth factor ligand inhibitor|VEGF-B ligand inhibitor,1689|15904|12525,Anticancer protein kinase inhibitor|Metastasis inhibitor|Angiogenesis inhibitor|Anticancer,62255|695|61|1545,Neuroendocrine tumor|Hepatocellular carcinoma|Sarcoma|Pancreas tumor|Stage IV melanoma|Metastatic colorectal cancer|Metastatic rectal cancer|Metastatic colon cancer|Metastatic ovary cancer|Metastatic renal cell carcinoma,1128|1767|194|249|3257|3658|3671|3672|3866|4250,Glioma|Age related macular degeneration|Small-cell lung cancer|Multiple myeloma|Melanoma|Ascites|Fallopian tube cancer|Psoriasis|Peritoneal tumor|B-cell lymphoma|Hormone refractory prostate cancer|Metastatic renal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Breast tumor|Diabetic retinopathy|Cancer|Solid tumor|Ovary tumor,1108|1226|1261|1828|205|2204|2243|281|3083|316|3246|3467|3665|3669|3713|49|576|651|725|799,Sanofi SA,1009547,Regeneron Pharmaceuticals Inc|Aventis SA,19214|27254,Regeneron Pharmaceuticals Inc,19214,,,,,,
3003,ABT-751,"ER-67487|ER-67865|ER-67880|E-7010 analogs, Abbott|E-7010|ABT-751",Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Research Code|Research Code,Cancer,Tubulin receptor antagonist,541,Anticancer|Vascular damaging agent,1545|2969,,,Non-small-cell lung cancer|Breast tumor|Cancer|Colorectal tumor|Renal tumor,1262|49|651|989|999,,,Abbott Laboratories|Eisai Co Ltd,13601|15872,Eisai Co Ltd,15872,,,,,,
30116,"forodesine (intravenous, cancer), BioCryst/ Mundipharma","Immucillin-H|forodesine hydrochloride|BCX-1777|forodesine|forodesine hydrochloride (intravenous, cancer), BioCryst/ Mundipharma|Fodosine|forodesine (intravenous, cancer), BioCryst/ Mundipharma",USAN|Research Code|USAN|INN|Trade Name,Cancer|Dermatologic,Purine nucleoside phosphorylase inhibitor,341,Systemic antipsoriatic product|Anticancer,15184|1545,,,B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Cutaneous T-cell lymphoma|Leukemia|Psoriasis|T-cell lymphoma|Solid tumor,1729|1734|1754|199|281|311|725,,,BioCryst Pharmaceuticals Inc|Mundipharma EDO GmbH|Albert Einstein College of Medicine,14695|24189|24282,Albert Einstein College of Medicine,24282,,,,,,
30142,vidutolimod,"Derp-1-Qbeta|CYT-001-DerQb|CYT-003-QbG10|Qa-Derp1, Cytos|AlphaVaccine (allergy/asthma), Cytos|Immunodrug vaccines (allergy/asthma), Cytos|allergy/asthma vaccine, Cytos Biotechnology|QbG10 Immunodrug carrier (allergy/asthma), Cytos|Immunodrug|CYT-003|TLR-9 agonist (HBV infection), Tekmira|ARB-1598|CMP-001, Checkmate Pharmaceuticals|CpG-A oligonucleotide (sc, stage IV skin melanoma/non-small cell lung cancer/metastatic colorectal cancer), Checkmate|vidutolimod|CMP-001",Research Code|Research Code|Trade Name|Research Code|Research Code|PINN|Research Code,Cancer|Dermatologic|Immune|Infection|Ocular|Respiratory,TLR-9 agonist,7827,Anticancer|Antiviral|Anti-inflammatory|Immunostimulant,1545|991|2953|393,Non-small-cell lung cancer|Hodgkins disease|Hepatocellular carcinoma|Lymphoma|Melanoma|Squamous cell carcinoma|Non-Hodgkin lymphoma|Merkel cell carcinoma|Stage III melanoma|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic head and neck cancer|Breast tumor,1262|161|1767|203|205|307|319|3235|3256|3257|3657|3658|3673|49,Atopic dermatitis|Allergic rhinitis|Allergy|Hepatitis B virus infection|Allergic conjunctivitis|Asthma|Cancer,1102|1107|12|152|2438|31|651,Checkmate Pharmaceuticals,1112678,Arbutus Biopharma Corp|OnCore Biopharma Inc|Roivant Sciences Ltd|Kuros Biosciences Ltd,1032153|1100124|1104160|26816,Kuros Biosciences Ltd,26816,,,,,,
3018,elsamitrucin,Antibiotic BBM 2478A|BBM-2478A|elsamicin-A|elsamitrucin|BMY-28090|BMS-181171|NSC-369327,Research Code|USAN|INN|Research Code|Research Code|Research Code,Cancer,Topoisomerase I inhibitor|Topoisomerase II inhibitor|DNA gyrase inhibitor,141|142|431,Anticancer,1545,,,Non-Hodgkin lymphoma|Cancer|Solid tumor,319|651|725,,,Bristol-Myers Squibb Co|Spectrum Pharmaceuticals Inc|NeoOncoRx Inc,15065|24232|28221,Bristol-Myers Squibb Co,15065,,,,,,
30214,"diphtheria/tetanus/pertussis vaccine, sanofi pasteur","Daptacel|Td5(l), Aventis Pasteur|DTaP vaccine, Aventis Pasteur|diphtheria/tetanus/pertussis vaccine, Aventis Pasteur|Td5(l), sanofi pasteur|DTaP vaccine, sanofi pasteur|diphtheria/tetanus/pertussis vaccine, sanofi pasteur",Trade Name,Infection,,,Protein subunit vaccine|Prophylactic vaccine|Toxoid vaccine,12372|12378|12375,Bordetella pertussis infection|Clostridium tetani infection|Corynebacterium diphtheriae infection,47|72|81,,,Sanofi Pasteur,22127,,,Sanofi Pasteur,22127,,,,,,
3033,matuzumab,"EMD-72000|matuzumab|EMD-62000|anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals|anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals|anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals",Research Code|INN|Analogue|Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,,,Non-small-cell lung cancer|Stomach tumor|Pancreas tumor|Uterine cervix tumor|Solid tumor|Ovary tumor|Colorectal tumor,1262|127|249|427|725|799|989,,,Merck KGaA|Merck Serono SA|Takeda Pharmaceutical Co Ltd,18101|19862|20300,Merck KGaA,18101,,,,,,
30361,ASTVAC-1,"hTERT RNA therapeutic, Geron/Merix|telomerase immunotherapy, Geron/Merix|cancer vaccine (telomerase), Geron/Merix|hTERT RNA therapeutic, Geron/Argos|telomerase immunotherapy, Geron/Argos|cancer vaccine (telomerase), Geron/Argos|hTERT RNA therapeutic, Geron|telomerase immunotherapy, Geron|cancer vaccine (telomerase), Geron|GRNVAC-1|ASTVAC-1|VAC-1",Research Code|Research Code|Research Code,Cancer,TERT gene modulator|LAMP gene modulator,22508|63084,Dendritic cell vaccine|Anticancer|Genetically engineered autologous cell vaccine|Therapeutic vaccine,102926|1545|4791|12379,Acute myelogenous leukemia|Cancer,1731|651,Prostate tumor,276,Lineage Cell Therapeutics Inc,14846,Asterias Biotherapeutics Inc|Geron Corp|CoImmune Inc (formerly Argos Therapeutics Inc),1074320|16315|28019,Geron Corp,16315,,,,,,
30376,pelitinib,EKB-569|EKI-569|WAY-EKB-569|pelitinib,Research Code|Research Code|Research Code|USAN|PINN,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3756|740,Anticancer protein kinase inhibitor|Anticancer,62255|1545,,,Non-small-cell lung cancer|Cancer|Colorectal tumor,1262|651|989,,,Wyeth Research,25247,Wyeth Research,25247,,,,,,
30379,bosutinib,"SKI-606|SKI-971|Src kinase inhibitors (oral), Wyeth|Bcr-Abl kinase inhibitors, Wyeth|Src kinase inhibitors (oral), Wyeth-Ayerst|bosutinib|SKI-758|SKI-015|Src kinase inhibitors (oral), Pfizer|Bcr-Abl kinase inhibitors, Pfizer|PF-5208763|Bosulif|Boslif|PF-05208763",Research Code|Research Code|USAN|PINN|Research Code|Research Code|Research Code|Trade Name|Trade Name|Research Code,Cancer|Genitourinary/Sexual Function|Neurology/Psychiatric,Abl tyrosine kinase inhibitor|Src tyrosine kinase inhibitor|DNA gyrase inhibitor,3524|3576|431,Anticancer protein kinase inhibitor,62255,Acute lymphoblastic leukemia|Chronic myelocytic leukemia|Dementia,1728|1735|90,Non-small-cell lung cancer|Intracranial hemorrhage|Autosomal dominant polycystic kidney disease|Pancreas tumor|Breast tumor|Cancer|Solid tumor,1262|1632|2300|249|49|651|725,Pfizer Inc,18767,Avillion LLP|Wyeth Research,1077973|25247,Wyeth Research,25247,,,,,,
30689,"radiolabeled DTPA-adenosylcobalamin, Copharos","111-In DAC|DAC, Copharos|vitamin B12-based imaging, Copharos|radiolabeled DTPA-adenosylcobalamin, Copharos|111-Indium DTPA-adenosylcobalamin",,,,,Imaging agent|Vitamin B12 modulator|Neoplasm diagnostic agent|CNS diagnostic agent|Endocrine diagnostic agent,4155|1601|7220|7211|7212,,,Metastasis|Breast tumor|Lung tumor|Brain tumor,1069|49|755|760,,,Copharos Inc,28042,University of Minnesota,20626,,,,,,
30712,"budesonide + formoterol fumarate, AstraZeneca","budesonide + formoterol, AstraZeneca|Budesonide-Formoterol mixt, AstraZeneca|budesonide + formoterol fumarate dihydrate|Symbicort|Symbicort Turbuhaler|Symbicort pMDI|Symbicort Rapihaler|Symbicort SMART|Symbicort Forte Turbuhaler|budesonide + formoterol fumarate, AstraZeneca|budesonide + formoterol fumarate|Symbicort Turbohaler",Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Infection|Respiratory,Beta 2 adrenoceptor agonist,40,Antiviral|Bronchodilator|Corticosteroid agonist|Steroidal anti-inflammatory,991|646|3189|2954,Coronavirus disease 19 infection|Chronic obstructive pulmonary disease|Asthma,10406|1185|31,,,AstraZeneca plc,14190,Astellas Pharma Inc,1013295,AstraZeneca plc,14190,,,,,,
3072,etoposide phosphate,etoposide|BMY-40481|etoposide phosphate|etopofos|Etopophos|VP-16|Vepesid|Eposide|Eposin|NSC-141540|VP-16-213|Nexvep,INN|Research Code|USAN|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Trade Name,Cancer,Topoisomerase II inhibitor,142,Anticancer alkylating agent,50,Small-cell lung cancer|Hodgkins disease|Acute myelogenous leukemia|Lymphoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Germ cell and embryonic cancer|Choriocarcinoma|Lung tumor,1261|161|1731|203|319|3246|3737|3738|755,,,CHEPLAPHARM Arzneimittel GmbH,1129377,Bristol-Myers Squibb Co,15065,Bristol-Myers Squibb Co,15065,,,,,,
3081,exemestane,Aromasin|exemestane|FCE-24304|Nikidess|PNU-971-ONC-0028|PNU-155971,Trade Name|INN|Research Code|Trade Name|Research Code|Research Code,Cancer,Aromatase inhibitor,76,Anticancer,1545,Breast tumor,49,Ovary tumor,799,Pfizer Inc,18767,Pharmacia & Upjohn AB,22008,Pharmacia & Upjohn AB,22008,,,,,,
30870,talimogene laherparepvec,"OncoVEX|OncoVEX-TNF-alpha|OncoVEX-TNF-alpha+GM-CSF|OncoVEX therapies (cancer), Amgen|ICP34.5-null herpes simplex virus-1, BioVex|OncoVEX GM-CSF vaccine|talminogene laherparepvec|JS1 34.5-hGMCSF 47-pA-|talimogene laherparepvec|T-VEC|Imlygic|oncolytic HSV1 therapy expressing GM-CSF (OncoVEX platform, melanoma), Amgen",Trade Name|Research Code|USAN|INN|Trade Name,Cancer,,,Anticancer|Immunostimulant,1545|393,Hepatocellular carcinoma|Sarcoma|Squamous cell carcinoma|Peritoneal tumor|Merkel cell carcinoma|Stage III melanoma|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic head and neck cancer|Inflammatory breast cancer|Breast tumor|Colorectal tumor,1767|194|307|3083|3235|3256|3257|3657|3658|3673|3948|49|989,Liver tumor|Melanoma|Pancreas tumor|Head and neck tumor|Solid tumor,202|205|249|623|725,BioVex Inc|Amgen Inc,27977|14109,,,BioVex Inc,27977,,,,,,
3120,"fenretinide (oral, HIV infection), NIAID","4-HPR|fenretinide|RWJ-16434|McN-R-1967|NSC-374551|fenretinide (oral)|retinoic acid p-hydroxyphenylamine|fenretinide (oral, HIV infection), NIAID",USAN|INN|Research Code|Research Code|Research Code,Cancer|Infection,VEGF receptor antagonist|FGF receptor antagonist,1722|168,Antiviral|Anticancer|Angiogenesis inhibitor|Anticancer protein kinase inhibitor|Retinoid modulator,991|1545|61|62255|824,,,Small-cell lung cancer|HIV infection|Nervous system tumor|Prostate tumor|Bladder tumor|Breast tumor|Solid tumor|Ovary tumor,1261|158|232|276|42|49|725|799,,,Johnson & Johnson|National Institutes of Health|National Institute of Allergy and Infectious Diseases,17332|20518|20520,McNeil Pharmaceuticals Inc,17562,,,,,,
3130,filgrastim,"filgrastim|KRN-8601|Neupogen|rhG-CSF|GRAN|KRN-8601E|CSF, Amgen|CSF-G, Amgen|G-CSF, Amgen|Neutropoietin|hG-CSF, Amgen|pluripoietin, Amgen|filgrastim (HemaGel ER formulation, RxKinetix)|Granulokine|Nupogen|r-metHuG-CSF|NSC-614629|Grasin",USAN|BAN|INN|Research Code|Trade Name|Trade Name|Research Code|Research Code|Trade Name,Cancer|Hematologic|Immune|Infection|Toxicity/Intoxication,GCSF receptor agonist,3151,Anticancer,1545,Neutropenia|Stem cell transplantation|Radiation sickness,1991|2990|367,Pneumonia|Breast tumor|Ovary tumor,360|49|799,Amgen Inc|Roche Holding AG|Kyowa Hakko Kirin Co Ltd,14109|19446|1042596,Kirin Brewery Co Ltd|Sankyo Co Ltd,17661|19658,Amgen Inc,14109,,,,,,
3131,finasteride,finasteride|MK-906|Proscar|Prostide|Eutiz|Prodel|YM-152|Andozac|MK-0906|Procure|Finastid|Finaspros|Chibro-Proscar,USAN|BAN|INN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Cancer|Genitourinary/Sexual Function,5-Alpha-reductase inhibitor,458,Anticancer,1545,Prostate hyperplasia,1241,Prostate tumor,276,Merck & Co Inc|Alfasigma SpA,18077|1153354,Astellas Pharma Inc|Yamanouchi Pharmaceutical Co Ltd|Sigma-Tau Ind Farm Riunite SpA|MSD Japan,1013295|20967|21159|24019,Merck & Co Inc,18077,,,,,,
31532,PEITC,phenethyl-isothiocyanate|PEITC,,Cancer,,,DNA modulator|Chemoprotectant|Anticancer,803|1276|1545,,,Prostate tumor|Lung tumor,276|755,,,New York University,20646,New York University,20646,,,,,,
3159,fluticasone propionate,fluticasone|fluticasone propionate|FN-25|SN-410|SN-411|Axotide|Flonase|Flovent|Flunase|Flutide|SN-411A|CCI-18781|Flovent Diskus|Flutide Diskus|Flutide Evohaler|Flixotide Evohaler|Flovent HFA,BAN|INN|USAN|Research Code|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Immune|Inflammatory|Other/Miscellaneous|Respiratory,,,Steroidal anti-inflammatory|Corticosteroid agonist|Anti-inflammatory|Anticancer,2954|3189|2953|1545,Allergic rhinitis|Asthma,1107|31,Sarcoidosis|Sinusitis|Chronic obstructive pulmonary disease|Nasal polyps|Otitis media|Cystic fibrosis,1036|1061|1185|3208|394|88,Glaxo Group Ltd|Hanmi Pharmaceutical Co Ltd|GlaxoSmithKline plc,16453|16611|28355,,,Glaxo Group Ltd,16453,,,,,,
31750,IRX-5183,"AGN-195183|VTP-195183|VTP-5183|NRX-5183|NRX-195183|IRX-5183 (oral, autoimmune disease), Io Therapeutics|retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics|RARa (oral, cancer/autoimmune disease), Io Therapeutics|IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics|IRX-5183|IRX-5183 (oral, cancer), Io Therapeutics",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Hematologic|Immune,Retinoic acid receptor alpha agonist,4094,Anticancer|Immunosuppressant,1545|396,Multiple myeloma,1828,Acute myelogenous leukemia|Acute promyelocytic leukemia|Neutropenia|Autoimmune disease|Breast tumor|Cancer,1731|1732|1991|36|49|651,Io Therapeutics Inc,1061417,NuRx Pharmaceuticals Inc|Allergan Ligand Retinoid Therapeutics Inc|Allergan Specialty Therapeutics Inc|Vitae Pharmaceuticals Inc,1032578|16824|25444|29775,Allergan Ligand Retinoid Therapeutics Inc,16824,,,,,,
31831,belimumab,"belimumab|LymphoStat-B|anti-BLyS antibody (rheumatoid arthritis / systemic lupus erythematosus), HGS|antibody (immunosupressant), HGS|antibody (autoimmune disease), HGS|anti-BLyS antibody (rheumatoid arthritis / systemic lupus erythematosus), HGS / GSK|Benlysta|HGS-1006|GSK-1550188",USAN|INN|Trade Name|Trade Name|Research Code|Research Code,Cancer|Cardiovascular|Genitourinary/Sexual Function|Hematologic|Immune|Musculoskeletal|Ocular|Respiratory,B-lymphocyte stimulator ligand inhibitor,12770,Anticancer monoclonal antibody|Immunosuppressant|Therapeutic antibody|Anticancer|Anti-inflammatory,55685|396|172641|1545|2953,Emphysema|Chronic obstructive pulmonary disease|Vasculitis|Lupus nephritis|Myositis|Thyroid associated ophthalmopathy|Kidney transplant rejection|Systemic lupus erythematosus,111|1185|1532|2404|2474|2967|2989|318,Scleroderma|Sjoegrens syndrome|Macroglobulinemia|Multiple sclerosis|Immune thrombocytopenic purpura|Renal disease|Rheumatoid arthritis|Membranous glomerulonephritis|Autoimmune disease|Cancer|Myasthenia gravis,1105|1148|1264|213|2259|286|291|3441|36|651|848,Human Genome Sciences Inc|GlaxoSmithKline plc,17002|28355,Cambridge Antibody Technology Group plc,24236,Human Genome Sciences Inc,17002,,,,,,
3195,"ganciclovir (oral), Roche Bioscience","ganciclovir|RS-21592|Cytovene|Cymevene|ganciclovir (oral), Roche Bioscience",INN|Research Code|Trade Name|Trade Name,Infection,DNA polymerase inhibitor|Transferase inhibitor,138|374,Viral replication inhibitor|Antiviral,1532|991,Viral infection|Cytomegalovirus infection,344|89,,,Roche Korea Co Ltd|Roche Palo Alto|Roche Holding AG|Recordati SpA,19462|19470|19446|24154,,,Roche Palo Alto,19470,,,,,,
31975,"personalized recombinant protein vaccines (cancer), Genitope","MyVax|GTOP-99|vaccine (NHL), Genitope|non-Hodgkin lymphoma vaccine, Genitope|recombinant Id immunotherapy, Genitope|B-cell non-Hodgkins lymphoma vaccine, Genitope|recombinant idiotype protein vaccines, Genitope|personalized recombinant protein vaccines (cancer), Genitope|MyVax Personalized Immunotherapy|Xi-20H5|Xi-3C9",Trade Name|Research Code|Trade Name|Research Code|Research Code,Cancer,,,Anticancer monoclonal antibody|Therapeutic vaccine|Immunomodulator,55685|12379|1596,,,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1734|1744|1745|1749|316|319,,,Genitope Corp,25258,Genitope Corp,25258,,,,,,
31977,varenicline,"CP 526555-18|varenicline tartrate|CP-526555|varenicline|alpha4/beta2 nicotinic receptor partial agonist, Pfizer|Champix|Chantix|KKM-164R",USAN|Research Code|INN|Trade Name|Trade Name|Research Code,Neurology/Psychiatric|Toxicity/Intoxication,Nicotinic ACh receptor alpha 4 subunit modulator|Nicotinic ACh receptor beta 2 subunit modulator|Nicotinic acetylcholine receptor modulator|Nicotinic acetylcholine receptor partial agonist,16386|16413|1166|16661,,,Alcoholism|Nicotine dependence|Cognitive disorder,11|235|353,Alzheimers disease|Spinocerebellar ataxia|Friedreich ataxia|Postherpetic neuralgia,14|2407|2974|3300,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
3199,gemcitabine,gemcitabine hydrochloride|gemcitabine|NSC-613327|dFdCTP|dFdC|dFdCyd|DDFC|LY-188011|Gemtro|Gemzar|difluorodeoxycytidine hydrochloride,USAN|USAN|BANN|INN|Research Code|Trade Name|Trade Name,Cancer,,,Cell cycle inhibitor|Anticancer antimetabolite|Anticancer|DNA synthesis inhibitor,767|1569|1545|140,Non-small-cell lung cancer|Biliary cancer|Lymphoma|Pancreas tumor|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic ovary cancer|Bladder tumor|Breast tumor|Hepatobiliary system tumor|Ovary tumor,1262|1516|203|249|3466|3657|3665|3669|3866|42|49|629|799,Renal cell carcinoma|Sarcoma|Leiomyosarcoma|Non-Hodgkin lymphoma|Metastatic renal cell carcinoma|Uterine cervix tumor|Head and neck tumor,1766|194|2446|319|4250|427|623,Eli Lilly & Co|Boryung Pharm Co Ltd,17810|14987,,,Eli Lilly & Co,17810,,,,,,
32051,dacetuzumab,"SGN-11|SGN-12|SGN-14|SGN-18|SGN-40|anti-CD40 mAbs (iv, NHL/MM/CLL), Seattle Genetics/Genentech|dacetuzumab|huS2C6|anti-CD40 humanized monoclonal antibodies (iv, non-Hodgkin lymphoma/multiple myeloma/ chronic lymphocytic leukemia), Seattle Genetics/ Genentech|PRO-64553|RG-3636",Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Research Code|USAN|PINN|Analogue|Research Code|Research Code,Cancer|Hematologic,CD40 ligand receptor antagonist,5142,Anticancer monoclonal antibody,55685,,,Hematological disease|Hodgkins disease|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Multiple myeloma|Non-Hodgkin lymphoma,142|161|1734|1749|1828|319,,,Genentech Inc|Seagen Inc,19453|25554,Seagen Inc,25554,,,,,,
32053,SGN-30,"SGN-30|chimeric mAb cAC10, Seattle Genetics|anti-CD30 mAb (lymphoma), Seattle Genetics|chimeric mAb AC10, Seattle Genetics",Research Code,Cancer|Immune,CD30 modulator,5110,Immunosuppressant|Anticancer monoclonal antibody,396|55685,,,Hodgkins disease|Cutaneous T-cell lymphoma|Anaplastic large cell lymphoma|Multiple sclerosis|Systemic lupus erythematosus|Non-Hodgkin lymphoma,161|1754|1755|213|318|319,,,Seagen Inc,25554,Seagen Inc,25554,,,,,,
32076,VP-701,"GS-7836|T-araC|4-thio-araC|OSI-7836|VP-701|4-thio-beta-D-arabinofuranosylcytosine|SR-9025|VP-700 series, Southern Research Institute|VP-700 series, Virium|VP-700 series, Macrochem|Thiarabine|VP-700 series, Access",Research Code|Research Code|Research Code|Research Code,Cancer|Immune,,,Angiogenesis inhibitor|Anticancer|DNA synthesis inhibitor,61|1545|140,,,Hematological neoplasm|Rheumatoid arthritis|Cancer|Solid tumor,2054|291|651|725,,,Virium Pharmaceuticals Inc|Gilead Sciences Inc|MacroChem Corp|OSI Pharmaceuticals Inc|Southern Research Institute|Abeona Therapeutics Inc,1030922|16450|17917|18676|20226|22881,Southern Research Institute,20226,,,,,,
32192,salirasib,"Th-101|FTS, Thyreos|ras antagonists, Thyreos|farnesylthiosalicyclic acid|salirasib|Ras-inhibitors (cancer), Concordia|FTS (oral, cancer), Concordia|farnesylthiosalicyclic acid (oral, cancer), Concordia|FTS|trans-farnesylthiosalicylic acid|S-trans|FTS (oral, cancer), Concordia/Ono|KD-032|ONO-7056",Research Code|USAN|INN|Research Code|Research Code,Cancer,Ras GTPase inhibitor|Rheb GTPase inhibitor,10451|40995,Anticancer,1545,,,Non-small-cell lung cancer|Pancreas tumor|Cancer|Solid tumor|Colorectal tumor,1262|249|651|725|989,,,Concordia Pharmaceuticals Inc|Kadmon Pharmaceuticals LLC|Ono Pharmaceutical Co Ltd|Tel Aviv University|Thyreos Corp,1019729|1054096|18681|25012|28372,Tel Aviv University,25012,,,,,,
32372,AMG-714,"AMG-714|HuMax-IL-15|human anti-IL-15 MAb, Genmab/ Amgen|PRV-015|anti-IL-15 human MAb (celiac disease), Amgen/ Provention Bio|anti-IL-15 human monoclonal antibody (celiac disease), Amgen/ Provention Bio|anti-IL-15 human MAb (celiac disease/vitiligo), Amgen/ Provention Bio",Research Code|Research Code,Dermatologic|Gastrointestinal|Immune|Inflammatory,IL-15 receptor antagonist,1727,Anti-inflammatory|Systemic antipsoriatic product,2953|15184,Celiac disease|Vitiligo,2539|346,Inflammatory disease|Psoriasis|Rheumatoid arthritis,188|281|291,Amgen Inc|Provention Bio Inc,14109|1149995,Celimmune LLC|Immunex Corp|Genmab A/S,1106166|14131|26469,Immunex Corp,14131,,,,,,
32373,zalutumumab,SF8|HuMax-EGFr|2F8|zalutumumab,Research Code|Research Code|USAN|INN,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Head and neck tumor,623,Non-small-cell lung cancer|Colorectal tumor,1262|989,Genmab A/S,26469,,,Genmab A/S,26469,,,,,,
3241,granisetron,granisetron|BRL-43694|granisetron hydrochloride|Kytril|Kevatril,BAN|INN|Research Code|USAN|Trade Name|Trade Name,Gastrointestinal,5-HT 3 receptor antagonist,15,Anti-emetic,2970,Emesis|Nausea|Radiotherapy induced emesis|Chemotherapy-induced emesis,110|226|3012|352,,,Taiyo Pharmaceuticals Industry|Atnahs Pharma UK Limited,1137333|1123655,Chugai Pharmaceutical Co Ltd|Roche Holding AG|SmithKline Beecham plc,15414|19446|19962,SmithKline Beecham plc,19962,,,,,,
32677,rivaroxaban,"BAY-59-7939|Factor Xa inhibitor (thrombosis), Bayer/ Ortho-McNeil|rivaroxaban|Xarelto|JNJ-39039039|Xarelto OD",Research Code|USAN|INN|Trade Name|Research Code|Trade Name,Cardiovascular|Genitourinary/Sexual Function|Hematologic|Inflammatory,Factor Xa antagonist,120,Antiarrhythmic agent|Coagulation inhibitor|Anti-inflammatory,449|659|2953,Lung embolism|Peripheral vascular disease|Thromboembolism|Acute coronary syndrome|Deep vein thrombosis|Coronary artery disease,1078|260|325|3258|574|80,Disseminated intravascular coagulation|Heparin induced thrombocytopenia|Congestive heart failure|Inflammatory disease|Proteinuria,103|1271|1559|188|277,Bayer AG|Janssen Pharmaceuticals Inc|Bayer China Co Ltd|Bayer Zydus Pharma Private Limited|Bayer Yakuhin Ltd,14455|25863|14469|1195010|14557,Johnson & Johnson,17332,Bayer AG,14455,,,,,,
3268,Engerix B,"Engerix B|GenHevac|HBV vaccine, SB|hepatitis B vaccine, SB|Engerix-B Junior|Engerix-B Kinder",Trade Name|Trade Name|Trade Name|Trade Name,Infection,,,Prophylactic vaccine|Protein subunit vaccine,12378|12372,Hepatitis B virus infection,152,,,GlaxoSmithKline plc,28355,SmithKline Beecham plc,19962,SmithKline Beecham plc,19962,,,,,,
32714,"recombinant human mannan-binding lectin (infection prevention), Helion","MBL replacement therapy, NatImmune|recombinant human mannan-binding protein, NatImmune/Enzon|rhMBL, NatImmune/Enzon|rhMBL, NatImmune|recombinant human mannan-binding lectin (infection prevention), Helion|EZN-2232",Research Code,Infection,Lectin mannose binding protein stimulator,58499,Antimicrobial,1593,Infectious disease,746,,,Helion Biotech ApS,1043533,Enzon Pharmaceuticals Inc|Azanta Danmark A/S,16045|28500,Azanta Danmark A/S,28500,,,,,,
32791,ABT-510,"DI-TSP|ABT-510|ABT-526|DI-TSPa|thrombospondin-1 peptide mimetics, Abbott",Research Code|Analogue|Research Code,Cancer,Platelet glycoprotein 4 stimulator,5129,Angiogenesis inhibitor|Anticancer,61|1545,,,Non-small-cell lung cancer|Lymphoma|Melanoma|Soft tissue sarcoma|Metastatic renal cell carcinoma|Head and neck tumor|Cancer|Solid tumor,1262|203|205|3378|4250|623|651|725,,,Abbott Laboratories,13601,Abbott Laboratories,13601,,,,,,
32980,mapatumumab,"TI-1|HGS-ETR1|TRAIL-R1 mAb, HGS|TRAIL-R1 mAb, HGS/Takeda|TRAIL receptor-1 mAbs, HGS|mapatumumab|Trail-R1 mAb|TRM-1|TAK-799",Research Code|USAN|INN|Research Code|Research Code,Cancer,TRAIL-1 receptor agonist,8229,Anticancer monoclonal antibody|Apoptosis stimulator,55685|1589,,,Non-small-cell lung cancer|Hepatocellular carcinoma|Multiple myeloma|Non-Hodgkin lymphoma|Uterine cervix tumor|Cancer|Solid tumor|Colorectal tumor,1262|1767|1828|319|427|651|725|989,,,Human Genome Sciences Inc|Takeda Pharmaceutical Co Ltd|Cambridge Antibody Technology Group plc|GlaxoSmithKline plc,17002|20300|24236|28355,Cambridge Antibody Technology Group plc,24236,,,,,,
3311,bicalutamide,bicalutamide|Casodex|Cosudex|ICI-176334|ICI176334-1,BANN|INN|Trade Name|Research Code|Research Code,Cancer,Androgen receptor antagonist,60,Anticancer,1545,Hormone dependent prostate cancer|Metastatic breast cancer,3247|3657,,,Juvise Pharmaceuticals|Alvogen Korea|AstraZeneca plc|ANI Pharmaceuticals Inc,1202144|1109820|14190|27120,Zeneca Group plc,16955,AstraZeneca plc,14190,,,,,,
33117,lucatumumab,"12.12|anti-CD40 MAbs, Chiron/Xoma|anti-CD40 monoclonal antibodies, Chiron/Xoma|CHIR-12.12|anti-CD40 MAbs, Novartis/Xoma|anti-CD40 monoclonal antibodies, Novartis/Xoma|HCD-122|lucatumumab",Research Code|Research Code|Research Code|USAN|PINN,Cancer|Dermatologic,CD40 ligand receptor antagonist,5142,Macrophage inhibitor|Systemic antipsoriatic product|Dendritic cell inhibitor|B-lymphocyte inhibitor|Immunosuppressant|Anticancer monoclonal antibody|Anti-inflammatory,7750|15184|173473|7740|396|55685|2953,,,Hodgkins disease|Chronic lymphocytic leukemia|Follicle center lymphoma|Multiple myeloma|Psoriasis|B-cell lymphoma|Non-Hodgkin lymphoma,161|1734|1745|1828|281|316|319,,,Chiron Corp|XOMA Corp|Novartis AG,15385|20954|23137,Chiron Corp,15385,,,,,,
3313,fulvestrant,ICI-182780|fulvestrant|Faslodex|ZD-182780|ZM-182780|Faslodext|ZD-9238,Research Code|BAN|INN|Trade Name|Research Code|Research Code|Trade Name|Research Code,Cancer|Endocrine/Metabolic|Genitourinary/Sexual Function|Inflammatory,Estrogen receptor antagonist,286,Anticancer hormone antagonist|Anticancer,62254|1545,Precocious puberty|Fallopian tube cancer|Peritoneal tumor|Metastatic breast cancer|Metastatic ovary cancer,1233|2243|3083|3657|3866,Fibrosis|Endometriosis|Uterus tumor,1127|113|740,AstraZeneca plc,14190,Zeneca Group plc,16955,AstraZeneca plc,14190,,,,,,
3321,anastrozole,anastrozole|Arimidex|ICI-D-1033|ZD-1033|D-1033,BANN|INN|Trade Name|Research Code|Research Code|Research Code,Cancer|Genitourinary/Sexual Function|Musculoskeletal,Aromatase inhibitor,76,Anticancer|Non-steroid hormone receptor antagonist,1545|1129,Endometrioid carcinoma|Metastatic breast cancer|Breast tumor|Ovary tumor,1705|3657|49|799,Infertility|Female infertility|Polyostotic fibrous dysplasia,1079|1080|3633,Juvise Pharmaceuticals|AstraZeneca plc|ANI Pharmaceuticals Inc|Alvogen Korea,1202144|14190|27120|1109820,Zeneca Group plc|Merck Serono SA,16955|19862,Zeneca Group plc,16955,,,,,,
3323,raltitrexed,ZD-1694|D-1694|ICI-D-1694|TDX|raltitrexed|Tomudex,Research Code|Research Code|Research Code|USAN|BAN|Trade Name,Cancer,Thymidylate synthase inhibitor,372,Folate synthesis inhibitor|Anticancer antimetabolite,553|1569,Colorectal tumor,989,Mesothelioma|Pancreas tumor|Solid tumor|Ovary tumor,1240|249|725|799,AstraZeneca plc|Zeneca Group plc|Hospira Inc,14190|16955|1010293,BTG plc|Institute of Cancer Research UK,15266|21072,AstraZeneca plc,14190,,,,,,
3342,LymphoScan,"LymphoScan|99mTc-ImmuRAID-LL2|99mTc-bectumomab, Immunomedics|technetium-99m-bectumomab, Immunomedics",Trade Name,Cancer,B-lymphocyte cell adhesion molecule modulator,5089,Immune diagnostic agent|Imaging agent|Radioimmunodiagnostic|Neoplasm diagnostic agent,7215|4155|4405|7220,,,Non-Hodgkin lymphoma,319,,,Immunomedics Inc|Adria Laboratories Inc,17204|18918,Immunomedics Inc,17204,,,,,,
33476,TG-4010,"TG-4010|MVA-Muc1-IL-2|MVA-TG-9931 (frozen suspension)|MUC1/IL-2 antigen therapy (gene transfer system, cancer), Transgene",Research Code,Cancer,IL2 gene stimulator|Mucin 1 modulator,1653|32076,Anticancer|Pox virus based gene therapy|Therapeutic vaccine|Recombinant viral vector vaccine,1545|4785|12379|12370,Prostate tumor|Metastatic renal cell carcinoma,276|4250,Non-small-cell lung cancer|Breast tumor|Lung tumor,1262|49|755,Transgene SA,23924,,,Transgene SA,23924,,,,,,
33494,milademetan monotosylate monohydrate,"E-2 ubiquitin ligase inhibitors, Rigel/Daiichi|E-3 ubiquitin ligase inhibitors, Rigel/Daiichi|ubiquitination pathway inhibitors (cancer/inflammation), Rigel/Daiichi|ubiquitination pathway inhibitors (cancer), Daiichi|DS-3032|DS-3032b|milademetan|milademetan monotosylate monohydrate|RAIN-32",Research Code|Research Code|INN|Research Code,Cancer|Inflammatory,Ubiquitin ligase inhibitor|E3 ubiquitin protein ligase MDM2 inhibitor,2965|51304,Anti-inflammatory|Synergist|Anticancer,2953|7293|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Sarcoma|Lymphoma|Hematological neoplasm|Liposarcoma|Advanced solid tumor,1272|1731|194|203|2054|2447|3713,Multiple myeloma|Inflammatory disease|Soft tissue sarcoma|Cancer,1828|188|3378|651,Rain Therapeutics Inc,1163708,Daiichi Sankyo Co Ltd|Daiichi Seiyaku Co Ltd|Rigel Pharmaceuticals Inc,1017506|15593|25471,Rigel Pharmaceuticals Inc,25471,,,,,,
3352,ING-1,"ING-1|ING-1 (heMAb)|ING-1 mAb, XOMA",Research Code|Research Code,Cancer,EpCAM modulator,14553,Anticancer monoclonal antibody,55685,,,Cancer,651,,,XOMA Corp,20954,XOMA Corp,20954,,,,,,
33591,lapatinib,lapatinib ditosylate|GW-572016|lapatinib|572016|GW-2016|GW-572016F|lapatinib ditosylate (USAN)|lapatinib ditosylate monohydrate|Tyverb|Tykerb,USAN|Research Code|INN|Research Code|Research Code|Research Code|USAN|Trade Name|Trade Name,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3756|740,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Glioblastoma|Pancreas tumor|Metastatic breast cancer|Breast tumor|Colorectal tumor,1262|2454|249|3657|49|989,Esophagus tumor|Stomach tumor|Renal cell carcinoma|Acoustic neuroma|Squamous cell carcinoma|Neurofibromatosis type II|Advanced solid tumor|Bladder tumor|Metastatic renal cell carcinoma|Uterine cervix tumor|Head and neck tumor|Cancer|Solid tumor|Lung tumor,1011|127|1766|2464|307|3522|3713|42|4250|427|623|651|725|755,Eddingpharm Inc|Novartis AG,1056888|23137,GlaxoSmithKline plc,28355,GlaxoSmithKline plc,28355,,,,,,
33630,enzastaurin,"LY-317615|317615.2HCl|enzastaurin|PKC-beta inhibitor, Lilly|enzastaurin hydrochloride|DB-102|Kinenza|AR-101",Research Code|USAN|INN|USAN|Research Code|Trade Name|Research Code,Cancer|Hematologic|Musculoskeletal,Protein kinase C beta inhibitor,3934,Angiogenesis inhibitor|Anticancer protein kinase inhibitor|Apoptosis stimulator,61|62255|1589,Diffuse large B-cell lymphoma|Ehlers Danlos syndrome|Glioblastoma,1749|2021|2454,Glioma|Small-cell lung cancer|Non-small-cell lung cancer|Macroglobulinemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Cutaneous T-cell lymphoma|Multiple myeloma|Peritoneal tumor|T-cell lymphoma|B-cell lymphoma|Hormone refractory prostate cancer|Metastatic renal cell carcinoma|Breast tumor|Carcinoma|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,1108|1261|1262|1264|1734|1744|1745|1754|1828|3083|311|316|3246|4250|49|54|651|725|799|989,Aytu BioScience Inc|Denovo Biopharma LLC,1108165|1076271,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
3364,peginterferon alfa-2b,"peginterferon alfa-2b|PEG-Intron|Sch-54031|PEG-Intron A|PEG-Intron and Rebetol combination|PEG-interferon alfa 2b, Enzon/Schering-Plough|PEG-interferon alfa-2b and ribavirin combination|Pegetron|Sylatron|ViraferonPeg|Cylatron|PegIntron|PEG-IFN alfa-2b|SCH-054031|Redipen",INN|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code,Cancer|Hematologic|Infection,Interferon alpha 2 ligand,214,Viral replication inhibitor|Anticancer,1532|1545,Hepatitis B virus infection|Hepatitis C virus infection|HIV-1 infection|Cholangiocarcinoma|Melanoma|Myelofibrosis,152|153|159|1765|205|2436,Chronic myelocytic leukemia|Viral infection|Metastatic renal cell carcinoma|Cancer|Solid tumor,1735|344|4250|651|725,Schering-Plough Corp|Merck & Co Inc,19711|18077,Enzon Pharmaceuticals Inc,16045,Enzon Pharmaceuticals Inc,16045,,,,,,
3365,Actimmune,"Imukin|Immukine|Imuforgamma|interferon (gamma1b), Toray|interferon gamma, Connetics|interferon (gamma1b), Daiichi|interferon (gamma1b), Genentech|interferon (gamma1b), Boehringer|interferon gamma, Connective Therapeutics|Actimmune|Immukin|interferon gamma-1b|DasKloster 1001-01|DK-1001, mondoBIOTECH|DK-1001, THERAMetrics|Imukine|interferon gamma-1b, Horizon/Clinigen",Trade Name|Trade Name|USAN|BANN|INN|Research Code|Research Code|Research Code|Trade Name,Cancer|Dermatologic|Gastrointestinal|Hematologic|Infection|Musculoskeletal|Neurology/Psychiatric|Respiratory,TGF beta receptor antagonist|Interferon gamma ligand|IL-4 receptor antagonist,377|51201|225,Collagen synthesis modulator|Anti-inflammatory|Anticancer hormone|Topical antipruritic product|Fibrosuppressant|Fungicide|RNA synthesis inhibitor|Viral replication inhibitor|Antibacterial|Antiparasitic|Anticancer protein kinase inhibitor,858|2953|62253|15180|664|1748|439|1532|1594|2638|62255,Osteopetrosis|Chronic granulomatous disease,1265|3074,Atopic dermatitis|Fungal infection|Cutaneous T-cell lymphoma|Renal cell carcinoma|Cryptococcus neoformans meningitis|Leishmania tropica infection|Liver disease|Mycobacterium infection|Mycobacterium tuberculosis infection|Friedreich ataxia|Asthma|Non-Hodgkin lymphoma|Metastatic bladder cancer|Metastatic breast cancer|Idiopathic pulmonary fibrosis|Solid tumor|Ovary tumor|Cystic fibrosis|Dermatological disease|Renal tumor,1102|124|1754|1766|1813|197|201|218|221|2974|31|319|3466|3657|3771|725|799|88|95|999,Clinigen Group plc|Horizon Therapeutics plc,1062207|1053335,Vidara Therapeutics LLC|Boehringer Ingelheim International GmbH|Connetics Corp|Genentech Inc|Maxygen LLC|InterMune Inc|Relief Therapeutics Holding AG,1067362|14881|15530|19453|24820|26430|29586,Genentech Inc,19453,,,,,,
33716,"CB-001, ViaCell","CB-001, ViaCell|stem cells, ViaCell",Research Code,Cancer|Endocrine/Metabolic,,,Anticancer,1545,,,Myelodysplastic syndrome|Multiple myeloma|Leukemia|Lymphoma|Insulin dependent diabetes,1272|1828|199|203|836,,,ViaCell Inc,28648,ViaCell Inc,28648,,,,,,
3373,pegilodecakin,"ilodecakin|Sch-52000|Tenovil|IL-10, Schering-Plough|rHuIL-10, Schering-Plough|interleukin-10, Schering-Plough|pegilodecakin|peg-IL-10|PEGylated human IL-10|AM-0010|LY-3500518",USAN|INN|Research Code|Trade Name|USAN|INN|Research Code|Research Code,Cancer|Cardiovascular|Dermatologic|Endocrine/Metabolic|Gastrointestinal|Hematologic|Immune|Infection|Inflammatory,Interleukin-10 ligand|IL-10 receptor agonist,12505|485,Anti-inflammatory|Vasoprotectant|Anticancer|Systemic antipsoriatic product|Antiviral,2953|2660|1545|15184|991,,,Reperfusion injury|Fibrosis|Non-small-cell lung cancer|Hepatitis|HIV infection|Hypercholesterolemia|Renal cell carcinoma|Inflammatory disease|Inflammatory bowel disease|Melanoma|Multiple sclerosis|Pancreas tumor|Non-alcoholic steatohepatitis|Psoriasis|Rheumatoid arthritis|Thrombocytopenia|Atherosclerosis|Ulcerative colitis|Viral infection|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Transplant rejection|Endotoxic shock|Cancer|Crohns disease|Colorectal tumor,1024|1127|1262|154|158|174|1766|188|189|205|213|249|2637|281|291|324|33|337|344|3665|3669|515|596|651|84|989,,,ARMO BioSciences Inc|Merck & Co Inc|Schering-Plough Corp,1088689|18077|19711,Schering-Plough Corp,19711,,,,,,
3374,oprelvekin,"oprelvekin|Neumega|YM-294|O-rhIL-11, Wyeth BioPharma|rhIL-11, Genetics Inst/Yamanouchi/Schering-Plough|interleukin-11, Genetics Inst/Yamanouchi/Schering-Plough",USAN|INN|Trade Name|Research Code,Dermatologic|Gastrointestinal|Hematologic|Immune,IL-11 receptor agonist|PDGF receptor agonist,486|547,Immunostimulant|Systemic antipsoriatic product,393|15184,Thrombocytopenia,324,Colitis|Von Willebrands disease|Psoriasis|Rheumatoid arthritis|Crohns disease,1072|1229|281|291|84,Wyeth Pharmaceuticals|Wyeth BioPharma,14199|20511,Pfizer Inc|Schering-Plough Corp|Yamanouchi Pharmaceutical Co Ltd,18767|19711|20967,Wyeth BioPharma,20511,,,,,,
34039,anamorelin,"RC-1291|ghrelin agonist, Rejuvenon|NSAC, Rejuvenon/Novo Nordisk|growth hormone secretagogues, Rejuvenon/Novo Nordisk|ghrelin agonist, Helsinn|NSAC, Sapphire/Novo Nordisk|growth hormone secretagogues, Sapphire/Novo Nordisk|anamorelin hydrochloride|RC-1291 HCl|RC-1291 hydrochloride|anamorelin|ONO-7643|ONO-07643|gastrointestinal system agent (tablet/oral formulation, aging/bone injury/anorexia nervosa/cachexia), Ono|Adlumiz",Research Code|USAN|Research Code|Research Code|INN|Research Code|Research Code|Trade Name,Musculoskeletal|Other/Miscellaneous,Ghrelin receptor agonist,7793,Gastrointestinal system agent|Steroid agonist|Appetite stimulator,1332|714|1839,Appetite loss|Cachexia|Fatigue,3038|425|829,Aging|Bone injury,1042|1091,CSC Pharmaceuticals Handels GmbH|Chugai Pharmaceutical Co Ltd|Gen Ilac|Helsinn Healthcare SA|Italfarmaco SpA|Specialised Therapeutics Australia Pty Ltd|Bial-Portela & Ca Sa|Helsinn Therapeutics Inc|Mundipharma International Corp Ltd|Stendhal International|Ono Pharmaceutical Co Ltd,26416|15414|1063033|27361|17278|1044298|1043896|1045202|1045514|1060314|18681,Novo Nordisk A/S|Sapphire Therapeutics Inc,18614|28717,Novo Nordisk A/S,18614,,,,,,
34085,"tanespimycin (HALT technology), Biogen","EC4|EC-5|EC-69|EC-71|HSP90 modulators (HALT technology), Conforma|17-AAG|CNF-1010|CNF-1010, Conforma|CNF-1010, Biogen|tanespimycin|tanespimycin (HALT technology), Biogen",Research Code|Research Code|Research Code|Research Code|Metabolite|Metabolite|USAN|INN|Metabolite,Cancer,Hsp 90 inhibitor,8012,Anticancer,1545,,,Chronic myelocytic leukemia|Solid tumor,1735|725,,,Biogen Inc|Conforma Therapeutics Corp,1005244|28712,Conforma Therapeutics Corp,28712,,,,,,
3411,itraconazole,itraconazole|oriconazole|R-51211|Sporanox|Oromyc|Intiazol|Itorizoru|JK-1211|Sporal|Itranax|Itrizol|Sempera|Itrizole|Itrizole Injection 1%|Orungal,USAN|BAN|INN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Dermatologic|Infection,Lanosterol-14 demethylase inhibitor,777,Ergosterol synthesis inhibitor|Systemic dermatological antifungal product|Fungicide,161|15178|1748,Fungal infection|Candida infection|Histoplasma infection|Blastomyces infection|Epidermophyton infection|Microsporum infection|Fungal respiratory tract infection|Onychomycosis|Fungal urinary tract infection|Fungal meningitis|Cryptococcus neoformans meningitis|Dermatophytosis|Pityriasis|Tinea corporis|Tinea cruris|Tinea pedis|Aspergillus infection|Trichophyton infection|Cryptococcus infection,124|1308|1320|1322|1326|1327|1486|1775|1799|1805|1813|2080|2151|2427|2428|2429|29|334|85,,,Johnson & Johnson,17332,Janssen-Cilag Ltd,17392,Johnson & Johnson,17332,,,,,,
34140,blinatumomab,"CD19XCD3|bscCD19xCD3 (cancer, BiTE), Micromet/MedImmune|anti-CD3/anti-CD19 bispecific T-cell engager (BiTE, acute lymphoblastic leukemia), Amgen/Astellas|MT-103 (cancer, BiTE), Micromet/MedImmune|MEDI-538|blinatumomab|MT-103, MedImmune|blinatumomab (cancer, BiTE), Micromet/MedImmune|bscCD19xCD3 (cancer, BiTE), Amgen|MT-103 (cancer, BiTE), Amgen|AMG-103|Blincyto|L01XC19",Research Code|USAN|INN|Research Code|Trade Name|Research Code,Cancer,CD3 modulator|B-lymphocyte antigen CD19 modulator,5023|5080,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator|Anticancer antibody,393|55685|7761|55684,B-cell acute lymphoblastic leukemia|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1729|1749|319,Chronic lymphocytic leukemia|Leukemia|Cancer,1734|199|651,Astellas Pharma Inc|Dr Reddy's Laboratories Ltd|Amgen KK (AABP)|BeiGene Co Ltd|Amgen Inc,1013295|29387|1089961|1063251|14109,Micromet Inc|MedImmune LLC|Amgen Research (Munich) GmbH,1020809|18008|21737,Amgen Research (Munich) GmbH,21737,,,,,,
3416,satraplatin,"BMS-182751|BMY-45594|JM-216|satraplatin|POplat|JM-118|JM-383|JM-518|diacetatodichloroplatinum compound (cancer), GPC Biotech/Yakult Honsha/Celgene|Orplatna|diacetatodichloroplatinum compound (cancer), Agennix/Yakult Honsha/Celgene",Research Code|Research Code|Research Code|USAN|INN|Research Code|Metabolite|Research Code|Metabolite|Research Code|Metabolite|Trade Name,Cancer,,,Anticancer alkylating agent|Anticancer,50|1545,,,Rectal tumor|Hormone refractory prostate cancer|Breast tumor|Carcinoma|Head and neck tumor|Cancer|Solid tumor|Lung tumor|Brain tumor|Ovary tumor,1055|3246|49|54|623|651|725|755|760|799,,,Agennix AG|Bristol-Myers Squibb Co|Bristol-Myers Squibb KK|Celgene Corp|Johnson Matthey plc|Yakult Honsha Co Ltd|GPC Biotech AG|NeoOncoRx Inc|Pharmion Corp,13765|15065|15134|15331|17609|20961|25202|28221|29253,Johnson Matthey plc,17609,,,,,,
34201,ALT-836,"Sunol-cH36|Factor X binding inhibitor, Sunol|IgG4 antibody (cardiovascular disease), Sunol|tissue factor monoclonals (cardiovascular disease), Sunol|TNX-832|ALT-836|tissue factor antagonist antibodies (acute respiratory distress syndrome/acute lung injury), Genentech/Altor|TF antagonist antibodies (acute respiratory distress syndrome/acute lung injury), Genentech/Altor|tissue factor antagonist antibodies (ARDS/ALI), Genentech/Altor|TF antagonist antibodies (ARDS/ALI), Genentech/Altor",Research Code|Research Code|Research Code,Cancer|Cardiovascular|Gastrointestinal|Infection|Respiratory,Tissue factor inhibitor,8039,Anticancer monoclonal antibody|Blood clotting modulator|Anti-inflammatory|Respiratory system agent,55685|986|2953|1470,,,Sepsis|Inflammatory bowel disease|Celiac disease|Acute lung injury|Cardiovascular disease|Cancer|Solid tumor|Respiratory distress syndrome,114|189|2539|2998|57|651|725|8,,,Altor BioScience Corp|Genentech Inc|Tanox Inc|Sunol Molecular Corp,1007204|19453|20318|25845,Sunol Molecular Corp,25845,,,,,,
3422,ketorolac,ketorolac|RS-37619|ketorolac tromethamine|BDPC|BPPC|Droal|Tonum|Findol|Lixidol|Toratex|Tora-Dol|Toradol IM|Toradol Oral,BAN|INN|Research Code|USAN|Trade Name|Trade Name|Trade Name,Neurology/Psychiatric,Cyclooxygenase inhibitor|Oxidoreductase inhibitor,132|406,Non-steroidal anti-inflammatory|Analgesic|Prostaglandin synthesis inhibitor,2955|2946|329,Pain,20,,,Atnahs Pharma UK Limited,1123655,Roche Holding AG|Roche Palo Alto|Dong Kook Pharmaceutical Co Ltd|Recordati SpA,19446|19470|21257|24154,Roche Palo Alto,19470,,,,,,
34281,Prevnar 13,"11vPnC, Pfizer|13vPnC, Pfizer|11vPnC, Wyeth-Lederle|13vPnC, Wyeth-Lederle|multivalent pneumococcal vaccines, Wyeth|multivalent pneumococcal vaccines, Wyeth-Lederle|13-valent pneumococcal conjugate vaccine, Pfizer|Prevnar 13|PCV-13|Prevenar 13|Prevnar 13 Infant|Prevnar 13 Adult|PF-05208760",Research Code|Trade Name|Research Code,Infection|Inflammatory,,,Anti-inflammatory|Prophylactic vaccine|Polysaccharide subunit vaccine,2953|12378|12373,Sepsis|Bacterial meningitis|Bacterial pneumonia|Streptococcus pneumoniae infection|Otitis media,114|1803|1815|313|394,,,Pfizer Inc,18767,Pfizer Vaccines,25584,Pfizer Vaccines,25584,,,,,,
34283,BMS-275183,"BMS-275183|oral taxane (cancer), Bristol-Myers Squibb|oral taxane (cancer), BMS|BMS-198246",Research Code|Research Code,Cancer,,,Microtubule stabilizer|Anticancer,2576|1545,,,Non-small-cell lung cancer|Cancer,1262|651,,,Bristol-Myers Squibb Co,15065,Bristol-Myers Squibb Co,15065,,,,,,
34323,talabostat,"PT-100|boroproline compounds, Point Therapeutics|Val-boro-Pro|talabostat|talabostat mesylate|boroproline compounds, DARA BioSciences",Research Code|Research Code|USAN|INN|USAN,Cancer|Hematologic,Seprase inhibitor|Dipeptidyl peptidase VIII inhibitor|Dipeptidyl peptidase IX inhibitor|Dipeptidyl peptidase IV inhibitor,10910|21597|21600|5537,Anticancer|DPP IV inhibitor antidiabetic product|Metastasis inhibitor,1545|38439|695,Non-small-cell lung cancer|Hematological disease|Chronic lymphocytic leukemia|Neutropenia|Melanoma|Pancreas tumor|Non-Hodgkin lymphoma|Renal tumor,1262|142|1734|1991|205|249|319|999,Cancer,651,Fortovia Therapeutics Inc,25179,Tufts University School of Medicine,22727,Tufts University School of Medicine,22727,,,,,,
3472,alvocidib,alvocidib|HMR-1275|flavopiridol|L-868275|NSC-649890|MDL-107826A|alvocidib hydrochloride|DSP-2033,USAN|PINN|Research Code|Research Code|Research Code|Research Code|USAN|Research Code,Cancer,Cyclin-dependent kinase-6 inhibitor|Cyclin-dependent kinase-4 inhibitor|Mcl-1 differentiation protein inhibitor|Cyclin-dependent kinase-9 inhibitor,4318|4314|11381|8110,Apoptosis stimulator|Anticancer protein kinase inhibitor|Synergist,1589|62255|7293,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,Esophagus tumor|Stomach tumor|Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Multiple myeloma|Lymphoma|Prostate tumor|Germ cell and embryonic cancer|Metastatic renal cell carcinoma|Cancer|Solid tumor|Lung tumor|Colon tumor,1011|127|1728|1734|1828|203|276|3737|4250|651|725|755|767,SDP Oncology,1216786,Sanofi SA|Tolero Pharmaceuticals Inc|National Cancer Institute (NCI)|Aventis Pharma AG|Hoechst Marion Roussel Inc,1009547|1069667|20519|25218|25224,National Cancer Institute (NCI),20519,,,,,,
3474,lamivudine,(-)-BCH-189|Epivir-HBV|Epivir|GR-109714X|Heptovir|lamivudine|Zeffix|Zefix|3TC|GG-714|BCH-790|NGPB-21|Heptodin|GR-103665|GR-109714,Research Code|Trade Name|Trade Name|Research Code|Trade Name|USAN|BAN|INN|Trade Name|Trade Name|Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code|Research Code,Infection,HIV-1 reverse transcriptase inhibitor|DNA polymerase inhibitor|Nucleoside reverse transcriptase inhibitor|RNA DNA polymerase inhibitor,1016|138|1832|551,HIV replication inhibitor|Antiviral,747|991,Hepatitis B virus infection|HIV infection,152|158,,,Glaxo Group Ltd|GlaxoSmithKline plc|Glaxo Group Research Ltd|ViiV Healthcare Ltd,16453|28355|27053|1050515,Shire BioChem Inc|GlaxoSmithKline Inc,14691|21948,Shire BioChem Inc,14691,,,,,,
34744,BMS-986253,"MDX-018|HuMax-Inflam|anti-inflammatory antibody, Medarex/Genmab|anti-inflammatory therapeutic, Genmab/Medarex|HuMax-IL8|BMS-986253|BMS-968253|IL-8 targeting antibody (intravenous, hematological neoplasm/COVID-19 associated respiratory disease), Bristol-Myers Squibb",Research Code|Trade Name|Research Code|Research Code,Cancer|Dermatologic|Immune|Infection|Inflammatory|Respiratory,IL-8 receptor antagonist,1580,Systemic antipsoriatic product|Antiviral|Anticancer monoclonal antibody|Anticancer|Anti-inflammatory|Respiratory system agent,15184|991|55685|1545|2953|1470,Coronavirus disease 19 infection|Non-small-cell lung cancer|Hepatocellular carcinoma|Inflammatory disease|Hematological neoplasm|Glioblastoma|Psoriasis|Squamous cell carcinoma|Larynx tumor|Hormone dependent prostate cancer|Stage IV melanoma|Autoimmune disease|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Respiratory disease|Mouth tumor|Pharynx tumor|Nasopharynx tumor,10406|1262|1767|188|2054|2454|281|307|3198|3247|3257|36|3673|3713|4250|711|793|794|795,Breast tumor|Cancer|Solid tumor,49|651|725,Bristol-Myers Squibb Co|Genmab A/S,15065|26469,Cormorant Pharmaceuticals|Medarex Inc,1075018|17968,Medarex Inc,17968,,,,,,
34867,"HER-2 peptide vaccine (cancer), Imugene","MVF HER2|HER-2 316-339|HER-2 628-647|cancer vaccine, Ohio State University|peptide vaccines, Ohio State University|HER-2 peptide vaccine (cancer), Ohio State University|trastuzumab like and pertuzumab-like HER-2 vaccine (cancer), Ohio State University|HER-2 peptide vaccine (cancer), Imugene|B-Vaxx|MVF HER-2 (597-626)|MVF HER-2 (266-296)",Research Code|Analogue|Research Code|Analogue|Research Code,Cancer,Erbb2 tyrosine kinase receptor inhibitor,3756,Therapeutic vaccine|Anticancer protein kinase inhibitor,12379|62255,Gastrointestinal stromal tumor|Breast tumor|Colon tumor|Ovary tumor,3205|49|767|799,Cancer,651,Imugene Ltd,1037404,Ohio State University,20649,Ohio State University,20649,,,,,,
3488,leflunomide,leflunomide|HWA-486|Arava|RS-34821|RS-61980,INN|Research Code|Trade Name|Research Code|Research Code|Metabolite,Immune,Dihydroorotate dehydrogenase inhibitor|Protein tyrosine kinase inhibitor,1716|385,Anti-inflammatory|Immunosuppressant,2953|396,Psoriatic arthritis|Rheumatoid arthritis,1781|291,Multiple sclerosis|Transplant rejection,213|515,Aventis Pharma AG|Aventis SA|Sanofi SA,25218|27254|1009547,Kyorin Pharmaceutical Co Ltd|Hoechst Marion Roussel Inc,17719|25224,Aventis Pharma AG,25218,,,,,,
3490,cladribine,cladribine|RWJ-26251|2-CdA|Leustatin|2-chlorodeoxyadenosine|NSC-105014F|Litak|Leustat,USAN|INN|Research Code|Trade Name|Research Code|Trade Name|Trade Name,Cancer|Immune,Adenosine deaminase inhibitor,24,Anticancer|Anti-inflammatory,1545|2953,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Hairy cell leukemia|Lymphoplasmacytic lymphoma|Lymphoma,1731|1734|1736|1743|203,Multiple sclerosis|Rheumatoid arthritis,213|291,Janssen Pharmaceutica NV|Ortho Biotech Products LP|Janssen-Cilag Ltd,17421|17570|17392,IVAX Corp|Scripps Research Institute,17284|21102,Scripps Research Institute,21102,,,,,,
3492,levofloxacin,"(-)-ofloxacin|(S)-ofloxacin|DR-3355|levofloxacin|Cravit|HR-355|DL-8280|Tavanic|Levaquin|Levoquin|ORF-18489|levofloxacin (oral, bacterial infection), Daiichi Seiyaku|levofloxacin (injectable, bacterial infection), Daiichi Sankyo|Cravit IV",Research Code|INN|Trade Name|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Research Code|Trade Name,Dermatologic|Gastrointestinal|Genitourinary/Sexual Function|Infection|Inflammatory|Respiratory,DNA gyrase inhibitor|Topoisomerase IV inhibitor,431|9320,Antibacterial|Systemic dermatological antibacterial product|Bacterial nucleic acid synthesis inhibitor,1594|15187|3984,Yersinia pestis infection|Legionella pneumophila infection|Acute bronchitis|Epididymitis|Bacterial urinary tract infection|Bacterial pneumonia|Cholecystitis|Mycobacterium tuberculosis infection|Cholangitis|Pyelonephritis|Acute sinusitis|Bacillus anthracis infection|Bacterial infection|Cystitis|Brucella infection|Peritonitis|Prostatitis|Bacterial skin infection,1397|1447|1487|1796|1798|1815|2019|221|2216|284|2999|39|40|403|424|452|473|485,Escherichia coli infection|Haemophilus influenzae infection|Moraxella catarrhalis infection|Streptococcus pyogenes infection|Enterococcus faecalis infection|Chlamydia pneumoniae infection|Klebsiella pneumoniae infection|Cellulitis|Pseudomonas aeruginosa infection|Staphylococcus aureus infection|Abscess|Streptococcus pneumoniae infection|Haemophilus parainfluenzae infection|Serratia marcescens infection|Enterobacter cloacae infection|Staphylococcus epidermidis infection|Mycoplasma pneumoniae infection|Staphylococcus saprophyticus infection|Pyoderma gangrenosum|Impetigo|Proteus mirabilis infection|Multidrug resistant infection,120|145|1455|1475|1482|1819|195|2525|280|308|3081|313|3261|3262|3269|3277|3318|3321|3517|401|456|758,CJ Corp|Daiichi Sankyo Co Ltd|Ranbaxy Laboratories Ltd|Sanofi SA|Daiichi Seiyaku Co Ltd|Johnson & Johnson,15473|1017506|21266|1009547|15593|17332,Kyowa Hakko Bio Co Ltd|First Pharmaceutical Sdn Bhd|Hoechst-Roussel Pharmaceuticals Inc,1043881|1066981|26078,Daiichi Seiyaku Co Ltd,15593,,,,,,
34985,milataxel,"MAC-321|TL-139 (injectable), Taxolog/Wyeth|MAC-321 (injectable), Taxolog/Wyeth|TL-00139 (injectable), Taxolog/Wyeth|milataxel|M-10|TL-00139|TL-139",Research Code|PINN|Research Code|Metabolite|Research Code|Research Code,Cancer,,,Microtubule stabilizer|Cell cycle inhibitor,2576|767,,,Non-small-cell lung cancer|Breast tumor|Cancer|Colorectal tumor,1262|49|651|989,,,Wyeth Pharmaceuticals|Taxolog Inc,14199|28852,Taxolog Inc,28852,,,,,,
3511,lometrexol,"lometrexol|LY-264618|lometrexol sodium|T-64|DDATHF|LY-249543|GARFT inhibitors, Lilly",BAN|INN|Research Code|USAN|Research Code|Research Code,Cancer,GAR transformylase inhibitor|Folate receptor antagonist,181|665,DNA synthesis inhibitor|Anticancer antimetabolite,140|1569,,,Non-small-cell lung cancer|Sarcoma|Melanoma|Breast tumor|Carcinoma|Head and neck tumor|Cancer,1262|194|205|49|54|623|651,,,Eli Lilly & Co|Tularik Inc,17810|20449,Eli Lilly & Co,17810,,,,,,
3516,loratadine,Claritin|loratadine|Loratidine|Sch-29851|Sch-434|Lisino|norata|Clarityn|Clarinase|Claritine|Clarityne|Fristamin|Claritin-D|Claritin EZ|Claritin-D 24|Claritin RediTabs|BAY-762211,USAN|BAN|INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code,Dermatologic|Immune|Inflammatory,Histamine H1 receptor antagonist,199,Systemic antipruritic product|Anti-inflammatory,15181|2953,Allergic rhinitis|Allergy|Pruritus|Urticaria|Rhinitis,1107|12|279|340|477,Eczema,109,Shionogi & Co Ltd|Bayer AG|Italfarmaco SpA,19898|14455|17278,Merck & Co Inc|Schering-Plough Corp,18077|19711,Schering-Plough Corp,19711,,,,,,
3517,losartan,losartan|E-3174|EXP-3174|losartan potassium|Cozaar|DUP-89|E-3340|MK-954|Avastar|DuP-753|Nu-Lotan|MK-0954|Cozaar Plus F|Entrizen,BANN|INN|Metabolite|Research Code|Metabolite|USAN|Trade Name|Research Code|Research Code|Research Code|Trade Name|Research Code|Trade Name|Research Code|Trade Name|Trade Name,Cardiovascular|Genitourinary/Sexual Function|Inflammatory,Angiotensin II AT-1 receptor antagonist|Angiotensin II receptor antagonist,788|64,Anti-inflammatory|Antihypertensive,2953|2657,Diabetic nephropathy|Fibrosis|Aortic aneurysm|Hypertension|Cardiac failure,100|1127|1607|178|55,,,Merck Sharp & Dohme Ltd|MSD Japan|Merck & Co Inc,18090|24019|18077,E I DuPont de Nemours & Co,15825,E I DuPont de Nemours & Co,15825,,,,,,
35340,cediranib,AZD-2171|cediranib|cediranib  maleate|Recentin|Zemfirza,Research Code|USAN|INN|USAN|Trade Name|Trade Name,Cancer,PDGF receptor beta antagonist|VEGF-3 receptor antagonist|VEGF-2 receptor antagonist|Kit tyrosine kinase inhibitor|VEGF-1 receptor antagonist,48492|3850|3848|3808|3846,Angiogenesis inhibitor|Anticancer protein kinase inhibitor,61|62255,Endometrioid carcinoma|Fallopian tube cancer|Peritoneal tumor|Ovary tumor,1705|2243|3083|799,Non-small-cell lung cancer|Acute myelogenous leukemia|Glioblastoma|Hormone refractory prostate cancer|Metastatic stomach cancer|Metastatic rectal cancer|Metastatic renal cell carcinoma|Breast tumor|Head and neck tumor|Solid tumor|Colorectal tumor,1262|1731|2454|3246|3666|3671|4250|49|623|725|989,AstraZeneca plc,14190,,,AstraZeneca plc,14190,,,,,,
3536,pemetrexed disodium,"LY-231514|pemetrexed disodium|pemetrexed|MTA|multitargeted antifolate, Lilly|Alimta|IND-40061|pemetrexed sodium hydrate|NSC-698037",Research Code|USAN|INN|INN|Trade Name|Research Code|Research Code,Cancer,GAR transformylase inhibitor|Thymidylate synthase inhibitor|Transferase inhibitor|DHFR inhibitor,181|372|374|135,Folate modulator|Anticancer antimetabolite|Anticancer,805|1569|1545,Mesothelioma|Metastatic bladder cancer|Metastatic non small cell lung cancer|Chordoma,1240|3466|3665|3736,Small-cell lung cancer|Stomach tumor|Biliary cancer|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Nasopharyngeal carcinoma|Osteosarcoma|Pancreas tumor|Gallbladder tumor|Hormone refractory prostate cancer|Metastatic stomach cancer|Breast tumor|Head and neck tumor|Solid tumor|Lung tumor|Ovary tumor|Colorectal tumor,1261|127|1516|1728|1731|1768|1772|249|3146|3246|3666|49|623|725|755|799|989,Eli Lilly & Co,17810,,,Eli Lilly & Co,17810,,,,,,
35419,pegargiminase,"Melanocid|ZK-207342|ADI-PEG-20|ADI-SS PEG 20,000 mw|PEGylated ADI, Phoenix|PEGylated arginine deiminase, Phoenix|PEGylated arginine deiminase, Schering AG/Phoenix|Hepacid|pegargiminase|ADI-SS",Trade Name|Research Code|Research Code|Trade Name|USAN|INN|Research Code,Cancer|Infection,Arginine deiminase stimulator,9822,Antiviral|Apoptosis stimulator|Radiosensitizer|Anticancer|Angiogenesis inhibitor|Synergist,991|1589|1542|1545|61|7293,Glioma|Mesothelioma|Non-small-cell lung cancer|Acute myelogenous leukemia|Hepatocellular carcinoma|Melanoma|Glioblastoma|Prostate tumor|Soft tissue sarcoma|Metastatic pancreas cancer|Advanced solid tumor|Uveal melanoma|Solid tumor,1108|1240|1262|1731|1767|205|2454|276|3378|3669|3713|3788|725,Small-cell lung cancer|Hepatitis C virus infection|Influenza virus infection|Hematological neoplasm|Pancreas tumor|Non-Hodgkin lymphoma|Viral infection|Metastatic breast cancer|Ovary tumor,1261|153|191|2054|249|319|344|3657|799,Polaris Pharmaceuticals Inc|TDW Pharmaceuticals,1039057|1045281,Bayer Schering Pharma AG|Phoenix Pharmacologics Inc,19687|25717,Phoenix Pharmacologics Inc,25717,,,,,,
3559,Oncolym,"Oncolym|LYM-1|LYM-2|90Y-Lym-1|ZK-207336|131I-LYM-1|67Cu-Lym-1|90Y-2IT-BAD-Lym-1|67Cu-2IT-BAT-Lym-1|131-I anti-HLA-DR10 mAB, Peregrine/Schering",Trade Name|Research Code|Research Code|Research Code|Research Code,Cancer,HLA class II antigen DRB1-10 beta inhibitor,19357,Anticancer monoclonal antibody|Radioimmunotherapeutic,55685|1552,,,B-cell lymphoma,316,,,Alpha Therapeutic Corp|Bayer Schering Pharma AG|Berlex Laboratories Inc|Avid Bioservices Inc,16577|19687|19693|20325,Avid Bioservices Inc,20325,,,,,,
35644,methoxy polyethylene glycol-epoetin beta,"R-744|Ro-50-3821|CERA, Roche/Nektar|CERA, Roche/Shearwater|second generation EPO, Roche|continuous erythropoietin receptor activator|Mircera|methoxy polyethylene glycol-epoetin beta|RG-744|epoetin beta pegol|epoetin beta pegol (genetic recombinant)|monopegylated epoetin beta|pegdarbepoetin beta|PEG-680-Ala-[30-Asn,32-Thr,87-Val,88-Asn,90-Thr]erythropoietin(human)-(1-165)",Research Code|Research Code|Trade Name|Research Code|INN,Genitourinary/Sexual Function|Hematologic,Erythropoietin receptor agonist,2501,Anti-inflammatory|Hematopoietic stimulator,2953|610,Anemia,17,Membranoproliferative glomerulonephritis,3840,Chugai Pharmaceutical Co Ltd|Vifor Pharma Group|Roche Holding AG,15414|16266|19446,Nippon Roche KK,19447,Roche Holding AG,19446,,,,,,
35729,tigatuzumab,"TRA-8|CS-1008|R-161460|DR5 mAb, Sankyo|DR5 mAb, Daiichi Sankyo|tigatuzumab",Research Code|Research Code|Research Code|INN,Cancer|Inflammatory,TRAIL-2 receptor agonist,8232,Macrophage inhibitor|Apoptosis stimulator|Anti-inflammatory|Anticancer monoclonal antibody,7750|1589|2953|55685,,,Non-small-cell lung cancer|Hepatocellular carcinoma|Pancreas tumor|Arthritis|Metastatic breast cancer|Cancer|Ovary tumor|Colorectal tumor,1262|1767|249|28|3657|651|799|989,,,Daiichi Sankyo Co Ltd|Daiichi Sankyo Inc|Sankyo Co Ltd|University of Alabama at Birmingham,1017506|1020322|19658|20524,University of Alabama at Birmingham,20524,,,,,,
35791,bavituximab,"3G4|9D2|anti-PS antibodies, University of Texas/Peregrine|anti-phosphatidylserine antibodies (VTA), Peregrine|anti-phosphatidylserine antibodies, University of Texas/Peregrine|bavituximab|Tarvacin|PGN-401|anti-PS antibodies, University of Texas/Avid Bioservices|anti-phosphatidylserine antibodies, University of Texas/Avid Bioservices",Research Code|Research Code|USAN|INN|Trade Name|Research Code,Cancer|Infection,Beta 2 glycoprotein 1 inhibitor,34768,Anticancer monoclonal antibody|Antiviral|Anticancer|Vascular damaging agent|Immunostimulant,55685|991|1545|2969|393,Hepatitis C virus infection|HIV infection|Hepatocellular carcinoma|Adenocarcinoma|Glioblastoma|Pancreas tumor|Hormone refractory prostate cancer|Stage IV melanoma|Viral infection|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Head and neck tumor|Solid tumor,153|158|1767|2399|2454|249|3246|3257|344|3657|3665|3666|3667|623|725,Cancer,651,OncXerna Therapeutics Inc,1160446,Avid Bioservices Inc|University of Texas System,20325|21864,University of Texas System,21864,,,,,,
35991,plinabulin,"phenylahistin|NPI-3001|NPI-3003|NPI-3004|NPI-3005|NPI-2352|NPI-2358|NPI-2386|NPI-2350a|halimide, UCSD/Nereus|phenylahistin series, Nereus|anti-microtubule agents (cancer), Nereus|anticancer agents (marine microbe-isolated), Nereus|halimide, Nereus|(S)-(-)-phenylahistin|NPI-2350|(-)-phenylahistin|KPU-2|KPU-02|KPU-35|plinabulin|halimide",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN,Cancer|Hematologic,Guanine nucleotide exchange factor stimulator|Tubulin receptor antagonist,10396|541,Microtubule inhibitor|Vascular damaging agent|Anticancer|Apoptosis stimulator|Angiogenesis inhibitor|Immunostimulant,2575|2969|1545|1589|61|393,Small-cell lung cancer|Non-small-cell lung cancer|Febrile neutropenia,1261|1262|3795,Cancer|Solid tumor,651|725,Dalian Wanchun Biotech|BeyondSpring Pharmaceuticals Inc,1076232|1092086,University of California San Diego|Nereus Pharmaceuticals Inc,25451|27672,University of California San Diego,25451,,,,,,
3610,meloxicam,meloxicam|Mobec|Mobic|Mobicox|Movalis|Movatec|Movicox|UH-AC-62-XX|UH-AE-62-XX,USAN|BAN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Research Code,Genitourinary/Sexual Function|Immune|Inflammatory|Musculoskeletal|Neurology/Psychiatric,Cyclooxygenase 2 inhibitor,1001,Prostaglandin synthesis inhibitor|Non-steroidal anti-inflammatory,329|2955,Pain|Osteoarthritis|Arthritis|Rheumatoid arthritis|Juvenile rheumatoid arthritis|Ankylosing spondylitis,20|245|28|291|3003|398,Dysmenorrhea,105,Abbott Laboratories|Boehringer Ingelheim International GmbH|Boehringer Ingelheim France SARL|Samil Pharmaceutical Co Ltd|Nippon Boehringer Ingelheim Co Ltd,13601|14881|22556|19562|22584,Daiichi Sankyo Co Ltd|Sumitomo Pharmaceuticals Co Ltd|Daiichi Seiyaku Co Ltd|Boehringer Ingelheim Korea Ltd,1017506|14911|15593|22562,Boehringer Ingelheim International GmbH,14881,,,,,,
36111,pidilizumab,"BAT antibody, CureTech|humanized immunomodulatory mAb, CureTech|StimuMab|CT-011|pidilizumab|BAT-1|MDV-9300",Research Code|USAN|INN|Research Code,Cancer|Infection,,,Anticancer monoclonal antibody|Anticancer|Antiviral,55685|1545|991,,,Glioma|Hepatitis C virus infection|Acute myelogenous leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|Hepatocellular carcinoma|Multiple myeloma|Hematological neoplasm|Prostate tumor|Stage IV melanoma|Cancer|Colorectal tumor,1108|153|1731|1745|1749|1750|1767|1828|2054|276|3257|651|989,,,Medivation Inc|Teva Pharmaceutical Industries Ltd|CureTech Ltd,1014884|20348|29045,CureTech Ltd,29045,,,,,,
36229,"MnSOD gene therapy (radiation exposure), University of Pittsburgh","VLTS-582|gene therapy (MnSOD), Valentis|gene therapy (manganese superoxide dismutase), Valentis|MnSOD gene therapy (radiation exposure), University of Pittsburgh|manganese superoxide dismutase gene therapy (radiation exposure), University of Pittsburgh",Research Code,Toxicity/Intoxication,Superoxide dismutase stimulator,479,Unspecified non-viral vector based gene therapy,4793,,,Radiation sickness,367,,,University of Pittsburgh-Office of Technology Management|Valentis Inc|University of Pittsburgh,1073057|14122|20659,University of Pittsburgh,20659,,,,,,
3634,mirtazapine,mepirzepine|mirtazapine|Org-3770|ME-2040|Remeron|Remeron Soltab|Zispin Soltab|Norset|Reflex|Promyrtil|Remergil|Zispin|Rexer|6-azamianserin,USAN|BAN|INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Musculoskeletal|Neurology/Psychiatric,5-HT 2 receptor antagonist|5-HT 3 receptor antagonist|Alpha 2 adrenoceptor antagonist,13|15|34,Antidepressant,2941,Fibromyalgia|Major depressive disorder,2527|4898,,,Meiji Seika Pharma Co Ltd|Dong Wha Pharmaceutical Co Ltd|Merck & Co Inc,18049|15745|18077,Organon International Inc|MSD OSS BV|Schering-Plough Corp,13807|13880|19711,MSD OSS BV,13880,,,,,,
36395,"ridaforolimus (intravenous), Merck & Co","AP-21626|AP-23573|mTOR inhibitors (cancer), ARIAD/Merck & Co|AP-23573 (intravenous), ARIAD/Merck & Co|deforolimus (intravenous), ARIAD/Merck & Co|deforolimus|MK-8669|ridaforolimus|ridaforolimus (intravenous), ARIAD/Merck & Co|ridaforolimus (intravenous), Merck & Co",Research Code|Research Code|Research Code|USAN|INN,Cancer,mTOR inhibitor,10240,Anticancer|Angiogenesis inhibitor|Smooth muscle cell proliferation inhibitor,1545|61|512,,,Glioma|Endometrioid carcinoma|Sarcoma|Leukemia|Lymphoma|Hormone refractory prostate cancer|Solid tumor,1108|1705|194|199|203|3246|725,,,ARIAD Pharmaceuticals Inc|Merck & Co Inc,14296|18077,ARIAD Pharmaceuticals Inc,14296,,,,,,
36433,mocetinostat dihydrobromide,"MG-4230|MG-4915|MG-5026|MGCD-0103|HDAC inhibitors (cancer), MethylGene|MGCD-0103 (oral), MethylGene/Taiho/Pharmion|histone deacetylase inhibitor (cancer), MethylGene/ Taiho/ Pharmion|MG-0103|MGCD-3650|histone deacetylase inhibitor (cancer), MethylGene/Taiho/Celgene|MGCD-0103 (oral), MethylGene/Taiho/Celgene|mocetinostat dihydrobromide|mocetinostat|MGCD-103",Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Research Code|Research Code|Research Code|USAN|USAN|INN|Research Code,Cancer,Histone deacetylase-11 inhibitor|Histone deacetylase-4 inhibitor|Histone deacetylase-3 inhibitor|Histone deacetylase-2 inhibitor|Caspase-3 stimulator|Caspase-7 stimulator|Histone deacetylase-1 inhibitor,7871|7850|7847|7844|7303|7315|7841,Anticancer|Apoptosis stimulator,1545|1589,,,Non-small-cell lung cancer|Myelodysplastic syndrome|Hodgkins disease|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Transitional cell carcinoma|Leukemia|Bladder cancer|Pancreas tumor|B-cell lymphoma|Non-Hodgkin lymphoma|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer|Solid tumor,1262|1272|161|1731|1734|1771|199|2380|249|316|319|3665|3713|651|725,,,Mirati Therapeutics Inc|Celgene Corp|Taiho Pharmaceutical Co Ltd|MethylGene Inc|Pharmion Corp,1085701|15331|18720|23090|29253,MethylGene Inc,23090,,,,,,
3645,modafinil,"modafinil|Alertec|Modiodal|Provigil|GRL-40476|Modavigil|Attenace|Sparlon|CN-801|AFT-801|Modasomil|Vigil, Cephalon",USAN|INN|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Trade Name|Trade Name,Neurology/Psychiatric,Alpha 1 adrenoceptor agonist,31,Antidepressant|Psychostimulant,2941|7225,Narcolepsy|Obstructive sleep apnea|Hypersomnia,1520|3519|400,Attention deficit hyperactivity disorder|Depression,34|93,Teva Pharmaceutical Industries Ltd|Seqirus|Alfresa Pharma Corp|Taiwan Biotech Co Ltd|Dompe Group|Mitsubishi Tanabe Pharma Corp|Merck Sharp & Dohme Ltd|Armstrong Laboratories Inc|H Lundbeck A/S|Cephalon Inc,20348|1113858|26053|1025479|26028|1035060|18090|1027088|17900|15358,bioCSL PTY Ltd|DRAXIS Health Inc|Laboratoire L Lafon SA|Tanabe Seiyaku Co Ltd,1083827|15659|17744|20315,Laboratoire L Lafon SA,17744,,,,,,
3648,molgramostim,"GM-CSF|Leucomax|molgramostim|Sch-39300|CSF-39300|CSF, Genetics Inst/Sandoz/Schering-Plough|SF-GM, Genetics Inst/Sandoz/Schering-Plough|CSF-GM, Genetics Inst/Sandoz/Schering-Plough|GM-CSF, Genetics Inst/Sandoz/Schering-Plough",Trade Name|USAN|BAN|INN|Research Code|Research Code,Hematologic,CSF-1 agonist|GM-CSF receptor agonist,420|410,Anticancer,1545,Leukopenia,680,,,Wyeth BioPharma|Sandoz AG|Schering-Plough Corp,20511|24514|19711,Novartis AG|Schering-Plough KK,23137|23497,Wyeth BioPharma,20511,,,,,,
36495,"isavuconazonium chloride/sulfate (oral), Basilea/Astellas","BAL-8557|Ro-0098246|BAL-8349|antifungals, Basilea|BMS-207147 prodrugs, Nippon Roche|ravuconazole prodrugs, Nippon Roche|BAL-8557 (oral), Basilea|RO-0098557|isavuconazole|RO-0094815|isavuconazonium chloride|isavuconazonium chloride/sulfate (oral), Basilea/Astellas|ASP-9766|isavuconazonium sulfate|isavuconazonium|Cresemba|AK-1820",Research Code|Prodrug|Research Code|Research Code|Research Code|Prodrug|INN|Research Code|INN|Research Code|USAN|USAN|Trade Name|Research Code,Infection,Lanosterol-14 demethylase inhibitor,777,Synergist|Ergosterol synthesis inhibitor|Fungicide,7293|161|1748,Fungal infection|Zygomycete infection|Mucor infection|Aspergillus infection,124|1370|1380|29,Candida infection,1308,Hikma Pharmaceuticals plc|Asahi Kasei Pharma Corp|Unimedic AB|Astellas Pharma Inc|Pfizer Inc|Avir Pharma Inc|Basilea Pharmaceutica International Ltd|Biotoscana International,1022379|14303|1074739|1013295|18767|1149364|28104|1063950,F Hoffmann-La Roche AG,26178,F Hoffmann-La Roche AG,26178,,,,,,
36518,AVE-9633,My9-6-DM1|huMy9-6-DM1|AVE-9633|huMy9-6-DM4,Research Code|Research Code,Cancer,Tubulin binding agent|CD33 modulator,499|5119,Immunotoxin|Anticancer monoclonal antibody,539|55685,,,Acute myelogenous leukemia,1731,,,Sanofi SA|ImmunoGen Inc|Aventis SA,1009547|17202|27254,ImmunoGen Inc,17202,,,,,,
36624,"omacetaxine mepesuccinate (injectable, cancer), ChemGenex/Hospira","homoharringtonine|homoharringtonine (injectable), ChemGenex|Ceflatonin|Myelostat|omacetaxine mepesuccinate|CGX-635|omacetaxine mepesuccinate (injectable), ChemGenex|omacetaxine mepesuccinate (injectable, cancer), ChemGenex/Hospira|Omapro|Tekinex|Synribo",Trade Name|Trade Name|USAN|INN|Research Code|Trade Name|Trade Name|Trade Name,Cancer,BCR gene inhibitor|MCL1 gene inhibitor,20723|31382,Apoptosis stimulator|Anticancer|Protein synthesis inhibitor|Angiogenesis inhibitor,1589|1545|339|61,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia,1272|1731|1735,Acute promyelocytic leukemia|Solid tumor,1732|725,Hospira Inc|Teva Pharmaceutical Industries Ltd|Cephalon Inc,1010293|20348|15358,ChemGenex Pharmaceuticals Ltd,29092,ChemGenex Pharmaceuticals Ltd,29092,,,,,,
36629,AVN-944,"AVN-944|inosine monophosphate dehydrogenase inhibitor (cancer), Avalon|IMPDH inhibitor (oral, cancer), Avalon/Vertex|inosine monophosphate dehydrogenase inhibitor (autoimmune disease/viral infection/cancer), Vertex|IMPDH inhibitor (autoimmune disease/viral infection/cancer), Vertex|VX-944",Research Code|Research Code,Cancer|Immune|Infection,Inosine monophosphate dehydrogenase inhibitor,629,Immunomodulator|Anticancer|Antiviral|Apoptosis stimulator|Angiogenesis inhibitor,1596|1545|991|1589|61,,,Hematological neoplasm|Pancreas tumor|Viral infection|Autoimmune disease|Cancer|Solid tumor,2054|249|344|36|651|725,,,Clinical Data Inc|Vertex Pharmaceuticals Inc|Avalon Pharmaceuticals Inc,1014919|20739|28144,Vertex Pharmaceuticals Inc,20739,,,,,,
36630,ipilimumab,"MDX-010|MDX-101|anti-CTLA4, Medarex|MDX-CTLA4|ipilimumab|BMS-734016|Yervoy|Winglore|CTLA-4 checkpoint inhibitor (cancer), Bristol-Myers Squibb",Research Code|Research Code|Research Code|USAN|INN|Research Code|Trade Name|Trade Name,Cancer|Genitourinary/Sexual Function|Infection,Cytotoxic T-lymphocyte protein-4 inhibitor,5482,Anticancer monoclonal antibody|Antiviral|T-lymphocyte stimulator|Anticancer|Immunostimulant,55685|991|7761|1545|393,Esophagus tumor|Rectal tumor|Neuroendocrine tumor|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Myelodysplastic syndrome|Gastrointestinal tumor|Biliary cancer|Hodgkins disease|Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Cholangiocarcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Sarcoma|Melanoma|Leiomyosarcoma|Liposarcoma|Glioblastoma|Carcinosarcoma|Squamous cell carcinoma|Vulvar intraepithelial neoplasia|Gallbladder tumor|Merkel cell carcinoma|Medullary thyroid cancer|Hormone refractory prostate cancer|Stage III melanoma|Stage IV melanoma|Vaginal cancer|Soft tissue sarcoma|Metastatic bladder cancer|Ovarian clear cell carcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Anaplastic thyroid cancer|Uveal melanoma|Ocular melanoma|Bladder tumor|Metastatic renal cell carcinoma|Salivary gland cancer|Gynecological disorder|Breast tumor|Solid tumor|Uterus tumor|Lung tumor|Kaposis sarcoma,1011|1055|1128|1240|1261|1262|1272|131|1516|161|1731|1749|1765|1766|1767|1768|194|205|2446|2447|2454|2614|307|3105|3146|3235|3240|3246|3256|3257|3291|3378|3466|3525|3657|3658|3665|3666|3667|3673|3713|3769|3788|3789|42|4250|4299|438|49|725|740|755|936,HIV infection|Chronic myelocytic leukemia|Lymphoma|Pancreas tumor|Hormone dependent prostate cancer|Genitourinary tract tumor|Ovary tumor|Colorectal tumor,158|1735|203|249|3247|613|799|989,Ono Pharmaceutical Co Ltd|Bristol-Myers Squibb Co,18681|15065,Medarex Inc,17968,Medarex Inc,17968,,,,,,
36669,trastuzumab emtansine,"Herceptin-DM1 conjugate, ImmunoGen/Genentech|trastuzumab-MCC-DM1|PRO-132365|Tmab-MCC-DM1|T-DM1|trastuzumab-DM1|trastuzumab emtansine|trastuzumab MCC mertansine|RG-3502|R-3502|RO-5304020|Kadcyla|ado-trastuzumab emtansine",Research Code|USAN|INN|Research Code|Research Code|Research Code|Trade Name,Cancer,Erbb2 tyrosine kinase receptor modulator|Tubulin receptor antagonist,3755|541,Anticancer monoclonal antibody|Anticancer|Immunotoxin|Microtubule inhibitor,55685|1545|539|2575,Metastatic breast cancer|Breast tumor,3657|49,Cholangiocarcinoma|Metastatic bladder cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Cancer,1765|3466|3665|3666|3669|651,Roche Holding AG|Genentech Inc|Chugai Pharmaceutical Co Ltd,19446|19453|15414,,,Genentech Inc,19453,,,,,,
3669,mycophenolate mofetil,"mycophenolate mofetil|RS-61443|mycophenolate mofetil hydrochloride|ME-MPA|Munoloc|RS-6143|CellCept Cap|R-99, Roche|CellCept|MMF|mycofenolate mofetil",USAN|INN|Research Code|Research Code|Trade Name|Research Code|Trade Name|Research Code|Research Code,Cardiovascular|Dermatologic|Gastrointestinal|Hematologic|Immune|Infection|Respiratory,Inosine monophosphate dehydrogenase inhibitor|PurH purine biosynthesis protein inhibitor,629|11778,Immunosuppressant|Antiviral|Anti-inflammatory,396|991|2953,Scleroderma|Lupus nephritis|Interstitial lung disease|Heart transplant rejection|Liver transplant rejection|Kidney transplant rejection|Lung transplant rejection|Pancreas transplant rejection|Transplant rejection|Graft versus host disease|Myasthenia gravis,1105|2404|2466|2987|2988|2989|3141|3142|515|616|848,Pemphigus|Inflammatory bowel disease|Multiple sclerosis|Respiratory syncytial virus infection|Rheumatoid arthritis|Thrombocytopenia|Restenosis|Autoimmune disease|Crohns disease,1114|189|213|287|291|324|330|36|84,Roche Holding AG|Chugai Pharmaceutical Co Ltd,19446|15414,Aspreva International Ltd|Vifor Pharma Group|Nippon Roche KK,1004419|16266|19447,Roche Holding AG,19446,,,,,,
3688,nedaplatin,nedaplatin|254-S|S-254|NSC-375101D,INN|Research Code|Research Code|Research Code,Cancer,,,Anticancer alkylating agent,50,Esophagus tumor|Testis tumor|Small-cell lung cancer|Non-small-cell lung cancer|Bladder cancer|Uterine cervix tumor|Carcinoma|Head and neck tumor|Ovary tumor,1011|1054|1261|1262|2380|427|54|623|799,,,Shionogi & Co Ltd,19898,,,Shionogi & Co Ltd,19898,,,,,,
37032,custirsen,"ISIS-112989|antisense clusterin inhibitor (anticancer), OncoGenex/Isis|OGX-011|custirsen|custirsen sodium|TV-1011",Research Code|Research Code|INN|USAN|Research Code,Cancer,CLU gene inhibitor,34774,Anticancer|Antisense oligonucleotide inhibitor,1545|7294,,,Non-small-cell lung cancer|Prostate tumor|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Breast tumor|Cancer|Solid tumor|Lung tumor,1262|276|3246|3247|49|651|725|755,,,Ionis Pharmaceuticals Inc|Achieve Life Sciences Inc|Teva Pharmaceutical Industries Ltd|OncoGenex Technologies Inc,17269|20225|20348|29233,Ionis Pharmaceuticals Inc,17269,,,,,,
3704,"nicotine transdermal, Ciba","nicotine|Habitrol|Nicopatch|Nicotell TTS|Nicotinell|Nicomed|nicotinell TTS|nicotine transdermal, Ciba",BANN|Trade Name|Trade Name,Toxicity/Intoxication,Nicotinic acetylcholine receptor agonist,275,,,Nicotine dependence,235,,,Ciba-Geigy Corp|Dr Reddy's Laboratories Ltd|Novartis AG|Pierre Fabre Group,24452|29387|23137|19087,,,Ciba-Geigy Corp,24452,,,,,,
3705,nicotine,"nicotine|Nicotrol|Nicorette|Nicotrol inhaler|Nicorette inhaler|nicotine transdermal, Kabi|nicotine transdermal, Cygnus|nicotine transdermal, Warner",BANN|Trade Name|Trade Name|Trade Name|Trade Name,Gastrointestinal|Toxicity/Intoxication,Nicotinic acetylcholine receptor agonist,275,,,Nicotine dependence,235,Ulcerative colitis,337,Kabi Pharmaceuticals|Johnson & Johnson|Warner-Lambert Co|Pharmacia & Upjohn AB|McNeil Consumer Products Co|Pharmacia & Upjohn Inc,22014|17332|20787|22008|17559|22006,Cygnus Inc,15570,Cygnus Inc,15570,,,,,,
37211,SDX-101,"R-etodolac|SDX-101 analogs (cancer), Salmedix|SDX-308|SDX-309|SDX-328|CEP-18082|SDX-101",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Hematologic,Nuclear factor kappa B inhibitor|Beta-catenin inhibitor|PPAR gamma agonist,2653|15709|2480,Anticancer|Apoptosis stimulator,1545|1589,,,Hematological disease|Chronic lymphocytic leukemia|Multiple myeloma|Prostate tumor,142|1734|1828|276,,,Cephalon Inc|Salmedix Inc,15358|29254,Salmedix Inc,29254,,,,,,
37311,"topotecan hydrochloride (liposomal/TCS, cancer), Spectrum Pharmaceuticals","Hycamtin|topotecan hydrochloride|topotecan|topotecan hydrochloride, Inex/GSK|topotecan (liposomal/ TCS, cancer), Tekmira|topotecan hydrochloride, Hana|topotecan (liposomal/ TCS, cancer), Hana Biosciences|topotecan (liposomal/TCS, cancer), Talon|topotecan (Optisome, cancer), Talon|topotecan (transmembrane carrier system, cancer), Talon|topotecan (liposomal/TCS, small cell lung/ovarian cancer), Talon|Brakiva|INX-0076|Topotecan-TCS|topotecan hydrochloride (liposomal/TCS, cancer), Talon|topotecan hydrochloride (liposomal/TCS, cancer), Spectrum Pharmaceuticals",Trade Name|USAN|BAN|INN|Trade Name|Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,Solid tumor,725,Cancer,651,Spectrum Pharmaceuticals Inc,24232,Talon Therapeutics Inc|Inex Pharmaceuticals Corp|GlaxoSmithKline plc,1010798|16173|28355,GlaxoSmithKline plc,28355,,,,,,
37331,tandutinib,"CT-53518|C2403-47|anti-Flt3 program, Millennium|anti-Flt3 program, COR Therapeutics|MLN-518|tandutinib|MLN-0518",Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer,Flt3 tyrosine kinase inhibitor|PDGF receptor antagonist|Kit tyrosine kinase inhibitor,3806|948|3808,Hematopoietic modulator|Anticancer protein kinase inhibitor,1678|62255,,,Glioma|Myelodysplastic syndrome|Acute myelogenous leukemia|Renal cell carcinoma|Glioblastoma|Prostate tumor,1108|1272|1731|1766|2454|276,,,COR Therapeutics Inc|Takeda Oncology,15543|21991,COR Therapeutics Inc,15543,,,,,,
3735,"octreotide acetate (long-acting formulation), Novartis","octreotide|octreotide acetate|Sandostatin LAR|Sandostatin LAR Depot|octreotide pamoate|octreotide acetate (long-acting formulation), Novartis|octreotide LAR|Sandostatin LP",BAN|INN|USAN|Trade Name|Trade Name,Cancer|Cardiovascular|Endocrine/Metabolic|Gastrointestinal|Genitourinary/Sexual Function|Ocular|Other/Miscellaneous,Somatostatin receptor agonist,1120,Growth hormone release inhibitor|Anticancer hormone|Anti-emetic|Antidiarrhoeal,3272|62253|2970|4007,Diarrhea|Neuroendocrine tumor|Gigantism|Acromegaly|Carcinoma,102|1128|1667|5|54,Emesis|Hepatocellular carcinoma|Short bowel syndrome|Varices|Hepatorenal syndrome|Obesity|Pancreas tumor|Thymoma|Breast tumor|Diabetic retinopathy,110|1767|2168|2179|2212|238|249|2939|49|576,Novartis AG,23137,Novartis Pharma KK|Italfarmaco SpA|Sandoz Ltd,16018|17278|24481,Novartis AG,23137,,,,,,
37370,azacitidine,5-azacytidine|NSC-102816|U-18496|Mylosar|WR-183027|ladakamycin|Vidaza|5-azacitidine|azacitidine|NS-17|5-aza|5-AZC|AZA-CR,Research Code|Research Code|Trade Name|Research Code|Trade Name|USAN|INN|Research Code,Cancer|Hematologic,DNA methyltransferase inhibitor,6512,Anticancer antimetabolite,1569,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelomonocytic leukemia,1272|1731|6833,Glioma|Hematological disease|Chronic lymphocytic leukemia|Follicle center lymphoma|Marginal zone B-cell lymphoma|Multiple myeloma|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic colorectal cancer|Bladder tumor|Metastatic renal cell carcinoma|Cancer|Solid tumor|Ovary tumor,1108|142|1734|1745|1746|1828|3246|3657|3658|42|4250|651|725|799,Nippon Shinyaku Co Ltd|Bristol-Myers Squibb Co|BeiGene Co Ltd|BL&H Co Ltd,18552|15065|1063251|1037227,Celgene Corp|Upjohn Inc|Pharmacia Corp|Pharmion Corp,15331|19025|27638|29253,Upjohn Inc,19025,,,,,,
3738,olanzapine,LY-170053|olanzapine|Lanzac|Zyprex|Olansek|Zyprexa|Zyprexa Zydis|olanzapine pamoate|Zyprexa IntraMuscular|Zyprexa Velotab|Zyprexa IM|ZYPEXA,Research Code|USAN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|USAN|Trade Name|Trade Name|Trade Name|Trade Name,Neurology/Psychiatric|Toxicity/Intoxication,Dopamine D3 receptor antagonist|Dopamine D4 receptor antagonist|Dopamine D2 receptor antagonist|Dopamine D1 receptor antagonist|5-HT 2 receptor antagonist,1191|801|150|148|13,Antipsychotic|Anti-emetic,2943|2970,Mania|Schizophrenia|Bipolar I disorder|Bipolar II disorder|Chemotherapy induced nausea and vomiting|Bipolar disorder,1957|299|3114|3115|3847|653,Alzheimers disease|Borderline personality disorder|Anorexia nervosa,14|1929|24,Eli Lilly & Co|Eli Lilly Japan KK,17810|22692,,,Eli Lilly & Co,17810,,,,,,
37391,"anti-CD45 mAbs (stem cell transplantation/cancer), Baylor College","AHCD45 therapy, Baylor College|anti-CD45 mAbs (stem cell transplantation/cancer), Baylor College|YTH-25.4|YTH-54.12|YTH-24|YTH-24/54",Research Code|Research Code|Research Code|Research Code,Cancer|Immune,CD45 antagonist,5171,Anticancer monoclonal antibody|Immunosuppressant,55685|396,,,Bone marrow transplantation|Cancer,46|651,,,Baylor College of Medicine,20534,Baylor College of Medicine,20534,,,,,,
37418,OXi-4503,"OXi-4503|second-generation VTA (OXi-4503), OXiGENE|Combretastatin A1 diphosphate|CA1P|OXi-4500|Combretastatin A1 diphosphate dipotassium|CA1P dipotassium",Research Code|Research Code|Metabolite,Cancer|Ocular,Tubulin modulator,814,Vascular damaging agent|Ophthalmological agent|Anticancer,2969|15128|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Stage IV melanoma,1272|1731|3257,Hepatocellular carcinoma|Ocular disease|Cancer|Solid tumor,1767|239|651|725,Mateon Therapeutics Inc,21303,Symphony ViDA Inc,1042594,Mateon Therapeutics Inc,21303,,,,,,
3750,ondansetron,ondansetron|GR-38032|GR-38032X|Zofran|Zophren|GG-032|SN-307|Zopram|GG-032X|Ramesin|Zamanol|Zophran|GR-38032F|Zofran ODT|ondansetron hydrochloride|Zofran Zydis|GR-C507/75|Zofran Konserveret,BAN|INN|Research Code|Research Code|Trade Name|Trade Name|Research Code|Research Code|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Research Code|USAN|Trade Name|Research Code|Trade Name,Gastrointestinal|Neurology/Psychiatric|Toxicity/Intoxication,5-HT 3 receptor antagonist,15,Anti-emetic,2970,Emesis|Radiotherapy induced emesis|Chemotherapy induced nausea and vomiting,110|3012|3847,Panic disorder|Nausea|Dementia,1279|226|90,Aspen PharmaCare Holdings Ltd|Novartis AG|Daiichi Sankyo Co Ltd,1019374|23137|1017506,Glaxo Group Ltd|Sankyo Co Ltd|GlaxoSmithKline plc,16453|19658|28355,Glaxo Group Ltd,16453,,,,,,
37613,maraviroc,"UK-427857|UK-107543|UK-372677|UK-382055|UK-408030|UK-370907|UK-378995|UK-395859|UK-418526|CCR5 antagonists (HIV infection), Pfizer|UK-374503|UK-179645|maraviroc|CCR5 antagonist (rheumatoid arthritis), Pfizer|UK-440103|Celsentri|Selzentry|DIN-02299844|CCR5 antagonist (Coronavirus disease 19 infection/ respiratory distress syndrome), ViiV Healthcare",Research Code|Research Code|Research Code|Research Code|Analogue|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|INN|Research Code|Trade Name|Trade Name|Research Code,Gastrointestinal|Immune|Infection|Respiratory,HIV-1 gp120 protein inhibitor|CCR5 chemokine antagonist|CD4 agonist,11219|3107|5027,Anti-inflammatory|HIV fusion inhibitor|Antiviral,2953|3980|991,Coronavirus disease 19 infection|HIV infection|Non-alcoholic steatohepatitis|Respiratory distress syndrome,10406|158|2637|8,Rheumatoid arthritis,291,ViiV Healthcare Ltd,1050515,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
37695,alacizumab pegol,alacizumab pegol|CDP-791,INN|Research Code,Cancer,VEGF-2 receptor antagonist,3848,Anticancer|Anticancer protein kinase inhibitor|Angiogenesis inhibitor,1545|62255|61,,,Non-small-cell lung cancer|Cancer|Solid tumor,1262|651|725,,,UCB Celltech|Imclone LLC,15336|17193,UCB Celltech,15336,,,,,,
37718,volociximab,"M-200|Eos-200-4|anti-AAB1 antibody (cancer), PDL|anti-alpha-5/beta-1 integrin Ab (cancer), PDL|anti-AAB1 antibody, Protein Design Labs|volociximab|anti-AAB1 antibody (cancer), EOS|anti-AAB1 antibody, PDL/Biogen Idec|anti-alpha-5/beta-1 integrin Ab (cancer), PDL/Biogen Idec|anti-AAB1 antibody, Protein Design Labs/Biogen Idec|anti-alpha-5/beta-1 integrin Ab (AMD), Ophthotech|anti-AAB1 antibody (AMD), Ophthotech|anti-alpha-5/beta-1 integrin Ab (cancer), Facet Biotech/Biogen Idec",Research Code|Research Code|USAN|INN,Cancer|Ocular,Integrin alpha-5/beta-1 modulator,5854,Ocular antineovascularisation agent|Apoptosis stimulator|Angiogenesis inhibitor|Anticancer monoclonal antibody,15148|1589|61|55685,,,Age related macular degeneration|Non-small-cell lung cancer|Renal cell carcinoma|Melanoma|Pancreas tumor|Peritoneal tumor|Solid tumor|Ovary tumor,1226|1262|1766|205|249|3083|725|799,,,Biogen Inc|IVERIC Bio Inc|AbbVie Biotherapeutics Inc|Abbott Laboratories|PDL BioPharma Inc|Eos Biotechnology Inc,1005244|1033865|1044720|13601|19162|25592,Eos Biotechnology Inc,25592,,,,,,
37719,"encequidar mesylate + paclitaxel (oral/ORASCOVERY, cancer), Hanmi / Athenex / PharmaEssentia","KR-30031 + paclitaxel|KR-30031 + paclitaxel (cancer), Hanmi|Oraxol|paclitaxel + HM-30181A|encequidar mesylate + paclitaxel (oral, cancer), Hanmi|paclitaxel + HM-30181A (oral/ORASCOVERY, cancer), Hanmi / Kinex|paclitaxel + HM-30181A (oral/ORASCOVERY, cancer), Hanmi / Kinex / PharmaEssentia|encequidar mesylate + paclitaxel (oral/ORASCOVERY, cancer), Hanmi / Athenex / PharmaEssentia|paclitaxel + encequidar mesylate|Ohraksol",Trade Name|Trade Name,Cancer,P-Glycoprotein 1 inhibitor,11495,Anticancer|Microtubule stabilizer,1545|2576,Angiosarcoma|Soft tissue sarcoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor|Breast tumor|Cancer,2443|3378|3466|3657|3665|3666|3667|3713|49|651,,,Athenex Inc|Hanmi Pharmaceutical Co Ltd|Guangzhou Xiangxue Pharmaceutical Co Ltd|Zenith Technology Corp Ltd|PharmaEssentia Corp,1016074|16611|1063220|21019|1019195,,,Hanmi Pharmaceutical Co Ltd,16611,,,,,,
3792,oxaliplatin,"NSC-266046|RP-54780|oxaliplatin|L-OHP|1670RB|Eloxatin|SR-96669|Eloxatine|RP-54780, 1-OHP|Elplat|GSOX|Eloxitin|Dacotin|Dacplat",Research Code|Research Code|USAN|INN|Trade Name|Research Code|Trade Name|Research Code|Trade Name|Research Code|Trade Name|Research Code|Trade Name|Trade Name|Trade Name,Cancer,,,DNA synthesis inhibitor|Anticancer alkylating agent|Anticancer,140|50|1545,Stomach tumor|Hepatocellular carcinoma|Pancreas tumor|Metastatic colorectal cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Small intestine cancer|Colon tumor|Colorectal tumor,127|1767|249|3658|3666|3669|4166|767|989,Esophagus tumor|Rectal tumor|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic esophageal cancer|Metastatic rectal cancer|Cancer,1011|1055|3246|3657|3667|3671|651,Yakult Honsha Co Ltd|Sanofi-Synthelabo|Sanofi SA|Sanofi (pre-1999),20961|26494|1009547|26495,Debiopharm SA|Eli Lilly & Co,15620|17810,Debiopharm SA,15620,,,,,,
3803,paclitaxel,"BMS-181339-01|NSC-125973|paclitaxel|Taxol|Taxol A|intaxel|taxol, BMS|taxol, NIH|taxol A, BMS|taxol A, NIH|paclitaxel, BMS|paclitaxel, NIH|Onxal|Bristaxol|Praxel|Anzatax|NSC-673089|Asotax",Research Code|Research Code|USAN|BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name,Cancer,,,Microtubule stabilizer|Cell cycle inhibitor|Anticancer|Vasoprotectant,2576|767|1545|2660,Esophagus tumor|Testis tumor|Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Angiosarcoma|Metastatic breast cancer|Germ cell and embryonic cancer|Uterine cervix tumor|Breast tumor|Head and neck tumor|Cancer|Ovary tumor|Kaposis sarcoma,1011|1054|1262|127|1705|2443|3657|3737|427|49|623|651|799|936,Lung tumor,755,Bristol-Myers Squibb KK|Bristol-Myers Squibb Co|National Cancer Institute (NCI)|HQ Specialty Pharma|Boryung Pharm Co Ltd,15134|15065|20519|1072198|14987,,,National Cancer Institute (NCI),20519,,,,,,
38131,milatuzumab,"LL1|hLL1|MyelomaCide|MelanomaCide|MyelomaCide Y-90|hCD74 antibody (mutilple myeloma/ melanoma), Immunomedics|milatuzumab|IMMU-115",Research Code|Research Code|Trade Name|Trade Name|Trade Name|USAN|INN|Research Code,Cancer|Immune,CD74 antagonist,5303,Anticancer monoclonal antibody|Radioimmunotherapeutic|Apoptosis stimulator,55685|1552|1589,,,Chronic lymphocytic leukemia|Mantle cell lymphoma|Multiple myeloma|Melanoma|Systemic lupus erythematosus|Non-Hodgkin lymphoma|Graft versus host disease,1734|1744|1828|205|318|319|616,,,Immunomedics Inc,17204,Immunomedics Inc,17204,,,,,,
38152,tasquinimod,"TASQ project, Active Biotech|prostate cancer therapeutic, Active Biotech|quinoline-3-carboxamide derivatives, Active Biotech|tasquinimod|ABR-215050",INN|Research Code,Cancer,S100 calcium binding protein A9 modulator,17321,Angiogenesis inhibitor|Immunomodulator|Thrombospondin modulator|Anticancer,61|1596|8019|1545,Acute leukemia|Hepatocellular carcinoma|Multiple myeloma|Cancer,1727|1767|1828|651,Stomach tumor|Renal cell carcinoma|Hormone refractory prostate cancer|Ovary tumor,127|1766|3246|799,Active Biotech AB|Ipsen,26312|17259,,,Active Biotech AB,26312,,,,,,
3821,PD-115934,PD-115934|NSC-366140|pyrazoloacridine,Research Code|Research Code|USAN,Cancer,Topoisomerase inhibitor,143,Anticancer alkylating agent,50,,,Cancer|Brain tumor,651|760,,,Parke-Davis & Co|NABTT CNS Consortium,20805|30664,Parke-Davis & Co,20805,,,,,,
38515,delanzomib,"CEP-1612|CEP-1508|CEP-3117|proteasome inhibitors, Cephalon|proteasome inhibitors, Cephalon/Novuspharma|proteasome inhibitors, Cephalon/Cell Therapeutics|CT-18770|CEP-18770|CEP-28331|delanzomib",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN,Cancer|Immune,Proteasome inhibitor|Immunoglobulin G antagonist,4917|5739,Anticancer|Apoptosis modulator|Anti-inflammatory,1545|1588|2953,,,Multiple myeloma|Systemic lupus erythematosus|Non-Hodgkin lymphoma|Cancer|Solid tumor,1828|318|319|651|725,,,CTI BioPharma Corp|Cephalon Inc|Novuspharma SpA,15337|15358|27036,Cephalon Inc,15358,,,,,,
38850,daporinad,WK-175|APO-866|FK-866|daporinad,Research Code|Research Code|Research Code|INN,Cancer|Immune,Nicotinamide phosphoribosyltransferase inhibitor,11722,Immunomodulator|Angiogenesis inhibitor|Apoptosis stimulator|Anticancer,1596|61|1589|1545,,,Chronic lymphocytic leukemia|Cutaneous T-cell lymphoma|Immune disorder|Leukemia|Melanoma|Cancer,1734|1754|185|199|205|651,,,Apoxis SA|Astellas Pharma Inc|Klinge Pharma GmbH|Astellas Pharma GmbH|TopoTarget A/S,1002960|1013295|16247|29344|29414,Astellas Pharma GmbH,29344,,,,,,
39122,palifosfamide,"ifosfamide analogs, Dekk-Tec|lysine-isophosphoramide mustard (L-IPM), Dekk-Tec|4-hydroperoxyifosfamide, Dekk-Tec|lysine-isophosphoramide mustard (cancer), ZIOPHARM|ifosfamide analogs, ZIOPHARM/Dekk-Tec|ZIO-202|ZIO-203|palifosfamide|IPM|Isophosphoramide mustard|lysine-isophosphoramide mustard|L-IPM|ZIO-201|palifosfamide lysine|Zymafos|L-IPM (cancer), ZIOPHARM|HO-IFOS, Dekk-Tec|palifosfamide-tris|palifosfamide-T|IPM-L|ZIO-201-T|palifosfamide tromethamine",Research Code|Research Code|USAN|INN|Research Code|Trade Name|USAN,Cancer,,,Anticancer|DNA modulator|Anticancer alkylating agent,1545|803|50,,,Testis tumor|Small-cell lung cancer|Sarcoma|Lymphoma|Soft tissue sarcoma|Metastatic breast cancer|Advanced solid tumor|Cancer|Ovary tumor,1054|1261|194|203|3378|3657|3713|651|799,,,ZIOPHARM Oncology Inc|Predictive Therapeutics|Dekk-Tec Inc,1009856|1122803|15652,Dekk-Tec Inc,15652,,,,,,
39124,robatumumab,"MAb-391|anti-IR3 antibodies, Schering-Plough|anti-IGFR1 antibodies (cancer), Schering-Plough|SCH-717454|robatumumab|anti-IGF-1R (cancer), Schering-Plough|19D12|anti-IGFR1 antibodies (cancer), Merck & Co",Research Code|Research Code|USAN|INN|Research Code,Cancer,Insulin-like growth factor 1 receptor antagonist|Insulin-like growth factor receptor modulator,3252|3250,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor|Anticancer hormone antagonist,55685|62255|62254,,,Osteosarcoma|Ewing sarcoma|Cancer|Colorectal tumor,1772|2975|651|989,,,Merck & Co Inc|Schering-Plough Corp,18077|19711,Schering-Plough Corp,19711,,,,,,
39158,"PR1 peptide antigen vaccine (leukemia), Vaccine Company","PR1 peptide antigen vaccine (leukemia), MD Anderson|PR1 peptide antigen vaccine (leukemia), Vaccine Company",,Cancer,Leukocyte proteinase-3 inhibitor,9336,Anticancer|Therapeutic vaccine,1545|12379,,,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia,1272|1731|1735,,,The Vaccine Company|MD Anderson Cancer Center,1033560|23382,MD Anderson Cancer Center,23382,,,,,,
39159,"belinostat (iv, cancer), Acrotech","PXD-101|HDAC inhibitors, TopoTarget/Curagen|histone deacetylase inhibitors, Prolifix|histone deacetylase inhibitors, TopoTarget/Curagen|PXD-101 (iv, cancer), TopoTarget/ Curagen|PX-089344|belinostat|belinostat (iv, cancer), TopoTarget/Curagen|belinostat (iv, cancer), BioAlliance Pharma/Spectrum|belinostat (iv, cancer), TopoTarget/Spectrum|belinostat (iv, cancer), Onxeo/Spectrum|Beleodaq|belinostat (iv, cancer), Acrotech",Research Code|Research Code|USAN|INN|Trade Name,Cancer|Inflammatory,Histone deacetylase inhibitor,2574,Synergist|Cell differentiation stimulator|Angiogenesis inhibitor|Anticancer|Apoptosis stimulator,7293|53574|61|1545|1589,Peripheral T-cell lymphoma|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic ovary cancer,1753|3246|3657|3866,Thyroid tumor|Mesothelioma|Non-small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Cutaneous T-cell lymphoma|Hepatocellular carcinoma|Multiple myeloma|Inflammatory disease|Sarcoma|Hematological neoplasm|Thymoma|T-cell lymphoma|B-cell lymphoma|Bladder tumor|Carcinoma|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,1134|1240|1262|1272|1731|1754|1767|1828|188|194|2054|2939|311|316|42|54|651|725|799|989,Acrotech Biopharma LLC|Pint Pharma,1179286|1110054,Servier Canada Inc|TopoTarget UK Ltd|Spectrum Pharmaceuticals Inc|CuraGen Corp|Onxeo SA|TopoTarget A/S,22730|23111|24232|25491|28048|29414,TopoTarget UK Ltd,23111,,,,,,
39169,luminespib,"CCT-018159|RBT-0028535|PH-3|VER-28535|VER-49009|CCT-066950|CCT-066952|CCT-066965|CCT-072440|CCT-0669963|RBT-0027129|RBT-0036283|RBT-0045856|Hsp 90 inhibitors (cancer), Vernalis/Novartis|Hsp 90 inhibitors, RiboTargets/Institute of Cancer Research|Hsp 90 inhibitors, Cancer Research Ventures/Vernalis|Hsp 90 inhibitors, Institute of Cancer Research/Vernalis|G-3130|G-3129|VER-50589|VER-27129|VER-49537|VER-510747|NVP-AUY-922|VER-52296|VER-45864|VER-51000|AUY-922|luminespib|luminespib mesylate",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|USAN,Cancer|Hematologic,ATPase inhibitor|Hsp 90 inhibitor,529|8012,Anticancer|Synergist|Apoptosis stimulator|Angiogenesis inhibitor,1545|7293|1589|61,Cancer,651,Non-small-cell lung cancer|Stomach tumor|B-cell acute lymphoblastic leukemia|Multiple myeloma|Lymphoma|Adenocarcinoma|Myelofibrosis|Gastrointestinal stromal tumor|Metastatic pancreas cancer|Advanced solid tumor|Breast tumor|Solid tumor|Colorectal tumor,1262|127|1729|1828|203|2399|2436|3205|3669|3713|49|725|989,Vernalis plc,15262,Cancer Research Ventures Ltd|Institute of Cancer Research UK|Novartis AG|RiboTargets Ltd,15935|21072|23137|24962,RiboTargets Ltd,24962,,,,,,
39172,brentuximab vedotin,"cBR96-Val-Cit-MMAF|auristatin E ADCs, Seattle Genetics|auristatin E conjugates, Seattle Genetics|anti-CD30 mAb/Auristatin E conjugates, Seagen|antibody-drug conjugates (anticancer), Seattle Genetics|1F6-mc-MMAF|cAC10 fragment MMAE conjugate (cancer), Seattle|anti-CD30 mAb/Auristatin F conjugates, Seattle|cAC10-mc-vc-PAB-monomethyl auristatin E|SGN-35|brentuximab vedotin|cAC10-mc-MMAF|Adcetris|cAC10-mc-vc-PAB-MMAE|cAC10-mafodotin|1F6-mafodotin|1F6-SGD-1269|cAC10-SGD-1269|cBR96-vc-MMAF|NSC-749710",Research Code|Research Code|USAN|INN|Trade Name|Research Code|Research Code,Cancer|Dermatologic|Immune,CD30 modulator|Tubulin receptor antagonist,5110|541,Anticancer monoclonal antibody|Immunotoxin|Microtubule inhibitor,55685|539|2575,Scleroderma|Mycosis fungoides|Mesothelioma|Hodgkins disease|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Anaplastic large cell lymphoma|Sezary syndrome|Adult T-cell lymphoma|Papulosis|Non-Hodgkin lymphoma|Post transplant lymphoproliferative disease|Advanced solid tumor,1105|1115|1240|161|1749|1753|1754|1755|1756|1757|2142|319|3530|3713,Acute lymphoblastic leukemia|Acute myelogenous leukemia|Hematological neoplasm|T-cell lymphoma|Systemic lupus erythematosus|Autoimmune disease|Graft versus host disease|Cancer|Solid tumor,1728|1731|2054|311|318|36|616|651|725,Takeda Pharmaceutical Co Ltd|Seagen Inc,20300|25554,Takeda Oncology,21991,Seagen Inc,25554,,,,,,
39209,axitinib,"AG-13736|AG-013736|VEGF/PDGF inhibitor, Agouron/Pfizer|axitinib|Inlyta",Research Code|Research Code|USAN|INN|Trade Name,Cancer,Bcr protein inhibitor|VEGF receptor antagonist|PDGF receptor antagonist|Tyrosine protein kinase ABL1 inhibitor|CD79 antagonist|VEGF-3 receptor antagonist|Protein tyrosine kinase inhibitor|CSF-1 antagonist|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist,13571|1722|948|81148|5320|3850|385|3154|3846|3848,Anticancer|Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Apoptosis inhibitor,1545|62255|61|1590,Neuroendocrine tumor|Non-small-cell lung cancer|Chronic myelocytic leukemia|Renal cell carcinoma|Multiple myeloma|Melanoma|Glioblastoma|Carcinoid tumor|Prostate tumor|Thymus neoplasm|Non-Hodgkin lymphoma|Gastrointestinal stromal tumor|Stage IV melanoma|Metastatic bladder cancer|Advanced solid tumor|Metastatic renal cell carcinoma,1128|1262|1735|1766|1828|205|2454|2538|276|2938|319|3205|3257|3466|3713|4250,Thyroid tumor|Mesothelioma|Stomach tumor|Myelodysplastic syndrome|Adrenal cortical carcinoma|Acute myelogenous leukemia|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Angiosarcoma|Pancreas tumor|Metastatic breast cancer|Metastatic colorectal cancer|Carcinoma|Cancer|Solid tumor|Colorectal tumor,1134|1240|127|1272|1648|1731|1767|1768|2443|249|3657|3658|54|651|725|989,Pfizer Inc,18767,SFJ Pharmaceuticals Inc,1052050,Pfizer Inc,18767,,,,,,
39257,"alvespimycin hydrochloride (intravenous), Kosan","DMAG|17-DMAG HCl|17-DMAG|NSC-707545|KOS-1022 (intravenous), Kosan|alvespimycin hydrochloride (intravenous), Kosan|alvespimycin|alvespimycin hydrochloride|KOS-1022|BMS-826476",INN|USAN|Research Code|Research Code,Cancer,Hsp 90 inhibitor,8012,Anticancer,1545,,,Leukemia|Cancer|Solid tumor,199|651|725,,,National Cancer Institute (NCI)|Kosan Biosciences Inc,20519|24027,National Cancer Institute (NCI),20519,,,,,,
39310,"HLA-A, B7.1-transfected adenocarcinoma vaccine, University of Miami","HLA-A, B7.1-transfected adenocarcinoma vaccine, University of Miami",,Cancer,,,Therapeutic vaccine|Anticancer,12379|1545,,,Non-small-cell lung cancer|Cancer|Lung tumor,1262|651|755,,,University of Miami,20622,University of Miami,20622,,,,,,
39591,gataparsen,"ISIS-23722|LY-2181308|survivin mRNA-targeting antisense oligonucleotides (cancer), Isis|survivin-targeting antisense oligonucleotides (cancer), Lilly|survivin ASO|gataparsen|gataparsen sodium",Research Code|Research Code|USAN|INN|USAN,Cancer,BIRC5 gene inhibitor,18160,Apoptosis stimulator|Antisense oligonucleotide inhibitor|Anticancer,1589|7294|1545,,,Non-small-cell lung cancer|Acute myelogenous leukemia|Hepatocellular carcinoma|Hormone refractory prostate cancer|Cancer,1262|1731|1767|3246|651,,,Ionis Pharmaceuticals Inc|Eli Lilly & Co,17269|17810,Ionis Pharmaceuticals Inc,17269,,,,,,
39615,ADVAX,"ADVAX|ADVAX1, Aaron Diamond AIDS Research Center|HIV-1 vaccine (gag, pol, env, tat and nef), ADARC|DNA vaccine (HIV-1), ADARC|HIV-1 vaccine (gag, pol, env, tat and nef), Aaron Diamond AIDS Research Center",,Infection,Nef gene modulator|ENV gene modulator|GAG gene modulator|TAT gene modulator,18812|35450|62226|45342,DNA vaccine|Prophylactic vaccine,1879|12378,,,HIV-1 infection,159,,,Aaron Diamond AIDS Research Center,24873,Aaron Diamond AIDS Research Center,24873,,,,,,
39730,mirabegron,"beta-3 adrenoceptor agonists (diabetes/obesity), Yamanouchi|YM-178|mirabegron|EB-178|solifenacin + mirabegron|Betanis|YM-178 OCAS|YM-178 OCAS-X|mirabegron OCAS|YM-178 OCAS-M|Myrbetriq|Betmiga",Research Code|USAN|INN|Research Code|Trade Name|Research Code|Research Code|Research Code|Trade Name|Trade Name,Endocrine/Metabolic|Gastrointestinal|Genitourinary/Sexual Function,Beta 3 adrenoceptor agonist,42,,,Erectile dysfunction|Overactive bladder|Interstitial cystitis|Neurogenic bladder|Achalasia,186|2376|2512|3794|421,Urinary dysfunction|Non-insulin dependent diabetes,483|837,Astellas Pharma Inc,1013295,Yamanouchi Pharmaceutical Co Ltd,20967,Yamanouchi Pharmaceutical Co Ltd,20967,,,,,,
39749,"calcitriol (high-dose oral formulation), Novacea/Schering-Plough","calcitriol (high-dose oral formulation), Novacea/Schering-Plough|DN-101|Asentar",Research Code|Trade Name,Cancer,,,Vitamin D analog|Anticancer,2593|1545,,,Non-small-cell lung cancer|Myelodysplastic syndrome|Pancreas tumor|Prostate tumor|Cancer,1262|1272|249|276|651,,,Transcept Pharmaceuticals Inc|Schering-Plough Corp,1004325|19711,Transcept Pharmaceuticals Inc,1004325,,,,,,
39809,"mutant ras vaccine, NCI","13 mer ras peptide, NCI|mutant ras vaccine, NCI|ras peptide vaccine, NCI",,Cancer,Ras GTPase modulator,10449,Therapeutic vaccine|Anticancer,12379|1545,,,Pancreas tumor|Cancer|Colorectal tumor,249|651|989,,,National Cancer Institute (NCI),20519,National Cancer Institute (NCI),20519,,,,,,
39855,5-Fluoro-2-deoxycytidine,5-Fluoro-2'-deoxycytidine|tetrahydrouridine|FdCyd|5-Fluoro-2-deoxycytidine,,Cancer,Methyltransferase inhibitor,1029,Anticancer,1545,,,Hematological neoplasm|Solid tumor,2054|725,,,City of Hope,20558,City of Hope,20558,,,,,,
40052,mitumprotimut-t,"FavId|tumor-specific idiotype protein and keyhole limpet hemocyanin conjugate immunotherapy (lymphoma), Favrille|mitumprotimut-t|Id-KLH|Specifid",Trade Name|USAN|Research Code,Cancer,,,Anticancer|Therapeutic vaccine|Protein subunit vaccine,1545|12379|12372,,,B-cell lymphoma,316,,,MMRGlobal,29502,MMRGlobal,29502,,,,,,
40061,pasireotide diaspartate,"pasireotide|somatostatin analog (neuroendocrine tumors/acromegaly/Cushing's disease), Novartis|SOM-230B|pasireotide diaspartate|Signifor|SOM-230",USAN|INN|Research Code|Trade Name|Research Code,Cancer|Endocrine/Metabolic|Gastrointestinal|Neurology/Psychiatric|Other/Miscellaneous,Somatostatin 5 receptor agonist|Somatostatin 2 receptor agonist|Somatostatin 3 receptor agonist|Somatostatin 1 receptor agonist,2571|2562|2565|2559,Analgesic|Growth hormone release inhibitor|Anticancer,2946|3272|1545,Thyroid tumor|Hormone refractory prostate cancer|Hypoglycemia|Cluster headache|Cushings disease,1134|3246|445|73|87,Neuroendocrine tumor|Gastrointestinal tumor|Nelson syndrome|Dumping syndrome|Meningioma|Carcinoid syndrome|Surgical procedure|Merkel cell carcinoma|Stage IV melanoma|Uveal melanoma|Acromegaly,1128|131|1679|2083|2802|2966|2979|3235|3257|3788|5,Recordati SpA,24154,Novartis AG|Novartis Pharma AG,23137|25599,Novartis Pharma AG,25599,,,,,,
40115,radium-223 dichloride,"ATI-BC-2|bone metastases therapy, Anticancer Therapeutic Inventions|radium-223 (bone metastases), Algeta|223Ra-based alpha-particle emitting therapy (bone metastases), Algeta|radium-223 dichloride|Alpharadin|radium Ra 223 dichloride|223Ra-chloride|Radium-223-chloride|BAY-88-8223|Xofigo",Research Code|Trade Name|USAN|Research Code|Trade Name,Cancer,,,Bone synthesis inhibitor|Radiotherapeutic|Anticancer,527|5721|1545,Osteosarcoma|Bone metastases|Hormone refractory prostate cancer|Metastatic renal cell carcinoma,1772|1829|3246|4250,Multiple myeloma|Metastatic breast cancer|Breast tumor|Cancer,1828|3657|49|651,Bayer AG,14455,Algeta ASA,28819,Algeta ASA,28819,,,,,,
40371,technetium (99mTc) etarfolatide,"99mTc-EC-20|111In-DTPA-folate|folate-targeted imaging agents (cancer/rheumatoid arthritis), Endocyte|technetium Tc 99m etarfolatide|FolateScan|technetium-99m-EC-20|EC-20-[99mTc]|technetium (99mTc) etarfolatide|Neocepri|Folcepri|Tc-99m-EC20|NMK-20",Research Code|USAN|Trade Name|Research Code|Research Code|PINN|Trade Name|Trade Name|Research Code|Research Code,Cancer|Immune|Inflammatory,Folate receptor modulator,1323,SPECT contrast agent|Endocrine diagnostic agent|Radiodiagnostic|Neoplasm diagnostic agent|Anti-inflammatory|Autoimmune diagnostic agent|CNS diagnostic agent,5556|7212|5720|7220|2953|7217|7211,,,Metastasis|Pituitary tumor|Non-small-cell lung cancer|Endometrioid carcinoma|Inflammatory disease|Rheumatoid arthritis|Metastatic renal cell carcinoma|Cancer|Ovary tumor,1069|1131|1262|1705|188|291|4250|651|799,,,Endocyte Inc|Nihon Medi-Physics Co Ltd,26000|26383,Endocyte Inc,26000,,,,,,
40532,tenofovir alafenamide fumarate,GS-7340|GS-7340 fumarate|tenofovir alafenamide|tenofovir alafenamide fumarate|GS-7340 hemifumarate|tenofovir alafenamide monofumarate|Vemlidy,Research Code|USAN|INN|USAN|Research Code|Trade Name,Infection,Nucleoside reverse transcriptase inhibitor,1832,Antiviral|HIV replication inhibitor,991|747,Hepatitis B virus infection,152,HIV infection,158,Gilead Sciences Inc,16450,,,Gilead Sciences Inc,16450,,,,,,
40694,romiplostim,"AMG-531|Mpl-binding peptibody (thrombocytopenia), Amgen|thrombopoietin agonist peptibody (thrombocytopenia), Amgen|romiplostim|Romiplate|Nplate",Research Code|USAN|INN|Trade Name|Trade Name,Cancer|Hematologic|Toxicity/Intoxication,Thrombopoietin receptor agonist,3610,Anticancer|Hematopoietic stimulator,1545|610,Aplastic anemia|Immune thrombocytopenic purpura|Thrombocytopenia|Radiation sickness,1006|2259|324|367,Myelodysplastic syndrome,1272,Amgen Inc|Kyowa Hakko Kirin Co Ltd,14109|1042596,Hypera Pharma SA,1058614,Amgen Inc,14109,,,,,,
40735,dovitinib,"GFKI-258|GFKI, Chiron|VEGFR kinase inhibitor, Chiron|growth factor kinase inhibitor, Chiron|VEGF receptor kinase inhibitor (cancer), Chiron|VEGF/FGF/PDGF receptor kinase inhibitor, Chiron|VEGFR kinase inhibitor, Novartis|VEGF receptor kinase inhibitor (cancer), Novartis|growth factor kinase inhibitor, Novartis|VEGF/FGF/PDGF receptor kinase inhibitor, Novartis|GFKI, Novartis|TKI-258|dovitinib|dovitinib lactate (USAN)|CHIR-258|dovitinib lactate|TK-1258|Dovitinib DPR|dovitinib, Allarity Therapeutics",Research Code|Research Code|INN|USAN|Research Code|Trade Name,Cancer,PDGF receptor antagonist|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist|VEGF-3 receptor antagonist|TrkA receptor antagonist|Ret tyrosine kinase receptor inhibitor|Kit tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|FGF3 receptor antagonist|FGF2 receptor antagonist|FGF1 receptor antagonist|CSF-1 antagonist|SL cytokine ligand inhibitor,948|3846|3848|3850|3840|3818|3808|3806|3688|3685|3682|3154|15591,Anticancer|Anticancer protein kinase inhibitor|Metastasis inhibitor|Angiogenesis inhibitor,1545|62255|695|61,Endometrioid carcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Osteosarcoma|Liver tumor|Gastrointestinal stromal tumor|Breast tumor,1705|1766|1767|1772|202|3205|49,Mesothelioma|Non-small-cell lung cancer|Hippel Lindau syndrome|Adrenal cortical carcinoma|Acute myelogenous leukemia|Multiple myeloma|Hematological neoplasm|Bladder cancer|Glioblastoma|Adenoid tumor|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic breast cancer|Metastatic stomach cancer|Advanced solid tumor|Inflammatory breast cancer|Metastatic renal cell carcinoma|Cancer|Solid tumor|Colorectal tumor,1240|1262|1612|1648|1731|1828|2054|2380|2454|3153|3246|3257|3657|3666|3713|3948|4250|651|725|989,OV-SPV2 ApS,1143038,Chiron Corp|Novartis AG,15385|23137,Chiron Corp,15385,,,,,,
40737,tiomolibdate choline,"ATN-224|angiogenesis inhibitor, Attenuon|superoxide dismutase 1 inhibitor, Attenuon|bis-choline tetrathiomolybdate|WTX-101|Decuprate|ALXN-1840|tiomolibdate choline|tiomolibdate choline (oral, wilson disease/amyotrophic lateral sclerosis), Alexion Pharmaceuticals",Research Code|Research Code|Trade Name|Research Code|USAN,Cancer|Gastrointestinal|Neurology/Psychiatric,Superoxide dismutase inhibitor,356,Anticancer|Copper metabolism modulator|Angiogenesis inhibitor|CNS modulator|Chelating agent,1545|56120|61|2939|105,Primary biliary cholangitis|Motor neurone disease|Wilson disease,1995|212|2219,Myelodysplastic syndrome|Multiple myeloma|Leukemia|Lymphoma|Prostate tumor|Breast tumor|Cancer|Solid tumor,1272|1828|199|203|276|49|651|725,Alexion Pharmaceuticals Inc,13979,Tactic Pharma LLC|Wilson Therapeutics AB|Immedica Pharma AB|University of Michigan|Attenuon LLC,1064214|1072712|1073345|20623|29190,University of Michigan,20623,,,,,,
40742,tertomotide,"GV-1001|HR-2802|telomerase vaccine (cancer, injectable/peptide), KAEL-GemVax|HR-2822|hTERT611-626|tertomotide|Riavax|KDDF-201609-02",Research Code|Research Code|Research Code|INN|Trade Name,Cancer|Genitourinary/Sexual Function|Immune|Infection|Neurology/Psychiatric,Telomerase modulator,1613,Nootropic agent|Antiviral|Anti-inflammatory|Therapeutic vaccine|Neuroprotectant|Protein subunit vaccine|Anticancer,284|991|2953|12379|1615|12372|1545,Prostate hyperplasia|Non-small-cell lung cancer|Alzheimers disease|Hepatitis B virus infection|Chronic lymphocytic leukemia|Melanoma|Multiple sclerosis|Pancreas tumor|Prostate tumor|Colorectal tumor,1241|1262|14|152|1734|205|213|249|276|989,Hepatocellular carcinoma|Solid tumor,1767|725,Samsung Pharmaceuticals|GemVax AS|KAEL-GemVax Co Ltd,1029835|29871|1101787,,,GemVax AS,29871,,,,,,
40750,"doxorubicin (heat-sensitive liposomes, cancer), Celsion GmbH","doxorubicin|LTSDEL, Celsion|drug delivery system (doxorubicin), Celsion|doxorubicin (heat-sensitive liposomes, cancer), Celsion|heat-sensitive liposomes (doxorubicin), Celsion|ThermoDox|LTLD, Celsion|lyso-thermosensitive liposomal doxorubicin, Celsion|lyso-thermosensitive liposomal doxorubicin, Celsion GmbH|doxorubicin (heat-sensitive liposomes, cancer), Celsion GmbH|drug delivery system (doxorubicin), Celsion GmbH|heat-sensitive liposomes (doxorubicin), Celsion GmbH",USAN|BAN|INN|Trade Name|Trade Name|Trade Name|Trade Name,Cancer,DNA polymerase inhibitor|Topoisomerase II inhibitor,138|142,DNA intercalator|Anticancer,750|1545,Bone tumor|Liver tumor|Bladder cancer|Glioblastoma|Pancreas tumor|Metastatic liver cancer|Metastatic breast cancer|Breast tumor,1012|202|2380|2454|249|3462|3657|49,Prostate tumor|Cancer,276|651,Yakult Honsha Co Ltd|Celsion Corp|Celsion GmbH,20961|25628|1258109,Zhejiang Hisun Pharmaceutical Co Ltd,1019688,Celsion Corp,25628,,,,,,
40855,saracatinib,AZD-0530|saracatinib|NSC-735464|saracatinib difumarate|ADZ-0530|AZ-0530|AZD-O530|AZ-10353926,Research Code|USAN|INN|Research Code|USAN|Research Code|Research Code|Research Code|Research Code,Cancer|Genitourinary/Sexual Function|Hematologic|Inflammatory|Musculoskeletal|Neurology/Psychiatric|Respiratory|Toxicity/Intoxication,Abl tyrosine kinase inhibitor|Fyn tyrosine kinase inhibitor|Src tyrosine kinase inhibitor,3524|3574|3576,Antipsychotic|Antiparkinsonian|Analgesic|Anti-inflammatory|Cell cycle inhibitor|Metastasis inhibitor|Neuroprotectant|Anticancer protein kinase inhibitor|Fibrosuppressant,2943|2947|2946|2953|767|695|1615|62255|664,Alcoholism|Alzheimers disease|Psychiatric disorder|Psychotic disorder|Ostealgia|Lymphangioleiomyomatosis|Fibrodysplasia ossificans progressiva|Idiopathic pulmonary fibrosis|Otitis media|Breast tumor,11|14|207|282|2854|3023|3219|3771|394|49,Hematological disease|Solid tumor|Colorectal tumor,142|725|989,Imperial College London|Mount Sinai School of Medicine|Medical Research Council|National Jewish Health|Baylor College of Medicine|University of Sheffield|AstraZeneca plc|Yale University,23577|20631|18438|18461|20534|21194|14190|20703,,,AstraZeneca plc,14190,,,,,,
41177,Combotox,Combotox|IgG-RFB4-dgA and IgG-HD37-dgA|ricin-conjugated anti-CD22 and anti-CD19|IMTOX 22|anti CD22/ricin|anti CD22/N97A|anti CD19 + anti CD22/N97A,,Cancer,B-lymphocyte antigen CD19 inhibitor|B-lymphocyte cell adhesion molecule inhibitor,5082|5091,Immunotoxin|Anticancer monoclonal antibody,539|55685,,,Leukemia,199,,,Abiogen Pharma SpA|University of Texas Southwestern Medical Center,25553|25760,University of Texas Southwestern Medical Center,25760,,,,,,
4119,tadalafil,"Cialis|GF-196960|IC-351|ICOS-351|tadalafil|GG-960|ICI-351|LY-450190|PDE 5 inhibitor, ICOS/Lilly|PDE V inhibitor, Lilly/ICOS|Adcirca|Zalutia|Tadalafil Lilly",Trade Name|Research Code|Research Code|Research Code|USAN|INN|Research Code|Research Code|Research Code|Trade Name|Trade Name,Cardiovascular|Endocrine/Metabolic|Genitourinary/Sexual Function|Musculoskeletal,PDE 5 inhibitor,778,Antihypertensive|Vasodilator|Muscle relaxant,2657|388|5557,Prostate hyperplasia|Erectile dysfunction|Pulmonary artery hypertension,1241|186|3510,Female sexual dysfunction|Hypertension|Duchenne dystrophy|Angina|Male sexual dysfunction|Cardiac failure|Diabetic complication,1276|178|2020|23|369|55|99,United Therapeutics Corp|Eli Lilly & Co|Nippon Shinyaku Co Ltd|Lupin Ltd,25439|17810|18552|21932,Chugai Lilly Clinical Research Co Ltd|Glaxo Group Ltd|Eli Lilly Japan KK|Lilly ICOS LLC,14165|16453|22692|26941,Lilly ICOS LLC,26941,,,,,,
4126,pioglitazone,pioglitazone hydrochloride|U 72107|pioglitazone|AD-4833|U-72107A|Actos OD|Actos|Glustin|TOMM40,USAN|INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Cardiovascular|Endocrine/Metabolic|Gastrointestinal|Genitourinary/Sexual Function|Immune|Neurology/Psychiatric,Insulin sensitizer|PPAR gamma agonist,1919|2480,Hypoglycemic agent|Neuroprotectant,399|1615,Urolithiasis|Non-insulin dependent diabetes,1046|837,Alzheimers disease|Hyperlipidemia|Multiple sclerosis|Non-alcoholic steatohepatitis|Atherosclerosis,14|175|213|2637|33,Takeda Pharma GmbH|Pfizer Inc|Teva Takeda Yakuhin Ltd|Eli Lilly & Co|Hikma Pharmaceuticals plc|Takeda Pharmaceutical Co Ltd|Celltrion Healthcare Co Ltd,20306|18767|1121665|17810|1022379|20300|1105372,Pharmacia & Upjohn Co,18995,Takeda Pharmaceutical Co Ltd,20300,,,,,,
4144,Prevnar,"PCV-7|PNCRM7|Prevnar|Prevenar|polyvalent pneumococcal vaccine, Praxis|pneumococcus/CRM-197 conjugate vaccine, Pfizer|vaccine (pneumococcal), Praxis/American Home Products|7vPnC, Pfizer|7VPCV",Research Code|Trade Name|Trade Name,Infection|Inflammatory,,,Prophylactic vaccine|Subunit vaccine,12378|12371,Streptococcus pneumoniae infection|Otitis media,313|394,,,Pfizer Vaccines|Yuhan Corp|Pfizer Inc,25584|20984|18767,,,Pfizer Vaccines,25584,,,,,,
4147,porfimer sodium,Photobarr|Photofrin|dihematoporphyrin ether|CL-184116|DHE|Photofrin 2|porfimer sodium,Trade Name|Trade Name|Research Code|USAN|BANN|INN,Cancer|Genitourinary/Sexual Function,,,Photosensitizer|Radical donator|Anticancer,799|415|1545,Esophagus tumor|Mesothelioma|Prostate hyperplasia|Stomach tumor|Bladder tumor|Uterine cervix tumor|Carcinoma|Lung tumor|Brain tumor,1011|1240|1241|127|42|427|54|755|760,Cholangiocarcinoma|Head and neck tumor|Kaposis sarcoma,1765|623|936,Sanofi Winthrop France SA|ADVANZ PHARMA Corp|Ipsen|Wyeth KK|Ligand Pharmaceuticals Inc|Pinnacle Biologics Inc|Cyanamid Benelux NV,26684|1083136|17259|22673|17808|1037721|14114,Axcan Pharma Inc|Novelion Therapeutics Inc|Takeda Pharmaceutical Co Ltd,1062963|19180|20300,Novelion Therapeutics Inc,19180,,,,,,
4155,pravastatin,"CS-514|Epastatin sodium|Mevalotin|Pravachol|pravastatin sodium|SQ-31000|eptastatin|pravastatin|Elisor|Liplat|Vasten|CS-514E|CS-514S|Lipostat|Selectin|lavastatin|ravaselect|eptastatin sodium|HMG-CoA reductase inhibitor (hypercholestrolemia), Bristol-Myers Squibb/ Merck Serono|Sanaprav",Research Code|Trade Name|Trade Name|USAN|Research Code|BAN|INN|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Trade Name|Trade Name|Trade Name,Endocrine/Metabolic,HMG CoA reductase inhibitor,205,Antihypercholesterolemic agent|Antihyperlipidemic agent,71|72,Lipid metabolism disorder,584,,,Daiichi Sankyo Co Ltd|Bristol-Myers Squibb Co,1017506|15065,Sankyo Co Ltd|Merck Serono SA,19658|19862,Sankyo Co Ltd,19658,,,,,,
41702,ponatinib,"oncogenic kinase inhibitors (cancer), ARIAD|AP-23464|AP-24534|dual Abl/Src inhibitors (cancer), ARIAD|AP-24283|ponatinib|ponatinib hydrochloride|Iclusig",Research Code|Research Code|Research Code|USAN|INN|USAN|Trade Name,Cancer,Bcr protein inhibitor|PDGF receptor antagonist|RET gene inhibitor|Protein tyrosine kinase inhibitor|Tek tyrosine kinase receptor inhibitor|Ret tyrosine kinase receptor inhibitor|Kit tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|EPH family tyrosine kinase inhibitor|Src tyrosine kinase inhibitor|ABL family tyrosine kinase inhibitor|VEGF receptor antagonist|FGF receptor antagonist,13571|948|45359|385|3834|3818|3808|3806|3762|3576|3522|1722|168,Anticancer protein kinase inhibitor|Apoptosis stimulator,62255|1589,Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia|Glioblastoma,1728|1731|1735|2454,Non-small-cell lung cancer|Endometrioid carcinoma|Gastrointestinal stromal tumor|Medullary thyroid cancer|Cancer|Solid tumor,1262|1705|3205|3240|651|725,Specialised Therapeutics Australia Pty Ltd|Pint Pharma|Incyte Corp|Angelini Pharma Inc|Otsuka Pharmaceutical Co Ltd|ARIAD Pharmaceuticals Inc|Biologix FZ Co|Gen Ilac|Medison Pharma Ltd|Takeda Pharmaceutical Co Ltd|Paladin Labs Inc,1044298|1110054|17216|1090265|18717|14296|1021693|1063033|29943|20300|27477,,,ARIAD Pharmaceuticals Inc,14296,,,,,,
41710,NSC 637037,O6-benzylguanine|Alkylade|NSC 637037|KRX-0402,Trade Name|Research Code|Research Code,Cancer,O6 methylguanine DNA alkyltransferase inhibitor,6518,Anticancer chemosensitizer,1586,,,Cutaneous T-cell lymphoma|Multiple myeloma|Sarcoma|Melanoma|Cancer|Brain tumor|Colorectal tumor,1754|1828|194|205|651|760|989,,,Paligent Inc|National Cancer Institute (NCI)|Pennsylvania State University|Keryx Biopharmaceuticals Inc|ACCESS Oncology Inc,19142|20519|25251|27395|29235,Pennsylvania State University,25251,,,,,,
4200,sirolimus,"rapamycin|AY-22989|sirolimus|NSC-226080|Rapamune|NSC-606698|rapamycin analogs, Pfizer|sirolimus analogs, Pfizer|NPC-12|Rapalimus",Research Code|USAN|BANN|INN|Research Code|Trade Name|Research Code|Research Code|Trade Name,Cancer|Immune|Neurology/Psychiatric,mTOR inhibitor,10240,T-lymphocyte inhibitor|Anticancer|Immunosuppressant|Protein synthesis inhibitor|Anticonvulsant agent,7760|1545|396|339|70,Epilepsy|Chondrosarcoma|Liposarcoma|Kidney transplant rejection|Lymphangioleiomyomatosis|Lymphatic system disease,119|2444|2447|2989|3023|779,Liver transplant rejection|Systemic lupus erythematosus|Graft versus host disease,2988|318|616,Nobelpharma Co Ltd|Pfizer Inc,1012128|18767,Wyeth|Wyeth Pharmaceuticals,14112|14199,Wyeth Pharmaceuticals,14199,,,,,,
42140,"mebendazole (cancer), Introgen Therapeutics","mebendazole|mebendazole (cancer), Introgen Therapeutics",USAN|BANN|INN,Cancer,Tubulin binding agent,499,Apoptosis stimulator|Cell cycle inhibitor|Microtubule inhibitor|Angiogenesis inhibitor,1589|767|2575|61,,,Cancer|Lung tumor,651|755,,,Introgen Therapeutics Inc,17255,Introgen Therapeutics Inc,17255,,,,,,
42147,fidaxomicin,"R-tiacumicin B|OPT-80|PAR-101|fidaxomicin|Difimicin|Dificid|Dificlir|fidaxomicin (oral suspension, C difficile infection), Optimer|fidaxomicin (oral suspension, C difficile infection), Cubist Pharmaceuticals|ASP-2819|Dafclir",Research Code|Research Code|USAN|INN|Trade Name|Trade Name|Research Code,Gastrointestinal|Infection,RNA polymerase inhibitor|Cytochrome P450 reductase inhibitor,347|416,Macrolide antibiotic|RNA synthesis inhibitor|Antibacterial|Bacterial protein synthesis inhibitor|Synergist,1540|439|1594|1538|7293,Diarrhea|Clostridium difficile infection,102|995,Enterococcus infection,1481,Specialised Therapeutics Australia Pty Ltd|Cubist Pharmaceuticals Inc|Tillotts Pharma AG|AstraZeneca plc|Astellas Pharma Inc|Merck & Co Inc,1044298|21697|22956|14190|1013295|18077,OBI Pharma Inc|Par Pharmaceutical Co Inc|Optimer Pharmaceuticals Inc,1089119|28968|29549,Optimer Pharmaceuticals Inc,29549,,,,,,
42203,JNK-401,CC-401|JNK-401,Research Code|Research Code,Cancer|Dermatologic|Endocrine/Metabolic|Inflammatory,Jun N terminal kinase-1 inhibitor|Jun N terminal kinase-2 inhibitor|Jun N terminal kinase inhibitor,4378|4380|4376,Anti-inflammatory|Anticancer protein kinase inhibitor|Immunomodulator|Anticancer|Systemic antipsoriatic product,2953|62255|1596|1545|15184,,,Acute myelogenous leukemia|Inflammatory disease|Psoriasis|Cancer|Diabetes mellitus,1731|188|281|651|97,,,Celgene Corp,15331,Celgene Corp,15331,,,,,,
42257,ispinesib,715992|ispinesib|SB-715992|ispinesib mesylate|SB-715992S|CK-0238273,Research Code|INN|Research Code|USAN|Research Code|Research Code,Cancer,Kinesin-like protein KIF11 inhibitor,11105,Cell cycle inhibitor,767,,,Non-small-cell lung cancer|Acute leukemia|Renal cell carcinoma|Hepatocellular carcinoma|Melanoma|Hormone refractory prostate cancer|Breast tumor|Head and neck tumor|Solid tumor|Ovary tumor|Colorectal tumor,1262|1727|1766|1767|205|3246|49|623|725|799|989,,,Cytokinetics Inc|GlaxoSmithKline plc,26068|28355,Cytokinetics Inc,26068,,,,,,
42299,ofatumumab,"HuMax-CD20|ofatumumab|2F2|anti-CD20 human monoclonal antibody (intravenous), GlaxoSmithKline/ Genmab|GSK-1841157|Arzerra",USAN|INN|Research Code|Trade Name,Cancer|Hematologic|Immune,B-lymphocyte antigen CD20 inhibitor,5085,Anticancer monoclonal antibody,55685,Chronic lymphocytic leukemia,1734,Macroglobulinemia|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Rheumatoid arthritis|B-cell lymphoma|Non-Hodgkin lymphoma,1264|1744|1745|1746|1749|291|316|319,Novartis AG,23137,Genmab A/S|GlaxoSmithKline plc,26469|28355,Genmab A/S,26469,,,,,,
4234,risedronate sodium,risedronate sodium|Residronate|risedronic acid|NE-58095|Actonil|HMR-4003|risedronate sodium hydrate|risedronate|NE-58093|Actonel|Libertas 150|Benet|Actonel EC|Actonel OaM|NE-58095NF|Optinate|Acrel,USAN|BAN|INN|Research Code|Trade Name|Research Code|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name,Inflammatory|Musculoskeletal,,,Bone resorption inhibitor|Osteoclast inhibitor,89|12596,Osteoporosis|Male osteoporosis|Postmenopausal osteoporosis|Pagets bone disease,246|2548|2549|2855,Osteoarthritis|Osteogenesis imperfecta|Bone resorption,245|2498|3443,Sanofi SA|Eisai Co Ltd|AbbVie Inc|Takeda Pharmaceutical Co Ltd|Ajinomoto Co Inc,1009547|15872|1072507|20300|13794,Handok-Aventis|Allergan plc|The Procter & Gamble Co|Aventis Pharma AG|Hoechst Marion Roussel Inc|Procter & Gamble Pharmaceuticals Inc|Warner Chilcott plc,1057390|1088700|19143|25218|25224|27500|27724,Procter & Gamble Pharmaceuticals Inc,27500,,,,,,
42577,AT-7519,"AT-660|AT-2035|AT-3409|AT-3864|AT-3969|AT-4720|CDK2 inhibitors, Astex|cyclin dependent kinase-2 inhibitors, Astex|AT-1772|AT-381|AT-3424|AT-3851|CDK2 inhibitors (cancer), Astex|AT-7519|AT-9211|AT-7519M",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Cyclin-dependent kinase-7 inhibitor|Cyclin-dependent kinase-9 inhibitor|RNA polymerase II inhibitor|Glycogen synthase kinase-3 beta inhibitor|Cyclin-dependent kinase-1 inhibitor|Cyclin-dependent kinase-2 inhibitor|Cyclin-dependent kinase-3 inhibitor|Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase-5 inhibitor|Cyclin-dependent kinase-6 inhibitor,4304|8110|6827|4360|4308|4310|4312|4314|4316|4318,Apoptosis stimulator|Anticancer protein kinase inhibitor|Cell cycle inhibitor,1589|62255|767,,,Chronic lymphocytic leukemia|Mantle cell lymphoma|Multiple myeloma|Hematological neoplasm|Non-Hodgkin lymphoma|Cancer|Solid tumor,1734|1744|1828|2054|319|651|725,,,Astex Pharmaceuticals Inc|Astex Therapeutics Ltd,21885|28026,Astex Therapeutics Ltd,28026,,,,,,
4271,ropivacaine,LEA-103|ropivacaine|AL-381|AL-281|Narapin|Naropin|Anapaine|ropivacaine hydrochloride|Naropin Polyamp|Narop,Research Code|INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name|USAN|Trade Name|Trade Name,Gastrointestinal|Neurology/Psychiatric,Sodium channel inhibitor,498,Local anesthetic|Analgesic,1669|2946,Anesthesia|Pain,19|20,Ulcerative colitis,337,Aspen PharmaCare Holdings Ltd|Pierrel SpA|AstraZeneca plc,1019374|22048|14190,Astra AB|AstraZeneca KK,16881|16893,AstraZeneca plc,14190,,,,,,
42759,elesclomol sodium,"STA-4783|STA-5370|immunomodulatory taxane enhancer (cancer), Synta|elesclomol|elesclomol sodium|immunomodulatory taxane enhancer (cancer), Madrigal",Research Code|Research Code|Metabolite|USAN|INN,Cancer,,,Electron transport chain pathway modulator|Copper uptake modulator|Anticancer|Copper metabolism modulator|Apoptosis stimulator,52502|56121|1545|56120|1589,Non-small-cell lung cancer|Acute myelogenous leukemia|Ovary tumor,1262|1731|799,Sarcoma|Melanoma|Hormone refractory prostate cancer|Breast tumor|Solid tumor,194|205|3246|49|725,Madrigal Pharmaceuticals Inc,30180,GlaxoSmithKline plc,28355,Madrigal Pharmaceuticals Inc,30180,,,,,,
42858,ustekinumab,"anti-IL-12p40/IL-23p40 mAb (inflammatory disorders), Centocor|CNTO-1275|ustekinumab|anti-IL-12/IL-23 mAb (inflammatory disorders), Centocor|Stelara",Research Code|USAN|INN|Trade Name,Dermatologic|Endocrine/Metabolic|Gastrointestinal|Immune|Inflammatory|Musculoskeletal,IL-12 receptor antagonist|IL-23 antagonist,1584|9748,Anti-inflammatory|Therapeutic antibody,2953|172641,Psoriatic arthritis|Pouchitis|Psoriasis|Ulcerative colitis|Crohns disease,1781|2468|281|337|84,Sarcoidosis|Atopic dermatitis|Primary biliary cholangitis|Multiple sclerosis|Rheumatoid arthritis|Spondylarthritis|Systemic lupus erythematosus|Hidradenitis suppurativa|Insulin dependent diabetes,1036|1102|1995|213|291|2921|318|3542|836,Mitsubishi Tanabe Pharma Corp|Janssen Biotech Inc|Janssen-Cilag Ltd,1035060|26997|17392,Johnson & Johnson,17332,Janssen Biotech Inc,26997,,,,,,
42998,tanezumab,"RI-206|RI-624|pain therapeutics, Pfizer|RN-624|recombinant humanized anti-NGF monoclonal (pain), Pfizer/Genentech|m-911|muMab 911|PF-4383119|PF-04383119|tanezumab",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN,Genitourinary/Sexual Function|Inflammatory|Musculoskeletal|Neurology/Psychiatric,NGF receptor antagonist|Nerve growth factor ligand inhibitor,264|70813,Therapeutic antibody|Anti-inflammatory|Analgesic,172641|2953|2946,Osteoarthritis|Cancer pain,245|3211,Diabetic neuropathy|Pain|Ostealgia|Lower back pain,101|20|2854|3437,Eli Lilly & Co|Pfizer Inc,17810|18767,Genentech Inc|Rinat-Pfizer Inc,19453|29177,Rinat-Pfizer Inc,29177,,,,,,
43078,"mifepristone (Cushing's syndrome/cancer), Corcept Therapeutics","mifepristone|RU-009|RU-39009|RU-43044|RU-044|C-1073|mifepristone (psychotic major depression/ weight gain prevention/ Cushing's syndrome), Corcept|mifepristone (Alzheimer's disease), Corcept|Corlux|mifepristone (Cushing's syndrome/psychotic major depression), Corcept|Korlym|Corluxin|mifepristone (Cushing's syndrome/cancer), Corcept Therapeutics",INN|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Endocrine/Metabolic|Neurology/Psychiatric,Progesterone receptor antagonist|Glucocorticoid receptor antagonist,532|1886,Anticancer|Antipsychotic|Antidepressant|Nootropic agent,1545|2943|2941|284,Hormone refractory prostate cancer|Cushings syndrome|Metastatic breast cancer|Metastatic non small cell lung cancer,3246|3484|3657|3665,Alzheimers disease|Psychotic disorder|Ovary tumor|Cushings disease|Depression,14|282|799|87|93,Corcept Therapeutics Inc,28807,,,Corcept Therapeutics Inc,28807,,,,,,
43178,"darinaparsin (iv, cancer), Solasia Pharma","MER-1|arsenic derivative, MD Anderson|arsenic derivative, MD Anderson Cancer Center|ZIO-101|organic arsenic derivatives (cancer), ZIOPHARM|organic arsenicals (cancer), ZIOPHARM|ZIO-101 (iv, cancer), ZIOPHARM|darinaparsin (iv, cancer), ZIOPHARM|darinaparsin|S-dimethylarsino-glutathione|SGLU1|darinaparsin (iv, cancer), Solasia Pharma|Zinapar|SP-02L|Z-101, ZIOPHARM",Research Code|Research Code|USAN|INN|Trade Name|Research Code|Research Code,Cancer,,,Cell cycle inhibitor|Apoptosis stimulator|Synergist|Anticancer,767|1589|7293|1545,Peripheral T-cell lymphoma,1753,Hepatocellular carcinoma|Multiple myeloma|Hematological neoplasm|Non-Hodgkin lymphoma|Cancer|Solid tumor,1767|1828|2054|319|651|725,Solasia Pharma KK|HB Human BioScience SAS|Meiji Seika Pharma Co Ltd,1034811|1154393|18049,ZIOPHARM Oncology Inc|MD Anderson Cancer Center,1009856|23382,MD Anderson Cancer Center,23382,,,,,,
43218,131I-radretumab,"L-19|L-19-SIP|125I-L-19|131I-L-19|L-19-IgG1|125I-L-19-SIP|131I-L-19-SIP|125I-L-19-IgG1|131I-L-19-IgG1|L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen|scFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen|single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen|L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen|scFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen|single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen|131I-radretumab|131I-L19 small immunoprotein",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,CD29 modulator,5107,Angiogenesis inhibitor|Radioimmunotherapeutic|Radiodiagnostic|Neoplasm diagnostic agent|Anticancer|SPECT contrast agent|Immune diagnostic agent,61|1552|5720|7220|1545|5556|7215,,,Metastasis|Non-small-cell lung cancer|Hodgkins disease|Metastatic brain cancer|Cancer|Lung tumor,1069|1262|161|3471|651|755,,,Bayer Schering Pharma AG|ETH Zurich|Philogen SpA,19687|23144|29032,ETH Zurich,23144,,,,,,
43299,abexinostat,"HDAC inhibitors (anticancer), Celera|CRA-026440|CG-781|HDAC inhibitors (anticancer), Pharmacyclics|histone deacetylase inhibitors (anticancer), Celera|histone deacetylase inhibitors (anticancer), Pharmacyclics|CRA-024781|abexinostat|PCI-24781|abexinostat hydrochloride|S-78454",Research Code|Research Code|Research Code|USAN|INN|Research Code|USAN|Research Code,Cancer,Histone deacetylase inhibitor,2574,Cell cycle inhibitor|Anticancer|Apoptosis stimulator|Radiosensitizer,767|1545|1589|1542,Mesothelioma|Small-cell lung cancer|Endometrioid carcinoma|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Transitional cell carcinoma|Sarcoma|Lymphoma|Hematological neoplasm|Fallopian tube cancer|Adenocarcinoma|Squamous cell carcinoma|Peritoneal tumor|Non-Hodgkin lymphoma|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma|Ureter cancer|Breast tumor|Solid tumor,1240|1261|1705|1744|1745|1749|1771|194|203|2054|2243|2399|307|3083|319|3257|3657|3665|3666|3667|3668|3673|3713|3866|4250|4265|49|725,Nasopharyngeal carcinoma,1768,Xynomic Pharmaceuticals Holdings Inc,1144229,Pharmacyclics Inc|Servier|Celera Group,19063|19863|27836,Celera Group,27836,,,,,,
43538,"ciclosporin (ophthalmic, dry eye), Allergan","cyclosporine A|ciclosporin|cyclosporine|ciclosporin (ophthalmic), Allergan|cyclosporin A (ophthalmic, dry eye), Allergan|ciclosporin (ophthalmic, dry eye), Allergan|cyclosporin A|Restasis|Restasis Multidose",BANN|INN|USAN|Trade Name|Trade Name,Ocular,,,Anti-inflammatory|Immunomodulator|Unspecified drug target|Immunosuppressant|Ophthalmological agent,2953|1596|59620|396|15128,Xerophthalmia,3016,Keratoconjunctivitis|Ocular disease|Uveitis,1296|239|341,AbbVie Inc,1072507,Allergan plc|Allergan Inc|Novartis AG,1088700|14042|23137,Novartis AG,23137,,,,,,
43738,pazopanib,"GW-786034|pazopanib hydrochloride|GW-786034B|pazopanib|786034|pazopanib (oral, cancer), Novartis|Armala|Votrient|Patorma|PZP-115891",Research Code|USAN|Research Code|INN|Research Code|Trade Name|Trade Name|Trade Name|Research Code,Cancer|Cardiovascular|Dermatologic|Ocular,VEGF-1 receptor antagonist|Kit tyrosine kinase inhibitor|Ltk tyrosine kinase receptor inhibitor|FGF3 receptor antagonist|FGF1 receptor antagonist|Itk tyrosine kinase inhibitor|Lck tyrosine kinase inhibitor|VEGF-2 receptor antagonist|PDGF receptor beta antagonist|PDGF receptor alpha antagonist|VEGF-3 receptor antagonist|Protein tyrosine kinase inhibitor,3846|3808|3738|3688|3682|3594|3584|3848|48492|48489|3850|385,Apoptosis stimulator|Anticancer|Anticancer protein kinase inhibitor|Angiogenesis inhibitor,1589|1545|62255|61,Thyroid tumor|Hereditary hemorrhagic telangiectasia|Prostate tumor|Merkel cell carcinoma|Soft tissue sarcoma|Aggressive fibromatosis|Metastatic renal cell carcinoma,1134|1879|276|3235|3378|3504|4250,Testis tumor|Glioma|Neuroendocrine tumor|Age related macular degeneration|Non-small-cell lung cancer|Hippel Lindau syndrome|Acute myelogenous leukemia|Cholangiocarcinoma|Renal cell carcinoma|Multiple myeloma|Liver tumor|Fallopian tube tumor|Fallopian tube cancer|Bladder cancer|Angiosarcoma|Chondrosarcoma|Liposarcoma|Psoriasis|Peritoneal tumor|Gallbladder tumor|Gastrointestinal stromal tumor|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic head and neck cancer|Advanced solid tumor|Uterine cervix tumor|Breast tumor|Solid tumor|Ovary tumor|Colorectal tumor,1054|1108|1128|1226|1262|1612|1731|1765|1766|1828|202|2242|2243|2380|2443|2444|2447|281|3083|3146|3205|3665|3666|3673|3713|427|49|725|799|989,Novartis AG|GlaxoSmithKline plc|Cure HHT,23137|28355|1166826,,,GlaxoSmithKline plc,28355,,,,,,
43817,VRDN-001,"EM-164|anti-IGF-1 receptor antibody (cancer), ImmunoGen|anti-insulin-like growth factor-1 receptor antibody, ImmunoGen|anti-IGF-1 receptor antibody (cancer), sanofi-aventis|anti-IGF-1 receptor antibody (cancer), Aventis|anti-insulin-like growth factor-1 receptor antibody, Aventis|anti-insulin-like growth factor-1 receptor antibody, sanofi-aventis|AVE-1642|VRDN-001|anti-insulin-like growth factor-1 receptor antibody (iv, thyroid eye disease) Viridian Therapeutics|ZB-001",Research Code|Research Code|Research Code|Research Code,Cancer|Ocular,Insulin-like growth factor 1 receptor antagonist,3252,Anticancer monoclonal antibody|Anticancer hormone antagonist|Anticancer protein kinase inhibitor,55685|62254|62255,Thyroid associated ophthalmopathy,2967,Liver tumor|Breast tumor|Cancer,202|49|651,Viridian Therapeutics Inc|Zenas BioPharma,1039629|1238947,Sanofi SA|Viridian Therapeutics Inc (pre-merger)|ImmunoGen Inc|Aventis SA,1009547|1226456|17202|27254,ImmunoGen Inc,17202,,,,,,
43959,racotumomab,"1E10|P3 MAb, CIM|1E10 anti-idiotypic MAb, Center of Molecular Immunology|racotumomab|Vaxira (lung cancer), Recombio",Research Code|Research Code|INN|Trade Name,Cancer,P3 protein modulator,13149,Anticancer monoclonal antibody|Therapeutic vaccine,55685|12379,Glioma|Non-small-cell lung cancer|Nephroblastoma|Neuroblastoma|Retinoblastoma|Ewing sarcoma|Cancer,1108|1262|1770|2726|289|2975|651,Small-cell lung cancer|Melanoma|Breast tumor|Lung tumor|Colorectal tumor,1261|205|49|755|989,HAS Biotech|Laboratorio Elea|The Center of Molecular Immunology|Eurofarma,1160108|30635|29496|1042566,Innogene Kalbiotech Pte Ltd|Recombio|Chemo-Romikin,1011255|1045745|1045746,The Center of Molecular Immunology,29496,,,,,,
43982,pimasertib hydrochloride,"AS-701173|AS-701255|MEK inhibitor 1, Merck Serono|1820|AS-701820|MSC-1936369B|AS-703026|pimasertib hydrochloride|pimasertib",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|USAN|INN,Cancer|Inflammatory,MEK-1 protein kinase inhibitor|MEK-2 protein kinase inhibitor,4762|4764,Anticancer|Anticancer protein kinase inhibitor|Anti-inflammatory|Synergist|Apoptosis stimulator,1545|62255|2953|7293|1589,Ovary tumor,799,Acute myelogenous leukemia|Inflammatory disease|Hematological neoplasm|Pancreas tumor|Stage IV melanoma|Metastatic colorectal cancer|Cancer|Solid tumor,1731|188|2054|249|3257|3658|651|725,Day One Biopharmaceuticals,1227462,Merck Serono SA|Serono Pharmaceutical Research Institute SA,19862|25501,Serono Pharmaceutical Research Institute SA,25501,,,,,,
44157,fostamatinib disodium,"R-091|R-406|R-950091|Syk kinase inhibitors (rheumatoid arthritis), Rigel|fostamatinib disodium|R-935788 sodium|R-788|fostamatinib|Tavalisse|tamatinib fosdium|R-406/788|R-935788|fostamatinib disodium hexahydrate|Tavlesse",Research Code|Research Code|Research Code|USAN|Research Code|USAN|INN|Trade Name|Research Code|Research Code|Trade Name,Cancer|Cardiovascular|Genitourinary/Sexual Function|Hematologic|Immune|Infection|Inflammatory,Syk tyrosine kinase inhibitor,3602,Anticancer protein kinase inhibitor|Macrophage inhibitor|Synergist|Antiviral|Anti-inflammatory|Apoptosis stimulator|Platelet aggregation modulator|Antiarteriosclerotic|B-lymphocyte inhibitor,62255|7750|7293|991|2953|1589|1445|2667|7740,Coronavirus disease 19 infection|Immune thrombocytopenic purpura|Autoimmune hemolytic anemia|IgA nephropathy,10406|2259|2643|3076,Acute myelogenous leukemia|Peripheral T-cell lymphoma|Inflammatory disease|Lymphoma|Rheumatoid arthritis|B-cell lymphoma|Systemic lupus erythematosus|Atherosclerosis|Solid tumor,1731|1753|188|203|291|316|318|33|725,Kissei Pharmaceutical Co Ltd|Medison Pharma Ltd|JW Pharmaceutical Corp|Grifols SA|Rigel Pharmaceuticals Inc,17665|29943|15411|16581|25471,AstraZeneca plc,14190,Rigel Pharmaceuticals Inc,25471,,,,,,
44243,"NGR-hTNF (intravenous infusion, solid tumors), MolMed","tumor necrosis factor therapy (recombinant protein), MolMed|vascular-targeted TNF (NGR-TNF), MolMed SpA|vascular-targeted TNF (solid tumors, iv/infusion/biological therapeutic), MolMed|Arenegyr|CD13 TNF-alpha conjugate (solid tumors), MolMed|NGR-hTNF (solid tumors), MolMed|NGR-015|Zafiride|NGR-hTNF (intravenous infusion, solid tumors), MolMed",Research Code|Trade Name,Cancer,Aminopeptidase N modulator|TNF alpha ligand,5062|6928,Anticancer permeability enhancer|Apoptosis stimulator|Anticancer|Vascular damaging agent,561|1589|1545|2969,Mesothelioma|Small-cell lung cancer|Diffuse large B-cell lymphoma|Hepatocellular carcinoma|Soft tissue sarcoma|Metastatic non small cell lung cancer|Solid tumor|Central nervous system tumor|Ovary tumor|Colorectal tumor,1240|1261|1749|1767|3378|3665|725|759|799|989,,,"AGC Biologics S.p.A.,",30663,,,"AGC Biologics S.p.A.,",30663,,,,,,
44258,aciclovir,aciclovir|acyclovir|Zovirax|Zovir,INN|USAN|Trade Name|Trade Name,Infection,DNA polymerase inhibitor,138,Antiviral|HSV replication inhibitor,991|783,Herpes simplex virus infection|Varicella zoster virus infection,157|392,,,GlaxoSmithKline plc|Renaissance Acquisition Holdings LLC,28355|1084601,,,Glaxo Group Ltd,16453,,,,,,
44279,amoxicillin,Amoxillin|amoxicillin|Hiconcil|amoxicillin (USAN)|Amoxil,BANN|INN|Trade Name|USAN|Trade Name,Infection,,,Bacterial cell wall synthesis inhibitor|Antibacterial,104|1594,Bacterial infection,40,,,Aspen Global Inc,1125088,Bristol-Myers Squibb Co|GlaxoSmithKline plc,15065|28355,GlaxoSmithKline plc,28355,,,,,,
44281,betamethasone,betamethasone|Diprolene|Diprosone|Rinderon|Diprolene AF,USAN|BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name,Dermatologic|Immune,,,Steroidal anti-inflammatory|Topical antipsoriatic product|Corticosteroid agonist|Topical antipruritic product,2954|15183|3189|15180,Lichen|Eczema|Prurigo|Discoid lupus erythematosus|Psoriasis|Dermatitis,1071|109|2157|2560|281|94,,,Merck & Co Inc|Schering-Plough Corp|Shionogi & Co Ltd,18077|19711|19898,,,Schering-Plough Corp,19711,,,,,,
44289,enalapril,enalapril|Vasotec|Renivace|Renitec|Mepril|Enaloc|Xanef|Racen|Vitobel|Innovace|Enapren|Converten|Naprilene|Presitan|Crinoren,BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Cardiovascular,ACE inhibitor,18,Antihypertensive,2657,Hypertension|Cardiac failure,178|55,,,Bausch Health Companies Inc|Merck & Co Inc|Laboratoires Merck Sharp & Dohme Chibret SA,17058|18077|18092,Biovail Corp,22413,Merck & Co Inc,18077,,,,,,
44292,fluconazole,Diflucan|fluconazole|UK-049858|Zoltec,Trade Name|USAN|BANN|INN|Research Code|Trade Name,Genitourinary/Sexual Function|Infection|Other/Miscellaneous,Lanosterol-14 demethylase inhibitor,777,Systemic dermatological antifungal product|Fungicide,15178|1748,Female genital tract infection|Dermatomycosis|Fungal infection|Candida infection|Fungal respiratory tract infection|Balanitis|Fungal urinary tract infection|Cryptococcus neoformans meningitis|Tinea corporis|Tinea cruris|Tinea pedis|Prophylaxis|Cryptococcus infection,1027|1109|124|1308|1486|1788|1799|1813|2427|2428|2429|706|85,Tinea capitis,2426,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
44294,iohexol,iohexol|Omnipaque,USAN|BANN|INN|Trade Name,Cardiovascular|Neurology/Psychiatric,,,X-ray contrast medium|Cardiovascular diagnostic agent,4157|7210,Spinal cord disease|Vascular disease,2920|742,,,Bayer AG|GE Healthcare,14455|25593,Daiichi Seiyaku Co Ltd,15593,GE Healthcare,25593,,,,,,
44295,iopamidol,iopamidol|Isovue|Iopamiro|Iopamiron|Niopam,USAN|INN|Trade Name|Trade Name|Trade Name|Trade Name,Cardiovascular|Gastrointestinal|Genitourinary/Sexual Function,,,Cardiovascular diagnostic agent|Gastrointestinal diagnostic agent|X-ray contrast medium,7210|7213|4157,Gastrointestinal disease|Liver disease|Renal disease|Cardiovascular disease,129|201|286|57,,,Bayer AG|Bracco SpA|Schering AG,14455|24368|1052089,,,Bracco SpA,24368,,,,,,
44299,ketoconazole,ketoconazole|Nizoral|Nizale,INN|Trade Name|Trade Name,Dermatologic|Infection,,,Ergosterol synthesis inhibitor|Anti-inflammatory|Systemic dermatological antifungal product|Fungicide,161|2953|15178|1748,Candida infection|Dermatophytosis|Folliculitis,1308|2080|2558,,,Janssen-Cilag Ltd|Johnson & Johnson,17392|17332,,,Johnson & Johnson,17332,,,,,,
44300,lovastatin,lovastatin|Mevacor,USAN|BANN|INN|Trade Name,Cancer|Cardiovascular|Endocrine/Metabolic,HMG CoA reductase inhibitor,205,Antiarteriosclerotic|Antihypercholesterolemic agent|Antihyperlipidemic agent|Anticancer,2667|71|72|1545,Lipid metabolism disorder,584,Glioma|Hypercholesterolemia|Atherosclerosis,1108|174|33,Merck & Co Inc,18077,,,Merck & Co Inc,18077,,,,,,
44303,midazolam hydrochloride,midazolam|Hypnovel|midazolam hydrochloride|Versed|Dormicum|Dormonid,INN|Trade Name|USAN|Trade Name|Trade Name|Trade Name,Neurology/Psychiatric,Benzodiazepine receptor agonist,81,Anxiolytic|General anesthetic,2942|1668,Anesthesia|Anxiety disorder,19|25,,,Maruishi Pharmaceutical Co Ltd|Roche Holding AG,17951|19446,Astellas Pharma Inc,1013295,Roche Holding AG,19446,,,,,,
44305,omeprazole,Prilosec|omeprazole|Omepral|Omeprazon|Antra|Losec|Mopral|Omeprazone|Ulcid|Antra MUPS,Trade Name|USAN|BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Cancer|Gastrointestinal|Infection,H+ K+ ATPase inhibitor,208,Anticancer|Antibacterial|Acid pump inhibitor antiulcerant product|Gastric secretion inhibitor,1545|1594|38200|182,Endocrine tumor|Gastroesophageal reflux|Helicobacter pylori infection|Zollinger-Ellison syndrome|Stomach ulcer|Duodenal ulcer|Esophagitis,1004|1243|149|1512|805|808|810,,,AstraZeneca plc|Taiyo Pharma Co ltd|CHEPLAPHARM Arzneimittel GmbH|Mitsubishi Tanabe Pharma Corp,14190|1231567|1129377|1035060,Astellas Pharma Inc|Mitsubishi Pharma Corp,1013295|20983,AstraZeneca plc,14190,,,,,,
44306,pentoxifylline,pentoxifylline|Trental|Torental LP|Pentoxil,USAN|BANN|INN|Trade Name|Trade Name|Trade Name,Cardiovascular,Phosphoric diester hydrolase inhibitor,8052,Platelet aggregation inhibitor,312,Peripheral arterial occlusive disease,1598,,,Sanofi SA,1009547,Aventis SA,27254,Aventis SA,27254,,,,,,
44308,"propofol, AstraZeneca/Fresenius","propofol|propofol, AstraZeneca/Fresenius|ICI-35868|Diprivan|Diprivan EDTA",USAN|BANN|INN|Research Code|Trade Name|Trade Name,Neurology/Psychiatric,,,Anxiolytic|Hypnotic|Unspecified drug target|General anesthetic,2942|2944|59620|1668,Anesthesia,19,,,Fresenius Kabi USA Inc|Aspen PharmaCare Holdings Ltd,27814|1019374,AstraZeneca plc|Imperial Chemical Industries Plc,14190|17015,Imperial Chemical Industries Plc,17015,,,,,,
44309,ranitidine,ranitidine|Zantac|ranitidine hydrochloride|Antak,USAN|INN|Trade Name|USAN|Trade Name,Gastrointestinal,Histamine H2 receptor antagonist,201,Histamine H2 antagonist antiulcerant product|Gastrointestinal system agent,38199|1332,,,Gastrointestinal disease,129,,,Daiichi Sankyo Co Ltd|Aspen PharmaCare Holdings Ltd|Concordia Pharmaceuticals Inc|Teligent Inc|Covis Pharma Sarl|Glaxo Group Ltd|Sankyo Co Ltd|GlaxoSmithKline plc,1017506|1019374|1019729|1040945|1067053|16453|19658|28355,Glaxo Group Ltd,16453,,,,,,
44313,simvastatin,simvastatin|MK-733|Lipovas|Zocor|MK-0733,USAN|BANN|INN|Research Code|Trade Name|Trade Name|Research Code,Endocrine/Metabolic|Neurology/Psychiatric,HMG CoA reductase inhibitor,205,Antihypercholesterolemic agent,71,Hypercholesterolemia,174,Alzheimers disease,14,Merck & Co Inc,18077,,,Merck & Co Inc,18077,,,,,,
44314,tamoxifen,"tamoxifen|tamoxifen, AstraZeneca|Nolvadex|Tamofen|Istubal|Valodex|Nolvadex D",BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Cancer|Endocrine/Metabolic|Genitourinary/Sexual Function,Estrogen receptor antagonist,286,Anticancer hormone antagonist|Anticancer,62254|1545,Metastatic breast cancer|Breast tumor,3657|49,Gynecomastia|Mastalgia,1659|2794,AstraZeneca plc,14190,Zeneca Group plc,16955,Zeneca Group plc,16955,,,,,,
44316,zidovudine,zidovudine|AZT|Retrovir,INN|Trade Name,Infection,Nucleoside reverse transcriptase inhibitor,1832,Antiviral|HIV replication inhibitor,991|747,HIV-1 infection,159,,,GlaxoSmithKline plc,28355,,,GlaxoSmithKline plc,28355,,,,,,
44318,isotretinoin,isotretinoin|Roaccutane|Accutane|Roacutan,INN|Trade Name|Trade Name|Trade Name,Cancer|Dermatologic,Retinoic acid receptor agonist,753,Vitamin A agonist|Anticancer,727|1545,Acne,3,Anal dysplasia,1517,Fortress Biotech Inc|Roche Holding AG,1032809|19446,,,Roche Holding AG,19446,,,,,,
44337,SNS-032,"BMS-387032|SNS-032|cyclin-dependent kinase inhibitor (cancer), Sunesis",Research Code|Research Code,Cancer,Cyclin-dependent kinase-7 inhibitor|Cyclin-dependent kinase-2 inhibitor|Cyclin-dependent kinase-9 inhibitor,4304|4310|8110,Radiosensitizer|Cell cycle inhibitor|Apoptosis stimulator|Anticancer protein kinase inhibitor,1542|767|1589|62255,,,B-cell lymphoma|Cancer|Solid tumor,316|651|725,,,Bristol-Myers Squibb Co|Viracta Therapeutics Inc,15065|27713,Bristol-Myers Squibb Co,15065,,,,,,
44363,trimethoprim + sulphamethoxazole,trimethoprim + sulphamethoxazole|trimethoprim + sulfamethoxazole|Bactrim|Septra|Bactrim F|Bactramin|Bactramin Combination Tablet|Bactramin Combination Granule|TMP-SMX|Baktar,Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Infection|Respiratory,DHFR inhibitor,135,Anti-inflammatory|Fungicide|Antibacterial,2953|1748|1594,Urinary tract infection|Acute bronchitis|Pneumocystis carinii infection|Bacterial infection|Respiratory tract infection,1009|1487|271|40|509,,,Chugai Pharmaceutical Co Ltd|AR Scientific Inc|Roche Holding AG|Shionogi & Co Ltd,15414|1014583|19446|19898,,,Roche Holding AG,19446,,,,,,
44365,nadroparin calcium,nadroparin|nadroparin calcium|Fraxiparine|Calciparine|Fraxodi,BANN|INN|Trade Name|Trade Name|Trade Name,Cardiovascular|Hematologic,Low molecular weight heparin,1741,,,Unstable angina|Thromboembolism|Acute coronary syndrome|Deep vein thrombosis|Blood clotting disorder,1584|325|3258|574|75,,,Aspen PharmaCare Holdings Ltd|GlaxoSmithKline plc,1019374|28355,Sanofi SA|Sanofi-Synthelabo,1009547|26494,Sanofi-Synthelabo,26494,,,,,,
44366,captopril,captopril|Lopril,USAN|BANN|INN|Trade Name,Cardiovascular,ACE inhibitor,18,Cardiac agent|Antihypertensive,966|2657,Hypertension|Cardiac failure,178|55,,,Bristol-Myers Squibb Co|Par Pharmaceutical Co Inc,15065|28968,,,Bristol-Myers Squibb Co,15065,,,,,,
44370,clindamycin,clindamycin|Cleocin|Dalacin|Cleocin T|Cleocin Pediatric|Dalacin T|Dalacin C|Dalacin S,USAN|BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Dermatologic|Gastrointestinal|Infection|Inflammatory|Musculoskeletal|Ocular|Respiratory,,,Bacterial protein synthesis inhibitor|Macrolide antibiotic|Antibacterial|Ribosome binding agent|Fungicide,1538|1540|1594|463|1748,Female genital tract infection|Sinusitis|Osteomyelitis|Sepsis|Gram negative bacterium infection|Gram positive bacterium infection|Bacteroides infection|Streptococcus pyogenes infection|Bacterial respiratory tract infection|Acute bronchitis|Bacterial pneumonia|Mycoplasma infection|Bacterial vaginosis|Laryngitis|Tonsillitis|Dacryocystitis|Empyema|Cellulitis|Acne vulgaris|Staphylococcus aureus infection|Abscess|Abdominal abscess|Staphylococcus infection|Streptococcus infection|Streptococcus pneumoniae infection|Otitis externa|Peptostreptococcus infection|Prevotella infection|Bacterial eye infection|Otitis media|Bacterial infection|Peritonitis|Pharyngitis|Bacterial skin infection|Bone and joint infection,1027|1061|1135|114|137|138|1393|1475|1484|1487|1815|222|2240|2339|2345|2387|2437|2525|3040|308|3081|3082|309|312|313|3242|3305|3314|3764|394|40|452|453|485|554,,,Pfizer Inc,18767,Pharmacia Corp,27638,Pharmacia Corp,27638,,,,,,
44375,warfarin,warfarin|Coumadin,BANN|INN|Trade Name,Cardiovascular|Hematologic,Factor VII antagonist|Factor IX antagonist|Factor IIa antagonist|Vitamin K epoxide reductase inhibitor|Factor X antagonist,114|113|111|10583|119,Coagulation inhibitor,659,Lung embolism|Phlebothrombosis|Thromboembolism,1078|1845|325,,,Bristol-Myers Squibb Co,15065,Endo Health Solutions Inc|DuPont Pharmaceuticals Ltd,26192|26873,Endo Health Solutions Inc,26192,,,,,,
44383,carboplatin,carboplatin|Paraplatin|BMY-26575|CBDCA,USAN|BANN|INN|Trade Name|Research Code,Cancer,,,Anticancer alkylating agent|DNA synthesis inhibitor,50|140,Testis tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Lymphoma|Uterine cervix tumor|Breast tumor|Head and neck tumor|Solid tumor|Ovary tumor,1054|1261|1262|127|203|427|49|623|725|799,Esophagus tumor|Neuroendocrine tumor|Hormone refractory prostate cancer,1011|1128|3246,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
44398,cimetidine,cimetidine|Tagamet,USAN|BANN|INN|Trade Name,Gastrointestinal,Histamine H2 receptor antagonist,201,Histamine H2 antagonist antiulcerant product|Gastric secretion inhibitor,38199|182,Gastroesophageal reflux|Stomach ulcer,1243|805,,,GlaxoSmithKline plc,28355,,,GlaxoSmithKline plc,28355,,,,,,
44399,"nitroglycerin (transdermal), Novartis","nitroglycerin|nitroglycerin (transdermal), Novartis|Transderm-Nitro|NITRODERM",USAN|Trade Name|Trade Name,Cardiovascular,,,NO receptor agonist|Vasodilator,277|388,Angina,23,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
44401,vancomycin,"vancomycin|Vancocin|vancomycin hydrochloride|Vancocin Pulvules|vancomycin hydrochloride (bacterial infection), Eli Lilly/ANI Pharmaceuticals/Flynn Pharma/Shionogi/Searchlight Pharma",USAN|BANN|INN|Trade Name|USAN|Trade Name,Gastrointestinal|Infection|Musculoskeletal|Other/Miscellaneous,Peptidoglycan recognition protein inhibitor,57003,Antibacterial|Bacterial cell wall synthesis inhibitor|RNA synthesis modulator,1594|104|1479,Pseudomembranous colitis|Osteomyelitis|Sepsis|MRSA infection|Bacterial pneumonia|Enterocolitis|Staphylococcus aureus infection|Staphylococcus infection|Streptococcus pneumoniae infection|Bacterial infection|Prophylaxis|Clostridium difficile infection,1073|1135|114|1267|1815|2088|308|309|313|40|706|995,,,Searchlight Pharma Inc|ANI Pharmaceuticals Inc|Flynn Pharma Ltd|Eli Lilly & Co|Shionogi & Co Ltd,1125241|27120|1037295|17810|19898,Iroko Pharmaceuticals LLC|Merus Labs International Inc|Shire ViroPharma|Norgine BV,1031963|1062392|19046|28724,Eli Lilly & Co,17810,,,,,,
44403,lidocaine,lidocaine|Xylocaine|Xyloproct|Xylocard|Polyamp 0.5%|lidocaine hydrochloride (USAN),BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|USAN,Neurology/Psychiatric,,,Local anesthetic|Unspecified drug target,1669|59620,Pain,20,,,Bristol-Myers Squibb Co|Aspen PharmaCare Holdings Ltd,15065|1019374,Abraxis BioScience Inc|AstraZeneca plc|Celgene Corp,1020514|14190|15331,AstraZeneca plc,14190,,,,,,
44409,Fluzone,"influenza virus vaccine, Aventis SA|Vaxigrip|Fluzone|Fluzone TIV|Mutagrip|Mutagrip S Pasteur|Vaccino Mutagrip Pasteur|Mutagrip S|Istivac|Mutagrip Pasteur 2011/2012",Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Infection,,,Prophylactic vaccine|Inactivated viral vaccine,12378|12367,Influenza virus infection,191,,,Sanofi SA|Aventis SA,1009547|27254,Sanofi Pasteur MSD,23408,Aventis SA,27254,,,,,,
44414,"beclomethasone dipropionate, (CFC-free), Teva","beclomethasone dipropionate|TMP-96|HFA-134a BDP, HMR|HFA-BDP extrafine aerosol, 3M|beclometasone (inhaled, CFC-free), Teva|beclomethasone dipropionate (inhaled), 3M|beclomethasone dipropionate (MDI formulation)|beclomethasone dipropionate (Easi-Breathe), Ivax|Qvar|AeroBec Autohaler|Aerobec Ventolair|beclomethasone dipropionate, (CFC-free), Teva|Qvar BAI|Qvar RediHaler|Qvar Digihaler",USAN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Respiratory,Glucocorticoid receptor agonist,3191,Bronchodilator|Steroidal anti-inflammatory,646|2954,Asthma,31,,,Sumitomo Dainippon Pharma Co Ltd|Teva Pharmaceutical Industries Ltd,1017117|20348,Dainippon Pharmaceutical Co Ltd|Glaxo Group Ltd|IVAX Corp|Johnson & Johnson|Merck & Co Inc|3M Pharmaceuticals|Schering-Plough KK,15606|16453|17284|17332|18077|21568|23497,3M Pharmaceuticals,21568,,,,,,
44438,ciprofloxacin hydrochloride,ciprofloxacin|ciprofloxacin hydrochloride|BAY-Q-3939|Cipro|Ciprobay|Ciproxan|Baycip|Ciflox|Ciproxin|Ciproxina|Ciproxine|Uniflox|Ciloxan,USAN|BANN|INN|USAN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Gastrointestinal|Genitourinary/Sexual Function|Infection|Inflammatory|Other/Miscellaneous|Respiratory,Topoisomerase IV inhibitor|DNA gyrase inhibitor,9320|431,Bacterial nucleic acid synthesis inhibitor|Systemic dermatological antibacterial product|Antibacterial,3984|15187|1594,Diarrhea|Haemophilus infection|Enterobacter infection|Chronic obstructive pulmonary disease|Escherichia coli infection|Gram negative bacterium infection|Bacteroides fragilis infection|Yersinia pestis infection|Citrobacter infection|Morganella infection|Proteus infection|Providencia infection|Serratia infection|Haemophilus influenzae infection|Moraxella catarrhalis infection|Streptococcus pyogenes infection|Enterococcus faecalis infection|Bacterial respiratory tract infection|Acute bronchitis|Shigella flexneri infection|Shigella sonnei infection|Shigella boydii infection|Shigella dysenteriae infection|Campylobacter jejuni infection|Epididymo-orchitis|Bacterial urinary tract infection|Bacterial pneumonia|Klebsiella pneumoniae infection|Neisseria gonorrhoeae infection|Pseudomonas aeruginosa infection|Pyelonephritis|Urethritis|Acute sinusitis|Staphylococcus aureus infection|Staphylococcus infection|Streptococcus pneumoniae infection|Pelvic inflammatory disease|Otitis externa|Salmonella typhi infection|Neisseria meningitidis infection|Bacillus anthracis infection|Otitis media|Bacterial infection|Cystitis|Proteus mirabilis infection|Prostatitis|Bacterial skin infection|Bone and joint infection|Gastrointestinal infection|Prophylaxis|Cystic fibrosis,102|1075|116|1185|120|137|1394|1397|1434|1437|1438|1439|1440|145|1455|1475|1482|1484|1487|1493|1494|1495|1496|1497|1797|1798|1815|195|227|280|284|2951|2999|308|309|313|3140|3242|348|389|39|394|40|403|456|473|485|554|577|706|88,,,Medsintez|Bayer AG|FUJIFILM Pharma Co Ltd,1074773|14455|1061684,Merck & Co Inc,18077,Bayer AG,14455,,,,,,
44481,"poly-cyclodextrin-PEG-camptothecin-conjugate (nanoparticle/intravenous, cancer), BlueLink Pharmaceuticals","camptothecin|Cyclosert-camptothecin, Insert Therapeutics|Cyclosert-camptothecin, Calando|Cyclosert-camptothecin, Cerulean Pharma|camptothecin nanoparticle (cancer), Cerulean Pharma|CRLX-101|CRLX-101-202|poly-CD-PEG-camptothecin|poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate|camptothecin (nanoparticle/intravenous, cancer), BlueLink Pharmaceuticals|davamotecan pegadexamer|poly-cyclodextrin-PEG-camptothecin-conjugate (nanoparticle/intravenous, cancer), BlueLink Pharmaceuticals|IT-101|NLG-207|camptothecin (nanoparticle/intravenous, cancer), Ellipses Pharma|EP-0057, Ellipses Pharma",Research Code|Research Code|INN|Research Code|Research Code,Cancer,Hypoxia inducible factor-1 alpha inhibitor|Topoisomerase I inhibitor,9680|141,Anticancer,1545,Fallopian tube cancer|Peritoneal tumor|Metastatic ovary cancer|Ovary tumor,2243|3083|3866|799,Rectal tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Advanced solid tumor|Metastatic renal cell carcinoma|Cancer,1055|1261|1262|127|3713|4250|651,Ellipses Pharma Ltd,1137885,Calando Pharmaceuticals Inc|Dare Bioscience Inc|BlueLink Pharmaceuticals,1013715|1032593|1145253,Calando Pharmaceuticals Inc,1013715,,,,,,
44499,sitagliptin,"MK-431|dipeptidyl peptidase IV inhibitors, Merck & Co|MK-0431|sitagliptin phosphate|ONO-5345|ONO-5435|sitagliptin|Januvia|DPP-IV inhibitors, Merck & Co|Xelevia|Tesavel|Glactiv|Ristaben|sitagliptin phosphate monohydrate",Research Code|Research Code|USAN|Research Code|Research Code|INN|Trade Name|Trade Name|Trade Name|Trade Name,Endocrine/Metabolic|Gastrointestinal,Dipeptidyl peptidase IV inhibitor,5537,Hypoglycemic agent|Glucagon-like peptide 1 metabolism modulator|DPP IV inhibitor antidiabetic product,399|3313|38439,Non-insulin dependent diabetes,837,Non alcoholic fatty liver disease|Glucose intolerance,3288|3498,Merck Sharp & Dohme Ltd|Almirall Prodesfarma SA|Julphar Gulf Pharmaceutical Industries|MSD Japan|Ono Pharmaceutical Co Ltd|Merck & Co Inc,18090|14061|26288|24019|18681|18077,,,Merck & Co Inc,18077,,,,,,
44521,IRX-2,"IRX-2|citoplurikin|cytokines containing adjuvant Th1 agonist  (sc, solid tumors), Brooklyn ImmunoTherapeutics",Research Code,Cancer|Genitourinary/Sexual Function,TNF alpha ligand|GCSF ligand|Interferon gamma ligand|Interleukin-6 ligand|Interleukin-2 ligand|Interleukin-1 ligand|Interleukin-8 ligand|GM-CSF ligand,6928|52970|51201|12493|12481|12472|12499|49776,Immunostimulant|Anticancer,393|1545,Cervical dysplasia|Prostate tumor|Squamous cell carcinoma|Vulvar intraepithelial neoplasia|Breast tumor|Head and neck tumor|Mouth tumor,1235|276|307|3105|49|623|793,,,Brooklyn ImmunoTherapeutics LLC,30720,,,Brooklyn ImmunoTherapeutics LLC,30720,,,,,,
44598,"furosemide (tablets), sanofi-aventis","furosemide|furosemide (tablets), sanofi-aventis|Lasix|HOE-058|Lasix Special",INN|Trade Name|Research Code|Trade Name,Cardiovascular,Solute carrier family 12A1 inhibitor,26860,Antihypertensive|Cardiac agent|Vasodilator|Diuretic agent,2657|966|388|137,Hypertension|Edema,178|402,,,Sanofi SA,1009547,Aventis SA,27254,Aventis SA,27254,,,,,,
44599,methylprednisolone (Pfizer),methylprednisolone|methylprednisolone acetate|methylprednisolone sodium succinate|PF-00345299|methylprednisolone (Pfizer)|Depo-Medrol|Solu-Medrol|Medrol|DEPO-MEDRONE,BANN|INN|USAN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Cancer|Dermatologic|Endocrine/Metabolic|Gastrointestinal|Genitourinary/Sexual Function|Hematologic|Immune|Inflammatory|Musculoskeletal|Ocular|Respiratory,,,Anticancer|Antibacterial|Corticosteroid agonist|Steroidal anti-inflammatory,1545|1594|3189|2954,Endocrine disease|Allergy|Gout|Hematological disease|Psoriatic arthritis|Leukemia|Lymphoma|Multiple sclerosis|Nephrotic syndrome|Ocular disease|Rheumatoid arthritis|Ulcerative colitis|Connective tissue disease|Enteritis|Respiratory disease|Dermatological disease,112|12|136|142|1781|199|203|213|2315|239|291|337|570|597|711|95,,,Pfizer Inc|Pharmacia Corp,18767|27638,,,Pharmacia Corp,27638,,,,,,
44601,lisinopril,lisinopril|lisinopril dihydrate|lisinopril (USAN)|Zestril|Prinivil|Longes|Acemin|Acerbon|Aceday|Listen|Lipril,USAN|BANN|INN|USAN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Cardiovascular|Genitourinary/Sexual Function,ACE inhibitor,18,Antihypertensive,2657,Hypertension|Renal disease,178|286,Autosomal dominant polycystic kidney disease,2300,Atnahs Pharma UK Limited|KYOWA Pharmaceutical Industry Co Ltd|AstraZeneca plc|moksha8 Pharmaceuticals Inc|Alvogen Inc,1123655|1127603|14190|1050182|1051273,Astra AB|Shionogi & Co Ltd,16881|19898,Merck & Co Inc,18077,,,,,,
4462,tirapazamine,SR-259075|SR-4233|tirapazamine|Tirazone|Win-59075|SR-4317|SR-4330|SR-4482|NSC-130181|TPZ,Research Code|Research Code|USAN|INN|Trade Name|Research Code|Research Code|Metabolite|Research Code|Metabolite|Research Code|Research Code,Cancer,,,Bioreducible cytotoxin|Anticancer|Anticancer chemosensitizer|Unspecified drug target,1585|1545|1586|59620,Uterine cervix tumor|Cancer,427|651,Non-small-cell lung cancer|Nasopharyngeal carcinoma|Sarcoma|Melanoma|Breast tumor|Head and neck tumor|Solid tumor|Lung tumor|Ovary tumor,1262|1768|194|205|49|623|725|755|799,National Cancer Institute (NCI)|SRI International|Fountain Medical Development Ltd|Teclison Ltd|Alcami Corp,20519|20234|1148967|1116794|1120841,Sanofi SA|Stanford University|Sanofi-Synthelabo|Sanofi (pre-1999)|Sanofi Inc,1009547|20679|26494|26495|26529,Stanford University,20679,,,,,,
4476,fondaparinux sodium,"SR-90107|Org-31540|Arixtra|fondaparinux sodium|IC-851589|SR-90107A|Xantidar|fondaparin sodium|pentasaccharide, Sanofi-Synthelabo/Organon|Quixidar|GSK-576428|fondaparinux|Arixtra®",Research Code|Research Code|Trade Name|USAN|BANN|INN|Research Code|Research Code|Trade Name|Trade Name|Research Code|Trade Name,Cardiovascular|Hematologic,Factor Xa antagonist,120,Coagulation inhibitor,659,Lung embolism|Thromboembolism|Acute coronary syndrome|Deep vein thrombosis,1078|325|3258|574,Thrombosis|Heparin induced thrombocytopenia,1076|1271,Viatris Inc|GlaxoSmithKline plc|Aspen PharmaCare Holdings Ltd,1136574|28355|1019374,Sanofi SA|Nippon Organon KK|MSD OSS BV|Mylan NV|Sanofi-Synthelabo|Sanofi Recherche SA,1009547|13849|13880|18439|26494|26658,Sanofi-Synthelabo,26494,,,,,,
44938,"rigosertib sodium (iv, MDS/solid tumors), Onconova/SymBio","ONO-106|ON-01910|ON-01910Na|styryl benzyl sulfone (cell cycle inhibitor), Onconova|Novonex|ON-01910.Na|ON-1910Na|Estybon|ON-1910 sodium|SyB-1101 (iv, MDS), SymBio|SyB-L-1101|rigosertib|rigosertib sodium|rigosertib sodium (iv, MDS/solid tumors), Onconova/SymBio|ON-1910N|rigosertib sodium (iv, MDS), Baxalta|BAX-2001",Research Code|Research Code|Research Code|Trade Name|Research Code|Research Code|Trade Name|Research Code|Research Code|USAN|INN|USAN|Research Code|Research Code,Cancer|Infection,Polo-like kinase 1 inhibitor|Jun N terminal kinase modulator|Cyclin-dependent kinase-1 inhibitor|AKT protein kinase inhibitor|MAP kinase inhibitor|Phosphoinositide 3-kinase inhibitor|Raf protein kinase inhibitor|Cyclin D1 inhibitor|BCL2L11 gene stimulator,4536|4375|4308|3859|2511|1575|4542|9488|48274,Antiviral|Anticancer protein kinase inhibitor|Cell cycle inhibitor|Apoptosis stimulator,991|62255|767|1589,Coronavirus disease 19 infection|Myelodysplastic syndrome|Melanoma|Squamous cell carcinoma,10406|1272|205|307,Acute lymphoblastic leukemia|Acute myelogenous leukemia|Hematological neoplasm|Metastatic pancreas cancer|Cancer|Solid tumor|Ovary tumor,1728|1731|2054|3669|651|725|799,Onconova Therapeutics Inc|Pint Pharma|Knight Therapeutics Inc|Specialised Therapeutics Asia Pte Ltd,30752|1110054|1093663|1157003,SymBio Pharmaceuticals Ltd|Baxalta Inc|HanX Biopharmaceuticals Inc|Baxter International Inc,1017747|1109518|1158103|14437,Onconova Therapeutics Inc,30752,,,,,,
45059,"NY-ESO-1 DNA vaccine (cancer), Ludwig Institute/PowderMed","cancer DNA vaccine, Ludwig Institute/PowderJect|NY-ESO-1 DNA vaccine, Ludwig Institute/PowderJect|NY-ESO-1 DNA vaccine (cancer), Ludwig Institute/PowderMed|anticancer DNA vaccine (powder injection, PMED), Ludwig Institute/PowderMed|NY-ESO-1 DNA vaccine (cancer), Ludwig Institute/Pfizer|anticancer DNA vaccine (powder injection, PMED), Ludwig Institute/Pfizer",,Cancer,Cancer testis antigen NY-ESO-1 modulator,50096,Anticancer|DNA vaccine|Therapeutic vaccine,1545|1879|12379,,,Cancer,651,,,PowderMed Ltd|Ludwig Institute for Cancer Research|PowderJect Pharmaceuticals plc,1008243|21091|24800,Ludwig Institute for Cancer Research,21091,,,,,,
4510,tacrolimus,"FK-506|FR-900506|fujimycin|L-679934|Prograf|tacrolimus|tsukubaenolide|tacrolimus (injectable), Fujisawa|FK-506 (oral), Fujisawa|tacrolimus (oral), Fujisawa|tacrolimus (oral), Astellas|FK-506 (oral), Astellas|tacrolimus (injectable), Astellas|Adbagraf|Prograf injection|Prograf capsule|Prograf granule|Modigraf|Hecoria",Research Code|Research Code|Research Code|USAN|BANN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Gastrointestinal|Genitourinary/Sexual Function|Immune|Infection|Neurology/Psychiatric,Calcineurin inhibitor,4010,Anti-inflammatory|Immunosuppressant|T-lymphocyte inhibitor,2953|396|7760,Lupus nephritis|Rheumatoid arthritis|Heart transplantation|Liver transplantation|Kidney transplantation|Lung transplantation|Ulcerative colitis|Pneumonia|Bone marrow transplantation|Transplant rejection|Myasthenia gravis,2404|291|2982|2983|2984|2985|337|360|46|515|848,IgA nephropathy|Stroke,3076|65,Astellas Pharma Inc|Janssen-Cilag Ltd,1013295|17392,Fujisawa Pharmaceutical Co Ltd,16227,Fujisawa Pharmaceutical Co Ltd,16227,,,,,,
4522,candesartan,"candesartan|Atacand|candesartan cilexetil|TCV-116|Blopress|Tiadyl|Blopres|H-212/91|Bliopress|Amias|Kenzen|Parapres|candesartan cilexetil (hypertension/cardiac failure), AstraZeneca/Cheplapharm",INN|Trade Name|USAN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Cardiovascular|Genitourinary/Sexual Function|Neurology/Psychiatric|Ocular|Toxicity/Intoxication,Angiotensin II receptor antagonist,64,Antihypertensive|Antiarrhythmic agent|Vasoprotectant,2657|449|2660,Hypertension|Cardiac failure,178|55,Diabetic nephropathy|Cardiotoxicity drug-induced|Atrial fibrillation|Migraine|Nephritis|Aortic stenosis|Renal disease|Restenosis|Diabetic retinopathy|Stroke,100|1090|1542|210|231|2383|286|330|576|65,CHEPLAPHARM Arzneimittel GmbH|AbbVie Inc|Almirall Prodesfarma SA|Hikma Pharmaceuticals plc|Teva Takeda Yakuhin Ltd|Takeda Pharmaceutical Co Ltd|GC Pharma|ANI Pharmaceuticals Inc,1129377|1072507|14061|1022379|1121665|20300|16583|27120,Abbott Laboratories|AstraZeneca plc|Astra AB,13601|14190|16881,Takeda Pharmaceutical Co Ltd,20300,,,,,,
4529,temozolomide,CCRG-81045|MB-39831|methazolastone|NSC-362856|temozolomide|Sch-52365|Temodal|Temodar|RP-46161|Astromide|Temcad,Research Code|Research Code|Research Code|USAN|Research Code|Trade Name|Trade Name|Research Code|Trade Name|Trade Name,Cancer,,,Anticancer alkylating agent,50,Glioma|Melanoma|Glioblastoma|Anaplastic astrocytoma|Gliosarcoma|Ewing sarcoma,1108|205|2454|2567|2727|2975,Metastasis|Small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Solid tumor,1069|1261|1272|1731|1734|725,Merck & Co Inc,18077,Rhone-Poulenc Rorer Ltd|Schering-Plough Corp|The University of Aston In Birmingham|Cancer Research Campaign Technology Ltd,19298|19711|21241|24077,The University of Aston In Birmingham,21241,,,,,,
45417,deferoxamine mesylate,deferoxamine mesylate|Desferal,USAN|Trade Name,Toxicity/Intoxication,,,Chelating agent,105,Metal intoxication,386,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
45536,tamibarotene,"AM-80|Amnoid|Tamibaro|tamibarotene|Amnolake|RR-110|oral tamibarotene (oncological/inflammatory indications), Nippon Shinyaku/R&R/TMRC/Innovive/Choongwae|TM-411|TOS-80T|Z-208|oral tamibarotene (oncological/inflammatory indications), Nippon Shinyaku/R&R/TMRC/CytRx/Choongwae|INNO-507|OMSO-728|SY-1425|OP-09",Research Code|Trade Name|Trade Name|INN|Trade Name|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Gastrointestinal|Hematologic|Inflammatory,Retinoic acid receptor alpha agonist,4094,Synergist|Anticancer,7293|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Acute promyelocytic leukemia|Neuroblastoma,1272|1731|1732|2726,Non-small-cell lung cancer|Hepatocellular carcinoma|Multiple myeloma|Inflammatory disease|Neutropenia|Crohns disease,1262|1767|1828|188|1991|84,"Toko Pharmaceutical Industries Co Ltd|Syros Pharmaceuticals|Ohara Pharmaceutical Co Ltd|GNI-EPS Pharmaceuticals, Inc|TMRC Co Ltd",1067033|1081616|1000882|1103205|1016661,Innovive Pharmaceuticals Inc|R&R Inc|LOTUS Pharmaceutical Co Ltd (JAPAN)|EPS Corp|JW Pharmaceutical Corp|CytRx Corp|Nippon Shinyaku Co Ltd|University of Tokyo|Zeria Pharmaceutical Co Ltd|Children's Hospital of Los Angeles,1011256|1030686|1078245|1095380|15411|15585|18552|20686|21023|21050,University of Tokyo,20686,,,,,,
45543,peginesatide,"Hematide|EPO mimetic (systemic, anemia), Affymax/Takeda|erythropoietin mimetic (systemic, anemia), Affymax/Takeda|AF-37702|peginesatide|Omontys",Trade Name|Research Code|USAN|INN|Trade Name,Hematologic,Erythropoietin ligand|Erythropoietin receptor agonist,12162|2501,Hematopoietic stimulator,610,,,Aplastic anemia|Anemia,1006|17,,,Takeda Pharmaceutical Co Ltd|Affymax Inc,20300|22211,Affymax Inc,22211,,,,,,
45562,tremelimumab,"ticilimumab|CP-675206|anti-huCTLA4  monoclonal IgG2 antibody (cancer), Pfizer|tremelimumab|MEDI-1123|PF-06753388|CTLA-4 checkpoint inhibitor (cancer), Pfizer/MedImmune/AstraZeneca",Research Code|USAN|INN|Research Code|Research Code,Cancer|Infection,Cytotoxic T-lymphocyte protein-4 inhibitor,5482,Immunostimulant|Anticancer|Anticancer monoclonal antibody|Antiviral|T-lymphocyte stimulator,393|1545|55685|991|7761,Esophagus tumor|Neuroendocrine tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Pancreatic ductal adenocarcinoma|Biliary cancer|Cholangiocarcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Multiple myeloma|Lymphoma|Fallopian tube cancer|Bladder cancer|Adenocarcinoma|Glioblastoma|Squamous cell carcinoma|Peritoneal tumor|Gallbladder tumor|Hormone refractory prostate cancer|Stage IV melanoma|Soft tissue sarcoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Germ cell and embryonic cancer|Anaplastic thyroid cancer|Solid tumor|Ovary tumor|Colorectal tumor,1011|1128|1261|1262|127|1507|1516|1765|1766|1767|1771|1828|203|2243|2380|2399|2454|307|3083|3146|3246|3257|3378|3466|3657|3658|3665|3737|3769|725|799|989,Mesothelioma|Gastrointestinal tumor|HIV infection|Pancreas tumor|Prostate tumor|Metastatic head and neck cancer|Metastatic renal cell carcinoma|Genitourinary tract tumor|Cancer,1240|131|158|249|276|3673|4250|613|651,MedImmune LLC,18008,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
45599,"L19-IL-2 fusion protein, Philogen","immunocytokine fusion protein, Bayer Schering|L19-IL-2 fusion protein, Bayer Schering|immunocytokine fusion protein, Philogen|L19-IL-2 fusion protein, Philogen|Darleukin",,Cancer,Interleukin-2 ligand|CD29 modulator|Fibronectin modulator,12481|5107|70171,Anticancer monoclonal antibody|Anticancer hormone|Angiogenesis inhibitor|Vascular damaging agent,55685|62253|61|2969,Diffuse large B-cell lymphoma|Pancreas tumor|Solid tumor,1749|249|725,Renal cell carcinoma|Lymphoma|Melanoma,1766|203|205,Philogen SpA,29032,Bayer Schering Pharma AG,19687,Philogen SpA,29032,,,,,,
4563,"doxorubicin (liposome formulation), Cephalon","doxorubicin|D-99|Evacet|Myocet|TLC-99|Lipidox|TLC-D-99|TLC-DOX99|doxorubicin, Liposome Co|doxorubicin (liposome formulation), Cephalon|doxorubicin hydrochloride|Adriamycin|LipoDox",USAN|BAN|INN|Research Code|Trade Name|Trade Name|Research Code|Trade Name|Research Code|Research Code|USAN|Trade Name|Trade Name,Cancer,DNA polymerase inhibitor|Topoisomerase II inhibitor,138|142,Anticancer|DNA intercalator,1545|750,Non-Hodgkin lymphoma|Breast tumor|Ovary tumor,319|49|799,Kaposis sarcoma,936,Teva Pharmaceutical Industries Ltd|Zeneus Pharma Ltd|Cephalon Inc,20348|1006337|15358,Elan Corp plc|The Liposome Company Inc|Pfizer Inc|Sopherion Therapeutics LLC,15873|17877|18767|30666,The Liposome Company Inc,17877,,,,,,
4565,"amphotericin B lipid complex (iv infusion, fungal infection), The Liposome Co/Teva Pharamceutical/Rhone-Poulenc/Sigma-Tau","Abelcet|fungilin|amphotericin B|ABLC|Fugizone|TLC-ABLC|amphotericin B lipid complex, Liposome Co|amphotericin B lipid complex (iv infusion, fungal infection), The Liposome Co/Teva Pharamceutical/Rhone-Poulenc/Sigma-Tau|LB-501",Trade Name|INN|Trade Name|Trade Name|Research Code|Research Code,Infection|Ocular,,,Antimicrobial permeability enhancer|Unspecified drug target|Fungicide|Antiparasitic,955|59620|1748|2638,Keratitis|Fungal infection|Leishmania tropica infection|Aspergillus infection|Candida albicans infection|Cryptococcus infection,1145|124|197|29|53|85,Cryptococcus neoformans infection,86,The Liposome Company Inc|Sigma-Tau Ind Farm Riunite SpA|Teva Sante SAS|Teva Pharmaceutical Industries Ltd|Wyeth-Ayerst International Inc|Bago|Leadiant Biosciences Inc|Rhone-Poulenc Rorer Inc|Esteve Pharmaceuticals SA,17877|21159|1006988|20348|14198|14346|19946|19365|16074,Enzon Pharmaceuticals Inc,16045,The Liposome Company Inc,17877,,,,,,
45663,tivantinib,"CO-650|ARQ-650|ARQ-650RP|ARQ-707|cancer survival protein modulation product, ArQule|650RP|CO-650 series (cancer), ArQule|tivantinib|cancer survival protein modulation program, ArQule|ARQ-197",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer,Hepatocyte growth factor receptor antagonist|MET gene modulator,675|18518,Anticancer protein kinase inhibitor,62255,,,Testis tumor|Non-small-cell lung cancer|Stomach tumor|Hepatocellular carcinoma|Sarcoma|Seminoma|Pancreas tumor|Prostate tumor|Carcinoma|Solid tumor|Lung tumor|Colorectal tumor,1054|1262|127|1767|194|2167|249|276|54|725|755|989,,,Daiichi Sankyo Co Ltd|Kyowa Hakko Kirin Co Ltd|Kyowa Hakko Kogyo Co Ltd|ArQule Inc|Cyclis Pharmaceuticals Inc,1017506|1042596|17724|21554|29865,Cyclis Pharmaceuticals Inc,29865,,,,,,
4567,etanercept,"rhu TNFR:Fc|etanercept|Enbrel|TNR-001|s-TNF-R, AHP|TNF receptor, Immunex|soluble TNF receptor, Amgen|soluble TNF receptor, Immunex|Enbrel Mini|Enbrel SureClick|PF-05208752",Research Code|USAN|BANN|INN|Trade Name|Research Code|Trade Name|Trade Name|Research Code,Cancer|Cardiovascular|Dermatologic|Gastrointestinal|Genitourinary/Sexual Function|Hematologic|Immune|Infection|Musculoskeletal|Neurology/Psychiatric|Other/Miscellaneous|Respiratory,TNF antagonist|TNF binding agent|Type II TNF receptor modulator,511|721|8222,Antiviral|Anti-inflammatory|Systemic antipsoriatic product|Immunosuppressant|Anticancer,991|2953|15184|396|1545,Psoriatic arthritis|Psoriasis|Rheumatoid arthritis|Spondylarthritis|Juvenile rheumatoid arthritis|Asthma|Ankylosing spondylitis|Kawasaki disease,1781|281|291|2921|3003|31|398|780,Endometriosis|Alzheimers disease|Hepatitis C virus infection|HIV infection|Hidradenitis|Inclusion body myositis|Bone marrow failure|Idiopathic pulmonary fibrosis|Cardiac failure|Graft versus host disease|Cancer|Malnutrition|Crohns disease,113|14|153|158|2110|3446|350|3771|55|616|651|652|84,Amgen Inc|Takeda Pharmaceutical Co Ltd|OJSC Farmak|Pfizer Inc|3SBio Inc,14109|20300|1052823|18767|1016672,Wyeth|Immunex Corp,14112|14131,Immunex Corp,14131,,,,,,
4577,topotecan,Hycamtin|SKF-104864|topotecan lactone|topotecan|NK-211|Evotopin|Hicamtin|Hycamtim|nogitecan|NSC-609699|hycaptamine|SKF-104864-A|hycamptamine|nogitecan HCl|SKFS-104864-A,Trade Name|Research Code|BAN|INN|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Research Code,Cancer|Hematologic,Topoisomerase I inhibitor,141,Anticancer,1545,Small-cell lung cancer|Uterine cervix tumor|Solid tumor|Lung tumor|Ovary tumor,1261|427|725|755|799,Metastasis|Glioma|Non-small-cell lung cancer|Acute myelogenous leukemia|Multiple myeloma|Leukemia|Lymphoma|Myeloproliferative disorder|Breast tumor|Carcinoma|Colon tumor,1069|1108|1262|1731|1828|199|203|273|49|54|767,GlaxoSmithKline plc|Nippon Kayaku Co Ltd|Novartis AG,28355|18535|23137,SmithKline Beecham plc|SmithKline Beecham Pharmaceuticals [US],19962|24151,SmithKline Beecham plc,19962,,,,,,
45841,lenvatinib mesylate,E-7080|ER-203492-00|lenvatinib mesylate|lenvatinib|Lenvima|Kisplyx|MK-7902|KN-581,Research Code|Research Code|USAN|USAN|INN|Trade Name|Trade Name|Research Code|Research Code,Cancer,FGF4 receptor antagonist|FGF3 receptor antagonist|FGF2 receptor antagonist|FGF1 receptor antagonist|Kit tyrosine kinase inhibitor|PDGF receptor beta antagonist|PDGF receptor alpha antagonist|VEGF-3 receptor antagonist|Ret tyrosine kinase receptor inhibitor|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist,3691|3688|3685|3682|3808|48492|48489|3850|3818|3846|3848,Angiogenesis inhibitor|Anticancer|Anticancer protein kinase inhibitor,61|1545|62255,Recurrent respiratory papillomatosis|Neuroendocrine tumor|Thyroid tumor|Small-cell lung cancer|Non-small-cell lung cancer|Gastrointestinal tumor|Biliary cancer|Endometrioid carcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Osteosarcoma|Sarcoma|Melanoma|Fallopian tube cancer|Bladder cancer|Adenocarcinoma|Leiomyosarcoma|Liposarcoma|Glioblastoma|Thymus neoplasm|Peritoneal tumor|Adenoid tumor|Medullary thyroid cancer|Stage III melanoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic head and neck cancer|Anaplastic thyroid cancer|Metastatic ovary cancer|Metastatic renal cell carcinoma|Breast tumor|Solid tumor|Ovary tumor,10408|1128|1134|1261|1262|131|1516|1705|1766|1767|1771|1772|194|205|2243|2380|2399|2446|2447|2454|2938|3083|3153|3240|3256|3257|3466|3657|3658|3665|3666|3673|3769|3866|4250|49|725|799,Glioma|Head and neck tumor|Cancer,1108|623|651,Eisai Co Ltd|Biotoscana International|Merck & Co Inc,15872|1063950|18077,SFJ Pharmaceuticals Inc,1052050,Eisai Co Ltd,15872,,,,,,
45844,cixutumumab,"IMC-A12|IGF-R1 antibodies (cancer), ImClone|cixutumumab|IMCL-A12|NSC-742460|LY-3012217",Research Code|USAN|INN|Research Code|Research Code|Research Code,Cancer,Insulin-like growth factor 1 receptor antagonist,3252,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,,,Neuroendocrine tumor|Mesothelioma|Hepatocellular carcinoma|Sarcoma|Liver tumor|Pancreas tumor|Thymoma|Hormone refractory prostate cancer|Breast tumor|Head and neck tumor|Cancer|Solid tumor|Lung tumor|Colorectal tumor,1128|1240|1767|194|202|249|2939|3246|49|623|651|725|755|989,,,Imclone LLC,17193,Imclone LLC,17193,,,,,,
45852,CBP-501,"CBP-501|G2 checkpoint abrogator peptide, CanBas/Takeda|calmodulin modulator peptide (mesothelioma/NSCLC), CanBas",Research Code,Cancer,Calmodulin modulator,864,Immunostimulant|Anticancer chemosensitizer,393|1586,Mesothelioma|Non-small-cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor,1240|1262|3669|3713,Cancer|Lung tumor|Ovary tumor,651|755|799,CanBas Co Ltd,28653,Takeda Pharmaceutical Co Ltd,20300,CanBas Co Ltd,28653,,,,,,
45902,ramucirumab,"IMC-1121B|anti-KDR antibodies, ImClone|anti-VEGFR2 antibodies, ImClone|ramucirumab|LY-3009806|Cyramza",Research Code|USAN|INN|Research Code|Trade Name,Cancer,VEGF-C ligand inhibitor|VEGF-2 receptor antagonist|VEGF-D ligand inhibitor|VEGF-A ligand inhibitor,12528|3848|12531|1689,Anticancer monoclonal antibody|Angiogenesis inhibitor|Anticancer protein kinase inhibitor,55685|61|62255,Esophagus tumor|Mesothelioma|Stomach tumor|Biliary cancer|Hepatocellular carcinoma|Adenocarcinoma|Carcinoid tumor|Soft tissue sarcoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Lung tumor,1011|1240|127|1516|1767|2399|2538|3378|3657|3658|3665|3666|3669|755,Glioblastoma|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic bladder cancer|Metastatic renal cell carcinoma|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,2454|3246|3257|3466|4250|651|725|799|989,Eli Lilly & Co,17810,Imclone LLC,17193,Imclone LLC,17193,,,,,,
4593,trimetrexate,NSC-328564|trimetrexate glucuronate|trimetrexate|NeuTrexin|NSC-352122|NSC-249008|JB-11|TMQ|CI-898,Research Code|USAN|USAN|BAN|INN|Trade Name|Research Code|Research Code|Research Code,Cancer|Infection,DHFR inhibitor|RNA polymerase inhibitor,135|347,Systemic antipsoriatic product|Antiparasitic|Protein synthesis inhibitor|Anticancer,15184|2638|339|1545,Neoplasm|Pneumocystis carinii infection|Protozoal infection,230|271|278,Colorectal tumor,989,Medimmune Oncology Inc|Eli Lilly & Co Ltd|Ipsen,27597|17829|17259,Warner-Lambert Co,20787,Pfizer Inc,18767,,,,,,
45937,"autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine","autologous vaccine (leukemia), Baylor College of Medicine/MaxCyte|IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine|IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine/MaxCyte|autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine|dual CD40 costimulator/IL-2 (autologous tumor vaccine, CLL), Baylor College of Medicine/MaxCyte",,Cancer,IL-2 receptor agonist|CD40 ligand receptor agonist,221|5141,Therapeutic vaccine|B-lymphocyte stimulator|Dendritic cell stimulator|Genetically engineered autologous cell vaccine|Anticancer|Macrophage stimulator,12379|7741|173472|4791|1545|7751,,,Chronic lymphocytic leukemia|Leukemia,1734|199,,,Baylor College of Medicine|MaxCyte Inc,20534|28015,Baylor College of Medicine,20534,,,,,,
45938,eprenetapopt,"PRIMA-1|apoptosis stimulators (iv, cancer), Karolinska Institute|mutant p53 reactivation compounds (iv, cancer), Karolinksa Institute|APR-246|p53 modulators (iv, cancer), Aprea|APR-017|APR-304|APR-305|APR-310|PRIMA-1-MET|eprenetapopt|active moiety 2-methylene-quinuclidin-3-one (iv, cancer), Aprea",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|INN,Cancer|Hematologic,p53 tumor suppressor protein stimulator,17120,Apoptosis stimulator|Anticancer,1589|1545,Esophagus tumor|Lymphoid leukemia|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Transitional cell carcinoma|Hematological neoplasm|Myeloproliferative disorder|Prostate tumor|Non-Hodgkin lymphoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor|Chronic myelomonocytic leukemia|Ovary tumor,1011|1255|1272|1731|1734|1744|1771|2054|273|276|319|3257|3466|3665|3666|3667|3713|6833|799,Non-small-cell lung cancer|Stomach tumor|Bladder cancer|Cancer,1262|127|2380|651,Aprea Therapeutics AB,1007940,Karolinska Institutet,21110,Karolinska Institutet,21110,,,,,,
4595,tropisetron,tropisetron|tropisetron hydrochloride|Novaban|Navoban|ICS-205-930,INN|BANN|Trade Name|Trade Name|Research Code,Gastrointestinal|Musculoskeletal,5-HT 3 receptor antagonist,15,Anti-emetic,2970,Myalgia|Gastrointestinal disease|Chemotherapy-induced emesis,1039|129|352,,,Alkopharma|Sandoz AG|ASTA Medica AG|Novartis AG|Genopharm,1094549|24514|15623|23137|DOL1000389,,,Novartis AG,23137,,,,,,
45963,AT-101,"(-)-gossypol|NSC-726190|BL-193|(-)-gossypol, NCI/University of Michigan|TW-37|Bcl-2/Bcl-xl inhibitors (cancer, tablet/natural product), University of Michigan/Ascenta|gossypol analogs, NCI/University of Michigan|(-)-gossypol (anticancer), Ascenta|AT-101|R-(-)-gossypol acetic acid|pan-Bcl-2 inhibitor (cancer), Ascenta/3SBio",Research Code|Research Code|Research Code|Research Code,Cancer,Mcl-1 differentiation protein inhibitor|Bcl-xL Bcl-2 associated death promotor inhibitor,11381|14541,Anticancer|Apoptosis stimulator|Synergist|Angiogenesis inhibitor,1545|1589|7293|61,Chronic lymphocytic leukemia,1734,Esophagus tumor|Glioma|Small-cell lung cancer|Non-small-cell lung cancer|Multiple myeloma|Glioblastoma|Non-Hodgkin lymphoma|Larynx tumor|Hormone refractory prostate cancer|Cancer,1011|1108|1261|1262|1828|2454|319|3198|3246|651,Ascenta Therapeutics Inc|Ascentage Pharma Group Corporation Ltd,1017308|1052437,3SBio Inc|University of Michigan,1016672|20623,University of Michigan,20623,,,,,,
45998,interferon alfa-2b,Intron A|interferon alfa-2b|Viraferon|interferon alpha-2b|Virtron|Alfatronol,Trade Name|USAN|INN|Trade Name|Trade Name,Cancer|Infection,Interferon alpha ligand modulator,917,Systemic dermatological antiviral product|Antiviral|Anticancer,15190|991|1545,Condyloma|Hepatitis B virus infection|Hepatitis C virus infection|Chronic myelocytic leukemia|Hairy cell leukemia|Follicle center lymphoma|Multiple myeloma|Melanoma|Carcinoid tumor|Non-Hodgkin lymphoma|Papillomavirus infection|Cancer|Kaposis sarcoma,1232|152|153|1735|1736|1745|1828|205|2538|319|396|651|936,,,Merck Sharp & Dohme Ltd|Merck & Co Inc|Schering-Plough Corp,18090|18077|19711,,,Schering-Plough Corp,19711,,,,,,
45999,amonafide L- malate,"amonafide L- malate|XLS-001|amonafide L-malate (iv, cancer), Antisoma|AS-1413|Xanafide",USAN|Research Code|Research Code|Trade Name,Cancer,Topoisomerase II inhibitor,142,Anticancer|DNA intercalator,1545|750,,,Acute myelogenous leukemia|Prostate tumor|Breast tumor,1731|276|49,,,Antisoma plc,14239,Antisoma plc,14239,,,,,,
46018,onartuzumab,"5D5 Fab (cancer), Genentech|HGF/c-Met antagonist, Genentech|onartuzumab|PRO-143966|MetMAb|RG-3638|RO-5490258",USAN|INN|Research Code|Research Code|Research Code,Cancer,MET gene modulator|Hepatocyte growth factor receptor antagonist,18518|675,Anticancer protein kinase inhibitor|Metastasis inhibitor|Anticancer monoclonal antibody,62255|695|55685,,,Metastasis|Non-small-cell lung cancer|Hepatocellular carcinoma|Glioblastoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Cancer|Solid tumor,1069|1262|1767|2454|3657|3658|3665|3666|651|725,,,Chugai Pharmaceutical Co Ltd|Roche Holding AG|Genentech Inc,15414|19446|19453,Genentech Inc,19453,,,,,,
46099,axalimogene filolisbac,"HPV E7 cancer vaccine (Listeria vector), Advaxis|listeriolysin-O (LLO)/HPV-16 E7 antigen fusion (HPV), Advaxis|axalimogene filolisbac|ADXS-HPV|ADXS11-001|Lovaxin C|AXAL|Raligize|Lm-LLO-E7",INN|Research Code|Research Code|Trade Name|Trade Name|Research Code,Cancer,Listeriolysin stimulator|Protein E7 stimulator,14513|58802,Antiviral|Therapeutic vaccine|T-lymphocyte stimulator|Live attenuated bacterial vaccine|Recombinant bacterial vector vaccine|Anticancer,991|12379|7761|12363|12369|1545,Non-small-cell lung cancer|Anal tumor|Uterine cervix tumor|Head and neck tumor|Cancer,1262|2193|427|623|651,Cervical dysplasia|Metastatic rectal cancer|Metastatic head and neck cancer|Lung tumor,1235|3671|3673|755,Advaxis Inc|Biocon Ltd|Knight Therapeutics Inc|Global BioPharma Inc,1002696|28769|1093663|1090865,Stendhal International,1060314,Advaxis Inc,1002696,,,,,,
46242,XL-999,XL-999|EXEL-0999,Research Code|Research Code,Cancer,Kit tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|PDGF receptor family inhibitor|FGF3 receptor modulator|FGF1 receptor antagonist|VEGF-2 receptor antagonist,3808|3806|3802|3686|3682|3848,Anticancer protein kinase inhibitor,62255,,,Non-small-cell lung cancer|Renal cell carcinoma|Cancer|Colon tumor|Ovary tumor,1262|1766|651|767|799,,,Symphony Evolution Inc|Exelixis Inc,1049056|22676,Exelixis Inc,22676,,,,,,
46323,QN-165,"AGRO-100|anticancer aptamers, Aptamera|AGRO-100 derivatives, Aptamera|nucleolin inhibitors (cancer), Aptamera|AS-1411|GRO-26B|ACT-GRO-777|nucleolin inhibitors (iv, acute myeloid leukemia), Advanced Cancer Therapeutics|nucleolin inhibitor (viral infection), Qualigen Therapeutics|nucleolin inhibitor (AML, RCC, pancreatic cancer, viral infections, SARS-CoV-2 infection), Qualigen Therapeutics|QN-165",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Infection,Nucleolin inhibitor|BCL2 gene inhibitor,15169|7709,Antiviral|Cell cycle inhibitor|Apoptosis stimulator|Antisense oligonucleotide inhibitor,991|767|1589|7294,Coronavirus disease 19 infection|Acute myelogenous leukemia|Renal cell carcinoma|Viral infection,10406|1731|1766|344,Non-small-cell lung cancer|Pancreas tumor|Metastatic renal cell carcinoma|Cancer|Solid tumor,1262|249|4250|651|725,Qualigen Therapeutics Inc,1054701,Aptamera Inc|Advanced Cancer Therapeutics|Antisoma plc|University of Louisville,1002893|1037221|14239|21246,Aptamera Inc,1002893,,,,,,
4648,venlafaxine hydrochloride,Wy-45030|venlafaxine hydrochloride|venlafaxine|Wy-45651|Wy-45655|venlafexine|Efexor|Efectin|Dobupal|Effexor|Efexor Depot,Research Code|USAN|BAN|INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Genitourinary/Sexual Function|Neurology/Psychiatric,,,5-HT uptake inhibitor|Antidepressant|Norepinephrine uptake inhibitor,3|2941|285,Major depressive disorder,4898,Pain|Attention deficit hyperactivity disorder|Premenstrual syndrome,20|34|480,Viatris Inc|Almirall Prodesfarma SA,1136574|14061,Wyeth|Pfizer Inc,14112|18767,Wyeth,14112,,,,,,
46678,galunisertib,"LY-566592|LY-2021154|TGF beta receptor I inhibitors (solid tumors), Eli Lilly|LY-2157299|LY-2109761|LY-580276|LY-550410|LY-364947|TGF beta inhibitor (cancer), Eli Lilly|galunisertib",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN,Cancer|Cardiovascular|Inflammatory,Alk-5 protein kinase inhibitor,4588,Anti-inflammatory|Anticancer protein kinase inhibitor|Antiarteriosclerotic,2953|62255|2667,,,Glioma|Non-small-cell lung cancer|Myelodysplastic syndrome|Hepatocellular carcinoma|Inflammatory disease|Carcinosarcoma|Stage IV melanoma|Atherosclerosis|Metastatic pancreas cancer|Metastatic rectal cancer|Advanced solid tumor|Cancer|Solid tumor,1108|1262|1272|1767|188|2614|3257|33|3669|3671|3713|651|725,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
46889,minocycline,minocycline|minocycline hydrochloride|Minocin,USAN|BAN|INN|USAN|Trade Name,Infection,,,Antimicrobial|Tetracycline,1593|1539,Bacterial infection,40,,,Wyeth KK|Takeda Pharmaceutical Co Ltd|Wyeth,22673|20300|14112,,,Wyeth,14112,,,,,,
46921,"levonorgestrel + estrogen, Bayer Schering","ethinylestradiol + levonorgestrel|Microgynon|levonorgestrel + estrogen, Schering AG|levonorgestrel + estrogen, Bayer Schering|Levlen|Microlite|Trionetta|Microgynon Fe|Minisiston|SHD-00342A|levonorgestrel + ethinylestradiol|NPC-16",Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Research Code,Genitourinary/Sexual Function,Estradiol agonist|Progesterone receptor agonist,536|624,Female contraceptive,7251,Female contraception,1778,,,Bayer AG|Alvogen Inc,14455|1051273,Schering AG,1052089,Schering AG,1052089,,,,,,
46927,doxycycline hyclate,doxycycline hyclate|doxycycline|VIBRA-TABS|Vibramycin|Vibramicina,USAN|INN|Trade Name|Trade Name|Trade Name,Dermatologic|Genitourinary/Sexual Function|Infection|Inflammatory|Other/Miscellaneous,,,Antiparasitic|Bacterial protein synthesis inhibitor|Ribosome binding agent|Antibacterial|Systemic dermatological antibacterial product,2638|1538|463|1594|15187,Female genital tract infection|Escherichia coli infection|Yersinia pestis infection|Bartonella infection|Haemophilus influenzae infection|Acinetobacter infection|Treponema infection|Bacterial respiratory tract infection|Listeria monocytogenes infection|Neisseria gonorrhoeae infection|Plasmodium falciparum infection|Rocky mountain spotted fever|Rickettsia infection|Urethritis|Acne|Shigella infection|Haemophilus ducreyi infection|Streptococcus pneumoniae infection|Fusobacterium infection|Enterobacter aerogenes infection|Mycoplasma pneumoniae infection|Treponema pallidum infection|Ureaplasma urealyticum infection|Borrelia recurrentis infection|Campylobacter fetus infection|Actinomyces israelii infection|Vibrio cholerae infection|Bacillus anthracis infection|Bacterial infection|Brucella infection|Clostridium infection|Gingivitis|Amoeba infection|Klebsiella infection|Chlamydia trachomatis infection|Prophylaxis|Chlamydia infection,1027|120|1397|1415|145|1453|1471|1484|200|227|267|2906|293|2951|3|301|3019|313|3275|3316|3318|332|3340|3342|3343|3345|343|39|40|424|428|469|534|638|68|706|778,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
46934,spironolactone,spironolactone|Aldactone,BANN|INN|Trade Name,Cardiovascular|Genitourinary/Sexual Function,Aldosterone antagonist,48,Diuretic agent|Antihypertensive,137|2657,Congestive heart failure|Hypertension|Nephrotic syndrome|Edema,1559|178|2315|402,,,CHEPLAPHARM Arzneimittel GmbH|Pfizer Inc|Pharmacia Corp,1129377|18767|27638,,,Pharmacia Corp,27638,,,,,,
46939,"olmesartan medoxomil + hydrochlorothiazide (hypertension), Sankyo","Benicar HCT|olmesartan + hydrochlorothiazide (hypertension), Sankyo|olmesartan medoxomil + hydrochlorothiazide|Olmetec Plus|CS-866CMB|olmesartan medoxomil + hydrochlorothiazide (hypertension), Sankyo|Openvas Co",Trade Name|Trade Name|Research Code|Trade Name,Cardiovascular,Angiotensin II receptor antagonist,64,Diuretic agent|Antihypertensive,137|2657,Hypertension,178,,,Sankyo Co Ltd|Daiichi Sankyo Co Ltd|Daewoong Pharmaceutical Co Ltd,19658|1017506|15587,,,Sankyo Co Ltd,19658,,,,,,
46958,KW-2449,"tumor antigen-specific mAb (cancer), Kyowa|tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin|KW-2449|tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo",Research Code,Cancer,Abl tyrosine kinase inhibitor|FGF1 receptor antagonist|Flt3 tyrosine kinase inhibitor,3524|3682|3806,Anticancer protein kinase inhibitor|Immunostimulant,62255|393,,,Acute myelogenous leukemia|Hematological neoplasm|Solid tumor,1731|2054|725,,,Kyowa Hakko Kirin Co Ltd|Kyowa Hakko Kogyo Co Ltd,1042596|17724,Kyowa Hakko Kogyo Co Ltd,17724,,,,,,
46983,dalotuzumab,"F-50035|cancer immunotherapy, Pierre Fabre|anti-IGF-1R monoclonal antibody (cancer), Merck & Co/Pierre Fabre|anti-IGF-1R mAb (cancer), Merck & Co|MK-0646|h7C10|dalotuzumab|7H2HM|A2CHM",Research Code|Research Code|USAN|INN,Cancer,Insulin-like growth factor 1 receptor antagonist,3252,Anticancer monoclonal antibody|Cell cycle inhibitor|Anticancer protein kinase inhibitor,55685|767|62255,,,Rectal tumor|Neuroendocrine tumor|Non-small-cell lung cancer|Pancreatic endocrine tumor|Metastatic breast cancer|Breast tumor|Cancer|Solid tumor|Colorectal tumor,1055|1128|1262|1510|3657|49|651|725|989,,,Merck & Co Inc|Pierre Fabre Group,18077|19087,Pierre Fabre Group,19087,,,,,,
47000,bendamustine,bendamustine|SyBL-0501|SyB L-0501|SDX-105|bendamustine hydrochloride|Inno-P08001|Treakisym|Ribovact|Benda|Symbenda|Innomustine|Ribomustin|Cytostasan|Levact|Treanda|SyB L-0501RI,INN|Research Code|Research Code|Research Code|USAN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code,Cancer|Endocrine/Metabolic,PARP modulator,2506,Anticancer alkylating agent,50,Metastasis|Amyloidosis|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma|Lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1069|1143|1734|1744|1745|1749|1828|203|316|319,Myelodysplastic syndrome|Hodgkins disease|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia|Plasmacytoma|Metastatic ovary cancer,1272|161|1728|1731|1735|1748|3866,SymBio Pharmaceuticals Ltd|Mundipharma EDO GmbH|Teva Pharmaceutical Industries Ltd|Cephalon Inc|Nuance Biotech Inc|Janssen-Cilag Ltd|Eisai Co Ltd|Astellas Pharma GmbH|Innopharmax Inc,1017747|24189|20348|15358|1118419|17392|15872|29344|1047623,Ribosepharm GmbH|Johnson & Johnson|H Lundbeck A/S|Jenapharm GmbH & Co KG|Salmedix Inc,16183|17332|17900|24030|29254,Jenapharm GmbH & Co KG,24030,,,,,,
47019,dimethyl fumarate,"BG-12|second-generation fumarate derivative (psoriasis), Fumapharm/Biogen|fumarate derivative (second-generation, psoriasis), Fumapharm/Biogen|BG-00012|dimethyl fumarate|dimethyl fumarate (oral, psoriasis), Biogen Idec|FAG-201|Panaclar|Tecfidera|dimethyl fumarate (oral, psoriasis), Biogen",Research Code|Research Code|USAN|Research Code|Trade Name|Trade Name,Dermatologic|Immune|Neurology/Psychiatric,Kelch like ECH associated protein 1 modulator|Nuclear erythroid 2-related factor 2 stimulator,48829|19507,Neuroprotectant|Immunomodulator,1615|1596,Scleroderma|Multiple sclerosis|Demyelinating disease,1105|213|92,Psoriasis|Rheumatoid arthritis,281|291,Eisai Co Ltd|Biogen Inc|UCB SA,15872|1005244|20452,Biogen Idec International GmbH,26039,Biogen Idec International GmbH,26039,,,,,,
4705,ibritumomab tiuxetan,"ibritumomab tiuxetan|90Y-2B8|SHL-749|111In-2B8|IDEC-Y2B8|IDEC-In2B8|90Y-anti-CD20, IDEC|111In-anti-CD20, IDEC|90Y-ibritumomab tiuxetan|111In-ibritumomab tiuxetan|yttrium-90-anti-CD20, IDEC|indium-111-anti-CD20, IDEC|yttrium-90-ibritumomab tiuxetan|indium-111-ibritumomab tiuxetan|DE-00749|Zevalin|BAY86-5128",INN|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code,Cancer,B-lymphocyte antigen CD20 modulator,5083,Anticancer monoclonal antibody|Radioimmunotherapeutic,55685|1552,Follicle center lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1745|316|319,Chronic lymphocytic leukemia|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma,1734|1744|1749|1828,CASI Pharmaceuticals Inc|Acrotech Biopharma LLC|Mundipharma International Corp Ltd|FUJIFILM Holdings Corp|Servier Canada Inc,21794|1179286|1045514|1037804|22730,Biogen Inc|Schering AG|Bayer AG|Bayer Yakuhin Ltd|CTI BioPharma Corp|IDEC Pharmaceuticals Corp|Genentech Inc|Spectrum Pharmaceuticals Inc|Dr Reddy's Laboratories Ltd,1005244|1052089|14455|14557|15337|17085|19453|24232|29387,IDEC Pharmaceuticals Corp,17085,,,,,,
4718,zileuton,A-64077|Leutrol|zileuton|Zyflo|Zyflo Filmtab|Filmtab,Research Code|Trade Name|USAN|BAN|INN|Trade Name|Trade Name|Trade Name,Dermatologic|Gastrointestinal|Musculoskeletal|Respiratory,5-Lipoxygenase inhibitor,247,Anticancer|Anti-inflammatory|Leukotriene B4 synthesis inhibitor,1545|2953|237,Asthma,31,Chronic obstructive pulmonary disease|Mastocytosis|Acne|Ulcerative colitis,1185|2795|3|337,Critical Therapeutics Inc,30201,Chiesi USA Inc|Abbott Laboratories,1043326|13601,Abbott Laboratories,13601,,,,,,
47197,AEG-35156,"AEG-161|GEM-640|XIAP-AS|AEG-35156|XIAP antisense (anticancer), Aegera/Hybridon|X-linked inhibitory apoptosis protein (antisense), Aegera|X-linked inhibitory apoptosis protein (antisense), Apoptogen|AEG-351569|XIAP antisense (anticancer), Aegera/Idera|X-linked inhibitory apoptosis protein (antisense), Aegera/Idera",Research Code|Research Code|Research Code|Research Code|Analogue,Cancer,BIRC4 gene inhibitor,18157,Antisense oligonucleotide inhibitor|Anticancer|Apoptosis stimulator,7294|1545|1589,,,Non-small-cell lung cancer|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Hepatocellular carcinoma|Lymphoma|Pancreas tumor|Breast tumor|Cancer|Solid tumor,1262|1731|1734|1767|203|249|49|651|725,,,Idera Pharmaceuticals Inc|Aegera Therapeutics Inc,17006|25069,Idera Pharmaceuticals Inc,17006,,,,,,
4735,valaciclovir,valaciclovir|valacyclovir|256-U-87|valaciclovir hydrochloride|256U|BW-256|BW-256U|Valtrex|Zelitrex,INN|Research Code|USAN|Research Code|Research Code|Research Code|Trade Name|Trade Name,Infection,DNA polymerase inhibitor,138,Antiviral|HSV replication inhibitor,991|783,Herpes simplex virus infection|Varicella zoster virus infection,157|392,Hepatitis C virus infection|Cytomegalovirus infection,153|89,GlaxoSmithKline plc|Aspen PharmaCare Holdings Ltd,28355|1019374,Glaxo Group Ltd,16453,Glaxo Group Ltd,16453,,,,,,
47599,Gendicine,"Gendicine|adenoviral gene therapy (p53), SiBiono|adenoviral gene therapy (cancer), SiBiono|Genkaxin|rAd-p53",Trade Name|Trade Name|Research Code,Cancer|Endocrine/Metabolic,TP53 gene stimulator,7692,Adenovirus based gene therapy|Hypoglycemic agent|Anticancer,4780|399|1545,Non-small-cell lung cancer|Hepatocellular carcinoma|Head and neck tumor|Diabetes mellitus,1262|1767|623|97,,,Shenzhen SiBiono Gene Technologies Co Ltd,1005243,,,Shenzhen SiBiono Gene Technologies Co Ltd,1005243,,,,,,
47600,EB-10,"EB-10|IMC-EB10|anti-Flt3 (monoclonal antibody, leukemia), ImClone|EB-10-MMAF|A2IN|D4-3|IMC-NC7",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Flt3 tyrosine kinase inhibitor,3806,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,,,Acute myelogenous leukemia|Leukemia,1731|199,,,Imclone LLC,17193,Imclone LLC,17193,,,,,,
47660,crenolanib,"CP-868596|PDGFR inhibitor (solid tumors), Pfizer|ARO-002|PDGFR inhibitor (solid tumors), Arog Pharmaceuticals|plarotinib|crenolanib besylate|crenolanib|CP-868596-26",Research Code|Research Code|USAN|USAN|INN|Research Code,Cancer|Musculoskeletal,Flt3 tyrosine kinase inhibitor|PDGF receptor alpha antagonist|PDGF receptor beta antagonist,3806|48489|48492,Synergist|Anticancer|Anticancer protein kinase inhibitor|Angiogenesis inhibitor,7293|1545|62255|61,Glioma|Stomach tumor|Acute myelogenous leukemia|Gastrointestinal stromal tumor|Soft tissue sarcoma,1108|127|1731|3205|3378,Non-small-cell lung cancer|Systemic mastocytosis|Cancer|Solid tumor,1262|3728|651|725,Ji Shanghai Biotechnology Co Ltd|Arog Pharmaceuticals Inc,1190074|1058191,OSI Pharmaceuticals Inc|Pfizer Inc,18676|18767,Pfizer Inc,18767,,,,,,
47727,"milatuzumab-doxorubicin conjugate (cancer), Immunomedics","IMMU-110|doxorubicin-hCD74 conjugate, Immunomedics|CD74-DOX|milatuzumab-doxorubicin conjugate (cancer), Immunomedics|hLL1-DOX",Research Code,Cancer,Topoisomerase II inhibitor|CD74 modulator|DNA polymerase inhibitor,142|5301|138,Anticancer antibody|Anticancer,55684|1545,,,Chronic lymphocytic leukemia|Multiple myeloma|Non-Hodgkin lymphoma|Cancer,1734|1828|319|651,,,Immunomedics Inc,17204,Immunomedics Inc,17204,,,,,,
47733,canakinumab,"ACZ-885|anti-IL-1 beta monoclonal antibody (inflammation/COVID-19-induced pneumonia/cytokine release syndrome), Novartis|canakinumab|Ilaris",Research Code|USAN|INN|Trade Name,Cancer|Cardiovascular|Endocrine/Metabolic|Hematologic|Immune|Infection|Inflammatory|Musculoskeletal|Ocular|Other/Miscellaneous|Respiratory,Interleukin-1 beta ligand inhibitor|Immunoglobulin G1 agonist,12479|5743,Cardioprotectant|Immunosuppressant|Anti-inflammatory|Antiviral|Therapeutic antibody|Anticancer monoclonal antibody,2659|396|2953|991|172641|55685,Sarcoidosis|Coronavirus disease 19 infection|Non-small-cell lung cancer|Gout|Viral pneumonia|Fever|Pancreas tumor|Adult onset Stills disease|Juvenile rheumatoid arthritis|Sickle cell anemia|Systemic inflammatory response syndrome|Muckle Wells syndrome|Familial mediterranean fever|Stage III melanoma|Stage IV melanoma|Autoimmune disease|Cryopyrin associated periodic syndrome|Familial cold autoinflammatory syndrome|CINCA syndrome|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Behcets disease|Non-insulin dependent diabetes,1036|10406|1262|136|1818|1833|249|3002|3003|303|3220|3222|3244|3256|3257|36|3601|3602|3603|3657|3665|3669|768|837,Chronic obstructive pulmonary disease|Age related macular degeneration|Vasculitis|Immune disorder|Osteoarthritis|Polymyalgia rheumatica|Rheumatoid arthritis|Xerophthalmia|Asthma|Atherosclerosis|Abdominal aortic aneurysm|Kawasaki disease|Insulin dependent diabetes,1185|1226|1532|185|245|2887|291|3016|31|33|3859|780|836,Novartis AG,23137,,,Novartis AG,23137,,,,,,
47735,"panobinostat (intravenous), Novartis","LBH-589 (intravenous), Novartis|LBH-589A|panobinostat|panobinostat (intravenous), Novartis|LBH-589|NVP-LBH-589|Faridak|Farydak",Research Code|USAN|INN|Research Code|Research Code|Trade Name|Trade Name,Cancer|Immune,Histone deacetylase inhibitor,2574,Anticancer|Apoptosis stimulator|Angiogenesis inhibitor,1545|1589|61,,,Small-cell lung cancer|Hormone refractory prostate cancer|Breast tumor|Graft versus host disease|Cancer,1261|3246|49|616|651,,,Novartis AG,23137,Novartis AG,23137,,,,,,
47820,olaratumab,"3G3 mAb (cancer), ImClone|PDGF mAb (cancer), ImClone|PDGF-alpha monoclonal antibody (cancer), ImClone/Eli Lilly|IMC-3G3|olaratumab|LY-3012207|PDGFRa mAb (cancer), Eli Lilly|Lartruvo",Research Code|USAN|INN|Research Code|Trade Name,Cancer,PDGF receptor alpha antagonist,48489,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Metastatic pancreas cancer,3669,Non-small-cell lung cancer|Glioblastoma|Prostate tumor|Gastrointestinal stromal tumor|Soft tissue sarcoma|Cancer|Solid tumor|Ovary tumor,1262|2454|276|3205|3378|651|725|799,Eli Lilly & Co,17810,Imclone LLC,17193,Imclone LLC,17193,,,,,,
47898,otlertuzumab,"CytoxB37G|CD37 antagonist, Trubion|SMIP-016|CD37-SMIP|Tru 16.4|G28-1 scFv-Ig|SMIP-016-GV|CD37 antagonist, Emergent|otlertuzumab|TRU-016",Research Code|USAN|Research Code,Cancer|Immune|Inflammatory,CD37 antagonist,5133,Immunomodulator|Anticancer monoclonal antibody|Apoptosis stimulator,1596|55685|1589,,,Chronic lymphocytic leukemia|Peripheral T-cell lymphoma|Inflammatory disease|B-cell lymphoma|Non-Hodgkin lymphoma|Autoimmune disease|Cancer,1734|1753|188|316|319|36|651,,,Emergent BioSolutions Inc|AbbVie Biotherapeutics Inc|Aptevo Therapeutics Inc|Abbott Laboratories|Trubion Pharmaceuticals Inc,1011990|1044720|1122543|13601|29947,Trubion Pharmaceuticals Inc,29947,,,,,,
47924,"clofarabine (oral), Genzyme","clofarabine|clofarabine (oral), Bioenvision/ILEX|clofarabine (oral), Genzyme|Clolar|SAR-393590|GZ-393590",USAN|BANN|INN|Trade Name|Research Code|Research Code,Cancer,,,Anticancer|DNA synthesis inhibitor|Unspecified drug target|Anticancer antimetabolite,1545|140|59620|1569,,,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Mantle cell lymphoma|T-cell lymphoma|B-cell lymphoma|Solid tumor,1272|1728|1731|1744|311|316|725,,,Sanofi Genzyme|Southern Research Institute|ILEX Oncology Inc|Bioenvision Inc,16299|20226|23744|26493,Southern Research Institute,20226,,,,,,
47941,GSK-1437173A,"adult varicella zoster vaccine (attenuated recombinant viral vaccine), GlaxoSmithKline|GSK-1437173A|adult herpes zoster vaccine (shingles prophylaxis), GlaxoSmithKline|HZ/su|Shingrix|GSK-137173A",Research Code|Trade Name|Research Code,Infection,,,Live attenuated viral vaccine|Subunit vaccine|Prophylactic vaccine,12364|12371|12378,Adult varicella zoster virus infection,1776,,,GlaxoSmithKline plc,28355,Japan Vaccine Co Ltd,1068620,GlaxoSmithKline plc,28355,,,,,,
48099,farletuzumab,"MORAb-003|monoclonal antibody (ovarian cancer), Morphotek|farletuzumab|monoclonal antibody (ovarian cancer), Eisai",Research Code|USAN|INN,Cancer,Folate receptor alpha antagonist,12800,Synergist|Anticancer monoclonal antibody,7293|55685,,,Pituitary adenoma|Metastatic non small cell lung cancer|Breast tumor|Cancer|Ovary tumor,1831|3665|49|651|799,,,Eurofarma|Eisai Co Ltd|Ludwig Institute for Cancer Research|University of Gothenburg|Morphotek Inc,1042566|15872|21091|25752|29741,Ludwig Institute for Cancer Research,21091,,,,,,
48119,vortioxetine hydrobromide,Lu-AA21004|vortioxetine|vortioxetine hydrochloride|vortioxetine hydrobromide|Brintellix|Trintellix,Research Code|USAN|INN|USAN|Trade Name|Trade Name,Neurology/Psychiatric,5-HT 1d receptor antagonist|Serotonin transporter inhibitor|5-HT 7 receptor antagonist|5-HT 1a receptor agonist|5-HT 1b receptor partial agonist|5-HT 3 receptor antagonist,11|13184|1922|6|81491|15,Nootropic agent|Antidepressant|Anxiolytic|5-HT uptake inhibitor,284|2941|2942|3,Binge eating disorder|Bipolar I disorder|Bipolar II disorder|Major depressive disorder,1909|3114|3115|4898,Generalized anxiety disorder|Anxiety disorder|Attention deficit hyperactivity disorder|Depression,1937|25|34|93,Takeda Pharmaceutical Co Ltd|H Lundbeck A/S,20300|17900,,,H Lundbeck A/S,17900,,,,,,
48224,MK-0752,"c-7617|MK-0752|MK-752|Notch signalling pathway inhibitor, Merck & Co",Research Code|Research Code|Research Code,Cancer|Neurology/Psychiatric,Gamma-secretase inhibitor|Notch antagonist,7578|8118,Neuroprotectant|CNS modulator|Anticancer,1615|2939|1545,,,Alzheimers disease|T-cell acute lymphoblastic leukemia|Breast tumor|Cancer,14|1730|49|651,,,Merck & Co Inc,18077,Merck & Co Inc,18077,,,,,,
48319,idelalisib,"PI3K delta inhibitors (inflammation/cancer), ICOS/Calistoga|IC-980033|IC-87114|P13K delta inhibitors (inflammation/cancer), Eli Lilly|lipid kinase inhibitors (inflammation/autoimmunity/cancer), ICOS|p110 delta PI3 kinase inhibitors (inflammation/cancer), ICOS|CAL-101|GS-1101|idelalisib|idelalisib (inflammation/autoimmunity/cancer), ICOS|lipid kinase inhibitors, ICOS|Zydelig",Research Code|Research Code|Research Code|Research Code|USAN|INN|Trade Name,Cancer|Endocrine/Metabolic|Hematologic|Immune|Inflammatory,Phosphoinositide-3 kinase delta inhibitor,11183,Anti-inflammatory|Apoptosis stimulator|Cell cycle inhibitor|Anticancer protein kinase inhibitor|Synergist,2953|1589|767|62255|7293,Non-small-cell lung cancer|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Myelofibrosis|Non-Hodgkin lymphoma,1262|1734|1744|1745|2436|319,Allergic rhinitis|Macroglobulinemia|Pancreatic ductal adenocarcinoma|Hodgkins disease|Inflammatory disease|Hematological neoplasm|AL amyloidosis,1107|1264|1507|161|188|2054|3492,Gilead Sciences Inc,16450,Calistoga Pharmaceuticals Inc|ICOS Corp|Eli Lilly & Co,1031135|17082|17810,ICOS Corp,17082,,,,,,
48344,CYT-107,"CYT-99007|IL-7, Cytheris|interleukin-7, Cytheris|CYT-107|glyco-rhIL-7|Glycosylated rhIL-7",Research Code|Research Code|Research Code,Cancer|Hematologic|Immune|Infection|Neurology/Psychiatric|Respiratory,IL-7 receptor agonist,489,Anticancer|Immunostimulant|Antiviral|Antibacterial,1545|393|991|1594,Coronavirus disease 19 infection|Hypoxia|Lymphocytopenia|Progressive multifocal leukoencephalopathy|Mycobacterium infection|Hormone refractory prostate cancer|Metastatic bladder cancer|Metastatic renal cancer|Urethral cancer|Respiratory failure|Ureter cancer|Bone marrow transplantation|Solid tumor,10406|1053|1992|1997|218|3246|3466|3467|3678|3914|4265|46|725,Sepsis|Hepatitis B virus infection|Hepatitis C virus infection|HIV infection|Transitional cell carcinoma|Melanoma|Epstein Barr virus infection|Metastatic renal cell carcinoma|Breast tumor|Immune deficiency|Cancer,114|152|153|158|1771|205|3299|4250|49|504|651,Revimmune,1006411,,,Revimmune,1006411,,,,,,
48357,armodafinil,"R-modafinil|R-isomer modafinil, Cephalon|armodafinil|Nuvigil|CEP-10953",USAN|PINN|Trade Name|Research Code,Neurology/Psychiatric|Other/Miscellaneous,Alpha 1 adrenoceptor agonist|Dopamine transporter inhibitor,31|13181,Psychostimulant,7225,Narcolepsy|Obstructive sleep apnea|Hypersomnia,1520|3519|400,Binge eating disorder|Schizophrenia|Bipolar disorder|Neurological disease|Fatigue,1909|299|653|677|829,H Lundbeck A/S|Teva-Handok|Cephalon Inc|Teva Pharmaceutical Industries Ltd,17900|1084465|15358|20348,,,Cephalon Inc,15358,,,,,,
48359,XL-844,XL-844,Research Code,Cancer,PDGF receptor antagonist|Checkpoint kinase 2 inhibitor|Checkpoint kinase 1 inhibitor|VEGF-2 receptor modulator|Flt3 tyrosine kinase modulator,948|4228|4438|3847|3805,Cell cycle inhibitor|Anticancer protein kinase inhibitor|Anticancer,767|62255|1545,,,Cancer,651,,,Exelixis Inc,22676,Exelixis Inc,22676,,,,,,
48537,"ciclosporin (ophthalmic, dry eye), Santen","cyclosporine A|ciclosporin|cyclosporine|NOVA-22008|cyclosporine (ophthalmic emulsion), Novagali|cyclosporine A (ophthalmic emulsion, dry eye), Novagali|cyclosporine A (ophthalmic, dry eye), Novagali|cyclosporin A|Vekacia|Cyclokat|ciclosporin (ophthalmic, dry eye), Santen|ciclosporin (ophthalmic emulsion), Novagali|Ikervis|Eyecurvis|Verkazia|NOVA-22007|DE-076C|DE-076B",BANN|INN|USAN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Research Code,Ocular,Calcineurin inhibitor,4010,Antiviral|Anti-inflammatory|Immunosuppressant|Ophthalmological agent,991|2953|396|15128,Keratoconjunctivitis|Xerophthalmia,1296|3016,Lacrimal gland disease,1147,Santen SAS|Santen Pharmaceutical Co Ltd,31632|19670,,,Santen SAS,31632,,,,,,
48577,OSI-930,"OSI-930|c-kit/KDR dual inhibitors (cancer), OSI Pharmaceuticals|OSI-817|Thiophenib|SIM-81",Research Code|Research Code|Research Code,Cancer,Kit tyrosine kinase inhibitor|VEGF-2 receptor antagonist,3808|3848,Angiogenesis inhibitor|Anticancer protein kinase inhibitor,61|62255,Cancer,651,Solid tumor,725,Simcere Pharmaceutical Group,1023261,Astellas Pharma Inc|OSI Pharmaceuticals Inc,1013295|18676,OSI Pharmaceuticals Inc,18676,,,,,,
48681,efatutazone,"CS-7017|PPAR gamma agonist (cancer), Sankyo/Daiichi Sankyo Inc|inolitazone|RS-5444|efatutazone",Research Code|Research Code|USAN|INN,Cancer,PPAR gamma agonist,2480,Anticancer,1545,Liposarcoma,2447,Esophagus tumor|Thyroid tumor|Non-small-cell lung cancer|Cancer|Colorectal tumor,1011|1134|1262|651|989,Daiichi Sankyo Inc,1020322,Daiichi Sankyo Co Ltd|Sankyo Co Ltd,1017506|19658,Sankyo Co Ltd,19658,,,,,,
48900,"theophylline, Mitsubishi Pharma","theophylline|theophylline, Mitsubishi Pharma|Theodur",Trade Name,Respiratory,,,Unspecified drug target|Bronchodilator,59620|646,Asthma,31,,,Mitsubishi Pharma Corp|BioPhausia AB,20983|26140,,,Mitsubishi Pharma Corp,20983,,,,,,
48945,"bupivacaine, AstraZeneca","bupivacaine|Marcaine|bupivacaine, AstraZeneca|DUR-843|Sensorcaine",USAN|INN|Trade Name|Research Code|Trade Name,Neurology/Psychiatric,Sodium channel inhibitor,498,Local anesthetic,1669,Topical anesthesia,328,,,Aspen PharmaCare Holdings Ltd,1019374,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
48946,dasatinib,"BMS-354825|Src/Abl kinase inhibitor (cancer), BMS|dasatinib|Sprycel|dasatinib (USAN)|NSC-732517|Spraicell|Spricel",Research Code|INN|Trade Name|USAN|Research Code|Trade Name,Cancer|Hematologic|Musculoskeletal,PDGF-B ligand inhibitor|Yes tyrosine kinase inhibitor|Bcr protein inhibitor|Abl tyrosine kinase inhibitor|Kit tyrosine kinase inhibitor|EPH family tyrosine kinase inhibitor|Ddr2 tyrosine kinase receptor inhibitor|Lck tyrosine kinase inhibitor|Src tyrosine kinase inhibitor|Fyn tyrosine kinase inhibitor,24539|14107|13571|3524|3808|3762|3752|3584|3576|3574,Anticancer protein kinase inhibitor|Anticancer|Angiogenesis inhibitor,62255|1545|61,Acute lymphoblastic leukemia|Chronic myelocytic leukemia|Lymphoplasmacytic lymphoma|Glioblastoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Breast tumor,1728|1735|1743|2454|3657|3665|49,Metastasis|Myelodysplastic syndrome|Cholangiocarcinoma|Multiple myeloma|Sarcoma|Melanoma|Fallopian tube cancer|Polycythemia vera|Pancreas tumor|Mastocytosis|Peritoneal tumor|Hormone refractory prostate cancer|Head and neck tumor|Solid tumor|Ovary tumor|Colorectal tumor,1069|1272|1765|1828|194|205|2243|2319|249|2795|3083|3246|623|725|799|989,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
48980,mirdametinib,"second generation MAP/ERK kinase [MEK]-1 inhibitor, Pfizer|PD-0325901|PD-325901|second generation MEK 1/2 inhibitor (oral, type 1 neurofibromatosis/advanced solid tumors), SpringWorks|mirdametinib",Research Code|Research Code,Cancer,MEK-2 protein kinase inhibitor|MEK-1 protein kinase inhibitor,4764|4762,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Glioma|Neurofibromatosis type I|Advanced solid tumor,1108|3521|3713,Non-small-cell lung cancer|Melanoma|Metastatic colorectal cancer|Metastatic pancreas cancer|Breast tumor|Cancer|Colon tumor,1262|205|3658|3669|49|651|767,SpringWorks Therapeutics Inc,1154395,Pfizer Inc,18767,SpringWorks Therapeutics Inc,1154395,,,,,,
49038,fresolimumab,"GC-1000 series, Genzyme/Cambridge Antibody Technologies|anti-TGF beta antibodies, Genzyme/Cambridge Antibody Technologies|fresolimumab|GC-1008|fresolumimab|GZ-402669",USAN|INN|Research Code|Research Code,Cancer|Gastrointestinal|Genitourinary/Sexual Function|Respiratory,TGF beta receptor antagonist,377,Fibrosuppressant|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,664|55685|62255,Liver fibrosis,2318,Glioma|Mesothelioma|Renal cell carcinoma|Melanoma|Focal segmental glomerulosclerosis|Idiopathic pulmonary fibrosis|Cancer,1108|1240|1766|205|3084|3771|651,Tianjin International Joint Academy of Biotechnology and Medicine,1054143,Sanofi Genzyme|MedImmune LLC|Cambridge Antibody Technology Group plc,16299|18008|24236,Cambridge Antibody Technology Group plc,24236,,,,,,
49057,belatacept,"LEA-029|L104EA29YIg|belatacept|BMS-224818|LEA-29Y|Nulojix|belatacept (iv, lung transplant rejection), Bristol-Myers Squibb|lymphocyte costimulation/CD28 inhibitor (iv, kidney/heart/lung transplant rejection), Bristol-Myers Squibb",Research Code|Research Code|USAN|INN|Research Code|Research Code|Trade Name,Immune,T cell surface glycoprotein CD28 inhibitor|Cytotoxic T-lymphocyte protein-4 modulator,5106|5480,Immunosuppressant|Lymphocyte inhibitor,396|7748,Heart transplant rejection|Kidney transplant rejection|Lung transplant rejection|Transplant rejection,2987|2989|3141|515,Rheumatoid arthritis|Liver transplant rejection|Islet cell transplant rejection|Bone marrow transplantation,291|2988|3481|46,Bristol-Myers Squibb Co,15065,Novartis AG,23137,Bristol-Myers Squibb Co,15065,,,,,,
49077,"metformin hydrochloride (extended release), Merck KGaA/BMS","metformin hydrochloride|metformin|metformin (extended release), Merck KGaA/BMS|Glucophage SR|Glucophage XR|Glifage XR|metformin hydrochloride (extended release), Merck KGaA/BMS",USAN|BAN|INN|Trade Name|Trade Name|Trade Name,Endocrine/Metabolic,AMP activated protein kinase stimulator,8805,Biguanide antidiabetic product|Hypoglycemic agent,38206|399,Non-insulin dependent diabetes,837,,,Acino Holding AG|Bristol-Myers Squibb Co|Merck Serono SA|Merck KGaA,1040020|15065|19862|18101,,,Merck KGaA,18101,,,,,,
49120,pegdinetanib,"TRINECTINs|Trinectins (anti-angiogenesis), Compound Therapeutics|Trinectin binding proteins, Compound Therapeutics/Phylos|CT-322|AdNectin VEGFR-2 inhibitor (anti-angiogenesis), Compound Therapeutics|Trinectins (anti-angiogenesis), Adnexus|AdNectin VEGFR-2 inhibitor (anti-angiogenesis), Adnexus|BMS-844203|pegdinetanib|Angiocept|Adnectin|VEGF R-2 Adnectin (oncology), Bristol-Myers Squibb",Trade Name|Research Code|Research Code|USAN|INN|Trade Name,Cancer,VEGF-2 receptor antagonist,3848,Anticancer protein kinase inhibitor|Angiogenesis inhibitor,62255|61,,,Non-small-cell lung cancer|Glioblastoma|Cancer|Colorectal tumor,1262|2454|651|989,,,Phylos Inc|Adnexus Therapeutics Inc,26959|30815,Phylos Inc,26959,,,,,,
49160,rocapuldencel-T,"cancer vaccine (tumor RNA), Merix|tumor antigen transfected dendritic cells (cancer), Merix|tumor antigen transfected dendritic cells (melanoma/renal tumor), Argos Therapeutics/Kirin|melanoma/renal tumor vaccine (tumor RNA), Argos Therapeutics/Kirin|RNA-loaded dendritic cell vaccine (melanoma/renal tumor), Argos Therapeutics/Kyowa Hakko Kirin|RNA-loaded dendritic cell vaccine (cancer), Merix|MB-002|AGS-003|dendritic cell vaccine (Arcelis, melanoma/renal tumor), Argos Therapeutics/Kirin|RNA-loaded dendritic cell vaccine (melanoma/renal tumor), Argos Therapeutics/Kirin|RNA-loaded dendritic cell vaccine (intradermal, renal cell carcinoma), Argos Therapeutics/Medinet|rocapuldencel-T|CMN-001",Research Code|Research Code|USAN|Research Code,Cancer,,,Dendritic cell vaccine|Therapeutic vaccine|Anticancer|Genetically engineered autologous cell vaccine,102926|12379|1545|4791,Metastatic renal cell carcinoma|Solid tumor,4250|725,Non-small-cell lung cancer|Renal cell carcinoma|Melanoma|Renal tumor,1262|1766|205|999,CoImmune Inc (formerly Argos Therapeutics Inc)|Medinet Co Ltd|Chongqing LUMMY Pharmaceutical Co Ltd,28019|1005970|1063173,Kirin Pharma Co Ltd|Kyowa Hakko Kirin Co Ltd|Kirin Brewery Co Ltd,1034843|1042596|17661,CoImmune Inc (formerly Argos Therapeutics Inc),28019,,,,,,
49338,motesanib diphosphate,"oral selective VEGFR/PDGFR/Kit kinase inhibitor (solid tumors), Amgen|motesanib diphosphate|motesanib|AMG-706",USAN|USAN|INN|Research Code,Cancer,VEGF-3 receptor antagonist|VEGF-2 receptor antagonist|VEGF-1 receptor antagonist|Kit tyrosine kinase inhibitor|PDGF receptor antagonist,3850|3848|3846|3808|948,Angiogenesis inhibitor|Anticancer protein kinase inhibitor,61|62255,,,Thyroid tumor|Non-small-cell lung cancer|Gastrointestinal tumor|Breast tumor|Cancer|Solid tumor|Colorectal tumor,1134|1262|131|49|651|725|989,,,Amgen Inc|Takeda Pharmaceutical Co Ltd|Takeda Oncology|Takeda Bio Development Center Ltd,14109|20300|21991|23215,Amgen Inc,14109,,,,,,
49339,trebananib,"tie-2 tyrosine kinase receptor antagonists (cancer), Amgen/Takeda|tie-2 tyrosine kinase receptor antagonists, Amgen/Takeda|tie-2 receptor antagonists, Amgen/Takeda|AMG-386|Peptidobody tie-2 tyrosine kinase receptor antagonists, Amgen|2xCon4C|Ab536|Angiopoietin-2 antagonists (cancer), Amgen/Takeda|Ang-2 antagonists (cancer), Amgen/Takeda|trebananib|L1-7",Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer,Angiopoietin ligand-1 inhibitor|Angiopoietin ligand-2 inhibitor|Tek tyrosine kinase receptor inhibitor,14320|14323|3834,Anticancer protein kinase inhibitor|Angiogenesis inhibitor,62255|61,,,Non-small-cell lung cancer|Gastrointestinal tumor|Hepatocellular carcinoma|Transitional cell carcinoma|Fallopian tube cancer|Glioblastoma|Peritoneal tumor|Metastatic gastrointestinal cancer|Metastatic renal cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic ovary cancer|Breast tumor|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,1262|131|1767|1771|2243|2454|3083|3460|3467|3665|3667|3866|49|651|725|799|989,,,Amgen Inc|Takeda Pharmaceutical Co Ltd|Takeda Bio Development Center Ltd,14109|20300|23215,Amgen Inc,14109,,,,,,
49407,"marizomib (iv, cancer), Triphase/Celgene","salinosporamide A|salinosporamide A, UCSD|NPI-0052|marizomib|marizomib (iv, cancer), Triphase/Celgene|marizomib (iv, cancer), Triphase|marizomib (iv, cancer), Celgene",Research Code|USAN|INN,Cancer|Hematologic|Infection|Inflammatory,Proteasome inhibitor,4917,Anti-inflammatory|Apoptosis stimulator|Antibacterial|Anticancer,2953|1589|1594|1545,Glioma|Glioblastoma,1108|2454,Macroglobulinemia|Multiple myeloma|Inflammatory disease|Lymphoma|Bacillus anthracis infection|Cancer|Solid tumor,1264|1828|188|203|39|651|725,Bristol-Myers Squibb Co,15065,Triphase Accelerator Corp|Celgene Corp|University of California San Diego|Nereus Pharmaceuticals Inc,1078415|15331|25451|27672,University of California San Diego,25451,,,,,,
49417,inalimarev + falimarev,"PANVAC-VF|CEA/MUC-1/VF/TRICOM (pancreatic cancer), Therion|therapeutic prime-boost vaccine (cancer), Therion|rV-CEA-MUC1-TRICOM + rF-CEA-MUC1-TRICOM prime-boost cancer vaccine, Therion|vaccinia vector-CEA-MUC1-TRICOM prime + fowl pox vector-CEA-MUC1-TRICOM boost, Therion|inalimarev + falimarev|inalimarev (CEA, MUC-1, Vaccinia virus) + falimarev (CEA, MUC-1, fowlpox virus)|PANVAC-V + PANVAC-F|PANVAC + PANVACF|rV-CEA-MUC1-TRICOM + rF-CEA-MUC1-TRICOM prime-boost cancer vaccine, NCI|CVAC-301|CV-301|ICAM-1, B7.1 and LFA-3 costimulator (TRICOM) prime-boost cancer vaccine, Bavarian Nordic|rV-CEA-MUC1-TRICOM + rF-CEA-MUC1-TRICOM prime-boost cancer vaccine, Bavarian Nordic|triple ICAM-1 costimulator/CD80 costimulator/LFA-3 costimulator (TRICOM) prime-boost cancer vaccine, Bavarian Nordic",Trade Name|Research Code|Research Code,Cancer,Mucin 1 modulator|ICAM-1 stimulator|CD58 agonist|CD66e modulator|CD80 agonist,32076|5223|5235|5281|5326,Recombinant viral vector vaccine|Therapeutic vaccine|T-lymphocyte stimulator|Anticancer,12370|12379|7761|1545,Non-small-cell lung cancer|Bladder cancer|Prostate tumor|Metastatic bladder cancer|Metastatic colorectal cancer|Metastatic pancreas cancer|Small intestine cancer,1262|2380|276|3466|3658|3669|4166,Pancreas tumor|Breast tumor|Carcinoma|Solid tumor|Ovary tumor|Colorectal tumor,249|49|54|725|799|989,National Cancer Institute (NCI),20519,BN ImmunoTherapeutics Inc|Therion Biologics Corp,1012937|20371,Therion Biologics Corp,20371,,,,,,
49441,RAV-12,"RAV-12|KID-3 antibody (cancer), Raven|anti-RAAG12 monoclonal antibody|anti-RAAG12 mab",Research Code,Cancer,,,Unspecified drug target|Anticancer monoclonal antibody|Anticancer,59620|55685|1545,,,Adenocarcinoma|Pancreas tumor|Solid tumor,2399|249|725,,,Raven Biotechnologies Inc|MacroGenics Inc,27634|29060,Raven Biotechnologies Inc,27634,,,,,,
49444,itarnafloxin,"CX-3385|CX-3543|c-Myc/VEGF oncogene inhibitor (cancer), Cylene|quadruplex DNA oncogene inhibitor (cancer), Cylene|quarfloxin|itarnafloxin",Research Code|Research Code|USAN|INN,Cancer,Nucleolin inhibitor,15169,Apoptosis stimulator|RNA synthesis inhibitor|Oncogene inhibitor,1589|439|794,,,Neuroendocrine tumor|Chronic lymphocytic leukemia|Leukemia|Carcinoid tumor|Cancer,1128|1734|199|2538|651,,,TetraGene LLC|Cylene Pharmaceuticals Inc,1091622|28603,Cylene Pharmaceuticals Inc,28603,,,,,,
49457,opaganib,"SKI-II|SKI-I|SKI-V|sphingosine kinase inhibitors (cancer), Apogee|ABC-294640|ABC-747080|ABC-294735|Yeliva|opaganib|sphingosine kinase inhibitors (cancer/COVID-19), RedHill|sphingosine kinase inhibitors (cancer/coronavirus disease 19 infection), RedHill",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name|INN,Cancer|Gastrointestinal|Infection|Inflammatory|Respiratory|Toxicity/Intoxication,Sphingosine kinase 2 inhibitor|Dihydroceramide delta 4 desaturase inhibitor,34149|53578,Antiviral|Anti-inflammatory|Angiogenesis inhibitor|Anticancer protein kinase inhibitor,991|2953|61|62255,Coronavirus disease 19 infection|Mucositis|Cholangiocarcinoma|Hormone refractory prostate cancer|Ulcerative colitis|Radiation sickness,10406|1263|1765|3246|337|367,Diffuse large B-cell lymphoma|Hepatocellular carcinoma|Viral pneumonia|Multiple myeloma|Inflammatory disease|Lymphoma|Pancreas tumor|Prostate tumor|Lung disease|Advanced solid tumor|Cancer,1749|1767|1818|1828|188|203|249|276|283|3713|651,RedHill Biopharma Ltd,1052603,Apogee Biotechnology Corp,1005502,Apogee Biotechnology Corp,1005502,,,,,,
49459,figitumumab,"CP-751871|PINT-8A1|PINT-9A2|PINT-11A4|IGF-1R human mAbs (rheumatoid arthritis), Pfizer|anti-insulin-like growth factor 1 receptor mAbs (cancer), Pfizer|IGF-1R human mAbs (cancer), Pfizer|figitumumab",Research Code|Research Code|Research Code|Research Code|USAN|INN,Cancer|Immune,Insulin-like growth factor 1 receptor antagonist,3252,Anticancer protein kinase inhibitor|Anticancer hormone antagonist|Anticancer monoclonal antibody|Anti-inflammatory,62255|62254|55685|2953,,,Non-small-cell lung cancer|Gastrointestinal tumor|Adrenal cortical carcinoma|Multiple myeloma|Sarcoma|Rheumatoid arthritis|Hormone refractory prostate cancer|Breast tumor|Cancer|Solid tumor,1262|131|1648|1828|194|291|3246|49|651|725,,,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
49510,necitumumab,"human EGF antibody, ImClone|Human EGF antibody vaccine, ImClone|necitumumab|IMC-11F8|Portrazza|LY-3012211",USAN|INN|Research Code|Trade Name|Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Metastatic non small cell lung cancer,3665,Non-small-cell lung cancer|Metastatic colorectal cancer|Advanced solid tumor|Solid tumor,1262|3658|3713|725,Eli Lilly & Co|Imclone LLC|Nippon Kayaku Co Ltd,17810|17193|18535,Bristol-Myers Squibb Co,15065,Imclone LLC,17193,,,,,,
49557,"sonolisib (oral, cancer), Cascadian Therapeutics","DJM-166|PX-2000|phosphatidylinositol-3-kinase inhibitors (cancer), Biomira|PX-866|phosphatidylinositol-3-kinase inhibitor (oral, cancer), Oncothyreon|sonolisib|sonolisib (oral, cancer), Oncothyreon|sonolisib (oral, cancer), Cascadian Therapeutics",Research Code|Research Code|Research Code|INN,Cancer,Phosphoinositide 3-kinase inhibitor|mTOR inhibitor|FGF-2 ligand inhibitor|Ribosomal protein S6 kinase stimulator,1575|10240|3618|8781,Anticancer protein kinase inhibitor,62255,,,Non-small-cell lung cancer|Melanoma|Glioblastoma|Prostate tumor|Metastatic colorectal cancer|Head and neck tumor|Cancer|Solid tumor,1262|205|2454|276|3658|623|651|725,,,Cascadian Therapeutics Inc|ProlX Pharmaceuticals LP,14774|26853,ProlX Pharmaceuticals LP,26853,,,,,,
49560,pictilisib,"PI-103|PI-103 series, PIramed|PI3K inhibitors (cancer), PIramed|phosphatidyinositol-3-kinase inhibitors (cancer), PIramed|PI-540|PI-509|PI-516|PI3K inhibitors (immune-inflammation), PIramed|PI3Kalpha inhibitors, PIramed/Genentech|PI-PFP|PI-IM|PI3K inhibitors, PIramed|GDC-0941|PI-620|GNE-477|GNE-493|RG-7321|pictrelisib|GNE-380|GNE-317|GNE-151|pictilisib|GNE-123|GNE-390|GNE-126",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code|Research Code|Research Code,Cancer|Immune|Inflammatory,NOTCH1 gene inhibitor|Phosphoinositide-3 kinase alpha inhibitor,37563|11177,Anticancer protein kinase inhibitor|Cell cycle inhibitor|Synergist|Anti-inflammatory|Apoptosis stimulator,62255|767|7293|2953|1589,,,Non-small-cell lung cancer|Multiple myeloma|Immune disorder|Inflammatory disease|Non-Hodgkin lymphoma|Metastatic breast cancer|Breast tumor|Cancer|Solid tumor,1262|1828|185|188|319|3657|49|651|725,,,Piramed Pharma|Chugai Pharmaceutical Co Ltd|Genentech Inc|Yamanouchi Pharmaceutical Co Ltd|Institute of Cancer Research UK|Ludwig Institute for Cancer Research|Cancer Research UK,1004213|15414|19453|20967|21072|21091|29469,Institute of Cancer Research UK,21072,,,,,,
49640,eftilagimod alfa,"soluble LAG-3 (ImmuFact, cancer), Immutep|soluble CD223 (ImmuFact, cancer), Immutep|eftilagimod alfa|EDP-202|IMP-321|EOC-202|Eftilagimod Alpha|Soluble LAG-3Ig|Efti|EOC-202, EOC pharma",INN|Research Code|Research Code|Research Code,Cancer|Immune|Infection,HLA class II antigen stimulator,19335,Macrophage stimulator|Anticancer|Immunostimulant|B-lymphocyte stimulator|Dendritic cell stimulator,7751|1545|393|7741|173472,Squamous cell carcinoma|Larynx tumor|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Head and neck tumor|Infectious disease|Mouth tumor|Pharynx tumor,307|3198|3257|3657|3665|3673|3713|623|746|793|794,Allergy|Melanoma|Pancreas tumor|Metastatic renal cell carcinoma|Cancer,12|205|249|4250|651,Taizhou Yibaikang Medical Technology Co Ltd|EOC Pharma Ltd|WuXi AppTec Co Ltd|Immutep SAS,1150587|1144925|1014227|1007701,Eddingpharm Inc,1056888,Immutep SAS,1007701,,,,,,
49721,denosumab,"anti-RANK-L mAb (bone diseases, rheumatoid arthritis), Amgen|RANK-L antagonist (monoclonal antibody), Amgen|denosumab|AMG-162|Prolia|Xgeva|Ranmark|Pralia",USAN|INN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Cancer|Endocrine/Metabolic|Musculoskeletal,Osteoclast differentiation factor ligand inhibitor,13538,Metastasis inhibitor|Anticancer|Therapeutic antibody|Bone resorption inhibitor,695|1545|172641|89,Hypercalcemia|Multiple myeloma|Bone metastases|Osteoporosis|Osteogenesis imperfecta|Male osteoporosis|Postmenopausal osteoporosis|Giant cell bone tumor|Bone resorption|Joint injury|Breast tumor,173|1828|1829|246|2498|2548|2549|2857|3443|3753|49,Osteopenia,2860,Chong Kun Dang Pharmaceutical Corp|BeiGene Co Ltd|Daiichi Sankyo Co Ltd|Dr Reddy's Laboratories Ltd|Amgen Inc|AstraZeneca KK,15410|1063251|1017506|29387|14109|16893,GlaxoSmithKline plc,28355,Amgen Inc,14109,,,,,,
49722,amuvatinib,MP-470|MP-470 hydrochloride|amuvatinib|amuvatinib hydrochloride,Research Code|Research Code|USAN|INN|USAN,Cancer,PDGF receptor alpha antagonist|Protein tyrosine kinase inhibitor|DNA repair protein RAD51 homolog 1 inhibitor|Kit tyrosine kinase inhibitor,48489|385|18832|3808,Anticancer chemosensitizer|Anticancer protein kinase inhibitor,1586|62255,,,Small-cell lung cancer|Solid tumor,1261|725,,,Montigen Pharmaceuticals Inc|Astex Pharmaceuticals Inc,1007653|21885,Montigen Pharmaceuticals Inc,1007653,,,,,,
49903,foretinib,"XL-880|EXEL-2880|kinase inhibitor (cancer), Exelixis|kinase inhibitor (oral, cancer), GlaxoSmithKline|1363089|GSK-1363089|GSK-089|foretinib|GSK-1363089G",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer,VEGF-2 receptor antagonist|Hepatocyte growth factor receptor antagonist,3848|675,Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Synergist,62255|61|7293,,,Non-small-cell lung cancer|Stomach tumor|Renal cell carcinoma|Liver tumor|Metastatic breast cancer|Head and neck tumor|Solid tumor,1262|127|1766|202|3657|623|725,,,Exelixis Inc|GlaxoSmithKline plc,22676|28355,Exelixis Inc,22676,,,,,,
50006,tosedostat,"aminopeptidase inhibitor (oral, cancer), Chroma|CHR-79888|tosedostat|CHR-2797",Research Code|Metabolite|USAN|INN|Research Code,Cancer,Leukotriene A4 hydrolase inhibitor|Aminopeptidase inhibitor,240|52,Anticancer,1545,,,Non-small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Cancer|Solid tumor,1262|1272|1731|1828|651|725,,,Vernalis plc|CTI BioPharma Corp|Ligand Pharmaceuticals Inc|Chroma Therapeutics Ltd,15262|15337|17808|29495,Vernalis plc,15262,,,,,,
50081,"terameprocol (injectable, cancer, influenza), Erimos","M4N|Mal.4|methylated NDGAs, Johns Hopkins|methylated NDGA, Johns Hopkins/Erimos|methylated NDGA, Johns Hopkins/BioCure|EM-1421|nordihydroguaiaretic acid derivatives, Erimos|terameprocol|terameprocol (injectable, cancer, influenza), Erimos",Analogue|Research Code|USAN|INN,Cancer|Infection,Survivin protein inhibitor|Transcription factor inhibitor,13608|2651,Anticancer|Antiviral,1545|991,Glioma|Influenza virus infection|Hematological neoplasm|Head and neck tumor|Solid tumor,1108|191|2054|623|725,HIV infection,158,Erimos Pharmaceutical LLC,1008250,Johns Hopkins University,20596,Johns Hopkins University,20596,,,,,,
50097,"vaccinia/fowl pox TRICOM vaccine (cancer), Therion","VF-TRICOM|rF-TRICOM|rV-TRICOM|pox virus TRICOM cancer vaccine, Therion/NCI|vaccinia/fowl pox TRICOM vaccine (cancer), Therion",Trade Name|Research Code|Research Code,Cancer,,,Therapeutic vaccine|Recombinant viral vector vaccine|Anticancer|DNA vaccine,12379|12370|1545|1879,,,Melanoma|Head and neck tumor,205|623,,,Therion Biologics Corp,20371,Therion Biologics Corp,20371,,,,,,
50280,lenzilumab,"KB-002|anti-GM-CSF mAb (autoimmune disease), Ludwig/KaloBios|anti-GM-CSF mAb (inflammatory disease/rheumatoid arthritis/asthma), KaloBios|lenzilumab|KB-003|anti-GM-CSF mAb (neurotoxicity drug-induced/chronic myelomonocytic leukemia/COVID-19 pneumonia/graft versus host disease/diffuse large B-cell lymphoma), Humanigen",Research Code|INN|Research Code,Cancer|Hematologic|Immune|Infection|Inflammatory|Neurology/Psychiatric|Respiratory|Toxicity/Intoxication,Immunoglobulin G1 modulator|GM-CSF ligand inhibitor|Immunoglobulin kappa modulator,5755|49777|63442,Anticancer monoclonal antibody|Antiviral|Anticancer|Anti-inflammatory,55685|991|1545|2953,Coronavirus disease 19 infection|Neurotoxicity drug-induced|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|High grade B-cell lymphoma|Viral pneumonia|Respiratory failure|Graft versus host disease|Chronic myelomonocytic leukemia,10406|1089|1745|1749|1750|1751|1818|3914|616|6833,Thrombocytopenic purpura|Alzheimers disease|Inflammatory disease|Rheumatoid arthritis|Asthma|Autoimmune disease,1133|14|188|291|31|36,Humanigen Inc|KPM Tech Co|Telcon RF Pharmaceutical Inc,31508|1225647|1184846,Ludwig Institute for Cancer Research,21091,Ludwig Institute for Cancer Research,21091,,,,,,
50341,neratinib,HKI-272|neratinib|PF-5208767|PB-272|PF-05208767|Nerlynx|CAN-030,Research Code|USAN|INN|Research Code|Research Code|Research Code|Trade Name|Research Code,Cancer,Erbb4 tyrosine kinase receptor inhibitor|Erbb2 tyrosine kinase receptor inhibitor|mTOR inhibitor|Epidermal growth factor receptor antagonist,3760|3756|10240|740,Anticancer protein kinase inhibitor,62255,Metastasis|Stomach tumor|Biliary cancer|Endometrioid carcinoma|Melanoma|Bladder cancer|Glioblastoma|Acoustic neuroma|Pancreas tumor|Prostate tumor|Neurofibromatosis type II|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Uterine cervix tumor|Breast tumor|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,1069|127|1516|1705|205|2380|2454|2464|249|276|3522|3657|3658|3665|427|49|651|725|799|989,,,Knight Therapeutics Inc|Specialised Therapeutics Asia Pte Ltd|Bixink Therapeutics Co Ltd|Medison Pharma Ltd|Pierre Fabre Group|Puma Biotechnology Inc|Pint Pharma,1093663|1157003|1211674|29943|19087|1065375|1110054,CANbridge Life Sciences Ltd|Wyeth|Pfizer Inc|Wyeth Research,1088011|14112|18767|25247,Wyeth,14112,,,,,,
50457,oxycodone + paracetamol,oxycodone + acetaminophen|oxycodone + paracetamol|Percocet|Endocet,Trade Name|Trade Name,Neurology/Psychiatric,Cyclooxygenase inhibitor|Opioid receptor agonist,132|287,Analgesic,2946,Pain,20,,,Endo International plc,1089706,Endo Health Solutions Inc,26192,Endo Health Solutions Inc,26192,,,,,,
50459,"vorinostat (intravenous), Merck & Co","SAHA|Suberoylanilide hydroxamic acid|SAHA (intravenous), Aton Pharma|suberanilohydroxamic acid (intravenous), Aton Pharma|suberoylanilide hydroxamic acid (intravenous), Aton Pharma|vorinostat (intravenous), Merck & Co|vorinostat|MK-0683|L-001079038|MSK-390",USAN|INN|Research Code|Research Code|Research Code,Cancer,Histone deacetylase inhibitor,2574,Anticancer,1545,,,Cancer,651,,,Merck & Co Inc|Columbia University|Memorial Sloan-Kettering Cancer Center|Aton Pharma Inc,18077|20559|22122|29378,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
50518,"aldoxorubicin (cancer), NantCell","DOXO-EMCH, University of Freiburg|doxorubicin prodrug, University of Freiburg|doxorubicin (hydrazone derivative), University of Freiburg|aldoxorubicin (cancer), CytRx|tumor-targeted doxorubicin conjugate, CytRx|aldoxorubicin|aldoxorubicin hydrochloride|DOXO-EMCH|INNO-206|Doxorubicin-EMCH|aldoxorubicin (cancer), NantCell|aldoxorubicin (cancer), ImmunityBio",USAN|INN|USAN,Cancer,Topoisomerase II inhibitor,142,DNA intercalator|Anticancer,750|1545,Small-cell lung cancer|Pancreatic ductal adenocarcinoma|Glioblastoma|Squamous cell carcinoma|Soft tissue sarcoma|Metastatic breast cancer|Metastatic pancreas cancer|Ovary tumor|Kaposis sarcoma,1261|1507|2454|307|3378|3657|3669|799|936,Cancer|Solid tumor,651|725,NantCell Inc,1104834,"Innovive Pharmaceuticals Inc|CytRx Corp|Tumor Biology Center, Freiburg",1011256|15585|27164,"Tumor Biology Center, Freiburg",27164,,,,,,
50532,"ARC-100 (iv, cancer/neurological disease/neurodegenerative disease), Cortice Biosciences","NBT-287|taxane analog, Tapestry Pharmaceuticals|TPI-287 (intravenous, cancer), Tapestry|TPI-287|ARC-100|ARC-100 (intravenous, cancer), Archer Biosciences|abeotaxane|ARC-100 (iv, cancer/neurological disease/neurodegenerative disease), Cortice Biosciences",Research Code|Research Code|Research Code,Cancer|Endocrine/Metabolic|Neurology/Psychiatric,Tubulin binding agent,499,Microtubule inhibitor|Anticancer|Neuroprotectant|Microtubule stabilizer,2575|1545|1615|2576,Alzheimers disease|Progressive supranuclear palsy|Melanoma|Neurodegenerative disease|Glioblastoma|Medulloblastoma|Neuroblastoma|Metastatic brain cancer|Breast tumor|Solid tumor,14|1998|205|233|2454|2533|2726|3471|49|725,Pancreas tumor|Hormone refractory prostate cancer|Brain tumor|Insulin dependent diabetes,249|3246|760|836,Cortice Biosciences Inc,1040507,Tapestry Pharmaceuticals Inc|Glenmark Pharmaceuticals Ltd,18457|29326,Tapestry Pharmaceuticals Inc,18457,,,,,,
50561,aglatimagene besadenovec,"TK|TKC|TKR|TKS|Adv-tk (gene therapy, cancer), Advantagene|oncolytic adenovirus therapy expressing HSV-tk (cancer), Advantagene|Adv-tk (pancreatic cancer), Advantagene|Adv-tk (prostate cancer), Advantagene|Adv-tk (cancer), Advantagene|Adv-tk (brain cancer), Advantagene|Gene Mediated Cytotoxic Immunotherapy|GMCI|aglatimagene besadenovec|ProstAtak|GliAtak|PancAtak|AdV-tk|aglatimagene besadenovec (prostate cancer), Advantagene|CAN-2409",Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|USAN|INN|Trade Name|Trade Name|Trade Name|Research Code|Research Code,Cancer|Respiratory,Thymidine kinase stimulator,6751,Immunostimulant|Anticancer,393|1545,Mesothelioma|Glioblastoma|Pancreas tumor|Prostate tumor|Metastatic non small cell lung cancer|Pleural disease|Brain tumor|Colon tumor|Ovary tumor,1240|2454|249|276|3665|704|760|767|799,Esophagus tumor|Non-small-cell lung cancer|Solid tumor,1011|1262|725,Candel Therapeutics Inc,1008731,Baylor College of Medicine,20534,Baylor College of Medicine,20534,,,,,,
50564,tergenpumatucel-L,"HyperAcute vaccine (lung cancer), NewLink|HyperAcute vaccine (intradermal, lung cancer), Newlink Genetics|tergenpumatucel-L|HAL|HyperAcute-Lung",USAN|Research Code|Trade Name,Cancer,Galactosyltransferase modulator,6604,Anticancer|Vaccine,1545|386,,,Non-small-cell lung cancer,1262,,,NewLink Genetics Corp,1008706,NewLink Genetics Corp,1008706,,,,,,
50871,KOS-1584,"R-1645|KOS-1584|9,10-didehydroepothilone D (iv, cancer), Kosan/Roche|second-generation epothilone D analog (iv, cancer), Kosan/Roche|second-generation epothilone D analog (iv, cancer), Bristol-Myer Squibb|9,10-didehydroepothilone D (iv, cancer), Bristol-Myer Squibb|9,10-didehydroepothilone D|(E)-9,10-didehydroepothilone D",Research Code|Research Code,Cancer,,,Anticancer|Microtubule stabilizer,1545|2576,,,Non-small-cell lung cancer|Solid tumor,1262|725,,,Bristol-Myers Squibb Co|Roche Holding AG|Kosan Biosciences Inc,15065|19446|24027,Kosan Biosciences Inc,24027,,,,,,
50890,"sEphB4-HSA recombinant fusion protein (cancer), VasGene Therapeutics","EphrinB2/EphB4 pathway antagonists, VasGene|sEphB4-HSA|sEphB4-Alb|sEphB4-HSA recombinant fusion protein (cancer), VasGene Therapeutics|Vas-01",Research Code,Cancer|Cardiovascular|Ocular,Ephrin B2 ligand inhibitor|Ephb4 tyrosine kinase receptor inhibitor,32291|3786,Anticancer|Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Antisense oligonucleotide inhibitor|Anticancer monoclonal antibody|Metastasis inhibitor,1545|62255|61|7294|55685|695,Myelodysplastic syndrome|Acute lymphoblastic leukemia|T-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia|Transitional cell carcinoma|Squamous cell carcinoma|Hormone refractory prostate cancer|Metastatic head and neck cancer|Chronic myelomonocytic leukemia|Solid tumor|Kaposis sarcoma,1272|1728|1730|1731|1735|1771|307|3246|3673|6833|725|936,Ocular disease|Angiogenesis disorder|Cancer,239|422|651,VasGene Therapeutics Inc,1005895,,,VasGene Therapeutics Inc,1005895,,,,,,
50935,cabozantinib,cabozantinib S-malate|cabozantinib|Cabometyx|Cometriq|BMS-907351|XL-184,USAN|USAN|INN|Trade Name|Trade Name|Research Code|Research Code,Cancer,Kit tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|MET tyrosine kinase receptor family inhibitor|Tyro3 tyrosine kinase receptor inhibitor|Mer tyrosine kinase receptor inhibitor|Axl tyrosine kinase receptor inhibitor|VEGF receptor antagonist|RET tyrosine kinase receptor family inhibitor|Hepatocyte growth factor receptor antagonist|VEGF-3 receptor antagonist|VEGF-2 receptor antagonist|VEGF-1 receptor antagonist|TrkB receptor antagonist|Tek tyrosine kinase receptor inhibitor,3808|3806|3796|3746|3744|3742|1722|3816|675|3850|3848|3846|3842|3834,Anticancer protein kinase inhibitor|Metastasis inhibitor|Synergist|Anticancer|Apoptosis stimulator,62255|695|7293|1545|1589,Esophagus tumor|Neuroendocrine tumor|Thyroid tumor|Non-small-cell lung cancer|Stomach tumor|Pancreatic endocrine tumor|Adrenal cortex neoplasm|Endometrioid carcinoma|Hepatocellular carcinoma|Osteosarcoma|Bladder cancer|Carcinoid tumor|Ewing sarcoma|Gastrointestinal stromal tumor|Medullary thyroid cancer|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Stage IV melanoma|Soft tissue sarcoma|Metastatic gastrointestinal cancer|Metastatic bladder cancer|Metastatic renal cancer|Neurofibromatosis type I|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Salivary gland cancer|Breast tumor|Head and neck tumor|Uterus tumor|Central nervous system tumor|Ovary tumor,1011|1128|1134|1262|127|1510|1646|1705|1767|1772|2380|2538|2975|3205|3240|3246|3247|3257|3378|3460|3466|3467|3521|3657|3658|3665|3666|3667|3673|4250|427|4299|49|623|740|759|799,Acute myelogenous leukemia|Renal cell carcinoma|Multiple myeloma|Bone metastases|Sarcoma|Melanoma|Glioblastoma|Advanced solid tumor|Cancer,1731|1766|1828|1829|194|205|2454|3713|651,Ipsen|Takeda Pharmaceutical Co Ltd|Exelixis Inc,17259|20300|22676,Bristol-Myers Squibb Co|Swedish Orphan Biovitrum AB,15065|28921,Exelixis Inc,22676,,,,,,
50948,APTO-253,"ML-133|LT-253|ML-series (anticancer), Lorus|LOR-253|ML-series (anticancer), Aptose|APTO-253|APTO-253 HCl|LOR-253 HCl",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,MYC gene inhibitor|Metal regulatory transcription factor-1 inhibitor|Kruppel like factor 4 stimulator|Cyclin D1 inhibitor,18604|13770|52801|9488,Apoptosis stimulator|Cell cycle inhibitor|Anticancer|Chelating agent,1589|767|1545|105,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,Cancer|Solid tumor,651|725,Aptose Biosciences Inc,17215,,,Aptose Biosciences Inc,17215,,,,,,
50996,patritumab,"anti-Her-3 human monoclonal antibody (epithelial-derived cancers), U3 Pharma/Amgen|U3-1287|patritumab|AMG-888",Research Code|INN,Cancer,Erbb3 tyrosine kinase receptor inhibitor,3758,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,,,Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Cancer|Solid tumor,3657|3665|3673|651|725,,,Daiichi Sankyo Co Ltd|Amgen Inc|Abgenix Inc|U3 Pharma AG,1017506|14109|23748|29136,U3 Pharma AG,29136,,,,,,
51089,roniciclib,"CDK inhibitors (anticancer), Bayer|cyclin-dependent kinase inhibitors (anticancer), Bayer|BAY-80-3000|roniciclib|BAY-1000394",Research Code|INN|Research Code,Cancer,Cyclin dependent kinase inhibitor,2596,Anticancer protein kinase inhibitor|Synergist|Cell cycle inhibitor,62255|7293|767,,,Small-cell lung cancer|Non-small-cell lung cancer|Cancer,1261|1262|651,,,Bayer AG,14455,Bayer AG,14455,,,,,,
5110,nicorandil,nicorandil|SG-75|Sigmart|U-64417|SG-86|Dancor|Ikorel|Adancor,USAN|BAN|INN|Research Code|Trade Name|Research Code|Metabolite|Trade Name|Trade Name|Trade Name,Cardiovascular|Neurology/Psychiatric,Potassium channel stimulator,313,Anxiolytic|Vasodilator|Antihypertensive,2942|388|2657,Angina|Acute coronary syndrome|Cardiac failure,23|3258|55,Brain hemorrhage|Cerebrovascular disease,315|64,Chugai Pharmaceutical Co Ltd|Merck Serono SA|Sanofi SA,15414|19862|1009547,Sanofi-Aventis US LLC|Merck KGaA|Rhone-Poulenc SA|Aventis SA,1023535|18101|19234|27254,Chugai Pharmaceutical Co Ltd,15414,,,,,,
51128,"lipegfilgrastim (neutropenia), BioGeneriX","glycoPEGylated G-CSF analogs (neutropenia), Neose/ BioGeneriX|biobetter pegfilgastrim, BioGeneriX|glycoPEGylated G-CSF analogs (sustained release/subcutaneous/protein recombinant, neutropenia), BioGenerix|lipegfilgrastim|GlycoPEG-(Met-des-1-Ala-des-37-Val-des-38-Ser-des-39-Glu)-GCSF|XM-22|lipegfilgrastim (neutropenia), Neose/ BioGeneriX|lipegfilgrastim (neutropenia), BioGeneriX|Lonquex",USAN|INN|Research Code|Trade Name,Hematologic,GCSF receptor agonist|GCSF ligand,3151|52970,Anticancer|Neutrophil stimulator|Hematopoietic stimulator,1545|7759|610,Neutropenia,1991,,,Teva Pharmaceuticals Australia Pty Ltd|Teva-Handok|Handok Inc|BioGeneriX AG|Teva Pharmaceutical Industries Ltd,1102588|1084465|19986|1007757|20348,Neose Technologies Inc,24203,Neose Technologies Inc,24203,,,,,,
51130,ISIS-EIF4ERx,"LY-2275796|eIF-4E-targeting antisense oligonucleotides (cancer), Lilly/Isis|eIF-4E-targeting antisense oligonucleotide (cancer), Lilly|ISIS-EIF4ERx|ISIS-183750|eIF-4E ASO (cancer), Eli Lilly/Isis",Research Code|Research Code|Research Code,Cancer,EIF4E gene inhibitor,37398,Anticancer|Angiogenesis inhibitor|Antisense oligonucleotide inhibitor|Apoptosis stimulator,1545|61|7294|1589,,,Non-small-cell lung cancer|Prostate tumor|Cancer,1262|276|651,,,Ionis Pharmaceuticals Inc|Eli Lilly & Co,17269|17810,Ionis Pharmaceuticals Inc,17269,,,,,,
51139,CRS-207,"Listeria monocytogenes-based immunotherapy (mesothelin-targeting), John Hopkins/Cerus|CRS-207|Listeria monocytogenes-based mesothelin vaccines (cancer), Cerus|Listeria monocytogenes-based immunotherapy (mesothelin-targeting), John Hopkins/Anza|ANZ-207|miralimogene ensolisbac",Research Code|Research Code|INN,Cancer,Mesothelin modulator,11484,Live attenuated bacterial vaccine|Therapeutic vaccine|Recombinant bacterial vector vaccine|Anticancer,12363|12379|12369|1545,,,Mesothelioma|Fallopian tube cancer|Pancreas tumor|Peritoneal tumor|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Solid tumor|Ovary tumor,1240|2243|249|3083|3666|3667|3669|725|799,,,Anza Therapeutics Inc|Chinook Therapeutics Inc|Johns Hopkins University|Cerus Corp,1039732|1039923|20596|24691,Johns Hopkins University,20596,,,,,,
51159,actoxumab,"CDA-1, Medarex|anti-Clostridium difficile toxin A antibody, Medarex|C difficile therapy (toxin A), Medarex|actoxumab|MK-3415|3D8|CDA-1|MBL-CDA1|MDX-066",USAN|INN|Research Code|Research Code,Gastrointestinal|Infection,,,Lipopolysaccharide binding agent|Bacterial pathogenicity factor modulator|Antidiarrhoeal|Unspecified drug target,395|3983|4007|59620,,,Diarrhea|Clostridium difficile infection,102|995,,,Massachusetts Biologic Laboratories|Medarex Inc,1040747|17968,Medarex Inc,17968,,,,,,
51160,nintedanib,"BIBF-1120|FGF/PDGF/VEGF receptor kinase inhibitors (cancer), Boehringer Ingelheim|angiokinase inhibitors (cancer), Boehringer Ingelheim|Vargatef|nintedanib|intedanib|nintedanib esylate|BIBF-1120 ES|Ofev|Ofeb|nintedanib ethanesulfonate|WeiJiaTe|Cyendiv",Research Code|Trade Name|USAN|PINN|USAN|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Immune|Infection|Respiratory,Lyn tyrosine kinase inhibitor|FGF1 receptor antagonist|FGF2 receptor antagonist|FGF3 receptor antagonist|Flt3 tyrosine kinase inhibitor|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist|VEGF-3 receptor antagonist|PDGF receptor alpha antagonist|PDGF receptor beta antagonist|PDGF receptor antagonist|FGF receptor antagonist|VEGF receptor antagonist|CSF-1 antagonist|Src tyrosine kinase inhibitor|Lck tyrosine kinase inhibitor,3586|3682|3685|3688|3806|3846|3848|3850|48489|48492|948|168|1722|3154|3576|3584,Antiviral|Fibrosuppressant|Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Vasodilator|Anticancer|Anti-inflammatory,991|664|62255|61|388|1545|2953,Coronavirus disease 19 infection|Scleroderma|Neuroendocrine tumor|Thyroid tumor|Stomach tumor|Acute myelogenous leukemia|Interstitial lung disease|Pneumoconiosis|Asbestosis|Silicosis|Acute lung injury|Squamous cell carcinoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic non small cell lung cancer|Idiopathic pulmonary fibrosis,10406|1105|1128|1134|127|1731|2466|2467|2599|2914|2998|307|3257|3378|3665|3771,Mesothelioma|Small-cell lung cancer|Endometrioid carcinoma|Hepatocellular carcinoma|Multiple myeloma|Bladder cancer|Glioblastoma|Hormone refractory prostate cancer|Metastatic colorectal cancer|Advanced solid tumor|Inflammatory breast cancer|Appendix adenoma|Metastatic renal cell carcinoma|Breast tumor|Cancer|Ovary tumor|Colorectal tumor,1240|1261|1705|1767|1828|2380|2454|3246|3658|3713|3948|3987|4250|49|651|799|989,Boehringer Ingelheim International GmbH,14881,,,Boehringer Ingelheim International GmbH,14881,,,,,,
51165,"sodium meta-arsenite (cancer/ pain/ COVID-19), Komipharm","KML-001|telomere inhibitors (cancer), Komipharm|Kominox|PAX-1|Panaphix|anti-SARS-CoV-2 program (COVID-19), Komipharm|sodium meta-arsenite (cancer/ pain/ COVID-19), Komipharm|sodium meta-arsenite",Research Code|Trade Name|Research Code|Trade Name,Cancer|Infection|Neurology/Psychiatric|Respiratory,,,Anticancer|Cell cycle inhibitor|Metastasis inhibitor|Analgesic|Antiviral|Apoptosis stimulator,1545|767|695|2946|991|1589,Coronavirus disease 19 infection|Non-small-cell lung cancer|Cholangiocarcinoma|Hepatocellular carcinoma|Glioblastoma|Prostate tumor|Non-Hodgkin lymphoma|Cancer pain|Pneumonia|Metastatic lung cancer|Solid tumor|Brain tumor|Respiratory distress syndrome,10406|1262|1765|1767|2454|276|319|3211|360|3668|725|760|8,Acute myelogenous leukemia|Uterine cervix tumor|Cancer,1731|427|651,Komipharm International Co Ltd,1004513,,,Komipharm International Co Ltd,1004513,,,,,,
51177,tasisulam,"Apoptosis stimulator (cancer), Lilly|LY-573636 sodium|tasisulam sodium|LY-573636Na|LY-573636|tasisulam",Research Code|USAN|Research Code|Research Code|INN,Cancer,,,Angiogenesis inhibitor|Cell cycle inhibitor|Anticancer|Apoptosis stimulator,61|767|1545|1589,,,Non-small-cell lung cancer|Acute myelogenous leukemia|Sarcoma|Lymphoma|Melanoma|Advanced solid tumor|Breast tumor|Cancer|Solid tumor|Ovary tumor|Renal tumor,1262|1731|194|203|205|3713|49|651|725|799|999,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
51180,emvododstat,"PTC-VG|PTC-VH|PTC-VJ|PTC-VK|VEGF expression inhibitors (cancer), PTC Therapeutics|anti-angiogenics (cancer), PTC Therapeutics|PTC-299|dihydroorotate dehydrogenase inhibitor (hematological cancer), PTC Therapeutics|DHODH inhibitor (hematological cancer), PTC Therapeutics|DHODH1 inhibitor (hematological cancer), PTC Therapeutics|PTC-WS|emvododstat",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|PINN,Cancer|Infection,Dihydroorotate dehydrogenase inhibitor|VEGF receptor antagonist|IL-6 receptor antagonist,1716|1722|471,Angiogenesis inhibitor|Antiviral|Synergist|Anticancer protein kinase inhibitor|Anticancer,61|991|7293|62255|1545,Coronavirus disease 19 infection|Myelodysplastic syndrome|Acute myelogenous leukemia,10406|1272|1731,Hematological neoplasm|Glioblastoma|Neurofibromatosis|Breast tumor|Cancer|Solid tumor|Kaposis sarcoma,2054|2454|2465|49|651|725|936,PTC Therapeutics Inc,28066,,,PTC Therapeutics Inc,28066,,,,,,
5119,lenograstim,"Myelostim|CSF, Chugai|G-CSF, AMRAD|G-CSF, Chugai|hG-CSF, Chugai|rHuG-CSF, Chugai|G-CSF, Rhone-Poulenc Rorer|lenograstim|Neutrogin|Granocyte",USAN|BANN|INN|Trade Name|Trade Name,Hematologic|Immune,GCSF receptor agonist,3151,Neutrophil stimulator|Hematopoietic stimulator|Immunostimulant,7759|610|393,Hematological disease|Immune disorder|Neutropenia,142|185|1991,,,Chugai Pharmaceutical Co Ltd|AMRAD Pharmaceuticals Pty Ltd,15414|14214,CHUGAI sanofi-aventis SNC|Rhone-Poulenc Rorer Ltd|Rhone-Poulenc Rorer Inc,15416|19298|19365,Chugai Pharmaceutical Co Ltd,15414,,,,,,
51203,felzartamab,"MOR-202|anti-CD38 antibodies, MorphoSys|HuCAL-mAb1, MorphoSys|HuCAL-mAb2, MorphoSys|HuCAL-mAb3, MorphoSys|MOR-03087|TJ-202|anti-CD38 fully human monoclonal antibody (recrurrent/refractory multiple myeloma), I-Mab Biopharma/MorphoSys|felzartamab",Research Code|Research Code|Research Code|INN,Cancer|Genitourinary/Sexual Function|Immune,ADP ribosyl cyclase-1 inhibitor,5136,Anticancer monoclonal antibody|Anti-inflammatory,55685|2953,Multiple myeloma|IgA nephropathy|Systemic lupus erythematosus|Membranous glomerulonephritis,1828|3076|318|3441,Acute myelogenous leukemia,1731,MorphoSys AG|I-Mab Biopharma,21404|1141058,Celgene Corp,15331,MorphoSys AG,21404,,,,,,
51234,tucidinostat,"Chidamide|HDAC1 antagonist (colon/lung cancers), Shenzhen Chipscreen Biosciences|HBI-8000|CS-055|tucidinostat|Epidaza",Trade Name|Research Code|Research Code|USAN|INN|Trade Name,Cancer,Histone deacetylase-10 inhibitor|Histone deacetylase-3 inhibitor|Histone deacetylase-2 inhibitor|Histone deacetylase-1 inhibitor,7868|7847|7844|7841,Anticancer|Synergist,1545|7293,Non-small-cell lung cancer|T-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Adult T-cell lymphoma|Renal cell carcinoma|Nasopharyngeal carcinoma|Melanoma|Non-Hodgkin lymphoma|Metastatic colorectal cancer|Breast tumor,1262|1730|1731|1749|1753|1754|1757|1766|1768|205|319|3658|49,Cancer|Solid tumor,651|725,Taiwan Specialty Pharma Corp|HUYA Bioscience International LLC|Eisai Co Ltd|Meiji Seika Pharma Co Ltd|Shenzhen Chipscreen Biosciences Ltd|GNT Biotech & Medicals Corp,1116787|1025858|15872|18049|1008516|1113381,,,Shenzhen Chipscreen Biosciences Ltd,1008516,,,,,,
51297,tozasertib,"VX-680|multi-kinase inhibitor (Aurora, ABL, Flt3), Merck & Co|MK-0457|tozasertib lactate|tozasertib|VRT-426|VRT-960",Research Code|Research Code|USAN|USAN|INN|Analogue|Analogue,Cancer,ABL family tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|Aurora protein kinase inhibitor,3522|3806|4412,Apoptosis modulator|Anticancer protein kinase inhibitor|Anticancer,1588|62255|1545,,,Acute lymphoblastic leukemia|Chronic myelocytic leukemia|Hematological neoplasm|Cancer|Solid tumor|Lung tumor|Colorectal tumor,1728|1735|2054|651|725|755|989,,,Merck & Co Inc|Vertex Pharmaceuticals Inc,18077|20739,Vertex Pharmaceuticals Inc,20739,,,,,,
51346,enobosarm,"Ostarine|selective androgen receptor modulator (muscle-wasting), GTx|SARM (muscle-wasting), GTx|SARM (muscle-wasting), Merck & Co|selective androgen receptor modulator (muscle-wasting), Merck & Co|MK-2866|GTx-024|enobosarm|S-22, GTx|VERU-024",Trade Name|Research Code|Research Code|USAN|INN|Research Code|Research Code,Cancer|Endocrine/Metabolic|Genitourinary/Sexual Function|Musculoskeletal|Other/Miscellaneous|Respiratory,Androgen receptor modulator,836,Muscle system agent|Anticancer,1408|1545,Metastatic breast cancer,3657,Chronic obstructive pulmonary disease|Duchenne dystrophy|Stress urinary incontinence|Testosterone deficiency|Sarcopenia|Cachexia|Breast tumor,1185|2020|2378|2639|3210|425|49,Veru Inc,1114402,Merck & Co Inc|GTx Inc,18077|27351,GTx Inc,27351,,,,,,
51379,"forodesine (oral, cancer), BioCryst/Mundipharma","forodesine hydrochloride|BCX-1777|forodesine hydrochloride (oral, cancer), BioCryst/Mundipharma|forodesine|Fodosine|forodesine (oral, cancer), BioCryst/Mundipharma|Mundesine",USAN|Research Code|USAN|INN|Trade Name|Trade Name,Cancer,Purine nucleoside phosphorylase inhibitor,341,Anticancer,1545,Peripheral T-cell lymphoma,1753,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Cutaneous T-cell lymphoma|T-cell lymphoma,1728|1734|1754|311,Mundipharma EDO GmbH,24189,BioCryst Pharmaceuticals Inc|Albert Einstein College of Medicine,14695|24282,Albert Einstein College of Medicine,24282,,,,,,
51388,nilotinib,AMN-107|nilotinib|AHT-202|BCG-463|BBT-594|AFG-210|nilotinib hydrochloride monohydrate|Tasigna,Research Code|USAN|BANN|INN|Research Code|Research Code|Research Code|Research Code|Trade Name,Cancer|Cardiovascular|Hematologic|Immune|Musculoskeletal|Neurology/Psychiatric,DDR tyrosine kinase receptor inhibitor|Kit tyrosine kinase inhibitor|PDGF receptor antagonist|Bcr protein inhibitor|Abl tyrosine kinase inhibitor,3748|3808|948|13571|3524,Antiparkinsonian|Anticancer protein kinase inhibitor,2947|62255,Alzheimers disease|Chronic myelocytic leukemia|Parkinsons disease|Giant cell bone tumor|Pigmented villonodular synovitis,14|1735|255|2857|3531,Glioma|Acute lymphoblastic leukemia|Pulmonary hypertension|Hypereosinophilic syndrome|Melanoma|Acoustic neuroma|Mastocytosis|Lewy body dementia|Gastrointestinal stromal tumor|Graft versus host disease|Cancer,1108|1728|1867|2036|205|2464|2795|3064|3205|616|651,Novartis AG|Georgetown University,23137|22821,,,Novartis AG,23137,,,,,,
5202,gemtuzumab ozogamicin,"CDP-771|CMA-676|gemtuzumab ozogamicin|Mylotarg|WAY-CMA-676|P67.6-MAb conjugate, Wyeth/Celltech|anti-CD33 calicheamicin drug conjugate|calicheamicin MAb conjugate, Wyeth/Celltech",Research Code|Research Code|USAN|INN|Trade Name|Research Code,Cancer,CD33 modulator|Calcium channel stimulator,5119|92,Immunotoxin|Anticancer monoclonal antibody|Apoptosis stimulator,539|55685|1589,Acute myelogenous leukemia,1731,,,Pfizer Inc,18767,UCB Celltech|Takeda Pharmaceutical Co Ltd|Wyeth Research,15336|20300|25247,Wyeth Research,25247,,,,,,
52139,ofloxacin,ofloxacin|Ocuflox|Floxin|Tarivid|Oflocet|Floxin Otic,USAN|BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Infection,DNA gyrase inhibitor,431,Antibacterial|Anti-inflammatory,1594|2953,Bacterial respiratory tract infection|Bacterial urinary tract infection|Bacterial infection,1484|1798|40,,,Sanofi SA|Daiichi Sankyo Co Ltd|Kolon Pharmaceuticals Inc,1009547|1017506|25443,Daiichi Seiyaku Co Ltd|Johnson & Johnson|Sanofi-Synthelabo,15593|17332|26494,Johnson & Johnson,17332,,,,,,
52196,tivozanib,"KRN-951|AV-951|quinoline-urea-derived VEGF inhibitor (cancer), Kirin|quinoline-urea-derived VEGF inhibitor (oral, cancer), AVEO Pharmaceuticals|tivozanib|quinoline-urea-derived VEGF inhibitor (oral, cancer), Kirin/ AVEO/ Astellas|ASP-4130|tivozanib hydrochloride|Tivopath|Fotivda",Research Code|Research Code|USAN|INN|Research Code|USAN|Trade Name|Trade Name,Cancer|Ocular,VEGF-3 receptor antagonist|Protein tyrosine kinase inhibitor|VEGF-2 receptor antagonist|Kit tyrosine kinase inhibitor|VEGF-1 receptor antagonist|PDGF receptor family inhibitor|MAP kinase inhibitor,3850|385|3848|3808|3846|3802|2511,Anticancer protein kinase inhibitor,62255,Hepatocellular carcinoma|Ocular disease|Metastatic renal cell carcinoma,1767|239|4250,Non-small-cell lung cancer|Gastrointestinal tumor|Renal cell carcinoma|Fallopian tube cancer|Prostate tumor|Peritoneal tumor|Breast tumor|Solid tumor|Colon tumor|Ovary tumor|Colorectal tumor,1262|131|1766|2243|276|3083|49|725|767|799|989,Kyowa Hakko Kirin Co Ltd|EUSA Pharma|AVEO Oncology,1042596|1107183|29820,Astellas Pharma Inc|IVERIC Bio Inc|Pharmstandard OJSC|Kirin Brewery Co Ltd,1013295|1033865|1047078|17661,Kirin Brewery Co Ltd,17661,,,,,,
52198,brivanib alaninate,"VEGFR-2 kinase inhibitor (cancer), BMS|Kdr/Flk-1 kinase inhibitors (cancer), BMS|vascular endothelial growth factor receptor 2 kinase inhibitors, Bristol-Myers Squibb|BMS-540215|brivanib alaninate|brivanib|ZL-2301",Research Code|USAN|INN|USAN|Research Code,Cancer,FGF receptor antagonist|VEGF-2 receptor antagonist,168|3848,Fibrosuppressant|Anticancer protein kinase inhibitor|Anti-inflammatory,664|62255|2953,Cholangiocarcinoma|Hepatocellular carcinoma|Metastatic liver cancer|Uterine cervix tumor,1765|1767|3462|427,Non-small-cell lung cancer|Gastrointestinal tumor|Sarcoma|Pancreas tumor|Advanced solid tumor|Breast tumor|Cancer|Ovary tumor|Colorectal tumor,1262|131|194|249|3713|49|651|799|989,Zai Lab Limited,1101935,Bristol-Myers Squibb Co,15065,Bristol-Myers Squibb Co,15065,,,,,,
52202,"retaspimycin (iv, cancer), Infinity","IPI-504|hsp90 inhibitor (iv, cancer), Infinity/MedImmune|IPI-504 (intravenous), Infinity/MedImmune|MEDI-561|retaspimycin hydrochloride (iv, cancer), Infinity/MedImmune|retaspimycin hydrochloride|retaspimycin|retaspimycin (iv, cancer), Infinity/MedImmune|retaspimycin (iv, cancer), Infinity",Research Code|Research Code|USAN|USAN|INN,Cancer,Flt3 tyrosine kinase modulator|Kit tyrosine kinase modulator|Hsp 90 inhibitor,3805|3807|8012,Anticancer|Apoptosis stimulator,1545|1589,,,Non-small-cell lung cancer|Multiple myeloma|Melanoma|Prostate tumor|Gastrointestinal stromal tumor|Metastatic non small cell lung cancer|Breast tumor|Cancer,1262|1828|205|276|3205|3665|49|651,,,MedImmune LLC|Infinity Pharmaceuticals Inc,18008|29753,Infinity Pharmaceuticals Inc,29753,,,,,,
52238,Vx-001,"Vx-001|HLA-A2 monopeptide vaccine (cancer), Vaxon|hTERT572Y peptide vaccine (cancer), Vaxon|TERT572 + TERT572Y peptide (cancer), Vaxon",Research Code,Cancer,HLA class I antigen A-2 alpha modulator|Telomerase modulator,19115|1613,Therapeutic vaccine|Anticancer,12379|1545,Non-small-cell lung cancer|Hepatocellular carcinoma|Glioblastoma|Breast tumor|Cancer,1262|1767|2454|49|651,,,Vaxon Biotech SA,1011269,,,Vaxon Biotech SA,1011269,,,,,,
52251,bafetinib,CNS-9|NS-187|INNO-406|bafetinib,Research Code|Research Code|Research Code|USAN|INN,Cancer|Hematologic|Musculoskeletal,Bcr protein inhibitor|Abl tyrosine kinase inhibitor|Fyn tyrosine kinase inhibitor|Lyn tyrosine kinase inhibitor,13571|3524|3574|3586,Anticancer protein kinase inhibitor,62255,,,Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Leukemia|Myelofibrosis|Glioblastoma|Hormone refractory prostate cancer|Bone resorption|Brain tumor,1734|1735|199|2436|2454|3246|3443|760,,,Innovive Pharmaceuticals Inc|CytRx Corp|Nippon Shinyaku Co Ltd,1011256|15585|18552,Nippon Shinyaku Co Ltd,18552,,,,,,
52568,SVV-001,"SVV-001|oncolytic Seneca Valley virus therapy (iv, cancer), NeoTropiX|NTX-010|TEM-8 targeting oncolytic virus therapy (solid tumors), Seneca Therapeutics",Research Code|Research Code,Cancer,Anthrax toxin receptor 1 modulator,35873,Anticancer|Immunostimulant,1545|393,Neuroendocrine tumor|Small-cell lung cancer|Solid tumor,1128|1261|725,Cancer,651,Seneca Therapeutics Inc,1220279,NeoTropiX Inc|Novartis AG,1007304|23137,Novartis AG,23137,,,,,,
52578,"mesna, Adherex","uromitexan|mesna|mesna, Adherex",Trade Name|INN,Cancer,,,Anticancer chemosensitizer|Unspecified drug target,1586|59620,,,Cancer,651,,,Fennec Pharmaceuticals Inc,26408,Fennec Pharmaceuticals Inc,26408,,,,,,
52597,"dendritic cell myeloma fusions (multiple myeloma), Dana Farber/Beth Israel Deaconess","dendritic cell myeloma fusions (multiple myeloma), Dana Farber/Beth Israel Deaconess|Fused dendritic cells plus myeloma cells, Dana Farber/Beth Israel Deaconess|Dendritic cells plus myeloma cells (multiple myeloma, Dana Farber/Beth Israel Deaconess|dendritic cell vaccine (myeloma cells), Dana Farber/Beth Israel Deaconess|DC/MM fusion vaccine (multiple myeloma), Dana Farber/Beth Israel Deaconess",,Cancer,,,Therapeutic vaccine|Anticancer|Dendritic cell vaccine,12379|1545|102926,Multiple myeloma,1828,,,Dana-Farber Cancer Institute Inc|Beth Israel Deaconess Medical Center,15615|24877,,,Dana-Farber Cancer Institute Inc,15615,,,,,,
5265,"divalproex sodium (oral extended-release), Sanofi","Abbott-50711|Depakote|divalproex sodium|valproate semisodium|valproic acid|Epival|valcote|Valproex|Deprakine|Deprakote|semisodium valproate|Depakine|Ergenyl|Epilim|Depakine Chronosphere|Depakine Chrono|Depakene|Depakon|Depakote Sprinkle|ABT-711|Depacon|Ergenyl Retard|Deprakine Retard|Epilim Chronosphere|Epilim Chrono|Micropakine|valproic acid (oral extended-release), Sanofi|Depakote Chrono|Depakote Chronosphere|Depakote ER|divalproex sodium (oral extended-release), Sanofi",Research Code|Trade Name|USAN|INN|INN|Trade Name|Trade Name|Trade Name|BAN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Neurology/Psychiatric,GABA receptor agonist|Sodium channel inhibitor,173|498,Anticonvulsant agent,70,Epilepsy|Mania|Migraine,119|1957|210,Schizophrenia,299,AbbVie Inc|Abbott Laboratories|Sanofi SA|Sanofi (pre-1999),1072507|13601|1009547|26495,Universite de Grenoble|Sanofi-Synthelabo,1086151|26494,Universite de Grenoble,1086151,,,,,,
5267,leuprorelin acetate,leuprorelin|Leuplin|leuprolide acetate|Lupron|TAP-144|TAP-144SR|Prostap|Enantone|Sixantone|Trenantone|Lucrin Depot|Lupron Depot-PED|leuprorelin SR|Leuplin 3M DPS|Lucrin|Lupron Depot|Procren Depot|Abbott-43818|Enanton|Leuplin PRO|leuprorelin acetate|Leuplin SR,INN|Trade Name|USAN|Trade Name|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Endocrine/Metabolic|Genitourinary/Sexual Function|Hematologic|Immune|Neurology/Psychiatric,GNRH receptor agonist,1092,Anticancer,1545,Endometriosis|Precocious puberty|Anemia|Uterine fibroids|Prostate tumor|Spinal and bulbar muscular atrophy|Hormone dependent prostate cancer|Breast tumor,113|1233|17|1780|276|3127|3247|49,Premature ovarian failure|Immune deficiency,1700|504,Orion Corp|Takeda Pharmaceutical Co Ltd|AbbVie Inc,18693|20300|1072507,Abbott Laboratories|TAP Pharmaceuticals Inc,13601|15931,Takeda Pharmaceutical Co Ltd,20300,,,,,,
52708,"lexibulin (iv infusion, cancer), YM BioSciences","CYT-997 (iv infusion, cancer), Cytopia|CYT-997|CYT-997 (iv infusion, cancer), YM BioSciences|lexibulin|lexibulin (iv infusion, cancer), YM BioSciences",Research Code|USAN|INN,Cancer,Tubulin binding agent,499,Vascular damaging agent|Cell cycle inhibitor|Microtubule inhibitor,2969|767|2575,,,Multiple myeloma|Glioblastoma|Solid tumor,1828|2454|725,,,YM BioSciences Inc|Cytopia Ltd,24845|27924,Cytopia Ltd,27924,,,,,,
52714,momelotinib,"JAK tyrosine kinase inhibitors (cardiovascular disease), Cytopia/Myomatrix|JAK2 tyrosine kinase inhibitors (cardiovascular disease), Cytopia/Myomatrix|JAK2 tyrosine kinase inhibitors (cancer/cardiovascular disease/myeloproliferative disorder), Cytopia|JAK2 tyrosine kinase inhibitors (cardiovascular disease), Cytopia|CYT-387|momelotinib|momelotinib dihydrochloride|GS-0387",Research Code|USAN|INN|USAN|Research Code,Cancer|Cardiovascular|Hematologic|Immune|Inflammatory,Jak1 tyrosine kinase inhibitor|Activin receptor antagonist|Jak2 tyrosine kinase inhibitor|Serine threonine protein kinase TBK1 modulator,3562|1605|3564|68993,Immunosuppressant|Cell cycle inhibitor|Anti-inflammatory|Antihypertensive|Apoptosis stimulator|Vascular agent|Anticancer protein kinase inhibitor,396|767|2953|2657|1589|945|62255,Thrombocythemia|Polycythemia vera|Myelofibrosis|Rheumatoid arthritis,2317|2319|2436|291,Pancreatic ductal adenocarcinoma|Pulmonary hypertension|Inflammatory disease|Myeloproliferative disorder|Thrombocytopenia|Metastatic non small cell lung cancer|Graft versus host disease|Cancer,1507|1867|188|273|324|3665|616|651,Sierra Oncology Inc,1015757,Cytopia Inc|Pulmokine Inc|Gilead Sciences Inc|YM BioSciences Inc,1006046|1057124|16450|24845,Cytopia Inc,1006046,,,,,,
52768,sapitinib,AZD-8931|sapitinib,Research Code|INN,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist|Erbb3 tyrosine kinase receptor inhibitor|EGFR family tyrosine kinase receptor inhibitor,3756|740|3758|3754,Anticancer protein kinase inhibitor,62255,,,Metastatic stomach cancer|Metastatic esophageal cancer|Breast tumor|Solid tumor,3666|3667|49|725,,,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
52780,nabilone,"nabilone|nabilone, Lilly|Cesamet",INN|Trade Name,Gastrointestinal|Neurology/Psychiatric,Cannabinoid receptor agonist,795,Analgesic|Anxiolytic|Anti-emetic,2946|2942|2970,Neuropathic pain|Chemotherapy-induced emesis,1295|352,Insomnia,750,Bausch Health Companies Inc|Eli Lilly & Co,17058|17810,,,Eli Lilly & Co,17810,,,,,,
52785,"dociparstat (iv, AML/acute lung injury/COVID-19), Chimerix","PGX-100|cardiac ischemia reperfusion injury therapy, ParinGenix|2-O, 3-O heparin (intravenous formulation), ParinGenix|ODSH (iv), ParinGenix|ODSH (iv), Cantex|CX-01|dociparstat sodium|dociparstat (intravenous, cancer/bone marrow transplantation), Cantex Pharmaceuticals|dociparstat (intravenous, cancer/bone marrow transplantation/traumatic brain injury/thrombocytopenia), Cantex Pharmaceuticals|dociparstat (intravenous, AML), Chimerix|dociparstat (iv, AML/acute lung injury/COVID-19), Chimerix|DSTAT",Research Code|Research Code|INN,Cancer|Cardiovascular|Gastrointestinal|Hematologic|Immune|Infection|Neurology/Psychiatric|Respiratory|Toxicity/Intoxication,Platelet factor 4 ligand inhibitor|Complement cascade inhibitor|CXCR4 chemokine modulator|Heparin agonist|P selectin antagonist|L selectin antagonist|High mobility group protein B1 inhibitor|Cathepsin G inhibitor|Stromal cell-derived factor 1 ligand modulator|Elastase inhibitor,3713|973|3135|2664|2609|2608|25931|98|14123|154,Anti-inflammatory|Antiviral|Anticancer,2953|991|1545,Coronavirus disease 19 infection|Acute myelogenous leukemia|Acute lung injury,10406|1731|2998,Reperfusion injury|Chronic obstructive pulmonary disease|Heparin induced thrombocytopenia|Myelodysplastic syndrome|Inflammatory bowel disease|Protein losing enteropathy|Plasmodium infection|Thrombocytopenia|Metastatic pancreas cancer|Radiation sickness|Traumatic brain injury|Bone marrow transplantation|Ischemic heart disease|Solid tumor,1024|1185|1271|1272|189|2156|268|324|3669|367|3733|46|56|725,Chimerix Inc,30079,Cantex Pharmaceuticals Inc,29951,Cantex Pharmaceuticals Inc,29951,,,,,,
52798,lebrikizumab,"TNX-650|anti-IL-13 humanized monoclonal antibody (cancer/asthma), Tanox|anti-IL-13 (mAb, asthma), Genentech|lebrikizumab|RG-3637|MILR-1444A|RO-5490255|lebri|DRM-06|LY-3650150",Research Code|USAN|INN|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Dermatologic|Inflammatory|Respiratory,IL-13 receptor antagonist,1663,Anti-inflammatory|Therapeutic antibody|Fibrosuppressant|Anticancer monoclonal antibody,2953|172641|664|55685,Atopic dermatitis,1102,Chronic obstructive pulmonary disease|Hodgkins disease|Inflammatory disease|Asthma|Idiopathic pulmonary fibrosis|Cancer,1185|161|188|31|3771|651,Eli Lilly & Co|Dermira Inc|Almirall Prodesfarma SA,17810|1065735|14061,Chugai Pharmaceutical Co Ltd|Genentech Inc|Tanox Inc,15414|19453|20318,Tanox Inc,20318,,,,,,
52955,SPC-3042,"SPC-3042|anti-Survivin (LNA antisense therapy), Santaris/Enzon|ENZ-3042|EZN-3042",Research Code|Research Code|Research Code,Cancer,BIRC5 gene inhibitor,18160,Antisense oligonucleotide inhibitor|Apoptosis stimulator|Anticancer,7294|1589|1545,,,Cancer,651,,,Roche Innovation Center Copenhagen A/S|Enzon Pharmaceuticals Inc,1004521|16045,Roche Innovation Center Copenhagen A/S,1004521,,,,,,
52963,beclanorsen,"SPC-2004|SPC-2993|anti-Bcl-2 (LNA antisense therapy), Santaris|beclanorsen|SPC-2996",Research Code|Research Code|INN|Research Code,Cancer,BCL2 gene inhibitor,7709,Anticancer|Apoptosis stimulator|Antisense oligonucleotide inhibitor,1545|1589|7294,,,Chronic lymphocytic leukemia|Cancer,1734|651,,,Roche Innovation Center Copenhagen A/S,1004521,Roche Innovation Center Copenhagen A/S,1004521,,,,,,
52967,apixaban,"razaxaban follow-on compound, Bristol-Myers Squibb/Pfizer|Factor Xa antagonist (follow-on), Bristol-Myers Squibb/Pfizer|BMS-562247|apixaban|Eliquis",Research Code|USAN|INN|Trade Name,Cardiovascular|Hematologic,Factor Xa antagonist,120,Coagulation inhibitor|Antiarrhythmic agent,659|449,Atrial fibrillation|Thromboembolism,1542|325,Acute coronary syndrome,3258,Bristol-Myers Squibb Co|Pfizer Inc,15065|18767,,,Bristol-Myers Squibb Co,15065,,,,,,
52978,quizartinib dihydrochloride,"AB-200382|AB-200432|AB-200434|Flt3 tyrosine kinase inhibitors, Ambit|AB-200243|AC-220|AB-515|AB-460|AC-886|Flt3 tyrosine kinase inhibitors, Ambit/Astellas|AB-530|quizartinib|quizartinib dihydrochloride|Vanflyta|ASP-2689",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|USAN|Trade Name|Research Code,Cancer,Flt3 tyrosine kinase inhibitor|Kit tyrosine kinase inhibitor|PDGF receptor antagonist,3806|3808|948,Anticancer protein kinase inhibitor|Apoptosis stimulator|Synergist,62255|1589|7293,Acute myelogenous leukemia,1731,Cancer|Solid tumor,651|725,Daiichi Sankyo Co Ltd,1017506,Astellas Pharma Inc|Ambit Biosciences Corp,1013295|29179,Ambit Biosciences Corp,29179,,,,,,
52982,amatuximab,"MORAb-009|monoclonal antibody (cancer), Morphotek|amatuximab|64Cu-MORAb-009|monoclonal antibody (cancer), Eisai",Research Code|USAN|INN|Research Code,Cancer,Mesothelin inhibitor,11486,Anticancer monoclonal antibody,55685,Mesothelioma,1240,Pancreas tumor|Cancer,249|651,Eisai Co Ltd,15872,National Cancer Institute (NCI)|Morphotek Inc,20519|29741,National Cancer Institute (NCI),20519,,,,,,
53029,"irinotecan sucrosofate (nanoliposomal, cancer), PharmaEngine/Merrimack/Shire","irinotecan|PEP-02 (nanoliposomal)|camptothecin derivative (cancer), PharmaEngine/HERMES|campothecin derivative (cancer), PharmaEngine|irinotecan sucrosofate (nanoliposomal, cancer), PharmaEngine/Merrimack/Shire|irinotecan sucrosofate|MM-398|PEP-02|nal-IRI|BAX-2398|Onivyde|Onyvide|SHP-673|camptothecin derivative (cancer), Ipsen/PharmaEngine/Servier",INN|Research Code|USAN|Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer|Gastrointestinal diagnostic agent|Endocrine diagnostic agent|Neoplasm diagnostic agent,1545|7213|7212|7220,Esophagus tumor|Glioma|Small-cell lung cancer|Stomach tumor|Pancreatic ductal adenocarcinoma|Biliary cancer|Pancreas tumor|Metastatic esophageal cancer|Metastatic pancreas cancer|Advanced solid tumor|Breast tumor|Solid tumor,1011|1108|1261|127|1507|1516|249|3667|3669|3713|49|725,Uterine cervix tumor|Cancer|Colorectal tumor,427|651|989,Merrimack Pharmaceuticals Inc|PharmaEngine Inc|Servier|Ipsen,27954|1013597|19863|17259,HERMES Biosciences|Baxalta Inc|Baxter International Inc|Shire plc,1005768|1109518|14437|24652,HERMES Biosciences,1005768,,,,,,
53039,moxetumomab pasudotox,"PE38-conjugated anti-CD22 immunotoxin (improved), Genencor/CAT/AstraZeneca|moxetumomab pasudotox|CAT-8015|GCR-8015|Lumoxiti|moxetumomab pasudotox-tdfk",USAN|INN|Research Code|Research Code|Trade Name,Cancer,B-lymphocyte cell adhesion molecule modulator,5089,Immunotoxin|Protein synthesis inhibitor|Anticancer monoclonal antibody,539|339|55685,Hairy cell leukemia,1736,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Hematological neoplasm|Non-Hodgkin lymphoma,1728|1734|2054|319,MedImmune LLC|AstraZeneca plc|Innate Pharma SA,18008|14190|28788,Genencor International Inc|National Cancer Institute (NCI)|Cambridge Antibody Technology Group plc,15856|20519|24236,National Cancer Institute (NCI),20519,,,,,,
53048,tucatinib,"ErbB-2 kinase inhibitors (breast cancer), Array Biopharma/Seagen|ARRY-333786|ARRY-380|ErbB-2 inhibitors (cancer), Array BioPharma/ Oncothyreon|ONT-380|irbinitinib|tucatinib|Tukysa|MK-7119",Research Code|Research Code|Research Code|USAN|INN|Trade Name|Research Code,Cancer|Gastrointestinal,Erbb2 tyrosine kinase receptor inhibitor,3756,Anticancer protein kinase inhibitor,62255,Biliary cancer|Cholangiocarcinoma|Liver disease|Gallbladder tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Uterine cervix tumor|Breast tumor|Cancer|Uterus tumor,1516|1765|201|3146|3657|3658|3665|3666|3667|427|49|651|740,Esophagus tumor|Stomach tumor,1011|127,Seagen Inc|AA-Med Pty Ltd|Merck & Co Inc,25554|1203670|18077,Cascadian Therapeutics Inc|Array BioPharma Inc,14774|25902,Array BioPharma Inc,25902,,,,,,
53058,"AT-9283 (iv, cancer), Astex","aurora kinase inhibitors (cancer), Astex|AT-9283|AT-9283 (iv, cancer), Astex|AT-9283 (iv, cancer), SuperGen|AT-9283 (iv, cancer), Otsuka",Research Code|Research Code,Cancer,Bcr protein inhibitor|Abl tyrosine kinase inhibitor|Jak2 tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|Aurora protein kinase 2 inhibitor|Aurora protein kinase 1 inhibitor,13571|3524|3564|3806|4420|4418,Anticancer protein kinase inhibitor|Anticancer,62255|1545,,,Acute myelogenous leukemia|Multiple myeloma|Hematological neoplasm|Cancer|Solid tumor,1731|1828|2054|651|725,,,Astex Pharmaceuticals Inc|Astex Therapeutics Ltd,21885|28026,Astex Therapeutics Ltd,28026,,,,,,
53059,linifanib,"tyrosine kinase inhibitors (cancer), Abbott|ABT-869|AL-39324|linifanib|RG-3635",Research Code|Research Code|USAN|INN|Research Code,Cancer,VEGF-2 receptor antagonist|VEGF-3 receptor antagonist|VEGF-1 receptor antagonist|Kit tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|CSF-1 antagonist,3848|3850|3846|3808|3806|3154,Angiogenesis inhibitor|Anticancer protein kinase inhibitor,61|62255,,,Non-small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Hepatocellular carcinoma|Metastatic renal cell carcinoma|Breast tumor|Cancer|Colorectal tumor,1262|1272|1731|1767|4250|49|651|989,,,Abbott Laboratories|Genentech Inc,13601|19453,Abbott Laboratories,13601,,,,,,
53074,rilotumumab,"AMG-102|anti-HGF/SF monoclonal antibody (cancer), Amgen|rilotumumab|antibody 2.12.1|NSC-750009",Research Code|USAN|INN|Research Code,Cancer,Hepatocyte growth factor ligand inhibitor,47114,Anticancer monoclonal antibody,55685,,,Small-cell lung cancer|Stomach tumor|Renal cell carcinoma|Hormone refractory prostate cancer|Metastatic stomach cancer|Solid tumor|Brain tumor|Colorectal tumor,1261|127|1766|3246|3666|725|760|989,,,Astellas Pharma Inc|Amgen KK (AABP)|Amgen Inc,1013295|1089961|14109,Amgen Inc,14109,,,,,,
53081,danusertib,"PHA-680632|Aurora kinase inhibitors (iv, chronic myeloid leukemia/solid tumors), Nerviano|PHA-739358|PHA-816359|PHA-680626|danusertib",Research Code|Research Code|Metabolite|Research Code|INN,Cancer,Abl tyrosine kinase inhibitor|Aurora protein kinase inhibitor|FGF1 receptor antagonist|Ret tyrosine kinase receptor inhibitor|TrkA receptor antagonist,3524|4412|3682|3818|3840,Anticancer protein kinase inhibitor|Cell cycle inhibitor,62255|767,Chronic myelocytic leukemia|Metastatic colorectal cancer|Metastatic pancreas cancer,1735|3658|3669,Multiple myeloma|Cancer|Solid tumor|Lung tumor,1828|651|725|755,Nerviano Medical Sciences Srl,1013717,,,Nerviano Medical Sciences Srl,1013717,,,,,,
53082,"cytarabine + daunorubicin (liposomal, intravenous, CombiPlex, cancer), Jazz Pharmaceuticals","cytarabine + daunorubicin (liposomal/intravenous, cancer), Celator|cytarabine + daunorubicin|CPX-351|cytarabine + daunorubicin (liposomal, intravenous, CombiPlex, cancer), Jazz Pharmaceuticals|NS-87|Vyxeos",Research Code|Research Code|Trade Name,Cancer,RNA polymerase inhibitor|DNA polymerase inhibitor,347|138,Anticancer,1545,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelomonocytic leukemia,1272|1728|1731|6833,Cancer,651,Nippon Shinyaku Co Ltd|Handok Inc|Jazz Pharmaceuticals plc,18552|19986|1007377,Celator Pharmaceuticals Inc,28879,Celator Pharmaceuticals Inc,28879,,,,,,
53085,REC-2282,"HDAC-42|histone deacetylase inhibitors, Ohio State University|VAD-20|VAD-18|OSU-HDAC-42|s-HDAC-42|NSC-736012|NSC-731438|AR-42 (cancer), Arno Therapeutics|NSC-D736012|AR-42|pan-histone deacetylase inhibitor (neurofibromatosis type 2), Recursion|REC-2282",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Histone deacetylase inhibitor,2574,Anticancer|Apoptosis stimulator,1545|1589,Neurofibromatosis type II,3522,Multiple myeloma|Hematological neoplasm|Acoustic neuroma|Meningioma|Cancer|Solid tumor,1828|2054|2464|2802|651|725,CereXis Inc,1207987,Arno Therapeutics Inc|Recursion Pharmaceuticals LLC|Ohio State University,1037343|1096979|20649,Ohio State University,20649,,,,,,
53090,"gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology","CP-4126|fatty acid gemcitabine prodrug (iv, lipid vector technology, cancer), Clavis|CP-4126 (iv, lipid vector technology, cancer), Clavis Pharma|gemcitabine elaidate|CP-4126 (intravenous, lipid vector technology, cancer), Clavis Pharma/Clovis Oncology|CO-101|CO-1.01|gemcitabine elaidate (intravenous, lipid vector technology), Clavis Pharma/Clovis Oncology|CO-101 (intravenous, lipid vector technology), Clavis Pharma/Clovis Oncology|gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology",Research Code|USAN|INN|Research Code|Research Code,Cancer,,,DNA synthesis inhibitor|Anticancer antimetabolite,140|1569,,,Non-small-cell lung cancer|Pancreas tumor|Cancer|Solid tumor,1262|249|651|725,,,Clovis Oncology Inc|Aqualis ASA,1047565|30630,Aqualis ASA,30630,,,,,,
53116,onvansertib fumarate,"Plk-1 kinase inhibitors (cancer), Nerviano|Polo-like kinase 1 inhibitors, Nerviano|pyrazoloquinazoline derivatives (cancer), Nerviano|NMS-1286937|NMS-P937|PCM-075|Plk-1 kinase inhibitors (oral, cancer), Trovagene|onvansertib fumarate|NMS-937|onvansertib",Research Code|Research Code|Research Code|USAN|Research Code|USAN|INN,Cancer,Polo-like kinase 1 inhibitor,4536,Anticancer protein kinase inhibitor|Cell cycle inhibitor|Apoptosis stimulator|Synergist,62255|767|1589|7293,Pancreatic ductal adenocarcinoma|Acute myelogenous leukemia|Adrenal gland tumor|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Metastatic colorectal cancer|Breast tumor|Cancer|Solid tumor,1507|1731|2049|319|3246|3658|49|651|725,,,Cardiff Oncology Inc,1052703,Nerviano Medical Sciences Srl,1013717,Nerviano Medical Sciences Srl,1013717,,,,,,
53127,apatorsen sodium,"Hsp27 inhibitors (cancer), OncoGenex|apatorsen|apatorsen sodium|OGX-427",USAN|INN|USAN|Research Code,Cancer,Heat shock protein 27 inhibitor|HSPB1 gene inhibitor|Androgen receptor antagonist,16691|21699|60,Apoptosis stimulator|Antisense oligonucleotide inhibitor|Anticancer,1589|7294|1545,,,Bladder cancer|Prostate tumor|Metastatic bladder cancer|Metastatic non small cell lung cancer|Metastatic lung cancer|Metastatic pancreas cancer|Cancer|Solid tumor,2380|276|3466|3665|3668|3669|651|725,,,Achieve Life Sciences Inc|University of British Columbia|OncoGenex Technologies Inc,20225|20532|29233,Achieve Life Sciences Inc,20225,,,,,,
53133,dabrafenib,"SB-590885|b-Raf inhibitors (cancer), GlaxoSmithKline|SB-244649|SB-477790|SB-602330|SB-699393|GSK-2118436A|dabrafenib|dabrafenib mesylate|GSK-2118436|GSK-436|Tafinlar|NSC-763760|GSK-2118436J|DRB-436|Rafinlar",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|USAN|Research Code|Research Code|Trade Name|Research Code|Research Code|Research Code|Trade Name,Cancer|Hematologic,Raf B protein kinase inhibitor,4548,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Glioma|Stage III melanoma|Stage IV melanoma|Metastatic non small cell lung cancer|Anaplastic thyroid cancer|Histiocytosis|Solid tumor,1108|3256|3257|3665|3769|4682|725,Non-small-cell lung cancer|Melanoma|Papillary thyroid tumor|Metastatic colorectal cancer|Cancer|Colorectal tumor,1262|205|3351|3658|651|989,Novartis AG,23137,GlaxoSmithKline plc,28355,GlaxoSmithKline plc,28355,,,,,,
53136,litronesib,"K-858|mitotic kinesin Eg5 inhibitor (cancer), Kyowa Hakko Kirin/Lilly|mitotic kinesin Eg5 inhibitor (cancer), Kyowa Hakko Kogyo/Lilly|litronesib|LY-2523355|KF-89617|Eg5 inhibitor (cancer), Eli Lilly",Research Code|USAN|INN|Research Code|Research Code,Cancer,Kinesin-like protein KIF11 inhibitor,11105,Anticancer|Cell cycle inhibitor|Apoptosis stimulator,1545|767|1589,,,Esophagus tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Acute myelogenous leukemia|Prostate tumor|Non-Hodgkin lymphoma|Breast tumor|Head and neck tumor|Cancer|Ovary tumor|Colorectal tumor,1011|1261|1262|127|1731|276|319|49|623|651|799|989,,,Kyowa Hakko Kirin Co Ltd|Kyowa Hakko Kogyo Co Ltd|Eli Lilly & Co,1042596|17724|17810,Kyowa Hakko Kogyo Co Ltd,17724,,,,,,
53152,sotrastaurin,"PKC inhibitors (transplant rejection), Novartis|protein kinase C inhibitors (immunosuppressant), Novartis|NVP-AEB-071|sotrastaurin|sotrastaurin acetate|AEB-071",Research Code|USAN|INN|USAN|Research Code,Cancer|Dermatologic|Gastrointestinal|Immune|Ocular,Protein kinase C delta inhibitor|Protein kinase C beta inhibitor|Protein kinase C alpha inhibitor|Protein kinase C eta inhibitor|Protein kinase C epsilon inhibitor|Protein kinase C theta inhibitor,3936|3934|3932|10592|3938|3946,Anticancer protein kinase inhibitor|Systemic antipsoriatic product|Cell cycle inhibitor|Ophthalmological agent|Immunosuppressant|Gastrointestinal system agent,62255|15184|767|15128|396|1332,,,Diffuse large B-cell lymphoma|Psoriasis|Heart transplant rejection|Liver transplant rejection|Kidney transplant rejection|Ulcerative colitis|Uveitis|Uveal melanoma|Transplant rejection,1749|281|2987|2988|2989|337|341|3788|515,,,Novartis AG,23137,Novartis AG,23137,,,,,,
53153,L-DOS47,"L-DOS47|antibody-targeted urease (cancer), Helix Biopharma/Canadian Research Council|Tumour Defence Breaker",Research Code|Trade Name,Cancer,CD66c antagonist|Urease stimulator,5273|7122,Anticancer monoclonal antibody,55685,Non-small-cell lung cancer|Metastatic pancreas cancer|Solid tumor,1262|3669|725,Pancreas tumor|Lung tumor,249|755,National Research Council of Canada|Helix BioPharma Corp,18632|24404,,,Helix BioPharma Corp,24404,,,,,,
53159,MKC-1,"Ro-27-0431|Ro-27-0997|Ro-27-1050|Ro-27-4006|Ro-28-0351|cell cycle inhibitor, Roche|cell cycle inhibitor (cancer), Miikana|MKC-1|Ro-31-7453|R-440",Research Code|Metabolite|Research Code|Metabolite|Research Code|Metabolite|Research Code|Metabolite|Research Code|Metabolite|Research Code|Research Code|Research Code,Cancer,Importin beta modulator|Tubulin binding agent,26084|499,Apoptosis stimulator|Cell cycle inhibitor|Anticancer,1589|767|1545,,,Non-small-cell lung cancer|Leukemia|Pancreas tumor|Breast tumor|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,1262|199|249|49|651|725|799|989,,,Miikana Therapeutics Inc|Hoffmann-La Roche Inc|CASI Pharmaceuticals Inc,1003989|19461|21794,Hoffmann-La Roche Inc,19461,,,,,,
53164,BIIB-021,"CNF-2024|synthetic Hsp90 inhibitors (cancer), Conforma|Hsp90 inhibitors (synthetic, cancer), Conforma|EC-78|EC-129|EC-137|EC-145, Conforma|EC-146|EC-147|Hsp90 inhibitor (cancer), Biogen Idec|EC-89|EC-82, Conforma|EC-138|EC-141|EC-144|EC-151|BIIB-021|CNF-3647",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Hsp 90 inhibitor,8012,Anticancer,1545,,,Hematological neoplasm|Gastrointestinal stromal tumor|Breast tumor|Cancer|Solid tumor,2054|3205|49|651|725,,,Biogen Inc|Conforma Therapeutics Corp,1005244|28712,Conforma Therapeutics Corp,28712,,,,,,
53174,"sodium stibogluconate (cancer), VioQuest","sodium stibogluconate|sodium stibogluconate (cancer), Greenwich|VQD-001|sodium stibogluconate (cancer), VioQuest|Lenocta",BANN|INN|Research Code|Trade Name,Cancer,Protein tyrosine phosphatase-1B inhibitor|Protein tyrosine phosphatase-2C inhibitor|Hematopoietic cell phosphatase inhibitor,7682|10327|7651,Anticancer protein kinase inhibitor,62255,,,Cancer|Solid tumor,651|725,,,VioQuest Pharmaceuticals Inc|Greenwich Therapeutics Inc|Cleveland Clinic Foundation,1009439|1014107|22123,Cleveland Clinic Foundation,22123,,,,,,
53175,"triciribine (iv, breast/ovarian cancer/AML), Prescient","triciribine (iv, cancer), VioQuest|tricyclic nucleoside (cancer), Greenwich|Akt phosphorylation inhibitor (cancer), Greenwich|TCN-P|VQD-002 (iv, cancer), VioQuest|API-2|TCN|triciribine|TCN-PM|triciribine phosphate|triciribine phosphate (iv, cancer), VioQuest|VD-0002|triciribine phosphate (iv, cancer), Cahaba|triciribine phosphate monohydrate|triciribine (iv, breast/ovarian cancer/AML), Prescient|PTX-200, Prescient|PTX-002, Prescient",Research Code|Research Code|Research Code|Research Code|INN|Research Code|USAN|Research Code|Research Code,Cancer|Immune,AKT protein kinase inhibitor,3859,Anticancer protein kinase inhibitor|Anticancer|Immunomodulator,62255|1545|1596,Acute myelogenous leukemia|Metastatic breast cancer|Breast tumor|Ovary tumor,1731|3657|49|799,Leukemia|Hematological neoplasm|Graft versus host disease|Cancer|Solid tumor,199|2054|616|651|725,Prescient Therapeutics Ltd,25731,VioQuest Pharmaceuticals Inc|Greenwich Therapeutics Inc|Cahaba Pharmaceuticals Inc|AKTivate Therapeutics Pty Ltd|University of South Florida,1009439|1014107|1048215|1103835|20677,University of South Florida,20677,,,,,,
53200,daratumumab,"HuMax, multiple myeloma|IgG1kappa antibody (multiple myeloma), Genmab|daratumumab|HuMax-CD38|3003-005|JNJ-54767414|Darzalex",USAN|INN|Research Code|Research Code|Research Code|Trade Name,Cancer|Endocrine/Metabolic|Immune,ADP ribosyl cyclase-1 inhibitor,5136,Apoptosis stimulator|Anticancer monoclonal antibody|Anticancer|Synergist|Anti-inflammatory|Therapeutic antibody,1589|55685|1545|7293|2953|172641,Myelodysplastic syndrome|B-cell acute lymphoblastic leukemia|T-cell acute lymphoblastic leukemia|Lymphoplasmacytic lymphoma|Precursor T-lymphoblastic lymphoma-leukemia|Multiple myeloma|Rheumatoid arthritis|T-cell lymphoma|AL amyloidosis|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Solid tumor,1272|1729|1730|1743|1752|1828|291|311|3492|3665|3713|4250|725,Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1744|1745|1749|319,Xian-Janssen Pharmaceutical Ltd|Janssen Biotech Inc,17608|26997,Genmab A/S,26469,Genmab A/S,26469,,,,,,
53201,"SNX-5422 (oral, cancer), Esanex","Hsp90 inhibitors (oral, cancer), Serenex|SC-107881|SNX-2112|SC-102112|SC-105422|SNX-5542|SNX-5422|SNX-5422 (oral, cancer), Pfizer|SN-5422|SNX-5422 (oral, cancer), Serenex|PF-4929113 (oral, cancer), Pfizer|PF-04928473|PF-4928473|PF-04929113|PF-4929113|SNX-5422 (oral, cancer), Esanex",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Hsp 90 inhibitor,8012,Apoptosis stimulator|Anticancer,1589|1545,Neuroendocrine tumor|Chronic lymphocytic leukemia|Non-Hodgkin lymphoma,1128|1734|319,Hematological neoplasm|Cancer|Solid tumor,2054|651|725,Esanex Inc,1070640,Pfizer Inc|Serenex Inc,18767|31435,Serenex Inc,31435,,,,,,
5321,indinavir,Crixivan|L-735524|MK-639|Compound J|indinavir|indinavir sulfate,Trade Name|Research Code|Research Code|INN|USAN,Infection,HIV protease inhibitor|HIV-1 protease inhibitor,204|768,Antiviral,991,HIV-1 infection,159,,,Merck & Co Inc,18077,,,Merck & Co Inc,18077,,,,,,
53217,navarixin,"PS-291822|PS-938285|PS-140430|respiratory disease therapeutics, Schering-Plough/Pharmacopeia|CXCR2 antagonist (chronic obstructive pulmonary disorder), Schering-Plough/Pharmacopeia|SCH-527123|SCH-N|CXCR2 antagonist (chronic obstructive pulmonary disorder), Merck & Co|CXCR2 receptor antagonist (COPD), Merck & Co|navarixin|navarixin (USAN)|MK-7123",Research Code|Research Code|Research Code|Research Code|Research Code|INN|USAN|Research Code,Cancer|Dermatologic|Inflammatory|Respiratory,CXCR2 chemokine antagonist,3131,Respiratory system agent|Anticancer|Anti-inflammatory|Systemic antipsoriatic product,1470|1545|2953|15184,Hormone refractory prostate cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer,3246|3658|3665,Chronic obstructive pulmonary disease|Inflammatory disease|Psoriasis|Asthma|Respiratory disease,1185|188|281|31|711,Merck & Co Inc,18077,Pharmacopeia Inc|Schering-Plough Corp,19062|19711,Pharmacopeia Inc,19062,,,,,,
53225,glesatinib glycolate,"multikinase inhibitors (cancer), Methylgene|MGCD-265|glesatinib glycolate|glesatinib",Research Code|USAN|INN,Cancer,Tek tyrosine kinase receptor inhibitor|Ron tyrosine kinase receptor inhibitor|Axl tyrosine kinase receptor inhibitor|VEGF-1 receptor antagonist|Hepatocyte growth factor receptor antagonist|VEGF-3 receptor antagonist|VEGF-2 receptor antagonist,3834|3800|3742|3846|675|3850|3848,Angiogenesis inhibitor|Anticancer protein kinase inhibitor,61|62255,,,Non-small-cell lung cancer|Metastatic non small cell lung cancer|Cancer,1262|3665|651,,,Mirati Therapeutics Inc|MethylGene Inc,1085701|23090,MethylGene Inc,23090,,,,,,
53227,obinutuzumab,"GA-101|anti-CD20 humanized mAb (GlycoMAb), Glycart|R-7159|afutuzumab|RO-5072759|obinutuzumab|RG-7159|Gazyva|Gazyvaro|Gasseba",Research Code|Research Code|Research Code|USAN|INN|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Genitourinary/Sexual Function|Immune,B-lymphocyte antigen CD20 inhibitor,5085,Immunomodulator|Anti-inflammatory|Anticancer monoclonal antibody|Therapeutic antibody|Apoptosis stimulator,1596|2953|55685|172641|1589,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Lupus nephritis|Non-Hodgkin lymphoma|Membranous glomerulonephritis|Metastatic renal cell carcinoma|Graft versus host disease,1734|1743|1744|1745|1746|2404|319|3441|4250|616,Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Multiple myeloma|Hematological neoplasm|End stage renal disease|Post transplant lymphoproliferative disease,1731|1749|1828|2054|3251|3530,Nippon Shinyaku Co Ltd|Genentech Inc|F Hoffmann-La Roche AG|Chugai Pharmaceutical Co Ltd|Biogen Inc,18552|19453|26178|15414|1005244,,,Roche GlycArt Ag,30654,,,,,,
53234,"852A (intravenous), Pfizer","852A|852A (cancer), 3M/University of Minnesota|TLR-7 agonist (intravenous, cancer), 3M|TLR-7 agonist (cancer), 3M/University of Minnesota|852A (intravenous), Pfizer|TLR-7 agonist (intravenous, cancer), Coley|3M-001|852A (intravenous), Coley",Research Code|Research Code,Cancer,TLR-7 agonist,7821,Anticancer|Immunomodulator,1545|1596,,,Melanoma|Hematological neoplasm|Uterine cervix tumor|Breast tumor|Solid tumor|Uterus tumor|Ovary tumor,205|2054|427|49|725|740|799,,,3M Pharmaceuticals|Coley Pharmaceutical Group Inc,21568|27288,3M Pharmaceuticals,21568,,,,,,
53239,cenersen,"EL-625|p53 antisense oligonucleotide (cancer), Eleos|OL(1)p53|cenersen sodium|cenersen|Aezea",Research Code|Research Code|USAN|INN|Trade Name,Cancer,TP53 gene modulator,7690,Antisense oligonucleotide inhibitor|Anticancer,7294|1545,Myelodysplastic syndrome,1272,Acute myelogenous leukemia|Chronic lymphocytic leukemia|B-cell lymphoma,1731|1734|316,Eleos Inc,1014394,,,Eleos Inc,1014394,,,,,,
53252,Endostar,"Endostar|recombinant human endostatin (cancer), Shandong Simcere Medgenn|Endu|YH-16",Trade Name|Trade Name|Research Code,Cancer|Gastrointestinal|Respiratory,VEGF receptor antagonist|Integrin alpha-V/beta-3 antagonist|Metalloprotease-2 inhibitor|Endostatin stimulator|Osteopontin ligand inhibitor|Hypoxia inducible factor-1 alpha inhibitor,1722|2458|2461|49941|14032|9680,Angiogenesis inhibitor|Apoptosis stimulator|Anticancer|Anticancer protein kinase inhibitor,61|1589|1545|62255,Esophagus tumor|Non-small-cell lung cancer|Melanoma|Ascites|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic esophageal cancer|Pleural disease,1011|1262|205|2204|3657|3658|3667|704,Small-cell lung cancer|Osteosarcoma|T-cell lymphoma|Neurofibromatosis type II|Brain tumor,1261|1772|311|3522|760,Shandong Simcere Medgenn Bio-Pharmaceutical Co Ltd,1014473,,,Shandong Simcere Medgenn Bio-Pharmaceutical Co Ltd,1014473,,,,,,
53258,ridaforolimus,"AP-23573|AP-23573 (oral), ARIAD/Merck & Co|deforolimus (oral), ARIAD/Merck & Co|deforolimus|MK-8669|ridaforolimus (oral, cancer), ARIAD/Merck|ridaforolimus|Taltorvic|Jenzyl",Research Code|Research Code|USAN|INN|Trade Name|Trade Name,Cancer|Neurology/Psychiatric,mTOR inhibitor,10240,Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Smooth muscle cell proliferation inhibitor,62255|61|512,,,Non-small-cell lung cancer|Endometrioid carcinoma|Osteosarcoma|Sarcoma|Neurodegenerative disease|Hormone refractory prostate cancer|Soft tissue sarcoma|Metastatic breast cancer|Breast tumor|Cancer|Solid tumor,1262|1705|1772|194|233|3246|3378|3657|49|651|725,,,ARIAD Pharmaceuticals Inc|Merck & Co Inc|MSD Japan,14296|18077|24019,ARIAD Pharmaceuticals Inc,14296,,,,,,
5326,montelukast sodium,montelukast sodium|montelukast|montercast|Singulair|Kipres|MK-476|MK-0476,USAN|INN|Trade Name|Trade Name|Research Code|Research Code,Immune|Respiratory,Leukotriene D4 antagonist,242,Bronchodilator|Anti-inflammatory,646|2953,Allergic rhinitis|Asthma,1107|31,Bronchiolitis,2976,MSD Japan|Kyorin Pharmaceutical Co Ltd|Merck Sharp & Dohme Ltd|Merck & Co Inc,24019|17719|18090|18077,,,Merck & Co Inc,18077,,,,,,
53301,RG-7356,"H460-16-2|ARH460-16-2|(ch)ARH460-16-2-IgG1|chimeric ARH460-16-2-IgG1|(ch)ARH460-16-2-IgG2|chimeric ARH460-16-2-IgG2|anti-CD44 antibody (cancer), ARIUS|AR-001 series, ARIUS|chARH460-16-2|muARH460-16-2|RO-5429083|RG-7356|anti-CD44 mAb (cancer), Roche",Research Code|Research Code|Analogue|Analogue|Analogue|Analogue|Analogue|Research Code|Research Code,Cancer|Gastrointestinal,Hyaluronic acid receptor antagonist,2618,Anticancer monoclonal antibody|Anti-inflammatory,55685|2953,,,Acute myelogenous leukemia|Inflammatory bowel disease|Cancer|Solid tumor,1731|189|651|725,,,Roche Holding AG|ARIUS Research Inc,19446|27752,ARIUS Research Inc,27752,,,,,,
53342,"vinorelbine (nano-emulsion), Mast Therapeutics","vinorelbine|vinorelbine (nano-emulsion), ADVENTRX|nano-emulsion vinorelbine, SD Pharmaceuticals|SDP-012|ANX-530|vinorelbine (nano-emulsion/injectable, NSCLC/breast tumor), SD Pharmaceuticals/ADVENTRX|nano-emulsion vinorelbine, ADVENTRX|Exelbine|vinorelbine (nano-emulsion), Mast Therapeutics",INN|Research Code|Research Code|Trade Name,Cancer,,,Microtubule inhibitor|Cell cycle inhibitor,2575|767,,,Non-small-cell lung cancer|Cancer,1262|651,,,SD Pharmaceuticals Inc|Mast Therapeutics Inc,1014697|27262,SD Pharmaceuticals Inc,1014697,,,,,,
53360,APO-010,"MegaFasL|soluble FasL (Mega-Ligand), Apoxis|cancer therapeutics (FasL), Apoxis|anticancer therapeutics (FasL), APoxis|APO-010|Soluble FasL (Mega-Ligand), TopoTarget|APO-010 DRP",Research Code|Research Code|Trade Name,Cancer,Fas ligand|CD95 agonist,13832|5366,Anticancer|Apoptosis stimulator,1545|1589,Multiple myeloma|Cancer,1828|651,Solid tumor,725,Oncology Venture ApS,1095288,Apoxis SA|TopoTarget A/S,1002960|29414,Apoxis SA,1002960,,,,,,
53423,pracinostat,"SB-939|SB-207, Helsinn|SB-869|histone deacetylase inhibitors (oral, solid tumors), S*Bio Pte Ltd|HDAC program (oral, solid tumors/hematological neoplasm), S*Bio Pte Ltd|HDAC inhibitors (oral, solid tumors/hematological neoplasm), S*Bio Pte Ltd|pracinostat",Research Code|Analogue|Analogue|INN,Cancer|Hematologic,Histone deacetylase inhibitor,2574,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm|Myelofibrosis|Prostate tumor,1272|1731|2054|2436|276,Thrombocythemia|Myeloproliferative disorder|Cancer|Solid tumor,2317|273|651|725,Berlin-Chemie AG|Endo International plc|Helsinn Group|Blanver Farmoquimica Ltda,18054|1089706|16646|1030148,S*BIO Pte Ltd|MEI Pharma Inc,27780|28700,S*BIO Pte Ltd,27780,,,,,,
53424,zotiraciclib citrate,"CDK/FLT3 inhibitors (oral, cancer), S*BIO/Tragara Pharmaceuticals|Sbio-300 series|EX45 CDK/Flt3i|SB-1317|multi-kinase program (oral, cancer), S*Bio Pte Ltd/Tragara Pharmaceuticals|cyclin dependent+Flt3 tyrosine kinase inhibitors (oral, cancer), S*Bio Pte Ltd/Tragara Pharamceuticals|Jak2 tyrosine kinase inhibitor/ERK 5 inhibitor (oral, cancer), S*Bio Pte Ltd|TG-02|cyclin dependent+Flt3 tyrosine kinase inhibitors (oral, cancer), S*Bio Pte Ltd/Adastra Pharmaceuticals|zotiraciclib|zotiraciclib citrate",Research Code|Research Code|Research Code|USAN,Cancer,Cyclin-dependent kinase-7 inhibitor|Flt3 tyrosine kinase inhibitor|Jak2 tyrosine kinase inhibitor|Cyclin-dependent kinase-1 inhibitor|Cyclin-dependent kinase-9 inhibitor|Cyclin-dependent kinase-5 inhibitor|Cyclin-dependent kinase-2 inhibitor,4304|3806|3564|4308|8110|4316|4310,Anticancer protein kinase inhibitor|Apoptosis stimulator,62255|1589,Glioma|Hepatocellular carcinoma|Hematological neoplasm|Glioblastoma|Anaplastic astrocytoma|Solid tumor,1108|1767|2054|2454|2567|725,Chronic lymphocytic leukemia|Multiple myeloma|Cancer,1734|1828|651,Adastra Pharmaceuticals Inc|Lee's Pharmaceutical Holdings Limited,1031241|1023179,S*BIO Pte Ltd,27780,S*BIO Pte Ltd,27780,,,,,,
53463,tilsotolimod,"HYB-2125|immunomodulatory oligonucleotide (hepatitis C virus infection), Hybridon|IMO (hepatitis C virus infection), Hybridon|immunomodulatory oligonucleotide (HCV), Idera|IMO (HCV), Idera|IMO-2125|tilsotolimod",Research Code|Research Code|INN,Cancer|Infection,TLR-9 agonist,7827,Immunostimulant|Antiviral|Anticancer,393|991|1545,Squamous cell carcinoma|Stage III melanoma|Stage IV melanoma|Metastatic head and neck cancer|Head and neck tumor|Solid tumor|Colorectal tumor,307|3256|3257|3673|623|725|989,Hepatitis C virus infection|Cancer,153|651,Idera Pharmaceuticals Inc,17006,Merck Serono SA,19862,Idera Pharmaceuticals Inc,17006,,,,,,
53500,CST-101,"ZRx-101|NK-92 cell-based therapy (cancer), ZelleRx|CST-101|Neukoplast|activated natural killer cells (cancer), NantKwest|aNK cells (cancer), NantKwest",Research Code|Trade Name,Cancer,,,Anticancer|Natural killer cell stimulator|Immunostimulant,1545|7757|393,Merkel cell carcinoma|Cancer,3235|651,,,NantKwest Inc|iNEXBio,1015036|1103731,Rush University Medical Center|CreaPlanet Co Ltd,1009311|1031550,Rush University Medical Center,1009311,,,,,,
53526,ontuxizumab,"humanized mAb (neovascular disease/cancer), Morphotek|anti-endosialin antibody (neovascular disease/cancer), Morphotek|anti-TEM1 antibody (neovascular disease/cancer), Morphotek|anti-tumor endothelial marker 1 antibody  (neovascular disease/cancer), Morphotek|ontuxizumab|MORAb-004|ontecizumab|anti-endosialin antibody (neovascular disease/cancer), Eisai|anti-TEM1 antibody (neovascular disease/cancer), Eisai|anti-tumor endothelial marker 1 antibody (neovascular disease/cancer), Eisai|humanized mAb (neovascular disease/cancer), Eisai",USAN|INN,Cancer,Endosialin inhibitor,47090,Anticancer monoclonal antibody|PET contrast agent|Gastrointestinal diagnostic agent|Imaging agent|Neoplasm diagnostic agent,55685|5555|7213|4155|7220,,,Melanoma|Soft tissue sarcoma|Metastatic colorectal cancer|Cancer|Solid tumor|Colorectal tumor,205|3378|3658|651|725|989,,,Eisai Co Ltd|Ludwig Institute for Cancer Research|Morphotek Inc,15872|21091|29741,Ludwig Institute for Cancer Research,21091,,,,,,
53528,Tc-99m-Oncardia,99mTc-EC-DG|technetium-99m-EC-DG|99mTc-ethylenedicysteine-glucosamine|technetium-99m-ethylenedicysteine-glucosamine|99mTc-EC-deoxyglucose|technetium-99m-EC-deoxyglucose|99mTc-EC-G|technetium-99m-EC-G|EC-DG-[99mTc]|99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine|Tc-99m-Oncardia,Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Cardiovascular,,,Radiodiagnostic|Anticancer|Cardiovascular diagnostic agent|SPECT contrast agent|Neoplasm diagnostic agent,5720|1545|7210|5556|7220,Non-small-cell lung cancer|Heart disease|Cancer|Lung tumor,1262|626|651|755,,,MJM Productos Farmaceuticos e de Radioprotecao Ltda|Cell>Point LLC|Hanmi Pharmaceutical Co Ltd,1067686|1008286|16611,,,Cell>Point LLC,1008286,,,,,,
53547,"aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer","VEGF trap (intravitreal, AMD), Regeneron|VEGF trap (intravitreal, age-related macular degeneration), Regeneron|aflibercept|aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer|VEGF Trap-Eye|VEGF Trap-Eye disease|BAY-86-5321|Eylea|ziv-aflibercept|aflibercept (intravitreal, ocular/uveal melanoma), Regeneron",USAN|INN|Research Code|Trade Name,Cancer|Ocular,Placenta growth factor ligand inhibitor|VEGF-A ligand inhibitor,15904|1689,Ocular antineovascularisation agent|Anticancer|Angiogenesis inhibitor,15148|1545|61,Hemangioma|Glaucoma|Retinopathy of prematurity|Retinal venous occlusion|Proliferative diabetic retinopathy|Non-proliferative diabetic retinopathy|Diabetic macular edema|Thyroid associated ophthalmopathy|Choroidal neovascularization|Macular edema|Wet age related macular degeneration|Uveal melanoma|Ocular melanoma|Diabetic retinopathy,1121|134|2478|2656|2657|2658|2659|2967|3138|3352|3354|3788|3789|576,,,Bayer AG|Bayer Yakuhin Ltd|Bayer Zydus Pharma Private Limited|Regeneron Pharmaceuticals Inc,14455|14557|1195010|19214,,,Regeneron Pharmaceuticals Inc,19214,,,,,,
53558,sepantronium bromide,"YM-155|survivin expression inhibitor, Astellas|survivin expression inhibitor, Yamanouchi|sepantronium bromide|PC-002",Research Code|USAN|INN|Research Code,Cancer,Survivin protein inhibitor|MYC gene modulator,13608|18602,Anticancer|Apoptosis stimulator,1545|1589,Diffuse large B-cell lymphoma|Hemangiosarcoma|Neuroblastoma,1749|2104|2726,Non-small-cell lung cancer|Melanoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Breast tumor|Solid tumor,1262|205|319|3246|49|725,Cothera Biosciences Inc,1197349,Astellas Pharma Inc|Yamanouchi Pharmaceutical Co Ltd,1013295|20967,Yamanouchi Pharmaceutical Co Ltd,20967,,,,,,
5356,sevoflurane,sevoflurane|Ultane|Sevorane|Sevofrane,USAN|BAN|INN|Trade Name|Trade Name|Trade Name,Neurology/Psychiatric,,,General anesthetic|Unspecified drug target,1668|59620,Anesthesia,19,,,AbbVie Inc,1072507,Sumitomo Dainippon Pharma Co Ltd|Abbott Laboratories|Baxter International Inc|Dainippon Pharmaceutical Co Ltd|Maruishi Pharmaceutical Co Ltd,1017117|13601|14437|15606|17951,Baxter International Inc,14437,,,,,,
53569,lintuzumab,"HuM195|Zamyl|KB-195|lintuzumab|HuM195, PDL|SMART M195, PDL|humanized M195, PDL|M195 (humanized), Protein Design Labs|SGN-33|anti-CD33 mAb (leukemia), Seattle Genetics|SMART M195|Humanized M195|M-195",Trade Name|Research Code|INN|Research Code|Research Code,Cancer,CD33 antagonist,5121,Anticancer monoclonal antibody,55685,,,Myelodysplastic syndrome|Acute myelogenous leukemia|Acute promyelocytic leukemia|Leukemia,1272|1731|1732|199,,,PDL BioPharma Inc|Seagen Inc,19162|25554,PDL BioPharma Inc,19162,,,,,,
53573,balixafortide,"POL-2438|POL-3026|CXCR4 antagonists (cancer/HIV), Polyphor|epitope mimetics (HIV fusion), Polyphor|CXCR4 antagonists, Polyphor|balixafortide|POL-6326|CXCR4 antagonists (intravenous, cancer/HIV/COVID-19), Polyphor",Research Code|Research Code|INN|Research Code,Cancer|Cardiovascular|Dermatologic|Immune|Infection|Inflammatory,CXCR4 chemokine antagonist,3137,Vulnerary agent|Immunomodulator|HIV fusion inhibitor|Anticancer|Anti-inflammatory|Antiviral,7292|1596|3980|1545|2953|991,Coronavirus disease 19 infection|HIV infection|Inflammatory disease|Myocardial infarction|Stem cell transplantation|Wound healing|Metastatic breast cancer|Cancer,10406|158|188|224|2990|347|3657|651,,,Polyphor Ltd|Shanghai Fosun Pharmaceutical (Group) Co Ltd,30053|1015871,,,Polyphor Ltd,30053,,,,,,
53589,"fluphenazine (multiple myeloma/psoriasis), Corridor Pharmaceuticals","fluphenazine|5-HT 1b antagonist (multiple myeloma/psoriasis), Immune Control|C-064|fluphenazine (multiple myeloma/psoriasis), Immune Control|fluphenazine (multiple myeloma/psoriasis), Corridor Pharmaceuticals",BANN|INN|Research Code,Cancer|Dermatologic,5-HT 1b receptor antagonist,558,Immunomodulator|Anticancer|Systemic antipsoriatic product,1596|1545|15184,,,Multiple myeloma|Psoriasis,1828|281,,,Immune Control Inc|Corridor Pharmaceuticals Inc,1014844|1055004,Immune Control Inc,1014844,,,,,,
5369,ribavirin,ICN-1229|NSC-163039|ribavirin|tribavirin|Vilona|Viramid|Rebetol|Virazid|Cotronak|Virazide|Ro-20-9963|Ribasphere|Ribapak|SCH-18908|SCH-018908,Research Code|Research Code|USAN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Research Code|Research Code,Infection,,,Antiviral|RNA synthesis inhibitor,991|439,Hepatitis C virus infection|Viral hemorrhagic fever,153|3503,Hantavirus infection|Hepatitis B virus infection|Herpes simplex virus infection|Varicella zoster virus infection,1032|152|157|392,Bausch Health Companies Inc|Schering-Plough Corp|Merck & Co Inc,17058|19711|18077,,,Bausch Health Companies Inc,17058,,,,,,
53745,ENMD-2076,"MKC-1260|aurora kinase inhibitor (cancer), Miikana|aurora kinase inhibitors (cancer), Miikana|aurora kinase inhibitors (oral, cancer), EntreMed|ENMD-981693|ENMD-2076|MKC-1693|aurora kinase inhibitors (oral, cancer), CASI Pharmaceuticals",Research Code|Research Code|Research Code|Research Code,Cancer,FGF3 receptor antagonist|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist|Aurora protein kinase 1 inhibitor|Aurora protein kinase 2 inhibitor|FGF1 receptor antagonist|Jak2 tyrosine kinase inhibitor|X-linked inhibitor of apoptosis protein inhibitor|Flt3 tyrosine kinase inhibitor,3688|3846|3848|4418|4420|3682|3564|13605|3806,Anticancer protein kinase inhibitor|Cell cycle inhibitor|Apoptosis stimulator|Angiogenesis inhibitor,62255|767|1589|61,Hepatocellular carcinoma|Breast tumor,1767|49,Soft tissue sarcoma|Ovarian clear cell carcinoma|Cancer|Ovary tumor,3378|3525|651|799,CASI Pharmaceuticals Inc,21794,Selected Value Therapeutics,1056578,Miikana Therapeutics Inc,1003989,,,,,,
53854,XL-281,"XL-281|Raf kinase inhibitors (cancer), Exelixis|EXEL-2819|Raf kinase inhibitor (cancer), Bristol-Myers Squibb|BMS-908662",Research Code|Research Code|Research Code,Cancer,Raf B protein kinase inhibitor|Raf 1 protein kinase inhibitor,4548|4550,Synergist|Anticancer protein kinase inhibitor,7293|62255,,,Melanoma|Cancer|Solid tumor|Colorectal tumor,205|651|725|989,,,Bristol-Myers Squibb Co|Exelixis Inc,15065|22676,Exelixis Inc,22676,,,,,,
53857,XL-228,"XL-228|IGF1R kinase inhibitors (iv, cancer), Exelixis|insulin-like growth factor 1 receptor kinase inhibitors, Exelixis",Research Code,Cancer,Insulin-like growth factor 1 receptor antagonist|Insulin-like growth factor 1 receptor modulator|Abl tyrosine kinase inhibitor|Src tyrosine kinase inhibitor|Aurora protein kinase inhibitor,3252|3254|3524|3576|4412,Anticancer protein kinase inhibitor,62255,,,Acute lymphoblastic leukemia|Chronic myelocytic leukemia|Multiple myeloma|Lymphoma|Cancer|Solid tumor,1728|1735|1828|203|651|725,,,Exelixis Inc,22676,Exelixis Inc,22676,,,,,,
53932,ralimetinib,"LY-479754|p38 MAP kinase inhibitors (inflammation, cancer), Lilly|LY-2231377|LY-2211877|LY-2180895|LY-2228820|ralimetinib mesylate|LY-2228820 dimesylate|LY-2322600|p38 MAP kinase inhibitor I (oncology), Eli Lilly|ralimetinib|LSN-2322600",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|Research Code|USAN|INN|Research Code,Cancer|Inflammatory,p38 MAP kinase alpha inhibitor|p38 MAP kinase beta inhibitor|p38 MAP kinase inhibitor,22696|22699|2419,Anticancer protein kinase inhibitor|Anti-inflammatory,62255|2953,,,Metastasis|Inflammatory disease|Fallopian tube cancer|Peritoneal tumor|Cancer|Ovary tumor,1069|188|2243|3083|651|799,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
53945,tirbanibulin,"src kinase inhibitors (cancer), Kinex|KX-2377|KX-1136-b|KX-305|KX-1136|KX2-391|KX2-377|KX1-174|KX2-305|KX1-002|KX-01|KX2-391 (oral, cancer), Kinex/Hanmi|src kinase inhibitors (oral, cancer), Kinex/ Hanmi|tirbanibulin|tirbanibulin (oral, actinic keratosis/cancer), Chongqing Jingdong|tirbanibulin mesylate",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|USAN,Cancer|Dermatologic,Src tyrosine kinase inhibitor|Tubulin binding agent,3576|499,Microtubule inhibitor|Anticancer protein kinase inhibitor|Cell cycle inhibitor,2575|62255|767,Acute myelogenous leukemia|Chronic myelocytic leukemia|Prostate tumor|Hormone refractory prostate cancer|Actinic keratosis|Cancer,1731|1735|276|3246|4560|651,Stomach tumor|Breast tumor|Solid tumor,127|49|725,Athenex Inc,1016074,Chongqing Jingdong Junzhuo Pharmaceutical Co Ltd|Hanmi Pharmaceutical Co Ltd,1178559|16611,Athenex Inc,1016074,,,,,,
53970,"teprotumumab (iv, thyroid eye disease), Genmab/Horizon Pharma","anti-IGF-1 receptor mAb, GenMab/Roche|teprotumumab|RV-001|teprotumumab (iv, thyroid eye disease/small cell lung cancer), Roche/River Vision/INSERM/Institut Gustave Roussy|R-1507|RG-1507|teprotumumab (iv, thyroid eye disease/diabetic macular edema), Genmab/River Vision|teprotumumab (iv, thyroid eye disease/diabetic macular edema), Genmab/Horizon Pharma|HZN-001|teprotumumab (iv, thyroid eye disease), Genmab/Horizon Pharma|Tepezza|teprotumumab-trbw|anti-IGF-1 receptor mAb, (sc, thyroid eye disease/scleroderma), Horizon Pharma",USAN|INN|Research Code|Research Code|Research Code|Research Code|Trade Name,Cancer|Immune|Ocular,Insulin-like growth factor 1 receptor antagonist,3252,Anticancer monoclonal antibody|Therapeutic antibody|Anticancer protein kinase inhibitor,55685|172641|62255,Scleroderma|Thyroid associated ophthalmopathy,1105|2967,Small-cell lung cancer|Non-small-cell lung cancer|Sarcoma|Diabetic macular edema|Breast tumor|Solid tumor,1261|1262|194|2659|49|725,Horizon Therapeutics plc,1053335,River Vision Development Corp|Chugai Pharmaceutical Co Ltd|INSERM|Roche Holding AG|Institut Gustave Roussy|F Hoffmann-La Roche AG|Genmab A/S,1079080|15414|17229|19446|21081|26178|26469,Genmab A/S,26469,,,,,,
53981,enzalutamide,"MDVN-300|MDVN-311|MDVN-312|prostate cancer therapeutics, Medivation|MDV-300|MDV-3100|RD-162'|RD-162|enzalutamide|Xtandi|ASP-9785",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Trade Name|Research Code,Cancer,DNA binding protein inhibitor|Prostate specific antigen modulator|Androgen receptor antagonist|Cytochrome P450 3A4 stimulator|Translocation associated protein inhibitor,18889|35354|60|7423|78089,Apoptosis stimulator|Anticancer,1589|1545,Endometrioid carcinoma|Adenocarcinoma|Prostate tumor|Squamous cell carcinoma|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Metastatic prostate cancer|Metastatic pancreas cancer|Salivary gland cancer|Head and neck tumor,1705|2399|276|307|3246|3247|3664|3669|4299|623,Hepatocellular carcinoma|Bladder cancer|Metastatic breast cancer|Breast tumor,1767|2380|3657|49,Pfizer Inc|Medivation Inc|Astellas Pharma Inc,18767|1014884|1013295,University of California,20547,University of California,20547,,,,,,
53984,pexastimogene devacirepvec,"JX-594|oncolytic vaccinia virus therapy expressing GM-CSF (cancer), Jennerex/Green Cross|TG-6006|pexastimogene devacirepvec|Pexa-Vec",Research Code|Research Code|USAN|INN,Cancer,GM-CSF receptor agonist,410,Immunostimulant|Anticancer,393|1545,Melanoma|Adenocarcinoma|Prostate tumor|Soft tissue sarcoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic renal cell carcinoma|Solid tumor|Colorectal tumor,205|2399|276|3378|3657|3658|4250|725|989,Renal cell carcinoma|Hepatocellular carcinoma|Cancer,1766|1767|651,Transgene SA|SillaJen Inc|Lee's Pharmaceutical Holdings Limited,23924|1094438|1023179,Jennerex Inc|GC Pharma,1016205|16583,Jennerex Inc,1016205,,,,,,
53987,H-101,"oncolytic adenovirus therapy (E1B-deficient, cancer), Shanghai Sunway|H-101|Oncorine",Research Code|Trade Name,Cancer|Hematologic,,,Immunostimulant|Anticancer,393|1545,Glioma|Nasopharyngeal carcinoma|Liver tumor|Pancreas tumor|Colorectal tumor,1108|1768|202|249|989,Non-small-cell lung cancer|Osteosarcoma|Bone marrow disease|Cancer,1262|1772|555|651,Shanghai Sunway Biotech Co Ltd,1009402,PolarisRx Corp,1036919,Shanghai Sunway Biotech Co Ltd,1009402,,,,,,
54016,inebilizumab,"B-cell depleting anti-CD19 monoclonal antibody, Cellective|MEDI-551|B-cell depleting anti-CD19 monoclonal antibody, MedImmune|CD19-1aFuc|inebilizumab|B-cell depleting anti-CD19 monoclonal antibody, Viela Bio|MT-0551|inebilizumab-cdon|Uplizna|VIB-0551",Research Code|USAN|INN|Research Code|Trade Name|Research Code,Cancer|Immune|Inflammatory|Neurology/Psychiatric,B-lymphocyte antigen CD19 inhibitor,5082,Anti-inflammatory|B-lymphocyte inhibitor|Therapeutic antibody|Anticancer monoclonal antibody,2953|7740|172641|55685,Inflammatory disease|Hematological neoplasm|Neuromyelitis optica|Kidney transplantation|Myasthenia gravis,188|2054|2316|2984|848,Scleroderma|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Multiple myeloma|Multiple sclerosis|B-cell lymphoma|Cancer,1105|1734|1749|1828|213|316|651,Viela Bio|Jiangsu Hansoh Pharmaceutical Group Co Ltd|Mitsubishi Tanabe Pharma Corp,1161121|1017684|1035060,Cellective Therapeutics Inc|MedImmune LLC,1010125|18008,Cellective Therapeutics Inc,1010125,,,,,,
54031,PRLX-93936,"PRLX-82845|PRLX-82845 series, Prolexys|selectively cytotoxic anti-cancer compounds, Prolexys/Whitehead Institute|erastin|PRLX-93936",Research Code|Research Code,Cancer,Ras GTPase inhibitor|Voltage dependent anion channel modulator,10451|24567,Anticancer|Apoptosis stimulator,1545|1589,,,Cancer|Solid tumor,651|725,,,Prolexys Pharmaceuticals Inc|Rines Therapeutics Ltd|Columbia University|Whitehead Institute for Biomedical Research,1005598|1103052|20559|20939,Whitehead Institute for Biomedical Research,20939,,,,,,
54071,iniparib,"PARP-1 inhibitors (cancer), BiPar|BSI-201|MS-292|iniparib|iniparib, BiPar|SAR-240550|iniparib, Octamer",Research Code|Research Code|USAN|INN|PINN|Research Code,Cancer|Infection,Poly ADP ribose polymerase 1 inhibitor,38283,DNA repair inhibitor|Antiviral|Anticancer chemosensitizer,11593|991|1586,,,Glioma|Small-cell lung cancer|Non-small-cell lung cancer|HIV infection|Metastatic breast cancer|Metastatic non small cell lung cancer|Breast tumor|Cancer|Solid tumor|Uterus tumor|Ovary tumor,1108|1261|1262|158|3657|3665|49|651|725|740|799,,,Sanofi SA|BiPar Sciences Inc|Octamer Inc,1009547|1016773|18637,Octamer Inc,18637,,,,,,
54093,romyelocel L,"CLT-008|stem cell therapy (neutropenia), Cellerant|myeloid progenitor cells (neutropenia/acute radiation syndrome/cord blood transfusion), Cellerant|romyelocel L",Research Code|Research Code|USAN,Cancer|Hematologic|Immune|Toxicity/Intoxication,,,Hematopoietic stimulator|Anticancer|Neutrophil stimulator,610|1545|7759,Acute myelogenous leukemia|Neutropenia|Stem cell transplantation|Radiation sickness,1731|1991|2990|367,,,Cellerant Therapeutics Inc,1010127,,,Cellerant Therapeutics Inc,1010127,,,,,,
54120,"PEGylated vorhyaluronidase (solid tumor/pancreatic cancer, Enhanze), Halozyme","PEG-rHuPH-20|PEGylated recombinant human hyaluronidase (stroke/cancer), Halozyme|hyaluronidase (human recombinant)|PH-20|rHuPH-20|PEGPH20|PEGylated hyaluronidase (cancer/stroke), Halozyme|PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme|hyaluronidase PH-20 human pegylated|vorhyaluronidase alfa|PEGylated hyaluronidase vorhyaluronidase alfa (intravenous, stroke/cancer), Halozyme|PEG-vorhyaluronidase alfa|PEGH-20|pegvorhyaluronidase alfa|PEGylated vorhyaluronidase (solid tumor/pancreatic cancer, Enhanze), Halozyme",USAN|Research Code|Research Code|Research Code|INN|Research Code|USAN|INN,Cancer,Hyaluronidase stimulator,8590,Anticancer|T-lymphocyte infiltration modulator,1545|5696,,,Cholangiocarcinoma|Gallbladder tumor|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Cancer,1765|3146|3657|3665|3666|3667|3669|651,,,Halozyme Therapeutics Inc,1010825,Halozyme Therapeutics Inc,1010825,,,,,,
54140,avdoralimab (IPH5401),"neutrazumab|anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2 Therapies/Novo Nordisk|NNC-0151-0000-0000|NN-8209|anti-C5aR-151|IPH-5401|avdoralimab (IPH5401)|anti-C5aR monoclonal antibodies (sc, non-small cell lung cancer/hepatocarcinoma/acute respiratory distress syndrome/COVID-19), Innate Pharma",Research Code|Research Code|Research Code|Research Code,Cancer|Dermatologic|Immune|Infection|Inflammatory|Respiratory,Complement C5a receptor antagonist|IL-8 receptor antagonist|Monocyte chemotactic protein 1 ligand inhibitor|CXCR1 chemokine antagonist,127|1580|17395|3128,Anticancer monoclonal antibody|Antiviral|Chemotaxis inhibitor|Anti-inflammatory|Anticancer,55685|991|5580|2953|1545,Non-small-cell lung cancer|Viral pneumonia|Liver tumor|Urticaria|Bullous pemphigoid|Solid tumor|Respiratory distress syndrome,1262|1818|202|340|6187|725|8,Coronavirus disease 19 infection|Inflammatory disease|Rheumatoid arthritis|Systemic lupus erythematosus|Cancer,10406|188|291|318|651,Innate Pharma SA,28788,G2 Therapies Ltd|Novo Nordisk A/S,1002660|18614,G2 Therapies Ltd,1002660,,,,,,
54174,AMG-110,"MT-110|bispecific EpCAM/CD3 antibody (BiTE, cancer), Micromet/Amgen|muS110|solitomab|anti-CD3/anti-EpCAM bispecific T-cell engager (BiTE, solid tumor), Amgen|AMG-110",Research Code|INN|Research Code,Cancer,CD3 modulator|EpCAM modulator,5023|14553,Anticancer antibody|Immunostimulant|T-lymphocyte stimulator,55684|393|7761,,,Solid tumor,725,,,Micromet Inc|Amgen Inc|Amgen Research (Munich) GmbH,1020809|14109|21737,Amgen Research (Munich) GmbH,21737,,,,,,
54184,"autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (leukemia/lymphoma), City of Hope Medical Center","CD19-specific autologous T-cell therapy (cancer), City of Hope|autologous T-cell therapy (cancer), City of Hope|CD19-specific autologous T-cell therapy (B-cell lymphoma), City of Hope|autologous T-cell therapy (B-cell lymphoma), City of Hope|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (leukemia/lymphoma), City of Hope Medical Center|anti-CD19 CAR T-cell therapy (leukemia/lymphoma), City of Hope Medical Center",,Cancer|Immune,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy|Anticancer,7761|393|4790|1545,Chronic lymphocytic leukemia|Hairy cell leukemia|Prolymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Post transplant lymphoproliferative disease|Burkitts lymphoma,1734|1736|1738|1743|1744|1745|316|319|3530|791,,,City of Hope,20558,,,City of Hope,20558,,,,,,
54202,"ezatiostat (oral), MabVax Therapeutics Holdings","TLK-199|TLK-199 (oral), Telik|Telintra (oral), Telik|ezatiostat|ezatiostat hydrochloride (oral), Telik|ezatiostat (oral), Telik|ezatiostat hydrochloride|Telintra|ezatiostat (oral), MabVax Therapeutics Holdings",Research Code|INN|USAN|Trade Name,Cancer|Hematologic,Glutathione S-transferase inhibitor,189,Hematopoietic stimulator|Anticancer,610|1545,,,Myelodysplastic syndrome|Neutropenia,1272|1991,,,MabVax Therapeutics Holdings Inc,20339,MabVax Therapeutics Holdings Inc,20339,,,,,,
54226,"panobinostat (oral), Novartis","LBH-589 (oral), Novartis|LBH-589B|panobinostat|panobinostat (oral), Novartis|LBH-589|NVP-LBH-589|Faridak|Farydak",Research Code|USAN|INN|Research Code|Research Code|Trade Name|Trade Name,Cancer|Hematologic|Immune|Infection,JAK2 gene inhibitor|Cytochrome P450 2D6 inhibitor|Histone deacetylase-2 inhibitor|Histone deacetylase-3 inhibitor|Histone deacetylase-6 inhibitor|Histone deacetylase inhibitor|Orphan nuclear hormone receptor NR4A1 agonist|Histone deacetylase-1 inhibitor,32722|7397|7844|7847|7856|2574|12949|7841,Angiogenesis inhibitor|Antiviral|Synergist|Anticancer|Cell cycle inhibitor|Apoptosis stimulator,61|991|7293|1545|767|1589,Glioma|Non-small-cell lung cancer|HIV-1 infection|Lymphoplasmacytic lymphoma|Multiple myeloma|Myelofibrosis|Sickle cell anemia|Metastatic breast cancer|Metastatic renal cell carcinoma|Colorectal tumor,1108|1262|159|1743|1828|2436|303|3657|4250|989,Neuroendocrine tumor|Myelodysplastic syndrome|Hodgkins disease|Acute myelogenous leukemia|Chronic myelocytic leukemia|Diffuse large B-cell lymphoma|Cutaneous T-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Stage IV melanoma|Soft tissue sarcoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Advanced solid tumor|Breast tumor|Graft versus host disease|Cancer,1128|1272|161|1731|1735|1749|1754|316|319|3246|3257|3378|3658|3665|3666|3713|49|616|651,Secura Bio Inc,1182172,Novartis AG,23137,Novartis AG,23137,,,,,,
54260,bezlotoxumab,"C difficile therapy (anti toxin-A and toxin-B antibody combination), Medarex|humanized monoclonal antibody combination (C difficile enterotoxins A and B, UltiMAb), Merck & Co/Medarex/Massachusetts Biologic Laboratories|MK-3415A|CDA-1 + CDB-1|GS-CDA1 + MDX-1388|MBL-CDA1 + MBL-CDB1|MDX-066 + MDX-1388|MK-3415 + MK-6072|actoxumab + bezlotoxumab|bezlotoxumab|MK-6072|MBL-CDB1|MDX-1388|Zinplava",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code|Research Code|Research Code|Trade Name,Infection,Clostridium difficile toxin B inhibitor,61979,Antibacterial|Antidiarrhoeal,1594|4007,Clostridium difficile infection,995,,,Merck & Co Inc,18077,Massachusetts Biologic Laboratories|Medarex Inc,1040747|17968,Medarex Inc,17968,,,,,,
54262,NP-50501,NP-50501|NSC-678515|FAU (2-F-Ara-deoxyuridine)|2'-fluorodeoxyuracil-beta-D-arabinofuranoside|FAU|deoxyuracil-beta-D-arabinofuranoside,Research Code|Research Code,Cancer,,,DNA synthesis inhibitor|Anticancer,140|1545,,,Cancer,651,,,Nascent Pharmaceuticals Inc|National Cancer Institute (NCI),1014689|20519,National Cancer Institute (NCI),20519,,,,,,
54288,"valsartan + amlodipine besylate (oral), Novartis","valsartan + amlodipine besylate (oral), Novartis|Diovan + amlodipine besylate (oral), Novartis|valsartan + amlodipine besylate|Exforge|Dafiro|Copalia|Imprida|Diovan + amlodipine besylate|VAA-489|CVAA-489|Exforge OD",Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Trade Name,Cardiovascular,Angiotensin II receptor antagonist|Calcium channel inhibitor,64|93,Antihypertensive,2657,Hypertension,178,,,UCB SA|Pfizer Inc|Novartis AG,20452|18767|23137,,,Novartis AG,23137,,,,,,
54402,Cavatak,"CAV21 (coe strain, Coxsackievirus A21, enterovirus) cancer therapy, ViroTarg|Cavatak|Coxsackievirus A21 (cancer), Psiron|CVA21|Coxsackievirus A21 (cancer), Viralytics|CAV-21 (coe strain, Coxsackievirus A21, enterovirus) cancer therapy, University of Newcastle|V-937|oncolytic coxsackievirus therapy (cancer), Viralytics",Trade Name|Research Code,Cancer,ICAM-1 modulator|CD55 modulator,5222|5225,Anticancer,1545,Hepatocellular carcinoma|Bladder cancer|Squamous cell carcinoma|Larynx tumor|Hormone refractory prostate cancer|Stage III melanoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Uveal melanoma|Mouth tumor|Pharynx tumor,1767|2380|307|3198|3246|3256|3257|3466|3657|3665|3666|3667|3673|3713|3788|793|794,Multiple myeloma|Melanoma|Glioblastoma|Cancer|Solid tumor,1828|205|2454|651|725,Viralytics Ltd,29011,ViroTarg Pty Ltd|University of Newcastle,1015218|23309,University of Newcastle,23309,,,,,,
54444,glembatumumab vedotin,"anti-glycoprotein NMB monoclonal antibody + monomethy-Auristatin E (cancer), Curagen|anti-gpNMB mAb- MMAE (iv, cancer), Curagen|CR-011-MMAE (iv, cancer), Curagen|anti-glycoprotein NMB monoclonal antibody + monomethy-Auristatin E (cancer), Celldex|CR-011-MMAE (iv, cancer), Celldex|anti-gpNMB mAb- MMAE (iv, cancer), Celldex|glembatumumab-mc-vc-PAB-MMAE|CR-011-vedotin|CR-011-mc-vc-PAB-MMAE|CDX-011|glembatumumab vedotin|CR011-vcMMAE",Research Code|USAN|INN|Research Code,Cancer,Transmembrane glycoprotein NMB modulator,11481,Anticancer monoclonal antibody|Immunotoxin|Microtubule inhibitor,55685|539|2575,,,Small-cell lung cancer|Osteosarcoma|Melanoma|Stage IV melanoma|Metastatic breast cancer|Uveal melanoma|Cancer,1261|1772|205|3257|3657|3788|651,,,CuraGen Corp|Celldex Therapeutics Inc,25491|25726,CuraGen Corp,25491,,,,,,
54449,afatinib,"BIBW-2992|dual EGFR/HER2 receptor tyrosine kinase inhibitor (solid tumors), Boehringer Ingelheim|afatinib|Tovok|Tomtovok|afatinib dimaleate|Giotrif|Gilotrif|Xovoltib",Research Code|USAN|INN|Trade Name|Trade Name|USAN|Trade Name|Trade Name|Trade Name,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Erbb3 tyrosine kinase receptor inhibitor|Erbb4 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3756|3758|3760|740,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Non-small-cell lung cancer|Transitional cell carcinoma|Adenocarcinoma|Pancreas tumor|Squamous cell carcinoma|Metastatic urinary tract cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Chordoma|Breast tumor|Solid tumor|Uterus tumor|Brain tumor,1262|1771|2399|249|307|3465|3665|3666|3667|3669|3673|3736|49|725|740|760,Glioma|Hormone refractory prostate cancer|Advanced solid tumor|Head and neck tumor|Colorectal tumor,1108|3246|3713|623|989,Boehringer Ingelheim (Canada) Ltd|Boehringer Ingelheim International GmbH,22582|14881,,,Boehringer Ingelheim International GmbH,14881,,,,,,
54452,rivoceranib mesylate,"VEGF receptor inhibitor (cancer), Advenchen|apatinib|VEGFR2 receptor inhibitor (cancer), LSK/ Jiangsu Henrui/ Bukwang|apatinib mesylate|rivoceranib|rivoceranib mesylate|YN-968D1|Aitan|VEGFR2 receptor inhibitor (uterine/cervical/ovarian cancer), Jiangsu Henrui",INN|USAN|Research Code|Trade Name,Cancer,Protein tyrosine kinase inhibitor|VEGF-2 receptor antagonist,385|3848,Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Anticancer,62255|61|1545,Glioma|Neuroendocrine tumor|Thyroid tumor|Small-cell lung cancer|Biliary cancer|Cholangiocarcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Osteosarcoma|Melanoma|T-cell lymphoma|Adenoid tumor|Hormone refractory prostate cancer|Soft tissue sarcoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic ovary cancer|Uterine cervix tumor|Breast tumor|Head and neck tumor|Solid tumor|Uterus tumor,1108|1128|1134|1261|1516|1765|1767|1768|1771|1772|205|311|3153|3246|3378|3658|3665|3666|3667|3866|427|49|623|725|740,Esophagus tumor|Stomach tumor|Cancer,1011|127|651,Jiangsu Hengrui Medicine Co Ltd|Elevar Therapeutics Inc,1006925|1045600,Advenchen Laboratories LLC|Bukwang Pharmaceutical Co Ltd,1017769|15280,Advenchen Laboratories LLC,1017769,,,,,,
54454,BI-2536,BI-2536|BI-2536-BS,Research Code|Research Code,Cancer,Polo-like kinase 1 inhibitor,4536,Cell cycle inhibitor|Apoptosis stimulator|Anticancer protein kinase inhibitor,767|1589|62255,,,Small-cell lung cancer|Non-small-cell lung cancer|Acute myelogenous leukemia|Pancreas tumor|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Head and neck tumor|Solid tumor,1261|1262|1731|249|319|3246|623|725,,,Boehringer Ingelheim International GmbH,14881,Boehringer Ingelheim International GmbH,14881,,,,,,
54469,vemurafenib,"B-Raf inhibitors (cancer), Plexxikon|PLX-3204|PLX-3331|PLX-4718|PLX-4720|PLx-4735|B-Raf inhibitors (cancer), Plexxikon/Roche|PLX-4032|R-7204|RG-7204|RO-5185426|vemurafenib|Zelboraf",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|PINN|Trade Name,Cancer|Hematologic,Raf B protein kinase inhibitor,4548,Apoptosis stimulator|Anticancer protein kinase inhibitor,1589|62255,Pituitary tumor|Chronic lymphocytic leukemia|Hairy cell leukemia|Cholangiocarcinoma|Sarcoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Histiocytosis,1131|1734|1736|1765|194|3257|3466|3658|3665|4682,Thyroid tumor|Multiple myeloma|Melanoma|Cancer|Solid tumor|Colorectal tumor,1134|1828|205|651|725|989,Chugai Pharmaceutical Co Ltd|Plexxikon Inc|Roche Holding AG,15414|29155|19446,,,Plexxikon Inc,29155,,,,,,
54485,xevinapant,"SM-122|SH-122|Smac mimetic (cancer), Ascenta|SM-164|SM-157|SM-406|SM-173|SM-163|SM-231|SM-186|SM-165|Smac mimetic SM-227|SM-1252|SM-1253|AT-406|SM-102|SM-130|Debio-1143|D-1143|xevinapant|smac mimetic (cancer), Merck KGaA",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN,Cancer|Infection,X-linked inhibitor of apoptosis protein inhibitor,13605,Anticancer|Synergist|Apoptosis stimulator|Antiviral|Radiochemosensitizer,1545|7293|1589|991|572,Small-cell lung cancer|Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|HIV infection|Squamous cell carcinoma|Metastatic colorectal cancer|Metastatic head and neck cancer|Advanced solid tumor|Mouth tumor|Pharynx tumor|Ovary tumor,1261|1262|1507|158|307|3658|3673|3713|793|794|799,Acute myelogenous leukemia|Breast tumor|Cancer,1731|49|651,Debiopharm SA|Merck KGaA,15620|18101,3SBio Inc|Ascenta Therapeutics Inc|Ascentage Pharma Group Corporation Ltd|University of Michigan,1016672|1017308|1052437|20623,University of Michigan,20623,,,,,,
54518,defactinib,"PF-941222|FAK inhibitors (cancer), Pfizer|VS-6063|defactinib|defactinib hydrochloride|PF-04554878|PF-4554878",Research Code|Research Code|USAN|INN|USAN|Research Code|Research Code,Cancer,Focal adhesion kinase inhibitor|Focal adhesion kinase-2 inhibitor,3540|3544,Apoptosis stimulator|Anticancer protein kinase inhibitor|Synergist|Anticancer,1589|62255|7293|1545,Mesothelioma|Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Endometrioid carcinoma|Pancreas tumor|Uveal melanoma|Ovary tumor|Colorectal tumor,1240|1262|1507|1705|249|3788|799|989,Cancer|Solid tumor,651|725,Verastem Oncology,1058061,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
54576,AFM-11,"AFM-11|anti-CD3/anti-CD19 tetravalent bispecific T-cell engager (TandAb, non-Hodgkin's lymphoma/acute lymphoblastic leukemia), Affimed|anti-CD19 and anti-CD3 TandAb (B-cell lymphoblastic leukemia), Affimed",Research Code,Cancer,CD3 modulator|B-lymphocyte antigen CD19 modulator,5023|5080,Natural killer T-lymphocyte stimulator|Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,173716|55685|7761|393,,,Acute lymphoblastic leukemia|Non-Hodgkin lymphoma,1728|319,,,Affimed NV,30783,Affimed NV,30783,,,,,,
54595,"genistein (oral suspension, radiotherapy-induced toxicity/ in SARS-CoV-2 infection (COVID-19)/pulmonary fibrosis), Humanetics","genistein|BIO-300|radioprotective therapy, Humanetics|genistein (oral suspension, radiotherapy-induced toxicity), Humanetics|BIO-300 MCM|genistein (oral suspension, radiotherapy-induced toxicity/ in SARS-CoV-2 infection (COVID-19)/pulmonary fibrosis), Humanetics",USAN|INN|Research Code|Research Code,Infection|Respiratory|Toxicity/Intoxication,,,Apoptosis inhibitor|Unspecified drug target|Antioxidant agent|Immunostimulant|Anti-inflammatory|Antiviral|Radioprotectant,1590|59620|74|393|2953|991|1465,Coronavirus disease 19 infection|Radiation sickness|Pulmonary fibrosis,10406|367|708,,,Humanetics Corp,26811,Henry M Jackson Foundation for the Advancement of Military Medicine,17319,Henry M Jackson Foundation for the Advancement of Military Medicine,17319,,,,,,
54601,carfilzomib,"PR-171|proteasome inhibitors (hematological malignancies), Proteolix|epoxomicin derivative (anticancer), Proteolix|carfilzomib|ONO-7057|carfilzomib (intravenous/Captisol-enabled, cancer), Onyx/Ligand|Kyprolis",Research Code|USAN|INN|Research Code|Trade Name,Cancer|Hematologic,Ubiquitin inhibitor|Proteasome inhibitor,58716|4917,Anticancer|Synergist,1545|7293,Neuroendocrine tumor|Acute lymphoblastic leukemia|Multiple myeloma,1128|1728|1828,Small-cell lung cancer|Macroglobulinemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Renal cell carcinoma|Hematological neoplasm|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Cancer|Solid tumor,1261|1264|1734|1744|1753|1754|1766|2054|319|3246|651|725,Amgen Inc|Ono Pharmaceutical Co Ltd|Dr Reddy's Laboratories Ltd|BeiGene Co Ltd,14109|18681|29387|1063251,Proteolix Inc|Onyx Pharmaceuticals Inc|Yale University,1017655|18683|20703,Yale University,20703,,,,,,
54609,"picropodophyllin (oral suspension, cancer), Axelar/ Cadila","IGF-1 inhibitors, Axelar/Biovitrum|insulin-like growth factor 1 inhibitors, Axelar/Biovitrum|IGF-1 inhibitors, Karolinska/Biovitrum|BVT-51004|picropodophyllin|cyclolignan picropodophyllin|IGF-1R inhibitor (cancer), Karolinska|AXL-1717|picropodophyllin, Axelar/Biovitrum|PPP|picropodophyllin (cancer), Karolinska|picropodophyllin (cancer), Axelar|picropodophyllin (oral suspension, cancer), Axelar|picropodophyllin (oral suspension, cancer), Axelar/ Cadila",Research Code|Research Code,Cancer,Insulin-like growth factor 1 receptor antagonist,3252,Anticancer hormone antagonist|Anticancer protein kinase inhibitor|Cell cycle inhibitor,62254|62255|767,Glioma|Non-small-cell lung cancer|Astrocytoma|Solid tumor,1108|1262|2453|725,Multiple myeloma|Cancer|Colon tumor,1828|651|767,Axelar AB|Cadila Pharmaceuticals Ltd,1008849|30025,Swedish Orphan Biovitrum AB,28921,Axelar AB,1008849,,,,,,
54624,regorafenib,"DAST inhibitor (cancer), Bayer|BAY-81-1557|dual acting kinase inhibitor (cancer), Bayer|dual acting multikinase inhibitor (cancer), Bayer|dual acting signal transduction inhibitor (cancer), Bayer|DAST (cancer), Bayer|regorafenib|DAST inhibitor|BAY-73-4506|Stivarga|fluoro-sorafenib|Bai Wan Ge",Research Code|USAN|INN|Research Code|Trade Name|Trade Name,Cancer,Caspase-9 stimulator|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist|VEGF-3 receptor antagonist|Raf B protein kinase inhibitor|Raf 1 protein kinase inhibitor|PDGF receptor beta modulator|Caspase-3 stimulator|TIE tyrosine kinase receptor inhibitor|RET tyrosine kinase receptor family inhibitor|Kit tyrosine kinase inhibitor|FGF receptor antagonist|Tek tyrosine kinase receptor inhibitor,7321|3846|3848|3850|4548|4550|48490|7303|3832|3816|3808|168|3834,Synergist|Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Colony stimulating factor receptor antagonist,7293|62255|61|69505,Esophagus tumor|Stomach tumor|Pancreatic ductal adenocarcinoma|Biliary cancer|Hepatocellular carcinoma|Osteosarcoma|Angiosarcoma|Rhabdomyosarcoma|Glioblastoma|Anaplastic astrocytoma|Squamous cell carcinoma|Gallbladder tumor|Adenoid tumor|Gastrointestinal stromal tumor|Soft tissue sarcoma|Metastatic bladder cancer|Metastatic colorectal cancer|Metastatic esophageal cancer|Head and neck tumor|Pharynx tumor|Ovary tumor|Colorectal tumor,1011|127|1507|1516|1767|1772|2443|2448|2454|2567|307|3146|3153|3205|3378|3466|3658|3667|623|794|799|989,Non-small-cell lung cancer|Fallopian tube cancer|Pancreas tumor|Peritoneal tumor|Metastatic renal cell carcinoma|Solid tumor,1262|2243|249|3083|4250|725,Bayer Yakuhin Ltd|Bayer AG,14557|14455,,,Bayer AG,14455,,,,,,
54625,paclitaxel trevatide,"paclitaxel/AngioPep-2 conjugate, AngioChem|paclitaxel (blood-brain barrier crossing formulation), AngioChem|paclitaxel-peptide conjugate (brain tumors), AngioChem|ANG-1005|paclitaxel AngioPep-2 conjugate|GRN-1005|paclitaxel/AngioPep-2 conjugate, Geron|paclitaxel trevatide|SNG-1005",Research Code|Research Code|INN|Research Code,Cancer,LDL receptor related protein-1 modulator,10295,Microtubule stabilizer|Anticancer,2576|1545,Glioma|Metastatic non small cell lung cancer|Brain tumor,1108|3665|760,,,Xinogen (Hong Kong) Pharma Co Ltd|AngioChem Inc,1158631|1018183,Geron Corp,16315,AngioChem Inc,1018183,,,,,,
54654,Imprime PGG,"Imprime PGG|PGG-Betafectin|BTH-1677|Imprime|Betafectin|IRI-1677|CD32a activator/complement receptor 3 activator (cancer), Immuno Research|FcgRIIa activator/CR3 activator (cancer), Immuno Research",Trade Name|Trade Name|Research Code|Research Code|Trade Name|Research Code,Cancer|Immune|Infection,Immunoglobulin gamma Fc receptor IIA agonist|CD11b agonist|Integrin beta-2 agonist|C-type lectin domain protein 7A stimulator,27987|5050|5078|53760,Dendritic cell stimulator|Immunostimulant|Synergist|Monocyte stimulator|Neutrophil stimulator|Natural killer cell stimulator|Anticancer|Antiparasitic|Macrophage stimulator,173472|393|7293|7753|7759|7757|1545|2638|7751,Non-small-cell lung cancer|Melanoma|Schistosomiasis|Metastatic colorectal cancer|Breast tumor,1262|205|298|3658|49,Chronic lymphocytic leukemia|Pancreas tumor|Non-Hodgkin lymphoma|Metastatic head and neck cancer|Immune deficiency|Head and neck tumor|Cancer|Colorectal tumor,1734|249|319|3673|504|623|651|989,Immuno Research,29406,,,Immuno Research,29406,,,,,,
54658,K562/GM-CSF,"K562/GM-CSF|GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins",,Cancer,,,Anticancer|Therapeutic vaccine|Immunomodulator|Genetically engineered autologous cell vaccine,1545|12379|1596|4791,,,Esophagus tumor|Metastasis|Mesothelioma|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia|Multiple myeloma|Sarcoma|Thymus neoplasm|Breast tumor|Cancer|Lung tumor,1011|1069|1240|1272|1731|1735|1828|194|2938|49|651|755,,,Cell Genesys Inc|National Cancer Institute (NCI)|Johns Hopkins University,15334|20519|20596,Johns Hopkins University,20596,,,,,,
54662,"ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis","INCB-20|INCB-000020|JAK inhibitors (oral, myeloproliferative disorders), Incyte|INCB-18424 (oral, myeloproliferative disorders), Incyte|INCB-018424|INCB-18424 (oral, myeloproliferative disorders), Incyte/Novartis|ruxolitinib|ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis|ruxolitinib phosphate|INC-424 (oral, myeloproliferative disorders), Incyte|INC-424|INCB-18424|Jakavi|Jakafi",Research Code|Research Code|Research Code|USAN|INN|USAN|Research Code|Research Code|Trade Name|Trade Name,Cancer|Genitourinary/Sexual Function|Hematologic|Immune|Infection|Inflammatory|Other/Miscellaneous|Respiratory,Jak1 tyrosine kinase inhibitor|Jak2 tyrosine kinase inhibitor,3562|3564,Immunomodulator|Anticancer|Anti-inflammatory|Anticancer protein kinase inhibitor|Antiviral,1596|1545|2953|62255|991,Coronavirus disease 19 infection|Hodgkins disease|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Eosinophilia|Hypereosinophilic syndrome|Hematological neoplasm|Splenomegaly|Thrombocythemia|Polycythemia vera|Myelofibrosis|Squamous cell carcinoma|T-cell lymphoma|B-cell lymphoma|Systemic inflammatory response syndrome|Metastatic breast cancer|Cachexia|Breast disease|Graft versus host disease|Head and neck tumor|Respiratory distress syndrome,10406|161|1728|1731|1734|1735|1983|2036|2054|2223|2317|2319|2436|307|311|316|3220|3657|425|557|616|623|8,Non-small-cell lung cancer|Multiple myeloma|Inflammatory disease|Leukemia|Thalassemia major|Myeloproliferative disorder|Prostate tumor|Rheumatoid arthritis|Metastatic pancreas cancer|Breast tumor|Cancer|Solid tumor|Colorectal tumor,1262|1828|188|199|2371|273|276|291|3669|49|651|725|989,Novartis AG|Incyte Corp,23137|17216,,,Incyte Corp,17216,,,,,,
54694,ganetespib,"Hsp90 inhibitor (intravenous, cancer), Synta|ganetespib|STA-9090|Hsp90 inhibitor (intravenous, cancer), Madrigal|ADX-1612",USAN|INN|Research Code|Research Code,Cancer|Immune|Infection,Jak2 tyrosine kinase inhibitor|Kit tyrosine kinase inhibitor|STAT-3 inhibitor|STAT-5 inhibitor|Hsp 90 inhibitor,3564|3808|7967|7973|8012,Apoptosis stimulator|Antiviral|Anticancer protein kinase inhibitor|Angiogenesis inhibitor,1589|991|62255|61,Lymphoproliferative disease|Coronavirus disease 19 infection|Mesothelioma|Fallopian tube cancer|Carcinosarcoma|Peritoneal tumor|Ovary tumor,1037|10406|1240|2243|2614|3083|799,Esophagus tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Myelodysplastic syndrome|Acute myelogenous leukemia|Hepatocellular carcinoma|Multiple myeloma|Sarcoma|Melanoma|Hematological neoplasm|Pancreas tumor|Squamous cell carcinoma|Gastrointestinal stromal tumor|Stage IV melanoma|Metastatic non small cell lung cancer|Ocular melanoma|Metastatic ovary cancer|Breast tumor|Head and neck tumor|Cancer|Solid tumor|Colorectal tumor,1011|1261|1262|127|1272|1731|1767|1828|194|205|2054|249|307|3205|3257|3665|3789|3866|49|623|651|725|989,Aldeyra Therapeutics Inc,1025141,Madrigal Pharmaceuticals Inc,30180,Madrigal Pharmaceuticals Inc,30180,,,,,,
54730,sotatercept,"bone loss therapy, Acceleron|ACE-011|activin IIa receptor antagonist (anemia, bone loss), Acceleron|RAP-011|sotatercept|ActRIIA-IgG1|ACE-011d|activin IIa receptor antagonist (anemia, bone loss), Acceleron/Bristol-Myers Squibb",Research Code|Research Code|USAN|INN|Research Code,Cardiovascular|Genitourinary/Sexual Function|Hematologic|Musculoskeletal,Bone morphogenetic protein-11 ligand inhibitor|Activin type-II receptor antagonist,6876|4578,Hematopoietic stimulator|Osteoblast modulator|Antihypertensive|Bone resorption inhibitor|Synergist,610|12592|2657|89|7293,Anemia|Beta thalassemia|Myelofibrosis|Pulmonary artery hypertension|Diamond Blackfan anemia,17|2369|2436|3510|3834,Sickle cell anemia|End stage renal disease|Bone resorption,303|3251|3443,Acceleron Pharma Inc|Bristol-Myers Squibb Co,1009646|15065,Celgene Corp,15331,Acceleron Pharma Inc,1009646,,,,,,
54745,galinpepimut-S,"INNO-305|WT1 heteroclitic peptide (cancer), Innovive|anti-WT1 T-cells vaccine (cancer), Innovive|WT1 T-cell vaccine (cancer), Innovive|WT1 heteroclitic peptide (cancer), CytRx|anti-WT1 T-cells vaccine (cancer), CytRx|WT1 T-cell vaccine (cancer), CytRx|WT-1 cancer vaccine, Sellas|galinpepimut-S|SLS-001|WT-1 A1 + WT-1 122 long + WT-1 427 long + WT-1 331 long|WT-1 A1|WT-1 122 long|WT-1 427 long|WT-1 331 long|GPS",Research Code|USAN|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Wilms tumor protein modulator|Zinc finger protein transcription factor modulator,30009|7495,Therapeutic vaccine|T-lymphocyte stimulator|Anticancer,12379|7761|1545,Mesothelioma|Small-cell lung cancer|Acute myelogenous leukemia|Chronic myelocytic leukemia|Nephroblastoma|Multiple myeloma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic ovary cancer|Ovary tumor,1240|1261|1731|1735|1770|1828|3657|3658|3866|799,Prostate tumor|Breast tumor|Cancer|Lung tumor|Colorectal tumor,276|49|651|755|989,3D Medicines Corporation|SELLAS Life Sciences Group Inc,1120744|1089264,Innovive Pharmaceuticals Inc|CytRx Corp|Memorial Sloan-Kettering Cancer Center,1011256|15585|22122,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
54799,ARQ-621,"ARQ-300RP|ARQ-621|Eg5 kinesin-like protein inhibitors (cancer), ArQule",Research Code|Research Code,Cancer,Kinesin-like protein KIF11 inhibitor,11105,Anticancer,1545,,,Cancer,651,,,ArQule Inc,21554,ArQule Inc,21554,,,,,,
54804,nivolumab,"MDX-1106|anti-PD-1 antibody (cancer), Ono/Medarex/BMS|BMS-936558|nivolumab|ONO-4538|MDX-1106-04|Opdivo|89Zr-nivolumab|PD-1 checkpoint inhibitor (cancer), Bristol-Myers Squibb/Ono|NIVO|BMS-986298|BMS-936558-01",Research Code|Research Code|USAN|INN|Research Code|Research Code|Trade Name|Research Code|Research Code,Cancer|Infection,Programmed cell death protein 1 inhibitor,67136,Anticancer|Antiviral|Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,1545|991|393|7761|55685,Esophagus tumor|Bone tumor|Testis tumor|Rectal tumor|Sepsis|Mesothelioma|Gonad tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Myelodysplastic syndrome|Leukoplakia|Pancreatic ductal adenocarcinoma|Biliary cancer|Hepatitis C virus infection|Hodgkins disease|Endometrioid carcinoma|Acute myelogenous leukemia|Chronic leukemia|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|Peripheral T-cell lymphoma|Renal cell carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Osteosarcoma|Multiple myeloma|Sarcoma|Liver tumor|Melanoma|Hematological neoplasm|Anal tumor|Fallopian tube cancer|Bladder cancer|Adenocarcinoma|Liposarcoma|Glioblastoma|Pancreas tumor|Anaplastic astrocytoma|Carcinosarcoma|Prostate tumor|Squamous cell carcinoma|Peritoneal tumor|T-cell lymphoma|Gallbladder tumor|Non-Hodgkin lymphoma|Larynx tumor|Merkel cell carcinoma|Medullary thyroid cancer|Hormone dependent prostate cancer|Stage III melanoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic liver cancer|Metastatic bladder cancer|Metastatic renal cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic colon cancer|Metastatic head and neck cancer|Advanced solid tumor|Germ cell and embryonic cancer|Anaplastic thyroid cancer|Uveal melanoma|Ocular melanoma|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Salivary gland cancer|Breast tumor|Head and neck tumor|Solid tumor|Central nervous system tumor|Colon tumor|Mouth tumor|Pharynx tumor|Ovary tumor|Kaposis sarcoma|Colorectal tumor,1011|1012|1054|1055|114|1240|1244|1261|1262|127|1272|1278|1507|1516|153|161|1705|1731|1733|1734|1735|1745|1749|1750|1753|1766|1767|1768|1771|1772|1828|194|202|205|2054|2193|2243|2380|2399|2447|2454|249|2567|2614|276|307|3083|311|3146|319|3198|3235|3240|3247|3256|3257|3378|3462|3466|3467|3657|3658|3664|3665|3666|3667|3669|3672|3673|3713|3737|3769|3788|3789|3866|4250|427|4299|49|623|725|759|767|793|794|799|936|989,Cancer|Uterus tumor,651|740,Ono Pharmaceutical Co Ltd|Bristol-Myers Squibb Co,18681|15065,Medarex Inc,17968,Ono Pharmaceutical Co Ltd,18681,,,,,,
54825,"resveratrol (oral, metabolic disorders/MELAS/cancer), Sirtris","resveratrol|resveratrol (oral, metabolic disorders/MELAS/cancer), Sirtris|second generation oral resveratrol analogs (diabetes, obesity), Sirtris|SRT-501 analogs (diabetes, obesity), Sirtris|SRT-A|SRT-B|SRT-C|SRT-501",INN|Research Code|Research Code|Research Code|Research Code,Cancer|Endocrine/Metabolic|Musculoskeletal|Neurology/Psychiatric|Other/Miscellaneous,NAD-dependent deacetylase sirtuin-1 stimulator|PPAR gamma coactivator 1-alpha stimulator,12017|13228,Nootropic agent|Neuroprotectant|Hypoglycemic agent|Anticancer|Lipid metabolism stimulator|Superoxide synthesis inhibitor,284|1615|399|1545|14333|720,,,Huntingtons chorea|Neurodegenerative disease|Obesity|MELAS syndrome|Cancer|Non-insulin dependent diabetes|Diabetes mellitus,170|233|238|2543|651|837|97,,,Sirtris Pharmaceuticals Inc,1009740,Sirtris Pharmaceuticals Inc,1009740,,,,,,
54827,CWP-291,CWP-231|CW-231|CWP-231A|CWP-232291|CWP-291|KDDF-201310-14|KDDF-201408-09,Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Beta-catenin inhibitor,15709,Antiviral|Anti-inflammatory|Anticancer,991|2953|1545,Stomach tumor|Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Cancer|Chronic myelomonocytic leukemia,127|1272|1731|1828|651|6833,,,JW Pharmaceutical Corp|Theriac Pharmaceutical Corp,15411|1047914,Chugai Pharmaceutical Co Ltd,15414,JW Pharmaceutical Corp,15411,,,,,,
54829,"indatuximab ravtansine (multiple myeloma/solid tumors), Biotest","anti-CD138 mAb (multiple myeloma), Biotest|nBT062-SMCC-DM1|nBT062-SPDB-DM4|nBT062-SPP-DM1|indatuximab ravtansine|indatuximab ravtansine (multiple myeloma/solid tumors), Biotest|BT-062",Research Code|Research Code|Research Code|INN|Research Code,Cancer|Immune,ADP ribosyl cyclase-1 modulator|Syndecan-1 inhibitor,5134|5454,Anticancer monoclonal antibody|Immunotoxin|Microtubule inhibitor,55685|539|2575,,,Transitional cell carcinoma|Multiple myeloma|Rheumatoid arthritis|Metastatic bladder cancer|Metastatic breast cancer|Solid tumor,1771|1828|291|3466|3657|725,,,Biotest AG,13737,Biotest AG,13737,,,,,,
54845,seribantumab,"ErbB antibodies (cancer), Merrimack|EGFR antibodies (cancer), Merrimack|MM-1x1 program (iv, cancer), Merrimack|ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis|EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis|seribantumab|SAR-256212|MM-121",USAN|INN|Research Code|Research Code,Cancer,Neuregulin-1 ligand inhibitor|Epidermal growth factor receptor antagonist|Erbb3 tyrosine kinase receptor inhibitor,12668|740|3758,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Advanced solid tumor|Cancer,3713|651,Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic ovary cancer,3657|3665|3866,Elevation Oncology,1187967,Sanofi SA|Merrimack Pharmaceuticals Inc,1009547|27954,Merrimack Pharmaceuticals Inc,27954,,,,,,
54915,ganitumab,"IGF-1R antagonist (cancer), Amgen/Takeda|AMG-479|insulin-like growth factor 1 antagonist (cancer), Amgen/Takeda|ganitumab",Research Code|USAN|INN,Cancer,Insulin-like growth factor 1 receptor antagonist|AKT protein kinase inhibitor,3252|3859,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Ewing sarcoma,2975,Neuroendocrine tumor|Small-cell lung cancer|Non-small-cell lung cancer|Pancreas tumor|Breast tumor|Cancer|Ovary tumor|Colorectal tumor,1128|1261|1262|249|49|651|799|989,NantCell Inc,1104834,NANTiBody LLC|Amgen Inc|Takeda Pharmaceutical Co Ltd|Takeda Bio Development Center Ltd,1112625|14109|20300|23215,Amgen Inc,14109,,,,,,
54918,FBT-A05,"trifunctional antibody therapy (blood malignancy), Fresenius/Trion|TPBs-05|Lymphomun|anti-CD20 bivalent monoclonal antibody (B-cell lymphoma, Triomab), Trion/Fresenius|FBT-A05|Bi-20|anti-CD3/anti-CD20 T-cell engager (Triomab, hematological cancer), Lindis",Research Code|Trade Name|Research Code|Research Code,Cancer,CD3 modulator|B-lymphocyte antigen CD20 modulator,5023|5083,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,,,Chronic lymphocytic leukemia|Hematological neoplasm|Non-Hodgkin lymphoma,1734|2054|319,,,Neovii Biotech GmbH|TRION Research GMBH|TRION Pharma GmbH,1011051|1065594|30224,TRION Pharma GmbH,30224,,,,,,
54931,CP-870893,"CD40 ligand (cancer), Pfizer|CP-870893|fully human CD40 agonist antibody, Pfizer|CD40 costimulator (cancer), Pfizer",Research Code,Cancer,CD40 ligand receptor agonist,5141,Immunostimulant|Dendritic cell stimulator|Macrophage stimulator|B-lymphocyte stimulator|Anticancer monoclonal antibody,393|173472|7751|7741|55685,,,Cancer,651,,,VLST Corp|Pfizer Inc,1024603|18767,Pfizer Inc,18767,,,,,,
54934,AZD-4877,"AZD-4877|anticancer therapeutic (solid tumors), AstraZeneca",Research Code,Cancer,Kinesin-like protein KIF11 inhibitor,11105,Cell cycle inhibitor|Anticancer protein kinase inhibitor,767|62255,,,Acute myelogenous leukemia|Bladder cancer|Solid tumor,1731|2380|725,,,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
5498,sovateltide,"IRL-1620|endothelin B agonists, Spectrum/Chicago|SPI-1620|ENDG-5010|ENDG-4020|PMZ-1620|Sovateltide|sovateltide",Research Code|Research Code|Research Code|Research Code|Research Code|INN|INN,Cancer|Cardiovascular|Neurology/Psychiatric,Endothelin ET-B receptor agonist,3163,Diuretic agent|Anticancer chemosensitizer|Neuroprotectant,137|1586|1615,Spinal cord injury|Alzheimers disease|Motor neurone disease|Ischemic stroke,1258|14|212|3676,Non-small-cell lung cancer|Biliary tumor|Cardiovascular disease|Stroke|Cancer|Neurological disease|Vascular disease|Brain injury,1262|1515|57|65|651|677|742|834,Pharmazz Inc,1093754,Chicago Labs Inc|EndogenX Inc|University of Illinois|Spectrum Pharmaceuticals Inc|Ciba-Geigy AG,1012584|1052174|20592|24232|24437,University of Illinois,20592,,,,,,
55085,filanesib,"ARRY-649|KSP inhibitors (cancer), Array|kinesin spindle protein inhibitors (cancer), Array|ARRY-520|filanesib|filanesib hydrochloride",Research Code|Research Code|USAN|INN|USAN,Cancer,Kinesin-like protein KIF11 inhibitor,11105,Cell cycle inhibitor|Synergist|Apoptosis stimulator,767|7293|1589,,,Acute myelogenous leukemia|Multiple myeloma|Cancer|Solid tumor,1731|1828|651|725,,,Array BioPharma Inc,25902,Array BioPharma Inc,25902,,,,,,
55105,"futuximab + modotuximab (cancer), Symphogen","chimeric IgG1 antibody 992 (cancer), Symphogen|chimeric IgG1 antibody 1024 (cancer), Symphogen|chimeric IgG1 antibodies 992 + 1024 (cancer), Symphogen|futuximab + modotuximab (cancer), Symphogen|modotuximab + futuximab (cancer), Symphogen|Sym-004, Symphogen",,Cancer,Epidermal growth factor receptor antagonist,740,Synergist|Anticancer monoclonal antibody|Cell cycle inhibitor|Apoptosis stimulator|Anticancer protein kinase inhibitor,7293|55685|767|1589|62255,Non-small-cell lung cancer|Glioblastoma|Squamous cell carcinoma|Metastatic colorectal cancer|Head and neck tumor|Solid tumor,1262|2454|307|3658|623|725,Esophagus tumor|Cancer,1011|651,Symphogen A/S,28600,Merck KGaA,18101,Symphogen A/S,28600,,,,,,
55106,Poly-ICLC,"Hiltonol|polyinosinic-polycytidilic acid|Poly-ICLC|interferon inducer (cancer/viral diseases), Oncovir|NSC-301463",Trade Name|Trade Name|Research Code,Cancer|Infection|Neurology/Psychiatric,Interferon agonist|TLR-3 agonist,212|7809,Immunostimulant|IL release stimulator|Corticosteroid agonist|Natural killer cell stimulator|Immunomodulator|Antiviral|TNF release modulator|T-lymphocyte stimulator|Anticancer,393|4994|3189|7757|1596|991|3510|7761|1545,Glioma|Mesothelioma|Non-Hodgkin lymphoma|Stage IV melanoma|Viral infection|Metastatic colon cancer|Stroke|Cancer|Solid tumor,1108|1240|319|3257|344|3672|65|651|725,Metastatic pancreas cancer,3669,Oncovir Inc,1006413,,,Oncovir Inc,1006413,,,,,,
55153,vintafolide,EC-145|EC-0255|EC-0260|vintafolide|MK-8109|Vynfinit,Research Code|Research Code|Research Code|USAN|INN|Research Code|Trade Name,Cancer,Folate receptor modulator,1323,Folate modulator|Microtubule inhibitor|Anticancer alkylating agent,805|2575|50,,,Non-small-cell lung cancer|Endometrioid carcinoma|Advanced solid tumor|Cancer|Lung tumor|Ovary tumor,1262|1705|3713|651|755|799,,,Merck & Co Inc|Endocyte Inc,18077|26000,Endocyte Inc,26000,,,,,,
55164,"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech","L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech|Graspa|ERY-ASP|ERY-001|eryaspase",Trade Name|Research Code,Cancer,Asparaginase stimulator,517,Anticancer,1545,Pancreatic ductal adenocarcinoma|Acute lymphoblastic leukemia|Metastatic breast cancer|Metastatic pancreas cancer|Solid tumor,1507|1728|3657|3669|725,Acute myelogenous leukemia|Pancreas tumor|Non-Hodgkin lymphoma|Cancer,1731|249|319|651,ERYtech Pharma SA,1019305,Teva Pharmaceutical Industries Ltd|Orphan Europe SARL,20348|24064,ERYtech Pharma SA,1019305,,,,,,
55169,Cresemba,"BAL-8557|BAL-8349|antifungals, Basilea|BAL-8557 (intravenous), Basilea|RO-0098557|isavuconazole|isavuconazonium chloride|isavuconazonium chloride/sulfate (intravenous), Basilea/Astellas|isavuconazonium sulfate|isavuconazonium|Cresemba|AK-1820",Research Code|Prodrug|Research Code|Research Code|Prodrug|INN|INN|USAN|USAN|Trade Name|Research Code,Infection,,,Synergist|Fungicide|Ergosterol synthesis inhibitor,7293|1748|161,Fungal infection|Zygomycete infection|Mucor infection|Aspergillus infection,124|1370|1380|29,Candida infection,1308,Basilea Pharmaceutica International Ltd|Pfizer Inc|Hikma Pharmaceuticals plc|Unimedic AB|Biotoscana International|Astellas Pharma Inc|Avir Pharma Inc|Asahi Kasei Pharma Corp,28104|18767|1022379|1074739|1063950|1013295|1149364|14303,,,Basilea Pharmaceutica International Ltd,28104,,,,,,
55173,Mycobacterium w,"cadi-05|poly-toll-like receptor agonist polyantigenic vaccine (cancer), Cadila|poly-TLR agonist polyantigenic vaccine (cancer), Cadila|Mycobacterium w|Cadi-Mw|poly-TLR agonist polyantigenic vaccine (COVID-19), Cadila|Sepsivac",Research Code|Trade Name|Trade Name,Cancer|Infection,TLR-9 agonist|TLR-4 agonist|TLR-2 agonist|Interferon gamma receptor agonist|MAPK gene modulator,7827|7812|7806|215|18476,Anticancer|Antiviral|Therapeutic vaccine|Antibacterial|Adjuvant,1545|991|12379|1594|524,Coronavirus disease 19 infection,10406,Non-small-cell lung cancer|Mycobacterium tuberculosis infection|Bladder cancer|Hormone refractory prostate cancer|Stage III melanoma|Stage IV melanoma|Cancer,1262|221|2380|3246|3256|3257|651,Cadila Pharmaceuticals Ltd,30025,,,Cadila Pharmaceuticals Ltd,30025,,,,,,
55219,"multipotent adult progenitor cell therapy (multiple sclerosis/ARDS/GvHD/Traumatic brain injury/stroke/spinal cord injury/immune disorder/myocardial infarction/COVID-19/pneumonia/ocular disease), Athersys/Healios","MultiStem|multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer|MAPC (ischemia/cerebral palsy), Athersys|MAPC (ischemia/cerebral palsy), Athersys/ Angiotech|multipotent adult progenitor cell therapy (ischemia/cerebral palsy), Athersys/ Angiotech|multipotent adult progenitor cell therapy (graft versus host disease), Athersys|multipotent adult progenitor cell therapy (spinal cord injury/traumatic brain injury), Athersys|multipotent adult progenitor cell therapy (inflammatory bowel disease), Athersys|multipotent adult progenitor cell therapy (inflammatory bowel disease), Pfizer|PF-05285401|multipotent adult progenitor cell therapy (Parkinson's disease), Athersys|MultiStem (Parkinson's disease), Athersys|multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD/MS), Athersys/Angiotech/Pfizer|multipotent adult progenitor cell therapy (multiple sclerosis), Athersys|MultiStem (acute respiratory distress syndrome), Athersys|multipotent adult progenitor cell therapy (ischemia/cerebral palsy), Athersys/ Healios|HLCM-051|multipotent adult progenitor cell therapy (ischemia/ARDS/ocular diseases), Athersys/ Healios|somatic stem cell regenerative therapy, HEALIOS|multipotent adult progenitor cell therapy (multiple sclerosis/ARDS/GvHD/Traumatic brain injury/stroke/spinal cord injury/immune disorder/myocardial infarction/COVID-19/pneumonia/ocular disease), Athersys/Healios|invimestrocel",Trade Name|Research Code|Research Code|PINN,Cardiovascular|Endocrine/Metabolic|Gastrointestinal|Immune|Infection|Inflammatory|Neurology/Psychiatric|Ocular|Respiratory,,,Neuroprotectant|Gastrointestinal system agent|Immunosuppressant|Angiogenesis inhibitor|Anti-inflammatory|Antiviral|Antiparkinsonian|Respiratory system agent|Cerebroprotectant|Hypoglycemic agent,1615|1332|396|61|2953|991|2947|1470|7266|399,Coronavirus disease 19 infection|Spinal cord injury|Immune disorder|Influenza virus infection|Multiple sclerosis|Myocardial infarction|Ocular disease|Multiple organ failure|Systemic inflammatory response syndrome|Pneumonia|Traumatic brain injury|Graft versus host disease|Stroke|Respiratory distress syndrome,10406|1258|185|191|213|224|239|3094|3220|360|3733|616|65|8,Congestive heart failure|Inflammatory bowel disease|Mucopolysaccharidosis type I|Parkinsons disease|Peripheral vascular disease|Cerebral palsy|Ulcerative colitis|Diabetes mellitus,1559|189|2250|255|260|2620|337|97,Healios KK|Athersys Inc,1071594|24760,Chugai Pharmaceutical Co Ltd|Angiotech Pharmaceuticals Inc|Pfizer Inc,15414|16022|18767,Athersys Inc,24760,,,,,,
55228,AF-122,"imidazole-substituted sterol derivatives, AFFICHEM/INSERM|dendrogenin A|AF-122|DDA, Affichem|dendrogenine A",Research Code,Cancer,Liver X receptor modulator,4029,Angiogenesis inhibitor|Cell differentiation stimulator|Immunostimulant|Cell cycle inhibitor,61|53574|393|767,Cancer,651,,,INSERM|Affichem USA Inc,17229|1118355,Affichem,1020182,INSERM,17229,,,,,,
55237,ibrutinib,"B-cell associated tyrosine kinase inhibitors (lymphoma, autoimmune disease), Pharmacyclics|PCI-32765|PCI-31523|B-cell-associated tyrosine kinase inhibitors (lymphoma, autoimmune disease), Celera|Btk inhibitors (autoimmune disease, lymphoma), Pharmacyclics|PCI-45261|B-cell-associated tyrosine kinase inhibitor (cancer), Pharmacyclics/Janssen Biotech|Btk inhibitor (cancer), Pharmacyclics/Janssen Biotech|ibrutinib|CRA-032765|Imbruvica|JNJ-54179060|Yi Ke",Research Code|Research Code|Research Code|USAN|INN|Research Code|Trade Name|Research Code|Trade Name,Cancer|Immune|Infection|Musculoskeletal|Respiratory,Btk tyrosine kinase inhibitor,3592,B-lymphocyte migration inhibitor|Anticancer protein kinase inhibitor|Respiratory system agent|Antiviral|Anti-inflammatory|Synergist|B-lymphocyte adhesion inhibitor|Cell cycle inhibitor|Chemotaxis inhibitor|Apoptosis stimulator,5710|62255|1470|991|2953|7293|5704|767|5580|1589,Coronavirus disease 19 infection|Neuroendocrine tumor|Stomach tumor|Myelodysplastic syndrome|B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Hairy cell leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Primary mediastinal large B-cell lymphoma|Renal cell carcinoma|Transitional cell carcinoma|Multiple myeloma|Carcinoid tumor|T-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Systemic mastocytosis|Metastatic renal cell carcinoma|Breast tumor|Graft versus host disease|Central nervous system tumor|Respiratory distress syndrome|Colorectal tumor,10406|1128|127|1272|1729|1734|1736|1743|1744|1745|1746|1750|1766|1771|1828|2538|311|316|319|3658|3665|3669|3728|4250|49|616|759|8|989,Allergic rhinitis|Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Lymphoma|Pancreas tumor|Autoimmune disease,1107|1731|1749|203|249|36,AbbVie Inc|Janssen Biotech Inc|Johnson & Johnson|Pharmacyclics Inc|Celera Group,1072507|26997|17332|19063|27836,,,Celera Group,27836,,,,,,
55250,evofosfamide,"TH-63|hypoxia-activated daunorubicin prodrugs (cancer), Threshold|TH-302|HAP-302|dibromo isophosphoramide mustard|evofosfamide|hypoxia-activated daunorubicin prodrugs (cancer), Molecular|evofosfamide, ImmunoGenesis",Research Code|Research Code|Research Code|USAN|INN,Cancer,Topoisomerase II inhibitor,142,Bioreducible cytotoxin|Anticancer alkylating agent,1585|50,Pancreatic ductal adenocarcinoma|Pancreas tumor|Squamous cell carcinoma|Hormone refractory prostate cancer|Head and neck tumor,1507|249|307|3246|623,Neuroendocrine tumor|Non-small-cell lung cancer|Biliary cancer|Hepatocellular carcinoma|Multiple myeloma|Leukemia|Melanoma|Astrocytoma|Gastrointestinal stromal tumor|Stage IV melanoma|Soft tissue sarcoma|Metastatic renal cell carcinoma|Cancer|Solid tumor,1128|1262|1516|1767|1828|199|205|2453|3205|3257|3378|4250|651|725,ImmunoGenesis Inc,1196113,Merck Serono SA|Molecular Templates Inc,19862|30181,Molecular Templates Inc,30181,,,,,,
55265,onalespib,"Hsp 90 inhibitors (iv/infusion, cancer), Astex|AT-13387|AT-12128|AT-13387AU|onalespib|onalespib lactate|AT13387A",Research Code|Research Code|Research Code|USAN|INN|USAN|Research Code,Cancer,Hsp 90 inhibitor,8012,Anticancer,1545,,,Non-small-cell lung cancer|Melanoma|Glioblastoma|Gastrointestinal stromal tumor|Hormone refractory prostate cancer|Cancer,1262|205|2454|3205|3246|651,,,Astex Pharmaceuticals Inc|Astex Therapeutics Ltd,21885|28026,Astex Therapeutics Ltd,28026,,,,,,
55283,Rh-Apo2L,"rh-Apo21|Apo21 (TRAIL) cancer gene therapy, Shanghai Qiaer Bio-Technology|Apo21 (TRAIL) cancer gene therapy, Aida|Rh-Apo2L|Apo21 (TRAIL) cancer gene therapy, Gebaide Bio-tech|Dulanaming",Research Code|Research Code,Cancer,TNF related apoptosis inducing ligand modulator,13588,Anticancer|Apoptosis inhibitor,1545|1590,Non-small-cell lung cancer|Stomach tumor|Pancreas tumor|Non-Hodgkin lymphoma|Cancer|Renal tumor,1262|127|249|319|651|999,,,Shanghai Gebaide Bio-tech Co Ltd,1090457,Shanghai Qiaer Bio-Technology Co Ltd,1020577,Shanghai Qiaer Bio-Technology Co Ltd,1020577,,,,,,
55287,"SD-101, TriSalus","HCV-ISS|HCV vaccine (ISS), Dynavax/Symphony Dynamo|SD-101, Dynavax|SD-101, TriSalus|TLR9 agonist (CpG-C class oligodeoxynucleotide vaccine, advanced solid tumors), TriSalus",Research Code,Cancer|Infection,Interleukin-29 ligand modulator|TLR-9 agonist|Interferon type I receptor agonist|Interferon alpha ligand modulator,14550|7827|8503|917,Antiviral|Anticancer|Therapeutic vaccine|Adjuvant,991|1545|12379|524,Pancreatic ductal adenocarcinoma|Stage IV melanoma|Metastatic liver cancer|Metastatic colorectal cancer|Metastatic pancreas cancer|Uveal melanoma|Breast tumor,1507|3257|3462|3658|3669|3788|49,Metastasis|Hepatitis C virus infection|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Lymphoma|Adenocarcinoma|B-cell lymphoma|Head and neck tumor|Cancer,1069|153|1743|1744|1745|1746|203|2399|316|623|651,TriSalus Life Sciences,1062820,Symphony Dynamo Inc|Dynavax Technologies Corp,1043091|24774,Dynavax Technologies Corp,24774,,,,,,
55288,trametinib,"MEK inhibitor (cancer, inflammation), GlaxoSmithKline|Erk inhibitor (cancer, inflammation), Japan Tobacco/GlaxoSmithKline|Mark inhibitor (cancer, inflammation), Japan Tobacco/GlaxoSmithKline|GSK-1120212|MEK inhibitor (oral, cancer), GlaxoSmithKline|JTP-74057 DMSO|GSK-1120212B|GSK-212|trametinib DMSO|trametinib dimethyl sulfoxide|trametinib|Mekinist|NSC-763093|TMT-212",Research Code|Research Code|Research Code|Research Code|USAN|INN|Trade Name|Research Code|Research Code,Cancer|Inflammatory,MEK-1 protein kinase inhibitor|MEK-2 protein kinase inhibitor,4762|4764,Anticancer protein kinase inhibitor|Synergist|Anticancer,62255|7293|1545,Glioma|Thyroid tumor|Non-small-cell lung cancer|Biliary cancer|Hairy cell leukemia|Multiple myeloma|Leukemia|Melanoma|Adenocarcinoma|Pancreas tumor|Gastrointestinal stromal tumor|Stage III melanoma|Stage IV melanoma|Neurofibromatosis type I|Metastatic colorectal cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Metastatic rectal cancer|Metastatic colon cancer|Germ cell and embryonic cancer|Anaplastic thyroid cancer|Uterine cervix tumor|Solid tumor,1108|1134|1262|1516|1736|1828|199|205|2399|249|3205|3256|3257|3521|3658|3664|3665|3671|3672|3737|3769|427|725,Inflammatory disease|Lymphoma|Cancer|Colorectal tumor,188|203|651|989,Novartis AG,23137,Japan Tobacco Inc|GlaxoSmithKline plc,17327|28355,Japan Tobacco Inc,17327,,,,,,
55293,P-276-00,"P-276-00|CDK4 inhibitor (cancer), Nicholas Piramal|P-664-02|CDK4 inhibitor (iv, cancer), NPIL Research & Development|CDK4 inhibitor (iv, cancer), Piramal|P-276|riviciclib",Research Code|Research Code|Research Code|INN,Cancer|Gastrointestinal,Cyclin-dependent kinase inhibitor 1B inhibitor|Cyclin-dependent kinase-4 inhibitor|Cyclin D1 inhibitor|Cyclin T inhibitor|Cyclin-dependent kinase-9 inhibitor,14217|4314|9488|9477|8110,Anticancer protein kinase inhibitor|Anti-inflammatory|Cell cycle inhibitor,62255|2953|767,,,Mucositis|Mantle cell lymphoma|Multiple myeloma|Melanoma|Pancreas tumor|Breast tumor|Head and neck tumor|Cancer,1263|1744|1828|205|249|49|623|651,,,Life Molecular Imaging|Piramal Phytocare Ltd,1006437|1037717,Life Molecular Imaging,1006437,,,,,,
55305,binimetinib,"MEK-1/2 inhibitors (tablet, inflammation, cancer), Array|binimetinib|ARRY-162|ARRY-438162|MEK-162|COMBO450|Balimek|ONO-7703|Mektovi",USAN|INN|Research Code|Research Code|Research Code|Research Code|Trade Name,Cancer|Cardiovascular|Immune|Inflammatory,MEK-1 protein kinase inhibitor|MEK protein kinase inhibitor|BRAF gene inhibitor|MEK-2 protein kinase inhibitor|PERK gene inhibitor,4762|4760|19457|4764|82203,Anticancer protein kinase inhibitor|Cell cycle inhibitor,62255|767,Thyroid tumor|Non-small-cell lung cancer|Multiple myeloma|Adenocarcinoma|Pancreas tumor|Gastrointestinal stromal tumor|Stage III melanoma|Stage IV melanoma|Neurofibromatosis type I|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,1134|1262|1828|2399|249|3205|3256|3257|3521|3658|3665|3713,Inflammatory disease|Noonan syndrome|Fallopian tube cancer|Prostate tumor|Rheumatoid arthritis|Peritoneal tumor|Uveal melanoma|Cancer|Ovary tumor|Colorectal tumor,188|2136|2243|276|291|3083|3788|651|799|989,Pierre Fabre Group|Medison Pharma Ltd|Ono Pharmaceutical Co Ltd|Array BioPharma Inc,19087|29943|18681|25902,Novartis AG,23137,Array BioPharma Inc,25902,,,,,,
55307,ficlatuzumab,"humanized anti-human growth factor monoclonal antibody (iv, cancer), AVEO/Merck & Co|anti-HGF (cancer), Schering-Plough/AVEO|anti-HGF (cancer), Merck & Co/AVEO|AVEO-299|ficlatuzumab|AV-299|SCH-900105",Research Code|USAN|INN|Research Code|Research Code,Cancer,Hepatocyte growth factor receptor antagonist,675,Anticancer|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,1545|55685|62255,Nasopharyngeal carcinoma|Nasal cancer|Pancreas tumor|Squamous cell carcinoma|Head and neck tumor|Mouth tumor|Pharynx tumor,1768|2347|249|307|623|793|794,Non-small-cell lung cancer|Acute myelogenous leukemia|Multiple myeloma|Cancer|Solid tumor,1262|1731|1828|651|725,AVEO Oncology,29820,Merck & Co Inc|Schering-Plough Corp,18077|19711,AVEO Oncology,29820,,,,,,
55314,FP-1039,"FPT-039|modified growth factor receptor (cancer), FivePrime Therapeutics|FP-1039|FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics|FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences|HGS-1036|GSK-3052230|3052330",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,FGF1 receptor antagonist,3682,Synergist|Anticancer protein kinase inhibitor|Angiogenesis inhibitor,7293|62255|61,,,Mesothelioma|Non-small-cell lung cancer|Endometrioid carcinoma|Cancer,1240|1262|1705|651,,,Five Prime Therapeutics Inc|Human Genome Sciences Inc|GlaxoSmithKline plc,1007248|17002|28355,Five Prime Therapeutics Inc,1007248,,,,,,
55361,yttrium Y 90 epratuzumab,"90Y-epratuzumab|111In-epratuzumab|yttrium-90-epratuzumab|indium-111-epratuzumab|epratuzumab (radiolabeled), Immunomedics|yttrium Y 90 epratuzumab|IMMU-102|yttrium Y 90 epratuzumab tetraxetan|90Y-epratuzumab tetraxetan|epratuzumab tetraxetan-[90Y]|Y90-epratuzumab|90Y-LymphoCide|yttrium-90-LymphoCide|epratuzumab-[111In]|epratuzumab-[90Y]|90Y-DOTA-hLL2",USAN|Research Code|USAN|Trade Name|Trade Name,Cancer,B-lymphocyte cell adhesion molecule inhibitor,5091,Anticancer monoclonal antibody|Radioimmunotherapeutic,55685|1552,,,Acute lymphoblastic leukemia|Non-Hodgkin lymphoma,1728|319,,,Immunomedics Inc,17204,Immunomedics Inc,17204,,,,,,
55408,"WT1 peptide vaccine (cancer), Charity Medical School of the Humboldt University of Berlin","WT1 peptide vaccine (cancer), Charity Medical School of the Humboldt University of Berlin|cancer vaccine (Wilms tumor gene 1 + KLH + GM-CSF advuvants), Humboldt University of Berlin",,Cancer,WT1 gene modulator,30012,Therapeutic vaccine|Anticancer,12379|1545,,,Leukemia,199,,,Charite Universitaetsmedizin Berlin,30065,Charite Universitaetsmedizin Berlin,30065,,,,,,
55435,PAT-SM6,"SAM-6|human Immunoglobulin-M antibody (pancreatic cancer), Acceptys|human monoclonal  IgM antibody (pancreatic cancer), Acceptys|PAT-SM6|human monoclonal IgM antibody (pancreatic cancer), Patrys|PAT-SAM6|human monoclonal IgM antibody (multiple myeloma/melanoma/cancer), Patrys",Research Code|Research Code|Research Code,Cancer,Grp78 calcium binding protein inhibitor|T-cell surface glycoprotein CD8 stimulator|Immunoglobulin M agonist,13395|5039|5741,LDL cholesterol modulator|Natural killer cell stimulator|Anticancer monoclonal antibody|Apoptosis stimulator,2516|7757|55685|1589,,,Multiple myeloma|Melanoma|Cancer,1828|205|651,,,Patrys Ltd|OncoMab GmbH|Acceptys Inc,1034206|30029|30814,OncoMab GmbH,30029,,,,,,
55529,samalizumab,"anti-CD200 mAb (CLL, multiple myeloma), Alexion|samalizumab|ALXN-6000|CD200 checkpoint inhibitor (cancer), Alexion Pharmaceuticals",USAN|INN|Research Code,Cancer,Membrane glycoprotein OX2 inhibitor,32580,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,,,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Multiple myeloma|Cancer|Solid tumor,1731|1734|1828|651|725,,,Alexion Pharmaceuticals Inc,13979,Alexion Pharmaceuticals Inc,13979,,,,,,
55541,18F-ML-10,18F-ML-10|ApoSense-PET|fluorine-18-ML-10|ApoSense [18F]-ML-10|18F-NST-ML-10|fluorine-18-NST-ML-10|ML-10-[18F]|Aposense ML-10|F-ML-10,Research Code|Trade Name|Trade Name|Research Code|Research Code|Research Code,Cancer|Cardiovascular|Neurology/Psychiatric,,,Immune diagnostic agent|PET contrast agent|Neoplasm diagnostic agent|Radiodiagnostic|CNS diagnostic agent|Cardiovascular diagnostic agent|Endocrine diagnostic agent,7215|5555|7220|5720|7211|7210|7212,,,Small-cell lung cancer|Non-Hodgkin lymphoma|Breast tumor|Head and neck tumor|Heart disease|Stroke|Lung tumor|Brain tumor|Ovary tumor,1261|319|49|623|626|65|755|760|799,,,Aposense Ltd,26957,Aposense Ltd,26957,,,,,,
55559,fluciclovine (18F),"syn-18F-FACBC|18F-labeled PET tracers (imaging agent), Emory|fluorine-18-labeled PET tracers (imaging agent), Emory|fluorine-18-syn-FACBC|NMK-36|GE-148-[18F]|18F-GE-148|fluorine-18-GE-148|18F-FACBC|fluorine-18-FACBC|FACBC-[18F]|fluciclovine (18F)|[18F]-fluciclovine|fluorine-18-fluciclovine|anti-18F-FACBC|fluciclovine F18|Axumin",Research Code|Research Code|Research Code|Research Code|INN|Trade Name,Cancer,,,Radiodiagnostic|Neoplasm diagnostic agent|Anticancer|Endocrine diagnostic agent|PET contrast agent,5720|7220|1545|7212|5555,Glioma|Transitional cell carcinoma|Bladder cancer|Prostate tumor|Metastatic breast cancer|Metastatic prostate cancer|Ovary tumor,1108|1771|2380|276|3657|3664|799,Cancer,651,Nihon Medi-Physics Co Ltd|Emory University|IASON Sp. z o.o.|DuChemBio Co Ltd|Blue Earth Diagnostics Ltd,26383|20573|1166815|1090216|1102488,GE Healthcare,25593,Emory University,20573,,,,,,
55560,birinapant,"Smac mimetics (cancer), TetraLogic|inhibitor of apoptosis protein antagonists (cancer), TetraLogic|XIAP antagonists (cancer), TetraLogic|GT-13065|TL-132711|birinapant|TL-32711|NSC-756502",Research Code|Research Code|USAN|INN|Research Code|Research Code,Cancer|Infection,Inhibitor of apoptosis protein 2 inhibitor|Inhibitor of apoptosis protein 1 inhibitor|X-linked inhibitor of apoptosis protein inhibitor|SMAC protein stimulator,13599|13602|13605|14457,Anticancer|Antiviral|Synergist|Apoptosis stimulator,1545|991|7293|1589,Squamous cell carcinoma|Solid tumor,307|725,Mesothelioma|Small-cell lung cancer|Stomach tumor|Myelodysplastic syndrome|Hepatitis B virus infection|Acute myelogenous leukemia|Cholangiocarcinoma|Fallopian tube cancer|Peritoneal tumor|Uterine cervix tumor|Head and neck tumor|Cancer|Chronic myelomonocytic leukemia|Ovary tumor|Colorectal tumor,1240|1261|127|1272|152|1731|1765|2243|3083|427|623|651|6833|799|989,IGM Biosciences Inc,1014332,TetraLogic Pharmaceuticals Corp|Medivir AB|Walter and Eliza Hall Institute of Medical Research,1021367|18015|21082,TetraLogic Pharmaceuticals Corp,1021367,,,,,,
55609,"olmesartan medoxomil + amlodipine besylate  (hypertension), Daiichi Sankyo","olmesartan + amlodipine (hypertension), Daiichi Sankyo|olmesartan medoxomil + amlodipine besylate|Sevikar|Azor|olmesartan medoxomil + amlodipine besylate  (hypertension), Daiichi Sankyo|Zolnor|Konverge",Trade Name|Trade Name|Trade Name|Trade Name,Cardiovascular,Angiotensin II receptor antagonist|Calcium channel inhibitor,64|93,Antihypertensive,2657,Hypertension,178,,,Daiichi Seiyaku Co Ltd|Merck Sharp & Dohme Pty Ltd|The Menarini Group|Daiichi Sankyo Co Ltd|Pfizer Inc|Daewoong Pharmaceutical Co Ltd|Sun Pharmaceutical Industries Ltd,15593|28606|18053|1017506|18767|15587|27561,Forest Laboratories Inc|Nycomed Inc|Ranbaxy Laboratories Ltd,16198|16859|21266,Daiichi Sankyo Co Ltd,1017506,,,,,,
55705,dacomitinib,PF-804|dacomitinib|PF-05199265|dacomitinib (USAN)|PF-00299804|PF-0299804|PF-299|PF-299804|Vizimpro,Research Code|INN|Research Code|USAN|Research Code|Research Code|Research Code|Trade Name,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Erbb4 tyrosine kinase receptor inhibitor|Protein tyrosine kinase inhibitor|Epidermal growth factor receptor antagonist,3756|3760|385|740,Anticancer protein kinase inhibitor|Cell cycle inhibitor|Anticancer,62255|767|1545,Metastatic breast cancer|Metastatic non small cell lung cancer,3657|3665,Penis tumor|Glioblastoma|Metastatic stomach cancer|Metastatic head and neck cancer|Solid tumor|Mouth tumor,1791|2454|3666|3673|725|793,Pfizer Inc,18767,SFJ Pharmaceuticals Inc,1052050,Pfizer Inc,18767,,,,,,
5571,Pixuvri,"BBR-2778|pixantrone|second-generation anthracenedione analog (iv, non Hodgkin's lymphoma/ multiple sclerosis), Cell Therapeutics|second-generation anthracenedione analog (iv, non Hodgkin's lymphoma/ multiple sclerosis), Roche/ Cell Therapeutics|pixantrone dimaleate|Pixuvri|second-generation anthracenedione analog (iv, non Hodgkin's lymphoma/ multiple sclerosis), Roche/CTI BioPharma Corp|second-generation anthracenedione analog (iv, non Hodgkin's lymphoma/ multiple sclerosis), CTI BioPharma Corp",Research Code|INN|USAN|Trade Name,Cancer|Immune,DNA gyrase inhibitor,431,Anticancer alkylating agent|Immunomodulator,50|1596,Non-Hodgkin lymphoma,319,Metastasis|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Leukemia|Lymphoma|Multiple sclerosis|Breast tumor|Solid tumor|Myasthenia gravis,1069|1734|1749|199|203|213|49|725|848,Servier,19863,CTI BioPharma Corp|Roche Holding AG|Neopharm Ltd|Boehringer Mannheim GmbH|Novuspharma SpA,15337|19446|21388|24098|27036,Roche Holding AG,19446,,,,,,
5573,exatecan,DX-8951f|exatecan mesylate|DX-8951a|DX-8951|exatecan|UM-1|UM-2|exatecan hydrochloride,Research Code|USAN|Research Code|Research Code|INN|Metabolite|Metabolite,Cancer|Other/Miscellaneous,Topoisomerase I inhibitor,141,Anticancer,1545,,,Xerostomia|Leukemia|Cancer|Solid tumor,1063|199|651|725,,,Daiichi Seiyaku Co Ltd,15593,Daiichi Seiyaku Co Ltd,15593,,,,,,
55737,agerafenib hydrochloride,"AB-024|B-RAF kinase inhibitors (melanoma), Ambit/Cephalon|CEP-32496|RXDX-105|agerafenib hydrochloride|agerafenib",Research Code|Research Code|Research Code|PINN,Cancer,Ret tyrosine kinase receptor inhibitor|Raf B protein kinase inhibitor|Epidermal growth factor receptor antagonist,3818|4548|740,Anticancer protein kinase inhibitor,62255,Advanced solid tumor|Cancer,3713|651,,,Ignyta Inc,1079441,Cephalon Inc|Ambit Biosciences Corp,15358|29179,Ambit Biosciences Corp,29179,,,,,,
55740,"quetiapine fumarate (once-daily sustained release tablet), AstraZeneca","quetiapine fumarate|quetiapine|quetiapine fumarate (once-daily sustained release tablet), AstraZeneca|FK-949E|Bipresso|Seroquel SR|Seroquel XR|Seroquel ER|Seroquel XRO|Xeroquel LP|quetiapine XR",USAN|INN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Neurology/Psychiatric|Toxicity/Intoxication,5-HT 2 receptor antagonist|Dopamine D2 receptor antagonist,13|150,Antidepressant|Antipsychotic,2941|2943,Mania|Schizophrenia|Bipolar II disorder|Major depressive disorder|Bipolar disorder|Depression,1957|299|3115|4898|653|93,Alcoholism|Generalized anxiety disorder|Insomnia,11|1937|750,Alvogen Korea|Astellas Pharma Inc|Distribution Solutions Phils Inc|CHEPLAPHARM Arzneimittel GmbH|Zuellig Pharma Holdings Pte Ltd|Luye Pharma Group Ltd,1109820|1013295|1227522|1129377|1138672|1015499,AstraZeneca plc|Bago,14190|14346,AstraZeneca plc,14190,,,,,,
55752,MelCancerVac,"MelCancerVac|MelCancerVax|dendritic cell vaccine (cancer), Enochian Biosciences|MCV|ENO-4001|ENOB-DB-01",Trade Name|Trade Name|Research Code|Research Code,Cancer,,,Dendritic cell vaccine|Therapeutic vaccine|Genetically engineered autologous cell vaccine|Anticancer,102926|12379|4791|1545,,,Non-small-cell lung cancer|Bladder cancer|Colorectal tumor,1262|2380|989,,,Enochian BioSciences Inc,31068,Enochian BioSciences Inc,31068,,,,,,
55798,crizotinib,PF-02341066|PF-2341066|crizotinib|PF-1066|Xalkori|NSC-749005,Research Code|Research Code|USAN|INN|Research Code|Trade Name|Research Code,Cancer,Anaplastic lymphoma kinase receptor inhibitor|MET tyrosine kinase receptor family inhibitor|Hepatocyte growth factor receptor antagonist|Ros1 tyrosine kinase receptor inhibitor|ALK tyrosine kinase receptor family inhibitor|Echinoderm microtubule like protein 4 inhibitor,3736|3796|675|3826|3851|48389,Anticancer protein kinase inhibitor,62255,Metastasis|Non-small-cell lung cancer|Stomach tumor|Anaplastic large cell lymphoma|Transitional cell carcinoma|Rhabdomyosarcoma|Glioblastoma|Neuroblastoma|Hormone refractory prostate cancer|Soft tissue sarcoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Uveal melanoma|Metastatic renal cell carcinoma|Breast tumor,1069|1262|127|1755|1771|2448|2454|2726|3246|3378|3657|3665|3713|3788|4250|49,Renal cell carcinoma|Cancer,1766|651,OxOnc Development LP|Pfizer Inc,1088238|18767,,,Pfizer Inc,18767,,,,,,
55799,CALAA-01,"CALAA-01|ribonucleotide reductase M2 subunit (RRM2)-targeted siRNA agent (RONDEL, intravenous, cancer), Calando",Research Code,Cancer,Ribonucleotide reductase gene inhibitor|Transferrin modulator,12773|1515,Anticancer|siRNA agent,1545|26035,,,Solid tumor,725,,,Calando Pharmaceuticals Inc,1013715,Calando Pharmaceuticals Inc,1013715,,,,,,
55813,mogamulizumab,"KW-0761|CC chemokine receptor-4 modulator (allergy + cancer, POTELLIGENT), Kyowa Hakko Kirin|CCR4 modulator (allergy + cancer, POTELLIGENT), Kyowa Hakko Kogyo|KW-0761 (allergy), Amgen|anti-CCR4 humanized mAb ( allergy), Amgen|AMG-761|CC chemokine receptor-4 modulator (allergy + cancer, POTELLIGENT), Kyowa Hakko Kogyo|mogamulizumab|Poteligio|KM-8761|Poteligeo|mogamulizumab-kpkc",Research Code|Research Code|USAN|INN|Trade Name|Research Code|Trade Name,Cancer|Immune|Infection|Musculoskeletal|Respiratory,CCR4 chemokine antagonist,3104,Immunomodulator|Antiviral|Anti-inflammatory|Anticancer monoclonal antibody,1596|991|2953|55685,Mycosis fungoides|Human T cell leukemia virus 1 infection|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Sezary syndrome|Adult T-cell lymphoma|Tropical spastic paraparesis|Advanced solid tumor,1115|167|1749|1753|1754|1756|1757|2001|3713,Allergy|Asthma|T-cell lymphoma|Metastatic non small cell lung cancer|Solid tumor,12|31|311|3665|725,Kyowa Hakko Kirin Co Ltd|Kyowa Hakko Kogyo Co Ltd,1042596|17724,Amgen Inc,14109,Kyowa Hakko Kogyo Co Ltd,17724,,,,,,
55852,linagliptin,BI-1356-BS|BI-1356|Ondero|linagliptin|linagliptine|Tradjenta|Trajenta|Trazenta|Trayenta,Research Code|Research Code|Trade Name|USAN|INN|Trade Name|Trade Name|Research Code|Trade Name,Endocrine/Metabolic,Dipeptidyl peptidase IV inhibitor,5537,Vulnerary agent|DPP IV inhibitor antidiabetic product|Hypoglycemic agent,7292|38439|399,Non-insulin dependent diabetes,837,,,Eli Lilly & Co|Lupin Ltd|Boehringer Ingelheim International GmbH,17810|21932|14881,,,Boehringer Ingelheim International GmbH,14881,,,,,,
55901,"belinostat (oral, cancer), Onxeo","PXD-101|PXD-101 (oral, solid tumors), TopoTarget/Curagen|HDAC inhibitor (oral, solid tumors), TopoTarget/CuraGen|histone deacetylase inhibitor (oral, solid tumors), TopoTarget/Curagen|PX-089344|belinostat|belinostat (oral, solid tumors), TopoTarget/Curagen|belinostat (oral, cancer), BioAlliance Pharma/Spectrum|belinostat (oral, cancer), TopoTarget/Spectrum|belinostat (oral, cancer), Onxeo/Spectrum|belinostat (oral, cancer), Onxeo",Research Code|Research Code|USAN|INN,Cancer,Histone deacetylase inhibitor,2574,Anticancer,1545,Non-Hodgkin lymphoma|Cancer,319|651,Non-small-cell lung cancer|Lymphoma|Solid tumor,1262|203|725,Onxeo SA,28048,Spectrum Pharmaceuticals Inc|CuraGen Corp|TopoTarget A/S,24232|25491|29414,TopoTarget A/S,29414,,,,,,
55927,linsitinib,"OSI-906|IGF-1R tyrosine kinase inhibitor (cancer), OSI Pharmaceuticals|insulin-like growth factor receptor-1 tyrosine kinase inhibitor (cancer), OSI Pharmaceuticals|apoptosis inhibitor (solid tumors, small molecule therapeutic), OSI Pharmaceuticals|linsitinib|ASP-7487|OSI-906AA",Research Code|USAN|INN|Research Code|Research Code,Cancer,Insulin receptor antagonist|Insulin-like growth factor 1 receptor antagonist,3248|3252,Anticancer protein kinase inhibitor|Apoptosis inhibitor,62255|1590,,,Non-small-cell lung cancer|Adrenal cortical carcinoma|Hepatocellular carcinoma|Multiple myeloma|Head and neck tumor|Solid tumor|Ovary tumor|Colorectal tumor,1262|1648|1767|1828|623|725|799|989,,,Astellas Pharma Inc|OSI Pharmaceuticals Inc,1013295|18676,OSI Pharmaceuticals Inc,18676,,,,,,
55929,conatumumab,"AMG-655|TRAIL receptor-2 mAb (cancer), Amgen/Takeda|conatumumab|TRAIL-R2 mAb",Research Code|USAN|INN,Cancer,TRAIL-2 receptor agonist,8232,Anticancer monoclonal antibody|Apoptosis stimulator,55685|1589,,,Non-small-cell lung cancer|Sarcoma|Lymphoma|Pancreas tumor|Cancer|Solid tumor|Colorectal tumor,1262|194|203|249|651|725|989,,,Amgen Inc|Takeda Pharmaceutical Co Ltd|Takeda Bio Development Center Ltd,14109|20300|23215,Amgen Inc,14109,,,,,,
55949,pepinemab,"VX-15|anti-CD100 MAb (autoimmune disease/cancer), Vaccinex|anti-semaphorin 4D monoclonal antibody (autoimmune disease/cancer), Vaccinex|plexin B1 antagonist (autoimmune disease/cancer), Vaccinex|VX-15/2503|pepinemab|anti-SEMA4D antibody, Vaccinex",Research Code|Research Code,Cancer|Immune|Neurology/Psychiatric,Semaphorin-4D inhibitor|Plexin B1 inhibitor,10970|23553,Neuroprotectant|Nootropic agent|Angiogenesis inhibitor|Synergist|Immunomodulator|Anticancer monoclonal antibody,1615|284|61|7293|1596|55685,Non-small-cell lung cancer|Alzheimers disease|Huntingtons chorea|Osteosarcoma|Multiple sclerosis|Pancreas tumor|Squamous cell carcinoma|Stage IV melanoma|Metastatic head and neck cancer|Head and neck tumor|Solid tumor|Colorectal tumor,1262|14|170|1772|213|249|307|3257|3673|623|725|989,Cancer,651,Vaccinex Inc,29595,Teva Pharmaceutical Industries Ltd,20348,Vaccinex Inc,29595,,,,,,
55976,CDX-1401,"CDX-1401|CD205 modulator (vaccine/mAb, solid tumor), Celldex|DEC-205-NY-ESO-1 vaccine (solid tumor), Celldex|rasdegafusp alfa",USAN,Cancer|Hematologic|Infection,Lymphocyte antigen 75 modulator|Cancer testis antigen NY-ESO-1 modulator,68361|50096,Anticancer|Anticancer monoclonal antibody|Antiviral,1545|55685|991,,,Myelodysplastic syndrome|HIV infection|Anemia|Acute myelogenous leukemia|Stage IV melanoma|Chronic myelomonocytic leukemia|Solid tumor,1272|158|17|1731|3257|6833|725,,,Celldex Therapeutics Inc (pre-merger)|Celldex Therapeutics Inc,1017309|25726,Celldex Therapeutics Inc (pre-merger),1017309,,,,,,
55989,"paclitaxel (nanoparticle, suspension, pancreatic cyst/ovarian cancer/prostate cancer/pancreatic cancer), NanOlogy/US Biotest","paclitaxel|paclitaxel (nanocrystalline, aqueous injectable, intraperitoneal sustained release suspension, cancer), CritiTech|Nanotax|paclitaxel (intraperitoneal nanoparticle, ovarian cancer), CritiTech/NanOlogy|paclitaxel (intraperitoneal nanoparticle, ovarian cancer), CritiTech/NanOlogy/US Biotest|paclitaxel (nanoparticle, suspension, pancreatic cyst/ovarian cancer/prostate cancer/pancreatic cancer), NanOlogy/US Biotest|NanoPac",USAN|BANN|INN|Trade Name|Trade Name,Cancer,Tubulin binding agent,499,Anticancer,1545,Small-cell lung cancer|Non-small-cell lung cancer|Pancreatic cystadenocarcinoma|Pancreas tumor|Prostate tumor|Ovary tumor,1261|1262|1508|249|276|799,Cancer,651,US Biotest Inc|NanOlogy LLC,1054867|1114892,CritiTech Inc,30791,CritiTech Inc,30791,,,,,,
55997,tabalumab,"LY-2127399|anti-BAFF humanized monoclonal antibody (rheumatoid arthritis/lupus), Eli Lilly|BAFF antibody (RA/lupus), Eli Lilly|tabalumab",Research Code|USAN|INN,Cancer|Immune,B-lymphocyte stimulator ligand inhibitor,12770,Anti-inflammatory|Immunosuppressant|Anticancer antibody,2953|396|55684,,,Multiple myeloma|Multiple sclerosis|Rheumatoid arthritis|Systemic lupus erythematosus,1828|213|291|318,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
5606,valspodar,PSC-833|SDZ-PSC-833|Amdray|valspodar|SDZ-214-103|NSC-648265,Research Code|Research Code|Trade Name|INN|Research Code|Research Code,Cancer|Infection,,,Anticancer multidrug resistance inhibitor|Radiochemosensitizer|Unspecified drug target,759|572|59620,,,Acute myelogenous leukemia|Multiple myeloma|Lymphoma|Plasmodium infection|Breast tumor|Cancer|Ovary tumor,1731|1828|203|268|49|651|799,,,Novartis Pharma KK|National Cancer Institute (NCI)|Novartis AG,16018|20519|23137,Novartis AG,23137,,,,,,
56236,ublituximab,"anti-CD20 antibody (lymphoma), LFB/GTC|chimeric anti-CD20 antibody (lymphoma), Laboratoire Francais du Fractionnement et des Biotechnologies|TG-20|ublituximab|LFB-R603|anti-CD20 antibody (lymphoma), TG Therapeutics|Utuxin|LABI-R603|TG-1101|TGTX-1101|TG-1011|rituximab biobetter, Il Dong",Research Code|USAN|INN|Research Code|Trade Name|Research Code|Research Code|Research Code|Research Code,Cancer|Hematologic|Immune|Neurology/Psychiatric,Immunoglobulin gamma Fc receptor IIIA agonist|B-lymphocyte antigen CD20 modulator,27981|5083,Immunostimulant|Anti-inflammatory|Anticancer monoclonal antibody|Leukocyte stimulator|Natural killer cell stimulator|T-lymphocyte stimulator,393|2953|55685|7747|7757|7761,Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Multiple sclerosis|Autoimmune disease|Cancer,1734|1749|213|36|651,Macroglobulinemia|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Leukemia|Lymphoma|Neuromyelitis optica|B-cell lymphoma|Non-Hodgkin lymphoma,1264|1744|1745|1746|199|203|2316|316|319,Ildong Pharmaceutical Co Ltd|TG Therapeutics Inc,17101|31093,LFB SA|rEVO Biologics Inc,25256|25900,LFB SA,25256,,,,,,
56251,"menadione (topical, skin rash), Spectrum Pharmaceuticals","menadione|menadione (topical, skin rash), Hana|vitamin K3 (topical, skin rash), Hana|menadione (topical, skin rash), Talon|menadione (topical, skin rash), Spectrum Pharmaceuticals",,Dermatologic,Protein tyrosine phosphatase inhibitor|EGFR family tyrosine kinase receptor stimulator,1651|8682,,,,,Skin allergy|Skin rash,1101|3020,,,Talon Therapeutics Inc|Spectrum Pharmaceuticals Inc|Albert Einstein College of Medicine,1010798|24232|24282,Albert Einstein College of Medicine,24282,,,,,,
56308,CBT-1,"CBT-1|p-glycoprotein inhibitor (cancer), CBA Pharma",Research Code|Trade Name,Cancer|Infection,P-Glycoprotein inhibitor,7494,Antibacterial|Anticancer chemosensitizer,1594|1586,Non-small-cell lung cancer|Cancer,1262|651,MRSA infection,1267,CBA Pharma Inc,15325,,,CBA Pharma Inc,15325,,,,,,
56368,veliparib,"PARP inhibitor (cancer), Abbott/NIH|NSC-737664|ABT-888|veliparib|ABT-620223|PARP inhibitor (testicular cancer/germ cell and embryonic cancer/seminoma), AbbVie",Research Code|Research Code|USAN|INN|Research Code,Cancer,Poly ADP ribose polymerase 1 inhibitor|Poly ADP ribose polymerase 2 inhibitor|PARP inhibitor,38283|38286|2507,Anticancer,1545,Testis tumor|Small-cell lung cancer|Lymphoma|Seminoma|Fallopian tube cancer|Peritoneal tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Germ cell and embryonic cancer|Ovary tumor,1054|1261|203|2167|2243|3083|3657|3658|3665|3669|3737|799,Metastasis|Glioma|Neuroendocrine tumor|Hepatocellular carcinoma|Multiple myeloma|Melanoma|Glioblastoma|Gliosarcoma|Prostate tumor|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic rectal cancer|Breast tumor|Cancer|Solid tumor|Colorectal tumor,1069|1108|1128|1767|1828|205|2454|2727|276|3246|3257|3671|49|651|725|989,AbbVie Inc,1072507,Abbott Laboratories,13601,Abbott Laboratories,13601,,,,,,
56406,"demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors), NanoCarrier/Orient Europharma","cisplatin|NC-6004|Nanoplatin|cisplatin (injectable, micelle), NanoCarrier/Debiopharm|cisplatin (injectable, micelle), NanoCarrier/Orient Europharma|demplatin pegraglumer|demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors), NanoCarrier/Orient Europharma",USAN|INN|Research Code|Trade Name|USAN|INN,Cancer,,,Cell cycle inhibitor|Microtubule stabilizer|Anticancer,767|2576|1545,Non-small-cell lung cancer|Biliary cancer|Bladder cancer|Pancreas tumor|Squamous cell carcinoma|Head and neck tumor|Cancer,1262|1516|2380|249|307|623|651,Solid tumor,725,NanoCarrier Co Ltd|Orient Europharma,29050|DOL1000087,Debiopharm SA,15620,NanoCarrier Co Ltd,29050,,,,,,
56409,BMS-690514,"BMS-690514|panHER/VEGFR-2 kinase inhibitor (cancer), BMS|panHER/VEGFR-2 kinase inhibitor (cancer), Bristol-Myers Squibb|BMS-399626|BMS-655875|ErbB/VEGF inhibitor (cancer), BMS",Research Code|Research Code|Research Code,Cancer,Epidermal growth factor receptor modulator|Erbb2 tyrosine kinase receptor inhibitor|Erbb3 tyrosine kinase receptor inhibitor|Erbb4 tyrosine kinase receptor inhibitor|VEGF-2 receptor antagonist,3605|3756|3758|3760|3848,Apoptosis stimulator|Anticancer protein kinase inhibitor,1589|62255,,,Non-small-cell lung cancer|Breast tumor|Solid tumor,1262|49|725,,,Bristol-Myers Squibb Co,15065,Bristol-Myers Squibb Co,15065,,,,,,
56423,IPI-493,"IPI-504|Hsp 90 inhibitors (oral, cancer), Infinity|IPI-493|17-AG|17-amino-geldanamycin",Research Code|Research Code|Research Code,Cancer,Hsp 90 inhibitor,8012,Apoptosis stimulator|Anticancer,1589|1545,,,Hematological neoplasm|Cancer|Solid tumor,2054|651|725,,,MedImmune LLC|Infinity Pharmaceuticals Inc,18008|29753,Infinity Pharmaceuticals Inc,29753,,,,,,
56514,"acadesine (intravenous, prodrug, B-CLL/MM/MCL), Advancell","acadesine|AICAR|acadesine (intravenous formulation, leukemia), Advanced In Vitro Cell Technologies|Acadra|ADV-P1|ATH-001|acadesine (intravenous, prodrug, B-CLL/MM/MCL), Advancell",USAN|BAN|INN|Trade Name|Research Code|Research Code,Cancer,AMP activated protein kinase stimulator,8805,Anticancer|Apoptosis stimulator,1545|1589,,,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Mantle cell lymphoma|Multiple myeloma|Chronic myelomonocytic leukemia,1272|1731|1734|1735|1744|1828|6833,,,Universitat de Barcelona|Advancell|BTG plc|Protherics plc,1003992|1011926|15266|19164,Universitat de Barcelona,1003992,,,,,,
56516,fedratinib dihydrochloride monohydrate,"TG-101193|TG-101348|JAK2 inhibitors (myeloproliferative disorder), TargeGen|JAK-2.V617F inhibitors (MPD), TargeGen|TG-101209|dual FLT3/JAK2 inhibitors (myeloproliferative disorders), TargeGen|FLT3/JAK2/Ret inhibitor (myeloproliferative disorders), TargeGen|SAR-302503|fedratinib|Inrebic|fedratinib dihydrochloride monohydrate|fedratinib hydrochloride",Research Code|Research Code|Research Code|Research Code|USAN|INN|Trade Name|USAN,Cancer|Hematologic,Jak2 tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|Ret tyrosine kinase receptor inhibitor,3564|3806|3818,Anticancer protein kinase inhibitor,62255,Thrombocythemia|Polycythemia vera|Myelofibrosis,2317|2319|2436,Myeloproliferative disorder|Solid tumor,273|725,Bristol-Myers Squibb Co,15065,Impact Biomedicines Inc|Celgene Corp|TargeGen Inc,1155296|15331|29571,TargeGen Inc,29571,,,,,,
56518,elotuzumab,"CS1 targeting humanized monoclonal antibody (mab, multiple myeloma), PDL|elotuzumab|HuLuc63|PDL-063|CS1 targeting humanized mAb (multiple myeloma), Bristol-Myers Squibb|CS1 targeting humanized mAb (multiple myeloma), Facet|anti-CS1 antibody (cancer), BMS/PDL|anti-CD37 mAb (multiple myeloma), Bristol-Myers Squibb|Empliciti|BMS-901608",USAN|INN|Research Code|Research Code|Trade Name|Research Code,Cancer,SLAM family member 7 inhibitor|Lymphocyte function antigen-3 receptor modulator,45395|5017,Anticancer monoclonal antibody,55685,Multiple myeloma,1828,,,Bristol-Myers Squibb Co|AbbVie Inc,15065|1072507,AbbVie Biotherapeutics Inc|Abbott Laboratories|PDL BioPharma Inc,1044720|13601|19162,PDL BioPharma Inc,19162,,,,,,
56544,cobimetinib,"MEK inhibitor (oral, cancer), Exelixis/Genentech|GDC-0973|XL-518|cobimetinib|cobimetinib butyrate|RG-7421|RG-7420 (GDC-0973)|cobimetinib fumarate|[14C]-GDC-0973|RO-5514041|Cotellic",Research Code|Research Code|USAN|INN|Research Code|Research Code|USAN|Research Code|Research Code|Trade Name,Cancer|Hematologic|Neurology/Psychiatric,MEK protein kinase inhibitor|MEK-1 protein kinase inhibitor|MEK-2 protein kinase inhibitor,4760|4762|4764,Anticancer protein kinase inhibitor|Synergist,62255|7293,Pituitary tumor|Pancreatic ductal adenocarcinoma|Acute myelogenous leukemia|Multiple myeloma|Sarcoma|Neurodegenerative disease|Stage III melanoma|Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Histiocytosis|Solid tumor|Ovary tumor,1131|1507|1731|1828|194|233|3256|3257|3658|3665|3666|4682|725|799,Transitional cell carcinoma|Melanoma|Metastatic head and neck cancer|Metastatic renal cell carcinoma|Breast tumor|Cancer,1771|205|3673|4250|49|651,Roche Holding AG|Chugai Pharmaceutical Co Ltd|Genentech Inc,19446|15414|19453,Exelixis Inc,22676,Exelixis Inc,22676,,,,,,
56589,IPH-2101,"IPH-2101|anti-KIR mAb (hematological cancer), Innate Pharma|anti-killer cell immunoglobulin-like receptor monoclonal antibody (hematological cancer), Innate Pharma|NN-1975|1-7F9|anti-killer cell immunoglobulin-like receptor monoclonal antibody (hematological cancer), Novo Nordisk|anti-KIR mAb (hematological cancer), Novo Nordisk|KIR checkpoint inhibitor (hematological cancer), Innate Pharma/Bristol-Myers Squibb",,Cancer|Infection,Killer cell Ig like receptor antagonist|CD158 antagonist|CD158a antagonist|CD158b1 antagonist,47549|5503|5504|5505,Anticancer monoclonal antibody|Immunostimulant|Antiviral|T-lymphocyte stimulator,55685|393|991|7761,,,Hepatitis C virus infection|Acute myelogenous leukemia|Multiple myeloma|Hematological neoplasm,153|1731|1828|2054,,,Bristol-Myers Squibb Co|Novo Nordisk A/S|Innate Pharma SA,15065|18614|28788,Innate Pharma SA,28788,,,,,,
56625,istiratumab,MM-141|istiratumab,Research Code|USAN|INN,Cancer,Insulin-like growth factor 1 receptor antagonist|Erbb3 tyrosine kinase receptor inhibitor,3252|3758,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,,,Pancreas tumor|Cancer,249|651,,,Merrimack Pharmaceuticals Inc,27954,Merrimack Pharmaceuticals Inc,27954,,,,,,
56629,talacotuzumab,"CSL-360|anti-CD123 mAb (acute myelogenous leukemia), CSL|therapeutic leukaemia antibody (AML), CSL|7G3|anti-IL3R alpha chain mAb (AML), CSL|anti-CD123 mAb (acute myelogenous leukemia), Janssen|anti-IL3R alpha chain mAb (AML), Janssen|talacotuzumab|JNJ-56022473|CSL-362|CD-123",Research Code|Research Code|INN|Research Code|Research Code|Research Code,Cancer|Immune,CDw123 antagonist,5429,Anticancer monoclonal antibody,55685,Systemic lupus erythematosus,318,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,CSL Ltd,15563,Celltrion Inc|Janssen Biotech Inc,1015645|26997,CSL Ltd,15563,,,,,,
56642,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics","VT-122|propranolol + etodolac (cachexia/cancer), Vicus Therapeutics|propranolol + etodolac|VT-11CR",Research Code|Research Code,Cancer|Other/Miscellaneous,MAP kinase inhibitor|Protein kinase A inhibitor|Phosphoinositide 3-kinase inhibitor|Transient receptor potential channel inhibitor|Cyclooxygenase 2 inhibitor|ORL1 receptor antagonist|Cyclooxygenase 1 inhibitor|STAT-3 inhibitor|Beta adrenoceptor antagonist|Prostanoid receptor antagonist,2511|1873|1575|15395|1001|2635|999|7967|38|318,Anticancer protein kinase inhibitor|Anticancer|Non-steroidal anti-inflammatory,62255|1545|2955,,,Glioma|Hepatocellular carcinoma|Pancreas tumor|Prostate tumor|Soft tissue sarcoma|Cachexia|Solid tumor|Lung tumor,1108|1767|249|276|3378|425|725|755,,,Vicus Therapeutics LLC,1023205,Vicus Therapeutics LLC,1023205,,,,,,
5665,"levetiracetam (oral), UCB","levetiracetam|UCB-L059|Keppra|UCB-L060|levetiracetam (oral), UCB|levetiracepam|L-059|E Keppra|E Keppra Dry Syrup",INN|Research Code|Trade Name|Research Code|Research Code|Trade Name|Trade Name,Neurology/Psychiatric,Synaptic vesicle glycoprotein 2A modulator,15477,Anticonvulsant agent,70,Epilepsy|Alzheimers disease,119|14,Diabetic neuropathy|Neuropathic pain|Migraine|Social phobia|Tardive dyskinesia|Bipolar disorder|Aggression,101|1295|210|3150|320|653|9,UCB SA,20452,Otsuka Pharmaceutical Co Ltd|SIBIA Neurosciences Inc,18717|26975,UCB SA,20452,,,,,,
56712,padeliporfin potassium,"WST-11|padeliporfin photodynamic therapy (age-related macular degeneration/cancer), Weizmann Institute|padeliporfin|padeliporfin photodynamic therapy (age-related macular degeneration/cancer), Steba Biotech|padeliporfin di-potassium|Tookad (Soluble)|palladium-bacteriopheophorbide monolysine taurine|Pd-bacteriopheophorbide monolysine taurine|Stakel|Tookad|padeliporfin potassium|padeliporfin ImPACT",Research Code|USAN|INN|Trade Name|Trade Name|Trade Name|USAN,Cancer|Ocular,,,Anticancer|Angiogenesis inhibitor|Ophthalmological agent|Photosensitizer|Unspecified drug target|Vascular damaging agent|Ocular antineovascularisation agent,1545|61|15128|799|59620|2969|15148,Esophagus tumor|Transitional cell carcinoma|Prostate tumor|Breast tumor,1011|1771|276|49,Age related macular degeneration|Non-small-cell lung cancer|Cholangiocarcinoma|Solid tumor,1226|1262|1765|725,Steba Biotech NV,30641,Weizmann Institute of Science,15489,Weizmann Institute of Science,15489,,,,,,
56724,PD-360324,"PD-360324|macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis, CLE), Pfizer|MCSF mAb (cutaneous lupus erythematosus, RA), Pfizer|PD-0360324",Research Code|Research Code,Immune|Inflammatory,CSF-1 antagonist,3154,Immunomodulator|Anticancer protein kinase inhibitor,1596|62255,,,Sarcoidosis|Cutaneous lupus erythematosus|Rheumatoid arthritis,1036|2559|291,,,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
56734,nirogacestat hydrobromide,"PF-03084014|gamma secretase inhibitor (cancer), Pfizer|PF-3084014|nirogacestat|nirogacestat hydrobromide|nirogacestat dihydrobromide",Research Code|Research Code|USAN|INN|USAN,Cancer|Neurology/Psychiatric,Gamma-secretase inhibitor,7578,Anticancer,1545,Multiple myeloma|Soft tissue sarcoma|Aggressive fibromatosis,1828|3378|3504,Alzheimers disease|Pancreatic ductal adenocarcinoma|Advanced solid tumor|Breast tumor|Cancer,14|1507|3713|49|651,SpringWorks Therapeutics Inc,1154395,Pfizer Inc,18767,SpringWorks Therapeutics Inc,1154395,,,,,,
56758,"dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute","mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute|dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute",,Cancer,p53 tumor suppressor protein modulator,17119,Therapeutic vaccine|Dendritic cell vaccine|Anticancer,12379|102926|1545,,,Squamous cell carcinoma|Head and neck tumor,307|623,,,National Cancer Institute (NCI),20519,National Cancer Institute (NCI),20519,,,,,,
56777,indoximod hydrochloride,"indoleamine 2,3-dioxygenase inhibitors (solid tumor), Newlink Genetics|NLG-001|1-methyl-D-tryptophan|D-1MT|D-1-methyltryptophan|Indoximod Prostate|Indoximod Breast|indoximod|NLG-8189|1-methyltryptophan|IDO checkpoint inhibitor (cancer), NewLink Genetics|indoximod hydrochloride",Research Code|Research Code|Trade Name|Trade Name|USAN|INN|Research Code,Cancer,"Indoleamine-pyrrole-2,3-dioxygenase inhibitor",6366,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,Acute myelogenous leukemia|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic pancreas cancer|Brain tumor,1731|3246|3257|3669|760,Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor,3657|3665|3713,NewLink Genetics Corp,1008706,,,NewLink Genetics Corp,1008706,,,,,,
56815,vismodegib,"small-molecule hedgehog antagonist (cancer), Curis/Genentech//Roche|Hedgehog antagonists (systemic formulation, cancer), Curis/Genentech/Roche|Hh antagonists (systemic formulation, cancer), Curis/Genentech//Roche|GDC-0449|R-3616|NSC-747691|vismodegib|RG-3616|Erivedge|Hedgehog Antagonist GDC-0449|RO-5450815",Research Code|Research Code|Research Code|USAN|INN|Research Code|Trade Name|Research Code,Cancer|Dermatologic|Hematologic|Respiratory,Smoothened receptor antagonist|Hedgehog protein inhibitor,11036|8134,Apoptosis stimulator|Anticancer,1589|1545,Basal cell carcinoma|Odontogenic tumor|Head and neck tumor,1764|2275|623,Stomach tumor|Myelodysplastic syndrome|Pancreatic ductal adenocarcinoma|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Sarcoma|Myelofibrosis|Meningioma|B-cell lymphoma|Basal cell nevus syndrome|Metastatic prostate cancer|Idiopathic pulmonary fibrosis|Cancer|Ovary tumor|Colorectal tumor,127|1272|1507|1731|1734|194|2436|2802|316|3382|3664|3771|651|799|989,Genentech Inc|Roche Holding AG,19453|19446,Chugai Pharmaceutical Co Ltd|Curis Inc|F Hoffmann-La Roche AG,15414|15549|26178,Curis Inc,15549,,,,,,
56854,zabinostat,"AZD-9468|AZD-8025|CXD-101|histone deacetylase (HDAC) inhibitor (cancer), AstraZeneca/Celleron Therapeutics|histone deacetylase (HDAC) inhibitor (colorectal cancer), AstraZeneca/Celleron Therapeutics|histone deacetylase (HDAC) inhibitor (lymphoma), AstraZeneca/Nuance Biotech|histone deacetylase (HDAC) inhibitor (peripheral T-cell Lymphoma), AstraZeneca/Nuance Biotech|zabinostat",Research Code|Research Code|Research Code,Cancer,Histone deacetylase inhibitor,2574,Anticancer|Immunomodulator,1545|1596,Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Hepatocellular carcinoma|Lymphoma|Pancreas tumor|T-cell lymphoma|Hormone refractory prostate cancer|Cancer|Colorectal tumor,1749|1753|1767|203|249|311|3246|651|989,,,Celleron Therapeutics Ltd|Nuance Biotech Inc,1037347|1118419,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
56902,RGI-2001,"KRN-7000|T-cell modulator (transplant rejection/autoimmune disease), REGiMMUNE|Multivax platform, Regimmune|KRN-7000, liposomal formulation (autoimmune disease), REGiMMUNE Corp|RGI-2001|ToleroVax|RGI-7000",Research Code|Research Code|Trade Name|Research Code,Endocrine/Metabolic|Hematologic|Immune,,,Immunomodulator|T-lymphocyte modulator|Natural killer T-lymphocyte stimulator,1596|5692|173716,Hemophilia|Graft versus host disease|Lysosome storage disease,439|616|648,Autoimmune disease,36,REGiMMUNE Corp,1030919,,,REGiMMUNE Corp,1030919,,,,,,
56926,SAR-103168,SAR-103168,Research Code,Cancer,Unspecified protein kinase inhibitor,9671,Anticancer protein kinase inhibitor,62255,,,Acute myelogenous leukemia,1731,,,Sanofi SA,1009547,Sanofi SA,1009547,,,,,,
56967,tagraxofusp,DT388IL-3|tagraxofusp|Elzonris|tagraxofusp-erzs|SL-401,Research Code|USAN|INN|Trade Name|Research Code,Cancer|Hematologic|Immune|Musculoskeletal,IL-3 receptor modulator|CDw123 modulator,3052|5427,Synergist|Protein synthesis inhibitor|Anticancer|Immunotoxin,7293|339|1545|539,Scleroderma|Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Hypereosinophilic syndrome|Hematological neoplasm|Myelofibrosis|Autoimmune disease|Systemic mastocytosis|Chronic myelomonocytic leukemia,1105|1272|1731|1828|2036|2054|2436|36|3728|6833,Hodgkins disease|Hairy cell leukemia|Myeloid leukemia|Mastocytosis,161|1736|223|2795,Nippon Shinyaku Co Ltd|Stemline Therapeutics Inc,18552|1031141,Scott And White Memorial Hospital|Duke University|Wake Forest University|Pharmacia Corp,1017176|20567|20699|27638,Scott And White Memorial Hospital,1017176,,,,,,
56991,etirinotecan pegol,"PEG-irinotecan, Nektar|PEGylated irinotecan prodrug (iv, cancer), Nektar|etirinotecan pegol|etirinotecan pegol tetrahydrochloride|etirinotecan pegol tetratriflutate|NKTR-102|Onzeald",USAN|INN|USAN|USAN|Research Code|Trade Name,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,,,Metastasis|Glioma|Small-cell lung cancer|Metastatic breast cancer|Metastatic colorectal cancer|Uterine cervix tumor|Solid tumor|Ovary tumor,1069|1108|1261|3657|3658|427|725|799,,,Daiichi Sankyo Co Ltd|Nektar Therapeutics,1017506|17221,Nektar Therapeutics,17221,,,,,,
56994,"CUDC-101 (iv/Captisol, cancer), Curis/Ligand","CUDC-101|CUDC-101 (iv/Captisol, cancer), Curis/Ligand",Research Code,Cancer,Histone deacetylase inhibitor|Erbb2 tyrosine kinase receptor inhibitor|Erbb3 tyrosine kinase receptor inhibitor|AKT protein kinase inhibitor|Epidermal growth factor receptor antagonist,2574|3756|3758|3859|740,Anticancer protein kinase inhibitor,62255,,,Advanced solid tumor|Head and neck tumor|Cancer,3713|623|651,,,Curis Inc|Ligand Pharmaceuticals Inc,15549|17808,Curis Inc,15549,,,,,,
57004,rabacfosadine,"GS-9219|PMEG prodrug (cancer), Gilead|rabacfosadine|VDC-1101",Research Code|USAN|INN|Research Code,Cancer,DNA polymerase inhibitor,138,Anticancer,1545,,,Chronic lymphocytic leukemia|Non-Hodgkin lymphoma|Cancer,1734|319|651,,,Gilead Sciences Inc,16450,Gilead Sciences Inc,16450,,,,,,
57007,pilaralisib,"XL-147|PI3K/EGFR inhibitor (cancer), Exelixis|phosphoinositide-3 kinase/epidermal growth factor receptor inhibito (cancer), Exelixis|PI3K/EGFR inhibitor (cancer), sanofi-aventis|SAR-245408|pilaralisib",Research Code|Research Code|USAN|INN,Cancer,Phosphoinositide 3-kinase inhibitor,1575,Anticancer protein kinase inhibitor,62255,,,Non-small-cell lung cancer|Endometrioid carcinoma|Hematological neoplasm|Breast tumor|Solid tumor,1262|1705|2054|49|725,,,Sanofi SA|Exelixis Inc,1009547|22676,Exelixis Inc,22676,,,,,,
57008,voxtalisib,"phosphoinositide-3 kinase/mTOR inhibitor (cancer), Exelixis|PI3K/mTOR inhibitor (cancer), Exelixis|PI3K/mTOR inhibitor (cancer), sanofi-aventis|voxtalisib|SAR-245409|XL-765",USAN|PINN|Research Code|Research Code,Cancer,mTOR inhibitor|Phosphoinositide 3-kinase inhibitor,10240|1575,Apoptosis stimulator|Anticancer protein kinase inhibitor,1589|62255,,,Non-small-cell lung cancer|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Glioblastoma|Breast tumor|Cancer|Solid tumor,1262|1734|1744|1745|1749|2454|49|651|725,,,Sanofi SA|Exelixis Inc,1009547|22676,Exelixis Inc,22676,,,,,,
57010,"TRC-102 (iv, cancer), Tracon","TRC-102 (iv, cancer), Tracon|methoxyamine (iv, chemotherapy resistance), Case/TRACON|TRC-102",Research Code,Cancer,,,Anticancer|DNA repair inhibitor,1545|11593,Hematological neoplasm|Solid tumor|Lung tumor,2054|725|755,Cancer,651,TRACON Pharmaceuticals Inc,1020043,Case Western Reserve University,20553,Case Western Reserve University,20553,,,,,,
57021,florbetaben (18F),"18F-AV-1/ZK|18F-AV-1|18F and 123I PET radiodiagnostics (beta-amyloid, Alzheimer's), University of Pennsylvania/Avid|fluorine-18-AV-1/ZK|fluorine-18 and iodine-123 PET radiodiagnostics (beta-amyloid, Alzheimer's), University of Pennsylvania/Avid|18F-stilbene radiodiagnostics (beta-amyloid, Alzheimer's) University of Pennsylvania/Avid|fluorine-18-stilbene radiodiagnostics (beta-amyloid, Alzheimer's) University of Pennsylvania/Avid|18F-BAY-94-9172|ZK-6013443|florbetaben (18F)|BAY-94-9172-[18F]|AV-1-[18F]|18F-florbetaben|fluorine-18-florbetaben|Neuraceq|florbetaben F18|18F-4-fluoro-L-ornithine|4-fluoro-L-ornithine-[18F]|Fluorine-18-4-fluoro-L-ornithine|4-[18F]fluoro-L-ornithine",Research Code|Research Code|Research Code|Research Code|Research Code|INN|Research Code|Research Code|Trade Name|USAN,Cancer|Endocrine/Metabolic|Neurology/Psychiatric,Beta amyloid modulator,2420,Neoplasm diagnostic agent|CNS diagnostic agent|Radiodiagnostic|PET contrast agent,7220|7211|5720|5555,Amyloidosis|Alzheimers disease|AL amyloidosis,1143|14|3492,Parkinsons disease|Cancer,255|651,PET Pharm Biotech Ltd|Ci-Co Healthcare|Life Molecular Imaging|ISOLOGIC Innovative Radiopharmaceuticals,1129682|1090208|1006437|1118535,Avid Radiopharmaceuticals Inc|Schering AG|Bayer AG|University of Pennsylvania,1018507|1052089|14455|20658,University of Pennsylvania,20658,,,,,,
57022,florbetapir (18F),"fluorine-18 PET radiodiagnostics (vesicular monoamine transporter, Parkinson's/dementia with Lewy bodies), Avid|18F PET radiodiagnostics (VMAT-2, Parkinson's/DLB/Diabetes/AD), Avid|fluorine-18 PET radiodiagnostics (vesicular monoamine transporter, Parkinson's/dementia with Lewy bodies / Diabetes with beta cell mass in pancreas), Avid|18F-AV-45|18F-AV-144|18F-AV-19|18F-AV-138|Fluorine-18-AV-45|AV-15-[18F]|18F florpiramine|florbetapir F-18|AV-138-[18F]|AV-144-[18F]|AV-19-[18F]|AV-144|AV-19|AV-138|florbetapir (18F)|Amyvid|18F-florbetapir|AV-45|Amividdo",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|INN|Trade Name|Research Code|Trade Name,Neurology/Psychiatric,Beta amyloid modulator,2420,Radiodiagnostic|PET contrast agent|CNS diagnostic agent,5720|5555|7211,Alzheimers disease|Frontotemporal dementia,14|2425,Neurodegenerative disease|Mild cognitive impairment|Cognitive disorder|Dementia,233|3122|353|90,Eli Lilly & Co|Avid Radiopharmaceuticals Inc|FUJIFILM Toyama Chemical Co Ltd,17810|1018507|22616,University of Michigan|University of Pennsylvania,20623|20658,University of Pennsylvania,20658,,,,,,
57025,"sirolimus (albumin-bound nanoparticle, cancer, intravenous), AADI","rapamycin|sirolimus|rapamycin (albumin-bound nanoparticle, intravenous), Abraxis|ABI-009|nab-rapamycin|sirolimus (albumin-bound nanoparticle, intravenous), Abraxis|sirolimus (albumin-bound nanoparticle, cancer, intravenous), Celgene|TARZIFYX|sirolimus (albumin-bound nanoparticle, cancer, intravenous), AADI|nab-Sirolimus|Fyarro",USAN|BANN|INN|Research Code|Trade Name|Research Code|Trade Name,Cancer|Cardiovascular|Infection|Neurology/Psychiatric,mTOR inhibitor,10240,Antihypertensive|Anticancer|Protein synthesis inhibitor|Antiviral|Anticonvulsant agent,2657|1545|339|991|70,Coronavirus disease 19 infection|Neuroendocrine tumor|Epilepsy|Vascular neoplasm|Osteosarcoma|Multiple myeloma|Sarcoma|Bladder cancer|Chondrosarcoma|Liposarcoma|Peripheral vascular disease|Ewing sarcoma|Pulmonary artery hypertension|Leigh disease|Metastatic colorectal cancer|Solid tumor,10406|1128|119|1539|1772|1828|194|2380|2444|2447|260|2975|3510|3632|3658|725,,,EOC Pharma Ltd|Aadi Bioscience Inc,1144925|1091054,Abraxis BioScience Inc|Celgene Corp,1020514|15331,Abraxis BioScience Inc,1020514,,,,,,
57048,dactolisib,"PI3K/mTOR inhibitor (cancer), Novartis|phosphatidylinositol-3-kinase/mTOR inhibitor (cancer), Novartis|BEZ-235|NVP-BEZ235|dactolisib|dactolisib tosylate|NVP-BEZ235-ANA|NVP-BEZ235-NX|RTB-101|mTORC1 inhibitors (respiratory tract infection), resTORbio",Research Code|Research Code|USAN|INN|USAN|Research Code|Research Code|Research Code,Cancer|Infection|Neurology/Psychiatric,Phosphoinositide 3-kinase inhibitor|mTOR complex 1 inhibitor|mTOR complex 2 inhibitor,1575|76090|76096,Anticancer protein kinase inhibitor|Antiviral|Neuroprotectant|Apoptosis stimulator,62255|991|1615|1589,Coronavirus disease 19 infection|Parkinsons disease,10406|255,Pancreatic endocrine tumor|Endometrioid carcinoma|Transitional cell carcinoma|Leukemia|Hematological neoplasm|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic renal cell carcinoma|Breast tumor|Respiratory tract infection|Cancer|Solid tumor,1510|1705|1771|199|2054|3246|3657|4250|49|509|651|725,Adicet Bio Inc,1118915,resTORbio Inc|Novartis AG,1147633|23137,Novartis AG,23137,,,,,,
57062,masitinib,"masitinib|c-kit inhibitor (mastocytosis/GIST), AB Science|AB-1010|Kinaction|Masican|Masiviera|Alsitek|Masipro",INN|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Dermatologic|Immune|Infection|Musculoskeletal|Neurology/Psychiatric|Respiratory,SARS coronavirus 3C protease like inhibitor|CSF-1 antagonist|Fyn tyrosine kinase inhibitor|Lyn tyrosine kinase inhibitor|FGF3 receptor antagonist|Kit tyrosine kinase inhibitor|Protein tyrosine kinase inhibitor|PDGF receptor antagonist,14523|3154|3574|3586|3688|3808|385|948,CNS modulator|Anti-inflammatory|Systemic antipsoriatic product|Anticancer|Neuroprotectant|Antiviral|Anticancer protein kinase inhibitor|Respiratory system agent|Antiparkinsonian,2939|2953|15184|1545|1615|991|62255|1470|2947,Coronavirus disease 19 infection|Chronic obstructive pulmonary disease|Gastrointestinal tumor|Alzheimers disease|Peripheral T-cell lymphoma|Motor neurone disease|Multiple sclerosis|Glioblastoma|Pancreas tumor|Parkinsons disease|Mastocytosis|Asthma|Hormone refractory prostate cancer|Metastatic liver cancer|Cognitive disorder|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Ischemic stroke|Metastatic ovary cancer|Breast tumor,10406|1185|131|14|1753|212|213|2454|249|255|2795|31|3246|3462|353|3657|3658|3665|3669|3673|3676|3866|49,Multiple myeloma|Progressive supranuclear palsy|Melanoma|Psoriasis|Rheumatoid arthritis|Metastatic stomach cancer,1828|1998|205|281|291|3666,AB Science SA|University of Chicago,30580|26013,,,AB Science SA,30580,,,,,,
57118,naloxegol,"PEG-naloxol (oral, opioid-induced constipation), Nektar|naloxegol|PEG-naloxol (oral, opioid-induced constipation), AstraZeneca/RedHill|NKTR-118|naloxegol oxalate|NKTR-118 oxalate|AZ-13337019 oxalate|Movantik|Moventig",USAN|INN|Research Code|USAN|Research Code|Research Code|Trade Name|Trade Name,Gastrointestinal,Opioid receptor mu antagonist,294,Analgesic,2946,Gastroparesis|Constipation,2100|404,Esophageal disease,242,Knight Therapeutics Inc|Kyowa Hakko Kirin Co Ltd|RedHill Biopharma Ltd,1093663|1042596|1052603,Daiichi Sankyo Co Ltd|AstraZeneca plc|Nektar Therapeutics,1017506|14190|17221,Nektar Therapeutics,17221,,,,,,
57139,XMT-1001,"topoisomerase inhibitor prodrug (cancer), Mersana|XMT-1001|MER-1001|camptothecin prodrug (Fleximer, cancer), Mersana",Research Code|Prodrug|Research Code|Prodrug,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,,,Solid tumor,725,,,Mersana Therapeutics Inc,1002523,Mersana Therapeutics Inc,1002523,,,,,,
57144,"docetaxel (Protein Stabilized Liposome, small cell lung cancer), Plus Therapeutics","docetaxel|docetaxel (PSL, cancer), Azaya|docetaxel (Protein Stabilized Liposome, cancer), Azaya|ATI-1123|docetaxel (PSN, cancer), Azaya|docetaxel (Protein Stabilized Nanoparticle, cancer), Azaya|docetaxel (Protein Stabilized Liposome, cancer), Azaya/ CANbridge|CAN-001|CAN-C5-001|docetaxel (Protein Stabilized Liposome, cancer), Cytori/ CANbridge|DocePLUS|docetaxel (Protein Stabilized Liposome, small cell lung cancer), Plus Therapeutics",USAN|INN|Research Code|Research Code|Research Code|Trade Name,Cancer,,,Anticancer|Microtubule inhibitor|Cell cycle inhibitor,1545|2575|767,Small-cell lung cancer,1261,Non-small-cell lung cancer|Advanced solid tumor|Cancer,1262|3713|651,Plus Therapeutics Inc,31598,Azaya Therapeutics Inc|CANbridge Life Sciences Ltd,1007966|1088011,Azaya Therapeutics Inc,1007966,,,,,,
57160,MDX-1411,"anti-CD70 human monoclonal antibody-drug conjugate (cancer), Medarex|MDX-1411",Research Code,Cancer,CD70 antigen inhibitor,5291,Anticancer monoclonal antibody|Immunotoxin,55685|539,,,Cancer,651,,,Medarex Inc,17968,Medarex Inc,17968,,,,,,
57161,MDX-1342,"anti-CD19 antibody (cancer), Medarex/BMS|MDX-1342|anti-CD19 (cancer), MDX/BMS",Research Code,Cancer|Immune,B-lymphocyte antigen CD19 inhibitor,5082,Immunotoxin|Anticancer monoclonal antibody|B-lymphocyte inhibitor,539|55685|7740,,,Chronic lymphocytic leukemia|Rheumatoid arthritis|Autoimmune disease|Cancer,1734|291|36|651,,,Medarex Inc,17968,Medarex Inc,17968,,,,,,
57177,drozitumab,"Apomab|DR5 receptor mab (iv, cancer), Genentech|RG-7425|PRO-95780|drozitumab",Research Code|Research Code|USAN|PINN,Cancer,Caspase stimulator|TRAIL-2 receptor agonist,2687|8232,Anticancer monoclonal antibody|Apoptosis stimulator,55685|1589,,,Non-small-cell lung cancer|Sarcoma|Non-Hodgkin lymphoma|Cancer|Colorectal tumor,1262|194|319|651|989,,,Genentech Inc,19453,Genentech Inc,19453,,,,,,
57182,"azacitidine (oral tablet, cancer), Celgene","azacitidine|azacitidine (oral, cancer), Pharmion|azacitidine (oral, cancer), Upjohn|azacitidine (oral, cancer), Celgene|CC-486|CC-4386|azacitidine (oral tablet, cancer), Celgene|Onureg",USAN|INN|Research Code|Research Code|Trade Name,Cancer,DNA methyltransferase inhibitor,6512,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Hairy cell leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Peripheral T-cell lymphoma|Angioimmunoblastic T-cell lymphoma|Lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Stage IV melanoma|Chronic myelomonocytic leukemia,1272|1731|1734|1736|1743|1744|1745|1746|1753|1758|203|316|319|3257|6833,Diffuse large B-cell lymphoma|Nasopharyngeal carcinoma|Hematological neoplasm|Metastatic breast cancer|Metastatic non small cell lung cancer|Cancer|Solid tumor,1749|1768|2054|3657|3665|651|725,Bristol-Myers Squibb Co,15065,Celgene Corp|Upjohn Inc|Pharmion Corp,15331|19025|29253,Upjohn Inc,19025,,,,,,
57205,pinatuzumab vedotin,"CD22-targeting antibody-drug conjugates (cancer), Genentech|anti-CD22-MC-MMAF|anti-CD22-MCC-DM1|anti-CD22-MC-monomethyl auristatin phenylalanine|CD22-targeting antibody-drug conjugate (hematological malignancies), Genentech|anti-CD22-MMAE|anti-CD22-mafodotin|anti-CD22-SGD-1269|pinatuzumab vedotin|anti-CD22-mc-MMAE|anti-CD22-mc-vc-PAB-MMAE|RG-7593|DCDT-2980S",USAN|INN|Research Code,Cancer,Tubulin receptor antagonist|B-lymphocyte cell adhesion molecule inhibitor,541|5091,Immunotoxin|Cell cycle inhibitor|Anticancer|Anticancer monoclonal antibody,539|767|1545|55685,,,Follicle center lymphoma|Diffuse large B-cell lymphoma|Hematological neoplasm|Cancer,1745|1749|2054|651,,,Genentech Inc,19453,Genentech Inc,19453,,,,,,
57210,dinaciclib,"SCH-727965|CDK 1/2/9 inhibitor (cancer), Schering-Plough/Pharmacopeia|CDK inhibitor (cancer), Schering-Plough|PS-095760|dinaciclib|CDK inhibitor (cancer), Merck & Co|NSC-727135|MK-7965",Research Code|Research Code|USAN|INN|PINN|Research Code|Research Code,Cancer,Cyclin-dependent kinase-2 inhibitor|Cyclin-dependent kinase-1 inhibitor|Cyclin-dependent kinase-9 inhibitor|Cyclin-dependent kinase-5 inhibitor,4310|4308|8110|4316,Apoptosis stimulator|Anticancer protein kinase inhibitor|Anticancer,1589|62255|1545,,,Non-small-cell lung cancer|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Advanced solid tumor|Breast tumor|Cancer,1262|1728|1731|1734|1744|3713|49|651,,,Merck & Co Inc|Pharmacopeia Inc|Schering-Plough Corp,18077|19062|19711,Pharmacopeia Inc,19062,,,,,,
57211,voruciclib,"CDK4 inhibitor (oral, cancer), NPIL Research & Development|CDK4 inhibitor (oral, cancer), Piramal Life Sciences|CDK4 inhibitor (oral, cancer), Piramal Healthcare|voruciclib|kinase inhibitor (cancer), Piramal|P-1446|P-1446A-05",INN|Research Code|Research Code,Cancer,Cyclin-dependent kinase-6 inhibitor|Cyclin-dependent kinase-9 inhibitor|Cyclin dependent kinase 4 inhibitor D inhibitor|Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase inhibitor 1 inhibitor|Cyclin-dependent kinase inhibitor 1B inhibitor,4318|8110|31670|4314|16139|14217,Anticancer protein kinase inhibitor,62255,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|B-cell lymphoma|Cancer,1731|1734|1744|1745|1749|316|651,Melanoma|Breast tumor|Head and neck tumor,205|49|623,MEI Pharma Inc,28700,Life Molecular Imaging|Piramal Phytocare Ltd|Presage Biosciences,1006437|1037717|1054862,Life Molecular Imaging,1006437,,,,,,
57232,pevonedistat,"MLN-4924|NEDD8 activating enzyme inhibitor (cancer), Millennium|NAE inhibitor (cancer), Millennium|pevonedistat|pevonedistat hydrochloride|TAK-924",Research Code|USAN|INN|USAN|Research Code,Cancer|Hematologic,Amyloid protein binding protein-1 inhibitor|Ubiquitin ligase modulator,15160|2963,Apoptosis stimulator|Anticancer,1589|1545,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Myelofibrosis|Advanced solid tumor|Metastatic ovary cancer|Chronic myelomonocytic leukemia,1272|1728|1731|1734|2436|3713|3866|6833,Cancer|Solid tumor,651|725,Takeda Oncology|Takeda Pharmaceutical Co Ltd,21991|20300,,,Takeda Oncology,21991,,,,,,
5728,anidulafungin,LY-303366|ECB|VER-002|V-echinocandin|Eraxis|anidulafungin|Ecalta|Eracsis,Research Code|Research Code|Research Code|Trade Name|USAN|INN|Trade Name|Trade Name,Infection,"1,3 beta glucan synthase inhibitor",61991,Antiparasitic|Fungicide|Fungal cell wall synthesis inhibitor,2638|1748|2956,Candida infection,1308,Fungal infection|Aspergillus infection,124|29,Pfizer Inc,18767,Eli Lilly & Co|Vicuron Pharmaceuticals Inc,17810|22323,Eli Lilly & Co,17810,,,,,,
57288,olaptesed pegol,"NOX-A12|CXCL12 inhibitor (spiegelmer, diabetic retinopathy/AMD/stem cell transplantation/pancreatic cancer/colorectal cancer), Noxxon|ocular antineovascularisation agent/angiogenesis inhibitor (diabetic retinopathy/AMD), NOXXON|SDF-1 inhbitor (spiegelmer, stem cell transplantation), NOXXON|olaptesed pegol",Research Code|INN,Cancer|Immune|Ocular,Stromal cell-derived factor 1 ligand inhibitor,14125,Stem cell stimulator|Angiogenesis inhibitor|Synergist|Chemosensitizer|Hematopoietic modulator|Anticancer,53559|61|7293|5725|1678|1545,Unidentified indication|Glioma|Non-small-cell lung cancer|Chronic lymphocytic leukemia|Multiple myeloma|Adenocarcinoma|Glioblastoma|Pancreas tumor|Stem cell transplantation|Metastatic pancreas cancer|Colorectal tumor,1005|1108|1262|1734|1828|2399|2454|249|2990|3669|989,Age related macular degeneration|Diabetic retinopathy|Brain tumor,1226|576|760,NOXXON Pharma AG,16013,,,NOXXON Pharma AG,16013,,,,,,
57293,PRO-131921,"3rd generation anti-CD20 mAb (hematological cancer), Genentech|anti-CD20 mAb (hematogical cancer), Genentech|third generation anti-CD20 mAb (hematological cancer), Genentech|PRO-131921|Non-Hodgkin lymphoma agent, Genentech",Research Code,Cancer,B-lymphocyte antigen CD20 inhibitor,5085,Anticancer monoclonal antibody,55685,,,Chronic lymphocytic leukemia|Hematological neoplasm|Non-Hodgkin lymphoma,1734|2054|319,,,Biogen Inc|Genentech Inc,1005244|19453,Genentech Inc,19453,,,,,,
57313,dalantercept,"ACE-041|chimeric receptor TGF beta antagonist (sc, solid tumors/multiple myeloma/AMD), Acceleron|RAP-041|recombinant ALK-1 signaling inhibitor (angiogenesis), Acceleron|Alk1-Fc|dalantercept",Research Code|Research Code|USAN|INN,Cancer|Inflammatory|Ocular,TGF beta receptor antagonist|Alk-1 protein kinase inhibitor|Bone morphogenetic protein-10 ligand modulator|Bone morphogenetic protein-9 ligand modulator,377|4580|6871|6868,Anticancer|Ocular antineovascularisation agent|Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Synergist,1545|15148|62255|61|7293,,,Age related macular degeneration|Endometrioid carcinoma|Hepatocellular carcinoma|Multiple myeloma|Fallopian tube cancer|Arthritis|Peritoneal tumor|Metastatic renal cancer|Metastatic head and neck cancer|Cancer|Solid tumor|Ovary tumor,1226|1705|1767|1828|2243|28|3083|3467|3673|651|725|799,,,Acceleron Pharma Inc,1009646,Acceleron Pharma Inc,1009646,,,,,,
57360,KW-2478,"KW-2478|HSP-90 inhibitor (intravenous, cancer), Kyowa Hakko Kirin",Research Code,Cancer,Hsp 90 inhibitor,8012,Anticancer,1545,,,Multiple myeloma|Hematological neoplasm|Cancer,1828|2054|651,,,Kyowa Kako KK|Kyowa Hakko Kirin Co Ltd,1003019|1042596,Kyowa Kako KK,1003019,,,,,,
57452,alisertib,MLN-8237|alisertib|TAK-823,Research Code|USAN|INN|Research Code,Cancer|Hematologic,Aurora protein kinase 2 inhibitor,4420,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Gastrointestinal tumor|Acute myelogenous leukemia|Metastatic lung cancer|Solid tumor|Central nervous system tumor,131|1731|3668|725|759,Esophagus tumor|Neuroendocrine tumor|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Myelodysplastic syndrome|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Myelofibrosis|B-cell lymphoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Metastatic non small cell lung cancer|Breast tumor|Head and neck tumor|Cancer|Burkitts lymphoma|Ovary tumor,1011|1128|1240|1261|1262|1272|1744|1745|1749|1753|2436|316|319|3246|3665|49|623|651|791|799,Takeda Oncology,21991,,,Takeda Oncology,21991,,,,,,
57470,Iodine (131I) apamistamab,"iodine-131-radiolabeled anti-CD45 antibody (leukemia), Fred Hutchinson Cancer Research Center|I-131-MOAB-BC8|131I monoclonal antibody, BC8|iodine-131-radiolabeled anti-CD45 antibody (leukemia), Actinium|Iomab-B|Iodine (131I) apamistamab|131I-BC8|Iodine-131-BC8|BC8-[131I]|apamistamab-[131I]|Iodine-131-apamistamab",Research Code|Research Code|Trade Name|USAN|INN|Research Code|Research Code|Research Code,Cancer,CD45 antagonist,5171,Immunomodulator|Radioimmunotherapeutic|Hematopoietic inhibitor|Anticancer monoclonal antibody,1596|1552|1677|55685,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Lymphoma,1272|1728|1731|203,Chronic lymphocytic leukemia|Multiple myeloma|Cancer,1734|1828|651,Actinium Pharmaceuticals Inc,24594,Fred Hutchinson Cancer Research Center,16218,Fred Hutchinson Cancer Research Center,16218,,,,,,
57635,"autologous tumor cell vaccine (leukemia), NCI","autologous tumor cell vaccine (leukemia), NCI",,Cancer,,,Anticancer|Therapeutic vaccine,1545|12379,,,Leukemia,199,,,National Cancer Institute (NCI),20519,National Cancer Institute (NCI),20519,,,,,,
57715,viagenpumatucel-L,"gp96-Ig secreting adenocarcinoma cell-based vaccine (NSCLC, HeatShock/ImPACT), Heat Biologics|Ad100-gp96Ig-HLA A1|HS-L1|HS-110|viagenpumatucel-L|gp96-Ig secreting adenocarcinoma cell-based vaccine (intradermal, advanced solid tumor), Heat Biologics",Research Code|Research Code|Research Code|USAN,Cancer,Endoplasmin modulator,14246,Therapeutic vaccine|Anticancer|T-lymphocyte stimulator,12379|1545|7761,Metastatic non small cell lung cancer|Advanced solid tumor,3665|3713,,,Heat Biologics Inc,1048466,University of Miami,20622,University of Miami,20622,,,,,,
57753,"cyclophosphamide (high dose, autoimmune disorders), Accentia","cyclophosphamide|Revimmune|cyclophosphamide (high dose, autoimmune disorders), Accentia|HiCy|Cyrevia",INN|Trade Name|Trade Name,Dermatologic|Gastrointestinal|Hematologic|Immune,,,Anticancer alkylating agent|Immunomodulator,50|1596,,,Aplastic anemia|Scleroderma|Pemphigus|Multiple sclerosis|Autoimmune hemolytic anemia|Rheumatoid arthritis|Sickle cell anemia|Systemic lupus erythematosus|Autoimmune disease|Transplant rejection|Graft versus host disease|Crohns disease|Myasthenia gravis,1006|1105|1114|213|2643|291|303|318|36|515|616|84|848,,,Biovest International Inc|Accentia BioPharmaceuticals Inc|Johns Hopkins University,1007305|1007306|20596,Johns Hopkins University,20596,,,,,,
57794,AZD-1480,"AZD-1480|Jak tyrosine kinase inhibitors (cancer), AstraZeneca",Research Code,Cancer|Hematologic,Jak2 tyrosine kinase inhibitor|Jak1 tyrosine kinase inhibitor,3564|3562,Anticancer protein kinase inhibitor,62255,,,Myeloproliferative disorder|Cancer|Solid tumor,273|651|725,,,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
57911,grapiprant (oral),"CJ-023423|RQ-00000007 (oral)|RQ-7|grapiprant|AAT-007|RQ-00000007|grapiprant (oral)|RMX-1002|ARY-007|IK-007|NB-002, Ningbo NewBay Medical Technology|3D-1002",Research Code|Research Code|Research Code|USAN|PINN|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Gastrointestinal|Immune|Inflammatory|Neurology/Psychiatric,EP4 prostanoid receptor antagonist,3478,Anti-inflammatory|Anticancer|Immunomodulator|Analgesic,2953|1545|1596|2946,Familial adenomatous polyposis|Pain|Osteoarthritis|Arthritis|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,1277|20|245|28|3658|3665|3713,Allergy|Inflammatory disease|Autoimmune disease|Cancer,12|188|36|651,3D Medicines Corporation|Ningbo NewBay Medical Technology Co Ltd|Ikena Oncology,1120744|1159491|1157956,RaQualia Pharma Inc|AskAt Inc|RMX Biopharmaceutical|Arrys Therapeutics|HaiHe Biopharma|Shanghai Haishi Biopharmaceutical|Pfizer Inc,1040956|1081844|1154018|1157960|1181217|1186025|18767,RMX Biopharmaceutical,1154018,,,,,,
57921,avadomide,"pleiotropic pathway modifiers (inflammatory disease), Celgene|CC-16057|CC-122 HCl|CC-122|pleiotropic pathway modulator (oral, cancer), Celgene|CC-122 hydrochloride|avadomide|avadomide hydrochloride|pleiotropic pathway modulator (oral, cancer), Bristol-Myers Squib",Research Code|Research Code|Research Code|USAN|INN|USAN,Cancer|Inflammatory,Protein cereblon modulator|Pleiotropic drug resistance transporter modulator,77059|30483,Anticancer|Angiogenesis inhibitor|Cell cycle inhibitor|Synergist|Immunomodulator|Anti-inflammatory|Apoptosis stimulator,1545|61|767|7293|1596|2953|1589,Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Hepatocellular carcinoma|Multiple myeloma|Non-Hodgkin lymphoma|Stage IV melanoma|Cancer|Solid tumor,1734|1745|1749|1767|1828|319|3257|651|725,Inflammatory disease|Glioblastoma,188|2454,Bristol-Myers Squibb Co|BeiGene Co Ltd,15065|1063251,Celgene Corp,15331,Celgene Corp,15331,,,,,,
57922,NHS-IL2-LT,"NHS-IL-2(D20T) immunocytokine, EMD Lexigen|NHS-IL2-LT|EMD-521873|immunocytokine (solid tumors), Merck Serono|Selectikine|MSB-0010445",Research Code|Research Code|Trade Name|Research Code,Cancer,IL-2 receptor agonist|Interleukin-2 ligand,221|12481,Anticancer|DNA modulator|Immunomodulator,1545|803|1596,,,Melanoma|Cancer|Solid tumor,205|651|725,,,Merck Serono SA|EMD Lexigen Research Center Corp,19862|21956,EMD Lexigen Research Center Corp,21956,,,,,,
58013,poziotinib,"pan-Her/EGFR inhibitors (cancer), Hanmi|poziotinib|NOV-120101|HM-78136B|NOV-1201",INN|Research Code|Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor|Erbb2 tyrosine kinase receptor inhibitor|Erbb4 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3754|3756|3760|740,Anticancer|Apoptosis stimulator|Anticancer protein kinase inhibitor,1545|1589|62255,Glioma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Breast tumor|Head and neck tumor|Colorectal tumor,1108|3657|3665|3713|49|623|989,Non-small-cell lung cancer|Metastatic stomach cancer|Cancer|Solid tumor,1262|3666|651|725,Luye Pharma Group Ltd|Spectrum Pharmaceuticals Inc|Hanmi Pharmaceutical Co Ltd,1015499|24232|16611,National OncoVenture,1072620,Hanmi Pharmaceutical Co Ltd,16611,,,,,,
58054,pacritinib,"JAK-2 kinase inhibitors (oral, myeloproliferative disorders/hematological neoplasms), S*Bio|EX58  JAK2i|pacritinib|SB-1518|ONX-0803|BAX-2201|Enpaxiq|Epjevy|pacritinib citrate|JAK2/IRAK-1/CSF1R/Fit3 tyrosine kinase inhibitors (oral, graft versus host disease/thrombocytopenia/myelofibrosis/lymphoma/COVID-19/respiratory distress syndrome), CTI Biopharma Corp|JAK-2 kinase inhibitors (oral, COVID-19), S*Bio",USAN|INN|Research Code|Research Code|Research Code|Trade Name|Trade Name,Cancer|Hematologic|Immune|Infection|Respiratory,IRAK-1 protein kinase inhibitor|Cytochrome P450 reductase inhibitor|CSF-1 antagonist|Jak2 tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor,4486|416|3154|3564|3806,Antiviral|Anticancer|Anticancer protein kinase inhibitor|Anti-inflammatory|Cell cycle inhibitor,991|1545|62255|2953|767,Coronavirus disease 19 infection|Chronic lymphocytic leukemia|Myelofibrosis|Thrombocytopenia|Graft versus host disease|Respiratory distress syndrome,10406|1734|2436|324|616|8,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia|Lymphoma|Hematological neoplasm|Polycythemia vera|Myeloproliferative disorder|Chronic myelomonocytic leukemia|Colorectal tumor,1272|1731|1735|203|2054|2319|273|6833|989,CTI BioPharma Corp,15337,Baxalta Inc|Baxter International Inc|Shire plc|S*BIO Pte Ltd,1109518|14437|24652|27780,S*BIO Pte Ltd,27780,,,,,,
58138,ianalumab,"NOV-5 program|fully human monoclonal antibodies (HuCAL, inflammation/leukemia), Novartis|VAY-736|BAFF-R mAb (leukemia/inflammation), Novartis|B-cell activating factor receptor monoclonal antibody (leukemia/inflammation), Novartis|ianalumab|lanalumab",Research Code|INN,Cancer|Dermatologic|Immune|Inflammatory|Respiratory,B-lymphocyte stimulator ligand modulator,12768,Anti-inflammatory|Anticancer monoclonal antibody|B-lymphocyte modulator|Anticancer,2953|55685|5702|1545,Pemphigus|Sjoegrens syndrome|Chronic lymphocytic leukemia|Rheumatoid arthritis|Autoimmune hepatitis|Systemic lupus erythematosus|Idiopathic pulmonary fibrosis,1114|1148|1734|291|3065|318|3771,Inflammatory disease|Multiple sclerosis,188|213,Novartis AG,23137,MorphoSys AG,21404,MorphoSys AG,21404,,,,,,
58145,Fluzone HD,"seasonal influenza vaccine (high-dose intramuscular), sanofi pasteur|Fluzone HD|Fluzone High Dose",Trade Name|Trade Name,Infection,,,Inactivated viral vaccine|Prophylactic vaccine,12367|12378,Influenza virus infection,191,,,Sanofi Pasteur,22127,,,Sanofi Pasteur,22127,,,,,,
58175,tafasitamab,"XmAb-5574|anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor|triple anti-CD19/FcgRIIa activator/FcgRIIIa activator (cancer), Xencor|XENP-5574|XmAb CD19|MOR-208|MOR-00208|tafasitamab|ENFORCER antibody|XmAb-CD19|triple anti-CD19/CD32a activator/CD16a activator (cancer), Xencor|tafasitamab-cxix|Monjuvi|Minjuvi",Research Code|Research Code|Research Code|Research Code|USAN|INN|Trade Name|Trade Name|Trade Name,Cancer|Immune,Immunoglobulin gamma Fc receptor IIA agonist|Immunoglobulin gamma Fc receptor IIIA agonist|B-lymphocyte antigen CD19 modulator,27987|27981|5080,Lymphocyte stimulator|Synergist|Immunostimulant|Anticancer monoclonal antibody,7749|7293|393|55685,Chronic lymphocytic leukemia|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma|Burkitts lymphoma,1734|1745|1746|1749|319|791,B-cell acute lymphoblastic leukemia|Prolymphocytic leukemia|Lymphoma|Autoimmune disease|Cancer,1729|1738|203|36|651,MorphoSys AG|Incyte Corp,21404|17216,Xencor Inc,27617,Xencor Inc,27617,,,,,,
58191,"crisantaspase (acute lymphoblastic leukemia), Jazz Pharmaceuticals","Erwinia chrysanthemi L-asparaginase (acute lymphoblastic leukemia), OPi/HPA|crisantaspase|asparaginase (Erwinia chrysanthemi)|Erwinaze|Erwinase|crisantaspase (acute lymphoblastic leukemia), OPi/HPA|OP-01|crisantaspase (acute lymphoblastic leukemia), Jazz Pharmaceuticals",INN|Trade Name|Trade Name|Research Code,Cancer,Asparaginase stimulator,517,Anticancer,1545,Acute lymphoblastic leukemia,1728,Hematological neoplasm,2054,Ohara Pharmaceutical Co Ltd|NovaMed Pharmaceuticals Inc|Clinigen Group plc,1000882|1033155|1062207,Health Protection Agency|Jazz Pharmaceuticals plc|EUSA Pharma USA|OPi SA,1006631|1007377|1031239|28650,Health Protection Agency,1006631,,,,,,
58200,oprozomib,"PR-047|PR-141|PR-928|proteasome inhibitor (oral, cancer), Proteolix Inc/Onyx Pharmaceuticals Inc|PR-924|proteasome inhibitor program (oral, cancer), Onyx Pharmaceuticals/Ono Pharmaceutical|ONX-0912|ONX-012|oprozomib|ONO-7058",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer|Hematologic,Proteasome inhibitor,4917,Apoptosis stimulator|Anticancer,1589|1545,,,Macroglobulinemia|Hepatocellular carcinoma|Multiple myeloma|Hematological neoplasm|Non-Hodgkin lymphoma|Cancer|Solid tumor,1264|1767|1828|2054|319|651|725,,,Proteolix Inc|Amgen Inc|Ono Pharmaceutical Co Ltd|Onyx Pharmaceuticals Inc,1017655|14109|18681|18683,Proteolix Inc,1017655,,,,,,
5827,bryostatin-1,bryostatin-1|NSC-339555|Bryol|bryolog|BMY-45618|bryostatin,Research Code|Trade Name|Research Code|Research Code,Cancer|Infection,Protein kinase C inhibitor,334,Anticancer|Antibacterial|Anticancer protein kinase inhibitor,1545|1594|62255,B-cell lymphoma,316,Gastrointestinal tumor|Chronic lymphocytic leukemia|Melanoma|Bacterial infection|Metastatic renal cell carcinoma|Cancer|Lung tumor,131|1734|205|40|4250|651|755,National Cancer Institute (NCI),20519,Bristol-Myers Squibb Co|Arizona State University|GPC Biotech AG,15065|20526|25202,Arizona State University,20526,,,,,,
58289,SRA-737,"selective Chk1 inhibitors (cancer), Sareum/ Institute of Cancer Research/ Cancer Research Technology|SAR-020106|CCT-244747|CCT-245737|selective Chk1 inhibitors (cancer), ProNai|PNT-737|SRA-737|SRA-737737",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Checkpoint kinase 1 inhibitor,4438,Radiosensitizer|Synergist|Anticancer protein kinase inhibitor,1542|7293|62255,Small-cell lung cancer|Non-small-cell lung cancer|Transitional cell carcinoma|Hormone refractory prostate cancer|Soft tissue sarcoma|Uterine cervix tumor|Cancer|Ovary tumor|Colorectal tumor,1261|1262|1771|3246|3378|427|651|799|989,,,Sierra Oncology Inc,1015757,Sareum Holdings plc|Institute of Cancer Research UK|Cancer Research UK|Cancer Research Technology Ltd,1018925|21072|29469|30620,Cancer Research UK,29469,,,,,,
58300,AB-16B5,"clusterin-specific antibodies (cancer), National Research Council of Canada|clusterin-specific antibodies (cancer), National Research Council Biotechnology Research Institute|secreted clusterin (sCLU)-targeting humanized monoclonal antibody (cancer), Alethia|clusterin-specific antibodies (cancer), Alethia Biotherapeutics|16B5|AB-16B5|clusterin-specific antibodies (cancer), National Research Council Biotechnology Research Institute/ International Biotechnology Center Generium",Research Code|Research Code,Cancer,Clusterin inhibitor|Immunoglobulin G2 modulator,14128|5756,Anticancer monoclonal antibody|Metastasis inhibitor,55685|695,Metastatic non small cell lung cancer|Cancer,3665|651,Non-small-cell lung cancer,1262,International Biotechnology Center Generium LLC|Alethia Biotherapeutics Inc,1065293|30105,National Research Council of Canada,18632,National Research Council of Canada,18632,,,,,,
58301,RO-4929097,"R-4733|Gamma-secretase inhibitor (oral, solid tumor), Roche|Notch signalling inhibitor (oral, solid tumor), Roche|RO-4929097|RG-4733|NSC-749225",Research Code|Research Code|Research Code|Research Code,Cancer,Gamma-secretase inhibitor|Notch antagonist,7578|8118,Anticancer,1545,,,Glioma|Non-small-cell lung cancer|Sarcoma|Fallopian tube cancer|Peritoneal tumor|Stage IV melanoma|Breast tumor|Solid tumor|Ovary tumor|Colorectal tumor,1108|1262|194|2243|3083|3257|49|725|799|989,,,Hoffmann-La Roche Inc|National Cancer Institute (NCI),19461|20519,Hoffmann-La Roche Inc,19461,,,,,,
58308,Betamarc,"Betamarc|appetite stimulant (cachexia/appetite loss), Anaborex",,Other/Miscellaneous,,,Appetite stimulator|Unspecified drug target,1839|59620,,,Appetite loss|Cachexia,3038|425,,,Anaborex Inc,1033374,Anaborex Inc,1033374,,,,,,
58354,BIO-11006 Inhalation Solution,BIO-11006|BIO-11006 Inhalation Solution,Research Code,Cancer|Respiratory,MARCKS protein inhibitor,40734,Respiratory system agent|Anti-inflammatory|Anticancer|Anticancer protein kinase inhibitor,1470|2953|1545|62255,Chronic obstructive pulmonary disease|Non-small-cell lung cancer|Respiratory distress syndrome,1185|1262|8,Cancer,651,BioMarck Pharmaceuticals Ltd,1022091,North Carolina State University,20636,North Carolina State University,20636,,,,,,
58365,quisinostat,"second-generation pan-HDAC inhibitors (cancer), Johnson & Johnson|JNJ-26481585|second-generation pan-histone deacetylase inhibitors (cancer), J&J|second-generation pan-HDAC inhibitors (cancer), Ortho Biotech Oncology Research & Development|quisinostat|quisinostat hydrochloride",Research Code|USAN|INN|USAN,Cancer,Prostate specific antigen inhibitor|Androgen receptor antagonist|Histone H3 modulator|Histone deacetylase-1 inhibitor|Histone deacetylase-2 inhibitor,35356|60|60273|7841|7844,Angiogenesis inhibitor|Anticancer|Apoptosis stimulator,61|1545|1589,Non-small-cell lung cancer|Sarcoma|Fallopian tube cancer|Peritoneal tumor|Metastatic ovary cancer|Breast tumor,1262|194|2243|3083|3866|49,Cutaneous T-cell lymphoma|Multiple myeloma|Cancer|Solid tumor,1754|1828|651|725,NewVac LLC,1066959,Johnson & Johnson|Johnson & Johnson Pharmaceutical Research & Development LLC,17332|29481,Johnson & Johnson,17332,,,,,,
58393,lutetium (177Lu) oxodotreotide,"177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema|177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema|177Lu-DOTA-[3-Tyr]octreotate (neuroendocrine tumors), Advanced Accelerator Applications|Lutathera|Lutetium-177-DOTA-[3-Tyr]-octreotate|Lutate|radiolutetium-177-DOTATATE|177Lu-DOTATATE|DOTA-[3-Tyr]-octreotate-[177Lu]|177Lu-DOTATATE (neuroendocrine tumors), Advanced Accelerator Applications|lutetium (177Lu) oxodotreotide|Lutetium-177- oxodotreotide|Lutetium oxodotreotide-[177Lu]|177Lu-oxodotreotide|F-1515",Trade Name|Trade Name|Research Code|INN|Research Code,Cancer,Somatostatin receptor modulator,1119,Endocrine diagnostic agent|Anticancer|Imaging agent|Radiotherapeutic|Neoplasm diagnostic agent|Radiodiagnostic,7212|1545|4155|5721|7220|5720,Neuroendocrine tumor|Small-cell lung cancer|Carcinoid tumor|Pheochromocytoma|Neuroblastoma|Paraganglioma|Metastatic lung cancer,1128|1261|2538|262|2726|2876|3668,,,Advanced Accelerator Applications SA|FUJIFILM Toyama Chemical Co Ltd,1017958|22616,BioSynthema Inc,30716,BioSynthema Inc,30716,,,,,,
58408,"E-6201 (hematological malignancies), Strategia Therapeutics/JS InnoPharm","E-6201 (intravenous, cancer), Eisai|MEK-1 inhibitor (intravenous, cancer), Eisai|E-6201|ER-803064|E-6201 (AML), Strategia Therapeutics|E-6201 (hematological malignancies), Strategia Therapeutics|E-6201 (hematological malignancies), Strategia Therapeutics/JS InnoPharm|JSI-1187",Research Code|Research Code,Cancer,MEK-1 protein kinase inhibitor|Flt3 tyrosine kinase inhibitor,4762|3806,Anticancer|Apoptosis stimulator|Anticancer protein kinase inhibitor,1545|1589|62255,Hematological neoplasm|Metastatic brain cancer|Advanced solid tumor,2054|3471|3713,Acute myelogenous leukemia|Cancer,1731|651,Js Innopharm (Shanghai) Ltd|Strategia Therapeutics Inc,1128772|1090440,Eisai Co Ltd,15872,Eisai Co Ltd,15872,,,,,,
58489,guadecitabine sodium,"S-110|DNA demethylating agent (myelodysplastic syndrome), Supergen|SGI-110|DNA demethylating agent (myelodysplastic syndrome/hepatocellular carcinoma/ovarian cancer/acute myelogenous leukemia), Supergen|guadecitabine|guadecitabine sodium|DNA demethylating agent (myelodysplastic syndrome/hepatocellular carcinoma/ovarian cancer/acute myelogenous leukemia/melanoma/non-small cell lung cancer), Supergen",Research Code|Research Code|USAN|INN|USAN,Cancer|Hematologic,Beta-catenin inhibitor|Secreted frizzled related protein-2 stimulator|DNA methyltransferase inhibitor,15709|15804|6512,Anticancer|Blood system agent|Synergist,1545|1546|7293,,,Small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Renal cell carcinoma|Fallopian tube cancer|Pheochromocytoma|Paraganglioma|Sickle cell anemia|Peritoneal tumor|Gastrointestinal stromal tumor|Stage IV melanoma|Metastatic liver cancer|Metastatic bladder cancer|Metastatic colorectal cancer|Advanced solid tumor|Germ cell and embryonic cancer|Chronic myelomonocytic leukemia|Solid tumor|Ovary tumor,1261|1272|1731|1766|2243|262|2876|303|3083|3205|3257|3462|3466|3658|3713|3737|6833|725|799,,,Taiho Oncology Inc|Taiho Pharma Canada Inc|Astex Pharmaceuticals Inc,1092741|1144560|21885,Astex Pharmaceuticals Inc,21885,,,,,,
58493,BIIB-022,BIIB-022|Anti-IGF-1R,Research Code,Cancer,Insulin-like growth factor 1 receptor antagonist,3252,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,,,Hepatocellular carcinoma|Solid tumor,1767|725,,,Biogen Inc,1005244,Biogen Inc,1005244,,,,,,
58504,sacituzumab govitecan,"anti-EGP-1 mAB/SN-38 conjugate (cancer), Immunomedics|hRS7-SN-38 conjugate|CL2-SN-38|hRS7-CL2A-SN-38|IMMU-132|RS7-SN38|humanized anti-TROP-2-SN-38 conjugate (cancer), Immunomedics|hRS7-SN-38 (antibody conjugate, cancer), Immunomedics|anti-TROP-2-SN-38|sacituzumab govitecan|isactuzumab govitecan|sacituzumab govitecan-hziy|Trodelvy|GS-0132",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Trade Name|Research Code,Cancer,Topoisomerase I inhibitor|Trop-2 calcium signal transducer inhibitor,141|17895,Synergist|Anticancer monoclonal antibody,7293|55685,Esophagus tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Follicle center lymphoma|Renal cell carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Bladder cancer|Glioblastoma|Pancreas tumor|Squamous cell carcinoma|Hormone refractory prostate cancer|Metastatic bladder cancer|Metastatic breast cancer|Uterine cervix tumor|Breast tumor|Head and neck tumor|Solid tumor|Ovary tumor,1011|1261|1262|127|1705|1745|1766|1767|1771|2380|2454|249|307|3246|3466|3657|427|49|623|725|799,Cancer,651,Everest Medicines Ltd|Immunomedics Inc|Gilead Sciences Inc,1157539|17204|16450,Seagen Inc,25554,Immunomedics Inc,17204,,,,,,
58535,tepotinib,"c-Met kinase inhibitors (cancer), Merck Serono|EMD-1214063|MSC-2156119J|tepotinib|Tepmetko|tepotinib hydrochloride|tepotinib hydrochloride hydrate",Research Code|Research Code|USAN|INN|Trade Name|USAN,Cancer,Hepatocyte growth factor receptor antagonist,675,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Non-small-cell lung cancer|Hepatocellular carcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma,1262|1767|3657|3658|3665|3666|3673|3713|4250,Cancer|Solid tumor,651|725,Merck KGaA,18101,,,Merck KGaA,18101,,,,,,
58557,Gardasil 9,"V-503|human papillomavirus vaccine (nonavalent), Merck & Co|9-valent HPV vaccine, Merck|Gardasil 9|9vHPV",Research Code|Trade Name,Cancer|Genitourinary/Sexual Function|Infection,,,Prophylactic vaccine|Protein subunit vaccine,12378|12372,Condyloma|Cervical dysplasia|Anal dysplasia|Anal tumor|Vulvar intraepithelial neoplasia|Vaginal cancer|Vaginal intraepithelial neoplasia|Papillomavirus infection|Uterine cervix tumor|Head and neck tumor,1232|1235|1517|2193|3105|3291|3292|396|427|623,,,Merck & Co Inc|MSD Japan|CSL Ltd|Korea Kolmar Holdings Co Ltd,18077|24019|15563|17678,GC Pharma|Sanofi Pasteur MSD,16583|23408,Merck & Co Inc,18077,,,,,,
58618,LY-3009120,"selective B-Raf inhibitors (cancer), Deciphera/Eli Lilly|DP-2743|DP-2854|DP-2512|DP-2874|DP-3346|dual B-RAF and C-RAF inhibitor (cancer), Deciphera|LY-3009120|Pan-Raf inhibitor (cancer), Eli Lilly|DP-4978|LSN-3074753",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Raf B protein kinase inhibitor|Raf A protein kinase inhibitor|Raf 1 protein kinase inhibitor,4548|4546|4550,Synergist|Anticancer protein kinase inhibitor,7293|62255,,,Cancer,651,,,Deciphera Pharmaceuticals LLC|Eli Lilly & Co,1009096|17810,Deciphera Pharmaceuticals LLC,1009096,,,,,,
58665,4SC-203,"SC-71710|protein kinase inhibitor (iv, AML), 4SC|angiogenesis inhibitor (iv, AML), 4SC|4iP active agent (cancer), 4SC/ProQinase|4SC-203",Research Code|Research Code,Cancer,VEGF-2 receptor antagonist|ALK tyrosine kinase receptor family inhibitor|Axl tyrosine kinase receptor inhibitor|SL cytokine ligand inhibitor|Focal adhesion kinase inhibitor|Flt3 tyrosine kinase inhibitor,3848|3851|3742|15591|3540|3806,Anticancer protein kinase inhibitor|Angiogenesis inhibitor,62255|61,,,Acute myelogenous leukemia|Solid tumor,1731|725,,,Reaction Biology Europe GmbH|4SC AG,1016204|28108,4SC AG,28108,,,,,,
58709,monalizumab,"IPH-22XX|Natural killer cell agonist (NK Platform, cancer), Innate Pharma/Novo Nordisk|NNC-0141-0000-0100|NNC-141-0100|Anti-NKG2a (rheumatoid athritis), Novo Nordisk/Innate|NN8765-3658|monalizumab|IPH-2201|NN-8765|NKG2A checkpoint inhibitor (iv, cancer), Innate Pharma/AstraZeneca|NKG2A checkpoint inhibitor (iv, metastatic HER2 positive breast cancer), AstraZeneca",Research Code|Research Code|Research Code|Research Code|INN|Research Code|Research Code,Cancer|Immune|Inflammatory,NKG2 A B activating NK receptor antagonist,77513,T-lymphocyte stimulator|Natural killer cell stimulator|Anticancer monoclonal antibody|Anti-inflammatory|Immunostimulant,7761|7757|55685|2953|393,Non-small-cell lung cancer|Chronic lymphocytic leukemia|Hematological neoplasm|Fallopian tube cancer|Squamous cell carcinoma|Peritoneal tumor|Metastatic breast cancer|Metastatic head and neck cancer|Advanced solid tumor|Cancer|Ovary tumor,1262|1734|2054|2243|307|3083|3657|3673|3713|651|799,Immune disorder|Inflammatory disease|Rheumatoid arthritis|Autoimmune disease,185|188|291|36,AstraZeneca plc,14190,Novo Nordisk A/S|Innate Pharma SA,18614|28788,Innate Pharma SA,28788,,,,,,
58728,briciclib sodium,"ON-013105|cyclin D1 inhibitor (iv prodrug, hematological malignancies), Onconova|styryl sulfone (iv prodrug, hematological malignancies), Onconova|ON-013105.Na|briciclib|ON 014185|briciclib sodium",Research Code|Research Code|USAN|INN|Research Code|USAN,Cancer,Eukaryotic initiation factor 4E2 inhibitor|Cyclin D1 inhibitor,37392|9488,Cell cycle inhibitor|Apoptosis stimulator,767|1589,Acute lymphoblastic leukemia|Lymphoma|Cancer|Solid tumor,1728|203|651|725,Hematological neoplasm,2054,Onconova Therapeutics Inc,30752,Pullan Consulting,1080963,Onconova Therapeutics Inc,30752,,,,,,
58733,OPB-31121,"OPB-31121|STAT-3 inhibitor (oral, cancer), Otsuka Pharmaceutical",Research Code,Cancer,STAT-3 inhibitor,7967,Cell cycle inhibitor,767,,,Hepatocellular carcinoma|Multiple myeloma|Non-Hodgkin lymphoma|Cancer|Solid tumor,1767|1828|319|651|725,,,Otsuka Pharmaceutical Co Ltd,18717,Otsuka Pharmaceutical Co Ltd,18717,,,,,,
58798,ImMucin,"MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/Hadassah Medical|ImMucin|VXL-100",Trade Name|Research Code,Cancer,Mucin 1 inhibitor,32078,Anticancer|Protein subunit vaccine|Therapeutic vaccine|Immunomodulator,1545|12372|12379|1596,Multiple myeloma|Metastatic breast cancer|Ovary tumor,1828|3657|799,Cancer,651,Vaxil BioTherapeutics Ltd,1036156,Hadassah Medical Organization,16594,Hadassah Medical Organization,16594,,,,,,
58812,RG-7112,"R-7112|MDM2 antagonist (solid tumor/hematological neoplasm), Roche|RG-7112|RO-5045337",Research Code|Research Code|Research Code,Cancer,Mdm2 p53-binding protein inhibitor|p53 tumor suppressor protein stimulator,10391|17120,Synergist|Anticancer|Apoptosis stimulator|Cell cycle inhibitor,7293|1545|1589|767,,,Hematological neoplasm|Solid tumor,2054|725,,,Hoffmann-La Roche Inc,19461,Hoffmann-La Roche Inc,19461,,,,,,
58877,"AlloStim (infusion formulation, hematological neoplasms), Immunovative Therapies/ Robert H Lurie Cancer Center","AlloStim|activated mismatched CD4+ memory T cells (hematological malignancies), Immunovative Therapies|activated T-Stim cells (iv infusion, hematological neoplasms), Immunovative|AlloStim (infusion formulation, hematological neoplasms), Immunovative|AlloStim-9 infusion + AlloStim-8 booster infusions (hematological cancers), Immunovative|AlloStim (infusion formulation, hematological neoplasms), Immunovative Therapies/ Robert H Lurie Cancer Center|InSituVax|StimVax",Trade Name,Cancer,,,Immunostimulant|Anticancer,393|1545,Hematological neoplasm|Metastatic colorectal cancer,2054|3658,Metastatic breast cancer,3657,Immunovative Therapies Ltd|Robert H Lurie Cancer Center,1016027|1038965,,,Immunovative Therapies Ltd,1016027,,,,,,
58878,LAG-525,"IMP-701|anti-membrane bound LAG-3 monoclonal antibody (ImmuTune, cancer/infectious disease), Immutep|LAG-525|anti-LAG-3 antibody (cancer), Novartis|LAG-3 checkpoint inhibitor (cancer), Novartis|ieramilimab",Research Code|Research Code|USAN|INN,Cancer|Infection,CD223 antagonist,8413,Antimicrobial|Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,1593|393|7761|55685,Mesothelioma|Hematological neoplasm|Stage III melanoma|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic renal cell carcinoma,1240|2054|3256|3257|3657|3665|3713|4250,Cancer|Solid tumor|Infectious disease,651|725|746,Novartis AG,23137,Immutep SAS|CoStim Pharmaceuticals Inc,1007701|1088885,Immutep SAS,1007701,,,,,,
58894,BI-505,"BI-505|ICAM-1-targeting antibody (FIRST, cancer), BioInvent",Research Code,Cancer,ICAM-1 modulator,5222,Anticancer monoclonal antibody|Apoptosis stimulator|Immunostimulant,55685|1589|393,,,Multiple myeloma|Cancer,1828|651,,,BioInvent International AB,18592,BioInvent International AB,18592,,,,,,
58903,"fentanyl (sublingual spray, pain), Insys Therapeutics","fentanyl|fentanyl (sublingual spray, pain), Insys Therapeutics|Fentanyl SL spray|Subsys|fentanyl (sublingual spray, pain), Lunatus",USAN|INN|Trade Name|Trade Name,Neurology/Psychiatric,Opioid receptor mu agonist,293,Analgesic,2946,Cancer pain,3211,Pain,20,Lunatus|BTcP Pharma LLC,1116810|1195603,Insys Therapeutics Inc,1033982,Insys Therapeutics Inc,1033982,,,,,,
58908,demcizumab,"tumor stem cell-targeting humanized monoclonal antibodies (cancer), OncoMed|tumor stem cell-targeting humanized mAbs (cancer), OncoMed|OMP-90R210|anti-DLL4 humanized monoclonal antibodies (cancer), OncoMed|demcizumab|OMP-21M18",Research Code|USAN|INN|Research Code,Cancer,Delta-like protein ligand 4 inhibitor,18193,Anticancer monoclonal antibody|Anticancer|Angiogenesis inhibitor,55685|1545|61,,,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Fallopian tube cancer|Peritoneal tumor|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Cancer|Ovary tumor,1262|1507|2243|3083|3658|3665|3669|651|799,,,OncoMed Pharmaceuticals Inc,1016154,OncoMed Pharmaceuticals Inc,1016154,,,,,,
58920,"combined PR1/WT1 vaccine (leukemia), NIH","combined PR1/WT1 vaccine (leukemia), NIH|proteinase 1/Wilms tumor 1 vaccine (leukemia), NIH",,Cancer,Wilms tumor protein modulator|Leukocyte proteinase-3 modulator,30009|9334,Anticancer|Therapeutic vaccine,1545|12379,,,Myeloid leukemia,223,,,National Institutes of Health,20518,National Institutes of Health,20518,,,,,,
58932,"genetically changed CD19-specific autologous T-cell therapy (B-cell malignancies), MD Anderson","genetically changed CD19-specific autologous T-cell therapy (B-cell malignancies), MD Anderson",,Cancer|Infection,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Genetically engineered autologous cell therapy|Fungicide,1545|4790|1748,Leukemia|B-cell lymphoma,199|316,Fungal infection,124,MD Anderson Cancer Center,23382,,,MD Anderson Cancer Center,23382,,,,,,
58934,"WT1-targeted autologous dendritic cell vaccine (cancer), University of Antwerp","WT1-targeted autologous dendritic cell vaccine (cancer), University of Antwerp|WT1 mRNA-loaded dendritic cell therapy (leukemia), University of Antwerp",,Cancer,Wilms tumor protein modulator,30009,Genetically engineered autologous cell vaccine|Dendritic cell vaccine|Therapeutic vaccine|Anticancer,4791|102926|12379|1545,Mesothelioma|Cancer,1240|651,,,University of Antwerp,22741,,,University of Antwerp,22741,,,,,,
58938,V-934/V-935,"telomerase-targeting DNA vaccine (cancer), Merck/IRBM/Inovio/Vical/Geron|hTERT DNA vaccine (cancer, MedPulser), Merck & Co/IRBM/Inovio/Vical/Geron|telomerase-targeting vaccine (cancer), Merck & Co/Geron|V-934/V-935|V934 DNA EP|V-935|telomerase reverse transcriptase DNA vaccine (cancer), Merck/IRBM/Inovio/Vical/Geron",Research Code|Research Code|Research Code,Cancer,Telomerase modulator,1613,Anticancer|DNA vaccine|Therapeutic vaccine,1545|1879|12379,,,Cancer|Solid tumor,651|725,,,Geron Corp|Merck & Co Inc,16315|18077,Geron Corp,16315,,,,,,
58939,mAb-216,"mAb-216|human monoclonal antibody (B-cell acute lymphoblastic leukemia), Stanford University|HuMab-216",Research Code,Cancer,,,Anticancer monoclonal antibody|Anticancer permeability enhancer|Unspecified drug target,55685|561|59620,,,B-cell acute lymphoblastic leukemia,1729,,,Stanford University,20679,Stanford University,20679,,,,,,
58959,BMS-813160,"CCR2/CCR5 dual antagonist (immunology), Bristol-Myers Squibb|CCR2/CCR5 chemokine antagonist (immune disorders, cardiovascular disorders), BMS|BMS-585059|CCR2/CCR5 dual antagonist (cardiovascular disease), Bristol-Myers Squibb|BMS-813160",Research Code|Research Code,Cancer|Cardiovascular|Genitourinary/Sexual Function|Immune,CCR2 chemokine antagonist|CCR5 chemokine antagonist,3098|3107,Immunomodulator|Cardiovascular agent|Anticancer,1596|965|1545,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Hepatocellular carcinoma|Advanced solid tumor|Metastatic renal cell carcinoma,1262|1507|1767|3713|4250,Immune disorder|Albuminuria|Cardiovascular disease,185|2285|57,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
58966,"fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx","4-HPR|fenretinide|fenretinide (iv), Children's Hospital LA|fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles|fenretinide (ILE formulation), Children's Hospital LA|fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx",USAN|INN,Cancer,FGF receptor antagonist|VEGF receptor antagonist,168|1722,Retinoid modulator|Anticancer protein kinase inhibitor|Angiogenesis inhibitor,824|62255|61,Peripheral T-cell lymphoma|Leukemia|Lymphoma|Neuroblastoma|Solid tumor,1753|199|203|2726|725,Cutaneous T-cell lymphoma|Hematological neoplasm|Cancer,1754|2054|651,CerRx Inc,1047175,Ascalon International Inc|National Institutes of Health|Children's Hospital of Los Angeles|John Wayne Cancer Institute,1054692|20518|21050|21849,Children's Hospital of Los Angeles,21050,,,,,,
58967,maveropepimut-S,"Survivac|Survivin-expressing tumor vaccine (solid tumors), Merck Serono|Survivin-expressing tumor vaccine (solid tumors), Merck KGaA|Survivin-expressing tumor vaccine (solid tumors), Survac|DPX-Survivac|Survivin-expressing tumor vaccine (DepoVax, solid tumors), Immunovaccine|DPX-R9F|Survivin-expressing tumor vaccine (DepoVax, solid tumors), IMV|maveropepimut-S",Research Code|USAN,Cancer,Survivin protein modulator|Stem cell antigen-1 stimulator|HLA class I antigen modulator,13606|15102|19109,T-lymphocyte stimulator|Therapeutic vaccine|Anticancer,7761|12379|1545,Non-small-cell lung cancer|Diffuse large B-cell lymphoma|High grade B-cell lymphoma|Hepatocellular carcinoma|Transitional cell carcinoma|Lymphoma|Fallopian tube cancer|Bladder cancer|Glioblastoma|Peritoneal tumor|Breast tumor|Brain tumor|Ovary tumor,1262|1749|1751|1767|1771|203|2243|2380|2454|3083|49|760|799,Solid tumor,725,IMV Inc,29718,Survac ApS|Merck KGaA|Merck Serono SA,1009358|18101|19862,Survac ApS,1009358,,,,,,
58973,CMV-MVA Triplex Vaccine,"CMV vaccine (MVA poxvirus vector), City of Hope|CMV-MVA|CMV-MVA Triplex Vaccine",Research Code,Cancer|Infection,,,Anticancer|Prophylactic vaccine|Subunit vaccine|Recombinant viral vector vaccine,1545|12378|12371|12370,Cancer|Cytomegalovirus infection,651|89,,,Helocyte Inc,1107677,City of Hope,20558,City of Hope,20558,,,,,,
58981,BHQ-880,"BHQ-880|anti-DKK1 monoclonal antibody (multiple myeloma), Novartis|BHQ-880A|HuCAL-derived monoclonal antibody (multiple mylenoma), MorphoSys|HuCAL-derived monoclonal antibody (multiple mylenoma), Novartis",Research Code|Research Code,Cancer,Osteocalcin stimulator|Alkaline phosphatase stimulator|Dickkopf-1 ligand inhibitor,49200|7580|12543,Anticancer monoclonal antibody|Bone resorption inhibitor|Bone synthesis stimulator|Osteoblast stimulator,55685|89|445|12593,Multiple myeloma,1828,Bone metastases,1829,Novartis AG,23137,MorphoSys AG,21404,MorphoSys AG,21404,,,,,,
58999,ISF-35,"Ad-ISF35|ISF-35|immune stimulating factor 35|CD40 costimulator (adenoviral vector, cancer), Memgen|rAd.CD40L|MEM-40",Research Code|Research Code,Cancer,CD40 ligand receptor agonist,5141,Macrophage stimulator|Immunostimulant|Anticancer|B-lymphocyte stimulator|Dendritic cell stimulator,7751|393|1545|7741|173472,Hepatocellular carcinoma|Bladder cancer|Stage IV melanoma|Metastatic non small cell lung cancer,1767|2380|3257|3665,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Hematological neoplasm|Non-Hodgkin lymphoma,1734|1744|1745|1749|2054|319,Memgen LLC,1032161,,,Memgen LLC,1032161,,,,,,
59007,XL-139,"SMO inhibitor (cancer), Bristol-Myers Squibb/Exelixis|smoothened 7TM receptor inhibitor (cancer), BMS/Exelixis|SMO antagonist (cancer), BMS/Exelixis|BMS-833923|XL-139",Research Code|Research Code,Cancer,Smoothened receptor antagonist,11036,Anticancer,1545,,,Small-cell lung cancer|Chronic myelocytic leukemia|Cancer|Solid tumor,1261|1735|651|725,,,Bristol-Myers Squibb Co|Exelixis Inc,15065|22676,Exelixis Inc,22676,,,,,,
59013,BIW-8962,BIW-8962,Research Code,Cancer,,,Ganglioside GM2 inhibitor|Anticancer monoclonal antibody,16796|55685,,,Multiple myeloma|Cancer|Lung tumor,1828|651|755,,,BioWa Inc|Kyowa Hakko Kirin Co Ltd|Kyowa Hakko Kogyo Co Ltd,1013130|1042596|17724,Kyowa Hakko Kogyo Co Ltd,17724,,,,,,
59018,EC-1456,EC-0531|EC-1456,Research Code|Research Code,Cancer,Folate receptor modulator,1323,Anticancer|Microtubule inhibitor,1545|2575,,,Cancer,651,,,Endocyte Inc,26000,Endocyte Inc,26000,,,,,,
5907,duloxetine,duloxetine|LY-248686|LY-223332|LY-223743|LY-223994|LY-227750|LY-227942|LY-228993|LY-248685|LY-264452|LY-264453|LY-267826|duloxetine-AD|duloxetine-UI|Symbalta|duloxetine hydrochloride|Cymbalta|Xeristar|Yentreve|Ariclaim|Duloxetine Boehringer Ingelheim,BANN|INN|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name|USAN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Genitourinary/Sexual Function|Inflammatory|Musculoskeletal|Neurology/Psychiatric|Other/Miscellaneous,,,Analgesic|Antidepressant|Anxiolytic|5-HT uptake inhibitor|Norepinephrine uptake inhibitor,2946|2941|2942|3|285,Diabetic neuropathy|Generalized anxiety disorder|Stress urinary incontinence|Musculoskeletal pain|Osteoarthritis|Fibromyalgia|Back pain|Lower back pain|Diabetic peripheral neuropathy|Major depressive disorder|Depression,101|1937|2378|2440|245|2527|3221|3437|3923|4898|93,Chronic fatigue syndrome|Panic disorder|Post traumatic stress disorder|Pain|Obsessive compulsive disorder,1058|1279|1935|20|468,Eli Lilly & Co|Shionogi & Co Ltd|Esteve Pharmaceuticals SA|SK Group,17810|19898|16074|26891,Boehringer Ingelheim International GmbH|Eli Lilly Japan KK,14881|22692,Eli Lilly & Co,17810,,,,,,
59120,denintuzumab mafodotin,"anti-CD19 antibody-drug conjugate (cancer), Seattle Genetics|anti-CD19 ADC (cancer), Seattle Genetics|SGN-19A|hBU12-vc-MMAE|hBU12-vc-vedotin|B-lymphocyte antigen CD19 inhibitor (cancer), Seattle Genetics|hBU12-mc-MMAF|denintuzumab mafodotin|SGN-CD19A|denintuzumab-vc-vedotin|denintuzumab-mc-MMAF",Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer,B-lymphocyte antigen CD19 modulator|Tubulin receptor antagonist,5080|541,Anticancer monoclonal antibody|Apoptosis stimulator|Microtubule inhibitor|Immunotoxin,55685|1589|2575|539,,,Follicle center lymphoma|Diffuse large B-cell lymphoma|Hematological neoplasm,1745|1749|2054,,,Seagen Inc,25554,Seagen Inc,25554,,,,,,
59143,clazakizumab,"ALD-518|anti-IL6 monoclonal antibody (rheumatoid arthritis/cancer), Alder Biopharmaceuticals/BMS|anti-IL6 mAb (rheumatoid arthritis/cancer), Alder/Bristol-Myers Squibb|clazakizumab|BMS-945429",Research Code|USAN|PINN|Research Code,Gastrointestinal|Hematologic|Immune|Infection|Other/Miscellaneous|Respiratory,IL-6 receptor antagonist,471,Anti-inflammatory|Antiviral,2953|991,Coronavirus disease 19 infection|Kidney transplant rejection|Organ transplant rejection|Lung failure|Respiratory distress syndrome,10406|2989|3878|3915|8,Anemia|Psoriatic arthritis|Rheumatoid arthritis|Oral mucositis|Cachexia|Graft versus host disease|Fatigue|Crohns disease,17|1781|291|3209|425|616|829|84,CSL Behring LLC|Vitaeris Inc,1007640|1123559,Alder Biopharmaceuticals Inc|Bristol-Myers Squibb Co,1014060|15065,Alder Biopharmaceuticals Inc,1014060,,,,,,
5915,eniluracil,776C85|eniluracil|5-EU|GW-776|BW-776-C85|5-ethynyluracil|ADH-300004|PCS-6422,Research Code|INN|Research Code|Research Code|Research Code|Research Code,Cancer,Dihydropyrimidine dehydrogenase inhibitor,782,Anticancer chemosensitizer,1586,Metastatic gastrointestinal cancer|Metastatic colorectal cancer|Advanced solid tumor,3460|3658|3713,Gastrointestinal tumor|Liver tumor|Pancreas tumor|Prostate tumor|Metastatic breast cancer|Breast tumor|Head and neck tumor|Cancer|Solid tumor|Colorectal tumor,131|202|249|276|3657|49|623|651|725|989,Processa Pharmaceuticals Inc,1150959,Elion Oncology Inc|Glaxo Group Ltd|Pierre Fabre Group|Fennec Pharmaceuticals Inc,1226473|16453|19087|26408,Glaxo Group Ltd,16453,,,,,,
59178,silmitasertib,"CK2 inhibitor (oral, cancer), Cylene|silmitasertib|CX-4945|CK2 inhibitor (oral, cancer/COVID-19), Senhwa Biosciences",INN|Research Code,Cancer|Infection,Casein kinase II inhibitor,4440,Anticancer protein kinase inhibitor|Synergist|Antiviral|Cell cycle inhibitor|Apoptosis stimulator,62255|7293|991|767|1589,Coronavirus disease 19 infection|Basal cell carcinoma|Cholangiocarcinoma|Medulloblastoma,10406|1764|1765|2533,Multiple myeloma|Cancer,1828|651,Senhwa Biosciences Inc,1091058,Cylene Pharmaceuticals Inc,28603,Cylene Pharmaceuticals Inc,28603,,,,,,
59200,BMS-936559,"MDX-1105|anti-PD-L1 humanized mAb (solid tumors), Medarex|anti-programmed cell death-ligand1 humanized mAb (solid tumors), Medarex|BMS-936559",Research Code|Research Code,Cancer|Infection,Programmed cell death ligand 1 inhibitor,14007,Anticancer monoclonal antibody|Antiviral|T-lymphocyte stimulator,55685|991|7761,,,Sepsis|HIV infection|Hematological neoplasm|Solid tumor,114|158|2054|725,,,Bristol-Myers Squibb Co|Medarex Inc,15065|17968,Medarex Inc,17968,,,,,,
5933,amrubicin,Calsed|S-5887|amrubicin hydrochloride|CNF-3140|amrubicin|SM-5887,Trade Name|Research Code|USAN|Research Code|USAN|INN|Research Code,Cancer|Cardiovascular,Topoisomerase II inhibitor|DNA gyrase inhibitor,142|431,DNA intercalator|Anticancer,750|1545,Small-cell lung cancer|Non-small-cell lung cancer,1261|1262,Multiple myeloma|Thymus neoplasm|Non-Hodgkin lymphoma|Metastatic breast cancer|Bladder tumor|Breast tumor|Cardiac failure|Cancer,1828|2938|319|3657|42|49|55|651,Sumitomo Pharmaceuticals Co Ltd|Nippon Kayaku Co Ltd,14911|18535,Sumitomo Dainippon Pharma Co Ltd|Cabrellis Pharmaceuticals Corp|Celgene Corp|Conforma Therapeutics Corp|Pharmion Corp,1017117|1020977|15331|28712|29253,Sumitomo Pharmaceuticals Co Ltd,14911,,,,,,
59365,ripretinib,"c-kit inhibitors (cancer), Deciphera|DP-3407|DP-3429|DP-3636|DP-3975|DP-2976|DP-4444|ripretinib|DCC-2618|Qinlock|ZL-2307",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|PINN|Research Code|Trade Name|Research Code,Cancer|Musculoskeletal,Kit tyrosine kinase inhibitor|PDGF receptor alpha antagonist,3808|48489,Anticancer protein kinase inhibitor,62255,Glioma|Non-small-cell lung cancer|Penis tumor|Melanoma|Gastrointestinal stromal tumor|Soft tissue sarcoma|Metastatic gastrointestinal cancer|Systemic mastocytosis|Germ cell and embryonic cancer|Solid tumor,1108|1262|1791|205|3205|3378|3460|3728|3737|725,Cancer,651,Specialised Therapeutics Asia Pte Ltd|Zai Lab Limited|Medison Pharma Ltd|Deciphera Pharmaceuticals LLC,1157003|1101935|29943|1009096,,,Deciphera Pharmaceuticals LLC,1009096,,,,,,
59381,"carcinoembryonic antigen autologous dendritic cell vaccine (cancer), Duke University","carcinoembryonic antigen autologous dendritic cell vaccine (cancer), Duke University|CEA RNA transfected autologous dendritic cell vaccine (cancer), Duke University",,Cancer,CD66e agonist,5268,Anticancer|Therapeutic vaccine|Genetically engineered autologous cell vaccine|Dendritic cell vaccine,1545|12379|4791|102926,,,Cancer,651,,,Duke University,20567,Duke University,20567,,,,,,
59431,"cositecan (oral), BioNumerik","BNP-1350|Karenitecin|BNP-1350 (oral), BioNumerik|cositecan|cositecan (oral), BioNumerik|MCC-12824",Research Code|Trade Name|USAN|INN|Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,,,Non-small-cell lung cancer|Cancer,1262|651,,,ASKA Pharmaceutical Co Ltd|BioNumerik Pharmaceuticals Inc,1019817|14778,BioNumerik Pharmaceuticals Inc,14778,,,,,,
59440,V-212,"heat-treated varicella zoster virus vaccine (herpes zoster), Merck & Co|V-212|heat-treated zoster vaccine (ZVHT), Merck & Co",Research Code,Infection,,,Prophylactic vaccine|Inactivated viral vaccine,12378|12367,Varicella zoster virus infection,392,,,Merck & Co Inc,18077,,,Merck & Co Inc,18077,,,,,,
59460,isatuximab,"anti-CD38 monoclonal antibody (leukemia), ImmunoGen/sanofi-aventis|isatuximab|SAR-650984|Sarclisa|isatuximab-irfc",USAN|INN|Research Code|Trade Name,Cancer|Hematologic,ADP ribosyl cyclase-1 inhibitor,5136,Anticancer monoclonal antibody|Apoptosis stimulator|Synergist,55685|1589|7293,Hodgkins disease|B-cell acute lymphoblastic leukemia|T-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Hepatocellular carcinoma|Multiple myeloma|Hematological neoplasm|Glioblastoma|Paraproteinemia|Metastatic colorectal cancer|Metastatic ovary cancer,161|1729|1730|1731|1749|1753|1767|1828|2054|2454|2649|3658|3866,Non-small-cell lung cancer|Precursor T-lymphoblastic lymphoma-leukemia|Hormone refractory prostate cancer|Metastatic head and neck cancer,1262|1752|3246|3673,Sanofi SA|Genzyme Ltd,1009547|16300,ImmunoGen Inc,17202,ImmunoGen Inc,17202,,,,,,
5948,SGN-15,"hBR96|SGN-15|BR96-DOX|BMS-182248|BMS-182248-01|doxorubicin-BR96 conjugate, BMS|doxorubicin-anti Lewis-Y related antigen antibody conjugate, BMS",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Topoisomerase II inhibitor|DNA polymerase inhibitor,142|138,Anticancer monoclonal antibody|Immunotoxin,55685|539,,,Non-small-cell lung cancer|Prostate tumor|Breast tumor|Carcinoma|Lung tumor|Colon tumor|Ovary tumor|Colorectal tumor,1262|276|49|54|755|767|799|989,,,Bristol-Myers Squibb Co|Medite Cancer Diagnostics Inc|Seagen Inc|rEVO Biologics Inc,15065|17318|25554|25900,Bristol-Myers Squibb Co,15065,,,,,,
59553,"olmesartan + amlodipine + hydrochlorothiazide (hypertension), Daiichi Sankyo","CS-8635|olmesartan + amlodipine + hydrochlorothiazide (hypertension), Daiichi Sankyo|amlodipine + olmesartan + hydrochlorothiazide (hypertension), Daiichi Sankyo|amlodipine + hydrochlorothiazide + olmesartan|Tribenzor|Sevikar HCT|Trisevikar|Konverge Plus|SEVIKAR PLUS",Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Cardiovascular,Calcium channel inhibitor|Angiotensin II AT-1 receptor antagonist,93|788,Diuretic agent|Antihypertensive,137|2657,Hypertension,178,,,Daiichi Sankyo Co Ltd|Merck Sharp & Dohme (Australia) Pty Ltd|The Menarini Group,1017506|1043009|18053,,,Daiichi Sankyo Co Ltd,1017506,,,,,,
5957,"budesonide (inhaled formulations), AstraZeneca","budesonide|Preferid|Pulmicort|Rhinocort|S-1320|Budoxis|Betactin|Horacort|Naricort|Inflammide|Rhinocort Aqua|eudragit L-100-55|Pulmicort Respules|Pulmaxan Turbuhaler|Pulmicort Turbuhaler|Rhinocort Turbuhaler|budesonide (inhaled formulations), AstraZeneca|budesonide, controlled release|Pulmicort Flexhaler|Budecort Aqua",USAN|BANN|INN|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Immune|Infection|Inflammatory|Other/Miscellaneous|Respiratory,,,Anticancer|Steroidal anti-inflammatory|Corticosteroid agonist|Anti-inflammatory|Antiviral,1545|2954|3189|2953|991,Coronavirus disease 19 infection|Allergic rhinitis|Chronic obstructive pulmonary disease|Croup|Asthma|Nasal polyps|Rhinitis,10406|1107|1185|2635|31|3208|477,Sinusitis,1061,Johnson & Johnson|AstraZeneca plc,17332|14190,Astra AB,16881,Astra AB,16881,,,,,,
59675,simotinib hydrochloride,"EGFR modulators (cancer), Advenchen/Simcere|simotinib|simotinib hydrochloride|SIM-6802|ximotini|AL-6802",Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer|Cancer,3665|651,,,Simcere Pharmaceutical Group|Advenchen Laboratories LLC,1023261|1017769,,,Advenchen Laboratories LLC,1017769,,,,,,
59806,burixafor,"TG-0054|CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology|burixafor|bulishafu|CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), GPCR Therapeutics",Research Code|INN,Cancer|Cardiovascular|Immune|Ocular,CXCR4 chemokine antagonist,3137,Stem cell stimulator|Ocular antineovascularisation agent|Anticancer chemosensitizer,53559|15148|1586,Leukemia|Myocardial infarction|Stem cell transplantation|Ischemia,199|224|2990|637,Age related macular degeneration|Intermittent claudication|Ocular disease|Diabetic retinopathy,1226|1865|239|576,GPCR Therapeutics Inc,1188923,TaiGen Biotechnology Co Ltd,28976,TaiGen Biotechnology Co Ltd,28976,,,,,,
59809,pyrotinib dimaleate,"receptor tyrosine kinase inhibitors (cancer), Shanghai Hengrui|pyrroltinib maleate (oral tablet, cancer), Jiangsu Hengrui Medicine|SHR-1258|pyrotinib (breast cancer), Jiangsu HengRui|HTI-1001|pyrotinib|SHR1258 dimaleate|pyrotinib dimaleate|Airuini",Research Code|Research Code|Research Code|Trade Name,Cancer,VEGF-2 receptor antagonist|Src tyrosine kinase inhibitor|EGFR family tyrosine kinase receptor inhibitor|Erbb2 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3848|3576|3754|3756|740,Anticancer protein kinase inhibitor,62255,Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Advanced solid tumor|Cancer,3657|3658|3665|3666|3713|651,,,HLB Life Science Co Ltd|Jiangsu Hengrui Medicine Co Ltd,1169726|1006925,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,,,,
59836,"amlodipine camsylate + losartan potassium (hypertension), Hanmi","losartan|Amosartan|amlodipine + losartan|amlodipine camsylate + losartan potassium|Simony|Cozaar XQ|amlodipine camsylate + losartan potassium (hypertension), Hanmi|Amorsartan|GSK-2944406|amlodipine camsylate + losartan potassium (hypertension), GlaxoSmithKline|HCP-0605",BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Research Code,Cardiovascular,Angiotensin II AT-1 receptor antagonist|Calcium channel inhibitor,788|93,Antihypertensive,2657,Hypertension,178,,,Hanmi Pharmaceutical Co Ltd|Merck & Co Inc,16611|18077,GlaxoSmithKline plc,28355,Hanmi Pharmaceutical Co Ltd,16611,,,,,,
59853,vadacabtagene leraleucel,"hCD19-targeting chimeric receptor-expressing allogeneic T-cell precursors (radiation-induced injury/cancer), Memorial Sloan Kettering|anti-CD19 CAR T-cell therapy (cancer), Memorial Sloan-Kettering Cancer Center|hCD19-targeting T-cell precursors (radiation-induced injury/cancer), MSKCC|anti-CD19 CAR T-cell therapy (cancer), Juno/Celgene|anti-CD19 CAR T-cell therapy (r/r ALL), Juno Therapeutics/Celgene/MSKCC|JCAR-015|19-28z CAR T cells|vadacabtagene leraleucel|JCAR-15",Research Code|USAN|INN|Research Code,Cancer|Toxicity/Intoxication,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,393|1545|7761|4790,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|B-cell lymphoma|Non-Hodgkin lymphoma,1728|1734|316|319,B-cell acute lymphoblastic leukemia|Radiation sickness|Cancer,1729|367|651,Memorial Sloan-Kettering Cancer Center|Bristol-Myers Squibb Co,22122|15065,Juno Therapeutics Inc|Celgene Corp,1090676|15331,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
59858,AMG-330,"anti-CD3/anti-CD33 bispecific T-cell engager (BiTE/Captisol, cancer), Micromet|MT-114|AMG-330|anti-CD3/anti-CD33 bispecific T-cell engager (BiTE/Captisol, cancer), Amgen|eluvixtamab",Research Code|Research Code|PINN,Cancer,CD3 modulator|CD33 modulator,5023|5119,Anticancer antibody|Immunostimulant|T-lymphocyte stimulator,55684|393|7761,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,Myeloid leukemia,223,Amgen Inc,14109,Micromet Inc,1020809,Micromet Inc,1020809,,,,,,
59923,adavosertib,"MK-1775|WEE1 kinase inhibitor (cancer), Merck & Co/AstraZeneca|AZD-1775|adavosertib",Research Code|Research Code|USAN|INN,Cancer,Wee-1 protein kinase inhibitor,4640,Anticancer chemosensitizer|Cell cycle checkpoint pathway modulator|Anticancer protein kinase inhibitor,1586|52469|62255,Small-cell lung cancer|Fallopian tube cancer|Pancreas tumor|Peritoneal tumor|Metastatic bladder cancer|Advanced solid tumor|Breast tumor|Head and neck tumor|Solid tumor|Uterus tumor|Large intestine tumor|Ovary tumor,1261|2243|249|3083|3466|3713|49|623|725|740|766|799,Glioma|Leukemia|Metastatic non small cell lung cancer|Uterine cervix tumor,1108|199|3665|427,Samsung Medical Center (SMC)|AstraZeneca plc,1004334|14190,Merck & Co Inc,18077,Merck & Co Inc,18077,,,,,,
59924,vistusertib,"KU-0063794|mTOR inhibitors (cancer), AstraZeneca|KU-63794|mTOR inhibitors (cancer), KuDOS|AZD-2014|vistusertib",Research Code|Research Code|USAN|INN,Cancer,mTOR complex 1 inhibitor|mTOR complex 2 inhibitor,76090|76096,Anticancer|Synergist|Anticancer protein kinase inhibitor,1545|7293|62255,,,Small-cell lung cancer|Non-small-cell lung cancer|Diffuse large B-cell lymphoma|Prostate tumor|Meningioma|Neurofibromatosis type I|Metastatic breast cancer|Metastatic stomach cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Cancer|Nerve tumor,1261|1262|1749|276|2802|3521|3657|3666|3713|4250|651|763,,,AstraZeneca plc|KuDOS Pharmaceuticals Ltd,14190|27874,KuDOS Pharmaceuticals Ltd,27874,,,,,,
59934,onatasertib,"mTOR kinase inhibitors, Celgene|TORKi CC-223|CC-223|ATG-008|onatasertib|TORC1/2 inhibitor (oral, solid tumors/hematological malignancies), Bristol-Myers Squibb",Research Code|Research Code|Research Code|USAN|INN,Cancer,mTOR complex 1 inhibitor|mTOR complex 2 inhibitor,76090|76096,Anticancer protein kinase inhibitor|Apoptosis stimulator|Synergist|Cell cycle inhibitor,62255|1589|7293|767,Non-small-cell lung cancer|Diffuse large B-cell lymphoma|Hepatocellular carcinoma|Multiple myeloma|Non-Hodgkin lymphoma|Advanced solid tumor|Cancer|Solid tumor,1262|1749|1767|1828|319|3713|651|725,,,Antengene Corp Ltd|Bristol-Myers Squibb Co,1152645|15065,Celgene Corp,15331,Celgene Corp,15331,,,,,,
59953,capmatinib hydrochloride,"capmatinib|INC-280|INCB-028060|INCB-28060|capmatinib hydrochloride|capmatinib dihydrochloride hydrate|c-Met tyrosine kinase inhibitor (oral, capsule/tablet, cancer), Novartis|Tabrecta",USAN|INN|Research Code|Research Code|Research Code|USAN|Trade Name,Cancer,MET tyrosine kinase receptor family inhibitor|Hepatocyte growth factor receptor antagonist,3796|675,Anticancer|Apoptosis stimulator|Anticancer protein kinase inhibitor,1545|1589|62255,Non-small-cell lung cancer|Renal cell carcinoma|Hepatocellular carcinoma|Glioblastoma|Stage III melanoma|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic renal cell carcinoma,1262|1766|1767|2454|3256|3257|3657|3665|3713|4250,Melanoma|Cancer|Solid tumor,205|651|725,Novartis AG,23137,Incyte Corp,17216,Incyte Corp,17216,,,,,,
59958,devimistat,"thioctans (injectable, cancer), Cornerstone Pharmaceuticals|lipoic acid derviatives (injectable, cancer), Cornerstone Pharmaceuticals|CPI-613|CPI-1410|thioctoids (cancer), Cornerstone Pharmaceuticals|thioctoids (cancer), Rafael Pharmaceuticals|lipoic acid derviatives (injectable, cancer), Rafael Pharmaceuticals|thioctans (injectable, cancer), Rafael Pharmaceuticals|devimistat|ONO-7912",Research Code|Research Code|Research Code,Cancer|Infection,Pyruvate dehydrogenase inhibitor|2 oxoglutarate dehydrogenase inhibitor|Pyruvate dehydrogenase kinase stimulator,1736|71551|8797,Anticancer|Antiviral|Synergist,1545|991|7293,Esophagus tumor|Gastrointestinal tumor|Biliary cancer|Human T cell leukemia virus 1 infection|Acute myelogenous leukemia|Peripheral T-cell lymphoma|Cholangiocarcinoma|Hematological neoplasm|Pancreas tumor|Prostate tumor|Ewing sarcoma|Soft tissue sarcoma|Metastatic colorectal cancer|Metastatic pancreas cancer|Burkitts lymphoma,1011|131|1516|167|1731|1753|1765|2054|249|276|2975|3378|3658|3669|791,Small-cell lung cancer|Non-small-cell lung cancer|Myelodysplastic syndrome|Cancer|Solid tumor,1261|1262|1272|651|725,Rafael Pharmaceuticals Inc|Ono Pharmaceutical Co Ltd,1006511|18681,,,Rafael Pharmaceuticals Inc,1006511,,,,,,
59969,ALD-151,"ALD-151|stem cell therapy (leukemia), Aldagen|ALDHbr Umbilical Cord Blood Cells|stem cell therapy (leukemia), Nuo Therapeutics",Research Code,Cancer|Hematologic,,,Anticancer,1545,,,Aplastic anemia|Cancer,1006|651,,,Nuo Therapeutics Inc|Aldagen Inc,1008992|1016148,Aldagen Inc,1016148,,,,,,
5999,"ciclosporin, Novartis","cyclosporine A|Neoral|Sandimmun|Sandimmune|ciclosporin|cyclosporine|OLO-400|ciclosporin, Novartis|cyclosporine, Novartis|cyclosporin A, Novartis|cyclosporin A|Sandimmun Neoral",Trade Name|Trade Name|Trade Name|BANN|INN|USAN|Research Code|Trade Name,Cardiovascular|Dermatologic|Genitourinary/Sexual Function|Hematologic|Immune|Ocular,Calcineurin inhibitor,4010,Anti-inflammatory|Immunosuppressant|Systemic antipsoriatic product,2953|396|15184,Aplastic anemia|Atopic dermatitis|Nephrotic syndrome|Psoriasis|Rheumatoid arthritis|Uveitis|Autoimmune disease|Transplant rejection|Behcets disease|Kawasaki disease|Myasthenia gravis,1006|1102|2315|281|291|341|36|515|768|780|848,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
60016,BI-811283,"BI-811283|aurora B kinase inhibitor (cancer), Boehringer Ingelheim",Research Code,Cancer,Aurora protein kinase 1 inhibitor,4418,Anticancer|Anticancer protein kinase inhibitor,1545|62255,,,Acute myelogenous leukemia|Solid tumor,1731|725,,,Boehringer Ingelheim International GmbH,14881,Boehringer Ingelheim International GmbH,14881,,,,,,
60044,"nucleoside analogs (iv, cancer), MD Anderson Cancer Center","8-chloro-adenosine|nucleoside analogs (iv, cancer), MD Anderson Cancer Center|8-Cl-Ado",,Cancer,RNA polymerase inhibitor,347,Anticancer,1545,Cancer,651,,,MD Anderson Cancer Center,23382,,,MD Anderson Cancer Center,23382,,,,,,
6009,samarium(153Sm) lexidronam,CYT-424|samarium-153-lexidronam|153Sm-EDTMP|Quadramet|samarium-153-EDTMP|153Sm-lexidronam|samarium(153Sm) lexidronam,Research Code|Trade Name|INN,Cancer|Immune|Neurology/Psychiatric,,,Anticancer|Radiotherapeutic|Radiochemosensitizer|Analgesic|Unspecified drug target,1545|5721|572|2946|59620,Pain|Cancer,20|651,Multiple myeloma|Prostate tumor|Rheumatoid arthritis,1828|276|291,Bayer Schering Pharma AG|Cytogen Corp|The Dow Chemical Co|CIS Bio International SAS,19687|15576|15748|14143,Bristol-Myers Squibb Pharma Co,26864,The Dow Chemical Co,15748,,,,,,
6012,AS-101,tellaxium trichloride glycol|AS-101|Ossirene|IVX-Q-101|CB-06-02,Research Code|Trade Name|Research Code|Research Code,Cancer|Cardiovascular|Dermatologic|Hematologic|Infection|Neurology/Psychiatric|Ocular,IL-6 receptor antagonist|Integrin alpha-4/beta-1 antagonist|IL-8 receptor antagonist|Retinal pigment epithelium protein stimulator,471|2510|1580|15288,Antiviral|Antiparkinsonian|Angiogenesis inhibitor|Cytokine synthesis stimulator|Anti-inflammatory|Immunomodulator|Chemoprotectant|Ophthalmological agent|Anticonvulsant agent|Radioprotectant|Anticancer,991|2947|61|938|2953|1596|1276|15128|70|1465|1545,Verruca vulgaris|Condyloma|Myelodysplastic syndrome|Acute myelogenous leukemia|Motor neurone disease|Ocular inflammation,1125|1232|1272|1731|212|686,Atopic dermatitis|Epilepsy|West Nile virus infection|Alopecia|HIV infection|Parkinsons disease|Psoriasis|Angiogenesis disorder|Bone marrow disease|Stroke|Cancer|Solid tumor,1102|119|1281|13|158|255|281|422|555|65|651|725,Miramar Therapeutics Inc|Biomas Inc|Bar-Ilan University|Cassiopea SpA,1064314|30183|20531|1110558,Wyeth|IVAX Corp|Cosmo Pharmaceuticals SpA,14112|17284|30714,Bar-Ilan University,20531,,,,,,
60159,SBC-014,"AVI-014|glycosylated recombinant G-CSF (neutropenia), AviGenics|glycosylated recombinant G-CSF (neutropenia), Synageva|SBC-014",Research Code|Research Code,Hematologic,GCSF receptor agonist,3151,Hematopoietic stimulator,610,,,Neutropenia,1991,,,Synageva BioPharma Corp,31234,Synageva BioPharma Corp,31234,,,,,,
60204,CTXT-102,"HDAC/Hsp 90 inhibitors (cancer/CNS), Curis|CUDC-0303|CUDC-305|HDAC/Hsp 90 inhibitors (cancer/CNS), Debiopharm|Debio-0932|CU-0305|CTXT-102",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Dermatologic|Musculoskeletal|Neurology/Psychiatric,Hsp 90 inhibitor,8012,Anticancer|Synergist,1545|7293,Psoriasis,281,Glioblastoma|Mastocytosis|Metastatic non small cell lung cancer|Metastatic renal cell carcinoma|Central nervous system disease|Cancer,2454|2795|3665|4250|60|651,Regranion LLC,1187305,Curis Inc|Debiopharm SA,15549|15620,Curis Inc,15549,,,,,,
60210,MK-2206,"MK-2206|NSC-749607|AKT inhibitors (cancer), Merck/Rutgers",Research Code|Research Code,Cancer,AKT protein kinase inhibitor,3859,Apoptosis stimulator|Anticancer protein kinase inhibitor|Cell cycle inhibitor|Synergist|Anticancer,1589|62255|767|7293|1545,,,Neuroendocrine tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,1128|3657|3658|3665|3713|651,,,Merck & Co Inc,18077,Merck & Co Inc,18077,,,,,,
60331,JVRS-100,"JuvImmune vaccine adjuvant, Juvaris|JVRS-100|JuvImmune vaccine adjuvant, Colby|CLDC adjuvant, Colby",Research Code,Cancer|Cardiovascular|Immune|Toxicity/Intoxication,TLR modulator,7799,Anticancer|Immunostimulant|Adjuvant|Radioprotectant,1545|393|524|1465,,,Reperfusion injury|Leukemia|Radiation sickness|Vaccination,1024|199|367|384,,,Colby Pharmaceutical Co|Juvaris BioTherapeutics Inc,1031137|30650,Juvaris BioTherapeutics Inc,30650,,,,,,
60414,lucitanib hydrochloride,"3800 project|lucitanib|E-3810, Advenchen Laboratories|lucitanib hydrochloride|delitinib (oral capsule, cancer), SFFT Developing/Shanghai Institute of Materia Medica|AL-3810|CO-3810|S-80881",USAN|INN|Research Code|Research Code|Research Code|Research Code,Cancer|Genitourinary/Sexual Function,Kit tyrosine kinase inhibitor|FGF3 receptor antagonist|FGF2 receptor antagonist|FGF1 receptor antagonist|VEGF-1 receptor antagonist|PDGF receptor beta antagonist|PDGF receptor alpha antagonist|Raf 1 protein kinase inhibitor|VEGF-3 receptor antagonist|VEGF-2 receptor antagonist,3808|3688|3685|3682|3846|48492|48489|4550|3850|3848,Anticancer|Angiogenesis inhibitor|Anticancer protein kinase inhibitor,1545|61|62255,Small-cell lung cancer|Nasopharyngeal carcinoma|Thymus neoplasm|Advanced solid tumor|Gynecological disorder|Solid tumor|Colon tumor|Ovary tumor,1261|1768|2938|3713|438|725|767|799,Non-small-cell lung cancer|Metastatic non small cell lung cancer|Breast tumor|Cancer,1262|3665|49|651,Clovis Oncology Inc|HaiHe Pharmaceuticals Co Ltd|Servier|SFFT Developing Co Ltd|Shanghai Institute of Materia Medica of the Chinese Academy of Sciences,1047565|1074074|19863|1073083|25314,Advenchen Laboratories LLC|Ethical Oncology Science SpA,1017769|1036665,Advenchen Laboratories LLC,1017769,,,,,,
60432,motolimod,"toll-like receptor modulators, VentiRx/Array|TLR modulators (cancer, allergy), VentiRx/Array|VTX-378|toll-like receptor modulators, VentiRx/ Celgene|toll-like receptor modulators (cancer, allergy), VentiRx/ Celgene|VTX-2337|motolimod|toll-like receptor modulators (cancer, allergy), VentiRx/Bristol-Myers Squibb",Research Code|Research Code|USAN|INN,Cancer|Immune,TLR-8 agonist,7824,Anticancer|Immunostimulant,1545|393,Fallopian tube cancer|Peritoneal tumor|Head and neck tumor|Cancer|Ovary tumor,2243|3083|623|651|799,Allergy|B-cell lymphoma,12|316,Bristol-Myers Squibb Co|VentiRx Pharmaceuticals Inc,15065|1031136,Celgene Corp|Array BioPharma Inc,15331|25902,Array BioPharma Inc,25902,,,,,,
60454,Nerofe,"Nerofe|thymus-expressed apoptosis factor/tumor-Cells apoptosis factor (cancer/inflammation/autoimmune disease), Immune System Key|TEAF/TCApF (cancer/inflammation/autoimmune disease), Immune System Key|dTCApF",Trade Name,Cancer|Cardiovascular|Endocrine/Metabolic|Immune|Inflammatory,Interleukin 1 like receptor 1 modulator,37117,Angiogenesis inhibitor|Anticancer|Anti-inflammatory|Hypoglycemic agent|Apoptosis stimulator,61|1545|2953|399|1589,Myelodysplastic syndrome|Acute myelogenous leukemia|Myocardial infarction|Autoimmune disease|Metastatic ovary cancer|Breast tumor|Diabetes mellitus,1272|1731|224|36|3866|49|97,Inflammatory disease|Cancer,188|651,Immune System Key Ltd,1020782,,,Immune System Key Ltd,1020782,,,,,,
60466,ASLAN-003,"DHODH inhibitor (rheumatoid arthritis/multiple sclerosis), Almirall|DHODH inhibitor (autoimmune disease), Alimirall|DHODH inhibitor (autoimmune disease), ASLAN|DHODH inhibitor (rheumatoid arthritis/multiple sclerosis), ASLAN|ASLAN-003|LAS-186323|DHODH inhibitor (rheumatoid arthritis/multiple sclerosis/AML), ASLAN|Dihydroorotate dehydrogenase inhibitor (oral, multiple sclerosis/Acute myelogenous leukemia/covid-19/dengue/zika virus/breast tumor/hepatocellular carinoma), ASLAN Pharmaceuticals Pte Ltd",Research Code|Research Code,Cancer|Gastrointestinal|Immune|Infection,Dihydroorotate dehydrogenase inhibitor|p53 tumor suppressor protein stimulator,1716|17120,Immunomodulator|Anticancer|Antiviral|Anti-inflammatory,1596|1545|991|2953,Coronavirus disease 19 infection|Acute myelogenous leukemia|Hepatocellular carcinoma|Inflammatory bowel disease|Multiple sclerosis|Dengue virus infection|Autoimmune disease|Breast tumor|Zika virus infection,10406|1731|1767|189|213|2458|36|49|6927,Rheumatoid arthritis|Cancer,291|651,BioGenetics CO LTD|ASLAN Pharmaceuticals Pte Ltd,1181689|1060968,Almirall Prodesfarma SA,14061,Almirall Prodesfarma SA,14061,,,,,,
6050,metformin hydrochloride,Glucophage|LA-6023|metformin hydrochloride|Diabetosan|Diabex|Fluamine|Flumamine|Gliguanid|metformin|Metgluco|Glucofit|Metfogamma|Siofor|Diabex XR|BMS-207150|SMP-862|Glifage IR|Diaformin|Glifage,Trade Name|Research Code|USAN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|BAN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Endocrine/Metabolic,AMP activated protein kinase stimulator,8805,Biguanide antidiabetic product|Anticancer|Hypoglycemic agent,38206|1545|399,Metastatic non small cell lung cancer|Non-insulin dependent diabetes,3665|837,,,Bristol-Myers Squibb Co|Sumitomo Dainippon Pharma Co Ltd|Merck Sante SA|Acino Holding AG|Daewoong Pharmaceutical Co Ltd|Merck KGaA|Merck Serono SA,15065|1017117|18118|1040020|15587|18101|19862,Sumitomo Chemical Co Ltd,20268,Merck Sante SA,18118,,,,,,
60512,erdafitinib,"fibroblast growth factor receptor inhibitors (cancer), Astex|FGFR inhibitors (cancer), Astex|fibroblast growth factor receptor inhibitors (cancer), Ortho Biotech|FGFR inhibitors (cancer), Astex/Centocor Ortho Biotech|FGFR inhibitors (cancer), Astex/Janssen Biotech|JNJ-42756493|JNJ-493|erdafitinib|Balversa",Research Code|Research Code|USAN|INN|Trade Name,Cancer,FGF3 receptor antagonist|FGF2 receptor antagonist|FGF1 receptor antagonist|FGF4 receptor antagonist,3688|3685|3682|3691,Anticancer|Anticancer protein kinase inhibitor|Angiogenesis inhibitor,1545|62255|61,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Cholangiocarcinoma|Hepatocellular carcinoma|Lymphoma|Metastatic bladder cancer|Metastatic non small cell lung cancer|Advanced solid tumor,1011|1262|127|1765|1767|203|3466|3665|3713,Squamous cell carcinoma|Urethral cancer|Cancer,307|3678|651,Johnson & Johnson|Janssen Biotech Inc,17332|26997,Ortho Biotech Products LP|Astex Therapeutics Ltd,17570|28026,Astex Therapeutics Ltd,28026,,,,,,
60527,"TF-2 plus diagnostic/therapeutic (cancer), Immunomedics","TF-2 plus 68Ga-IMP-288 (imaging, cancer), Immunomedics|TF-2 plus 177Lu-IMP-288 (imaging, cancer), Immunomedics|TF-2 plus 111In-IMP-288 (imaging, cancer), Immunomedics|TF-2 plus diagnostic/therapeutic (cancer), Immunomedics|TF-2 plus 18F-IMP-449  (imaging, cancer), Immunomedics",,Cancer,CD66e antagonist,5275,PET contrast agent|Neoplasm diagnostic agent|Radioimmunodiagnostic|Radioimmunotherapeutic|Gastrointestinal diagnostic agent|Anticancer|Endocrine diagnostic agent,5555|7220|4405|1552|7213|1545|7212,,,Small-cell lung cancer|Medullary thyroid cancer|Breast tumor|Cancer|Lung tumor|Colorectal tumor,1261|3240|49|651|755|989,,,Immunomedics Inc,17204,Immunomedics Inc,17204,,,,,,
60549,"TRC-102 (oral, cancer), Tracon","methoxyamine|TRC-102 (oral, cancer), Tracon|methoxyamine (oral, chemotherapy resistance), Case/TRACON|TRC-102",Research Code,Cancer,,,DNA repair inhibitor|Anticancer,11593|1545,Glioma|Mesothelioma|Non-small-cell lung cancer|Lymphoma|Glioblastoma|Metastatic colon cancer|Advanced solid tumor|Ovary tumor,1108|1240|1262|203|2454|3672|3713|799,Cancer,651,TRACON Pharmaceuticals Inc,1020043,Case Western Reserve University,20553,Case Western Reserve University,20553,,,,,,
60655,olvimulogene nanivacirepvec,"GL-ONC1|recombinant vaccinia virus (injectable, cancer), Genelux|GLV-1h68|oncolytic vaccinia virus therapy expressing hNIS (cancer), Genelux|Olvi-Vec|olvimulogene nanivacirepvec",Research Code|Research Code|USAN|INN,Cancer,,,Endocrine diagnostic agent|Immunostimulant|Anticancer|Neoplasm diagnostic agent|Gastrointestinal diagnostic agent|Imaging agent,7212|393|1545|7220|7213|4155,Mesothelioma|Fallopian tube cancer|Peritoneal tumor|Head and neck tumor|Lung tumor|Ovary tumor,1240|2243|3083|623|755|799,Advanced solid tumor|Cancer,3713|651,Genelux Corp,1011595,,,Genelux Corp,1011595,,,,,,
60671,"lentinan (stabilized powder formulation), GlycaNova","lentinan|MM-10-001|medicinal shitake mushroom derivatives (cancer, infectious disease), GlycaNova|triple helix  beta-1,6, beta-1,3-glucan immunostimulatory agents (cancer, infectious disease), GlycaNova|lentinan (stabilized powder formulation), GlycaNova|MM-10-01",Research Code|Research Code,Cancer|Infection,Integrin alpha-M/beta-2 modulator,6037,Antimicrobial|Anticancer|Immunostimulant,1593|1545|393,Non-small-cell lung cancer|Cancer|Infectious disease,1262|651|746,,,GlycaNova Norge AS,1012696,,,GlycaNova Norge AS,1012696,,,,,,
60702,"Factor 5A siRNA + Factor 5A plasmid nanoparticle (in vivo-jetPEI, iv, MM/MCL/DLBCL), Sevion Therapeutics","Factor 5A siRNA + Factor 5A plasmid nanoparticle (in vivo-jetPEI, iv, multiple myeloma), Senesco|SNS-01|SNS-101|SNS-01-T|Factor 5A siRNA + Factor 5A plasmid nanoparticle (in vivo-jetPEI, iv, MM/MCL/DLBCL), Senesco|Factor 5A siRNA + Factor 5A plasmid nanoparticle (in vivo-jetPEI, iv, multiple myeloma/ mantle cell lymphoma/diffuse large B-cell lymphoma), Senesco|Factor 5A siRNA + Factor 5A plasmid nanoparticle (in vivo-jetPEI, iv, MM/MCL/DLBCL), Sevion Therapeutics",Research Code|Research Code|Research Code,Cancer,EIF5A gene inhibitor|CD79B gene stimulator|NF kappa B activating protein inhibitor,26959|75418|76436,Synergist|Apoptosis stimulator|Plasmid based gene therapy|siRNA agent|Anticancer,7293|1589|4788|26035|1545,,,Mantle cell lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma,1744|1749|1828,,,Eloxx Pharmaceuticals Inc,30017,Eloxx Pharmaceuticals Inc,30017,,,,,,
60856,"ebselen (oral/capsule, hearing loss), Sound Pharmaceuticals","ebselen|ebselen (oral/capsule, hearing loss), Sound Pharmaceuticals|SPI-3005",USAN|INN|Research Code,Other/Miscellaneous,Glutathione peroxidase stimulator,6362,Chemoprotectant,1276,Hearing loss,2328,,,Sound Pharmaceuticals Inc,31099,,,Sound Pharmaceuticals Inc,31099,,,,,,
60859,CMVPepVax,"CMVpp65-A0201|CMV vaccine (pp65 antigen), City of Hope|PADRE-CMV|Tet-CMV|CMVPepVax|IRB-12022",Research Code,Infection,CMV 65kDa lower matrix phosphoprotein modulator,52420,Prophylactic vaccine|Protein subunit vaccine,12378|12372,Cytomegalovirus infection,89,,,Helocyte Inc,1107677,City of Hope,20558,City of Hope,20558,,,,,,
60880,Polyphenon E (oral),"Polyphenon E|Veregen|Polyphenon E (oral)|oral polyphenols, Mitsui/Polyphenon|oral sinecatechins, Mitsui/Polyphenon",Trade Name|Trade Name|Trade Name,Cancer,,,Anticancer|Unspecified drug target,1545|59620,,,Chronic lymphocytic leukemia|Bladder cancer|Prostatic intraepithelial neoplasia|Cancer,1734|2380|3231|651,,,Polyphenon Pharma|Mitsui Norin Co Ltd,1041105|18232,Mitsui Norin Co Ltd,18232,,,,,,
60912,antroquinonol,"antroquinonol|fungal extract (cancer), Golden Biotechnology|Hocena|GHCovid-2-001|GHAML-2-001",Research Code|Research Code,Cancer|Dermatologic|Endocrine/Metabolic|Genitourinary/Sexual Function|Infection|Neurology/Psychiatric,MEK-1 protein kinase inhibitor|Ras gene inhibitor,4762|7694,Antiviral|Anticancer protein kinase inhibitor|Anti-inflammatory,991|62255|2953,Coronavirus disease 19 infection|Atopic dermatitis|Non-small-cell lung cancer|Alzheimers disease|Hepatitis B virus infection|Acute myelogenous leukemia|Hypercholesterolemia|Hyperlipidemia|Hepatocellular carcinoma|Pancreas tumor,10406|1102|1262|14|152|1731|174|175|1767|249,Nephritis|Cancer,231|651,BNC Korea|Golden Biotechnology Corp,1219678|1021543,,,Golden Biotechnology Corp,1021543,,,,,,
60930,domatinostat tosylate,"4SC-202|HDAC isoenzymes 1, 2, 3 inhibitor/mitotic inhibitor (oral tablet, cancer/hematological neoplasms), 4SC|histone deacetylase inhibitor (cancer), 4SC|SC-85958|domatinostat tosylate|domatinostat",Research Code|Research Code|INN,Cancer,Histone deacetylase-2 inhibitor|Histone deacetylase-1 inhibitor|Lysine specific histone demethylase 1 modulator|Histone deacetylase-3 inhibitor,7844|7841|14679|7847,Immunomodulator|Synergist|Anticancer|Cell cycle inhibitor,1596|7293|1545|767,Gastrointestinal tumor|Transitional cell carcinoma|Hematological neoplasm|Pancreas tumor|Merkel cell carcinoma|Stage III melanoma|Stage IV melanoma|Cancer,131|1771|2054|249|3235|3256|3257|651,,,4SC AG,28108,Takeda Pharmaceuticals International GmbH|Takeda GmbH,1002503|14069,Takeda GmbH,14069,,,,,,
60944,GSK-2130579A,"GSK-2130579A|WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline|WT1 ASCI, GlaxoSmithKline|WT1 vaccine, GlaxoSmithKline|leukemia vaccine, GlaxoSmithKline",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Wilms tumor protein inhibitor,30011,Anticancer|Therapeutic vaccine,1545|12379,,,Acute myelogenous leukemia,1731,,,GlaxoSmithKline plc,28355,GlaxoSmithKline plc,28355,,,,,,
60946,margetuximab,"next-generation anti-Her2/neu mAbs (cancer), MacroGenics|MGAH-22|trastuzumab biobetter (cancer), Korea Green Cross/ MacroGenics|margetuximab|Margenza|margetuximab-cmkb",Research Code|USAN|INN|Trade Name,Cancer,Erbb2 tyrosine kinase receptor inhibitor,3756,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,Stomach tumor|Metastatic breast cancer|Metastatic stomach cancer|Advanced solid tumor,127|3657|3666|3713,Breast tumor|Cancer|Solid tumor,49|651|725,MacroGenics Inc|Zai Lab Limited|GC Pharma,29060|1101935|16583,,,MacroGenics Inc,29060,,,,,,
60970,surufatinib,"anticancer agents, Hutchison|HMPL-012|VEGFR-1, 2, 3 and FGFR 1 inhibitor (oral, cancer), Hutchison|kinase inhibitors (cancer), Hutchison|sulfatinib|suofantini|surufatinib|Sulanda",Research Code|USAN|INN|Trade Name,Cancer,CSF-1 antagonist|FGF1 receptor antagonist|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist|VEGF-3 receptor antagonist,3154|3682|3846|3848|3850,Angiogenesis inhibitor|Anticancer protein kinase inhibitor|Anticancer,61|62255|1545,Neuroendocrine tumor|Pancreatic endocrine tumor|Biliary cancer|Medullary thyroid cancer|Metastatic lung cancer|Advanced solid tumor|Small intestine cancer|Solid tumor,1128|1510|1516|3240|3668|3713|4166|725,Cancer,651,Hutchison Medipharma Enterprises Ltd,1011918,,,Hutchison Medipharma Enterprises Ltd,1011918,,,,,,
6104,lansoprazole,A-65006|AG-1749|Agopton|Ilsatec|lansoprazole|Lanzor|Ogastro|Prevacid|proMP|Zoton|Dakar|Lanzo|Ogasto|Opiren|Prezal|Lansone|Bamalite|Laprazole|Lansox|Limpidex|Ogast|Takepron|Lansap|Takepron Capsules 15|Takepron OD Tablets 15|Lanzol|Solutab|Bylans|Lanston|ZOTROLE,Research Code|Research Code|Trade Name|Trade Name|USAN|BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Cancer|Gastrointestinal|Infection,H+ K+ ATPase inhibitor,208,Gastric secretion inhibitor|Antibacterial|Acid pump inhibitor antiulcerant product|Anticancer,182|1594|38200|1545,Gastroesophageal reflux|Gastrointestinal disease|Helicobacter pylori infection|Zollinger-Ellison syndrome|Peptic ulcer|Ulcer|Stomach ulcer|Duodenal ulcer|Esophagitis,1243|129|149|1512|258|372|805|808|810,,,Pfizer Inc|Abbott Laboratories|Almirall Prodesfarma SA|Jeil Pharmaceutical Co Ltd|Takeda Pharmaceutical Co Ltd|Teva Takeda Yakuhin Ltd|Alfasigma SpA|Sanofi SA,18767|13601|14061|17331|20300|1121665|1153354|1009547,American Cyanamid Co|TAP Pharmaceuticals Inc|Teva Pharmaceutical Industries Ltd|Sigma-Tau Ind Farm Riunite SpA|Aventis Pharma AG|Roussel Uclaf SA|Albert Roussel Pharma GmbH,14113|15931|20348|21159|25218|26119|26122,Takeda Pharmaceutical Co Ltd,20300,,,,,,
61056,"candesartan cilexetil + amlodipine besilate (hypertension), Takeda","Unisia|candesartan cilexetil + amlodipine besylate|candesartan cilexetil + amlodipine besylate (hypertension), Takeda|candesartan cilexetil + amlodipine besilate (hypertension), Takeda|candesartan cilexetil + amlodipine besilate|TCV-116 + amlodipine besilate (hypertension), Takeda|amlodipine besilate + candesartan cilexetil (hypertension), Takeda|TCV-116CCB",Trade Name|Research Code,Cardiovascular,Angiotensin II receptor antagonist|Calcium channel inhibitor,64|93,Antihypertensive,2657,Hypertension,178,,,Takeda Pharmaceutical Co Ltd|Teva Takeda Yakuhin Ltd,20300|1121665,,,Takeda Pharmaceutical Co Ltd,20300,,,,,,
61109,etoposide toniribate,"topoisomerase inhibitors (cancer), GenPat77|CAP-7.1|topoisomerase II inhibitor (Prodrug, cancer), CellAct Pharma|GP-7.1|etoposide toniribate|pro-CAP-7.1|EDO-S7.1",Research Code|Research Code|INN|Research Code|Research Code,Cancer,Topoisomerase II inhibitor,142,Anticancer|Anticancer alkylating agent,1545|50,Biliary cancer|Solid tumor,1516|725,Small-cell lung cancer|Non-small-cell lung cancer|Cancer,1261|1262|651,Imbrium Therapeutics LP|Mundipharma EDO GmbH,1181645|24189,CellAct Pharma GmbH|GenPat77 Pharmacogenetics AG|Charite Universitaetsmedizin Berlin,1040609|28510|30065,Charite Universitaetsmedizin Berlin,30065,,,,,,
61169,motixafortide,"BKT-140|CXCR4 antagonist (cancer/COVID-19 associated ARDS), Biokine|BKT-140 (sc, cancer/stem cell mobilization), Biokine|BL-8040|motixafortide",Research Code|Research Code|INN,Cancer|Hematologic|Immune|Infection|Respiratory,CXCR4 chemokine antagonist,3137,Stem cell modulator|Anticancer|Apoptosis stimulator|Antiviral,53558|1545|1589|991,Coronavirus disease 19 infection|Stomach tumor|Acute lymphoblastic leukemia|Acute myelogenous leukemia|T-cell lymphoma|Metastatic pancreas cancer|Hematopoietic stem cell transplantation|Respiratory distress syndrome,10406|127|1728|1731|311|3669|3888|8,Aplastic anemia|Leukopenia drug induced|Myelodysplastic syndrome|Multiple myeloma|Thrombocytopenia|Metastatic non small cell lung cancer|Cancer,1006|1008|1272|1828|324|3665|651,Biokine Therapeutics Ltd|BioLineRx Ltd,1011989|1008903,,,Biokine Therapeutics Ltd,1011989,,,,,,
61205,ferric carboxymaltose,ferric carboxymaltose|VIT-45|Ferinject|Injectafer|Z-213|Renegy|Iroprem,USAN|BANN|INN|Research Code|Trade Name|Trade Name|Research Code|Trade Name|Trade Name,Hematologic|Neurology/Psychiatric,,,Blood system agent|Iron uptake stimulator,1546|493,Restless legs syndrome|Iron deficiency anemia,1774|3191,,,American Regent Inc|Vifor-Fresenius Medical Care Renal Pharma Ltd|Vifor Pharma Group|Zeria Pharmaceutical Co Ltd|Vifor Pharma Ltd|Hikma Pharmaceuticals plc,24732|1058402|16266|21023|16268|1022379,,,Vifor Pharma Ltd,16268,,,,,,
61285,CryoStim,"CryoStim|in-situ therapeutic cancer vaccine (disseminated metastatic tumors), Immunovative|AlloStim (intratumoral formulation, metastatic tumors), Immunovative",Trade Name,Cancer,,,Anticancer|Therapeutic vaccine|Adjuvant,1545|12379|524,,,Metastasis|Hepatocellular carcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Solid tumor,1069|1767|3657|3658|725,,,Immunovative Therapies Ltd,1016027,Immunovative Therapies Ltd,1016027,,,,,,
61287,niraparib,"MK-4827|PARP-1/-2 inhibitor (oral, cancer), Merck & Co/TESARO|niraparib|1038915-60-4|JNJ-64091742|ZL-2306|Zejula|niraparib tosilate monohydrate|GSK-3985771",Research Code|USAN|INN|Research Code|Research Code|Trade Name|Research Code,Cancer,Poly ADP ribose polymerase 1 inhibitor|Poly ADP ribose polymerase 2 inhibitor,38283|38286,Anticancer|DNA repair inhibitor|Synergist,1545|11593|7293,Mesothelioma|Small-cell lung cancer|Biliary cancer|Endometrioid carcinoma|Cholangiocarcinoma|Renal cell carcinoma|Transitional cell carcinoma|Fallopian tube cancer|Ewing sarcoma|Squamous cell carcinoma|Peritoneal tumor|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Metastatic bladder cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Advanced solid tumor|Uveal melanoma|Metastatic ovary cancer|Uterine cervix tumor|Breast tumor|Head and neck tumor|Cancer|Ovary tumor,1240|1261|1516|1705|1765|1766|1771|2243|2975|307|3083|3246|3247|3466|3657|3658|3664|3665|3666|3667|3669|3713|3788|3866|427|49|623|651|799,Chronic lymphocytic leukemia|Prolymphocytic leukemia|Mantle cell lymphoma|Glioblastoma|Stage IV melanoma,1734|1738|1744|2454|3257,Janssen Biotech Inc|TESARO Inc|GlaxoSmithKline plc|Medison Pharma Ltd|Takeda Pharmaceutical Co Ltd|Zai Lab Limited,26997|1054559|28355|29943|20300|1101935,Merck & Co Inc,18077,Merck & Co Inc,18077,,,,,,
6135,oltipraz,oltipraz|RP-35972,INN|Research Code,Cancer|Infection,Reverse transcriptase inhibitor|Glutathione S-transferase stimulator,345|766,Antiparasitic|Chemoprotectant|Anticancer,2638|1276|1545,,,HIV infection|Prostate tumor|Lung tumor|Colon tumor,158|276|755|767,,,National Cancer Institute (NCI),20519,Rhone-Poulenc SA,19234,,,,,,
61366,"ixazomib citrate (iv, cancer), Millennium","proteasome inhibitor (iv, cancer), Millennium|MLN-9708|MLN-9708 (intravenous, cancer), Millennium|MLN-2238|ixazomib citrate|ixazomib citrate (iv, cancer), Millennium",Research Code|Research Code|Metabolite|USAN,Cancer,Proteasome inhibitor,4917,Anticancer,1545,Acute lymphoblastic leukemia|Precursor T-lymphoblastic lymphoma-leukemia|Lymphoma|Cancer,1728|1752|203|651,,,Takeda Oncology,21991,,,Takeda Oncology,21991,,,,,,
61421,calaspargase pegol,"next generation pegylated asparaginase (solid tumor/lymphoma), Enzon Pharmaceuticals|EZN-2285|SC-PEG E coli L-asparaginase, Enzon|calaspargase pegol|Oncaspar-IV|SC-PEG asparaginase|SHP-663|Asparlas|calaspargase pegol - mknl|SC Oncaspar|calaspargase pegol-mknl",Research Code|USAN|INN|Trade Name|Research Code|Trade Name,Cancer,Asparaginase stimulator,517,Anticancer,1545,Acute lymphoblastic leukemia,1728,Lymphoma|Solid tumor,203|725,SERVIER Pharmaceuticals LLC,1164017,Baxalta Inc|Enzon Pharmaceuticals Inc|Sigma-Tau Ind Farm Riunite SpA|Shire plc,1109518|16045|21159|24652,Enzon Pharmaceuticals Inc,16045,,,,,,
61456,avasopasem manganese,"SC-72325A|M-40419|anticancer agent, Kereos|imisopasem manganese enantiomer (cancer), Kereos|KM-4419|GC-4419|GC-4419 dichloro|avasopasem manganese",Research Code|Research Code|Research Code|Research Code|USAN|INN,Cancer|Gastrointestinal|Infection|Neurology/Psychiatric|Other/Miscellaneous|Respiratory,Superoxide dismutase stimulator,479,Antioxidant agent|Analgesic|Anti-inflammatory|Anticancer|Antiviral|Radioprotectant,74|2946|2953|1545|991|1465,Coronavirus disease 19 infection|Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Pancreas tumor|Adult respiratory distress syndrome|Squamous cell carcinoma|Oral mucositis|Head and neck tumor|Esophagitis,10406|1262|1507|249|2562|307|3209|623|810,Pain|Solid tumor,20|725,Galera Therapeutics Inc,1054887,Kereos Inc|Metaphore Pharmaceuticals Inc,1007195|26986,Metaphore Pharmaceuticals Inc,26986,,,,,,
61522,GNKG-168,GNKG-168,Research Code,Cancer,,,Immunostimulant|Anticancer,393|1545,,,Leukemia,199,,,Changchun Huapu Biotechnology Co Ltd|SBI Biotech Co Ltd,1012503|1042195,Changchun Huapu Biotechnology Co Ltd,1012503,,,,,,
61526,ulocuplumab,MDX-1338|BMS-936564|ulocuplumab,Research Code|Research Code|USAN|INN,Cancer,CXCR4 chemokine antagonist,3137,Angiogenesis inhibitor|Apoptosis stimulator|Anticancer monoclonal antibody,61|1589|55685,Acute myelogenous leukemia|Lymphoplasmacytic lymphoma|Multiple myeloma|Advanced solid tumor,1731|1743|1828|3713,Cancer,651,Bristol-Myers Squibb Co,15065,Medarex Inc,17968,Medarex Inc,17968,,,,,,
61546,Kanglaite injection,Kanglaite injection|KLTi,,Cancer|Other/Miscellaneous,,,Unspecified drug target|Anticancer,59620|1545,Non-small-cell lung cancer|Hepatocellular carcinoma|Pancreas tumor|Prostate tumor|Cachexia|Solid tumor,1262|1767|249|276|425|725,,,KangLaiTe USA Inc,1041903,,,KangLaiTe USA Inc,1041903,,,,,,
61558,tovetumab,"anti-PDGFR-alpha modulators (iv infusion, cancer), MedImmune|MEDI-575|platelet derived growth factor receptor alpha modulators (cancer), MedImmune|tovetumab",Research Code|USAN|INN,Cancer,PDGF receptor alpha antagonist,48489,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,,,Non-small-cell lung cancer|Glioblastoma|Cancer|Solid tumor,1262|2454|651|725,,,MedImmune LLC,18008,MedImmune LLC,18008,,,,,,
6156,fludarabine,Fludara|fludarabine phosphate|NSC-312887|fludarabine|SH-537|SH-584|SH-586|SH-L-573A|2-F-AraAMP|Fludara iv|Fludara Oral|Oforta|SHT-586|BAY-86-4864|Beneflur,USAN|Research Code|INN|Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code|Research Code|Trade Name,Cancer|Dermatologic,Ribonucleotide reductase inhibitor|DNA primase inhibitor|DNA polymerase alpha inhibitor,346|6830|51708,Anticancer antimetabolite|DNA synthesis inhibitor,1569|140,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Mantle cell lymphoma|Multiple myeloma|Lymphoma|Non-Hodgkin lymphoma,1272|1731|1734|1735|1744|1828|203|319,Psoriasis,281,Sanofi Genzyme|Bayer AG|Sanofi SA,16299|14455|1009547,Antisoma plc|Berlex Laboratories Inc|Southern Research Institute,14239|19693|20226,Southern Research Institute,20226,,,,,,
61560,imgatuzumab,"anticancer agent (iv, solid tumor/NHL/HL), Roche|Glycoengineered anti-EGFR antibody (GlycoMAb, injectable, solid tumor), Glycart|EGFR-targeting antibody (glycoengineered, solid tumor), Roche|imgatuzumab|GA-201|R-7160|RG-7160|RO-5083945|89Zr-imgatuzumab",USAN|INN|Research Code|Research Code|Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,,,Non-small-cell lung cancer|Head and neck tumor|Solid tumor|Colorectal tumor,1262|623|725|989,,,Hoffmann-La Roche AG|Roche GlycArt Ag,19449|30654,Roche GlycArt Ag,30654,,,,,,
61616,volasertib,BI-6727|volasertib,Research Code|USAN|INN,Cancer,Polo-like kinase 1 inhibitor,4536,Mitotic cell cycle pathway modulator|Synergist|Cell cycle inhibitor|Anticancer protein kinase inhibitor|Mitosis inhibitor|Apoptosis stimulator,52473|7293|767|62255|56466|1589,Rhabdomyosarcoma,2448,Non-small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Bladder cancer|Advanced solid tumor|Chronic myelomonocytic leukemia|Solid tumor|Ovary tumor,1262|1272|1731|1753|1754|2380|3713|6833|725|799,Oncoheroes Biosciences Inc,1195147,Boehringer Ingelheim International GmbH,14881,Boehringer Ingelheim International GmbH,14881,,,,,,
61736,"CNDO-109-activated allogeneic NK cell therapy (cancer), Fortress Biotech","CNDO-102|natural killer cell activator (cancer immunotherapy), Royal Free Hospital/ Coronado|CNDO-109|CNDO-109-AANK cells (cancer), Coronado|CNDO-109-activated allogeneic NK cell therapy (cancer), Coronado|CNDO-109-activated allogeneic NK cell therapy (cancer), Fortress Biotech",Research Code|Research Code,Cancer,,,Anticancer|Natural killer cell stimulator,1545|7757,,,Acute myelogenous leukemia|Multiple myeloma|Solid tumor,1731|1828|725,,,Fortress Biotech Inc|Royal Free and University College Medical School,1032809|21059,Royal Free and University College Medical School,21059,,,,,,
61802,JSP-191,"AMG-191|JSP-191|humanized anti-CD117 monoclonal antibody, Jasper Therapeutics",Research Code|Research Code,Cancer|Hematologic|Immune|Inflammatory,Kit tyrosine kinase inhibitor,3808,Anti-inflammatory|Anticancer protein kinase inhibitor|Stem cell factor modulator,2953|62255|4114,Myelodysplastic syndrome|Anemia|Acute myelogenous leukemia|Sickle cell anemia|Chronic granulomatous disease|Fanconi anemia|Autoimmune disease|Severe combined immunodeficiency syndrome,1272|17|1731|303|3074|3497|36|3623,Inflammatory disease,188,Jasper Therapeutics Inc,1201219,Amgen Inc,14109,Amgen Inc,14109,,,,,,
61823,varlilumab,"CD27-targeting human antibodies (cancer), Celldex Therapeutics|varlilumab|CDX-1127|CD27 costimulator (cancer), Celldex Therapeutics",USAN|INN|Research Code,Cancer,CD27 agonist,5102,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Non-small-cell lung cancer|Hematological neoplasm|Fallopian tube cancer|Glioblastoma|Squamous cell carcinoma|Peritoneal tumor|B-cell lymphoma|Stage II melanoma|Stage III melanoma|Stage IV melanoma|Metastatic colorectal cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma,1262|2054|2243|2454|307|3083|316|3255|3256|3257|3658|3713|3866|4250,Cancer|Solid tumor,651|725,Celldex Therapeutics Inc,25726,,,Celldex Therapeutics Inc,25726,,,,,,
61874,prexigebersen,"growth factor-bound protein-2 modulator (liposomal, cancer), Bio-Path|liposomal Grb-2 modulator (cancer), Bio-Path|L-Grb-2 (cancer), Bio-Path|prexigebersen|BP-100-1.01|L-Grb-2|Liposomal Grb-2|BP-1001, Bio-Path",INN|Research Code,Cancer,GRB2 gene inhibitor,25898,Anticancer|RNA interference agent,1545|26034,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia|Breast tumor|Cancer,1272|1728|1731|1735|49|651,,,Bio-Path Holdings Inc,1043698,MD Anderson Cancer Center,23382,MD Anderson Cancer Center,23382,,,,,,
61901,buparlisib,"PI3K inhibitor (cancer), Novartis|phosphatidylinositol-3-kinase inhibitor (cancer), Novartis|NVP-BKM-120|BKM-120|BKM-210|buparlisib|buparlisib hydrochloride|phosphatidylinositol-3-kinase inhibitor (cancer), Adlai Nortye Biopharma|AN-2025",Research Code|Research Code|Research Code|USAN|PINN|USAN|Research Code,Cancer|Hematologic,Phosphoinositide 3-kinase inhibitor,1575,Anticancer protein kinase inhibitor|Apoptosis stimulator|Angiogenesis inhibitor|Metastasis inhibitor|Synergist,62255|1589|61|695|7293,Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Hematological neoplasm|Myelofibrosis|Metastatic head and neck cancer,1744|1745|1749|2054|2436|3673,Endometrioid carcinoma|Glioblastoma|Non-Hodgkin lymphoma|Gastrointestinal stromal tumor|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Uterine cervix tumor|Cancer|Solid tumor,1705|2454|319|3205|3246|3257|3657|3665|427|651|725,Adlai Nortye Pharmaceutical Co Ltd,1111343,Novartis AG,23137,Novartis AG,23137,,,,,,
61921,BMS-817378,BMS-817378|BMS-794833|SIM-817378|maitatinib|metatinib tromethamine,Research Code|Research Code,Cancer,VEGF-2 receptor antagonist|Hepatocyte growth factor receptor antagonist,3848|675,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Metastatic liver cancer|Metastatic stomach cancer|Solid tumor,3462|3666|725,,,Simcere Pharmaceutical Group,1023261,Bristol-Myers Squibb Co,15065,Bristol-Myers Squibb Co,15065,,,,,,
61922,LCL-161,LCL-161,Research Code,Cancer|Hematologic,X-linked inhibitor of apoptosis protein inhibitor|SMAC protein modulator,13605|14456,Anticancer|Apoptosis stimulator,1545|1589,Small-cell lung cancer|Non-small-cell lung cancer|Renal cell carcinoma|Multiple myeloma|Myelofibrosis|Metastatic breast cancer|Breast tumor|Solid tumor|Ovary tumor|Colorectal tumor,1261|1262|1766|1828|2436|3657|49|725|799|989,Cancer,651,MD Anderson Cancer Center|Novartis AG,23382|23137,,,Novartis AG,23137,,,,,,
61926,"sonidegib (oral), Novartis","LDE-225 (oral), Novartis|SMO inhibitor (cancer), Novartis|smoothened inhibitor (cancer), Novartis|LAB-687|NVP-LDE-225|NVP-LDE-225 (oral), Novartis|LDE-225|erismodegib|erismodegib (oral), Novartis|sonidegib|sonidegib (oral), Novartis|sonidegib phosphate|LDE-255|Odomzo",Research Code|Research Code|Research Code|USAN|INN|USAN|Research Code|Trade Name,Cancer|Dermatologic|Hematologic,Smoothened receptor antagonist|Hedgehog protein inhibitor,11036|8134,Anticancer,1545,Basal cell carcinoma|Basal cell nevus syndrome,1764|3382,Small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia|Hepatocellular carcinoma|Multiple myeloma|Sarcoma|Hematological neoplasm|Myelofibrosis|Pancreas tumor|Medulloblastoma|Breast tumor|Cancer|Solid tumor,1261|1272|1731|1735|1767|1828|194|2054|2436|249|2533|49|651|725,Sun Pharmaceutical Industries Ltd|Novartis AG,27561|23137,,,Novartis AG,23137,,,,,,
61956,SCH-900776,"CHK-1 inhibitor (cancer), Schering-Plough|checkpoint kinase 1 inhibitor (cancer), Schering-Plough|SCH-900776|checkpoint kinase 1 inhibitor (cancer), Merck & Co|MK-8776",Research Code|Research Code,Cancer,Checkpoint kinase 1 inhibitor,4438,Cell cycle inhibitor|Anticancer protein kinase inhibitor,767|62255,,,Neoplasm,230,,,Merck & Co Inc|Schering-Plough Corp,18077|19711,Schering-Plough Corp,19711,,,,,,
62014,spebrutinib,"AVL-101|Btk inhibitors (cancer), Avila|AVL-291|Btk inhibitors (cancer), Celgene|CC-292|CNX-652|AVL-292|spebrutinib|spebrutinib besylate|CC-90008",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|USAN|Research Code,Cancer|Immune,Btk tyrosine kinase inhibitor,3592,Anticancer|Anti-inflammatory|Synergist|Immunosuppressant|Anticancer protein kinase inhibitor,1545|2953|7293|396|62255,Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma,1734|1749,Multiple myeloma|Rheumatoid arthritis|Non-Hodgkin lymphoma|Autoimmune disease|Cancer,1828|291|319|36|651,Bristol-Myers Squibb Co,15065,Avila Therapeutics Inc|Celgene Corp,1044109|15331,Avila Therapeutics Inc,1044109,,,,,,
62015,"rituximab + hyaluronidase (Non-Hodgkin's lymphoma/diffuse large B-cell lymphoma/chronic lymphocytic leukemia, Enhanze), Roche/Halozyme","rituximab (sc, Enhanze hyaluronidase formulation), Roche|RG-105|rituximab sc|rituximab (sc, rHuPH20 formulation, Non-Hodgkin's lymphoma/diffuse large B-cell lymphoma/chronic lymphocytic leukemia), Roche|MabThera SC|Rituxan SC|Rituxin SC|Rituxan Hycela|rituximab (sc, human recombinant hyaluronidase, Non-Hodgkin's lymphoma), Roche|rituximab + hyaluronidase (Non-Hodgkin's lymphoma/diffuse large B-cell lymphoma/chronic lymphocytic leukemia, Enhanze), Roche/Halozyme",Research Code|Trade Name|Trade Name,Cancer,B-lymphocyte antigen CD20 inhibitor,5085,Anti-inflammatory|Anticancer monoclonal antibody,2953|55685,Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1734|1745|1749|319,Unidentified indication,1005,Roche Holding AG,19446,,,Roche Holding AG,19446,,,,,,
62047,roneparstat,SST-0001|roneparstat|LB-401,Research Code|INN|Research Code,Cancer,Heparanase inhibitor,2606,Angiogenesis inhibitor|Anticancer,61|1545,Hematological neoplasm,2054,Multiple myeloma|Cancer,1828|651,Leadiant Biosciences Inc,19946,Alfasigma SpA|Sigma-Tau Ind Farm Riunite SpA,1153354|21159,Sigma-Tau Ind Farm Riunite SpA,21159,,,,,,
6206,acetyl-L-carnitine hydrochloride,acetyl-L-carnitine hydrochloride|ST-200|TA-803|Zibren|Ceredon|L-Branigen|Neuroactil|levacecarnine|levocarnitine acetate hydrochloride|acetyl-L-carnitine,Research Code|Research Code|Trade Name,Cancer|Endocrine/Metabolic|Neurology/Psychiatric|Other/Miscellaneous,Bcl 2 binding component 3 stimulator,53256,Analgesic|Neuroprotectant|Anticancer|Apoptosis stimulator|Nootropic agent,2946|1615|1545|1589|284,Fragile X syndrome|Alzheimers disease|Rett syndrome|Lebers hereditary optic atrophy|Dementia,123|14|3119|3450|90,Diabetic neuropathy|Psychiatric disorder|Motor neurone disease|Peripheral neuropathy|Complex regional pain syndrome|HIV-associated lipodystrophy|Cerebral infarction|Cancer|Fatigue,101|207|212|259|2618|2642|62|651|829,Leadiant Biosciences Inc|Alfasigma SpA,19946|1153354,Bago|Glaxo Group Ltd|Tanabe Seiyaku Co Ltd|Parke-Davis & Co|Sigma-Tau Ind Farm Riunite SpA|Prodotti Formenti Srl|SmithKline Beecham Corp|Laboratoires Houde SA|Roussel Uclaf Corp|F Hoffmann-La Roche AG,14346|16453|20315|20805|21159|24017|24155|26125|26135|26178,Sigma-Tau Ind Farm Riunite SpA,21159,,,,,,
62081,DKN-01,"anti-Dkk1 mAb (multiple myeloma/cancer/bone fractures), Eli Lilly/Dekkun Corp|Mab B3 (anti-Dickkopf-1 chimeric mAb, bone disease/cancer), Eli Lilly|LY-2812176|biological therapy (cancer) 1, Eli Lilly|DKN-01",Research Code|Research Code,Cancer,Dickkopf-1 ligand inhibitor,12543,Bone synthesis stimulator|Anticancer monoclonal antibody|Anticancer,445|55685|1545,Esophagus tumor|Stomach tumor|Biliary cancer|Endometrioid carcinoma|Cholangiocarcinoma|Hepatocellular carcinoma|Adenocarcinoma|Gallbladder tumor|Hormone refractory prostate cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Uterus tumor|Ovary tumor,1011|127|1516|1705|1765|1767|2399|3146|3246|3666|3667|740|799,Multiple myeloma|Metastatic non small cell lung cancer|Advanced solid tumor,1828|3665|3713,Leap Therapeutics Inc|BeiGene Co Ltd,1065870|1063251,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
62084,letermovir,"antiviral therapy, AiCuris|AIC-246|letermovir|non-nucleosidic terminase inhibitor (oral, HCMV infection), AiCuris|MK-8228|Prevymis|AIC-001|BAY-73-6327|BAY-73-6327-N",Research Code|USAN|INN|Research Code|Trade Name|Research Code|Research Code|Research Code,Infection,Large terminase protein inhibitor,70071,CMV replication inhibitor,2833,Cytomegalovirus infection,89,Viral infection,344,Merck & Co Inc,18077,AiCuris Anti-infective Cures GmbH,1020319,AiCuris Anti-infective Cures GmbH,1020319,,,,,,
62117,TAK-901,"TAK-901|aurora B kinase inhibitor (cancer, iv), Takeda",Research Code,Cancer,Aurora protein kinase 1 inhibitor,4418,Cell cycle inhibitor|Anticancer protein kinase inhibitor|Apoptosis stimulator|Anticancer,767|62255|1589|1545,,,Hematological neoplasm|Solid tumor,2054|725,,,Takeda Oncology,21991,Takeda Oncology,21991,,,,,,
62139,lurbinectedin,"anticancer agents (natural product), PharmaMar|PM-01183|PM-00113|PM-01120|PM-050489|PM-1183|tryptamicidin|lurbinectedin|Zepsyre|LY-01017|Zepzelca",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Trade Name|Research Code|Trade Name,Cancer,TAT protein inhibitor|RNA polymerase II inhibitor,359|6827,Synergist|Apoptosis stimulator|Anticancer|DNA repair inhibitor,7293|1589|1545|11593,Mesothelioma|Small-cell lung cancer|Biliary tumor|Endometrioid carcinoma|Ewing sarcoma|Metastatic breast cancer|Germ cell and embryonic cancer|Head and neck tumor|Solid tumor,1240|1261|1515|1705|2975|3657|3737|623|725,Non-small-cell lung cancer|Acute leukemia|Hematological neoplasm|Pancreas tumor|Metastatic pancreas cancer|Metastatic colon cancer|Cancer|Lung tumor|Ovary tumor,1262|1727|2054|249|3669|3672|651|755|799,Specialised Therapeutics Australia Pty Ltd|Adium Pharma SA|PharmaMar SA|MegaPharm Ltd|Specialised Therapeutics Asia Pte Ltd|Boryung Pharm Co Ltd|Immedica Pharma AB|Luye Pharma Group Ltd,1044298|1218632|17927|26786|1157003|14987|1073345|1015499,Jazz Pharmaceuticals Inc.|Chugai Pharmaceutical Co Ltd,1166665|15414,PharmaMar SA,17927,,,,,,
62159,"F-16-IL-2 fusion protein (cancer), Philogen","F-16-IL-2|Teleukin|F-16-IL-2 fusion protein (cancer), Philogen",,Cancer,Interleukin-2 ligand|Tenascin modulator,12481|15357,Anticancer monoclonal antibody|Vascular damaging agent,55685|2969,Acute myelogenous leukemia,1731,Merkel cell carcinoma|Stage IV melanoma|Metastatic non small cell lung cancer|Breast tumor|Solid tumor,3235|3257|3665|49|725,Philogen SpA|Boehringer Ingelheim International GmbH,29032|14881,,,Philogen SpA,29032,,,,,,
62215,LY-2090314,"GSK-3 inhibitors (type 2 diabetes, cancer), Eli Lilly|glycogen synthase kinase-3 inhibitors, Eli Lilly|LY-2090314|GSK3-beta inhibitor (cancer), Eli Lilly",Research Code,Cancer|Endocrine/Metabolic,Glycogen synthase kinase-3 beta inhibitor,4360,Anticancer chemosensitizer|Anticancer protein kinase inhibitor|Hypoglycemic agent,1586|62255|399,,,Acute myelogenous leukemia|Metastatic pancreas cancer|Cancer|Non-insulin dependent diabetes,1731|3669|651|837,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
62259,luspatercept,"ACE-536|growth and differentiation factor (GDF) protein-based therapy (anemia associated with myelodysplastic syndrome), Acceleron|GDF ligands and receptors modulator (anemia), Acceleron|Anemia therapy, Acceleron|RAP-536|GDF ligands and receptors modulator (anemia associated with myelodysplastic syndrome), Acceleron/ Celgene|luspatercept|ACE-536d|REBLOZYL|luspatercept-aamt",Research Code|Research Code|USAN|INN|Research Code|Trade Name|Trade Name,Cancer|Hematologic,TGF beta receptor antagonist|TGF beta ligand inhibitor|GDF modulator,377|69025|7908,Anticancer protein kinase inhibitor|Hematopoietic stimulator,62255|610,Myelodysplastic syndrome|Anemia|Beta thalassemia|Myelofibrosis,1272|17|2369|2436,Sickle cell anemia,303,Bristol-Myers Squibb Co,15065,Acceleron Pharma Inc|Celgene Corp,1009646|15331,Acceleron Pharma Inc,1009646,,,,,,
62275,cobicistat,"GS-9350|antiretroviral boosting agent, Gilead Sciences|cobicistat|antiretroviral boosting agent, Gilead Sciences/ Japan Tobacco|Tybost",Research Code|USAN|INN|Trade Name,Infection,Cytochrome P450 3 inhibitor,7418,Antiviral|Synergist,991|7293,HIV-1 infection,159,,,Gilead Sciences Inc|Japan Tobacco Inc,16450|17327,,,Gilead Sciences Inc,16450,,,,,,
62282,"trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme","trastuzumab (subcutaneous/hyaluronidase formulation, HER2-positive breast cancer), Roche/Halozyme|trastuzumab (sc, rHuPH20 formulation, breast cancer), Roche/Halozyme|Herceptin SC|Herceptin Hylecta|trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme",Trade Name,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Hyaluronidase stimulator,3756|8590,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Metastatic breast cancer|Breast tumor,3657|49,,,Roche Holding AG|Genentech Inc,19446|19453,Halozyme Therapeutics Inc,1010825,Halozyme Therapeutics Inc,1010825,,,,,,
62303,AZD-4573,"cyclin-dependent kinase 9 inhibitors (inflammatory diseases), Probiodrug|CDK9 inhibitors (inflammatory diseases), Probiodrug|CDK9 inhibitors (inflammatory diseases/ cancer), AstraZeneca|cyclin-dependent kinase 9 inhibitors (inflammatory diseases/ cancer), AstraZeneca|AZ-5576|AZD-4573|AZD-5576|PC-585|AZD-4753|AZ-13810325",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Inflammatory,Cyclin-dependent kinase-9 inhibitor,8110,Anticancer protein kinase inhibitor|Apoptosis stimulator|Anti-inflammatory,62255|1589|2953,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma|Inflammatory disease|Hematological neoplasm|Non-Hodgkin lymphoma|Chronic myelomonocytic leukemia,1272|1728|1731|1734|1744|1749|1828|188|2054|319|6833,Cancer,651,AstraZeneca plc,14190,Vivoryon Therapeutics NV,25288,Vivoryon Therapeutics NV,25288,,,,,,
62388,225Ac-lintuzumab,actinium-225-HuM-195|SMART actinium-225-M195|225Ac-HuM-195|SMART 225Ac-M195|225Ac-lintuzumab|actinium-225-M195|HuM-195 [225Ac]|HuM-195-Ac-225|Actimab-A|Actimab-M|lintuzumab-Ac225|Actimab-MDS|actinium (225Ac) lintuzumab satetraxetan|lintuzumab satetraxetan [225Ac]|225Ac- lintuzumab satetraxetan,Trade Name|Trade Name|INN,Cancer,CD33 antagonist,5121,Radioimmunotherapeutic|Anticancer monoclonal antibody|Hematopoietic inhibitor,1552|55685|1677,Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma,1272|1731|1828,,,Actinium Pharmaceuticals Inc,24594,PDL BioPharma Inc,19162,PDL BioPharma Inc,19162,,,,,,
62390,tomaralimab,"OPN-305|toll-like receptor specific monoclonal antibodies (inflammatory diseases), Opsona|TLR-specific mAbs (kidney transplant rejection), Opsona|OPN-301|tomaralimab",Research Code|Research Code|PINN,Cancer|Cardiovascular|Immune|Inflammatory,TLR-2 antagonist,7807,Cardioprotectant|Anticancer monoclonal antibody|Anti-inflammatory,2659|55685|2953,,,Myelodysplastic syndrome|Inflammatory disease|Myocardial infarction|Pancreas tumor|Kidney transplant rejection|Transplant rejection|Cancer,1272|188|224|249|2989|515|651,,,Opsona Therapeutics Ltd,1015439,Opsona Therapeutics Ltd,1015439,,,,,,
62393,fluciclatide F 18,"18F-AH-111585|18F-labeled cyclic RGD peptide (PET imaging agent, cancer), GE Healthcare|alpha-V/beta-3 integrin binding PET imaging agent (injectable, cancer), GE Healthcare|Fluorine-18 AH-111585|AH-111585 [18F]|fluciclatide F 18|18F-fluciclatide|fluorine-18-fluciclatide|fluciclatide (18F)",Research Code|Research Code|Research Code|USAN|INN,Cancer,Integrin alpha-V/beta-3 modulator,6063,Imaging agent|Neoplasm diagnostic agent|Radiodiagnostic,4155|7220|5720,,,Solid tumor,725,,,GE Healthcare,25593,GE Healthcare,25593,,,,,,
62417,sapanisertib,"mTORC1/mTORC2 inhibitors (oral, cancer), Intellikine|INK-128|mTORC1/mTORC2 inhibitors (oral, cancer), Millennium|MLN-0128|sapanisertib|TAK-228",Research Code|Research Code|USAN|INN|Research Code,Cancer|Hematologic,mTOR complex 1 inhibitor|mTOR complex 2 inhibitor,76090|76096,Anticancer|Metastasis inhibitor|Anticancer protein kinase inhibitor|Synergist,1545|695|62255|7293,Metastatic ovary cancer,3866,Macroglobulinemia|Endometrioid carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Multiple myeloma|Lymphoma|Fallopian tube cancer|Prostate tumor|Peritoneal tumor|Merkel cell carcinoma|Anaplastic thyroid cancer|Metastatic renal cell carcinoma|Breast tumor|Cancer|Solid tumor|Renal tumor,1264|1705|1767|1771|1828|203|2243|276|3083|3235|3769|4250|49|651|725|999,Takeda Oncology,21991,Intellikine Inc,1045250,Intellikine Inc,1045250,,,,,,
62418,duvelisib,"PI3Kdelta/gamma inhibitors (oral, inflammation/respiratory disease/cancer), Intellikine|phosphoinositide-3 kinase delta/gamma (oral, inflammation/respiratory disease/cancer), Intellikine|INK-055|INK-713|INK-1048|PI3Kdelta/gamma inhibitors (oral, inflammation/respiratory disease/cancer), Intellikine/ Infinity|IPI-145|PI3Kdelta/gamma inhibitors (oral, inflammation/cancer), Intellikine/ Infinity/ Mundipharma|INK-1197|duvelisib|ABBV-954|PI3Kdelta/gamma inhibitors (cancer), Verastem/Yakult|PI3Kdelta/gamma inhibitors (cancer), Yakult|PI3K delta/gamma inhibitors (oral, cancer), Infinity/AbbVie|Copiktra|duvelisib hydrate (oral, inflammation/respiratory disease/cancer), Intellikine/ Infinity/Verastem/Yakult/AbbVie|duvelisib hydrate|YHI-1702|VS-0145",Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code|Trade Name|Research Code|Research Code,Cancer|Immune|Infection|Inflammatory|Respiratory,Phosphoinositide-3 kinase gamma inhibitor|Phosphoinositide-3 kinase delta inhibitor,11186|11183,Anticancer protein kinase inhibitor|Apoptosis stimulator|Antiviral|Immunosuppressant,62255|1589|991|396,Coronavirus disease 19 infection|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Peripheral T-cell lymphoma|Lymphoma|Hematological neoplasm|Squamous cell carcinoma|T-cell lymphoma|Stage IV melanoma|Head and neck tumor|Cancer,10406|1734|1744|1745|1753|203|2054|307|311|3257|623|651,Cutaneous T-cell lymphoma|Inflammatory disease|Rheumatoid arthritis|Asthma|Non-Hodgkin lymphoma|Autoimmune disease|Respiratory disease,1754|188|291|31|319|36|711,Secura Bio Inc|Sanofi SA|CSPC Pharmaceuticals Group Limited|Verastem Oncology|Yakult Honsha Co Ltd,1182172|1009547|1033194|1058061|20961,Intellikine Inc|Mundipharma International Corp Ltd|AbbVie Inc|Infinity Pharmaceuticals Inc,1045250|1045514|1072507|29753,Intellikine Inc,1045250,,,,,,
62429,S-588410,"peptide vaccine (bladder cancer), Shionogi|peptide vaccine (bladder cancer), OncoTherapy Science|peptide vaccine (lung/ esophagael cancer/gastric cancer), OncoTherapy Science|peptide vaccine (lung/ esophagael cancer), Shionogi|S-288310|S-488410|S-488401|S-488402|S-488403|asudemotide|S-588410",Research Code|Research Code|Research Code|Research Code|Research Code|INN|Research Code,Cancer,,,Therapeutic vaccine|T-lymphocyte stimulator|Protein subunit vaccine|Anticancer,12379|7761|12372|1545,Esophagus tumor|Bladder cancer,1011|2380,Stomach tumor|Metastatic non small cell lung cancer|Hepatobiliary system tumor|Lung tumor,127|3665|629|755,Shionogi & Co Ltd,19898,OncoTherapy Science Inc|University of Tokyo,1004292|20686,OncoTherapy Science Inc,1004292,,,,,,
62430,gemogenovatucel-T,"personalized cancer vaccine, Gradalis|Personalized Vaccine|FANG vaccine|autologous GMCSF + bi-shRNAfurin expressing vaccine (cancer), Gradalis|Vigil EATC|gemogenovatucel-T|IND-14205|Vigil, Gradalis|bi-shRNAfurin and GMCSF augmented autologous tumor cell immunotherapy",Trade Name|Research Code|Trade Name,Cancer,CSF2 gene stimulator|FURIN gene inhibitor,21480|37734,T-lymphocyte stimulator|shRNA agent|Genetically engineered autologous cell vaccine|Therapeutic vaccine|Anticancer,7761|38420|4791|12379|1545,Non-small-cell lung cancer|Ewing sarcoma|Advanced solid tumor|Breast tumor|Ovary tumor,1262|2975|3713|49|799,Stage IV melanoma|Metastatic colorectal cancer|Cancer,3257|3658|651,Gradalis Inc,1035822,,,Gradalis Inc,1035822,,,,,,
62547,VS-6766,"RO-5126766|dual Raf/MEK protein kinase inhibitor (solid tumors), Roche|CH-5126766|CKI-27|R-7304|RG-7304|VS-6766",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Raf 1 protein kinase inhibitor|Raf B protein kinase inhibitor|BRAF gene inhibitor|MEK-1 protein kinase inhibitor,4550|4548|19457|4762,Anticancer|Synergist|Anticancer protein kinase inhibitor,1545|7293|62255,Endometrioid carcinoma|Multiple myeloma|Pancreas tumor|Metastatic non small cell lung cancer|Uveal melanoma|Solid tumor|Ovary tumor|Colorectal tumor,1705|1828|249|3665|3788|725|799|989,,,Verastem Oncology,1058061,Chugai Pharmaceutical Co Ltd|Roche Holding AG,15414|19446,Chugai Pharmaceutical Co Ltd,15414,,,,,,
62577,epacadostat,"indoleamine 2,3-dioxygenase 1 inhibitors (cancer), Incyte|INCB-24360-203|epacadostat|INCB-24360|INCB-024360|IDO checkpoint inhibitor (cancer), Incyte",Research Code|USAN|INN|Research Code|Research Code,Cancer,Indoleamine pyrrole 2 3-dioxygenase 1 inhibitor,64856,T-lymphocyte stimulator|Synergist|Anticancer|Immunostimulant,7761|7293|1545|393,Pancreatic ductal adenocarcinoma|Endometrioid carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Sarcoma|Hemangiosarcoma|Angiosarcoma|Leiomyosarcoma|Liposarcoma|Glioblastoma|Thymus neoplasm|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic rectal cancer|Advanced solid tumor,1507|1705|1768|1771|194|2104|2443|2446|2447|2454|2938|3658|3665|3671|3713,Metastasis|Non-small-cell lung cancer|Myelodysplastic syndrome|Fallopian tube cancer|Bladder cancer|Peritoneal tumor|Stage III melanoma|Stage IV melanoma|Metastatic head and neck cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Head and neck tumor|Cancer|Solid tumor|Ovary tumor,1069|1262|1272|2243|2380|3083|3256|3257|3673|4250|427|623|651|725|799,Incyte Corp,17216,,,Incyte Corp,17216,,,,,,
6259,"tocilizumab (intravenous), Roche/Chugai","hPM-1|MR16-1|atlizumab|IL-6 receptor MAb, Chugai|anti-interleukin-6 receptor MAb, Chugai|MRA|R-1569|tocilizumab|Actemra|RoActemra|RG-1569|RO-4877533|tocilizumab (intravenous), Roche/Chugai",Research Code|Research Code|Research Code|USAN|INN|Trade Name|Trade Name|Research Code|Research Code,Cancer|Cardiovascular|Gastrointestinal|Immune|Infection|Inflammatory|Musculoskeletal|Neurology/Psychiatric|Toxicity/Intoxication,IL-6 receptor modulator|IL-6 receptor antagonist,3058|471,Antiviral|Anti-inflammatory|Anticancer monoclonal antibody|Antihypertensive|Therapeutic antibody|Analgesic,991|2953|55685|2657|172641|2946,Coronavirus disease 19 infection|Castlemans disease|Chronic lymphocytic leukemia|Viral pneumonia|Motor neurone disease|Osteoarthritis|Polymyalgia rheumatica|Rheumatoid arthritis|Adult onset Stills disease|Juvenile rheumatoid arthritis|Pulmonary artery hypertension|Autoimmune encephalomyelitis|Toxicity,10406|1294|1734|1818|212|245|2887|291|3002|3003|3510|3858|735,Takayasus arteritis|Multiple myeloma|Temporal arteritis|Pancreas tumor|Systemic lupus erythematosus|Ankylosing spondylitis|Behcets disease|Crohns disease,1537|1828|1850|249|318|398|768|84,JW Pharmaceutical Corp|Roche Holding AG|Chugai Pharmaceutical Co Ltd,15411|19446|15414,,,Chugai Pharmaceutical Co Ltd,15414,,,,,,
62658,SIM-0702,"Endostar Depot for Injection|recombinant human endostatin (injectable microsphere depot, cancer), Simcere|SIM-0702",Research Code,Cancer,Endostatin stimulator,49941,Anticancer|Angiogenesis inhibitor,1545|61,,,Cancer,651,,,Simcere Pharmaceutical Group,1023261,Simcere Pharmaceutical Group,1023261,,,,,,
62665,tisotumab vedotin,"anti-tissue factor human antibody (cancer), Genmab|tisotumab|tisotumab vedotin|HuMax-TF-ADC|TF-011-MMAE|HuMax-TF|TF-011-monomethyl auristatin E",USAN|INN|USAN|INN|Research Code|Research Code|Research Code,Cancer,Tissue factor inhibitor,8039,Anticancer monoclonal antibody|Immunomodulator,55685|1596,Endometrioid carcinoma|Fallopian tube cancer|Squamous cell carcinoma|Peritoneal tumor|Hormone refractory prostate cancer|Metastatic bladder cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Uterine cervix tumor,1705|2243|307|3083|3246|3466|3658|3665|3667|3669|3673|3713|3866|427,Cancer,651,Genmab A/S|Seagen Inc,26469|25554,,,Genmab A/S,26469,,,,,,
62668,"fludarabine phosphate GDEPT (PNP gene therapy), PNP Therapeutics/University of Alabama/Southern Research Institute","purine nucleoside phosphorylase gene therapy (cancer), PNP Therapeutics|fludarabine phosphate GDEPT (PNP gene therapy), PNP Therapeutics/University of Alabama/Southern Research Institute|Ad/PNP/fludarabine monophosphate gene-directed enzyme prodrug therapy (solid tumors), PNP Therapeutics|d/PNP-F-araAMP (GDEPT), PNP Therapeutics|Gedeptin",Trade Name,Cancer,Purine nucleoside phosphorylase modulator|Ribonucleotide reductase inhibitor|DNA polymerase alpha inhibitor|DNA primase inhibitor,1463|346|51708|6830,Anticancer antimetabolite|Anticancer|DNA synthesis inhibitor,1569|1545|140,Head and neck tumor|Solid tumor,623|725,,,PNP Therapeutics Inc,1008164,Southern Research Institute|University of Alabama at Birmingham,20226|20524,University of Alabama at Birmingham,20524,,,,,,
62700,PEG-ENDO,"SIM-0710|recombinant human endostatin (PEGylated, cancer), Shandong Simcere Medgenn/Simcere/China Pharmaceutical University|PEG-Endostar for Injection|Endu-PEG injection|PEG-ENDO",Research Code|Research Code,Cancer,Endostatin stimulator,49941,Angiogenesis inhibitor|Anticancer,61|1545,Metastatic non small cell lung cancer|Advanced solid tumor,3665|3713,Cancer,651,China Pharmaceutical University|Simcere Pharmaceutical Group,21231|1023261,,,China Pharmaceutical University,21231,,,,,,
62761,"CD19-targeted allogeneic T-cell therapy (acute lymphoblastic leukemia), Baylor College of Medicine","CD19-targeted allogeneic T-cell therapy (acute lymphoblastic leukemia), Baylor College of Medicine|CARCD19 multivirus CTL",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Antiviral|T-lymphocyte modulator|Anticancer,991|5692|1545,,,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Non-Hodgkin lymphoma,1728|1734|319,,,Baylor College of Medicine,20534,Baylor College of Medicine,20534,,,,,,
62934,CV-9201,"CV-9201|RNActive RNA-based vaccine (NY-ESO-1, MAGE-C1/CT7, MAGE-C2/CT10, NSCLC), CureVac|CV-9201-1|CV-9201-2|CV-9201-3|CV-9201-4|CV-9201-5",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,CTAG1 gene stimulator|MAGEC2 gene stimulator|MAGEC1 gene stimulator|BIRC5 gene stimulator|TPBG gene stimulator,50100|22103|22100|18159|69576,RNA vaccine|Anticancer|Therapeutic vaccine,12377|1545|12379,,,Non-small-cell lung cancer,1262,,,CureVac AG,31507,CureVac AG,31507,,,,,,
6295,tinzaparin sodium,"heparin (low molecular weight), Novo|tinzaparin sodium|Innohep|Logiparin|LHN-1",USAN|BANN|INN|Trade Name|Trade Name|Research Code,Hematologic,Factor Xa antagonist|Low molecular weight heparin|Antithrombin III,120|1741|75,Coagulation inhibitor|Antioxidant agent,659|74,Thromboembolism|Deep vein thrombosis,325|574,,,Bristol-Myers Squibb Co|LEO Pharma A/S,15065|17774,CSL Ltd|Novo Nordisk A/S|Bristol-Myers Squibb Pharma Co,15563|18614|26864,LEO Pharma A/S,17774,,,,,,
62957,"pexidartinib hydrochloride  (cancer/inflammatory disease), Plexxikon","Fms/Kit/Flt-3-ITD inhibitor (cancer/inflammatory disease), Plexxikon|pexidartinib hydrochloride|pexidartinib|PLX3397 hydrochloride|PLX-3397|FP-113|Turalio|pexidartinib hydrochloride  (cancer/inflammatory disease), Plexxikon",USAN|USAN|INN|Research Code|Research Code|Research Code|Trade Name,Cancer|Inflammatory|Musculoskeletal|Neurology/Psychiatric,SL cytokine ligand inhibitor|CSF-1 antagonist|Kit tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor,15591|3154|3808|3806,Apoptosis stimulator|Neuroprotectant|Anticancer protein kinase inhibitor|Synergist|Anti-inflammatory|Anticancer,1589|1615|62255|7293|2953|1545,Prolymphocytic leukemia|Sarcoma|Fallopian tube cancer|Peritoneal tumor|Stage IV melanoma|Lymphoblastic leukemia|Neurofibromatosis type I|Pigmented villonodular synovitis|Metastatic breast cancer|Metastatic pancreas cancer|Solid tumor|Nerve tumor|Ovary tumor|Colorectal tumor,1738|194|2243|3083|3257|3436|3521|3531|3657|3669|725|763|799|989,Alzheimers disease|Hodgkins disease|Acute myelogenous leukemia|Inflammatory disease|Glioblastoma|Gliosarcoma|Hormone refractory prostate cancer|Stage III melanoma,14|161|1731|188|2454|2727|3246|3256,Daiichi Sankyo Co Ltd|Plexxikon Inc,1017506|29155,,,Plexxikon Inc,29155,,,,,,
62966,StemEx,"StemEx|donor cord blood stem cells (stem cell transplantation), Gamida Cell|carlecortemcel-L",Trade Name,Immune,,,Unspecified drug target|Stem cell modulator,59620|53558,,,Stem cell transplantation,2990,,,Gamida-Teva Joint Venture|Gamida Cell Ltd|Teva Pharmaceutical Industries Ltd,1052404|16005|20348,Gamida-Teva Joint Venture,1052404,,,,,,
63031,"CKD-581 (iv, cancer), Chong Kun Dang","CKD-581|histone deacetylase inhibitor (solid tumor), Chong Kun Dang|HDAC inhibitor (solid tumor), Chong Kun Dang Pharmaceutical|CKD-581 (iv, cancer), Chong Kun Dang|alteminostat|alteminostat, Chong Kun Dang|alteminostat mesylate",Research Code|INN,Cancer,Caspase-9 stimulator|Caspase-7 stimulator|Caspase-3 stimulator|Histone deacetylase inhibitor,7321|7315|7303|2574,Apoptosis stimulator|Synergist|Anticancer,1589|7293|1545,Multiple myeloma|Lymphoma,1828|203,Solid tumor,725,Chong Kun Dang Pharmaceutical Corp,15410,,,Chong Kun Dang Pharmaceutical Corp,15410,,,,,,
6306,aldesleukin,"aldesleukin|Proleukin|Macrolin IL-2|rhIL-2, Chiron|recombinant IL-2, Chiron|NSC-373364",INN|Trade Name|Trade Name|Research Code,Cancer|Immune|Infection|Neurology/Psychiatric,Interleukin-2 ligand,12481,Anticancer|Antiviral,1545|991,HIV infection|Melanoma|Motor neurone disease|Stage IV melanoma|Metastatic renal cell carcinoma|Graft versus host disease|Cancer,158|205|212|3257|4250|616|651,Leukemia|Non-Hodgkin lymphoma|Breast tumor|Lung tumor|Ovary tumor,199|319|49|755|799,Clinigen Group plc,1062207,Chiron Corp|Roche Holding AG|Chiron Therapeutics|Novartis AG|MegaPharm Ltd|Prometheus Laboratories Inc,15385|19446|22703|23137|26786|DOL1000583,Chiron Corp,15385,,,,,,
63079,"suramin sodium (low-dose, cancer), Optimum Therapeutics","suramin|suramin sodium|suramin (low-dose, cancer), Optimum Therapeutics|suramin hexasodium|suramin sodium (low-dose, cancer), Optimum Therapeutics",INN|USAN,Cancer,,,Anticancer chemosensitizer|Protozoacide|Anthelmintic|Unspecified drug target,1586|8165|7227|59620,,,Non-small-cell lung cancer|Cancer,1262|651,,,Optimum Therapeutics LLC,1032001,Optimum Therapeutics LLC,1032001,,,,,,
63135,"doxorubicin (encapsulated nanoparticle, bone cancer), Intezyne Technologies","daunorubicin|doxorubicin|daunorubicin (encapsulated nanoparticle, breast cancer), Intezyne Technologies|IT-143|doxorubicin (encapsulated nanoparticle, breast cancer), Intezyne Technologies|doxorubicin (encapsulated nanoparticle, bone cancer), Intezyne Technologies",BANN|INN|USAN|BAN|INN|Research Code,Cancer,,,Anticancer,1545,,,Solid tumor,725,,,Intezyne Technologies Inc,1020777,Intezyne Technologies Inc,1020777,,,,,,
63137,GI-6207,"GI-6207|CEA-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune/NCI|CEA-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune/NCI/Celgene|CEA-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), NantCell",Research Code,Cancer,CD66 modulator,5262,Recombinant fungal vector vaccine|Anticancer|Therapeutic vaccine,33963|1545|12379,Medullary thyroid cancer,3240,Cancer,651,NantCell Inc,1104834,Celgene Corp|GlobeImmune Inc,15331|28802,GlobeImmune Inc,28802,,,,,,
63173,IMMU-114,"HLA-DR mAb (cancer), Immunomedics|IMMU-114",Research Code,Cancer|Immune,Immunoglobulin G4 modulator|HLA class II antigen inhibitor,5760|19336,Anticancer monoclonal antibody,55685,B-cell lymphoma|Cancer,316|651,Autoimmune disease,36,Immunomedics Inc,17204,,,Immunomedics Inc,17204,,,,,,
6318,99mTc-sestamibi,Tc-MIBI|Miraluma|sestamibi|99mTc-sestamibi|technetium-99m sestamibi|RP-30|Cardiolite,Trade Name|USAN|INN|Trade Name,Cancer|Cardiovascular|Endocrine/Metabolic,,,Cardiovascular diagnostic agent|Radiodiagnostic|Endocrine diagnostic agent|Imaging agent|Neoplasm diagnostic agent|Immune diagnostic agent,7210|5720|7212|4155|7220|7215,Hyperparathyroidism|Breast tumor|Myocardial disease|Coronary artery disease,176|49|671|80,Cancer|Kawasaki disease,651|780,Bristol-Myers Squibb Pharma Co|Lantheus Holdings Inc,26864|1004416,Bristol-Myers Squibb Co,15065,Bristol-Myers Squibb Pharma Co,26864,,,,,,
63187,entrectinib,"ALK inhibitor (cancer), Nerviano Medical Sciences|entrectinib|RXDX-101|NMS-E628|NMS-628|RG-6268|Rozlytrek",USAN|INN|Research Code|Research Code|Research Code|Research Code|Trade Name,Cancer,Ros1 tyrosine kinase receptor inhibitor|Anaplastic lymphoma kinase receptor inhibitor|TrkA receptor antagonist|TrkC receptor antagonist|TrkB receptor antagonist,3826|3736|3840|3844|3842,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Neuroendocrine tumor|Thyroid tumor|Non-small-cell lung cancer|Anaplastic large cell lymphoma|Cholangiocarcinoma|Renal cell carcinoma|Sarcoma|Neuroblastoma|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Uveal melanoma|Metastatic ovary cancer|Salivary gland cancer|Solid tumor|Lung tumor|Brain tumor|Colorectal tumor,1128|1134|1262|1755|1765|1766|194|2726|3257|3657|3658|3665|3669|3673|3713|3788|3866|4299|725|755|760|989,Acute myelogenous leukemia|Cancer,1731|651,Roche Holding AG|Chugai Pharmaceutical Co Ltd|Genentech Inc,19446|15414|19453,Nerviano Medical Sciences Srl|Ignyta Inc,1013717|1079441,Nerviano Medical Sciences Srl,1013717,,,,,,
63191,GS-9820,"CAL-120|PI3K beta and delta inhibitor (solid tumor), Calistoga|GS-9820|acalisib",Research Code|Research Code|INN,Cancer,Phosphoinositide-3 kinase delta inhibitor|Phosphoinositide-3 kinase beta inhibitor,11183|11180,Anticancer protein kinase inhibitor|Synergist,62255|7293,,,Lymphoid leukemia|Multiple myeloma|Solid tumor,1255|1828|725,,,Calistoga Pharmaceuticals Inc|Gilead Sciences Inc,1031135|16450,Calistoga Pharmaceuticals Inc,1031135,,,,,,
63193,sitravatinib,"MG-516|multikinase inhibitor (oral, cancer), Methylgene|MG-91516|sitravatinib|MGCD-516|MGCD-0516|multikinase inhibitor (oral, cancer), Mirati Therapeutics/BeiGene|sitravatinib malate|MGCD-516 malate",Research Code|Research Code|USAN|INN|Research Code|Research Code|USAN,Cancer,Axl tyrosine kinase receptor inhibitor|Mer tyrosine kinase receptor inhibitor|PDGF receptor antagonist|Hepatocyte growth factor receptor antagonist|VEGF-3 receptor antagonist|VEGF-2 receptor antagonist|VEGF-1 receptor antagonist|Trk tyrosine kinase receptor inhibitor|Ret tyrosine kinase receptor inhibitor|Kit tyrosine kinase inhibitor|Tyro3 tyrosine kinase receptor inhibitor|DDR tyrosine kinase receptor inhibitor|EPH family tyrosine kinase inhibitor,3742|3744|948|675|3850|3848|3846|3838|3818|3808|3746|3748|3762,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Biliary cancer|Hepatocellular carcinoma|Transitional cell carcinoma|Liposarcoma|Squamous cell carcinoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma|Solid tumor,1516|1767|1771|2447|307|3257|3466|3657|3665|3666|3713|3866|4250|725,Melanoma|Cancer,205|651,Mirati Therapeutics Inc|BeiGene Co Ltd,1085701|1063251,MethylGene Inc,23090,MethylGene Inc,23090,,,,,,
63252,merestinib,"LY-2801653|MET, RON, ROS1, AXL, MERTK, Tie2/TEK and MKNK1/2 inhibitor (cancer), Eli Lilly|merestinib|dual Axl checkpoint inhibitor/Mer checkpoint inhibitor (oral, cancer), Eli Lilly",Research Code|USAN|INN,Cancer,TrkC receptor antagonist|MNK1 protein kinase inhibitor|MNK2 protein kinase inhibitor|Hepatocyte growth factor receptor antagonist|TrkB receptor antagonist|Ros1 tyrosine kinase receptor inhibitor|TrkA receptor antagonist|Ron tyrosine kinase receptor inhibitor|Mer tyrosine kinase receptor inhibitor|Axl tyrosine kinase receptor inhibitor|Hepatocyte growth factor receptor modulator,3844|3900|3902|675|3842|3826|3840|3800|3744|3742|3607,Metastasis inhibitor|Anticancer protein kinase inhibitor|Dendritic cell stimulator|Macrophage stimulator|Immunostimulant,695|62255|173472|7751|393,,,Biliary cancer|Acute myelogenous leukemia|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Uveal melanoma|Cancer,1516|1731|3658|3665|3713|3788|651,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
63253,brigatinib,"ALK/EGFR inhibitors (cancer), ARIAD|AP-26113|anaplastic lymphoma kinase/EGFR inhibitors (cancer), Ariad|brigatinib|Alunbrig",Research Code|USAN|INN|Trade Name,Cancer,Anaplastic lymphoma kinase receptor inhibitor|ROS1 gene inhibitor|Epidermal growth factor receptor antagonist|Ros1 tyrosine kinase receptor inhibitor,3736|72492|740|3826,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Anaplastic large cell lymphoma|Ependymoma|Meningioma|Neurofibromatosis type II|Metastatic non small cell lung cancer|Advanced solid tumor,1755|2455|2802|3522|3665|3713,Non-small-cell lung cancer|Cancer,1262|651,ARIAD Pharmaceuticals Inc,14296,,,ARIAD Pharmaceuticals Inc,14296,,,,,,
63260,doxorubicin orotate,doxorubicin orotate|DOX-O,,Cancer,Topoisomerase II inhibitor|DNA polymerase inhibitor,142|138,Anticancer,1545,,,Cancer,651,,,SavviPharm Inc,1037477,SavviPharm Inc,1037477,,,,,,
63267,fimepinostat,"HDAC/PI3 kinase inhibitor (oral, cancer), Curis|histone deacetylase/phosphatidylinositol-3 kinase inhibitor (oral, cancer), Curis|fimepinostat|CUDC-907",USAN|INN|Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor|Phosphoinositide-3 kinase beta inhibitor|Phosphoinositide-3 kinase alpha inhibitor|Histone deacetylase-1 inhibitor|Histone deacetylase-10 inhibitor|Histone deacetylase-6 inhibitor|Histone deacetylase-3 inhibitor|Histone deacetylase-2 inhibitor,11183|11180|11177|7841|7868|7856|7847|7844,Anticancer protein kinase inhibitor|Synergist|Anticancer,62255|7293|1545,Glioma|Thyroid tumor|Diffuse large B-cell lymphoma|Glioblastoma|Medulloblastoma|Anaplastic astrocytoma|Advanced solid tumor|Breast tumor|Carcinoma|Ovary tumor,1108|1134|1749|2454|2533|2567|3713|49|54|799,Multiple myeloma|Lymphoma|Hematological neoplasm|Cancer|Solid tumor,1828|203|2054|651|725,Curis Inc,15549,,,Curis Inc,15549,,,,,,
63298,MG-4101,"MG-4101|MG-401|allogeneic natural killer cell therapy (cancer), Mogam/Green Cross|allogenic natural killer cell therapy (cancer), Morgam/GC Pharma|allogenic natural killer cell therapy (intravenous, hepatocellular carcinoma/Non Hodgkin lymphoma), Morgam/GC Pharma|AB-101, Artiva",Research Code|Research Code,Cancer,,,Anticancer|Immunostimulant|Natural killer cell stimulator,1545|393|7757,Hepatocellular carcinoma|Pancreas tumor|Non-Hodgkin lymphoma|Cancer,1767|249|319|651,Lymphoma,203,Mogam Biotechnology Institute|GC Pharma|Artiva Biotherapeutics Inc,24600|16583|1190967,,,Mogam Biotechnology Institute,24600,,,,,,
63416,serabelisib,"phosphoinositide-3 kinase alpha inhibitors (cancer), Intellikine|PI3Kalpha inhibitors (cancer), Intellikine|phosphoinositide-3 kinase alpha inhibitor (solid tumor), Intellikine|phosphoinositide-3 kinase alpha inhibitor (solid tumor), Millennium|serabelisib|MLN-1117|INK-1117|TAK-117|PETRA-06|phosphoinositide-3 kinase alpha inhibitor (solid tumor), Takeda Oncology|phosphoinositide-3 kinase alpha inhibitor (solid tumor), Petra Pharma",INN|Research Code|Research Code|Research Code|Research Code,Cancer,Phosphoinositide-3 kinase alpha inhibitor,11177,Apoptosis stimulator|Anticancer protein kinase inhibitor|Angiogenesis inhibitor,1589|62255|61,Advanced solid tumor|Metastatic ovary cancer|Solid tumor,3713|3866|725,Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Metastatic renal cancer|Metastatic breast cancer|Metastatic renal cell carcinoma|Cancer|Renal tumor,1262|127|1705|3467|3657|4250|651|999,Takeda Oncology|Petra Pharma Corp,21991|1118067,Intellikine Inc,1045250,Intellikine Inc,1045250,,,,,,
63450,"IGF-1-methotrexate (intravenous, myelodysplastic syndrome/chronic myelomonocytic leukemia/oligoblastic acute myelogenous leukemia), IGF Oncology","IGF-1-methotrexate (cancer), IGF Oncology|long-R3-IGF-1-methotrexate (cancer), IGF Oncology|765-IGF-MTX|IGF-1-methotrexate (intravenous, myelodysplastic syndrome/chronic myelomonocytic leukemia/oligoblastic acute myelogenous leukemia), IGF Oncology",Research Code,Cancer,Folate receptor antagonist|Insulin like growth factor 1 ligand modulator,665|12164,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Lymphoma|Chronic myelomonocytic leukemia|Solid tumor,1272|1731|203|6833|725,Cancer,651,IGF Oncology LLC,1014169,,,IGF Oncology LLC,1014169,,,,,,
63496,biropepimut-S,"GL-0817|MAGE-A3 peptide antigen cancer vaccine, Gliknik|MAGE-A3 Trojan Peptide Vaccine|biropepimut-S",Research Code|USAN,Cancer,Melanoma associated antigen 3 inhibitor,21960,Protein subunit vaccine|Anticancer|Immunomodulator|Therapeutic vaccine,12372|1545|1596|12379,Multiple myeloma|Squamous cell carcinoma|Head and neck tumor,1828|307|623,,,Gliknik Inc,1046890,,,Gliknik Inc,1046890,,,,,,
63628,"ACM-001, Actimed Therapeutics","MT-102, PsiOxus|S-pindolol|MT-102, Myotec|espindolol, PsiOxus|MT-102, Actimed Therapeutics|ACM-001, Actimed Therapeutics",Research Code|Research Code|Research Code,Musculoskeletal|Other/Miscellaneous,,,Energy metabolism modulator|Steroid agonist,1732|714,Cachexia,425,Sarcopenia,3210,Actimed Therapeutics Ltd,1178569,PsiOxus Therapeutics Ltd,1058712,PsiOxus Therapeutics Ltd,1058712,,,,,,
63644,AMG-900,AMG-900,Research Code,Cancer,Aurora C protein kinase inhibitor|Aurora protein kinase 1 inhibitor|Aurora protein kinase 2 inhibitor,4414|4418|4420,Anticancer protein kinase inhibitor|Anticancer,62255|1545,,,Hematological neoplasm|Solid tumor,2054|725,,,Amgen Inc,14109,Amgen Inc,14109,,,,,,
63656,ensartinib,"ALK inhibitors (cancer), Xcovery|anaplastic lymphoma kinase inhibitors (cancer), Xcovery|X-276|X-353|X-376|ALK inhibitor (cancer), Betta Pharmaceuticals|ensartinib|X-396|Ensacove",Research Code|Research Code|Research Code|USAN|INN|Research Code|Trade Name,Cancer|Hematologic,Anaplastic lymphoma kinase receptor inhibitor|Ros1 tyrosine kinase receptor inhibitor,3736|3826,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Melanoma|Neuroblastoma|Non-Hodgkin lymphoma|Histiocytosis|Central nervous system tumor,1262|205|2726|319|4682|759,Advanced solid tumor|Cancer,3713|651,Xcovery Inc|Betta Pharmaceuticals Co Ltd,1038090|1051889,,,Xcovery Inc,1038090,,,,,,
63663,"H1N1 pandemic influenza vaccine (AS03 adjuvanted) 1, GlaxoSmithKline","H1N1 pandemic influenza vaccine (AS03 adjuvanted) 1, GlaxoSmithKline|GSK-2340272A|influenza vaccines (intramuscular, influenza virus infection), GlaxoSmithKline|GSK-2340269A|Pandemrix (H1N1)|GSK-2340274A|GSK-2340273A|H1N1 pandemic influenza vaccine 1 (AS03 adjuvanted), GSK|GSK2592984A",Research Code|Research Code|Research Code|Research Code|Research Code,Infection,,,Inactivated viral vaccine|Prophylactic vaccine,12367|12378,Influenza virus infection,191,,,GlaxoSmithKline plc,28355,,,GlaxoSmithKline plc,28355,,,,,,
63685,"ALT-801 (donor lymphocyte infusion, cancer), Altor","c264sc-TCR-IL2 (donor lymphocyte infusion, cancer), Altor|ALT-801 (donor lymphocyte infusion, cancer), Altor|STAR-Ck (donor lymphocyte infusion, cancer), Altor|STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor|Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor",Research Code|Research Code,Cancer,IL-2 receptor agonist|p53 tumor suppressor protein modulator,221|17119,Lymphocyte stimulator|Anticancer|Immunostimulant,7749|1545|393,,,Acute myelogenous leukemia|Cancer,1731|651,,,Altor BioScience Corp,1007204,Altor BioScience Corp,1007204,,,,,,
63698,flotegatide (18F),"SMIBR-K5|18F-SMIBR-K5|cyclic triazole bearing RGD peptide integrin alpha-v beta-3 imaging agent (cancer), Siemens|18F-RGD-K5|fluorine-18-SMIBR-K5|RGD-K5-[18F]|flotegatide (18F)|18F-flotegatide|fluorine-18-flotegatide|SMIBR-K5-[18F]",Research Code|Research Code|Research Code|Research Code|INN,Cancer|Cardiovascular,Integrin alpha-V/beta-3 modulator,6063,Radiodiagnostic|Neoplasm diagnostic agent|Cardiovascular diagnostic agent|PET contrast agent,5720|7220|7210|5555,Carotid stenosis|Cancer,1615|651,,,Siemens Medical Solutions Molecular Imaging,1020079,,,Siemens Medical Solutions Molecular Imaging,1020079,,,,,,
63729,F-18-VM4-037,"F-18-labelled VM4-037|F-18-VM4-037|F-18-labelled imaging agent (Cancer), Siemens Molecular Imaging",Research Code,Cancer,,,Radiodiagnostic|Neoplasm diagnostic agent|Imaging agent,5720|7220|4155,,,Cancer,651,,,Siemens Medical Solutions Molecular Imaging,1020079,Siemens Medical Solutions Molecular Imaging,1020079,,,,,,
63737,"18F-flortanidazole PET imaging agent (cancer), Threshold Pharmaceuticals","F-18-labelled HX4|F-18-labelled PET imaging agent (cancer), Siemens Molecular Imaging|flortanidazole (18F)|fluorine18-flortanidazole|18F-flortanidazole|F-18-HX4|18F-flortanidazole PET imaging agent (cancer), Siemens Molecular Imaging|18F-flortanidazole PET imaging agent (cancer), Threshold Pharmaceuticals",USAN|INN|Research Code,Cancer,,,Neoplasm diagnostic agent|Radiodiagnostic|Imaging agent,7220|5720|4155,,,Cancer,651,,,Siemens Medical Solutions Molecular Imaging|Molecular Templates Inc,1020079|30181,Siemens Medical Solutions Molecular Imaging,1020079,,,,,,
63757,MM-151,MM-151,Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor|Anticancer polyclonal antibody|Anticancer|Anticancer monoclonal antibody,62255|55686|1545|55685,,,Advanced solid tumor|Cancer|Colorectal tumor,3713|651|989,,,Merrimack Pharmaceuticals Inc,27954,Merrimack Pharmaceuticals Inc,27954,,,,,,
63799,"uprosertib + trametinib (cancer), Laekna Therapeutics","GSK-2141795 + trametinib|AKT inhibitor (oral, cancer), GlaxoSmithKline|GSK-795 + trametinib|uprosertib + trametinib (cancer), GlaxoSmithKline|uprosertib + trametinib|uprosertib + trametinib (cancer), Novartis|UPB-795|uprosertib + trametinib (cancer), Laekna Therapeutics|LAE-003",Research Code|Research Code|Research Code|Research Code,Cancer|Cardiovascular,MEK-2 protein kinase inhibitor|MEK-1 protein kinase inhibitor|AKT protein kinase inhibitor,4764|4762|3859,Anticancer protein kinase inhibitor,62255,Endometrioid carcinoma|Acute myelogenous leukemia|Hereditary hemorrhagic telangiectasia|Melanoma|Pancreas tumor|Uterine cervix tumor|Cancer|Ovary tumor|Colorectal tumor,1705|1731|1879|205|249|427|651|799|989,,,Laekna Therapeutics Shanghai Co Ltd,1168911,Novartis AG|GlaxoSmithKline plc,23137|28355,GlaxoSmithKline plc,28355,,,,,,
63818,parsatuzumab,"anti-EGFL7 fully humanized monoclonal antibody (cancer), Genentech|MEGF-0444A|anticancer agent (iv, cancer), Genentech|parsatuzumab|RO-5490248|RG-7414",Research Code|USAN|INN|Research Code|Research Code,Cancer,EGF like domain containing protein 7 inhibitor,35650,Angiogenesis inhibitor|Anticancer monoclonal antibody,61|55685,,,Non-small-cell lung cancer|Cancer|Solid tumor|Colorectal tumor,1262|651|725|989,,,Chugai Pharmaceutical Co Ltd|Genentech Inc,15414|19453,Genentech Inc,19453,,,,,,
63832,talazoparib tosylate,"PARP inhibitors (solid tumors), LEAD Therapeutics|BMN-673|BMN-628|talazoparib|talazoparib tosylate|LT-00673|LT-673|MDV-3800|PF-06944076|Talzenna|talazoparib tosilate",Research Code|Research Code|USAN|PINN|USAN|Research Code|Research Code|Research Code|Research Code|Trade Name,Cancer,Poly ADP ribose polymerase 1 inhibitor|Poly ADP ribose polymerase 2 inhibitor,38283|38286,Anticancer|Synergist,1545|7293,Small-cell lung cancer|Non-small-cell lung cancer|Endometrioid carcinoma|Acute myelogenous leukemia|Pancreas tumor|Ewing sarcoma|Squamous cell carcinoma|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor|Metastatic ovary cancer|Head and neck tumor,1261|1262|1705|1731|249|2975|307|3246|3247|3257|3657|3658|3666|3667|3713|3866|623,Metastasis|Hematological neoplasm|Fallopian tube cancer|Peritoneal tumor|Breast tumor|Solid tumor,1069|2054|2243|3083|49|725,Pfizer Inc|Medivation Inc,18767|1014884,LEAD Therapeutics Inc|BioMarin Pharmaceutical Inc,1035637|25861,LEAD Therapeutics Inc,1035637,,,,,,
63858,"LB-100, Lixte","LB-100, Lixte|Protein phosphatase 2A inhibitor (achondroplasia), Lixte Biotechnology",Research Code,Cancer|Cardiovascular|Musculoskeletal|Neurology/Psychiatric,Protein phosphatase 2A inhibitor,49900,Anticancer|Synergist|Antidepressant|DNA repair inhibitor,1545|7293|2941|11593,Glioma|Small-cell lung cancer|Myelodysplastic syndrome|Chronic lymphocytic leukemia|Hepatocellular carcinoma|Oligodendroglioma|Achondroplasia|Astrocytoma|Glioblastoma|Angelman syndrome|Soft tissue sarcoma|Ischemia|Cancer|Depression,1108|1261|1272|1734|1767|2273|2395|2453|2454|3364|3378|637|651|93,,,Lixte Biotechnology Holdings Inc|Taipei Medical University,1034140|1018364,,,Lixte Biotechnology Holdings Inc,1034140,,,,,,
6386,trastuzumab,"trastuzumab|Herceptin|4D5|R-597|HER-2 MAb|Ro-45-2317|rhuMAb-HER2|HER-2 humanized MAb|humanized 4D5, Genentech|anti-HER-2 MAb, Genentech|humanized anti-c-erbB-2 mAb, Genentech|humanized anti-p185HER2 Mab, Genentech|RG-597|RO-0452317|Herclon",INN|Trade Name|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name,Cancer|Genitourinary/Sexual Function,Erbb2 tyrosine kinase receptor inhibitor,3756,Anticancer monoclonal antibody|Apoptosis stimulator|Cell cycle inhibitor|Anticancer protein kinase inhibitor,55685|1589|767|62255,Esophagus tumor|Metastatic breast cancer|Metastatic stomach cancer|Breast tumor|Uterus tumor,1011|3657|3666|49|740,Vulva disease|Pancreas tumor|Prostate tumor|Metastatic bladder cancer|Lung tumor|Ovary tumor|Colorectal tumor,2232|249|276|3466|755|799|989,Cipla Ltd|Genentech Inc|Roche Holding AG|Chugai Pharmaceutical Co Ltd,15503|19453|19446|15414,,,Genentech Inc,19453,,,,,,
63880,imaradenant,"A2a receptor antagonist (Parkinsons disease), Heptares|A2a receptor antagonist (Parkinsons disease), Shire|A2a receptor antagonist (attention deficit hyperactivity disorder), Heptares|A2a receptor antagonist (cancer), Heptares/ AstraZeneca|AZD-4635|HTL-1071|A2aR checkpoint inhibitor (solid tumor), Heptares/AstraZeneca|A2aR checkpoint inhibitor (solid tumor), Sosei Heptares/AstraZeneca|HTL-001071|imaradenant",Research Code|Research Code|Research Code|USAN|INN,Cancer|Neurology/Psychiatric,Adenosine A2a receptor antagonist,596,Antiparkinsonian|Neuroprotectant|Anticancer|Immunostimulant|T-lymphocyte stimulator|Nootropic agent,2947|1615|1545|393|7761|284,Non-small-cell lung cancer|Prostate tumor|Hormone refractory prostate cancer|Metastatic non small cell lung cancer|Advanced solid tumor,1262|276|3246|3665|3713,Parkinsons disease|Attention deficit hyperactivity disorder|Cancer,255|34|651,AstraZeneca plc,14190,Heptares Therapeutics Ltd|Shire plc,1037349|24652,Heptares Therapeutics Ltd,1037349,,,,,,
63929,PKI-179,"PKI-179|phosphoinositide 3-kinase inhibitor (cancer, oral), Wyeth|phosphoinositide 3-kinase inhibitor (cancer, oral), Pfizer|PI3K inhibitor (cancer, oral), Wyeth",Research Code,Cancer,mTOR inhibitor|Phosphoinositide 3-kinase inhibitor,10240|1575,Anticancer protein kinase inhibitor,62255,,,Cancer,651,,,Wyeth|Pfizer Inc,14112|18767,Wyeth,14112,,,,,,
63930,gedatolisib,PKI-587|PF-05212384|PF-384|gedatolisib,Research Code|Research Code|Research Code|USAN|INN,Cancer,mTOR inhibitor|Phosphoinositide 3-kinase inhibitor,10240|1575,Anticancer protein kinase inhibitor,62255,Metastatic breast cancer|Advanced solid tumor,3657|3713,Endometrioid carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Cancer,1705|3658|3665|651,Celcuity LLC|Pfizer Inc,1091022|18767,Wyeth,14112,Wyeth,14112,,,,,,
63971,BP-100-1.02,"liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path|BP-100-1.02|liposomal Bcl-2 (lymphoma/solid tumor), MD Anderson Cancer Center|BP-1002|L-Bcl-2|liposomal Bcl-2 (iv, lymphoma/solid tumor/mantle cell lymphoma/peripheral T-cell lymphoma/cutaneous T-cell lymphoma/follicular lymphoma/marginal zone lymphoma/diffuse large cell lymphoma/hodgkin lymphoma/Waldenstrom Macroglobulinemia), Bio-Path",Research Code|Research Code|Research Code,Cancer,BCL2 gene inhibitor,7709,Antisense oligonucleotide inhibitor|Anticancer,7294|1545,Hodgkins disease|Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Lymphoma|Solid tumor,161|1734|1743|1744|1745|1747|1749|1753|1754|203|725,,,Bio-Path Holdings Inc,1043698,MD Anderson Cancer Center,23382,MD Anderson Cancer Center,23382,,,,,,
64036,PF-4691502,"PF-04691502|PI3K/mTOR inhibitor (cancer), Pfizer|PF-4691502|PF-04691503|PF-502|PF-06465603|PF-0, Pfizer",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,mTOR inhibitor|Phosphoinositide 3-kinase inhibitor,10240|1575,Anticancer protein kinase inhibitor,62255,,,Endometrioid carcinoma|Breast tumor|Cancer,1705|49|651,,,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
64055,letetresgene autoleucel,"adoptive T-cell therapy (cancer), Adaptimmune|adoptive T-cell therapy (multiple myeloma, synovial sarcoma, melanoma), Adaptimmune|enhanced TCR-transduced autologous T cells (cancer), Adaptimmune|genetically engineered NY-ESO-1-specific (c259) T cells  (cancer), Adaptimmune|anti-NY-ESO/HLA‐A*0201 TCR T-cell therapy (cancer), Adaptimmune/GlaxoSmithKline|NY-ESOc259T|NY-ESO TCR|NY-ESO-1 TCR-engineered T-Cells, Adaptimmune|3377794|GSK-3377794|NY-ESO SPEAR T-cell therapy (cancer), Adaptimmune|NY-ESO-1c259 SPEAR T-cells|NY-ESO-1 TCR-T|anti-LAGE-1/HLA‐A*0201 TCR T-cell therapy (cancer), Adaptimmune/GlaxoSmithKline|anti-NY-ESOc259T SLLMWITQC/HLA‐A*0201 TCR T-cell therapy (cancer), Adaptimmune/GlaxoSmithKline|HLA‐A*0201‐SLLMWITQC TCR T-cell therapy (cancer), Adaptimmune/GlaxoSmithKline|GSK'794|letetresgene autoleucel|lete-cel",Research Code|Research Code|Research Code|INN,Cancer,HLA class I antigen A-2 alpha modulator|Cancer testis antigen NY-ESO-1 modulator|Cancer testis antigen 2 modulator,19115|50096|70057,Anticancer|Genetically engineered autologous cell therapy|Immunostimulant|T-lymphocyte stimulator,1545|4790|393|7761,Multiple myeloma|Liposarcoma|Soft tissue sarcoma|Metastatic non small cell lung cancer,1828|2447|3378|3665,Esophagus tumor|Melanoma|Cancer|Ovary tumor,1011|205|651|799,GlaxoSmithKline plc,28355,Adaptimmune Therapeutics plc,1047486,Adaptimmune Therapeutics plc,1047486,,,,,,
6408,vinorelbine,vinorelbine|vinorelbine monotartrate|vinorelbine tartrate|KW-2307|KW-3407|Navelbine|Eunades,INN|USAN|Research Code|Research Code|Trade Name,Cancer,,,Cell cycle inhibitor|Anticancer|Microtubule inhibitor,767|1545|2575,Mesothelioma|Non-small-cell lung cancer|Multiple myeloma|Prostate tumor|Metastatic breast cancer|Metastatic non small cell lung cancer|Uterine cervix tumor|Head and neck tumor,1240|1262|1828|276|3657|3665|427|623,Hormone refractory prostate cancer|Breast tumor|Lung tumor|Brain tumor,3246|49|755|760,Kyowa Hakko Kogyo Co Ltd|Biotoscana International|ASTA Medica AG|Pierre Fabre Group|Boehringer Ingelheim International GmbH,17724|1063950|15623|19087|14881,Glaxo Wellcome (formerly The Wellcome Foundation)|Burroughs Wellcome Inc|GlaxoSmithKline plc,21564|21565|28355,Pierre Fabre Group,19087,,,,,,
6415,tocladesine,"tocladesine|NSC-614491|Adenazole|NSC-354258|purine ribonucleosides, ICN|purine ribonucleosides, Valeant|8-Cl-cAMP",INN|Research Code|Trade Name|Research Code|Metabolite,Cancer|Dermatologic,,,DNA synthesis inhibitor|Anticancer|RNA synthesis inhibitor|Systemic antipsoriatic product,140|1545|439|15184,,,Leukemia|Psoriasis|Colon tumor,199|281|767,,,Bausch Health Companies Inc,17058,Bausch Health Companies Inc,17058,,,,,,
64165,ricolinostat,"HDAC-6 inhibitors (cancer, inflammatory disease), Acetylon|HDAC-6 inhibitors (multiple myeloma), Acetylon|HDAC-6 inhibitors (rheumatoid arthritis), Acetylon|NK-308|ACY-1215|rocilinostat|ricolinostat|ACY-63|HDAC-6 inhibitors (rheumatoid arthritis), Regenacy Pharmaceuticals/Bristol-Myers Squibb",Research Code|Research Code|USAN|INN|Research Code,Cancer|Genitourinary/Sexual Function|Neurology/Psychiatric|Other/Miscellaneous,Histone deacetylase-1 inhibitor|Histone deacetylase-2 inhibitor|Histone deacetylase-6 inhibitor,7841|7844|7856,Anticancer|Cell cycle inhibitor|Synergist|Apoptosis stimulator,1545|767|7293|1589,Diabetic neuropathy|Cholangiocarcinoma|Multiple myeloma|Lymphoma|Polycystic kidney disease|Peripheral neuropathy|Cilia disease|Cancer|Charcot Marie Tooth disease|Neuropathy,101|1765|1828|203|2298|259|3637|651|67|678,,,Beijing 3E-Regenacy Pharmaceuticals Co.|Regenacy Pharmaceuticals LLC|Bristol-Myers Squibb Co|3E Bioventures Capital,1232694|1140343|15065|1228257,Acetylon Pharmaceuticals Inc|Celgene Corp,1049061|15331,Acetylon Pharmaceuticals Inc,1049061,,,,,,
64205,glasdegib,"PF-04449913|sonic hedgehog inhibitor (oral/tablet/capsule, cancers), Pfizer|glasdegib|PF-913|glasdegib maleate|Daurismo",Research Code|USAN|INN|Research Code|Trade Name,Cancer|Hematologic,Smoothened receptor antagonist,11036,Cell cycle inhibitor|Anticancer,767|1545,Acute myelogenous leukemia,1731,Myelodysplastic syndrome|Hematological neoplasm|Myelofibrosis|Advanced solid tumor|Cancer|Chronic myelomonocytic leukemia,1272|2054|2436|3713|651|6833,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
64217,uproleselan sodium,"E-Selectin antagonists (oral, diabetic angiopathy), GlycoMimetics|E-selectin antagonists (metastasis/pancreas cancer/thromboembolism), GlycoMimetics|GMI-1271|uproleselan sodium|uproleselan|APL-106",Research Code|USAN|USAN|INN|Research Code,Cancer|Cardiovascular|Hematologic|Toxicity/Intoxication,E selectin antagonist,2607,Anticancer|Coagulation inhibitor|Anti-inflammatory|Synergist,1545|659|2953|7293,Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Toxicity,1272|1731|1828|735,Metastasis|Diabetic angiopathy|Myocardial infarction|Pancreas tumor|Thromboembolism|Deep vein thrombosis,1069|1624|224|249|325|574,Apollomics Inc|GlycoMimetics Inc,1129041|31655,,,GlycoMimetics Inc,31655,,,,,,
64231,copanlisib hydrochloride,"PI3K inhibitor (cancer), Bayer|BAY-80-6946|copanlisib|copanlisib hydrochloride|Aliqopa|copanlisib dihydrochloride",Research Code|USAN|INN|USAN|Trade Name,Cancer,Phosphoinositide 3-kinase inhibitor,1575,Apoptosis stimulator|Anticancer protein kinase inhibitor|Anticancer,1589|62255|1545,Non-small-cell lung cancer|B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Splenic marginal zone lymphoma|Peripheral T-cell lymphoma|Cholangiocarcinoma|Hepatocellular carcinoma|Osteosarcoma|Rhabdomyosarcoma|Neuroblastoma|Ewing sarcoma|T-cell lymphoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Breast tumor,1262|1729|1734|1743|1745|1746|1747|1753|1765|1767|1772|2448|2726|2975|311|319|3246|3658|3665|3673|3713|49,Mantle cell lymphoma|Diffuse large B-cell lymphoma|Cancer,1744|1749|651,Bayer AG,14455,,,Bayer AG,14455,,,,,,
64299,icotinib hydrochloride,BPI-2009-H|icotinib|icotinib hydrochloride|Conmanna|Conmana|Commana|BPI-2009,Research Code|Trade Name|Trade Name|Trade Name|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Non-small-cell lung cancer|Neurofibromatosis type II,1262|3522,Nasopharyngeal carcinoma|Metastatic esophageal cancer|Metastatic pancreas cancer,1768|3667|3669,Betta Pharmaceuticals Co Ltd,1051889,Beta Pharma Inc,1004107,Betta Pharmaceuticals Co Ltd,1051889,,,,,,
64322,LY-2510924,"LY-2510924|CXCR4 peptide inhibitor (cancer), Eli Lilly",Research Code,Cancer,CXCR4 chemokine antagonist,3137,Synergist|Anticancer,7293|1545,Metastatic pancreas cancer|Metastatic rectal cancer|Advanced solid tumor,3669|3671|3713,Small-cell lung cancer|Metastatic renal cell carcinoma|Cancer,1261|4250|651,Eli Lilly & Co,17810,,,Eli Lilly & Co,17810,,,,,,
64464,"docetaxel (improved version), SK Chemicals/Teva","docetaxel|SID-530|docetaxel (improved version), SK Chemicals/Teva",USAN|INN|Research Code,Cancer,,,Cell cycle inhibitor|Microtubule stabilizer|Apoptosis stimulator,767|2576|1589,Cancer,651,,,Teva Pharmaceutical Industries Ltd,20348,SK Chemicals Co Ltd,26914,SK Chemicals Co Ltd,26914,,,,,,
64468,AZD-4547,"AZD-4547|FGF receptor antagonist (cancer), AstraZeneca/Abbisko|ABSK-091",Research Code|Research Code,Cancer,FGF1 receptor antagonist|FGF2 receptor antagonist|FGF3 receptor antagonist,3682|3685|3688,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Transitional cell carcinoma|Advanced solid tumor,1771|3713,Non-small-cell lung cancer|Metastatic stomach cancer|Breast tumor|Cancer|Solid tumor,1262|3666|49|651|725,Abbisko Therapeutics Co Ltd,1138884,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
64480,melphalan flufenamide hydrochloride,"dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides|melphalan flufenamide|melphalan flufenamide hydrochloride|mel-flufen|J-1|Ygalo|melflufen hydrochloride|CK-1535|Pepaxto",USAN|INN|USAN|Research Code|Trade Name|Research Code|Trade Name,Cancer|Endocrine/Metabolic,Aminopeptidase modulator|Caspase-3 stimulator,1768|7303,Synergist|Apoptosis stimulator|Anticancer|Anticancer alkylating agent|Angiogenesis inhibitor,7293|1589|1545|50|61,Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Multiple myeloma|Non-Hodgkin lymphoma|AL amyloidosis|Breast tumor,1731|1749|1828|319|3492|49,Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Lymphoma|Hematological neoplasm|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic ovary cancer|Cancer|Ovary tumor,1240|1261|1262|203|2054|3466|3657|3665|3866|651|799,Oncopeptides AB,29334,,,Oncopeptides AB,29334,,,,,,
64703,"melphalan (intravenous/Captisol, multiple myeloma), Spectrum / CASI Pharmaceuticals","melphalan|melphalan (intravenous/Captisol, multiple myeloma), CyDex Pharmaceuticals|CDX-353|melphalan hydrochloride|melphalan (intravenous/Captisol, multiple myeloma), Spectrum Pharmaceuticals|melphalan (intravenous/Captisol, multiple myeloma), Spectrum / CASI Pharmaceuticals|Evomela|Captisol-enabled Melphalan|CE Melphalan",USAN|BANN|INN|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Endocrine/Metabolic,,,DNA synthesis inhibitor|Anticancer alkylating agent,140|50,Multiple myeloma|AL amyloidosis,1828|3492,,,CASI Pharmaceuticals Inc|Acrotech Biopharma LLC,21794|1179286,CyDex Pharmaceuticals Inc|Spectrum Pharmaceuticals Inc,21986|24232,CyDex Pharmaceuticals Inc,21986,,,,,,
64842,lexaptepid pegol,"NOX-H94|spiegelmer hepcidin inhibitor (inflammation-induced anemia), NOXXON|lexaptepid pegol",Research Code|INN,Hematologic,Hepcidin inhibitor,18367,Iron metabolism modulator,834,,,Anemia,17,,,NOXXON Pharma AG,16013,NOXXON Pharma AG,16013,,,,,,
64875,"recombinant human thrombopoietin (sc, idiopathic thrombocytopenic purpura/thrombocytopenia/aplastic anemia), 3SBio","TPIAO|recombinant human thrombopoietin (sc, idiopathic thrombocytopenic purpura/thrombocytopenia/aplastic anemia), 3SBio|rhTPO (sc, ITP/thrombocytopenia/aplastic anemia), 3SBio|TPO-105|TPO-106",Trade Name|Research Code|Research Code,Hematologic,Thrombopoietin receptor agonist,3610,,,Aplastic anemia|Thrombocytopenic purpura|Thrombocytopenia,1006|1133|324,,,3SBio Inc,1016672,,,3SBio Inc,1016672,,,,,,
64947,ixazomib citrate,"MLN-9708|MLN-9708 (oral, cancer), Millennium|proteasome inhibitor (oral, cancer), Millennium|MLN-9708 (oral, multiple myeloma/amyloidosis), Millennium|ixazomib citrate|ixazomib citrate (oral, multiple myeloma/amyloidosis), Takeda|Ninlaro|enlairui",Research Code|USAN|Trade Name,Cancer|Endocrine/Metabolic|Immune|Infection,Proteasome inhibitor,4917,Anticancer|Anti-inflammatory|Antiviral|Osteoclast inhibitor,1545|2953|991|12596,HIV infection|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Multiple myeloma|Lymphoma|Bladder cancer|Breast tumor,158|1743|1744|1828|203|2380|49,Amyloidosis|Hematological neoplasm|Lupus nephritis|Cancer|Solid tumor,1143|2054|2404|651|725,Takeda Oncology,21991,,,Takeda Oncology,21991,,,,,,
65045,prexasertib,"LCI-1|back-up checkpoint kinase 1 inhibitor (cancer), Eli Lilly|back-up Chk1 inhibitor (cancer), Eli Lilly|LY-2606368|Chk1 Inhibitor II (cancer), Elil Lilly|LY-2606368 MsOH H2O|LY-2606368 mesylate monohydrate|prexasertib|prexasertib mesylate monohydrate|ACR-368",Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer,Checkpoint kinase 2 inhibitor|Checkpoint kinase 1 inhibitor,4228|4438,Anticancer protein kinase inhibitor,62255,Solid tumor|Ovary tumor,725|799,Small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Metastatic prostate cancer|Metastatic head and neck cancer|Advanced solid tumor|Breast tumor|Cancer,1261|1272|1731|3664|3673|3713|49|651,Acrivon Therapeutics Inc,1164032,ICOS Corp|Eli Lilly & Co|Array BioPharma Inc,17082|17810|25902,Array BioPharma Inc,25902,,,,,,
65094,"EC-17, Endocyte","EC-17|folate receptor modulator (renal cell carcinoma), Endocyte|EC-17, Endocyte",Research Code,Cancer,Folate receptor modulator,1323,Immunomodulator|Anticancer,1596|1545,,,Renal cell carcinoma,1766,,,Endocyte Inc,26000,Endocyte Inc,26000,,,,,,
65242,AMG-820,AMG-820|AMB-051|AMB-05X,Research Code|Research Code|Research Code,Cancer,CSF-1 antagonist,3154,Macrophage modulator|Anticancer|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,5662|1545|55685|62255,Giant cell bone tumor,2857,Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic colon cancer|Advanced solid tumor,3665|3669|3672|3713,Lifemax Laboratories Inc,1111202,Amgen Inc,14109,Amgen Inc,14109,,,,,,
65313,AS-15 adjuvant,"AS-15 adjuvant|SB-AS15|QS-21 + MPL + CpG (vaccination), GSK",Research Code,Immune,,,Adjuvant,524,,,Vaccination,384,,,GlaxoSmithKline plc,28355,GlaxoSmithKline plc,28355,,,,,,
65328,"polymeric nanoparticle docetaxel (Accurin, solid tumors), Pfizer","docetaxel|polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics|BIND-014|polymeric nanoparticle docetaxel (Accurin, solid tumors), DNIB Unwind|polymeric nanoparticle docetaxel (Accurin, solid tumors), Pfizer",USAN|INN|Research Code,Cancer,Prostate specific antigen modulator|Glutamate carboxypeptidase II inhibitor,35354|9269,Anticancer|Cell cycle inhibitor|Microtubule inhibitor,1545|767|2575,,,Non-small-cell lung cancer|Cholangiocarcinoma|Squamous cell carcinoma|Metastatic prostate cancer|Uterine cervix tumor|Cancer|Urinary tract tumor,1262|1765|307|3664|427|651|738,,,DNIB Unwind Inc|Pfizer Inc,1035105|18767,DNIB Unwind Inc,1035105,,,,,,
65353,alpelisib,"PI3K-alpha inhibitor (cancer), Novartis|phosphoinositide 3-kinase alpha inhibitor (cancer), Novartis|NVP-BYL719|alpelisib|BYL-719|Piqray",Research Code|USAN|INN|Research Code|Trade Name,Cancer|Endocrine/Metabolic,Phosphoinositide-3 kinase alpha inhibitor,11177,Anticancer protein kinase inhibitor,62255,Growth disorder|Metastatic breast cancer,140|3657,Esophagus tumor|Rectal tumor|Non-small-cell lung cancer|Multiple myeloma|Metastatic colorectal cancer|Metastatic head and neck cancer|Advanced solid tumor|Solid tumor,1011|1055|1262|1828|3658|3673|3713|725,Novartis AG,23137,,,Novartis AG,23137,,,,,,
65360,ribociclib,"CDK4/6 inhibitor (cancer), Novartis/Astrex|LEE-011|cyclin-dependent kinase 4/6 inhibitor (cancer), Astrex/Novartis|ribociclib|ribociclib succinate|Kisqali|Kisqali Femara Co-Pack",Research Code|INN|USAN|Trade Name|Trade Name,Cancer|Hematologic,Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase-6 inhibitor,4314|4318,Anticancer|Cell cycle inhibitor|Synergist|Anticancer protein kinase inhibitor,1545|767|7293|62255,Myelofibrosis|Medulloblastoma|Peritoneal tumor|Stage IV melanoma|Metastatic breast cancer|Breast tumor|Solid tumor|Central nervous system tumor|Brain tumor|Ovary tumor,2436|2533|3083|3257|3657|49|725|759|760|799,Glioma|Neuroendocrine tumor|Non-small-cell lung cancer|Endometrioid carcinoma|Liposarcoma|Glioblastoma|Metastatic liver cancer|Metastatic head and neck cancer|Teratoma|Cancer,1108|1128|1262|1705|2447|2454|3462|3673|4404|651,Novartis AG,23137,Astex Therapeutics Ltd,28026,Novartis AG,23137,,,,,,
65371,"vocimagene amiretrorepvec + 5-fluorouracil prodrug (cancer), Tocagen","combination vector-delivered gene therapy/5-flurocytosine (5-FC) prodrug (cancer), Tocagen|vocimagene amiretrorepvec|Toca-FC|Toca-511 + Toca-FC (cancer), Tocagen|vocimagene amiretrorepvec + extended-release flucytosine (cancer), Tocagen|Toca-511|cytosine deaminase gene therapy (CDA, retroviral vector) + 5-flucytosine (cancer), Tocagen|vocimagene amiretrorepvec + 5-fluorouracil prodrug (cancer), Tocagen|DNA (Synthetic Toca 511-encoding Retroviral Vector AC3-yCD2(V))|ABC-511/FC|DB-107",USAN|INN|Research Code|Research Code|Research Code,Cancer,Cytosine deaminase inhibitor|CDA gene stimulator,9272|18219,Anticancer|DNA synthesis inhibitor|Retrovirus based gene therapy|Anticancer chemosensitizer,1545|140|4782|1586,Glioma|Lymphoma|Glioblastoma|Anaplastic astrocytoma|Solid tumor,1108|203|2454|2567|725,Oligodendroglioma|Bladder cancer|Cancer,2273|2380|651,ApolloBio Corp|Forte Biosciences Inc,1143621|1051749,,,Forte Biosciences Inc,1051749,,,,,,
65395,enkastim-iv,"enkastim-iv|Hsp 70-derived peptide vaccine (intravenous formulation/cancer), multimmune GmbH|Hsp 70-derived peptide vaccine (iv formulation/cancer), multimmune/Technical University of Munich",,Cancer,Hsp 70 stimulator,8005,Anticancer|Natural killer cell stimulator|Therapeutic vaccine,1545|7757|12379,Non-small-cell lung cancer,1262,Cancer,651,Alphageneron Pharmaceuticals Inc|multimmune GmbH|Technical University of Munich,1235602|1014764|25011,,,multimmune GmbH,1014764,,,,,,
65405,"low-dose itraconazole, Mayne/ Glenmark/ ISDIN/ HedgePath/ Boryung","itraconazole|low-dose itraconazole (fungal infection), HalcyGen|SUBA-itraconazole|Subazole|Subacap|low-dose itraconazole (fungal infection), Mayne Pharma Group|Lozanoc|low-dose itraconazole, Mayne/ Glenmark/ ISDIN/ HedgePath/ Boryung|Tolsura",USAN|BAN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Cancer|Dermatologic|Infection,Lanosterol-14 demethylase inhibitor,777,Anticancer|Fungicide|Ergosterol synthesis inhibitor|Angiogenesis inhibitor|Systemic dermatological antifungal product,1545|1748|161|61|15178,Fungal infection|Histoplasma infection|Blastomyces infection|Prostate tumor|Aspergillus infection|Hormone refractory prostate cancer|Basal cell nevus syndrome|Metastatic non small cell lung cancer|Cancer,124|1320|1322|276|29|3246|3382|3665|651,Onychomycosis,1775,Inhibitor Therapeutics Inc|ISDIN SA|Boryung Pharm Co Ltd|Mayne Pharma Group Ltd|Mayne Pharma Pty Ltd|Glenmark Pharmaceuticals Ltd,25684|1021534|14987|1037040|31290|29326,,,Mayne Pharma Pty Ltd,31290,,,,,,
65426,edicotinib,"JNJ-40346527|FMS inhibitor (oral, inflammatory disease), Johnson & Johnson|JNJ-527|JNJ-244|PRV-6527|edicotinib|JNJ-6527|edicotinib hydrochloride|JNJ-40346527 hydrochloride",Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code|USAN,Cancer|Gastrointestinal|Immune|Inflammatory,CSF-1 antagonist,3154,Anticancer protein kinase inhibitor|Anti-inflammatory,62255|2953,Crohns disease,84,Hodgkins disease|Inflammatory disease|Rheumatoid arthritis,161|188|291,Provention Bio Inc,1149995,Johnson & Johnson Pharmaceutical Research & Development LLC,29481,Johnson & Johnson Pharmaceutical Research & Development LLC,29481,,,,,,
65472,zenocutuzumab,"human therapeutic antibodies (Bispecifics, cancer/viral infections), Merus|human bispecific antibodies (Biclonics, cancer), Merus|HER family modulators (cancer), Merus|MCLA-128|zenocutuzumab|PB-4188",Research Code|INN|Research Code,Cancer|Infection,Erbb2 tyrosine kinase receptor inhibitor|Erbb3 tyrosine kinase receptor inhibitor,3756|3758,Antiviral|Anticancer protein kinase inhibitor|Anticancer monoclonal antibody|Anticancer,991|62255|55685|1545,Endometrioid carcinoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer|Solid tumor,1705|3657|3665|3666|3669|3713|3866|725,Viral infection,344,Merus BV,1008818,,,Merus BV,1008818,,,,,,
65500,SKI-G-801,"protein kinase inhibitors (cancer), Oscotec/Genosco|G-749|flt3 kinase inhibitor (cancer), Genosco|SKI-G-801|G-801|SKI-G-749",Research Code|Research Code|Research Code|Research Code,Cancer,Flt3 tyrosine kinase inhibitor|Axl tyrosine kinase receptor inhibitor,3806|3742,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Acute myelogenous leukemia|Breast tumor|Lung tumor,1731|49|755,Pancreas tumor,249,Oscotec Inc|Genosco,1008033|1062034,,,Oscotec Inc,1008033,,,,,,
65601,ABTL-0812,"LP-182A1|LP-10218|ABTL-0812|sodium 2-hydroxylinoleic (oral, cancer), Ability Pharmaceuticals",Research Code|Research Code|Research Code,Cancer|Inflammatory,TRIB3 gene stimulator|Autophagy protein stimulator,32576|68033,Anticancer|Anti-inflammatory,1545|2953,Glioma|Non-small-cell lung cancer|Biliary cancer|Endometrioid carcinoma|Adenocarcinoma|Neuroblastoma|Metastatic pancreas cancer|Breast tumor|Cancer,1108|1262|1516|1705|2399|2726|3669|49|651,Inflammatory disease|Pancreas tumor,188|249,SciClone Pharmaceuticals LLC|Ability Pharmaceuticals SL|Lipopharma Therapeutics SL,19829|1057397|1043693,,,Lipopharma Therapeutics SL,1043693,,,,,,
65609,vorolanib,"X-82|CM-082|VEGFR and PDGFR tyrosine kinase inhibitor (age-related macular degeneration), Tyrogenex/Xcovery Vision|vorolanib|EYP-1901",Research Code|Research Code|USAN|INN|Research Code,Cancer|Ocular,VEGF-1 receptor antagonist|Ret tyrosine kinase receptor inhibitor|Kit tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor|CSF-1 antagonist|VEGF-2 receptor antagonist|PDGF receptor antagonist,3846|3818|3808|3806|3154|3848|948,Angiogenesis inhibitor|Ocular antineovascularisation agent|Metastasis inhibitor|Anticancer|Anticancer protein kinase inhibitor,61|15148|695|1545|62255,Age related macular degeneration|Small-cell lung cancer|Non-small-cell lung cancer|Hepatocellular carcinoma|Myopia|Retinal venous occlusion|Thymus neoplasm|Choroidal neovascularization|Stage IV melanoma|Wet age related macular degeneration|Metastatic brain cancer|Metastatic stomach cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Diabetic retinopathy|Solid tumor,1226|1261|1262|1767|2006|2656|2938|3138|3257|3354|3471|3666|3713|4250|576|725,Neuroendocrine tumor|Acute myelogenous leukemia,1128|1731,Xcovery Vision|EyePoint Pharmaceuticals Inc|Xcovery Holdings Inc|Challenge Meditech Company Co Ltd,1062139|1007372|1186236|1101660,TyrogeneX|Equinox Science LLC,1049780|1153766,TyrogeneX,1049780,,,,,,
65615,APX-005M,"EPI-0050|anti-CD40 humanized monoclonal antibody (RabMab/MLG, myeloma/CLL/NHL), Epitomics|anti-CD40 humanized monoclonal antibody (RabMab/MLG, myeloma/CLL/NHL), Apexigen|APX-005|APX-005M|anti-CD40 humanized monoclonal antibody (RabMab/MLG, myeloma/CLL/NHL/metastatic melanoma), Apexigen|anti-CD40 humanized monoclonal antibody (RabMab/MLG, myeloma/CLL/NHL/metastatic melanoma/ esophageal cancer), Apexigen|CD40 costimulator (cancer), Apexigen|sotigalimab",Research Code|Research Code|Research Code|PINN,Cancer,CD40 ligand receptor agonist,5141,B-lymphocyte stimulator|Dendritic cell stimulator|Anticancer monoclonal antibody|Immunostimulant|Macrophage stimulator,7741|173472|55685|393|7751,Esophagus tumor|Stomach tumor|Chronic lymphocytic leukemia|Renal cell carcinoma|Multiple myeloma|Adenocarcinoma|Non-Hodgkin lymphoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic rectal cancer|Metastatic ovary cancer|Solid tumor|Central nervous system tumor,1011|127|1734|1766|1828|2399|319|3257|3378|3665|3669|3671|3866|725|759,,,Apexigen Inc,1055952,Epitomics Inc,1007047,Epitomics Inc,1007047,,,,,,
65865,afuresertib,"GSK-2110183|2110183|AKT protein kinase inhibitor (cancer), GlaxoSmithKline|afuresertib|afuresertib hydrochloride|ASB-183|LAE-002|pan AKT protein kinase inhibitor (cancer), Laekna Therapeutics",Research Code|Research Code|USAN|INN|USAN|Research Code|Research Code,Cancer|Hematologic,AKT protein kinase inhibitor,3859,Anticancer protein kinase inhibitor|Synergist|Anticancer,62255|7293|1545,Stomach tumor|Fallopian tube cancer|Peritoneal tumor|Hormone refractory prostate cancer|Metastatic breast cancer|Solid tumor|Ovary tumor,127|2243|3083|3246|3657|725|799,Chronic lymphocytic leukemia|Multiple myeloma|Hematological neoplasm|Histiocytosis|Cancer,1734|1828|2054|4682|651,Laekna Therapeutics Shanghai Co Ltd,1168911,Novartis AG|GlaxoSmithKline plc,23137|28355,GlaxoSmithKline plc,28355,,,,,,
65876,"umeclidinium bromide + vilanterol trifenatate (COPD, inhalant), GlaxoSmithKline/Theravance","573719 + 642444 (COPD, inhalant), GlaxoSmithKline|GSK-573719 + GSK-642444 (COPD, inhalant), GlaxoSmithKline|GSK-573719 + vilanterol  (COPD, inhalant), GSK/Theravance|umeclidinium + vilanterol (COPD, inhalant), GlaxoSmithKline/Theravance|Zephyr|UMEC/VI|Anoro Ellipta|Anoro|umeclidinium bromide + vilanterol trifenatate (COPD, inhalant), GlaxoSmithKline/Theravance|umeclidinium bromide + vilanterol trifenatate|UMEC + GW-642444-M|Laventair|Ou Le Xin|GSK-2592356",Trade Name|Trade Name|Trade Name|Trade Name|Research Code,Respiratory,Muscarinic receptor antagonist|Beta 2 adrenoceptor agonist,259|40,Bronchodilator,646,Chronic obstructive pulmonary disease,1185,,,Innoviva Inc|GlaxoSmithKline plc,25920|28355,,,GlaxoSmithKline plc,28355,,,,,,
6600,"bexarotene (oral formulation), Eisai/Bausch Health","bexarotene|LDG 1069|LG-1069|LGD 1069|ALRT-1069|Targretin capsules|LGD-1069 oral formulation|Targretin oral formulation|bexarotene (oral formulation), Ligand|bexarotene (oral formulation), Eisai|BSC-1|bexarotene (oral formulation), Eisai/Bausch Health",USAN|BANN|INN|Research Code|Research Code|Trade Name|Research Code|Trade Name|Research Code,Cancer|Dermatologic|Endocrine/Metabolic,Insulin sensitizer|Retinoid X receptor modulator,1919|4058,Systemic antipsoriatic product|Anticancer|Hypoglycemic agent,15184|1545|399,Cutaneous T-cell lymphoma,1754,Non-small-cell lung cancer|Gastrointestinal tumor|Renal cell carcinoma|Prostate tumor|Psoriasis|Squamous cell carcinoma|Breast tumor|Head and neck tumor|Cancer|Lung tumor|Ovary tumor|Non-insulin dependent diabetes,1262|131|1766|276|281|307|49|623|651|755|799|837,Ewopharma AG|Bausch Health Companies Inc|Teva Pharmaceutical Industries Ltd|Ferrer Internacional SA|Minophagen Pharm Co|Alfa Wassermann SpA|Eisai Co Ltd,17764|17058|20348|16118|18222|13983|15872,Zeneus Pharma Ltd|Cephalon Inc|Ligand Pharmaceuticals Inc|Eli Lilly & Co|Elan Pharmaceuticals Inc,1006337|15358|17808|17810|26414,Ligand Pharmaceuticals Inc,17808,,,,,,
66051,ipatasertib,GDC-0068|ipatasertib dihydrochloride|ipatasertib|RG-7440|RO-5532961,Research Code|USAN|INN|Research Code|Research Code,Cancer,AKT protein kinase inhibitor|Fatty acid transport protein inhibitor,3859|9237,Anticancer protein kinase inhibitor,62255,Fallopian tube cancer|Glioblastoma|Peritoneal tumor|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic prostate cancer|Advanced solid tumor|Metastatic ovary cancer|Solid tumor,2243|2454|3083|3246|3657|3664|3713|3866|725,Metastatic stomach cancer|Breast tumor,3666|49,Roche Holding AG|Genentech Inc|Chugai Pharmaceutical Co Ltd,19446|19453|15414,Array BioPharma Inc,25902,Array BioPharma Inc,25902,,,,,,
66114,cerdulatinib,"Syk/JAK multikinase inhibitor (oral, NHL/CLL/RA), Portola Pharmaceuticals|PRT-2070|cerdulatinib|PRT-062070|ALXN-2075",Research Code|USAN|INN|Research Code|Research Code,Cancer|Immune,JAK tyrosine kinase inhibitor|Syk tyrosine kinase inhibitor,3560|3602,Anti-inflammatory|Anticancer protein kinase inhibitor|Synergist|Apoptosis stimulator,2953|62255|7293|1589,Mycosis fungoides|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Sezary syndrome|Non-Hodgkin lymphoma,1115|1734|1744|1745|1749|1753|1754|1756|319,Anaplastic large cell lymphoma|Angioimmunoblastic T-cell lymphoma|Liver tumor|Nasal cancer|Rheumatoid arthritis|Spleen tumor|Intestine tumor,1755|1758|202|2347|291|3386|765,Portola Pharmaceuticals Inc,1005894,Astellas Pharma Inc,1013295,Astellas Pharma Inc,1013295,,,,,,
66153,vantictumab,"Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals|OMP-18R5|frizzled-7 receptor targeted mAb (cancer), Oncomed/Bayer Schering|vantictumab",Research Code|USAN|INN,Cancer,Wnt ligand inhibitor|Beta-catenin inhibitor|Frizzled-8 receptor antagonist|Frizzled-7 receptor antagonist|Frizzled-5 receptor antagonist|Frizzled-2 receptor antagonist|Frizzled-1 receptor antagonist,12709|15709|11027|11024|11018|11009|11006,Anticancer monoclonal antibody|Stem cell inhibitor,55685|53560,Non-small-cell lung cancer|Pancreas tumor|Breast tumor|Solid tumor,1262|249|49|725,Cancer,651,OncoMed Pharmaceuticals Inc,1016154,Bayer Schering Pharma AG,19687,OncoMed Pharmaceuticals Inc,1016154,,,,,,
66168,BAY-86-9596,"18-F PET tracer (diagnostic imaging), Bayer|diagnostic 18F-labeled PET tracer, Bayer|D-FMT|18F-labeled PET imaging agent (cancer), Bayer Schering Pharma|D-18F-fluoromethyl tyrosine|D-fluoromethyl tyrosine-[18F]|BAY-86-9596",Research Code,Cancer,,,PET contrast agent|Neoplasm diagnostic agent|Radiodiagnostic,5555|7220|5720,,,Cancer,651,,,Bayer AG,14455,Bayer AG,14455,,,,,,
6617,UCN-01,7-hydroxystaurosporine|UCN-01|UCN-02|UCN-01-Me|UCN 01-Pr|KW-2401|NSC-638850|KRX-0601,Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Cyclin dependent kinase inhibitor|Protein kinase C inhibitor|3 phosphoinositide protein kinase inhibitor|Checkpoint kinase 1 inhibitor,2596|334|3867|4438,Anticancer protein kinase inhibitor|Cell cycle inhibitor,62255|767,,,Small-cell lung cancer|Myelodysplastic syndrome|Acute leukemia|Chronic lymphocytic leukemia|Pancreas tumor|Metastatic renal cell carcinoma|Cancer|Ovary tumor,1261|1272|1727|1734|249|4250|651|799,,,Kyowa Hakko Kogyo Co Ltd|National Cancer Institute (NCI)|Keryx Biopharmaceuticals Inc,17724|20519|27395,Kyowa Hakko Kogyo Co Ltd,17724,,,,,,
66170,LY-2584702,"LY-S6K1|LY-S6K1 tosylate|p70 S6 kinase inhibitor (cancer), Eli Lilly|LY-S6K1 HCl|LY-2584702",Research Code|Research Code,Cancer,Ribosomal protein S6 kinase-1 inhibitor,3992,Anticancer protein kinase inhibitor,62255,,,Cancer,651,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
66198,KA-10X,"KA-10X|KA-101|KA-102|RasGAP/RasGAP binding protein antagonist peptides (cancer), Wuhan Katygen Pharmaceuticals|G3BP antagonist peptides (cancer), Wuhan KatyGen Pharmaceuticals|Ankelitai",Research Code|Research Code|Research Code,Cancer,Ras GTPase modulator,10449,Anticancer,1545,,,Cancer,651,,,HUYA Bioscience International LLC|Wuhan KatyGen Pharmaceuticals Inc,1025858|1053397,Wuhan KatyGen Pharmaceuticals Inc,1053397,,,,,,
66207,duligotuzumab,"EGFR/HER3 dual monoclonal antibody, Genentech|anti-HER3 EGFR DAF MAb, Genentech|duligotumab|duligotuzumab|MEHD-7945A|RG-7597",USAN|PINN|Research Code|Research Code,Cancer,Erbb3 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3758|740,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,,,Squamous cell carcinoma|Metastatic colorectal cancer|Head and neck tumor|Cancer|Solid tumor,307|3658|623|651|725,,,Genentech Inc,19453,Genentech Inc,19453,,,,,,
66251,florilglutamic acid (18F),"BAY-94-9392|cysteine glutamate transporter-targeted PET tracer (cancer/inflammation), Bayer|Fluorine-18-florilglutamic acid|florilglutamic acid (18F)|FSPG|cysteine glutamate transporter-targeted PET tracer (cancer/inflammation), Piramal|18F-florilglutamic acid|18F-FSPG",Research Code|INN|Research Code,Cancer|Inflammatory,Cysteine glutamate transporter modulator,21056,Anticancer|Radiodiagnostic|Gastrointestinal diagnostic agent|Neoplasm diagnostic agent|PET contrast agent|Inflammation diagnostic agent,1545|5720|7213|7220|5555|7218,Cancer,651,Inflammatory disease,188,Life Molecular Imaging,1006437,Bayer AG,14455,Bayer AG,14455,,,,,,
66286,LY-2874455,"FGF receptor inhibitor (cancer), Eli Lilly|LY-2874455",Research Code,Cancer,FGF1 receptor antagonist|FGF2 receptor antagonist|FGF4 receptor antagonist|FGF3 receptor antagonist,3682|3685|3691|3688,Anticancer protein kinase inhibitor|Angiogenesis inhibitor,62255|61,,,Metastasis|Acute myelogenous leukemia|Cancer,1069|1731|651,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
66312,"triptolide prodrug (pancreatic cancer), Minneamrita Therapeutics","triptolide|Minnelide|triptolide prodrug (pancreatic cancer), Minneamrita Therapeutics|triptolide prodrug (acute myeloid leukemia), Minneamrita Therapeutics",Trade Name,Cancer|Gastrointestinal,Hsp 70 inhibitor,8006,Anticancer|Anti-inflammatory,1545|2953,Gastrointestinal tumor|Acute myelogenous leukemia|Pancreas tumor|Pancreatitis|Cancer,131|1731|249|250|651,,,University of Minnesota|Minneamrita Therapeutics LLC,20626|1080114,,,University of Minnesota,20626,,,,,,
66403,ilorasertib,"multikinase inhibitor (acute myeloid leukemia), Abbott|Aurora/VEGFR/PDGFR kinase inhibitor (acute myeloid leukemia), Abbott|Aurora/VEGFR/PDGFR kinase inhibitor (cancer), Abbott|ABT-348|A-968660|ilorasertib",Research Code|Research Code|USAN|INN,Cancer,VEGF receptor antagonist|Src tyrosine kinase inhibitor|Aurora C protein kinase inhibitor|Aurora protein kinase 1 inhibitor|Aurora protein kinase 2 inhibitor|PDGF receptor antagonist,1722|3576|4414|4418|4420|948,Colony stimulating factor receptor antagonist|Anticancer protein kinase inhibitor|Anticancer|Apoptosis stimulator,69505|62255|1545|1589,Advanced solid tumor,3713,Hematological neoplasm|Solid tumor,2054|725,AbbVie Inc,1072507,Abbott Laboratories,13601,Abbott Laboratories,13601,,,,,,
66417,napabucasin,"napabucasin|BBI-608|GB-608|BB-608|GB-201, 1Globe Biomedical",USAN|INN|Research Code|Research Code|Research Code,Cancer,Beta-catenin modulator|Homeobox protein NANOG modulator|STAT-3 inhibitor,15707|34280|7967,Anticancer|Stem cell inhibitor,1545|53560,Mesothelioma|Gastrointestinal tumor|Hepatocellular carcinoma|Melanoma|Hematological neoplasm|Glioblastoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Breast tumor|Solid tumor|Ovary tumor,1240|131|1767|205|2054|2454|3658|3665|49|725|799,Non-small-cell lung cancer|Stomach tumor|Pancreas tumor|Metastatic pancreas cancer|Cancer|Colorectal tumor,1262|127|249|3669|651|989,SDP Oncology|Sumitomo Dainippon Pharma Co Ltd|1Globe Biomedical Co Ltd,1216786|1017117|1101661,Boston Biomedical Inc,1038949,Boston Biomedical Inc,1038949,,,,,,
66427,trilaciclib dihydrochloride,"bone marrow suppression therapy (oral), G-Zero Therapeutics|CDK4/6 inhibitors (bone marrow suppression), G-Zero Therapeutics|CDK4/6 inhibitors (bone marrow suppression), G1 Therapeutics|G1T-100182|G1T28-1|G1T28-1 (iv, cancer/bone marrow suppression), G1 Therapeutics|G1T-28|trilaciclib|Cosela|trilaciclib dihydrochloride|trilaciclib  (bone marrow suppression), G1 Therapeutics",Research Code|Research Code|Research Code|USAN|INN|Trade Name,Cancer|Hematologic,Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase-6 inhibitor,4314|4318,Anticancer protein kinase inhibitor|Hematopoietic inhibitor|Synergist|Cell cycle inhibitor|Chemoprotectant|Stem cell inhibitor|Radioprotectant,62255|1677|7293|767|1276|53560|1465,Small-cell lung cancer|Transitional cell carcinoma|Neutropenia|Metastatic bladder cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Bone marrow depression|Breast tumor|Solid tumor,1261|1771|1991|3466|3657|3658|3665|3826|49|725,Cancer|Colorectal tumor,651|989,G1 Therapeutics Inc|Simcere Pharmaceutical Group,1054091|1023261,University of North Carolina,20634,University of North Carolina,20634,,,,,,
66458,nidanilimab,"anti-IL1RAP antibody (leukemia), Cantargia|CAN-04|anti-IL1RAP mAb (leukemia/solid tumor), Cantargia|nidanilimab|nadunolimab",Research Code|USAN|PINN|PINN,Cancer,IL-1 receptor accessory protein inhibitor,8272,Anticancer monoclonal antibody,55685,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Transitional cell carcinoma|Leukemia|Melanoma|Bladder cancer|Squamous cell carcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Head and neck tumor,1262|1507|1771|199|205|2380|307|3657|3658|3665|623,Solid tumor,725,Cantargia AB,1054135,,,Cantargia AB,1054135,,,,,,
66499,tarloxotinib bromide,"SN-29926|SN-29966|hypoxia-selective multikinase inhibitors (lung cancer), Proacta|hypoxia-activated irreversible pan-erbB inhibitors, Proacta|SN-32793|hypoxia-selective multikinase inhibitors (lung cancer), Proacta/ Yakult Honsha|hypoxia-selective multikinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha|HSMKIs (cancer), Proacta|SN-33999|hypoxia-activated irreversible pan-erbB inhibitors (NSCLC), Proacta/Yakult Honsha|hypoxia-activated irreversible pan-HER inhibitors (NSCLC), Proacta/Yakult Honsha|PR-509E|TH-4000|PR-610|tarloxotinib bromide|Hypoxin|Tarlox",Research Code|Research Code|Prodrug|Research Code|Research Code|Research Code|Research Code|Research Code|INN|Trade Name,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist|Erbb4 tyrosine kinase receptor inhibitor,3756|740|3760,Bioreducible cytotoxin|Anticancer protein kinase inhibitor,1585|62255,Non-small-cell lung cancer|Advanced solid tumor,1262|3713,Skin cancer|Head and neck tumor|Solid tumor,2170|623|725,Rain Therapeutics Inc,1163708,University of Auckland|Yakult Honsha Co Ltd|Proacta Inc|Molecular Templates Inc,20647|20961|29494|30181,University of Auckland,20647,,,,,,
66527,OPB-51602,OPB-51602|OPB-51822,Research Code|Metabolite,Cancer,STAT-3 inhibitor|STAT-5 inhibitor,7967|7973,Anticancer,1545,,,Non-small-cell lung cancer|Hematological neoplasm|Cancer,1262|2054|651,,,Otsuka Pharmaceutical Co Ltd,18717,Otsuka Pharmaceutical Co Ltd,18717,,,,,,
66590,RG-7444,"MFGR-1877S|RG-7444|anti-FGFR3 humanized mAb (multiple myeloma/bladder cancer), Genentech|R3Mab",Research Code|Research Code,Cancer,FGF3 receptor antagonist,3688,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,,,Multiple myeloma|Bladder cancer|Cancer|Solid tumor,1828|2380|651|725,,,Genentech Inc,19453,Genentech Inc,19453,,,,,,
66603,rociletinib,"epidermal growth factor receptor mutant-selective inhibitor (oral, T790M mutant-targeting, non-small-cell lung cancer), Avila Therapeutics/Clovis Oncology|EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC), Avila Therapeutics/Clovis Oncology|EMSI (oral, T790M mutant-targeting, NSCLC), Avila Therapeutics/Clovis Oncology|CNX-419|EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC), Celgene/Clovis Oncology|EMSI (oral, T790M mutant-targeting, NSCLC), Celgene/Clovis Oncology|790M mutant-targeting, non-small-cell lung cancer), Celgene/Clovis Oncology|EGFR mutant-selective inhibitor (tablet, NSCLC), Celgene/Clovis Oncology|rociletinib|CO-1686|AVL-301|rociletinib hydrobromide|rociletinib (T790M-mutation-targeting, NSCLC), Clovis|Xegafri",Research Code|USAN|INN|Research Code|Research Code|Trade Name,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Apoptosis stimulator|Anticancer protein kinase inhibitor,1589|62255,,,Non-small-cell lung cancer,1262,,,Avila Therapeutics Inc|Clovis Oncology Inc,1044109|1047565,Avila Therapeutics Inc,1044109,,,,,,
66796,"netupitant + palonosetron (oral, chemotherapy-induced nausea), Helsinn","palonosetron + netupitant (oral, chemotherapy-induced nausea), Helsinn|NETU-PALO FDC (oral/ chemotherapy-induced nausea), Helsinn|palonosetron + netupitant|netupitant + palonosetron (oral, chemotherapy-induced nausea), Helsinn/ STA/ IS Pharma/ Taiho/ Riemser/ Eisai/ CJ/ Vifor|Akynzeo|NEPA|NEPA FDC|netupitant + palonosetron (oral, chemotherapy-induced nausea), Helsinn",Trade Name,Toxicity/Intoxication,NK1 receptor antagonist|5-HT 3 receptor antagonist,266|15,Analgesic|Anti-emetic|Gastrointestinal system agent,2946|2970|1332,Chemotherapy induced nausea and vomiting,3847,,,Grunenthal GmbH|Mundipharma International Corp Ltd|Helsinn Healthcare SA|Vifor Pharma Ltd|Riemser Pharma GmbH|Berlin-Chemie AG|CJ Corp|Eisai Inc|Glenmark Pharmaceuticals Ltd|Specialised Therapeutics Australia Pty Ltd|Chugai Pharmaceutical Co Ltd|Taiho Pharmaceutical Co Ltd|Purdue Pharma Canada|Helsinn Birex Pharmaceuticals Ltd,16587|1045514|27361|16268|1003824|18054|15473|19620|29326|1044298|15414|18720|24192|16648,Sinclair Pharma plc|IS Pharma plc,29560|30713,Helsinn Healthcare SA,27361,,,,,,
6680,temoporfin,KW-2345|EF-9|Foscan|m-THPC|temoporfin,Research Code|Research Code|Trade Name|USAN|BANN,Cancer,,,Anticancer|Photosensitizer|Radiosensitizer|Unspecified drug target,1545|799|1542|59620,Head and neck tumor,623,Bone metastases|Pancreas tumor|Prostate tumor|Skin tumor|Pharynx tumor,1829|249|276|722|794,Scotia QuantaNova|Merck Serono SA|biolitec AG,24740|19862|28532,Boehringer Ingelheim International GmbH|Kyowa Hakko Kogyo Co Ltd|Scotia Holdings plc|Efamol,14881|17724|19835|26927,Efamol,26927,,,,,,
66828,bemcentinib,"Axl receptor tyrosine kinase inhibitors (cancer), BerGenBio|R-428|BGB-324|Axl receptor tyrosine kinase inhibitor (cancer), BerGenBio|bemcentinib|Axl checkpoint inhibitor (oral, cancer), BerGenBio",Research Code|Research Code|USAN|INN,Cancer|Gastrointestinal|Infection|Respiratory,Axl tyrosine kinase receptor inhibitor,3742,Macrophage stimulator|Anticancer protein kinase inhibitor|Metastasis inhibitor|Angiogenesis inhibitor|Synergist|Dendritic cell stimulator|Antiviral|Immunostimulant|Apoptosis stimulator,7751|62255|695|61|7293|173472|991|393|1589,Coronavirus disease 19 infection|Mesothelioma|Myelodysplastic syndrome|Acute myelogenous leukemia|Glioblastoma|Non-alcoholic steatohepatitis|Stage III melanoma|Stage IV melanoma|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Idiopathic pulmonary fibrosis|Inflammatory breast cancer,10406|1240|1272|1731|2454|2637|3256|3257|3665|3669|3771|3948,Metastatic breast cancer|Cancer,3657|651,BerGenBio AS,1048426,Rigel Pharmaceuticals Inc,25471,Rigel Pharmaceuticals Inc,25471,,,,,,
66849,TXA-127,"angiotensin (1-7)|angiotensin II 1-7 (sc, thrombocytopenia/stem cell transplantation/HIV-related lymphocytopenia/acute respiratory distress syndrome), Tarix|angiotensin II 1-7 (sc, thrombocytopenia), University of Southern California|TXA-127|angiotensin II 1-7 (sc, thrombocytopenia/stem cell transplantation/HIV-related lymphocytopenia/acute respiratory distress syndrome/pulmonary arterial hypertension), Tarix|angiotensin II 1-7 (sc, thrombocytopenia/stem cell transplantation/HIV-related lymphocytopenia/acute respiratory distress syndrome/pulmonary arterial hypertension/Marfan syndrome), Tarix|angiotensin II 1-7 (sc, duchenne dystrophy/muscular dystrophy/motor neurone disease/peripheral vascular disease/stem cell transplantation/Marfan syndrome/epidermolysis bullosa dystrophica/stroke/diabetes mellitus), Constant Therapeutics|angiotensin II 1-7 (COVID-19), Constant Therapeutics",Research Code,Cancer|Cardiovascular|Dermatologic|Endocrine/Metabolic|Hematologic|Immune|Infection|Musculoskeletal|Neurology/Psychiatric|Respiratory|Toxicity/Intoxication,Angiotensin II receptor modulator,1168,Radioprotectant|Antihypertensive|Respiratory system agent|Antiviral|Hematopoietic stimulator|Hypoglycemic agent|Chemoprotectant|Anticancer,1465|2657|1470|991|610|399|1276|1545,Coronavirus disease 19 infection|Epidermolysis bullosa|Duchenne dystrophy|Motor neurone disease|Muscular dystrophy|Peripheral vascular disease|Stem cell transplantation|Limb girdle muscular dystrophy|Marfan syndrome|Epidermolysis bullosa dystrophica|Stroke|Diabetes mellitus,10406|1112|2020|212|215|260|2990|3250|3379|3744|65|97,Myelodysplastic syndrome|Lymphocytopenia|Adult respiratory distress syndrome|Acute lung injury|Thrombocytopenia|Pulmonary artery hypertension|Radiation sickness|Graft versus host disease,1272|1992|2562|2998|324|3510|367|616,Tarix Orphan LLC|US Biotest Inc|Constant Therapeutics LLC,1108670|1054867|1052051,University of Southern California,20673,University of Southern California,20673,,,,,,
6690,becatecarin,"BMY-27557|NSC-655649|NSC-D640199|BMY-27557-14|rebeccamycin analog, Exelixis/BMS|becatecarin|BMS-181176|XL-119",Research Code|Research Code|Analogue|Research Code|Research Code|USAN|INN|Research Code|Research Code,Cancer,Topoisomerase II inhibitor,142,DNA intercalator|Anticancer,750|1545,,,Non-small-cell lung cancer|Biliary cancer|Renal cell carcinoma|Leukemia|Breast tumor|Cancer,1262|1516|1766|199|49|651,,,Bristol-Myers Squibb Co|Exelixis Inc|Helsinn Healthcare SA,15065|22676|27361,Bristol-Myers Squibb Co,15065,,,,,,
6692,natalizumab,"natalizumab|AN-100226|mAN100226|natulizumb|VLA-4 mAb, Athena|alpha-4/beta1-integrin mAb, Athena|Antegren|Tysabri|BG-00002",INN|Research Code|Research Code|Trade Name|Trade Name|Research Code,Cancer|Gastrointestinal|Immune|Neurology/Psychiatric,Integrin alpha-4/beta-1 antagonist|Cell adhesion molecule inhibitor,2510|650,Therapeutic antibody|Antiviral|Anticancer monoclonal antibody|Anticonvulsant agent|Leukocyte migration inhibitor|Anti-inflammatory,172641|991|55685|70|5601|2953,Multiple myeloma|Multiple sclerosis|Graft versus host disease|Crohns disease,1828|213|616|84,Epilepsy|Rheumatoid arthritis|Ulcerative colitis|Ischemic stroke,119|291|337|3676,Eisai Co Ltd|Biogen Inc|UCB SA|Stendhal International,15872|1005244|20452|1060314,Biogen Inc (FL)|Elan Corp plc|Axogen Ltd,14729|15873|24316,Elan Corp plc,15873,,,,,,
67007,mitazalimab,"ADC-1013|immunotherapeutic (antibody, cancer) Alligator Bioscience/BioInvent|JNJ-64457107|JNJ-7107|mitazalimab|CD40 costimulator (prostate tumor), Janssen",Research Code|Research Code|Research Code|PINN,Cancer,CD40 ligand receptor agonist,5141,Anticancer monoclonal antibody|Macrophage stimulator|B-lymphocyte stimulator|Dendritic cell stimulator|Immunostimulant,55685|7751|7741|173472|393,Pancreatic ductal adenocarcinoma|Metastatic pancreas cancer|Advanced solid tumor,1507|3669|3713,Prostate tumor|Cancer,276|651,Alligator Bioscience AB,31344,BioInvent International AB|Janssen Biotech Inc,18592|26997,Alligator Bioscience AB,31344,,,,,,
67117,NEO-201,"16C3|h16C3|NEO-201|tumor-specific variants of carcinoembryonic antigen-related cell adhesion molecules 5/6-targeted humanized monoclonal antibody (cancer), Neogenix|tumor-specific variants of CEACAM 5/6-targeted hmAb (cancer), Neogenix|tumor-specific variants of CEACAM 5/6-targeted hmAb (cancer), Precision Biologics|tumor-specific variants of carcinoembryonic antigen-related cell adhesion molecules 5/6-targeted humanized monoclonal antibody (cancer), Precision Biologics|dual CEACAM-5/CEACAM-6 checkpoint inhibitor (cancer), NeoGenix Oncology",Research Code,Cancer,CD66c antagonist|CD66e antagonist,5273|5275,Anticancer monoclonal antibody|Immunostimulant|Natural killer cell stimulator|T-lymphocyte stimulator,55685|393|7757|7761,Non-small-cell lung cancer|Pancreas tumor|Squamous cell carcinoma|Breast tumor|Lung tumor|Ovary tumor|Colorectal tumor,1262|249|307|49|755|799|989,,,Precision Biologics Inc,1072388,NeoGenix Oncology Inc,1026735,NeoGenix Oncology Inc,1026735,,,,,,
67172,zandelisib,"delta selective PI3K inhibitors (cancer/inflammation), Pathway Therapeutics|delta selective phosphatidylinositol-3-kinase inhibitors (cancer/inflammation), Pathway Therapeutics/University of Auckland|PWT-143|ME-401|delta selective PI3K inhibitors (cancer/inflammation), MEI Pharma/Kyowa Hakko Kirin|zandelisib",Research Code|Research Code|PINN,Cancer|Inflammatory|Respiratory,Phosphoinositide-3 kinase delta inhibitor,11183,Anti-inflammatory|Anticancer protein kinase inhibitor,2953|62255,Chronic lymphocytic leukemia|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1734|1745|1746|1749|319,Inflammatory disease|Lymphoma|Hematological neoplasm|B-cell lymphoma|Cancer|Respiratory disease|Solid tumor,188|203|2054|316|651|711|725,MEI Pharma Inc|Kyowa Hakko Kirin Co Ltd,28700|1042596,Pathway Therapeutics Ltd|University of Auckland,1040247|20647,University of Auckland,20647,,,,,,
67179,ETBX-011,"Ad5-CEA vaccine (sc, cancer), Etubics/Duke Comprehensive Cancer Center|Ad5[E1-, E2b-]-CEA(6D)|ETBX-011|adenovirus vector vaccine (sc, cancer), Etubics/Duke Comprehensive Cancer Center|CEA-based Ad5-vector vaccine (sc, cancer), Etubics/Duke Comprehensive Cancer Center",Research Code|Research Code,Cancer,CD66 modulator,5262,Anticancer|Recombinant viral vector vaccine|Therapeutic vaccine,1545|12370|12379,Colon tumor,767,,,Duke University|Etubics Corp,20567|1034204,,,Etubics Corp,1034204,,,,,,
67208,CAP-100,"anti-CCR7 monoclonal antibody (cancer), Catapult therapeutics/Pepscan Systems|CAP-100",Research Code,Cancer,CCR7 chemokine antagonist,3113,Anticancer|Anticancer monoclonal antibody,1545|55685,Chronic lymphocytic leukemia|T-cell lymphoma|B-cell lymphoma|Cancer,1734|311|316|651,,,Catapult Therapeutics BV,1184333,Pepscan Systems BV,30801,Catapult Therapeutics BV,1184333,,,,,,
67280,"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska","AKN-028|Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska",Research Code,Cancer,Flt3 tyrosine kinase inhibitor|Kit tyrosine kinase inhibitor,3806|3808,Anticancer protein kinase inhibitor,62255,,,Acute myelogenous leukemia,1731,,,Akinion Pharmaceuticals AB,1054502,,,,,,,,
67344,ETBX-021,"adenovirus vector E2b-deleted HER2 targeting vaccine (E.C7 cell line, breast cancer), Etubics/Duke Comprehensive Cancer Center|Ad5 [E1-, E2b-]-HER2/neu vaccine, Etubics/Duke Comprehensive Cancer Center|ETBX-021",Research Code,Cancer,Erbb2 tyrosine kinase receptor modulator,3755,Anticancer|Therapeutic vaccine|Recombinant viral vector vaccine,1545|12379|12370,Metastatic breast cancer|Breast tumor,3657|49,,,Duke University|NantWorks LLC|Etubics Corp,20567|1103920|1034204,,,Etubics Corp,1034204,,,,,,
6736,rituximab,"IDEC-102|IDEC-C2B8|rituximab|R-105|anti-CD20 monoclonal antibody|rituximab/IDEC-Y2B8, IDEC/Genentech/Roche/Zenyaku|RG-105|Rituxan|MabThera|Ristova",Research Code|Research Code|USAN|BANN|INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Cardiovascular|Dermatologic|Gastrointestinal|Genitourinary/Sexual Function|Hematologic|Immune|Inflammatory|Musculoskeletal|Neurology/Psychiatric|Ocular,B-lymphocyte antigen CD20 inhibitor,5085,Therapeutic antibody|Anti-inflammatory|Anticancer monoclonal antibody,172641|2953|55685,Scleroderma|Pemphigus|Thrombocytopenic purpura|Vasculitis|Polyarteritis nodosa|Hodgkins disease|Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Wegener granulomatosis|Nephrotic syndrome|Rheumatoid arthritis|Liver transplant rejection|Kidney transplant rejection|B-cell lymphoma|Non-Hodgkin lymphoma|Burkitts lymphoma,1105|1114|1133|1532|1536|161|1734|1745|1749|1888|2315|291|2988|2989|316|319|791,Sarcoidosis|Lymphoproliferative disease|Sjoegrens syndrome|Factor VIII deficiency|Glomerulonephritis|Hemolytic anemia|Multiple sclerosis|Lupus nephritis|Churg-Strauss syndrome|Dermatomyositis|Polymyositis|Scleritis|Peripheral neuropathy|Systemic lupus erythematosus|Ulcerative colitis|Orbital inflammatory disease|Graft versus host disease,1036|1037|1148|121|135|143|213|2404|2409|2475|2476|2497|259|318|337|3785|616,Chugai Pharmaceutical Co Ltd|Biogen Inc|Roche Holding AG|Genentech Inc|Cipla Ltd|Zenyaku Kogyo Co Ltd,15414|1005244|19446|19453|15503|21022,IDEC Pharmaceuticals Corp|Nippon Roche KK|XOMA Corp,17085|19447|20954,IDEC Pharmaceuticals Corp,17085,,,,,,
67388,GSK-2302032A,"GSK-2302032A|recombinant preferentially expressed antigen of melanoma immunotherapeutic vaccine (non-small cell lung cancer), GlaxoSmithKline|PRAME ASCI (NSCLC), GSK",Research Code,Cancer,Tumor expressed melanoma antigen modulator,18578,Therapeutic vaccine|Anticancer,12379|1545,,,Non-small-cell lung cancer,1262,,,GlaxoSmithKline plc,28355,GlaxoSmithKline plc,28355,,,,,,
67531,Fluzone QIV IM,"seasonal influenza vaccine (quadrivalent), Sanofi Pasteur|Fluzone QIV|QIV Fluzone|Fluzone QIV IM|FluQuadri|FluQuadri Junior|Fluzone QIV HD|VaxigripTetra|Shenzhen Quadrivalent Influenza Vaccine|Vaxigrip Tetra|Efluelda",Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Infection,,,Prophylactic vaccine|Inactivated viral vaccine,12378|12367,Influenza virus infection,191,,,Sanofi Pasteur,22127,,,Sanofi Pasteur,22127,,,,,,
6759,atiprimod,SKF-106615|atiprimod dihydrochloride|atiprimod|SKF-106615-A2,Research Code|USAN|INN|Research Code,Cancer|Gastrointestinal|Immune|Musculoskeletal,,,Anti-inflammatory|Angiogenesis inhibitor|Anticancer,2953|61|1545,,,Neuroendocrine tumor|Myelodysplastic syndrome|Multiple myeloma|Leukemia|Rheumatoid arthritis|Bone disease|Cancer|Solid tumor|Colon tumor|Crohns disease,1128|1272|1828|199|291|45|651|725|767|84,,,SmithKline Beecham plc|AnorMED Inc|Synergy Pharmaceuticals Inc|Callisto Pharmaceuticals Inc,19962|23816|25766|29619,SmithKline Beecham plc,19962,,,,,,
67600,DEBIO-1562,"IMGN-529|K1753A/DM-1 conjugate (cancer, TAP), ImmunoGen|K7153A-SMCC-DM1|anti-CD37/maytansinoid derivative conjugate (cancer, TAP), ImmunoGen|naratuximab emtansine|naratuximab-SMCC-DM1|DEBIO-1562",Research Code|Research Code|INN|Research Code,Cancer,CD37 antagonist,5133,Anticancer monoclonal antibody|Microtubule inhibitor|Apoptosis stimulator,55685|2575|1589,Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1734|1749|319,B-cell lymphoma,316,Debiopharm SA,15620,ImmunoGen Inc,17202,ImmunoGen Inc,17202,,,,,,
67737,flumatinib,flumatinib|HH-GV-678|flumatinib mesylate|fumatini mesylate|hausen xin fu|Hansoh Xinfu,Research Code|Trade Name|Trade Name,Cancer,Abl tyrosine kinase inhibitor,3524,Anticancer protein kinase inhibitor,62255,Chronic myelocytic leukemia,1735,,,Jiangsu Hansoh Pharmaceutical Group Co Ltd,1017684,Jiangsu Hengrui Medicine Co Ltd,1006925,Jiangsu Hansoh Pharmaceutical Group Co Ltd,1017684,,,,,,
6782,prinomastat,AG-3340|prinomastat|AG-2393|AG-3354|AG-3362,Research Code|INN|Analogue|Research Code|Analogue|Research Code|Analogue|Research Code,Cancer|Immune|Ocular,Metalloprotease-2 inhibitor|Gelatinase inhibitor|Collagenase inhibitor|Metalloprotease-3 inhibitor,2461|441|125|2400,Anticancer,1545,,,Age related macular degeneration|Myelodysplastic syndrome|Neoplasm|Prostate tumor|Rheumatoid arthritis|Lung tumor|Brain tumor,1226|1272|230|276|291|755|760,,,Pfizer Inc|Roche Palo Alto|F Hoffmann-La Roche AG|Agouron Pharmaceuticals Inc,18767|19470|26178|26488,Pfizer Inc,18767,,,,,,
67892,"epoetin alfa (Procrit/Eprex), Johnson & Johnson","epoetin alfa|Eprex|Procrit|erythropoietin, Johnson|epoetin alfa (Procrit/Eprex), Johnson & Johnson",USAN|BAN|INN|Trade Name|Trade Name,Cancer|Hematologic|Neurology/Psychiatric,Erythropoietin ligand,12162,Anticancer|Hematopoietic stimulator,1545|610,Anemia,17,Myelodysplastic syndrome|Stroke|Brain injury,1272|65|834,Janssen-Cilag Ltd|Johnson & Johnson,17392|17332,Amgen Inc,14109,Amgen Inc,14109,,,,,,
67946,CellProtect,"natural killer cell therapy (autologous, multiple myeloma), Avaris/Karolinska Institute|expanded autologous NK cell therapy (CellProtect, multiple myeloma), Avaris/Karolinska|natural killer cell therapy (autologus, multiple myeloma/acute myeloid leukemia/neuroblastoma), Avaris/Karolinska Institute|CellProtect",,Cancer,,,Natural killer cell stimulator|Anticancer,7757|1545,Multiple myeloma,1828,Acute myelogenous leukemia|Neuroblastoma,1731|2726,XNK Therapeutics AB,1123456,Avaris AB|Karolinska Institutet,1003172|21110,Karolinska Institutet,21110,,,,,,
6796,ancestim,"ancestim|Stemgen|SCF, Amgen|rhSCF, Amgen|stem cell factor, Amgen",USAN|INN|Trade Name,Cancer|Hematologic,,,Hematopoietic stimulator|Anticancer,610|1545,Bone marrow failure,350,Aplastic anemia|Anemia|Lymphoma|Myeloproliferative disorder|Non-Hodgkin lymphoma,1006|17|203|273|319,Swedish Orphan Biovitrum AB,28921,Amgen Inc,14109,Amgen Inc,14109,,,,,,
6797,"epoetin alfa (Epogen), Amgen","epoetin alfa|Epogen|Erypo|Espo|Epoade|Globuren|KRN-5702E|EPO, Amgen|erythropoietin, Amgen|epoetin alfa (Epogen), Amgen",USAN|BAN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name,Hematologic,Erythropoietin ligand,12162,Hematopoietic stimulator,610,Anemia,17,,,Amgen Inc|Kyowa Hakko Kirin Co Ltd,14109|1042596,Kirin Brewery Co Ltd|Sankyo Co Ltd,17661|19658,Amgen Inc,14109,,,,,,
68280,VB-10.NEO,"therapeutic DNA vaccines (advanced or metastatic solid tumors), Vaccibody|therapeutic DNA vaccines (prostate cancer/melanoma), Vaccibody/University of Southampton|VB-10.NEO",Research Code,Cancer,,,DNA vaccine|Therapeutic vaccine|Anticancer|Synergist,1879|12379|1545|7293,Non-small-cell lung cancer|Renal cell carcinoma|Melanoma|Squamous cell carcinoma|Stage IV melanoma|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Metastatic renal cell carcinoma|Genitourinary tract tumor|Head and neck tumor,1262|1766|205|307|3257|3665|3673|4250|613|623,Prostate tumor|Cancer,276|651,Genentech Inc,19453,Vaccibody AS|University Of Southampton,1035099|20678,Vaccibody AS,1035099,,,,,,
68444,"iron sucrose injection (iron deficiency anemia), Vifor/American Regent/Galenica","Venofer|iron sucrose injection (iron deficiency anemia), Vifor/Luitpold/Galenica/American Regent|iron sucrose|iron sucrose injection (iron deficiency anemia), Vifor/American Regent/Galenica",Trade Name|USAN|BANN,Hematologic|Neurology/Psychiatric|Other/Miscellaneous,,,Iron uptake stimulator,493,Anemia|Iron deficiency anemia,17|3191,Restless legs syndrome|Fatigue,1774|829,American Regent Inc|Vifor-Fresenius Medical Care Renal Pharma Ltd|Vifor Pharma Ltd,24732|1058402|16268,,,Vifor Pharma Ltd,16268,,,,,,
68479,AZD-3965,"AZD-3965|monocarboxylate transporter-1 inhibitor (cancer), AstraZeneca/Cancer Research Technology",Research Code,Cancer,Monocarboxylate transporter-1 inhibitor,13013,Anticancer,1545,Diffuse large B-cell lymphoma|Cancer|Burkitts lymphoma,1749|651|791,,,Cancer Research UK,29469,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
6850,infliximab,"Avakine|infliximab|Remicad|CenTNF|TA-650|cA2 antibody|anti-TNF-alpha MAb, Tanabe|anti-TNF-alpha MAb, Centocor|SCH-215596|Remicade",Trade Name|INN|Research Code|Research Code|Trade Name,Cancer|Cardiovascular|Dermatologic|Gastrointestinal|Immune|Infection|Inflammatory|Musculoskeletal|Other/Miscellaneous|Respiratory,TNF alpha ligand inhibitor|TNF binding agent,381|721,Antiviral|Anticancer monoclonal antibody|Analgesic|Anti-inflammatory|Systemic antipsoriatic product,991|55685|2946|2953|15184,Psoriatic arthritis|Psoriasis|Rheumatoid arthritis|Ulcerative colitis|Ankylosing spondylitis|Behcets disease|Kawasaki disease|Crohns disease,1781|281|291|337|398|768|780|84,Sarcoidosis|Chronic obstructive pulmonary disease|Hepatitis C virus infection|Multiple myeloma|Osteoarthritis|Polymyalgia rheumatica|Asthma|Cachexia|Cardiac failure|Graft versus host disease|Cancer,1036|1185|153|1828|245|2887|31|425|55|616|651,Johnson & Johnson|Xian-Janssen Pharmaceutical Ltd|Janssen Biotech Inc|Janssen Biologics BV|Merck & Co Inc|Mitsubishi Tanabe Pharma Corp,17332|17608|26997|1062953|18077|1035060,Schering-Plough Corp|Tanabe Seiyaku Co Ltd,19711|20315,Centocor Ortho Biotech Services,1112040,,,,,,
68516,GSK-2241658A,"GSK-2241658A|2241658A|recombinant NY-ESO-1 antigen immunotherapeutic vaccine (melanoma), GlaxoSmithKline|NY-ESO-1 ASCI (melanoma), GSK",Research Code|Research Code,Cancer,Cancer testis antigen NY-ESO-1 modulator,50096,Anticancer|Therapeutic vaccine,1545|12379,Melanoma,205,,,GlaxoSmithKline plc,28355,,,GlaxoSmithKline plc,28355,,,,,,
6861,lobaplatin,lobaplatin|D-19466,INN|Research Code,Cancer,,,Anticancer alkylating agent|Anticancer,50|1545,Small-cell lung cancer|Chronic myelocytic leukemia|Breast tumor|Cancer,1261|1735|49|651,Esophagus tumor|Ovary tumor,1011|799,Zentaris GmbH,29069,Atani KK|ASTA Medica AG,1043332|15623,ASTA Medica AG,15623,,,,,,
68820,mirvetuximab soravtansine,"IMGN-853|huFR107-SPDB-DM4|FOLR1-targeting DM4 conjugates (cancer), Immunogen|M9346A-sulfo-SPDB-DM4|mirvetuximab soravtansine|MIRV|HDM-2002",Research Code|USAN|INN|Research Code,Cancer,Folate receptor alpha antagonist|Tubulin receptor antagonist,12800|541,Microtubule inhibitor|Anticancer|Anticancer monoclonal antibody|Immunotoxin,2575|1545|55685|539,Endometrioid carcinoma|Fallopian tube cancer|Carcinosarcoma|Peritoneal tumor|Advanced solid tumor|Metastatic ovary cancer|Uterus tumor|Ovary tumor,1705|2243|2614|3083|3713|3866|740|799,Metastatic breast cancer|Metastatic non small cell lung cancer,3657|3665,Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd|ImmunoGen Inc,29401|17202,,,ImmunoGen Inc,17202,,,,,,
68953,"AC-480 (iv, cancer), Ambit","AC-480|AC-480 (iv, cancer), Ambit|AC-480IV|HER-1, 2, 3, 4 tyrosine kinase inhibitor (iv, solid tumors), Ambit Biosciences",Research Code|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor|Erbb2 tyrosine kinase receptor inhibitor|Erbb3 tyrosine kinase receptor inhibitor|Erbb4 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3754|3756|3758|3760|740,Anticancer protein kinase inhibitor,62255,,,Solid tumor,725,,,Bristol-Myers Squibb Co|Ambit Biosciences Corp,15065|29179,Bristol-Myers Squibb Co,15065,,,,,,
69009,"taladegib (oral, cancer), Ignyta","LY-2940680|smoothened receptor antagonist (oral, cancer), Eli Lilly|hedgehog/SMO antagonist (cancer), Eli Lilly|taladegib|taladegib (oral, cancer), Lilly|taladegib (oral, cancer), Ignyta",Research Code|USAN|INN,Cancer,Smoothened receptor antagonist,11036,Anticancer,1545,,,Esophagus tumor|Small-cell lung cancer|Rhabdomyosarcoma|Medulloblastoma|Advanced solid tumor|Cancer,1011|1261|2448|2533|3713|651,,,Ignyta Inc|Eli Lilly & Co,1079441|17810,Eli Lilly & Co,17810,,,,,,
69066,alectinib,"ALK inhibitor (NSCLC), Chugai|CH-5424802|AF-802|alectinib|RG-7853|RO-5424802|Alecensa|Alecensaro",Research Code|Research Code|USAN|INN|Research Code|Trade Name|Trade Name,Cancer,RET tyrosine kinase receptor family inhibitor|Anaplastic lymphoma kinase receptor inhibitor|ALK tyrosine kinase receptor family inhibitor,3816|3736|3851,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Thyroid tumor|Non-small-cell lung cancer|Anaplastic large cell lymphoma|Lymphoma|Metastatic non small cell lung cancer|Solid tumor,1134|1262|1755|203|3665|725,,,Chugai Pharmaceutical Co Ltd|Roche Holding AG,15414|19446,,,Chugai Pharmaceutical Co Ltd,15414,,,,,,
69095,capivasertib,"AZD-5363|Akt inhibitor (cancer), Astex/ICR/Cancer Research/AstraZeneca|capivasertib",Research Code|INN,Cancer,AKT protein kinase inhibitor|AKT1 protein kinase inhibitor|AKT3 protein kinase inhibitor|AKT2 protein kinase inhibitor,3859|3861|3865|3863,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Fallopian tube cancer|Peritoneal tumor|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Metastatic breast cancer|Advanced solid tumor|Ovary tumor,1262|127|1705|2243|3083|3246|3247|3657|3713|799,Hematological neoplasm|Prostate tumor|Cancer,2054|276|651,Samsung Medical Center (SMC)|AstraZeneca plc,1004334|14190,Institute of Cancer Research UK|Astex Therapeutics Ltd|Cancer Research Technology Ltd,21072|28026|30620,Institute of Cancer Research UK,21072,,,,,,
69125,COM-701,"CGEN-15021|CGEN-15021T (recombinant fusion protein, autoimmune diseases), Compugen|CGEN-15091|CGEN-15092|CGEN-15031|CGEN-15051|CGEN-15027|CGEN-15029|COM-701|PVRIG-checkpoint inhibitor (cancer), Compugen|CGEN-15029 checkpoint inhibitor (cancer), Compugen",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Immune,Transmembrane protein PVRIG inhibitor,108320,Anticancer monoclonal antibody|Anticancer|T-lymphocyte stimulator|Immunostimulant,55685|1545|7761|393,Endometrioid carcinoma|Fallopian tube cancer|Peritoneal tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic ovary cancer|Cancer,1705|2243|3083|3657|3658|3665|3713|3866|651,Autoimmune disease,36,Compugen Ltd,27293,,,Compugen Ltd,27293,,,,,,
6916,"interleukin-2 gene therapy, St Jude/Baylor","SJNB-JF-IL-2|gene therapy (IL-2), St Jude/Baylor|interleukin-2 gene therapy, St Jude/Baylor|neuroblastoma vaccine (IL-2 gene), St Jude/Baylor",,Cancer,Interleukin-2 ligand,12481,Anticancer|Genetically engineered autologous cell therapy,1545|4790,,,Nervous system tumor,232,,,Baylor College of Medicine|St Jude Children's Research Hospital|Genetic Therapy Inc,20534|21814|24493,St Jude Children's Research Hospital,21814,,,,,,
69196,tolinapant,"IAP inhibitors (cancer), Astex|AT-IAP|ASTX-660|IAP inhibitors (capsule, oral, cancer/acute myeloid leukemia), Astex|tolinapant",Research Code|Research Code,Cancer,X-linked inhibitor of apoptosis protein inhibitor|Inhibitor of apoptosis protein 1 inhibitor|Inhibitor of apoptosis protein 2 inhibitor,13605|13602|13599,Apoptosis stimulator|Immunomodulator|Anticancer,1589|1596|1545,Acute myelogenous leukemia|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Adult T-cell lymphoma|Lymphoma|T-cell lymphoma|Advanced solid tumor,1731|1753|1754|1757|203|311|3713,Cancer,651,Astex Therapeutics Ltd,28026,,,Astex Therapeutics Ltd,28026,,,,,,
69243,umbralisib,"RP-5152|RP-5237|PI3K delta inhibitors (cancer), Rhizen/Incozen|PI3K delta inhibitors (B-cell lymphoma/hematological cancers), Incozen/Rhizen|TGR-1202|TG-1202|RV-1001|umbralisib tosylate|umbralisib|RP-5264|RP-5307|dual PI3Kdelta/CK1 inhibitor (cancer), TG Therapeutics|Ukoniq",Research Code|Research Code|Research Code|Research Code|Research Code|USAN|USAN|INN|Research Code|Research Code|Trade Name,Cancer|Hematologic|Immune,Phosphoinositide-3 kinase delta inhibitor|Casein kinase-I epsilon inhibitor,11183|4296,Anticancer protein kinase inhibitor|Synergist|Anticancer|Apoptosis stimulator|Cell cycle inhibitor,62255|7293|1545|1589|767,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Non-Hodgkin lymphoma,1734|1744|1745|1746|319,Hodgkins disease|Diffuse large B-cell lymphoma|Hematological neoplasm|Multiple sclerosis|Polycythemia vera|Myelofibrosis|B-cell lymphoma|Autoimmune disease|Cancer|Solid tumor,161|1749|2054|213|2319|2436|316|36|651|725,TG Therapeutics Inc|Incozen Therapeutics Pvt Ltd,31093|1050981,Rhizen Pharmaceuticals SA,1052344,Rhizen Pharmaceuticals SA,1052344,,,,,,
69254,"ciclopirox olamine (oral, hematological malignancies), BioTheryX","ciclopirox olamine|BTX-10504|ciclopirox olamine (oral, hematological malignancies), BioTheryX",USAN|Research Code,Cancer,,,Anticancer|Fungicide,1545|1748,,,Acute myelogenous leukemia|Hematological neoplasm,1731|2054,,,BioTheryX Inc,1058331,BioTheryX Inc,1058331,,,,,,
69272,"paclitaxel-PM (iv, cancer), Samyang/CJ Corp/Sorrento/NantPharma","paclitaxel|paclitaxel-PM (iv, cancer), Samyang|Genexol-PM|Cynviloq|IG-001|NBN-paclitaxel|paclitaxel-PM (iv, cancer), Samyang/CJ Corp/Sorrento|Paxus-PM|paclitaxel-PM (iv, cancer), Samyang/CJ Corp/Sorrento/NantPharma|Nant-paclitaxel",USAN|BANN|INN|Trade Name|Trade Name|Research Code|Trade Name|Research Code,Cancer,,,Microtubule stabilizer|Anticancer,2576|1545,Non-small-cell lung cancer|Hepatocellular carcinoma|Bladder cancer|Pancreas tumor|Breast tumor|Solid tumor|Lung tumor|Ovary tumor,1262|1767|2380|249|49|725|755|799,,,Samyang Corp|CJ Corp|NantPharma LLC|Sorrento Therapeutics Inc,23369|15473|1071890|1048574,IGDRASOL,1080026,Samyang Corp,23369,,,,,,
69300,BI-836826,"CD37 antibodies (B-cell malignancies), Boehringer Ingelheim|mAb 37.1|mAb 37.2|BI-836826",Research Code|Research Code|Research Code,Cancer,CD37 antagonist,5133,B-lymphocyte inhibitor|Apoptosis stimulator|Anticancer antibody,7740|1589|55684,Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1734|1749|319,Hematological neoplasm,2054,Boehringer Ingelheim International GmbH,14881,,,Boehringer Ingelheim International GmbH,14881,,,,,,
69303,AB-023,"anti-human Factor XI mAbs (Thrombosis/Sepsis/Myocardial infarction), Aronora/Vanderbilt University/Oregon Health Sciences University|AXIMAB|AB-022|14-E11|xisomab 3G3|AB-023",Research Code|Research Code|Research Code|Research Code|Research Code,Cardiovascular|Hematologic|Infection,Factor XI antagonist,14804,Coagulation inhibitor,659,Thrombosis|Sepsis|Myocardial infarction,1076|114|224,,,Aronora Inc|Oregon Health Sciences University|Vanderbilt University,1058489|22708|20693,,,Aronora Inc,1058489,,,,,,
69328,BI-836880,"nanobody therapeutics (cancer), Ablynx/ Boehringer Ingelheim|anti-VEGF/Ang-2 nanobody therapeutic (solid tumor), Boehringer Ingelheim|BI-836880",Research Code,Cancer,Angiopoietin-related protein-2 inhibitor|VEGF-A ligand inhibitor|VEGF receptor antagonist,10499|1689|1722,Anticancer protein kinase inhibitor,62255,Gastrointestinal tumor|Anal tumor|Squamous cell carcinoma|Metastatic non small cell lung cancer|Advanced solid tumor,131|2193|307|3665|3713,Cancer,651,Boehringer Ingelheim International GmbH,14881,Ablynx NV,31338,Ablynx NV,31338,,,,,,
69364,MB-106,"anti-CD20 CAR T-cell therapy (non-Hodgkin lymphoma), Fred Hutchinson Cancer Research Center|CD20-specific scFvFc:CD28:CD137:zeda chimeric immunoreceptor T-cell therapy (non-Hodgkin lymphoma), Fred Hutchinson Cancer Research Center|anti-CD20 T-cell therapy (NHL), Fred Hutchinson|anti-CD20 CAR T-cell therapy (non-Hodgkin lymphoma), Fred Hutchinson/Mustang|CD20-specific scFvFc:CD28:CD137:zeda chimeric immunoreceptor T-cell therapy (non-Hodgkin lymphoma), Fred Hutchinson/Mustang|anti-CD20 T-cell therapy (NHL), Fred Hutchinson/Mustang|MB-106",Research Code,Cancer,B-lymphocyte antigen CD20 modulator,5083,Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant,1545|7761|4790|393,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1734|1743|1744|1745|1746|1749|319,,,Fred Hutchinson Cancer Research Center|Mustang Bio Inc,16218|1107137,,,Fred Hutchinson Cancer Research Center,16218,,,,,,
69366,"anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute","anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute|CD20Bi activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute|CD20Bi-armed ATC (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute|CD20Bi aATC",,Cancer,B-lymphocyte antigen CD20 modulator|CD3 modulator,5083|5023,Anticancer|Anticancer monoclonal antibody,1545|55685,,,Multiple myeloma|Non-Hodgkin lymphoma,1828|319,,,Barbara Ann Karmanos Cancer Institute|Wayne State University,14383|20702,Barbara Ann Karmanos Cancer Institute,14383,,,,,,
69403,enadenotucirev,"ColoAd1|oncolytic Ad11/Ad3 chimeric group B adenovirus (cancer), PsiOxus|enadenotucirev|oncolytic adenovirus therapy (solid tumor), PsiOxus",INN,Cancer,,,Anticancer|Immunostimulant,1545|393,Metastatic bladder cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic rectal cancer|Metastatic head and neck cancer|Salivary gland cancer|Ovary tumor,3466|3658|3665|3671|3673|4299|799,Cancer|Solid tumor,651|725,PsiOxus Therapeutics Ltd,1058712,Hybrid BioSystems Ltd|Bayer Schering Pharma AG,1054907|19687,Hybrid BioSystems Ltd,1054907,,,,,,
69407,MUC1-Poly-ICLC,"MUC1-Poly-ICLC|Mucin1 peptide vaccine (cancer), University of Pittsburgh",Research Code,Cancer,Mucin 1 modulator,32076,Prophylactic vaccine|Therapeutic vaccine|Protein subunit vaccine|Anticancer,12378|12379|12372|1545,Metastatic non small cell lung cancer|Colon tumor,3665|767,Solid tumor|Colorectal tumor,725|989,University of Pittsburgh,20659,,,University of Pittsburgh,20659,,,,,,
69428,selinexor,"nuclear transport inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics|selective nuclear export inhibitors (autoimmune diseases/HIV/cancer), Karyopharm Therapeutics|SINE (autoimmune diseases/HIV/cancer), Karyopharm Therapeutics|KPT-XXX|selective nuclear export inhibitors (autoimmune/inflammation/HIV/cancer/dermatological disease), Karyopharm Therapeutics|KPT-185|KPT-249|KPT-276|KPT-207|KPT-225|KPT-251|CRM-1 inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics|Exportin-1 inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics|KPT-SINE|KPT-330|selinexor|KCP-330|SINE-KPT-330|ONO-7705|ATG-010|XPOVIO|Xpovio|selective nuclear export inhibitors (COVID-19), Karyopharm Therapeutics|Nexpovio",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code|Research Code|Research Code|Research Code|Trade Name|Trade Name|Trade Name,Cancer|Hematologic|Immune|Infection,Exportin 1 inhibitor,21606,Antiviral|Synergist|Apoptosis stimulator|Cell cycle inhibitor|Anticancer,991|7293|1589|767|1545,Coronavirus disease 19 infection|Non-small-cell lung cancer|Myelodysplastic syndrome|Endometrioid carcinoma|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Multiple myeloma|Sarcoma|Myelofibrosis|Liposarcoma|Glioblastoma|Neuroblastoma|Thymoma|Ewing sarcoma|T-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Soft tissue sarcoma|Metastatic breast cancer|Cancer|Solid tumor|Nerve tumor|Colorectal tumor,10406|1262|1272|1705|1731|1734|1749|1753|1828|194|2436|2447|2454|2726|2939|2975|311|316|319|3378|3657|651|725|763|989,Rectal tumor|Neuroendocrine tumor|Small-cell lung cancer|Gastrointestinal tumor|Cutaneous T-cell lymphoma|Hematological neoplasm|Pancreas tumor|Systemic lupus erythematosus|Hormone refractory prostate cancer|Viral infection|Uterine cervix tumor|Female genital tract tumor|Head and neck tumor|Lung tumor|Ovary tumor,1055|1128|1261|131|1754|2054|249|318|3246|344|427|606|623|755|799,Deqi (Zhejiang) Pharmaceutical Technology Co Ltd|Promedico Co Ltd|Karyopharm Therapeutics Inc|Ono Pharmaceutical Co Ltd,1160109|1113287|1049781|18681,,,Karyopharm Therapeutics Inc,1049781,,,,,,
6943,treosulfan,Ovastat|NSC-39069|treosulfan|Treograft|Trecondi|Trecondyv,Trade Name|Research Code|BAN|INN|Trade Name|Trade Name,Cancer|Endocrine/Metabolic|Hematologic|Immune,,,Anticancer alkylating agent,50,Non-small-cell lung cancer|Acute lymphoblastic leukemia|Stem cell transplantation|Squamous cell carcinoma|Bone marrow failure|Immune deficiency|Hemoglobinopathy|Inborn error of metabolism|Ovary tumor,1262|1728|2990|307|350|504|620|636|799,Myelodysplastic syndrome|Acute myelogenous leukemia|Melanoma|Multiple sclerosis|Ewing sarcoma,1272|1731|205|213|2975,Medac GmbH|Leo Pharmaceuticals|Medexus Pharmaceuticals Inc,17967|17772|1045798,AltaRex Medical Corp,24738,Leo Pharmaceuticals,17772,,,,,,
69455,rivogenlecleucel,"CaspaCIDe DLI (graft versus host disease), Bellicum Pharmaceuticals|allodepleted T cells transduced with inducible caspase 9 suicide gene + rimiducid (infusion, graft versus host disease), Bellicum Pharmaceuticals|CaspaCIDe donor lymphocyte infusion (graft versus host disease), Bellicum Pharmaceuticals|CaspaCIDe|BPX-501|BPZ-1001|rivogenlecleucel|rivo-cel",Trade Name|Research Code|Research Code|USAN|INN|Trade Name,Immune,CASP9 gene stimulator,17039,Immunomodulator,1596,Hematopoietic stem cell transplantation|Graft versus host disease,3888|616,,,Bellicum Pharmaceuticals Inc,1023406,,,Bellicum Pharmaceuticals Inc,1023406,,,,,,
69540,WT1-CTL,"FPI-01|WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals|WT-1 analog peptide vaccine (acute myeloid leukemia/mesothelioma/cancer), Formula Pharmaceuticals Inc(US)/ Memorial Sloan-Kettering Cancer Center|WT1-CTL|ATA-520",Research Code|Research Code|Research Code,Cancer,Wilms tumor protein modulator,30009,Anticancer|Therapeutic vaccine|T-lymphocyte stimulator,1545|12379|7761,Cancer|Ovary tumor,651|799,Mesothelioma|Acute myelogenous leukemia|Multiple myeloma,1240|1731|1828,Atara Biotherapeutics Inc,1074591,Formula Pharmaceuticals Inc|Memorial Sloan-Kettering Cancer Center,1059000|22122,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
69609,danvatirsen,"ISIS-STAT3Rx|STAT-3-targeting antisense oligonucleotide (cancer), Isis|ISIS-481464|AZD-9150|ISIS-STAT3-2.5Rx|STAT3-ASO|IONIS-STAT3-2.5Rx|danvatirsen|STAT-3-targeting antisense oligonucleotide (cancer), Ionis Pharmaceuticals",Research Code|Research Code|Research Code|Research Code|Research Code|INN,Cancer,STAT3 gene inhibitor,19075,Apoptosis stimulator|Anticancer|Antisense oligonucleotide inhibitor,1589|1545|7294,Non-small-cell lung cancer|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Cancer,1262|1749|319|3658|3665|3669|3673|651,Hepatocellular carcinoma|Lymphoma|Pancreas tumor|Advanced solid tumor|Colorectal tumor,1767|203|249|3713|989,Ionis Pharmaceuticals Inc|AstraZeneca plc,17269|14190,,,Ionis Pharmaceuticals Inc,17269,,,,,,
6962,L-651582,L-651582|NSC-609974|CAI|carboxyamidotriazole,Research Code|Research Code,Cancer,Calcium channel inhibitor,93,Anticancer|Angiogenesis inhibitor,1545|61,,,Non-small-cell lung cancer|Renal cell carcinoma|Solid tumor|Ovary tumor,1262|1766|725|799,,,Merck & Co Inc|National Cancer Institute (NCI),18077|20519,Merck & Co Inc,18077,,,,,,
69661,tarextumab,"notch receptor modulator (mAb, solid tumor), Oncomed/GlaxoSmithKline|notch 2/3 receptor inhibitor (mAb, solid tumors), Oncomed pharmaceuticals|tarextumab|OMP-59R5|Tarextumumab",USAN|INN|Research Code,Cancer,Notch-2 receptor antagonist|Notch-3 receptor antagonist,8548|8551,Anticancer monoclonal antibody,55685,,,Small-cell lung cancer|Pancreas tumor|Solid tumor,1261|249|725,,,OncoMed Pharmaceuticals Inc|GlaxoSmithKline plc,1016154|28355,OncoMed Pharmaceuticals Inc,1016154,,,,,,
69727,Hizentra,"Hizentra|IgPro20|20% liquid subcutaneous immunoglobulin therapy (primary immunodeficiency), CSL Behring",Trade Name|Research Code,Hematologic|Immune|Inflammatory|Neurology/Psychiatric,Immunoglobulin agonist,5731,Anti-inflammatory,2953,Scleroderma|Chronic inflammatory demyelinating polyneuropathy|Dermatomyositis|Hypogammaglobulinemia|Immune deficiency|Myopathy|Myasthenia gravis,1105|2381|2475|3839|504|672|848,,,CSL Behring LLC,1007640,,,CSL Behring LLC,1007640,,,,,,
69738,"glutamine (oral, short bowel syndrome), Emmaus","L-glutamine (oral, short bowel syndrome), Emmaus|NutreStore|glutamine|glutamine (oral, short bowel syndrome), Emmaus",Trade Name|USAN|INN,Gastrointestinal,,,Gastrointestinal system agent|Unspecified drug target,1332|59620,Short bowel syndrome,2168,,,Emmaus Life Sciences Inc,1040742,,,Emmaus Life Sciences Inc,1040742,,,,,,
69749,enoblituzumab,"MGA-271|Anti-B7-H3|enoblituzumab|B7-H3 checkpoint inhibitor (solid tumors), MacroGenics",Research Code|USAN|INN,Cancer,CD276 antigen inhibitor,48837,T-lymphocyte stimulator|Anticancer monoclonal antibody|Anticancer|Immunostimulant,7761|55685|1545|393,Non-small-cell lung cancer|Renal cell carcinoma|Melanoma|Bladder cancer|Neuroblastoma|Prostate tumor|Squamous cell carcinoma|Larynx tumor|Metastatic head and neck cancer|Breast tumor|Solid tumor|Mouth tumor|Pharynx tumor,1262|1766|205|2380|2726|276|307|3198|3673|49|725|793|794,Head and neck tumor,623,I-Mab Biopharma|MacroGenics Inc,1141058|29060,,,MacroGenics Inc,29060,,,,,,
69763,Oshadi D,"Oshadi D|DNAse (oral nanoparticle biomatrix-embedded formulation), Oshadi Drug Administration|Deoxyribonuclease (oral formulation, cancer/SLE), Oshadi Drug Administration",Research Code,Cancer|Immune,Deoxyribonuclease modulator,1303,Anticancer,1545,Mesothelioma|Basal cell carcinoma|Systemic lupus erythematosus|Metastatic non small cell lung cancer|Cancer,1240|1764|318|3665|651,,,Oshadi Drug Administration Ltd,1048613,,,Oshadi Drug Administration Ltd,1048613,,,,,,
69764,Oshadi R,Oshadi R,Research Code,Cancer,,,Anticancer,1545,Mesothelioma|Basal cell carcinoma|Metastatic non small cell lung cancer,1240|1764|3665,Cancer,651,Oshadi Drug Administration Ltd,1048613,,,Oshadi Drug Administration Ltd,1048613,,,,,,
69775,INXN-2001 + veledimex regimen,"IL-12 gene therapy (UltraVector, cancer), Ziopharm/Intrexon|INXN-2001|INXN-2001 + INXN-1001 regimen|Ad-RTS-IL-12|IL-12 adenoviral gene therapy (intratumoral)/activator small-molecule (oral) (RheoSwitch/UltraVector, cancer), Intrexon/ZIOPHARM|INXN-2001/AD-1001 regimen|ZIN-ATI-001|IL-12 DNA|Ad-RTS-mIL-12|Ad-RTS-hIL-12|Controlled IL-12|INXN-2001 + veledimex regimen",Research Code|Research Code|Research Code|Research Code,Cancer,IL12 gene stimulator,4965,Adenovirus based gene therapy|Immunostimulant|Anticancer,4780|393|1545,Glioma|Glioblastoma|Stage III melanoma|Stage IV melanoma|Metastatic breast cancer,1108|2454|3256|3257|3657,Melanoma,205,Precigen Inc|ZIOPHARM Oncology Inc,1021778|1009856,,,ZIOPHARM Oncology Inc,1009856,,,,,,
69788,AO-176,"anti-CD47 mAbs (hypertension/tissue ischemia/organ transplants/leukemia), Vasculox|Vx-1004|anti-CD47 mAbs (hypertension/tissue ischemia/organ transplants/leukemia), Tioma Therapeutics|Ti-061|AO-104|Ti-104|AO-176|Ti-176|AO-108|Ti-108|Vx-1000R|CD47 checkpoint inhibitor (hypertension/tissue ischemia/organ transplants/leukemia), Arch Oncology|anti-CD47 mAbs (hypertension/tissue ischemia/organ transplants/leukemia/solid tumor), Arch Oncology|CD47 checkpoint inhibitor (advanced solid tumors), Arch Oncology",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Cardiovascular|Immune,CD47 antagonist,5185,Vascular agent|Macrophage stimulator|Immunostimulant|Antihypertensive|Anticancer monoclonal antibody|Anticancer,945|7751|393|2657|55685|1545,Esophagus tumor|Mesothelioma|Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Acute myelogenous leukemia|Multiple myeloma|Hematological neoplasm|Fallopian tube cancer|Squamous cell carcinoma|Peritoneal tumor|Hormone refractory prostate cancer|Papillary thyroid tumor|Advanced solid tumor|Head and neck tumor|Ovary tumor,1011|1240|1262|127|1705|1731|1828|2054|2243|307|3083|3246|3351|3713|623|799,Pulmonary hypertension|Organ transplantation|Ischemia|Cancer,1867|3004|637|651,Arch Oncology,1059414,,,Arch Oncology,1059414,,,,,,
69858,ceritinib,"LDK-378|ALK inhibitor (oral, cancer), Novartis|ceritinib|Zykadia",Research Code|USAN|INN|Trade Name,Cancer,Ros1 tyrosine kinase receptor inhibitor|ALK tyrosine kinase receptor family inhibitor|Anaplastic lymphoma kinase receptor inhibitor|Insulin receptor tyrosine kinase inhibitor|Insulin-like growth factor 1 receptor antagonist,3826|3851|3736|3792|3252,Apoptosis stimulator|Anticancer protein kinase inhibitor|Synergist|Anticancer,1589|62255|7293|1545,Esophagus tumor|Stomach tumor|Anaplastic large cell lymphoma|Cholangiocarcinoma|Hepatocellular carcinoma|Hematological neoplasm|Pancreas tumor|Neuroblastoma|Metastatic non small cell lung cancer|Advanced solid tumor|Anaplastic thyroid cancer,1011|127|1755|1765|1767|2054|249|2726|3665|3713|3769,Glioblastoma,2454,Novartis AG,23137,,,Novartis AG,23137,,,,,,
69883,"DNA vaccine (intramuscular electroporation, leukemia), University of Southampton/Inovio","DNA vaccine (intramuscular electroporation, leukemia), University of Southampton/Inovio|p.DOM-WT1-126|p.DOM-WT1-37|pWT1",Research Code|Research Code|Research Code,Cancer,Wilms tumor protein inhibitor,30011,Therapeutic vaccine|DNA vaccine|Anticancer,12379|1879|1545,,,Acute myelogenous leukemia|Chronic myelocytic leukemia,1731|1735,,,GeneOne Life Science Inc|University Of Southampton|Inovio Pharmaceuticals Inc,1043985|20678|22403,University Of Southampton,20678,,,,,,
69888,utomilumab,"PF-05082566|4-1BB agonist (iv, cancer), Pfizer|CD137 agonist (iv, cancer), Pfizer|anti-4-1BB (iv, cancer), Pfizer|MOR-7480|MOR-7483|PFE-1 antibody (HuCAL, cancer), Pfizer/MorphoSys|utomilumab|PFE-05082566|PF-2566|TNFRSF9 agonist  (iv, cancer), Pfizer|4-1BB costimulator (HuCAL, cancer), Pfizer/Morphosys",Research Code|Research Code|Research Code|USAN|INN|Research Code|Research Code,Cancer,CDw137 agonist,5450,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,,,Diffuse large B-cell lymphoma|High grade B-cell lymphoma|Non-Hodgkin lymphoma|Advanced solid tumor|Cancer|Solid tumor,1749|1751|319|3713|651|725,,,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
69914,fruquintinib,fruquintinib|fukuitini|HMPL-013|aiyoute|Elunate,INN|Research Code|Trade Name|Trade Name,Cancer,VEGF-3 receptor antagonist|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist,3850|3846|3848,Anticancer protein kinase inhibitor|Angiogenesis inhibitor|Anticancer,62255|61|1545,Non-small-cell lung cancer|Endometrioid carcinoma|Liver tumor|Thymus neoplasm|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Solid tumor|Ovary tumor|Renal tumor,1262|1705|202|2938|3657|3658|3666|3667|725|799|999,Small-cell lung cancer|Stomach tumor|Cancer,1261|127|651,Eli Lilly & Co|Hutchison Medipharma Enterprises Ltd,17810|1011918,,,Hutchison Medipharma Enterprises Ltd,1011918,,,,,,
69972,GO-203-2C,"GO-203-2C|MUC1 inhibitors (cancer), Genus Oncology|mucin 1 inhibitors (cancer), Genus Oncology|MUC1 inhibitor (iv, cancer), Genus Oncology|GO-201|GO-203",Research Code|Research Code|Research Code,Cancer,Mucin 1 inhibitor,32078,Anticancer|Apoptosis stimulator,1545|1589,Acute myelogenous leukemia|Solid tumor,1731|725,Cancer,651,Genus Oncology LLC,1053735,,,Genus Oncology LLC,1053735,,,,,,
70035,emibetuzumab,"bispecific c-Met monoclonal antibody (cancer), Lilly|LY-2875358|c-Met mAb (cancer), Eli Lilly|anti-c-Met antibody (cancer), Lilly|LA-480|emibetuzumab",Research Code|Research Code|USAN|INN,Cancer,Hepatocyte growth factor receptor antagonist,675,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,,,Non-small-cell lung cancer|Stomach tumor|Renal cell carcinoma|Hepatocellular carcinoma|Cancer,1262|127|1766|1767|651,,,Innovent Biologics Inc|Eli Lilly & Co,1070750|17810,Eli Lilly & Co,17810,,,,,,
7014,cytarabine ocfosfate,YNK-01|Fosteabine|Starasid|cytarabine ocfosfate|cytarabine ocphosphate,Research Code|Trade Name|Trade Name,Cancer,DNA polymerase inhibitor|RNA polymerase inhibitor,138|347,Anticancer,1545,Myelodysplastic syndrome|Leukemia,1272|199,Liver tumor|Cancer,202|651,Nippon Kayaku Co Ltd|Yamasa Shoyu Co Ltd,18535|20973,ASTA Medica AG,15623,Nippon Kayaku Co Ltd,18535,,,,,,
70146,pinometostat,"EPZ-004777|DOT1L inhibitors (mixed lineage leukemia), Epizyme/GlaxoSmithKline|DOT1L inhibitors (leukemia), Epizyme/GSK|EPZ-5676|EZ-5676|pinometostat",Research Code|Research Code|Research Code|INN,Cancer,Histone H3 K79 methyltransferase inhibitor,77609,Anticancer|Synergist|Apoptosis stimulator,1545|7293|1589,Acute leukemia|Acute lymphoblastic leukemia|Acute myelogenous leukemia,1727|1728|1731,,,Bristol-Myers Squibb Co|Epizyme Inc,15065|1048714,Celgene Corp,15331,Epizyme Inc,1048714,,,,,,
70147,tazemetostat hydrobromide,"EZH2 inhibitors (cancer), EpiZyme/Eisai|EPZ-5687|EPZ-005687|E-7438|EPZ-6438|tazemetostat|Tazverik|tazemetostat hydrobromide",Research Code|Research Code|Research Code|Research Code|USAN|INN|Trade Name|USAN,Cancer,Enhancer of zeste homolog 2 inhibitor|Histone lysine methyltransferase inhibitor,43815|7783,Anticancer|Synergist,1545|7293,Mesothelioma|Small-cell lung cancer|Endometrioid carcinoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Renal cell carcinoma|Sarcoma|Hematological neoplasm|Peritoneal tumor|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Ovarian clear cell carcinoma|Chordoma|Breast tumor|Solid tumor,1240|1261|1705|1745|1749|1766|194|2054|3083|319|3246|3525|3736|49|725,Metastatic non small cell lung cancer|Ovary tumor,3665|799,Eisai Co Ltd|Epizyme Inc,15872|1048714,,,Epizyme Inc,1048714,,,,,,
7015,glufosfamide,"D-19575|glufosfamide|Glufosamide|beta-D-GLU-IPM|glufosfamide (iv, pancreatic tumor) , Eleison Pharmaceuticals/ China Oncology Focus",Research Code|INN|Trade Name,Cancer,,,Anticancer alkylating agent,50,Pancreas tumor,249,Small-cell lung cancer|Non-small-cell lung cancer|Sarcoma|Breast tumor|Solid tumor|Brain tumor|Colon tumor|Ovary tumor,1261|1262|194|49|725|760|767|799,Rafa Laboratories Ltd|Eleison Pharmaceuticals Inc|China Oncology Focus Limited,26232|1050273|1156919,MediBIC|Daewoong Pharmaceutical Co Ltd|ASTA Medica AG|Baxter Oncology GmbH|Molecular Templates Inc,1012583|15587|15623|29750|30181,ASTA Medica AG,15623,,,,,,
70164,Fotolon,"chlorin e6|Fotolon|photodynamic inactivation (mycobacterial infection), Apocare Pharma|photodynamic therapy (cancer), Apocare Pharma/axios Pharma|lyophilised trisodium salt of Chlorin e6 (infusion, NSCLC), Apocare Pharma|chlorin e6 trisodium",Trade Name,Cancer|Infection,,,Photosensitizer|Anticancer|Unspecified drug target|Antibacterial,799|1545|59620|1594,Non-small-cell lung cancer|Mycobacterium infection|Cancer,1262|218|651,,,Apocare Pharma GmbH|axios Pharma GMBH,1047475|1060650,,,Apocare Pharma GmbH,1047475,,,,,,
70199,taselisib,GDC-0032|RG-7604|taselisib|RO-5537381|GDC-0326,Research Code|Research Code|USAN|INN|Research Code,Cancer,Phosphoinositide 3-kinase inhibitor,1575,Anticancer protein kinase inhibitor,62255,,,Non-small-cell lung cancer|Non-Hodgkin lymphoma|Metastatic breast cancer|Breast tumor|Solid tumor,1262|319|3657|49|725,,,Chugai Pharmaceutical Co Ltd|Roche Holding AG|Genentech Inc,15414|19446|19453,Genentech Inc,19453,,,,,,
70204,NewGam,"NewGam|Panzyga|human immunoglobulin (10% solution), Octpharma",Trade Name|Trade Name,Cancer|Cardiovascular|Hematologic|Immune|Infection|Neurology/Psychiatric,,,Anti-inflammatory|Unspecified drug target|Anticancer|Anticancer antibody|Anxiolytic|Antibacterial|Immunomodulator,2953|59620|1545|55684|2942|1594|1596,Guillain Barre syndrome|Chronic lymphocytic leukemia|Multiple myeloma|Pediatric psychiatric disorder|Sydenham chorea|Immune thrombocytopenic purpura|Chronic inflammatory demyelinating polyneuropathy|Anxiety disorder|Sensory disorder|Tourette syndrome|Emotional lability|Systemic lupus erythematosus|Hypogammaglobulinemia|Bacterial infection|Obsessive compulsive disorder|Immune deficiency|Mood disorder|Neurological disease|Kawasaki disease|Aggression,141|1734|1828|1946|1999|2259|2381|25|2693|2941|3093|318|3839|40|468|504|533|677|780|9,Thrombocytopenia,324,Octapharma AG,18638,,,Octapharma AG,18638,,,,,,
70218,"allogeneic cell vaccine (non-small cell lung cancer), University of Kentucky","1650-G|allogeneic cell vaccine (non-small cell lung cancer), University of Kentucky",Research Code,Cancer,GM-CSF ligand,49776,Anticancer|Therapeutic vaccine,1545|12379,,,Non-small-cell lung cancer,1262,,,University of Kentucky,20600,University of Kentucky,20600,,Clorgiline|Clorgyline,Monoamine Oxidase-A (MAO-A) Inhibitors,449,,
7024,IMGN-289,"EGFR-targeted MAb-DM1 conjugate, ImmunoGen|anti-EGFR-DM1, ImmunoGen|IMGN-289|J-2898-A-DM1 conjugate, ImmunoGen|laprituximab emtansine",Research Code|INN,Cancer,Epidermal growth factor receptor antagonist,740,Microtubule inhibitor|Immunotoxin|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,2575|539|55685|62255,,,Squamous cell carcinoma|Metastatic non small cell lung cancer|Breast tumor|Head and neck tumor|Solid tumor,307|3665|49|623|725,,,ImmunoGen Inc|Takeda Pharmaceutical Co Ltd,17202|20300,ImmunoGen Inc,17202,,,,,,
70300,lirilumab,"anti-killer cell immunoglobulin-like receptor monoclonal antibody (hematological cancers), Innate Pharma/Bristol-Myers Squibb|anti-KIR mAb (hematological cancers), Innate Pharma/BMS|anti-KIR (oncology), Bristol-Myers Squibb|lirilumab|IPH-2102|BMS-986015|KIR checkpoint inhibitor (cancer), Innate Pharma/Bristol-Myers Squibb/Ono|ONO-4483",USAN|INN|Research Code|Research Code|Research Code,Cancer,CD158a antagonist|CD158b2 antagonist|CD158b1 antagonist|CD158 antagonist|Killer cell Ig like receptor antagonist,5504|5506|5505|5503|47549,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody|Natural killer cell stimulator,7761|393|55685|7757,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Bladder cancer|Advanced solid tumor|Head and neck tumor|Cancer|Solid tumor,1272|1731|1734|2380|3713|623|651|725,Hematological neoplasm,2054,Bristol-Myers Squibb Co|Ono Pharmaceutical Co Ltd,15065|18681,Innate Pharma SA,28788,Innate Pharma SA,28788,,,,,,
70304,AMG-319,AMG-319,Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor,11183,Anticancer protein kinase inhibitor,62255,,,Lymphoid leukemia|Squamous cell carcinoma|Head and neck tumor|Solid tumor,1255|307|623|725,,,Amgen Inc,14109,Amgen Inc,14109,Oxadilene|Pavabid,Papaverine hydrochloride,Phosphodiesterase PDE10A Inhibitors,1536,Signal Transduction Modulators,1402
70309,DS-2248,DS-2248,Research Code,Cancer,Hsp 90 inhibitor,8012,Anticancer,1545,,,Solid tumor,725,,,Daiichi Sankyo Co Ltd,1017506,Daiichi Sankyo Co Ltd,1017506,,,,,,
7035,labetuzumab,"labetuzumab|CEA-Cide|CEA-Cide(Y-90)|ImmuRAIT-CEA(I-131)|hAFP antibody, Immunomedics|hCEA antibody, Immunomedics|ImmuRAIT-AFP(I-131), Immunomedics|90Y-labetuzumab|yttrium-90-labetuzumab|131I-labetuzumab|iodine-131-labetuzumab|IMMU-111|IMMU-100|hMN-14|MN-14|IMMU-101|hCEA-I-131|hCEA-Y-90",USAN|INN|Trade Name|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,CD66e antagonist,5275,Radioimmunotherapeutic|Anticancer monoclonal antibody,1552|55685,,,Small-cell lung cancer|Pancreas tumor|Non-Hodgkin lymphoma|Breast tumor|Solid tumor|Ovary tumor|Colorectal tumor,1261|249|319|49|725|799|989,,,Immunomedics Inc,17204,Immunomedics Inc,17204,,,,,,
70525,amlodipine besylate + valsartan + hydrochlorothiazide,"valsartan + amlodipine besylate + hydrochlorothiazide (oral), Novartis|amlodipine besylate + valsartan + hydrochlorothiazide|Exforge HCT|Copalia HCT|Imprida HCT|Dafiro HCT|Ejocia HCT",Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Cardiovascular,Angiotensin II receptor antagonist|Calcium channel inhibitor,64|93,Antihypertensive|Diuretic agent,2657|137,Hypertension,178,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
70566,"MV-NIS therapy (oncolytic virotherapy/iv, cancer), Mayo Clinic","oncolytic measles virus therapy expressing NIS (intratumoral, Head and neck tumor), Nisco International|MV-NIS (intratumoral, SCCHN), Nisco International Inc|MV-NIS therapy (oncolytic virotherapy/iv, cancer), Mayo Clinic",,Cancer,,,Immunostimulant|Anticancer,393|1545,Mesothelioma|Transitional cell carcinoma|Multiple myeloma|Fallopian tube cancer|Nervous system tumor|Bladder cancer|Metastatic breast cancer|Head and neck tumor|Ovary tumor,1240|1771|1828|2243|232|2380|3657|623|799,,,Mayo Clinic Foundation,21111,Nisco International  Inc,1060505,Mayo Clinic Foundation,21111,,,,,,
70596,TSR-011,"ALK inhibitors (oral, non-small cell lung cancer), Amgen/TESARO|anaplastic lymphoma kinase inhibitors (oral, non-small cell lung cancer), TESARO|TSR-011|TSR-012|TRK inhibitor|belizatinib",Research Code|Research Code|INN,Cancer,Anaplastic lymphoma kinase receptor inhibitor|Trk tyrosine kinase receptor inhibitor,3736|3838,Anticancer protein kinase inhibitor,62255,,,Cancer,651,,,TESARO Inc|Amgen Inc,1054559|14109,Amgen Inc,14109,,,,,,
70636,CERC-007,"interleukin 18-targeted monoclonal antibody (inflammation), MedImmune|anti-IL-18 mAb (inflammation), MedImmune|MEDI-2338|AEVI-007|auto-inflammatory disease therapy, Aevi Genomic Medicine|CERC-007|70636 anti-IL-18-mAb (iv, Still's disease/ juvenile idiopathic arthritis/multiple myelom), Aevi Genomic Medicine",Research Code|Research Code|Research Code,Cancer|Immune|Inflammatory|Respiratory,IL-18 antagonist,4813,Respiratory system agent|Anticancer|Anti-inflammatory,1470|1545|2953,Multiple myeloma|Arthritis|Adult onset Stills disease,1828|28|3002,Chronic obstructive pulmonary disease|Inflammatory disease,1185|188,Aevi Genomic Medicine Inc|Cerecor Inc,31288|1062536,MedImmune LLC,18008,MedImmune LLC,18008,,,,,,
70665,XMT-1522,"antibody-drug conjugates (cancer), Mersana Therapeutics|antibody-drug conjugates (cancer), Mersana/Endo|anti-HER-2 ADC (cancer), Mersana/Endo|XMT-1522|anti-HER2 antibody-auristatin conjugates (cancer), Mersana Therapeutics/ Endo International|auristatin-polymer conjugates (cancer), Mersana Therapeutics|Dolaflexin|trastuzumab-dolaflexin|TAK-522",Research Code|Trade Name|Research Code,Cancer,Erbb2 tyrosine kinase receptor inhibitor,3756,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor|Synergist,55685|62255|7293,,,Non-small-cell lung cancer|Stomach tumor|Breast tumor|Cancer,1262|127|49|651,,,Mersana Therapeutics Inc|Endo International plc|Takeda Pharmaceutical Co Ltd|Endo Health Solutions Inc,1002523|1089706|20300|26192,Mersana Therapeutics Inc,1002523,,,,,,
70667,pembrolizumab,"MK-3475|SCH-900475|lambrolizumab|lambrolizumab, Merck|pembrolizumab|Keytruda|PD-1 checkpoint inhibitor (cancer), Merck & Co",Research Code|Research Code|USAN|INN|Trade Name,Cancer|Hematologic,Programmed cell death protein 1 inhibitor,67136,Apoptosis stimulator|T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,1589|7761|393|55685,Esophagus tumor|Recurrent respiratory papillomatosis|Mycosis fungoides|Neuroendocrine tumor|Thyroid tumor|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Myelodysplastic syndrome|Leukoplakia|Gastrointestinal tumor|Pancreatic ductal adenocarcinoma|Biliary cancer|Hodgkins disease|Endometrioid carcinoma|B-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Sezary syndrome|Basal cell carcinoma|Cholangiocarcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Osteosarcoma|Penis tumor|Multiple myeloma|Sarcoma|Lymphoma|Adrenal gland tumor|Melanoma|Hematological neoplasm|Skin cancer|Anal tumor|Fallopian tube cancer|Neoplasm|Bladder cancer|Adenocarcinoma|Myelofibrosis|Glioblastoma|Pancreas tumor|Meningioma|Thymus neoplasm|Thymoma|Squamous cell carcinoma|Peritoneal tumor|Adenoid tumor|Non-Hodgkin lymphoma|Merkel cell carcinoma|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Stage III melanoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic liver cancer|Metastatic urinary tract cancer|Metastatic bladder cancer|Metastatic brain cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Choriocarcinoma|Anaplastic thyroid cancer|Uveal melanoma|Metastatic ovary cancer|Inflammatory breast cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Breast tumor|Head and neck tumor|Nerve tumor|Ovary tumor|Kaposis sarcoma|Colorectal tumor,1011|10408|1115|1128|1134|1240|1261|1262|127|1272|1278|131|1507|1516|161|1705|1729|1731|1734|1744|1745|1749|1750|1753|1754|1756|1764|1765|1766|1767|1768|1771|1772|1791|1828|194|203|2049|205|2054|2170|2193|2243|230|2380|2399|2436|2454|249|2802|2938|2939|307|3083|3153|319|3235|3246|3247|3256|3257|3378|3462|3465|3466|3471|3657|3658|3665|3666|3667|3669|3673|3713|3738|3769|3788|3866|3948|4250|427|49|623|763|799|936|989,Glioma|Cancer|Solid tumor,1108|651|725,Merck & Co Inc,18077,LifeArc|MSD OSS BV|Schering-Plough Corp,1054893|13880|19711,LifeArc,1054893,,,,,,
7067,imiquimod,imiquimod|R-837|S-26308|MLD-39|MTD-39|Zartra|DZ-2636|Beselna Cream|Zyclara|Aldara|Vyloma,USAN|INN|Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Cancer|Dermatologic|Genitourinary/Sexual Function|Infection,TLR-7 agonist,7821,Anticancer|Antiviral|Immunostimulant|Topical dermatological antiviral product|Interferon modulator,1545|991|393|15189|1379,Keratosis|Mycosis fungoides|Condyloma|Basal cell carcinoma,1057|1115|1232|1764,Verruca vulgaris|Herpes simplex virus infection|Molluscum contagiosum infection|Genitourinary disease|Cytomegalovirus infection,1125|157|211|366|89,Mylan NV|Mochida Pharmaceutical Co Ltd|3M Pharmaceuticals|Bayer Healthcare Dermatology Unit|Bausch Health Companies Inc|iNova Pharmaceuticals Pty Ltd,18439|18278|21568|1012372|17058|1037334,Graceway Pharmaceuticals Inc|Daiichi Seiyaku Co Ltd|Medicis Pharmaceutical Corp|Meda AB,1019027|15593|18005|18954,3M Pharmaceuticals,21568,,,,,,
70678,xentuzumab,"BI-836845|IGF pathway modulator (iv, cancer), Boehringer Ingelheim|xentuzumab",Research Code|PINN,Cancer,Insulin-like growth factor-2 ligand inhibitor|Insulin like growth factor 1 ligand inhibitor,82197|162882,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody|Synergist,62255|55685|7293,Non-small-cell lung cancer|Hormone refractory prostate cancer|Metastatic breast cancer,1262|3246|3657,Solid tumor,725,Boehringer Ingelheim International GmbH,14881,,,Boehringer Ingelheim International GmbH,14881,,,,,,
70732,polatuzumab vedotin,"DCDS-4501A|polatuzumab vedotin|anti-CD79b-mc-vc-PAB-MMAE|anti-CD79b-vedotin|anti-CD79b antibody-acMMAE conjugate (hematological cancer), Genentech|RG-7596|RO-5541077|polatuzumab vedotin-piiq|Polivy|anti-CD79b antibody-monomethyl auristatin E conjugate (hematological cancer), Genentech",Research Code|USAN|INN|Research Code|Research Code|Research Code|Trade Name,Cancer,CD79b antagonist,5322,Immunotoxin|Cell cycle inhibitor|Microtubule inhibitor|Anticancer monoclonal antibody,539|767|2575|55685,Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1749|319,Chronic lymphocytic leukemia|Follicle center lymphoma|Hematological neoplasm,1734|1745|2054,Genentech Inc|Chugai Pharmaceutical Co Ltd,19453|15414,,,Genentech Inc,19453,,,,,,
70745,PRI-724,"PRI-724|wnt inhibitor (iv, cancer), Prism Biolab/Eisai|C-28, Prism Biolab Corporation|CBP/beta-catenin inhibitor (cancer), Prism Biolab/Eisai|OP-724",Research Code|Metabolite|Research Code,Cancer|Gastrointestinal|Inflammatory,Beta-catenin inhibitor|CREB binding protein inhibitor,15709|67694,Anticancer|Anti-inflammatory,1545|2953,Fibrosis|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia|Primary biliary cholangitis|Metastatic colorectal cancer|Cancer|Liver cirrhosis,1127|1272|1731|1735|1995|3658|651|70,,,PRISM Pharma Co Ltd|Eisai Co Ltd|Ohara Pharmaceutical Co Ltd,1051166|15872|1000882,,,PRISM Pharma Co Ltd,1051166,,,,,,
7080,Pneumovax 23,"Pneumovax 23|vaccine (pneumococcal), Merck|PN-23|V-110|Pneumovax II|Pulmovax|PPSV-23|Pneumovax NP|23vPPV|PPV-23|Prodiax-23",Trade Name|Research Code|Research Code|Trade Name|Trade Name|Research Code|Trade Name|Research Code|Research Code|Research Code,Infection|Inflammatory,,,Polysaccharide subunit vaccine|Prophylactic vaccine,12373|12378,Streptococcus pneumoniae infection|Otitis media,313|394,,,Merck & Co Inc|MSD Japan|Seqirus|Laboratorios Farmaceuticos Rovi SA,18077|24019|1113858|21332,CSL Ltd|Sanofi Pasteur MSD,15563|23408,Merck & Co Inc,18077,,,,,,
70824,anetumab ravtansine,"anti-mesothelin immunoconjugates (cancer), Bayer|mesothelin-ADC (cancer), Bayer|anti-mesothelin antibody-maytansinoid conjugate (cancer), Bayer|anti-mesothelin antibody-DM4 conjugate (cancer), Bayer|anetumab ravtansine|BAY-94-9343",INN|Research Code,Cancer,Mesothelin inhibitor|Immunoglobulin G1 modulator,11486|5755,Anticancer monoclonal antibody|Microtubule inhibitor,55685|2575,Metastatic pancreas cancer|Advanced solid tumor|Cancer|Solid tumor|Lung tumor|Ovary tumor,3669|3713|651|725|755|799,Mesothelioma,1240,Bayer AG,14455,,,Bayer AG,14455,,,,,,
70865,ladiratuzumab vedotin,"anti-Liv-1 antibody-drug conjugate (cancer), Seattle Genetics|anti-Liv-1 mAb/monomethyl auristatin E ADC (cancer), Seattle Genetics|anti-SLC39A6 mAb/monomethyl auristatin E ADC (cancer), Seagen|ladiratuzumab vedotin|SGN-LIV1A|MK-6440",INN|Research Code|Research Code,Cancer,Zinc transporter SLC39A6 modulator|Tubulin receptor antagonist,33277|541,Anticancer monoclonal antibody|Microtubule inhibitor|Immunotoxin,55685|2575|539,Small-cell lung cancer|Stomach tumor|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic head and neck cancer,1261|127|3246|3257|3657|3665|3667|3673,,,Merck & Co Inc|Seagen Inc,18077|25554,,,Seagen Inc,25554,,,,,,
70877,molibresib,"ApoA1 upregulating agents (atherosclerosis), GSK|GSK-525762A|GSK-525762|GSK-1324726A|I-BET-726|molibresib|I-BET-762|GSK-525762C|525762|BET inhibitor (oral, cancer), GlaxoSmithKline|GSK'762",Research Code|Research Code|Research Code|Research Code|INN|Research Code|Research Code|Research Code|Research Code,Cancer|Cardiovascular,APOA1 gene stimulator|Bromodomain containing protein inhibitor,26250|34558,Anticancer|Anti-inflammatory|Synergist|Apoptosis stimulator,1545|2953|7293|1589,,,Rectal tumor|Small-cell lung cancer|Non-small-cell lung cancer|Acute myelogenous leukemia|Multiple myeloma|Adenocarcinoma|Neuroblastoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Atherosclerosis|Metastatic breast cancer|Cancer|Solid tumor|Colorectal tumor,1055|1261|1262|1731|1828|2399|2726|319|3246|33|3657|651|725|989,,,GlaxoSmithKline plc,28355,GlaxoSmithKline plc,28355,,,,,,
70895,venetoclax,ABT-199|GDC-0199|RG-7601|venetoclax|Venclexta|RO-5537382|Venclyxto|A-1195425.0,Research Code|Research Code|Research Code|USAN|INN|Trade Name|Research Code|Trade Name|Research Code,Cancer|Immune,Bcl-2 protein inhibitor,16111,Apoptosis stimulator|Synergist|Anticancer|Anti-inflammatory,1589|7293|1545|2953,Small-cell lung cancer|Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|High grade B-cell lymphoma|Multiple myeloma|Lymphoma|Neuroblastoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Metastatic breast cancer|Solid tumor,1261|1272|1728|1731|1734|1744|1745|1749|1751|1828|203|2726|319|3246|3657|725,Systemic lupus erythematosus|Cancer,318|651,Genentech Inc|AbbVie Inc,19453|1072507,Abbott Laboratories|Walter and Eliza Hall Institute of Medical Research,13601|21082,Abbott Laboratories,13601,,,,,,
70933,savolitinib,"c-Met inhibitor (cancer), Hutchison|savolitinib|AZD-6094|HM-5016504|HMPL-504|Volitinib|wolitini|Orpathys",INN|Research Code|Research Code|Research Code|Trade Name|Trade Name,Cancer,Hepatocyte growth factor receptor antagonist,675,Anticancer protein kinase inhibitor,62255,Stomach tumor|Adenocarcinoma|Hormone refractory prostate cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic renal cell carcinoma|Solid tumor,127|2399|3246|3658|3665|4250|725,Renal cell carcinoma,1766,AstraZeneca plc|Hutchison Medipharma Enterprises Ltd,14190|1011918,,,Hutchison Medipharma Enterprises Ltd,1011918,,,,,,
70942,"enfortumab vedotin (iv, cancer), Agensys/Seagen","AGS-22M6/monomethyl auristatin E conjugate (solid tumors), Agensys/Seattle Genetics|ASG-22ME|ASG-22M6E|enfortumab vedotin|ASG-22CE|AGS-22M|AGS-M6|enfortumab vedotin (iv, cancer), Agensys/Seagen|AGS-22CE|AGS-22ME|AGS-22M6E|Padcev|enfortumab vedotin-ejfv",Research Code|Research Code|USAN|INN|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name,Cancer,Poliovirus receptor-related protein 4 modulator,64791,Microtubule inhibitor|Anticancer monoclonal antibody,2575|55685,Metastasis|Non-small-cell lung cancer|Transitional cell carcinoma|Squamous cell carcinoma|Larynx tumor|Hormone refractory prostate cancer|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Mouth tumor|Pharynx tumor|Ovary tumor,1069|1262|1771|307|3198|3246|3466|3657|3665|3666|3667|3673|3713|793|794|799,Solid tumor,725,Agensys Inc|Baxter Oncology GmbH|Seagen Inc|Astellas Pharma Inc,14386|29750|25554|1013295,,,Agensys Inc,14386,,,,,,
71026,RRx-001,"dinitroazetidines (radiation sensitizer, cancer), RadioRx|ABDNAZ|RRx-001|dual CD47 checkpoint inhibitor/SIRPa checkpoint inhibitor (cancer), EpiCentrx",,Cancer|Other/Miscellaneous|Toxicity/Intoxication,Programmed cell death ligand 1 inhibitor|CD47 antagonist|DNA methyltransferase inhibitor|Epigen modulator|Tyrosine phosphatase substrate 1 inhibitor,14007|5185|6512|61896|53055,Anticancer|Radical donator|Immunostimulant|Radiosensitizer|Angiogenesis inhibitor|NO receptor agonist|Apoptosis stimulator|Bioreducible cytotoxin|Macrophage stimulator,1545|415|393|1542|61|277|1589|1585|7751,Glioma|Neuroendocrine tumor|Small-cell lung cancer|Non-small-cell lung cancer|Cholangiocarcinoma|Lymphoma|Glioblastoma|Gliosarcoma|Prostate tumor|Oral mucositis|Radiation sickness|Advanced solid tumor|Cancer|Brain tumor|Spinal cord tumor|Ovary tumor|Colorectal tumor,1108|1128|1261|1262|1765|203|2454|2727|276|3209|367|3713|651|760|761|799|989,Bone tumor|Stomach tumor|Hepatocellular carcinoma|Osteosarcoma|Multiple myeloma|Liver tumor|Breast tumor,1012|127|1767|1772|1828|202|49,EpiCentrx Inc|SciClone Pharmaceuticals LLC,1007800|19829,,,EpiCentrx Inc,1007800,,,,,,
71028,MT-3724,"anti-CD20 engineered toxin bodies (lymphoma), Molecular Templates|anti-CD20 ETBs (lymphoma), Molecular Templates|MT-3724",Research Code,Cancer,Ribosomal protein inhibitor|B-lymphocyte antigen CD20 modulator,33497|5083,Synergist|Anticancer|Immunotoxin,7293|1545|539,,,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Hematological neoplasm|Non-Hodgkin lymphoma,1734|1744|1745|1749|2054|319,,,Molecular Templates Inc (pre-merger)|Molecular Templates Inc,29709|30181,Molecular Templates Inc (pre-merger),29709,,,,,,
71087,"docetaxel (polymeric micelle, solid tumor), Samyang","docetaxel|docetaxel (polymeric micelle, solid tumor), Samyang|SYP-0704A|docetaxel-PM|Nanoxel-PM|Nanoxel M",USAN|INN|Research Code|Trade Name|Trade Name,Cancer,,,Microtubule inhibitor|Anticancer,2575|1545,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Bladder cancer|Prostate tumor|Breast tumor|Head and neck tumor|Ovary tumor,1011|1262|127|2380|276|49|623|799,Solid tumor,725,Samyang Corp,23369,,,Samyang Corp,23369,,,,,,
71132,GDA-201,"natural killer cell program (cancer), Gamida cell|NK cell program (cancer), Gamida cell|NAM-NK|GDA-201",Research Code|Research Code,Cancer,,,Anticancer|Natural killer cell stimulator,1545|7757,Multiple myeloma|Non-Hodgkin lymphoma|Cancer,1828|319|651,,,Gamida Cell Ltd,16005,,,Gamida Cell Ltd,16005,,,,,,
71149,omidubicel,"NiCord|haematopoietic stem cell therapy (hematological malignancy/autoimmune/metabolic disease), Gamida Cell|CordIn|omidubicel",Trade Name|Trade Name|USAN|INN,Cancer|Endocrine/Metabolic|Hematologic|Immune,,,Immunomodulator|Anticancer|Unspecified drug target|Hematopoietic stimulator,1596|1545|59620|610,Aplastic anemia|Myelodysplastic syndrome|Acute leukemia|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia|Lymphoma|Hematological neoplasm|Beta thalassemia|Sickle cell anemia,1006|1272|1727|1728|1731|1735|203|2054|2369|303,Autoimmune disease|Hemoglobinopathy|Metabolic disorder,36|620|655,Gamida Cell Ltd,16005,,,Gamida Cell Ltd,16005,,,,,,
7121,sargramostim,"GM-CSF|GM-CSF, Amgen|GM-CSF, Immunex|GM-CSF, Behringwerke|GM-CSF, Berlex/Schering|sargramostim|Leukine|Prokine|BI 61.012|SHL-04023",INN|Trade Name|Trade Name|Research Code|Research Code,Cancer|Gastrointestinal|Hematologic|Immune|Infection|Neurology/Psychiatric|Respiratory|Toxicity/Intoxication,CSF-1 agonist|GM-CSF receptor agonist,420|410,Antiviral|Hematopoietic stimulator|Immunostimulant|Antiparkinsonian|Anticancer,991|610|393|2947|1545,Coronavirus disease 19 infection|Alzheimers disease|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Melanoma|Parkinsons disease|Non-Hodgkin lymphoma|Stage III melanoma|Stage IV melanoma|Radiation sickness|Respiratory failure|Bone marrow transplantation|Leukopenia,10406|14|1731|1734|205|255|319|3256|3257|367|3914|46|680,Sepsis|Fungal infection|Mucositis|HIV infection|Influenza virus infection|Pancreas tumor|Infectious disease|Crohns disease,114|124|1263|158|191|249|746|84,Bayer AG|Partner Therapeutics Inc,14455|1159631,Amgen Inc|Wyeth|Immunex Corp|Sanofi Genzyme|Behringwerke AG|Nihon Schering KK|Berlex Laboratories Inc,14109|14112|14131|16299|16816|19691|19693,Immunex Corp,14131,,,,,,
71227,"ruxolitinib (sustained release, myelofibrosis), Incyte","INCB-018424|ruxolitinib|ruxolitinib (sustained release, myelofibrosis), Incyte",Research Code|USAN|INN,Hematologic,Jak2 tyrosine kinase inhibitor|Jak1 tyrosine kinase inhibitor,3564|3562,Anticancer protein kinase inhibitor|Anti-inflammatory,62255|2953,,,Thrombocythemia|Polycythemia vera|Myelofibrosis,2317|2319|2436,,,Incyte Corp,17216,Incyte Corp,17216,,,,,,
71246,H3B-8800,"anticancer program, H3 Biomedicine|SF3B1 modulators (cancer), H3 Biomedicine|6-deoxypladienolide D|H3B-8800",Research Code,Cancer,Splicing factor 3B subunit 1 modulator|Splicing factor 3B modulator,76765|71837,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelomonocytic leukemia,1272|1731|6833,Cancer,651,H3 Biomedicine Inc|Eisai Co Ltd,1059601|15872,,,H3 Biomedicine Inc,1059601,,,,,,
71250,SEL-120,"SEL-120|SEL-120-1|haspin kinase/cyclin-dependent kinase-9 inhibitors (cancer), Selvita|CDK-8 inhibitors (colorectal cancer), Selvita|SEL-120-34|CDK-8/19 inhibitors (oral, AML/HR-MDS), Selvita|haspin kinase/cyclin-dependent kinase-9 inhibitors (cancer), Ryvu Therapeutics|CDK-8 inhibitors (colorectal cancer), Ryvu Therapeutics|CDK-8/19 inhibitors (oral, AML/HR-MDS), Ryvu Therapeutics|SEL120-34A|RVU-120",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,IL-6 receptor antagonist|RNA polymerase II inhibitor|GSG2 protein kinase inhibitor|Mcl-1 differentiation protein inhibitor|Cyclin-dependent kinase-8 inhibitor,471|6827|4432|11381|4320,Cell cycle inhibitor|Apoptosis stimulator|Anticancer protein kinase inhibitor|Anticancer,767|1589|62255|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Metastatic breast cancer|Cancer|Solid tumor,1272|1731|3657|651|725,,,Ryvu Therapeutics,1196240,Selvita (CRO),1062326,Selvita (CRO),1062326,,,,,,
7126,dexrazoxane,ADR-529|dexrazoxane|ICRF-187|NSC-169780|Zinecard|Eucardion|Cardioxane,Research Code|INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name,Toxicity/Intoxication,,,Chemoprotectant|Free radical scavenger|Cardioprotectant,1276|170|2659,Cardiotoxicity drug-induced,1090,,,Clinigen Group plc|Pharmacia & Upjohn Inc|Novartis AG|Chiron Corp|Eurocetus Srl,1062207|22006|23137|15385|15402,Imperial Cancer Research Technology Ltd|Adria Laboratories Inc,17210|18918,Imperial Cancer Research Technology Ltd,17210,,,,,,
71359,TTI-621,"SIRPalpha Fc (acute myeloid leukemia), Trillium Therapeutics|SIRPaFc|TTI-621|SIRPa-IgG1 Fc, Trillium Therapeutics|dual CD47 checkpoint inhibitor/strong FcgR activator (cancer), Trillium Therapeutics|ontorpacept|CD47 checkpoint inhibitor (cancer), Trillium Therapeutics",Research Code|Research Code|PINN,Cancer|Hematologic,Immunoglobulin gamma Fc receptor agonist|CD47 antagonist,16018|5185,Anticancer|Immunostimulant|Leukocyte stimulator|Apoptosis stimulator|Macrophage stimulator,1545|393|7747|1589|7751,Mycosis fungoides|Small-cell lung cancer|Myelodysplastic syndrome|Hodgkins disease|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Multiple myeloma|Lymphoma|Melanoma|Hematological neoplasm|Leiomyosarcoma|Myeloproliferative disorder|Squamous cell carcinoma|Merkel cell carcinoma|Soft tissue sarcoma|Solid tumor,1115|1261|1272|161|1728|1731|1734|1749|1753|1754|1828|203|205|2054|2446|273|307|3235|3378|725,Cancer,651,Trillium Therapeutics Inc,1010234,Hospital for Sick Children|The University Health Network|Trillium Therapeutics,16994|28443|29738,The University Health Network,28443,,,,,,
71402,"eribulin mesylate (liposomal formulation, cancer), Eisai","eribulin mesylate|Halaven|eribulin mesylate (liposomal formulation, cancer), Eisai|Halaven (liposomal, cancer), Eisai|E-7389-LF",USAN|Trade Name|Research Code,Cancer,,,Microtubule inhibitor|Cell cycle inhibitor|Anticancer,2575|767|1545,Small-cell lung cancer|Adenocarcinoma|Metastatic breast cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor|Solid tumor,1261|2399|3657|3666|3667|3713|725,,,Eisai Co Ltd,15872,,,Eisai Co Ltd,15872,,,,,,
71403,cusatuzumab,"SIMPLE antibody technology lead (autoimmunity, inflammation, cancer), argenx|anti-CD70 humanized monoclonal antibody (autoimmunity, inflammatory diseases, cancer), argenx|cusatuzumab|ARGX-110|anti-CD70 humanized monoclonal antibody (cancer), argenx/Cilag|anti-CD70 humanized monoclonal antibody (acute myeloid leukemia/myelodysplastic syndrome/hematological malignancies), argenx/Cilag|JNJ-4550|JNJ-74494550",INN|Research Code|Research Code|Research Code,Cancer|Hematologic|Immune|Inflammatory,CD70 antigen inhibitor,5291,Anticancer monoclonal antibody|Anti-inflammatory,55685|2953,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia|Cutaneous T-cell lymphoma|Nasopharyngeal carcinoma,1272|1731|1735|1754|1768,Macroglobulinemia|Inflammatory disease|Autoimmune disease|Cancer,1264|188|36|651,argenx SE|Cilag Ltd,1041264|17353,The Leukemia & Lymphoma Society,1038741,argenx SE,1041264,,,,,,
71436,CC-115,"dual DNA-PK/mTOR inhibitor (oral, cancer), Celgene|CC-115|CC-0483115|dual DNA-PK/mTOR inhibitor (oral, cancer), Bristol-Myers Squibb",Research Code|Research Code,Cancer,mTOR inhibitor|DNA dependent protein kinase inhibitor,10240|25889,Anticancer protein kinase inhibitor,62255,Chronic lymphocytic leukemia|Multiple myeloma|Glioblastoma|Non-Hodgkin lymphoma|Solid tumor,1734|1828|2454|319|725,,,Bristol-Myers Squibb Co,15065,Celgene Corp,15331,Celgene Corp,15331,,,,,,
71482,LV-305,"DC-NILV-based cancer vaccine, Immune Design|ID-LV based cancer vaccine, Immune Design|LV-305|ID-LV305|dendritic cell-targeted lentiviral vector expressing NY-ESO-1 gene, Immune Design",Research Code|Research Code,Cancer,Cancer testis antigen NY-ESO-1 inhibitor|T-cell surface glycoprotein CD8 stimulator,50098|5039,Therapeutic vaccine|Anticancer,12379|1545,Sarcoma|Liposarcoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Ovary tumor,194|2447|3257|3378|3657|3665|799,Cancer,651,Immune Design Corp,1040366,,,Immune Design Corp,1040366,,,,,,
71488,MB-107,"IL2RG-transduced autologous CD34+ hematopoietic stem cell therapy (X-linked SCID), St Jude Children's Research Hospital|CL20-4i-EF/a-hyc-OPT|IND-14570|IL2RG-transduced autologous bone marrow-derived CD34-positive hematopoietic stem cell therapy (X-linked severe combined immunodeficiency), Mustang Bio|MB-107",Research Code|Research Code,Immune,IL2RG gene stimulator,58814,Genetically engineered autologous cell therapy|Immunostimulant,4790|393,Severe combined immunodeficiency syndrome,3623,,,Mustang Bio Inc,1107137,St Jude Children's Research Hospital,21814,St Jude Children's Research Hospital,21814,,,,,,
71539,CEN-109,CEN-109|18F-EF5,Research Code|Research Code,Cancer,,,Radiodiagnostic|PET contrast agent|Neoplasm diagnostic agent,5720|5555|7220,,,Cancer,651,,,Centella Therapeutics Inc,1062535,Centella Therapeutics Inc,1062535,,,,,,
71577,CAR-CD44v6,"CD44 variant 6 targeting T-cell therapy (cancer), San Raffaele Scientific Institute/MolMed|CAR-CD44v6|anti-CD44v6 CAR T-cell therapy (cancer), San Raffaele Scientific Institute/MolMed|CD44v6CAR.28z|CAR-T CD44v6",Research Code|Research Code|Research Code,Cancer,Hyaluronic acid receptor modulator,1368,Immunostimulant|Anticancer|T-lymphocyte stimulator,393|1545|7761,Acute myelogenous leukemia|Multiple myeloma|Cancer,1731|1828|651,,,"AGC Biologics S.p.A.,",30663,Istituto Scientifico H San Raffaele,25126,Istituto Scientifico H San Raffaele,25126,,,,,,
71637,lifastuzumab vedotin,"DNIB-0600A|antibody-drug conjugate (NSCLC/ovarian cancer), Genentech|anti-NaPi2b antibody-cytotoxic agent conjugate (ovarian cancer/NSCLC), Genentech|anti-NaPi2b antibody-MMAE conjugate|anti-NaPi2b antibody-vedotin conjugate|lifastuzumab vedotin|RG-7599",Research Code|USAN|INN|Research Code,Cancer,Sodium phosphate cotransporter 2B inhibitor,32671,Microtubule inhibitor|Anticancer monoclonal antibody|Immunotoxin,2575|55685|539,,,Non-small-cell lung cancer|Cancer|Ovary tumor,1262|651|799,,,Genentech Inc,19453,Genentech Inc,19453,,,,,,
71657,"rigosertib sodium (oral capsule, MDS/squamous cell carcinoma/solid tumors), Onconova/SymBio","ON-01910Na|Novonex|ON-01910.Na|ON-1910Na|Estybon|ON-1910 sodium|ON-01910.Na (capsule, myelodysplastic syndrome/solid tumor), Onconova|Estybon (capsule, myelodysplastic syndrome/solid tumor), Onconova|Novonex (capsule, myelodysplastic syndrome/solid tumor), Onconova|ONO-106 (capsule, myelodysplastic syndrome/solid tumor), Onconova|ON-01910 sodium (capsule, myelodysplastic syndrome/solid tumor), Onconova|SyB-1101 (oral, MDS), SymBio|SyB C-1101|rigosertib|rigosertib sodium|rigosertib sodium (oral capsule, MDS/squamous cell carcinoma/solid tumors), Onconova/SymBio",Research Code|Trade Name|Research Code|Research Code|Trade Name|Research Code|Research Code|USAN|INN|USAN,Cancer|Hematologic|Infection,Phosphoinositide 3-kinase inhibitor|MAP kinase inhibitor|AKT protein kinase inhibitor|Cyclin-dependent kinase-1 inhibitor|Jun N terminal kinase modulator|Polo-like kinase 1 inhibitor|BCL2L11 gene stimulator,1575|2511|3859|4308|4375|4536|48274,Blood system agent|Apoptosis stimulator|Anticancer protein kinase inhibitor|Antiviral|Synergist|Cell cycle inhibitor,1546|1589|62255|991|7293|767,Coronavirus disease 19 infection|Myelodysplastic syndrome|Anemia|Acute myelogenous leukemia|Chronic myelocytic leukemia|Renal cell carcinoma|Myelofibrosis|Squamous cell carcinoma|Stage IV melanoma|Metastatic non small cell lung cancer|Cancer,10406|1272|17|1731|1735|1766|2436|307|3257|3665|651,Solid tumor,725,Onconova Therapeutics Inc|Knight Therapeutics Inc|Pint Pharma|Specialised Therapeutics Asia Pte Ltd|SymBio Pharmaceuticals Ltd,30752|1093663|1110054|1157003|1017747,HanX Biopharmaceuticals Inc|Baxter International Inc,1158103|14437,Onconova Therapeutics Inc,30752,,,,,,
71660,"vaccine (pentavalent, small-cell lung cancer), Memorial Sloan-Kettering","vaccine (pentavalent, small-cell lung cancer), Memorial Sloan-Kettering|GD2/Gd3/Globo H/Fucosyl GM1/polysialic acid vaccine (KLH/OPT-821-conjugated, small-cell lung cancer), Memorial Sloan-Kettering|KLH/OPT-821 pentavalent vaccine (adjuvanted, small-cell lung cancer), Memorial Sloan-Kettering",,Cancer,,,Adjuvant|Prophylactic vaccine|Anticancer,524|12378|1545,,,Small-cell lung cancer,1261,,,Memorial Sloan-Kettering Cancer Center,22122,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
71662,"peptide-based PET radiotracer (breast cancer), Stanford University Medical Center","18F-FPPRGD2|peptide-based PET radiotracer (breast cancer), Stanford University Medical Center|PEG3-E[c(RGDyk)]2",,Cancer,Integrin alpha-V/beta-3 modulator,6063,Radiodiagnostic|PET contrast agent|Neoplasm diagnostic agent|Radiopharmaceutical,5720|5555|7220|1617,,,Cancer,651,,,Stanford University,20679,Stanford University,20679,,,,,,
71752,MORAb-066,"MORAb-066|anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek",Research Code,Cancer,Tissue factor inhibitor,8039,Anticancer monoclonal antibody,55685,,,Pancreas tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer,249|3657|3658|3665|3669,,,Janssen Biotech Inc|Morphotek Inc,26997|29741,Janssen Biotech Inc,26997,,,,,,
71860,MPC-CBE,"mesenchymal precursor cells (bone marrow transplantation), Mesoblast/Cephalon|MPC-CBE",Research Code,Immune,,,Hematopoietic stimulator|Stem cell stimulator,610|53559,,,Umbilical cord stem cell transplantation,3889,,,Mesoblast Ltd|Cephalon Inc,1024520|15358,Mesoblast Ltd,1024520,,,,,,
7190,contusugene ladenovec,"INGN-004|INGN-201|Ad-p53, Introgen|Advexin|Ad5CMV-p53|contusugene ladenovec|oncolytic adenovirus therapy expressing p53 (cancer), MultiVir|Ad-p53 (head and neck tumor), p53|Ad-p53 (colorectal liver metastasis), MultiVir|oncolytic adenovirus therapy expressing p53 (solid tumor), Introgen|Ad-p53 (intratumoral, colorectal liver metastasis/head and neck tumor), MultiVir",Research Code|Research Code|Trade Name|Research Code|USAN|INN,Cancer|Immune,TP53 gene stimulator,7692,Anticancer|Immunostimulant|Adenovirus based gene therapy,1545|393|4780,Hepatocellular carcinoma|Metastatic liver cancer|Metastatic colorectal cancer|Metastatic colon cancer|Head and neck tumor,1767|3462|3658|3672|623,Esophagus tumor|Immune disorder|Liver tumor|Neoplasm|Pancreas tumor|Prostate tumor|Li Fraumeni syndrome|Bladder tumor|Breast tumor|Cancer|Lung tumor|Brain tumor|Ovary tumor|Colorectal tumor,1011|185|202|230|249|276|3100|42|49|651|755|760|799|989,MultiVir Inc,1063558,Introgen Therapeutics Inc|Centelion SAS,17255|19428,Introgen Therapeutics Inc,17255,,,,,,
71963,ProHema,"FT-1050-treated umbilical cord stem cell therapy (hematopoietic stem cell engraftment), Fate Therapeutics|ProHema|ProHema-CB",Trade Name|Research Code,Endocrine/Metabolic|Immune,,,Hematopoietic stimulator|Anticancer|Stem cell modulator,610|1545|53558,,,Stem cell transplantation|Metabolic disorder,2990|655,,,Fate Therapeutics Inc,1036293,Fate Therapeutics Inc,1036293,,,,,,
71976,TVB-2640,"small molecule inhibitor (viral infection), 3-V Biosciences|fatty acid synthase modulators (HCV infection), 3-V Biosciences Inc|FASN inhibitors (HCV infection), 3-V Biosciences Inc|TVB-2640|TVB-3166|FASN inhibitors (cancer/HCV/RSV/HSV infection), 3-V Biosciences Inc|TVB-3150|TVB-3199|TVB-3664|TVB-3693|ASC-40",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Endocrine/Metabolic|Gastrointestinal|Infection,Fatty acid synthase inhibitor,6589,Apoptosis stimulator|Antiviral|Hepatitis C virus replication inhibitor|Anticancer|Synergist|Anti-inflammatory,1589|991|15319|1545|7293|2953,Non-small-cell lung cancer|Hepatitis C virus infection|Herpes simplex virus infection|Astrocytoma|Glioblastoma|Non-alcoholic steatohepatitis|Respiratory syncytial virus infection|Metabolic syndrome X|Metastatic breast cancer|Advanced solid tumor|Colon tumor,1262|153|157|2453|2454|2637|287|3294|3657|3713|767,Cancer,651,Ascletis Pharmaceutical Co Ltd|Sagimet Biosciences,1150890|1050172,,,Sagimet Biosciences,1050172,,,,,,
7200,213Bi-lintuzumab,yttrium-90-HuM195|bismuth-213-HuM195|SMART bismuth-213-M195|SMART Y90-M195|SMART 213Bi-M195|Y90-HuM195|213Bi-HuM195|alpha-particle-emitting radioisotope-linked lintuzumab|HuM-195-Bi-213|Bismab-A|213Bi-lintuzumab,Trade Name,Cancer,CD33 modulator,5119,Radioimmunotherapeutic|Anticancer monoclonal antibody,1552|55685,,,Acute myelogenous leukemia,1731,,,Kanebo KK|PDL BioPharma Inc|Memorial Sloan-Kettering Cancer Center|Actinium Pharmaceuticals Inc,17636|19162|22122|24594,PDL BioPharma Inc,19162,,,,,,
72012,MP-0250,"MP-0250|designed ankyrin repeat proteins (cancer), Molecular Partners|anti-VEGF/HGF DARPins (cancer), Molecular Partners|MP-0250 DARPin",Research Code,Cancer,Hepatocyte growth factor receptor antagonist|VEGF receptor antagonist,675|1722,Anticancer protein kinase inhibitor|Angiogenesis inhibitor,62255|61,Multiple myeloma|Solid tumor,1828|725,Non-small-cell lung cancer|Cancer,1262|651,Molecular Partners AG,1032289,,,Molecular Partners AG,1032289,,,,,,
72029,olmutinib,"EGFR mutant selective inhibitor (cancer), Hanmi|EMSI (T790M-positive NSCLC), Hanmi|olmutinib|Olita|BI-1482694|olmutinib HCl monohydrate|olmutinib hydrochloride monohydrate|HM-61713|ZL-2303|olmutinib hydrochloride",USAN|INN|Trade Name|Research Code|Research Code|Research Code|USAN,Cancer,EGFR family tyrosine kinase receptor inhibitor|Protein tyrosine kinase inhibitor,3754|385,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer,1262,Cancer|Lung tumor,651|755,Hanmi Pharmaceutical Co Ltd,16611,Zai Lab Limited|Boehringer Ingelheim International GmbH,1101935|14881,Hanmi Pharmaceutical Co Ltd,16611,,,,,,
72133,nogapendekin alfa,"ALT-803|IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience|modified human IL-15 (malaria), Altor BioScience|N-803|nogapendekin alfa|Anktiva",Research Code|USAN|INN|Trade Name,Cancer|Infection,IL-15 receptor modulator|IL-15 receptor agonist,3083|3085,T-lymphocyte stimulator|Antiviral|Natural killer cell stimulator|Anticancer|Immunostimulant|Antiparasitic,7761|991|7757|1545|393|2638,Coronavirus disease 19 infection|Small-cell lung cancer|Non-small-cell lung cancer|HIV infection|Acute myelogenous leukemia|Hepatocellular carcinoma|Multiple myeloma|Hematological neoplasm|Bladder cancer|Glioblastoma|Plasmodium infection|Squamous cell carcinoma|Non-Hodgkin lymphoma|Merkel cell carcinoma|Hormone refractory prostate cancer|Stage IV melanoma|Soft tissue sarcoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Breast tumor|Head and neck tumor|Cancer|Burkitts lymphoma|Colorectal tumor,10406|1261|1262|158|1731|1767|1828|2054|2380|2454|268|307|319|3235|3246|3257|3378|3657|3665|3666|3669|4250|427|49|623|651|791|989,,,Beike Biotechnology Co Ltd|Altor BioScience Corp|NantKwest Inc,1049528|1007204|1015036,,,Altor BioScience Corp,1007204,,,,,,
72166,"YPEG-filgrastim (febrile neutropenia), Amoytop/BioGeneric Pharma","YPEG-filgrastim (febrile neutropenia), Amoytop/BioGeneric Pharma|YPEG-rhG-CSF (febrile neutropenia), Amoytop|YPEG-filgrastim (febrile neutropenia), Tonghua Dongbao|Paijin",,Hematologic,GCSF receptor agonist|GCSF ligand,3151|52970,Hematopoietic stimulator,610,Neutropenia|Febrile neutropenia,1991|3795,,,Amoytop Biotech Co Ltd|BioGeneric Pharma,1028796|1083848,,,Amoytop Biotech Co Ltd,1028796,,,,,,
72178,dostarlimab,"ANA-011|ANA-11|anti-PD-1 mAb program (cancer immunotherapy), AnaptysBio|ANB-011|TSR-042|PD-1 checkpoint inhibitor (SHM-XEL, advanced solid tumors), TESARO|dostarlimab|GSK-4057190|GSK-4057190A|dostarlimab-gxly|Jemperli",Research Code|Research Code|Research Code|Research Code|USAN|INN|Research Code|Research Code|Trade Name,Cancer,Programmed cell death protein 1 inhibitor,67136,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Rectal tumor|Non-small-cell lung cancer|Endometrioid carcinoma|Squamous cell carcinoma|Stage III melanoma|Stage IV melanoma|Metastatic liver cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Uterine cervix tumor|Breast tumor,1055|1262|1705|307|3256|3257|3462|3657|3665|3669|3673|3713|3866|427|49,Cancer|Ovary tumor,651|799,GlaxoSmithKline plc,28355,AnaptysBio Inc|TESARO Inc,1032144|1054559,AnaptysBio Inc,1032144,,,,,,
72330,cabiralizumab,"anti-colony stimulating factor 1 receptor humanized monoclonal antibody (autoimmune disease), FivePrime Therapeutics|anti-CSF1R hmAb (autoimmune disease), FivePrime Therapeutics|cabiralizumab|FPA-008|ONO-4687|BMS-986227",INN|Research Code|Research Code|Research Code,Cancer|Immune|Inflammatory|Musculoskeletal,CSF-1 antagonist,3154,Osteoclast inhibitor|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor|Anti-inflammatory,12596|55685|62255|2953,Glioma|Non-small-cell lung cancer|Biliary cancer|Peripheral T-cell lymphoma|Renal cell carcinoma|Hematological neoplasm|Giant cell bone tumor|Squamous cell carcinoma|Larynx tumor|Pigmented villonodular synovitis|Metastatic head and neck cancer|Breast tumor|Head and neck tumor|Solid tumor|Mouth tumor|Pharynx tumor|Nasopharynx tumor|Ovary tumor,1108|1262|1516|1753|1766|2054|2857|307|3198|3531|3673|49|623|725|793|794|795|799,Fibrosis|Pancreas tumor|Rheumatoid arthritis|Autoimmune disease|Metastatic pancreas cancer|Cancer,1127|249|291|36|3669|651,Ono Pharmaceutical Co Ltd|Bristol-Myers Squibb Co|Amgen Inc,18681|15065|14109,Five Prime Therapeutics Inc,1007248,Five Prime Therapeutics Inc,1007248,,,,,,
7237,denileukin diftitox,"DAB389-IL-2|denileukin diftitox|LY-335348|Ontak|Onzar|IL-2 fusion toxin, Ligand|interleukin-2 fusion toxin, Ligand|IL-2 fusion toxin, Seragen|IL-2 fusion toxin, Eisai|interleukin-2 fusion toxin, Seragen|interleukin-2 fusion toxin, Eisai|E-7272|E-7777|E-7272 + E-7777|Remitoro",Research Code|USAN|INN|Research Code|Trade Name|Trade Name|Research Code|Research Code,Cancer|Dermatologic|Immune|Infection,NAD ADP ribosyltransferase stimulator|Elongation factor 2 inhibitor|Interleukin-2 ligand,6674|53707|12481,Anticancer|Systemic antipsoriatic product|Antiviral|Protein synthesis inhibitor|Anticancer hormone|Immunomodulator|Immunotoxin,1545|15184|991|339|62253|1596|539,Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Non-Hodgkin lymphoma,1753|1754|319,Atopic dermatitis|Non-small-cell lung cancer|Alopecia|HIV infection|Chronic lymphocytic leukemia|Lymphoma|Melanoma|Psoriasis|Rheumatoid arthritis|Graft versus host disease|Head and neck tumor|Lung tumor|Dermatitis,1102|1262|13|158|1734|203|205|281|291|616|623|755|94,Dr Reddy's Laboratories Ltd|Eisai Co Ltd|TSD Japan,29387|15872|1036309,Ajinomoto Co Inc|Ligand Pharmaceuticals Inc|Eli Lilly & Co|Seragen Inc,13794|17808|17810|25767,Seragen Inc,25767,,,,,,
72393,"rituximab biosimilar, Pfizer","rituximab|PF-05280586|rituximab biosimilar, Pfizer|Ruxience|rituximab-pvvr",USAN|BANN|INN|Research Code|Trade Name,Cancer|Cardiovascular|Dermatologic|Genitourinary/Sexual Function|Immune|Inflammatory,B-lymphocyte antigen CD20 inhibitor,5085,Anti-inflammatory|Anticancer monoclonal antibody,2953|55685,Granulomatosis|Lymphoproliferative disease|Pemphigus|Vasculitis|Chronic lymphocytic leukemia|Follicle center lymphoma|Wegener granulomatosis|Rheumatoid arthritis|Non-Hodgkin lymphoma,1035|1037|1114|1532|1734|1745|1888|291|319,Nephrotic syndrome|Tissue transplant rejection,2315|3879,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
72524,dinutuximab,"ch14.18 (intravenous), United Therapeutics/National Cancer Institute|dinutuximab|Unituxin|ch14.18-UTC|OP-08",USAN|INN|Trade Name|Research Code|Research Code,Cancer,,,Anticancer|Anticancer monoclonal antibody|Ganglioside GD2 inhibitor,1545|55685|47084,Small-cell lung cancer|Osteosarcoma|Neuroblastoma,1261|1772|2726,,,National Cancer Institute (NCI)|United Therapeutics Corp|Ohara Pharmaceutical Co Ltd,20519|25439|1000882,,,National Cancer Institute (NCI),20519,,,,,,
72527,SAR-125844,"met inhibitor (iv, cancer), sanofi-aventis|SAR-125844",Research Code,Cancer,Hepatocyte growth factor receptor antagonist,675,Anticancer protein kinase inhibitor,62255,,,Non-small-cell lung cancer|Solid tumor,1262|725,,,Sanofi SA|Ligand Pharmaceuticals Inc,1009547|17808,Sanofi SA,1009547,,,,,,
72538,abemaciclib,"LY-2835219|CDK 4/6 dual inhibitor (oral, cancer), Eli Lilly|bemaciclib|abemaciclib|Verzenio|Verzenios|VerzenioTM",Research Code|USAN|INN|Trade Name|Trade Name|Trade Name,Cancer,Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase-6 inhibitor|PIM-1 protein kinase inhibitor,4314|4318|4528,Apoptosis stimulator|Cell cycle inhibitor|Anticancer protein kinase inhibitor|Synergist|Anticancer,1589|767|62255|7293|1545,Metastasis|Glioma|Mesothelioma|Stomach tumor|Biliary cancer|Endometrioid carcinoma|Mantle cell lymphoma|Cholangiocarcinoma|Bladder cancer|Liposarcoma|Glioblastoma|Neuroblastoma|Squamous cell carcinoma|Gallbladder tumor|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Breast tumor,1069|1108|1240|127|1516|1705|1744|1765|2380|2447|2454|2726|307|3146|3246|3657|3673|3713|4250|49,Metastatic non small cell lung cancer|Metastatic pancreas cancer|Cancer,3665|3669|651,Eli Lilly & Co,17810,,,Eli Lilly & Co,17810,,,,,,
72557,famitinib L-malate,"famitinib|tyrosine-kinase inhibitor (oral, cancer), Jiangsu Hengrui|c-Kit/VEGFR2/PDGFR/VEGFR3/Flt1/Flt3 inhibitor (oral, cancer), Jiangsu Hengrui|famitinib L-malate|SHR-1020",Research Code,Cancer|Genitourinary/Sexual Function|Respiratory,FGF receptor modulator|Flt3 tyrosine kinase inhibitor|Kit tyrosine kinase inhibitor|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist|VEGF-3 receptor antagonist|PDGF receptor antagonist,3679|3806|3808|3846|3848|3850|948,Anti-inflammatory|Anticancer protein kinase inhibitor,2953|62255,Neuroendocrine tumor|Small-cell lung cancer|Endometrioid carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Osteosarcoma|Gastrointestinal stromal tumor|Medullary thyroid cancer|Metastatic non small cell lung cancer|Idiopathic pulmonary fibrosis|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Gynecological disorder|Breast tumor|Genitourinary tract tumor|Solid tumor|Colorectal tumor,1128|1261|1705|1768|1771|1772|3205|3240|3665|3771|3866|4250|427|438|49|613|725|989,Cholangiocarcinoma,1765,Jiangsu Hengrui Medicine Co Ltd,1006925,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,,,,
72635,ivosidenib,"isocitrate dehydrogenase inhibitors (cancer), Agios/Celgene|IDH inhibitors (cancer), Agios/Celgene|Agios IDH|IDH-1/IDH-2 inhibitors (cancer), Agios/Celgene|AG-120|isocitrate dehydrogenase-1 inhibitor (oral, cancer), Agios/Celgene|AGI-14100|ivosidenib|Tibsovo|CS-3010|AGI-16678|ivosidenib tablets|isocitrate dehydrogenase-1 inhibitor (oral tablet, cancer), Agios/Celgene|aifunibu",Research Code|Research Code|USAN|INN|Trade Name|Research Code|Research Code|Trade Name,Cancer,IDH1 gene inhibitor,67514,Anticancer,1545,Glioma|Myelodysplastic syndrome|Acute myelogenous leukemia|Cholangiocarcinoma|Chondrosarcoma|Advanced solid tumor|Chronic myelomonocytic leukemia,1108|1272|1731|1765|2444|3713|6833,Cancer|Solid tumor,651|725,CStone Pharmaceuticals|Servier,1126254|19863,Agios Pharmaceuticals Inc|Celgene Corp,1040627|15331,Agios Pharmaceuticals Inc,1040627,,,,,,
72681,"defibrotide (iv, veno-occlusive disease), Gentium","defibrotide (iv, veno-occlusive disease), Gentium/Sigma-Tau|Defitelio|defibrotide (iv, veno-occlusive disease), Gentium|NS-73",Trade Name|Research Code,Cardiovascular|Genitourinary/Sexual Function|Hematologic|Immune|Infection|Respiratory|Toxicity/Intoxication,,,Vasoprotectant|Anticancer|Antiviral|Unspecified drug target|Coagulation inhibitor,2660|1545|991|59620|659,Coronavirus disease 19 infection|Neurotoxicity drug-induced|Acute chest syndrome|Venous occlusive disease|Thrombotic microangiopathy|Graft versus host disease|Respiratory distress syndrome,10406|1089|3282|3413|3699|616|8,Diabetic nephropathy,100,Medison Pharma Ltd|Nippon Shinyaku Co Ltd|PharmaSwiss SA|Gen Ilac|Biologix FZ Co|Swedish Orphan Biovitrum AB|Handok Inc|Gentium SpA|Clinigen Group plc,29943|18552|1015038|1063033|1021693|28921|19986|31491|1062207,Crinos SpA|Leadiant Biosciences Inc|Link Pharmaceuticals Ltd,15550|19946|24364,Gentium SpA,31491,,,,,,
72699,atezolizumab,"RG-7746|anti-PDL1 MAb (solid tumors), Genentech|atezolizumab|RG-7446|MPDL-3280A|RO-5541267|Tecentriq|PD-L1 checkpoint inhibitor (cancer), Genentech/Roche/Chugai",Research Code|USAN|INN|Research Code|Research Code|Research Code|Trade Name,Cancer,Programmed cell death ligand 1 inhibitor,14007,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Mycosis fungoides|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Myelodysplastic syndrome|Pancreatic ductal adenocarcinoma|Biliary cancer|Hodgkins disease|Endometrioid carcinoma|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Sezary syndrome|Renal cell carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Fallopian tube cancer|Bladder cancer|Liposarcoma|Pancreas tumor|Thymus neoplasm|Squamous cell carcinoma|Peritoneal tumor|Gallbladder tumor|Non-Hodgkin lymphoma|Merkel cell carcinoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Advanced solid tumor|Anaplastic thyroid cancer|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Breast tumor|Female genital tract tumor|Head and neck tumor|Chronic myelomonocytic leukemia|Ovary tumor,1115|1240|1261|1262|127|1272|1507|1516|161|1705|1731|1734|1743|1744|1745|1746|1747|1749|1756|1766|1767|1771|2243|2380|2447|249|2938|307|3083|3146|319|3235|3257|3378|3466|3657|3658|3665|3667|3713|3769|3866|4250|427|49|606|623|6833|799,Gastrointestinal tumor|Multiple myeloma|Anal tumor|Hormone refractory prostate cancer|Metastatic lung cancer|Solid tumor,131|1828|2193|3246|3668|725,Genentech Inc|Chugai Pharmaceutical Co Ltd|Roche Holding AG,19453|15414|19446,,,Genentech Inc,19453,,,,,,
7274,anakinra,"anakinra|Antril|IL-1ra, Amgen|IL-1 antagonist, InSite Vision|Kineret",USAN|INN|Trade Name|Trade Name,Dermatologic|Endocrine/Metabolic|Gastrointestinal|Immune|Infection|Inflammatory|Neurology/Psychiatric|Ocular|Other/Miscellaneous|Respiratory,Type I IL-1 receptor antagonist,8266,Antiviral|Immunosuppressant|Anti-inflammatory,991|396|2953,Inner ear disease|Coronavirus disease 19 infection|Gout|Sanfilippo syndrome|Rheumatoid arthritis|Adult onset Stills disease|Juvenile rheumatoid arthritis|Muckle Wells syndrome|Familial mediterranean fever|Ulcerative colitis|Autoinflammatory disease|Cryopyrin associated periodic syndrome|Familial cold autoinflammatory syndrome|Respiratory distress syndrome,1022|10406|136|2255|291|3002|3003|3222|3244|337|3600|3601|3602|8,Sepsis|Inflammatory bowel disease|Osteoarthritis|Psoriasis|Asthma|Neuritis|Ocular inflammation,114|189|245|281|31|3537|686,Menarini Asia-Pacific|Swedish Orphan Biovitrum AB|MegaPharm Ltd,1055394|28921|26786,Amgen Inc,14109,Amgen Inc,14109,,,,,,
72743,birtamimab,"antibody therapy (AL amyloidosis), Neotope Biosciences|NEOD-001|monoclonal antibody therapy (AL amyloidosis), Onclave|birtamimab|ELT1-01|Hu2A4",Research Code|USAN|INN|Research Code|Research Code,Endocrine/Metabolic,Serum amyloid A protein inhibitor|Amyloid protein deposition inhibitor,56655|621,,,AL amyloidosis,3492,Amyloidosis,1143,Prothena Corp plc,1064629,Onclave Therapeutics Ltd|Elan Corp plc,1071105|15873,Elan Corp plc,15873,,,,,,
72768,TAS-114,"TAS-114|dUTPase inhibitor as DPD inhibitor potentiator (oral, solid tumor), Taiho|deoxyuridine 5-triphosphate nucleotidehydrolase inhibitor as dihydropyrimidine dehydrogenase inhibitor potentiator (oral, solid tumor), Taiho|fluoropyrimidine enhancer (oral, solid tumor), Taiho|deoxyuridine 5-triphosphate nucleotidehydrolase inhibitor as dihydropyrimidine dehydrogenase inhibitor potentiator (oral, solid tumor), Taiho Pharmaceutical/Taiho Oncology",Research Code,Cancer,dUTP pyrophosphatase inhibitor|Dihydropyrimidine dehydrogenase inhibitor,22573|782,Anticancer,1545,Metastatic non small cell lung cancer|Metastatic stomach cancer,3665|3666,Solid tumor,725,Taiho Oncology Inc|Taiho Pharmaceutical Co Ltd,1092741|18720,,,Taiho Pharmaceutical Co Ltd,18720,,,,,,
72980,lutetium (177Lu) lilotomab satetraxetan,"Betalutin|177Lu-tetraxetan-tetulomab (non-Hodgkin's lymphoma), Nordic Nanovector|177Lu-DOTA-HH1|177Lu-DOTA-tetulomab|177Lu-tetraxetan-tetulomab|177Lu-lilotomab satetraxetan|lilotomab satetraxetan-[177Lu]|lutetium (177Lu) lilotomab satetraxetan|Lymrit 37-05|177Lu-satetraxetan-lilotomab",Trade Name|INN|Research Code,Cancer,B-lymphocyte antigen CD20 stimulator|CD37 antagonist,5084|5133,Anticancer|Radioimmunotherapeutic|Anticancer monoclonal antibody,1545|1552|55685,Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1743|1744|1745|1746|1749|319,,,Nordic Nanovector ASA,1064011,,,Nordic Nanovector ASA,1064011,,,,,,
72983,GSK-2816126,EZH2 inhibitor (cancer) GlaxoSmithKline|GSK-126 (EZH2)|GSK-641|GSK-343|GSK-2816126|GSK-9726|GSK-2816126A,Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Enhancer of zeste homolog 2 inhibitor,43815,Anticancer,1545,,,Cancer,651,,,GlaxoSmithKline plc,28355,GlaxoSmithKline plc,28355,,,,,,
73003,belapectin,GR-MD-02|galactoarabino-rhamnogalacturonate|belapectin,Research Code|USAN,Cancer|Cardiovascular|Dermatologic|Gastrointestinal|Genitourinary/Sexual Function|Infection|Respiratory,Galectin-3 inhibitor,9979,Antiviral|Anticancer|Systemic antipsoriatic product|Antihypertensive|Anti-inflammatory,991|1545|15184|2657|2953,Coronavirus disease 19 infection|Non-small-cell lung cancer|Liver disease|Liver fibrosis|Non-alcoholic steatohepatitis|Psoriasis|Stage IV melanoma|Esophageal varices|Head and neck tumor|Liver cirrhosis,10406|1262|201|2318|2637|281|3257|3838|623|70,Diabetic nephropathy|Atopic dermatitis|Melanoma|Pulmonary artery hypertension|Cancer|Pulmonary fibrosis,100|1102|205|3510|651|708,Providence Cancer Center|Bioxytran Inc|Galectin Therapeutics Inc,1043995|1175279|29637,,,Galectin Therapeutics Inc,29637,,,,,,
7310,ritonavir,ritonavir|ABT-538|Abbott-84538|A-84538|Norvir|novir,USAN|BANN|INN|Research Code|Research Code|Research Code|Trade Name,Infection,HIV protease inhibitor|Cytochrome P450 3A4 inhibitor|HIV-1 protease inhibitor,204|7424|768,Antiviral,991,HIV infection,158,,,AbbVie Inc|Abbott Laboratories,1072507|13601,Dainippon Pharmaceutical Co Ltd,15606,Abbott Laboratories,13601,,,,,,
73109,CYAD-01,"chNKG2D T-cell therapy (cancer), OnCyte|NKG2D-expressing CAR T-cell therapy (cancer), Celdara|NKRx|CM-CS1|chNKG2D T-cell therapy (cancer), Celdara/OnCyte|CAR-NKG2D|NKR-2|anti-NKG2D-ligand CAR T-cell therapy (autologous, cancer), Celyad Oncology|extracellular NKG2D + transmembrane DAP10 + intracellular CD3 zeta CAR T-cell therapy (cancer), Celyad Oncology|CYAD-01|CAR-T NKG2D (autologous)",Trade Name|Research Code|Research Code|Research Code|Research Code,Cancer,NKG2D ligand modulator,26384,T-lymphocyte stimulator|Anticancer|Immunostimulant|Genetically engineered autologous cell therapy,7761|1545|393|4790,Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Metastatic colorectal cancer|Cancer,1272|1731|1828|3658|651,,,Celyad Oncology,1034997,Celdara Medical LLC|Oncyte,1054170|1104560,Celdara Medical LLC,1054170,,,,,,
73144,"combined bacteriolytic therapy (cancer), BioMed Valley Discoveries","combined bacteriolytic therapy (cancer), BioMed Valley Discoveries|COBALT (cancer), BioMed Valley Discoveries|BVD-CNV (cancer), BioMed Valley Discoveries|Clostridium novyi-NT spores + chemotherapy (cancer), BioMed Valley Discoveries|BVD-CNV/IT|BVD-CNV/IV|CNV-NT|Clostridium novyi-NT|C novyi-NT",,Cancer,,,Immunostimulant|Anticancer,393|1545,Solid tumor,725,Cancer,651,BioMed Valley Discoveries,1063567,Johns Hopkins University,20596,Johns Hopkins University,20596,,,,,,
73206,bimagrumab,"anti-activin type IIB monoclonal antibody (cachexia/myositis), Novartis|HuCAL-derived monoclonal antibody (myositis/cachexia), MorphoSys AG|HuCAL-derived monoclonal antibody (myositis/cachexia), Novartis|bimagrumab|BYM-338",USAN|INN|Research Code,Endocrine/Metabolic|Musculoskeletal|Other/Miscellaneous,Activin type-IIB receptor antagonist|Activin type-II receptor antagonist,4574|4578,Hypoglycemic agent|Anti-inflammatory|Muscle system agent,399|2953|1408,Non-insulin dependent diabetes,837,Bone injury|Myositis|Sarcopenia|Inclusion body myositis|Cachexia|Atrophy,1091|2474|3210|3446|425|546,Novartis AG,23137,MorphoSys AG,21404,MorphoSys AG,21404,,,,,,
73238,MM-310,MM-310,,Cancer,Epha2 tyrosine kinase receptor inhibitor,3766,Anticancer protein kinase inhibitor,62255,,,Cancer,651,,,Merrimack Pharmaceuticals Inc,27954,Merrimack Pharmaceuticals Inc,27954,,,,,,
73301,SB-31,"SB Injection|SB-31|saponins (cancer), SBPharmaceutical",Research Code,Cancer,,,Anticancer,1545,,,Non-small-cell lung cancer|Stomach tumor|Hepatocellular carcinoma|Cancer,1262|127|1767|651,,,SBPharmaceutical IND Co Ltd,1064618,SBPharmaceutical IND Co Ltd,1064618,,,,,,
73305,"pentamidine isethionate (cancer), Oncozyme Pharma","pentamidine|pentamidine isethionate (cancer), Oncozyme Pharma|pentamidine isethionate|OCZ103-OS",INN|USAN|Research Code,Cancer,Endonuclease inhibitor|Exonuclease inhibitor,1310|404,Apoptosis stimulator|DNA repair inhibitor|Anticancer,1589|11593|1545,,,Liver tumor|Pancreas tumor|Metastatic non small cell lung cancer|Breast tumor|Colon tumor|Ovary tumor,202|249|3665|49|767|799,,,Verlyx Pharma Inc,28794,Verlyx Pharma Inc,28794,,,,,,
7342,BMS-214662,"BMS-214662|BMS-186511|BMS-193269|Ras farnesyl transferase inhibitors, BMS|BMS-206635",Research Code|Analogue|Research Code|Analogue|Research Code|Research Code,Cancer,Ras GTPase inhibitor|Protein farnesyltransferase inhibitor,10451|1875,Anticancer,1545,,,Non-small-cell lung cancer|Pancreas tumor|Head and neck tumor|Cancer|Colorectal tumor,1262|249|623|651|989,,,Bristol-Myers Squibb Co,15065,Bristol-Myers Squibb Co,15065,,,,,,
73472,tesevatinib,"XL-647, Exelixis|EXEL-7647|tesevatinib|tesevatinib (cancer), Exelixis|KD-019|KD-020|tesevatinib (cancer), Kadmon Pharmaceuticals|tesevatinib (oral, NSCLC/prostate cancer/breast cancer/autosomal recessive and dormant polycystic kidney disease), Kadmon Pharmaceuticals|tesevatinib (oral, NSCLC/prostate cancer/breast cancer/autosomal recessive and dormant polycystic kidney disease, glioblastoma), Kadmon Pharmaceuticals",Research Code|Research Code|USAN|INN|Research Code|Research Code,Cancer|Genitourinary/Sexual Function,EGFR family tyrosine kinase receptor inhibitor|Erbb2 tyrosine kinase receptor inhibitor|Ephb4 tyrosine kinase receptor inhibitor|VEGF-2 receptor antagonist|VEGF-3 receptor antagonist|Epidermal growth factor receptor antagonist|VEGF receptor antagonist|Src tyrosine kinase inhibitor,3754|3756|3786|3848|3850|740|1722|3576,Anticancer|Anticancer protein kinase inhibitor|Angiogenesis inhibitor,1545|62255|61,Non-small-cell lung cancer|Autosomal recessive polycystic kidney disease|Autosomal dominant polycystic kidney disease|Glioblastoma|Prostate tumor|Breast tumor,1262|2299|2300|2454|276|49,Metastatic non small cell lung cancer|Cancer,3665|651,Kadmon Pharmaceuticals LLC,1054096,Symphony Evolution Inc|Exelixis Inc,1049056|22676,Exelixis Inc,22676,,,,,,
73477,NBTXR-3,"NBTXR-3|hafnium oxide crystal nanoparticles (NanoXray, cancer), Nanobiotix|PEP-503|NBTRXR-3|STING agonist (cancer), Nanobiotix|Hensify",Research Code|Research Code|Research Code|Trade Name,Cancer,Stimulator of interferon genes protein stimulator,89933,Anticancer|Dendritic cell stimulator|Immunostimulant|Adjuvant|T-lymphocyte stimulator|Radiosensitizer,1545|173472|393|524|7761|1542,Esophagus tumor|Rectal tumor|Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Liver tumor|Adenocarcinoma|Prostate tumor|Squamous cell carcinoma|Larynx tumor|Soft tissue sarcoma|Metastatic liver cancer|Metastatic head and neck cancer|Lung tumor|Mouth tumor|Pharynx tumor,1011|1055|1262|1507|202|2399|276|307|3198|3378|3462|3673|755|793|794,Pancreas tumor|Cancer,249|651,LianBio Co Ltd|PharmaEngine Inc|Nanobiotix,1219797|1013597|1018340,,,Nanobiotix,1018340,,,,,,
73497,QBKPN,"site-specific immunotherapeutic (lung cancer), Qu Biologics|QBKPN|lung SSI, Qu Biologics|QBKPN-01|QBKPN SSI",Research Code|Research Code,Cancer|Infection|Respiratory,,,Immunostimulant|Anticancer|Anti-inflammatory|Immunomodulator,393|1545|2953|1596,Coronavirus disease 19 infection|Chronic obstructive pulmonary disease|Non-small-cell lung cancer|Asthma|Lung tumor,10406|1185|1262|31|755,Cancer,651,Qu Biologics Inc,1064833,,,Qu Biologics Inc,1064833,,,,,,
73502,RG-7598,"DFRF-4539A|RG-7598|antibody-drug conjugate (multiple myeloma), Genentech",Research Code|Research Code,Cancer,,,Anticancer monoclonal antibody,55685,,,Multiple myeloma,1828,,,Genentech Inc,19453,Genentech Inc,19453,,,,,,
73554,HMPL-523,HMPL-281|HM-029|HMPL-523|HM-0523,Research Code|Research Code|Research Code|Research Code,Cancer|Dermatologic|Hematologic|Immune|Inflammatory,Syk tyrosine kinase inhibitor,3602,Anticancer protein kinase inhibitor|Anti-inflammatory,62255|2953,Acute myelogenous leukemia|Hematological neoplasm|Immune thrombocytopenic purpura|Psoriasis|Rheumatoid arthritis|Systemic lupus erythematosus|Non-Hodgkin lymphoma|Thrombocytopenia,1731|2054|2259|281|291|318|319|324,Inflammatory disease|Cancer,188|651,Hutchison Medipharma Enterprises Ltd,1011918,,,Hutchison Medipharma Enterprises Ltd,1011918,,,,,,
73607,"posaconazole (delayed release/oral tablet), Merck & Co","posaconazole|Noxafil|posaconazole (solid oral tablet), Merck & Co|Spriafil|MK-5592 (solid oral tablet), Merck & Co|posaconazole (delayed release/oral tablet), Merck & Co|Noxafil Gastro Resistant",USAN|BANN|INN|Trade Name|Trade Name|Trade Name,Infection,Lanosterol-14 demethylase inhibitor,777,Ergosterol synthesis inhibitor|Fungicide,161|1748,Fungal infection,124,Aspergillus infection,29,Merck & Co Inc,18077,,,Merck & Co Inc,18077,,,,,,
73650,DCP-001,"DCP-001|allogeneic dendritic cell vaccine (intradermal, acute myelogenous leukemia), DCPrime|DCOne vaccine (intradermal, acute myelogenous leukemia), DCPrime|allogeneic dendritic cell vaccine (intradermal, acute myelogenous leukemia/multiple myeloma), DCPrime|DCOne vaccine (intradermal, acute myelogenous leukemia/multiple myeloma), DCPrime",Research Code,Cancer,,,Dendritic cell vaccine|Anticancer|Therapeutic vaccine|Immunomodulator,102926|1545|12379|1596,Acute myelogenous leukemia|Multiple myeloma|Ovary tumor,1731|1828|799,,,DCPrime BV,1045472,,,DCPrime BV,1045472,,,,,,
73707,89Zr-Df-IAB-22M2C,"T-cell co-receptor targeting PET imaging agent (antibody fragment, cancer/inflammation/transplantation), ImaginAb|CD8 targeting PET imaging agent (antibody fragment, cancer/inflammation/transplantation), ImaginAb|IAB-22G3M1|IAB-22M2C|89Zr-Df-IAB-22M2C",Research Code|Research Code|Research Code,Cancer|Immune|Inflammatory,T-cell surface glycoprotein CD8 inhibitor,5040,Neoplasm diagnostic agent|Immunodiagnostic agent|PET contrast agent,7220|4404|5555,Stage IV melanoma|Advanced solid tumor|Cancer,3257|3713|651,Inflammatory disease|Transplantation,188|2980,ImaginAb Inc|Torreya,1050190|1088205,,,ImaginAb Inc,1050190,,,,,,
73731,pelabresib,"BET inhibitors (cancer), Constellation Pharmaceuticals|BET bromodomain inhibitors (cancer), Constellation Pharmaceuticals|CPI-203|CPI-267203|CPI-232|CPI-0610|pelabresib",Research Code|Research Code|Research Code|Research Code,Cancer|Hematologic|Immune|Respiratory,Bromodomain containing protein 4 inhibitor|Bromodomain containing protein inhibitor|Myc proto-oncogene protein inhibitor,34570|34558|14615,Anticancer|Apoptosis stimulator|Anti-inflammatory,1545|1589|2953,Thrombocythemia|Myelofibrosis,2317|2436,Myelodysplastic syndrome|Acute leukemia|Multiple myeloma|Lymphoma|Polycythemia vera|Autoimmune disease|Cancer|Cystic fibrosis,1272|1727|1828|203|2319|36|651|88,Constellation Pharmaceuticals Inc,1039065,,,Constellation Pharmaceuticals Inc,1039065,,,,,,
73754,GI-6301,"GI-6301|Tarmogen vaccine (triple negative breast cancer), GlobeImmune|Tarmogen vaccine (triple negative breast cancer), GlobeImmune/Celgene|GI-6300|Yeast-brachyury vaccine (cancer), GlobeImmune|Tarmogen vaccine (triple negative breast cancer), NantCell|Tarmogen vaccine (triple negative breast cancer), ImmunityBio",Research Code|Research Code,Cancer,Brachyury protein modulator,62319,Therapeutic vaccine|Anticancer|Recombinant fungal vector vaccine,12379|1545|33963,Chordoma|Cancer,3736|651,Breast tumor,49,NantCell Inc,1104834,Celgene Corp|GlobeImmune Inc,15331|28802,GlobeImmune Inc,28802,,,,,,
73837,"Anvirzel (sublingual, cancer), Nerium","Anvirzel|Anvirzel (sublingual, cancer), Nerium",Trade Name,Cancer,Nuclear factor kappa B inhibitor,2653,Apoptosis stimulator|Anticancer,1589|1545,Cancer,651,,,Nerium Biotechnology Inc,1047570,,,Nerium Biotechnology Inc,1047570,,,,,,
73839,OCV-501,OCV-501|graunimotide,Research Code|INN,Cancer,Wilms tumor protein inhibitor,30011,Therapeutic vaccine|Anticancer,12379|1545,,,Acute myelogenous leukemia,1731,,,International Institute Of Cancer Immunology Inc|Otsuka Pharmaceutical Co Ltd,1032856|18717,International Institute Of Cancer Immunology Inc,1032856,,,,,,
73843,encorafenib,"LGX-818|Raf inhibitor (oral, melanoma), Novartis|encorafenib|ONO-7702|Braftovi|encorafinib|PF-07263896",Research Code|USAN|INN|Research Code|Trade Name|Research Code,Cancer,Raf B protein kinase inhibitor,4548,Synergist|Anticancer protein kinase inhibitor,7293|62255,Thyroid tumor|Multiple myeloma|Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,1134|1828|3257|3658|3665|3713,Stage III melanoma,3256,Medison Pharma Ltd|Array BioPharma Inc|Pierre Fabre Group|Ono Pharmaceutical Co Ltd,29943|25902|19087|18681,Novartis AG,23137,Novartis AG,23137,,,,,,
73916,tabelecleucel,"allogeneic EBV-CTL therapy (lymphoproliferative disease), Atara Biotherapeutics|EBV-CTL|ATA-129|tabelecleucel|tab-cel|anti-EBV allogeneic T cell therapy (lymphoproliferative disease), Atara Biotherapeutics",Research Code|Research Code|USAN|INN|Trade Name,Cancer|Hematologic|Immune,,,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,Lymphoproliferative disease|Nasopharyngeal carcinoma|Sarcoma|Hematological neoplasm|Leiomyosarcoma|Post transplant lymphoproliferative disease|Hemophagocytic lymphohistiocytosis,1037|1768|194|2054|2446|3530|4727,,,Atara Biotherapeutics Inc,1074591,Memorial Sloan-Kettering Cancer Center,22122,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
7413,darbepoetin alfa,"Aranesp|darbepoetin alfa|KRN-321|NESP, Amgen|novel erythropoiesis stimulating protein, Amgen|KER-321|recombinant erythropoietin analog, Amgen|Nespo",Trade Name|INN|Research Code|Research Code|Trade Name,Hematologic,Erythropoietin ligand,12162,Hematopoietic stimulator|Anticancer,610|1545,Anemia,17,,,Kyowa Hakko Kirin Co Ltd|Amgen Inc,1042596|14109,Kirin Brewery Co Ltd|Kirin-Amgen Inc,17661|17662,Amgen Inc,14109,,,,,,
74173,MK-8242,MK-8242|SCH-900242,Research Code|Research Code,Cancer,Mdm2 p53-binding protein inhibitor|E3 ubiquitin protein ligase MDM2 inhibitor,10391|51304,Anticancer,1545,,,Acute myelogenous leukemia|Advanced solid tumor,1731|3713,,,Merck & Co Inc,18077,Merck & Co Inc,18077,,,,,,
74212,PIM-447,LGH-477|LGH-447|PIM-447,Research Code|Research Code|Research Code,Cancer|Hematologic,PIM protein kinase inhibitor|PIM-2 protein kinase inhibitor|PIM-3 protein kinase inhibitor|PIM-1 protein kinase inhibitor,4522|4524|4526|4528,Cell cycle inhibitor|Apoptosis stimulator|Anticancer protein kinase inhibitor|Synergist,767|1589|62255|7293,,,Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Myelofibrosis,1272|1731|1828|2436,,,Novartis AG,23137,Novartis AG,23137,,,,,,
74301,"MFE-23-CD3z T cell therapy (cancer), Cancer Research UK","MFE-23-CD3z T cell therapy (cancer), Cancer Research UK|anti-CEA CAR T-cell therapy (cancer), Cancer Research UK",,Cancer,CD66e modulator,5281,Genetically engineered autologous cell therapy|Anticancer|Immunostimulant|T-lymphocyte stimulator,4790|1545|393|7761,Cancer,651,,,Cancer Research UK,29469,,,Cancer Research UK,29469,,,,,,
74303,BNC-105P,BNC-105P,Research Code|Prodrug,Cancer,Tubulin receptor antagonist,541,Vascular damaging agent|Angiogenesis inhibitor|Anticancer,2969|61|1545,Mesothelioma|Chronic lymphocytic leukemia|Metastatic renal cell carcinoma|Ovary tumor,1240|1734|4250|799,Cancer,651,Bionomics Ltd,29256,,,Bionomics Ltd,29256,,,,,,
74305,GSK-2636771,GSK-2636771A|GSK-2636771B|GSK-2636771,Research Code|Research Code|Research Code,Cancer,Phosphoinositide-3 kinase beta inhibitor|AKT protein kinase inhibitor,11180|3859,Synergist|Anticancer protein kinase inhibitor,7293|62255,,,Stage IV melanoma|Advanced solid tumor,3257|3713,,,GlaxoSmithKline plc,28355,GlaxoSmithKline plc,28355,,,,,,
74319,taminadenant,"adenosine A2a antagonist (Parkinson's disease), Palobiofarma|PBF-509|adenosine A2a antagonist (oral, Parkinson's disease), Palobiofarma|A2aR checkpoint inhibitor (solid tumor), Palobiofarma/Novartis|NIR-178|taminadenant",Research Code|Research Code|INN,Cancer|Neurology/Psychiatric,Adenosine A2a receptor antagonist,596,Anticancer|Antiparkinsonian|Immunostimulant|T-lymphocyte stimulator,1545|2947|393|7761,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Hippel Lindau syndrome|Diffuse large B-cell lymphoma|Renal cell carcinoma|Melanoma|Bladder cancer|Pancreas tumor|Pheochromocytoma|Paraganglioma|Metastatic breast cancer|Metastatic ovary cancer|Breast tumor|Head and neck tumor|Colorectal tumor,1262|1507|1612|1749|1766|205|2380|249|262|2876|3657|3866|49|623|989,Parkinsons disease|Attention deficit hyperactivity disorder|Cancer|Solid tumor,255|34|651|725,Novartis AG,23137,Palobiofarma SL,1035311,Palobiofarma SL,1035311,,,,,,
74322,idasanutlin,"RO-5503781|MDM2 antagonist (oral, cancer), Roche|p53-MDM2 binding inhibitor (oral, cancer), Roche|RG-7388|MDM2-p53 binding inhibitor (oral, cancer), Roche|idasanutlin",Research Code|Research Code|USAN|INN,Cancer|Hematologic,Mdm2 p53-binding protein inhibitor,10391,Anticancer|Apoptosis stimulator|Synergist,1545|1589|7293,,,Acute lymphoblastic leukemia|Acute myelogenous leukemia|Hematological neoplasm|Thrombocythemia|Polycythemia vera|Neuroblastoma|Non-Hodgkin lymphoma|Metastatic colorectal cancer|Cancer|Solid tumor,1728|1731|2054|2317|2319|2726|319|3658|651|725,,,Roche Holding AG,19446,Roche Holding AG,19446,,,,,,
74360,iadademstat dihydrochloride,"LSD-1 inhibitors (HSV infection/blood cancer), Oryzon Genomics|ORY-1001|RO-7051790|RG-6016|iadademstat|iadademstat dihydrochloride|LSD-1 inhibitors (oral, small cell lung cancer/acute myeloid leukemia), Oryzon Genomics",Research Code|Research Code|Research Code|INN,Cancer|Infection,Lysine specific histone demethylase 1 inhibitor,14681,Antiviral|Anticancer,991|1545,Small-cell lung cancer|Acute myelogenous leukemia,1261|1731,Herpes simplex virus infection|Cancer,157|651,Oryzon Genomics SA,1015480,Roche Holding AG,19446,Oryzon Genomics SA,1015480,,,,,,
74370,"voxtalisib + pimasertib hydrochloride (cancer), Sanofi/Merck KGaA","XL-765 + pimasertib hydrochloride (cancer), Sanofi/Merck KGaA|SAR-245409 + MSC-1936369B (cancer), Sanofi Merck KGaA|SAR-245409 + pimasertib hydrochloride (cancer), Sanofi/Merck KGaA|XL-765 + pimasertib hydrochloride|SAR245409 + MSC1936369B|SAR245409 + pimasertib hydrochloride|voxtalisib + pimasertib hydrochloride|voxtalisib + pimasertib hydrochloride (cancer), Sanofi/Merck KGaA",,Cancer,mTOR inhibitor|MEK-2 protein kinase inhibitor|MEK-1 protein kinase inhibitor|Phosphoinositide 3-kinase inhibitor,10240|4764|4762|1575,Anticancer protein kinase inhibitor,62255,,,Cancer|Solid tumor|Ovary tumor,651|725|799,,,Sanofi SA|Merck KGaA,1009547|18101,Merck KGaA,18101,,,,,,
74405,VLX-1570,"b-AP15|deubiquitinase inhibitors (multiple myeloma), Vivolux|VLX-1570",Research Code|Research Code,Cancer,Ubiquitin carboxyl hydrolase isozyme L5 inhibitor|Ubiquitin thioesterase-14 inhibitor|Proteasome inhibitor,20945|11300|4917,Anticancer|Metastasis inhibitor|Apoptosis stimulator,1545|695|1589,Multiple myeloma|Cancer,1828|651,,,Vivolux AB|Karolinska Institutet,1063137|21110,,,Vivolux AB,1063137,,,,,,
74543,senaparib,"PARP-1 inhibitor (cancer), IMPACT Therapeutics|IMP-4297|IMP-04297|senaparib|IMP-427|JS-109",Research Code|Research Code|Research Code,Cancer,Poly ADP ribose polymerase 2 inhibitor|Poly ADP ribose polymerase 1 inhibitor,38286|38283,Anticancer,1545,Small-cell lung cancer|Adenocarcinoma|Prostate tumor|Hormone refractory prostate cancer|Advanced solid tumor|Metastatic ovary cancer|Breast tumor,1261|2399|276|3246|3713|3866|49,Cancer|Ovary tumor,651|799,Shanghai Junshi Biosciences Co Ltd|IMPACT Therapeutics Inc,1104388|1066022,,,IMPACT Therapeutics Inc,1066022,,,,,,
74558,NMS-088,"dual Flt3/Kit inhibitor (cancer), Nerviano|NMS-P948|NMS-P088|NMS-088|NMS-03592088",Research Code|Research Code|Research Code|Research Code,Cancer,CSF-1 antagonist|Kit tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor,3154|3808|3806,Synergist|Anticancer protein kinase inhibitor,7293|62255,Acute myelogenous leukemia|Chronic myelomonocytic leukemia,1731|6833,Cancer,651,Nerviano Medical Sciences Srl,1013717,,,Nerviano Medical Sciences Srl,1013717,,,,,,
74641,spanlecortemlocel,"LFU-835|umbilical cord stem cell therapy (hematological cancer), Novartis|LFU-835-expanded umbilical cord stem cell therapy (hematopoetic stem cell transplant), Novartis|StemRegenin 1|SR1|spanlecortemlocel|LFU-835-expanded umbilical cord stem cell therapy (hematopoetic stem cell transplant/ inherited metabolic disorder), Magenta|umbilical cord stem cell therapy (hematopoetic stem cell transplant/ inherited metabolic disorder), Magenta|HSC-835|MGTA-456",Research Code|INN|Research Code|Research Code,Immune,AHR gene inhibitor,82574,Stem cell stimulator|Hematopoietic stimulator,53559|610,Hematopoietic stem cell transplantation,3888,,,Magenta Therapeutics Inc,1140317,Novartis AG,23137,Novartis AG,23137,,,,,,
74658,F-18,"calanolide A analog (HIV), Institute of Materia Medica|F-18",Research Code,Infection,Non-nucleoside reverse transcriptase inhibitor,1833,Antiviral,991,HIV infection,158,,,Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College,19595,,,Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College,19595,,,,,,
74669,CD24-IgFc,"rheumatoid arthritis therapy, OncoImmune|CD-24 modulator (rheumatoid arthritis), OncoImmune|CD-24 targeting drug therapy (rheumatoid arthritis), OncoImmune|CD24-IgFc|CD24-Fc|CD-24 modulator (rheumatoid arthritis/multiple sclerosis/graft versus host disease/COVID-19/metastatic cancer), OncoImmune|SACCOVID|MK-7110",Trade Name|Research Code,Cancer|Immune|Infection,Signal transducer CD24 modulator,5095,Immunosuppressant|Anti-inflammatory|Antiviral|Anticancer,396|2953|991|1545,Multiple sclerosis|Rheumatoid arthritis|Graft versus host disease,213|291|616,Coronavirus disease 19 infection|Stage IV melanoma|Metastatic colorectal cancer|Metastatic renal cell carcinoma,10406|3257|3658|4250,OncoImmune Inc,1049281,Merck & Co Inc,18077,OncoImmune Inc,1049281,,,,,,
74733,depatuxizumab mafodotin,"ABT-414|EGFR antibody-drug conjugate (cancer), Abbott|EGFR-ADC (cancer), Abbott|EGFR antibody-drug conjugate (cancer), AbbVie|EGFR-ADC (cancer), AbbVie|anti-EGFR antibody-MMAF conjugate, AbbVie|ABT-806-MMAF conjugate|depatuxizumab mafodotin|andepatuzumab mafodotin|ABBV-414|Depatux-M",Research Code|USAN|INN|Research Code|Trade Name,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor|Microtubule inhibitor|Immunotoxin|Anticancer monoclonal antibody,62255|2575|539|55685,Breast tumor,49,Non-small-cell lung cancer|Glioblastoma|Gliosarcoma|Cancer|Solid tumor,1262|2454|2727|651|725,AbbVie Inc,1072507,Abbott Laboratories,13601,Abbott Laboratories,13601,,,,,,
74755,ilixadencel,"dendritic cell vaccine (cancer), Immunicum|COMBIG-vaccine (cancer), Immunicum|COMBIG-DC|COMBIG-RCC|COMBIG-MEL|INTUVAC-RCC|INTUVAC|INTUVAX|INTUVAX RCC|INTUVAX-HCC|INTUVAX-GIST|ilixadencel",Trade Name|INN,Cancer,,,Dendritic cell vaccine|Anticancer|Adjuvant|Therapeutic vaccine,102926|1545|524|12379,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Biliary cancer|Hepatocellular carcinoma|Melanoma|Squamous cell carcinoma|Gastrointestinal stromal tumor|Soft tissue sarcoma|Metastatic renal cell carcinoma|Head and neck tumor,1011|1262|127|1516|1767|205|307|3205|3378|4250|623,Cancer,651,Institute for Cancer Vaccines and Immunotherapy|Immunicum AB,1070230|1006069,,,Immunicum AB,1006069,,,,,,
7484,rimiducid,"AP-1903|AP-1966|AP-1889|AP-1903 + ARGENT (GvHD), ARIAD/Genovo/Washington/Raffaele|Dimerizer Drug, AP-1903|rimiducid",Research Code|Research Code|Research Code|Trade Name|USAN|INN,Immune,,,Unspecified drug target|Immunosuppressant,59620|396,,,Bone marrow transplantation|Graft versus host disease,46|616,,,ARIAD Pharmaceuticals Inc|Genovo Inc|University of Washington|Istituto Scientifico H San Raffaele,14296|19041|20701|25126,ARIAD Pharmaceuticals Inc,14296,,,,,,
74889,lumretuzumab,"GE-huMAb HER3 (solid tumors), Roche|anti-HER3 monoclonal antibody (solid tumors), Roche|glycoengineered anti-HER3 monoclonal antibody (solid tumors), Roche|lumretuzumab|RO-5479599|RG-7116",USAN|INN|Research Code|Research Code,Cancer,Erbb3 tyrosine kinase receptor inhibitor,3758,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,,,Non-small-cell lung cancer|Breast tumor|Solid tumor,1262|49|725,,,F Hoffmann-La Roche AG,26178,F Hoffmann-La Roche AG,26178,,,,,,
74941,SOT-101,CYP-0150|RLI|RLI-15|SO-C101|SOT-101,Research Code|Research Code|Research Code|Research Code,Cancer,IL-2 receptor agonist|IL-15 receptor agonist|Interleukin 15 ligand,221|3085|51216,Anticancer|Immunostimulant,1545|393,Thyroid tumor|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Biliary cancer|Renal cell carcinoma|Hepatocellular carcinoma|Melanoma|Skin cancer|Anal tumor|Bladder cancer|Thymus neoplasm|Squamous cell carcinoma|Merkel cell carcinoma|Advanced solid tumor|Uterine cervix tumor|Breast tumor|Head and neck tumor|Cancer|Ovary tumor,1134|1240|1261|1262|127|1516|1766|1767|205|2170|2193|2380|2938|307|3235|3713|427|49|623|651|799,,,Sotio AS,1077346,Cytune Pharma,1066345,Cytune Pharma,1066345,,,,,,
74946,Bifico,Bifico|bifid-triple viable capsules,Trade Name,Gastrointestinal,,,Antidiarrhoeal|Gastrointestinal system agent|Unspecified drug target,4007|1332|59620,Diarrhea|Functional bowel disorder|Constipation,102|1269|404,,,Shanghai Sine Pharmaceutical Co Ltd,1066785,,,Shanghai Sine Pharmaceutical Co Ltd,1066785,,,,,,
74974,AZD-1208,"AZD-1208|pim kinase inhibitor (cancer), Astrazeneca",Research Code,Cancer,PIM protein kinase inhibitor,4522,Anticancer protein kinase inhibitor,62255,,,Acute myelogenous leukemia|Lymphoma|Advanced solid tumor|Cancer,1731|203|3713|651,,,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
74994,"beta-elemene (intravenous emulsion, brain tumor), CSPC Yuanda (Dalian) Pharmaceutical","beta-elemene (intravenous emulsion, brain tumor), CSPC Yuanda (Dalian) Pharmaceutical|beta-elemene|youlineng|Ailineng",Trade Name|Trade Name,Cancer,,,Unspecified drug target|Anticancer,59620|1545,Solid tumor,725,,,CSPC Yuanda (Dalian) Pharmaceutical,1066800,,,CSPC Yuanda (Dalian) Pharmaceutical,1066800,,,,,,
74998,"pegfilgrastim follow-on biologic, CSPC","pegfilgrastim|PEG-GCSF (neutropenia), CSPC|Jinyouli|PEG-filgrastim (neutropenia), CSPC|pegfilgrastim follow-on biologic, CSPC|津优力|PEG-rhGCSF injection",USAN|BANN|INN|Trade Name|Trade Name,Hematologic,GCSF ligand|GCSF receptor agonist,52970|3151,,,Neutropenia,1991,,,CSPC Pharmaceuticals Group Limited,1033194,,,CSPC Pharmaceuticals Group Limited,1033194,,,,,,
75058,Hemay-020,Hemay-020,Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Cancer,651,,,Tianjin Hemay Bio-Tech Co Ltd|Hainan Generalsanyang Pharmaceutical Co Ltd,1010186|1079150,,,Tianjin Hemay Bio-Tech Co Ltd,1010186,,,,,,
75079,"rucaparib camsylate (oral, solid tumors), Clovis","rucaparib|CO-338|rucaparib camsylate (oral, solid tumors), Clovis|rucaparib camsylate|Rubraca",USAN|INN|Research Code|USAN|Trade Name,Cancer,PARP inhibitor|Poly ADP ribose polymerase 1 inhibitor|Poly ADP ribose polymerase 3 inhibitor|Poly ADP ribose polymerase 2 inhibitor,2507|38283|38289|38286,Anticancer,1545,Esophagus tumor|Mesothelioma|Endometrioid carcinoma|Transitional cell carcinoma|Fallopian tube cancer|Bladder cancer|Peritoneal tumor|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Metastatic bladder cancer|Ovarian clear cell carcinoma|Metastatic breast cancer|Metastatic prostate cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer|Uterine cervix tumor|Breast tumor|Solid tumor|Ovary tumor,1011|1240|1705|1771|2243|2380|3083|3246|3247|3466|3525|3657|3664|3666|3669|3713|3866|427|49|725|799,Metastatic renal cancer|Urethral cancer|Cancer,3467|3678|651,Clovis Oncology Inc,1047565,Pfizer Inc|The University of Newcastle Upon Tyne|Agouron Pharmaceuticals Inc|Cancer Research Technology Ltd,18767|21243|26488|30620,The University of Newcastle Upon Tyne,21243,,,,,,
75085,dubermatinib,Huntsman Cancer Institute-2084|TP-0903|HCI-2084|dubermatinib|dubermatinib tartrate,Research Code|Research Code|Research Code|USAN|PINN|USAN,Cancer,Axl tyrosine kinase receptor inhibitor|Mer tyrosine kinase receptor inhibitor|Aurora protein kinase inhibitor,3742|3744|4412,Anticancer protein kinase inhibitor|Apoptosis stimulator,62255|1589,Non-small-cell lung cancer|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Melanoma|Advanced solid tumor|Solid tumor|Ovary tumor|Colorectal tumor,1262|1731|1734|205|3713|725|799|989,Cancer,651,SDP Oncology,1216786,Tolero Pharmaceuticals Inc,1069667,Tolero Pharmaceuticals Inc,1069667,,,,,,
75104,T-allo10,"Tr1 adoptive cell therapy (GvHD), San Raffaele Telethon Institute for Gene Therapy|T-allo10|alloantigen-specific IL-10 anergized T cells (intravenous/infusion, GvHD), Stanford University",,Immune,,,Regulatory T lymphocyte stimulator|Immunosuppressant|Anticancer,174667|396|1545,Graft versus host disease,616,,,Stanford University,20679,San Raffaele Telethon Institute for Gene Therapy,1005750,San Raffaele Telethon Institute for Gene Therapy,1005750,,,,,,
75109,tegavivint,BC-2059|tegatrabetan|tegavivint,Research Code|INN,Cancer,Beta-catenin inhibitor|F box WD repeat protein TBL1XR1 inhibitor,15709|73266,Synergist|Anticancer|Apoptosis stimulator,7293|1545|1589,Non-small-cell lung cancer|Acute myelogenous leukemia|Multiple myeloma|Sarcoma|Lymphoma|Aggressive fibromatosis|Cancer|Solid tumor,1262|1731|1828|194|203|3504|651|725,,,Iterion Therapeutics|Apollomics Inc,1065976|1129041,,,Iterion Therapeutics,1065976,,,,,,
75147,"modified anti-CD19 T-cell therapy (B-cell malignancies), Fred Hutchinson Cancer Research Center","modified anti-CD19 T-cell therapy (B-cell malignancies), Fred Hutchinson Cancer Research Center",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Genetically engineered autologous cell therapy,1545|4790,Hematological neoplasm,2054,,,Fred Hutchinson Cancer Research Center,16218,,,Fred Hutchinson Cancer Research Center,16218,,,,,,
75157,"WT1-dendritic cell vaccine (hematological cancer), National Institutes of Health","WT1-dendritic cell vaccine (hematological cancer), National Institutes of Health",,Cancer,Wilms tumor protein modulator,30009,Therapeutic vaccine|Anticancer|Dendritic cell vaccine|Protein subunit vaccine,12379|1545|102926|12372,,,Hematological neoplasm,2054,,,National Institutes of Health,20518,National Institutes of Health,20518,,,,,,
75446,eftozanermin alfa,"APG-350|TRAIL receptor agonists (solid tumor), Apogenix/AbbbVie|APG-880|ABBV-621|TRAIL receptor agonist (iv, solid tumors/hematological malignancies), AbbVie|eftozanermin alfa|HERA-TRAIL",Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer,TRAIL receptor agonist,8226,Apoptosis stimulator|Anticancer|Synergist,1589|1545|7293,Multiple myeloma|Hematological neoplasm|Solid tumor,1828|2054|725,,,AbbVie Inc,1072507,Apogenix GmbH,1033114,Apogenix GmbH,1033114,,,,,,
75511,depoxythilone,UTD-1|depoxythilone|utidelone|BGE-5|youtidelong,Research Code|Research Code,Cancer|Genitourinary/Sexual Function,,,Microtubule stabilizer|Anticancer|Angiogenesis inhibitor,2576|1545|61,Gastrointestinal tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Gynecological disorder|Head and neck tumor|Solid tumor,131|3657|3658|3665|438|623|725,,,Beijing Biostar Technologies Ltd,1067464,Chinese Academy of Medical Sciences & Peking Union Medical College,1066199,Beijing Biostar Technologies Ltd,1067464,,,,,,
75627,GB-1275,"integrin CD11b/CD18 agonists (inflammation), Adhaere|leukadherins|integrin CD11b/CD18 agonists (oral, inflammation/cancer), Adhaere|GB-1275|CD11b agonist (oral, inflammation/cancer), Adhaere/Gossamer|integrin CD11b/CD18 agonists (oral, inflammation/cancer), Adhaere/Gossamer|ADH-503",Research Code|Research Code,Cancer|Inflammatory,CD11b agonist|Integrin beta-2 agonist,5050|5078,Anticancer|Anti-inflammatory|Leukocyte inhibitor,1545|2953|7746,Stomach tumor|Pancreatic ductal adenocarcinoma|Inflammatory disease|Pancreas tumor|Squamous cell carcinoma|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic esophageal cancer|Colorectal tumor,127|1507|188|249|307|3246|3657|3667|989,Advanced solid tumor|Cancer,3713|651,Gossamer Bio,1158771,Adhaere Pharmaceuticals Inc,1067421,Adhaere Pharmaceuticals Inc,1067421,,,,,,
75654,CLR-124,"124I-NM-404|124I-CLR-1404|iodine-124-CLR-1404|iodine-124-NM-404|CLR-1404-[124I]|NM-404-[124I]|LIGHT (cancer), Novelos Therapeutics|small molecule phospholipid ether analogs (cancer imaging), University of Michigan|CLR-124|I-124-CLR1404",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,,,PET contrast agent|Neoplasm diagnostic agent|Radiodiagnostic|Radiotherapeutic,5555|7220|5720|5721,,,Glioblastoma|Solid tumor,2454|725,,,Cellectar LLC|University of Michigan|Cellectar Biosciences Inc,1016193|20623|27692,University of Michigan,20623,,,,,,
75813,relatlimab,"anti-LAG-3 (cancer), Bristol-Myers Squibb|anti-lymphocyte activation gene-3 antibody (cancer), BMS|anti-CD223 antibody (oncology), Bristol-Myers Squibb|BMS-986016|ONO-4482|LAG-3 checkpoint inhibitor (cancer), Bristol-Myers Squibb/Ono|relatlimab|LAG-3 checkpoint inhibitor (cancer/multiple myeloma), Bristol-Myers Squibb/Ono|LAG-3 checkpoint inhibitor (iv, solid tumor/non-small cell lung cancer/gastric cancer/esophageal cancer/melanoma/head and neck squamous cell carcinoma/multiple myeloma/hepatocellular carcinoma), Bristol-Myers Squibb/Ono",Research Code|Research Code|USAN|INN,Cancer,CD223 antagonist,8413,T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7761|393|55685,Hodgkins disease|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Hepatocellular carcinoma|Multiple myeloma|Melanoma|Glioblastoma|Squamous cell carcinoma|Non-Hodgkin lymphoma|Stage IV melanoma|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Uveal melanoma|Metastatic renal cell carcinoma|Solid tumor,161|1734|1749|1767|1828|205|2454|307|319|3257|3665|3666|3667|3673|3713|3788|4250|725,Cancer,651,Ono Pharmaceutical Co Ltd|Bristol-Myers Squibb Co,18681|15065,,,Bristol-Myers Squibb Co,15065,,,,,,
75822,pegteograstim,"pegfilgrastim biobetter (neutropenia), Green Cross|GCPGC|pegteograstim|Neulapeg|pegfilgrastim biobetter (neutropenia), GC Pharma",INN|Trade Name,Hematologic,GCSF receptor agonist,3151,Hematopoietic stimulator,610,Neutropenia,1991,,,GC Pharma,16583,,,GC Pharma,16583,,,,,,
75832,navoximod,"IDO pathway inhibitors (solid tumor), NewLink Genetics|indoleamine 2,3-dioxygenase pathway inhibitors (cancer), NewLink Genetics|navoximod|G-6078|GDC-0919|RG-6078|IDO-IN-7|RO-7077339|NLG-919|IDO checkpoint inhibitor (solid tumor), NewLink Genetics",USAN|INN|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,"Indoleamine-pyrrole-2,3-dioxygenase inhibitor",6366,Immunostimulant|Anticancer|T-lymphocyte stimulator,393|1545|7761,Solid tumor,725,Cancer,651,NewLink Genetics Corp,1008706,Chugai Pharmaceutical Co Ltd|Genentech Inc,15414|19453,NewLink Genetics Corp,1008706,,,,,,
75912,entospletinib,"Syk inhibitor (rheumatoid arthritis), Gilead|entospletinib|GS-9973|entospletinib bis-mesylate",USAN|INN|Research Code,Cancer|Hematologic|Immune,Syk tyrosine kinase inhibitor,3602,Anticancer protein kinase inhibitor|Anti-inflammatory,62255|2953,Acute myelogenous leukemia,1731,Macroglobulinemia|B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Hematological neoplasm|Rheumatoid arthritis|Non-Hodgkin lymphoma|Graft versus host disease|Cancer,1264|1729|1734|1744|1749|2054|291|319|616|651,Kronos Bio Inc,1165232,Gilead Sciences Inc,16450,Gilead Sciences Inc,16450,,,,,,
76019,PVX-410,"PVX-410|smoldering multiple myeloma vaccine, OncoPep|smoldering multiple myeloma vaccine, Dana-Farber Cancer Institute|HLA-2 specific peptides (smoldering multiple myeloma/metastatic triple negative breast cancer), OncoPep",Research Code,Cancer,X box binding protein 1 modulator|SLAM family member 7 modulator|Syndecan-1 modulator,47247|45393|5452,Therapeutic vaccine|Anticancer,12379|1545,Multiple myeloma|Metastatic breast cancer|Breast tumor,1828|3657|49,,,Dana-Farber Cancer Institute Inc|OncoPep Inc,15615|1068051,,,Dana-Farber Cancer Institute Inc,15615,,,,,,
76126,zalifrelimab,"fully human antibodies (cancer, NSCLC), 4-Antibody|fully human antibodies (cancer, NSCLC), Agenus|CTLA-4 targeted antibody program (cancer, NSCLC), 4-Antibody/Ludwig Institute for Cancer Research|AGEN-1884|CTLA-4 checkpoint inhibitor (Retrocyte, cancer/NSCLC), 4-Antibody|zalifrelimab",Research Code|USAN|INN,Cancer,CD80 modulator|CD86 modulator|Cytotoxic T-lymphocyte protein-4 inhibitor,5325|5343|5482,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,Angiosarcoma|Soft tissue sarcoma|Metastatic pancreas cancer|Advanced solid tumor|Uterine cervix tumor|Cancer,2443|3378|3669|3713|427|651,Metastatic non small cell lung cancer,3665,4-Antibody AG|Agenus Inc|Betta Pharmaceuticals Co Ltd|Ludwig Institute for Cancer Research|Recepta biopharma,1022553|23221|1051889|21091|1035632,,,Ludwig Institute for Cancer Research,21091,,,,,,
7620,Roferon-A,"Roferon-A|Canferon A|Ro-25-3036|recombinant IFN alpha-2a, Roche|interferon (recombinant, alpha-2a), Roche",Trade Name|Trade Name|Research Code,Cancer|Infection,Interferon alpha 2 ligand,214,Anticancer hormone|Antiviral,62253|991,Hepatitis B virus infection|Hepatitis C virus infection|Chronic myelocytic leukemia|Hairy cell leukemia|Cutaneous T-cell lymphoma|Renal cell carcinoma|Melanoma|Neoplasm|Non-Hodgkin lymphoma|Viral infection|Metastatic renal cell carcinoma|Kaposis sarcoma,152|153|1735|1736|1754|1766|205|230|319|344|4250|936,Glioma|HIV infection|Liver tumor,1108|158|202,Roche Holding AG|Takeda Pharmaceutical Co Ltd,19446|20300,Genentech Inc,19453,Hoffmann-La Roche Inc,19461,,,,,,
7624,enistimagene setitucel + damistimagene matitucel,"GVAX|CG-8123|Bystander GVAX|vaccine (intradermal, cancer), Somatix|GM-CSF-producing cell vaccine (intradermal, cancer), Cell Genesys/ Takeda|CG1940/CG8711|GM-CSF-producing cell vaccine (intradermal, cancer), BioSante/Takeda|GM-CSF-producing cell vaccine (intradermal, cancer), Aduro|GM-K562|Colon cancer tumor vaccine|GVAX Pancreas Panc 10.05|enistimagene setitucel|damistimagene matitucel|GVAX Pancreas Panc 6.03|DE-125B|DE-125|GVAX Pancreas|enistimagene setitucel + damistimagene matitucel",Trade Name|Research Code|Trade Name|Research Code|Research Code|USAN|USAN|Research Code|Research Code,Cancer,Programmed cell death protein 1 inhibitor|Interferon gamma receptor agonist|GM-CSF receptor agonist,67136|215|410,Therapeutic vaccine|Anticancer,12379|1545,Myelodysplastic syndrome|Pancreatic ductal adenocarcinoma|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Neuroblastoma|Metastatic pancreas cancer|Colorectal tumor,1272|1507|1731|1734|2726|3669|989,Chronic myelocytic leukemia|Renal cell carcinoma|Multiple myeloma|Melanoma|Pancreas tumor|Prostate tumor|Breast tumor|Cancer|Lung tumor|Ovary tumor,1735|1766|1828|205|249|276|49|651|755|799,Chinook Therapeutics Canada Inc|Dana-Farber Cancer Institute Inc,1188489|15615,Chinook Therapeutics Inc|Cell Genesys Inc|Japan Tobacco Inc|Takeda Pharmaceutical Co Ltd|Janssen Biotech Inc|ANI Pharmaceuticals Inc,1039923|15334|17327|20300|26997|27120,Cell Genesys Inc,15334,,,,,,
76546,KN-01,"ceramide-encapsulated nanoliposomes (cancer), Keystone Nano|CNL (cancer), Keystone|C6 ceramide nanoliposome (cancer), Keystone Nano|KN-01|KN-001, Keystone Nano|Ceraxa",Research Code,Cancer,,,Unspecified drug target|Anticancer|Apoptosis stimulator,59620|1545|1589,Acute myelogenous leukemia|Leukemia|Advanced solid tumor,1731|199|3713,Cancer,651,Keystone Nano Inc,1041904,,,Keystone Nano Inc,1041904,,,,,,
76609,"rezafungin acetate (intravenous, fungal infections), Cidara Therapeutics/ Mundipharma","SP-3025 (intravenous, fungal infection), Seachaid|biafungin (intravenous, fungal infection), Seachaid|biafungin acetate|SP-3025|CD-101 acetate|biafungin (intravenous, fungal infection), Cidara Therapeutics|rezafungin acetate|rezafungin|biafungin|CD-101, Seachaid|rezafungin acetate (intravenous, fungal infection), Cidara Therapeutics|CD-101 IV|rezafungin acetate (intravenous, fungal infections), Cidara Therapeutics/ Mundipharma",Research Code|Research Code|USAN|INN|USAN|Research Code,Infection,"1,3 beta glucan synthase inhibitor",61991,Fungicide,1748,Candida infection|Pneumocystis carinii infection|Aspergillus infection,1308|271|29,Fungal infection,124,Mundipharma International Corp Ltd|Cidara Therapeutics Inc,1045514|1097902,Seachaid Pharmaceuticals Inc,1060661,Seachaid Pharmaceuticals Inc,1060661,,,,,,
76625,VS-4718,"PND-1186|focal adhesion kinase program (cancer), Verastem Inc|VS-5095|FAK program (cancer), Verastem/Scripps Research Institute/Poniard|SR-2516|FAK/PYK2 dual inhibitors (cancer), Verastem|focal adhesion kinase/proline-rich tyrosine kinase 2 dual inhibitors (cancer), Verastem|VS-4718",Research Code|Research Code|Research Code|Research Code,Cancer,Focal adhesion kinase inhibitor,3540,Anticancer protein kinase inhibitor|Synergist|Anticancer|Apoptosis stimulator,62255|7293|1545|1589,Uveal melanoma,3788,Cancer,651,Verastem Oncology,1058061,Poniard Pharmaceuticals Inc|Scripps Research Institute|University of California San Diego,18472|21102|25451,Scripps Research Institute,21102,,,,,,
76794,MRX-34,"MiR-Rx34|miR-34a mimetic (lung cancer), Mirna Therapeutics|MRX-01|MRX-34",Research Code|Research Code|Research Code,Cancer,,,miRNA agent|Anticancer,38419|1545,,,Cancer,651,,,Mirna Therapeutics Inc,1038576,Mirna Therapeutics Inc,1038576,,,,,,
76860,AL-2846,AL-2846,Research Code,Cancer,Axl tyrosine kinase receptor inhibitor|Ron tyrosine kinase receptor inhibitor|Kit tyrosine kinase inhibitor|Ret tyrosine kinase receptor inhibitor|VEGF-1 receptor antagonist|VEGF-3 receptor antagonist|VEGF-2 receptor antagonist|Hepatocyte growth factor receptor antagonist,3742|3800|3808|3818|3846|3850|3848|675,Anticancer protein kinase inhibitor,62255,Glioma|Stomach tumor|Liver tumor|Prostate tumor|Medullary thyroid cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Cancer,1108|127|202|276|3240|3658|3665|3669|651,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,Advenchen Laboratories LLC,1017769,Advenchen Laboratories LLC,1017769,,,,,,
76862,AL-8326,AL-8326,Research Code,Cancer,PDGF receptor antagonist|Aurora protein kinase 1 inhibitor|VEGF-3 receptor antagonist|VEGF-1 receptor antagonist|Ret tyrosine kinase receptor inhibitor|Kit tyrosine kinase inhibitor|FGF receptor antagonist|VEGF-2 receptor antagonist,948|4418|3850|3846|3818|3808|168|3848,Anticancer protein kinase inhibitor,62255,Small-cell lung cancer|Endometrioid carcinoma|Metastatic pancreas cancer|Metastatic ovary cancer|Uterine cervix tumor|Cancer,1261|1705|3669|3866|427|651,,,Advenchen Laboratories LLC,1017769,,,Advenchen Laboratories LLC,1017769,,,,,,
77056,"integrin alpha-v-beta6 antibody-drug conjugate (cancer), Seattle Genetics","integrin alpha-v-beta6 antibody-drug conjugate (cancer), Seattle Genetics|h15H3-vcMMAE|h15H3-mcMMAF|h15H3-mafodotin|h15H3-SGD-1269|SGN-B6A",Research Code|Research Code|Research Code|Research Code,Cancer,Integrin alpha-V/beta-6 antagonist,2961,Anticancer antibody,55684,Squamous cell carcinoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Metastatic ovary cancer|Uterine cervix tumor,307|3466|3657|3665|3666|3667|3669|3673|3866|427,Cancer,651,Seagen Inc,25554,,,Seagen Inc,25554,,,,,,
77057,SGN-2FF,"protein fucosylation inhibitor (cancer), Seattle Genetics|SGD-2083|2-fluorofucose|2-flurofucose, Seattle Genetics|SGN-2FF",Research Code|Research Code,Cancer|Hematologic,GDP fucose synthetase inhibitor,6327,Anti-inflammatory|Anticancer,2953|1545,,,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Renal cell carcinoma|Bladder cancer|Sickle cell anemia|Squamous cell carcinoma|Breast tumor|Head and neck tumor|Solid tumor|Colorectal tumor,1011|1262|127|1766|2380|303|307|49|623|725|989,,,Seagen Inc,25554,Seagen Inc,25554,,,,,,
77108,"TAA-targeted autologous T-cell therapy (pancreatic cancer/lymphoma/multiple myeloma/acute lymphoblastic leukemia), Baylor College of Medicine/Marker therapeutics","TAA-targeted autologous T-cell therapy (cancer), Baylor College of Medicine|TAA-specific autologous cytotoxic T-cell lymphocyte therapy (cancer), Baylor College of Medicine|TAA-targeted autologous T-cell therapy (SSX2, MAGEA4, survivin, PRAME, NY-ESO-1), Baylor College of Medicine|TAA-targeted autologous T-cell therapy (pancreatic cancer/lymphoma/multiple myeloma/acute lymphoblastic leukemia), Baylor College of Medicine/Marker therapeutics|MAAP T-cell therapy (pancreatic cancer/breast cancer/lymphoma/multiple myeloma/acute lymphoblastic leukemia), Marker Therapeutics/ Baylor College of Medicine)",,Cancer,Melanoma associated antigen 4 modulator|Tumor expressed melanoma antigen modulator|Survivin protein modulator|Synovial sarcoma X breakpoint protein 2 modulator|Cancer testis antigen NY-ESO-1 modulator,21961|18578|13606|44305|50096,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,Hodgkins disease|Multiple myeloma|Lymphoma|Pancreas tumor|Non-Hodgkin lymphoma|Breast tumor,161|1828|203|249|319|49,Cancer,651,Baylor College of Medicine|Marker Therapeutics Inc,20534|27762,,,Baylor College of Medicine,20534,,,,,,
7711,perifosine,perifosine|D-21266|KRX-0401|perifosin|NSC-639966|ASTA-D21266|IND-58156|AEZS-104|YHI-1003,INN|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Hematologic,Phosphoinositide 3-kinase inhibitor|AKT protein kinase inhibitor,1575|3859,Apoptosis stimulator|Synergist|Anticancer protein kinase inhibitor|Radiochemosensitizer,1589|7293|62255|572,,,Glioma|Mesothelioma|Non-small-cell lung cancer|Macroglobulinemia|Gastrointestinal tumor|Multiple myeloma|Sarcoma|Leukemia|Liver tumor|Melanoma|Pancreas tumor|Neuroblastoma|Prostate tumor|Non-Hodgkin lymphoma|Metastatic renal cell carcinoma|Breast tumor|Head and neck tumor|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,1108|1240|1262|1264|131|1828|194|199|202|205|249|2726|276|319|4250|49|623|651|725|799|989,,,Hikma Pharmaceuticals plc|ASTA Medica AG|Handok Inc|Yakult Honsha Co Ltd|AEterna Zentaris Inc|Kayaku ASTA Medica Co Ltd|Keryx Biopharmaceuticals Inc|Zentaris GmbH|ACCESS Oncology Inc,1022379|15623|19986|20961|22711|27393|27395|29069|29235,ASTA Medica AG,15623,,,,,,
77179,BNT-411,"TLR agonists (cancer immunotherapy), 4SC/BioNTech|TLR agonists (CIT), 4SC|SC-2|SC-1, 4SC|4SC-CIT|SC-1.2|BNT-411",Research Code|Research Code|Research Code|Research Code,Cancer,TLR agonist|TLR-7 agonist,7800|7821,Anticancer|Adjuvant|Immunostimulant,1545|524|393,Small-cell lung cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Solid tumor,1261|3665|3669|725,Cancer,651,4SC Discovery GmbH|BioNTech SE,1066894|1047330,4SC AG,28108,4SC AG,28108,,,,,,
7719,dolastatin-10,NSC-376128|dolastatin-10,Research Code,Cancer,,,Anticancer|Microtubule modulator,1545|563,,,Acute leukemia|Cancer,1727|651,,,National Cancer Institute (NCI),20519,National Cancer Institute (NCI),20519,,,,,,
77234,ALRN-6924,"stapled p53 peptides (cancer), Aileron/Roche|ATSP-7041|dual MDM2/MDMX inhibitors (stapled peptides, p53-dependent cancers), Aileron/Roche|ALRN-6924",Research Code|Research Code,Cancer|Hematologic,p53 tumor suppressor protein stimulator|Mdm4 protein inhibitor|Mdm2 p53-binding protein inhibitor,17120|18364|10391,Apoptosis stimulator|Anticancer,1589|1545,Non-small-cell lung cancer|Myelodysplastic syndrome|Acute leukemia|Acute myelogenous leukemia|Peripheral T-cell lymphoma|Lymphoma|Metastatic non small cell lung cancer|Bone marrow depression|Breast tumor|Solid tumor|Brain tumor,1262|1272|1727|1731|1753|203|3665|3826|49|725|760,Cancer,651,Aileron Therapeutics Inc,1031301,Roche Holding AG,19446,Aileron Therapeutics Inc,1031301,,,,,,
77270,BCL-201,"Bcl-2 inhibitors (cancer), Servier/Vernalis/Novartis|Servier1|S-55746|BCL-201|S-055746",Research Code|Research Code|Research Code,Cancer,Bcl-2 protein inhibitor,16111,Synergist|Apoptosis stimulator|Anticancer,7293|1589|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Non-Hodgkin lymphoma,1272|1731|1734|1744|1745|319,Cancer,651,Novartis AG|Servier,23137|19863,Vernalis plc,15262,Servier,19863,,,,,,
77319,"multivirus-specific CTLs (EBV, CMV, adenovirus, HHV6, BK virus infection), Baylor College of Medicine","multivirus-specific cytotoxic T-cell therapy (EBV, CMV, adenovirus, HHV6, BK virus infection), Baylor College of Medicine|multivirus-specific CTLs (EBV, CMV, adenovirus, HHV6, BK virus infection), Baylor College of Medicine|rapidly generated CTLs (viral infection), Baylor College of Medicine|multivirus-specific cytotoxic T-cell therapy(BK virus, cytomegalovirus, adenovirus, Epstein-Barr viral infection), Baylor College of Medicine",,Infection,,,Antiviral|Immunostimulant|T-lymphocyte stimulator|Unspecified drug target,991|393|7761|59620,Herpesvirus type 6 infection|Epstein Barr virus infection|BK virus infection|Adenovirus infection|Cytomegalovirus infection,1122|3299|3499|7|89,,,Baylor College of Medicine,20534,,,Baylor College of Medicine,20534,,,,,,
77326,ulixertinib,BVD-VTX|ulixertinib hydrochloride|ulixertinib|BVD-ERK|BVD-ERK/ST|BVD-ERK/HM|BVD-523|BVD-523FB|VRT-752271,Research Code|INN|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Extracellular signal related kinase-2 inhibitor|Extracellular signal related kinase-1 inhibitor,4366|4364,Anticancer|Anticancer protein kinase inhibitor|Synergist,1545|62255|7293,Myelodysplastic syndrome|Acute myelogenous leukemia|Uveal melanoma|Cancer|Solid tumor,1272|1731|3788|651|725,,,BioMed Valley Discoveries,1063567,Vertex Pharmaceuticals Inc,20739,Vertex Pharmaceuticals Inc,20739,,,,,,
77343,zanubrutinib,"target-3 (solid/hematological tumors), BeiGene|BTK inhibitor (solid/hematological tumors), BeiGene|zanubrutinib|BGB-3111|BDB-3111|BRUKINSA|zanubrutinib (COVID-19), BeiGene",INN|Research Code|Research Code|Trade Name,Cancer|Immune|Infection,Btk tyrosine kinase inhibitor,3592,Antiviral|Anti-inflammatory|Anticancer protein kinase inhibitor,991|2953|62255,Coronavirus disease 19 infection|Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Lupus nephritis|B-cell lymphoma|Non-Hodgkin lymphoma,10406|1734|1743|1744|1745|1746|1747|1749|2404|316|319,Hematological neoplasm|Solid tumor,2054|725,BeiGene Co Ltd,1063251,,,BeiGene Co Ltd,1063251,,,,,,
77347,tislelizumab,"mAbs target-7 (solid/hematological cancers), BeiGene|BGB-108|PD-1 mAb (solid/hematological cancers), BeiGene|PD-1 checkpoint inhibitor (solid/hematological cancers), BeiGene|immune checkpoint inhibitor (solid/hematological cancers), BeiGene|tislelizumab|PD-1 checkpoint inhibitor (cancer), BeiGene/Novartis|BGB-A317|VDT-482",Research Code|INN|Research Code|Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Esophagus tumor|Small-cell lung cancer|Stomach tumor|Biliary cancer|Hodgkins disease|Peripheral T-cell lymphoma|Anaplastic large cell lymphoma|Angioimmunoblastic T-cell lymphoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor,1011|1261|127|1516|161|1753|1755|1758|1767|1768|1771|3257|3466|3658|3665|3666|3667|3673|3713|3866|4250|427,Metastatic lung cancer|Cancer|Solid tumor,3668|651|725,BeiGene Co Ltd|Novartis AG,1063251|23137,Celgene Corp,15331,BeiGene Co Ltd,1063251,,,,,,
77410,"dexamethasone (liposome formulation, castration resistant prostate carcinoma/multiple myeloma), Enceladus","dexamethasone|dexamethasone (liposome formulation, castration resistant prostate carcinoma), Enceladus|Oncocort|dexamethasone (liposome formulation, castration resistant prostate carcinoma/multiple myeloma), Enceladus",BANN|INN,Cancer,Phospholipase A2 inhibitor|Glucocorticoid receptor agonist,305|3191,IL-5 release inhibitor|Anticancer|IL-4 release inhibitor|IL-3 release inhibitor|IL-1 release inhibitor,4931|1545|3514|4926|219,Multiple myeloma|Hormone refractory prostate cancer,1828|3246,,,Enceladus Pharmaceuticals,1038779,,,Enceladus Pharmaceuticals,1038779,,,,,,
77588,bempegaldesleukin,"NKTR-214|bempegaldesleukin|BMS-986321|IL-2 (PEGylated, cancer), Nektar Therapeutics/BMS|ONO-7911|IL-2 (PEGylated, bladder cancer), Nektar Therapeutics/BMS|BEMPEG",Research Code|USAN|INN|Research Code|Research Code|Trade Name,Cancer|Infection,IL-2 receptor agonist|CD122 agonist,221|5425,Natural killer cell stimulator|Synergist|T-lymphocyte stimulator|Immunostimulant|Anticancer,7757|7293|7761|393|1545,Coronavirus disease 19 infection|Glioma|Sarcoma|Hematological neoplasm|Bladder cancer|Rhabdomyosarcoma|Ependymoma|Medulloblastoma|Neuroblastoma|Ewing sarcoma|Squamous cell carcinoma|Non-Hodgkin lymphoma|Merkel cell carcinoma|Hormone refractory prostate cancer|Stage III melanoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Head and neck tumor|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,10406|1108|194|2054|2380|2448|2455|2533|2726|2975|307|319|3235|3246|3256|3257|3466|3657|3665|3713|4250|623|651|725|799|989,Pancreas tumor,249,Nektar Therapeutics|Ono Pharmaceutical Co Ltd|Bristol-Myers Squibb Co,17221|18681|15065,,,Nektar Therapeutics,17221,,,,,,
77692,"CBL-0137 (iv, cancer), Incuron","CBL-0137|CBLC-137 (iv, cancer), Incuron|CBL-0137 (iv, cancer), Incuron|curaxin (iv, cancer), Incuron|CBLC-137|curaxin-137|CBL-137|CBLB-137",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Nuclear factor kappa B inhibitor|Heat shock factor protein 1 inhibitor|FACT complex inhibitor|TP53 gene stimulator,2653|33800|82240|7692,Synergist|Apoptosis inhibitor|Anticancer,7293|1590|1545,Hepatocellular carcinoma|Glioblastoma|Neuroblastoma|Soft tissue sarcoma|Cancer,1767|2454|2726|3378|651,,,Incuron LLC|Cleveland BioLabs Inc,1051583|1015134,,,Incuron LLC,1051583,,,,,,
77728,DS-3078,"DS-3078a|mTORC1/2 inhibitor (oral, cancer), Daiichi Sankyo|dual TORC1/2 inhibitor (oral, cancer), Daiichi Sankyo|DS-3078",Research Code|Research Code,Cancer,mTOR complex 2 inhibitor|mTOR complex 1 inhibitor,76096|76090,Anticancer protein kinase inhibitor,62255,,,Lymphoma|Advanced solid tumor,203|3713,,,Daiichi Sankyo Co Ltd,1017506,Daiichi Sankyo Co Ltd,1017506,,,,,,
7780,"interleukin-12, NIH","Interleukin 12 (human)|Il-12, NIH|interleukin-12, NIH",,Cancer|Infection,Interleukin 12 ligand,51207,Anticancer|Antiparasitic,1545|2638,,,Multiple myeloma|Schistosomiasis,1828|298,,,National Institutes of Health,20518,National Institutes of Health,20518,,,,,,
77804,G-305,"therapeutic vaccine (GLA adjuvanted, cancer), Immune Design|GLA-SE + melanoma antigens (cancer), Immune Design|G-305|ID-G305|IDC-G305|GLA-SE + NY-ESO-1 protein|NY-ESO-1 protein + GLA-SE|baloramotide",Research Code|Research Code|Research Code|INN,Cancer|Immune,Cancer testis antigen NY-ESO-1 modulator|TLR-4 agonist,50096|7812,Anticancer|Adjuvant|Therapeutic vaccine,1545|524|12379,,,Vaccination|Cancer,384|651,,,Immune Design Corp,1040366,Immune Design Corp,1040366,,,,,,
77919,tirabrutinib hydrochloride,"ONO-4059|GS-4059|tirabrutinib hydrochloride|tirabrutinib|Btk tyrosine kinase inhibitor (oral/tablet/capsule, B-cell malignancies/autoimmune diseases), Ono Pharmaceutical/Gilead|Velexbru",Research Code|Research Code|INN|Trade Name,Cancer|Dermatologic|Immune,Btk tyrosine kinase inhibitor,3592,Synergist|Anticancer protein kinase inhibitor|Anti-inflammatory,7293|62255|2953,Scleroderma|Pemphigus|Lymphoplasmacytic lymphoma|Urticaria|Central nervous system tumor,1105|1114|1743|340|759,Sjoegrens syndrome|Chronic lymphocytic leukemia|Rheumatoid arthritis|B-cell lymphoma|Systemic lupus erythematosus|Non-Hodgkin lymphoma|Autoimmune disease,1148|1734|291|316|318|319|36,Gilead Sciences Inc|Ono Pharmaceutical Co Ltd,16450|18681,,,Ono Pharmaceutical Co Ltd,18681,,,,,,
77963,WT-2725,WT-2725,,Cancer,Wilms tumor protein modulator,30009,T-lymphocyte stimulator|Protein subunit vaccine|Anticancer|Therapeutic vaccine,7761|12372|1545|12379,Hematological neoplasm|Solid tumor,2054|725,Cancer,651,Sumitomo Dainippon Pharma Co Ltd,1017117,Chugai Pharmaceutical Co Ltd,15414,Sumitomo Dainippon Pharma Co Ltd,1017117,,,,,,
78007,JCAR-014,"anti-CD19 CAR autologous T-cell therapy (B-cell malignancies), NCI|anti-CD19 CAR T-cell therapy (B-cell malignancies), NCI|anti-CD19 autologous T-cell therapy (B-cell malignancies), National Cancer Institute|JCAR-014|anti-CD19 CAR T-cell therapy (cancer), Juno Therapeutics",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy|Immunostimulant,7761|1545|4790|393,,,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Hematological neoplasm|Non-Hodgkin lymphoma,1728|1734|2054|319,,,Juno Therapeutics Inc|Celgene Corp|National Cancer Institute (NCI),1090676|15331|20519,Juno Therapeutics Inc,1090676,,,,,,
7810,"trifluridine + tipiracil hydrochloride (oral), Taiho","MUP-98156 + F3dThd, Taiho|trifluridine + MUP-98156 (oral combination), Taiho|TAS-102|trifluridine + MUP-98156|trifluridine + tipiracil hydrochloride (oral), Taiho|trifluridine + tipiracil  hydrochloride|Lonsurf|S-95005|Orcantas",Research Code|Research Code|Research Code|Trade Name,Cancer,Thymidylate synthase inhibitor|Thymidine phosphorylase inhibitor,372|6679,Nucleic acid metabolism modulator|Angiogenesis inhibitor|Anticancer|DNA synthesis inhibitor,1758|61|1545|140,Biliary cancer|Cholangiocarcinoma|Bladder cancer|Adenocarcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer,1516|1765|2380|2399|3658|3665|3666|3667|3669,Small-cell lung cancer|Cancer|Colorectal tumor,1261|651|989,Jeil Pharmaceutical Co Ltd|Taiho Pharmaceutical Co Ltd|Servier|Taiho Oncology Inc|TTY Biopharm Co Ltd,17331|18720|19863|1092741|29954,,,Taiho Pharmaceutical Co Ltd,18720,,,,,,
78215,vactosertib,"TGF-beta type 1 receptor kinase inhibitors (metastasis/fibrosis), Ewha|EW-7197|NOV-130101|ALK-5 modulator (solid tumor), National OncoVenture|NOV-1301|TGF-beta type 1 receptor kinase inhibitors (metastasis/fibrosis/solid tumor), MedPacto|TEW-7197|vactosertib",Research Code|Research Code|Research Code|Research Code|USAN|INN,Cancer|Inflammatory,Alk-5 protein kinase inhibitor,4588,Synergist|Anti-inflammatory|Fibrosuppressant|Metastasis inhibitor|Anticancer|Anticancer protein kinase inhibitor,7293|2953|664|695|1545|62255,Myelodysplastic syndrome|Hepatocellular carcinoma|Transitional cell carcinoma|Multiple myeloma|Bladder cancer|Pancreas tumor|Stage IV melanoma|Aggressive fibromatosis|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Urethral cancer|Advanced solid tumor|Ureter cancer|Lung tumor,1272|1767|1771|1828|2380|249|3257|3504|3657|3658|3664|3665|3666|3667|3678|3713|4265|755,Metastasis|Fibrosis|Solid tumor,1069|1127|725,MedPacto Inc|National OncoVenture,1097085|1072620,Ewha Womans University,1008023,Ewha Womans University,1008023,,,,,,
78298,E-10A,"adeno virus based recombinant human endostatin gene therapy (cancer), Guangzhou Doublle Bioproducts/Sun Yat-Sen University|E-10A|recombinant human endostatin adenovirus (cancer), Guangzhou Doublle Bioproducts/Sun Yat-Sen University",Research Code,Cancer,Endostatin modulator,49940,Apoptosis stimulator|Adenovirus based gene therapy|Synergist|Anticancer|Angiogenesis inhibitor,1589|4780|7293|1545|61,Nasopharyngeal carcinoma|Head and neck tumor|Cancer,1768|623|651,Solid tumor,725,Guangzhou Doublle Bioproducts Co Ltd|Guangzhou Xintaida Biotechnology Co Ltd|Marsala Biotech Inc,1059755|1187106|1070402,Sun Yat-Sen University,1004360,Guangzhou Doublle Bioproducts Co Ltd,1059755,,,,,,
78484,"bevacizumab biosimilar, Boehringer Ingelheim","bevacizumab|BI-695502|bevacizumab biosimilar, Boehringer Ingelheim",INN|Research Code,Cancer,VEGF ligand inhibitor,12521,Angiogenesis inhibitor|Anticancer monoclonal antibody,61|55685,Non-small-cell lung cancer|Metastatic colorectal cancer,1262|3658,Cancer|Colorectal tumor,651|989,Boehringer Ingelheim International GmbH,14881,,,Boehringer Ingelheim International GmbH,14881,,,,,,
78554,"multiple HLA-A2402 restricted epitope peptide vaccine (sc, NSCLC), University of Tokyo/OncoTherapy Science","Multiple peptide vaccine (metastatic NSCLC), OncoTherapy science/Tokyo University|URLC10 + TTK + VEGFR1 + VEGFR2-derived HLA-A2402 restricted epitope peptide multiple vaccine (NSCLC), University of Tokyo|multiple HLA-A2402 restricted epitope peptide vaccine (sc, NSCLC), University of Tokyo/OncoTherapy Science",,Cancer,VEGF-1 receptor modulator|VEGF-2 receptor modulator|TTK gene modulator,3845|3847|49901,Anticancer|Protein subunit vaccine|Therapeutic vaccine,1545|12372|12379,,,Metastatic non small cell lung cancer|Breast tumor,3665|49,,,OncoTherapy Science Inc|University of Tokyo,1004292|20686,University of Tokyo,20686,,,,,,
78615,MED-1007,"EGFR inhbitors (lung cancer), Medolution|MED-1007|ML-007|kenaitinib|TL-007|keynatinib",Research Code|Research Code|Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor,62255,B-cell lymphoma|Metastatic non small cell lung cancer,316|3665,Lung tumor,755,MedoLution Ltd,1058673,Logix Pharmaceuticals Inc,1109147,MedoLution Ltd,1058673,,,,,,
7871,pirfenidone,"AMR-69|Deskar|pirfenidone|S-7701|p38 MAP kinase inhibitor (oral, fibrosis/ multiple sclerosis), Marnac/ InterMune|Esbriet|Pirespa|RG-6062|RO-0220912|S-770108",Research Code|Trade Name|USAN|INN|Research Code|Trade Name|Trade Name|Research Code|Research Code|Research Code,Cancer|Cardiovascular|Hematologic|Immune|Inflammatory|Respiratory,PDGF receptor antagonist|TGF beta receptor antagonist|p38 MAP kinase inhibitor,948|377|2419,Fibrosuppressant|Anticancer|Collagen synthesis inhibitor|TNF alpha synthesis inhibitor|Anti-inflammatory,664|1545|124|382|2953,Interstitial lung disease|Lung transplantation|Idiopathic pulmonary fibrosis|Cardiac failure,2466|2985|3771|55,Scleroderma|Fibrosis|Multiple sclerosis|Hermansky-Pudlak syndrome|Neurofibromatosis,1105|1127|213|2277|2465,Roche Holding AG|Ildong Pharmaceutical Co Ltd|Shionogi & Co Ltd,19446|17101|19898,Marnac Inc|Bayer Schering Pharma AG|InterMune Inc,17947|19687|26430,Marnac Inc,17947,,,,,,
78796,"filgrastim biosimilar, ratiopharm","filgrastim|filgrastim biosimilar, ratiopharm|Ratiograstim",USAN|BAN|INN|Trade Name,Hematologic,GCSF receptor agonist|GCSF ligand,3151|52970,Neutrophil stimulator|Hematopoietic stimulator,7759|610,Neutropenia,1991,,,ratiopharm GmbH,18186,,,ratiopharm GmbH,18186,,,,,,
7880,biricodar,biricodar|VX-710|Incel|VX-710-3|biricodar dicitrate,INN|Research Code|Trade Name|Analogue|Research Code|USAN,Cancer,,,Anticancer chemosensitizer|Anticancer multidrug resistance inhibitor|Unspecified drug target,1586|759|59620,,,Small-cell lung cancer|Sarcoma|Prostate tumor|Breast tumor|Ovary tumor,1261|194|276|49|799,,,BioChem Therapeutic Inc|Vertex Pharmaceuticals Inc|Shire plc,14692|20739|24652,Vertex Pharmaceuticals Inc,20739,,,,,,
78809,birabresib dihydrate,"OTX-015|BRD 2/3/4 selective inhibitor (oral, cancer), OncoEthix|Y-803 (hematological cancer), OncoEthix|Y-803|birabresib dihydrate|birabresib|MK-8628",Research Code|Research Code|USAN|PINN|Research Code,Cancer,Bromodomain containing protein 3 inhibitor|Bromodomain containing protein 2 inhibitor|Bromodomain containing protein 4 inhibitor,34567|34564|34570,Anticancer,1545,,,Acute myelogenous leukemia|Hematological neoplasm|Glioblastoma|Advanced solid tumor|Cancer,1731|2054|2454|3713|651,,,Mitsubishi Tanabe Pharma Corp|OncoEthix|Merck & Co Inc,1035060|1047043|18077,Mitsubishi Tanabe Pharma Corp,1035060,,,,,,
78816,"filgrastim biosimilar, Teva/Nippon Kayaku","filgrastim|XM-02|filgrastim biosimilar, Teva|Neutroval|Filgrastim-Teva|Filgrastim-Mepha|filgrastim biosimilar, Teva/Nippon Kayaku|Tevagrastim|TKN-732|tbo-filgrastim|Granix",USAN|BAN|INN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name,Hematologic|Immune,GCSF receptor agonist|GCSF ligand,3151|52970,Hematopoietic stimulator|Neutrophil stimulator,610|7759,Neutropenia|Hematopoietic stem cell transplantation,1991|3888,,,Mepha Pharma AG|Aspen PharmaCare Australia Pty Ltd|Nippon Kayaku Co Ltd|Teva Pharmaceutical Industries Ltd,24287|1019376|18535|20348,,,Teva Pharmaceutical Industries Ltd,20348,,,,,,
78822,"EGFR BATs (solid tumor), Roger Williams Medical Center/Barbara Ann Karmanos Cancer Institute/University of Virginia","EGFRBi-armed activated autologous T cells (solid tumors), Roger Williams Medical Center/Barbara Ann Karmanos Cancer Institute/University of Virginia|anti-CD3/anti-EGFR bispecific T-cell engager-armed activated autologous T cells (solid tumors), Roger Williams Medical Center/Barbara Ann Karmanos Cancer Institute/University of Virginia|EGFR BATs (solid tumor), Roger Williams Medical Center/Barbara Ann Karmanos Cancer Institute/University of Virginia|anti-CD3 and anti-EGFR bispecific antibody-armed activated autologous T cells (solid tumors), Roger Williams Medical Center/Barbara Ann Karmanos Cancer Institute/University of Virginia|anti-CD3/EGFR antibody armed autologous T cells (solid tumors), Roger Williams Medical Center/Barbara Ann Karmanos Cancer Institute/University of Virginia|anti-CD3/EGFR antibody-armed T cells (solid tumors), Roger Williams Medical Center/Barbara Ann Karmanos Cancer Institute/University of Virginia|autologous T cells (solid tumors), Barbara Ann Karmanos Cancer Institute|solid tumor therapy, Barbara Ann Karmanos Cancer Institute",Research Code,Cancer,Epidermal growth factor receptor modulator|CD3 modulator,3605|5023,Anticancer antibody|Immunostimulant|T-lymphocyte stimulator|Anticancer,55684|393|7761|1545,Glioblastoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Solid tumor,2454|3658|3665|3669|725,,,Barbara Ann Karmanos Cancer Institute|University of Virginia|Roger Williams Medical Center,14383|20695|28132,,,Barbara Ann Karmanos Cancer Institute,14383,,,,,,
78828,"bevacizumab biosimilar, Prestige BioPharma","undisclosed biosimilar (rectum cancer), Hanwha Chemical|HD-204|bevacizumab biosimilar, Prestige BioPharma",Research Code,Cancer,VEGF ligand inhibitor,12521,Anticancer monoclonal antibody|Anti-inflammatory|Angiogenesis inhibitor,55685|2953|61,Metastatic non small cell lung cancer|Solid tumor,3665|725,Rectal tumor,1055,Huons Co Ltd|Prestige Biopharma,1023043|1141975,Hanwha Corp,22805,Hanwha Corp,22805,,,,,,
78830,124I-zelavespib,"124I-zelavespib|Hsp-90-targeted PET imaging agent (cancer), Memorial Sloan-Kettering Cancer Center|zelavespib-124-PUH-71|zelavespib-[124I]",Research Code|Research Code|Research Code,Cancer|Neurology/Psychiatric,Hsp 90 modulator,8010,PET contrast agent|Radiodiagnostic|Neoplasm diagnostic agent|CNS diagnostic agent,5555|5720|7220|7211,Alzheimers disease|Cancer,14|651,,,Samus Therapeutics Inc|Memorial Sloan-Kettering Cancer Center,1106247|22122,,,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
78878,18F-AlF-NOTA-PRGD2,"18F-AlF-NOTA-PRGD2|alphaV-beta3 integrin receptor-targeted PET imaging agent (cancer), National Institutes of Health|Fluorine-18-AlF-NOTA-PRGD2|AlF-NOTA-PRGD2-[18F]",Research Code,Cancer,Integrin alpha-V/beta-3 modulator,6063,PET contrast agent|Radiodiagnostic|Neoplasm diagnostic agent,5555|5720|7220,Cancer,651,,,National Institutes of Health,20518,,,National Institutes of Health,20518,,,,,,
78894,"trastuzumab biosimilar, Pfizer","trastuzumab|PF-05280014|trastuzumab biosimilar, Pfizer|Trazimera|trastuzumab-qyyp|Trastuzumab BS, Pfizer",INN|Research Code|Trade Name|Trade Name,Cancer,Erbb2 tyrosine kinase receptor inhibitor,3756,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,Metastatic breast cancer|Metastatic stomach cancer|Breast tumor,3657|3666|49,,,Pfizer Inc,18767,Pfizer Japan Inc,18801,Pfizer Inc,18767,,,,,,
78939,"bevacizumab biosimilar, Celltrion","bevacizumab|CT-P16|bevacizumab biosimilar, Celltrion",INN|Research Code,Cancer,VEGF ligand inhibitor,12521,Angiogenesis inhibitor|Anticancer monoclonal antibody,61|55685,Metastatic colorectal cancer|Metastatic non small cell lung cancer|Cancer,3658|3665|651,,,Celltrion Inc,1015645,,,Celltrion Inc,1015645,,,,,,
78947,"rituximab biosimilar, Celltrion/ Mundipharm/ Teva/ Nippon Kayaku","rituximab|CT-P10|Celltrion rituximab|Truxima|rituximab biosimilar, Celltrion/ Mundipharm/ Teva/ Nippon Kayaku|Blitzima|Tuxella|Ritemvia|rituximab-abbs",USAN|BANN|INN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name,Cancer|Cardiovascular|Immune|Inflammatory,B-lymphocyte antigen CD20 inhibitor,5085,Anticancer monoclonal antibody|Anti-inflammatory,55685|2953,Vasculitis|Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Wegener granulomatosis|Neoplasm|Rheumatoid arthritis|Non-Hodgkin lymphoma,1532|1734|1745|1749|1888|230|291|319,,,Vcell Healthcare Limited|Celltrion Inc|Orion Corp|Nippon Kayaku Co Ltd|Teva Pharmaceutical Industries Ltd|Mundipharma International Corp Ltd|Hikma Pharmaceuticals plc,1190985|1015645|18693|18535|20348|1045514|1022379,,,Celltrion Inc,1015645,,,,,,
78948,"erythropoietin biosimilar, Hospira/Pfizer","Erythropoietin-zeta|erythropoietin biosimilar, Hospira/Pfizer|Retacrit|epoetin zeta|Epoetin Hospira|B-03XA01",Trade Name|INN|Trade Name|Research Code,Genitourinary/Sexual Function|Hematologic,Erythropoietin ligand|Erythropoietin receptor agonist,12162|2501,Hematopoietic stimulator,610,Anemia|Renal injury,17|3108,,,Vifor Pharma Ltd|Hospira Inc,16268|1010293,,,Hospira Inc,1010293,,,,,,
79018,PEG-BCT-100,"PEG-BCT-100|rhArg-peg|rhArgI-peg5000|pegylated recombinant human arginase (cancer), Bio-Cancer Treatment International",Research Code,Cancer|Ocular,Arginase stimulator,7085,Anticancer,1545,Glioma|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Renal cell carcinoma|Hepatocellular carcinoma|Sarcoma|Neuroblastoma|Retinopathy|Hormone refractory prostate cancer|Stage IV melanoma|Advanced solid tumor|Cancer,1108|1728|1731|1766|1767|194|2726|288|3246|3257|3713|651,Leukemia|Lymphoma,199|203,Bio-Cancer Treatment International Ltd|Bio-Cancer Treatment (Shanghai) Co Ltd,1006274|1073114,,,Bio-Cancer Treatment International Ltd,1006274,,,,,,
79036,CT-1530,"leukemia therapy, Centaurus Biopharma|Target-3|CT-1530",Research Code|Research Code,Cancer,Btk tyrosine kinase inhibitor,3592,Anticancer protein kinase inhibitor,62255,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|B-cell lymphoma,1734|1743|1744|316,,,Centaurus BioPharma Co Ltd,1069948,,,Centaurus BioPharma Co Ltd,1069948,,,,,,
79064,"bevacizumab biosimilar, Mylan/Biocon","bevacizumab|bevacizumab biosimilar, Mylan/Biocon|MYL-1402O|KRABEVA|Abevmy",INN|Research Code|Trade Name|Trade Name,Cancer,VEGF ligand inhibitor,12521,Angiogenesis inhibitor|Anticancer monoclonal antibody,61|55685,Unidentified indication|Non-small-cell lung cancer|Glioblastoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Cancer|Brain tumor|Ovary tumor|Renal tumor,1005|1262|2454|3657|3658|4250|427|651|760|799|999,,,Biocon Ltd|Mylan NV,28769|18439,,,Biocon Ltd,28769,,,,,,
79178,ADCT-602,"antibody-drug conjugates (cancer), ADC Therapeutics/ Cancer Research Technology|ADCT-602|Epratuzumab-cys-SG3249|hLL2-cys-SG3249|antibody-drug conjugates (cancer/B-cell acute lymphoblastic leukemia), ADC Therapeutics/ Cancer Research Technology",Research Code,Cancer,B-lymphocyte cell adhesion molecule inhibitor,5091,Anticancer antibody,55684,B-cell acute lymphoblastic leukemia|Cancer,1729|651,,,Cancer Research Technology Ltd|ADC Therapeutics Sarl|Overland ADCT BioPharma (CY) Limited,30620|1068935|1232531,,,ADC Therapeutics Sarl,1068935,,,,,,
79242,itacitinib,INCB-039110|INCB-39110|itacitinib|itacitinib adipate|INCB039110 adipate|IBI-377,Research Code|Research Code|USAN|INN|USAN|Research Code,Cancer|Dermatologic|Gastrointestinal|Hematologic|Immune|Inflammatory|Respiratory,Jak1 tyrosine kinase inhibitor,3562,Bronchodilator|Apoptosis stimulator|Anticancer protein kinase inhibitor|Systemic antipsoriatic product|Anti-inflammatory|Anticancer,646|1589|62255|15184|2953|1545,Non-small-cell lung cancer|Diffuse large B-cell lymphoma|Hepatocellular carcinoma|Thrombocythemia|Polycythemia vera|Myelofibrosis|Leiomyosarcoma|Liposarcoma|Cutaneous lupus erythematosus|Bronchiolitis|B-cell lymphoma|Systemic inflammatory response syndrome|Stage IV melanoma|Soft tissue sarcoma|Metastatic non small cell lung cancer|Advanced solid tumor|Graft versus host disease,1262|1749|1767|2317|2319|2436|2446|2447|2559|2976|316|3220|3257|3378|3665|3713|616,Hodgkins disease|Psoriasis|Rheumatoid arthritis|Ulcerative colitis|Metastatic pancreas cancer,161|281|291|337|3669,Incyte Corp|Innovent Biologics Inc,17216|1070750,,,Incyte Corp,17216,,,,,,
79273,"filgrastim biosimilar, Hospira/Pfizer","filgrastim|filgrastim follow-on biologic, PLIVA|filgrastim biosimilar, Hospira/Pfizer|Nivestim|Nivestym|filgrastim-aafi",USAN|BAN|INN|Trade Name|Trade Name,Hematologic,GCSF receptor agonist|GCSF ligand,3151|52970,Neutrophil stimulator|Hematopoietic stimulator,7759|610,Neutropenia|Febrile neutropenia,1991|3795,,,Hospira Inc,1010293,Mayne Pharma Group Ltd|Barr Pharmaceuticals Inc|PLIVA dd,1037040|14354|19117,PLIVA dd,19117,,,,,,
7934,"doxorubicin (liposomal, STEALTH), Alza","doxorubicin|S-DOX|Caelyx|DOX-SL|SL-Dox|doxorubicin HCl|STEALTH (doxorubicin)|doxorubicin, ALZA/Schering|doxorubicin (liposomal, STEALTH), Alza|Doxil|doxorubicin hydrochloride|pegylated liposomal doxorubicin|JNS-002|NSC-712227",USAN|BAN|INN|Trade Name|Research Code|Trade Name|USAN|Research Code|Research Code,Cancer,DNA polymerase inhibitor|Topoisomerase II inhibitor,138|142,DNA intercalator|Anticancer,750|1545,Multiple myeloma|Metastatic breast cancer|Cancer|Ovary tumor|Kaposis sarcoma,1828|3657|651|799|936,Non-small-cell lung cancer|Hepatocellular carcinoma|Leukemia|Prostate tumor|T-cell lymphoma|Soft tissue sarcoma|Metastatic renal cancer|Metastatic colorectal cancer|Breast tumor|Head and neck tumor,1262|1767|199|276|311|3378|3467|3658|49|623,Janssen-Cilag Ltd|SEQUUS Pharmaceuticals Inc|Baxter International Inc|Mochida Pharmaceutical Co Ltd,17392|26337|14437|18278,ALZA Corp|Johnson & Johnson|Ortho Biotech Products LP|Merck & Co Inc|Schering-Plough Corp,14095|17332|17570|18077|19711,SEQUUS Pharmaceuticals Inc,26337,,,,,,
79389,"anti-MiHA donor T-lymphocytes (cancer), IRIC/HMR/Universite de Montreal/SpecificiT","immunodominant minor histocompatibility antigens (cancer), Institute for Research in Immunology and Cancer|anti-minor histocompatibility complex donor T-lymphocytes (cancer), IRIC/ Hopital Maisonneuve-Rosemont/Universite de Montreal/SpecificiT|anti-MiHA donor T-lymphocytes (cancer), IRIC/HMR/Universite de Montreal/SpecificiT",,Cancer,,,Immunostimulant|T-lymphocyte stimulator|Anticancer,393|7761|1545,Cancer,651,,,Hopital Maisonneuve-Rosemont|IRICoR|SpecificiT Pharma Inc|Universite De Montreal|Institute for Research in Immunology and Cancer,1014786|1066466|1153689|21280|1067253,,,Institute for Research in Immunology and Cancer,1067253,,,,,,
79391,"rituximab biosimilar, Sandoz","rituximab|rituximab biosimilar, Sandoz|GP-2013|Rixathon|Riximyo|Rituximab BS",USAN|BANN|INN|Research Code|Trade Name|Trade Name,Cancer|Cardiovascular|Hematologic|Immune|Inflammatory,B-lymphocyte antigen CD20 inhibitor,5085,Anticancer monoclonal antibody|Anti-inflammatory,55685|2953,Vasculitis|Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Wegener granulomatosis|Rheumatoid arthritis|Non-Hodgkin lymphoma|Idiopathic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura,1532|1734|1745|1749|1888|291|319|7642|9342,,,Sandoz International GmbH|Novartis AG|Kyowa Hakko Kirin Co Ltd,1017404|23137|1042596,,,Sandoz International GmbH,1017404,,,,,,
79437,"filgrastim biosimilar, Sandoz","filgrastim|EP-2006|filgrastim biosimilar, Sandoz|Zarzio|Filgrastim Hexal|filgrastim biosimilar, Hexal|Zarxio|Filgrastim BS|filgrastim-sndz",USAN|BAN|INN|Research Code|Trade Name|Trade Name|Trade Name,Hematologic|Immune,GCSF receptor agonist|GCSF ligand,3151|52970,Neutrophil stimulator|Hematopoietic stimulator,7759|610,Neutropenia|Stem cell transplantation,1991|2990,,,Sawai Pharmaceutical Co Ltd|Sandoz International GmbH,19683|1017404,,,Sandoz International GmbH,1017404,,,,,,
79510,DCR-M1711,"anti-Myc DsiRNAs (cancer), Dicerna|DCR-M1711|DCR-MYC",Research Code|Research Code,Cancer,Myc proto-oncogene protein inhibitor,14615,siRNA agent|Anticancer,26035|1545,,,Hepatocellular carcinoma|Cancer|Solid tumor,1767|651|725,,,Dicerna Pharmaceuticals Inc,1040605,Dicerna Pharmaceuticals Inc,1040605,,,,,,
79749,tisagenlecleucel,"anti-CD19-CAR-transduced autologous T cells (B-cell leukemia/lymphoma), Abramson Cancer Center of the University of Pennsylvania|CART-19|anti-CD19 CAR T-cell therapy (B-cell leukemia/lymphoma), Novartis|CTL-019|tisagenlecleucel-T|tisagenlecleucel|Kymriah",Research Code|Research Code|USAN|USAN|INN|Trade Name,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Anticancer,393|7761|4790|1545,Hodgkins disease|Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|High grade B-cell lymphoma|Multiple myeloma|Lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Central nervous system tumor,161|1728|1729|1745|1749|1751|1828|203|316|319|759,Chronic lymphocytic leukemia|Mantle cell lymphoma|Leukemia,1734|1744|199,Abramson Cancer Center of the University of Pennsylvania|Novartis AG,1053899|23137,,,Abramson Cancer Center of the University of Pennsylvania,1053899,,,,,,
7975,Annamycin,"Annamycin|AR-522|anthracycline, Aronex|anthracycline, Callisto|Annamycin LF|L-Annamycin|Liposomal Annamycin",Research Code,Cancer,,,Anticancer|Synergist|DNA intercalator,1545|7293|750,Acute lymphoblastic leukemia|Acute myelogenous leukemia|Osteosarcoma|Soft tissue sarcoma|Metastatic lung cancer|Breast tumor|Colorectal tumor,1728|1731|1772|3378|3668|49|989,Small-cell lung cancer|Chronic myelocytic leukemia|Melanoma,1261|1735|205,Dermin Spzoo|Moleculin Biotech Inc,1119588|1040651,AnnaMed Inc|Aronex Pharmaceuticals Inc|MD Anderson Cancer Center|Callisto Pharmaceuticals Inc,1115512|22276|23382|29619,MD Anderson Cancer Center,23382,,,,,,
79764,"bevacizumab biosimilar, SPH-BIOCAD (HK)/Biocad","bevacizumab|bevacizumab biosimilar, Biocad/Hengrui Medicine|BCD-021|bevacizumab biosimilar, SPH-BIOCAD (HK)/Biocad",INN|Research Code,Cancer|Ocular,VEGF ligand inhibitor,12521,Anticancer monoclonal antibody|Angiogenesis inhibitor,55685|61,Metastatic colorectal cancer|Metastatic non small cell lung cancer,3658|3665,Wet age related macular degeneration|Colorectal tumor,3354|989,Biocad Ltd|SPH-BIOCAD (HK) Limited,1035286|1250828,Jiangsu Hengrui Medicine Co Ltd,1006925,Biocad Ltd,1035286,,,,,,
79786,DTRM-505,"mTOR inhibitor (undisclosed indication), DTRM BIOPHARMA|DTRM-505",Research Code,Cancer,Btk tyrosine kinase inhibitor|mTOR inhibitor,3592|10240,Anticancer protein kinase inhibitor,62255,Chronic lymphocytic leukemia|B-cell lymphoma|Non-Hodgkin lymphoma,1734|316|319,,,DTRM Biopharma Co Ltd,1071880,,,DTRM Biopharma Co Ltd,1071880,,,,,,
79899,ICT-1001,"semi-allogenic tumor DNA-transfected human MRC-5 fibroblast vaccine (non-small cell lung cancer), Immune Cell Therapy Inc/University of Pittsburgh|DNA-transfected MRC-5 fibroblast vaccine (NSCLC), Immune Cell Therapy Inc/University of Pittsburgh|ICT-1001",Research Code,Cancer,,,Therapeutic vaccine|Anticancer,12379|1545,,,Non-small-cell lung cancer,1262,,,UC San Diego Moores Cancer Center|Immune Cell Therapy Inc|Baylor College of Medicine|University of Pittsburgh|MD Anderson Cancer Center,1061569|1071882|20534|20659|23382,University of Pittsburgh,20659,,,,,,
79933,samotolisib,"LY-3023414|PI3 kinase/mTOR dual inhibitor (cancer), Eli Lilly|samotolisib",Research Code|USAN|INN,Cancer,mTOR inhibitor|Phosphoinositide 3-kinase inhibitor,10240|1575,Anticancer protein kinase inhibitor|Synergist,62255|7293,,,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Endometrioid carcinoma|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Metastatic breast cancer|Cancer|Solid tumor,1262|1507|1705|319|3246|3657|651|725,,,Eli Lilly & Co,17810,Eli Lilly & Co,17810,,,,,,
79986,BMS-986012,"anti-fucosyl GM1 (oncology), Bristol-Myers Squibb|anti-fucosyl GM1 antibody (cancer), BMS|BMS-986012",Research Code,Cancer,,,Ganglioside GM1 modulator|Anticancer monoclonal antibody,16791|55685,Small-cell lung cancer,1261,Cancer,651,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
80087,"pegfilgrastim biosimilar, Jiangsu Hengrui","pegfilgrastim biosimilar, Jiangsu Hengrui|19K|mecapegfilgrastim|HHPG-19K|Aiduo",Research Code|INN|Research Code|Trade Name,Hematologic,GCSF receptor agonist,3151,Hematopoietic stimulator,610,Neutropenia,1991,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,,,,
80138,"auranofin (oral, chronic lymphocytic leukemia), University of Kansas Medical Center/The Leukemia and Lymphoma Society/NIH","auranofin|auranofin (oral, chronic lymphocytic leukemia), University of Kansas Medical Center/The Leukemia and Lymphoma Society/NIH",USAN|BANN|INN,Cancer,,,Anticancer,1545,,,Chronic lymphocytic leukemia,1734,,,The Leukemia & Lymphoma Society|National Institutes of Health|University of Kansas Medical Center,1038741|20518|27708,University of Kansas Medical Center,27708,,,,,,
80172,"allogeneic anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia), University College London","CD19-specific EBV-CTL therapy (acute lymphoblastic leukemia), University College London|CD19 chimeric antigen receptor immunotherapy (acute lymphoblastic leukemia), University College London|CD19-targeted Epstein-Barr virus-specific cytotoxic T-lymphocytes (acute lymphoblastic leukemia), University College London|CD19-zeta chimeric receptor-transduced donor-derived EBV-CTLs (acute lymphoblastic leukemia), University College London|allogeneic anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia), University College London",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,Diffuse large B-cell lymphoma,1749,B-cell acute lymphoblastic leukemia|Cancer,1729|651,University College London,23505,,,University College London,23505,,,,,,
80187,"autologous cytotoxic T-cells + IL2 + GM-CSF combination therapy (multiple myeloma), Dartmouth-Hitchcock Medical Center","autologous cytotoxic T-cells + IL2 + GM-CSF combination therapy (multiple myeloma), Dartmouth-Hitchcock Medical Center|cytotoxic T cells + IL-2 + GM-CSF combination therapy (multiple myeloma), Dartmouth-Hitchcock Medical Center/The Leukemia and Lymphoma Society",,Cancer,,,Anticancer|T-lymphocyte stimulator,1545|7761,,,Multiple myeloma,1828,,,The Leukemia & Lymphoma Society|Dartmouth-Hitchcock Medical Center,1038741|30837,Dartmouth-Hitchcock Medical Center,30837,,,,,,
8023,romidepsin,"depsipeptide, NCI/Fujisawa|romidepsin|Istodax",Research Code|USAN|INN|Trade Name,Cancer,Histone deacetylase inhibitor,2574,Apoptosis stimulator|Cell cycle inhibitor|Synergist|Anticancer,1589|767|7293|1545,Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Metastatic breast cancer,1753|1754|3657,Non-small-cell lung cancer|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Multiple myeloma|Pancreas tumor|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Cancer|Colorectal tumor,1262|1731|1734|1828|249|319|3246|3673|3713|4250|651|989,Celgene Corp|Bristol-Myers Squibb Co,15331|15065,Gloucester Pharmaceuticals Inc|Fujisawa Pharmaceutical Co Ltd,1007694|16227,Fujisawa Pharmaceutical Co Ltd,16227,,,,,,
8047,bevacizumab,"bevacizumab|R-435|rhuMAb-VEGF, Genentech|anti-VEGF antibody, Genentech|Avastin|G6-31|G6.31|RG-435|NSC-704865|Altuzan|RO-4876646",INN|Research Code|Trade Name|Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code,Cancer|Neurology/Psychiatric|Ocular,VEGF ligand inhibitor,12521,Anti-inflammatory|Anticancer|Anticancer monoclonal antibody|Angiogenesis inhibitor,2953|1545|55685|61,Glioma|Small-cell lung cancer|Endometrioid carcinoma|Hepatocellular carcinoma|Sarcoma|Fallopian tube cancer|Glioblastoma|Neuroblastoma|Ewing sarcoma|Peritoneal tumor|Stage IV melanoma|Metastatic brain cancer|Neurofibromatosis type II|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Cerebral edema|Ovary tumor|Colorectal tumor,1108|1261|1705|1767|194|2243|2454|2726|2975|3083|3257|3471|3522|3657|3658|3665|3666|3669|3866|4250|427|63|799|989,Neuroendocrine tumor|Age related macular degeneration|Mesothelioma|Non-small-cell lung cancer|Myelodysplastic syndrome|Biliary cancer|Hodgkins disease|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Renal cell carcinoma|Multiple myeloma|Liver tumor|Melanoma|Neuromyelitis optica|Pancreas tumor|Carcinoid tumor|Meningioma|B-cell lymphoma|Gastrointestinal stromal tumor|Hormone refractory prostate cancer|Metastatic bladder cancer|Metastatic head and neck cancer|Germ cell and embryonic cancer|Breast tumor|Genitourinary tract tumor|Solid tumor|Colon tumor,1128|1226|1240|1262|1272|1516|161|1734|1749|1766|1828|202|205|2316|249|2538|2802|316|3205|3246|3466|3673|3737|49|613|725|767,Cipla Ltd|Chugai Pharmaceutical Co Ltd|Genentech Inc|F Hoffmann-La Roche AG|Roche Holding AG,15503|15414|19453|26178|19446,,,Genentech Inc,19453,,,,,,
8050,"thalidomide, Bristol-Myers Squibb","thalidomide|Thalomid|Synovir|Thalidomide Pharmion|Thalidomide Celgene|thalidomide, Bristol-Myers Squibb|CC-2001",USAN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Research Code,Cancer|Dermatologic|Endocrine/Metabolic|Gastrointestinal|Hematologic|Immune|Inflammatory|Neurology/Psychiatric,,,Anticancer|Anti-inflammatory|Antibacterial|Angiogenesis inhibitor|TNF alpha synthesis inhibitor|Immunomodulator,1545|2953|1594|61|382|1596,Multiple myeloma|Erythema nodosum leprae,1828|3584,AIDS related complex|Amyloidosis|Small-cell lung cancer|Macroglobulinemia|Myelodysplastic syndrome|Chronic lymphocytic leukemia|Hepatocellular carcinoma|Inflammatory disease|Pain|Melanoma|Glioblastoma|Prostate tumor|Rheumatoid arthritis|Ulcerative colitis|Metastatic renal cell carcinoma|Behcets disease|Crohns disease|Colorectal tumor,10|1143|1261|1264|1272|1734|1767|188|20|205|2454|276|291|337|4250|768|84|989,Bristol-Myers Squibb Co,15065,Celgene Corp|Pharmion Corp,15331|29253,Celgene Corp,15331,,,,,,
80571,MS-20,MS-20|MicroSoy-20|Chemo Young,Research Code|Trade Name,Cancer|Other/Miscellaneous,,,Immunomodulator|Antioxidant agent|Anticancer|Natural killer cell stimulator|Antimicrobial,1596|74|1545|7757|1593,Cancer,651,Fever|Liver tumor,1833|202,Microbio Co Ltd,1013008,,,Microbio Co Ltd,1013008,,,,,,
80635,"irinotecan hydrochloride (liposome formulation, cancer/advanced solid tumor), Luye Pharma Group","irinotecan hydrochloride|irinotecan|LY-01610|irinotecan hydrochloride (liposome formulation, cancer/advanced solid tumor), Luye Pharma Group",USAN|INN|Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,Esophagus tumor|Small-cell lung cancer|Pancreas tumor|Advanced solid tumor|Colorectal tumor,1011|1261|249|3713|989,Cancer,651,Luye Pharma Group Ltd,1015499,,,Luye Pharma Group Ltd,1015499,,,,,,
8064,thymalfasin,thymalfasin|thymosin alpha1 human|Zadaxin|Timosina|thymosin alpha 1|Talpha 1|ST-1472,USAN|INN|Trade Name|Trade Name|Research Code,Cancer|Immune|Infection,Thymosin receptor agonist,3409,Anticancer hormone|Antiviral|Angiogenesis stimulator|Immunostimulant|Adjuvant,62253|991|62|393|524,Sepsis|Hepatitis B virus infection|Hepatitis C virus infection|Influenza virus infection|DiGeorge syndrome|Vaccination|Immune deficiency|Cancer,114|152|153|191|2668|384|504|651,Non-small-cell lung cancer|HIV infection|Hepatocellular carcinoma|Melanoma|Aspergillus infection|Lung tumor|Renal tumor,1262|158|1767|205|29|755|999,SciClone Pharmaceuticals LLC|Alfasigma SpA,19829|1153354,RegeneRx Biopharmaceuticals Inc|CJ Corp|Sigma-Tau Ind Farm Riunite SpA|Schering-Plough KK|Sclavo SpA,14063|15473|21159|23497|25836,RegeneRx Biopharmaceuticals Inc,14063,,,,,,
80661,TAK-243,"E1 activating enzyme inhibitors (cancer), Millennium Pharmaceuticals|ubiquitin activating enzyme 1 inhibitors (cancer), Millennium Pharmaceuticals|UBA1 inhibitors (cancer), Millennium Pharmaceuticals|MLN-7243|TAK-243",Research Code|Research Code,Cancer,Ubiquitin like activating enzyme 1 inhibitor,52056,Anticancer|Apoptosis stimulator,1545|1589,,,Cancer|Solid tumor,651|725,,,Takeda Oncology,21991,Takeda Oncology,21991,,,,,,
80744,ningetinib tosilate,CT-053|CT-053PTSA|ningetinib|ningetinib tosilate|ninggetini|ningetinib toluenesulfonate,Research Code|Research Code|INN,Cancer,Ron tyrosine kinase receptor inhibitor|Flt3 tyrosine kinase inhibitor|Mer tyrosine kinase receptor inhibitor|Axl tyrosine kinase receptor inhibitor|VEGF-2 receptor antagonist|Hepatocyte growth factor receptor antagonist,3800|3806|3744|3742|3848|675,Angiogenesis inhibitor|Anticancer protein kinase inhibitor,61|62255,Glioma|Acute myelogenous leukemia|Renal cell carcinoma|Metastatic non small cell lung cancer,1108|1731|1766|3665,Solid tumor,725,HEC Pharm,1028084,,,HEC Pharm,1028084,,,,,,
80773,onvatilimab,"VISTA checkpoint inhibitor (cancer), ImmuNext/Janssen Biotech|VISTA pathway antagonists (cancer), ImmuNext/Janssen Biotech|anti-VISTA (cancer), ImmuNext/Janssen Biotech|JNJ-61610588|13-F-3|onvatilimab|CI-8993",Research Code|Research Code|USAN|INN|Research Code,Cancer,Stress induced secreted protein 1 inhibitor,34609,Anticancer|Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,1545|55685|393|7761,Advanced solid tumor|Cancer,3713|651,,,ImmuNext Inc|Curis Inc,1072699|15549,ImmuRx Inc|Janssen Biotech Inc,1037719|26997,ImmuNext Inc,1072699,,,,,,
80869,"mercaptopurine (oral suspension, acute lymphoblastic leukemia), Nova","mercaptopurine (oral suspension, acute lymphoblastic leukemia), Nova|Xaluprine|mercaptopurine|Purixan|Allmercap|mercaptopurine (oral suspension, acute lymphoblastic leukemia), Nova/Link Healthcare",Trade Name|BANN|INN|Trade Name|Trade Name,Cancer,,,Anticancer antimetabolite,1569,Acute lymphoblastic leukemia,1728,,,LINK Healthcare Pte Ltd|Trimedica Ltd|Nova Laboratories Ltd|Rare Disease Therapeutics Inc,1079424|1074755|1058817|29704,,,Nova Laboratories Ltd,1058817,,,,,,
80957,CMD-602,"WT1 TCR gene therapy (acute myeloid leukemia/chronic myeloid leukemia), University College London|WT1 TCR-transduced T-cells (acute myeloid leukemia/chronic myeloid leukemia), University College London|WT1 TCR-transduced T-cells (acute myeloid leukemia/chronic myeloid leukemia/myelodysplastic syndrome), University College London/ Catapult Therapy TCR|WT1 TCR-transduced T-cells (Dominant TCR, AML/CML/MDS), UCL/Catapult Therapy|CMD-602|anti-WT1/HLA-A*0201 TCR T-cell therapy (AML/MDS/NSCLC), UCL/Cell Medica|anti-WT1 TCR transfected autologous T-cells (AML/MDS/NSCLC), Cell Medica/UCL",Research Code,Cancer,HLA class I antigen A-2 alpha modulator|Wilms tumor protein modulator,19115|30009,Immunostimulant|Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,393|1545|7761|4790,,,Non-small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia|Leukemia,1262|1272|1731|1735|199,,,Kuur Therapeutics|Catapult Therapy TCR Ltd|University College London,1041182|1096454|23505,University College London,23505,,,,,,
80963,TG-1801,"kappa-lambda body (cancer), NovImmune|NI-1701|triple CD47 checkpoint inhibitor/anti-CD19/FcR activator (cancer), Novimmune/TG Therapeutics|TG-1801|triple CD47 checkpoint inhibitor/anti-CD19/FcR activator (cancer), Light Chain Bioscience/TG Therapeutics",Research Code|Research Code,Cancer,Immunoglobulin Fc receptor agonist|B-lymphocyte antigen CD19 modulator|CD47 antagonist,16012|5080|5185,Anticancer antibody|Anticancer|Immunostimulant|Natural killer cell stimulator|Macrophage stimulator|Leukocyte stimulator,55684|1545|393|7757|7751|7747,Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Cancer,1734|1744|1745|1746|1749|1750|316|319|651,,,TG Therapeutics Inc|Light Chain Bioscience,31093|27747,,,Light Chain Bioscience,27747,,,,,,
80986,CM-24,"CM-10|CM-24|humanized monoclonal IgG4 antibody (cancer), cCAM|Anti-CEACAM1 antibody (cancer), cCAM|MK-6018|CEACAM-1 checkpoint inhibitor (cancer), cCAM Biotherapeutics|humanized monoclonal IgG4 antibody (non small cell lung cancer), Kitov Pharmaceuticals|humanized monoclonal IgG4 antibody (non small cell lung cancer/Metastatic pancreas cancer/Stage IV melanoma/Metastatic colorectal cancer/Metastatic ovary cancer/Papillary thyroid tumor/Adenocarcinoma), Purple Biotech",Research Code|Research Code|Research Code,Cancer,CD66a antagonist,5271,Anticancer monoclonal antibody|Immunostimulant|Natural killer cell stimulator|T-lymphocyte stimulator,55685|393|7757|7761,Adenocarcinoma|Stage IV melanoma|Papillary thyroid tumor|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer,2399|3257|3351|3658|3665|3669|3713|3866,,,Purple Biotech Ltd,1064310,cCAM Biotherapeutics|FameWave Ltd,1073048|1184630,cCAM Biotherapeutics,1073048,,,,,,
81124,MEN-1703,"SEL-24|SEL-24-B58|second generation of SEL-24 program (cancer), Selvita|SEL-24B|SEL-24-B489|second generation SEL-24 compounds (cancer), Selvita|MEN-1703|second generation of SEL-24 program (cancer), Ryvu Therapeutics|second generation SEL-24 compounds (cancer), Ryvu Therapeutics|PIM/FLT3 kinase inhibitor (oral, acute myeloid leukemia), Ryvu Therapeutics/Berlin-Chemie Menarini",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,PIM protein kinase inhibitor|Flt3 tyrosine kinase inhibitor,4522|3806,Anticancer protein kinase inhibitor|Synergist,62255|7293,Acute myelogenous leukemia|Multiple myeloma,1731|1828,Cancer,651,Ryvu Therapeutics|Berlin-Chemie AG,1196240|18054,Selvita (CRO),1062326,Selvita (CRO),1062326,,,,,,
8114,EF-5,EF-5|NSC-684681,Research Code|Research Code,Immune,,,Immunosuppressant|Unspecified drug target,396|59620,,,Sjoegrens syndrome|Rheumatoid arthritis,1148|291,,,Scotia Holdings plc,19835,Scotia Holdings plc,19835,,,,,,
81144,BI-836858,"BI-836858|mAb 33.1, Boehringer Ingelheim RCV|Fc-engineered IgG1 mAb to CD33 (acute myelogenous leukemia), Boehringer Ingelheim RCV",Research Code,Cancer,CD33 antagonist,5121,Anticancer monoclonal antibody,55685,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Boehringer Ingelheim International GmbH,14881,,,Boehringer Ingelheim International GmbH,14881,,,,,,
81193,durvalumab,"MEDI-4736|durvalumab|Imfinzi|PD-L1 checkpoint inhibitor (cancer), Medarex/AstraZeneca",Research Code|USAN|INN|Trade Name,Cancer|Hematologic,Programmed cell death ligand 1 inhibitor,14007,Immunostimulant|Anticancer monoclonal antibody|Anticancer|T-lymphocyte stimulator,393|55685|1545|7761,Esophagus tumor|Neuroendocrine tumor|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Myelodysplastic syndrome|Gastrointestinal tumor|Biliary cancer|Endometrioid carcinoma|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Cholangiocarcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Multiple myeloma|Lymphoma|Fallopian tube cancer|Neoplasm|Bladder cancer|Glioblastoma|Pancreas tumor|Squamous cell carcinoma|Peritoneal tumor|T-cell lymphoma|Gallbladder tumor|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Stage IV melanoma|Vaginal tumor|Soft tissue sarcoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic colon cancer|Germ cell and embryonic cancer|Anaplastic thyroid cancer|Metastatic ovary cancer|Uterine cervix tumor|Breast tumor|Female genital tract tumor|Male genital tract tumor|Solid tumor|Urinary tract tumor|Mouth tumor|Pharynx tumor|Ovary tumor|Colorectal tumor,1011|1128|1240|1261|1262|1272|131|1516|1705|1731|1734|1744|1745|1749|1753|1765|1766|1767|1768|1828|203|2243|230|2380|2454|249|307|3083|311|3146|319|3246|3257|3293|3378|3466|3657|3658|3664|3665|3666|3667|3669|3672|3737|3769|3866|427|49|606|650|725|738|793|794|799|989,Myelofibrosis|Metastatic head and neck cancer,2436|3673,AstraZeneca plc|Bristol-Myers Squibb Co|MedImmune LLC,14190|15065|18008,Celgene Corp,15331,MedImmune LLC,18008,,,,,,
8121,"epoetin beta, Roche","rHuEPO, Genetics Inst/Chugai/Boehringer|recombinant human erythropoietin, Chugai|epoetin beta, Roche|erythropoietin, Genetics Institute/Chugai/Roche|epoetin beta, Genetics Inst/Chugai/Boehringer Mannheim|epoetin beta|EPOCH|Epogin|Marogen|NeoRecormon|Recormon|Epogin Subcutaneous Injection Syringe 24000|RO-2053859",USAN|BANN|INN|Trade Name|Trade Name|Trade Name|Trade Name|Research Code,Hematologic|Neurology/Psychiatric,Erythropoietin ligand,12162,Hematopoietic stimulator,610,Aplastic anemia|Anemia|Blood transfusion,1006|17|44,Brain hemorrhage,315,Roche Holding AG|Chugai Pharmaceutical Co Ltd|Boehringer Mannheim GmbH,19446|15414|24098,Wyeth BioPharma,20511,Wyeth BioPharma,20511,,,,,,
81215,crenigacestat,"LY-3039478|notch signalling inhibitor (gamma secretase SMI, cancer), Eli Lilly|notch inhibitor II (cancer), Eli Lilly|gamma secretase inhibitor (notch pathway, cancer), Eli Lilly|crenigacestat|JSMD-194",Research Code|USAN|INN|Research Code,Cancer,Notch receptor modulator|Gamma-secretase inhibitor|APRIL receptor modulator,8116|7578|8255,Anticancer|Synergist,1545|7293,Multiple myeloma,1828,T-cell acute lymphoblastic leukemia|T-cell lymphoma|Advanced solid tumor|Cancer,1730|311|3713|651,Bristol-Myers Squibb Co,15065,Juno Therapeutics Inc|Celgene Corp|Eli Lilly & Co,1090676|15331|17810,Eli Lilly & Co,17810,,,,,,
81234,"yttrium 90-labelled BC8 (hematological cancer), Fred Hutchinson Cancer Research Center","90Y-BC8|yttrium 90-labelled BC8 (hematological cancer), Fred Hutchinson Cancer Research Center|90Y-BC8-DOTA",Research Code|Research Code,Cancer,CD45 antagonist,5171,Anticancer|Anticancer monoclonal antibody|Radioimmunotherapeutic,1545|55685|1552,Hodgkins disease|Mantle cell lymphoma|Hematological neoplasm|T-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,161|1744|2054|311|316|319,,,Fred Hutchinson Cancer Research Center,16218,,,Fred Hutchinson Cancer Research Center,16218,,,,,,
81294,IGN-523,"anti-AML-01 to AML-08 mAb (acute myelogenous leukemia), Igenica|IGN-523",Research Code|Research Code,Cancer,CD98 antagonist,5376,Anticancer monoclonal antibody|Apoptosis stimulator,55685|1589,,,Acute myelogenous leukemia|Lung tumor,1731|755,,,Igenica Inc,1049783,Igenica Inc,1049783,,,,,,
81415,lifileucel,"Contego|autologous tumor infiltrating lymphocyte cell therapy (cancer), Genesis Biopharma|LN-144|LN-145|autologous tumor infiltrating lymphocyte cell therapy (cancer), Iovance Biotherapeutics|lifileucel",Trade Name|Research Code|Research Code|USAN|INN,Cancer,,,T-lymphocyte stimulator|Anticancer|Immunostimulant,7761|1545|393,Pancreatic ductal adenocarcinoma|Osteosarcoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Uterine cervix tumor|Ovary tumor,1507|1772|3257|3378|3657|3665|3673|427|799,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Transitional cell carcinoma|Metastatic bladder cancer|Metastatic renal cancer|Urethral cancer|Cancer,1731|1734|1771|3466|3467|3678|651,Iovance Biotherapeutics Inc,1057053,,,Iovance Biotherapeutics Inc,1057053,,,,,,
81447,vodobatinib,"SUN K-706|K-0706|SCO-088|SCC-138|Brc-Abl/Fyn tyrosine protein kinase inhibitor (oral, Parkinson's disease/CML/ALL), SPARC|Brc-Abl/Fyn tyrosine protein kinase inhibitor (oral, Parkinson's disease/CML/ALL/lewy body dementia), SPARC|vodobatinib",Research Code|Research Code|Research Code|Research Code|USAN|PINN,Cancer|Neurology/Psychiatric,Abl tyrosine kinase inhibitor|Fyn tyrosine kinase inhibitor,3524|3574,Anticancer protein kinase inhibitor|Antiparkinsonian|Neuroprotectant,62255|2947|1615,Acute lymphoblastic leukemia|Chronic myelocytic leukemia|Parkinsons disease|Lewy body dementia,1728|1735|255|3064,,,Sun Pharmaceutical Advanced Research Co Ltd,1035705,,,Sun Pharmaceutical Advanced Research Co Ltd,1035705,,,,,,
81474,axicabtagene ciloleucel,"eACT (cancer), Kite Pharma|anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma), Kite Pharma|axicabtagene ciloleucel|KTE-C19|axicel|axi-cel|Yescarta|FKC-876|KTE-X19",USAN|INN|Research Code|Trade Name|Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Anticancer|Immunostimulant|Genetically engineered autologous cell therapy,7761|1545|393|4790,Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|High grade B-cell lymphoma|Leukemia|B-cell lymphoma,1745|1746|1749|1750|1751|199|316,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Non-Hodgkin lymphoma,1728|1734|1744|319,Daiichi Sankyo Co Ltd|Fosun Kite|Shanghai Fosun Pharmaceutical (Group) Co Ltd|Kite Pharma Inc,1017506|1181265|1015871|1056870,Cabaret Biotech Ltd,1096601,Cabaret Biotech Ltd,1096601,,,,,,
81564,"bevacizumab biosimilar, Centus Biotherapeutics","bevacizumab|bevacizumab biosimilar, Fujifilm Kyowa Kirin Biologics|FKB-238|bevacizumab biosimilar, Fujifilm Kyowa Kirin Biologics/ AstraZeneca|bevacizumab biosimilar, Centus Biotherapeutics|Equidacent|L-01-XC-07",INN|Research Code|Trade Name|Research Code,Cancer,VEGF ligand inhibitor,12521,Angiogenesis inhibitor|Anticancer monoclonal antibody,61|55685,Renal cell carcinoma|Fallopian tube cancer|Peritoneal tumor|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic rectal cancer|Metastatic colon cancer|Uterine cervix tumor|Ovary tumor,1766|2243|3083|3657|3665|3671|3672|427|799,Cancer,651,Centus Biotherapeutics Ltd,1125934,Fujifilm Kyowa Kirin Biologics Co Ltd,1068941,Fujifilm Kyowa Kirin Biologics Co Ltd,1068941,,,,,,
81574,ethaselen,"thioredoxin reductase inhibitor (orally disintegrating tablet, cancer), Tibet Cheezheng Tibetan Medicine/Keaise Medicine/Peking University Health Science Center|BBSKE|ethaselen (orally disintegrating tablet, cancer), Tibet Cheezheng Tibetan Medicine/Keaise Medicine/Peking University Health Science Center|organoselenium antitumor (orally disintegrating tablet), Tibet Cheezheng Tibetan Medicine/Keaise Medicine Corporation/Peking University Health Science Center|ethaselen",Research Code,Cancer,Thioredoxin reductase 1 inhibitor,69211,Anticancer,1545,Cancer,651,,,Keaise Medicine Corp|Tibet Cheezheng Tibetan Medicine Co Ltd|Peking University Health Science Center,1062241|1074383|25344,,,Peking University Health Science Center,25344,,,,,,
81647,UCART-19,"allogeneic T-cell therapy (leukemia), Cellectis|UCART-19|S-68587|anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), Servier/Pfizer",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,B-cell acute lymphoblastic leukemia,1729,Lymphoid leukemia|Leukemia,1255|199,Servier|Allogene Therapeutics Inc,19863|1162743,Pfizer Inc|Cellectis SA,18767|29822,Cellectis SA,29822,,,,,,
8165,tiotropium bromide,"Ba-679 BR|Spiriva|tiotropium bromide|BA-679|Respimat (tiotropium), BI|Spiriva Respima|Tiotropium Respimat|Spiriva HandiHaler|Spiriva Respimat|Favint Respimat",Research Code|Trade Name|USAN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Respiratory,Muscarinic receptor antagonist|Muscarinic M1 receptor antagonist|Muscarinic M3 receptor antagonist,259|261|262,Anti-inflammatory|Synergist|Bronchodilator,2953|7293|646,Chronic obstructive pulmonary disease|Asthma,1185|31,Cystic fibrosis,88,Boehringer Ingelheim International GmbH,14881,Pfizer Inc,18767,Boehringer Ingelheim International GmbH,14881,,,,,,
81717,"radiolabeled bevacizumab (cancer/pulmonary arterial hypertension), University of Groningen","radiolabeled bevacizumab (cancer), University of Groningen|89Zr-bevacizumab|Zirconium-89 labeled bevacizumab (cancer), University of Groningen|radiolabeled bevacizumab (cancer/pulmonary arterial hypertension), University of Groningen|89Zr-N-sucDf-bevacizumab|Zirconium-89-bevacizumab|bevacizumab-[89Zr]",Research Code|Research Code|Research Code|Research Code,Cancer|Cardiovascular,VEGF ligand modulator,12519,PET contrast agent|Neoplasm diagnostic agent|Radiodiagnostic|Imaging agent|Cardiovascular diagnostic agent,5555|7220|5720|4155|7210,Pulmonary artery hypertension|Metastatic renal cell carcinoma|Cancer,3510|4250|651,,,Rijksuniversiteit te Groningen,20581,,,Rijksuniversiteit te Groningen,20581,,,,,,
81768,pimitespib,"TAS-116|THS-1593|ATP-competitive Hsp90alpha/beta inhibitor (oral, gastrointestinal stromal tumor/advanced solid tumor), Taiho|pimitespib",Research Code|Research Code|INN,Cancer,Heat shock protein HSP90 alpha inhibitor|Heat shock protein HSP90 beta inhibitor,63353|63356,Synergist|Apoptosis stimulator|Anticancer,7293|1589|1545,Gastrointestinal stromal tumor|Advanced solid tumor,3205|3713,Cancer,651,Taiho Pharmaceutical Co Ltd,18720,,,Taiho Pharmaceutical Co Ltd,18720,,,,,,
81772,futibatinib,"TAS-2985|FGFR inhibitors (cancer), Taiho Pharmaceutical Co Ltd|irreversible FGFR inhibitor (oral, cancer), Taiho Pharmaceutical/Taiho Oncology|futibatinib|TAS-120|FGFR inhibitor (cancer/Endometrial carcinoma/hepatocellular carcinoma) Taiho|FGFR infibitor (oral, Breast cancer/Endometrial carcinoma/hepatocellular carcinoma/Esophageal cancer/Stomach cancer/Cholangiocarcinoma/Solid tumor) Taiho|FGFR infibitor (oral, Breast cancer/endometrial carcinoma/hepatocellular carcinoma/esophageal cancer/stomach cancer/cholangiocarcinoma/solid tumor/urothelial carcinoma) Taiho",Research Code|USAN|INN|Research Code,Cancer|Hematologic,FGF3 receptor antagonist|FGF2 receptor antagonist|FGF1 receptor antagonist|FGF receptor antagonist|FGF4 receptor antagonist,3688|3685|3682|168|3691,Anticancer protein kinase inhibitor,62255,Endometrioid carcinoma|Cholangiocarcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Myeloproliferative disorder|Metastatic breast cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor,1705|1765|1767|1771|273|3657|3666|3667|3713,Cancer,651,Taiho Pharmaceutical Co Ltd|Taiho Oncology Inc,18720|1092741,,,Taiho Pharmaceutical Co Ltd,18720,,,,,,
81774,vadastuximab talirine,"SGN-CD33A|CD33-targeted antibody-drug conjugate (acute myeloid leukemia), Seattle Genetics|CD33-targeted ADC (AML), Seattle Genetics|SGD-1882|h2H12ec-SGD-1910|vadastuximab talirine|vadastuximab|33A",Research Code|Research Code|Research Code|USAN|INN|USAN|INN|Research Code,Cancer,CD33 antagonist,5121,Synergist|Cell cycle inhibitor|Anticancer monoclonal antibody|Apoptosis stimulator|DNA intercalator,7293|767|55685|1589|750,,,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Seagen Inc,25554,Seagen Inc,25554,,,,,,
81805,radgocitabine,DFP-10917|NS-917|radgocitabine,Research Code|Research Code|PINN,Cancer,,,G2-M checkpoint pathway modulator|Anticancer|Apoptosis stimulator,52471|1545|1589,Acute lymphoblastic leukemia|Acute myelogenous leukemia,1728|1731,,,Nippon Shinyaku Co Ltd|Delta-Fly Pharma Inc,18552|1062114,,,Delta-Fly Pharma Inc,1062114,,,,,,
81901,abivertinib,"aiweitini|EGFR inhibitors (oral, cancer), ACEA Biosciences|avitinib|AC-0010|ACEA-0010|AC-010|abivertinib|abivertinib maleate|AC-0010-MA|STI-5656",Research Code|Research Code|Research Code|USAN|INN|USAN|Research Code|Research Code,Cancer|Infection|Respiratory,EGFR gene inhibitor|Btk tyrosine kinase inhibitor,17952|3592,Anticancer protein kinase inhibitor|Antiviral|Anticancer,62255|991|1545,Coronavirus disease 19 infection|Chronic lymphocytic leukemia|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Viral pneumonia|Lymphoma|Non-Hodgkin lymphoma|Metastatic non small cell lung cancer|Respiratory distress syndrome,10406|1734|1744|1749|1818|203|319|3665|8,Cancer,651,Sorrento Therapeutics Inc|ACEA Biosciences Inc,1048574|1006647,,,ACEA Biosciences Inc,1006647,,,,,,
81927,KRT-232,"AMG-232|Mouse double minute 2 homolog inhibitor (solid tumor/melanoma), Amgen/GlaxoSmithkline|MDM2 inhibitor (solid tumor/melanoma), Amgen/GlaxoSmithkline|KRT-232|MDM2 inhibitor (myelofibrosis/polycythemia vera/merkel cell lymphoma/acute myeloid leukemia), Kartos Therapeutics",Research Code|Research Code,Cancer|Hematologic,Mdm2 p53-binding protein inhibitor|E3 ubiquitin protein ligase MDM2 inhibitor,10391|51304,Synergist|Cell cycle inhibitor|Anticancer|Apoptosis stimulator,7293|767|1545|1589,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Chronic myelocytic leukemia|Diffuse large B-cell lymphoma|Thrombocythemia|Polycythemia vera|Myelofibrosis|Myeloproliferative disorder|Non-Hodgkin lymphoma|Merkel cell carcinoma,1731|1734|1735|1749|2317|2319|2436|273|319|3235,Multiple myeloma|Stage IV melanoma|Advanced solid tumor,1828|3257|3713,Kartos Therapeutics Inc,1171249,Amgen Inc,14109,Amgen Inc,14109,,,,,,
81932,OPB-111077,"OPB-111077|STAT inhibitors (cancer), Otsuka Pharmaceutical|STAT-3 inhibitor (cancer), Otsuka Pharmaceutical",Research Code,Cancer,STAT-3 inhibitor,7967,Anticancer|Electron transport inhibitor,1545|518,Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Nasopharyngeal carcinoma|Advanced solid tumor|Cancer,1731|1749|1768|3713|651,Hepatocellular carcinoma,1767,Otsuka Pharmaceutical Co Ltd,18717,,,Otsuka Pharmaceutical Co Ltd,18717,,,,,,
81949,BION-1301,"anti-APRIL monoclonal antibodies (cancer), BioNovion|human APRIL.01A|human APRIL.03A|hA.01A|hA.03A|BION-1301|anti-APRIL monoclonal antibodies (cancer), Aduro BioTech Europe|anti-APRIL monoclonal antibodies (IgA nephropathy/ cancer), Aduro BioTech Europe",Research Code,Cancer|Genitourinary/Sexual Function,Tumor necrosis factor ligand 13 inhibitor|APRIL receptor antagonist,48495|8257,Anticancer monoclonal antibody|Anti-inflammatory,55685|2953,Multiple myeloma|IgA nephropathy,1828|3076,Cancer,651,Chinook Therapeutics Canada Inc,1188489,Aduro Biotech Holdings Europe Bv,1075382,Aduro Biotech Holdings Europe Bv,1075382,,,,,,
81951,BION-1402,"anti-CD27 monoclonal antibody agonist (cancer), BioNovion|hCD27.15|BION-1402|anti-CD27 monoclonal antibody agonist (cancer), Aduro|CD27 costimulator (cancer), Aduro/Merck & Co",Research Code|Research Code,Cancer,CD27 agonist,5102,Natural killer cell stimulator|T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody,7757|7761|393|55685,,,Solid tumor,725,,,Chinook Therapeutics Inc|Aduro Biotech Holdings Europe Bv|Merck & Co Inc,1039923|1075382|18077,Aduro Biotech Holdings Europe Bv,1075382,,,,,,
82113,Hx-DR5-01/05,"IDD-004|Hx-DR5-01|Hx-DR5-05|HexaBody-DR5|DR5-targeting mAb (HexaBody, cancer), Genmab|Hx-DR5-01/05|MR-009E|GEN-1029|HexaBody-DR5/DR5|benufutamab",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|INN,Cancer,TRAIL-2 receptor agonist,8232,Anticancer monoclonal antibody,55685,Glioma|Non-small-cell lung cancer|Stomach tumor|Renal cell carcinoma|Transitional cell carcinoma|Pancreas tumor|Breast tumor|Cancer|Colorectal tumor,1108|1262|127|1766|1771|249|49|651|989,,,Genmab A/S,26469,iDD biotech,1066452,iDD biotech,1066452,,,,,,
82222,"leukemia-associated RNA transfected autologous dendritic cell vaccine, (acute myeloid leukemia), Ludwig-Maximilians/Medigene","leukemia-associated RNA transfected autologous dendritic cell vaccine, (acute myeloid leukemia), Ludwig-Maximilians|leukemia-associated RNA transfected autologous dendritic cell vaccine, (acute myeloid leukemia), Ludwig-Maximilians/Medigene|leukemia-associated RNA transfected autologous dendritic cell vaccine, (acute myeloid leukemia), Ludwig-Maximilians/Trianta|leukemia-associated RNA transfected autologous dendritic cell vaccine, (acute myeloid leukemia), Helmholtz Zentrum Munchen/Max Delbruck Center|WT1/PRAME vaccination",,Cancer,WT1 gene stimulator|PRAME gene stimulator,30013|71055,Therapeutic vaccine|Dendritic cell vaccine|Genetically engineered autologous cell vaccine|Anticancer,12379|102926|4791|1545,Acute myelogenous leukemia,1731,,,MediGene AG|Ludwig-Maximilians University of Munich|Medigene Immunotherapies GmbH,24224|22137|1092495,Helmholtz Zentrum München|Max Delbruck Centrum Fur Molekulare Medizin,16588|17961,Ludwig-Maximilians University of Munich,22137,,,,,,
82234,"ONC-201, Oncoceutics/ Ohara Pharmaceutical","ONC-200 series (cancer), Oncoceutics|TIC-10|imidazolinopyrimidinones (cancer), Oncoceutics|ONC-201, Oncoceutics|NSC-350625|ONC-201, Oncoceutics/ Ohara Pharmaceutical|OP-10|ONC-201 dihydrochloride",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Dopamine D2 receptor antagonist|ATP-dependent Clp protease stimulator,150|26613,Apoptosis stimulator|Anticancer|Synergist,1589|1545|7293,Glioma|Neuroendocrine tumor|Stomach tumor|Myelodysplastic syndrome|Endometrioid carcinoma|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma|Liver tumor|Rhabdomyosarcoma|Glioblastoma|Ependymoma|Medulloblastoma|Neuroblastoma|Ewing sarcoma|Non-Hodgkin lymphoma|Metastatic breast cancer|Solid tumor,1108|1128|127|1272|1705|1728|1731|1744|1749|1828|202|2448|2454|2455|2533|2726|2975|319|3657|725,Advanced solid tumor|Breast tumor|Cancer,3713|49|651,China Resources Sanjiu Medical and Pharmaceutical Co Ltd|Oncoceutics Inc|Ohara Pharmaceutical Co Ltd,1091659|1048147|1000882,,,Oncoceutics Inc,1048147,,,,,,
82321,GSK-3174998,"OX40 agonist antibodies (cancer), GlaxoSmithKline/MD Anderson|GSK-3174998|OX40 costimulator (cancer), GlaxoSmithKline/MD Anderson|OX40 agonist antibodies (iv, cancer/d solid tumors), GlaxoSmithKline|GSK'998",Research Code|Research Code,Cancer,OX-40 receptor agonist,5443,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,,,Hematological neoplasm|Advanced solid tumor|Cancer|Solid tumor,2054|3713|651|725,,,MD Anderson Cancer Center|GlaxoSmithKline plc,23382|28355,MD Anderson Cancer Center,23382,,,,,,
82338,"T-rapamycin cell donor lymphocyte infusions (Lymphoma), National Cancer Institute","T-rapamycin cell donor lymphocyte infusions (Lymphoma), National Cancer Institute",,Cancer,,,Anticancer,1545,,,Lymphoma,203,,,National Cancer Institute (NCI),20519,National Cancer Institute (NCI),20519,,,,,,
82426,magrolimab,"CD47 checkpoint inhibitor (cancer), Stanford University/Forty Seven/Oxford University|Hu5F9-G4|humanized anti-CD47 antibody (cancer), Stanford University/Forty Seven/Oxford University|magrolimab|humanized anti-CD47 antibody (cancer), Stanford University/Forty Seven/Oxford University/Ono|ONO-7913|GS-4721",USAN|INN|Research Code|Research Code,Cancer,CD47 antagonist,5185,Macrophage stimulator|Immunostimulant|Anticancer monoclonal antibody|Synergist,7751|393|55685|7293,Myelodysplastic syndrome|Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Multiple myeloma|Non-Hodgkin lymphoma|Metastatic bladder cancer|Metastatic breast cancer|Advanced solid tumor|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,1272|1731|1749|1828|319|3466|3657|3713|651|725|799|989,Bladder cancer,2380,Gilead Sciences Inc|Forty Seven Inc|Ono Pharmaceutical Co Ltd,16450|1120033|18681,Stanford University,20679,Stanford University,20679,,,,,,
82536,BI-1206,"BI-1206|6G11|FcgRIIb checkpoint inhibitor (leukemia/lymphoma), BioInvent|CD32b checkpoint inhibitor (cancer), BioInvent",Research Code,Cancer,Immunoglobulin gamma Fc receptor IIB antagonist,27991,Natural killer cell stimulator|Macrophage stimulator|Immunostimulant|Anticancer monoclonal antibody,7757|7751|393|55685,Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Stage IV melanoma|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,1744|1745|1746|316|319|3257|3665|3713|651,Chronic lymphocytic leukemia,1734,CASI Pharmaceuticals Inc|BioInvent International AB,21794|18592,Cancer Research Technology Ltd,30620,BioInvent International AB,18592,,,,,,
8255,nelfinavir,AG-1343|nelfinavir mesylate|AG-1346|LY-312857|nelfinavir|Viracept,Research Code|USAN|Research Code|Research Code|INN|Trade Name,Infection,HIV protease inhibitor|HIV-1 protease inhibitor,204|768,Antiviral,991,HIV infection,158,,,Japan Tobacco Inc|Mitsubishi Pharma Corp|Dong-A ST Co Ltd|ViiV Healthcare Ltd,17327|20983|15742|1050515,Chugai Pharmaceutical Co Ltd|Pfizer Inc|Roche Holding AG|Nippon Roche KK|F Hoffmann-La Roche AG|Agouron Pharmaceuticals Inc,15414|18767|19446|19447|26178|26488,Pfizer Inc,18767,,,,,,
82701,MCLA-117,"MCLA-117|bispecific human antibodies targeting CD3 and CLEC12A (Biclonics, AML), Merus|Fc-silenced anti-CD3/anti-CLEC12A bispecific T-cell engager (Bioclonics ENGAGE, acute myeloid leukemia/myelodysplastic syndrome), Merus",Research Code,Cancer,CD3 modulator|C-type lectin domain protein 12A modulator,5023|82256,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Merus BV,1008818,,,Merus BV,1008818,,,,,,
82937,DI-B4,DI-B4,Research Code,Cancer,B-lymphocyte antigen CD19 inhibitor,5082,Anticancer monoclonal antibody,55685,Chronic lymphocytic leukemia|B-cell lymphoma,1734|316,Cancer,651,Merck KGaA|Cancer Research UK,18101|29469,,,Merck KGaA,18101,,,,,,
83026,aspacytarabine,"Astarabine|cytarabine-asparagine conjugate (leukemia), BioSight|BST-236|Asp(cytarabine)|aspacytarabine",Trade Name|Research Code|PINN,Cancer,,,Anticancer,1545,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia|Non-Hodgkin lymphoma,1272|1728|1731|1735|319,,,BioSight Ltd,29548,,,BioSight Ltd,29548,,,,,,
83049,"bevacizumab biosimilar, AbbVie / Amgen/ Daiichi Sankyo","bevacizumab|bevacizumab biosimilar, Actavis/Amgen|bevacizumab biosimilar, Watson Pharmaceuticals/Amgen|ABP-215|bevacizumab biosimilar, Allergan/Amgen|bevacizumab beta|bevacizumab biosimilar, Allergan/ Amgen/ Daiichi Sankyo|bevacizumab-awwb|Mvasi|Kyomarc|bevacizumab biosimilar, AbbVie / Amgen/ Daiichi Sankyo",INN|Research Code|INN|Trade Name|Trade Name,Cancer,VEGF ligand inhibitor,12521,Angiogenesis inhibitor|Anticancer monoclonal antibody,61|55685,Fallopian tube cancer|Glioblastoma|Peritoneal tumor|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Breast tumor|Cancer|Ovary tumor,2243|2454|3083|3658|3665|4250|427|49|651|799,,,AbbVie Inc|Amgen Inc|Daiichi Sankyo Co Ltd,1072507|14109|1017506,Allergan plc|Actavis Inc,1088700|21717,Amgen Inc,14109,,,,,,
83065,avelumab,"anti-PD-L1 mAb (solid tumors), Merck Serono|programmed cell death ligand 1 mAb (solid tumors), Merck Serono|anti-PD-L1 mAb (solid tumors), Merck Serono/ Pfizer|avelumab|MSB-0010718C|PF-06834635|MSB0010682|Bavencio|PD-L1 checkpoint inhibitor (cancer), Merck KGaA/Pfizer",USAN|INN|Research Code|Research Code|Research Code|Trade Name,Cancer|Neurology/Psychiatric,Programmed cell death ligand 1 inhibitor,14007,Anticancer monoclonal antibody|Immunostimulant|Anti-inflammatory|T-lymphocyte stimulator|Anticancer,55685|393|2953|7761|1545,Testis tumor|Neuroendocrine tumor|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Hodgkins disease|Endometrioid carcinoma|Acute myelogenous leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Nasopharyngeal carcinoma|Osteosarcoma|Penis tumor|Neoplastic meningitis|Lymphoma|Anal tumor|Bladder cancer|Angiosarcoma|Glioblastoma|Pancreas tumor|Thymus neoplasm|Squamous cell carcinoma|Gastrointestinal stromal tumor|Merkel cell carcinoma|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic urinary tract cancer|Metastatic bladder cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic rectal cancer|Advanced solid tumor|Metastatic ovary cancer|Small intestine cancer|Metastatic renal cell carcinoma|Genitourinary tract tumor|Colon tumor|Ovary tumor,1054|1128|1240|1261|1262|161|1705|1731|1745|1749|1753|1768|1772|1791|1814|203|2193|2380|2443|2454|249|2938|307|3205|3235|3246|3257|3465|3466|3657|3658|3665|3671|3713|3866|4166|4250|613|767|799,Adrenal cortical carcinoma|Mantle cell lymphoma|Hepatocellular carcinoma|Transitional cell carcinoma|Hematological neoplasm|Metastatic stomach cancer|Metastatic head and neck cancer|Head and neck tumor|Solid tumor,1648|1744|1767|1771|2054|3666|3673|623|725,Merck KGaA|Merck Serono SA|Pfizer Inc,18101|19862|18767,,,Merck KGaA,18101,,,,,,
83076,GNX-102,"GNX-102|anti-TACAs humanized antibody (advanced solid tumors), GlycoNex|anti-tumor-associated carbohydrate antigen mAb (advanced solid tumor), GlycoNex",Research Code,Cancer,,,Anticancer monoclonal antibody|Unspecified drug target,55685|59620,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Hepatocellular carcinoma|Melanoma|Bladder cancer|Pancreas tumor|Prostate tumor|Uterine cervix tumor|Breast tumor|Lung tumor|Ovary tumor|Colorectal tumor,1011|1262|127|1767|205|2380|249|276|427|49|755|799|989,Advanced solid tumor,3713,GlycoNex Inc,1052861,,,GlycoNex Inc,1052861,,,,,,
83081,AVID-100,"antibody-drug conjugate (EGFR modulator), AvidBiologics|ADC (EGFR modulator), AvidBiologics|AVID-100|ADC (EGFR modulator), Formation Biologics|antibody-drug conjugate (EGFR modulator), Formation Biologics",Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Immunotoxin|Anticancer antibody|Anticancer protein kinase inhibitor,539|55684|62255,Non-small-cell lung cancer|Metastatic breast cancer|Metastatic head and neck cancer|Advanced solid tumor|Breast tumor|Head and neck tumor,1262|3657|3673|3713|49|623,Cancer,651,Forbius,1078063,,,Forbius,1078063,,,,,,
8312,XR-5000,XR-5000|SN-22995|DACA|NSC-601316|NSC-672819,Research Code|Research Code|Research Code|Research Code,Cancer,Topoisomerase I inhibitor|Topoisomerase II inhibitor,141|142,DNA intercalator|Anticancer,750|1545,,,Non-small-cell lung cancer|Sarcoma|Melanoma|Glioblastoma|Breast tumor|Carcinoma|Solid tumor|Lung tumor|Brain tumor|Colon tumor|Ovary tumor,1262|194|205|2454|49|54|725|755|760|767|799,,,University of Auckland|European Organisation for Research and Treatment of Cancer (EORTC)|Cancer Research Campaign Technology Ltd|Xenova Ltd,20647|23119|24077|25708,University of Auckland,20647,,,,,,
83195,"tigecycline (iv infusion, acute myeloid leukemia), UHN","tigecycline|tigecycline (iv infusion, acute myeloid leukemia), UHN|tigecycline (iv infusion, acute myeloid leukemia), Stem Cell Therapeutics|tigecycline (iv infusion, acute myeloid leukemia), Trillium Therapeutics",USAN|PINN,Cancer,,,Anticancer|Tetracycline,1545|1539,,,Acute myelogenous leukemia,1731,,,Trillium Therapeutics Inc|The University Health Network,1010234|28443,The University Health Network,28443,,,,,,
8324,canfosfamide,TER-296|TER-324|TER-332|TER-338|canglustratide hydrochloride|TER-286|TLK-286|canfosfamide hydrochloride|canfosfamide|Telcyta,Research Code|Prodrug|Research Code|Prodrug|Research Code|Prodrug|Research Code|Prodrug|Research Code|Research Code|USAN|INN|Trade Name,Cancer,Glutathione S-transferase P modulator,14020,Anticancer alkylating agent|Cell cycle inhibitor|Apoptosis stimulator,50|767|1589,,,Non-small-cell lung cancer|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma|Non-Hodgkin lymphoma|Breast tumor|Carcinoma|Cancer|Lung tumor|Colon tumor|Ovary tumor,1262|1744|1749|1828|319|49|54|651|755|767|799,,,Taiho Pharmaceutical Co Ltd|MabVax Therapeutics Holdings Inc,18720|20339,MabVax Therapeutics Holdings Inc,20339,,,,,,
83355,FF-10501 hydrate,FF-10501|FF-10501-01|FF-10501 hydrate,Research Code|Research Code|Research Code,Cancer,Inosine monophosphate dehydrogenase inhibitor,629,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelomonocytic leukemia,1272|1731|6833,,,FUJIFILM Holdings Corp,1037804,,,FUJIFILM Holdings Corp,1037804,,,,,,
83456,SCT-200,"recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody, Sinocelltech|recombinant humanized anti-hEGFR mAb, Sinocelltech|SCT-200",Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody|Anticancer,62255|55685|1545,Squamous cell carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Breast tumor,307|3658|3665|3667|3673|3713|49,Cancer,651,Sinocelltech Ltd,1079269,,,Sinocelltech Ltd,1079269,,,,,,
83514,DCVAC/LuCa,DCVAC/LuCa,,Cancer,,,Anticancer|Dendritic cell vaccine|Therapeutic vaccine,1545|102926|12379,Non-small-cell lung cancer|Metastatic non small cell lung cancer,1262|3665,Lung tumor,755,Sotio AS,1077346,,,Sotio AS,1077346,,,,,,
83537,"donafenib tosylate (oral tablet, cancer), Suzhou Zelgen Biopharmaceutical","donafenib tosylate (oral tablet, cancer), Suzhou Zelgen Biopharmaceutical|CM-4307|donafenib|donafenib tosylate|Zepsun|zepusheng",Research Code|Trade Name|Trade Name,Cancer,Tyrosine kinase receptor inhibitor|Raf protein kinase inhibitor,3520|4542,Anticancer protein kinase inhibitor|Angiogenesis inhibitor,62255|61,Esophagus tumor|Thyroid tumor|Gastrointestinal tumor|Endometrioid carcinoma|Acute myelogenous leukemia|Cholangiocarcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Squamous cell carcinoma|Metastatic gastrointestinal cancer|Metastatic colorectal cancer|Metastatic stomach cancer|Advanced solid tumor|Head and neck tumor,1011|1134|131|1705|1731|1765|1766|1767|1768|307|3460|3658|3666|3713|623,Cancer,651,Suzhou Zelgen Biopharmaceuticals Co Ltd,1065043,,,Suzhou Zelgen Biopharmaceuticals Co Ltd,1065043,,,,,,
83613,18F-Fluoro-PEG6-IPQA,18F-Fluoro-PEG6-IPQA|18F-PEG6-IPQA,,Cancer,,,Neoplasm diagnostic agent|PET contrast agent|Radiodiagnostic,7220|5555|5720,,,Solid tumor,725,,,MD Anderson Cancer Center,23382,MD Anderson Cancer Center,23382,,,,,,
83615,NIZ-985,"recombinant interleukin-15 (cancer), NCI|heterodimeric IL-15|IL-15/sIL-15Ra|hetIL-15|heterodimeric IL15:IL15Ra|recombinant interleukin-15 (cancer), NCI/Admune Therapeutics|recombinant interleukin-15 (cancer), NCI/Novartis|NIZ-985",Research Code,Cancer|Infection,Interleukin 15 ligand,51216,Antiviral|Anticancer,991|1545,Metastasis|HIV infection|Metastatic renal cancer|Solid tumor,1069|158|3467|725,,,Novartis AG|National Cancer Institute (NCI),23137|20519,Admune Therapeutics LLC,1095563,National Cancer Institute (NCI),20519,,,,,,
83774,andecaliximab,"GS-5745|andecaliximab|Matrix metalloproteinase-9 inhibitor (rheumatoid arthritis), Gilead Sciences Inc",Research Code|USAN|INN,Cancer|Gastrointestinal|Immune|Respiratory,Metalloprotease-9 inhibitor,2462,Anti-inflammatory|Anticancer monoclonal antibody,2953|55685,,,Chronic obstructive pulmonary disease|Stomach tumor|Rheumatoid arthritis|Ulcerative colitis|Metastatic stomach cancer|Solid tumor|Crohns disease|Cystic fibrosis,1185|127|291|337|3666|725|84|88,,,Gilead Sciences Inc,16450,Gilead Sciences Inc,16450,,,,,,
83781,GM.CD40L cell vaccine,"GM.CD40L cell vaccine|GM-CSF- and CD40L-expresing autologous tumor cell vaccine (intradermal, cancer), H Lee Moffitt Cancer Center/National Cancer Institute|dual CD40 costimulator/GM-CSF (autologous tumor cell vaccine, cancer), H Lee Moffitt Cancer Center/National Cancer Institute",,Cancer,GM-CSF receptor agonist|Chemokine CC21 ligand|CD40 ligand receptor agonist,410|51072|5141,Therapeutic vaccine|Anticancer|Genetically engineered autologous cell vaccine,12379|1545|4791,Mantle cell lymphoma|Melanoma|Lung tumor,1744|205|755,,,H Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI),29603|20519,,,H Lee Moffitt Cancer Center and Research Institute,29603,,,,,,
83846,"melanoma-associated antigen 12 peptide vaccine (cancer), NCI","melanoma-associated antigen 12 peptide vaccine (cancer), NCI|MAGE-12 peptide vaccine (cancer), NCI",,Cancer,,,Anticancer|Therapeutic vaccine,1545|12379,,,Cancer,651,,,National Cancer Institute (NCI),20519,National Cancer Institute (NCI),20519,,,,,,
83847,mik-beta-1,"mik-beta-1|anti-CD122 mAb(CLL), NCI",,Cancer,CD122 modulator,5424,Anticancer monoclonal antibody,55685,,,Chronic lymphocytic leukemia,1734,,,National Cancer Institute (NCI),20519,National Cancer Institute (NCI),20519,,,,,,
83873,osimertinib,"AZ-5104|AZ-7550|osimertinib|AZD-9291|osimertinib mesylate|Tagrisso|mereletinib|osimertinib (T790M-mutation-targeting, NSCLC), AstraZeneca",Research Code|Metabolite|Research Code|Metabolite|USAN|INN|Research Code|USAN|Trade Name,Cancer,Protein tyrosine kinase inhibitor|Epidermal growth factor receptor antagonist,385|740,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Metastatic non small cell lung cancer,1262|3665,,,AstraZeneca plc,14190,,,AstraZeneca plc,14190,,,,,,
83902,tenalisib,"RP-6530|PI3K delta/gamma dual inhibitor (oral, cancer/inflammation), Rhizen|tenalisib|PI3K delta/gamma dual inhibitor (oral, cancer/inflammation), Rhizen/Icozen",Research Code|INN,Cancer|Inflammatory,Phosphoinositide-3 kinase delta inhibitor|Phosphoinositide-3 kinase gamma inhibitor|QSK serine threonine protein kinase inhibitor,11183|11186|4252,Anti-inflammatory|Anticancer protein kinase inhibitor|Apoptosis stimulator|Anticancer|Synergist,2953|62255|1589|1545|7293,Hodgkins disease|Chronic lymphocytic leukemia|Follicle center lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Inflammatory disease|Hematological neoplasm|T-cell lymphoma|Non-Hodgkin lymphoma|Cancer,161|1734|1745|1753|1754|188|2054|311|319|651,,,Rhizen Pharmaceuticals SA|Incozen Therapeutics Pvt Ltd|Curon Biopharmaceutical Limited,1052344|1050981|1214848,,,Rhizen Pharmaceuticals SA,1052344,,,,,,
83962,"entospletinib + idelalisib (hematological malignancies), Gilead","GS-9973 + idelalisib (hematological malignancies), Gilead|entospletinib + idelalisib (hematological malignancies), Gilead|entospletinib + idelalisib|GS-9973 + idelalisib",,Cancer,Phosphoinositide-3 kinase delta inhibitor|Syk tyrosine kinase inhibitor,11183|3602,Anticancer protein kinase inhibitor,62255,,,Hematological neoplasm|Cancer,2054|651,,,Gilead Sciences Inc,16450,Gilead Sciences Inc,16450,,,,,,
84048,"MSC-1, Northern Biologics","MSC-1 (cancer), Mosaic Biomedicals|MSC-1, Northern Biologics|anti-LIF mAb (intravenous, cancer), Northern Biologics|anti-leukemia inhibitory factor mAb (intravenous, cancer), Northern Biologics|MSC-1, Northern Biologics/Celgene|anti-LIF mAb (intravenous, cancer), Northern Biologics/Bristol-Myers Squibb",Research Code,Cancer,Leukemia inhibitory factor receptor antagonist|Aminopeptidase N inhibitor,3710|5064,Therapeutic antibody|Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,172641|55685|393|7761,Non-small-cell lung cancer|Pancreas tumor|Advanced solid tumor|Ovary tumor,1262|249|3713|799,Cancer,651,Northern Biologics (formerly Northern LP)|Bristol-Myers Squibb Co,1217069|15065,Mosaic Biomedicals|Northern Biologics Inc|Celgene Corp,1080571|1103768|15331,Mosaic Biomedicals,1080571,,,,,,
84060,idecabtagene vicleucel,"bb-2121|anti B-cell maturation antigen-targeting chimeric antigen receptor T-cells (hematological malignancies), bluebird bio|BCMA-targeting CAR T-cells (hematological malignancies), bluebird bio|anti-BCMA CAR T-cell therapy (hematological malignancies), bluebird bio/Celgene|idecabtagene vicleucel|ide-cel|Abecma",Research Code|USAN|INN|Trade Name,Cancer,APRIL receptor modulator,8255,Genetically engineered autologous cell therapy|Immunostimulant|Anticancer|T-lymphocyte stimulator,4790|393|1545|7761,Multiple myeloma,1828,Hematological neoplasm|Cancer,2054|651,bluebird bio Inc|Bristol-Myers Squibb Co,16284|15065,Celgene Corp,15331,bluebird bio Inc,16284,,,,,,
84086,SLC-391,"AXL tyrosine kinase receptor inhibitors (cancer), SignalChem|SLC-366|SLC-391|SLC-0211|Axl checkpoint inhibitor (cancer), SignalChem Life Sciences|AXL tyrosine kinase receptor inhibitors (cancer, advanced solid tumors), SignalChem|AXL tyrosine kinase receptor inhibitors (metastatic non-small cell lung cancer), SignalChem",Research Code|Research Code,Cancer,Axl tyrosine kinase receptor inhibitor,3742,Immunostimulant|Anticancer protein kinase inhibitor|Anticancer|Dendritic cell stimulator|Macrophage stimulator,393|62255|1545|173472|7751,Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,3665|3713|651,,,SignalChem Life Sciences,1063445,,,SignalChem Life Sciences,1063445,,,,,,
8416,marimastat,BB-2516|marimastat|TA-2516,Research Code|USAN|INN|Research Code,Cancer,Matrix metalloprotease inhibitor,253,Anticancer,1545,,,Esophagus tumor|Stomach tumor|Bone metastases|Melanoma|Pancreas tumor|Prostate tumor|Breast tumor|Head and neck tumor|Cancer|Lung tumor|Brain tumor|Ovary tumor|Colorectal tumor,1011|127|1829|205|249|276|49|623|651|755|760|799|989,,,Vernalis plc|Schering-Plough Corp|Tanabe Seiyaku Co Ltd,15262|19711|20315,Vernalis plc,15262,,,,,,
84217,pegzilarginase,"L-arginine degrading enzymes (cancer), Aeglea Biotherapeutics|L-arginine degrading enzymes (cancer), University of Texas System|AERase|engineered human arginase-1 enzyme (cancer/hyperargininemia), Aeglea BioTherapeutics|pegzilarginase|AEB-1102|Co-ArgI-PEG",Research Code|USAN|INN|Research Code,Cancer|Endocrine/Metabolic,Arginase-I stimulator,7088,Anticancer|Synergist,1545|7293,Small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Melanoma|Uveal melanoma|Amino acid and protein metabolism disorder,1261|1272|1731|205|3788|482,Cancer,651,Immedica Pharma AB|Aeglea BioTherapeutics Inc,1073345|1080637,University of Texas System,21864,University of Texas System,21864,,,,,,
84239,imifoplatin,"PT-112|phosphaplatin compounds (cancer), Phosplatin|phosphaplatin compounds (cancer), Ohio University|PT-112 and its analogs (cancer), Phosplatin|imifoplatin",Research Code|INN,Cancer,,,Immunostimulant|T-lymphocyte stimulator|Apoptosis stimulator|Anticancer,393|7761|1589|1545,Non-small-cell lung cancer|Stomach tumor|Hepatocellular carcinoma|Transitional cell carcinoma|Multiple myeloma|Thymoma|Squamous cell carcinoma|Hormone refractory prostate cancer|Metastatic breast cancer|Advanced solid tumor|Breast tumor|Head and neck tumor|Cancer|Colorectal tumor,1262|127|1767|1771|1828|2939|307|3246|3657|3713|49|623|651|989,,,Phosplatin Therapeutics LLC|SciClone Pharmaceuticals LLC,1080640|19829,Ohio University,20648,Ohio University,20648,,,,,,
84250,"tocilizumab (subcutaneous), Roche/Chugai","atlizumab|IL-6 receptor MAb, Chugai|anti-interleukin-6 receptor MAb, Chugai|MRA|R-1569|tocilizumab|Actemra|RoActemra|RG-1569|RO-4877533|tocilizumab (subcutaneous), Roche/Chugai|MRA-SC",Research Code|Research Code|USAN|INN|Trade Name|Trade Name|Research Code|Research Code|Research Code,Cardiovascular|Immune|Neurology/Psychiatric|Respiratory,IL-6 receptor antagonist,471,Anti-inflammatory|Antiviral|Therapeutic antibody,2953|991|172641,Vasculitis|Takayasus arteritis|Temporal arteritis|Interstitial lung disease|Rheumatoid arthritis|Juvenile rheumatoid arthritis,1532|1537|1850|2466|291|3003,Scleroderma,1105,Chugai Pharmaceutical Co Ltd|JW Pharmaceutical Corp|Roche Holding AG,15414|15411|19446,,,Chugai Pharmaceutical Co Ltd,15414,,,,,,
84390,"BET inhibitors (cancer), Zenith Epigenetics","BET inhibitors (cancer), Zenith Epigenetics|RVX-2135|BET inhibitors (cancer), Resverlogix|ZEN-3365|ZEN-003365|ZEN-3309|ZEN-3212",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,MYC gene inhibitor|Bromodomain containing protein inhibitor,18604|34558,Apoptosis stimulator|Anticancer,1589|1545,,,Acute myelogenous leukemia|Chronic leukemia|Multiple myeloma,1731|1733|1828,,,Resverlogix Corp|Zenith Epigenetics Ltd,1007048|1084523,Resverlogix Corp,1007048,,,,,,
84412,CB-5083,"p97 inhibitors (cancer), Cleave Biosciences|CL-973134|CL-974521|CL-974039|CL-974386|CL-970294|CB-5083",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Neurology/Psychiatric,Transitional endoplasmic ATPase inhibitor|AAA ATPase inhibitor,26608|36013,Apoptosis stimulator|Musculoskeletal system modulator|Anticancer,1589|7235|1545,Multiple myeloma|Myopathy|Solid tumor,1828|672|725,Cancer,651,Cleave Therapeutics Inc,1065450,,,Cleave Therapeutics Inc,1065450,,,,,,
84437,"recombinant human endostatin (iv, NSCLC), Denovo Biopharma/Wuzhong Group","recombinant human endostatin (intravenous, advanced non-small cell lung cancer), Wuzhong Group|Sulijia|endostatin human|DB-108|recombinant human endostatin (iv, NSCLC), Denovo Biopharma/Wuzhong Group",Trade Name|Research Code,Cancer,Endostatin stimulator,49941,Anticancer protein kinase inhibitor|Apoptosis stimulator|Angiogenesis inhibitor,62255|1589|61,Metastatic non small cell lung cancer,3665,Cancer,651,Denovo Biopharma LLC|Jiangsu Wuzhong Pharmaceutical Group Corp,1076271|1072333,,,Jiangsu Wuzhong Pharmaceutical Group Corp,1072333,,,,,,
84524,telaglenastat hydrochloride,"CB-839|glutaminase inhibitors (oral, cancer), Calithera Bioscience|telaglenastat|glutaminase inhibitors (oral, cancer/anaplastic astrocytoma), Calithera Bioscience|telaglenastat hydrochloride|CB-839 HCl",Research Code|USAN|INN|USAN|Research Code,Cancer,Glutaminase inhibitor,85018,Cell cycle inhibitor|Anticancer|Apoptosis stimulator|Synergist,767|1545|1589|7293,Myelodysplastic syndrome|Pancreatic ductal adenocarcinoma|Renal cell carcinoma|Melanoma|Hematological neoplasm|Adenocarcinoma|Anaplastic astrocytoma|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic renal cell carcinoma,1272|1507|1766|205|2054|2399|2567|3246|3657|3658|3665|3713|4250,Non-small-cell lung cancer|Cancer|Solid tumor|Colorectal tumor,1262|651|725|989,Calithera Biosciences Inc|Sanford-Burnham Medical Research Institute,1055363|17746,,,Calithera Biosciences Inc,1055363,,,,,,
84557,CJM-112,CJM-112,Research Code,Cancer|Dermatologic|Immune|Respiratory,Interleukin 17 ligand inhibitor,14131,Immunomodulator|Anticancer|Anti-inflammatory,1596|1545|2953,Multiple myeloma|Acne vulgaris|Asthma attack,1828|3040|3452,Multiple sclerosis|Psoriasis|Hidradenitis suppurativa,213|281|3542,Novartis AG,23137,,,Novartis AG,23137,,,,,,
84665,ceralasertib,AZD-6738|ceralasertib,Research Code|USAN|INN,Cancer,Serine threonine protein kinase ATR inhibitor|Phosphatidylinositol 3 kinase subunit 3 inhibitor,24838|45587,Synergist|Anticancer protein kinase inhibitor|Anticancer,7293|62255|1545,Small-cell lung cancer|Stomach tumor|Myelodysplastic syndrome|Pancreatic ductal adenocarcinoma|Biliary cancer|Endometrioid carcinoma|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Cholangiocarcinoma|Renal cell carcinoma|Transitional cell carcinoma|Osteosarcoma|Melanoma|Fallopian tube cancer|Adenocarcinoma|Carcinosarcoma|Squamous cell carcinoma|Peritoneal tumor|Gallbladder tumor|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Uterine cervix tumor|Chronic myelomonocytic leukemia|Uterus tumor|Ovary tumor,1261|127|1272|1507|1516|1705|1734|1749|1765|1766|1771|1772|205|2243|2399|2614|307|3083|3146|319|3246|3257|3657|3665|3666|3669|3673|3713|4250|427|6833|740|799,Prolymphocytic leukemia|B-cell lymphoma|Cancer,1738|316|651,AstraZeneca plc|Samsung Medical Center (SMC),14190|1004334,,,AstraZeneca plc,14190,,,,,,
84695,catequentinib,"anlotinib dihydrochloride|VEGFR2/VEGFR3 inhibitor (capsule, cancer), Jiangsu Chia Tai Tianqing Pharmaceutical|AL-3818, Jiangsu Chia-tai Tianqing Pharmaceutical|anlotinib|AL-3818|FuKeWei|FOCUS-V|catequentinib|catequentinib dihydrochloride",Research Code|Research Code|Trade Name,Cancer,FGF1 receptor antagonist|FGF receptor antagonist|FGF2 receptor antagonist|PDGF receptor beta antagonist|PDGF receptor alpha antagonist|VEGF-3 receptor antagonist|FGF3 receptor antagonist|FGF4 receptor antagonist|Kit tyrosine kinase modulator|RET tyrosine kinase receptor family inhibitor|VEGF-1 receptor antagonist|VEGF-2 receptor antagonist,3682|168|3685|48492|48489|3850|3688|3691|3807|3816|3846|3848,Anticancer protein kinase inhibitor,62255,Esophagus tumor|Bone tumor|Glioma|Neuroendocrine tumor|Small-cell lung cancer|Stomach tumor|Gastrointestinal tumor|Biliary cancer|Endometrioid carcinoma|Diffuse large B-cell lymphoma|Cholangiocarcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Sarcoma|Melanoma|Fallopian tube cancer|Leiomyosarcoma|Glioblastoma|Ewing sarcoma|Peritoneal tumor|Medullary thyroid cancer|Soft tissue sarcoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Uterine cervix tumor|Urinary tract tumor|Ovary tumor,1011|1012|1108|1128|1261|127|131|1516|1705|1749|1765|1767|1768|194|205|2243|2446|2454|2975|3083|3240|3378|3658|3665|3673|3713|4250|427|738|799,Thyroid tumor|Cancer,1134|651,Advenchen Laboratories LLC|CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1017769|1025425,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,,,,,,
84701,AZD-2811,"kinase inhibitor (Accurin nanomedicine, cancer), BIND Therapeutics/ AstraZeneca|AZD1152-hQPA Accurins (nanoparticle, cancer), Astrazeneca/BIND|AZD-2811|aurora kinase B inhibitor (Accurin nanomedicine, cancer), BIND Therapeutics/ AstraZeneca|kinase inhibitor (Accurin nanomedicine, cancer), DNIB Unwind/AstraZeneca",Research Code,Cancer,Aurora protein kinase 1 inhibitor,4418,Anticancer protein kinase inhibitor,62255,Small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Advanced solid tumor,1261|1272|1731|3713,Cancer,651,AstraZeneca plc,14190,DNIB Unwind Inc,1035105,DNIB Unwind Inc,1035105,,,,,,
84805,AZD-8186,AZD-8186,Research Code,Cancer,Phosphoinositide-3 kinase beta inhibitor,11180,Anticancer protein kinase inhibitor,62255,,,Advanced solid tumor|Cancer|Solid tumor,3713|651|725,,,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
84912,olverembatinib dimesylate,"GZD-824|Bcr-Abl inhibitors (chronic myeloid leukemia), Guangzhou Institutes of Biomedicine and Health|D-824|Bcr-Abl inhibitors (chronic myeloid leukemia), Guangzhou Shunjian Biomedical Technology|HQP-1351|GIBH-824|APG-1351|olverembatinib|olverembatinib dimesylate|olverembatinib dimethanesulfonate",Research Code|Research Code|Research Code|Research Code|PINN,Cancer,Bcr protein inhibitor|ABL family tyrosine kinase inhibitor|Kit tyrosine kinase inhibitor,13571|3522|3808,Synergist|Anticancer protein kinase inhibitor,7293|62255,Acute lymphoblastic leukemia|Chronic myelocytic leukemia|Gastrointestinal stromal tumor,1728|1735|3205,,,Innovent Biologics Inc|Ascentage Pharma Group Corporation Ltd,1070750|1052437,Guangzhou Institutes of Biomedicine and Health,1053800,Guangzhou Institutes of Biomedicine and Health,1053800,,,,,,
84994,"chromene COX-2 inhibitors (tablets/capsules, inflammation/acute pain/cancer), Guangzhou Institutes of Biomedicine and Health/ Euclises","chromene COX-2 inhibitors (oral, inflammation/acute pain/cancer), Guangzhou Institutes of Biomedicine and Health|GIBH-1008|GIBH-1010|GIBH-1014|GIBH-1018|chromene COX-2 inhibitors (tablets/capsules, inflammation/acute pain/cancer), Guangzhou Institutes of Biomedicine and Health/ Euclises|ECP-1014|ECP-1012",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Immune|Inflammatory|Neurology/Psychiatric,Cyclooxygenase 2 inhibitor,1001,Anti-inflammatory|Analgesic|Anticancer,2953|2946|1545,Non-small-cell lung cancer|Inflammatory disease|Pain|Rheumatoid arthritis|Metastatic brain cancer|Head and neck tumor|Cancer|Solid tumor|Colorectal tumor,1262|188|20|291|3471|623|651|725|989,,,Guangzhou Institutes of Biomedicine and Health|Euclises Pharmaceuticals Inc,1053800|1073044,,,Guangzhou Institutes of Biomedicine and Health,1053800,,,,,,
85105,"entinostat + erlotinib (NSCLC), Syndax Pharmaceuticals/University of Colorado","entinostat + erlotinib (NSCLC), Syndax Pharmaceuticals/University of Colorado|entinostat + erlotinib",,Cancer,Histone deacetylase inhibitor|EGFR family tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,2574|3754|740,Anticancer protein kinase inhibitor,62255,,,Non-small-cell lung cancer,1262,,,Syndax Pharmaceuticals Inc|University of Colorado System,1031631|25520,University of Colorado System,25520,,,,,,
85284,BPI-9016M,"BPI-9000|BPI-9016M|c-met and Axl tyrosine kinase inhibitor(oral/tablet, cancer), Beta Pharma|BPI-9016",Research Code|Research Code|Research Code,Cancer,Axl tyrosine kinase receptor inhibitor|Hepatocyte growth factor receptor antagonist,3742|675,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Solid tumor,1262|725,,,Betta Pharmaceuticals Co Ltd,1051889,,,Betta Pharmaceuticals Co Ltd,1051889,,,,,,
85394,CD19CAR-28-zeta T cells,"anti-CD19 CAR T-cell therapy (lymphoma/multiple myeloma), Baylor College of Medicine|CD19CAR-28-zeta T cells",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,Chronic lymphocytic leukemia|Multiple myeloma|Lymphoma|Non-Hodgkin lymphoma,1734|1828|203|319,,,Baylor College of Medicine,20534,,,Baylor College of Medicine,20534,,,,,,
85411,cirmtuzumab,"anti-ROR1 mAbs (cancer), University of California San Diego|UC-961ADC3|Cirmtuzumab Vedotin|UC-961|cirmtuzumab|anti-ROR1 mAbs (cancer), Oncternal",Research Code|Research Code,Cancer,Ntrkr1 tyrosine kinase receptor inhibitor,3822,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,55685|62255,Endometrioid carcinoma|Chronic lymphocytic leukemia|Mantle cell lymphoma|B-cell lymphoma|Metastatic breast cancer|Ovary tumor,1705|1734|1744|316|3657|799,Cancer,651,Oncternal Therapeutics Inc,1122183,University of California San Diego,25451,University of California San Diego,25451,,,,,,
85487,luxeptinib,"CG-026806|Btk/Syk/VEGFR-2 inhibitors (cancer/rheumatoid arthritis), CrystalGenomics|Brutons tyrosine kinase/Spleen tyrosine kinase/VEGFR-2 inhibitors (cancer/rheumatoid arthritis), CrystalGenomics|CG-026828|Btk/Syk/VEGFR-2 inhibitors (oral, cancer), CrystalGenomics|CG'806|CG-806|FLT3/BTK kinase inhibitor (cancer), CrystalGenomics/Aptose Biosciences|luxeptinib",Research Code|Research Code|Research Code|Research Code|USAN,Cancer|Immune,Btk tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor,3592|3806,Synergist|Anti-inflammatory|Anticancer protein kinase inhibitor,7293|2953|62255,Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Leukemia|Lymphoma|Hematological neoplasm|Non-Hodgkin lymphoma,1272|1731|1734|1744|199|203|2054|319,Rheumatoid arthritis,291,Aptose Biosciences Inc|CrystalGenomics Inc,17215|1003254,,,CrystalGenomics Inc,1003254,,,,,,
85497,tinostamustine,"NL-101 (cancer), Northlake Biosciences/Mundipharma/Hangzhou Minsheng|NL-101|EDO-S101|tinostamustine|tinostamustine (cancer), Northlake Biosciences/Mundipharma/Hangzhou Minsheng|tinostamustine (intravenous, hematological cancer/solid tumors), Northlake Biosciences/Mundipharma/Hangzhou Minsheng|CY-190602",Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer|Cardiovascular,Histone deacetylase inhibitor,2574,Anti-inflammatory|Cell cycle inhibitor|Apoptosis stimulator|Anticancer alkylating agent,2953|767|1589|50,Small-cell lung cancer|Vasculitis|Hodgkins disease|Prolymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Multiple myeloma|Hematological neoplasm|Glioblastoma|Non-Hodgkin lymphoma|Soft tissue sarcoma|Breast tumor|Cancer|Ovary tumor,1261|1532|161|1738|1744|1745|1753|1754|1828|2054|2454|319|3378|49|651|799,,,Mundipharma EDO GmbH|Hangzhou Minsheng Pharmaceutical Group Company Ltd,24189|1028428,Mundipharma International Corp Ltd|Crystal Biopharmaceutical LLC|Northlake Biosciences LLC,1045514|1055652|1056099,Crystal Biopharmaceutical LLC,1055652,,,,,,
85503,lifirafenib,"BeiGene-283|BRAF kinase inhibitor (cancer), BeiGene/Merck KGaA|BGB-283|BRAF and EGFR dual inhibitor (cancer), BeiGene/Merck KGaA|lifirafenib|lifirafenib maleate|BGB-283 sesqui-maleate|lifirafenib sesqui-maleate",Research Code|Research Code|USAN|INN|USAN,Cancer,Epidermal growth factor receptor antagonist|Raf B protein kinase inhibitor,740|4548,Anticancer protein kinase inhibitor|Anticancer,62255|1545,Thyroid tumor|Endometrioid carcinoma|Hepatocellular carcinoma|Melanoma|Stage IV melanoma|Ovarian clear cell carcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer,1134|1705|1767|205|3257|3525|3658|3665|3666|3669|3713|3866,Cancer,651,BeiGene Co Ltd,1063251,Merck Serono SA,19862,BeiGene Co Ltd,1063251,,,,,,
85598,HL-085,"HL-085|MEK inhibitor (cancer), Tianjin Binjiang Pharma",Research Code,Cancer,MEK protein kinase inhibitor,4760,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Stage IV melanoma|Metastatic colorectal cancer|Advanced solid tumor,1262|3257|3658|3713,Cancer,651,Kechow Pharma Inc,1115232,,,Kechow Pharma Inc,1115232,,,,,,
85603,Oncoquest-CLL,"IL-2/TMA-S (liposome based vaccine, Aggregon, chronic lymphocytic leukemia), Xeme Biopharma|Oncoquest-CLL|IL-2/TMA-S (liposome based vaccine, Aggregon, CLL), Xeme Biopharma",Trade Name,Cancer,Interleukin-2 ligand,12481,Anticancer|Therapeutic vaccine,1545|12379,Chronic lymphocytic leukemia,1734,Cancer,651,Xeme Biopharma Inc,1060613,,,Xeme Biopharma Inc,1060613,,,,,,
85671,"temozolomide (oral capsule, glioma), Jiangsu Tasly Diyi Pharmaceutical","temozolomide|temozolomide (oral capsule, glioma), Jiangsu Tasly Diyi Pharmaceutical|Diqing",USAN|Trade Name,Cancer,DNA methyltransferase inhibitor,6512,Anticancer alkylating agent,50,Glioma,1108,,,Jiangsu Tasly Diyi Pharmaceutical Co Ltd,1027711,,,Jiangsu Tasly Diyi Pharmaceutical Co Ltd,1027711,,,,,,
85691,STM-434,"STM-217|recombinant human soluble activin type 2B receptor Fc fusion protein (cancer), Amgen/Atara Biotherapeutics|STM-434|STM-434/s",Research Code|Research Code|Research Code,Cancer,Activin type-IIB receptor antagonist,4574,Anticancer protein kinase inhibitor,62255,,,Unidentified indication|Cancer|Solid tumor|Ovary tumor,1005|651|725|799,,,Atara Biotherapeutics Inc|Amgen Inc,1074591|14109,Amgen Inc,14109,,,,,,
85714,"anti-PSMA CAR T-cell therapy (prostate cancer), Memorial Sloan-Kettering Cancer Center","anti-PSMA CAR T-cell therapy (prostate cancer), Memorial Sloan-Kettering Cancer Center",,Cancer,Glutamate carboxypeptidase II modulator,9267,Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer,393|4790|7761|1545,Metastatic prostate cancer,3664,,,Memorial Sloan-Kettering Cancer Center,22122,,,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
85761,camidanlumab tesirine,"HuMax-TAC-drug conjugate (leukemia/lymphoma, pyrrolobenzodiazepine (PBD)-based warhead), Genmab / ADC|HuMax-TAC-ADC|camidanlumab tesirine|ADCT-301|Cami-T|SUR-301|IL-2RA-targeting antibody (NHL/HL/DLBCL/AML/advanced solid tumors/myelodysplastic syndrome/myeloproliferative neoplasms), ADC Therapeutics",INN|Research Code|Research Code,Cancer|Hematologic,IL-2 receptor alpha subunit inhibitor,5100,Anticancer monoclonal antibody|Synergist|Anti-inflammatory,55685|7293|2953,Myelodysplastic syndrome|Hodgkins disease|Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Cutaneous T-cell lymphoma|Leukemia|Lymphoma|Myeloproliferative disorder|Squamous cell carcinoma|Non-Hodgkin lymphoma|Stage IV melanoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma|Colon tumor|Burkitts lymphoma,1272|161|1728|1729|1731|1743|1744|1745|1746|1749|1753|1754|199|203|273|307|319|3257|3466|3657|3658|3665|3666|3667|3669|3673|3713|3866|4250|767|791,,,ADC Therapeutics Sarl|Genmab A/S,1068935|26469,,,Genmab A/S,26469,,,,,,
85767,ravoxertinib,RG-7842|GDC-0994|GDC-0094|ravoxertinib,Research Code|Research Code|Research Code|USAN|INN,Cancer,Extracellular signal related kinase-1 inhibitor|Extracellular signal related kinase-2 inhibitor,4364|4366,Cell cycle inhibitor|Anticancer protein kinase inhibitor,767|62255,,,Solid tumor,725,,,Genentech Inc|Array BioPharma Inc,19453|25902,Genentech Inc,19453,,,,,,
85786,APG-1387,APG-1387|SM-1387,Research Code|Research Code,Cancer|Infection,Inhibitor of apoptosis protein 2 inhibitor|Inhibitor of apoptosis protein 1 inhibitor|X-linked inhibitor of apoptosis protein inhibitor|Kidney inhibitor of apoptosis protein inhibitor,13599|13602|13605|13614,Synergist|Anti-inflammatory|Anticancer|Antiviral|Apoptosis stimulator,7293|2953|1545|991|1589,Hepatitis B virus infection|Hematological neoplasm|Metastatic colorectal cancer|Metastatic pancreas cancer|Advanced solid tumor|Head and neck tumor,152|2054|3658|3669|3713|623,Breast tumor|Cancer,49|651,Ascentage Pharma Group Corporation Ltd,1052437,,,Ascentage Pharma Group Corporation Ltd,1052437,,,,,,
85967,CC-90002,"CC-90002|Ca ImmRx|CD47 checkpoint inhibitor (cancer), INHIBRx/Celgene|Ca ImmunoRx Ab|INBRX-103",Research Code|Research Code,Cancer,CD47 antagonist,5185,Immunostimulant|Anticancer monoclonal antibody|Macrophage stimulator,393|55685|7751,Non-Hodgkin lymphoma,319,Myelodysplastic syndrome|Acute myelogenous leukemia|Lymphoma|Cancer|Solid tumor,1272|1731|203|651|725,Bristol-Myers Squibb Co,15065,Inhibrx Inc|Celgene Corp,1063813|15331,Inhibrx Inc,1063813,,,,,,
8618,zosuquidar,"zosuquidar|LY-335979|RS-33295-198|zosuquidar trihydrochloride|LY-395599|LY-389551|LY-395598|LY-395597|multidrug resistance inhibitor, Lilly|KAN-979",INN|Research Code|Research Code|USAN|Metabolite|Metabolite|Metabolite|Metabolite|Research Code,Cancer,P-Glycoprotein 1 inhibitor,11495,Anticancer|Anticancer multidrug resistance inhibitor,1545|759,,,Cancer,651,,,Kanisa Pharmaceuticals Inc|Chugai Lilly Clinical Research Co Ltd|Eli Lilly & Co|Roche Palo Alto,1026139|14165|17810|19470,Roche Palo Alto,19470,,,,,,
86183,"decitabine + cedazuridine (oral, myelodysplastic syndrome/chronic myelomonocytic leukemia), Astex","ASTX-727|decitabine + E-7727 (oral, myelodysplastic syndrome), Astex|decitabine + E-7727|decitabine + cedazuridine|decitabine + cedazuridine (oral, myelodysplastic syndrome), Astex|decitabine + cedazuridine (oral, myelodysplastic syndrome/chronic myelomonocytic leukemia), Astex|decitabine + cedazuridine (oral, myelodysplastic syndrome/chronic myelomonocytic leukemia/acute myelogenous leukemia), Astex|Inqovi",Research Code|Trade Name,Cancer|Hematologic,Cytosine DNA methyltransferase inhibitor|Cytidine deaminase inhibitor,6515|7117,Anticancer antimetabolite,1569,Metastasis|Glioma|Myelodysplastic syndrome|Acute myelogenous leukemia|Hematological neoplasm|Myeloproliferative disorder|Metastatic breast cancer|Advanced solid tumor|Chronic myelomonocytic leukemia|Nerve tumor,1069|1108|1272|1731|2054|273|3657|3713|6833|763,,,Astex Pharmaceuticals Inc|Taiho Pharma Canada Inc|Taiho Oncology Inc,21885|1144560|1092741,,,Astex Pharmaceuticals Inc,21885,,,,,,
86232,PF-06263507,PF-06263507,Research Code,Cancer,Trophoblast glycoprotein inhibitor,14329,Anticancer antibody,55684,,,Solid tumor,725,,,Pfizer Inc|Oxford BioMedica plc,18767|23434,Oxford BioMedica plc,23434,,,,,,
86278,larotrectinib sulfate,"oncogenic activating mutation-targeting compound (cancer), Array BioPharma/ Loxo Oncology|tyrosine kinase inhibitor (oral, cancer), Array BioPharma/Loxo Oncology|LOXO-101|larotrectinib|larotrectinib sulfate|Vitrakvi|BAY-2757556",Research Code|USAN|INN|USAN|Trade Name|Research Code,Cancer,Trk tyrosine kinase receptor inhibitor,3838,Anticancer protein kinase inhibitor,62255,Hematological neoplasm|Advanced solid tumor|Solid tumor,2054|3713|725,Cancer,651,Bayer AG,14455,Loxo Oncology at Lilly|Array BioPharma Inc,1086092|25902,Array BioPharma Inc,25902,,,,,,
86441,nemvaleukin alfa,"RDB-1419|RDB-1450|ALKS-4230|intermediate-affinity IL-2 receptor agonist (advanced solid tumors), Alkermes|intermediate-affinity IL-2 receptor agonist (cancer), Alkermes|nemvaleukin alfa",Research Code|Research Code|Research Code|PINN,Cancer,IL-2 receptor agonist,221,Immunostimulant|Anticancer|Natural killer cell stimulator|T-lymphocyte stimulator,393|1545|7757|7761,Renal cell carcinoma|Melanoma|Squamous cell carcinoma|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Colon tumor,1766|205|307|3257|3657|3658|3673|3713|3866|767,Cancer,651,Alkermes plc,14005,,,Alkermes plc,14005,,,,,,
86460,KO-539,"menin/MLL interaction inhibitor (leukemia), University of Michigan|MI-2-2|menin MLL inhibitors (oral, leukemia), Kura Oncology|MI-463|MI-503|MI-136|MIV-6|MI-258|MI-1|KO-382|KO-539",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Menin inhibitor|Myeloid lymphoid leukemia protein inhibitor,37755|44220,Anticancer|Apoptosis stimulator,1545|1589,Acute myelogenous leukemia,1731,Leukemia|Prostate tumor,199|276,Kura Oncology Inc,1106202,University of Michigan,20623,University of Michigan,20623,,,,,,
86472,zanidatamab,"bi-specific antibody (cancer), Zymeworks|bi-specific Azymetric antibody (ZymeCAD, cancer), Zymeworks|ZW-25|HER-2 modulator (breast cancer), Zymeworks|HER-2 inhibitor (iv, cancers, Zymeworks|zanidatamab",Research Code|INN,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Complement C1q related factor modulator,3756|47073,Anticancer antibody|Anticancer protein kinase inhibitor|Immunostimulant,55684|62255|393,Non-small-cell lung cancer|Stomach tumor|Gastrointestinal tumor|Biliary cancer|Endometrioid carcinoma|Cholangiocarcinoma|Adenocarcinoma|Carcinosarcoma|Gallbladder tumor|Metastatic breast cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Breast tumor|Cancer|Ovary tumor|Colorectal tumor,1262|127|131|1516|1705|1765|2399|2614|3146|3657|3666|3667|49|651|799|989,Esophagus tumor,1011,BeiGene Co Ltd|Zymeworks Inc,1063251|1038924,,,Zymeworks Inc,1038924,,,,,,
86549,rovalpituzumab tesirine,rovalpituzumab tesirine|SC16LD6.5|Rova-T|D6.5,USAN|INN|Research Code|Research Code,Cancer,Delta-like protein ligand 3 inhibitor,18190,Anticancer monoclonal antibody|DNA intercalator,55685|750,,,Neuroendocrine tumor|Small-cell lung cancer|Advanced solid tumor,1128|1261|3713,,,Stemcentrx Inc|AbbVie Inc,1063564|1072507,Stemcentrx Inc,1063564,,,,,,
86597,enasidenib,"AGI-6780|isocitrate dehydrogenase-2 inhibitor (oral, cancer/type II D-2 hydroxyglutaric aciduria), Agios/Celgene|AGI-12026|enasidenib|AG-221|CC-90007|enasidenib mesylate|AG-221 mesylate|Idhifa|AGI-12910",Research Code|Research Code|USAN|INN|Research Code|Research Code|USAN|Research Code|Trade Name|Research Code,Cancer|Genitourinary/Sexual Function,Mitochondrial isocitrate dehydrogenase inhibitor,67505,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,Advanced solid tumor|Glutaric aciduria|Cancer,3713|5426|651,Bristol-Myers Squibb Co,15065,Agios Pharmaceuticals Inc|Celgene Corp,1040627|15331,Agios Pharmaceuticals Inc,1040627,,,,,,
86611,fluazolepali,"fluazolepali|small molecule therapeutic (oral/capsule, undisclosed indication), Jiangsu Hansoh Pharmaceutical|fluzoparib|SHR-3162|poly ADP ribose polymerase 1/2 inhibitor (oral, ovarian cancer), Jiangsu Hengrui Medicine|PARP1/PARP2 inhibitor (oral, ovarian cancer), Jiangsu Hengrui Medicine|airuiyi",Research Code|Trade Name,Cancer,Poly ADP ribose polymerase 2 inhibitor|Poly ADP ribose polymerase 1 inhibitor,38286|38283,Anticancer,1545,Small-cell lung cancer|Stomach tumor|Fallopian tube cancer|Peritoneal tumor|Hormone refractory prostate cancer|Metastatic pancreas cancer|Breast tumor|Solid tumor|Ovary tumor,1261|127|2243|3083|3246|3669|49|725|799,,,Jiangsu Hengrui Medicine Co Ltd,1006925,Jiangsu Hansoh Pharmaceutical Group Co Ltd,1017684,Jiangsu Hansoh Pharmaceutical Group Co Ltd,1017684,,,,,,
86613,"cafusertib hydrochloride (iv, acute myeloid leukemia), Jiangsu Hansoh Pharmaceutical","kafuseti hydrochloride (injectable), Jiangsu Hansoh Pharmaceutical|cafusertib hydrochloride (iv, acute myeloid leukemia), Jiangsu Hansoh Pharmaceutical",,Cancer,Polo-like kinase inhibitor,4530,Anticancer protein kinase inhibitor,62255,,,Acute myelogenous leukemia|Solid tumor,1731|725,,,Jiangsu Hansoh Pharmaceutical Group Co Ltd,1017684,Jiangsu Hansoh Pharmaceutical Group Co Ltd,1017684,,,,,,
86615,M2ES,"M2ES|PEGylated recombinant human endostatin (cancer), Protgen/Tsinghua University|CRB-0401",Research Code|Research Code,Cancer,Endostatin stimulator,49941,Angiogenesis inhibitor|Anticancer,61|1545,Metastatic non small cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor,3665|3669|3713,,,Tsinghua University|Protgen Ltd,1005253|1024338,,,Protgen Ltd,1024338,,,,,,
86642,"CD25/71 allodepleted donor T-cell therapy (immune disease), UCL/MRC","CD25/71 allodepleted donor T-cell therapy (immune disease), UCL/MRC",,Immune,,,T-lymphocyte modulator,5692,Immune disorder,185,,,Medical Research Council|University College London,18438|23505,,,University College London,23505,,,,,,
86751,gilteritinib,gilteritinib|gilteritinib fumarate|ASP-2215 hemifumarate|ASP-2215|Xospata,USAN|INN|USAN|Research Code|Research Code|Trade Name,Cancer,Axl tyrosine kinase receptor inhibitor|Flt3 tyrosine kinase inhibitor,3742|3806,Anticancer protein kinase inhibitor|Apoptosis stimulator|Synergist,62255|1589|7293,Acute myelogenous leukemia|Solid tumor,1731|725,Non-small-cell lung cancer|Cancer,1262|651,Astellas Pharma Inc,1013295,Kotobuki Pharmaceutical Co Ltd,17687,Kotobuki Pharmaceutical Co Ltd,17687,,,,,,
86898,"bisantrene hydrochloride (acute myeloid leukemia), Race Oncology","bisantrene|UPI-928|bisantrene hydrochloride (acute myeloid leukemia), Update Pharma|bisantrene hydrochloride|bisantrene hydrochloride (acute myeloid leukemia), Race Oncology|CS-1, Race Oncology|bisantrene hydrochloride (acute myeloid leukemia/skin cancer/ovary tumor/breast tumor), Race Oncology",INN|Research Code|USAN|Research Code,Cancer,Protein FTO inhibitor|Telomerase inhibitor,54067|1614,Immunostimulant|Macrophage stimulator|DNA intercalator|Anticancer,393|7751|750|1545,Acute myelogenous leukemia|Skin cancer|Breast tumor|Ovary tumor,1731|2170|49|799,,,Race Oncology Ltd|BL&H Co Ltd,1138198|1037227,Update Pharma Inc,1087140,Update Pharma Inc,1087140,,,,,,
86929,[18F]-SKI-249380,"[18F]-SKI-249380|PET imaging agent (cancer), Memorial Sloan-Kettering Cancer Center",Research Code,Cancer,,,Radioimmunodiagnostic|Neoplasm diagnostic agent|Imaging agent,4405|7220|4155,,,Cancer,651,,,Memorial Sloan-Kettering Cancer Center,22122,Memorial Sloan-Kettering Cancer Center,22122,,,,,,
86938,dezapelisib,"PI3K delta inhibitor (1) (B-cell lymphoma), Incyte|INCB-40093|dezapelisib|INCB-040093",Research Code|USAN|INN|Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor,11183,Anticancer protein kinase inhibitor,62255,Hodgkins disease|B-cell lymphoma,161|316,,,Incyte Corp,17216,,,Incyte Corp,17216,,,,,,
86946,DPV-001,"DRibbles vaccine (NSCLC), Mayo Clinic/NCI/UbiVAc|DPV-001|DRibbles vaccine (cancer), Mayo Clinic/NCI/UbiVac|DPV-003|DPV-002|allogeneic DRibbles multivalent autophagosome vaccine (ultrasound-guided injection, NSCLC/TNBC/HNSCC), Canwell Pharma/UbiVac",Research Code|Research Code|Research Code,Cancer,,,Unspecified drug target|Therapeutic vaccine|Anticancer,59620|12379|1545,Non-small-cell lung cancer|Metastatic breast cancer|Breast tumor|Head and neck tumor,1262|3657|49|623,Bladder cancer|Pancreas tumor|Prostate tumor|Cancer,2380|249|276|651,Canwell Pharma Inc|Mayo Clinic Foundation|UbiVac|National Cancer Institute (NCI),1241667|21111|1086637|20519,,,Mayo Clinic Foundation,21111,,,,,,
8713,sildenafil citrate,sildenafil citrate|UK 92480-10|sildenafil|UK-92480|Viagra|Patrex|Revatio,USAN|INN|Research Code|Trade Name|Trade Name|Trade Name,Cardiovascular|Endocrine/Metabolic|Genitourinary/Sexual Function|Neurology/Psychiatric,PDE 5 inhibitor,778,Vasodilator|5-HETE modulator|Antihypertensive,388|882|2657,Erectile dysfunction|Pulmonary artery hypertension,186|3510,Female sexual dysfunction|Neuropathic pain|Metabolic syndrome X|Diastolic heart failure|Persistent pulmonary hypertension of the newborn,1276|1295|3294|3296|3660,Viatris Inc,1136574,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
8714,voriconazole,UK-109496|Vfend|voriconazole|Pinup,Research Code|Trade Name|USAN|INN|Trade Name,Infection,Lanosterol-14 demethylase inhibitor,777,Ergosterol synthesis inhibitor|Fungicide|Systemic dermatological antifungal product,161|1748|15178,Dermatomycosis|Fungal infection|Aspergillus fumigatus infection|Candida infection|Candida krusei infection|Fusarium infection|Scedosporium infection|Fungal urinary tract infection|Cryptococcus neoformans meningitis|Aspergillus infection,1109|124|1307|1308|1310|1337|1347|1799|1813|29,,,Pfizer Ltd|Pfizer Inc,18862|18767,,,Pfizer Ltd,18862,,,,,,
87196,cobolimab,"anti T-cell immunoglobulin mucin protein-3 mAbs (cancer immunotherapy), AnaptysBio|anti TIM-3 mAbs (cancer immunotherapy), AnaptysBio|anti TIM-3 mAbs (cancer immunotherapy), TESARO|anti T-cell immunoglobulin mucin protein-3 mAbs (cancer immunotherapy), TESARO|TSR-022|TIM-3 checkpoint inhibitor (SHM-XEL, cancer), AnaptysBio/TESARO|cobolimab|GSK-4069889|GSK-4069889A",Research Code|USAN|PINN|Research Code|Research Code,Cancer,Hepatitis A virus cellular receptor 2 antagonist,34783,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator|Anticancer,55685|393|7761|1545,Non-small-cell lung cancer|Squamous cell carcinoma|Stage III melanoma|Stage IV melanoma|Metastatic liver cancer|Advanced solid tumor,1262|307|3256|3257|3462|3713,Cancer,651,GlaxoSmithKline plc,28355,AnaptysBio Inc|TESARO Inc,1032144|1054559,AnaptysBio Inc,1032144,,,,,,
87352,"CDCA1/IMP-3 derived peptide vaccine (sc, NSCLC), Tokyo University","CDCA1/IMP-3 derived peptide vaccine (sc, NSCLC), Tokyo University",,Cancer,,,Anticancer|Therapeutic vaccine,1545|12379,,,Non-small-cell lung cancer,1262,,,University of Tokyo,20686,University of Tokyo,20686,,,,,,
87375,SKLB-1028,SKLB-1028,Research Code,Cancer,ABL family tyrosine kinase inhibitor|EGFR family tyrosine kinase receptor inhibitor|Flt3 tyrosine kinase inhibitor,3522|3754|3806,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Acute myelogenous leukemia,1262|1731,,,CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd,1047791,Sichuan University,1003379,Sichuan University,1003379,,,,,,
8747,palivizumab,palivizumab|MEDI-493|Synagis,INN|Research Code|Trade Name,Infection|Respiratory,Respiratory syncytial virus protein F modulator,52108,Antiviral,991,Respiratory syncytial virus infection,287,Cystic fibrosis,88,Swedish Orphan Biovitrum AB|AbbVie Inc,28921|1072507,Abbott Laboratories|American Cyanamid Co|Dainippon Pharmaceutical Co Ltd|MedImmune LLC,13601|14113|15606|18008,MedImmune LLC,18008,,,,,,
87488,MRX-2843,"UNC-569A|UNC-569|Mer tyrosine kinase inhibitors (cancer), Meryx|UNC-1062|UNC-2881|Mer-selective inhibitors (cancer/thrombosis), Meryx|UNC-Mer-TKI-1|UNC-Mer-TKI-2|UNC-2250|MRX-6361|Mer tyrosine kinase inhibitors (cancer), University of North Carolina/University of Colorado at Denver and Health Sciences Center|mer-selective inhibitors (cancer/thrombosis), University of North Carolina/University of Colorado|UNC-2025|MRX-2843|dual Mer/Flt3-selective inhibitors (cancer/thrombosis), Meryx|dual Mer/Flt3-selective inhibitors (oral capsule, cancer/thrombosis/advanced solid tumors), Meryx|UNC-2371|UNC-4203",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Hematologic,Mer tyrosine kinase receptor inhibitor|Flt3 tyrosine kinase inhibitor,3744|3806,Anticancer protein kinase inhibitor|Platelet aggregation inhibitor|Synergist|Apoptosis stimulator|Coagulation inhibitor,62255|312|7293|1589|659,Thrombosis|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Advanced solid tumor,1076|1728|1731|3713,Cancer,651,Meryx Inc|Betta Pharmaceuticals Co Ltd,1100821|1051889,University of Colorado at Denver and Health Sciences Center|University of North Carolina,1033110|20634,University of North Carolina,20634,,,,,,
87511,berzosertib,"VE-822|VX-970|M-66207|berzosertib|M-6620|ATR inhibitor (oral, solid tumors), Merck KGaA",Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer|Infection,Serine threonine protein kinase ATR inhibitor,24838,Antiviral|Anticancer protein kinase inhibitor|Synergist,991|62255|7293,Esophagus tumor|Coronavirus disease 19 infection|Neuroendocrine tumor|Small-cell lung cancer|Non-small-cell lung cancer|Osteosarcoma|Fallopian tube cancer|Leiomyosarcoma|Hormone refractory prostate cancer|Metastatic bladder cancer|Metastatic brain cancer|Metastatic prostate cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Uterine cervix tumor|Breast tumor,1011|10406|1128|1261|1262|1772|2243|2446|3246|3466|3471|3664|3673|3713|3866|427|49,,,University of California Los Angeles|Merck KGaA,25623|18101,Vertex Pharmaceuticals Inc,20739,Vertex Pharmaceuticals Inc,20739,,,,,,
8752,Cervarix,"Cervarix|MEDI-503|MEDI-504|HPV vaccine, MedImmune/SB|HPV vaccine, MedImmune/GSK|human papillomavirus vaccine (HPV-16 + HPV-18), MedImmune/GSK|MEDI-517|MEDI-503 + MEDI-504, MedImmune/GSK|580299|GSK-580299|HPV-16/18 L1 AS04 vaccine",Trade Name|Research Code|Research Code|Research Code|Research Code|Research Code,Infection,,,Protein subunit vaccine|Prophylactic vaccine,12372|12378,Papillomavirus infection,396,,,GlaxoSmithKline plc|SK Bioscience,28355|1167268,MedImmune LLC|SmithKline Beecham plc,18008|19962,MedImmune LLC,18008,,,,,,
87597,KPT-9274,"PAK4/NAMPT dual inhibitors (oral, cancer), Karyopharm Therapeutics|KPT-8752|KPT-7523|KPT-7651|KPT-9274|KPT-9307|KPT-9331|KPT-7189|KPT-6604|KCP-9274|PAK4/NAMPT dual inhibitors (oral, cancer), Karyopharm/ Antengene|ATG-019",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,Nicotinamide phosphoribosyltransferase inhibitor|PAK-4 protein kinase inhibitor,11722|4710,Synergist|Cell cycle inhibitor|Anticancer|Anticancer protein kinase inhibitor|Apoptosis stimulator,7293|767|1545|62255|1589,Pancreatic endocrine tumor|Acute myelogenous leukemia|Lymphoplasmacytic lymphoma|Non-Hodgkin lymphoma|Stage IV melanoma|Advanced solid tumor|Cancer,1510|1731|1743|319|3257|3713|651,,,Karyopharm Therapeutics Inc|Antengene Corp Ltd,1049781|1152645,,,Karyopharm Therapeutics Inc,1049781,,,,,,
87598,GSK-2879552,"LSD-1 inhibitors (cancer), GlaxoSmithKline|GSK-2879552|GSK-519|GSK-690",Research Code|Research Code|Research Code,Cancer,Lysine specific histone demethylase 1 inhibitor,14681,Cell cycle inhibitor|Anticancer|Cell differentiation stimulator,767|1545|53574,Myelodysplastic syndrome,1272,Small-cell lung cancer|Acute myelogenous leukemia|Cancer,1261|1731|651,GlaxoSmithKline plc,28355,,,GlaxoSmithKline plc,28355,,,,,,
87642,UV-1,"UV-1|synthetic peptide based therapeutic vaccine (intradermal, prostate cancer/non-small cell lung cancer), Ultimovacs/Oslo University Hospital|dendritic cell based therapeutic vaccine (intradermal, prostate cancer/non-small cell lung cancer), Trianta/Oslo University Hospital",Research Code,Cancer,Telomerase inhibitor,1614,Synergist|Protein subunit vaccine|T-lymphocyte stimulator|Anticancer|Therapeutic vaccine,7293|12372|7761|1545|12379,Mesothelioma|Non-small-cell lung cancer|Melanoma|Prostate tumor|Stage IV melanoma|Metastatic ovary cancer|Lung tumor,1240|1262|205|276|3257|3866|755,Cancer,651,Oslo University Hospital|Ultimovacs AS,1049414|1078587,,,Ultimovacs AS,1078587,,,,,,
87937,Pirotinib,Pirotinib|KBP-5209|5209,Research Code|Research Code,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Erbb3 tyrosine kinase receptor inhibitor|Erbb4 tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3756|3758|3760|740,Anticancer protein kinase inhibitor,62255,Advanced solid tumor|Cancer|Lung tumor,3713|651|755,,,Xuanzhu Pharma Co Ltd,1099478,,,Xuanzhu Pharma Co Ltd,1099478,,,,,,
87940,CFI-400945 fumarate,"CFI-440945|CFI-400945|CFI-400945 fumarate|polo-like kinase 4 (PLK4) inhibitor (oral tablet, advanced cancer/MDS/AML/metastatic breast tumor/brain tumor), The University Health Network|polo-like kinase 4 (PLK4) inhibitor (oral tablet, advanced cancer/MDS/AML/metastatic breast tumor/brain tumor), Treadwell Therapeutics/Ann & Robert H Lurie Children's Hospital|945|400945",Research Code|Research Code|Research Code,Cancer,Polo-like kinase 4 inhibitor,4538,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Metastasis|Myelodysplastic syndrome|Acute myelogenous leukemia|Hormone refractory prostate cancer|Metastatic breast cancer|Chronic myelomonocytic leukemia,1069|1272|1731|3246|3657|6833,Breast tumor|Cancer|Brain tumor,49|651|760,Treadwell Therapeutics,1203627,The University Health Network|Ann & Robert H Lurie Children's Hospital of Chicago,28443|29835,The University Health Network,28443,,,,,,
87948,"infliximab biosimilar, Mabpharm/Sorrento Therapeutics","infliximab|infliximab biosimilar, BioMab Pharmaceuticals|infliximab biobetter, Mabtech/Sorrento|STI-002|Baileiting|CMAB-008|infliximab biosimilar, Mabpharm/Sorrento Therapeutics",INN|Research Code|Research Code,Dermatologic|Gastrointestinal|Immune|Musculoskeletal,TNF alpha ligand inhibitor|TNF binding agent,381|721,Anti-inflammatory,2953,Psoriasis|Rheumatoid arthritis|Ulcerative colitis|Ankylosing spondylitis|Crohns disease,281|291|337|398|84,,,Mabpharm Ltd|Shandong Kexing Bioproducts Co Ltd|Sorrento Therapeutics Inc,1112405|1071589|1048574,,,Mabpharm Ltd,1112405,,,,,,
88045,lorlatinib,"PF-06463922|lorlatinib|ALK/ROS1 inhibitor (oral, cancer), Pfizer|Lorbrena|Lorviqua",Research Code|USAN|INN|Trade Name|Trade Name,Cancer,Anaplastic lymphoma kinase receptor inhibitor|Ros1 tyrosine kinase receptor inhibitor,3736|3826,Apoptosis stimulator|Cell cycle inhibitor|Anticancer protein kinase inhibitor,1589|767|62255,Metastasis|Anaplastic large cell lymphoma|Neuroblastoma|Metastatic non small cell lung cancer,1069|1755|2726|3665,Lung tumor,755,CStone Pharmaceuticals|Pfizer Inc,1126254|18767,,,Pfizer Inc,18767,,,,,,
88056,CMB-305,CMB-305|ID-CMB305|LV-305 + G-305,Research Code|Research Code,Cancer,Cancer testis antigen NY-ESO-1 modulator|T-cell surface glycoprotein CD8 stimulator|TLR-4 agonist,50096|5039|7812,Anticancer|T-lymphocyte stimulator|Therapeutic vaccine,1545|7761|12379,Non-small-cell lung cancer|Melanoma|Liposarcoma|Soft tissue sarcoma|Solid tumor|Ovary tumor,1262|205|2447|3378|725|799,,,Immune Design Corp,1040366,,,Immune Design Corp,1040366,,,,,,
88079,RXDX-106,"CEP-40783|RXDX-106|triple Axl checkpoint inhibitor/Mer checkpoint inhibitor/Tyro3 checkpoint inhibitor (advanced solid tumors), Ignyta",Research Code|Research Code,Cancer,Axl tyrosine kinase receptor inhibitor|Mer tyrosine kinase receptor inhibitor|Tyro3 tyrosine kinase receptor inhibitor|Hepatocyte growth factor receptor antagonist,3742|3744|3746|675,Macrophage stimulator|Dendritic cell stimulator|Immunostimulant|Anticancer protein kinase inhibitor,7751|173472|393|62255,Advanced solid tumor,3713,Cancer,651,Ignyta Inc,1079441,Cephalon Inc|Teva Pharmaceutical Industries Ltd,15358|20348,Cephalon Inc,15358,,,,,,
88090,JNJ-64041757,ADU-214|JNJ-757|JNJ-64041757|pemlimogene merolisbac|JNJ-1757,Research Code|Research Code|Research Code|INN|Research Code,Cancer,Mesothelin modulator|Epidermal growth factor receptor modulator,11484|3605,Anticancer|Live attenuated bacterial vaccine|Therapeutic vaccine,1545|12363|12379,Metastatic non small cell lung cancer,3665,Non-small-cell lung cancer|Ovary tumor,1262|799,Janssen Biotech Inc,26997,Chinook Therapeutics Inc,1039923,Chinook Therapeutics Inc,1039923,,,,,,
88116,TTI-101,"C-188-9|STAT3 inhibitor (cancer), Stemmed/Baylor College of Medicine/Tvardi Therapeutics|C-188|MM-206|TTI-101|STAT3 inhibitor (oral, advanced solid tumors), Tvardi Therapeutics",Research Code|Research Code|Research Code|Research Code,Cancer|Other/Miscellaneous|Respiratory,STAT-3 inhibitor,7967,Apoptosis stimulator|Anti-inflammatory|Anticancer,1589|2953|1545,Stomach tumor|Gastrointestinal tumor|Hepatocellular carcinoma|Squamous cell carcinoma|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Cachexia,127|131|1767|307|3257|3657|3658|3665|3673|3713|425,Asthma|Cancer,31|651,Tvardi Therapeutics Inc|Stemmed Ltd,1169247|1088655,Baylor College of Medicine,20534,Baylor College of Medicine,20534,,,,,,
88172,DBPR-112,DBPR-112,Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor,62255,Head and neck tumor|Lung tumor,623|755,Cancer,651,National Health Research Institutes,29596,,,National Health Research Institutes,29596,,,,,,
88224,ASP-5878,ASP-5878,Research Code,Cancer,FGF receptor antagonist,168,Anticancer protein kinase inhibitor|Anticancer,62255|1545,,,Solid tumor,725,,,Astellas Pharma Inc|Kotobuki Pharmaceutical Co Ltd,1013295|17687,Astellas Pharma Inc,1013295,,,,,,
88231,PEN-866,"Hsp90 inhibitor-SN-38 conjugate (cancer), Synta|HDC SN-38|STA-12-8666|Hsp90 inhibitor-SN-38 conjugate (cancer), Madrigal|PEN-866|STA-8666",Research Code|Research Code|Prodrug|Research Code|Prodrug|Research Code|Prodrug,Cancer,Topoisomerase I inhibitor|Hsp 90 inhibitor,141|8012,Anticancer,1545,Small-cell lung cancer|Stomach tumor|Sarcoma|Rhabdomyosarcoma|Pancreas tumor|Advanced solid tumor|Breast tumor|Ovary tumor|Colorectal tumor,1261|127|194|2448|249|3713|49|799|989,Cancer,651,SciClone Pharmaceuticals LLC|Tarveda Therapeutics Inc,19829|1067358,Madrigal Pharmaceuticals Inc,30180,Madrigal Pharmaceuticals Inc,30180,,,,,,
88238,MK-1026,"Bruton's tyrosine kinase inhibitors (DLBCL), ArQule|ARQ-531|MK-1026",Research Code|Research Code,Cancer,Btk tyrosine kinase inhibitor|Trk tyrosine kinase receptor inhibitor,3592|3838,Anticancer protein kinase inhibitor,62255,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Hematological neoplasm,1734|1743|1744|1745|1746|1749|2054,,,Merck & Co Inc,18077,ArQule Inc,21554,ArQule Inc,21554,,,,,,
88239,BT-1718,"bicycles program (peptide, cancer), Bicycle Therapeutics|bicyclic peptides (cancer), Bicycle Therapeutics|BDC-9|BTBCD-9|BT-1718|BDC-17",Research Code|Research Code|Research Code|Research Code,Cancer,Metalloprotease-14 modulator|Tubulin modulator,12909|814,Anticancer,1545,Esophagus tumor|Non-small-cell lung cancer|Advanced solid tumor,1011|1262|3713,Breast tumor|Cancer,49|651,Bicycle Therapeutics Ltd,1050067,,,Bicycle Therapeutics Ltd,1050067,,,,,,
88275,ION-251,"antisense oligonucleotides (multiple myeloma), Isis|antisense oligonucleotides (multiple myeloma), Ionis Pharmaceuticals|IONIS-IRF4-2.5Rx|ION-251",Research Code|Research Code,Cancer,IRF4 gene inhibitor,18790,Anticancer|Antisense oligonucleotide inhibitor|Synergist|Apoptosis stimulator,1545|7294|7293|1589,Multiple myeloma,1828,,,Ionis Pharmaceuticals Inc,17269,,,Ionis Pharmaceuticals Inc,17269,,,,,,
88321,amivantamab,"EM1-mAb|EM1-mAb (bispecific EGFR-cMet antibody, cancer), Janssen Research & Development|JNJ-61186372|anti-EGFR/cMet antibody (intravenous, non-small cell lung cancer), Genmab/Janssen|JNJ-6372|amivantamab|CNTO-4424|Ami-LC-MD|Ami-LC|Ami-HC|Ami-HC-CF|amivantamab-vmjw|RYBREVANT|JNJ-372",Research Code|Research Code|INN|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor|Hepatocyte growth factor receptor antagonist,3754|675,Anticancer|Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,1545|62255|55685,Mesothelioma|Hepatocellular carcinoma|Squamous cell carcinoma|Medullary thyroid cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma,1240|1767|307|3240|3657|3658|3665|3666|3667|3673|3713|3866|4250,Cancer,651,Janssen Research & Development LLC,1067538,Genmab A/S,26469,Janssen Research & Development LLC,1067538,,,,,,
88468,flotetuzumab,"anti-CD3/anti-CD123 bispecific T-cell engager (DART, hematological malignancy), MacroGenics|flotetuzumab|DART 123 (cancer), Servier|MGD-006|S-80880|CD123 x CD3 DART Bi-Specific Antibody|CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody",USAN|INN|Research Code|Research Code,Cancer|Musculoskeletal,CD3 modulator|CDw123 modulator,5023|5427,Anticancer antibody|Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55684|55685|393|7761,Myelodysplastic syndrome|Hodgkins disease|Acute leukemia|Acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia|T-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia|Hairy cell leukemia|Hematological neoplasm|Systemic mastocytosis,1272|161|1727|1728|1729|1730|1731|1735|1736|2054|3728,,,MacroGenics Inc,29060,Servier,19863,MacroGenics Inc,29060,,,,,,
88475,pamiparib,"PARP inhibitor (cancer), BeiGene/Merck Serono|PARP 1/2 inhibitor (oral, cancer), BeiGene|pamiparib|BGB-290",INN|Research Code,Cancer,Poly ADP ribose polymerase 1 inhibitor|Poly ADP ribose polymerase 2 inhibitor,38283|38286,Anticancer,1545,Glioma|Small-cell lung cancer|Fallopian tube cancer|Glioblastoma|Peritoneal tumor|Hormone refractory prostate cancer|Metastatic stomach cancer|Advanced solid tumor|Breast tumor|Ovary tumor,1108|1261|2243|2454|3083|3246|3666|3713|49|799,Cancer,651,BeiGene Co Ltd,1063251,Merck Serono SA,19862,BeiGene Co Ltd,1063251,,,,,,
88581,RG-6146,"bromodomain inhibitors (cancer), Tensha|(S)-JQ35|RG-6146|TEN-010|RO-6870810",Research Code|Research Code|Research Code|Research Code,Cancer,Bromodomain containing protein inhibitor|Bromodomain containing protein 2 inhibitor|Bromodomain containing protein 3 inhibitor|Bromodomain containing protein 4 inhibitor,34558|34564|34567|34570,Anticancer,1545,,,Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Advanced solid tumor|Metastatic ovary cancer|Breast tumor|Carcinoma|Cancer,1272|1731|1828|3713|3866|49|54|651,,,Tensha Therapeutics Inc|Dana-Farber Cancer Institute Inc|Roche Holding AG,1064821|15615|19446,Dana-Farber Cancer Institute Inc,15615,,,,,,
88596,Sym-015,"Sym-015|recombinant mAbs mixture (cancer), Symphogen|tumor and stromal targeting recombinant mAbs (cancer), Symphogen|recombinant mAbs mixture (advanced solid tumors/advanced NSCLC), Symphogen",,Cancer,Hepatocyte growth factor receptor antagonist,675,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor|Synergist,55685|62255|7293,Metastatic non small cell lung cancer|Advanced solid tumor,3665|3713,Cancer,651,Symphogen A/S,28600,,,Symphogen A/S,28600,,,,,,
8860,fexofenadine,fexofenadine|fexofenadine hydrochloride|Allegra|Telfast|MDL-16455|fexofenadine HCl|terfenadine carboxylate|terfenadine acid metabolite|M-016455,INN|INN|Trade Name|Trade Name|Research Code|Research Code,Dermatologic|Immune|Respiratory,Histamine H1 receptor antagonist,199,Anti-inflammatory|Topical antipruritic product,2953|15180,Pruritus|Seasonal allergic rhinitis|Urticaria,279|3202|340,Atopic dermatitis|Asthma|Perennial allergic rhinitis,1102|31|3201,Sanofi SA,1009547,Aventis Pharma AG|Aventis Pharma Ltd|Hoechst Marion Roussel Inc|Shionogi Pharma Inc|Aventis SA,25218|25220|25224|25987|27254,Aventis SA,27254,,,,,,
88642,ATRC-101,"ATRC-101|human antibodies (Immune Repertoire Capture, Driver Antigen Engagement, cancer), Atreca|Program 100, Atreca",Research Code,Cancer,,,Anticancer monoclonal antibody|Unspecified drug target,55685|59620,Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Metastatic ovary cancer|Cancer,3257|3657|3658|3665|3713|3866|651,,,Atreca Inc,1072197,,,Atreca Inc,1072197,,,,,,
88688,LXG-250,"huCART-19|anti-CD19 chimeric antigen receptor T-cells (second generation, cancer), University of Pennsylvania/Novartis|anti-CD19 CAR T-cell therapy (cancer), University of Pennsylvania/Novartis|anti-CD19 CAR-transduced autologous T-cells (second generation, cancer), University of Pennsylvania/Novartis|CTL-119|LXG-250",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Immunostimulant|Anticancer|Genetically engineered autologous cell therapy,7761|393|1545|4790,B-cell acute lymphoblastic leukemia|Multiple myeloma|Non-Hodgkin lymphoma,1729|1828|319,Cancer,651,University of Pennsylvania|Novartis AG,20658|23137,,,University of Pennsylvania,20658,,,,,,
88723,asciminib,"ABL-001|allosteric Bcr-Abl inhibitor (CML/ALL), Novartis|asciminib|asciminib hydrochloride",Research Code|USAN|INN|USAN,Cancer,Bcr protein inhibitor|Abl tyrosine kinase inhibitor,13571|3524,Anticancer protein kinase inhibitor,62255,Acute lymphoblastic leukemia|Chronic myelocytic leukemia,1728|1735,,,Novartis AG,23137,,,Novartis AG,23137,,,,,,
8876,Nystatin LF,nystatin A1|Nystan|Oxacyclooctatriacontane|AR-121|Nyotran|Nystatin LF|nystatin,Research Code|Trade Name|USAN|BANN|INN,Infection,,,Fungicide|Ergosterol modulator|Cholesterol modulator,1748|839|857,,,Fungal infection|Cryptococcus neoformans meningitis|Aspergillus infection|Candida albicans infection,124|1813|29|53,,,Abbott Laboratories|Aronex Pharmaceuticals Inc|Agenus Inc|MD Anderson Cancer Center,13601|22276|23221|23382,MD Anderson Cancer Center,23382,,,,,,
8877,AR-623,tretinoin|AR-623|L-ATRA|ATRA-IV|ATRAGEN|LipoATRA|Tretinoin LF|tretinoin liposome for injection|liposomal-all trans retinoic acid|IDP-121,USAN|BAN|INN|Research Code|Trade Name|Trade Name|Trade Name|Research Code,Cancer|Hematologic,,,Hematopoietic stimulator|Retinoid modulator|Cell cycle inhibitor|Anticancer,610|824|767|1545,,,Hematological disease|Acute myelogenous leukemia|Acute promyelocytic leukemia|Cutaneous T-cell lymphoma|Renal cell carcinoma|Prostate tumor|Non-Hodgkin lymphoma|Bladder tumor,142|1731|1732|1754|1766|276|319|42,,,Aronex Pharmaceuticals Inc|Agenus Inc,22276|23221,Aronex Pharmaceuticals Inc,22276,,,,,,
8888,"hydroxycarbamide (sickle cell anemia, thrombocythemia, polycythemia), BMS","Biosuppressin|Hidrix|Hydrea|Hydreia|Hydura|Litalir|NSC-32065|Onco-carbide|SQ-1089|Droxia|hydroxyurea, BMS|hydroxyurea|hydroxycarbamide (sickle cell anemia, thrombocythemia, polycythemia), BMS|hydroxycarbamide",Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Research Code|Trade Name|USAN|BANN|INN,Hematologic|Infection,Ribonucleotide reductase inhibitor|Hemoglobin synthesis modulator,346|5714,HIV replication inhibitor|Platelet aggregation inhibitor,747|312,Thrombocythemia|Polycythemia vera|Sickle cell anemia,2317|2319|303,HIV infection,158,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
88965,QBM-076,QBM-076,Research Code,Respiratory,,,Unspecified drug target,59620,,,Chronic obstructive pulmonary disease,1185,,,Novartis AG,23137,Novartis AG,23137,,,,,,
88976,"bevacizumab biosimilar, Pfizer","bevacizumab|bevacizumab biosimilar, Pfizer|PF-06439535|Zirabev|bevacizumab sequel|bevacizumab-bvzr",INN|Research Code|Trade Name|Trade Name,Cancer,VEGF ligand inhibitor,12521,Anticancer monoclonal antibody|Angiogenesis inhibitor,55685|61,Glioblastoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic rectal cancer|Metastatic colon cancer|Metastatic renal cell carcinoma|Uterine cervix tumor,2454|3657|3658|3665|3671|3672|4250|427,Glioma|Non-small-cell lung cancer|Breast tumor|Cancer|Ovary tumor,1108|1262|49|651|799,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
89071,fenebrutinib,GDC-0853|RG-7845|RO-7010939|fenebrutinib,Research Code|Research Code|Research Code|USAN|INN,Cancer|Dermatologic|Immune,Btk tyrosine kinase inhibitor,3592,Anticancer protein kinase inhibitor|Anti-inflammatory|Immunosuppressant,62255|2953|396,Multiple sclerosis|Systemic lupus erythematosus|Urticaria,213|318|340,Chronic lymphocytic leukemia|Rheumatoid arthritis|B-cell lymphoma|Autoimmune disease,1734|291|316|36,Genentech Inc,19453,Chugai Pharmaceutical Co Ltd,15414,Genentech Inc,19453,,,,,,
89076,OX-001,"mAbs (BioWa ADCC, acute myeloid leukemia), Menarini/ Oxford BioTherapeutics|OX-357|MEN-1112|OBT-357|OX-001|anti-CD157 mAb (BioWa ADCC/intravenous, acute myeloid leukemia), Menarini/ Oxford BioTherapeutics",Research Code|Research Code|Research Code|Research Code,Cancer,ADP ribosyl cyclase-2 inhibitor,10907,Anticancer monoclonal antibody,55685,Acute myelogenous leukemia,1731,,,The Menarini Group|Oxford BioTherapeutics Ltd,18053|1021134,,,Oxford BioTherapeutics Ltd,1021134,,,,,,
89100,NeoVax,"NeoVax|neoantigen vaccine (cancer), Dana Farber Cancer Institute",Research Code,Cancer,,,Therapeutic vaccine|Anticancer,12379|1545,Endometrioid carcinoma|Chronic lymphocytic leukemia|Fallopian tube cancer|Glioblastoma|Carcinosarcoma|Peritoneal tumor|Ovarian clear cell carcinoma|Metastatic ovary cancer|Cancer|Renal tumor,1705|1734|2243|2454|2614|3083|3525|3866|651|999,,,Dana-Farber Cancer Institute Inc,15615,,,Dana-Farber Cancer Institute Inc,15615,,,,,,
89138,rogaratinib,"BAY-1163877|pan-FGFR inhibitor (cancer), Bayer|rogaratinib",Research Code|INN,Cancer,FGF1 receptor antagonist|FGF2 receptor antagonist|FGF4 receptor antagonist|FGF3 receptor antagonist,3682|3685|3691|3688,Anticancer protein kinase inhibitor,62255,Transitional cell carcinoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer,1771|3466|3657|3665|3713|651,,,Bayer AG,14455,,,Bayer AG,14455,,,,,,
89150,"paclitaxel (liposomal/intravenous, ovarian cancer/breast cancer/NSCLC), Luye","paclitaxel|paclitaxel (liposomal/intravenous, ovarian cancer/breast cancer/NSCLC), Luye|Lipusu",USAN|BANN|INN|Trade Name,Cancer,,,Vasoprotectant|Microtubule stabilizer|Anticancer,2660|2576|1545,Non-small-cell lung cancer|Breast tumor|Ovary tumor,1262|49|799,,,Luye Pharma Group Ltd,1015499,,,Luye Pharma Group Ltd,1015499,,,,,,
89188,mivavotinib,TAK-659|mivavotinib|mivavotinib monocitrate|mivavotinib citrate|TAK-659 citrate,Research Code|USAN|INN|USAN,Cancer,Syk tyrosine kinase inhibitor|Flt3 tyrosine kinase inhibitor,3602|3806,Anticancer protein kinase inhibitor,62255,Acute lymphoblastic leukemia,1728,Acute myelogenous leukemia|Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Lymphoma|Non-Hodgkin lymphoma|Solid tumor,1731|1734|1745|1749|203|319|725,Takeda Oncology,21991,,,Takeda Oncology,21991,,,,,,
89200,belantamab mafodotin,"GSK-2857916|humanized Fc-engineered anti-B cell maturation antigen-MMAF mAb-drug conjugate (cancer), GlaxoSmithKline/Dana-Farber Cancer Institute|J6M0-mcMMAF|belantamab mafodotin|GSK'916|BLENREP|Blenrep|belantamab mafodotin-blmf",Research Code|Research Code|USAN|INN|Research Code|Trade Name|Trade Name|Trade Name,Cancer,APRIL receptor modulator,8255,Immunotoxin|Microtubule modulator|Synergist|Anticancer monoclonal antibody,539|563|7293|55685,Multiple myeloma,1828,,,GlaxoSmithKline plc,28355,Dana-Farber Cancer Institute Inc,15615,GlaxoSmithKline plc,28355,,,,,,
8934,irofulven,"HMAF|irofulven|MGI-114|NSC-683863|Acylfulvene|acylfulvenes, MGI|hydroxymethylacylfulvene, MGI|IND-55804|E-7850|Irofulven DRP|Irofulven-1|LP-100, Lantern Pharma|Irofulven, Allarity Therapeutics",PINN|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code,Cancer,Topoisomerase I modulator|Checkpoint kinase 2 modulator,1512|4227,DNA synthesis inhibitor|Apoptosis stimulator|Anticancer multidrug resistance inhibitor|Anticancer alkylating agent,140|1589|759|50,Hormone refractory prostate cancer,3246,Glioma|Thyroid tumor|Stomach tumor|Hepatocellular carcinoma|Sarcoma|Leukemia|Melanoma|Pancreas tumor|Metastatic renal cell carcinoma|Breast tumor|Cancer|Uterus tumor|Lung tumor|Ovary tumor|Colorectal tumor,1108|1134|127|1767|194|199|205|249|4250|49|651|740|755|799|989,Oncology Venture ApS,1095288,Lantern Pharma Inc|Dainippon Pharmaceutical Co Ltd|Eisai Co Ltd|MGI Pharma Inc|University of California San Diego,1106466|15606|15872|18203|25451,University of California San Diego,25451,,,,,,
8946,olmesartan medoxomil,CS-866|olmesartan medoxomil|CS-866DM|CS-866RN|Olmetec|Benicar|Votum|Benevas|Benitec|Olvance|Olmetec OD|Olmeta|Openvas|Benetor|Olmes|R-88536,Research Code|USAN|INN|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code,Cardiovascular|Genitourinary/Sexual Function,Angiotensin II AT-1 receptor antagonist,788,Antihypertensive|Vasodilator,2657|388,Hypertension,178,Diabetic nephropathy|Glomerulonephritis,100|135,Daiichi Sankyo Co Ltd|The Menarini Group|Sankyo Co Ltd|Sankyo Pharma Inc|Pfizer Inc|Daewoong Pharmaceutical Co Ltd|Sun Pharmaceutical Industries Ltd|Sankyo Europe GmbH|Merck & Co Inc,1017506|18053|19658|27147|18767|15587|27561|19666|18077,Kowa Co Ltd|Schering-Plough Corp|Ranbaxy Pharmaceuticals Inc,17688|19711|29267,Sankyo Co Ltd,19658,,,,,,
89502,FORE-8394,PLX-8394|FORE-8394,Research Code|Research Code,Cancer,Raf B protein kinase inhibitor,4548,Anticancer protein kinase inhibitor,62255,Cancer,651,,,Novellus Inc,1209190,Plexxikon Inc,29155,Plexxikon Inc,29155,,,,,,
8955,carvedilol,carvedilol|BM-14190|Coreg|DQ-2466|SKF-105517|Artist|Kredex|Dimitone|Eucardic|Coropress|Dilatrend|Carvipress|Coreg IR,USAN|BAN|INN|Research Code|Trade Name|Research Code|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name,Cardiovascular,Alpha adrenoceptor antagonist|Beta adrenoceptor antagonist,30|38,Antioxidant agent|Cardiac agent|Class II antiarrhythmic agent|Antihypertensive,74|966|66|2657,Atrial fibrillation|Hypertension|Angina|Cardiac failure|Coronary artery disease,1542|178|23|55|80,,,SmithKline Beecham plc|Boehringer Mannheim Corp|Daiichi Seiyaku Co Ltd|Ercopharm A/S|Eisai Co Ltd|Boehringer Mannheim GmbH|Roche Holding AG|Daiichi Sankyo Co Ltd,19962|25476|15593|18694|15872|24098|19446|1017506,,,Roche Holding AG,19446,,,,,,
89583,avapritinib,"KIT D816V inhibitor (systemic mastocytosis), Blueprint Medicines|BLU-285|avapritinib|avapritinib (GIST/systemic mastocytosis), Blueprint Medicines|avapritinib (GIST/systemic mastocytosis), Blueprint Medicines/CStone Pharmaceuticals|AYVAKIT",Research Code|USAN|INN|Trade Name,Cancer|Musculoskeletal,Kit tyrosine kinase inhibitor|PDGF receptor alpha antagonist,3808|48489,Anticancer protein kinase inhibitor,62255,Gastrointestinal stromal tumor|Systemic mastocytosis|Solid tumor,3205|3728|725,Neoplasm,230,Blueprint Medicines Corp|CStone Pharmaceuticals,1067683|1126254,,,Blueprint Medicines Corp,1067683,,,,,,
89637,vecabrutinib,vecabrutinib|SNS-062|vecabrutinib succinate|SNS-062 succinate,USAN|INN|Research Code|USAN,Cancer,Btk tyrosine kinase inhibitor,3592,Anticancer protein kinase inhibitor|Anticancer,62255|1545,,,Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Hematological neoplasm|Non-Hodgkin lymphoma,1734|1743|1744|1745|1746|1749|2054|319,,,Biogen Inc|Viracta Therapeutics Inc,1005244|27713,Biogen Inc,1005244,,,,,,
89666,INCAGN-1949,"OX40 costimulator (Retrocyte, cancer), 4-Antibody/Incyte|anti-OX40 agonist monoclonal antibody (cancer), 4-Antibody/Ludwig Institute/Memorial Sloan-Kettering Cancer Center|INCAGN-1949|INCAGN-01949",Research Code|Research Code,Cancer,OX-40 receptor agonist,5443,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator|Anticancer,55685|393|7761|1545,Advanced solid tumor,3713,Cancer,651,4-Antibody AG|Incyte Corp,1022553|17216,Ludwig Institute for Cancer Research|Memorial Sloan-Kettering Cancer Center,21091|22122,4-Antibody AG,1022553,,,,,,
89714,acalabrutinib,acalabrutinib|ACP-196|Calquence|ACP-5862|Benzamide|acalabrutinib maleate,USAN|INN|Research Code|Trade Name|Research Code|USAN,Cancer|Immune|Infection,Btk tyrosine kinase inhibitor,3592,Anticancer|Anticancer protein kinase inhibitor|Antiviral|Apoptosis stimulator|Anti-inflammatory,1545|62255|991|1589|2953,Non-small-cell lung cancer|Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|High grade B-cell lymphoma|Multiple myeloma|Glioblastoma|B-cell lymphoma|Non-Hodgkin lymphoma|Metastatic head and neck cancer|Graft versus host disease|Ovary tumor,1262|1734|1743|1744|1745|1746|1749|1750|1751|1828|2454|316|319|3673|616|799,Coronavirus disease 19 infection|Rheumatoid arthritis|Metastatic bladder cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Cancer,10406|291|3466|3665|3669|651,Acerta Pharma BV|AstraZeneca plc,1089086|14190,,,Acerta Pharma BV,1089086,,,,,,
8976,rosiglitazone,BRL-49653|rosiglitazone|rosiglitazone maleate|Avandia|BRL 49653C,Research Code|BANN|INN|USAN|Trade Name|Research Code,Cardiovascular|Dermatologic|Endocrine/Metabolic|Gastrointestinal|Immune|Neurology/Psychiatric|Respiratory,Insulin sensitizer|PPAR gamma agonist,1919|2480,Hypoglycemic agent,399,Non-insulin dependent diabetes,837,Alzheimers disease|Psoriasis|Rheumatoid arthritis|Asthma|Atherosclerosis|Ulcerative colitis|Cognitive disorder,14|281|291|31|33|337|353,GlaxoSmithKline plc|SmithKline Beecham plc,28355|19962,,,SmithKline Beecham plc,19962,,,,,,
89787,"chlorogenic acid (intramuscular, cancer), Jiuzhang Biochemical Engineering Science & Technology Development","chlorogenic acid|chlorogenic acid (intramuscular, cancer), Jiuzhang Biochemical Engineering Science & Technology Development|lvyuansuan|CD223 checkpoint inhibitor (cancer), Jiuzhang Biochemical Engineering Science & Technology Development|LAG-3 checkpoint inhibitor (cancer), Jiuzhang Biochemical Engineering Science & Technology Development",,Cancer,CD223 antagonist,8413,Immunostimulant|T-lymphocyte stimulator|Anticancer|Apoptosis stimulator,393|7761|1545|1589,Glioblastoma|Lung tumor,2454|755,Cancer,651,Jiuzhang Biochemical Engineering Science & Technology Development Co Ltd,1084254,,,Jiuzhang Biochemical Engineering Science & Technology Development Co Ltd,1084254,,,,,,
89803,"omaveloxolone (oral, Friedreich's ataxia/mitochondrial myopathy/melanoma), Reata/AbbVie","RTA-408, Reata Pharmaceuticals|RTA-408|RTA-408 (oral, non-small cell lung cancer), Reata Pharmaceuticals/AbbVie|ABT-RTA-408|RTA-ABT-408|RTA-408 (mitochondrial myopathies), Reata Pharmaceuticals/AbbVie|omaveloxolone|omaveloxolone (oral, non-small cell lung cancer), Reata Pharmaceuticals/AbbVie|omaveloxolone (oral, Friedreich's ataxia/mitochondrial myopathy/melanoma), Reata/AbbVie",Research Code|Research Code|Research Code|USAN|INN,Cancer|Musculoskeletal|Neurology/Psychiatric,Nuclear erythroid 2-related factor 2 stimulator,19507,Anti-inflammatory|Anticancer|Antioxidant agent,2953|1545|74,Mitochondrial myopathy|Friedreich ataxia|Stage IV melanoma,2541|2974|3257,Metastatic non small cell lung cancer,3665,Reata Pharmaceuticals Inc,1003618,AbbVie Inc,1072507,Reata Pharmaceuticals Inc,1003618,,,,,,
89885,FDC-101,"dendritic cell based vaccine (prostate cancer), Medigene|dendritic cell based vaccine (prostate cancer), Trianta|dendritic cell based vaccine (prostate cancer), Helmholtz Zentrum Munchen/Max Delbruck Center|dendritic cell based vaccine (acute myeloid leukemia/prostate cancer), Medigene/ Cytovant|FDC-101|CVT-DC-01",Research Code|Research Code,Cancer,WT1 gene modulator|PRAME gene stimulator,30012|71055,Dendritic cell vaccine|Anticancer|Therapeutic vaccine,102926|1545|12379,Acute myelogenous leukemia|Prostate tumor|Cancer,1731|276|651,,,Cytovant Sciences HK Limited|Medigene Immunotherapies GmbH|MediGene AG,1184119|1092495|24224,Helmholtz Zentrum München|Max Delbruck Centrum Fur Molekulare Medizin,16588|17961,Helmholtz Zentrum München,16588,,,,,,
89988,naquotinib mesylate,ASP-8273|naquotinib|naquotinib mesylate,Research Code|USAN|INN|USAN,Cancer,EGFR family tyrosine kinase receptor inhibitor|Epidermal growth factor receptor antagonist,3754|740,Anticancer protein kinase inhibitor|Apoptosis stimulator,62255|1589,,,Non-small-cell lung cancer|Metastatic non small cell lung cancer|Cancer,1262|3665|651,,,Astellas Pharma Inc,1013295,Astellas Pharma Inc,1013295,,,,,,
8999,flurbiprofen sodium,flurbiprofen sodium|Ocufen|(.+-.)-Flurbiprofen|AGN-101289,USAN|Trade Name|Research Code,Ocular,Cyclooxygenase inhibitor,132,Non-steroidal anti-inflammatory,2955,Ocular inflammation,686,,,AbbVie Inc|Horus Pharma,1072507|1065759,Allergan plc|Allergan Inc,1088700|14042,Allergan Inc,14042,,,,,,
90046,BPI-15000,BPI-15000|BPI-15086,Research Code|Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer|Anticancer protein kinase inhibitor,1545|62255,,,Non-small-cell lung cancer|Cancer,1262|651,,,Betta Pharmaceuticals Co Ltd,1051889,Betta Pharmaceuticals Co Ltd,1051889,,,,,,
90067,H-1299,"H-1299|tumor lysate vaccine (iscomatrix adjuvanted, im, cancer), NCI",Research Code,Cancer,,,Therapeutic vaccine|Anticancer,12379|1545,Esophagus tumor|Cancer|Lung tumor,1011|651|755,,,National Cancer Institute (NCI),20519,,,National Cancer Institute (NCI),20519,,Zetidoline,Dopamine D2 Receptor (DRD2) Antagonists,125,Signal Transduction Modulators,1402
90233,odronextamab,"anti-CD20/anti-CD3 bispecific antibody (cancer), Regeneron|REGN-1979|anti-CD3/anti-CD20 bispecific T-cell engager (cancer), Regeneron|CD20XCD3|odronextamab",Research Code|USAN|INN,Cancer,CD3 modulator|B-lymphocyte antigen CD20 modulator,5023|5083,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1728|1734|1745|1749|319,Hodgkins disease|Cancer,161|651,Regeneron Pharmaceuticals Inc|Zai Lab Limited,19214|1101935,,,Regeneron Pharmaceuticals Inc,19214,,Ipsalazide,,,,
90238,INCAGN-2385,"LAG-3 targeted antibody program, 4-Antibody/Ludwig Institute for Cancer Research|LAG-3 targeted antibody program (cancer), 4-Antibody/Ludwig Institute for Cancer Research|LAG-3 targeted antibody program (cancer), 4-Antibody/ Incyte|LAG-3 checkpoint inhibitor (cancer), 4-Antibody/Incyte|INCAGN-2385|INCAGN-02385",Research Code|Research Code,Cancer,CD223 antagonist,8413,T-lymphocyte stimulator|Anticancer antibody|Immunostimulant,7761|55684|393,Esophagus tumor|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Endometrioid carcinoma|Diffuse large B-cell lymphoma|Renal cell carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Melanoma|Squamous cell carcinoma|Merkel cell carcinoma|Stage III melanoma|Stage IV melanoma|Advanced solid tumor|Uterine cervix tumor|Breast tumor|Cancer|Ovary tumor|Colorectal tumor,1011|1240|1261|1262|127|1705|1749|1766|1767|1771|205|307|3235|3256|3257|3713|427|49|651|799|989,,,Incyte Corp|Agenus Inc,17216|23221,4-Antibody AG|Ludwig Institute for Cancer Research,1022553|21091,4-Antibody AG,1022553,,Oxaprotiline hydrochloride,Norepinephrine Reuptake Inhibitors,63,Signal Transduction Modulators,1402
90239,INCAGN-2390,"TIM-3 targeted antibody program, 4-Antibody/Ludwig Institute for Cancer Research|TIM-3 targeted antibody program (cancer), 4-Antibody/Ludwig Institute for Cancer Research|TIM-3 targeted antibody program (cancer), 4-Antibody/ Incyte|TIM-3 checkpoint inhibitor (cancer), 4-Antibody/Incyte|INCAGN-2390|INCAGN-02390",Research Code|Research Code,Cancer,Hepatitis A virus cellular receptor 2 antagonist,34783,Anticancer antibody|T-lymphocyte stimulator|Immunostimulant,55684|7761|393,Stage III melanoma|Stage IV melanoma|Advanced solid tumor|Cancer,3256|3257|3713|651,,,Agenus Inc|Incyte Corp,23221|17216,4-Antibody AG|Ludwig Institute for Cancer Research,1022553|21091,4-Antibody AG,1022553,,,,,,
9028,tositumomab,"Bexxar|B-1 therapy|tositumomab|iodine-131-tositumomab|anti-CD20, Coulter|anti-B1 antibody, Coulter|131I-anti-B1 therapy|131I-tositumomab|iodine-131-anti-B1 therapy",Trade Name|INN,Cancer,B-lymphocyte antigen CD20 modulator,5083,Anticancer monoclonal antibody|Anticancer|Radioimmunotherapeutic,55685|1545|1552,,,Chronic lymphocytic leukemia|Multiple myeloma|Non-Hodgkin lymphoma,1734|1828|319,,,Australian Nuclear Science & Technology Organization|Corixa Corp|SmithKline Beecham plc|Coulter Pharmaceutical Inc|GE Healthcare|GlaxoSmithKline plc,14338|15542|19962|25485|25593|28355,Coulter Pharmaceutical Inc,25485,,,,,,
90287,ImmuniCell,"autologous gamma delta T-cell therapy (cancer), TC BioPharm|ImmuniCell",Trade Name,Cancer,,,Anticancer|Immunostimulant,1545|393,Renal cell carcinoma|Stage IV melanoma|Metastatic non small cell lung cancer,1766|3257|3665,Cancer,651,TC BioPharm Ltd,1093918,,,TC BioPharm Ltd,1093918,,,,,,
90401,RP-323,PD-616|12-O-tetra-decanoyl-phorbol-13-acetate|TPA|RP-323,Research Code|Research Code,Cancer|Neurology/Psychiatric,Protein kinase C stimulator,335,Anticancer|Antiparkinsonian|Apoptosis stimulator,1545|2947|1589,Myelodysplastic syndrome|Hodgkins disease|Acute myelogenous leukemia|Parkinsons disease,1272|161|1731|255,,,Hypgen Inc|Rich Pharmaceuticals Inc,1150953|1094173,Biosuccess Biotech Co,1041317,Biosuccess Biotech Co,1041317,,,,,,
9049,"cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical","cytarabine|Ara-C|NS-101|DepoFoam (cytarabine)|cytarabine (SR formulation), DepoTech/Chiron|cytarabine (sustained release, DepoFoam), SkyePharma|Cytosar|DepoCyte|DepoCyt|Savedar|DTC-101|cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical|Cytosar-U",USAN|BANN|INN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name,Neurology/Psychiatric,DNA polymerase inhibitor|RNA polymerase inhibitor,138|347,Anticancer,1545,Neoplastic meningitis,1814,,,Mundipharma International Corp Ltd|Pfizer Inc|Pacira BioSciences Inc|Sigma-Tau Ind Farm Riunite SpA|Napp Pharmaceutical Group Ltd,1045514|18767|26338|21159|18449,Chiron Corp|Enzon Pharmaceuticals Inc|Nippon Shinyaku Co Ltd|Pharmacia & Upjohn SpA|Paladin Labs Inc,15385|16045|18552|18917|27477,Pacira BioSciences Inc,26338,,,,,,
90494,GEN-009,"first-generation neoantigen vaccine (cancer), Genocea Biosciences/Dana-Farber Cancer Institute|GEN-009",Research Code,Cancer,CD4 agonist|T-cell surface glycoprotein CD8 stimulator,5027|5039,Therapeutic vaccine|Protein subunit vaccine|Anticancer,12379|12372|1545,Non-small-cell lung cancer|Renal cell carcinoma|Transitional cell carcinoma|Melanoma|Bladder cancer|Squamous cell carcinoma|Cancer,1262|1766|1771|205|2380|307|651,,,Genocea Biosciences Inc|Dana-Farber Cancer Institute Inc,1033185|15615,,,Genocea Biosciences Inc,1033185,Visacor,Epanolol,beta-Adrenoceptor Antagonists,44,Signal Transduction Modulators,1402
90585,selpercatinib,"Loxo-102|RET inhibitor (cancer), Eli Lilly/Loxo Oncology/Array BioPharma|R-001, Array Biopharma|R-002, Array Biopharma|LOXO-292|selpercatinib|RET inhibitor (cancer), Eli Lilly/Loxo Oncology at Lilly/Array BioPharma|LY-3527723|Retevmo",Research Code|Research Code|Research Code|Research Code|USAN|PINN|Research Code|Trade Name,Cancer,Ret tyrosine kinase receptor inhibitor,3818,Anticancer protein kinase inhibitor,62255,Thyroid tumor|Fibrosarcoma|Pancreas tumor|Medullary thyroid cancer|Papillary thyroid tumor|Soft tissue sarcoma|Metastatic non small cell lung cancer|Metastatic colon cancer|Advanced solid tumor,1134|2445|249|3240|3351|3378|3665|3672|3713,Cancer,651,Loxo Oncology at Lilly,1086092,Array BioPharma Inc,25902,Array BioPharma Inc,25902,,,,,,
90590,PLX-038,"PEG-SN-38 (cancer), ProLynx|pegylated SN-38 prodrug (cancer), ProLynx|PL-0264|PLX-0264|DFP-13318|PEG-SN-38 (cancer), ProLynx/Delta-Fly|pegylated SN-38 prodrug (cancer), ProLynx/Delta-Fly|PLX-038",Research Code|Research Code|Research Code|Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,Small-cell lung cancer|Solid tumor,1261|725,Cancer,651,Delta-Fly Pharma Inc|ProLynx LLC,1062114|1051551,,,ProLynx LLC,1051551,,,,,,
90616,"B-001, Shanghai Pharmaceuticals","anti-CD20 humanized mAb (iv, non-Hodgkin lymphoma), Shanghai Pharmaceuticals|B-001, Shanghai Pharmaceuticals|B-001-A",Research Code,Cancer|Immune,B-lymphocyte antigen CD20 inhibitor,5085,Anticancer monoclonal antibody,55685,Multiple sclerosis|Non-Hodgkin lymphoma,213|319,,,Shanghai Pharmaceuticals Holding Co Ltd,1060612,,,Shanghai Pharmaceuticals Holding Co Ltd,1060612,,,Dopamine Receptor Agonists,129,Signal Transduction Modulators,1402
9063,"thrombopoietin, Genentech/Pharmacia","thrombopoietin|PNU-196444|PNU-444-ONC-0003|TPO, Genentech/P&U|thrombopoietin, Genentech/Pharmacia|platelet growth factor, Genentech/Pharmacia & Upjohn|rhTPO, Genentech/Pharmacia|recombinant human thrombopoietin, Genentech/Pharmacia|PN-152243",Research Code|Research Code|Research Code,Hematologic,Thrombopoietin receptor agonist,3610,Hematopoietic stimulator,610,,,Thrombocytopenia,324,,,Genentech Inc|Pharmacia & Upjohn Inc|Pharmacia Corp,19453|22006|27638,Genentech Inc,19453,,,,,,
90646,APL-101,"small molecule therapy (oral/enteric-coated capsule), Beijing Purunao Biotech|boruitinib|cMET inhibitor (cancer), Crown Bioscience|CBT-101|PLB-1001|bozitinib|CBI-3103|CBT-101, CBT Pharmaceuticals/Beijing Pearl Biotechnology|APL-101|c-met inhibitor (oral, cancer/NSCLC/RCC/HCC/glioblastoma), Apollomics",Research Code|Research Code|Trade Name|Research Code|Research Code|Research Code,Cancer,Hepatocyte growth factor receptor antagonist,675,Anticancer protein kinase inhibitor,62255,Esophagus tumor|Glioma|Non-small-cell lung cancer|Stomach tumor|Renal cell carcinoma|Hepatocellular carcinoma|Adenocarcinoma|Glioblastoma|Metastatic non small cell lung cancer|Advanced solid tumor|Cancer|Solid tumor|Lung tumor|Brain tumor|Renal tumor,1011|1108|1262|127|1766|1767|2399|2454|3665|3713|651|725|755|760|999,,,Beijing Purunao Biotech Co Ltd|Apollomics Inc|Strata Oncology,1094627|1129041|1124765,Crown Bioscience Inc,1051206,Crown Bioscience Inc,1051206,,,,,,
90713,telisotuzumab vedotin,"anti-c-Met-monomethyl auristatin E ADC|anti-c-Met-MMAE ADC|telisotuzumab vedotin|ABBV-399|ABT-399|anti-c-Met-monomethyl auristatin E ADC (Intravenous, solid tumors/NSCLC), AbbVie|Teliso-V",USAN|INN|Research Code|Research Code|Trade Name,Cancer,Hepatocyte growth factor receptor antagonist,675,Anticancer|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor|Microtubule inhibitor,1545|55685|62255|2575,Metastatic non small cell lung cancer|Advanced solid tumor|Solid tumor,3665|3713|725,,,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,3-Deazauridine,,,,
90747,"risperidone + rumenic acid (oral, cancer), ValiSeek","VAL-401|risperidone + rumenic acid (oral, cancer), ValiSeek|risperidone + rumenic acid|3 hydroxyacyl CoA dehydrogenase type 2 inhibitor (oral, cancer), ValiSeek|reformulation of risperidone + rumenic acid (oral, cancer), ValiSeek",Research Code,Cancer,3 hydroxyacyl CoA dehydrogenase type 2 inhibitor,80682,Anticancer,1545,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Cancer,1262|1507|651,,,ValiSeek,1094839,Tangent Reprofiling,1044158,Tangent Reprofiling,1044158,,Vindeburnol,,,,
90757,nazartinib,"nazartinib|EGF-816|mutant-selective EGFR inhibitor (T790M-mutated NSCLC), Novartis",INN|Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer|Advanced solid tumor,3665|3713,Non-small-cell lung cancer,1262,Novartis AG,23137,Genomics Institute of the Novartis Research Foundation,25551,Genomics Institute of the Novartis Research Foundation,25551,,Baker's triazine antifolate|Triazinate,Dihydrofolate Reductase (DHFR) Inhibitors,413,,
90834,"bevacizumab biosimilar, Betta Pharmaceuticals/Mabworks Biotech","bevacizumab|MIL-60|bevacizumab biosimilar, Mabworks Biotech|bevacizumab biosimilar, Betta Pharmaceuticals/Mabworks Biotech",INN|Research Code,Cancer,VEGF ligand inhibitor,12521,Angiogenesis inhibitor|Anticancer monoclonal antibody,61|55685,Metastatic colorectal cancer|Metastatic non small cell lung cancer,3658|3665,,,Betta Pharmaceuticals Co Ltd,1051889,Mabworks Biotech Co Ltd,1046203,Mabworks Biotech Co Ltd,1046203,Daim|Selecal,Tilisolol hydrochloride,beta-Adrenoceptor Antagonists,44,Signal Transduction Modulators,1402
90835,AGS-67E,"AGS-67E|anti-CD37 IgG2 mAb (cancer), Agensys/Seattle Genetics",Research Code,Cancer,CD37 antagonist,5133,Immunotoxin|Anticancer monoclonal antibody|Microtubule inhibitor,539|55685|2575,,,Hematological neoplasm|Cancer,2054|651,,,Agensys Inc,14386,Agensys Inc,14386,,,,,,
90873,"OXPHOS inhibitor (cancer), MD Anderson Cancer Center","OXPHOS inhibitor (cancer), MD Anderson Cancer Center|IACS-1131|IACS-010759|IACS-10759",Research Code|Research Code|Research Code,Cancer,Mitochondrial complex I inhibitor|NAD synthase inhibitor,12234|2671,Anticancer|Synergist|Apoptosis stimulator,1545|7293|1589,Acute myelogenous leukemia|Mantle cell lymphoma|Lymphoma|Advanced solid tumor,1731|1744|203|3713,Cancer,651,MD Anderson Cancer Center,23382,,,MD Anderson Cancer Center,23382,,Mafosfamide cyclohexylamine salt,DNA-Damaging Drugs,1404,,
90887,MAGE-A10C796T,"autologous T-cell therapy (breast cancer, NSCLC), Adaptimmune|MAGE-A10 TCR|MAGE-A10 T|MAGE-A10 SPEAR|MAGE-A10C796T|anti-MAGE-A10/HLA-A*0201/HLA-A*0206 TCR T cell therapy (cancer), Adaptimmune|ADP-A2M10|olitresgene autoleucel",Research Code|Research Code|Research Code|INN,Cancer,HLA class I antigen A-2 alpha modulator|Melanoma associated antigen 10 modulator,19115|21976,T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy|Immunostimulant,7761|1545|4790|393,Non-small-cell lung cancer|Transitional cell carcinoma|Melanoma|Bladder cancer|Breast tumor|Head and neck tumor,1262|1771|205|2380|49|623,,,Adaptimmune Therapeutics plc,1047486,,,Adaptimmune Therapeutics plc,1047486,Masacin Aerosol|Meptin|Onsukil Aerosol|Procadil Aerosol,Procaterol hydrochloride hemihydrate,beta2-Adrenoceptor Agonists,60,Signal Transduction Modulators,1402
90987,simlukafusp alfa,"GA-501|FAP-IL2v|FAP-targeted IL-2v antibody (cancer), Hoffmann-La Roche|RO-6874281|RG-7461|FAP-targeted IL-2v antibody (solid tumor/RCC/metastatic melanoma), Hoffmann-La Roche|simlukafusp alfa",Research Code|Research Code|Research Code|USAN|INN,Cancer,Interleukin-2 ligand|Seprase inhibitor|AFAP1 like protein 2 modulator,12481|10910|72862,Immunostimulant|Anticancer antibody,393|55684,,,Pancreatic ductal adenocarcinoma|Squamous cell carcinoma|Stage IV melanoma|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Uterine cervix tumor|Cancer|Solid tumor,1507|307|3257|3665|3667|3673|3713|4250|427|651|725,,,Chugai Pharmaceutical Co Ltd|Roche Holding AG,15414|19446,Roche Holding AG,19446,,,,,,
91071,PF-06664178,RN-927C|PF-06664178,Research Code|Research Code,Cancer,Trop-2 calcium signal transducer modulator,17893,Anticancer antibody|Microtubule inhibitor,55684|2575,,,Solid tumor|Lung tumor,725|755,,,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
91106,"BET inhibitors (oral, cancer), Bayer HealthCare AG","BET inhibitors (oral, cancer), Bayer HealthCare AG|BET-BAY-002|BAY-1238097|BAY-671|BAY-356",Research Code|Research Code|Research Code,Cancer,Bromodomain containing protein 3 inhibitor|Bromodomain testis-specific protein inhibitor|Bromodomain containing protein 4 inhibitor|Bromodomain containing protein 2 inhibitor,34567|87945|34570|34564,Anticancer,1545,,,Cancer,651,,,Bayer HealthCare AG,1003983,Bayer HealthCare AG,1003983,Halospor|Pansporin,Cefotiam hydrochloride,Penicillin-Binding Protein (PBP) (Bacterial) Inhibitors,7079,Cell Wall Biosynthesis Inhibitors,2788
9112,trabectedin,"ecteinascidin-743|ET-743, University of Illinois|Pt-650|Ect-743|phthalascidin|trabectedin|Yondelis",Research Code|Research Code|Research Code|Analogue|USAN|INN|Trade Name,Cancer,,,Anticancer alkylating agent|Cell cycle inhibitor|DNA modulator|Anticancer,50|767|803|1545,Mesothelioma|Leiomyosarcoma|Liposarcoma|Meningioma|Peritoneal tumor|Soft tissue sarcoma|Advanced solid tumor|Ovary tumor,1240|2446|2447|2802|3083|3378|3713|799,Non-small-cell lung cancer|Endometrioid carcinoma|Metastatic breast cancer|Metastatic prostate cancer|Metastatic pancreas cancer|Breast tumor|Carcinoma|Cancer|Solid tumor|Lung tumor,1262|1705|3657|3664|3669|49|54|651|725|755,MegaPharm Ltd|Key Oncologics (Pty) Ltd|Stada Arzneimittel AG|Taiho Pharmaceutical Co Ltd|Valeo Pharma Inc|Onko Ilac San ve Tic AS|PharmaMar SA|Adium Pharma SA|Otsuka Holdings Co Ltd|TTY Biopharm Co Ltd|Johnson & Johnson|Specialised Therapeutics Asia Pte Ltd|R-Pharm,26786|27745|20236|18720|1051954|1219802|17927|1218632|1040632|29954|17332|1157003|1059001,Centocor Ortho Biotech Services|University of Illinois,1112040|20592,University of Illinois,20592,,,,,,
91145,"bevacizumab biosimilar, Bio-Thera Solutions","bevacizumab|recombinant humanized anti-VEGF monoclonal antibody, Bio-Thera Solutions|bevacizumab biosimilar, Bio-Thera Solutions|BAT-1706",INN|Research Code,Cancer,VEGF ligand inhibitor,12521,Anticancer|Anticancer monoclonal antibody|Anticancer protein kinase inhibitor,1545|55685|62255,Hepatocellular carcinoma|Fallopian tube cancer|Glioblastoma|Peritoneal tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Cancer,1767|2243|2454|3083|3657|3658|3665|4250|427|651,Solid tumor,725,BeiGene Co Ltd|Bio-Thera Solutions Ltd|Biomm SA|Cipla Ltd,1063251|1084235|1106969|15503,,,Bio-Thera Solutions Ltd,1084235,,Ramoplanin A1,,,,
91183,"mitoxantrone hydrochloride (liposome, lymphoma/solid tumors), CSPC Zhongqi Pharmaceutical Technology","mitoxantrone hydrochloride|mitoxantrone|mitoxantrone hydrochloride (liposome, lymphoma/solid tumors), CSPC Zhongqi Pharmaceutical Technology|PLM-60",USAN|BANN|INN|Research Code,Cancer,Topoisomerase II modulator,1513,Anticancer|DNA intercalator,1545|750,Small-cell lung cancer|Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Hepatocellular carcinoma|Transitional cell carcinoma|Lymphoma|Non-Hodgkin lymphoma|Metastatic breast cancer|Metastatic stomach cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Solid tumor,1261|1731|1749|1753|1767|1771|203|319|3657|3666|3673|3713|3866|725,Cutaneous T-cell lymphoma,1754,CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd,1047791,,,CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd,1047791,,,,,,
91190,"NMP (oral, cancer), Peter MacCallum Cancer Centre","NMP (oral, cancer), Peter MacCallum Cancer Centre|N-methylpyrrolidone compounds (cancer), Peter MacCallum Cancer Centre|N-methyl-2-pyrrolidone|NMP",,Cancer,Interferon regulatory factor 4 inhibitor,18763,Immunomodulator|Anticancer,1596|1545,Multiple myeloma,1828,Cancer,651,Peter MacCallum Cancer Centre,22207,,,Peter MacCallum Cancer Centre,22207,,,,,,
91217,ASTVAC-2,"VAC-2|allogenic hES cell-derived dendritic cell therapy (therapeutic vaccine, cancer), Asterias Biotherapeutics|GRNVAC-2|ASTVAC-2|allogenic hES cell-derived dendritic cell therapy (therapeutic vaccine, cancer), BioTime",Research Code|Research Code|Research Code,Cancer|Infection,Telomerase modulator,1613,Anticancer|Dendritic cell vaccine|Therapeutic vaccine|Antiviral,1545|102926|12379|991,Coronavirus disease 19 infection|Non-small-cell lung cancer|Acute myelogenous leukemia,10406|1262|1731,Cancer,651,Lineage Cell Therapeutics Inc,14846,Asterias Biotherapeutics Inc|Geron Corp,1074320|16315,Geron Corp,16315,,,,,,
9123,plitidepsin,"dehydrodidemnin B|Aplidina|DDB, PharmaMar|Aplidine|Aplidin|Aplidin(R)|plitidepsin|eukaryotic translation elongation factor 1 alpha 2 inhibitor (COVID-19), PharmaMar",Trade Name|Trade Name|INN,Cancer|Hematologic|Infection,Elongation factor 1 alpha 2 modulator|VEGF-1 receptor modulator,28406|3845,Anticancer|Cell cycle inhibitor|Apoptosis stimulator|Antiviral,1545|767|1589|991,Coronavirus disease 19 infection|Acute lymphoblastic leukemia|Multiple myeloma|Myelofibrosis|T-cell lymphoma|Cancer,10406|1728|1828|2436|311|651,Thyroid tumor|Small-cell lung cancer|Non-small-cell lung cancer|Acute myelogenous leukemia|Melanoma|Liposarcoma|Pancreas tumor|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Bladder tumor|Head and neck tumor|Solid tumor|Colorectal tumor|Renal tumor,1134|1261|1262|1731|205|2447|249|319|3246|42|623|725|989|999,Specialised Therapeutics Asia Pte Ltd|Specialised Therapeutics Australia Pty Ltd|Boryung Pharm Co Ltd|TTY Biopharm Co Ltd|Pint Pharma|MegaPharm Ltd|PharmaMar SA|Chugai Pharma Europe Ltd|Eczacibasi Ozgun Kimyasal Urunler Sanayi ve Ticaret AS,1157003|1044298|14987|29954|1110054|26786|17927|23864|30256,,,PharmaMar SA,17927,,,,,,
91256,XmAb-698,"bispecific antibody program (CD3 x CD38 target, cancer), Xencor|XmAb-13243|XmAb-13551|bispecific CD3/CD38 targeting antibody program (multiple myeloma), Amgen|XmAb-15426|anti-CD3/anti-CD38 bispecific T-cell engager (XmAb, multiple myeloma), Xencor/Amgen|AMG-424|XmAb-698",Research Code|Research Code|Research Code|Research Code|Research Code,Cancer,CD3 modulator|ADP ribosyl cyclase-1 modulator,5023|5134,T-lymphocyte stimulator|Immunostimulant|Anticancer antibody,7761|393|55684,Multiple myeloma,1828,Cancer,651,Xencor Inc,27617,Amgen Inc,14109,Xencor Inc,27617,,,,,,
91257,vibecotamab,"bispecific antibody program (CD3 x CD123 target, acute myelogenous leukemia), Xencor/ Novartis|XmAb-14045|SQZ-622|anti-CD3/anti-CD123 bispecific T-cell engager (FcRn-mediated half-life extension, hematological malignancy), Xencor/Novartis|vibecotamab",Research Code|Research Code|USAN|INN,Cancer,CD3 modulator|CDw123 modulator|IgG receptor FcRn large subunit p51 modulator,5023|5427|72028,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,B-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic myelocytic leukemia|Hematological neoplasm|Advanced solid tumor,1729|1731|1735|2054|3713,,,Xencor Inc|Novartis AG,27617|23137,,,Xencor Inc,27617,,,,,,
91370,"olorofim (intravenous infusion, aspergillosis/other fungal infections), F2G","F-901318|F-901318 (intravenous infusion, aspergillosis/other fungal infections), F2G|olorofim|olorofim (intravenous infusion, aspergillosis/other fungal infections), F2G",Research Code|INN,Infection,Dihydroorotate dehydrogenase inhibitor,1716,Fungicide,1748,Aspergillus fumigatus infection|Blastomyces infection|Scedosporium infection|Aspergillus infection,1307|1322|1347|29,,,F2G Ltd,29821,,,F2G Ltd,29821,Benadryl|Butix,Diphenhydramine hydrochloride,Histamine H1 Receptor Antagonists,196,Signal Transduction Modulators,1402
91386,PDC*lung,"PDC*lung|PDC*lung-01 (NSCLC), PDC*line Pharma",,Cancer,,,Anticancer|Therapeutic vaccine|Dendritic cell vaccine,1545|12379|102926,Non-small-cell lung cancer,1262,,,PDC*Line Pharma|LG Chem Ltd,1096380|22235,,,PDC*Line Pharma,1096380,Nardil,Phenelzine sulfate,Monoamine Oxidase MAO Inhibitors,448,,
91398,siremadlin,"HDM-201|p53-Mdm2 inhibitors (cancer), Novartis Institutes for Biomedical Research|NVP-HDM-201|siremadlin",Research Code|Research Code|INN,Cancer|Hematologic,Mdm2 p53-binding protein inhibitor,10391,Anticancer|Apoptosis stimulator,1545|1589,,,Non-small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Renal cell carcinoma|Polycythemia|Thrombocythemia|Myelofibrosis|Liposarcoma|Uveal melanoma|Breast tumor|Cancer|Colorectal tumor,1262|1272|1731|1766|1827|2317|2436|2447|3788|49|651|989,,,Novartis AG,23137,Novartis AG,23137,Paxipam,Halazepam,GABA(A) BZ Site Receptor Agonists,191,Signal Transduction Modulators,1402
91519,"vorhyaluronidase alfa (cancer, Enhanze), Hangzhou Anruipu Biological Technology/Halozyme","hyaluronidase (human recombinant)|rHuPH-20|recombinant human hyaluronidase (CHO, cancer), Hangzhou Anruipu Biological Technology|vorhyaluronidase alfa|vorhyaluronidase alfa (CHO, cancer), Hangzhou Anruipu Biological Technology|vorhyaluronidase alfa (cancer, Enhanze), Hangzhou Anruipu Biological Technology/Halozyme",USAN|Research Code|INN,Cancer,Hyaluronidase PH20 modulator,69413,Synergist|Anticancer,7293|1545,,,Cancer,651,,,Hangzhou Anruipu Biological Technology Co Ltd,1074376,Hangzhou Anruipu Biological Technology Co Ltd,1074376,Bretylate|Bretylol,Bretylium tosilate|Bretylium tosylate,,,,
91530,"murine anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy (cancer), NIH/Kite Pharma","murine anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy (cancer), NIH/Kite Pharma|anti-NY-ESO-1 T-cell therapy (cancer), Kite Pharma",,Cancer,HLA class I antigen A-2 alpha modulator|Cancer testis antigen NY-ESO-1 modulator,19115|50096,Anticancer|T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant,1545|7761|4790|393,Metastasis,1069,,,Kite Pharma Inc,1056870,National Institutes of Health,20518,National Institutes of Health,20518,Persantin|Persantin Retard,Dipyridamole,"Multidrug Resistance-Associated Protein 4 (ABCC4; MRP4) Inhibitors|Equilibrative Nucleoside Transporter ENT1 Inhibitors|Phosphodiesterase PDE3 Inhibitors|cGMP-Specific 3',5'-Cyclic Phosphodiesterase (PDE5A; PDE5) Inhibitors",682|2389|469|471,Signal Transduction Modulators,1402
91554,ACP-319,"ACP-319|PIK3 delta inhibitor (cancer, oral), Acerta",Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor,11183,Anticancer,1545,Chronic lymphocytic leukemia|B-cell lymphoma,1734|316,,,Acerta Pharma BV,1089086,,,Acerta Pharma BV,1089086,,,,,,
91599,"dalpiciclib (CDK4/6 inhibitor, oral, cancer), Jiangsu Hengrui Medicine","SHR-6390|CDK4/6 inhibitor (oral, cancer), Jiangsu Hengrui Medicine|dalpiciclib|dalpiciclib (CDK4/6 inhibitor, oral, cancer), Jiangsu Hengrui Medicine",Research Code|PINN,Cancer,Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase-6 inhibitor,4314|4318,Anticancer protein kinase inhibitor,62255,Stage IV melanoma|Metastatic breast cancer|Metastatic stomach cancer|Advanced solid tumor|Head and neck tumor,3257|3657|3666|3713|623,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,Jiangsu Hengrui Medicine Co Ltd,1006925,,,,,,
91601,IMGN-779,"IMGN-779|DGN-462/Z4681A (AML) conjugate, ImmunoGen|DNA-alkylating payload/anti-CD33 antibody (AML) conjugate, ImmunoGen|anti-CD33 antibody-drug conjugate (AML), ImmunoGen",Research Code,Cancer,CD33 antagonist,5121,Immunotoxin|Synergist|Anticancer alkylating agent|Anticancer monoclonal antibody,539|7293|50|55685,,,Acute myelogenous leukemia,1731,,,ImmunoGen Inc,17202,ImmunoGen Inc,17202,Cyclomen|Danatrol|Danocrine|Danol|Optina|Vasaloc,Danazol,TNF-alpha Modulators,2053,Signal Transduction Modulators,1402
91627,ALLO-647,"CAR T-cell therapy (cancer), Cellectis/ Pfizer|UCART-S1|CAR T-cell therapy (cancer), Cellectis/ Allogene|ALLO-647|anti-CD52 monoclonal antibody (lymphodepletion agent/CAR T persisitence), Allogene",Research Code|Research Code,Cancer,CD52 modulator,5216,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Follicle center lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma|Non-Hodgkin lymphoma|Metastatic renal cell carcinoma|Cancer,1745|1749|1828|319|4250|651,,,Cellectis SA|Allogene Therapeutics Inc,29822|1162743,Pfizer Inc,18767,Cellectis SA,29822,Eumovate,Clobetasone butyrate,,,,
91639,sabatolimab,"TIM-3 antagonist (cancer), CoStim|MBG-453|TIM-3 antagonist (cancer), Novartis|HAVCR2 antagonist (cancer), CoStim|HAVCR2 antagonist (cancer), Novartis|HAVCR2 mAb (cancer), CoStim|TIM-3 mAb (cancer), CoStim|HAVCR2 mAb (cancer), Novartis|TIM-3 mAb (cancer), Novartis|MGB-453|TIM-3 checkpoint inhibitor (cancer), Novartis|sabatolimab",Research Code|Research Code|INN,Cancer|Hematologic,Hepatitis A virus cellular receptor 2 antagonist,34783,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Myelodysplastic syndrome|Acute myelogenous leukemia|Polycythemia|Thrombocythemia|Myelofibrosis|Glioblastoma|Cancer|Chronic myelomonocytic leukemia,1272|1731|1827|2317|2436|2454|651|6833,,,Novartis AG,23137,CoStim Pharmaceuticals Inc,1088885,CoStim Pharmaceuticals Inc,1088885,,,,,,
91645,"amlodipine besylate + losartan potassium (hypertension), Korea United","UI-15AML055MT|amlodipine besylate + losartan potassium (hypertension), Korea United|Losasc|amlodipine besylate + losartan potassium",Research Code|Trade Name,Cardiovascular,Angiotensin II AT-1 receptor antagonist|Calcium channel inhibitor L-type,788|2588,Antihypertensive,2657,Hypertension,178,,,Korea United Pharm Inc,1006636,,,Korea United Pharm Inc,1006636,,,,,,
9174,vatalanib,"CGP-79787|vatalanib|CGP-79787D|PTK-787|ZK-222584|PTK/ZK|DE-00268|PTK-787A|VEGF-RKI|VEGR-TKI|PTK/ZK, Novartis/Schering|VEGF-TK inhibitor, Novartis/Schering|angiogenesis inhibitor, Novartis/Schering|finasunate|pynasunate|angiogenesis inhibitor, Novartis/Bayer Schering|VEGF-TK inhibitor, Novartis/Bayer Schering|PTK/ZK, Novartis/Bayer Schering|ZK-22584",Research Code|USAN|INN|Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name|Trade Name|Research Code,Cancer|Ocular,VEGF receptor antagonist|PDGF receptor antagonist,1722|948,Anticancer protein kinase inhibitor|Angiogenesis inhibitor,62255|61,,,Age related macular degeneration|Non-small-cell lung cancer|Myelodysplastic syndrome|Acute myelogenous leukemia|Glioblastoma|Prostate tumor|Meningioma|Carcinoma|Cancer|Solid tumor|Ovary tumor|Kaposis sarcoma|Colorectal tumor,1226|1262|1272|1731|2454|276|2802|54|651|725|799|936|989,,,Bayer Schering Pharma AG|Novartis AG,19687|23137,Novartis AG,23137,,,,,,
91821,111In-amatuximab,111In-amatuximab,,Cancer,Mesothelin modulator,11484,Anticancer|Neoplasm diagnostic agent|Radiodiagnostic|Imaging agent,1545|7220|5720|4155,,,Cancer,651,,,National Cancer Institute (NCI)|Morphotek Inc,20519|29741,Morphotek Inc,29741,,,,,,
91867,KHK-2823,KHK-2823,Research Code,Cancer,CDw123 antagonist,5429,Anticancer monoclonal antibody,55685,Myelodysplastic syndrome|Acute myelogenous leukemia,1272|1731,,,Kyowa Hakko Kirin Pharma Inc,17727,,,Kyowa Hakko Kirin Pharma Inc,17727,,,,,,
9193,motexafin gadolinium,"gadolinium texaphyrin|motexafin gadolinium|PCI-0120|Xcytrin|Gd-Tex, Pharmacyclics|Gd-Tex",USAN|Research Code|Trade Name,Cancer|Infection|Neurology/Psychiatric,Thioredoxin reductase modulator,6505,Gastrointestinal diagnostic agent|CNS diagnostic agent|MRI imaging agent|Apoptosis stimulator|Radiochemosensitizer|Anticancer|Antiviral|Immune diagnostic agent|Neoplasm diagnostic agent,7213|7211|4158|1589|572|1545|991|7215|7220,,,Non-small-cell lung cancer|HIV infection|Chronic lymphocytic leukemia|Multiple myeloma|Neurodegenerative disease|Glioblastoma|Pancreas tumor|Non-Hodgkin lymphoma|Metastatic renal cell carcinoma|Cancer|Lung tumor|Brain tumor,1262|158|1734|1828|233|2454|249|319|4250|651|755|760,,,Pharmacyclics Inc,19063,Pharmacyclics Inc,19063,,,,,,
9196,motexafin lutetium,Antrin|Lu-Tex|lutetium texaphyrin|Lutrin|motexafin lutetium|Motexafin lutetium hydrate|PCI-0123 hydrate|Optrin|PCI-0123,Trade Name|Research Code|Trade Name|USAN|INN|Research Code|Trade Name|Research Code,Cancer|Cardiovascular|Ocular,,,Unspecified drug target|Anticancer|Photosensitizer|Antiarteriosclerotic,59620|1545|799|2667,,,Age related macular degeneration|Melanoma|Ocular disease|Peripheral vascular disease|Prostate tumor|Atherosclerosis|Breast tumor|Cancer|Coronary artery disease,1226|205|239|260|276|33|49|651|80,,,Nycomed AS|Alcon Inc|Alcon Pharmaceuticals Ltd|Pharmacyclics Inc|National Cancer Institute (NCI),16832|18478|18491|19063|20519,Pharmacyclics Inc,19063,,,,,,
91964,tusamitamab ravtansine,"SAR-408701|anti-CEACAM5 ADC (intravenous/infusion, colorectal cancer, Metastatic non small cell lung cancer, stomach cancer, solid tumor), Sanofi|tusamitamab ravtansine",Research Code|PINN,Cancer,CD66e antagonist,5275,Anticancer monoclonal antibody,55685,Stomach tumor|Metastatic non small cell lung cancer|Advanced solid tumor|Solid tumor|Colorectal tumor,127|3665|3713|725|989,,,Sanofi SA,1009547,ImmunoGen Inc,17202,ImmunoGen Inc,17202,,,,,,
91985,"miR-15/16 mimics (EGFR-targeted minicells, malignant pleural mesothelioma), EnGeneIC","miR-15/16 mimics (EGFR-targeted minicells, malignant pleural mesothelioma), EnGeneIC|TargomiRs|EGFR-EDV-miR-16",,Cancer,Epidermal growth factor receptor modulator,3605,miRNA agent|Apoptosis stimulator|Anticancer|Cell cycle inhibitor,38419|1589|1545|767,Mesothelioma,1240,,,EnGeneIC Ltd,30135,,,EnGeneIC Ltd,30135,,,,,,
92012,LOP-628,"LOP-628|c-KIT antibody-drug conjugate (cancer), Novartis|c-KIT ADC (cancer), Novartis",Research Code,Cancer,Kit tyrosine kinase modulator,3807,Immunotoxin|Anticancer antibody,539|55684,,,Cancer,651,,,Novartis AG,23137,Novartis AG,23137,,,,,,
92056,RG-7775,"RO-6839921|RG-7775|MDM2 antagonist (iv prodrug, acute myelogenous leukemia), Roche",Research Code|Research Code,Cancer,Mdm2 p53-binding protein inhibitor,10391,Anticancer,1545,,,Acute myelogenous leukemia|Cancer,1731|651,,,Roche Holding AG,19446,Roche Holding AG,19446,,,,,,
92063,"dexamethasone acetate (high-dose formulation, multiple myeloma), Laboratories CTRS","dexamethasone|dexamethasone (high-dose formulation, multiple myeloma), Laboratories CTRS|dexamethasone acetate|Neofordex|dexamethasone acetate (high-dose formulation, multiple myeloma), Laboratories CTRS",BANN|INN|USAN|BANN|Trade Name,Cancer,Glucocorticoid receptor agonist,3191,Steroidal anti-inflammatory|Anticancer,2954|1545,Multiple myeloma,1828,,,Laboratoires CTRS,1088756,,,Laboratoires CTRS,1088756,,,,,,
92118,plamotamab,"bispecific antibody program (CD3 x CD20 target, B-cell malignancies), Xencor/Novartis|XmAb-13676|XmAb-13677|THG-338|XENP-13677|anti-CD3/anti-CD20 bispecific T-cell engager (B-cell malignancies), Xencor/Novartis|plamotamab",Research Code|Research Code|Research Code|Research Code|USAN|INN,Cancer,CD3 modulator|B-lymphocyte antigen CD20 modulator,5023|5083,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1734|1745|1749|319,Hematological neoplasm,2054,Xencor Inc,27617,Novartis AG,23137,Xencor Inc,27617,,,,,,
92128,CT-707,"CT-707|multi-kinase inhibitor (oral granules, NSCLC), Centaurus BioPharma|ALK/FAK/PYK2 inhibitor (oral granules, NSCLC), Centaurus BioPharma|SY-707",Research Code|Research Code,Cancer,Focal adhesion kinase-2 inhibitor|Anaplastic lymphoma kinase receptor inhibitor,3544|3736,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer,1262,,,Shouyao Holdings (Beijing) Co Ltd|Centaurus BioPharma Co Ltd,1204681|1069948,,,Centaurus BioPharma Co Ltd,1069948,,,,,,
92133,"inebilizumab + rituximab (hematological malignancies), MedImmune/AstraZeneca/Genentech","rituximab|inebilizumab + rituximab (hematological malignancies), MedImmune/AstraZeneca/Genentech|anti-CD19 mAb + anti-CD20 mAb (B-cell malignancies), MedImmune/Genentech/AstraZeneca",USAN|BANN|INN,Cancer,B-lymphocyte antigen CD19 inhibitor|B-lymphocyte antigen CD20 inhibitor,5082|5085,Anticancer monoclonal antibody,55685,,,Hematological neoplasm,2054,,,MedImmune LLC|Genentech Inc,18008|19453,MedImmune LLC,18008,,,,,,
92236,ASN-003,EN-3352|ASN-003,Research Code|Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor|Phosphoinositide-3 kinase alpha inhibitor|Phosphoinositide 3-kinase inhibitor|Raf B protein kinase inhibitor,11183|11177|1575|4548,Anticancer protein kinase inhibitor|Synergist|Anticancer,62255|7293|1545,Stage IV melanoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,3257|3658|3665|3713,Cancer,651,Asana BioSciences LLC,1096790,Endo Pharmaceuticals Solutions Inc,17247,Endo Pharmaceuticals Solutions Inc,17247,,,,,,
92240,gusacitinib,"ASN-002, Asana Biosciences|SYK/JAK dual inhibitor (solid tumor), Asana BioSciences|dualSYK/JAK inhibitor (oral tablet, solid tumor/atopic dermatitis/lymphoma/myelofibrosis/eczema), Asana BioSciences|gusacitinib|gusacitinib hydrochloride|ASN-002 hydrochloride",Research Code|USAN|PINN|USAN,Cancer|Dermatologic|Hematologic|Inflammatory,Jak1 tyrosine kinase inhibitor|Jak2 tyrosine kinase inhibitor|JAK tyrosine kinase inhibitor|Syk tyrosine kinase inhibitor|Jak3 tyrosine kinase inhibitor|Non receptor tyrosine kinase TYK2 antagonist,3562|3564|3560|3602|3566|66313,Anti-inflammatory|Anticancer protein kinase inhibitor,2953|62255,Eczema|Atopic dermatitis,109|1102,Chronic lymphocytic leukemia|Peripheral T-cell lymphoma|Inflammatory disease|Lymphoma|Myelofibrosis|Non-Hodgkin lymphoma|Cancer|Solid tumor,1734|1753|188|203|2436|319|651|725,Asana BioSciences LLC,1096790,,,Asana BioSciences LLC,1096790,,,,,,
92243,"ASN-004, Asana Biosciences","ASN-004, Asana Biosciences",,Cancer,Trophoblast glycoprotein modulator,14327,Anticancer antibody,55684,Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic ovary cancer|Breast tumor|Cancer|Solid tumor|Ovary tumor|Colorectal tumor,3657|3658|3665|3866|49|651|725|799|989,,,Asana BioSciences LLC,1096790,,,Asana BioSciences LLC,1096790,,,,,,
92246,ASN-007,"ASN-007|ERK inhibitors (cancer), Asana BioSciences|ERAS-007",Research Code|Research Code,Cancer,Extracellular signal related kinase-1 inhibitor|MAP kinase inhibitor|Extracellular signal related kinase-2 inhibitor,4364|2511|4366,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Metastasis|Pancreatic ductal adenocarcinoma|Neoplasm|Pancreas tumor|Stage IV melanoma|Metastatic non small cell lung cancer|Metastatic lung cancer|Metastatic pancreas cancer|Metastatic colon cancer|Advanced solid tumor|Cancer|Solid tumor|Colon tumor,1069|1507|230|249|3257|3665|3668|3669|3672|3713|651|725|767,,,Erasca,1177568,Asana BioSciences LLC,1096790,Asana BioSciences LLC,1096790,,,,,,
92343,PF-06821497,"EZH2 inhibitor (prostate cancer), Pfizer|PF-06821497",Research Code,Cancer,Enhancer of zeste homolog 2 inhibitor,43815,Anticancer,1545,Small-cell lung cancer|Follicle center lymphoma|Diffuse large B-cell lymphoma|Hormone refractory prostate cancer,1261|1745|1749|3246,,,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
92371,cofetuzumab pelidotin,PF-06647020|PTK7-ADC|anti-PTK7-auristatin|cofetuzumab pelidotin|PTK7-Aur0101|PF-7020|ABBV-647,Research Code|USAN|INN|Research Code|Research Code,Cancer,Tubulin modulator|PTK7 tyrosine kinase receptor modulator,814|3813,Cell cycle inhibitor|Immunotoxin|Anticancer monoclonal antibody,767|539|55685,Non-small-cell lung cancer|Solid tumor,1262|725,,,Pfizer Inc|AbbVie Inc,18767|1072507,Stemcentrx Inc,1063564,Stemcentrx Inc,1063564,,,,,,
92429,lisocabtagene maraleucel,"anti-CD19 CAR T-cell therapy (leukemia), Juno Therapeutics|lisocabtagene maraleucel|JCAR-017|liso-cel|SCRI-CAR19v1|anti-CD19 CAR T-cell therapy (iv/infusion, B-cell malignancies), Celgene Corp|Breyanzi",USAN|INN|Research Code|Trade Name,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|High grade B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1729|1734|1744|1745|1746|1749|1750|1751|316|319,Leukemia,199,Bristol-Myers Squibb Co,15065,Juno Therapeutics Inc|Celgene Corp,1090676|15331,Juno Therapeutics Inc,1090676,,,,,,
92462,mezagitamab,"TAK-079|anti-CD38 mAb (intravenous/subcutaneous, multiple myeloma/systemic lupus erythematosus/autoimmune disease), Takeda|anti-CD38 mAb (intravenous/subcutaneous, multiple myeloma/systemic lupus erythematosus/ myasthenia gravis/primary immune thrombocytopenia/), Takeda|mezagitamab",Research Code|USAN|INN,Cancer|Hematologic|Immune,ADP ribosyl cyclase-1 inhibitor,5136,Anticancer monoclonal antibody|Anti-inflammatory,55685|2953,Multiple myeloma|Systemic lupus erythematosus|Thrombocytopenia|Myasthenia gravis,1828|318|324|848,Rheumatoid arthritis|Autoimmune disease,291|36,Takeda Pharmaceutical Co Ltd,20300,,,Takeda Pharmaceutical Co Ltd,20300,,,,,,
9247,tretinoin,"tretinoin|all-trans-Retinoic acid|Vesanoid|NSC-122758|ATRA, Roche|tretinoin, Roche|all-trans retinoic acid, Roche|IDP-121",USAN|BAN|INN|Trade Name|Research Code|Research Code,Cancer,Retinoic acid receptor agonist,753,Anticancer,1545,Acute promyelocytic leukemia,1732,,,Roche Holding AG|OncBioMune Mexico SA de CV|Fuji Pharma Co Ltd|CHEPLAPHARM Arzneimittel GmbH,19446|1121411|1045871|1129377,Chugai Pharmaceutical Co Ltd,15414,Roche Holding AG,19446,,,,,,
92497,CC-90003,"extracellular signal-regulated kinase inhibitor (cancer), Celgene|ERK inhibitor (cancer), Celgene|mitogen-activated protein kinase inhibitor (cancer), Celgene|MAPK inhibitor (cancer), Celgene|CC-90003",Research Code,Cancer,Extracellular signal related kinase inhibitor,173760,Anticancer protein kinase inhibitor,62255,,,Cancer,651,,,Celgene Corp,15331,Celgene Corp,15331,,,,,,
92504,"olorofim (oral, Aspergillus/Scedosporium/other fungal infections), F2G","F-901318|F-901318 (oral, aspergillosis), F2G|olorofim|olorofim (oral, Aspergillus/Scedosporium/other fungal infections), F2G",Research Code|INN,Infection,Dihydroorotate dehydrogenase inhibitor,1716,Fungicide|Anticancer,1748|1545,Fungal infection|Blastomyces infection|Scedosporium infection|Aspergillus infection,124|1322|1347|29,Aspergillus fumigatus infection,1307,F2G Ltd,29821,,,F2G Ltd,29821,,,,,,
92578,VL-2397,ASP-2397|VL-2397,Research Code|Research Code,Infection,,,Unspecified drug target|Fungicide,59620|1748,,,Aspergillus infection,29,,,Astellas Pharma Inc|Brickell Biotech Inc,1013295|20743,Astellas Pharma Inc,1013295,,,,,,
92600,"candesartan + amlodipine (hypertension), CJ Healthcare","candesartan|candesartan + amlodipine|candesartan + amlodipine (hypertension), CJ Corp|CJ-30059|Machkhan|candesartan + amlodipine (hypertension), CJ Healthcare",INN|Research Code|Trade Name,Cardiovascular,Angiotensin II receptor antagonist|Calcium channel inhibitor,64|93,Cardioprotectant|Antihypertensive,2659|2657,Hypertension,178,Angina,23,HK inno.N Corp,1096009,CJ Corp,15473,CJ Corp,15473,,,,,,
92605,enapotamab vedotin,"Axl-ADCs|enapotamab vedotin|AXL modulator human antibody (cancer), Genmab|AXL-107-MMAE|HuMax-AXL-ADC",INN,Cancer,Axl tyrosine kinase receptor modulator,3741,Anticancer|Anticancer protein kinase inhibitor|Anticancer monoclonal antibody|Microtubule inhibitor,1545|62255|55685|2575,,,Thyroid tumor|Non-small-cell lung cancer|Endometrioid carcinoma|Sarcoma|Melanoma|Uterine cervix tumor|Cancer|Ovary tumor,1134|1262|1705|194|205|427|651|799,,,Genmab A/S,26469,Genmab A/S,26469,,,,,,
92656,RGX-104,RGX-101|RGX-104,Research Code|Research Code,Cancer,Liver X receptor agonist|APOE gene stimulator,4030|26283,Metastasis inhibitor|Anticancer,695|1545,Neuroendocrine tumor|Small-cell lung cancer|Non-small-cell lung cancer|Renal cell carcinoma|Lymphoma|Melanoma|Bladder cancer|Glioblastoma|Breast tumor|Ovary tumor,1128|1261|1262|1766|203|205|2380|2454|49|799,Advanced solid tumor|Solid tumor,3713|725,RGenix Inc,1100408,,,RGenix Inc,1100408,,,,,,
92721,CYT-0851,"RAD51 inhibitors (cancer/autoimmune diseases), Cyteir|C-1523|CYT-01A|CYT-01B|CYT-0851|CYT-0853|CYT-0178",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code,Cancer|Endocrine/Metabolic|Immune,DNA repair protein RAD51 homolog 1 inhibitor,18832,Anticancer|Hypoglycemic agent,1545|399,Small-cell lung cancer|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma|Hematological neoplasm|Pancreas tumor|Squamous cell carcinoma|B-cell lymphoma|Non-Hodgkin lymphoma|Soft tissue sarcoma|Autoimmune disease|Advanced solid tumor|Breast tumor|Head and neck tumor|Cancer|Ovary tumor|Insulin dependent diabetes,1261|1734|1744|1745|1749|1828|2054|249|307|316|319|3378|36|3713|49|623|651|799|836,,,Jackson Laboratory|Cyteir Therapeutics Inc,24423|1100498,,,Cyteir Therapeutics Inc,1100498,,,,,,
92776,BB-MPI-03,BB-MPI-03,Research Code,Cancer,,,Anticancer|Immunomodulator,1545|1596,,,Hematological neoplasm,2054,,,BenovusBio LLC,1100435,BenovusBio LLC,1100435,,,,,,
92778,disitamab vedotin,"anti-HER2 mAb-MMAE ADC (cancer), Yantai Rongchang Biotechnologies|anti-HER2 mAb-MMAE antibody drug conjugate (cancer), Yantai Rongchang Biotechnologies|RC-48|RC48-ADC|anti-HER2 mAb-MMAE ADC (cancer), RemeGen|anti-HER2 mAb-MMAE antibody drug conjugate (cancer), RemeGen|disitamab vedotin|aidixi|weidixituo",Research Code|INN|Trade Name,Cancer,Erbb2 tyrosine kinase receptor inhibitor|Tubulin receptor antagonist,3756|541,Immunotoxin|Microtubule inhibitor|Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,539|2575|62255|55685,Stomach tumor|Biliary cancer|Transitional cell carcinoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer,127|1516|1771|3657|3665|3666,Solid tumor,725,RemeGen Ltd,1044479,,,RemeGen Ltd,1044479,,,,,,
92818,BI-1361849,CV-9202|BI-1361849,Research Code|Research Code,Cancer,BIRC5 gene modulator|MAGEC1 gene modulator|MAGEC2 gene modulator|CTAG1 gene modulator|MUC1 gene modulator|TPBG gene modulator,18158|22099|22102|50099|32115|69575,RNA vaccine|Therapeutic vaccine|Anticancer,12377|12379|1545,Non-small-cell lung cancer,1262,,,Boehringer Ingelheim International GmbH|CureVac AG,14881|31507,Unilfarma Lda,22598,CureVac AG,31507,,,,,,
92901,"dexrazoxane hydrochloride (anthracycline-induced cardiomyopathy), Satiscor","dexrazoxane|dexrazoxane hydrochloride (anthracycline-induced cardiomyopathy), Satiscor|dexrazoxane hydrochloride",INN,Toxicity/Intoxication,,,Chelating agent|Cardioprotectant,105|2659,,,Cardiotoxicity drug-induced,1090,,,Satiscor LLC,1100802,Satiscor LLC,1100802,,,,,,
9291,dalteparin sodium,Boxol|FR-860|K-2165|Fragmine|KABI-2165|LigoFragmin|Fragmin 5000 IU|dalteparin sodium|Fragmin,Trade Name|Research Code|Research Code|Trade Name|Research Code|Trade Name|Trade Name|USAN|BANN|INN|Trade Name,Cardiovascular|Dermatologic|Hematologic,Factor IIa antagonist|Factor Xa antagonist|Low molecular weight heparin,111|120|1741,,,Lung embolism|Coronary thrombosis|Thromboembolism|Deep vein thrombosis,1078|1587|325|574,Vascular occlusive disease|Diabetic foot ulcer,3412|790,Pfizer Inc|Kissei Pharmaceutical Co Ltd|Eisai Co Ltd,18767|17665|15872,Pharmacia & Upjohn Inc|Pharmacia & Upjohn AB|Kabi Pharmacia AB|Pharmacia Corp,22006|22008|22028|27638,Kabi Pharmacia AB,22028,,,,,,
9298,Thymoglobulin,Thymoglobuline|Thymoglobulin|anti-Thymocyte-globulin (rabbit)|GZ-427051,Trade Name|Trade Name|Research Code,Cancer|Endocrine/Metabolic|Hematologic|Immune,Somatostatin receptor agonist,1120,Anticancer polyclonal antibody|Anticancer|Growth hormone release inhibitor|Immunosuppressant,55686|1545|3272|396,Aplastic anemia|Heart transplant rejection|Liver transplant rejection|Kidney transplant rejection|Stem cell transplantation|Lung transplant rejection|Pancreas transplant rejection|Transplant rejection|Graft versus host disease,1006|2987|2988|2989|2990|3141|3142|515|616,Myelodysplastic syndrome|T-cell lymphoma|Bone marrow transplantation|Insulin dependent diabetes,1272|311|46|836,Sanofi SA|Sanofi Genzyme|Sanofi Pasteur,1009547|16299|22127,Pasteur Merieux Serums et Vaccins SA|SangStat Medical Corp|IMTIX-Sangstat,19266|19651|30165,Pasteur Merieux Serums et Vaccins SA,19266,,,,,,
93002,UCART-123,"UCART-123|anti-CD123 CAR T-cell therapy (AML), Cellectis",Research Code,Cancer,CDw123 modulator,5427,Anticancer|Immunostimulant|T-lymphocyte stimulator,1545|393|7761,Acute myelogenous leukemia|Hematological neoplasm,1731|2054,,,Cellectis SA|MD Anderson Cancer Center,29822|23382,,,Cellectis SA,29822,,,,,,
9302,ranpirnase,"Onconase|ranpirnase|proapoptotic amphibian ribonuclease (cancer/ HIV), Alfacell|proapoptotic amphibian ribonuclease (cancer/ HIV), Tamir|TMR-004|RanTop",Trade Name|USAN|INN|Research Code|Trade Name,Cancer|Infection|Toxicity/Intoxication,Ribonuclease stimulator,9167,Antiviral|Radiochemosensitizer|Anticancer|Apoptosis stimulator,991|572|1545|1589,Coronavirus disease 19 infection|Ebola virus infection|Condyloma|Hepatitis C virus infection|HIV infection|Coronavirus infection|Respiratory syncytial virus infection|Papillomavirus infection|Orthomyxovirus infection|Rhabdovirus infection|Cytomegalovirus infection,10406|1049|1232|153|158|1782|287|396|691|714|89,Mesothelioma|Non-small-cell lung cancer|Hematological neoplasm|Pancreas tumor|Prostate tumor|Viral infection|Radiation sickness|Breast tumor|Zika virus infection|Solid tumor|Renal tumor,1240|1262|2054|249|276|344|367|49|6927|725|999,Leidos Inc|Tamir Biotechnology Inc,1102034|13981,GENESIS Pharma SA|US Pharmacia SP ZOO|Par Specialty Pharmaceuticals|BL&H Co Ltd|MegaPharm Ltd,1020077|1033864|1034976|1037227|26786,Tamir Biotechnology Inc,13981,,,,,,
93020,CAEL-101,"11-1F4|CAEL-101|11-14F|[124I]-CAEL-101|Amyloid protein deposition inhibitor (iv, ALAmyloidosis) Alexion/Caelum Biosciences|124I-labeled 11-1F4, Caelum",Research Code|Research Code|Research Code,Endocrine/Metabolic,Amyloid protein deposition inhibitor,621,Imaging agent|Radioimmunotherapeutic|Neuroprotectant|Radiodiagnostic|Radioimmunodiagnostic|PET contrast agent,4155|1552|1615|5720|4405|5555,AL amyloidosis,3492,,,Caelum Biosciences Inc|Alexion Pharmaceuticals Inc,1141705|13979,National Cancer Institute (NCI)|Columbia University|University of Tennessee|Siemens AG,20519|20559|26292|31035,Columbia University,20559,,,,,,
93084,zorifertinib,AZD-3759|zorifertinib,Research Code|INN,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer,3665,,,Alpha Biopharma Inc,1156120,AstraZeneca plc,14190,AstraZeneca plc,14190,,,,,,
9311,pirarubicin,1609RB|Berirubin|Pinorubin|tirarubicin|Theprubicine|Therarubicin|pirarubicin,Research Code|Trade Name|Trade Name|Trade Name|Trade Name|INN,Cancer,,,RNA synthesis inhibitor|Anticancer,439|1545,Liver tumor|Pancreas tumor|Breast tumor|Female genital tract tumor|Head and neck tumor,202|249|49|606|623,Carcinoma,54,Meiji Seika Pharma Co Ltd|Laboratoires Roger Bellon SA|Almirall Prodesfarma SA|Mercian Corp,18049|19237|14061|18076,Microbial Chemistry Research Foundation|Behringwerke AG,14851|16816,Microbial Chemistry Research Foundation,14851,,,,,,
93115,GS-9901,GS-9901,Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor,11183,Anticancer protein kinase inhibitor,62255,,,Cancer,651,,,Gilead Sciences Inc,16450,Gilead Sciences Inc,16450,,,,,,
93133,lirametostat,"CPI-1205|EZH2 inhibitors (lymphoma), Constellation Pharmaceuticals|EZH2 inhibitors (oral formulation, lymphoma/metastatic castration-resistant prostate cancer/melanoma), Constellation Pharmaceuticals|lirametostat",Research Code|PINN,Cancer,Enhancer of zeste homolog 2 inhibitor,43815,Synergist|Apoptosis stimulator|Anticancer,7293|1589|1545,Melanoma|B-cell lymphoma|Hormone refractory prostate cancer|Advanced solid tumor,205|316|3246|3713,Lymphoma,203,Constellation Pharmaceuticals Inc,1039065,,,Constellation Pharmaceuticals Inc,1039065,,,,,,
93240,PBF-1129,"PBF-1250|PBF-1129|A2bR checkpoint inhibitor (cancer/idiopathic pulmonary fibrosis), Palobiofarma",Research Code|Research Code,Cancer|Respiratory,Adenosine A2b receptor antagonist,598,Anti-inflammatory|Immunostimulant|T-lymphocyte stimulator|Anticancer,2953|393|7761|1545,Metastatic non small cell lung cancer|Idiopathic pulmonary fibrosis|Cancer,3665|3771|651,,,Palobiofarma SL,1035311,,,Palobiofarma SL,1035311,,,,,,
93260,ACTR-087 + rituximab,"anti-CD20 mAb + CD16V-BB-zeta T cells (B-cell leukemia/lymphoma), National University of Singapore/Unum Therapeutics|ACTR-087|ATTCK-20|ACTR-087 + rituximab|anti-CD20 mAb + chimeric CD16V-41BB-CD3zeta receptor T cells (B-cell leukemia/lymphoma), National University of Singapore/Unum Therapeutics|anti-CD20 mAb + CD16 anti-Fc CAR T-cell therapy (B-cell leukemia/lymphoma), National University of Singapore/Unum Therapeutics",Research Code,Cancer,B-lymphocyte antigen CD20 inhibitor,5085,T-lymphocyte stimulator|Genetically engineered autologous cell therapy|Immunostimulant|Anticancer monoclonal antibody|Anticancer,7761|4790|393|55685|1545,Chronic lymphocytic leukemia|B-cell lymphoma|Non-Hodgkin lymphoma,1734|316|319,,,Cogent Biosciences Inc,1101952,National University of Singapore,20633,National University of Singapore,20633,,,,,,
93268,18F-fludarabine,"18F-fludarabine|177-Fluorine-fludarabine|radiolabeled fludarabine (lymphoma imaging), Cyceron",,Cancer,,,Immune diagnostic agent|DNA synthesis inhibitor|Neoplasm diagnostic agent|PET contrast agent,7215|140|7220|5555,,,Lymphoma,203,,,GIP Cyceron,1101957,GIP Cyceron,1101957,,,,,,
93297,CC-99712,"antibody drug conjugate (cancer), Sutro/Celgene|antibody drug conjugate (BCMA, multiple myeloma), Sutro/Celgene|CC-99712|antibody drug conjugate (BCMA inhibitor, multiple myeloma), Sutro/Bristol-Myers Squibb",Research Code,Cancer,APRIL receptor antagonist,8257,Anticancer antibody|Anticancer,55684|1545,Multiple myeloma,1828,,,Sutro Biopharma Inc|Bristol-Myers Squibb Co,1036455|15065,Celgene Corp,15331,Sutro Biopharma Inc,1036455,,,,,,
93298,M-1231,"antibody drug conjugate (cancer), Sutro/EMD Serono|M-1231|EGFR/Mucin 1 bispecific antibody drug conjugate (cancer), Sutro/EMD Serono",,Cancer,Epidermal growth factor receptor modulator|Mucin 1 modulator,3605|32076,Anticancer antibody|Anticancer,55684|1545,Squamous cell carcinoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer,307|3657|3665|3667|3668|3673|3713|3866,Esophagus tumor|Non-small-cell lung cancer|Cancer,1011|1262|651,Sutro Biopharma Inc|EMD Serono Inc,1036455|1035512,,,Sutro Biopharma Inc,1036455,,,,,,
93299,STRO-001,"antibody drug conjugates (cancer), Sutro|CD74 targeting antibody drug conjugates (cancer), Sutro|STRO-001|SP-7676|SP-7675|anti-CD74 antibody-maytansinoid conjugate (B-cell malignancies, Sutro Biopharma|SP-7219",Research Code|Research Code|Research Code|Research Code,Cancer,CD74 modulator,5301,Microtubule inhibitor|Anticancer antibody|Immunotoxin,2575|55684|539,Acute myelogenous leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma|B-cell lymphoma|Non-Hodgkin lymphoma,1731|1744|1745|1749|1828|316|319,Cancer,651,Sutro Biopharma Inc,1036455,,,Sutro Biopharma Inc,1036455,,,,,,
93438,taletrectinib,"DS-6051|DS-6051b|NTRK (TrkA)/ROS1 inhibitor (cancer), AnHeart Therapeutics|AB-106|taletrectinib|NTRK (TrkA)/ROS1 inhibitor (solid tumor/Non small cell lung cancer), AnHeart Therapeutics|NTRK (TrkA)/ROS1 inhibitor (cancer), Innovent Biologics",Research Code|Research Code|Research Code|PINN,Cancer,Ros1 tyrosine kinase receptor inhibitor|TrkA receptor antagonist,3826|3840,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer|Solid tumor|Central nervous system tumor,3665|725|759,,,Innovent Biologics Inc|NewGLab Pharma Inc|AnHeart Therapeutics Inc,1070750|1214718|1177488,Daiichi Sankyo Co Ltd,1017506,Daiichi Sankyo Co Ltd,1017506,,,,,,
93581,duvortuxizumab,"CD19xCD3 DART antibody (cancer), MacroGenics/Janssen|duvortuxizumab|JNJ-64052781|MGD-011|anti-CD3/anti-CD19 bispecific T-cell engager (DART, cancer), MacroGenics/Janssen",USAN|INN|Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator|CD3 modulator,5080|5023,Immunostimulant|Anticancer antibody|T-lymphocyte stimulator,393|55684|7761,,,Hematological neoplasm,2054,,,Janssen Biotech Inc|MacroGenics Inc,26997|29060,MacroGenics Inc,29060,,,,,,
93584,SEA-CD40,"SEA-CD40|SEA-m1C10|CD40-targeted antibody (solid tumors/hematological malignancies), Seattle Genetics|CD40 costimulator (SEA technology, solid tumor/hematological neoplasm), Seattle Genetics",Research Code,Cancer,CD40 ligand receptor agonist,5141,Macrophage stimulator|Immunostimulant|Anticancer monoclonal antibody|B-lymphocyte stimulator|Dendritic cell stimulator,7751|393|55685|7741|173472,Metastasis|Non-small-cell lung cancer|Hodgkins disease|Follicle center lymphoma|Diffuse large B-cell lymphoma|Melanoma|Pancreas tumor|Squamous cell carcinoma|B-cell lymphoma|Non-Hodgkin lymphoma|Metastatic non small cell lung cancer|Head and neck tumor,1069|1262|161|1745|1749|205|249|307|316|319|3665|623,Solid tumor,725,Seagen Inc,25554,,,Seagen Inc,25554,,,,,,
93599,toripalimab,"recombinant humanized anti-PD1 mAb, Shanghai Junshi Biosciences|PD-1 checkpoint inhibitor (cancer), Shanghai Junshi Biosciences|TeRuiPuLi|TAB-001|toripalimab|Tuoyi|JS-001|Treipril|tripleitriumab|teriprizumab",Research Code|INN|Trade Name|Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Neuroendocrine tumor|Small-cell lung cancer|Stomach tumor|Cholangiocarcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Hematological neoplasm|Stage IV melanoma|Soft tissue sarcoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic head and neck cancer|Advanced solid tumor|Solid tumor|Urinary tract tumor,1128|1261|127|1765|1766|1767|1768|1771|2054|3257|3378|3657|3658|3665|3667|3673|3713|725|738,Non-small-cell lung cancer|Liver tumor|Melanoma,1262|202|205,AstraZeneca plc|Coherus BioSciences Inc|Shanghai Junshi Biosciences Co Ltd,14190|1069851|1104388,,,Shanghai Junshi Biosciences Co Ltd,1104388,,,,,,
93652,numidargistat,"arginase inhibitors (oral, cancer), Calithera Biosciences|CB-1158|INCB-01158|INCB-001158|arginase 1 and 2 inhibitor (oral, cancer/advanced solid tumor/colorectal/endometrioid/biliary/esophagus/ovary/multiple myeloma), Incyte|numidargistat",Research Code|Research Code|Research Code|USAN|INN,Cancer,Arginase inhibitor|T cell receptor antagonist,7084|74844,Natural killer cell inhibitor|Anticancer,7756|1545,Esophagus tumor|Mesothelioma|Non-small-cell lung cancer|Stomach tumor|Biliary cancer|Endometrioid carcinoma|Renal cell carcinoma|Transitional cell carcinoma|Multiple myeloma|Melanoma|Bladder cancer|Squamous cell carcinoma|Advanced solid tumor|Head and neck tumor|Cancer|Lung tumor|Ovary tumor|Colorectal tumor,1011|1240|1262|127|1516|1705|1766|1771|1828|205|2380|307|3713|623|651|755|799|989,,,Incyte Corp|Calithera Biosciences Inc,17216|1055363,Mars Symbioscience,1103761,Mars Symbioscience,1103761,,,,,,
93796,INCB-52793,"INCB-052793|JAK-1 inhibitor (oral tablet, advanced malignancies), Incyte|INCB-52793",Research Code|Research Code,Cancer|Hematologic,Jak1 tyrosine kinase inhibitor,3562,Anticancer|Synergist|Anticancer protein kinase inhibitor,1545|7293|62255,Myelodysplastic syndrome|Hematological neoplasm|Myeloproliferative disorder,1272|2054|273,Acute myelogenous leukemia|Cancer,1731|651,Incyte Corp,17216,,,Incyte Corp,17216,,,,,,
93851,PF-06459988,PF-06459988,Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor,62255,,,Non-small-cell lung cancer,1262,,,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
93905,CSG-GPC3,"KJgpc3-001|genetically-modified CAR T-cell therapy (hepatocellular carcinoma/lung cancer), CARsgen|genetically-modified chimeric antigen receptor-T cell therapy (hepatocellular carcinoma/lung cancer), CARsgen|anti-GPC3 CAR T-cell therapy (HCC/LSCC), CARsgen|CSG-GPC3|CAR-GPC3 T-cells|CT-0180",Research Code|Research Code|Research Code|Research Code,Cancer,Glypican-3 modulator,9953,T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy|Immunostimulant,7761|1545|4790|393,Stomach tumor|Hepatocellular carcinoma|Breast tumor|Lung tumor,127|1767|49|755,,,Carsgen Therapeutics Ltd,1103310,,,Carsgen Therapeutics Ltd,1103310,,,,,,
93969,pelcitoclax,"a dual specific Bcl-2/Bcl-xL inhibitor (cancer), Ascentage Pharma/University of Michigan|BM-1252|APG-1252|pelcitoclax",Research Code|Research Code|PINN,Cancer|Hematologic,Bcl-xL Bcl-2 associated death promotor inhibitor|Bcl-2 protein inhibitor,14541|16111,Synergist|Anticancer,7293|1545,Neuroendocrine tumor|Small-cell lung cancer|Non-small-cell lung cancer|Stomach tumor|Lymphoma|Myelofibrosis|Metastatic breast cancer|Solid tumor|Colorectal tumor,1128|1261|1262|127|203|2436|3657|725|989,,,Ascentage Pharma Group Corporation Ltd,1052437,University of Michigan,20623,University of Michigan,20623,,,,,,
93970,INVAC-1,"INVAC-1|anticancer DNA vaccine, Invectys",Research Code,Cancer,Telomerase modulator,1613,Therapeutic vaccine|DNA vaccine|Anticancer,12379|1879|1545,Chronic lymphocytic leukemia|Cancer,1734|651,,,Invectys,1088324,,,Invectys,1088324,,,,,,
94076,JCAR-018,"anti-CD22 CAR T-cell therapy (hematological malignancies), Juno|anti-CD22 CAR|m971-BBz CAR|JCAR-018|anti-CD22 CAR T-cell therapy (hematological malignancies), Bristol-Myers Squibb",Research Code,Cancer,B-lymphocyte cell adhesion molecule modulator,5089,Immunostimulant|T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy,393|7761|1545|4790,Acute lymphoblastic leukemia|Hairy cell leukemia|Lymphoma|Non-Hodgkin lymphoma,1728|1736|203|319,Hematological neoplasm,2054,Bristol-Myers Squibb Co|National Cancer Institute (NCI),15065|20519,Lentigen Technology Inc|Juno Therapeutics Inc|Celgene Corp,1018047|1090676|15331,Lentigen Technology Inc,1018047,,,,,,
94079,PF-06747143,PF-06747143,Research Code,Cancer,CXCR4 chemokine antagonist,3137,Anticancer monoclonal antibody,55685,,,Acute myelogenous leukemia|Hematological neoplasm,1731|2054,,,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
94082,AZD-5991,"Mcl-1 inhibitors (hematological malignancies), AstraZeneca|AZ-MC1|AZD-5991",Research Code,Cancer,Mcl-1 differentiation protein inhibitor,11381,Apoptosis stimulator|Synergist|Anticancer,1589|7293|1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Multiple myeloma|Melanoma,1272|1731|1828|205,Hematological neoplasm|Cancer,2054|651,AstraZeneca plc,14190,,,AstraZeneca plc,14190,,,,,,
94096,pemrametostat,"protein arginine methyltransferase 5 inhibitors (Non-Hodgkin lymphoma), Epizyme/GlaxoSmithKline|PRMT5 inhibitors (cancer), Epizyme/GlaxoSmithKline|EPZ-015666|GSK-3235025|YQ-3628|GSK-591|GSK-3203591|EPZ015866|GSK-3326595|EPZ-015938|protein arginine methyltransferase 5 inhibitors (oral, cancer), GlaxoSmithKline|GSK'595|EPZ015938|3326595|GSK-595|EPZ-015866|protein arginine methyltransferase 5 inhibitors (oral, non-Hodgkin lymphoma/breast adenocarcinoma/acute myelogenous leukemia/chronic myelomonocytic leukemia/solid tumor), GlaxoSmithKline|pemrametostat",Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|Research Code|PINN,Cancer,Protein arginine N-methyltransferase 5 inhibitor,14756,Anticancer|Cell cycle inhibitor,1545|767,Myelodysplastic syndrome|Acute myelogenous leukemia|Adenocarcinoma|Non-Hodgkin lymphoma|Breast tumor|Chronic myelomonocytic leukemia|Solid tumor,1272|1731|2399|319|49|6833|725,Cancer,651,GlaxoSmithKline plc,28355,Epizyme Inc,1048714,Epizyme Inc,1048714,,,,,,
94136,ALLO-715,"UCART-BCMA|anti-BCMA CAR T-cell therapy (multiple myeloma), Cellectis/Pfizer|ALLO-715|anti-BCMA engineered allogenic chimeric antigen receptor (CAR) T-cell therapy (iv, relapsed/refractory multiple myeloma), Allogene Therapeutics/Pfizer|BCMA-targeted allogenic CAR T-cell therapy (iv, relapsed/refractory multiple myeloma), Allogene Therapeutics/Cellectis|Anti-BCMA AlloCAR T Therapy",Research Code|Research Code,Cancer,APRIL receptor modulator,8255,Anticancer|T-lymphocyte stimulator|Immunostimulant,1545|7761|393,Multiple myeloma,1828,,,Allogene Therapeutics Inc,1162743,Pfizer Inc|Cellectis SA,18767|29822,Cellectis SA,29822,,,,,,
94202,BPX-701,"BPX-701|anti-PRAME/HLA-A*0201 TCR T-cell therapy (cancer), Leiden University Medical Center/Bellicum",Research Code,Cancer,Tumor expressed melanoma antigen modulator|HLA class I antigen A-2 alpha modulator,18578|19115,Anticancer|Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,1545|393|4790|7761,Myelodysplastic syndrome|Acute myelogenous leukemia|Melanoma,1272|1731|205,,,Bellicum Pharmaceuticals Inc,1023406,Leiden University Medical Center,27406,Leiden University Medical Center,27406,,,,,,
94212,GTA-002,"ex vivo-generated NK cells derived from CD34+ hematopoietic cells (AML), Glycostem|oNKord|GTA-002",Trade Name|Research Code,Cancer,,,Anticancer|Natural killer cell stimulator,1545|7757,Acute myelogenous leukemia|Multiple myeloma|Melanoma|Solid tumor|Colorectal tumor,1731|1828|205|725|989,,,Glycostem BV,1031641,,,Glycostem BV,1031641,,,,,,
94223,ivuxolimab,"PF-04518600|PF-8600|OX40 costimulator (cancer), Pfizer|ivuxolimab",Research Code|Research Code|USAN|INN,Cancer,OX-40 receptor agonist,5443,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,,,Advanced solid tumor,3713,,,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
94239,linrodostat,"IDO-1 inhibitors (cancer), Flexus Biosciences|cancer immunotherapy program 1, Flexus Biosciences|IDO-1 inhibitors (cancer), Bristol-Myers Squibb|FLX-B|IDO inhibitors (cancer), Bristol-Myers Squibb|BMS-986205|F-001287|IDO checkpoint inhibitor (cancer), Bristol-Myers Squibb|ONO-7701|IDO-1 checkpoint inhibitor (cancer), Bristol-Myers Squibb/Ono|linrodostat|linrodostat mesylate",Research Code|Research Code|Research Code|Research Code|USAN|INN|USAN,Cancer,Indoleamine pyrrole 2 3-dioxygenase 1 inhibitor,64856,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,Endometrioid carcinoma|Hepatocellular carcinoma|Hematological neoplasm|Bladder cancer|Carcinosarcoma|Stage IV melanoma|Metastatic renal cell carcinoma|Solid tumor,1705|1767|2054|2380|2614|3257|4250|725,Metastatic non small cell lung cancer|Metastatic head and neck cancer|Cancer,3665|3673|651,Bristol-Myers Squibb Co|Ono Pharmaceutical Co Ltd,15065|18681,Flexus Biosciences Inc,1102843,Flexus Biosciences Inc,1102843,,,,,,
94241,FLX-925,AMG-925|FLX-925,Research Code|Research Code,Cancer,Flt3 tyrosine kinase inhibitor|Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase-6 inhibitor,3806|4314|4318,Anticancer protein kinase inhibitor,62255,,,Acute myelogenous leukemia|Cancer,1731|651,,,Flexus Biosciences Inc|RAPT Therapeutics Inc|Amgen Inc,1102843|1110021|14109,Amgen Inc,14109,,,,,,
9425,9-aminocamptothecin,9-amino-20 (S)-camptothecin|9-aminocamptothecin|NSC-603071|9-AC,Research Code,Cancer,Topoisomerase I inhibitor,141,Anticancer,1545,,,Stomach tumor|Leukemia|Pancreas tumor|Prostate tumor|Bladder tumor|Carcinoma|Head and neck tumor|Cancer|Lung tumor|Colorectal tumor|Renal tumor,127|199|249|276|42|54|623|651|755|989|999,,,IDEC Pharmaceuticals Corp|National Cancer Institute (NCI)|Pharmacia & Upjohn Inc|RTI International,17085|20519|22006|23125,RTI International,23125,,,,,,
94256,lerociclib,G1T38-1|G1T-38|lerociclib|GB-491,Research Code|Research Code|USAN|Research Code,Cancer,Cyclin-dependent kinase-4 inhibitor|Cyclin-dependent kinase-6 inhibitor,4314|4318,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Metastatic breast cancer|Breast tumor,1262|1507|3657|49,Cancer,651,EQRx|Genor Biopharma Co Ltd,1203707|1056962,G1 Therapeutics Inc,1054091,G1 Therapeutics Inc,1054091,,,,,,
94305,nedisertib,MSC-2490484A|M-3814|nedisertib|peposertib,Research Code|Research Code|PINN,Cancer,DNA dependent protein kinase inhibitor,25889,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Glioma|Small-cell lung cancer|Acute leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Adenocarcinoma|Glioblastoma|Pancreas tumor|Gliosarcoma|Squamous cell carcinoma|Larynx tumor|Metastatic rectal cancer|Metastatic head and neck cancer|Advanced solid tumor|Mouth tumor|Pharynx tumor,1108|1261|1727|1731|1734|2399|2454|249|2727|307|3198|3671|3673|3713|793|794,,,Merck KGaA,18101,,,Merck KGaA,18101,,,,,,
94313,OXS-1550,"DT-2219|DT-2219-ARL|OXS-1550|antibody-drug conjugate targeting CD19/CD22 (B-cell malignancies/non-Hodgkins lymphoma), Oxis Biotech|GTB-1550",Research Code|Research Code|Research Code,Cancer,B-lymphocyte cell adhesion molecule modulator|B-lymphocyte antigen CD19 modulator,5089|5080,Anticancer|Immunotoxin,1545|539,Leukemia|B-cell lymphoma|Non-Hodgkin lymphoma,199|316|319,,,GT Biopharma Inc,18728,Oxis Biotech Inc|University of Minnesota,1102833|20626,University of Minnesota,20626,,,,,,
94420,cibisatamab,"RO-6958688|T-cell bispecific antibody (iv, solid tumors), Roche|RG-7802|anti-CD3/anti-CEA bispecific T-cell engager (TCB, solid tumors), Roche|CEA-TCB|cibisatamab",Research Code|Research Code|Research Code|INN,Cancer,CD66e modulator|CD3 modulator,5281|5023,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Stomach tumor|Pancreas tumor|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor|Solid tumor,127|249|3658|3665|3713|725,,,Roche Holding AG|Chugai Pharmaceutical Co Ltd,19446|15414,,,Roche Holding AG,19446,,,,,,
94454,TP-0184,"ALK2 inhibitors (anemia), Tolero Pharmaceuticals|TP-0184|ALK2 inhibitor (oral, solid tumors), Tolero Pharmaceuticals|itacnosertib",Research Code|USAN|INN,Cancer|Hematologic,Alk-5 protein kinase inhibitor|Alk-2 protein kinase inhibitor,4588|4582,Anticancer|Anticancer protein kinase inhibitor,1545|62255,Anemia|Solid tumor,17|725,,,SDP Oncology,1216786,Tolero Pharmaceuticals Inc,1069667,Tolero Pharmaceuticals Inc,1069667,,,,,,
9446,etalocib,LY-293111|VML-495|VML-295|etalocib|LY-293111Na,Research Code|Research Code|Research Code|USAN|INN|Research Code,Cancer|Dermatologic|Gastrointestinal|Immune|Inflammatory|Respiratory,Leukotriene BLT receptor antagonist|5-Lipoxygenase inhibitor|PPAR gamma agonist,3166|247|2480,Anticancer|Anti-inflammatory|Systemic antipsoriatic product,1545|2953|15184,,,Non-small-cell lung cancer|Inflammatory disease|Inflammatory bowel disease|Pancreas tumor|Psoriasis|Rheumatoid arthritis|Asthma|Ulcerative colitis|Cancer,1262|188|189|249|281|291|31|337|651,,,Eli Lilly & Co|Vernalis Group plc,17810|27600,Eli Lilly & Co,17810,,,,,,
94490,KITE-222,"anti-CLL1 CAR T-cell therapy (eACT, cancer), Kite/ Amgen|KITE-796|anti-CLL1 CAR T-cell therapy (AML), Gilead|KITE-222",Research Code|Research Code,Cancer,C-type lectin domain protein 12A modulator,82256,Anticancer|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant,1545|4790|7761|393,Acute myelogenous leukemia,1731,,,Gilead Sciences Inc,16450,Kite Pharma Inc|Amgen Inc,1056870|14109,Kite Pharma Inc,1056870,,,,,,
94500,"bevacizumab biosimilar, Shandong Luye Pharmaceutical","bevacizumab|bevacizumab biosimilar, Shandong Luye Pharmaceutical|LY-01008|Boyounuo",INN|Research Code|Trade Name,Cancer,VEGF receptor antagonist,1722,Anticancer monoclonal antibody|Angiogenesis inhibitor|Anticancer protein kinase inhibitor,55685|61|62255,Non-small-cell lung cancer|Colorectal tumor,1262|989,Cancer,651,Luye Pharma Group Ltd,1015499,Shandong Boan Biotech Co Ltd,1104555,Shandong Boan Biotech Co Ltd,1104555,,,,,,
94571,JTCR-016,"JTCR-016|anti-WT1/HLA-A*0201 TCR T-cell therapy (AML/MDS/CML/NSCLC/mesothelioma), Fred Hutchinson/Juno Therapeutics|anti-WT1/HLA-A*0201 TCR T-cell therapy (AML/MDS/CML/NSCLC/mesothelioma), Fred Hutchinson/Bristol-Myers Squibb",Research Code,Cancer,HLA class I antigen A-2 alpha modulator|Wilms tumor protein modulator,19115|30009,Anticancer|Immunostimulant|T-lymphocyte stimulator|Genetically engineered autologous cell therapy,1545|393|7761|4790,Mesothelioma|Myelodysplastic syndrome|Acute myelogenous leukemia|Chronic myelocytic leukemia|Metastatic non small cell lung cancer,1240|1272|1731|1735|3665,,,Fred Hutchinson Cancer Research Center|Bristol-Myers Squibb Co,16218|15065,Juno Therapeutics Inc|Celgene Corp,1090676|15331,Fred Hutchinson Cancer Research Center,16218,,,,,,
94617,"oncolytic VSV therapy expressing IFN-beta and sodium-iodine symporter (cancer), Vyriad/MedImmune","oncolytic VSV (cancer), Omnis|oncolytic VSV (cancer), Omnis/MedImmune|oncolytic VSV therapy expressing IFN-beta and sodium-iodine symporter (cancer), Vyriad/MedImmune|VSV-IFNbeta-NIS|Voyager-V1|VV1",,Cancer,Interferon beta ligand,481,Anticancer|Immunostimulant,1545|393,Non-small-cell lung cancer|Gastrointestinal tumor|Endometrioid carcinoma|Hepatocellular carcinoma|Squamous cell carcinoma|Stage IV melanoma|Metastatic colorectal cancer|Advanced solid tumor|Head and neck tumor,1262|131|1705|1767|307|3257|3658|3713|623,Melanoma,205,Vyriad Inc|MedImmune LLC,1121040|18008,Omnis Pharma Inc,1104729,Omnis Pharma Inc,1104729,,,,,,
94645,mobocertinib,AP-32788|TAK-788|mobocertinib,Research Code|Research Code|INN,Cancer,Epidermal growth factor receptor antagonist|Erbb2 tyrosine kinase receptor inhibitor,740|3756,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer,3665,Non-small-cell lung cancer,1262,Takeda Pharmaceutical Co Ltd|ARIAD Pharmaceuticals Inc,20300|14296,Mayne Pharma Group Ltd,1037040,ARIAD Pharmaceuticals Inc,14296,,,,,,
94677,"anti-CD19 CAR T-cell therapy (cancer), Precigen/ZIOPHARM","non-viral adoptive CAR T-cell therapies (cancer), Intrexon/ ZIOPHARM|anti-CD19 CAR T-cell therapy (cancer), Intrexon/ZIOPHARM|second-generation anti-CD19 CAR T-cell therapy (cancer), Intrexon/ZIOPHARM|second-generation non-viral adoptive CAR T-cell therapy (cancer), Intrexon/ ZIOPHARM|anti-CD19 CAR T-cell therapy (cancer), Precigen/ZIOPHARM",,Cancer,B-lymphocyte antigen CD19 modulator,5080,T-lymphocyte stimulator|Anticancer|Immunostimulant|Genetically engineered autologous cell therapy,7761|1545|393|4790,Lymphoma,203,Cancer,651,ZIOPHARM Oncology Inc|Precigen Inc,1009856|1021778,University of Minnesota|MD Anderson Cancer Center,20626|23382,University of Minnesota,20626,,,,,,
94819,camrelizumab,"recombinant humanized anti-PD1 antibody, Jiangsu Hengrui Pharmaceutical|INCSHR-1210|camrelizumab|SHR-1210|PD-1 checkpoint inhibitor (cancer), Shanghai Hengrui Pharmaceutical/Incyte/Atridia",Research Code|INN|Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Small-cell lung cancer|Biliary cancer|Hodgkins disease|Endometrioid carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Osteosarcoma|Glioblastoma|T-cell lymphoma|Medullary thyroid cancer|Soft tissue sarcoma|Metastatic liver cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic rectal cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Cancer|Uterus tumor,1261|1516|161|1705|1767|1768|1771|1772|2454|311|3240|3378|3462|3657|3658|3665|3666|3667|3671|3713|3866|4250|427|651|740,Non-small-cell lung cancer|Stage IV melanoma,1262|3257,Shanghai Hengrui Pharmaceutical Co Ltd|CrystalGenomics Inc,1033640|1003254,Incyte Corp,17216,Shanghai Hengrui Pharmaceutical Co Ltd,1033640,,,,,,
94822,pemigatinib,INCB-054828|pemigatinib|INCB-54828|IBI-375|Pemazyre,Research Code|USAN|INN|Research Code|Research Code|Trade Name,Cancer|Hematologic,FGF1 receptor antagonist|FGF2 receptor antagonist|FGF3 receptor antagonist,3682|3685|3688,Anticancer protein kinase inhibitor,62255,Endometrioid carcinoma|Acute myelogenous leukemia|Cholangiocarcinoma|Transitional cell carcinoma|Hematological neoplasm|Myeloproliferative disorder|Metastatic bladder cancer|Advanced solid tumor|Solid tumor,1705|1731|1765|1771|2054|273|3466|3713|725,,,Innovent Biologics Inc|Incyte Corp,1070750|17216,,,Incyte Corp,17216,,,,,,
94824,INCB-054329,INCB-054329|INCB-54329,Research Code|Research Code,Cancer|Hematologic,Bromodomain containing protein inhibitor,34558,Anticancer|Synergist,1545|7293,Hematological disease|Cancer,142|651,,,Incyte Corp,17216,,,Incyte Corp,17216,,,,,,
94852,CA-170,"programmed death ligand 1 antagonist (cancer), Aurigene|programmed death ligand 1 antagonist (cancer), Aurigene/Curis|CA-170|VISTA, PD-L1 checkpoint inhibitor (cancer), Aurigene/Curis|AUPM-170|PD-L1, VISTA checkpoint inhibitor (cancer), Aurigene/Curis|VISTA and PD-L1 checkpoint inhibitor (cancer), Aurigene/Curis|dual PD-L1 checkpoint inhibitor/VISTA checkpoint inhibitor (cancer), Aurigene/Curis",Research Code,Cancer,Stress induced secreted protein 1 inhibitor|Programmed cell death ligand 1 inhibitor,34609|14007,Anticancer|T-lymphocyte stimulator|Immunostimulant,1545|7761|393,Mesothelioma|Non-small-cell lung cancer|Lymphoma|Advanced solid tumor|Cancer,1240|1262|203|3713|651,,,Aurigene Discovery Technologies Ltd|Curis Inc,30044|15549,,,Aurigene Discovery Technologies Ltd,30044,,,,,,
94875,BMS-986148,BMS-986148,Research Code,Cancer,Mesothelin modulator,11484,Anticancer monoclonal antibody|Anticancer,55685|1545,Advanced solid tumor,3713,Metastasis,1069,Bristol-Myers Squibb Co,15065,,,Bristol-Myers Squibb Co,15065,,,,,,
94883,AUTO-2,"chimeric antigen receptor T-cell therapy (cancer), Autolus|CAR T-cell therapy (cancer), Autolus|dual anti-BCMA/anti-TACI CAR T-cell therapy (APRIL-based, cancer), Autolus|APRIL-CAR|AUTO-2",Research Code|Research Code,Cancer,APRIL receptor modulator|Tumor necrosis factor 13B receptor modulator,8255|53119,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,Multiple myeloma,1828,Cancer,651,Autolus Therapeutics Ltd,1105192,,,Autolus Therapeutics Ltd,1105192,,,,,,
9489,"vaccine (Her-2/neu), Corixa/GlaxoSmithKline","Her-2/neu vaccine, Corixa/GlaxoSmithKline|HER-2/neu peptide vaccines + GM-CSF, Corixa|vaccine (Her-2/neu), Corixa/GlaxoSmithKline|Her-2/neu peptide vaccine E75 + GM-CSF, Corixa|microsphere encapsulated Her-2/neu peptide vaccine, Corixa/GlaxoSmithKline|HER2 ASCI|HER2 antigen specific cancer immunotherapeutic",,Cancer,Erbb2 tyrosine kinase receptor modulator,3755,Therapeutic vaccine|Anticancer,12379|1545,,,Breast tumor|Cancer|Lung tumor|Ovary tumor,49|651|755|799,,,Corixa Corp|University of Washington|GlaxoSmithKline Biologicals,15542|20701|24166,University of Washington,20701,,,,,,
94966,HMPL-689,HMPL-689,Research Code,Cancer,Phosphoinositide-3 kinase delta inhibitor,11183,Anticancer protein kinase inhibitor,62255,Chronic lymphocytic leukemia|Follicle center lymphoma|Marginal zone B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma|Cancer,1734|1745|1746|316|319|651,,,Hutchison Medipharma Enterprises Ltd,1011918,,,Hutchison Medipharma Enterprises Ltd,1011918,,,,,,
95011,"amphotericin B (LNC, oral cochleate formulation, fungal infection), Matinas BioPharma/NIAID","amphotericin B|amphotericin B (oral cochleate formulation, fungal infection), Matinas BioPharma/NIAID|MAT-2203|amphotericin B (LNC, oral cochleate formulation, fungal infection), Matinas BioPharma/NIAID",INN|Research Code,Infection,,,Antiparasitic|Anti-inflammatory|Fungicide|Ergosterol modulator,2638|2953|1748|839,Fungal infection|Candida infection|Cryptococcus neoformans meningitis|Mucocutaneous candidiasis|Cryptococcus infection,124|1308|1813|3051|85,Leishmania infection,1136,Matinas BioPharma Holdings Inc,1087072,Aquarius Biotechnologies Inc,1092314,Aquarius Biotechnologies Inc,1092314,,,,,,
95126,mavelertinib,PF-06747775|PF-6459988|epidermal growth factor receptor (EGFR) T790M inhibitor (NSCLC) Pfizer|mavelertinib|PF-7775,Research Code|Research Code|USAN|INN|Research Code,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor,62255,,,Non-small-cell lung cancer,1262,,,Pfizer Inc,18767,Pfizer Inc,18767,,,,,,
95130,ProTmune,"dexamethasone|dmPGE2|dmPGE2 + dexamethasone modulated mobilized peripheral blood (hematologic malignancies), Fate Therapeutics|FT-1050 + FT-4145 modulated mPB (hematologic malignancies), Fate Therapeutics|ProTmune|FT-1050|FT-4145",BANN|INN|Trade Name|Research Code|Research Code,Immune,,,Unspecified drug target|Immunostimulant,59620|393,,,Hematopoietic stem cell transplantation|Graft versus host disease,3888|616,,,Fate Therapeutics Inc,1036293,Fate Therapeutics Inc,1036293,,,,,,
95147,feladilimab,"ICOS costimulator (cancer), GlaxoSmithKline|GSK-3359609|H2L5 IgG4PE (cancer), Glaxosmithkline|GSK-609|feladilimab|H2L5 IgG4PE (cancer, metastatic head and neck cancer, squamous cell carcinoma, pharynx tumor, larynx tumor), Glaxosmithkline",Research Code|Research Code|USAN|PINN,Cancer,Inducible T-cell co-stimulator stimulator,15391,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Non-small-cell lung cancer|Renal cell carcinoma|Melanoma|Bladder cancer|Squamous cell carcinoma|Larynx tumor|Hormone refractory prostate cancer|Metastatic head and neck cancer|Advanced solid tumor|Pharynx tumor,1262|1766|205|2380|307|3198|3246|3673|3713|794,Head and neck tumor|Cancer,623|651,GlaxoSmithKline plc,28355,INSERM,17229,INSERM,17229,,,,,,
95176,BPI-7711,"BPI-4039|EGFR T790M inhibitors (non-small cell lung cancer), Beta Pharma|BPI-7711|rezivertinib",Research Code|Research Code|USAN|INN,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor,62255,Metastatic non small cell lung cancer,3665,,,Beta Pharma Inc|CSPC Pharmaceuticals Group Limited,1004107|1033194,,,Beta Pharma Inc,1004107,,,,,,
95195,"anti-CD19 CAR T-cell therapy (cancer), Southwest Hospital Chongqing","anti-CD19 CAR T-cell therapy (cancer), Southwest Hospital Chongqing",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|T-lymphocyte stimulator|Immunostimulant|Genetically engineered autologous cell therapy,1545|7761|393|4790,B-cell acute lymphoblastic leukemia|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1729|1734|1749|319,,,Southwest Hospital Chongqing,1056033,,,Southwest Hospital Chongqing,1056033,,,,,,
95204,cemiplimab,"anti-PD1 mAb (cancer/basal cell carcinoma/metastasis/renal cell carcinoma/multiple myeloma/squamous cell carcinoma/NSCLC/uterine cervix tumor/melanoma/head and neck tumor/advanced prostate cancer), Regeneron/Sanofi|PD-1 checkpoint inhibitor (cancer), Regeneron Pharmaceuticals/Sanofi|cemiplimab|REGN-2810|Libtayo|cemiplimab-rwlc|SAR-439684",USAN|INN|Research Code|Trade Name|Research Code,Cancer|Infection,Programmed cell death protein 1 inhibitor,67136,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator|Anti-inflammatory|Antiviral,55685|393|7761|2953|991,Metastasis|Non-small-cell lung cancer|Hepatitis B virus infection|Hodgkins disease|Endometrioid carcinoma|Diffuse large B-cell lymphoma|Peripheral T-cell lymphoma|Basal cell carcinoma|Hepatocellular carcinoma|Lymphoma|Melanoma|Fallopian tube cancer|Glioblastoma|Squamous cell carcinoma|Peritoneal tumor|Merkel cell carcinoma|Hormone refractory prostate cancer|Hormone dependent prostate cancer|Stage III melanoma|Stage IV melanoma|Metastatic breast cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Breast tumor|Head and neck tumor|Solid tumor|Colorectal tumor,1069|1262|152|161|1705|1749|1753|1764|1767|203|205|2243|2454|307|3083|3235|3246|3247|3256|3257|3657|3664|3665|3669|3713|3866|4250|427|49|623|725|989,Multiple myeloma|Cancer,1828|651,Sanofi SA|Regeneron Pharmaceuticals Inc,1009547|19214,,,Regeneron Pharmaceuticals Inc,19214,,,,,,
95206,Temferon,"HIV-derived lentivirus delivered gene therapy (solid tumor), Genenta Science|Temferon",Trade Name,Cancer,Interferon gene stimulator,21638,Immunomodulator|Anticancer|Retrovirus based gene therapy,1596|1545|4782,Multiple myeloma|Glioblastoma,1828|2454,Solid tumor,725,Genenta Science SpA,1105348,,,Genenta Science SpA,1105348,,,,,,
95228,C-CAR-011,"anti-CD19 CAR T-cell therapy (B-cell leukemias), Chinese PLA General Hospital|anti-CD19 CAR T-cell therapy (B-cell leukemias/lymphoma), Cellular Biomedicine|anti-CD19 CAR T-cell therapy (diffuse large B-cell lymphoma), Cellular Biomedicine|C-CAR-011|CBM-C19.1",Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Immunostimulant|Genetically engineered autologous cell therapy|Anticancer|T-lymphocyte stimulator,393|4790|1545|7761,B-cell acute lymphoblastic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|Non-Hodgkin lymphoma,1729|1744|1745|1749|1750|319,B-cell lymphoma,316,Cellular Biomedicine Group Inc,1080369,Chinese PLA General Hospital Medical School Of Chinese PLA,1021685,Chinese PLA General Hospital Medical School Of Chinese PLA,1021685,,,,,,
95248,CBM-C20.1,"anti-CD20 CAR T-cell therapy (leukemia/lymphoma), Chinese PLA General Hospital|anti-CD20 CAR T-cell therapy (leukemia/lymphoma), Cellular Biomedicine|CBM-C20.1",Research Code,Cancer,B-lymphocyte antigen CD20 modulator,5083,Immunostimulant|T-lymphocyte stimulator|Anticancer|Genetically engineered autologous cell therapy,393|7761|1545|4790,Hematological neoplasm|Non-Hodgkin lymphoma,2054|319,Leukemia|Lymphoma,199|203,Cellular Biomedicine Group Inc,1080369,Chinese PLA General Hospital Medical School Of Chinese PLA,1021685,Chinese PLA General Hospital Medical School Of Chinese PLA,1021685,,,,,,
95309,parsaclisib,"INCB-050465|INCB-50465|PI3K delta inhibitor (2) (B-cell lymphoma), Incyte|parsaclisib|PI3K delta inhibitor (2) (oral, B-cell lymphoma/ALL/Pemphigus), Incyte|IBI-376|parsaclisib hydrochloride",Research Code|USAN|INN|Research Code|USAN,Cancer|Dermatologic|Hematologic|Immune,Phosphoinositide-3 kinase delta inhibitor,11183,Synergist|Anticancer protein kinase inhibitor|Anti-inflammatory|Anticancer,7293|62255|2953|1545,Sjoegrens syndrome|Acute lymphoblastic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Splenic marginal zone lymphoma|Diffuse large B-cell lymphoma|Polycythemia vera|Lupus nephritis|Myelofibrosis|Autoimmune hemolytic anemia|B-cell lymphoma|Thrombocytopenia|Advanced solid tumor|Cancer,1148|1728|1744|1745|1746|1747|1749|2319|2404|2436|2643|316|324|3713|651,Pemphigus|Breast tumor,1114|49,Incyte Corp|Innovent Biologics Inc,17216|1070750,,,Incyte Corp,17216,,,,,,
9544,doconexent ethyl + icosapent ethyl,"Omacor|K-85|omega-3 fatty acids, Pronova|omega-3 acid ethyl esters 90|Lovaza|omega-3-acid ethyl esters|doconexent ethyl + icosapent ethyl|Esapent|Eskim|Seacor|Zodin|TAK-085|GSK-2212836|Lotriga",Trade Name|Research Code|Trade Name|USAN|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Research Code|Trade Name,Cardiovascular|Endocrine/Metabolic,Acyltransferase inhibitor,1054,Essential fatty acid|Anti-inflammatory|Antihypercholesterolemic agent|Hypertriglyceridemic agent|Antihyperlipidemic agent|Antihypertriglyceridemic agent|Antiarrhythmic agent,1618|2953|71|7019|72|7018|449,Hyperlipidemia|Hypertriglyceridemia|Myocardial infarction,175|2236|224,Atrial fibrillation,1542,Reliant Pharmaceuticals Inc|Pronova BioPharma ASA|Ferrer Internacional SA|Abbott Laboratories|Pharma Lab|Mediwin Limited|Kuhnil Pharmaceutical Co Ltd|Pfizer Inc|Takeda Pharmaceutical Co Ltd|Solvay SA|Pierre Fabre Group|Prospa BV,28150|18590|16118|13601|1076399|1076144|27398|18767|20300|20199|19087|23375,BASF SE|GlaxoSmithKline plc,14356|28355,Pronova BioPharma ASA,18590,,,,,,
95488,ABBV-221,"ABBV-221|anti-EGFR antibody-drug conjugate (solid tumors), AbbVie|anti-EGFR ADC (solid tumors), AbbVie|losatuxizumab vedotin",Research Code|INN,Cancer,Epidermal growth factor receptor antagonist,740,Anticancer protein kinase inhibitor|Immunotoxin|Anticancer monoclonal antibody,62255|539|55685,,,Solid tumor,725,,,AbbVie Inc,1072507,AbbVie Inc,1072507,,,,,,
95543,cobomarsen,"miR-155 inhibitors (hematological malignancies/amyotrophic lateral sclerosis), miRagen Therapeutics|MRG-106|M-11667|cobomarsen|cobomarsen sodium",Research Code|Research Code|USAN|INN|USAN,Cancer,,,miRNA agent|Anticancer,38419|1545,,,Mycosis fungoides|Chronic lymphocytic leukemia|Diffuse large B-cell lymphoma|Cutaneous T-cell lymphoma|Adult T-cell lymphoma|Non-Hodgkin lymphoma,1115|1734|1749|1754|1757|319,,,Viridian Therapeutics Inc,1039629,Viridian Therapeutics Inc,1039629,,,,,,
95617,pralsetinib,"inhibitor of RET kinase mutations and fusions (NSCLC, thyroid cancer), Blueprint Medicines|BLU-667|BLU-6864|mutant RET kinase inhibitors (cancer), Blueprint Medicines|mutant RET kinase inhibitors (cancer), Blueprint Medicines/CStone Pharmaceuticals|CS-3009|pralsetinib|BLU-123244|X-581238|Gavreto|RG-6396",Research Code|Research Code|Research Code|Research Code|Research Code|Trade Name|Research Code,Cancer,Ret tyrosine kinase receptor inhibitor,3818,Anticancer protein kinase inhibitor,62255,Thyroid tumor|Cholangiocarcinoma|Pancreas tumor|Medullary thyroid cancer|Papillary thyroid tumor|Metastatic non small cell lung cancer|Advanced solid tumor|Anaplastic thyroid cancer|Colon tumor,1134|1765|249|3240|3351|3665|3713|3769|767,Cancer,651,Roche Holding AG|Blueprint Medicines Corp|CStone Pharmaceuticals|Genentech Inc,19446|1067683|1126254|19453,,,Blueprint Medicines Corp,1067683,,,,,,
95618,orlotamab,"MGD-009|anti-CD3 + anti-B7-H3 bispecific antibody (solid tumors), MacroGenics|anti-CD3 + anti-CD276 bispecific antibody (solid tumors), MacroGenics|anti-CD3/anti-B7-H3 T-cell engager (DART, solid tumors), MacroGenics|orlotamab",Research Code|USAN,Cancer,CD276 antigen modulator|CD3 modulator,48835|5023,Anticancer antibody|Immunostimulant|T-lymphocyte stimulator,55684|393|7761,,,Advanced solid tumor|Solid tumor,3713|725,,,MacroGenics Inc,29060,MacroGenics Inc,29060,,,,,,
95620,cosibelimab,"anti PD-L1 antibody (hematological malignancies), Checkpoint/TG Therapeutics|anti PD-L1 antibody (cancer), Checkpoint / TG Therapeutics|anti PD-L1 antibody (cancer), Dana-Farber|CK-301|PD-L1 checkpoint inhibitor (cancer), TG Therapeutics/Checkpoint Therapeutics|TG-1501|cosibelimab",Research Code|Research Code|USAN|INN,Cancer,Programmed cell death ligand 1 inhibitor,14007,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody|Anticancer,393|7761|55685|1545,Mesothelioma|Non-small-cell lung cancer|Hodgkins disease|Endometrioid carcinoma|Renal cell carcinoma|Melanoma|Hematological neoplasm|Skin cancer|Bladder cancer|Squamous cell carcinoma|Non-Hodgkin lymphoma|Merkel cell carcinoma|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Solid tumor|Colorectal tumor,1240|1262|161|1705|1766|205|2054|2170|2380|307|319|3235|3665|3673|725|989,Cancer,651,Checkpoint Therapeutics Inc|TG Therapeutics Inc,1106471|31093,Dana-Farber Cancer Institute Inc,15615,Dana-Farber Cancer Institute Inc,15615,,,,,,
9563,etaracizumab,Vitaxin|medi-523|Vitaxin-2|second generation Vitaxin|MEDI-522|etaracizumab|Abegrin|LM-609,Trade Name|Research Code|Research Code|USAN|INN|Trade Name|Research Code,Cancer|Dermatologic|Immune|Inflammatory,Integrin alpha-V/beta-3 antagonist,2458,Anticancer monoclonal antibody|Apoptosis stimulator|Angiogenesis inhibitor|Systemic antipsoriatic product,55685|1589|61|15184,,,Metastasis|Inflammatory disease|Sarcoma|Melanoma|Leiomyosarcoma|Osteoarthritis|Prostate tumor|Psoriasis|Rheumatoid arthritis|Cancer|Solid tumor|Colorectal tumor,1069|188|194|205|2446|245|276|281|291|651|725|989,,,Medite Cancer Diagnostics Inc|MedImmune LLC,17318|18008,Medite Cancer Diagnostics Inc,17318,,,,,,
95670,SAF-189s,"ALK inhibitor (oral/capsule, cancer), Chongqing Fochon Pharmaceutical/Shanghai Institute of Materia Medica|furuitinib succinate|dingersuan furuitini|FC-110|SAF-189s|SAF-189|foritinib succinate|foritinib succinate (oral, non-small cell lung cancer/solid tumor), Chongqing Fochon Pharmaceuticals/Shanghai Fosun Pharmaceutical (Group)|ALK/ROS1 inhibitor (oral, non-small cell lung cancer/solid tumor), Chongqing Fochon Pharmaceuticals|SAT-189",Research Code|Research Code|Research Code|Research Code,Cancer,Anaplastic lymphoma kinase receptor inhibitor|Ros1 tyrosine kinase receptor inhibitor,3736|3826,Anticancer protein kinase inhibitor,62255,Non-small-cell lung cancer|Advanced solid tumor|Cancer,1262|3713|651,,,Chongqing Fochon Pharmaceuticals Co Ltd|Shanghai Institute of Materia Medica of the Chinese Academy of Sciences,1063683|25314,,,Shanghai Institute of Materia Medica of the Chinese Academy of Sciences,25314,,,,,,
95708,IDH-305,"IDH-305|IDH-1 inhibitor (cancer), Novartis",Research Code,Cancer,Mitochondrial isocitrate dehydrogenase inhibitor,67505,Anticancer,1545,Metastasis|Glioma,1069|1108,Cancer,651,Novartis Pharmaceuticals Corp,24818,,,Novartis Pharmaceuticals Corp,24818,,,,,,
95768,BAY-1093884,"BAY-1093884|anti TFPI antibody (hemophilia), Bayer|anti tissue factor pathway inhibitor (hemophilia), Bayer|befovacimab",Research Code|INN,Hematologic,Tissue factor pathway inhibitor inhibitor,13106,Coagulation stimulator,968,,,Factor VIII deficiency|Factor IX deficiency|Hemophilia,121|1228|439,,,Bayer AG,14455,Bayer AG,14455,,,,,,
95918,"bevacizumab biosimilar, Innovent Biologics","bevacizumab|bevacizumab biosimilar, Innovent Biologics|IBI-305|Byvasda",INN|Research Code|Trade Name,Cancer,VEGF ligand inhibitor,12521,Angiogenesis inhibitor|Anticancer monoclonal antibody,61|55685,Stomach tumor|Hepatocellular carcinoma|Glioblastoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Cancer,127|1767|2454|3658|3665|651,,,Innovent Biologics Inc|PT Etana Biotechnologies Indonesia|Coherus BioSciences Inc,1070750|1233375|1069851,,,Innovent Biologics Inc,1070750,,,,,,
95923,sintilimab,"anti-PD1 antibody (cancer), Eli Lilly/Innovent|PD-1 checkpoint inhibitor (cancer), Innovent/Eli Lilly|xindi|xindili|sintilimab|IBI-308|Tyvyt|cindilizumab",INN|Research Code|Trade Name,Cancer,Programmed cell death protein 1 inhibitor,67136,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Small-cell lung cancer|Stomach tumor|Hodgkins disease|Peripheral T-cell lymphoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Melanoma|Adenocarcinoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic lung cancer|Uterine cervix tumor|Cancer|Solid tumor,1261|127|161|1753|1767|1768|205|2399|3658|3665|3667|3668|427|651|725,Esophagus tumor|Advanced solid tumor,1011|3713,Eli Lilly & Co|Innovent Biologics Inc,17810|1070750,,,Innovent Biologics Inc,1070750,,,,,,
95929,mivebresib,ABBV-075|mivebresib,Research Code|INN,Cancer|Hematologic,Bromodomain containing protein inhibitor,34558,Anticancer,1545,Small-cell lung cancer|Non-small-cell lung cancer|Acute myelogenous leukemia|Multiple myeloma|Myelofibrosis|Prostate tumor|Non-Hodgkin lymphoma|Breast tumor|Cancer,1261|1262|1731|1828|2436|276|319|49|651,Hematological neoplasm|Solid tumor,2054|725,AbbVie Inc,1072507,,,AbbVie Inc,1072507,,,,,,
96104,citarinostat,ACY-241|citarinostat|CC-96241,Research Code|USAN|INN|Research Code,Cancer,Histone deacetylase-6 inhibitor,7856,Anticancer,1545,,,Mantle cell lymphoma|Multiple myeloma|Melanoma|Advanced solid tumor,1744|1828|205|3713,,,Acetylon Pharmaceuticals Inc|Celgene Corp,1049061|15331,Acetylon Pharmaceuticals Inc,1049061,,,,,,
96193,spartalizumab,"PD1 targeting immunotherapy program (cancer), Novartis AG|anti-PD-1 antibody (advanced cancer), Novartis|spartalizumab|PD-1 checkpoint inhibitor (cancer), Novartis|PDR-001",USAN|INN,Cancer|Hematologic,Programmed cell death protein 1 inhibitor,67136,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Metastasis|Neuroendocrine tumor|Thyroid tumor|Mesothelioma|Small-cell lung cancer|Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Hippel Lindau syndrome|Endometrioid carcinoma|Diffuse large B-cell lymphoma|Cholangiocarcinoma|Renal cell carcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Transitional cell carcinoma|Multiple myeloma|Sarcoma|Lymphoma|Hematological neoplasm|Thrombocythemia|Polycythemia vera|Bladder cancer|Myelofibrosis|Glioblastoma|Pancreas tumor|Pheochromocytoma|Paraganglioma|Squamous cell carcinoma|Stage III melanoma|Stage IV melanoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Advanced solid tumor|Anaplastic thyroid cancer|Uveal melanoma|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Head and neck tumor,1069|1128|1134|1240|1261|1262|1507|1612|1705|1749|1765|1766|1767|1768|1771|1828|194|203|2054|2317|2319|2380|2436|2454|249|262|2876|307|3256|3257|3657|3658|3665|3666|3667|3669|3713|3769|3788|3866|4250|427|623,Endocrine tumor|Melanoma|Cancer,1004|205|651,Novartis AG|Novartis Pharmaceuticals Corp,23137|24818,CoStim Pharmaceuticals Inc,1088885,CoStim Pharmaceuticals Inc,1088885,,,,,,
9636,talotrexin,PT-523|NSC-633713|PT-633|10-deaza-PT-523|talotrexin|talotrexin ammonium|NSC-712783|Talvesta,Research Code|Research Code|Analogue|Research Code|Analogue|INN|USAN|Research Code|Trade Name,Cancer,Folate receptor antagonist,665,Anticancer antimetabolite,1569,,,Non-small-cell lung cancer|Acute lymphoblastic leukemia|Breast tumor|Solid tumor|Lung tumor,1262|1728|49|725|755,,,Talon Therapeutics Inc|Dana-Farber Cancer Institute Inc|Astex Pharmaceuticals Inc,1010798|15615|21885,Dana-Farber Cancer Institute Inc,15615,,,,,,
96475,oleclumab,"MEDI-9447|CD73 checkpoint inhibitor (cancer), MedImmune|CD73 antagonist (cancer), MedImmune|oleclumab",Research Code|USAN|INN,Cancer,CD73 antagonist,5300,T-lymphocyte stimulator|Immunostimulant|Leukocyte stimulator|Anticancer monoclonal antibody,7761|393|7747|55685,Non-small-cell lung cancer|Pancreatic ductal adenocarcinoma|Bladder cancer|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,1262|1507|2380|3246|3657|3658|3665|3713,Prostate tumor|Cancer,276|651,MedImmune LLC,18008,,,MedImmune LLC,18008,,,,,,
96482,"cetuximab biobetter (solid tumors/colorectal cancer/head and neck cancer), Shanghai Henlius Biotech","cetuximab|HLX-07|cetuximab biobetter (solid tumors/colorectal cancer/head and neck cancer), Shanghai Henlius Biotech",INN|Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Angiogenesis inhibitor|Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,61|62255|55685,Squamous cell carcinoma|Advanced solid tumor|Head and neck tumor|Solid tumor|Lung tumor|Colorectal tumor,307|3713|623|725|755|989,,,Henlix Biotech Co Ltd|Hengenix Biotech Inc|Shanghai Henlius Biotech Co Ltd,1156265|1185825|1073079,Henlius Biopharmaceuticals Inc|Henlix Inc,1072684|1118244,Shanghai Henlius Biotech Co Ltd,1073079,,,,,,
96487,serplulimab,"HLX-10|PD-1 checkpoint inhibitor (solid tumor), Shanghai Henlius|anti-PD-1 mAb, Shanghai Henlius Biotech|anti-PD-1 mAb (solid tumor), Henlius Biopharmaceuticals/ Kalbe Genexine Biologics|PD-1 checkpoint inhibitor (solid tumor), Henlius Biopharmaceuticals/ Kalbe Genexine Biologics|serplulimab",Research Code|INN,Cancer|Hematologic|Infection,Programmed cell death protein 1 inhibitor,67136,Anti-inflammatory|T-lymphocyte stimulator|Immunostimulant|Anticancer monoclonal antibody|Antiviral|Anticancer,2953|7761|393|55685|991|1545,Thrombosis|Small-cell lung cancer|Stomach tumor|Hepatitis B virus infection|Hepatocellular carcinoma|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Advanced solid tumor|Uterine cervix tumor|Breast tumor|Solid tumor,1076|1261|127|152|1767|3665|3667|3713|427|49|725,,,Henlix Inc|Kalbe Genexine Biologics|Shanghai Henlius Biotech Co Ltd|Henlix Biotech Co Ltd,1118244|1194985|1073079|1156265,Henlius Biopharmaceuticals Inc,1072684,Shanghai Henlius Biotech Co Ltd,1073079,,,,,,
96497,TAS-4464,"TAS-4464|NEDD8 activating enzyme E1 inhibitors (cancer), Taiho Pharmaceutical|NAE inhibitors (cancer), Taiho Pharmaceutical",,Cancer,Amyloid protein binding protein-1 inhibitor,15160,Anticancer,1545,,,Multiple myeloma|Lymphoma|Cancer,1828|203|651,,,Taiho Pharmaceutical Co Ltd,18720,Taiho Pharmaceutical Co Ltd,18720,,,,,,
96499,BAY-1143269,"BAY-1143269|MAP kinase-interacting serine/threonine-protein kinase 1 (cancer), Bayer Pharma|MKNK1 inhibitor (cancer), Bayer Pharma",Research Code,Cancer,MNK1 protein kinase inhibitor,3900,Anticancer protein kinase inhibitor,62255,,,Cancer,651,,,Bayer AG,14455,Bayer AG,14455,,,,,,
96572,vopratelimab,"ICOS agonist monoclonal antibody (solid tumors), Jounce Therapeutics|JTX-2011|ICOS agonist immunotherapy (solid tumors), Jounce Therapeutics|ICOS costimulator (cancer), Jounce Therapeutics|vopratelimab",Research Code|INN,Cancer,Inducible T-cell co-stimulator stimulator,15391,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Non-small-cell lung cancer|Stomach tumor|Transitional cell carcinoma|Melanoma|Metastatic non small cell lung cancer|Advanced solid tumor|Breast tumor|Head and neck tumor,1262|127|1771|205|3665|3713|49|623,Cancer,651,Jounce Therapeutics Inc,1079075,,,Jounce Therapeutics Inc,1079075,,,,,,
96652,uzansertib,"INCB-053914|pan-PIM kinase inhibitors (cancer), Incyte|INCB-53914|uzansertib",Research Code|Research Code|INN,Cancer,PIM protein kinase inhibitor,4522,Synergist|Anticancer protein kinase inhibitor,7293|62255,Plasmacytoma|Diffuse large B-cell lymphoma|Multiple myeloma|Hematological neoplasm|Solid tumor,1748|1749|1828|2054|725,Cancer,651,Incyte Corp,17216,,,Incyte Corp,17216,,,,,,
96656,HLX-55,"KTN-0216|HLX-55|anti-cMET mAb (stomach cancer/glioblastoma), Shanghai Fosun/Shanghai Henlius/Celldex Therapeutics/Kolltan Pharmaceuticals",Research Code|Research Code,Cancer,Hepatocyte growth factor receptor antagonist|Immunoglobulin G2 modulator,675|5756,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Stomach tumor|Glioblastoma|Advanced solid tumor|Cancer,127|2454|3713|651,Neuroblastoma,2726,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Kolltan Pharmaceuticals Inc|Celldex Therapeutics Inc,1044856|25726,Kolltan Pharmaceuticals Inc,1044856,,,,,,
96690,vorasidenib citrate,AG-881|vorasidenib|vorasidenib citrate|AG-881 citrate|AG-881 hemicitrate hemihydrate|AGI-23088|AGI-0023088,Research Code|INN|USAN|Research Code|Research Code|Research Code,Cancer,Mitochondrial isocitrate dehydrogenase inhibitor|Cytoplasmic isocitrate dehydrogenase inhibitor,67505|67508,Anticancer,1545,Glioma,1108,Acute myelogenous leukemia|Cancer|Solid tumor,1731|651|725,Servier,19863,Agios Pharmaceuticals Inc|Celgene Corp,1040627|15331,Agios Pharmaceuticals Inc,1040627,,,,,,
96775,MG1MA3,"cancer vaccine (Maraba virus, lung cancer), Turnstone Biologics|MG1MA3|MG1-MAGEA3|MG1 Maraba/MAGE-A3|Ad-MG1-MAGEA3",,Cancer,MAGEA3 gene modulator,22048,Therapeutic vaccine|Anticancer|Recombinant viral vector vaccine,12379|1545|12370,Squamous cell carcinoma|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Advanced solid tumor,307|3257|3657|3665|3667|3713,,,Turnstone Biologics Inc,1108679,,,Turnstone Biologics Inc,1108679,,,,,,
96818,"azacytidine (inhaled aerosol, lung cancer), Albert Einstein College of Medicine","5-azacitidine|azacitidine|5-azacytidine (inhaled aerosol, lung cancer), Albert Einstein College of Medicine|azacytidine (inhaled aerosol, lung cancer), Albert Einstein College of Medicine",USAN|INN,Cancer,DNA methyltransferase inhibitor,6512,Anticancer antimetabolite,1569,Non-small-cell lung cancer,1262,Lung tumor,755,Albert Einstein College of Medicine,24282,,,Albert Einstein College of Medicine,24282,,,,,,
96857,"MVA-p53 vaccine, Tara Immuno-Oncology","p53MVA vaccine, City of Hope/National Cancer Institute|MVA-p53 vaccine, Tara Immuno-Oncology",,Cancer,,,Anticancer|Therapeutic vaccine,1545|12379,Fallopian tube cancer|Peritoneal tumor|Solid tumor|Ovary tumor,2243|3083|725|799,,,Tara Immuno-Oncology LLC,1104562,City of Hope,20558,City of Hope,20558,,,,,,
9687,lumiliximab,"gomiliximab|IDEC-152|lumiliximab|ST-152|SI-3401|PRIMATIZED anti-CD23 antibody, IDEC",Research Code|USAN|INN|Research Code|Research Code,Cancer|Immune|Inflammatory|Respiratory,Immunoglobulin epsilon Fc receptor II modulator,5092,Immunomodulator|Apoptosis stimulator|Anticancer monoclonal antibody|Anti-inflammatory,1596|1589|55685|2953,,,Allergic rhinitis|Allergy|Chronic lymphocytic leukemia|Asthma|Rhinitis,1107|12|1734|31|477,,,Biogen Inc|IDEC Pharmaceuticals Corp|Seikagaku Corp|Taisho Pharmaceutical Co Ltd,1005244|17085|19844|20289,IDEC Pharmaceuticals Corp,17085,,,,,,
96916,KITE-718,"MAGE A3/A6 targeting T-cell therapy (cancer), Kite Pharma|KITE-718|anti-MAGE A3/MAGE A6/HLA-DPB1*0401 TCR T-cell therapy (cancer), Kite Pharma",Research Code,Cancer,HLA class II antigen modulator|Melanoma associated antigen 3 modulator|Melanoma associated antigen 6 modulator,19334|21958|21967,Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Anticancer,393|4790|7761|1545,Cancer,651,,,Kite Pharma Inc,1056870,,,Kite Pharma Inc,1056870,,,,,,
96932,ombipepimut-S,adegramotide + nelatimotide|nelatimotide + adegramotide|elatipepimut-S + adegramotide|adegrapepimut-S + nelatimotide|ombipepimut-S|DSP-7888|adegramotide acetate + nelatimotide triflutate|adegrapepimut-S acetate + nelatimotide triflutate|elatipepimut-S triflutate + adegramotide acetate|nelatimotide triflutate + adegramotide acetate|nelatimotide trifluoroacetate+ adegramotide acetate,USAN|Research Code,Cancer|Gastrointestinal,Wilms tumor protein modulator,30009,Therapeutic vaccine|Anticancer|T-lymphocyte stimulator,12379|1545|7761,Glioma|Non-small-cell lung cancer|Stomach tumor|Myelodysplastic syndrome|Renal cell carcinoma|Hepatocellular carcinoma|Transitional cell carcinoma|Melanoma|Hematological neoplasm|Peritoneal disease|Fallopian tube cancer|Glioblastoma|Squamous cell carcinoma|Uterine cervix tumor|Head and neck tumor|Solid tumor|Ovary tumor|Colorectal tumor,1108|1262|127|1272|1766|1767|1771|205|2054|2203|2243|2454|307|427|623|725|799|989,,,Sumitomo Dainippon Pharma Co Ltd,1017117,,,Sumitomo Dainippon Pharma Co Ltd,1017117,,,,,,
96941,"anti-CD19 CAR T-cell therapy (leukemia), Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital","anti-CD19 CAR T-cell therapy (leukemia), Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital|anti-CD19 CAR T-cells (leukemia), Dana-Farber Cancer Institute/MSKCC/Boston Children's Hospital",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant,1545|4790|7761|393,Leukemia,199,,,Dana-Farber Cancer Institute Inc|Memorial Sloan-Kettering Cancer Center|Boston Children's Hospital,15615|22122|24334,,,Dana-Farber Cancer Institute Inc,15615,,,,,,
96986,"bevacizumab biosimilar, Genor Biopharma","bevacizumab|GB-222|bevacizumab biosimilar, Genor Biopharma",INN|Research Code,Cancer,VEGF ligand inhibitor,12521,Angiogenesis inhibitor|Anticancer monoclonal antibody,61|55685,Glioma|Non-small-cell lung cancer|Metastatic colorectal cancer,1108|1262|3658,Solid tumor,725,Genor Biopharma Co Ltd,1056962,,,Genor Biopharma Co Ltd,1056962,,,,,,
9699,talactoferrin alfa,"rhLF, Agennix|lactoferrin, Agennix|rh lactoferrin, Agennix|talactoferrin|talactoferrin alfa|talactoferrin alpha|Lactoferrin (human recombinant)|lactoferrin (NSCLC/nosocomial infection/renal cell carcinoma/sepsis), Agennix",USAN|INN,Cancer|Dermatologic|Gastrointestinal|Infection|Respiratory,Lactoferrin stimulator,17846,Immunomodulator|Anticancer|Antibacterial|Anti-inflammatory,1596|1545|1594|2953,,,Sepsis|Non-small-cell lung cancer|Gastrointestinal disease|Renal cell carcinoma|Asthma|Solid tumor|Infectious disease|Dermatological disease,114|1262|129|1766|31|725|746|95,,,Agennix AG,13765,Agennix AG,13765,,,,,,
97027,"azilsartan + amlodipine + hydrochlorothiazide (hypertension), Takeda","TAK-536TCH|azilsartan + amlodipine + hydrochlorothiazide (hypertension), Takeda|azilsartan + amlodipine + hydrochlorothiazide|TAK-536 + amlodipine + hydrochlorothiazide",Research Code,Cardiovascular,Calcium channel inhibitor|Angiotensin II receptor antagonist,93|64,Diuretic agent|Antihypertensive,137|2657,,,Hypertension,178,,,Takeda Pharmaceutical Co Ltd,20300,Takeda Pharmaceutical Co Ltd,20300,,,,,,
97070,GEN-1042,"bispecific anti-CD40/anti-CDw137 antibody (DuoBody, cancer), BioNTech/Genmab|DuoBody-CD40x41BB|dual CD40 costimulator/4-1BB costimulator (DuoBody, cancer), BioNTech/Genmab|GEN-1042|BNT-312",Research Code|Research Code,Cancer,CD40 ligand receptor agonist|CDw137 agonist,5141|5450,Dendritic cell stimulator|Anticancer antibody|Macrophage stimulator|Immunostimulant|B-lymphocyte stimulator,173472|55684|7751|393|7741,Non-small-cell lung cancer|Stage IV melanoma|Advanced solid tumor|Colorectal tumor,1262|3257|3713|989,Melanoma,205,Genmab A/S|BioNTech SE,26469|1047330,,,BioNTech SE,1047330,,,,,,
97230,AMV-564,"anti-CD3/anti-CD33 bispecific T-cell engager (cancer), Amphivena Therapeutics/Janssen|AMV-564",Research Code,Cancer,CD33 modulator|CD3 modulator,5119|5023,Immunostimulant|T-lymphocyte stimulator|Anticancer antibody,393|7761|55684,Myelodysplastic syndrome|Acute myelogenous leukemia|Advanced solid tumor,1272|1731|3713,Cancer,651,Amphivena Therapeutics Inc|Janssen Biotech Inc,1107363|26997,,,Amphivena Therapeutics Inc,1107363,,,,,,
97294,VSV-hIFNbeta-NIS,"recombinant vesicular stomatitis virus (cancer), University of Tennessee/Mayo Clinic|BOEC-VSV-IFN-beta|VSV-hIFNbeta-NIS|VSV-mIFN-NIS|oncolytic VSV therapy expressing IFN-beta and sodium-iodide symporter (cancer), University of Tennessee/Mayo Clinic",,Cancer,Interferon beta ligand,481,Immunostimulant|Anticancer,393|1545,Endometrioid carcinoma|Acute myelogenous leukemia|Multiple myeloma|T-cell lymphoma|Cancer,1705|1731|1828|311|651,,,University of Tennessee|Mayo Clinic Foundation,26292|21111,,,University of Tennessee,26292,,,,,,
97321,"bevacizumab biosimilar, Samsung Bioepis","bevacizumab|SB-8|bevacizumab biosimilar, Samsung Bioepis|AYBINTIO|615, 3SBio|Onbevzi",INN|Research Code|Trade Name|Research Code,Cancer,VEGF ligand inhibitor,12521,Anti-inflammatory|Angiogenesis inhibitor|Anticancer monoclonal antibody,2953|61|55685,Fallopian tube cancer|Peritoneal tumor|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Ovary tumor,2243|3083|3657|3658|3665|4250|427|799,,,Merck & Co Inc|Samsung Bioepis|3SBio Inc|Mundipharma International Corp Ltd,18077|1071703|1016672|1045514,,,Samsung Bioepis,1071703,,,,,,
9736,AN-9,pivaloyloxymethyl butyrate|AN-9|Pivanex|Pivanex Injection,Research Code|Trade Name|Trade Name,Cancer,Histone deacetylase inhibitor,2574,Anticancer|Apoptosis stimulator|Cell cycle inhibitor,1545|1589|767,,,Glioma|Non-small-cell lung cancer|Chronic lymphocytic leukemia|Hepatocellular carcinoma|Melanoma|Head and neck tumor|Cancer,1108|1262|1734|1767|205|623|651,,,Titan Pharmaceuticals Inc|Bar-Ilan University|Windtree Therapeutics Inc,20377|20531|24963,Bar-Ilan Research & Development Co Ltd,22647,,,,,,
9741,CDX-301,"Mobist|Moblsta|Flt-3 ligand, Amgen|Flt-3 ligand, Immunex|Flt-3/Flk-2 ligand, Immunex|Flt-3 ligand (stem cell mobilizer), Viacell|CDX-301|Flt-3 ligand (sc, cancer, NSCLC, stem cell transplantation, B-cell lymphoma, metastatic melanoma, autoimmune disease), Celldex|Mobista|Flt-3 ligand (sc, cancer, NSCLC, stem cell transplantation, B-cell lymphoma, metastatic melanoma, autoimmune disease/prostate cancer), Celldex|Flt-3 ligand (sc, cancer/NSCLC/stem cell transplantation/B-cell lymphoma/metastatic melanoma/autoimmune disease/pancreatic ductal adenocarcinoma), Celldex|rhuFlt3L|Flt3L",Trade Name|Trade Name|Research Code|Trade Name|Research Code|Research Code,Cancer|Immune|Infection,SL cytokine ligand,15590,Antiviral|Synergist|Therapeutic vaccine|Immunomodulator|Hematopoietic modulator|Anticancer,991|7293|12379|1596|1678|1545,Pancreatic ductal adenocarcinoma|HIV infection|Stem cell transplantation|B-cell lymphoma|Hormone refractory prostate cancer|Stage IV melanoma|Metastatic non small cell lung cancer,1507|158|2990|316|3246|3257|3665,Immune disorder|Prostate tumor|Transplantation|Carcinoma|Cancer,185|276|2980|54|651,Celldex Therapeutics Inc,25726,Wyeth|Immunex Corp|Imclone LLC|ViaCell Inc,14112|14131|17193|28648,Immunex Corp,14131,,,,,,
97463,TQB-2450,"anti PD-L1 mAb (cancer), Crown Bioscience|CBT-502|TQB-2450|PD-L1 checkpoint inhibitor (cancer), CBT Pharmaceuticals|APL-502|anti-programmed cell death ligand 1 (PD-L1) (cancer/non-hodgkin lymphoma), Apollomics|PD-L1 checkpoint inhibitor (cancer/classical hodgkin lymphoma), Apollomics/Chia Tai Tianqing Pharmaceutical Group",Research Code|Research Code|Research Code,Cancer|Infection,Programmed cell death ligand 1 inhibitor,14007,Immunostimulant|Antiviral|T-lymphocyte stimulator|Anticancer monoclonal antibody|Anti-inflammatory,393|991|7761|55685|2953,Metastasis|Small-cell lung cancer|Biliary cancer|Hepatitis B virus infection|Hodgkins disease|Endometrioid carcinoma|Primary mediastinal large B-cell lymphoma|Cholangiocarcinoma|Hepatocellular carcinoma|Nasopharyngeal carcinoma|Stage IV melanoma|Soft tissue sarcoma|Metastatic non small cell lung cancer|Metastatic ovary cancer|Metastatic renal cell carcinoma|Uterine cervix tumor|Breast tumor|Head and neck tumor|Cancer,1069|1261|1516|152|161|1705|1750|1765|1767|1768|3257|3378|3665|3866|4250|427|49|623|651,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd|Apollomics Inc,1025425|1129041,Crown Bioscience Inc,1051206,Crown Bioscience Inc,1051206,,,,,,
97465,geptanolimab,"anti PD-1 mAb (cancer), Crown Bioscience|jienuo mAb, Genor Biopharma|genolimzumab|PD-1 checkpoint inhibitor (cancer), CBT Pharmaceuticals/Genor Biopharma|jeno mAb (intravenous, cancer), CBT Pharmaceuticals/Crown Bioscience/Genor Biopharma|GB-226|CBT-501|PD-1 checkpoint inhibitor (cancer), Apollomics/Genor BioPharm|geptanolimab|APL-501",Research Code|Research Code|Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator,55685|393|7761,Stomach tumor|Primary mediastinal large B-cell lymphoma|Peripheral T-cell lymphoma|Renal cell carcinoma|Hepatocellular carcinoma|Hematological neoplasm|Thymus neoplasm|Soft tissue sarcoma|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Uterine cervix tumor|Cancer|Solid tumor,127|1750|1753|1766|1767|2054|2938|3378|3658|3665|427|651|725,,,Apollomics Inc|Genor Biopharma Co Ltd,1129041|1056962,Crown Bioscience Inc,1051206,Crown Bioscience Inc,1051206,,,,,,
9754,palanosetron hydrochloride,RS-25259-197|palonosetron|RS-42358|RS-25259-007|palanosetron hydrochloride|Aloxi|Onicit|Paloxi,Research Code|USAN|INN|Research Code|Research Code|USAN|Trade Name|Trade Name|Trade Name,Gastrointestinal,5-HT 3 receptor antagonist,15,Anti-emetic,2970,Emesis|Nausea|Chemotherapy-induced emesis,110|226|352,,,Taiho Pharmaceutical Co Ltd|PharmaSwiss SA|Vifor Pharma Ltd|Chugai Pharmaceutical Co Ltd|Angelini Pharma SpA|Mundipharma International Corp Ltd|Italfarmaco SpA|CJ Corp|Vifor Pharma Group|Pfizer Inc|Swedish Orphan Biovitrum AB|Rafa Laboratories Ltd|Berlin-Chemie AG|Helsinn Healthcare SA|CSC Pharmaceuticals Handels GmbH|Purdue Pharma LP|Merck & Co Inc|Riemser Pharma GmbH,18720|1015038|16268|15414|14233|1045514|17278|15473|16266|18767|28921|26232|18054|27361|26416|24191|18077|1003824,PT Kalbe Farma Tbk|Specialised Therapeutics Australia Pty Ltd|Specialised Therapeutics Asia Pte Ltd|Ribosepharm GmbH|MGI Pharma Inc|Roche Palo Alto|Schering-Plough Corp|Therabel Pharma NV|Cambridge Laboratories Ltd|Sinclair Pharma plc,1027766|1044298|1157003|16183|18203|19470|19711|20365|28740|29560,Roche Palo Alto,19470,,,,,,
97554,ABBV-838,"ABBV-838|anti-CS1 ADC (solid tumors), AbbVie|anti-CS1 antibody-drug conjugate (solid tumors), AbbVie|azintuxizumab vedotin",Research Code|INN,Cancer,SLAM family member 7 inhibitor,45395,Mitosis inhibitor|Anticancer monoclonal antibody,56466|55685,,,Multiple myeloma,1828,,,AbbVie Inc,1072507,AbbVie Inc,1072507,,,,,,
97774,tomivosertib,"eFT-508|MNK 1/2 protein kinase inhibitors (cancer), eFFECTOR Therapeutics|MNK 1/2 protein kinase inhibitors (oral, cancer), eFFECTOR Therapeutics|tomivosertib|tomivosertib hydrochloride",Research Code|USAN|INN|USAN,Cancer,MNK1 protein kinase inhibitor|MNK2 protein kinase inhibitor,3900|3902,Immunostimulant|Anticancer protein kinase inhibitor|Synergist,393|62255|7293,Non-small-cell lung cancer|Diffuse large B-cell lymphoma|Hepatocellular carcinoma|Transitional cell carcinoma|Lymphoma|Hormone refractory prostate cancer|Metastatic breast cancer|Metastatic colorectal cancer|Head and neck tumor|Solid tumor,1262|1749|1767|1771|203|3246|3657|3658|623|725,Cancer,651,eFFECTOR Therapeutics Inc,1083818,,,eFFECTOR Therapeutics Inc,1083818,,,,,,
97828,"[18F] FMISO PET agent (hepatocellular carcinoma), National Institutes of Health Clinical Center","[18F] FMISO PET agent (hepatocellular carcinoma), National Institutes of Health Clinical Center|18F-FMISO|Fluoro-18-FMISO|FMISO-[18F]|18F-fluoromisonidazole",,Cancer,,,PET contrast agent|Gastrointestinal diagnostic agent|Sensitizer|Neoplasm diagnostic agent,5555|7213|5717|7220,Hepatocellular carcinoma,1767,Liver tumor|Cancer,202|651,National Institutes of Health Clinical Center,1069368,,,National Institutes of Health Clinical Center,1069368,,,,,,
9814,belagenpumatucel-L,"lung cancer/ astrocytoma vaccine, NovaRx|antisense (TGFbeta) lung cancer/ astrocytoma vaccine, NovaRx|Lucanix|belagenpumatucel-L",Trade Name|USAN,Cancer,,,Antisense oligonucleotide inhibitor|Therapeutic vaccine|Anticancer|TGF beta gene inhibitor,7294|12379|1545|3976,,,Non-small-cell lung cancer|Lung tumor,1262|755,,,Immune Response BioPharma Inc|Sidney Kimmel Cancer Center|Activate Immunotherapy,17199|22971|29145,Sidney Kimmel Cancer Center,22971,,,,,,
98245,FT-516,"iPSC-derived targeted immunotherapy (cancer/acute myelogenous leukemia/non-hodgkin lymphoma/multiple myeloma), Fate Therapeutics/University of Minnesota|hnCD16-iNK|FT-516|allogeneic natural killer cell therapy (cancer), Fate Therapeutics/ University of Minnesota|hnCD16-expressing iPSC-derived NK cell therapy (cancer), Fate Therapeutics/University of Minnesota",Research Code,Cancer|Infection,,,Anticancer|Immunostimulant|Antiviral|Natural killer cell stimulator,1545|393|991|7757,Coronavirus disease 19 infection|Acute myelogenous leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Multiple myeloma|Fallopian tube cancer|Peritoneal tumor|B-cell lymphoma|Non-Hodgkin lymphoma|Advanced solid tumor|Ovary tumor,10406|1731|1745|1749|1828|2243|3083|316|319|3713|799,Hematological neoplasm|Cancer,2054|651,Fate Therapeutics Inc,1036293,University of Minnesota,20626,University of Minnesota,20626,,,,,,
98289,mosunetuzumab,"T-cell directed bispecific CD20/CD3 targeting compound, Genentech|RO-7030816|mosunetuzumab|anti-CD3/anti-CD20 bispecific T-cell engager (TDB, B-cell malignancies), Genentech|RG-7828|BTCT-4465A|CD20-TDB",Research Code|INN|Research Code|Research Code|Research Code,Cancer,B-lymphocyte antigen CD20 modulator|CD3 modulator,5083|5023,T-lymphocyte stimulator|Anticancer monoclonal antibody|Immunostimulant,7761|55685|393,Chronic lymphocytic leukemia|Follicle center lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|High grade B-cell lymphoma|B-cell lymphoma|Non-Hodgkin lymphoma,1734|1745|1749|1750|1751|316|319,,,Genentech Inc|Chugai Pharmaceutical Co Ltd,19453|15414,,,Genentech Inc,19453,,,,,,
9829,Busulfex,"busulfan|KRN-246|Busilvex|Busulfex|Busulfanex|busulfan, MD Anderson|busulfan, Orphan Medical|KER-246|Myleran",BANN|INN|Research Code|Trade Name|Trade Name|Trade Name|Research Code|Trade Name,Cancer|Immune,,,Anticancer|Anticancer alkylating agent,1545|50,Hodgkins disease|Non-Hodgkin lymphoma|Bone marrow transplantation,161|319|46,,,Biotoscana International|Otsuka Pharmaceutical Co Ltd|Aspen PharmaCare Holdings Ltd|MD Anderson Cancer Center|Pierre Fabre Group|Orphan Medical Inc|GlaxoSmithKline plc,1063950|18717|1019374|23382|19087|18710|28355,Kyowa Hakko Kirin Co Ltd|Kirin Brewery Co Ltd|PDL BioPharma Inc,1042596|17661|19162,MD Anderson Cancer Center,23382,,,,,,
98372,"SC-002, Stemcentrx","SC-002, Stemcentrx|antibody-drug conjugate (SCLC), Stemcentrx|Rova-T Next-Gen",Research Code,Cancer,,,Anticancer antibody|Unspecified drug target,55684|59620,Small-cell lung cancer,1261,Neuroendocrine tumor,1128,AbbVie Inc,1072507,Stemcentrx Inc,1063564,Stemcentrx Inc,1063564,,,,,,
98392,"nimotuzumab biosimilar, Shanghai JMT-Bio","nimotuzumab|JMT-101|nimotuzumab biosimilar, Shanghai JMT-Bio",INN|Research Code,Cancer,Epidermal growth factor receptor modulator|Erbb2 tyrosine kinase receptor modulator|Epidermal growth factor receptor antagonist,3605|3755|740,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody,62255|55685,Metastatic colorectal cancer|Metastatic non small cell lung cancer|Advanced solid tumor,3658|3665|3713,Cancer,651,Shanghai JMT-Bio Inc,1112022,,,Shanghai JMT-Bio Inc,1112022,,,,,,
98415,DTRMWXHS-12,DTRMWXHS-12|DTRM-12,Research Code|Research Code,Cancer,Btk tyrosine kinase inhibitor,3592,Anticancer protein kinase inhibitor,62255,Chronic lymphocytic leukemia|Mantle cell lymphoma|B-cell lymphoma,1734|1744|316,Lymphoma,203,DTRM Biopharma Co Ltd,1071880,,,DTRM Biopharma Co Ltd,1071880,,,,,,
98482,seclidemstat,"SP-2577|seclidemstat mesylate|seclidemstat|LSD1 reversible inhibitor (oral tablet, cancer), Salarius Pharmaceuticals",Research Code|INN,Cancer,Lysine specific histone demethylase 1 inhibitor,14681,Anticancer,1545,Myelodysplastic syndrome|Endometrioid carcinoma|Rhabdomyosarcoma|Glioblastoma|Ewing sarcoma|Hormone refractory prostate cancer|Stage IV melanoma|Ovarian clear cell carcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Advanced solid tumor|Metastatic ovary cancer|Breast tumor|Chronic myelomonocytic leukemia|Ovary tumor,1272|1705|2448|2454|2975|3246|3257|3525|3657|3658|3713|3866|49|6833|799,,,Salarius Pharmaceuticals Inc,1098716,Salarius Pharmaceuticals LLC,1070264,Salarius Pharmaceuticals LLC,1070264,,,,,,
98558,E-7046,"E-7046|PGE2 inhibitors (solid tumor), Eisai|AN-0025",Research Code,Cancer,EP4 prostanoid receptor antagonist,3478,Anticancer,1545,Rectal tumor|Non-small-cell lung cancer|Transitional cell carcinoma|Squamous cell carcinoma|Metastatic esophageal cancer|Uterine cervix tumor|Breast tumor|Solid tumor|Colorectal tumor,1055|1262|1771|307|3667|427|49|725|989,,,Eisai Co Ltd|Adlai Nortye Pharmaceutical Co Ltd,15872|1111343,,,Eisai Co Ltd,15872,,,,,,
98615,trastuzumab deruxtecan,DS-8201|trastuzumab deruxtecan|DS-8201a|fam-trastuzumab deruxtecan|Enhertu|T-DXd|fam-trastuzumab deruxtecan-nxki,Research Code|USAN|INN|Research Code|Trade Name,Cancer,Topoisomerase I inhibitor|Erbb2 tyrosine kinase receptor inhibitor,141|3756,Anticancer protein kinase inhibitor|Anticancer monoclonal antibody|Apoptosis stimulator,62255|55685|1589,Stomach tumor|Biliary cancer|Endometrioid carcinoma|Transitional cell carcinoma|Osteosarcoma|Metastatic bladder cancer|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic stomach cancer|Metastatic esophageal cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic ovary cancer|Uterine cervix tumor,127|1516|1705|1771|1772|3466|3657|3658|3665|3666|3667|3669|3713|3866|427,Carcinosarcoma|Uterus tumor|Colorectal tumor,2614|740|989,AstraZeneca plc|Daiichi Sankyo Co Ltd,14190|1017506,,,Daiichi Sankyo Co Ltd,1017506,,,,,,
98616,bintrafusp alfa,"MSB-0011359C|M-7824|bi-functional immunotherapy (solid tumors), Merck Serono|dual PD-L1 checkpoint inhibitor/TGF beta inhibitor (bispecific antibody, cancer), Merck KGaA|bifunctional PD-L1 checkpoint inhibitor and TGF-beta trap (solid tumor), EMD Serono|anti-PD-L1/TGF-beta trap fusion protein (solid tumor), Merck KGaA|avelumab Fc domain/TGF-beta receptor II fusion protein (solid tumors), Merck KGaA|bintrafusp alfa|avelumab Fc domain/TGF-beta receptor II fusion protein (solid tumors), Merck KGaA/ GlaxoSmithKline|avelumab Fc domain/TGF-beta receptor II fusion protein (solid tumors), Baxter Oncology/Merck KGaA/ GlaxoSmithKline|GSK-4045154",Research Code|Research Code|USAN|INN|Research Code,Cancer,Programmed cell death ligand 1 inhibitor|TGF beta ligand inhibitor,14007|69025,Anticancer monoclonal antibody|Anticancer|T-lymphocyte stimulator|Anticancer protein kinase inhibitor|Immunostimulant,55685|1545|7761|62255|393,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Biliary tumor|Cholangiocarcinoma|Nasopharyngeal carcinoma|Bladder cancer|Adenocarcinoma|Leiomyosarcoma|Liposarcoma|Squamous cell carcinoma|Gallbladder tumor|Soft tissue sarcoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Urethral cancer|Advanced solid tumor|Uterine cervix tumor|Breast tumor|Head and neck tumor|Uterus tumor|Renal tumor,1011|1262|127|1515|1765|1768|2380|2399|2446|2447|307|3146|3378|3657|3665|3678|3713|427|49|623|740|999,Transitional cell carcinoma,1771,GlaxoSmithKline plc|Merck KGaA,28355|18101,,,Merck KGaA,18101,,,,,,
98626,repotrectinib,"TPX-0005|ALK/ROS1/TRK inhibitors (solid tumors), TP Therapeutics/Patheon/INC Research|luoputini|ropotrectinib|repotrectinib",Research Code|INN|PINN,Cancer,Jak2 tyrosine kinase inhibitor|Focal adhesion kinase inhibitor|Src tyrosine kinase inhibitor|Anaplastic lymphoma kinase receptor inhibitor|Ros1 tyrosine kinase receptor inhibitor|Trk tyrosine kinase receptor inhibitor,3564|3540|3576|3736|3826|3838,Anticancer protein kinase inhibitor|Synergist,62255|7293,Anaplastic large cell lymphoma|Metastatic non small cell lung cancer|Advanced solid tumor|Central nervous system tumor,1755|3665|3713|759,Cancer,651,Zai Lab Limited|Turning Point Therapeutics Inc,1101935|1112197,,,Turning Point Therapeutics Inc,1112197,,,,,,
98765,AMG-228,"AMG-228|GITR costimulator (solid tumor), Amgen",Research Code,Cancer,Activation-inducible TNF receptor agonist,8259,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator,393|55685|7761,,,Solid tumor,725,,,Amgen Inc,14109,Amgen Inc,14109,,,,,,
98772,APG-115,APG-115|alrizomadlin,Research Code,Cancer|Ocular,Mdm2 p53-binding protein inhibitor,10391,Apoptosis stimulator|Synergist|Anticancer,1589|7293|1545,Non-small-cell lung cancer|Stomach tumor|Myelodysplastic syndrome|Acute myelogenous leukemia|Prolymphocytic leukemia|Lymphoma|Hematological neoplasm|Liposarcoma|Stage IV melanoma|Dry age related macular degeneration|Soft tissue sarcoma|Advanced solid tumor|Salivary gland cancer,1262|127|1272|1731|1738|203|2054|2447|3257|3355|3378|3713|4299,Cancer,651,Ascentage Pharma Group Corporation Ltd,1052437,,,Ascentage Pharma Group Corporation Ltd,1052437,,,,,,
98829,cyclophosphamide monohydrate,cyclophosphamide|Endoxan|cyclophosphamide monohydrate,INN|Trade Name,Cancer,,,Anticancer|Unspecified drug target,1545|59620,Lymphoma,203,,,Shionogi & Co Ltd,19898,,,Shionogi & Co Ltd,19898,,,,,,
98837,praluzatamab ravtansine,"DM4 tubulin inhibitor conjugated, CD166-targeted, antibody prodrug (Probody, cancer), CytomX|CX-2009|praluzatamab ravtansine",Research Code|INN,Cancer,Activated leukocyte adhesion molecule modulator,5525,Microtubule inhibitor|Anticancer antibody,2575|55684,Endometrioid carcinoma|Cholangiocarcinoma|Metastatic breast cancer|Metastatic prostate cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer,1705|1765|3657|3664|3665|3673|3713|3866,Cancer,651,CytomX Therapeutics Inc,1045603,ImmunoGen Inc,17202,ImmunoGen Inc,17202,,,,,,
98881,"MiHA-loaded PD-L-silenced DC vaccination (hematological malignancies), Radboud University","MiHA-loaded PD-L-silenced DC vaccination (hematological malignancies), Radboud University",,Cancer,,,Dendritic cell vaccine|Anticancer|Therapeutic vaccine,102926|1545|12379,Hematological neoplasm,2054,,,Radboud University,1031299,,,Radboud University,1031299,,,,,,
9892,B43-genistein,B43-genistein,,Cancer,B-lymphocyte antigen CD19 modulator|Protein tyrosine kinase inhibitor,5080|385,Anticancer monoclonal antibody|Anticancer protein kinase inhibitor|Immunotoxin,55685|62255|539,,,Acute lymphoblastic leukemia,1728,,,University of Minnesota,20626,University of Minnesota,20626,,,,,,
98928,zotatifin,"eIF4A inhibitors (cancer), eFFECTOR Therapeutics|eukaryotic initiation factor 4A inhibitors (cancer), eFFECTOR Therapeutics|eFT-226|zotatifin",Research Code|USAN|INN,Cancer|Infection,Eukaryotic initiation factor 4A-I inhibitor,20912,Viral replication inhibitor|Antiviral|Anticancer|Synergist,1532|991|1545|7293,Coronavirus disease 19 infection|Lymphoma|Adenocarcinoma|Pancreas tumor|Advanced solid tumor|Cancer,10406|203|2399|249|3713|651,,,eFFECTOR Therapeutics Inc,1083818,,,eFFECTOR Therapeutics Inc,1083818,,,,,,
98935,AMG-224,AMG-224,Research Code,Cancer,APRIL receptor modulator,8255,Anticancer antibody,55684,,,Multiple myeloma,1828,,,Amgen Inc,14109,Amgen Inc,14109,,,,,,
98940,UCART-CS1,"UCART-CS1|anti-CS1 CAR T-cell therapy (multiple myeloma/ALL), Cellectis/MD Anderson Cancer Center|UCART-CS1A",Research Code|Research Code,Cancer,SLAM family member 7 modulator,45393,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,T-cell acute lymphoblastic leukemia|Multiple myeloma,1730|1828,,,MD Anderson Cancer Center|Cellectis SA,23382|29822,,,Cellectis SA,29822,,,,,,
98941,UCART-22,"UCART-22|anti-CD22 CAR T-cell therapy (AML/CLL/ALL), Cellectis",Research Code,Cancer,B-lymphocyte cell adhesion molecule modulator,5089,T-lymphocyte stimulator|Immunostimulant|Anticancer,7761|393|1545,B-cell acute lymphoblastic leukemia|T-cell acute lymphoblastic leukemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia,1729|1730|1731|1734,,,Cellectis SA,29822,,,Cellectis SA,29822,,,,,,
98970,P-BCMA-101,"anti-BCMA CAR T-cell therapy (multiple myeloma), Poseida|P-BCMA-101",Research Code,Cancer,APRIL receptor modulator,8255,Anticancer|Genetically engineered autologous cell therapy|Immunostimulant|T-lymphocyte stimulator,1545|4790|393|7761,Multiple myeloma|Prostate tumor,1828|276,,,Poseida Therapeutics Inc,1109809,,,Poseida Therapeutics Inc,1109809,,,,,,
98972,CX-2029,"Probody drug conjugates targeting CD-71 (cancer), CytomX|Probody drug conjugates targeting CD-71 (cancer), CytomX/ AbbVie|CX-2029|ABBV-2029|anti-CD71 probody drug conjugate (cancer), CytomX/Abbvie|ABBV-CX-2029",Research Code|Research Code|Research Code,Cancer,CD71 modulator,5292,Anticancer antibody,55684,Esophagus tumor|Non-small-cell lung cancer|Stomach tumor|Diffuse large B-cell lymphoma|Pancreas tumor|Squamous cell carcinoma|Head and neck tumor|Solid tumor,1011|1262|127|1749|249|307|623|725,Cancer,651,AbbVie Inc|CytomX Therapeutics Inc,1072507|1045603,,,CytomX Therapeutics Inc,1045603,,,,,,
99008,"Ad26.Mod.HIV + MVA mosaic vaccine + gp140 (HIV infection), Janssen Vaccines & Prevention/Beth Israel Deaconess Medical Center/NIAID/Military HIV Research Program/International AIDS Vaccine Initiative/ The Ragon Institute of MGH, MIT and Harvard","HIV vaccine (gp140 protein), Crucell Holland/NIAID|Ad26.Mod.HIV vaccine, Crucell/Beth Israel Deaconess Medical Center/NIAID/MHRP/International AIDS Vaccine Initiative|Ad26.Mod.HIV + MVA mosaic vaccine + gp140|Ad26.Mos.HIV vaccine|Ad26.Mos.HIV vaccine, Janssen Vaccines & Prevention/Beth Israel Deaconess Medical Center/NIAID/MHRP/International AIDS Vaccine Initiative|Ad26.Mod.HIV + MVA mosaic vaccine + gp140 (HIV infection), Janssen Vaccines & Prevention/Beth Israel Deaconess Medical Center/NIAID/Military HIV Research Program/International AIDS Vaccine Initiative/ The Ragon Institute of MGH, MIT and Harvard|Ad26.Mod.HIV + MVA mosaic vaccine + gp140 (HIV infection), Janssen Vaccines & Prevention/BIDMC/ NIAID/MHRP/ International AIDS Vaccine Initiative/ The Ragon Institute of MGH, MIT and Harvard",Research Code|Research Code|Research Code,Infection,,,Recombinant viral vector vaccine|Prophylactic vaccine|Antiviral|Therapeutic vaccine|Protein subunit vaccine,12370|12378|991|12379|12372,HIV infection,158,,,National Institute of Allergy and Infectious Diseases|International AIDS Vaccine Initiative|US Military HIV Research Program|Janssen Vaccines & Prevention BV|Beth Israel Deaconess Medical Center|The Ragon Institute of MGH,20520|1014416|1073709|28808|24877|1099414,,,Janssen Vaccines & Prevention BV,28808,,,,,,
99061,CC-95775,"FT-1101|pan-BET inhibitor (oral, hematological/solid tumors), Celgene|CC-95775|pan-BET inhibitor (oral, hematological/solid tumors), Bristol-Myers Squibb",Research Code|Research Code,Cancer,Bromodomain containing protein 2 inhibitor|Bromodomain containing protein 3 inhibitor|Bromodomain containing protein 4 inhibitor|Bromodomain testis-specific protein inhibitor,34564|34567|34570|87945,Anticancer,1545,Myelodysplastic syndrome|Acute myelogenous leukemia|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|Basal cell carcinoma|B-cell lymphoma|Non-Hodgkin lymphoma|Advanced solid tumor,1272|1731|1749|1750|1764|316|319|3713,Hematological neoplasm,2054,Bristol-Myers Squibb Co,15065,FORMA Therapeutics Inc|Celgene Corp,1043304|15331,FORMA Therapeutics Inc,1043304,,,,,,
99084,BGT-001,"small molecule therapeutic (oral/tablet, cancer), Shanghai Institute of Materia Medica|beisainuota|bisthianostat|BGT-001",Research Code,Cancer,Histone deacetylase inhibitor,2574,Anticancer,1545,Multiple myeloma,1828,Cancer,651,Shanghai Theorion Pharmaceutical Co Ltd|Shanghai Institute of Materia Medica of the Chinese Academy of Sciences,1169441|25314,,,Shanghai Institute of Materia Medica of the Chinese Academy of Sciences,25314,,,,,,
99150,eganelisib,"IPI-549|PI3K-gamma inhibitor (oral, solid tumor), Infinity Pharmaceuticals|eganelisib",Research Code,Cancer,Phosphoinositide-3 kinase gamma inhibitor,11186,Immunomodulator|Anticancer|Macrophage modulator|Anticancer protein kinase inhibitor,1596|1545|5662|62255,Mesothelioma|Adrenal cortex neoplasm|Transitional cell carcinoma|Bladder cancer|Stage IV melanoma|Metastatic renal cancer|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Metastatic ovary cancer|Ovary tumor,1240|1646|1771|2380|3257|3467|3657|3665|3673|3866|799,Renal cell carcinoma|Cancer|Solid tumor,1766|651|725,Infinity Pharmaceuticals Inc,29753,Intellikine Inc,1045250,Intellikine Inc,1045250,,,,,,
99166,TQ-B3139,TQ-B3139,Research Code,Cancer,Hepatocyte growth factor receptor antagonist|Ros1 tyrosine kinase receptor inhibitor|ALK tyrosine kinase receptor family inhibitor,675|3826|3851,Anticancer protein kinase inhibitor,62255,Diffuse large B-cell lymphoma|Neuroblastoma|Metastatic non small cell lung cancer|Advanced solid tumor|Lung tumor,1749|2726|3665|3713|755,Metastasis,1069,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd|Centaurus BioPharma Co Ltd,1025425|1069948,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,,,,,,
99186,"anti-CD19 CAR T-cell therapy (B-cell malignancies), Beijing Doing Biomedical","anti-CD19 CAR T-cell therapy (B-cell malignancies), Beijing Doing Biomedical",,Cancer,B-lymphocyte antigen CD19 modulator,5080,Genetically engineered autologous cell therapy|T-lymphocyte stimulator|Immunostimulant|Anticancer,4790|7761|393|1545,B-cell acute lymphoblastic leukemia|B-cell lymphoma|Non-Hodgkin lymphoma|Lymphoblastic leukemia,1729|316|319|3436,,,Beijing Doing Biomedical Technology Co Ltd,1113838,,,Beijing Doing Biomedical Technology Co Ltd,1113838,,,,,,
99199,BGB-3245,"RAF dimer inhibitor, BeiGene|BGB-3245",Research Code,Cancer,Raf protein kinase inhibitor,4542,Anticancer protein kinase inhibitor,62255,Advanced solid tumor|Cancer,3713|651,,,BeiGene Co Ltd|MapKure LLC,1063251|1188667,,,BeiGene Co Ltd,1063251,,,,,,
99202,BGB-A425,"Tim-3 mAb (cancer), BeiGene|BGB-A425|TIM-3 checkpoint inhibitor (cancer), BeiGene",Research Code,Cancer,Hepatitis A virus cellular receptor 2 antagonist,34783,Immunostimulant|T-lymphocyte stimulator|Anticancer monoclonal antibody,393|7761|55685,Advanced solid tumor,3713,Cancer,651,BeiGene Co Ltd,1063251,,,BeiGene Co Ltd,1063251,,,,,,
99215,SRK-181,"TGF-beta-1 inhibitors (cancer), Scholar Rock/Johnson & Johnson|SRK-181",Research Code,Cancer,TGF beta 1 ligand inhibitor,3699,Anticancer monoclonal antibody|Immunostimulant,55685|393,Non-small-cell lung cancer|Transitional cell carcinoma|Stage IV melanoma|Advanced solid tumor|Cancer,1262|1771|3257|3713|651,Solid tumor,725,Johnson & Johnson|Scholar Rock Inc,17332|1091868,,,Scholar Rock Inc,1091868,,,,,,
99292,CPI-006,"humanized anti-CD73 mAb (cancer), Corvus|CPX-006|CPI-006|CD73 checkpoint inhibitor (cancer), Corvus|humanized anti-CD73 mAb (COVID-19), Corvus|CD73 checkpoint inhibitor(cancer/infectious diseases/autoimmune diseases), Corvus/Angel|mupadolimab",Research Code|Research Code,Cancer|Infection,CD73 antagonist,5300,Leukocyte stimulator|Anticancer monoclonal antibody|Immunostimulant|T-lymphocyte stimulator|Antiviral,7747|55685|393|7761|991,Endometrioid carcinoma|Sarcoma|Bladder cancer|Squamous cell carcinoma|Metastatic breast cancer|Metastatic colorectal cancer|Metastatic non small cell lung cancer|Metastatic pancreas cancer|Advanced solid tumor|Metastatic renal cell carcinoma|Uterine cervix tumor|Cancer|Ovary tumor,1705|194|2380|307|3657|3658|3665|3669|3713|4250|427|651|799,Coronavirus disease 19 infection,10406,Angel Pharmaceuticals|Corvus Pharmaceuticals Inc,1232824|1112757,,,Corvus Pharmaceuticals Inc,1112757,,,,,,
99316,CSG-CD19,"CSG-CD19|anti-CD19 CAR T-cell therapy (blood cancer), CARsgen|CT-032",Research Code|Research Code,Cancer,B-lymphocyte antigen CD19 modulator,5080,Anticancer|Immunostimulant|Genetically engineered autologous cell therapy|T-lymphocyte stimulator,1545|393|4790|7761,Hematological neoplasm|Non-Hodgkin lymphoma,2054|319,,,Carsgen Therapeutics Ltd,1103310,,,Carsgen Therapeutics Ltd,1103310,,,,,,
99365,TK-216,"ets-family transcription factor inhibitor (cancer), Tokalas|TK-216|ets-family transcription factor inhibitor (cancer), Oncternal Therapeutics|SPH-8216",Research Code|Research Code,Cancer,ETS transcription factor inhibitor|EWS Fli1 protein inhibitor,20954|76223,Anticancer|Synergist,1545|7293,Acute myelogenous leukemia|Ewing sarcoma|Cancer,1731|2975|651,,,Shanghai Pharmaceuticals Holding Co Ltd|Oncternal Therapeutics Inc,1060612|1122183,Tokalas Inc,1114656,Tokalas Inc,1114656,,,,,,
99380,GRN-1201,GRN-1201,Research Code,Cancer,,,Protein subunit vaccine|Therapeutic vaccine|Anticancer,12372|12379|1545,Melanoma|Metastatic non small cell lung cancer,205|3665,Solid tumor,725,BrightPath Biotherapeutics Co Ltd,1013288,,,BrightPath Biotherapeutics Co Ltd,1013288,,,,,,
99441,IBI-318,"IBI-318|anti-PD-1/anti-PD-L1  recombinant fully human bispecific antibody (cancer), Adimab/Eli Lilly/Innovent",Research Code,Cancer,Programmed cell death ligand 1 inhibitor|Immunoglobulin G1 agonist|Programmed cell death protein 1 inhibitor,14007|5743|67136,T-lymphocyte stimulator|Immunostimulant|Anticancer antibody,7761|393|55684,Small-cell lung cancer|Hepatocellular carcinoma|Hematological neoplasm|Skin cancer|T-cell lymphoma|Advanced solid tumor|Cancer,1261|1767|2054|2170|311|3713|651,,,Adimab LLC|Eli Lilly & Co|Innovent Biologics Inc,1043519|17810|1070750,,,Adimab LLC,1043519,,,,,,
99474,tebotelimab,"MGD-013|anti-PD1 + anti-LAG3 bispecific antibody (cancer), MacroGenics|MGA-012 + MG-14.99|dual LAG-3 checkpoint inhibitor/PD-1 checkpoint inhibitor (cancer), MacroGenics|tebotelimab",Research Code|INN,Cancer,Programmed cell death protein 1 inhibitor|CD223 antagonist,67136|8413,Immunostimulant|Anticancer antibody|T-lymphocyte stimulator,393|55684|7761,Esophagus tumor|Stomach tumor|Diffuse large B-cell lymphoma|Cholangiocarcinoma|Hepatocellular carcinoma|Hematological neoplasm|Squamous cell carcinoma|Larynx tumor|Stage IV melanoma|Metastatic liver cancer|Metastatic stomach cancer|Metastatic head and neck cancer|Advanced solid tumor|Breast tumor|Mouth tumor|Pharynx tumor|Ovary tumor,1011|127|1749|1765|1767|2054|307|3198|3257|3462|3666|3673|3713|49|793|794|799,Cancer,651,MacroGenics Inc|Zai Lab Limited,29060|1101935,,,MacroGenics Inc,29060,,,,,,
99475,MGC-018,"humanized B7-H3 antibody drug conjugate, MacroGenics|duocarmycin analog-anti-B7-H3 antibody conjugate (solid tumor), MacroGenics|B7-H3 checkpoint inhibitor (solid tumor), MacroGenics|MGC-018",Research Code,Cancer,CD276 antigen inhibitor,48837,T-lymphocyte stimulator|Anticancer alkylating agent|Anticancer|Immunostimulant|Anticancer antibody,7761|50|1545|393|55684,Hormone refractory prostate cancer|Stage IV melanoma|Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor,3246|3257|3657|3665|3673|3713,Solid tumor,725,MacroGenics Inc,29060,,,MacroGenics Inc,29060,,,,,,
99482,efineptakin alfa,"Hyleukin|GX-17|NIT-01|Hyleukin monotherapy (lymphopenia), NeoImmuneTech|IL-7-hyFc|IL-7-hyFc (lymphopenia/HPV infection), Genexine/NeoImmuneTech|efineptakin alfa|IL-7-hyFc (lymphopenia/HPV infection), Genexine/ NeoImmuneTech/ I-Mab|IL-7-hyFc (lymphopenia/HPV infection/advanced solid tumor), Genexine|HyLeukin-7|NT-17|TJ-107|rhIL-7-hyFc|NT-I7|IL-7-hyFc (lymphopenia/HPV infection/advanced solid tumor/COVID-19), NeoImmuneTech|2026634-47-7|Il-7 Hybrid Fc",Research Code|Research Code|INN|Research Code|Research Code|Research Code|Research Code,Cancer|Hematologic|Infection|Neurology/Psychiatric,Interleukin-7 ligand|IL-7 receptor agonist,12496|489,Immunostimulant|Antiviral|T-lymphocyte stimulator|Anticancer,393|991|7761|1545,Esophagus tumor|Coronavirus disease 19 infection|Glioma|Cervical dysplasia|Small-cell lung cancer|Non-small-cell lung cancer|Diffuse large B-cell lymphoma|Hepatocellular carcinoma|Lymphocytopenia|Progressive multifocal leukoencephalopathy|Melanoma|Skin cancer|Adenocarcinoma|Glioblastoma|Pancreas tumor|Squamous cell carcinoma|Merkel cell carcinoma|Metastatic stomach cancer|Metastatic esophageal cancer|Advanced solid tumor|Papillomavirus infection|Uterine cervix tumor|Breast tumor|Head and neck tumor|Cancer|Solid tumor|Kaposis sarcoma|Colorectal tumor,1011|10406|1108|1235|1261|1262|1749|1767|1992|1997|205|2170|2399|2454|249|307|3235|3666|3667|3713|396|427|49|623|651|725|936|989,,,I-Mab Biopharma|Genexine Co Ltd|Kalbe Genexine Biologics|NeoImmuneTech Inc,1141058|29830|1194985|1109239,,,Genexine Co Ltd,29830,,,,,,
99519,PEN-221,"PEN-221|cytotoxic DM1 program (neuroendocrine tumor/small cell lung cancer), Tarveda Therapeutics|SSTR2 targeted peptide-DM1 conjugate (neuroendocrine tumor/small cell lung cancer), Tarveda Therapeutics|(Tyr3,Cys8) octreotate-mertansinse conjugate|(Tyr3,Cys8) octreotate-DM1 conjugate",Research Code,Cancer,Somatostatin 2 receptor modulator,2561,Microtubule inhibitor|Anticancer,2575|1545,Neuroendocrine tumor|Small-cell lung cancer|Metastatic gastrointestinal cancer|Metastatic pancreas cancer,1128|1261|3460|3669,,,Tarveda Therapeutics Inc,1067358,,,Tarveda Therapeutics Inc,1067358,,,,,,
9953,pitavastatin,nisvastatin|NK-104 (lactone)|P-872441|NK-104|pitavastatin|KN-104|itabastatin|Pitava|itavastatin|pitavastatin calcium|Livalo|Livazo|Alipza|Redevant|NKS-104|Livalo OD|1-PC-002|Pivasta,Research Code|Research Code|Research Code|INN|Research Code|Trade Name|Trade Name|Trade Name|Trade Name|Research Code|Trade Name|Research Code,Endocrine/Metabolic,HMG CoA reductase inhibitor,205,Antihypercholesterolemic agent|Antihyperlipidemic agent|Antihypertriglyceridemic agent,71|72|7018,Hypercholesterolemia|Hyperlipidemia|Familial hypercholesterolemia,174|175|3204,,,PT Tanabe Indonesia|Esteve Pharmaceuticals SA|Merck Serono SA|Kowa Co Ltd|Abbott Laboratories|Solvay Pharma|BiOLAB Farmaceutica|Zydus-Cadila Group|Recordati SpA|Eli Lilly & Co|Taiwan Tanabe Seiyaku Co Ltd|JW Pharmaceutical Corp|Laboratorios Delta Ltda|Algorithm SAL,1049166|16074|19862|17688|13601|1040352|30087|29062|24154|17810|1049165|15411|23296|1051961,Daiichi Sankyo Co Ltd|Nissan Chemical Corp|Sankyo Co Ltd|Novartis AG,1017506|18563|19658|23137,Nissan Chemical Corp,18563,,,,,,
99563,sasanlimab,"PF-06801591|PD-1 checkpoint inhibitor (cancer), Pfizer|sasanlimab|RN-888",Research Code|USAN|INN|Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Anticancer monoclonal antibody|T-lymphocyte stimulator|Immunostimulant,55685|7761|393,Esophagus tumor|Stomach tumor|Endometrioid carcinoma|Cholangiocarcinoma|Renal cell carcinoma|Transitional cell carcinoma|Sarcoma|Bladder cancer|Pancreas tumor|Prostate tumor|Squamous cell carcinoma|Stage IV melanoma|Metastatic gastrointestinal cancer|Metastatic bladder cancer|Metastatic non small cell lung cancer|Metastatic head and neck cancer|Advanced solid tumor|Metastatic ovary cancer|Lung tumor,1011|127|1705|1765|1766|1771|194|2380|249|276|307|3257|3460|3466|3665|3673|3713|3866|755,Hodgkins disease|Cancer,161|651,Pfizer Inc,18767,,,Pfizer Inc,18767,,,,,,
99590,"daratumumab + hyaluronidase-fihj (fixed-dose combination, multiple myeloma/ amyloidosis), Janssen Biotech","daratumumab|daratumumab (sc Enhanze, multiple myeloma), Janssen|Darzalex Faspro|daratumumab + hyaluronidase-fihj|daratumumab + hyaluronidase-fihj (fixed-dose combination, multiple myeloma/ amyloidosis), Janssen Biotech|Darzalex sc|Darzquro|DARA SC|Dalacuro",USAN|INN|Trade Name|Research Code|Trade Name|Trade Name,Cancer|Endocrine/Metabolic|Neurology/Psychiatric,ADP ribosyl cyclase-1 inhibitor,5136,Anticancer|Immunomodulator|Anticancer monoclonal antibody|Apoptosis stimulator,1545|1596|55685|1589,Alzheimers disease|Multiple myeloma|AL amyloidosis,14|1828|3492,,,Janssen Biotech Inc,26997,,,Janssen Biotech Inc,26997,,,,,,
99639,TQ-B3101,TQ-B3101,Research Code,Cancer,Anaplastic lymphoma kinase receptor inhibitor|Ros1 tyrosine kinase receptor inhibitor|Hepatocyte growth factor receptor antagonist,3736|3826|675,Anticancer protein kinase inhibitor,62255,Metastasis|Stomach tumor|Anaplastic large cell lymphoma|Metastatic non small cell lung cancer|Advanced solid tumor,1069|127|1755|3665|3713,Lymphoma,203,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd|Southeast University,1025425|1008666,,,CP Group Chia Tai Tianqing Pharmaceutical Group Co Ltd,1025425,,,,,,
99653,SGN-CD123A,"SGN-CD123A|CD123-targeted antibody drug conjugate (acute myelogenous leukemia), Seattle Genetics",Research Code,Cancer,CDw123 antagonist,5429,Immunomodulator|Anticancer monoclonal antibody,1596|55685,,,Acute myelogenous leukemia,1731,,,Seagen Inc,25554,Seagen Inc,25554,,,,,,
99730,FCN-411,FCN-411,Research Code,Cancer,EGFR family tyrosine kinase receptor inhibitor,3754,Anticancer protein kinase inhibitor,62255,Metastatic breast cancer|Metastatic non small cell lung cancer|Metastatic esophageal cancer|Metastatic head and neck cancer,3657|3665|3667|3673,,,Chongqing Fochon Pharmaceuticals Co Ltd,1063683,,,Chongqing Fochon Pharmaceuticals Co Ltd,1063683,,,,,,
99820,eltanexor,KPT-8602|eltanexor|KPTI 8602|ONO-7706|ATG-016,Research Code|INN|Research Code|Research Code|Research Code,Cancer|Gastrointestinal,Exportin 1 inhibitor,21606,Anticancer|Anti-inflammatory|Apoptosis stimulator|Synergist,1545|2953|1589|7293,Myelodysplastic syndrome|Acute lymphoblastic leukemia|Acute myelogenous leukemia|Multiple myeloma|Inflammatory bowel disease|Non-Hodgkin lymphoma|Hormone refractory prostate cancer|Advanced solid tumor|Cancer|Colorectal tumor,1272|1728|1731|1828|189|319|3246|3713|651|989,Solid tumor,725,Karyopharm Therapeutics Inc|Antengene Corp Ltd,1049781|1152645,Ono Pharmaceutical Co Ltd,18681,Karyopharm Therapeutics Inc,1049781,,,,,,
99823,FF-10101,FF-10101|FF-10101-01,Research Code|Research Code,Cancer,Flt3 tyrosine kinase inhibitor,3806,Anticancer protein kinase inhibitor,62255,Acute myelogenous leukemia,1731,Cancer,651,FUJIFILM Holdings Corp,1037804,,,FUJIFILM Holdings Corp,1037804,,,,,,
99850,"arsenic trioxide (oral, acute promyelocytic leukemia), Orsenix Holdings","arsenic trioxide|arsenic trioxide (oral, acute promyelocytic leukemia), Orsenix Holdings|ORH-2014|SY-2101, Syros Pharmaceuticals",USAN|Research Code,Cancer,,,Anticancer,1545,Acute myelogenous leukemia|Acute promyelocytic leukemia|Hematological neoplasm,1731|1732|2054,,,Syros Pharmaceuticals|Orsenix Holdings BV,1081616|1116159,,,Orsenix Holdings BV,1116159,,,,,,
99857,ADXS-NEO,"neoepitope-based immunotherapy (cancer, Lm), Advaxis|ADXS-NEO|neoepitope-based immunotherapy (cancer, Lm), Amgen|Lm based vaccine (infusion, metastatic colon cancer/metastatic NSCLC/metastatic head and neck cancer) Amgen",,Cancer,,,T-lymphocyte stimulator|Recombinant bacterial vector vaccine|Genetically engineered autologous cell therapy|Anticancer,7761|12369|4790|1545,Transitional cell carcinoma|Stage IV melanoma|Metastatic non small cell lung cancer|Metastatic colon cancer|Metastatic head and neck cancer,1771|3257|3665|3672|3673,Cancer,651,Advaxis Inc,1002696,Amgen Inc,14109,Advaxis Inc,1002696,,,,,,
99904,lazertinib,"GNS-1480|EGFR tyrosine kinase inhibitors (cancer), Yuhan Corp|lazertinib|PD-L1 checkpoint inhibitor (cancer), Genosco/Yuhan|YH-25448|EGFR tyrosine kinase inhibitor (cancer), Genosco|EGFR tyrosine kinase inhibitor (NSCLC), Yuhan/ Janssen Biotech|JNJ-1937|JNJ-73841937|Leclaza",Research Code|INN|Research Code|Research Code|Research Code|Trade Name,Cancer,Programmed cell death ligand 1 inhibitor|Epidermal growth factor receptor antagonist,14007|740,Anticancer protein kinase inhibitor|T-lymphocyte stimulator|Immunostimulant,62255|7761|393,Metastatic non small cell lung cancer,3665,Non-small-cell lung cancer|Cancer,1262|651,Janssen Biotech Inc|Yuhan Corp,26997|20984,Shandong Luoxin Pharmaceutical Group Stock Co Ltd|Genosco,1054140|1062034,Genosco,1062034,,,,,,
99927,NKTR-255,"NKTR-255|IL-15 receptor agonist (cancer), Nektar Therapeutics",Research Code,Cancer,IL-15 receptor agonist,3085,Synergist|Anticancer|Immunostimulant,7293|1545|393,Multiple myeloma|Squamous cell carcinoma|Non-Hodgkin lymphoma|Metastatic colorectal cancer|Metastatic head and neck cancer,1828|307|319|3658|3673,Cancer,651,Nektar Therapeutics,17221,,,Nektar Therapeutics,17221,,,,,,
99944,JTX-4014,"T effector cell modulator therapy (cancer), Jounce|JTX-4014|PD-1 checkpoint inhibitor (cancer), Jounce|anti-PD-1 IgG mAb (iv, solid tumors), Jounce Therapeutics|pimivalimab",Research Code,Cancer,Programmed cell death protein 1 inhibitor,67136,Immunostimulant|Anticancer monoclonal antibody|T-lymphocyte stimulator|Anticancer,393|55685|7761|1545,Metastatic non small cell lung cancer|Advanced solid tumor,3665|3713,Cancer,651,Jounce Therapeutics Inc,1079075,,,Jounce Therapeutics Inc,1079075,,,,,,
99989,"apilimod dimesylate (capsule, B-cell non-Hodgkins lymphoma/Chronic lymphocytic leukemia/amyotrophic lateral sclerosis), AI Therapeutics","apilimod mesylate|apilimod|apilimod dimesylate (capsule, B-cell non-Hodgkins lymphoma), Lam Therapeutics|LAM-002A|apilimod dimesylate|apilimod mesylate (capsule, B-cell non-Hodgkins lymphoma), Lam Therapeutics|LAM-002|apilimod dimesylate (capsule, B-cell non-Hodgkins lymphoma/Chronic lymphocytic leukemia/amyotrophic lateral sclerosis/COVID-19), AI Therapeutics",USAN|INN|Research Code|Research Code,Cancer|Infection|Neurology/Psychiatric,IL-12 receptor antagonist|Transcription factor EB stimulator|FYVE finger phosphoinositide kinase inhibitor|IL-23 antagonist,1584|30070|63413|9748,Anticancer|Antiviral,1545|991,Coronavirus disease 19 infection|Chronic lymphocytic leukemia|Mantle cell lymphoma|Follicle center lymphoma|Marginal zone B-cell lymphoma|Diffuse large B-cell lymphoma|Primary mediastinal large B-cell lymphoma|Motor neurone disease|Non-Hodgkin lymphoma,10406|1734|1744|1745|1746|1749|1750|212|319,,,AI Therapeutics,1084743,,,AI Therapeutics,1084743,,,,,,
99997,CA-4948,"IRAK4 inhibitors (cancer), Aurigene|CA-4948|AU-4948|IRAK4 inhibitors (anemia), Aurigene/Curis",Research Code|Research Code,Cancer|Hematologic,IRAK-4 protein kinase inhibitor|Flt3 tyrosine kinase inhibitor,10562|3806,Anticancer protein kinase inhibitor|Synergist,62255|7293,Myelodysplastic syndrome|Anemia|Acute myelogenous leukemia|Chronic lymphocytic leukemia|Lymphoplasmacytic lymphoma|Diffuse large B-cell lymphoma|Non-Hodgkin lymphoma,1272|17|1731|1734|1743|1749|319,Cancer,651,Curis Inc|Aurigene Discovery Technologies Ltd,15549|30044,,,Aurigene Discovery Technologies Ltd,30044,,,,,,
